News Feed

All psychedelic policy, research, and clinical developments — 1164 items.

Clinical research New Review published

2026 review: Mechanism-aligned ketamine therapy for TRD

Mechanism-aligned ketamine therapy for treatment-resistant depression: a 2026 update—toward an integrative mechanistic framework for clinical translation
Why it matters ▲ Favorable
This review synthesizes recent mechanistic evidence on ketamine’s effects in treatment-resistant depression, emphasizing the interplay of biological and experiential factors and proposing a clinically actionable framework for future research and individualized care. By integrating advances since 2021, it highlights the importance of context, psychotherapy, and safety in optimizing ketamine therapy. The framework aims to inform patient selection and treatment protocols, supporting more durable and targeted interventions in psychiatric care.
Ketamine is increasingly understood to exert therapeutic effects through multiple interacting biological and experiential processes rather than a single pharmacological mechanism. In treatment-resistant depression (TRD), where conventional monoaminergic antidepressants often fail, ketamine’s rapid effects are thought to emerge through the coordinated, temporally structured engagement of five interacting domains: NMDAR modulation, neuroplastogenic processes, anti-inflammatory signaling, entropic brain state modulation, and psychedelic/mystical phenomenology. Building on the previously proposed systems-level model, this narrative review integrates foundational mechanistic evidence with peer-reviewed research published through April 2026, with particular emphasis on advances since the 2021 framework. It further considers how chronic stress, developmental trauma, and attachment disruption may shape treatment resistance and influence response across major depressive disorder, posttraumatic stress disorder, suicidality, and related refractory conditions; these developmental and relational factors are conceptualized as cross-cutting substrates of treatment resistance rather than as a sixth mechanism of ketamine action. By aligning ketamine’s biological and experiential effects with therapeutic context, psychotherapy, and structured integration, the proposed framework offers a clinically interpretable perspective to inform future research and support more individualized, durable, and mechanism-aligned approaches to treatment. The review also addresses ketamine’s medical, psychiatric, and contextual risks, arguing that safety considerations are integral to mechanism-aligned care. The framework is intended to generate testable predictions regarding patient selection, treatment timing, and durability of response, supporting future controlled evaluation.
US Congress / Policy New House panel approval

US House panel backs psychedelic mental healthcare for veterans

Psychedelic mental healthcare for veterans wins bipartisan backing from US House panel
Why it matters ▲ Favorable
Bipartisan support from a US House panel signals growing momentum for federal action on psychedelic mental health care for veterans. This development could accelerate research funding, reduce legal barriers, and expand access pathways for clinical use, particularly for PTSD and related conditions. The move also increases industry and clinical interest in veteran-focused psychedelic therapies, but final passage and implementation remain pending.
US / Federal New Federal funding announced

HHS announces major new federal funding for psychedelic research, ibogaine focus

HHS announces new funding opportunities for psychedelics, with focus on ibogaine
Why it matters ▲ Favorable
The Department of Health and Human Services' new funding for psychedelic research marks a significant federal commitment to advancing clinical and translational work on rapid-acting psychotropic drugs, including ketamine, psilocybin, and especially ibogaine. The $20M NIMH research network and ARPA-H's targeted ibogaine investment will accelerate rigorous studies, support infrastructure, and may reduce barriers for future clinical development. This move signals growing mainstream acceptance and could catalyze further public and private investment in the field.
Last week, the Department of Health and Human Services (HHS) announced two new investments to promote the development of psychedelics to treat mental illness. First, the National Institute of Mental Health (NIMH) published a $20 million notice of funding opportunity to support the development of a research network to study rapid‐acting psychotropic interventional drugs such as ketamine, esketamine, psilocybin and other emerging treatments for serious mental illnesses. Second, investments up to $4.9 million through the Advanced Research Projects Agency for Health (ARPA‐H) were announced to advance the development of ibogaine as a potential treatment for post‐traumatic stress disorder (PTSD) and other serious mental illnesses.
Clinical research New Scoping review published

Scoping review maps LSD clinical trials for pain and neuropsychiatric use

Repurposing of LSD — a scoping review of current clinical trials
Why it matters ◈ Mixed
This comprehensive review highlights a global surge in clinical research on LSD, with three phase 3 trials underway and early signals of benefit for anxiety and depression. The analysis underscores the need for more robust phase 2 and 3 data, especially as microdosing efficacy remains unproven and results are inconsistent. The findings will inform researchers, sponsors, and regulators about the current landscape and gaps in evidence, shaping future trial design and investment priorities.
LSD was banned in many countries for a very long time and was purchased by users for recreational use on the black market. Since 2014, there has been steady growth in interest in its potential use in treating pain disorders and neuropsychiatric conditions. Consequently, an increasing number of studies on the repurposing of LSD have been conducted; in some cases, the conditions treated corresponded to those in studies from the 1950s and 1960s, while in others, the scope was expanded to include new areas of application. Clinicaltrials.org, ANZCTR, the Netherlands trial registry and PubMed research were used to identify the clinical trials. For this publication, 51 studies were analyzed, 25 of which were published. The goal is to map the status quo of the current state of research and analyze the study design. The analysis parameters included study design, conditions, sponsoring, study location, and overall outcome. Most studies are still in phase 1, followed by phase 2. Three phase 3 studies are currently being conducted. The condition entities were: alcohol use disorder (n = 1), anxiety disorders (n = 3), Attention-Deficit/Hyperactivity Disorder (ADHD) (n = 1), cluster headache (chronic and non-chronic, n = 2); major depressive disorder (n = 4), premenstrual disorders (premenstrual syndrome (PMS)) and Premenstrual Dysphoric Disorder (PMDD) (n = 1), palliative care/end-of-life distress (n = 2). The most used dosage is 100 µg. Most studies are interventional RCTs using inactive placebos and are conducted in Switzerland, followed by the USA, the Netherlands, and New Zealand/Australia. The outcome of the published trials was analyzed further. So far, LSD shows possible benefits in the treatment of anxiety disorders and major depressive disorders. The effectiveness of microdosing could not be adequately proven, and the results varied greatly, which could be due to differences in dosage and administration. More detailed studies, particularly phase 2 or phase 3 studies, are needed to make more informed statements.
Industry / FDA / DEA New FDA decision pending

Compass Pathways Nears FDA Decision; Focus Shifts to DEA Scheduling

Compass Pathways Nears FDA Decision as Psychedelics' Real Hurdle Moves to the DEA
Why it matters ◈ Mixed
Compass Pathways is approaching a pivotal FDA decision for its psychedelic therapy, signaling a potential landmark for industry and patient access. However, the article highlights that the next major barrier will be DEA scheduling, which could delay or complicate real-world availability even after FDA approval. This underscores the dual regulatory hurdles facing psychedelic medicines in the US. Stakeholders should closely monitor both agencies, as DEA action will be critical for prescriber and patient access.
Neuroscience New Peer-reviewed study published

Simulated weightlessness increases depersonalisation in healthy adults

Gravity shapes the self: experimental evidence from simulated weightlessness
Why it matters ▲ Favorable
This study provides experimental evidence that disrupting vestibular-gravity signals can acutely alter bodily self-consciousness, as measured by increased depersonalisation in healthy individuals. These findings may inform mechanistic models of altered states of consciousness relevant to psychedelic research, particularly regarding the neural basis of self-experience and sensory integration. While not directly about psychedelics, the work is relevant for researchers exploring the neurobiology of ego dissolution and perceptual changes. It may also inspire translational work on how environmental or sensory manipulations interact with psychedelic states.
Gravity is a constant of life on Earth, yet its role in shaping the sense of self remains poorly understood. Here, we tested the hypothesis that bodily self-consciousness depends on the continuous alignment between vestibular signals and an internal model of gravity. Using the European Space Agency (ESA)’s frictionless air-bearing platform, we simulated weightlessness in healthy participants. Depersonalisation, characterised by a sense of detachment from one’s body or self, was assessed before and after exposure using the Cambridge Depersonalisation Scale. Results revealed a significant increase in depersonalisation scores following simulated weightlessness, indicating that even brief disruption of vestibular-gravity signals alter the sense of self. These findings provide the first experimental evidence linking altered gravity conditions to depersonalisation in healthy individuals. We propose that gravity acts as a strong prior constraining multisensory integration and anchoring bodily self-consciousness. When this prior is violated, sensory conflict emerges, leading to altered self-consciousness. Neuroanatomical overlap between vestibular and self-processing networks further supports this mechanism. Our results demonstrate that gravity is not merely a physical constraint, but a fundamental determinant of conscious experience.
Neuroscience New Peer-reviewed study published

Multi-omics study finds shared astrocytic responses to diverse psychoactives

Integrated multi-omics analyses reveal candidate astrocytic signalling responses shared across pharmacologically distinct psychoactive compounds
Why it matters ▲ Favorable
This study reveals that pharmacologically distinct psychoactive drugs, including psilocin, may trigger convergent molecular responses in human astrocyte-like cells. The identification of shared astrocytic signalling pathways across substances could inform future research on the neurobiology of psychedelics and other psychoactives, and potentially guide the development of new therapeutic approaches for substance use disorders. While preclinical, these findings offer mechanistic insight relevant to both basic science and translational research.
Astrocytes are increasingly recognised as contributors to the neuroadaptations that underlie substance use disorders, but most studies examine single drugs, and it remains unclear whether pharmacologically distinct substances engage a common astrocytic response. Here, we apply an integrated multi-omic approach to two human astrocyte-like cell lines, KNS-42 and SVG-A, exposed to ethanol, Δ9-tetrahydrocannabinol, cocaine, morphine or psilocin, to profile the transcriptome in both cell lines and the phosphoproteome and metabolome in KNS-42. Both cell lines expressed transcripts for several canonical targets of these compounds, including opioid (OPRM1, OPRD1) receptors and serotonin receptors and the astrocytic glutamate transporter SLC1A3, with the cannabinoid receptor CN1 and the glutamate transporter SLCA2 detected in KNS-42 cells only. KNS-42 and SVG-A diverged transcriptionally, as expected for developmentally distinct astrocytes. Despite this, the chemically distinct psychoactive compounds converged on a small set of candidate molecular features: seven phosphoproteins (including vimentin, MAP1B and AHNAK) and thirteen putatively annotated metabolite features, each representing greater overlap than expected by chance. The shared response across multi-omic layers implicated cytoskeletal and Rho-GTPase signalling, cell-cycle regulation and, putatively, nucleotide catabolism. Our findings indicate that distinct psychoactive compounds may converge on a small number of astrocytic processes and we provide an interactive data application for exploring astrocytic responses to psychoactive compounds.
Clinical research New Review published

Review: Evidence & uncertainties in psychedelic treatment for SUDs

Psychedelic‐assisted treatment for substance use disorders: Evidence and uncertainties
Why it matters ◈ Mixed
This review highlights persistent gaps in evidence for psychedelic-assisted treatment of substance use disorders, especially regarding durability of benefits, masking, and integration with psychological care. The authors stress that current data—especially from non-clinical settings—are insufficient to establish therapeutic efficacy, and call for larger, longer, and more rigorous trials. The findings underscore the need for careful design and regulatory oversight as the field moves toward broader clinical and policy adoption.
treatment, support and aftercare, access and eligibility, and the regulatory requirements under which services would operate.The therapeutic use of psychedelics outside formal clinical programmes raises different questions.Krawczyk et al. [9] analysed discussions in two online opioid-recovery communities and found differing views about the benefits, limitations and risks of using psychedelics to manage opioid use.In a nationally representative United States survey Priest et al. [10] estimated that 26.5% of adults who had ever used psilocybin had microdosed on their most recent occasion of use.Improving mental and physical health were prominent motivations among those who reported microdosing.These studies describe experiences, attitudes and motivations outside clinical programmes.They do not establish therapeutic benefit.Taken together, these contributions identify questions that confirmatory trials need to resolve.Among these are: do benefits persist?How are outcomes influenced by compromised masking?Do psychedelic drugs add to the psychological intervention with which they are delivered?Larger samples and longer follow-up are needed to address these questions and provide more complete reporting of potential harms.Research on delivery will also need to establish what staffing, support and aftercare these interventions require.The next stage of research should clarify both their clinical effects and the conditions under which any benefits can best be achieved.
Neuroscience New Review published

Review exposes translational gaps in animal models for psychedelic research

Animal models in psychedelic research – Tripping over translation
Why it matters ◈ Mixed
This systematic review highlights major methodological weaknesses in preclinical psychedelic research, especially the lack of attention to 'set and setting,' individual differences, and social context in animal models. These gaps may explain inconsistent findings and hinder translation to human trials, raising concerns for both research validity and future clinical development. The authors offer practical recommendations, which, if adopted, could improve the predictive value of animal studies for human therapeutic outcomes.
Psychedelic substances show promise for treating psychiatric disorders including depression, anxiety, and PTSD, but the neurobiological mechanisms underlying their therapeutic effects remain poorly understood. Preclinical findings have so far been inconsistent, limiting mechanistic insights. We argue this translational gap is exacerbated by systematic disconnects between conditions thought to shape therapeutic outcomes in humans and those employed in animal research. In this review, we analyse 266 rodent psychedelic studies published between 2014 and 2026 in order to generate a systematic audit of experimental conditions and behavioural assays currently applied in the field. Specifically, we first assessed adherence to welfare practices paralleling "set and setting" factors critical to human therapy. We found that most studies contained stress-inducing factors: only a minority reported active-phase testing (14%), environmental enrichment (7%), or refined handling protocols (21%), while drug administration almost universally relied on stress-inducing, restraint-requiring methods. Second, we evaluated the capacity of behavioural assays to capture experiential dynamics, revealing that most studies rely on brief, constrained testing with isolated behavioural markers that fail to capture the multidimensional, temporally evolving nature of psychedelic states. Beyond these methodological gaps, we identify a third critical factor largely absent from preclinical research: individual differences and social context. Most animal studies use group-level, cross-sectional designs that cannot characterize heterogeneous treatment responses or social mechanisms implicated in therapeutic change. We propose that improving translation requires a fundamental reorientation: from brief testing of stressed, isolated animals toward longitudinal tracking of individuals in enriched social environments using comprehensive behavioural characterization. We end by offering practical advice on how to implement some of these considerations in animal psychedelic research.
Neuroscience New Preclinical research

Novel NMDAR PAMs show improved properties for neuropsychiatric drug development

Development of Second Generation Thieno[2,3- d ]pyrimidin-4-one Derivatives as Positive Allosteric Modulators of the N -Methyl- d -Aspartate Receptor
Why it matters ▲ Favorable
This preclinical research describes a new class of NMDAR positive allosteric modulators with improved pharmacological properties, targeting mechanisms relevant to depression and anxiety. While not directly psychedelic, this work is highly relevant to the broader neuropsychiatric drug development landscape and may influence future approaches to rapid-acting antidepressants. The findings may inform both mechanistic research and industry interest in next-generation CNS therapeutics.
The N-methyl-d-aspartate receptor (NMDAR) is a ligated-gated cation channel that mediates excitatory synaptic transmission in the central nervous system. These receptors are involved in important brain functions and have been implicated in many neuropathological conditions. Four GluN2 subunits assemble with GluN1 to produce a series of NMDAR subtypes that are expressed in different subpopulations of neurons at different times. Among the GluN2 subunits, the GluN2D-containing NMDARs are highly expressed in inhibitory interneurons, which are key targets for drug development. Positive allosteric modulators (PAMs) have been proposed to be useful in several neuropsychiatric indications, including schizophrenia and depression. We have previously discovered EU 1622-240, a novel GluN2B/C/D-biased PAM with favorable oral bioavailability, CNS exposure, and anxiolytic activity in rodents. However, it was a P-gp inhibitor, cleared rapidly, and poorly absorbed in vivo. Through an extensive SAR, we now present EU 1622-287 with improved solubility, oral bioavailability, brain exposure, and anxiolytic effects.
Neuroscience New Preclinical research published

Psilocybin shown to inhibit CGRP and boost antitumor immunity in HNSCC models

Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models
Why it matters ▲ Favorable
This preclinical study identifies high-dose psilocybin as a CGRP inhibitor that transiently reduces tumor growth and enhances antitumor immunity in head and neck squamous cell carcinoma models. The findings suggest a novel neuroimmune mechanism by which psychedelics may impact cancer biology, with corroborative evidence from human plasma analyses. While early-stage, this work opens a potential new research avenue for psychedelic compounds in oncology and immunotherapy, warranting further translational and clinical investigation.
Neurogenic inflammation is one component that sculpts the immune milieu of solid tumors. However, it remains unclear how the sensory-neuroimmune axis shapes the immune microenvironment in cold tumors to bolster treatment resistance. Using orthotopic head and neck squamous cell carcinoma (HNSCC) models, we demonstrate tumor growth-induced sensory hyperexcitability, and that surgical sensory signaling interruption reduced tumor growth. Genetic knockout of a key neuropeptide released by sensory neurons, calcitonin gene-related peptide (CGRP), encoded by Calca, produced eradication when paired with radioimmunotherapy. Such treatment reduced Treg infiltration and immunosuppressive function in Calca knockout mice. We also observed that high-dose psilocybin functions as a CGRP inhibitor and transiently reduces tumor growth by increasing antitumor immunity. Additionally, psilocybin increased circulating serotonin, which was partially reversed with platelet activation inhibitor, clopidogrel. We observed differential effects on CD8 and Treg functionality by psilocin in vitro. Correlational analyses in plasma from human subjects following a single-dose psilocybin corroborated these findings. Together, this work underscores the complex interaction of neurogenic inflammation and the tumor immune microenvironment, highlighting a potential therapeutic avenue for HNSCC and other solid tumors.
Neuroscience New Published research

Historeceptomics reveals ketamine's brain region targets and effects

Historeceptomics Profiling of Ketamine
Why it matters ▲ Favorable
This study advances understanding of ketamine's mechanism by mapping its activity across brain regions and receptor targets using Historeceptomics. The findings clarify how ketamine's antidepressant and dissociative effects may arise from specific neural circuits and receptor interactions. This mechanistic insight could inform safer clinical use, guide drug development, and help differentiate therapeutic from adverse effects for ketamine and related compounds.
Ketamine elicits distinctive neuropsychiatric phenotypes from a complex and as yet elusive mechanism of action. Here, we applied an updated Historeceptomics approach to identify molecular targets and brain tissues that may contribute to its antidepressant, analgesic, and dissociative effects. Historeceptomics generates multidimensional target-tissue fingerprints by integrating drug-target activity with tissue-specific target expression, providing an anatomic profile of drug action. The results suggest that ketamine activity on NMDA receptors in the prefrontal and cingulate cortices and the amygdala may contribute to ketamine improvements in social functioning for MDD. However, this same receptor-tissue activity may invoke hallucinatory effects at higher intensity or with engagement of additional brain regions. The central nervous system (CNS) fingerprint for ketamine was compared with those of other psychoactive drugs, showing overlap with fingerprints from other antidepressant, hallucinogenic, and analgesic drugs. Some ketamine effects may be traced to specific enantiomers or metabolites of ketamine. These findings provide new insights into the mechanisms by which ketamine elicits its unique phenotype and demonstrate the utility of using Historeceptomics to understand complex drug action.
Pharmaceutical analysis New Peer-reviewed review published

NIRS advances for water analysis in pharma and nutraceuticals

Water as an analytical target in near-infrared spectroscopy: from pharmaceutical quality control to nutraceutical authenticity
Why it matters ▲ Favorable
This review highlights advances in using near-infrared spectroscopy (NIRS) to analyze water's role in pharmaceutical and nutraceutical manufacturing, proposing new frameworks for quality control. While not specific to psychedelics, these analytical improvements could enhance quality assurance and regulatory compliance for psychedelic drug developers and manufacturers. The work is relevant for process optimization and safety in the broader pharmaceutical sector, including emerging psychedelic medicines.
Water often plays a critical role across all stages of drug development and manufacturing — governing not only solubility and bioavailability, but also solid-state transformations, granulation behavior, freeze-drying stability, and product authenticity. Near-infrared spectroscopy (NIRS) has become an indispensable tool in pharmaceutical analysis — rapid, non-destructive, and applicable across the full range of development and manufacturing stages. Yet one of its most distinctive features remains underutilized: water absorbs strongly in the NIR region providing a wealth of information, with different absorbance bands reflecting distinct hydrogen-bonding environments and water molecular structures that are directly relevant to pharmaceutical quality. This review explores how water molecular structure, tracked via NIRS, may represent previously underrecognized CQAs that Analytical Quality by Design (AQbD) frameworks have historically underexploited. Drawing on case studies spanning pharmaceutical quality control, process analytical technology (PAT), traditional Chinese medicine (TCM) extraction, and nutraceutical authenticity assessment, this review compiles and assigns specific water-sensitive NIR absorbance bands across these contexts, proposes a systematic Combination Band Water Matrix Coordinates (CB-WAMACs) framework for the analytically underexplored ∼1,880–2,020 nm spectral region, and shows how the capacity of NIR methods to resolve these water-sensitive bands and track their responses can serve as a Critical Method Attribute (CMA) within AQbD-structured method development, aligned with Analytical Target Profiles (ATPs) and developed in a manner consistent with International Council for Harmonization (ICH) Q14 guidelines. As a non-destructive, fast, and cost-effective analytical platform, NIRS holds significant promise for advancing pharmaceutical safety, manufacturing efficiency, and nutraceutical authenticity.
Clinical research New Peer-reviewed publication

Psilocybin and escitalopram show distinct brain reconfiguration in depression

Modelling vortex interactions reveals distinct patterns of brain reconfiguration following psilocybin and escitalopram
Why it matters ▲ Favorable
This study provides new mechanistic insight into how psilocybin and escitalopram differently reorganize brain dynamics in patients with major depressive disorder, using advanced fMRI modelling. The findings highlight that psilocybin induces more pronounced changes in brain connectivity and modularity than escitalopram, but both share turbulence increases linked to clinical improvement. This work advances the understanding of psychedelic mechanisms and could inform biomarker development and future trial design.
Major depressive disorder is a leading cause of disability, yet how interventions reorganise brain dynamics remains poorly understood. Here, we investigated how psilocybin and escitalopram reshape brain dynamics in depression using pre- and post-treatment resting-state functional magnetic resonance imaging (fMRI) from a double-blind randomised controlled trial ( NCT03429075 ). We compared two whole-brain modelling approaches: conventional signal-space modelling describing interactions between regional brain signals, and vortex-space modelling capturing interactions between evolving patterns of local synchronisation. This represents the first application of vortex-space modelling to a psychiatric disorder. Vortex space was more sensitive than signal space in most analyses, including distinguishing treatment-related brain states, relating baseline connectivity to clinical improvement and predicting response to escitalopram. Our results further revealed distinct patterns of reorganisation following the two interventions. Psilocybin produced widespread increases in vortex-space effective connectivity and reduced network modularity, whereas escitalopram showed no comparable changes. Despite these differences, greater increases in brain turbulence (i.e., spatiotemporal variability in local synchronisation) were associated with greater symptom reduction in both treatments, with a significant post-treatment increase in responders. These findings suggest that psilocybin and escitalopram may reorganise brain dynamics in markedly different ways and yet share dynamical features associated with clinical improvement. Overall, vortex-space modelling offers a promising framework for characterising brain dynamics in depression and its successful treatment.
Clinical research New Patient experience report

Some patients report new troubles after psychedelic treatment

For some patients, psychedelic treatment brings new troubles in its aftermath
Why it matters ◈ Mixed
Emerging reports of adverse or challenging outcomes following psychedelic therapy highlight the need for robust post-treatment monitoring and support structures. This underscores the importance of informed consent, risk communication, and further research into both the benefits and potential harms of psychedelic interventions. Stakeholders should pay close attention to these patient experiences as the field moves toward broader clinical adoption.
Clinical research New Peer-reviewed study published

Mescaline enhances emotional empathy via 5-HT2A receptor activation

Mescaline enhances emotional empathy via 5-HT 2A receptor activation
Why it matters ▲ Favorable
This placebo-controlled crossover study demonstrates that mescaline acutely increases emotional empathy and plasma oxytocin in healthy adults, effects mediated by 5-HT2A receptor activation. The findings add to the mechanistic understanding of classic psychedelics’ impact on social cognition, supporting further investigation of mescaline for psychiatric and empathogenic applications. While the study is small and in healthy volunteers, it provides a scientific rationale for future clinical trials targeting empathy deficits.
Background: Classic psychedelics are being re-investigated as treatments for psychiatric disorders. Deficits in social cognition and empathy are associated with various neuropsychiatric conditions and impaired mental health. Recent studies indicate that lysergic acid diethylamide and psilocybin may affect emotional processing and empathy, but acute effects of mescaline, another classic serotonergic psychedelic, have not yet been studied. Aims: To assess the acute effects of different mescaline doses on empathy and plasma oxytocin, and to determine the role of serotonin 5-hydroxytryptamine-2A (5-HT 2A ) receptor activation in mediating these effects. Methods: In a placebo-controlled, double-blind, random-order crossover study (NCT04849013), 16 healthy participants (aged 25–55 years, 8 women) received placebo, mescaline (100, 200, 400, and 800 mg), and 800 mg mescaline plus 40 mg ketanserin (5-HT 2A receptor antagonist). Cognitive and emotional empathy were assessed with the Multifaceted Empathy Test (MET) at 6 hours. Subjective empathogenic effects were repeatedly rated on visual analog scales, and plasma oxytocin concentrations were measured up to 30 hours after drug administration. Results: Mescaline induced dose-dependent subjective feelings of happiness and trust. On the MET, mescaline significantly enhanced emotional empathy in a dose-dependent manner but reduced cognitive empathy. Plasma oxytocin concentrations increased dose-dependently but were significantly elevated only after 400 and 800 mg mescaline compared with placebo. Co-administration of ketanserin blocked the mescaline-induced effects on empathy and oxytocin release. Conclusions: These results provide further evidence that classic psychedelics acutely alter empathy and plasma oxytocin concentrations by interacting with 5-HT 2A receptors.
Clinical research New Systematic review underway

Meta-analysis of psilocybin and LSD for anxiety in RCTs underway

Efficacy and safety of classic serotonergic psychedelics (psilocybin and LSD) for anxiety: a systematic review, meta-analysis and dose-response analysis of randomized controlled trials
Why it matters ▲ Favorable
This systematic review and meta-analysis could clarify the efficacy and safety profile of psilocybin and LSD for anxiety disorders, including dose-response relationships. While not a primary trial or regulatory move, it may inform future research design and clinical guidelines by aggregating RCT data. The undergraduate project status limits immediate impact, but the synthesis could be valuable for researchers and clinicians.
This systematic review and meta-analysis will evaluate the efficacy and safety of psilocybin and lysergic acid diethylamide (LSD), compared with placebo or a low-dose control, in adults with clinically significant anxiety (anxiety disorders or anxiety associated with life-threatening illness). It will also explore whether the anxiolytic effect depends on dose, including the low-dose and microdose range. It is conducted as an undergraduate final degree project (Trabajo Fin de Grado) at the University of Granada.
Clinical research New Published study

Study examines reproducibility of psilocybin research findings

Psilocybin reproducibility.
Why it matters ◈ Mixed
Reproducibility is a critical concern for the credibility and regulatory acceptance of psychedelic research. This study addresses whether psilocybin research findings can be reliably replicated, which impacts the field’s scientific rigor and informs regulatory and clinical adoption. While not a legal or policy move, it signals the field’s maturation and the need for robust methodologies before broader medical or policy shifts.
Federal Register / Legal New Complaint filed

Federal Register: Complaint initiates procedural schedule

Complaint
Why it matters ◈ Mixed
A complaint has been filed at the federal level, triggering a procedural schedule and setting a deadline for notices of intervention. This marks the start of a legal process that could impact regulatory or enforcement policy, but the subject matter and implications for psychedelic research or access are not yet clear. Stakeholders should monitor for further filings or case details that may affect law or industry.
This document provides the deadline date to file a notice of intervention and discusses aspects of the procedural schedule and case management procedures.
Neuroscience New Perspective published

Glymphatic system proposed as target in treatment-resistant depression

A state-dependent glymphatic dimension in major depressive disorder: implications for treatment resistance
Why it matters ▲ Favorable
This Perspective highlights the glymphatic system as a potentially modifiable physiological factor in treatment-resistant depression (TRD), linking sleep, astrocytic, and vascular dynamics to illness persistence. It suggests that interventions including ketamine, esketamine, and serotonergic psychedelics may influence this system, opening new research avenues for understanding and treating TRD. While not a clinical trial or legal change, this work frames future studies that could impact psychedelic research and therapeutic strategies.
The glymphatic system refers to cerebrospinal fluid-interstitial fluid exchange and proposed drainage pathways shaped by sleep, arousal, vascular dynamics, and astrocytic organization. This physiology offers a way to connect disturbances that often coexist in major depressive disorder (MDD): disrupted sleep, fatigue, cognitive slowing, and stress-related abnormalities. We propose that difficulty establishing or maintaining a coordinated sleep-astrocyte-vascular state may contribute to illness persistence in some patients. Treatment-resistant depression (TRD) provides a setting in which this possibility can be examined across the course of treatment. Preclinical studies link stress and depressive-like behavior to astrocytic injury, aquaporin-4 dysregulation, and altered fluid transport. Human imaging findings vary across depressive phenotypes. In a dedicated TRD study, a higher diffusion tensor imaging along the perivascular space (DTI-ALPS) ratio was partly driven by reduced denominator diffusivity, illustrating the importance of interpreting this indirect index at component level. Whole-brain spatiotemporal models provide a complementary account of the neural activity accompanying these physiological states. Ketamine/esketamine, transcranial magnetic stimulation, and chronobiological interventions offer different ways to investigate treatment-related change; serotonergic psychedelics provide an exploratory extension. Longitudinal studies can establish how changes in sleep, fluid-sensitive imaging, and neural dynamics relate temporally to clinical recovery. This Perspective therefore develops a potentially modifiable physiological dimension of persistent depressive illness and defines how it can be tested.
Clinical research New Qualitative study published

Addiction professionals weigh psychedelics for AUD prevention

Addiction professionals’ perspectives on classic psychedelics as prevention interventions for alcohol use disorder
Why it matters ◈ Mixed
This qualitative study surfaces expert hypotheses and implementation barriers for using classic psychedelics in indicated prevention of alcohol use disorder, but does not provide efficacy data. The findings highlight conceptual promise, workforce and regulatory challenges, and the need for further research on safety, effectiveness, and equitable access. This work may inform future trial design and policy discussions, but is not a practice-changing result.
Introduction Alcohol use disorder (AUD) remains a pervasive public health issue, often rooted in complex biological, psychological, social, and spiritual factors that traditional prevention methods may not adequately address. This qualitative study explored professionals’ perspectives on the potential of classic psychedelics within an indicated prevention framework for AUD, focusing on intervention before a diagnosable disorder develops. Methods This study employed a qualitative, exploratory design utilizing semi-structured interviews to investigate professionals’ perceptions of the potential of classic psychedelics as prevention interventions for AUD, with findings interpreted within an indicated prevention framework. The sample was made up of professionals with expertise in both substance use disorder (SUD) treatment and psychedelics. Participants were required to have at least 3 years of professional experience providing treatment or care for SUDs, as well as a self-assessed moderate to expert understanding of the biopsychosocial-spiritual (BPSS) model and classic psychedelics. Ultimately, 17 professionals participated in this study. The data collection process involved semi-structured interviews conducted via Google Meet. Each interview lasted approximately 60 to 90 min. This study employed reflexive thematic analysis, a flexible and iterative approach to analyzing qualitative data that emphasizes the active role of the researcher in meaning-making. Results Reflexive thematic analysis revealed six themes reflecting participants’ perspectives on limitations of existing prevention approaches, participants’ perceptions of the potential relevance of psychedelics across BPSS dimensions, the role of connection, prevention potential, barriers to implementation, and pathways forward. Participants discussed possible neurobiological change, emotional processing, social reconnection, and spiritual meaning-making while also identifying legal restrictions, stigma, clinician training, safety, cost, accessibility, and equity as important considerations. Drawing on the findings and the study’s theoretical frameworks, the author developed the Psychedelic Prevention Diffusion Model (PPDM), a conceptual synthesis integrating the BPSS model, diffusion of innovations theory, and the Spectrum of Prevention. Discussion The findings do not establish the preventive efficacy of classic psychedelics but identify hypotheses and implementation considerations for future research on psychedelic-assisted indicated prevention. Further investigation should examine safety and effectiveness alongside workforce preparation, policy and regulation, community participation, cultural responsiveness, and equitable access.
Neuroscience New Biosynthetic pathway published

Biosynthetic pathway for β-carbolines in ayahuasca plants discovered

Discovery of the β-Carboline Biosynthetic Pathway Enables In Planta Reconstruction of the Amazonian Brew Ayahuasca
Why it matters ▲ Favorable
This discovery enables controlled, sustainable biosynthesis of both β-carbolines and DMT in model plants. This could facilitate standardized research materials for clinical trials, reduce reliance on wild-harvested plants, and open new avenues for pharmaceutical development and crop engineering. The work also provides molecular tools for future studies on ayahuasca's pharmacology and conservation.
β-Carbolines are bioactive indole alkaloids with remarkable pharmacological properties and a defining role in ayahuasca, a traditional Amazonian shamanic brew, where their inhibition of monoamine oxidases enables the oral activity of the psychoactive N,N -dimethyltryptamine (DMT). Yet, despite their longstanding medicinal and cultural significance, the biosynthetic origin of β-carbolines in plants remains largely unresolved. Here, we uncover key steps underlying the biosynthesis of harmine, the major bioactive β-carboline alkaloid in Peganum harmala , by integrating spatial metabolite and transcriptome profiling with enzyme characterization and pathway reconstruction. We discovered four enzymes that enable de novo harmine biosynthesis in Nicotiana benthamiana and revealed how two closely related cytochrome P450s exhibit divergent regioselectivity, directing tryptamine towards either β-carboline or serotonin biosynthesis. Structural modeling and targeted mutagenesis pinpoint active-site residues that switch this regioselectivity, revealing a molecular basis for diversification of tryptamine metabolism. By combining distinct tryptamine pathways, we achieved de novo co-production of β-carbolines and DMT in N. benthamiana and P. harmala hairy roots without supplementing exogenous precursors. Together, these findings unlock β-carboline biosynthesis for future sustainable bioproduction with broad opportunities spanning medicine, crop protection, and biodiversity conservation.
Clinical research Peer-reviewed study published

Study links ketamine experience intensity to antidepressant outcomes

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes.
Why it matters ◈ Mixed
This study provides evidence that the intensity of psychedelic experiences during ketamine treatment correlates with antidepressant efficacy. The findings may inform clinical protocols, suggesting that subjective experience could be a relevant marker or mediator of therapeutic benefit. This could influence trial design, regulatory guidance, and insurance coverage for psychedelic-assisted therapies. However, further research is needed to clarify causality and optimize treatment parameters.
Neuroscience Review published

Review: Non-hallucinogenic psychedelic analogs for depression

Strukturne modifikacije psihodelika u cilju razvoja nehalucinogenih analoga sa antidepresivnim potencijalom
Why it matters ▲ Favorable
This review synthesizes evidence that structural modifications to classic psychedelics can yield non-hallucinogenic analogs retaining antidepressant and neuroplastic effects. The identification of compounds like AAZ-A-154, BOL-148, 25CN-NBOH, and TBG highlights a promising direction for safer, scalable therapeutics. If these findings translate to clinical efficacy, they could expand access and reduce regulatory and safety barriers for psychedelic-inspired treatments.
Introduction: Conventional antidepressants (SSRIs, SNRIs), although effective in treating classic forms of depression, exhibit limitations regarding slow onset of action and insufficient efficacy in patients suffering from treatment-resistant depression. Classic psychedelics demonstrate rapid and sustained effects by stimulating neuroplasticity via 5-HT2A receptors. However, their application is constrained by pronounced hallucinogenic effects. Aim: To review and systematize current scientific knowledge on the mechanisms of action of classic psychedelics, as well as to analyze structural modification strategies aimed at developing non-hallucinogenic analogs with potential antidepressant activity and an improved safety profile. Materials and Methods: A literature search of scientific databases – PubMed, MEDLINE, and Google Scholar – was conducted for the period from 2016 to 2026 using relevant keywords. Scientific papers investigating psychedelics, neuroplasticity, 5HT-2A receptors, and structural modifications were analyzed. Results: Specific structural modifications yielded analogs with reduced or completely eliminated hallucinogenic potential while preserving the stimulation of neuroplasticity and BDNF expression. Among tryptamines, bulky substitution of psilocin produced the analog AAZ-A-154. In the ergoline class, C2 bromination of LSD generated BOL-148 (2-bromo-LSD). For phenethylamines, modification of 25C-NBOMe (cyano group introduction and hydroxylation) developed the analog 25CN-NBOH. In ibogaine alkaloids, simplification of the polycyclic skeleton and relocation of the methoxy group yielded tabernanthalog (TBG), successfully eliminating hallucinogenic effects and cardiotoxicity. Conclusion: Rational design and structural modification of classic psychedelics enable the successful decoupling of antidepressant efficacy from hallucinogenic effects. Newly synthesized non-hallucinogenic psychoplastogens represent a highly promising class of future therapeutics that could enable safer, simpler, and more widely accessible management of depressive disorders.
Neuroscience New modeling method published

StaGIC enables improved inference of brain circuit heterogeneity from imaging

Multistage gradient-based whole-cortex modeling for joint inference of regional circuit heterogeneity and interregional structural connectivity
Why it matters ▲ Favorable
This work introduces a new computational method (StaGIC) for inferring regional circuit heterogeneity and structural connectivity from non-invasive neuroimaging data. While not directly about psychedelics, this approach could enhance mechanistic studies of how psychedelics alter brain network dynamics, support more precise biomarker development, and inform computational psychiatry models relevant to psychedelic clinical trials. The method's improved accuracy over diffusion MRI for long-range connections may be particularly valuable for research on distributed brain effects of psychedelic compounds.
Current non-invasive neuroimaging methods cannot directly resolve regional circuit heterogeneity and interregional structural connectivity, limiting mechanistic understanding of brain structure-function relationships and accurate whole-brain modeling. Here we introduce StaGIC (Staged Gradient-based Inference of Circuitry), a method that jointly infers regional circuit heterogeneity and model-constrained structural connectivity (SC) from resting-state functional connectivity (FC) and functional connectivity dynamics (FCD). Ablation and synthetic-recovery experiments show that staged optimization improves fits to functional data and ground-truth parameter recovery, with inferred SC remaining highly consistent across retained solutions from independent optimization runs. In human data, freely optimized regional parameters exhibit consistent relationships with cortical hierarchy across parcellations, while SC inference substantially improves FC reconstruction. In macaque and marmoset data, inferred SC shows stronger correlation with tracer-derived projections than diffusion MRI estimates, particularly for long-range connections. As a proof of concept in computational psychiatry, group-level models of major depressive disorder (MDD) reproduce MDD-associated FC differences and generate exploratory hypotheses about hierarchical differentiation and interregional projection organization. StaGIC thus provides a differentiable framework for inferring multiscale cortical organization from non-invasive functional imaging.
Neuroscience Review published

Review: Data‐Driven EEG‐fMRI Fusion for Latent Neural Inference

Data‐Driven EEG ‐ fMRI Fusion: From Multimodal Integration to Latent Neural Inference
Why it matters ◈ Mixed
This review synthesizes two decades of methods for combining EEG and fMRI data to infer latent neural processes, a technique increasingly relevant for understanding the brain's response to psychedelics. While not specific to psychedelics, advances in multimodal fusion could improve mechanistic insight in clinical trials and basic research. However, the lack of universal standards and interpretability challenges remain barriers to routine application in psychedelic studies.
Simultaneous electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) capture neural dynamics across complementary temporal and spatial scales, but analyzing them jointly is difficult: the two modalities differ in measurement mechanisms, temporal resolution, and neurovascular coupling. EEG‐fMRI fusion can be framed as an inverse problem, where the goal is to recover latent neural processes only partially observed through electrophysiological and hemodynamic signals. Here, we review data‐driven fusion methods published between 2000 and 2025, focusing on techniques that identify shared neural representations across modalities. We organize methods by fusion strategies (symmetric vs. asymmetric), methodological objectives (factorization vs. translation), and modeling assumptions (linear vs. nonlinear), and discuss evaluation metrics and visualization strategies in current use. A recurring finding is the absence of a universal validation standard and the difficulty of interpreting latent multimodal components. Across neurological, psychiatric, and cognitive applications, EEG‐fMRI fusion has revealed distributed network dynamics not accessible through unimodal analyses, though temporal misalignment, noise‐induced coupling, and model‐dependent interpretation remain persistent challenges. We close by discussing directions including nonlinear modeling, flexible coupling frameworks, and large‐scale group‐level fusion, and situate the field within a broader view of EEG‐fMRI fusion as a problem of latent neural inference.
Clinical research Peer-reviewed cohort study

BC study links prescribed safer supply to reduced depression, illicit use

Associations between receipt of prescribed safer supply and health and social outcomes in the short term: a prospective cohort study
Why it matters ◈ Mixed
This prospective cohort study from British Columbia provides early evidence that prescribed safer supply (PSS) may reduce depression and unregulated substance use among recipients. However, the short-term design and modest sample size limit generalizability, and no significant changes were observed in other health or social outcomes. The findings support further research and policy development for integrating PSS with broader support services, but do not directly address psychedelics or alter legal risk for psychedelic research or access.
BACKGROUND: British Columbia, Canada introduced clinical guidance to support the prescription of pharmaceutical alternatives to the toxic unregulated drug supply in 2020, also known as prescribed safer supply (PSS). This provincial prospective cohort study evaluates the associations between PSS receipt and self-reported health and social outcomes. METHODS: Data were collected in 2020-2021 using a longitudinal survey of people who had received a prescription or were seeking one (n = 161), with up to 5 time points per participant over 3 months. Generalised estimating equations were used to assess the effects of time-varying prescription exposure (yes/no) on outcomes over the follow-up period, controlling for encounters with police and bylaw officers, service use, social support, and sociodemographic characteristics. Outcomes included quality of life (EuroQOL-5D), depression (PHQ-2), anxiety (GAD-2), frequency of unregulated substance use, COVID-19 protective behaviours, and reliance on criminalized income sources. RESULTS: PSS receipt was negatively associated with depression (adj. b = -0.44, 95% CI= -0.81, -0.08) and frequency of unregulated substance use (adj. b = -0.23, 95% CI = -0.45, -0.014) over the study period. Independent of PSS receipt, there was no evidence of change in outcomes over the 12 weeks, except for a small increase in COVID-19 protective behaviours over time (adj. b = 0.004, 95% CI = 0.001, 0.007). DISCUSSION: Findings signal the potential promise of PSS, along with the need for improvement of existing service models. Further research is needed to inform the development of models that combine prescriptions with comprehensive services and supports to maximize positive outcomes.
Clinical research Review published

Review: Monoamine-targeting drugs for PTSD—mechanisms, efficacy, and gaps

Pharmacologic Rationale and Clinical Evidence for Treatments that Target Monoamine Dysregulation in Post-Traumatic Stress Disorder: A Narrative Review
Why it matters ◈ Mixed
This narrative review synthesizes the clinical evidence and pharmacologic rationale for monoamine-targeting drugs in PTSD, highlighting that only sertraline and paroxetine are approved in the US and parts of Europe, with other agents used off-label and with mixed results. The review underscores the limited efficacy of current treatments and the mechanistic gaps in addressing PTSD symptom clusters, which is highly relevant for researchers developing novel therapeutics—including psychedelic compounds that may act on monoaminergic systems. While not directly about psychedelics, the article frames the unmet need and biological rationale that underpins ongoing psychedelic PTSD trials.
Post-traumatic stress disorder (PTSD) can develop following exposure to a traumatic event and is characterized by the presentation of symptoms across four symptom clusters: intrusion (re-experiencing), avoidance, negative cognitions and mood, and alterations in arousal and reactivity. Post-traumatic stress disorder is associated with a considerable clinical, humanistic, and economic burden. There are only two approved pharmacological treatments for PTSD in the USA and certain European countries: the selective serotonin reuptake inhibitors, sertraline and paroxetine (approvals vary by country). Off-label and non-evidence-based treatments are frequently used in an attempt to address the spectrum of PTSD symptoms. Understanding the biological basis of PTSD can aid in understanding the efficacy and safety profiles of current on-label and off-label treatments for PTSD and is key to the development of effective treatment approaches. The aim of this article is to review the rationale, mechanisms of action, efficacy on diagnostic PTSD symptoms, and safety of drugs targeting monoamine dysregulation in PTSD. Research has indicated that dysregulation of norepinephrine (also known as noradrenaline), serotonin, and dopamine signaling may contribute to the presentation of PTSD symptoms across all four symptom clusters and impact the fear, stress, and reward processes. The monoamine system underlies several on-label and off-label pharmacological treatment approaches in PTSD, including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and atypical antipsychotics. Sertraline and paroxetine, together with off-label venlafaxine, have the greatest evidence for efficacy. Off-label risperidone and brexpiprazole have been studied in a large number of participants, with mixed results. By considering the unique monoamine receptor binding profiles of individual treatments, it may be possible to understand the mechanistic basis behind differences in the clinical profiles of each agent in the treatment of PTSD.
Clinical research Study announced

Psilocybin may improve difficult depression symptom, study finds

Psilocybin may improve a difficult-to-treat symptom of depression, study finds
Why it matters ▲ Favorable
New clinical research suggests psilocybin could address a challenging symptom of depression, which may inform future therapeutic applications and trial designs. While promising, the lack of detail on study design, endpoints, or regulatory context limits immediate impact for access or legal risk. This adds to the growing body of evidence supporting psychedelic-assisted therapies but does not yet shift policy or clinical practice.
Neuroscience Peer-reviewed study published

LSD and First Episode Psychosis Show Partial Neural Overlap, Study Finds

Reconsidering the Psychotomimetic Properties of LSD: Connectome-Based Classification Reveals Partial Overlap with First Episode Psychosis
Why it matters ◈ Mixed
This study provides new evidence that the neural effects of LSD partially overlap with those seen in first episode psychosis, particularly in attention and sensorimotor networks. This challenges simplistic views of LSD as a pure 'psychotomimetic' and highlights the importance of nuanced models for both psychiatric research and psychedelic medicine. The findings may inform risk assessments, trial design, and mechanistic hypotheses for both psychedelic therapy and psychosis research.
The acute effects of lysergic acid diethylamide (LSD) have long been compared to early psychosis. Despite this, no studies have compared the acute effects of LSD and psychosis on resting-state functional connectivity (RSFC) with parallel approaches. We used connectome-based classification, a data-driven method, to distinguish between medication-naïve, non-affective first episode psychosis (FEP) and the acute effects of LSD. Separate classifiers were trained to distinguish the acute effects of LSD from placebo and FEP patients from matched healthy controls. The LSD-placebo classifier was then validated on an external LSD-placebo dataset. The network-interaction classifiers with good discriminability were then applied across datasets to evaluate whether LSD-related connectivity patterns could classify FEP as being LSD-like and vice versa. Subsequently, we investigated univariate RSFC between select networks, based on which network-interactions the classifiers suggested might overlap in LSD and FEP. Cross-application of externally validated LSD-placebo classifiers revealed partial overlap between LSD and FEP, particularly involving the dorsal attention network (DAN) and sensorimotor network (SMN). Application of the most discriminant FEP-HC network-interaction classifiers revealed that LSD displayed select similarities with FEP. Univariate network analysis also supports between-network DAN and SMN dysconnectivity being a point of convergence. Our findings indicate that neural correlates of FEP might have select overlaps with changes in brain functioning produced by LSD. These results suggest serotonergic dysfunction might play a role in the early stages of psychosis and necessitate future studies directly comparing FEP and LSD.
Clinical research Peer-reviewed study published

Subjective psychedelic intensity predicts ketamine antidepressant outcomes

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes
Why it matters ▲ Favorable
Higher subjective psychedelic intensity during sublingual ketamine treatment is robustly linked to better antidepressant outcomes, independent of dose. This large, real-world cohort study supports the clinical relevance of first-person experience in ketamine therapy, suggesting that measuring and potentially optimizing subjective effects could improve treatment response. The findings may inform future trial designs, mechanistic research, and clinical protocols for psychedelic and ketamine-based interventions.
RATIONALE: Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. OBJECTIVES: To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. METHODS: In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. RESULTS: Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. CONCLUSIONS: Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.
Federal policy / Veterans Advocacy push

Veterans groups urge VA, Congress to prepare for FDA-approved psychedelics

Veterans groups urge VA, Congress to prepare for FDA-approved psychedelics for mental health treatment
Why it matters ▲ Favorable
Major veterans organizations are publicly calling on the VA and Congress to proactively plan for the integration of FDA-approved psychedelic therapies for mental health. This signals growing political and community pressure to ensure access and infrastructure for veterans, a key population in psychedelic medicine debates. The move could accelerate federal policy development, funding, and clinical adoption, and signals to industry and researchers that demand and advocacy are mounting.
Clinical research Peer-reviewed review published

Scoping review: Compassion and self-compassion in psychedelic studies

Compassion and psychedelics: a scoping review of self-compassion, compassion for others, and compassion-related processes
Why it matters ▲ Favorable
This scoping review synthesizes evidence that self-compassion increases are a consistent outcome of MDMA- and psilocybin-assisted therapy, with some support for compassion as a mediator of clinical change. The review highlights methodological gaps, including inconsistent measurement of compassion for others and limited mechanistic studies. This work informs future trial design and outcome selection, and supports the relevance of compassion as a therapeutic target in psychedelic research.
Introduction: Compassion and self-compassion are transdiagnostic processes relevant to psychological distress, shame, interpersonal functioning, and treatment engagement, and have received increasing attention in psychedelic research. Yet this literature remains dispersed across substances, populations, and study designs. This scoping review maps how compassion-related constructs have been conceptualized, measured, and interpreted in empirical studies of psychedelic and related psychoactive substances. Materials and Methods: Searches of Ovid MEDLINE ALL, APA PsycInfo, Embase, and Scopus identified empirical studies examining compassion, self-compassion, or related constructs in relation to psychedelic substances, MDMA, ketamine/esketamine, or psychedelic-adjacent interventions. Data were extracted on design, population, substance, compassion measure or theme, and the role of compassion as an outcome, mediator, predictor, or qualitative finding. Methodological quality was appraised using the Mixed Methods Appraisal Tool. Results: Forty-eight papers, represented by 49 appraised study entries, were included. Studies comprised clinical trials, naturalistic and ceremonial studies, surveys, qualitative interviews, and mixed-methods designs. Evidence was strongest for self-compassion, particularly in MDMA-and psilocybin-assisted therapy. Quantitative studies supported acute, post-acute, and longer-term self-compassion increases, and self-compassion was examined as an outcome, mediator of clinical change, and potential predictor of experience quality. Compassion for others more often emerged as an acute outcome or qualitative theme but was rarely assessed using validated quantitative measures. Few studies assessed compassion from others or fears of compassion. Measures varied widely, and most studies used the Self-Compassion Scale total score. Deleted: ped Discussion: Compassion, particularly self-compassion, is a promising but underdeveloped explanatory construct in psychedelic research. Greater conceptual clarity, validated measurement of other-directed compassion, and prospective mechanistic studies are needed.
Clinical research Retrospective study published

Dissociation in Esketamine Therapy Not Linked to Antidepressant Efficacy

Beyond Side Effects: The Role of Dissociation in Esketamine Therapy for Treatment-Resistant Depression
Why it matters ◈ Mixed
This study finds that while dissociation is common during esketamine therapy and more pronounced in patients with trauma-related comorbidities, it does not diminish the antidepressant effect of esketamine for treatment-resistant depression. The transient association between dissociation and short-term mood worsening suggests a need for brief integration support, but dissociation itself appears to be an epiphenomenon rather than a barrier to clinical benefit. These findings inform clinical practice and safety monitoring for esketamine and may have implications for other psychedelic therapies.
Dissociation is a common acute effect of esketamine and has been hypothesized to influence antidepressant outcomes in treatment-resistant depression. However, its clinical relevance, particularly among patients with trauma-related comorbidities, remains uncertain. We conducted a retrospective chart review of 51 adults with treatment-resistant depression treated with intranasal esketamine in a specialized outpatient esketamine unit at Lev Hasharon Mental Health Center, Israel (2021–2025), where treatment was delivered according to a structured induction and maintenance protocol. Baseline trait dissociation was assessed using the Dissociative Experiences Scale-II (DES-II), and session-related state dissociation was measured weekly with the Peritraumatic Dissociative Experiences Questionnaire (PDEQ). Depressive severity was monitored via QIDS-SR16 at and throughout treatment. Associations between dissociation and depressive outcomes were examined using correlation and linear mixed-effects models. Higher trait dissociation was associated with greater depressive severity (r = .28, p = .03) and was elevated among patients with trauma-related comorbidities. Despite this, dissociation did not affect the pace or magnitude of improvement in depressive symptoms over weeks of treatment. Trait and state dissociation were moderately correlated (r = .310, p = .038), indicating that individuals with higher trait dissociative tendencies experienced stronger in-session dissociation. While session-level dissociation showed a trend-level association with higher depressive scores at the following visit (p ≈ .06), it did not diminish antidepressant efficacy. Elevated trait dissociation and trauma-related psychopathology amplify initial depressive burden but do not hinder esketamine’s effect. The transient link between in-session dissociation and short-term mood worsening echoes patterns seen in psychedelic-assisted therapy and highlights the value of brief, post-session integration support. Dissociation appears to be an epiphenomenon rather than a determinant of treatment success.
Industry / Clinical research Pipeline update

Optimi Health amends Phase 2b, plans Phase 3, and US IND filings for psychedelics

Optimi Health Updates Psychedelic Clinical Pipeline with Amended OPTI-101 Phase 2b, Planned OPTI-201 Phase 3 and U.S. IND Filings
Why it matters ▲ Favorable
Optimi Health's update signals continued momentum in late-stage psychedelic clinical trials, with a Phase 2b amendment, planned Phase 3, and US IND filings. This reflects growing industry commitment to advancing psychedelic therapeutics toward regulatory approval in the US. The move may increase competitive pressure and provide new data for researchers and clinicians, though details on compounds and indications are not specified.
Clinical research Clinical guidance published

Clinical review: Hospital management of ketamine use and complications

Management of the hospitalized patient who uses ketamine
Why it matters ◈ Mixed
This review highlights the growing clinical burden of ketamine use and its complications in hospital settings, reflecting both increased medical and nonmedical use. It outlines acute and chronic management strategies, identifies gaps in evidence for withdrawal treatment, and underscores the need for harm reduction and early intervention for ketamine use disorder. The findings are relevant for clinicians, researchers, and policymakers as ketamine prescribing expands and hospital encounters rise.
Ketamine use is increasing across medical and nonmedical settings, with expanding off-label outpatient and telehealth-based prescribing, leading hospitalists to care for patients with acute ketamine intoxication, withdrawal, and chronic complications. Acute ketamine intoxication presents as a dissociative toxidrome managed with supportive care, low-stimulation environments, and benzodiazepines for agitation. Withdrawal is characterized primarily by neuropsychiatric symptoms, with limited evidence guiding treatment beyond symptomatic management. Chronic use may result in multisystem complications, including uropathy, cholangiopathy, cardiomyopathy, and neuropsychiatric sequelae, which can mimic common inpatient conditions. Hospitalization represents a key opportunity to identify ketamine use disorder, initiate harm reduction strategies, and manage complications.
State legal challenge Oral arguments heard

Psilocybin home services case argued at UO law school

Why it matters ◈ Mixed
This case tests the legal boundaries of Oregon's psilocybin services law, specifically whether home-based facilitation is permitted under current regulations. The outcome could significantly affect access models, business operations, and regulatory clarity for psilocybin services in Oregon and potentially inform other jurisdictions. Stakeholders should monitor for precedent-setting implications on service delivery and legal risk.
Neuroscience Review published

GABAergic neuron dysfunction reviewed in psychiatric disorders

The role of GABAergic inhibitory neurons in psychiatric disorders: insights from cellular and genomic studies
Why it matters ◈ Mixed
This review synthesizes the latest multi-omic and cellular evidence linking GABAergic interneuron dysfunction to major psychiatric disorders, highlighting both the complexity and the promise of cell-type-specific approaches for future therapeutics. While not directly about psychedelics, the findings are highly relevant for researchers exploring mechanisms of action and potential targets for psychedelic interventions, especially as these compounds may modulate E/I balance. The review underscores the need for more precise, subtype-specific clinical strategies, which could inform future trial design and biomarker discovery in the psychedelic field.
The excitatory/inhibitory (E/I) balance is fundamental for proper neural circuit function, and its disruption has emerged as a convergent mechanism across multiple psychiatric disorders. Primarily, GABAergic inhibitory neurons play essential roles in regulating network dynamics, necessary for physiological, cognitive and emotional processing. This review synthesizes current evidence from genetic, epigenetic, transcriptomic, and cellular studies implicating GABAergic neuron dysfunction in autism spectrum disorder (ASD), major depressive disorder (MDD), schizophrenia (SCZ), and bipolar disorder (BD). We first define the E/I balance and its functional implications for neural circuit dynamics and define the main GABAergic subtypes: Parvalbumin (PVALB), Somatostatin (SST), Vasoactive Intestinal Peptide neurons (VIP) and Lysosomal Associated Membrane Protein Family Member 5/Paired Box 6 positive GABAergic neurons (LAMP5/PAX6+). We then examine GABAergic involvement across distinct neurodevelopmental phases, highlighting critical windows of vulnerability where perturbations can produce lasting consequences. Subsequently, we synthesize and discuss disorder-specific evidence across ASD, MDD, SCZ, and BD, which share substantial clinical overlap and converging genetic architectures. High-resolution single-cell and spatial transcriptomic approaches have fundamentally transformed our understanding, revealing that rather than a uniform global deficit, these conditions exhibit localized, cell-type-specific dysregulations that target distinct interneuron subpopulations in a region- and disorder-dependent manner. Methodological advances now enable integration of genomic risk with cell-type-specific transcriptomic and epigenomic profiles, though challenges remain in translating these findings to clinical applications. Despite promising preclinical evidence, clinical trials targeting GABAergic signaling have yielded mixed results, underscoring the complexity of inhibitory circuit dysfunction and the need for more precise, subtype-specific therapeutic strategies. Leveraging these high-resolution, multi-omic insights holds significant promise for refining psychiatric nosology, discovering reliable biomarkers, and advancing targeted therapeutics and personalized medicine.
Neuroscience Review published

PVN identified as hub for pain-emotion comorbidity in new review

Hypothalamic paraventricular nucleus: A central hub for pain-emotion comorbidity
Why it matters ▲ Favorable
This review synthesizes evidence positioning the hypothalamic paraventricular nucleus (PVN) as a central integrator of pain and emotional disorders, highlighting neuropeptide systems relevant to both. Understanding PVN circuitry may inform more precise interventions for chronic pain and mood comorbidity, a key target population for psychedelic and neuromodulatory therapies. While not directly addressing psychedelics, the mechanistic focus on stress, neuroinflammation, and neuromodulation is highly relevant for translational research and trial design.
Chronic pain and emotional disorders, particularly depression and anxiety, are highly comorbid and mutually reinforcing, but their shared mechanisms remain unclear. This review highlights the hypothalamic paraventricular nucleus (PVN) as a key hub integrating stress, pain, and emotion, with a focus on two opposing neuropeptide systems: corticotropin-releasing hormone (CRH) and oxytocin (OXT). Chronic pain and stress promote sustained CRH activation and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, thereby favoring pain sensitization and negative affect, whereas OXT exerts analgesic, anxiolytic, and antidepressant effects. We propose that CRH-driven HPA hyperactivity coupled with relative OXT insufficiency is the core mechanism underlying pain-emotion comorbidity, further amplified by neuroinflammation and immune-neural crosstalk. We also summarize current pharmacological and non-pharmacological interventions targeting this circuitry and discuss emerging directions, including single-cell and spatial transcriptomics, circuit-specific manipulations, brain-penetrant ligands, and stratified neuromodulation. The PVN-centered framework may facilitate the development of precise therapies for patients with chronic pain and emotional disorders.
Clinical research Peer-reviewed study published

Study: Not all psychedelic self-transcendence linked to positive outcomes

Multidimensional Self-Transcendent Experiences in Psychedelic Use: Distinct Associations with Mindset, Affect, and Positive Effects
Why it matters ◈ Mixed
This study provides evidence that only certain types of self-transcendent experiences—those rich in positive affect and connection—are consistently associated with psychological and therapeutic benefits following psychedelic use. The findings suggest that mindset and intention at ingestion may shape the quality and impact of these experiences, which has implications for clinical trial design, therapeutic protocols, and harm reduction. The nuanced distinction between types of self-transcendence could inform both research endpoints and practitioner training.
Self-transcendent experiences are recognized as potent facilitators of well-being across contemplative, spiritual, and healing practices, and are increasingly emphasized in psychedelic use and psychedelic-assisted therapies. Their phenomenology, however, remains incompletely delineated. This study sought to clarify higher-order dimensions of psychedelic-occasioned self-transcendent experiences and examine whether distinct types of experiences have psychological significance. In an online cross-sectional study, adults reported on a prior experience with psilocybin, 3,4-methylenedioxymethamphetamine (MDMA) or cannabis. Given small observed associations between substance type and self-transcendent experience, this secondary data analysis was conducted on the pooled sample (N = 397). An exploratory factor analysis identified higher-order dimensions of self-transcendent experience, and regression analyses examined their associations with mindset at ingestion, acute negative experiences during, and persisting positive effects. Two interrelated but distinct factors emerged. The Connection and Positive Emotions factor (feelings of connection and interrelatedness, positive and self-transcendent emotions) was associated with mindset prior to use (spiritual–prosocial motivations, therapeutic/healing purpose, clarity of intentions, state of surrender, less apprehension), lower negative affect during the experience, and more positive persisting effects. The Time, Space, and Self-Transcendence factor (loss of sense of self, distortions in time/space, ineffability) was also linked to spiritual–prosocial motivations and surrender, but was associated with greater apprehension and recreational intentions, more negative affect, and had no association with positive persisting effects. Results support a multidimensional conceptualization of self-transcendent experience, highlighting that only certain types—particularly affectively positive, connection-rich ones—appear linked to psychological and therapeutic benefit.
Clinical research Peer-reviewed RCT published

RCT: Psilocybin alters sleep neurophysiology in MDD/AUD patients

Psilocybin induces delayed and dynamic changes in human sleep neurophysiology: Results from a randomized controlled trial of psilocybin assisted therapy in patients with comorbid major depressive and alcohol use disorder
Why it matters ▲ Favorable
This randomized controlled trial provides new evidence that psilocybin-assisted therapy induces delayed and dynamic changes in sleep neurophysiology in patients with comorbid major depressive and alcohol use disorders. The findings highlight that sleep EEG may serve as a sensitive biomarker for neurophysiological changes post-psilocybin, with implications for understanding therapeutic mechanisms and optimizing treatment protocols. While not directly regulatory, these results are relevant for researchers designing future trials and for clinicians interested in the broader neurobiological effects of psychedelic therapy.
Abstract Rationale Psilocybin has demonstrated therapeutic potential for major depressive disorder (MDD) and alcohol use disorder (AUD). However, its effects on sleep neurophysiology, particularly beyond the acute pharmacological period, remain poorly understood. Objectives To characterise the acute and post-acute temporal dynamics of sleep neurophysiology following psilocybin-assisted therapy in individuals with comorbid MDD and AUD. Methods In a randomised, placebo-controlled trial, 40 participants (psilocybin: n = 22; placebo: n = 18) underwent home-based sleep electroencephalographic (EEG) monitoring for three nights preceding and seven nights following administration. Longitudinal changes in spectral activity, sleep architecture, and sleep continuity were examined using nonlinear mixed-effects models. Results Significant treatment-by-night interactions revealed delayed, nonlinear alterations in sleep neurophysiology following psilocybin administration, with limited acute effects. NREM slow-wave activity (SWA), NREM sigma, REM sigma, and REM beta exhibited distinct curvilinear trajectories, reaching local minima (SWA) or maxima (sigma and beta) approximately 3–4 nights after administration. Sleep efficiency and total sleep time increased during the first three post-treatment nights, whereas sleep architecture, REM density, sleep onset latency, and delta sleep ratio remained largely unchanged. On the first post-treatment night, increased sleep efficiency was the only observed change, with no significant spectral or architectural alterations. Conclusions Psilocybin-assisted therapy induces delayed, dynamic alterations in human sleep neurophysiology extending beyond the acute pharmacological period. These findings suggest that sleep EEG may provide a sensitive measure of evolving neurophysiological processes following psilocybin administration.
Clinical research Thesis published

Multi-study thesis analyzes transformative strategies in trauma therapy incl. psychedelics

Integrating Transformative and Existential Strategies into Trauma-Focused Psychotherapy: A Multi-Study Analysis of EMDR, 3MDR, and Psychedelic-Assisted Group Therapy
Why it matters ▲ Favorable
This thesis synthesizes qualitative and mixed-methods research on trauma therapies, including a scoping review of psychedelic-assisted group therapy, highlighting the potential for existential and transformative strategies to address deeper layers of suffering beyond symptom reduction. While not a pivotal trial or regulatory event, it provides valuable context for clinicians and researchers seeking to integrate psychedelic modalities with established trauma-focused approaches, and underscores the importance of meaning-making and group dynamics in therapeutic outcomes.
This thesis explores the question: “Can incorporating transformation strategies within trauma therapies help patients reach deeper existential aspects of their suffering and lead to more effective therapy?”, “Does interpersonal interaction (either therapeutic relationship with a therapist or group dynamics in group psychedelic assisted therapy (PAP)) facilitate the therapeutic process?”, and “How does transformation strategies contribute to accessing deeper layers of pain and meaning in therapy?”. Chapter 1 begins with an introduction, presenting the need for more effective treatments that go beyond symptom reduction to address the deeper layers of patient suffering, given that structured manualized medical-model approaches are not effective for all patients. It then introduces the concepts of existential and transformation strategies/approaches in psychotherapy. Chapter 2 presents a secondary qualitative analysis of 18 psychiatric outpatients with suicidal ideation who participated in 12 sessions of web-based EMDR, a trauma-focused therapy. EMDR was delivered flexibly, with attention to important transformation processes as they arose. Over the course of treatment, three existentially grounded descriptive themes emerged: (1) Self-against-self, (2) The anguish of being, and (3) Existential despair. The findings suggest that many individuals with chronic suicidality face profound existential crises—an aspect rarely addressed in manualized therapies. Chapter 3 is a mixed methods case study demonstrating the personalized use of Multi-modal, Motion-assisted Memory Desensitization and Reconsolidation (3MDR) adapted for the treatment of PTSD, dissociative subtype, with a person with dissociative identity disorder (DID). The standardized protocol was modified through incorporating a titrated, transformative and attachment-informed approach, which was necessary to navigate challenges such as severe relational trauma, emotional dysregulation, and dissociative symptoms preventing access to explicit memories. In addition to improvements in PTSD, anxiety, and depression symptom scores, physical symptoms, and functioning, she reported resolution of existential themes (e.g., increased sense of personal agency) and post-traumatic growth. Analysis of interviews recorded during the follow-up sessions revealed descriptive themes: (1) Synergistic components; (2) Cooling the symptoms of stress and overwhelm; and (3) The joy of self-discovery, capacity and growth. In addition to symptom improvement, the therapeutic process became a pathway for self-discovery and growth, allowing her to be more present in the moment and to reconnect with her body as a source of wisdom. These developments align closely with the most fundamental existential concepts, particularly responsibility, freedom, and the search for meaning. Chapter 4 presents a scoping review of 30 studies on psychedelic-assisted group therapy, including the use of LSD, psilocybin, ketamine, DMT, and MDMA. The majority of the studies used an inner-directed approach to psychotherapy to capitalize on the unique characteristics of psychedelic substances to overcome psychological defenses and improve access to unconscious psychic material. Reported outcomes frequently included profound spiritual or mystical experiences, increased social connectedness, and enriched emotional expression. The findings also indicated improvements such as reduced symptoms of depression, anxiety, and trauma, along with increased self-compassion and access to unconscious content. Overall, the results were largely positive. This therapeutic model emphasizes the participant’s inner healing intelligence (IHI) as the main driver of change, with the therapeutic relationship and group processes supporting self-directed healing and growth (O’Donnell et al., 2024). Chapter 5 concludes with a discussion of the previous chapters, including limitations and implications for future research. In this thesis, the common thread is how
Clinical research Scoping review announced

Scoping review to map ketamine-augmented psychotherapy for depression

The Impact of Ketamine-Augmented Psychotherapy on Neurocognitive Factors in Unipolar Depressive Disorders: A Scoping Review
Why it matters ◈ Mixed
This scoping review will systematically map the evidence on neurocognitive outcomes of ketamine-augmented psychotherapy (KAP) in unipolar depression. While it will not provide pooled efficacy estimates, it will clarify the research landscape, identify methodological gaps, and inform future clinical trial design. This is a useful resource for researchers and clinicians, but does not itself change access, legal status, or regulatory policy.
1. Background and rationale Unipolar depressive disorders are associated with substantial symptom burden and functional impairment. Global burden-of-disease analyses document the considerable population-level impact of depressive disorders (Rong et al., 2025). In Germany, nationwide outpatient claims data indicate an increase in recorded depression diagnoses over time; such administrative trends should not be equated with changes in the underlying population prevalence (Steffen et al., 2020). The diagnostic experience and social framing of depression have also been examined, underscoring the complexity of how depressive suffering is understood and classified (Petersen & Madsen, 2017). Beyond affective symptoms, unipolar depression is associated with neurocognitive difficulties affecting attention, processing speed, learning, memory, inhibitory control, cognitive flexibility, and other executive functions. These difficulties are clinically relevant because cognitive deficits can be linked to impaired everyday functioning (McIntyre et al., 2013). Cognitive and psychosocial limitations may persist even after symptomatic response to conventional antidepressant treatment (Papalexi et al., 2022). Accordingly, neurocognitive symptoms constitute an important treatment target, as reflected in research reviewing therapeutic approaches to cognitive dysfunction in unipolar depression (Salagre et al., 2017). Ketamine and esketamine have been investigated as rapidly acting antidepressant interventions, particularly in major depressive disorder and treatment-resistant depression (TRD). The selected publication window begins in 2000, the year of an early placebo-controlled clinical study reporting antidepressant effects of ketamine in depressed patients (Berman et al., 2000). This starting date is a pragmatic methodological boundary, not a claim that ketamine or cognition research began in that year. This review focuses specifically on ketamine-augmented psychotherapy (KAP), defined as a protocol-specified combination of ketamine or esketamine administration with a structured psychotherapeutic intervention. Routine monitoring or non-specific supportive contact alone does not establish KAP. Because psychotherapy may be incompletely indexed in bibliographic records, the primary search will not require psychotherapy terms; eligibility screening will establish whether structured psychotherapy was delivered. The evidence may vary across ketamine protocols, psychotherapeutic approaches, cognitive instruments, assessment times, populations, and comparators. A scoping review is therefore appropriate to characterize the breadth of research and identify gaps rather than produce a single pooled efficacy estimate. Reporting will be guided by PRISMA-ScR and the JBI approach to scoping reviews. 2. Objectives and review question Primary objective: systematically map published evidence on objective and subjective neurocognitive changes in adults with unipolar depressive disorders receiving protocol-defined ketamine-augmented psychotherapy, and characterize the studies, populations, interventions, measurements, and comparison conditions represented. Review question: How do objectively and subjectively assessed neurocognitive factors change among adults with unipolar depressive disorders undergoing ketamine-augmented psychotherapy, and what study, population, intervention, and comparator characteristics are represented in the existing literature? Secondary mapping objectives include identifying studied cognitive domains, measures and assessment time points; describing ketamine/esketamine and psychotherapy protocols; distinguishing TRD populations; and locating evidence clusters and gaps. A comparator is not required for inclusion. 3. Eligibility criteria: Population–Concept–Context (PCC) Eligibility will be assessed against the Population–Concept–Context framework and prespecified study-design criteria rather than inferred from search filters. Scientific publi
Clinical research Research profile

AI-guided precision therapeutics for depression at PreDIC, Taiwan

Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression
Why it matters ▲ Favorable
This profile highlights a leading center integrating AI, neuroimaging, and advanced therapeutics—including psychedelics and ketamine—for treatment-resistant depression in Taiwan. The work advances precision psychiatry and may inform global standards for staging and matching patients to novel interventions. The center's adoption of psychedelics as emerging treatments signals growing clinical and research interest in Asia, with implications for access, technology transfer, and international collaboration.
Cheng-Ta Li, MD, PhD, has devoted his career to a deceptively simple question: why do patients with apparently similar depression follow such different paths, and can psychiatry learn to tell them apart before treatment begins? A psychiatrist and neuroscientist, he is Professor at the School of Medicine and Institute of Brain Science of National Yang Ming Chiao Tung University and directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital. Opened in June 2022 as Taiwan's first center devoted to precision care for depression, PreDIC concentrates on treatment-resistant depression (TRD) and has since recorded more than 20,000 patient visits. Its guiding idea is that treatment resistance is not a yes-or-no verdict but a continuum, one that can be staged by severity and degree of refractoriness. To give that idea clinical form, Dr. Li and his team built AI-PreDIC®, a patented platform that reads clinical data alongside EEG and FDG-PET to estimate where each patient stands, an early step toward bringing TRD staging into routine practice. The center rests on a long record of research. His 2014 randomized sham-controlled trial in Brain was among the first large trials of theta-burst stimulation for refractory depression, and his group went on to help establish theta-burst stimulation, repetitive transcranial magnetic stimulation, and low-dose ketamine and esketamine in Taiwanese psychiatry. His population studies have shown, among other findings, that TRD runs strongly in families. Today his attention turns to the brain networks through which specific treatments act, to TMS-EEG measures of cortical excitation and inhibition, to imaging biomarkers and machine learning that might match patients to therapies, and to emerging treatments such as psychedelics. The author of more than 300 peer-reviewed publications, he has carried this science into patents, technology transfer, clinical consensus, and professional training. He is also founding President of the Taiwanese Society of Brain Stimulation and has served as Secretary General of the Asian College of Neuropsychopharmacology. In this Genomic Press Interview, he reflects on the patients and the early skepticism that drew him to brain stimulation, the mentors who shaped his scientific values, and his hope of moving depression care from trial and error toward precision.
Clinical research Peer-reviewed review published

Review: Rapid antidepressant effects of anesthetic and perioperative drugs

Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries
Why it matters ◈ Mixed
This narrative review synthesizes the clinical and mechanistic evidence for rapid-acting antidepressant effects of anesthetic and perioperative drugs, with ketamine and esketamine showing the strongest clinical evidence for rapid symptom relief in treatment-resistant depression and acute suicidality. Nitrous oxide and other agents show early promise but lack robust data. The review highlights the need for agent-specific monitoring and underscores the translational gap between preclinical mechanisms and clinical outcomes, which is critical for researchers, clinicians, and policymakers evaluating new rapid-acting interventions.
Rapid symptom relief remains an important unmet need in treatment-resistant depression (TRD) and in depressive episodes accompanied by acute suicidal ideation or behavior. This narrative review examines anesthetic and perioperative drugs that have been proposed as rapid-acting antidepressants. N-methyl-D-aspartate (NMDA)-receptor blockade, increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput, and brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB)–mechanistic target of rapamycin complex 1 (mTORC1) signaling provide a predominantly preclinical account of rapid synaptic plasticity, and randomized trials show improvement in depressive symptoms within hours to days. Ketamine and esketamine have the strongest evidence, with variable response- and remission-rates and limited sustained duration of benefit across studies. Intravenous ketamine can rapidly reduce suicidal ideation, but it does not replace comprehensive suicide-prevention care. Intranasal esketamine reduces depressive symptoms in TRD and in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior; a separate effect on suicidal ideation or suicide prevention has not been demonstrated. Nitrous oxide has encouraging phase 2 evidence, though the primary-outcome point estimate was modest with wide confidence intervals and narrowly missed conventional statistical significance. Evidence for propofol and volatile anesthetics remains limited to small experimental studies. Tramadol is better viewed as a pharmacologic clue than as an antidepressant treatment. Clinical translation requires agent-specific monitoring, defined maintenance and stopping rules, and attention to cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks. This is a narrative review without formal meta-analysis; findings should be interpreted considering heterogeneous trial designs and variable sample sizes.
Neuroscience Published study

Deep learning improves calcium imaging analysis for neuronal dynamics

Deep learning classifies calcium imaging dynamics using time-series representations
Why it matters ▲ Favorable
This study introduces a deep learning framework that enhances the reliability and scalability of calcium imaging data analysis, a key tool in neuroscience and pharmacology. Improved classification of neuronal activity could accelerate preclinical research on psychedelics and other neuroactive compounds by providing more robust and generalizable data analysis. While not directly a regulatory or clinical milestone, this methodological advance may indirectly benefit drug discovery and mechanistic studies in the psychedelic field.
Abstract Calcium imaging data are challenging to analyze reliably because signal extraction and segmentation can vary across recordings and acquisition settings. This study aims to develop a segmentation-agnostic deep learning framework for classifying neuronal dynamics across different spatial resolutions and acquisition frequencies. Fluorescence time series were transformed into compact, fixed-size matrices based on quantile transition patterns. These standardized representations were classified using convolutional neural networks. Performance was evaluated using stratified hold-out testing and receiver operating characteristic analysis. Multiple quantile-based representations were evaluated under whole-image and grid-based preprocessing strategies, and robustness was assessed under reduced temporal resolution and controlled noise perturbations. Across all preprocessing strategies and representation variants, the framework achieved strong and consistent classification performance, achieving precision = 0.99, sensitivity = 0.99, and specificity = 0.99 in independent validation. Classification performance remained high under moderate noise perturbations but declined progressively as perturbation magnitude increased. The proposed segmentation-agnostic framework provides a robust, scalable, and generalizable strategy for analyzing calcium imaging dynamics, enabling efficient characterization of neuronal activity in pharmacological and systems neuroscience applications.
Neuroscience Review published

mGlu2 antagonists may boost scopolamine's antidepressant effects

Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression
Why it matters ▲ Favorable
This review highlights a novel mechanism—mGlu2 receptor antagonism—for enhancing scopolamine’s rapid antidepressant effects while reducing cognitive side effects. While not a psychedelic, scopolamine’s rapid action and the mechanistic overlap with glutamatergic modulation are highly relevant for next-generation depression therapeutics. The findings could inform future clinical trial designs and targets for both psychedelic and non-psychedelic rapid-acting antidepressants.
Conventional antidepressants remain not effective enough to treat depression, with only 30–40% of patients achieving full remission. This has intensified the call for a deeper understanding of depression’s biological mechanisms, moving beyond the traditional monoaminergic hypothesis. The cholinergic hypothesis, first proposed in the 1970s, has gained renewed interest due to the rapid antidepressant effects of scopolamine, a muscarinic receptor antagonist. Despite its potential, scopolamine’s side effects hinder clinical use. Recent research highlights dysregulation of glutamatergic neurotransmission in depression, and targeting metabotropic glutamate (mGlu) receptors presents a novel therapeutic strategy. Evidence suggests that mGlu 2 receptors play a critical role in the rapid antidepressant effect, and mGlu 2 receptor antagonists possess antidepressant-like potential in animal models of depression. Importantly, mGlu 2 antagonists such as LY341495 or the mGlu 2 negative allosteric modulator VU6001966, when coadministered with scopolamine, enhance scopolamine’s antidepressant efficacy while reducing cognitive side effects. Data indicate that ligands of other mGlu receptor subtypes, including group III mGlu receptors, may also enhance the therapeutic effects of scopolamine while avoiding undesirable effects. This review study underscores the urgent need for innovative approaches to depression treatment, emphasizing the importance of mGlu 2 as a promising target for future therapeutic development, especially as co-treatment with low doses of scopolamine. The mechanism related to the potentiation of the antidepressant effect of scopolamine by VU6001966, including activation of AMPA receptors and BDNF–TrkB signaling, is also discussed.
Neuroscience Review published

Review: Revisiting serotoninergic mechanisms in antidepressants & psychedelics

From antidepressants to psychedelics: revisiting the pharmacology of so-called serotoninergic treatments
Why it matters ▲ Favorable
This review challenges the traditional view that SSRIs and psychedelics act primarily via serotonin transporter inhibition, highlighting the role of TrkB as a potential unifying target for antidepressant effects. This mechanistic insight could inform future drug development, trial design, and biomarker selection in psychedelic research. It also suggests new directions for understanding efficacy and safety profiles in both established and emerging psychiatric treatments.
Recent years have seen a resurgence of interest in serotoninergic psychedelics as potential treatment for diverse psychiatric disorders. Here, we will delve into the molecular mechanisms of drugs used to treat depression and obsessive-compulsive disorder (OCD), with implications on the mechanism of action of so-called ''serotoninergic'' psychedelics as well as selective serotonin reuptake inhibitors (SSRIs). In particular, we argue that the pharmacokinetic and pharmacodynamic properties of SSRIs suggest that the inhibition of the serotonin transporter (SERT) alone does not provide a comprehensive account of their clinical effects. On the contrary, the SSRI posology required to treat depression and OCD is consistent with their major molecular target(s) displaying an SSRI affinity much lower than SERT. Such is the case for the tyrosine receptor kinase B (TrkB), recently described as a putative target for drugs with antidepressant effects. TrkB might thus provide a unifying framework for understanding the therapeutic effects of antidepressant drugs. We finally discuss the pharmacological implications of this hypothesis on the therapeutical potential of psychedelics.
Industry New program announced

The Mend launches ketamine depression program in Bangkok

The Mend announces new ketamine programme for depression in Bangkok
Why it matters ▲ Favorable
The Mend's launch of a ketamine program for depression in Bangkok signals growing international interest in psychedelic-assisted therapies and expanding access in Southeast Asia. While details on the clinical model and regulatory pathway are not provided, this move could influence regional policy and market development. Researchers and operators should monitor for regulatory responses and potential data sharing from this program.
Clinical research Perspective published

Perspective questions ketamine trial design in depression research

Ketamine after the hype: What are we actually treating?
Why it matters ◈ Mixed
This perspective highlights critical gaps between clinical trial evidence for ketamine and real-world treatment decisions in depression care. It urges the field to refine definitions of treatment-resistant depression, improve patient selection, and focus on patient-important outcomes. Researchers and clinicians should heed these methodological critiques to enhance the translational value of future trials and ensure that evidence meaningfully guides practice.
ObjectiveKetamine has transformed depression research by demonstrating rapid antidepressant effects through mechanisms beyond monoaminergic neurotransmission. This perspective argues that the ketamine story also provides an opportunity to re-examine broader conceptual and methodological challenges in depression research, including the definition of treatment-resistant depression, patient selection, recruitment strategies, outcome measures and the interpretation of clinical trials.ConclusionsRather than questioning whether ketamine works, this perspective asks whether depression research generates evidence that meaningfully informs clinical decisions. Differences in patient populations, recruitment strategies, expectations and outcome measures may substantially shape treatment estimates. More precise clinical characterisation and greater emphasis on patient-important outcomes may help bridge the gap between efficacy demonstrated in trials and the choice of treatment for individual patients.
Neuroscience Meta-analysis published

Meta-analysis clarifies context dependence in psychedelic critical period reopening

The social conditioned place preference assay is sensitive to drug dose, training regimen, and social context
Why it matters ◈ Mixed
This meta-analysis addresses conflicting findings about psilocybin's ability to reopen social reward learning critical periods, attributing discrepancies to methodological differences rather than a true failure to replicate. The results reinforce the importance of context, dose, and training regimen in interpreting preclinical psychedelic studies. This adds nuance for researchers designing translational studies and may inform future clinical trial protocols, but does not directly impact legal or regulatory status.
Beginning in the 1960s, researchers have understood that one of the unique properties of psychedelic drugs is that their effects are modified by the context in which they are taken (also known as their set and setting dependence). To date, 7 different studies have shown that critical period reopening is a shared property across psychedelic drugs, including ketamine, MDMA, psilocybin, LSD, and ibogaine. Moreover, the context dependence of psychedelics effects has been recapitulated for both MDMA and ketamine. Recently, Lu et al., Nature Neuroscience 2026 (PMID: 42972049) have claimed that psilocybin does not reopen the social reward learning critical period, which the authors interpret as a failure to replicate previously published results. Here, we re-analyzed results across three published datasets (Nardou et al., Nature 2019; Nardou et al., Nature 2023; Lu et al., Nature Neuroscience 2026) in order to compare the impact of dose, training regimen, and social context on the social conditioned place preference (social CPP) assay. Our analysis reveals that methodological modifications likely account for Lu and colleagues inability to reopen the social reward learning critical period with psilocybin. Nevertheless, because their results recapitulate previous findings that psychedelics effects are context dependent, they support rather than challenge the growing literature demonstrating that psychedelics reopen critical periods.
Neuroscience Meta-analysis published

Meta-analysis: Self arises from shifting coalitions in the brain

"The self" as shifting coalitions of brain systems in a continuous configuration space
Why it matters ◈ Mixed
This large meta-analysis challenges the idea of a single neural core for self-related processing, instead proposing a distributed, dynamic model. For psychedelic research, this supports theories that altered states modulate self-experience by shifting coalitions of brain systems, not by targeting a single region. The findings may inform future mechanistic studies and interpretation of neuroimaging in psychedelic trials, but have limited direct impact on law or clinical access.
Philosophers and psychologists distinguish many forms of self, yet neuroimaging results often implicate a shared core in the cortical midline or insula. We propose self-related processing arises from shifting coalitions of distributed brain systems, without a core. In a meta-analysis of 912 neuroimaging publications, titles and abstracts clustered into ten forms, including autobiographical memory, body ownership and interoception. No single location was significant in all ten associated brain maps, although each occupied different parts and amounts of midline and insular territory. Their differences were distributed across the brain. Regional patterns varied with study context, corresponded selectively with aspects of consciousness and resembled maps of general functions. Brain patterns combined at continuously varying strengths predicted regions reported in held-out publications better than single patterns or on/off combinations. Self-related processing therefore has no core and arises from shifting coalitions of distributed brain systems whose graded contributions define a continuous configuration space.
Neuroscience Peer-reviewed neuroscience study

Psilocybin induces acute and persistent neuronal changes in mice

Tracking single neurons across days reveals acute and persistent effects of psilocybin in the mouse brain
Why it matters ▲ Favorable
This study provides the first direct evidence of psilocybin's sustained impact on neuronal firing in the mouse brain, revealing both acute and persistent modulation across key brain regions. The use of advanced Neuropixels probes to track single neurons over time strengthens the mechanistic case for psilocybin's long-term neuroplastic effects, which is highly relevant for translational research into psychiatric treatment. These findings could inform dosing strategies, safety monitoring, and future clinical trial design for psilocybin-based therapies.
The psychedelic psilocybin offers a novel approach to treat depression and other psychiatric disorders. A single dose of psilocybin induces rapid neuroplastic effects that persist for many weeks to months. However, psilocybin's effect on neural firing beyond its systemic presence, and the neural mechanisms linking these acute and sustained effects remain unknown. Using chronically implanted Neuropixels probes, we tracked 1,692 neurons spanning prefrontal and hippocampal regions following saline and psilocybin injections and 24 h later. Psilocybin bidirectionally modulated firing acutely in a cell-type and region-specific manner. Persistent firing (24 h post-injection) is net suppressed relative to saline, including in acutely activated neurons. The late acute response, but not early peak response, predicted a neuron's firing 24 h later. To our knowledge, this is the first evidence that directly reveals psilocybin's sustained impacts on neuronal firing, providing key insight into the circuitry accompanying its lasting cognitive and behavioral alterations.
Clinical research Phase 3 readout

Helus' modified psychedelic meets endpoints in phase 3 depression trial

Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
Why it matters ▲ Favorable
A chemically modified psychedelic compound from Helus has achieved key endpoints in a phase 3 trial for depression, signaling a potentially pivotal advance for both research and commercial access. This result could accelerate regulatory review and heighten industry and investor interest in next-generation psychedelic therapeutics. The success of a modified molecule also suggests innovation beyond classic compounds, with implications for IP, safety, and clinical adoption.
Neuroscience Peer-reviewed study

Shared depression circuit identified via gray matter mapping

Heterogeneous Negative Gray Matter Volume Deviations Converge on a Shared Depression Circuit Associated With Symptoms and rTMS Response
Why it matters ▲ Favorable
This study identifies a reproducible brain circuit underlying major depressive disorder (MDD), linking structural brain changes to symptom severity and response to rTMS. While not directly about psychedelics, these findings advance understanding of depression neurobiology, which is highly relevant for psychedelic research targeting MDD. The results may inform future trial design, patient stratification, and neuromodulation approaches, including those combining psychedelics with brain stimulation.
Major depressive disorder (MDD) is characterized by marked heterogeneity in regional negative gray matter volume (GMV) deviations, obscuring the network basis of the disorder. Here, subject-specific normative GMV deviation maps are integrated with the human connectome using atrophy network mapping. Extreme negative GMV deviations in a medication-naive, first-episode MDD discovery cohort (n = 105) and an independent multisite validation cohort (n = 1265) converge on a reproducible depression circuit characterized by positive connectivity with subcortical-limbic regions and negative connectivity with frontoparietal and default mode network hubs. Circuit coupling tracks depressive symptom severity, follows gradients of depression-risk gene expression, and shows preliminary translational relevance: stronger negative connectivity at individualized rTMS targets is associated with greater clinical improvement. These findings reconcile heterogeneous structural deviations with the shared MDD phenotype and may inform future circuit-based neuromodulation studies.
Clinical research Qualitative study published

Qualitative study: MDMA-assisted therapy for social anxiety disorder

MDMA-Assisted Therapy for Social Anxiety Disorder: A Qualitative Analysis of Patient Experiences of Change
Why it matters ▲ Favorable
This is the first qualitative study exploring patient experiences with MDMA-assisted therapy for social anxiety disorder. The findings highlight perceived therapeutic mechanisms, such as increased emotional processing, self-compassion, and relational improvements. While not a pivotal trial, these insights are valuable for designing future clinical protocols and understanding patient-centered outcomes, supporting the rationale for further research and potential clinical application.
Objective: This study represents the first qualitative analysis to explore experiences of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) for people with social anxiety disorder. Method: Following two MDMA (midomafetamine) sessions, participants (N = 20) completed semi-structured interviews of their treatment experiences. Team members derived themes pertaining to what aspects of treatment participants felt contributed to therapeutic benefit through reflexive thematic analysis. Results: Five themes were identified: 1) Healing Catalysed by Gently Facing Difficult Experiences (sub-themes: Moving from Criticism to Curiosity and Compassion; Enhanced Capacity to Access and Process Emotions); 2) Meaning Making through Broadened Perspectives of Self and Others (sub-themes: Clarity on the Origins of Distress; Deeper Understanding of Authentic Self; Interconnectedness and Oneness); 3) From Intellectual to Felt Knowing through Embodied States (sub-themes: Emotional Experiencing and Release; Feeling Safe and at Ease with Oneself); 4) Learning New Relational Patterns through Vulnerable Self-Expression; and 5) MDMA Experiences as Anchor for Ongoing Self-Discovery. Conclusion: Overall, participants felt that MDMA in the context of a safe therapeutic container facilitated them facing, deeply feeling and embodying emotions, which catalysed new insights and healing. By feeling more connected and at ease with themselves and with others, participants gained the motivation to show up authentically in their relationships.
Clinical research Exploratory RCT results

Trait absorption linked to ketamine benefit in TRD: MUSIK trial exploratory results

Trait absorption association with ketamine’s benefits and drug-context interactions in treatment-resistant depression: exploratory results from the MUSIK randomized clinical trial
Why it matters ▲ Favorable
This exploratory RCT suggests that the personality trait 'absorption' predicts greater antidepressant response and mystical-type experiences from ketamine therapy in treatment-resistant depression, especially when paired with music-based support. If replicated, these findings could inform patient selection and individualized approaches in psychedelic-assisted therapy, potentially improving outcomes and resource allocation. The study also highlights the importance of drug-context interactions in maximizing therapeutic benefit.
Ketamine exerts rapid antidepressant effects in treatment-resistant depression (TRD) but therapeutic predictors remain elusive. The personality trait absorption – tendencies for immersive sensory, imaginative, and emotional experiences – influences responses to serotonergic psychedelics, like psilocybin, but has not been studied for ketamine. This study explores trait absorption’s influences on ketamine-therapy for TRD, including interactions with music- versus mindfulness-based support. This exploratory analysis draws on the MUSIK trial (NCT04701866), a multi-site, parallel, single-blind RCT at two Montreal hospitals, whose primary outcome examined hemodynamic effects of pairing ketamine with music. Thirty-two adults (aged 18-75 years) with severe TRD, receiving a structured psychedelic ketamine-therapy intervention, were randomized 1:1 to receive either music (n = 15) or matched non-music support (n = 17) during their six infusions (0.5 mg/kg over 40 min) over four weeks. Outcome assessors but not participants were blinded. Across 181 infusions, this exploratory outcome examined associations between baseline absorption and (1) changes in depression, anxiety, and suicidality; and (2) mystical/emotional experiences using linear correlations and multilevel models. Baseline trait absorption is associated (p ≤ .002) with pre-post improvements in depression (r = .721), anxiety (r = .546), and mean/peak Mystical Experience Questionnaire scores (r = .528-.637). In multilevel models, higher absorption is associated with steeper declines in depression and suicidality. Three-way interactions with timepoint and group suggest that music, versus matched non-music support, is associated with greater depression improvements in higher-absorption individuals (p <.001). Although confirmation in larger studies is required, this exploratory study suggests that trait absorption relates to ketamine’s benefits for TRD. Observed drug-context interactions highlight possible strategies for individuallytailoring ketamine-therapy. Low-dose ketamine can be very beneficial for severe depression even when other treatments have not helped. However, much remains unknown about how ketamine works and who might most benefit. This study explored how a personality trait called absorption may influence the benefits of a series of ketamine doses, paired with either music- or mindfulness-based support, for adults with severe depression. Trait absorption reflects an individual’s tendencies to become deeply immersed in sensory, imaginative, and emotional experiences. The results suggest that higher trait absorption is associated with greater benefits from ketamine, especially when administered with music. This may be because high-absorption individuals tend to have more significant ketamine experiences – indeed, the study found that higher trait absorption was associated with more mystical-like ketamine experiences. If confirmed, these results may help guide patient selection and the personalized use of mindfulness or music in ketamine therapy for depression. Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either music or mindfulness, for treatment-resistant depression. Higher absorption is associated with larger antidepressant effects, reduced suicidality, and more mystical experiences, especially with music-based support.
Clinical research Research published

Blood plasma markers predict psilocybin, ketamine response in depression

Blood Plasma Markers Predict Effectiveness of Psilocybin and Ketamine for Depression
Why it matters ▲ Favorable
Identification of blood plasma biomarkers that predict individual response to psilocybin and ketamine could enable more personalized and effective psychedelic-assisted treatments for depression. This finding may improve patient selection, reduce trial-and-error prescribing, and accelerate clinical research by offering objective endpoints. It also supports the development of companion diagnostics, which could become a key differentiator in the emerging psychedelic medicine industry.
Clinical research Phase 2 trial result

Small trial: IV ketamine safe, effective for treatment-resistant bipolar depression

Ketamine found safe and effective for treatment‐resistant bipolar depression in small trial
Why it matters ▲ Favorable
This small trial provides early evidence that IV ketamine may be safe and effective for patients with treatment-resistant bipolar depression, a population with limited options. If confirmed in larger studies, this could expand ketamine's clinical use beyond major depressive disorder and inform future regulatory or guideline updates. However, the trial's small size means further research is needed before practice or policy changes.
Intravenous (IV) ketamine has already been shown effective in the treatment of major depressive disorder, but whether the medication is safe and effective for bipolar depression is not known.
Clinical research Meta-analysis published

Meta-analysis: Antipsychotic relapse risk tied to severity, not withdrawal

Meta‐analysis shows rapid relapse after antipsychotic discontinuation linked to baseline severity, not withdrawal
Why it matters ◈ Mixed
A new meta-analysis finds that rapid relapse after stopping antipsychotics is primarily linked to baseline illness severity rather than withdrawal effects. This challenges the common assumption that withdrawal is the main driver of relapse, which may influence future clinical trial design and patient management strategies. For psychedelic research, the findings could inform inclusion/exclusion criteria and safety monitoring in studies involving patients with a history of antipsychotic use.
Antipsychotics when taken on a long‐term basis can have adverse effects, prompting discontinuation. However, numerous studies have shown that antipsychotic discontinuation comes with an increased risk of relapse, the course of which appears to be heterogeneous.
Clinical research Scoping review announced

Scoping review: IV ketamine for TRD in resource-limited settings

Repurposing Generic Intravenous Racemic Ketamine from Anesthesia to Treatment-Resistant Depression in Resource-Limited Settings: A Scoping Review
Why it matters ▲ Favorable
This review could provide critical evidence supporting the use of low-cost, generic IV ketamine for treatment-resistant depression (TRD), especially in public health systems unable to afford patented esketamine. By mapping global clinical outcomes, it may inform hospital policy, expand access in resource-limited settings, and challenge the dominance of more expensive formulations. The findings could influence both clinical practice and procurement decisions, with downstream effects on market structure and patient care.
Background & Purpose: Treatment-Resistant Depression (TRD) is a significant clinical challenge. While patented nasal esketamine is cost-prohibitive for public healthcare systems, generic intravenous (IV) racemic ketamine is already widely available in hospital operating rooms at a fraction of the cost, though its use remains largely restricted to anesthesia. This scoping review maps global evidence on IV racemic ketamine for TRD, focusing specifically on clinical efficacy to support hospital administrators in evaluating its feasibility for public health adoption. Core Research Focus: - What are the reported clinical response and remission rates of IV racemic ketamine for unipolar and bipolar TRD? Methodology (PCC Framework & PubMed Search): Following Joanna Briggs Institute (JBI) methodology, eligibility criteria are structured using the PCC framework: - Population (P): Patients of any age with unipolar or bipolar Treatment-Resistant Depression (TRD). - Concept (C): Repurposed generic intravenous (IV) racemic ketamine and its clinical efficacy outcomes. - Context (C): Global clinical settings where evaluating low-cost generic alternatives is clinically relevant. To maintain a focused scope, the literature search will be conducted exclusively via PubMed. Studies will be screened to extract clinical response/remission metrics, demonstrating the therapeutic viability of repurposing existing hospital ketamine stock.
Clinical research Phase 3 readout

Single‐dose psilocybin outperforms placebo for MDD in community setting

Single‐dose psilocybin superior to placebo for MDD in community setting
Why it matters ▲ Favorable
This study reports that a single dose of psilocybin is superior to placebo for major depressive disorder (MDD) in a community setting. This is a pivotal finding, as it suggests real-world effectiveness outside of highly controlled academic centers and supports broader accessibility. The result could accelerate regulatory and payer acceptance, influence clinical guidelines, and expand research into scalable models for psychedelic therapy. It has significant implications for patient care and the future of depression treatment.
Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.
Neuroscience Peer-reviewed study published

dMRI models show limited sensitivity to ketamine-induced brain changes in mice

Multishell diffusion MRI models have limited sensitivity to ketamine-induced microstructural changes in the mouse brain
Why it matters ◈ Mixed
This study finds that current in vivo multishell diffusion MRI models may not reliably detect ketamine-induced dendritic remodeling in the mouse brain, despite histological evidence of such changes. This limits the immediate utility of dMRI as a noninvasive biomarker for monitoring ketamine's neuroplastic effects in psychiatric research or clinical settings. The result is important for researchers and drug developers seeking objective imaging endpoints for psychedelic or rapid-acting antidepressant trials. Further methodological advances or alternative imaging approaches may be needed to track subtle neuroplasticity in vivo.
Gray matter neuronal morphology is relevant to psychiatric diseases and pharmacotherapies. For instance, ketamine rapidly induces dendritic remodeling and spinogenesis which are required for its therapeutic effects in psychiatric disorders. A noninvasive biomarker of this phenomenon could aid in treatment response monitoring, patient stratification, or drug development. In principle, diffusion magnetic resonance imaging (dMRI) is sensitive to microstructure and could provide the desired approach. Here, we used three multishell dMRI-based models (diffusion tensor, neurite orientation dispersion and density, and diffusion kurtosis) in vivo to interrogate ketamine-induced microstructural changes in wild type mice and in the SAPAP3 knockout mouse model of compulsive behavior. Although histological analyses confirmed ketamine-induced increases in cortical synapse markers, we observed no corresponding changes in dMRI metrics. In Monte Carlo simulations of diffusion in scenes solely containing realistic dendrites, dMRI was sensitive to small morphological changes across gradient amplitudes only in noiseless conditions. In contrast, the same dMRI acquisitions resolved baseline microstructural differences between sexes and between SAPAP3 knockout and wild type mice, supporting the sensitivity of the method as implemented. Our findings suggest that the in vivo dMRI acquisition and modeling approaches used here lack sensitivity to detect the subtle dendritic morphology changes induced by ketamine.
Clinical research Proof-of-concept trial proposed

MDMA-assisted psychotherapy proposed for sexual offending prevention

Could an empathogen like MDMA help prevent sexual offending?
Why it matters ◈ Mixed
This proposal outlines the first ethically rigorous trial of MDMA-assisted psychotherapy aimed at preventing sexual offending in help-seeking individuals with paraphilic disorders. If conducted, it could open a novel research and clinical frontier, but also raises significant ethical, safety, and regulatory questions. The trial would adapt established PTSD protocols with enhanced safeguards, potentially informing both public health and criminal justice approaches if early results are promising.
ABSTRACT No psychological treatment for sexual offending has been shown, under rigorous controlled conditions, to reduce reoffending, and most people arrested for a sexual offense have no prior conviction. Prevention must begin upstream, with those who recognize their risk and seek help. The psychology of sexual offending overlaps with that of posttraumatic stress disorder (PTSD): shame, mistrust, and difficulty tolerating closeness, often rooted in abuse. MDMA-assisted psychotherapy may act on this psychology, lowering shame and fear while increasing closeness and emotional empathy. In two phase 3 trials, 67% and 71% of MDMA-treated participants no longer met PTSD criteria, versus 32% and 48% with placebo. Existing pharmacology for paraphilic disorders reduces deviant sexual interest and preoccupation but leaves empathy and self-regulation unchanged. Although MDMA may increase sexual desire, it delays orgasm and often impairs erectile and ejaculatory function, favoring closeness over culmination. We hypothesize that MDMA-assisted psychotherapy could address the gap left by existing pharmacology and reduce the risk of sexual offending in help-seeking people with paraphilic disorders. To test this hypothesis, we propose a small, ethically scrupulous proof-of-concept trial in voluntary, community-based participants, adapting the manualized protocol developed by the Multidisciplinary Association for Psychedelic Studies for PTSD. Safeguards should include co-therapist dyads, continuous recording with independent review, a touch protocol precluding sexual contact, deviant sexual interest as a prespecified safety outcome with a stopping rule, and sustained aftercare. Such a trial would be a first step toward prevention.
Neuroscience Method published

SpaCoDA enables rapid, accurate spatial transcriptomics at cohort scale

SpaCoDA: fast compositional deconvolution maps recurrent cellular niches across hundreds of spatial transcriptomics sections
Why it matters ▲ Favorable
This new computational method, SpaCoDA, significantly accelerates and improves the accuracy of spatial transcriptomics analyses, enabling cell-type and niche mapping across large tissue cohorts. While not directly about psychedelics, this tool could facilitate research into brain tissue microenvironments, disease subtypes, and therapeutic targets relevant to neuropsychiatric and neurodegenerative conditions. Its scalability and precision may indirectly benefit psychedelic research by supporting high-resolution studies of brain tissue before and after intervention.
Abstract Background Spot-based spatial transcriptomics such as 10x Visium measures a mixture of cells in each spot. Estimating the cell-type composition of each spot against a single-cell reference is the first step towards cell-level maps of tissue microenvironments, but the most accurate deconvolution methods are slow and memory-intensive at the scale of current atlases, and there still need an established way to make tissue niches comparable across hundreds of sections. Results We present SpaCoDA, which fits each spot by variance-weighted non-negative least squares against a reference signature, re-estimates a gene-level platform factor between iterations, and converts RNA shares into cell fractions using cell-size and marker-capture factors. Niches are identified within each section from fused compositional (Aitchison distances) and spatial distances, and their prototypes are integrated across sections into meta-niches. Across 123 simulated configurations under three reference-mismatch scenarios, SpaCoDA was the only one of nine methods ranked within the top two on all four evaluation metrics in every scenario, second to RCTD in mean rank. On 12 imaging-derived datasets with known composition (six Xenium datasets, each evaluated at two annotation levels, and six CosMx/Xenium datasets from three patients), it achieved the best mean rank in every summary, while running 4 to about 1,800-fold faster than the other eight methods (233-fold faster than RCTD by median runtime) with the lowest peak memory. Applied to 254 breast cancer and 181 glioblastoma sections (about 1.18 million spots), SpaCoDA identified 29 and 31 meta-niches, respectively. In breast cancer, the expression signature of a B-cell and plasma-cell meta-niche was associated with longer overall survival in TCGA-BRCA and METABRIC and was higher in tumors with a pathological complete response (pCR) to neoadjuvant therapy in I-SPY2. In glioblastoma, signatures of a perivascular antigen-presenting myeloid meta-niche and of a proliferative, hypoxic meta-niche were associated with shorter survival in TCGA-GBM and three CGGA glioma cohorts. Conclusions SpaCoDA combines competitive accuracy with orders-of-magnitude lower computational cost, making composition and niche analysis practical at cohort scale. It provides a practical framework for such analyses, enabling disease subtyping and the identification of novel therapeutic targets, and shows promise for clinical translation.
Clinical research Systematic review published

Systematic review: Cost-effectiveness of psychedelic therapies for depression & PTSD

Cost-effectiveness of psychedelic-assisted therapies for depression and post-traumatic stress disorder: A systematic review
Why it matters ▲ Favorable
This systematic review synthesizes available evidence on the cost-effectiveness of psychedelic-assisted therapies for depression and PTSD. While not a clinical trial or policy move, such analyses are increasingly important for payers, policymakers, and providers evaluating whether to support or reimburse these treatments. The review may inform future health economic modeling, insurance decisions, and research funding priorities, but its direct impact will depend on the strength and recency of the underlying studies.
Neuroscience Peer-reviewed study

Breathwork induces neural states mirroring psychedelics, EEG study finds

Neural and Experiential Dynamics of High-Ventilation Breathwork Mirror Psychedelic States
Why it matters ▲ Favorable
This study demonstrates that high-ventilation breathwork can reliably induce neural and experiential states closely resembling those produced by classical psychedelics. The findings suggest that non-pharmacological interventions may access similar altered states, potentially broadening research models and therapeutic options. This could inform both mechanistic neuroscience and the development of new, lower-risk interventions for mental health. The work also provides a comparative framework for future studies on the neural basis of altered states.
High-ventilation breathwork (HVB) is a simple breathing technique that nevertheless frequently triggers experiences resembling psychedelic states. While recent studies have begun to pinpoint physiological and neural changes involved in altered states of consciousness (ASCs) evoked by HVB, the interplay between neural and experiential dynamics throughout an HVB session remains unclear. Here we tracked neural activity (via 64-channel EEG recordings) as well as subjective experience depth and content in 25 experienced HVB practitioners across resting-state recordings interleaved throughout a naturalistic HVB session. We find that neural dynamics evoked by HVB emulate the most robust neural signatures of classical psychedelic states, specifically (1) loosening of temporal structure, including broadband cortical desynchronization, increased signal complexity, and decreased oscillatory power in the Alpha (8 - 13 Hz) range, and (2) reorganization of spatial structure, including a flattening of cortical processing hierarchy. These neural effects directly correlated with participants subjective depth with minute resolution, but were not explained by isolated features of HVB such as music listening or active interoception. Together, these results identify unifying neural features of psychedelic-like ASCs regardless of induction method, demonstrating that cortical states triggered by psychedelics can also be accessed by non-pharmacological routes, and breathwork is a powerful way to do so.
Clinical research Peer-reviewed narrative review

Review: Safety & implementation of emerging TRD treatments (ketamine, psilocybin, rTMS)

From rapid response to real-world readiness: Safety monitoring, maintenance strategies, and implementation outcomes for emerging treatments in treatment-resistant depression: A narrative review
Why it matters ◈ Mixed
This review synthesizes current evidence on rapid-acting and psychedelic-assisted interventions for treatment-resistant depression, highlighting both their promise and the substantial gaps in long-term safety, maintenance, and real-world implementation. It underscores the need for standardized safety monitoring, individualized care plans, and robust implementation research to ensure these therapies can be safely and equitably integrated into clinical practice. The article is a useful resource for researchers and clinicians, but does not itself shift policy or access.
Background : Treatment-resistant depression (TRD) remains a major therapeutic challenge despite advances in pharmacotherapy and neuromodulation. Rapid-acting treatments, including ketamine and esketamine, have expanded treatment options, while psychedelic-assisted interventions and accelerated repetitive transcranial magnetic stimulation (rTMS) continue to develop. However, rapid symptom improvement does not necessarily translate into sustained remission, functional recovery, or accessible long-term care. Objective : This narrative review examines emerging treatments for TRD, emphasizing safety monitoring, maintenance and discontinuation strategies, patient-centred outcomes, and implementation challenges. Findings : Evidence supports the rapid antidepressant effects of ketamine and esketamine in appropriately selected patients, although treatment durability and maintenance requirements differ. Esketamine has randomized evidence supporting relapse prevention among selected responders, while long-term extension studies provide additional, albeit limited, safety information. Psilocybin-assisted interventions show promising antidepressant effects, but uncertainties remain regarding long-term outcomes, psychological support, and generalizability. Accelerated and connectivity-guided neuromodulation may reduce treatment burden, although further replication and longer follow-up are required. Across treatment approaches, patient selection, adverse-event surveillance, relapse prevention, affordability, and service capacity influence clinical translation. Conclusion : Sustainable progress in TRD requires more than demonstrating acute efficacy. Standardized safety reporting, individualized maintenance planning, longitudinal assessment of functional outcomes, and implementation research are essential to establish whether emerging treatments can deliver safe, durable, and equitable benefits in routine psychiatric practice.
FDA / Federal policy FDA program sunset, NDA submitted, federal research funds

FDA ends speedy review; Compass submits psilocybin NDA; $25M for ibogaine research

FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research
Why it matters ◈ Mixed
The FDA ending its expedited drug review program could slow future psychedelic approvals, raising barriers for sponsors and potentially delaying patient access. Meanwhile, Compass Pathways' submission of a New Drug Application for psilocybin marks a pivotal regulatory milestone for the field. The federal commitment of $25 million for ibogaine and other psychotropic research signals growing government support and could catalyze new studies and industry interest. These moves together represent a major inflection point for psychedelic medicine's regulatory and research landscape.
Clinical research Study protocol announced

Ambulatory study to track psilocybin's daily-life effects in depression trial

How Does Psilocybin Affect Daily Life Experience and Behavior? Protocol For a Multimethod Ambulatory Assessment Study Within a Clinical Trial of Psilocybin for Depression
Why it matters ▲ Favorable
This protocol outlines a novel, real-world assessment of psilocybin's impact on daily functioning and behavior in patients with major depressive disorder. By embedding ecological momentary assessment and passive audio sampling into a clinical trial, the study aims to clarify factors that predict positive or adverse outcomes after psilocybin dosing. Results could inform both clinical practice and future trial design, especially regarding safety monitoring and patient selection.
Introduction: Although psilocybin has shown promise for treating depression, responses vary considerably, with some individuals experiencing limiting improvement and even adverse effects. Research has largely relied on assessments conducted at discrete time points, providing limited insight into how post-psilocybin change unfolds in everyday life. The Dial-In study aims to characterize daily-life processes associated with differential responses to psilocybin, including factors associated with improvement or worsening following challenging dosing experiences. Methods and Analysis: Dial-In is a prospective, observational, multi-method longitudinal study embedded within a clinical trial administering 25 mg of psilocybin to up to 141 adults with major depressive disorder. Ambulatory assessments combine ecological momentary assessment (EMA) and voice diaries for 14 days pre- and post- dosing, and passive audio sampling via the Electronically Activated Recorder (EAR) for three four-day periods to characterize everyday affect, behavior, reflections, and social interactions. Outcomes include depressive symptoms, psychological well-being, and psychedelic-related adverse effects assessed through eight weeks post-dose. Analyses will examine whether affective sudden gains and losses, social support, interpersonal conflict, conversational focus, reflection and rigidity predict differential outcomes. Additional analyses will test whether these factors moderate associations between challenging dosing experiences and clinical outcomes. Ethics and Dissemination: The project was approved by WCG Institutional Review Board, with Emory University relying on WCG as the reviewing board. All participants provide written informed consent. Findings will be disseminated through peer-reviewed publications and scientific presentations.
Clinical practice / Community Trend reported

Veterans turn to ketamine therapy for depression relief

Why it matters ◈ Mixed
Growing use of ketamine therapy among veterans highlights unmet mental health needs and demand for alternative treatments. While not a regulatory or legal development, this trend signals both increasing off-label use and potential market growth, as well as ongoing gaps in access to evidence-based psychedelic therapies. The lack of body text limits insight into regulatory or research implications, but the story underlines the need for rigorous clinical trials and policy clarity.
Industry / Research Infrastructure Field analysis

DeSci: Blockchain's impact on security and openness in science

Decentralized science (DeSci): How blockchain reconfigures the balance between security and openness in science
Why it matters ◈ Mixed
This study analyzes how decentralized science (DeSci) organizations use blockchain to balance security and openness in scientific research, including sensitive domains like psychedelics. It highlights how inherited crypto norms influence data governance, participation, and control in open science, which may affect research transparency, access, and community trust. While not specific to psychedelics, the findings are relevant for stakeholders considering DeSci models for funding, data sharing, or governance in psychedelic research.
Science and innovation are increasingly shaped by security agendas, making their combination with openness more difficult. Decentralized Science (DeSci) is a recent initiative that explicitly experiments with reconciling security and openness in open innovations by using blockchain technologies. Yet DeSci adopts technologies developed by libertarian and crypto-market projects, which can create conflicts with scientific and organizational goals. How do these organizations address the combination of security and openness, and how do they align their goals with the prior norms embedded in the technologies they adopt? Combining institutional entrepreneurship with actor-network theory, the study analyzes public documents from 25 DeSci organizations and traces how actors legitimize novel formats by theorizing the links between problem framing, scientific norms, and inherited norms in blockchain design. The study identifies five configurations of DeSci organizations. Crypto-commonal and commonal open science types use blockchain to secure data and decision-making while focusing on community products, whereas the open science type treats blockchain mainly as infrastructure supporting transparent research processes. The crypto-libertarian type focuses on resistance to external control, while libertarian open science prioritizes the personal security of participants in sensitive research. DeSci organizations selectively align their goals with prior technological norms: they predominantly adopt Ethereum-style crypto-commonal scripts of cooperative, token-mediated coordination, while hybrid types re-script these norms by combining them with scientific goals. The study contributes to research on digital infrastructures of open innovation by showing that technologies do not merely facilitate knowledge exchange but also shape how openness, security, participation, ownership, and control can be combined.
Neuroscience Peer-reviewed article

Critique of Entropic Brain and Irruption Theories in Consciousness Research

Mind your head: Entropic Brain, irruption theory and the intelligibility problem
Why it matters ◈ Mixed
This paper critically examines two influential frameworks—Entropic Brain Hypothesis (EBH) and Irruption Theory (IT)—that are frequently referenced in psychedelic neuroscience. It highlights conceptual limitations in using neural entropy as a direct correlate of subjective experience, challenging key assumptions that underpin much current psychedelic research. While not a direct legal or clinical development, the critique may influence future research design, interpretation of neuroimaging studies, and the philosophical underpinnings of psychedelic science.
Abstract The entropic brain hypothesis (EBH) and irruption theory (IT) are two recent frameworks to investigate consciousness by examining neural entropy. While they differ in their theoretical commitments, both aim to advance neuroscientific investigations of consciousness without succumbing to the intelligibility problem: the impossibility for scientific inquiries to provide intelligible access to subjective experience. This paper examines each framework in turn and argues that they face distinct but important limitations. I show that the EBH overreaches its descriptive scope when claiming that variations in neural entropy correspond not only to statistical uncertainty but also to the felt uncertainty of subjective experience. In doing so, the EBH attempts to establish an intelligible relation between neural dynamics and experiential properties by assuming the existence of a shared quality between neural processes and experience. This constitute an instance of the intelligibility problem. IT, by contrast, explicitly acknowledges the intelligibility problem and proposes a theoretical framework intended to circumvent it while preserving the possibility of identifying a neural signature of consciousness. However, I argue that, despite the merit of acknowledging the intelligibility problem, IT incurs in different yet equally significant issues linked to the assumption that mental activity can be indirectly quantified by measurements of neural entropy.
Federal grants / research policy Funding opportunity announced

FY27 Social Impact Partnerships Act: Funding Opportunity Announced

FY27 Social Impact Partnerships To Pay for Results Act Notice of Funding Opportunity
Why it matters ◈ Mixed
This federal notice opens a funding opportunity for outcome-based social impact projects, including those potentially relevant to psychedelic-assisted interventions if applicants can demonstrate rigorous evaluation plans. While not specific to psychedelics, the program's emphasis on randomized controlled trials and robust evaluation could support innovative research or service delivery models in behavioral health, contingent on successful proposals. The requirement for objective, independent outcome metrics and data access may present both opportunities and barriers for psychedelic research teams seeking to demonstrate impact at scale.
Provide an evaluation design plan summary by following the following guidelines. Limit this to 3 pages or fewer. The summary should provide information demonstrating that the proposed evaluation will be designed to determine whether the outcomes were achieved as a result of the intervention. The summary must address the following six topics: i. Outcome metrics and data sources. Identify the outcome metric or metrics that will be used to determine whether the project achieved its outcome goals. For each metric, identify the data source, data owner, expected outcome target or payment threshold, and why the metric is an independent, objective indicator of impact that is not subject to manipulation by the service provider, intermediary, investors, or other project partners. ii. Evaluation design and comparison group. Identify the proposed evaluation design, such as a randomized controlled trial, regression discontinuity design, difference-in-differences design, matched comparison design, or another rigorous methodology. Describe the treatment group, the control or comparison group, how each group will be formed, and the expected difference in services received by each group. Briefly explain how the design will support causal conclusions. iii. Randomization feasibility. State whether random assignment is feasible. If random assignment is feasible, briefly describe how it would occur. If random assignment is not feasible, explain why and identify the strongest feasible alternative evaluation method. iv. Preliminary power calculation. Provide a preliminary power calculation for each primary outcome or payment metric. Identify the expected treatment and control or comparison group sizes, the expected effect the intervention is designed to achieve, and whether the proposed sample is large enough to detect that effect. Briefly state the main assumptions that affect the calculation, such as attrition, missing data, take-up, clustering, or repeated observations. v. Data access. Identify the data needed to conduct the evaluation, including data needed to measure outcomes, construct the treatment and control or comparison groups, and assess baseline characteristics. State the status of access to each major data source, including whether data-use agreements, memoranda of understanding, consent forms, or other approvals are in place or will be needed. If federal administrative data are required, identify the federal data source, expected access pathway, and any known gaps or risks. vi. Main risks to the evaluation. Identify the most important risks to the evaluation's ability to produce credible causal estimates, such as insufficient sample size, missing data, attrition, weak service contrast, contamination, changes in policy or service availability, implementation challenges, or inability to access required data. Briefly describe how the Applicant and independent evaluator expect to mitigate these risks. At the application stage, Applicants are not required to provide final regression equations, final covariate specifications, minimum detectable impact estimates, final hypothesis testing procedures, or a full implementation evaluation protocol. If selected for an award, the Awardee must submit a full Evaluation Design Plan after award, in the form and timeline required by Treasury. See Appendix III for a description of what will be required in the final evaluation design plan. (5) Independent evaluator qualifications: Provide a summary explaining the independence of the evaluator from the other entities involved in the project and the evaluator's experience in conducting rigorous evaluations of program effectiveness including, where available, well-implemented RCTs and quasi-experimental analyses on the intervention or similar interventions. When discussing experience, please note both personnel and organization experience. Applicants must address the following qualifications of the evaluator. Please limit this to 3 pages or fewer. i. Experience working with the datasets the project expects to use; ii. Prior work in conducting implementation and causal impact evaluation and how their past methodologies and evaluation design experience will be used in the proposed project. Please provide examples of evaluations that they have completed of similar size, scope and complexity; iii. Qualifications of the key personnel designing and overseeing the evaluation and ensuring its quality, including their education or training and type and years of experience; iv. Experience in managing similar evaluation protocols (e.g., type of sampling, data collection, analysis); and v. Experience dealing with unforeseen data or implementation issues in other program evaluations. Provide specific examples and experiences dealing with unforeseen data or implementation issues. (6) Independent evaluator contract or agreement. Provide a copy of the contract or agreement to be entered into between the State or local government and the independent evaluator. The contract or agreement must address the following information. i. Plan to obtain relevant datasets from various sources, for example, local agencies, state agencies, or other federal agencies, including the responsibilities of the grantee and evaluator in accomplishing this task; ii. Design and coding of a management information system, as needed, that is tailored for research or evaluation, to track participants and/or to obtain individual level data; iii. Collection or assessment of individual-level data. The independent evaluator must work directly with the Applicant and other organizations to enter into one or more agreements for the access and use of the data. These agreements must include assuring data quality and adherence to all federal and state data privacy statutes and policies and to all applicable data security standards; iv. Institutional Review Board (IRB) approval or a plan to get IRB approval to ensure the protection of human subjects, to the extent applicable; and v. Submission of progress reports to Treasury, the Interagency Council, and the head of the relevant agency in accordance with the reporting requirements described in Section 8.B.b, Evaluation Progress Reports and Section 8.B.c, Evaluation Final Report. vi. A payment plan that details the annual payment schedule that aligns with the other requirements of the independent evaluator. The selection of an independent evaluator is subject to the procurement requirements of the Uniform Guidance, including those related to competitive procurement.\11\ ---------------------------------------------------------------------------
US / Federal Federal funding announced

Trump administration to invest millions in psychedelics research for mental health

Why it matters ▲ Favorable
Major federal investment signals a pivotal shift in US government support for psychedelic research, likely accelerating clinical trials and expanding access to funding for academic and industry-led studies. This move could reduce regulatory barriers, attract private capital, and catalyze new treatment development for mental health conditions. Stakeholders should monitor implementation details and agency priorities to assess impact on research access and future policy.
US Federal policy Federal funding announced

Trump officials announce federal funding for ibogaine PTSD research

WATCH: Trump administration officials announce PTSD research funding for psychedelic drug ibogaine
Why it matters ▲ Favorable
Federal funding for ibogaine research signals a significant shift in US policy toward exploring psychedelics for PTSD treatment. This move could accelerate clinical trials, reduce regulatory barriers, and encourage private investment in ibogaine-based therapies. It also marks a rare bipartisan moment for psychedelic science, potentially expanding access and legitimizing research into substances previously sidelined by federal law.
Clinical research Analytical method validated

Validated UPLC-MS/MS method for esketamine and metabolites in dog plasma

Development and full validation of a UPLC-MS/MS method for the simultaneous quantification of esketamine, noresketamine, and hydroxynoresketamine in beagle dog plasma and its application to a pharmacokinetic study
Why it matters ▲ Favorable
This study reports the first validated method for simultaneous quantification of esketamine and its major metabolites in beagle dog plasma. The assay's high sensitivity and efficiency will facilitate preclinical pharmacokinetic and mechanistic research, supporting translational studies of esketamine as a rapid-acting antidepressant. While not a direct regulatory or legal development, this advance improves the toolkit for researchers and may accelerate drug development pipelines.
Background Esketamine (ESK), the S-enantiomer of ketamine, has garnered significant clinical interest as a rapid-acting antidepressant. Its pharmacokinetic profile is critically shaped by its major metabolites, noresketamine (NESK) and hydroxynoresketamine (HNESK), which may contribute to its overall pharmacological effects. Reliable bioanalytical methods for simultaneous quantification of ESK and these metabolites in preclinical species are essential for translational research. Methods We developed and comprehensively validated a highly sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the concurrent determination of ESK, NESK, and HNESK in beagle dog plasma. Analyte separation was achieved on a UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm) using gradient elution with a mobile phase composed of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4 mL/min, with a total run time of 4.0 min. Methoxyphenamine served as the internal standard. Detection was performed in positive electrospray ionization mode with multiple reaction monitoring, employing specific ion transition pairs for each target compound to guarantee selectivity and accuracy. Sample preparation involved a simple one-step protein precipitation with acetonitrile using only 100 µL of plasma. Results The method exhibited excellent linearity across the tested concentration ranges, with all calibration curves yielding determination coefficients (R 2 ) exceeding 0.999 7. The lower limits of quantification were 1 ng/mL for both ESK and NESK, and 0.5 ng/mL for HNESK. Intra- and inter-batch precision (RSD, %) ranged from 3.17% to 14.22% for ESK, 5.41%–10.94% for NESK, and 4.70%–12.40% for HNESK, while accuracy (RE, %) was within ±15% for all analytes. Matrix effects were well controlled (ME%: 93.27%–104.59%), and mean extraction recoveries exceeded 80.22%. Stability under relevant storage and handling conditions was also confirmed, along with satisfactory dilution integrity for 2-fold dilution. The validated method was successfully applied to a pharmacokinetic study in beagle dogs following a single intramuscular dose of 1.0 mg/kg ESK, providing reliable concentration-time profiles for all three analytes. Conclusion This is the first reported UPLC-MS/MS method enabling simultaneous quantification of ESK, NESK, and HNESK in beagle dog plasma. The assay features a short run time (4.0 min), simple sample preparation, low plasma volume requirement (100 µL), and excellent sensitivity, making it a robust and practical analytical tool for preclinical pharmacokinetic investigations and future mechanistic studies of ESK and its active metabolites.
Industry / FDA NDA submitted

Compass Pathways submits FDA application for psilocybin therapy

Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
Why it matters ▲ Favorable
Compass Pathways' completion of an FDA application for psilocybin therapy marks a pivotal step toward potential regulatory approval and commercial launch in the US. This milestone signals that late-stage clinical data are likely supportive and that the company is readying for market entry, which could reshape access, investment, and clinical practice. The move will intensify focus on FDA review timelines, reimbursement, and implementation challenges for psychedelic-assisted therapies.
FDA / DEA Interim final rule in effect

DEA places oveporexton (Orzeyful) in Schedule IV after FDA approval

Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV
Why it matters ▲ Favorable
The DEA's placement of oveporexton in Schedule IV enables its legal prescription and commercial launch following FDA approval for narcolepsy type 1. This scheduling reflects a relatively low abuse potential, facilitating access for patients and providers while maintaining regulatory oversight. The move signals continued regulatory coordination for novel CNS therapeutics and may set precedent for future scheduling of new psychoactive compounds.
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.
Neuroscience Preclinical research

Serotonin in rat prefrontal cortex modulates retrieval-induced forgetting

Serotonin signaling in the rat prefrontal cortex is required for Retrieval-Induced Forgetting
Why it matters ▲ Favorable
This study identifies specific serotonin receptor subtypes in the prefrontal cortex as key regulators of adaptive forgetting in rats, implicating 5-HT2A and 5-HT1A receptors in memory competition. The findings provide mechanistic insight into how serotonergic modulation affects memory processes, which is highly relevant to the development of psychedelic-based therapeutics targeting 5-HT2A receptors. Understanding these pathways could inform future clinical trial design and therapeutic strategies for conditions involving memory dysfunction or maladaptive memory persistence.
Forgetting is a ubiquitous phenomenon actively promoted in many species. The act of remembering some experiences can cause forgetting of others in both humans and rats. We previously found that when rats retrieve a memory to guide exploration, it reduces later retention of other competing memories encoded in that environment. As with humans, this retrieval-induced forgetting (RIF) relies on prefrontal control processes, is competition-dependent, and cue-independent. RIF is thought to be driven by inhibitory control signals from the prefrontal cortex that target areas where memories are stored. Serotonin plays a crucial role in behaviors requiring high cognitive demand, including memory processes, partly through its modulation of prefrontal cortex activity. However, its potential involvement in regulating active forgetting remains unexplored. Here, in male and female rats performing a task known to induce RIF, we pharmacologically manipulated serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors and their downstream effectors in the medial prefrontal cortex (mPFC). Our findings reveal a specific role for prefrontal serotonin signaling in RIF. Whereas 5-HT2C receptor manipulation had no effect, activating 5-HT1A or blocking 5-HT2A receptors in the mPFC abolished RIF. By contrast, activating 5-HT2A receptors promotes RIF under conditions in which it is normally reduced. Further analyses identified the PI3K/AKT pathway as a downstream effector of 5-HT2A receptor signaling, suggesting a specific molecular mechanism through which serotonin modulates inhibitory control over memory. These results uncover a previously unrecognized serotonergic modulation of adaptive forgetting, identifying specific receptor subtypes that link prefrontal serotonin signaling to inhibitory control over memory competition. Significance statement Forgetting is an essential, active process that helps the brain stay flexible and focused. In both humans and animals, remembering one thing can lead to forgetting competing memories, a phenomenon called retrieval-induced forgetting (RIF). Our research shows that serotonin, a neurotransmitter best known for its role in mood, also actively regulates which memories are forgotten. In rats, we found that serotonin signaling in the prefrontal cortex regulates adaptive forgetting: 5-HT2A receptor signaling promotes RIF, whereas activation of 5-HT1A receptors disrupts it. We further identified PI3K/AKT signaling as a key downstream effector of 5-HT2A receptor activation in this process. These findings matter because the mechanisms of active forgetting remain poorly understood, and their disruption may contribute to psychopathological conditions.
Neuroscience Peer-reviewed study published

Aphantasia linked to fewer PTSD intrusions, similar distress

People with aphantasia report fewer PTSD intrusions but similar distress after trauma
Why it matters ◈ Mixed
This study suggests that mental imagery plays a key role in how trauma is re-experienced, but not in the overall distress it causes. For psychedelic research, which often investigates imagery-rich therapeutic processes for PTSD, these findings highlight the need to consider individual differences in imagery ability. The results may inform trial design, screening, and interpretation of outcomes in psychedelic-assisted therapy for trauma-related disorders.
Abstract People with aphantasia, who lack mental imagery, report fewer intrusive memories after trauma. Imagery is central to cognitive models of post-traumatic stress disorder (PTSD), but whether it makes trauma harmful is unknown; previous studies neither measured exposure nor tested questionnaire equivalence without imagery. We surveyed 340 adults with congenital aphantasia, 261 with imagery from the same community and 471 controls. Questionnaires functioned broadly equivalently. At equal exposure, people with aphantasia reported fewer intrusions and less avoidance, more trauma amnesia and less depersonalisation, but similar depression, anxiety, mood and arousal. Trauma was associated with their distress no less strongly than in people with imagery. Importantly, at equal exposure and distress, they had about half the odds of controls of reaching the PTSD screening cut-off. Imagery appears tied to how trauma is re-experienced, not how much distress follows it; low PTSD checklist score without imagery does not mean trauma had little effect.
Clinical research Review published

Review: Clinical risks and trends in novel psychoactive substances (NPS)

Novel psychoactive substances: clinical challenges and therapeutic approaches
Why it matters ◈ Mixed
This review highlights the growing complexity and clinical risks associated with next-generation psychedelics and other novel psychoactive substances (NPS). The findings underscore the challenges for clinicians and toxicologists, including detection difficulties and unpredictable effects, which have direct implications for research safety protocols, regulatory oversight, and harm reduction. The rapid evolution of NPS chemistry and effects signals a need for ongoing surveillance and updated clinical guidance, impacting both legal frameworks and future research design.
Introduction : New psychoactive substances (NPS) constitute a dynamic and diverse class of compounds marked by ongoing structural changes and expanding variability. Recent trends encompass newly developed synthetic cannabinoids, designer benzodiazepine derivatives, emerging dissociative agents, next-generation psychedelics, and highly potent synthetic opioids, as well as semisynthetic and plant-based substances such as kratom. Aim : To examine current trends and emerging developments within the NPS landscape, with a particular focus on newly identified substances, their mechanisms of action, and the clinical risks they pose. Materials and methods : A narrative review of current scientific literature and toxicological data was performed. Relevant publications were identified through nonsystematic searches of PubMed, Scopus, and Web of Science, supplemented by reports from international early warning systems, with an emphasis on newly recognized classes of NPS, their structural derivatives, and their clinical management. Results : Recent advances in the field of NPS are marked by greater molecular variability, strong receptor activity, and unpredictable pharmacokinetic behavior. Many newly developed synthetic cannabinoids function as full CB1 receptor agonists-unlike traditional cannabinoids-leading to severe clinical outcomes such as seizures, psychosis, and cardiovascular disturbances. Novel benzodiazepine-like compounds exhibit considerable toxicity even at low doses, while emerging dissociative agents and psychedelics are linked to significant neuropsychiatric effects. Synthetic opioids constitute a particularly high-risk subgroup due to their exceptional potency and narrow therapeutic window, and certain fentanyl analogues can induce fatal respiratory depression at microgram levels. Conclusion : A key clinical concern is the frequent occurrence of polydrug use, alongside the limited ability of standard toxicology screens to detect many NPS, which necessitates the use of more advanced analytical approaches. Management remains largely supportive and nonspecific, and most therapeutic recommendations are extrapolated from conventional substance use disorders. Ongoing surveillance and timely updates of toxicological knowledge are crucial to address the rapidly evolving and highly dynamic NPS market.
Neuroscience Preclinical study published

DMT and harmine modulate IL10 in TRD patient-derived microglia-like cells

DMT and harmine responses in monocyte-derived microglia- like cells from patients with treatment-resistant depression
Why it matters ◈ Mixed
This exploratory study found that DMT increased IL10 expression in microglia-like cells derived from patients with treatment-resistant depression, suggesting a potential anti-inflammatory effect. However, the small sample size and lack of matched healthy controls limit the generalizability and clinical relevance of the findings. The results highlight IL10 as a candidate biomarker for future replication studies, but do not yet inform clinical or regulatory decisions. Researchers should view this as early-stage mechanistic evidence rather than a basis for patient care or policy change.
Abstract Purpose To examine cytokine, surface-marker, and morphological responses to N, N-dimethyltryptamine (DMT) and harmine in lipopolysaccharide (LPS)-challenged monocyte-derived microglia-like cells (iMGs) from patients with treatment-resistant depression (TRD). Methods This exploratory study used assay-specific subsets of a cohort of four healthy controls and seven patients with TRD. The principal pharmacological assays used TRD-derived iMGs. Parallel cultures were compared under control conditions, LPS alone (100 ng/mL, 24 h), or LPS followed by DMT (90 µg/mL) or harmine (35 µM) for 3 h. Cytokine transcripts and surface-marker positivity were evaluated in four donors, and high-content imaging in three. Results DMT increased IL10 expression relative to LPS alone (mean difference, 0.4088; 95% confidence interval, 0.1546–0.6629; Tukey-adjusted p = 0.0134). LPS increased IL6 relative to control (adjusted p = 0.0305), whereas neither compound significantly reduced IL6 after adjustment. CD86 and CD200 positivity showed no significant condition effects. Process number showed an overall condition effect (exact Friedman p = 0.017), without significant drug-versus-LPS contrasts after Holm correction. Conclusion IL10 transcription is a candidate response measure for replication. Small donor samples, the absence of matched healthy-control pharmacological assays, and concentration-selection limitations prevent inference about disease specificity, generalized anti-inflammatory activity, or clinical efficacy.
Neuroscience Preclinical/Translational study

Adiponectin-frontothalamic pathway mediates rapid antidepressant effects of exercise

An adiponectin-frontothalamic pathway mediates the rapid antidepressant effects of acute exercise
Why it matters ▲ Favorable
This study elucidates a novel endocrine-frontothalamic mechanism underlying the rapid antidepressant effects of acute exercise, identifying a specific adiponectin-activated circuit from the ACC to the thalamus. While not directly related to psychedelics, the work offers mechanistic insight into rapid-acting antidepressant pathways, which may inform both psychedelic and non-psychedelic intervention research. It highlights the potential for exercise-based prescriptions and could inspire comparative or combinatorial studies with psychedelic therapies targeting rapid mood improvement.
Abstract Conventional antidepressants suffer from a therapeutic lag, highlighting an urgent need for rapid-acting interventions vital to preventing clinical escalation and acute depressive crises. While acute exercise provides immediate antidepressant effects, the underlying body-brain mechanisms remain elusive. Here, we identify a frontothalamic circuit mediating the rapid behavioral benefits of acute running exercise. In rodents, glutamatergic projections from the anterior cingulate cortex (ACC) to the anterodorsal thalamus (AD) are necessary and sufficient to drive post-exercise behavioral rescue. This pathway is activated by the exercise-induced release of the systemic exerkine adiponectin, which acts via AdipoR1 in the ACC to recruit downstream AD projections. Translationally, adiponectin levels after a single session of acute exercise in humans correlate with increased frontothalamic functional connectivity. Our findings map an endocrine-frontothalamic axis governing rapid mood state transitions, offering a mechanistic blueprint for targeted "exercise prescriptions" to prevent acute depressive episodes.
Clinical research Peer-reviewed review

Ketamine noninferior to ECT for treatment-resistant depression

Ketamine for Treatment-Resistant Depression
Why it matters ▲ Favorable
This review affirms that ketamine offers rapid, clinically meaningful antidepressant effects for adults with treatment-resistant depression, with efficacy comparable to electroconvulsive therapy and a more favorable adverse event profile. The findings reinforce ketamine's growing role in psychiatric practice, supporting its consideration as a frontline intervention for TRD. This evidence may influence clinical guidelines, insurance coverage, and further research investment in ketamine-based therapies.
OBJECTIVE: This discussion paper provides psychiatric nurses with a comprehensive, balanced review of the current evidence on the use of ketamine for treatment-resistant depression (TRD), including its mechanisms of action, clinical indications, administration, and key clinical considerations. METHODS: Recent clinical evidence on ketamine use for TRD is reviewed in this discussion paper. RESULTS: Current evidence indicates that among adults with TRD receiving psychiatric care, ketamine can produce rapid, clinically meaningful antidepressant effects, with an estimated number needed to treat (NNT) of 3 within 1 day to 1 week following treatment and 9 at 4 weeks. Evidence also suggests that ketamine is noninferior to electroconvulsive therapy (ECT), a well-established and highly effective treatment for severe depression and TRD. Compared with ECT, ketamine has also been associated with fewer memory-related adverse effects and a lower overall adverse-event rate (25% vs. 32%). Together, these findings support the potential role of ketamine in psychiatric practice when accompanied by appropriate patient assessment, monitoring, and follow-up. CONCLUSION: It is imperative that clinicians remain informed about emerging treatments for TRD and maintain open, informed dialogue with patients about its therapeutic potential.
Neuroscience SfN 2026 review

Review: Mechanisms of Ketamine & Psychedelics in Rapid Antidepressant Action

From Rapid Synaptic Events to Lasting Antidepressant States: Convergent and Divergent Mechanisms of Ketamine and Psychedelics
Why it matters ▲ Favorable
This review synthesizes cutting-edge research on the synaptic and circuit-level mechanisms underlying the rapid and lasting antidepressant effects of ketamine and psychedelics. By detailing convergent and divergent pathways, it informs future trial design, biomarker discovery, and therapeutic optimization for treatment-resistant depression. The focus on neuroplasticity and cell-type specificity will help researchers and clinicians target interventions more precisely, supporting translational efforts in psychedelic medicine.
Rapid-acting antidepressants have challenged the long-standing view that therapeutic improvement in major depressive disorder requires chronic treatment with monoaminergic agents. Ketamine and classical psychedelics act through distinct proximal targets, yet both can produce rapid and persistent behavioral effects that implicate synaptic and circuit plasticity as the core mechanisms of antidepressant action. This review, based on a minisymposium presented at the 2026 Society for Neuroscience meeting, examines how brief pharmacological perturbations translate into lasting changes in mood-related networks. We first discuss hippocampal mechanisms underlying ketamine action, which include brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)-dependent homeostatic potentiation, TrkB cross talk with metabotropic glutamate receptor 5 (mGluR5) at CA3→CA1 synapses, extracellular signal-regulated kinase (ERK)-dual-specificity phosphatase 6 (DUSP6)-mediated extension of synaptic metaplasticity, and BDNF release at mossy fiber synapses and dentate gyrus neuronal maturation. We then consider how these local plasticity mechanisms interface with distributed circuits that regulate motivation, stress coping, and reward. Across brain regions, emerging work highlights the importance of cell type- and region-specific mechanisms that mediate ketamine's therapeutic actions. We expand on local prefrontal cortical inhibitory cellular signaling dynamics, including the interplay of various G-protein-coupled receptors (GPCRs) in cortical somatostatin interneurons and input-specific adaptations in accumbal circuits. Finally, we compare ketamine with psilocybin, an emerging therapeutic classic psychedelic for treatment-resistant depression that targets the 5-hydroxytryptamine 2A (5-HT2A) receptor primarily. A recurring theme is that an interplay of GPCRs can help shape the timing, localization, and persistence of ketamine-induced neuroplasticity. Together, these studies suggest that antidepressant efficacy arises not from a single pathway or brain region but from coordinated, temporally staged plasticity across molecules, synapses, cells, and circuits.
Clinical research Systematic review published

Meta-analysis: Ketamine/esketamine for suicidal ideation in depression

Ketamine and esketamine for suicidal ideation in depression: a systematic review and meta-analysis of randomized controlled trials
Why it matters ◈ Mixed
This systematic review finds moderate-certainty evidence that ketamine reduces suicidal ideation acutely in depression, but the effect size is uncertain and evidence for esketamine is weaker. Safety signals (dissociation, dizziness, blood pressure) are noted, but data are limited. The findings highlight the need for larger, better-designed trials to clarify efficacy, durability, and safety, informing both clinical practice and regulatory decisions.
Abstract Background Suicidal ideation is a major clinical problem in depressive disorders, while conventional antidepressants have delayed effects. Ketamine and esketamine may provide rapid relief, but their effects on suicidal ideation, durability, suicidal behavior, and safety remain uncertain. Aim To evaluate the efficacy, durability, suicidal-behavior outcomes, acceptability, and safety of ketamine and esketamine for suicidal ideation in adults with depression. Methods PubMed/MEDLINE, Scopus, Web of Science Core Collection, and the Cochrane Library were searched from inception through 23 August 2026. Twelve randomized controlled trials (RCTs), involving 1,127 randomized participants, were included. Ketamine and esketamine were analyzed separately. The primary outcome was suicidal-ideation severity at the earliest post-treatment assessment within 24 h. A 72-hour fallback was used for suicidal-ideation remission when no earlier eligible assessment was available. Random-effects meta-analyses used restricted maximum likelihood (REML), with Hartung–Knapp confidence intervals for analyses including at least three trials and classic Wald-type confidence intervals for two-trial analyses. Results Ketamine was associated with lower suicidal-ideation severity in the primary acute analysis (5 trials; 247 participants; Hedges g = − 0.76, 95% CI − 1.14 to − 0.38; I² = 6%; moderate-certainty evidence). Esketamine showed a smaller and imprecise effect (2 trials; 286 participants; g = − 0.21, 95% CI − 0.44 to 0.02; low-certainty evidence). Evidence for suicidal-ideation remission and suicide attempts was imprecise. The acute effect of ketamine on depressive-symptom severity was uncertain, whereas esketamine reduced Montgomery–Åsberg Depression Rating Scale (MADRS) scores. Dissociation was more frequent with both interventions; dizziness and increased blood pressure were also more frequent with esketamine. These safety findings were limited by sparse data and variation in outcome ascertainment. Conclusion Ketamine showed a short-term reduction in suicidal-ideation severity in a small, methodologically limited RCT evidence base, but the magnitude of the drug-specific effect remains uncertain. Evidence for esketamine, remission, durability, prevention of suicidal behavior, and comparative safety remains limited or imprecise. Larger, better-masked trials using standardized suicidality measures and longer follow-up are needed.
Clinical research Phase 3 RCT published

Esketamine-based regimen reduces early postop anxiety in hysterectomy patients

Effect of an esketamine-based opioid-sparing perioperative regimen on early postoperative anxiety in women undergoing total laparoscopic hysterectomy: a randomized participant- and outcome-assessor-blinded controlled trial
Why it matters ◈ Mixed
This randomized controlled trial finds that an esketamine-based, opioid-sparing regimen reduced anxiety and improved recovery metrics at 24 hours post-hysterectomy, but these benefits did not persist at 72 hours. The regimen was not associated with increased neuropsychiatric adverse events, supporting its short-term safety profile. While esketamine is not a classic psychedelic, its NMDA antagonism and emerging perioperative use are of interest for researchers and clinicians exploring alternatives to opioids and adjuncts for mental health. The findings may inform future perioperative protocols and broader research into dissociative anesthetics for anxiety and recovery.
Background Postoperative anxiety is common after hysterectomy and may impair recovery. We evaluated whether an esketamine-based opioid-sparing perioperative regimen could reduce early postoperative anxiety in women undergoing total laparoscopic hysterectomy. Methods In this single-center, randomized, participant- and outcome-assessor-blinded controlled trial, women aged 45–60 years were assigned 1:1 to Group K or Group C. Group K received an esketamine-based opioid-sparing perioperative regimen comprising esketamine during anesthesia induction and maintenance and esketamine-containing patient-controlled intravenous analgesia, together with lower protocol-specified sufentanil and remifentanil dosing. Group C received a conventional opioid-based perioperative regimen, with normal saline used as the study-drug control. The primary outcome was the Self-Rating Anxiety Scale (SAS) score on postoperative day 1 (POD 1). Secondary outcomes included POD three anxiety, quality of recovery, pain, sleep, postoperative nausea and vomiting, and neuropsychiatric adverse events. Results Of 170 randomized patients, 167 were included in the modified intention-to-treat analysis (83 in Group C and 84 in Group K). POD 1 SAS scores assessed 24 h after surgery were lower in Group K than in Group C, whereas no significant between-group difference was observed at 72 h after surgery (POD 3), after completion of PCIA. Group K also had higher QoR-15 scores, lower POD 1 pain and insomnia scores, and longer device-estimated total and deep sleep duration. No statistically significant between-group differences were observed in the incidences of the recorded common adverse events. Conclusion An esketamine-based opioid-sparing perioperative regimen was associated with lower SAS scores at 24 h after surgery during the early postoperative treatment period; however, this between-group difference was not maintained at 72 h after completion of PCIA. Clinical Trial Registration [ https://www.chictr.org.cn/historyversionpub.html?regno=ChiCTR2300074484 ]: identifier [ChiCTR2300074484].
Forensic science / Legal practice Book published

New forensic drug analysis guide bridges science and legal practice

Forensic Drug Analysis for Toxicologists: From Crime Scene to Court
Why it matters ▲ Favorable
This publication provides updated methodologies and best practices for forensic toxicologists, with relevance for legal cases involving narcotic and psychotropic substances, including psychedelics. While not a direct policy or regulatory change, it may influence courtroom standards, expert testimony, and the evidentiary reliability of drug analysis in legal proceedings. Researchers and legal professionals working on psychedelic-related cases may benefit from its technical and procedural insights.
The field of forensic drug analysis is rapidly advancing, driven by innovations in technology and analytical instrumentation. These advancements have significant implications for forensic science and criminal justice. Forensic Drug Analysis for Toxicologists serves as a guide for toxicologists in forensic science, law enforcement, and the legal system, highlighting methodologies, best practices, and the integration of science within legal frameworks. This book describes advanced analytical techniques, such as instrumental methods of analysis, electromagnetic spectrum, spectrophotometry, stringent quality control protocols, and cutting-edge technologies that enhance the accuracy and reliability of toxicological assessments. By bridging technical insights with procedural requirements, this account offers a holistic understanding of forensic drug analysis and its applications. Key Features: • Provides fundamental insights and basic knowledge in forensic science, forensic medicine, and toxicology in a clear and accessible manner. • Includes an introduction to narcotic and psychotropic drugs, drug of abuse, classification and properties of NDPS, and conventional methods of analysis. • Reviews the legal framework and regulatory standards and provides tips for court testimony.
Neuroscience Peer-reviewed analysis

Philosophical critique of ego-dissolution in 5-MeO-DMT experiences

Psychedelic ego-dissolution: a philosophical and qualitative critique
Why it matters ◈ Mixed
This paper challenges prevailing interpretations of ego-dissolution in psychedelic research, arguing that even extreme 5-MeO-DMT experiences may involve a minimal form of self-consciousness rather than total selflessness. The authors' qualitative analysis of 411 trip reports highlights ambiguities in language and interpretation, urging caution in drawing ontological conclusions from subjective reports. This work may influence how future clinical and mechanistic studies conceptualize and measure ego-dissolution, with implications for therapeutic models and informed consent.
Ego-dissolution is a phenomenon of central interest across interdisciplinary research on psychedelics. In this paper, we present a philosophical and qualitative critique of the claim that ego-dissolution can result in conscious states with no phenomenal sense of self, i.e., states that completely lack any form of self-consciousness. We first turn to recent publications by Chris Letheby and Raphaël Millière, for whom trip reports of experiences induced by 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) present clear evidence for the existence of totally selfless experiential states. Their claim is undermined, we argue, by the fact that they operate with overinflated notions of 'self' and 'self-consciousness,' meaning that more minimal forms are available and arguably still present in 5-MeO-DMT experiences. We then perform a qualitative thematic analysis of 411 5-MeO-DMT trip reports. Pointing to the ambiguous language of the trip reports, the self-admitted inadequacy of the descriptions and the affective dimension of the reported experiences, we argue that claims concerning total selflessness are unwarranted and instead offer an alternative interpretation: extreme ego-dissolution during 5-MeO-DMT experiences involves a radically minimal form of self-consciousness, one in which the identity of the subject is experienced as unfamiliar and underdetermined. This article is part of the discussion meeting issue 'From being to identity: analysis and synthesis of the self'.
Clinical research Reference model published

Open reference PK/PD model for anaesthesia digital twin published

Pharmacokinetic--pharmacodynamic blueprints for the anaesthetized adult digital twin: a coupled five-layer specification with an open reference implementation
Why it matters ◈ Mixed
This open-source, multi-drug PK/PD model for anaesthesia provides a new in-silico framework for simulating and individualizing drug effects in adults. While not directly focused on psychedelics, the approach could inform future research on polypharmacy, closed-loop control, and individualized dosing in psychedelic-assisted therapies—especially for complex clinical settings. The model is not yet clinically validated, but it sets a technical foundation for more precise, data-driven interventions.
General anaesthesia is a multi-drug intervention, yet the pharmacokinetic–pharmacodynamic (PK/PD) models that guide it are applied one drug at a time. As precision anaesthesia and closed-loop control move toward clinical reality, this fragmentation becomes a central obstacle: no reference maps validated PK/PD models across drug classes onto the clinical signals they drive, specifies the interactions that couple them, and states the result precisely enough to be implemented. This review addresses that gap in three steps. First, the validated single-agent models for hypnotics, opioids, neuromuscular blockers, vasoactive drugs and volatile agents are consolidated into a covariate-aware selection guide that includes the organ-function covariates omitted by anthropometric models. Second, the resulting architecture is converted into a complete mathematical specification: an enumerated state vector with units and initial conditions, an input vector that includes surgical stimulus, the equations of five pharmacodynamic layers (hypnosis, nociception, respiratory safety, haemodynamics, neuromuscular blockade), the mechanistic couplings that link them, and an observation model that treats the bispectral index as a confounded measurement of a latent hypnotic state rather than as that state itself. Third, an open reference implementation supports three in-silico demonstrations: a coupled clinical case, a quantification of what monitor feedback adds to an open-loop population prediction, and a Fisher-information analysis of which parameters are identifiable from which signals. Individualising the twin on twenty minutes of monitoring reduced the median error of a subsequent fifteen-minute-ahead bispectral index prediction from 18.4% to 5.8%, while leaving the underlying effect-site concentration no better estimated, which delimits both the value and the limits of model-based prediction. A prioritised research agenda follows. The framework is a pharmacological substrate and an in-silico test-bench, not a clinically validated device.
Clinical research Peer-reviewed trial published

Psilocybin trial shows improved self-concept and reduced depression

Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients
Why it matters ▲ Favorable
This randomized, placebo-controlled trial provides further evidence that a single moderate dose of psilocybin can significantly reduce depressive symptoms and improve self-concept in patients with major depressive disorder. The study also links these psychological changes to specific neural markers, supporting mechanistic hypotheses about psychedelic therapy. While the sample size is modest, the findings reinforce the therapeutic potential of psilocybin and highlight self-related cognitive processes as a key target for future research and protocol development.
Abstract Psychedelic-assisted therapy, particularly with psilocybin, is increasingly proposed as a treatment for major depressive disorder, yet the neural and psychological mechanisms underlying its effects remain under investigation. In a randomized, double-blind, placebo-controlled clinical trial, individuals diagnosed with major depressive disorder received a single, moderate dose of psilocybin (0.215 mg kg−1) or placebo, with the same psychological support. We analysed N = 37 individuals with major depressive disorder undergoing assessments of depressive symptoms (Beck's depression inventory and Montgomery–Åsberg depression rating scale), self-concept (Frankfurt self-concept scale) and neural markers of self-referential processing using an fMRI-based task. Compared with placebo, the psilocybin group exhibited significant reductions in depressive symptoms and a significant increase in positive self-concept two weeks after substance administration. Changes in self-concept were significantly correlated with decreased depressive scores. Neuroimaging revealed psilocybin-associated modulation of caudate activation during externally oriented attention after two weeks, contrasting with placebo-induced caudate changes during self-referential processing. These findings extend prior evidence linking psychedelics to changes in self-referential processing and self-concept and demonstrate that such changes occur concurrently with reductions in depressive symptoms. Future research should aim to replicate and extend these results and refine therapy protocols targeting self-processing and self-concept in psychedelic-assisted therapy in major depressive disorder. This article is part of the discussion meeting issue ‘From being to identity: analysis and synthesis of the self’.
Clinical research Peer-reviewed study

Group support predicts emotional breakthrough in DMT–harmine group therapy

Beyond dose. Perceived group support as a person-level predictor of emotional breakthrough and psychological insight during DMT–harmine administration
Why it matters ▲ Favorable
This randomized-controlled trial provides evidence that perceived group support significantly predicts emotional breakthrough and psychological insight during DMT–harmine administration, independent of dose. The findings highlight the importance of social context and personality traits in shaping acute psychedelic experiences, suggesting that group dynamics may be a key variable in optimizing therapeutic outcomes. This could inform future clinical protocols and training for psychedelic-assisted therapy, especially in group settings.
Abstract Dose-escalation studies with dimethyltryptamine (DMT) show robust increases in emotional breakthrough, mystical experience, and psychological insight at higher doses, but with substantial inter-individual variability, suggesting factors beyond pharmacology shape response profiles. Growing evidence points to the clinical relevance of social factors, especially in group-based psychedelic therapy. Using data from a randomized-controlled trial, we investigated oromucosal DMT-harmine administration in a group setting and identified a three-layer architecture of acute psychedelic experience. First, dose scaled all three primary subjective outcomes. Second, perceived group support, reflecting stable between-person differences rather than session-to-session fluctuations, accounted for a substantial share of dose-independent between-subject variance in emotional breakthrough and psychological insight, though not in mystical-type experience. Third, pre-session affective personality, indexed by an approach-withdrawal composite, predicted group appraisal, with more approach-oriented profiles linked to more favorable perceptions of the group context. We situate these findings within the current research landscape and discuss the clinical implications of this three-layer framework for acute psychedelic experience.
Clinical research Commentary published

HIV-positive individuals largely excluded from pivotal psychedelic trials

As psychedelic drugs near FDA decisions, people with HIV remain absent from trials, commentary says
Why it matters ◈ Mixed
As FDA decisions on psychedelic drugs approach, the exclusion of people with HIV from clinical trials raises concerns about equity, safety, and generalizability of results. This gap could limit future access and informed prescribing for a key population with unique medical needs. Researchers and sponsors may face calls to address these exclusions in ongoing and future studies.
FDA / DEA FDA approval anticipated

Psilocybin could be first FDA-approved classic psychedelic for depression

Shrooms Could Be the First Classic Psychedelic the FDA Approves for Depression
Why it matters ▲ Favorable
If psilocybin becomes the first classic psychedelic approved by the FDA for depression, it would mark a watershed moment for both research and patient access in the US. This would set a regulatory precedent, open new pathways for clinical use, and likely accelerate investment and further research into other psychedelic compounds. The move would also have significant implications for insurance coverage, prescriber risk, and the structure of the emerging psychedelic medicine industry.
Neuroscience Review published

Review: Intranasal nanocarrier CNS delivery in MS—translational outlook

Intranasal nanocarrier-based drug delivery in multiple sclerosis: therapeutic cargo, CNS targeting and translational challenges
Why it matters ◈ Mixed
This review synthesizes the state of intranasal and nanocarrier-based CNS drug delivery for multiple sclerosis, emphasizing preclinical promise but highlighting the lack of robust clinical validation. While not directly about psychedelics, the translational challenges and comparative framework are highly relevant for psychedelic researchers seeking to optimize CNS delivery and clinical development of novel compounds. The findings underscore the need for standardized pharmacokinetic and efficacy studies before such delivery platforms can be widely adopted in neuropsychiatric or neurodegenerative indications.
Efficiently delivering therapeutics to the central nervous system (CNS) remains a major challenge in multiple sclerosis (MS), particularly for strategies targeting CNS-resident pathology, neuroprotection, or remyelination. This review provides a delivery- and formulation-centered comparative analysis of CNS drug delivery strategies for MS, integrating administration route, nanocarrier design, evidence level, and translational feasibility within a unified framework. A structured narrative review was conducted using literature identified through PubMed, Scopus, and Google Scholar, encompassing conventional and alternative administration routes, including intranasal (IN) delivery, and lipid-based, polymeric, and hybrid nanocarrier systems. Strategies were evaluated using predefined criteria, including BBB permeability or CNS exposure, targeting capability, bioavailability, formulation characteristics, and translational feasibility. A semi-quantitative heatmap based on a predefined ordinal scoring system and available experimental and clinical evidence was developed to enable transparent comparison. Conventional systemic administration may be limited by systemic exposure, first-pass metabolism, and restricted CNS access. IN administration is a promising investigational approach to enhance CNS exposure for selected compounds; however, evidence for direct nose-to-brain (N2B) transport depends on the drug, formulation, and experimental model. Nanocarriers can improve solubility and stability, protect against degradation, enable controlled release, and may enhance CNS exposure or cellular targeting in selected preclinical settings. Nevertheless, evidence for BBB penetration, direct CNS targeting, and therapeutic efficacy remains predominantly preclinical, with limited standardized pharmacokinetic and clinical validation. Overall, the comparative framework highlights the importance of jointly considering administration route, nanocarrier properties, and evidence maturity to guide rational CNS delivery design and future translational development in MS.
Neuroscience Review published

Beta oscillations as mechanistic target for psychosis predictive deficits

Beta Oscillations as a Mechanistic Target for Predictive Processing Deficits in Psychosis
Why it matters ▲ Favorable
This review synthesizes evidence that beta-band oscillations may underlie predictive processing deficits in psychosis, proposing them as a tractable physiological target. While not directly related to psychedelics, the mechanistic insights could inform future research on how psychedelic compounds interact with cortical oscillations and predictive processing, potentially guiding new intervention strategies. The findings highlight the need for standardized metrics and individualized approaches, which may shape future clinical trial designs.
Abstract Background Predictive processing abnormalities offer a unifying account of perceptual and expressive disturbances in psychosis, yet their cortical implementation remains incompletely understood. Emerging evidence positions beta-band oscillations and their transient burst dynamics as a biologically plausible mechanism through which top-down contextual information may stabilize internal models. Study Design This narrative review synthesizes evidence from electrophysiology, laminar physiology, computational modelling, language research, and clinical neuroimaging to evaluate beta oscillations as a mechanistic target for predictive processing deficits in psychosis. We integrate data from modified predictive routing frameworks and dendritic computation models to clarify how beta dynamics may prepare cortical pathways for predicted inputs. Study Results Across sensory, motor, cognitive, and language domains, schizophrenia features impaired generation, timing, and contextual deployment of beta activity. Psychomotor beta abnormalities provide the strongest direct clinical evidence, while findings related to disorganization and context-dependent cognition provide convergent support. Perceptual and positive symptom associations remain preliminary. Laminar and computational findings indicate that beta bursts can arise from the integration of apical (contextual) and basal (sensory) dendritic inputs in layer 5 pyramidal neurons, providing a mechanistic substrate for top-down predictions. Beta disruptions, therefore, may contribute to disorganization, psychomotor dysfunction, and impaired contextual stabilization. Early neuromodulation, pharmacologic, and neurofeedback studies suggest that beta dynamics are modifiable. Conclusions Beta oscillations provide a tractable candidate physiological target for linking predictive processing abnormalities to deficits in psychosis. Standardizing burst metrics and developing individualized, closed-loop approaches will be critical for advancing beta-based interventions.
Clinical research Retrospective study published

Esketamine may reduce postoperative depression risk in hysterectomy patients

A predictive nomogram based on sub-anesthetic esketamine and clinical variables for estimating the risk of postoperative depression following laparoendoscopic single-site hysterectomy
Why it matters ◈ Mixed
This retrospective study suggests that perioperative esketamine administration is associated with reduced risk of postoperative depression in patients undergoing LESS hysterectomy. The predictive nomogram developed showed good discrimination but poor calibration, indicating overfitting and limiting immediate clinical utility. While the findings support further exploration of esketamine's antidepressant effects in surgical populations, external validation is required before adoption in practice. The study adds incremental evidence for esketamine's role in perioperative mental health but does not alter regulatory or access frameworks.
Objective To construct a nomogram combining sub-anesthetic esketamine administration with perioperative clinical characteristics for predicting postoperative depression in patients undergoing laparoendoscopic single-site (LESS) hysterectomy. Methods Clinical records from 326 patients who underwent LESS hysterectomy were retrospectively reviewed. Participants were randomly assigned to training ( n =228) and internal validation ( n = 98) cohorts at a 7:3 ratio. Using the 17-item Hamilton Depression Rating Scale (HAMD-17) on postoperative day 7, patients in the training cohort were classified into depression (HAMD-17 ≥ 7) and non-depression (HAMD-17 < 7) groups. A nomogram was established, and its discrimination, calibration, and clinical utility were evaluated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). Results Postoperative depression occurred in 23.62% (77/326) of patients: 22.81% (52/228) and 25.51% (25/98) in the training and internal validation cohorts, respectively. Multivariable logistic regression identified the 12-hour postoperative visual analogue scale (VAS) score (OR = 3.165, 95% CI: 1.223–8.192), increasing age (OR = 1.126, 95% CI: 1.053–1.205), and prolonged operative duration (OR = 1.046, 95% CI: 1.014–1.078) as independent risk factors (all P < 0.05), whereas higher preoperative serum albumin (OR = 0.785, 95% CI: 0.684–0.900), single-dose esketamine (OR = 0.290, 95% CI: 0.118–0.714), and continuous-dose esketamine (OR = 0.306, 95% CI: 0.116–0.803) were protective (all P < 0.05). The nomogram achieved areas under the ROC curve of 0.884 (95% CI: 0.829–0.942) and 0.772 (95% CI: 0.637–0.906) in the training and validation cohorts. Calibration was good in the training cohort (slope = 1.000, intercept = 0.000) but was poor in the internal validation cohort (slope = 0.467, 95% CI: 0.215–0.719; intercept = −0.925, 95% CI: −1.386 to −0.464; Brier score = 0.167), indicating systematic overestimation of predicted risk and overfitting. DCA indicated favorable clinical utility. SHapley Additive exPlanations ranked predictors as operative time, age, preoperative albumin, esketamine administration, and 12-hour VAS score. Conclusion The nomogram demonstrated acceptable discrimination but poor calibration in internal validation, systematically overestimating postoperative depression risk; it should be regarded as an exploratory tool for postoperative risk stratification and requires external validation and recalibration before any clinical application. Chinese Clinical Trial Registry Number ChiCTR2500103453
Industry / FDA FDA submission announced

Compass Pathways files for FDA approval as competitors approach

Psychedelic pioneer Compass files for FDA approval as rivals close in
Why it matters ▲ Favorable
Compass Pathways' FDA submission marks a pivotal moment for the psychedelic medicine field, signaling the first major regulatory filing for a psychedelic-assisted therapy in the US. This move could set a precedent for how the FDA evaluates and potentially approves psychedelic treatments, impacting research priorities, investment, and patient access. The competitive landscape is intensifying, which may accelerate innovation and regulatory engagement. Stakeholders should closely monitor the FDA's response and the implications for future applications.
Clinical research Peer-reviewed review published

Review: Psilocybin & MDMA for treatment-resistant depression and PTSD

Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders
Why it matters ◈ Mixed
This narrative review synthesizes a decade of evidence on psilocybin and MDMA-assisted therapies for depression and PTSD, highlighting moderate efficacy and acceptable tolerability in controlled settings. However, it underscores persistent methodological limitations—such as blinding, expectancy bias, and population diversity—as well as unresolved safety concerns, especially for patients with neuropsychiatric comorbidities. The authors urge clinical caution and call for more rigorous, diverse, and long-term studies before widespread adoption, signaling both promise and ongoing uncertainty for researchers and clinicians.
Objective: To describe the pharmacological mechanisms, clinical efficacy, and safety of psilocybin- and MDMA-assisted therapies for depression and post-traumatic stress disorder (PTSD), while critically examining the methodological limitations of current evidence. Methods: This narrative, non-systematic literature review was conducted between September and November 2026. PubMed/MEDLINE was searched for publications from January 2016 to November 2026. Randomized clinical trials, systematic reviews, meta-analyses, and studies addressing mechanisms of action and safety were considered. Twelve references were selected and qualitatively synthesized. Results: Psilocybin demonstrated significant reductions in depressive symptoms, with a moderate pooled effect size (Hedges' g = 0.66). Evidence specifically concerning treatment-resistant depression remains limited. MDMA-assisted psychotherapy showed significant reductions in PTSD severity in two phase 3 trials, with favorable response and remission rates. Both interventions presented acceptable tolerability under controlled clinical conditions, although transient adverse effects were frequent. Serious adverse events were reported particularly among individuals with pre-existing neuropsychiatric conditions. Major limitations included difficulties with blinding, expectancy bias, uncertain long-term efficacy, and limited population diversity. Conclusion: Psychedelic-assisted therapies represent promising investigational approaches in psychiatry. However, methodological limitations and safety uncertainties warrant clinical caution and further rigorous research before broader therapeutic implementation.
Neuroscience Peer-reviewed study published

VR gameplay alters EEG complexity, flow, and ego dissolution

Virtual reality as a neural state-modulating technology: EEG complexity during VR gameplay versus VR gameplay viewing
Why it matters ◈ Mixed
This study demonstrates that immersive VR gameplay can modulate neural complexity and subjective states such as flow and ego dissolution, paralleling some effects seen with psychedelics. VR may offer a controllable, non-pharmacological tool for probing altered states of consciousness in laboratory settings. While not directly impacting psychedelic law or access, these findings could inform future research design and comparative studies between VR and psychedelic interventions.
Pharmacological agents and brain stimulation can modulate conscious states, but offer limited control over the structure of the experience itself. Virtual reality (VR) can alter subjective experience while allowing its structure to be experimentally controlled. Neural signal complexity has been used to characterize altered states under psychedelics and anesthesia, but its profile during immersive task absorption remains unclear. We compared VR gameplay with VR gameplay viewing in 36 adults, combining electroencephalography (EEG) with assessments of flow and ego dissolution. Participants either actively played an immersive VR game or passively viewed a prerecorded first-person gameplay video full-screen in the headset. We quantified Lempel-Ziv complexity, sample entropy, approximate entropy, and singular value decomposition entropy. VR gameplay was associated with lower EEG complexity across four broadband measures, with large effects at frontal and parietal midline sites (all corrected p < .001). The VR gameplay group also reported higher flow ( d = 1.17) and, in an exploratory comparison, higher ego dissolution ( d = 1.11). Within-condition correlations between complexity and either subjective measure did not survive correction for multiple comparisons. These findings extend neural-complexity research on altered states to immersive gameplay. VR’s capacity to vary the content and structure of an activity provides an experimental route to studying how designed experiences shape conscious state, with their neural and experiential effects assessed together.
FDA / DEA NDA submitted

COMP360 Psilocybin NDA Submitted to FDA for TRD

COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
Why it matters ▲ Favorable
COMPASS Pathways has submitted a New Drug Application (NDA) to the FDA for COMP360 psilocybin therapy in treatment-resistant depression. This is a pivotal regulatory step, signaling that the company believes its clinical data package is sufficient for review and potential approval. If accepted, this could lead to the first FDA-approved psilocybin-based therapy, reshaping access, legal risk, and the commercial landscape for psychedelic medicine in the US. Stakeholders should monitor the FDA's response and advisory committee scheduling.
Neuroscience Preclinical research published

Neutrophil-derived MMP9 mediates rapid antidepressant effects of DOM, ketamine

Deciphering MMP9‑Driven Mechanisms Underlying Rapid Antidepressant Effects from the Perspective of Neutrophil Homeostasis
Why it matters ▲ Favorable
This study identifies neutrophil-derived MMP9 as a key mediator of rapid antidepressant effects for compounds like DOM and ketamine, linking peripheral immune status to central nervous system plasticity. The findings suggest that immune profiling could inform individualized treatment strategies and highlight new molecular targets for precision psychiatry. While preclinical, this mechanistic insight may shape future trial design and biomarker development in psychedelic and rapid-acting antidepressant research.
Abstract Background: Depression exhibits marked clinical heterogeneity, and peripheral neutrophil functional status is closely associated with disease progression and treatment response; however, its role in rapid antidepressant action remains poorly understood. Methods: Taking neutrophil homeostasis as the entry point, this study integrated single-cell transcriptomic sequencing, primary cell functional assays, a Transwell in vitro blood–brain barrier (BBB) model, and three mouse models of depression with distinct neutrophil functional states to systematically dissect the immune mechanism by which matrix metalloproteinase-9 (MMP9) mediates rapid antidepressant effects. Results: The results showed that MMP9 originates predominantly from peripheral neutrophils, whereas brain-resident cells exhibit extremely low basal expression that cannot be substantially upregulated by drug stimulation. The rapid-acting antidepressants 2,5-dimethoxy-4-methylamphetamine (DOM) and ketamine (KET) activate phosphoinositide 3-kinase-protein kinase B (PI3K-Akt) signaling in neutrophils, driving polarization toward an N2 anti-inflammatory phenotype with a moderate upregulation of MMP9 expression. Under neutrophil-homeostatic conditions, MMP9 crosses the BBB via caveolin-1-mediated transcytosis in endothelial cells, without disrupting tight junctions or relying on neutrophil brain infiltration. Upon entering the brain, MMP9 degrades perineuronal nets (PNNs), restores dendritic–spine plasticity, and recovers gamma-oscillation circuit function, thereby mediating rapid antidepressant effects. Notably, therapeutic efficacy was strictly dependent on neutrophil functional status: suppression of neutrophil function depleted peripheral MMP9 supply and markedly attenuated drug responses, which could be rescued by hippocampal MMP9 replenishment; whereas hyperactivation of neutrophils generated excessive, neurotoxic MMP9, and inhibiting MMP9 activity restored drug sensitivity. Conclusions: These findings indicate that neutrophil-derived MMP9 is a key effector molecule linking peripheral immune status to central rapid antidepressant efficacy, and provide an experimental basis and novel molecular targets for neutrophil-state-based immune subtyping of depression and individualized precision intervention.
Clinical research Scoping review published

Review: LLMs in Clinical Trials—Applications, Gaps, and Validation Needs

Large Language Models Across the Clinical Trial Lifecycle: A Scoping Review of Applications, Methodologies, and Validation Gaps
Why it matters ◈ Mixed
This review systematically maps how large language models (LLMs) are being applied across clinical trial stages, highlighting both promising use cases and significant validation gaps. For psychedelic research, this signals growing opportunities to leverage AI for trial design, recruitment, and analysis, but also underscores the need for rigorous, real-world validation before widespread adoption. Stakeholders should note the current evidence gaps and prioritize transparent governance and clinical relevance as LLMs move toward operational use.
Abstract Large language models (LLMs) are increasingly being incorporated into clinical trial research, yet evidence of their utility is fragmented across isolated tasks, trial stages, model architectures, and evaluation strategies. This fragmentation makes it difficult to determine where LLMs provide meaningful value, where evidence remains preliminary, and what barriers limit their translation into routine clinical research. We therefore systematically characterized generative LLM applications across the clinical trial lifecycle, defined here as the interconnected stages of trial design, participant recruitment, trial conduct, and data analysis. We reviewed 71 studies published between January 2023 and August 2025 and examined their applications, technical approaches, and validation strategies. LLM applications were concentrated in Analysis (40.8%) and Recruitment (31.0%), followed by Design (18.3%) and Conduct (5.6%). Among all studies, 34 (47.9%) reported better performance than traditional machine-learning or previous language-model comparators, whereas 32 (45.1%) did not include such comparisons. Human-based evaluation was reported in 25 studies (35.2%), but prospective and operational validation remained limited. By mapping applications and evidentiary maturity across the full clinical trial lifecycle, this review identifies a substantial gap between rapidly expanding technical capabilities and evidence supporting real-world implementation. These findings provide a structured evidence base for prioritizing rigorous validation, transparent governance, and clinically meaningful evaluation as LLMs transition from experimental tools toward operational components of clinical research.
Clinical research Systematic review published

Systematic review: Psilocybin for anorexia nervosa shows early promise, but evidence limited

Psilocybin for anorexia nervosa: efficacy, safety, and durability of clinical effects: a systematic review of clinical trials
Why it matters ◈ Mixed
This systematic review finds that psilocybin-assisted interventions may improve eating-disorder psychopathology and related symptoms in adults with anorexia nervosa, but current evidence is limited to small, uncontrolled trials. While some benefits persisted up to 12 months, safety concerns—including serious psychiatric events and hypoglycemia—were noted. The lack of randomized controlled trials and small sample sizes preclude definitive conclusions. The review underscores the urgent need for larger, well-controlled studies to assess efficacy and safety before clinical or regulatory adoption.
Introduction: Anorexia nervosa is a severe psychiatric disorder with substantial morbidity and limited pharmacological treatment options. Psilocybin-assisted interventions have emerged as a potential novel approach, but evidence specific to anorexia nervosa remains limited. Objective: To evaluate the efficacy, safety, tolerability, and durability of psilocybin-based interventions in adults with anorexia nervosa. Methods: Registered in the International Prospective Register of Systematic Reviews (PROSPERO number CRD420261479321). The review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched. Prospective clinical trials evaluating psilocybin in adults with anorexia nervosa were eligible. Outcomes included eating-disorder psychopathology, associated psychiatric symptoms, weight-related outcomes, safety, acceptability, and durability. Findings were synthesized narratively according to study design and outcome domain. Results: Two independent uncontrolled prospective trials involving 31 participants met the inclusion criteria. Psilocybin administration was associated with improvements in global and domain-specific eating-disorder psychopathology, motivation for recovery, body-image anxiety, anxiety symptoms, eating-related preoccupations, and functional impairment, although findings were heterogeneous across outcomes. Some improvements persisted beyond the immediate treatment period, with follow-up extending to 12 months in one study. Acute tolerability was generally acceptable, although serious psychiatric events and hypoglycemia were reported. The absence of randomized comparators and the small, highly selected samples precluded causal inference and quantitative meta-analysis. Conclusion: Psilocybin-assisted interventions show promising preliminary clinical signals in anorexia nervosa, including improvements in eating-disorder psychopathology and selected associated outcomes. However, current evidence remains insufficient to establish efficacy or generalizable safety. Well-powered randomized controlled trials with rigorous medical monitoring and longer follow-up are warranted.
Neuroscience Preclinical study published

SERT inhibition reduces ketamine reward liability, preserves antidepressant effect

Serotonin Reuptake Inhibition Reduces NMDAR-Associated Reward Liability Without Compromising Rapid Antidepressant Efficacy
Why it matters ▲ Favorable
This preclinical research demonstrates that combining serotonin reuptake inhibition with NMDAR antagonism can preserve ketamine's rapid antidepressant effects while reducing its dopamine-driven reward liability. The findings suggest a path to novel antidepressants with lower abuse potential, which could address regulatory and safety concerns that currently limit ketamine's clinical use. This could influence future drug development and reshape the risk-benefit calculus for rapid-acting antidepressants.
Ketamine has changed the treatment landscape for depression by providing rapid antidepressant effects, yet its clinical utility remains limited by psychotomimetic effects and abuse potential. It remains unclear whether rapid antidepressant efficacy can be dissociated from mesolimbic dopamine activation and its associated reward-related effects. Here, we show that the serotonin reuptake inhibitor escitalopram, by enhancing serotonergic signaling, attenuates S-ketamine-induced dopamine (DA) release in the nucleus accumbens (NAc). Inspired by this finding, we designed and evaluated VV147 by incorporating SERT inhibition into NMDAR antagonism to reduce the reward-related liability of NMDAR blockade. Unlike S-ketamine, VV147 did not increase NAc dopamine signaling but retained rapid antidepressant effects in chronic stress models of depression. Together, these findings suggest a potential dissociation between rapid antidepressant efficacy and acute dopamine activation, providing a possible strategy for developing rapid-acting antidepressants with reduced dopamine-related reward effects.
Industry Series C funding

Delix raises $100M for non-hallucinatory psychedelic depression drug

J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
Why it matters ▲ Favorable
Delix Therapeutics’ $100M Series C, backed by J&J, signals major pharma interest in non-hallucinogenic psychedelic analogs for depression. This funding round validates investor confidence in next-gen neuroplastogen approaches, which may sidestep regulatory and clinical challenges tied to classic psychedelics’ hallucinatory effects. If successful, these compounds could expand access and adoption in mainstream psychiatry, but questions remain about comparative efficacy and regulatory pathways.
Clinical research Trial announced

Ketamine trial targets PTSD in emergency workers

Why it matters ▲ Favorable
A new clinical trial investigating ketamine for PTSD in emergency workers signals growing interest in novel interventions for trauma-related disorders. This study could provide valuable data on efficacy and safety in a high-risk, underserved population. Positive results may inform future access, clinical protocols, and regulatory pathways for ketamine use in mental health.
Neuroscience Genetic target study published

Genetic study identifies druggable targets for major depressive disorder

Multi‐Omics Mendelian Randomization Prioritizes Candidate Druggable Genes for Major Depressive Disorder
Why it matters ▲ Favorable
This multi-omics Mendelian randomization study prioritizes six druggable genes as potential targets for major depressive disorder (MDD), several of which are implicated in neuroinflammation and immune regulation. While not directly related to psychedelics, these findings could inform future research on the molecular mechanisms underlying depression and guide the development of novel therapeutics, including those leveraging psychedelic compounds. The identification of genetically supported targets may also influence industry R&D strategies and clinical trial design for MDD.
This study aimed to prioritize candidate druggable genes for major depressive disorder (MDD) using Mendelian randomization (MR) integrated with expression (eQTL) and protein quantitative trait loci (pQTL) data. We conducted a systematic MR analysis combining cis-eQTL and cis-pQTL data from blood and brain tissues to assess the causal effects of druggable genes on MDD, using FinnGen R9 GWAS summary statistics. Bayesian colocalization analysis confirmed shared genetic variants, while sensitivity analyses (MR-Egger, weighted median, MR-PRESSO) tested robustness. A phenome-wide MR (Phe-MR) assessed broader trait associations. To evaluate translational potential, we mapped candidate genes to known drugs using DrugBank, ChEMBL, and ClinicalTrials.gov.Six candidate druggable genes (MAPK3, PSMB9, SIGLEC9, MST1, BTN3A1, and TAPBP) showed significant associations with MDD across multiple eQTL and pQTL datasets. These genes are involved in biological processes related to neuroinflammation, immune regulation, and apoptosis. Colocalization analyses supported shared genetic signals between the identified genes and MDD, while phenome-wide analyses identified associations with additional diseases and traits that may be relevant for future translational research. Through MR analysis, six candidate druggable genes were prioritized from 6889 potential druggable genes as significantly associated with MDD. Among them, MAPK3, MST1, and SIGLEC9 showed consistent evidence across multiple analyses and emerged as genetically supported candidate targets for future investigation.
Clinical research Narrative review published

Review: Limited evidence for medication (incl. psychedelics) in FND treatment

Medication in Functional Neurological Disorder: Harm, Help or Adjunct to Psychotherapy?
Why it matters ◈ Mixed
This review finds insufficient controlled evidence that psychedelics or other medications directly benefit functional neurological disorder (FND) beyond treating comorbidities. Most evidence for drug interventions, including ketamine and psychedelics, comes from small or uncontrolled studies. The review highlights harm from inappropriate prescribing and calls for randomized trials of antidepressants and deprescribing strategies, signaling a need for more rigorous research before psychedelic therapies can be considered for FND.
People with functional neurological disorder (FND) are prescribed many drugs, yet treatment reviews focus on psychotherapy and physiotherapy and give medication little attention.This narrative review, based on a structured search of PubMed and Embase, asks three questions from a psychiatric perspective: when medication harms people with FND, what it offers for comorbid psychiatric conditions or functional symptoms, and how it should sit alongside psychotherapy.Findings are synthesised narratively; no formal risk-of-bias assessment or certainty grading was performed.Harm is the best-documented effect of medication in FND.Antiseizure drugs are often given for misdiagnosed functional seizures, and each failed drug trial is associated with a longer delay to the correct diagnosis.Benzodiazepine prescribing is common and tends to continue after diagnosis.In emergencies, prolonged functional seizures treated as status epilepticus are associated with escalating doses, respiratory depression and intubation.In case reports, some drugs, including levetiracetam and interferon, were temporally associated with the onset or worsening of functional symptoms.In small studies, withdrawal of antiseizure drugs after a confident diagnosis appeared safe and may itself have reduced attacks.Evidence of benefit is weak.Antidepressants appear to help mainly when depression or anxiety drives the presentation, and there is insufficient controlled evidence to show whether any drug adds to psychotherapy for the functional symptoms themselves.Benzodiazepines have performed no better than psychological approaches in acute settings, and placebo responses are large.Evidence for antipsychotics, drug-assisted interviews, electroconvulsive therapy, ketamine and psychedelics comes from small or uncontrolled studies.There is no good evidence that medication directly treats FND, and insufficient evidence to show whether adding it to psychotherapy improves functional symptoms.Its main roles are as a source of harm to be reviewed and withdrawn, and as support in treating comorbid depression, anxiety and post-traumatic stress disorder alongside psychological and physiotherapy-based treatment.We propose a stepwise approach: confirm the diagnosis, review and withdraw unnecessary drugs, plan emergency care, treat comorbidity, and keep psychotherapy and physiotherapy central.Randomised trials of antidepressants added to psychotherapy, and of deprescribing beyond antiseizure drugs, are research priorities.
AI & Digital Health Preprint audit announced

Audit: How LLMs Recommend Mental Health Interventions to Users

Curbside Chatbots: Auditing the Mental Health Interventions Large Language Models Recommend to Clinicians, Caregivers, and Patients
Why it matters ◈ Mixed
This large-scale audit highlights that language models are already influencing mental health advice given to clinicians, caregivers, and patients, including potential recommendations for psychedelic interventions. The findings raise concerns about consistency, appropriateness, and the risk of unvalidated or hedged advice being presented as clinical guidance. As LLMs are increasingly integrated into digital health tools, their outputs may shape patient expectations and provider decision-making, underscoring the need for regulatory and ethical frameworks. Researchers and industry should monitor how AI-driven recommendations intersect with emerging psychedelic therapies.
Users are asking language models mental health questions and are receiving answers. We audited what 41 language models recommend to users when the same clinical information reaches them from three footings: a clinician describing a patient, a caregiver describing a loved one, or a person describing themselves. Across 19 case vignettes and five questions, we collected 35,055 free-text responses, extracted every intervention named with a validated judge, and had 29 models rate the full option lists on a seven-point Likert scale for the same cases. Models largely recommend what they rate well, with recommendation behavior differing by footing, and many models offering clinicians a consultation-style response and lay users hedged, simplified advice. When asked about recommendations for a specific intervention type, models more often named options they themselves rated below zero as initial choices, usually with conditions attached. We will release the instrument, code, and full corpus on publication as a living audit.
Clinical research Review published

Review: Psychedelics as emerging treatments for gambling disorder

Current perspectives in the pharmacological treatment of gambling disorder: psychedelics and beyond
Why it matters ◈ Mixed
This review highlights growing interest in psychedelics and neuroplasticity-based interventions for gambling disorder, a condition lacking approved pharmacological treatments. While the evidence remains preliminary and largely preclinical or early-phase, the article underscores the need for adequately powered, controlled clinical trials before any clinical adoption. The review may stimulate further research and funding, but does not yet change access, legal risk, or standard of care.
INTRODUCTION: Gambling disorder (GD) is a heterogeneous behavioral addiction associated with dysregulated reward processing, impaired executive control, stress-system dysfunction, and maladaptive neuroplasticity. Despite its considerable clinical, social, and economic burden, no medication is currently approved specifically for GD, and available pharmacological strategies remain off label. AREAS COVERED: This narrative review examines established and emerging pharmacological approaches to GD. PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language literature published between January 2010 and January 2026. Opioid antagonists show the most consistent, although still limited, therapeutic signal with potential benefits in selected patients with prominent gambling urges, whereas evidence for antidepressants, mood stabilizers, antiepileptic drugs, and antipsychotics remains heterogeneous. Glutamatergic, noradrenergic, endocannabinoid, and orexin-related interventions are biologically plausible but largely experimental. Psychedelic and neuroplasticity-oriented treatments, including psilocybin, ketamine/esketamine, and 3,4-Methylenedioxymethamphetamine (MDMA)-assisted interventions, may target cognitive inflexibility, compulsive behavior, and maladaptive reward learning. EXPERT OPINION: The available evidence supports a cautious, mechanism-informed approach to pharmacological research, while underscoring the need for adequately powered clinical trials and prospective evaluation of clinically relevant treatment-response indicators. Pharmacotherapy for GD should move toward phenotype-informed, multimodal treatment rather than a one-size-fits-all model. Emerging neuroplasticity-based interventions are promising, but adequately powered, controlled, and longitudinal trials are required before clinical implementation.
Clinical research Peer-reviewed study published

Psilocybin's antidepressant effects not linked to increased SV2A binding

Rapid antidepressant effects of psilocybin without increased SV2A binding: baseline binding predicts response
Why it matters ◈ Mixed
This study challenges the hypothesis that psilocybin's rapid antidepressant effects in MDD are mediated by detectable increases in synaptic density as measured by SV2A PET imaging. While robust clinical improvement was observed, no group-level change in SV2A binding was detected, suggesting alternative mechanisms may underlie therapeutic benefit. Notably, higher baseline SV2A binding predicted better response, hinting at a potential biomarker for patient stratification in future trials. This has implications for both mechanistic research and clinical trial design in psychedelic medicine.
We report a pre-registered [11C]UCB-J PET sub-study of a recently published randomized trial in which a single psilocybin dose produced rapid and sustained antidepressant effects in major depressive disorder (MDD). Synaptic loss has been implicated in MDD, and psychedelics induce synaptic remodeling in preclinical models within 24 hours, raising the possibility that psilocybin's antidepressant effects involve increased synaptic density. We used the PET radioligand [11C]UCB-J targeting synaptic vesicle glycoprotein 2A (SV2A) to test this in thirty-five participants with moderate-to-severe recurrent MDD randomized 1:1 to a single dose of 25 mg psilocybin or 100 mg niacin placebo, both with psychotherapeutic support. [11C]UCB-J PET was performed 2-7 days before and 15 (+/-7) days after dosing. Despite significant clinical improvement in the psilocybin group, we found no evidence of a group-level increase in SV2A binding (VT or BPND) relative to niacin in the hippocampus or frontal cortex. In secondary analyses, higher baseline VT was associated with greater subsequent clinical improvement in the psilocybin group; this survived FDR correction at Day 8 and Day 15 (two of three pre-registered timepoints). Change in VT was associated with greater subsequent clinical improvement in unadjusted analyses, but these associations were attenuated after adjustment for baseline VT and baseline MADRS and did not survive FDR correction. These findings indicate that substantial antidepressant improvement after psilocybin can occur without a detectable group-level increase in SV2A binding, while raising the possibility that baseline SV2A binding could help identify individuals more likely to respond.
Clinical research Methodology debate

Psychedelic Trials Need Better Blinding: UMBRAA's Potential Role

Psychedelic Trials Need Better Blinding: What UMBRAA Could Contribute
Why it matters ◈ Mixed
Blinding remains a major methodological challenge in psychedelic clinical trials, impacting the reliability of efficacy and safety data. The discussion of UMBRAA (Unmatched Blinding Randomization and Assessment Approach) highlights ongoing efforts to improve trial design and reduce expectancy bias. While not a regulatory or legal development, advances in blinding methodology are highly relevant for researchers and sponsors aiming for robust, credible results.
Neuroscience Peer-reviewed review published

Review: Mechanisms of Psychedelic Metaplasticity and Persistence

Mechanisms of Psychedelic Metaplasticity: Intracellular Receptor Pharmacology, Epigenomic Priming and Candidate Substrates of Persistence—A Narrative Review
Why it matters ◈ Mixed
This review clarifies the current limits of mechanistic understanding for how psychedelics induce persistent effects, highlighting that claims of weeks-long biological changes are not yet causally demonstrated at the chromatin level. The article synthesizes evidence on intracellular 5-HT2A receptor pools, neurotrophin signaling, and epigenomic priming, but notes that most data are limited to a single compound, brain region, and short time windows in animal models. The authors propose falsifiable criteria to guide future research, which is critical for translating basic findings into clinical and regulatory contexts.
A single dose of a serotonergic psychedelic produces benefits that persist for weeks beyond drug elimination, yet the substrate holding that capacity across the days-to-weeks consolidation window is undefined. Psychedelics are described as metaplastogens, agents that durably modulate the capacity for subsequent plasticity rather than sustaining a plastic state. This review assembles the candidate substrates and grades the evidence as established, indirectly supported or hypothetical. Intracellular serotonin 2A (5-HT2A) receptor pools and neurotrophin convergence are reviewed. Cortical histone H3 lysine 27 acetylation (H3K27ac) data show a persistent bidirectional change at seven days: elevated elements enriched for rhythmic processes alongside depotentiated enhancers annotated to synaptic plasticity. Because acetylation turns over within minutes to hours where it has been measured-a premise untested at these elements-we propose, as a framework rather than a demonstrated mechanism, that the signal reflects a displaced regulatory set-point, not a retained mark. The evidence base is narrow: one compound, frontal cortex of adult male mice, bulk neuronal nuclei, nothing beyond seven days and no causal test. Claims of persistence over weeks therefore concern the behavioural phenotype, not the chromatin state. The review closes with six falsifiable criteria and a matrix discriminating competing accounts.
Clinical research Psychometric validation study

Polish validation of tools measuring attitudes toward psychedelics in psychology students

Assessment of the Psychometric Properties of the Polish Versions of Instruments Measuring Attitudes Toward Psychedelics and Their Therapeutic Use (APQ), and Attitudes Toward Evidence-Based Practice (EBPAS-15) Among Psychology Students
Why it matters ▲ Favorable
This study validates Polish-language tools for measuring attitudes toward psychedelics and evidence-based practice among psychology students. Reliable, culturally-adapted instruments are essential for research on clinician and student perspectives, which may influence future adoption of psychedelic-assisted therapy in Poland. While not a legal or clinical breakthrough, this work supports the infrastructure for future research, workforce training, and policy development.
Clinical applications of psychedelic substances and Psychedelic-Assisted Therapy (PAT) are areas of growing interest that also raise significant social concerns. Despite existing controversies and legal restrictions, empirical research on the use of psychedelic substances, such as psilocybin, mescaline, MDMA, LSD, DMT, and ibogaine, in the treatment of conditions including treatment-resistant depression, post-traumatic stress disorder (PTSD), existential anxiety, and substance use disorders is developing. Such research is also being conducted in Poland. Legislative processes underway in several countries in Europe, the United States, Canada, and Australia suggest that Psychedelic-Assisted Therapy (PAT) may be incorporated into clinical practice in the future. In a previous study on attitudes toward psychedelics and their therapeutic use among mental health professionals in Poland, questionnaires measuring attitudes toward psychedelics (APQ, COPS), attitudes toward evidence-based practice (EBPAS-15), trust in science (Trust in Science Short Scale), and other cognitive and existential factors were used. Using instruments in a subsequent study whose psychometric properties have not yet been sufficiently examined in the Polish population provides an opportunity to evaluate them in a separate study sample. The assessment of the psychometric properties of measurement instruments is important for determining the extent to which the scores obtained using them are reliable and valid, and whether the instruments can be used in further research. In particular, it is important to examine the properties of the Polish versions of the questionnaires in a sample of psychology students, who constitute a group of future mental health professionals. The aim of the study is to assess selected psychometric properties of the Polish versions of the APQ and EBPAS-15 in a sample of psychology students. The study will focus on evaluating the measurement properties of instruments assessing attitudes toward psychedelics and their therapeutic use and attitudes toward evidence-based practice. The main research questions are: - Do the Polish versions of the APQ, EBPAS-15 demonstrate satisfactory psychometric properties in a sample of psychology students? -Do the individual questionnaires, APQ and EBPAS-15, demonstrate satisfactory reliability? - Are the scores obtained using the questionnaires associated in ways consistent with theoretical expectations? - Can distinct profiles of students be identified based on their scores on the questionnaires measuring attitudes toward psychedelics and attitudes toward evidence-based practice? - What attitudes toward psychedelics and their therapeutic use do psychology students hold? The study will be anonymous and conducted online using standardized questionnaires and a self-developed survey. The results may contribute to a better understanding of the psychometric properties of the Polish versions of the questionnaires used in a sample of psychology students and to an assessment of their usefulness in further research on attitudes toward psychedelics and their therapeutic use, attitudes toward evidence-based practice, and trust in science. They may also provide data on the attitudes of future mental health professionals toward psychedelics and their therapeutic use.
US Customs / Import Policy Federal rule in effect

US imposes stricter rules on foreign importers of record

Heightened Requirements for Foreign Importers of Record
Why it matters ◈ Mixed
New CBP regulations increase compliance burdens for foreign entities importing goods, including controlled substances or research materials, into the US. This may complicate or delay the importation of psychedelic compounds for research, clinical trials, or commercial use, particularly for non-US manufacturers and CROs. Licensed customs brokers face greater oversight and risk, potentially affecting supply chain reliability for research and industry operators.
This document amends the U.S. Customs and Border Protection (CBP) regulations, consistent with Section 2 of Executive Order 14411, "Strengthening Customs Enforcement," by establishing new requirements for foreign importers of record (IORs) when making entry, and corresponding responsibilities for licensed customs brokers with regard to their clients. The new regulations also set forth consequences for foreign IORs and customs brokers who fail to comply with the new requirements.
Clinical research Systematic review published

Systematic review: Psilocybin therapy for alcohol use disorder shows low-certainty evidence

Psilocybin-assisted therapy for alcohol use disorder: A systematic review of randomized controlled trials
Why it matters ◈ Mixed
This systematic review finds that current RCT evidence does not establish psilocybin-assisted therapy as effective for alcohol use disorder, with all outcomes at high risk of bias and low certainty. While some trials reported reduced heavy-drinking days or improved abstinence, results were inconsistent and limited by methodological weaknesses. The review underscores the need for larger, more rigorous trials with objective endpoints and longer follow-up to clarify efficacy and safety for AUD. This is a cautionary signal for researchers, clinicians, and policymakers considering psilocybin for addiction treatment.
To critically synthesize randomized controlled evidence on the efficacy, relapse prevention, durability, and safety of psilocybin-assisted therapy in adults with alcohol use disorder (AUD), distinguishing alcohol-consumption reduction, abstinence, and relapse outcomes.PubMed, Scopus, Web of Science, and the Cochrane Library were searched without date or language restrictions.Three randomized controlled trials involving 165 participants met the eligibility criteria.Owing to clinical and methodological heterogeneity, findings were synthesized narratively without meta-analysis.One trial reported significantly fewer heavy-drinking days with psilocybin than with active placebo.A second found no significant differences in alcohol consumption, abstinence, or relapse at 4 weeks or 6 months.A small feasibility trial reported higher 12-week abstinence with 25-mg than with 1-mg psilocybin; however, this result was based on few participants and was sensitive to missing-data assumptions.Improvements in craving and selected psychiatric outcomes were also reported, but durable benefits remained uncertain.Adverse effects were generally transient, and no deaths were reported.All assessed outcomes were judged at high overall risk of bias, particularly because of functional unblinding affecting self-reported outcomes.Certainty was low for heavy-drinking days and very low for other outcomes.Current evidence does not establish the efficacy of psilocybin-assisted therapy for AUD or demonstrate relapse-prevention benefits.Larger randomized trials with credible controls, standardized therapeutic protocols, objective alcohol-use measures, and longer follow-up are warranted.
Clinical research Scoping review published

UK review maps definitions of psychedelic therapy for depression

Defining and Conceptualising Psychedelic-Assisted Therapy for Depression in the United Kingdom: A Scoping Review
Why it matters ▲ Favorable
This scoping review systematically maps how psychedelic-assisted therapy (PAT) for depression is defined and conceptualized in UK-based research, highlighting significant heterogeneity in approaches and terminology. By clarifying definitions and conceptual frameworks, the review aims to support more consistent research, clinical practice, and policy development as PAT trials expand in the UK. While not a regulatory or clinical breakthrough, this work is valuable for standardizing discourse and reducing misinterpretation risks as the NHS and UK researchers increase engagement with PAT.
Background Psychedelic-Assisted Therapy (PAT) interventions vary considerably across studies for a variety of reasons, including the nature of the condition or disorder being treated, the psychedelic substances being used, and the procedural protocols being implemented or developed. The way PAT is both defined and conceptualised in the wider literature can also vary significantly, both within and between professions. This may result from an array of factors, including one’s views on PAT’s ‘mechanisms of action’ (focus of therapeutic change), or the applied theoretical and therapeutic emphases. With such variance, there is a risk for findings to be misinterpreted, which may adversely impact both research and clinical practice. Rationale for Scoping Review With the aim of enhancing clarity within the literature base, a scoping review was planned to map definitions and conceptualisations of PAT across the literature. To offer greater clinical and research utility, focus for this review was given to PAT for one specific condition, within one geographical area, addressing the following question: “How is psychedelic-assisted therapy for depression defined and conceptualised in UK-based research, and where does conceptual heterogeneity exist?” Depression was chosen for review as it is one of the most researched areas of PAT globally. Studies were restricted to those conducted within the UK with UK populations as we hope to capture definitions and conceptualisations which may be uniquely shaped by the UK’s cultural context. Though PAT treatments may not be common practice within the UK, they are currently available in some forms in parts of the country. Clinical trials using both classic and non-classic psychedelics to support people with mental health conditions are also currently underway in the UK in partnership with the NHS (Imperial College London, 2026; Northern Centre for Mood Disorders, 2026). This suggests that the NHS may increasingly offer PAT as a treatment option. This review may support both research and clinical practice by contributing towards a shared understanding of how PAT for depression is defined and conceptualised in the UK. The enhanced clarity this review aims to produce may help facilitate multidisciplinary dialogues around PAT, mitigating risks of misunderstandings.
Professional organizations Petition announced

Psychologists petition APA for psychedelic science division

Psychologists petition to create a psychedelic science division within the APA
Why it matters ▲ Favorable
Psychologists petitioning the American Psychological Association (APA) to create a psychedelic science division signals growing mainstream acceptance and institutional interest in the field. If successful, this could increase research funding, professional legitimacy, and clinical training opportunities, while accelerating integration of psychedelic science into psychological practice. The move may also influence policy advocacy and ethical standards for psychedelic research and care.
Clinical research Headline claim

Psilocybin could be used to treat cocaine addiction

Why it matters ◈ Mixed
This headline signals growing scientific and public interest in psilocybin as a potential treatment for stimulant use disorders, including cocaine addiction. However, without details on the underlying study, trial phase, or regulatory context, the news remains preliminary. Researchers and clinicians should monitor for peer-reviewed data and trial registration to assess clinical significance and future access implications.
Neuroscience Critical review published

Review links exceptional experiences to altered states, including psychedelics

Beyond self, time, and space: exceptional experiences and altered states of consciousness
Why it matters ◈ Mixed
This critical review synthesizes evidence on exceptional (parapsychological) experiences and their overlap with altered states of consciousness, including those induced by psychedelics. It highlights methodological challenges and calls for integrating qualitative and quantitative approaches to better understand the phenomenology and mechanisms of such experiences. While not directly advancing clinical or legal access, the work may inform future research design and ethical considerations in psychedelic studies.
Exceptional experiences commonly described as parapsychological or as extra-sensory—including precognition, telepathic impressions, meaningful coincidences, and other forms of anomalous cognition—remain among the most controversial topics in consciousness research. Population studies consistently demonstrate that such experiences are widespread across cultures and appear to transcend ordinary spatial and temporal constraints. This critical review focuses on methodological challenges and theoretical implications of investigating phenomena that may suggest forms of non-local consciousness. Experimental research has produced small but statistically significant effects in several domains; however, inconsistent replication outcomes, limited effect sizes, and the apparent elusiveness of effects continue to challenge interpretation. One central difficulty is that spontaneous exceptional experiences often emerge within emotionally meaningful personal contexts that are difficult to reproduce under controlled laboratory conditions. To address this limitation, the potential contributions of qualitative approaches, including phenomenological methods that can capture the experiential richness, contextual factors, and temporal dynamics of anomalous experiences are highlighted. A particular focus of this review is the relationship between exceptional experiences and altered states of consciousness (ASC). Across meditation, psychedelic experiences, Floatation-REST, and other ASC-inducing practices, individuals frequently report mystical transformations including dissolution of body boundaries, a sense of timelessness, and unity experiences. These phenomenological characteristics closely resemble descriptions associated with non-local consciousness that appear to exceed ordinary spatial and temporal limitations. It is argued that progress in this field requires methodological pluralism, integrating rigorous quantitative experimentation with qualitative investigation of first-person experience. Such an approach may help clarify whether exceptional experiences represent cognitive constructions or indications of more fundamental properties of consciousness.
Clinical research Study result announced

Ketamine-assisted mindfulness may reduce opioid cravings via body awareness

Mindfulness therapy assisted by ketamine may strengthen body awareness to reduce opioid cravings
Why it matters ▲ Favorable
This study suggests that combining ketamine with mindfulness therapy could enhance body awareness and help reduce opioid cravings. If validated, this approach may offer a novel adjunct for opioid use disorder treatment, expanding the therapeutic toolkit beyond traditional pharmacotherapies. The findings support further research into psychedelic-assisted behavioral interventions, but clinical adoption will depend on replication and regulatory guidance.
Public health research Review published

Review: Chemsex, PrEP, and Gaps in Comprehensive Sexual Health

Bridging the Prevention Divide: Chemsex, PrEP, and the Challenges of Comprehensive Sexual Health
Why it matters ◈ Mixed
This review highlights persistent gaps in HIV prevention among chemsex participants, despite high awareness and willingness to use PrEP. The findings underscore that structural barriers—such as cost, fragmented services, and lack of provider training—are key obstacles to sustained engagement with biomedical prevention. While not a legal or regulatory move, the analysis is relevant for public health policy, harm reduction programs, and future research design, especially regarding underserved populations beyond MSM. Integrated, person-centered care models are recommended to address these divides.
This review examines the bidirectional relationship between chemsex and HIV pre-exposure prophylaxis (PrEP): chemsex practice among individuals engaged with PrEP, and PrEP awareness, willingness, and uptake among those who practice chemsex. We introduce the concept of a prevention divide, a persistent gap between elevated HIV/STI risk and sustained engagement with biomedical prevention, shaped by psychosocial, behavioural, and structural factors. Individuals who engage in chemsex, often characterized by polysubstance use, condomless sex, and multiple partners, frequently exhibit high risk for HIV and STI acquisition, yet this awareness does not consistently translate into preventive action. Despite elevated HIV vulnerability, barriers such as cost, poor mental health, and structural exclusion continue to hinder engagement with PrEP. Longitudinal and cross-sectional studies from Europe, Asia, North and South America confirm strong associations between chemsex and bacterial STIs, while also highlighting increased PrEP acceptability and adherence among high-risk subgroups. Yet, consistent with the disproportionate HIV burden among MSM, the existing literature remains largely centred on this population, leaving disaggregated data on heterosexuals, transgender people, sex workers, and migrants comparatively scarce. Across both directions, the gap is rarely one of motivation: chemsex users are frequently receptive to PrEP, and PrEP users who practice chemsex often engage strongly in the short term, but rather one of sustained structural support, as cost, fragmented services, and limited provider training determine whether prevention translates into durable protection. Integrated, person-centred care combining behavioural health, harm reduction, and social support is vital to closing this divide equitably.
Federal regulation EPA rule in effect

EPA issues SNURs for select chemicals under TSCA

Significant New Use Rules on Certain Chemical Substances (25-3.5e)
Why it matters ◈ Mixed
EPA's new Significant New Use Rules (SNURs) under TSCA impose pre-notification and review requirements for manufacturers or processors of certain chemicals, including those with potential relevance to psychedelic research or synthesis. This could impact the supply chain for research chemicals, requiring additional compliance steps and potentially delaying access for scientific or commercial purposes. While not a direct scheduling action, SNURs can create regulatory friction for labs, startups, or suppliers working with affected substances.
EPA is issuing significant new use rules (SNURs) under the Toxic Substances Control Act (TSCA) for certain chemical substances that were the subject of premanufacture notices (PMNs) and are also subject to an Order issued by EPA pursuant to TSCA. The SNURs require persons to notify EPA at least 90 days before commencing the manufacture (defined by statute to include import) or processing of any of these chemical substances for an activity that is designated as a significant new use in the SNUR. The required notification initiates EPA's evaluation of the conditions of that use for that chemical substance. In addition, the manufacture or processing for the significant new use may not commence until EPA has conducted a review of the required notification; made an appropriate determination regarding that notification; and taken such actions as required by that determination.
Neuroscience Peer-reviewed study published

Psilocybin alters nucleus accumbens via astrocytic gene regulation

Psilocybin modulates nucleus accumbens activity via astrocytic transcriptional regulation.
Why it matters ▲ Favorable
This study identifies a novel mechanism by which psilocybin modulates brain activity, specifically implicating astrocytic transcriptional changes in the nucleus accumbens. The findings deepen scientific understanding of psilocybin’s neurobiological effects, which could inform the design of future clinical trials and therapeutic strategies. This mechanistic insight may also support regulatory arguments for further research access and underscores the need to monitor non-neuronal targets in psychedelic drug development.
Neuroscience Peer-reviewed study published

Psilocybin modulates NAc activity via astrocytic transcriptional regulation

Psilocybin modulates nucleus accumbens activity via astrocytic transcriptional regulation
Why it matters ▲ Favorable
This study uncovers a novel mechanism by which psilocybin modulates inhibitory signaling in the nucleus accumbens via astrocyte-specific transcriptional regulation. The identification of astrocytic NFATc4 and ALDH5A1 as key mediators of GABA homeostasis advances understanding of how serotonergic psychedelics affect mesolimbic circuits. These findings may inform future translational research and therapeutic strategies targeting mood and addiction disorders, and provide a mechanistic basis for clinical observations.
Abstract Psilocybin is a serotonergic hallucinogen that acts primarily through 5-HT₂A receptor signaling, yet the mechanisms by which it regulates mesolimbic inhibitory tone remain poorly understood. Here we investigated how psilocybin and structurally related synthetic tryptamines modulate inhibitory signaling in the nucleus accumbens (NAc) and whether astrocyte-associated mechanisms contribute to this process. Psilocybin-like tryptamines that generalized to the psilocybin cue increased NAc neuronal activity while reducing extracellular GABA levels, identifying diminished NAc GABAergic tone as a neurochemical correlate of psilocybin-like behavioral responses. Consistent with this interpretation, local pharmacological modulation of NAc GABA receptor signaling altered psilocybin-appropriate responding. We next examined the cellular and molecular basis of this GABAergic regulation. Ex vivo whole-cell recordings revealed that psilocin, the active metabolite of psilocybin, reduced tonic GABA current in NAc medium spiny neurons without affecting miniature inhibitory postsynaptic currents, indicating preferential modulation of tonic rather than miniature synaptic inhibition. Cell-type-specific analyses further showed that psilocybin selectively reduced intracellular GABA levels in astrocytes, but not neurons. Psilocybin increased astrocytic NFATc4 and ALDH5A1 protein expression together with enhanced H3K27 acetylation, and ChIP–qPCR analysis showed increased NFATc4 occupancy at the Aldh5a1 promoter. Consistent with upstream serotonergic signaling, psilocin-induced calcium responses in astrocytes were attenuated by 5-HT₂A receptor antagonism. Together, these findings support a model in which psilocybin modulates mesolimbic inhibitory tone through astrocyte-associated regulation of NAc GABA homeostasis. Our findings further identify astrocytic NFATc4-associated transcriptional regulation as a mechanism linked to ALDH5A1 expression, astrocytic GABA homeostasis and tonic inhibitory regulation in the NAc.
Clinical practice Practice guide published

Pharmacist Guide to Psilocybin and Psychedelic-Assisted Psychotherapy

Why it matters ▲ Favorable
This publication signals growing mainstream acceptance and clinical integration of psilocybin-assisted psychotherapy. By equipping pharmacists with knowledge on pharmacology, safety, and drug interactions, it supports safer patient care as access expands. While not a regulatory or legal change, it reflects the field's maturation and the need for interdisciplinary education as psychedelic therapies move toward broader clinical use.
PURPOSE: This primer is designed to provide a broad overview of psilocybin and its use in medically supervised settings as part of psychedelic-assisted psychotherapy. This article will act as a framework to give practicing pharmacists the knowledge they need regarding pharmacology, pharmacokinetics, contraindications, adverse effects, and drug interactions that would impact safe use of psilocybin in medical settings. SUMMARY: Psychedelic-assisted psychotherapy has re-emerged in the last twenty years as a potential pathway to address a variety of mental health disorders. Interest in psilocybin has experienced a renaissance, and there have been pushes at federal, state, and local levels to expand access to this agent in research settings and within psychotherapy offices. While generally considered a very safe therapy, psilocybin does have several contraindications and clinically relevant drug-drug interactions that need to be considered when evaluating patient candidacy for psilocybin-assisted psychotherapy. CONCLUSION: Pharmacists play an important role in ensuring safe and effective use of psilocybin as it becomes more readily available and utilized across the globe. Recognition of relevant contraindications and drug-drug interactions is particularly essential to this process.
Clinical research / Rural health Perspective published

Rural health systems weigh psilocybin vs ibogaine for behavioral health

Which Psychedelic Therapy Should Rural Health Systems Pursue First: Psilocybin or Ibogaine?
Why it matters ◈ Mixed
This analysis highlights the practical and regulatory challenges rural health systems face in adopting psychedelic therapies, emphasizing psilocybin's relative readiness over ibogaine due to evidence, safety, and regulatory clarity. Ibogaine's potential for opioid use disorder is noted, but safety and evidence gaps limit its near-term viability. The piece signals where research, investment, and policy attention may focus as rural systems plan for future psychedelic service delivery.
Rural health systems encounter disproportionate behavioral health burdens, including higher suicide rates, overdose mortality, poverty, and reduced access to specialty mental health and addiction care. As psychedelic-assisted therapies move toward possible clinical implementation, rural leaders may need to decide which therapies merit investment planning. This point–counterpoint compares psilocybin and ibogaine from a rural health system perspective rather than as a conventional pharmacologic review. Psilocybin currently has a more developed clinical evidence base, service delivery model, and regulatory pathway than ibogaine, although uncertainty remains regarding efficacy, approval, reimbursement, cost, and equitable access. Ibogaine may warrant additional research investment because it targets severe or treatment-refractory opioid use disorder, a smaller but high-risk population in many rural communities. However, its cardiac risks, limited evidence from controlled trials, and need for high-acuity monitoring make broad rural implementation premature. A phased approach may allow rural systems to focus on conditional psilocybin implementation planning while supporting carefully monitored ibogaine research partnerships.
Clinical research Systematic evidence audit published

Audit: Have MDMA/psilocybin trials tested TRIM Hypothesis 3 at 12 months?

Has Hypothesis 3 of the Trauma-Resilience Integration Model (TRIM) ever been tested? A pre-registered evidence audit of the MDMA- and psilocybin-assisted therapy randomized trial literature: comparator type, outcome scale, and duration of controlled follow-up.
Why it matters ◈ Mixed
This systematic audit clarifies whether existing MDMA- and psilocybin-assisted therapy trials have rigorously tested long-term comparative efficacy against traditional therapy comparators, as specified by the TRIM model. The study does not generate new data or meta-analyze effects, but it highlights gaps in trial design—especially regarding comparator selection and long-term (12-month) controlled follow-up. This is important for researchers and regulators seeking robust evidence on the durability and comparative value of psychedelic-assisted therapy, and may inform future trial protocols and evidence standards.
The Trauma-Resilience Integration Model (TRIM; Krieger, manuscript submitted to Psychological Trauma: Theory, Research, Practice, and Policy, November 2026) prints a testable Hypothesis 3: in randomized controlled trials, psychedelic-assisted therapy (psilocybin or MDMA) outperforms a traditional-therapy comparator on a validated symptom scale, with the advantage still present at 12 months. This study is a systematic evidence audit of the published randomized trial literature for MDMA-assisted therapy and psilocybin therapy. It does not collect new data and it does not meta-analyse effect sizes. It asks whether any published trial has ever constituted a test of Hypothesis 3 as printed, by scoring every eligible trial against the hypothesis's three testability requirements (comparator type, outcome scale, controlled follow-up duration), and it reports the longest controlled follow-up in the literature and the results at the longest follow-ups, with controlled and uncontrolled data stated separately.
Clinical research Peer-reviewed study published

Oral Ketamine Studied as Adjunct for Burn Wound Care

Oral Ketamine Adjunct for Wound Care in Patients With Burn Injuries.
Why it matters ◈ Mixed
This peer-reviewed study investigates oral ketamine as an adjunctive therapy for pain management in burn wound care, expanding the clinical evidence base for ketamine's use outside anesthesia and psychiatry. The findings may inform future clinical protocols and support off-label use, but policy and access implications remain limited until larger trials or regulatory reviews are conducted. The study highlights ongoing interest in repurposing ketamine for acute care settings, which could influence both hospital practice and future research funding.
Neuroscience Peer-reviewed study published

Brain hierarchy disruptions mark Alzheimer's progression, new imaging study finds

Disruptions in brain hierarchical organisation reveal Alzheimer's disease progression
Why it matters ▲ Favorable
This study introduces an advanced neuroimaging framework to sensitively detect and stage Alzheimer's disease by assessing disruptions in brain hierarchical organization. While not directly related to psychedelics, the methodology and findings could inform future research on how psychedelic compounds affect large-scale brain networks, especially in neurodegenerative contexts. The work may help researchers design trials or biomarkers for interventions—including psychedelic-assisted therapies—targeting network-level brain changes.
Abstract Alzheimer’s disease arises from interacting amyloid, tau, and neurodegenerative processes, and is associated with large-scale network dysfunction and reduced brain dynamics complexity. However, it remains unclear whether disease progression alters the causal hierarchical organisation of large-scale brain dynamics. We examined hierarchical brain organisation across the Alzheimer’s disease continuum using multimodal neuroimaging from 134 participants in the Alzheimer’s Disease Neuroimaging Initiative (46 amyloid-negative cognitively normal, 36 amyloid-positive cognitively normal, 31 amyloid-positive mild cognitive impairment, and 21 amyloid-positive Alzheimer’s disease dementia; mean age 73.9 ± 6.2 years). Participants underwent resting-state functional magnetic resonance imaging and positron emission tomography, with amyloid and tau imaging available in 121 individuals. We estimated the generative effective connectivity using whole-brain modelling and quantified hierarchy through trophic levels and directedness using an ecology-inspired framework. Group differences were assessed using non-parametric permutation testing with covariate adjustment and false discovery rate correction. A supervised machine learning framework using logistic regression with nested cross-validation and Monte Carlo resampling evaluated whether hierarchical features could classify disease stage. Associations with amyloid, tau burden, and grey matter volume, and cognitive performance were examined using mixed-effects ridge regression and multiple linear regression adjusted for age, gender, education and APOE-ε4 carrier status. Amyloid-negative cognitively normal exhibited a well-stratified hierarchy in which somatomotor and frontoparietal regions acted as sources, the default mode network occupied an intermediate integrative position, and memory, limbic, and visual systems acted as sinks. Across the clinical spectrum, we observed a progressive flattening of hierarchical organisation, characterised by reduced trophic levels in the somatomotor, salience, control, and default mode networks, and increased hierarchical positioning of visual and thalamic regions. Hierarchical features classified disease stage, including the preclinical distinction between amyloid-negative and amyloid-positive cognitively normal, indicating sensitivity to early stages. Hierarchical alterations were associated with amyloid, tau, and neurodegeneration. Moreover, they predicted cognitive impairment across all clinical tests. These findings suggest that Alzheimer’s pathology selectively disrupts hierarchical brain organisation. Our ecology-inspired framework offers a sensitive, non-invasive approach linking molecular pathology to large-scale network reconfiguration and cognitive decline, providing additional information beyond conventional correlation-based or graph-theoretical metrics, revealing its potential as a neuroimaging marker for early detection and disease staging across the Alzheimer’s continuum.
Clinical research Peer-reviewed review published

Review: Clinical Pharmacology of 5-MeO-DMT in Treatment-Resistant Depression

From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression
Why it matters ▲ Favorable
This review synthesizes current knowledge on the clinical pharmacology of mebufotenin (5-MeO-DMT) for treatment-resistant depression, highlighting its potential as a novel therapeutic agent. While not a new trial or regulatory move, it provides a valuable resource for researchers and industry stakeholders evaluating the translational prospects of 5-MeO-DMT. The review may inform future trial design and regulatory pathways, but its immediate impact is limited by the lack of new data or citations.
Clinical research Peer-reviewed study

Ketamine alters emotional evidence integration in dynamic environments

Context-dependent effects of ketamine on emotional evidence integration
Why it matters ▲ Favorable
This double-blind, placebo-controlled study demonstrates that ketamine modulates how humans integrate emotional information over time, particularly in response to environmental volatility. The findings advance understanding of ketamine’s neurocognitive effects and may inform its therapeutic use for affective disorders. While not directly tied to regulatory or market changes, this research provides mechanistic insight relevant for clinical trial design and translational psychiatry.
Understanding others' emotions requires continuously integrating noisy affective information as emotional states change over time. Research on emotion processing, however, has thus far focused on static environments or discrete events. Here, we developed a continuous emotional evidence integration task in which participants had to track the average emotional state in a rapidly changing sequence of faces under different levels of environmental volatility. This allowed us to examine emotion integration in changing environments. In online (n=92) and in-person (n=29) cohorts, participants integrated emotional information over longer timescales in stable environments while relying more strongly on recent evidence under volatility, consistent with principles established in perceptual decision-making. We further examined whether this process was modulated by ketamine, an NMDA receptor antagonist associated with evidence integration in the perceptual domain. We conducted a double-blind, placebo-controlled, within-subject study and probed emotion integration during the post-acute period, approximately 1.5 hours after the infusion. Ketamine modulated the temporal weighting of emotional evidence, shifting the balance between recent and past information depending on environmental volatility. Together, these findings show that emotional evidence integration dynamically adapts to the statistical structure of the environment and that ketamine can further modulate this process, which may have relevance for affective disorders.
Clinical research Peer-reviewed review published

Critical review: Oral ketamine for resistant depression & suicidality

How to Give Oral Ketamine Therapy for Treatment of Resistant Depression and Suicidality: A Critical Review
Why it matters ◈ Mixed
This review synthesizes emerging evidence that oral ketamine may offer a safer, more tolerable alternative to IV ketamine for treatment-resistant depression and suicidality. However, substantial heterogeneity in dosing and administration protocols—and a lack of high-powered comparative trials—limits definitive clinical guidance. The findings highlight the need for standardized protocols and robust RCTs before oral ketamine can be widely recommended, signaling a key research gap for clinicians and industry.
Objective: To critically review the empirical literature on oral ketamine dosing strategies and administration procedures; and provide pragmatic clinical considerations for its use in out-patient psychiatric settings for treatment-resistant depression and suicidality.Methods: A structured search of PubMed and Google Scholar was conducted to identify peer-reviewed studies published till April 2026.Studies including at least ten participants with depression or suicidality receiving oral ketamine were narratively synthesized.Results: Sixteen studies were reviewed.Dosing strategies showed substantial heterogeneity.They were broadly divided into fixed-dosing (n = 11); and individualized dose-titration (n = 5) protocols.Considerable heterogeneity was observed in patient populations, dosing regimens, treatment duration, and outcome measures.Oral ketamine was most commonly prepared by diluting injectable racemic ketamine in water or juice.Several studies employed gradual ingestion ("sipping"), although direct pharmacokinetic comparisons with bolus administration are lacking.Across study designs, oral ketamine was generally associated with clinically meaningful improvements in depressive symptoms and suicidality and demonstrated superior tolerability profile compared to intravenous ketamine.Preliminary evidence suggests that repeated treatment sessions and individualized dose-titration strategies may improve tolerability and clinical outcomes; however, these observations require confirmation in adequately powered comparative trials.Conclusion: Oral ketamine therapy appears to be a promising and safer alternative to intravenous ketamine infusion for providing rapid relief in resistant depression and suicidality.Although preliminary findings suggest efficacy comparable to other ketamine administration routes, equivalence with intravenous ketamine has not been unequivocally established.Standardized treatment protocols and high-quality randomized trials are needed before definitive clinical recommendations can be made.
Neuroscience Peer-reviewed study

Immune biomarkers linked to antidepressant response and brain changes in MDD

Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
Why it matters ◈ Mixed
This study identifies peripheral immune markers, particularly IL-13, as potential predictors of antidepressant response and brain structural changes in major depressive disorder (MDD). While not directly involving psychedelics, the findings are relevant for psychedelic research as they highlight immune and neuroplastic mechanisms that may overlap with those hypothesized for psychedelic therapies. The work may inform future biomarker-driven trials and mechanistic studies in psychiatric populations, including those using novel treatments.
Immune dysregulation is implicated in major depressive disorder (MDD), but its links to clinical features and in vivo brain phenotypes remain uncertain. We examined ten plasma biomarkers in 36 unmedicated MDD patients and 48 control participants using high-sensitivity immune profiling at baseline, alongside PET/MR imaging of brain serotonin transporter (SERT) binding and regional structural measures. Patients underwent three months of antidepressant treatment and were followed up with MR imaging. Glial fibrillary acidic protein (GFAP) was higher in MDD patients (β = 0.66, 95% CI 0.22 - 1.11), and interleukin-33 (IL-33) correlated with subcortical volumes across all participants (β = 0.22, 95% CI 0.07 - 0.38). No marker correlated with SERT binding or cortical thickness after correction, and neither SERT binding nor brain structural measures differed by diagnosis. In the longitudinal analysis, interleukin-13 (IL-13) was associated with greater antidepressant response during first-line treatment with escitalopram (β = 1.09, 95% CI 0.56 - 1.61). IL-15 and IL-13 showed nominal associations with hippocampal volume increase after treatment. These findings suggest astroglial involvement in MDD and that peripheral immune states relate to subcortical brain structure. IL-13 is a candidate prognostic marker of response to selective serotonin reuptake inhibitors. Its tentative association with longitudinal changes in hippocampal volume suggests that immune processes in MDD may be related to both the capacity for clinical improvement and brain structural plasticity during treatment.
Clinical research Phase 2 trial results

iTBS may extend ketamine's antidepressant effects in TRD: Phase 2 trial

Intermittent theta burst stimulation to extend early ketamine response in treatment‐resistant depression: A preliminary enriched randomized, double‐blind, sham‐controlled trial
Why it matters ▲ Favorable
This randomized, double-blind, sham-controlled Phase 2 trial provides preliminary evidence that intermittent theta-burst stimulation (iTBS) following ketamine infusions may sustain antidepressant effects in treatment-resistant depression (TRD) patients. The study found significant overall symptom reduction with iTBS and exploratory evidence of brain network changes, though some endpoints did not reach statistical significance. These findings are relevant for researchers and clinicians seeking to improve durability of ketamine's effects, and may inform future combination protocols in TRD. Larger trials are needed to confirm clinical and mechanistic implications.
BACKGROUND: Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but these benefits diminish within days. Whether intermittent theta-burst stimulation (iTBS) can sustain ketamine response and whether such effects are associated with changes in large-scale brain networks are unclear. METHODS: Adults with TRD who exhibited an antidepressant response to two low-dose ketamine infusions (0.5 mg/kg) were randomized to 5 days of accelerated iTBS or sham stimulation. The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores across the Phase 2 period through Day 49. Resting-state functional MRI was obtained at baseline and after the stimulation course to examine thalamocortical and corticostriatal connectivity. RESULTS: Among 45 enrolled participants, 5 did not complete ketamine induction and 2 withdrew before randomization. Thirty-eight were randomized to active iTBS (n = 19) or sham iTBS (n = 19), and 37 completed follow-up through Day 49 (non-completion rate, 17.8%). In the intention-to-treat analysis, the Phase 2 mixed-effects model showed a significant overall group effect favoring active iTBS (P = 0.020), without a significant group × time interaction. Exploratory remission rates were higher with active iTBS at Days 15 and 29. Response maintenance favored active iTBS but did not reach statistical significance (log-rank P = 0.063). Exploratory fMRI analyses in 15 participants suggested differential group-by-time changes in thalamocortical and corticostriatal connectivity. CONCLUSION: In this enriched trial, ketamine infusion followed by iTBS was associated with lower overall depressive symptom severity during the randomized follow-up period through Day 49 among early ketamine responders. Exploratory fMRI analyses suggested treatment-related network changes.
Neuroscience Peer-reviewed review published

Gasdermin family reviewed in depression-linked neuroinflammation

The gasdermin family in depression-associated neuroinflammation: established evidence, emerging mechanisms, and therapeutic perspectives
Why it matters ◈ Mixed
This review synthesizes emerging evidence on the role of gasdermin-mediated pyroptosis in depression-associated neuroinflammation, highlighting GSDMD as the most substantiated target and identifying GSDME as a plausible candidate for further study. While the findings are preclinical and mechanistic, they may inform future research on novel therapeutic targets—including those relevant for psychedelic interventions that modulate neuroinflammatory pathways. The article clarifies current knowledge gaps and experimental priorities, but does not directly impact legal or regulatory frameworks.
Depression is a highly heterogeneous psychiatric disorder and represents a major public health burden. Its pathophysiology involves interacting alterations in neural, immune, metabolic, and psychosocial processes, and neuroinflammatory abnormalities appear to be particularly relevant in biologically defined subsets of patients and experimental contexts. In recent years, pyroptosis, a gasdermin-mediated form of inflammatory membrane permeabilization and lytic cell death, has attracted increasing attention as a potential link between cellular stress, immune activation, and depression-associated neuroinflammation. Current evidence is predominantly preclinical and has focused mainly on the NLRP3/caspase-1/GSDMD pathway, with depression-specific evidence being strongest for GSDMD. Importantly, however, the level of experimental support varies substantially across studies, ranging from changes in inflammasome and pyroptosis-related markers to detection of active gasdermin fragments and genetic or functional validation. In contrast, the potential involvement of other gasdermin family members remains less well established. GSDME represents a comparatively plausible emerging candidate because caspase-3-mediated cleavage can redirect apoptotic signaling toward inflammatory lytic cell death under appropriate cellular conditions. By comparison, the proposed roles of GSDMC, GSDMB, and GSDMA currently rely more heavily on mechanistic evidence from other neurological, immune, infectious, neoplastic, or barrier-associated conditions. In this review, we integrate current findings across the gasdermin family while explicitly distinguishing depression-specific evidence from mechanistic extrapolation. We further evaluate the evidence according to disease context, cell type, gasdermin cleavage, pore formation, functional cell death, and causal validation. This framework aims to clarify what is currently established, what remains biologically plausible, and which experiments are required to determine whether non-GSDMD gasdermins contribute to depression-associated neuroinflammation.
Clinical research Published study

Prior psychedelic use, diagnosis linked to support for PAT in small survey

Psychedelic Use and Mental Health Diagnosis Shape Attitudes Toward Psychedelic-Assisted Therapy
Why it matters ◈ Mixed
This small cross-sectional survey suggests that individuals with prior psychedelic use or a mental health diagnosis are more willing to recommend and support the legalization of psychedelic-assisted therapy (PAT). However, the study's limited sample size, nonrandom recruitment, and self-reported data restrict its generalizability and policy relevance. The findings highlight the need for larger, more rigorous studies to understand how experience and diagnosis shape attitudes toward PAT, which could inform future education and adoption strategies.
Psychedelic-assisted therapy (PAT) has gained renewed scientific attention as trials of psilocybin, MDMA, and related compounds report improvements in depression, post-traumatic stress disorder, and substance use disorders. Public attitudes and clinician willingness may affect future adoption, but factors associated with these attitudes remain incompletely understood. This cross-sectional study assessed whether attitudes toward PAT and daily prescription medications differed by prior psychedelic use, self-reported mental health diagnosis, and healthcare-worker status. Adults aged 21 years or older were recruited through social media and text messages to complete an anonymous online convenience survey. Ninety-nine respondents were included. Measures included lifetime psychedelic use, diagnosis status, healthcare-worker status, attitudes toward daily medication, interest in alternatives to daily medication, willingness to recommend research-supported PAT, and support for therapeutic legalization. Independent-samples 𝑡 tests and Fisher exact tests were used for group comparisons. Respondents with prior psychedelic use (𝑛 = 34) reported greater willingness to recommend PAT than those without prior use (𝑛 = 65; mean, 3.65 vs 2.40; 𝑃 = .0017) and greater support for therapeutic legalization (mean, 8.79 vs 7.61; 𝑃 = .0018). Respondents with a self-reported mental health diagnosis (𝑛 = 56) reported greater willingness to recommend PAT than those without a diagnosis (𝑛 = 43; mean, 3.88 vs 2.02; 𝑃 < .001). Interest in alternatives to daily medication was similarly high across diagnosis groups (mean, 4.16 vs 4.18; 𝑃 = .925). Healthcare-worker status was not associated with measured attitudes. Prior psychedelic use and self-reported mental health diagnosis were associated with greater willingness to recommend research-supported PAT; prior use was also associated with greater support for therapeutic legalization. The small, nonrandom convenience sample and self-reported measures limit generalizability and preclude causal inference. Larger studies should assess how education, clinical exposure, and counseling influence informed engagement with PAT.
Clinical research Mechanistic risk analysis published

Mechanistic risk analysis: BAV vulnerability to cannabis, tryptamines, neuroplastogens

The Bicuspid Aortic Valve Within the Therapeutic Window of Cannabis, Tryptamines, and Novel Neuroplastogen Analogs: A Mechanistic Risk Analysis Anchored to a Reconstructed openSNP Genotype Cohort
Why it matters ◈ Mixed
This mechanistic analysis highlights potential cardiac risks for individuals with bicuspid aortic valve (BAV) exposed to cannabis, tryptamines, or novel neuroplastogen analogs, emphasizing the need for pharmacogenomic risk stratification in psychedelic research and clinical use. The study proposes distinct risk pathways for each drug class and calls for registry-scale validation, raising important safety and ethics considerations for trial design and patient selection. While not clinical guidance, these hypotheses could inform future regulatory and research protocols, especially for populations with common cardiovascular genetic variants.
Bicuspid aortic valve (BAV) is the most common congenital cardiac malformation and converts the aortic valve and proximal aorta into unusually vulnerable target tissues: a calcification-prone valve seated in front of an aneurysm-prone media governed by transforming growth factor-β (TGF-β) signalling and nitric oxide (NO) homeostasis. We ask where the therapeutic windows of three expanding drug classes — cannabis, tryptamines (psilocybin/psilocin, DMT, 5-MeO-DMT), and non-hallucinogenic neuroplastogen analogues — sit relative to that vulnerability. We integrate receptor pharmacology (CB1/CB2; 5-HT2A/5-HT2B; biased agonism), exposure patterns separating macrodose from microdose regimens, and the convergent effector pathways through which each class could plausibly interact with BAV disease, and we anchor the analysis to a reconstructed genetic resource: the complete archived openSNP phenotype-361 (“Bicuspid aortic valve”) cohort (22 members; 19 with recoverable genotypes across a 17-SNP panel), rebuilt from Internet Archive holdings after the platform closed in April 2025. We propose that the three classes threaten BAV through separable doors — cannabis hemodynamically and vasculopathically, tryptamines through 5-HT2B-mediated valvular fibrosis, and neuroplastogen analogues, by medicinal-chemistry design, through neither — and that cumulative 5-HT2B receptor occupancy above endogenous tone, not binding affinity, is the operative risk variable. Descriptively, most genotyped cohort members carry at least one TGFB1 −509 variant allele and five of eight covered members carry a NOS3 −786C allele, demonstrating that the substrate for pharmacogenomic interaction is common rather than rare. We close with an exposure × phenotype risk-stratification matrix and six falsifiable hypotheses for a registry-scale test. This is a hypothesis-generating mechanistic analysis, not clinical guidance.
Neuroscience Theoretical framework published

New theory links DMT and ketamine anesthesia via Sigma-1 and entropic overload

Anesthesia via Dissociative Overload: A Unified Theoretical Framework Linking DMT and Ketamine Through Sigma-1 Convergence, Entropic Saturation, and Workspace Flooding
Why it matters ▲ Favorable
This paper proposes a unified mechanism for how DMT and ketamine induce anesthesia, challenging the traditional suppression model and suggesting a saturative, information-overload pathway mediated by Sigma-1 receptor activity and cortical entropy. If validated, this could reshape clinical understanding of dissociative anesthetics, inform trial design, and open new research on non-GABAergic anesthesia. The framework also generates testable predictions, potentially accelerating translational work and clarifying the neurobiological basis of psychedelic and anesthetic states.
General anesthesia has long been understood as a unitary phenomenon driven by neural suppression — a reduction in cortical activity, entropy, and complexity that renders the brain unable to sustain conscious processing. Yet two structurally and pharmacologically distinct compounds, N,N-Dimethyltryptamine (DMT) and ketamine, produce clinical unresponsiveness while maintaining or increasing cortical complexity, a pattern fundamentally incompatible with the suppression paradigm. No existing theoretical framework explains how these orthogonal compounds converge on a common anesthetic mechanism that operates through informational excess rather than deprivation. Here, we propose a novel unified framework for “Anesthesia via Dissociative Overload,” arguing that DMT and ketamine achieve unresponsiveness not by silencing neural activity but by saturating cortical information processing beyond the capacity for coherent external-world modeling. The framework integrates three levels of analysis: (1) molecular convergence on the Sigma-1 receptor (σ1R) and a prefrontal glutamate surge as shared pharmacological endpoints despite distinct primary targets (5-HT2A vs. NMDA); (2) entropic saturation, whereby maintained or elevated neural entropy during unresponsiveness reflects informational overload rather than a monitoring artifact; and (3) workspace flooding, in which mass cortical activation overwhelms the Global Neuronal Workspace’s serial bottleneck, collapsing the predictive coding hierarchy and preventing coherent broadcasting of external stimuli. This framework proposes a dual taxonomy of anesthesia — Suppressive (GABAergic, entropy-reducing) versus Saturative (glutamatergic/serotonergic, entropy-preserving) — and generates six falsifiable predictions distinguishing the two modes. The Dissociative Overload model reframes general anesthesia as a family of states unified by the failure to model external reality, achievable through either information deprivation or information saturation. While the framework is empirically grounded for ketamine, its extension to DMT-induced anesthesia constitutes a central prediction awaiting direct experimental validation.
Industry NDA submission imminent

Compass to imminently submit psilocybin depression drug for approval

Compass to submit psilocybin depression drug for approval imminently after stock wobbles
Why it matters ▲ Favorable
Compass Pathways is preparing to submit its psilocybin therapy for depression to regulators, marking a pivotal moment for psychedelic medicine and the industry. If accepted, this would be the first-ever regulatory filing for a synthetic psilocybin product targeting major depressive disorder, signaling a potential shift toward mainstream medical acceptance. The move follows notable market volatility, highlighting the high stakes and investor scrutiny in this emerging sector. Approval could set a precedent for future psychedelic drug development and access.
Clinical research Peer-reviewed study published

Polydrug use, recreational motives linked to lower PTSD after mass trauma

Polydrug use and recreational motives are associated with lower posttraumatic symptoms in survivors of a mass trauma event
Why it matters ◈ Mixed
This large, longitudinal study finds that survivors of mass trauma who engaged in polydrug use—especially for recreational rather than self-medication motives—reported lower PTSD symptom severity over time. The findings challenge assumptions about drug use post-trauma and suggest that context and motivation may play a critical role in outcomes. While not an interventional trial, the results are highly relevant for researchers, clinicians, and policymakers considering the nuanced relationship between drug use (including psychedelics) and trauma recovery. The study underscores the need for further research on motive-driven substance use and its implications for mental health interventions.
Objective: Drug use after trauma is common, but polydrug use patterns, motives, and associations with subsequent symptoms are poorly understood. We examined these associations among mass-casualty terror attack survivors, 72% of whom used drugs immediately before trauma exposure. Methods: Survivors of the October 7, 2023 Nova Festival attack reported use of six drug types (alcohol, cannabis, ketamine, stimulants, MDMA, psychedelics) and motives (avoidance, emotional regulation, self-medication, sleep, recreation) longitudinally at three timepoints (TP): 1-6 months (N=772), 8-12 months (N=453), and 17-24 months (N=302) post-attack. Separate latent class analyses of TP2 data characterized drug use, motives, and their combination. Linear regression and mixed-effects models examined associations between class membership and PTSD Checklist for DSM-5 (PCL-5) scores, adjusting for age, sex, time since trauma, and TP1 PCL-5 scores. Results: At TP2, 70% reported polydrug use, 17% used one drug, and 13% reported no use. The high drug-load class (mean 4.6 drug types) had lower PCL-5 scores than the low drug-load class (mean 1.5 drug types); this difference was evident among participants using ≥4 drug types and persisted through TP3. The self-medication-motive class had higher PCL-5 scores than the recreational-motive class. In joint analyses, recreational-motive users at both low and high drug loads had lower PCL-5 scores than participants reporting self-medication motives and primarily cannabis use. Conclusions: Polydrug use was common among the mass-trauma survivors in our study. Self-medication motives were associated with higher PTSD symptom severity than recreational motives. Unexpectedly, higher polydrug use was associated with lower PTSD symptom scores.
Preclinical research Preclinical animal study

Psychotria nemorosa alkaloids reduce fibromyalgia-like symptoms in mice

Alkaloid fraction of Psychotria nemorosa reduces fibromyalgia-like symptoms in mice
Why it matters ▲ Favorable
This preclinical study reports that an alkaloid fraction from Psychotria nemorosa reduces pain, fatigue, and anxiety-like behaviors in a mouse model of fibromyalgia, without notable adverse effects. While promising for future drug discovery, the findings are limited to animal models and do not yet translate to human clinical use. The results highlight a potential new research pathway for non-opioid, alkaloid-based treatments for chronic pain and comorbid symptoms, but further investigation into mechanisms, efficacy, and safety is essential before clinical or regulatory impact.
Fibromyalgia is a syndrome characterised by widespread chronic pain, often accompanied by comorbidities such as fatigue, anxiety, and depression. Pharmacological treatments offer only partial relief of symptoms and can cause significant adverse effects. Therefore, finding new treatments is crucial. Psychotria nemorosa, a species rich in indole alkaloids, has garnered interest due to its acute antinociceptive properties observed in vivo and its effects on monoamine oxidase A and B in in vitro assays. Additionally, alkaloids are recognised for their antinociceptive effects, as well as their anxiolytic and antidepressant properties. Therefore, we examined the effects of the alkaloid fraction of P. nemorosa in a model that simulates fibromyalgia symptoms in male Swiss. Initially, the antinociceptive effects of the fraction (3, 10, and 30 mg/kg, administered orally) were tested in capsaicin- and formalin-induced nociception, and potential adverse effects on locomotion and body temperature were evaluated. Next, the 30 mg/kg dose was tested in the reserpine-induced fibromyalgia model for mechanical, cold, and heat sensitivity, muscle strength, and behaviours resembling depression and anxiety. The P. nemorosa alkaloid fraction (30 mg/kg) decreased capsaicin- and formalin-induced nociception without affecting locomotion or body temperature. It also alleviated mechanical and cold allodynia, thermal hyperalgesia, muscle fatigue, and anxiety-like behaviour caused by reserpine, although it did not show an antidepressant-like effect. These results suggest that the P. nemorosa alkaloid fraction has therapeutic potential for treating fibromyalgia pain and related conditions such as fatigue and anxiety. They also emphasise the need for further research into its mechanisms and its long-term safety.
Neuroscience Review published

BDNF pathway reviewed as target for treatment-resistant depression

Targeting BDNF to Overcome Treatment Resistance in Depression: Research Progress from Mechanism to Clinic
Why it matters ▲ Favorable
This review highlights the central role of BDNF/TrkB signaling in treatment-resistant depression and outlines molecular mechanisms underlying antidepressant response and resistance. The article synthesizes evidence on genetic, epigenetic, and environmental factors influencing BDNF function, and proposes BDNF-targeted strategies for precision psychiatry. For psychedelic research, the findings are highly relevant as many psychedelic compounds (e.g., psilocybin, ketamine) are hypothesized to exert antidepressant effects via neuroplasticity and BDNF modulation, informing both mechanistic studies and clinical trial design.
Depression ranks among the top causes of disability worldwide. About 40%-50% of the patients have insufficient response to conventional antidepressants, and treatment resistance has become a core clinical bottleneck. BDNF, as a key regulatory molecule of neuroplasticity, is regarded as the common final pathway of antidepressant action. This article systematically reviews the biological basis of the BDNF/TrkB signaling pathway and its differential mechanisms in treatment sensitivity and resistance. In the sensitive state, antidepressants up-regulate BDNF in the hippocampal dentate gyrus and TrkB signaling in the dorsal raphe nucleus through epigenetic modification, and promote neurogenesis and synaptic remodeling; in the resistant state, the high methylation of the BDNF promoter, the imbalance of pro-BDNF/mBDNF conversion, the disorder of TrkB conduction and the impairment of neurogenesis together constitute the molecular basis. In addition, this article sorts out the regulatory effects of genetic polymorphism, environmental stress, inflammation and the gut microbiota-gut-brain axis on the BDNF treatment response, and discusses the BDNF-based treatment stratification strategy, and holds that targeting the BDNF system is expected to provide a new strategy for the precise treatment of treatment-resistant depression.
Neuroscience Peer-reviewed study published

New 5-HT2A receptor pathway linked to psychedelic drug effects discovered

A novel 5-HT 2A receptor-linked signalling pathway involving NAADP-mediated lysosomal Ca 2+ release
Why it matters ▲ Favorable
This study identifies a previously unknown NAADP-mediated lysosomal Ca2+ signaling pathway downstream of the 5-HT2A receptor, activated by both serotonin and psychedelic drugs. The pathway appears to be essential for both hallucinogenic and neuroplastic effects in animal models, suggesting a new mechanistic target for therapeutic development. This finding could inform the design of next-generation psychedelics and help explain differential effects among compounds, with implications for both basic research and clinical translation.
Currently there is major research interest in the therapeutic potential of serotonergic psychedelic drugs across a range of neuropsychiatric disorders 1-3 . Such drugs exert psychedelic and neuroplastic effects, both likely linked to therapeutic outcomes, via agonist action at the 5-HT 2A receptor 4-7 . This receptor is assumed to generate downstream intracellular signalling via an interaction with either G q protein coupling and formation of the second messenger inositol trisphosphate (IP 3 ), or through triggering the effector β-arrestin2. Central to the IP 3 pathway is mobilisation of Ca 2+ stored in the endoplasmic reticulum (ER). Here, we report the unexpected discovery that the 5-HT 2A receptor also signals via an additional second messenger, nicotinic acid adenine dinucleotide phosphate (NAADP), which mobilises Ca 2+ release from lysosomal stores. This effect was revealed through measurement of changes in cellular NAADP levels, pharmacological inhibition of NAADP and direct biosensor measurement of lysosomal Ca 2+ release and was produced not only by 5-HT but also by a range of psychedelic drugs in a receptor-specific manner. Moreover, genetic ablation of the NAADP pathway reduced markers of both hallucinogenic and neuroplastic effects of psychedelic drug administration in mouse models. These findings reveal the involvement of a novel, therapeutically relevant signalling pathway in psychedelic drug action.
Neuroscience Preclinical study published

Ketamine shows anti-dyskinetic and anti-parkinsonian effects in female rats

The anti-dyskinetic and the anti-parkinsonian effects of sub-anesthetic ketamine are also present in female preclinical models
Why it matters ▲ Favorable
This preclinical study demonstrates that sub-anesthetic ketamine reduces dyskinesia and improves motor function in female rat models of Parkinson's disease, mirroring prior results in males. The findings address a critical gap in sex representation in neuropharmacology and support the translational rationale for clinical trials of ketamine in L-DOPA-induced dyskinesia (LID) across sexes. This could inform future research design and regulatory considerations for repurposing ketamine in movement disorders.
Biological sex is an important determinant of neuropharmacological response, yet females remain underrepresented in preclinical studies of Parkinson's disease (PD) and L-DOPA-induced dyskinesia (LID). We previously demonstrated that sub-anesthetic ketamine reduces established LID, attenuates dyskinesia development, and produces anti-parkinsonian effects in male unilateral 6-hydroxydopamine (6-OHDA) rat models. However, whether these therapeutic effects extend to females remained unknown. Here, we evaluated the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine in female Sprague-Dawley rats using the attenuation and established models of LID. In the attenuation paradigm, unilateral 6-OHDA-lesioned females received repeated L-DOPA administration with either ketamine (20 mg/kg, i.p.; 10-h dosing paradigm) or vehicle. Ketamine significantly attenuated the progressive development of dyskinesia, indicating that early intervention modified the trajectory of LID expression. In the established LID paradigm, ketamine produced robust significant acute reductions in abnormal involuntary movements (AIMs) after dyskinesia had fully developed, and these significant effects persisted for up to 49 days following treatment, demonstrating sustained suppression of dyskinesia severity. To determine whether ketamine altered therapeutic motor function, forelimb adjusting steps testing was performed in female unilateral 6-OHDA rats. Ketamine did not impair L-DOPA-mediated motor improvement suggesting compatibility with the gold standard medication. Ketamine was also by itself associated with significantly improved stepping performance during ketamine treatment conditions, indicating acute anti-parkinsonian motor benefit. Together, these findings demonstrate that the anti-dyskinetic and anti-parkinsonian effects of ketamine extend to female preclinical models and strengthen the translational rationale for repurposing sub-anesthetic ketamine as a potential therapeutic strategy for individuals with LID.
Clinical research Systematic review published

Systematic review: Psilocybin therapy for cancer-related distress shows promise

Psilocybin-Assisted Therapy for Cancer-Related Psychological and Existential Distress in Adults with Cancer: An Integrative Systematic Review
Why it matters ▲ Favorable
This systematic review synthesizes evidence that psilocybin-assisted therapy yields rapid, durable reductions in depression, anxiety, and existential distress among adults with cancer, with no serious adverse events reported. The review highlights both the therapeutic potential and the need for further rigorous, controlled studies, particularly in palliative care. The findings may inform future clinical trial design, regulatory decisions, and access discussions for this population.
Psilocybin-assisted therapy has reemerged as a promising intervention for distress associated with cancer and life-threatening illness. This integrative systematic review evaluated evidence on the safety, efficacy, and therapeutic impact of psilocybin-assisted therapy in adults with cancer experiencing depression, anxiety and existential distress. Following PRISMA guidelines, PubMed, Scopus, Google Scholar, and CINAHL databases were searched from 10 August 2025 to 31 October 2025. Eleven eligible reports derived from six independent clinical cohorts met inclusion criteria. Psilocybin was generally administered as a single supervised moderate-to-high dose (25-30 mg/70 kg), within structured preparation, dosing, and integration. Across all designs, psilocybin produced rapid and enduring reductions in depression, anxiety, existential distress, and fear of death, with benefits lasting 2-6 months and, in some cases, up to 4.5 years. Qualitative findings highlighted enhanced emotional clarity, acceptance, spiritual well-being, and reconnection with meaning. Five of the 11 reports met Mixed Methods Appraisal Tool (MMAT) criteria; concerns in others involved assessor blinding, representativeness, confounding control, or mixed-methods integration. No psilocybin-related serious adverse events were reported; transient cardiovascular changes, headache, nausea, anxiety or emotional distress, and occasional brief psychotic-like symptoms occurred. Psilocybin-assisted therapy may be promising but still investigational palliative pharmacotherapy-related intervention for cancer-related psychological and existential distress.
Clinical research Preprint released

Scoping review of outcomes in psychedelic therapy for life-limiting illness

Outcomes and measurement instruments in clinical trials of psychedelic-assisted therapy for life-limiting illness: a scoping review
Why it matters ◈ Mixed
This preprint reviews how outcomes and measurement tools are selected in clinical trials of psychedelic-assisted therapy for patients with life-limiting illnesses. Standardizing outcome measures is crucial for comparing studies and advancing evidence-based practice in this emerging field. While not a regulatory or legal development, this work informs trial design and may influence future guidelines for research and care.
Clinical research Narrative review published

Real-world esketamine outcomes surpass trials: review analyzes causes

INTRANASAL ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION: WHY DO REAL-WORLD CLINICAL PRACTICE OUTCOMES SURPASS THOSE OF CLINICAL TRIALS? A NARRATIVE REVIEW
Why it matters ◈ Mixed
This review highlights a key discrepancy: real-world clinical outcomes for intranasal esketamine in treatment-resistant depression appear stronger than those reported in controlled trials, largely due to methodological differences. The findings caution against overinterpreting real-world effectiveness as proof of greater efficacy, emphasizing the need for rigorous comparative studies and ongoing outcome monitoring. This matters for clinicians, payers, and policymakers assessing esketamine's value, as well as for researchers designing future studies and registries.
Intranasal esketamine was approved for the treatment of treatment-resistant depression on the basis of randomized clinical trials whose effects, when pooled in meta-analyses, were of modest magnitude. In contrast, observational studies conducted in routine clinical practice have reported substantial symptom reductions and increasing remission rates over follow-up. This review aimed to critically analyze the discrepancy between the efficacy observed in clinical trials and the effectiveness described in real-world studies, discussing the methodological, clinical and pharmacological factors that may explain it. This is a narrative literature review, with searches in the PubMed/MEDLINE, Scopus, Web of Science and Cochrane Library databases, covering publications from 2019 to 2026 and selecting twelve core references, including pivotal trials, meta-analyses, prospective cohorts and retrospective studies. The evidence shows that clinical trials yielded modest differences relative to the comparator, largely because the control group also received a new oral antidepressant and because placebo response in ketamine and esketamine studies is high. In real-world studies, the absence of a control group, therapeutic expectation, patient selection, dose flexibility and loss to follow-up tend to inflate effect sizes, although these settings also reveal progressive functional gains and benefits in populations excluded from trials. It is concluded that the apparent superiority of clinical practice outcomes should not be interpreted as evidence of greater efficacy, but rather as a reflection of different designs and questions. The critical integration of both sources, combined with controlled comparative studies and the monitoring of functional outcomes, is necessary to guide the rational use of esketamine in treatment-resistant depression.
Clinical research Systematic review published

Systematic review highlights gaps in PAP implementation research

From Evidence to Practice: A Systematic Review of Implementation of Psychedelic-Assisted Psychotherapy
Why it matters ◈ Mixed
This systematic review identifies a significant lack of research on the real-world implementation of psychedelic-assisted psychotherapy (PAP). While efficacy evidence for PAP is growing, the translation of these therapies into accessible clinical practice remains underexplored. The review underscores the need for more implementation science to guide safe and effective adoption, which is critical for researchers, clinicians, and industry stakeholders planning for future scale-up and regulatory compliance.
Background: Evidence supporting psychedelic-assisted psychotherapy (PAP) for treating posttraumatic stress disorder, depression, and other historically difficult to treat mental health disorders is growing rapidly. Interest from the public and within the US government to provide access to these treatments has also grown. Considering the gap between discovery of effective treatments and implementing them in clinical settings, it is important to synthesize current knowledge of implementing these complex treatment modalities to aid efforts for systematic implementation going forward. Objectives: The specific objectives of this systematic review were to: (1) identify extant literature on implementation of PAP, and (2) synthesize and present findings to understand current implementation knowledge and inform future directions. Methods: This systematic review followed the procedures outlined in Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. Six databases were searched using a string developed with the keywords “implementation,” “psychedelic (methylenedioxymethamphetamine, psilocybin, lysergic acid diethylamide, ketamine),” and “psychotherapy” along with Elsevier expansions and synonyms. The study only included peer-reviewed research on PAP, which reported on the implementation of the interventions. The implementation science framework, the Practical, Robust, implementation and Sustainability Model, guided the data extraction and synthesis about implementation-relevant factors. Results: A total of 2,406 articles were identified, and 2,074 of these were screened by title and abstract after the initial elimination of duplicates and sources that were not peer-reviewed research articles (e.g., gray literature). Forty-seven were retrieved for full text review, and 20 studies were included in the review. Most studies (15) were cross-sectional surveys and/or qualitative interviews assessing organizational perspective. The remaining (5) presented included aspects of patient perspective (2), infrastructure (2), and patient characteristics (1). Conclusion: There is a noticeable gap in implementation-focused research on best practices for translating PAP from academic settings into accessible clinical programs. Addressing this gap is essential to support the safe and effective implementation of PAP in real-world settings.
Neuroscience Preclinical multi-lab study

Multi-lab study finds modest, inconsistent persistent effects of psilocybin in mice

A multi-institutional investigation of psilocybin’s effects on mouse behavior
Why it matters ◈ Mixed
This large, multi-institutional preclinical study challenges prior claims about robust, lasting behavioral effects of psilocybin in animal models. While acute effects were reliably observed, persistent changes in anxiety, depression-like behaviors, and social learning were not consistently replicated across labs. These findings raise important questions about the translational value of preclinical psilocybin research and underscore the need for rigorous, reproducible science before extrapolating to clinical outcomes.
Studies reporting novel therapeutic effects of psychedelic drugs are rapidly emerging. However, the reproducibility and reliability of these findings could remain uncertain for years. Here, we implemented a multi-institutional collaborative approach to define the robust and replicable effects of the psychedelic drug psilocybin on mouse behavior. Five laboratories performed the same experiments to test the acute and persistent effects of psilocybin (2 mg/kg, IP) on various behaviors that psychedelics have been proposed to affect, including anxiety-related approach-avoidance, exploration, sociability, depression-related behaviors, fear extinction, and social reward learning. Through this coordinated approach, we found that psilocybin had several robust and replicable acute effects on mouse behavior, including increased anxiety- and avoidance-related behaviors and decreased fear expression. Surprisingly, however, we found that psilocybin did not have replicable effects 24 hours post psilocybin administration on reducing anxiety- and depression-like behaviors or facilitating fear extinction learning. Additionally, we were unable to observe psilocybin-induced alterations in social preference or social reward learning. Overall, our comprehensive characterization of psilocybin's acute and persistent behavioral effects using ~200 total male and female mice per experiment spread across five independent labs demonstrates with unique certainty several acute drug effects and suggests that psilocybin's persistent effects in mice may be more modest and inconsistent than previously suggested. We believe this unusual multi-laboratory, highly coordinated research effort serves as a model for facilitating the generation of replicable results and consequently will reduce efforts based on unreliable and spurious results.
Neuroscience Peer-reviewed study published

AI-guided chemistry yields novel 5-HT2A agonist and antagonist candidates

Mechanism-guided generative chemistry yields distinct agonist-like and antagonist-like ligand populations for the serotonin 5-HT2A receptor
Why it matters ▲ Favorable
This study demonstrates a sophisticated AI-driven approach to designing novel ligands for the serotonin 5-HT2A receptor, a key target in psychedelic drug development. The workflow successfully generated chemically distinct agonist-like and antagonist-like molecules, potentially accelerating the discovery of new therapeutic compounds. While the results are computational and require experimental validation, the approach could streamline preclinical candidate selection and diversify the pipeline for both psychedelic and non-psychedelic CNS drugs.
Abstract Designing serotonin 5-HT2A receptor ligands with a specified functional direction is difficult because binding affinity, assay-derived mechanism labels, molecular properties and receptor conformation are only partially coupled. We developed a mechanism-guided generative chemistry workflow integrating curated ChEMBL data, scaffold-aware supervised learning, a recurrent SMILES prior, reinforcement learning, medicinal-chemistry prioritization, receptor-context docking, MM-GBSA rescoring and property-adjusted contact analysis. The dataset comprised 8,949 measurements and 6,252 compounds. A five-seed binding Ki ensemble achieved scaffold-test mean absolute error of 0.588 pChEMBL and R² of 0.607; non-generalizing functional EC50 models were excluded from the reward. Separate campaigns generated 500 valid unique agonist-like and 500 antagonist-like molecules. Antagonist-like candidates showed higher predicted affinity and mechanism-label confidence, whereas agonist-like candidates showed higher QED, greater internal diversity and lower training-set similarity. Matched frozen-prior sampling showed only modest policy-level shifts from the already HTR2A-focused prior, whereas the reward-retained candidate populations were strongly enriched for the campaign objectives. Native-ligand redocking reproduced four deposited poses with heavy-atom RMSD values of 0.357–1.082 Å. Under fully contact-neutral pose selection and the prespecified repeated-measures model, S242, L229 and L362 showed FDR-supported campaign-by-receptor-context interactions; S242 and L229 retained the directions observed with the original selector, whereas L362 emerged in the contact-neutral analysis. The study identifies distinct model-defined chemical regimes and links campaign-level property drift to receptor-contact topology; generated compounds remain computational hypotheses requiring experimental validation.
Neuroscience Peer-reviewed study published

INMT enzyme mapped near Golgi in human neurons, clarifying endogenous DMT synthesis

Mapping Endogenous Psychedelic Chemistry: Indolethylamine N-Methyltransferase (INMT) Localizes Proximal to the Golgi Apparatus of Human Neurons
Why it matters ▲ Favorable
This study provides the first protein-level evidence of INMT localization in human neurons, clarifying where endogenous DMT may be synthesized in the brain. By mapping INMT to the cis-Golgi network, the research offers a mechanistic basis for the role of endogenous psychedelics and may inform future clinical and therapeutic strategies. These findings could help bridge basic neuroscience with clinical research on psychedelic mechanisms, supporting new hypotheses for psychiatric treatment.
N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic with a history of ethnobotanical use and emerging clinical efficacy for neuropsychiatric disorders. Following Julius Axelrod's pioneering studies showing DMT production in human tissues, DMT has been proposed as an endogenous neuromodulator because it is a serotonin 2A receptor (5-HT2A R) agonist. However, the DMT-producing enzyme, indolethylamine N-methyltransferase (INMT), has not been characterized at the protein level in the human central nervous system. Here, we validated an anti-INMT antibody and used immunocytochemistry to show that INMT localizes in close proximity to other DMT biosynthetic enzymes near the cytosolic face of the cis-Golgi network in human induced pluripotent stem cell-derived neurons, with immunoreactivity observed across multiple neuronal Golgi phenotypes. Notably, both DMT-like and 5-HT2A R immunoreactivity also partially localized in close proximity to the Golgi apparatus. Our results establish the first protein-level characterization of INMT in human neurons and identify the cis-Golgi network as a candidate microdomain for psychedelic tryptamine biosynthesis. We propose that INMT catalytic activity at the cis-Golgi network creates an enriched region of membrane-permeable psychedelic tryptamines that can access an intracellular 5- HT2A R pool. These findings provide new tools and insights that can inform efforts to understand the mechanism of action of psychedelics under clinical investigation and to target endogenous tryptamines therapeutically.
Neuroscience Theoretical framework published

New theory: Authority-Level Priors constrain identity in predictive processing

Authority-Level Priors: An Under-Specified Constraint in Hierarchical Predictive Processing
Why it matters ◈ Mixed
This paper proposes a new computational model—Authority-Level Priors (ALPs)—that could explain why explicit belief change often fails to shift stress reactivity or autonomic responses, a phenomenon relevant to psychedelic therapy and mental health interventions. The model suggests that certain identity-level beliefs are structurally protected from revision, which may help clarify why some therapeutic effects are durable or resistant. While not directly about psychedelics, the framework could inform future research on how psychedelic experiences interact with identity-level priors and regulatory processes, potentially guiding clinical trial design and mechanistic hypotheses.
Abstract Hierarchical predictive processing explains adaptive behaviour through precision-weighted inference within a single generative model. Yet explicit belief revision and increased confidence in adaptive self-models often fail to produce corresponding changes in stress reactivity or autonomic regulation. This asymmetry suggests that the framework leaves formally under-specified a governance-level constraint concerning which identity-level hypotheses are permitted to regulate autonomic and behavioural control under uncertainty. We introduce Authority-Level Priors (ALPs) as meta-structural constraints defining a regulatory-admissible subset ${\mathcal{H}}_{\mathrm{auth}}\subset \mathcal{H}$ of identity-level hypotheses. ALPs are not additional representational states, nor hyperpriors over precision; rather, they constrain which hypotheses are admissible for regulatory control, independent of precision-weighted inference operating within that admissible set. Precision determines influence conditional on admissibility, whereas ALPs determine admissibility itself. This distinction offers an explanation for why explicit belief updating and repeated practice readily modify representational beliefs while autonomic threat responses and identity-level predictions often remain stable despite contradictory evidence and sustained effort. We provide a minimal computational formalisation in which policy optimisation is restricted to policies generated by authorised hypotheses, yielding testable predictions concerning stress-reactivity dynamics, recovery time constants, compensatory control engagement, and cross-context behavioural persistence. Neurobiologically, ALPs are hypothesised to manifest functionally through distributed prefrontal arbitration and control networks involved in rule maintenance, conflict monitoring, and top-down modulation. The proposal is compatible with variational active inference and introduces no additional inferential operators, instead formalising a boundary condition required for determinate identity–regulation mapping when multiple high-precision hypotheses coexist. Such a restriction is expressible within existing active-inference schemes; what ALPs specify is a constraint indexed to identity-level hypotheses that is not obligatorily revised by the evidence updating their posterior probability or precision. The central discriminating prediction is that regulatory change following a governance shift should not be anticipated by model-based estimates of posterior probability or precision obtained independently of regulatory measures. ALPs are advanced as an architectural hypothesis to be evaluated through computational modelling and longitudinal stress-induction paradigms.
Clinical research Systematic review published

Systematic review finds no effective drugs for prolonged grief disorder

Pharmacological treatment of bereavement-related distress: a systematic review
Why it matters ◈ Mixed
This systematic review finds no evidence that current pharmacological treatments are effective for prolonged grief disorder, underscoring a significant unmet need in mental health care. The lack of effective medications may open the door for research into novel interventions, including psychedelic-assisted therapies, for bereavement-related distress. Researchers and industry stakeholders may see this as justification for prioritizing clinical trials of psychedelics in this indication. Weak study quality and inconsistent reporting highlight the need for rigorous future trials.
Background: With the recent addition of prolonged grief disorder into diagnostic manuals both in the United States (i.e. DSM-5-TR) and internationally (i.e. ICD-11), interest in pharmacologic treatment for grief has increased.Objective: Here, we review how bereavement-related psychological distress, including treating depression secondary to bereavement, has been addressed pharmacologically and the efficacy of these treatments.Methods: Included studies focused on (1) patients bereaved by any cause, (2) patients suffering from bereavement-related mental health problems, and (3) pharmacotherapy interventions to treat those bereavement-related mental health problems. Six databases (MEDLINE, Embase, the Cochrane Library, APA PsycInfo, Scopus, and Web of Science) were searched on 1 October 2020, and updated through 18 December 2024. Studies were selected by two independent reviewers and data were extracted and analysed qualitatively and quantitatively, with meta-analysis performed to calculate standardized mean differences (SMD) of treatment effects. Bias was assessed using the NIH Study Quality Assessment Tools.Results: Thirty-three studies (10 case series/studies, 7 cohort studies, 16 clinical trials) comprising 211,920 participants met eligibility criteria. Of nine medication classes represented, antidepressants were most commonly studied. No medications reduced grief symptomatology across any controlled studies; antidepressants and a beta blocker plus aspirin intervention appeared efficacious for depression symptomatology in bereaved individuals. SMD of effect of pharmacologic intervention on grief over control was negligible (−0.06 [95% CI, –0.31–0.19], data from three studies); SMD of effect of pharmacologic intervention on depression over control was small and not significant (–0.29 [95% CI, –0.68–0.10], data from two studies). Overall, study quality was low.Conclusions: Weak methodology and inconsistent data reporting presented challenges to synthesizing results. There is no evidence to support the use of current pharmacologic treatment for prolonged grief disorder, highlighting the need for further research to fill this gap in treatment options.
Neuroscience Preprint released

LaBraM: Large-scale EEG foundation model sets new benchmarks

LaBraM at Scale: Scaling Data and Models for EEG Pretraining
Why it matters ▲ Favorable
This work advances large-scale EEG foundation models, improving accuracy on diverse neural tasks and offering new tools for brain data analysis. While not directly about psychedelics, scalable EEG models could enhance research on neural correlates of psychedelic states, biomarker discovery, and clinical trial endpoints. The results highlight the importance of model and data scale for downstream adaptation, which may accelerate translational neuroscience relevant to psychedelic medicine.
LaBraM, an early EEG foundation model, demonstrated that large-scale EEG pretraining can yield strong representations for diverse downstream tasks. Building on this foundation, we expand pretraining data and model capacity while retaining its core encoder and objective. We train ten encoders with 5.8 million to 1.97 billion parameters on three EEG collections spanning 25,067 to 79,910 hours, adapting signal preparation and training to heterogeneous recordings. Across 23 tasks, Atom-L* reaches 59.05% mean balanced accuracy at its best evaluated full fine-tuning (Full-FT) checkpoint, 3.61 percentage points above the strongest baseline EEG foundation model. Quark-G leads linear probing (LP) at 54.33%, a 1.24-point margin. Both also lead average task rank. At the last evaluated checkpoints, larger encoders improve Full-FT more consistently than LP, and stronger LP does not guarantee stronger Full-FT. Preserving patch structure improves LP over average pooling. Data-fraction experiments suggest capacity-dependent saturation, while checkpoint trajectories show that downstream performance can decline as pretraining loss falls. Joint classification with a shared Qwen3 readout reaches 50.50% with Molecule-H and Qwen3-8B; increasing language-model size provides no consistent gain. These results demonstrate the value of scaling LaBraM and the importance of matching pretraining scale to downstream adaptation.
Clinical research Narrative review published

Review: Music therapy and psychedelics synergize in psychiatric care

Therapeutic Harmony: Combining Music Therapy and Psychedelic Treatments in Psychiatric Care
Why it matters ▲ Favorable
This narrative review highlights the potential for combining music therapy with psychedelic treatment to enhance outcomes in psychiatric disorders such as depression, anxiety, and PTSD. While the evidence base is still emerging, the review underscores the need for further research into this integrative approach, especially regarding long-term effects and mechanisms. This could inform future clinical trial designs and therapeutic protocols, offering new directions for both researchers and clinicians.
Focusing on the synergistic efficacy of music therapy and psychedelic treatment in improving patient recovery, this paper addresses their possible integration in the treatment of psychiatric diseases. The authors give background in the introduction on the need of looking for alternative therapies for psychiatric disorders, presenting music therapy to enhance emotional and cognitive well-being in patients and psychedelic treatment as a hopeful approach for treating conditions untreatable with conventional techniques. An integrative narrative review, choosing studies that address the use of music therapy, psychedelic treatment, and a combination of the two, constitutes the approach taken in this paper. The findings indicate that both treatments greatly help to reduce symptoms of mental diseases including anxiety, depression, and PTSD as well as speed up patient recovery. By offering a more immersive and efficient experience in mental treatment, further studies combining these two therapies could deepen our knowledge of how to maximize therapeutic strategies. Though there are still gaps in research that have to be filled, particularly regarding long-term effects and the mechanisms underlying the interaction between the two, the findings of this review suggest that the combination of music therapy and psychedelic treatment has great potential to improve the quality of psychiatric care.
Forensic science / Drug market Forensic research published

Enantioselective analysis of ketamine in seized 'pink cocaine' samples

Enantioselective Analysis of Ketamine and Other Substances Commonly Found in “Pink Cocaine” Preparations via Capillary Electrophoresis and Liquid Chromatography With Ultraviolet Detection
Why it matters ◈ Mixed
This study provides validated methods for rapid enantioselective analysis of ketamine and related substances in illicit drug samples, supporting forensic source attribution and regulatory enforcement. The finding that nearly all seized ketamine is racemic suggests minimal diversion of pharmaceutical (S)-ketamine into illicit markets, with implications for both law enforcement and public health surveillance. Continuous chiral monitoring is recommended to detect any future shifts in market composition that could affect legal risk, clinical outcomes, or regulatory response.
Rising seizures of illicit ketamine-in pure crystalline form and in complex preparations such as pink cocaine-have heightened interest in tracing its origin. As many psychoactive drugs are chiral, knowledge of their enantiomeric composition in seized samples can support source attribution and legal assessment under drug control laws. Enantioselective methods were optimized for five chiral substances commonly found in pink cocaine, namely ketamine, amphetamine, MDMA, tramadol, and mephedrone; the achiral substances 2C-B, lidocaine, and caffeine were also included. Capillary electrophoresis (CE) was performed using sulfated β-cyclodextrin as chiral selector in the run buffer. A CE-UV short-end injection method enabled enantioselective analysis of ketamine in crystalline samples within 4 min (resolution: 6). A CE-UV long-end injection method enabled enantioselective separation of complex mixtures within 17 min (resolution: 2.7-11.1). For high-performance liquid chromatography (HPLC)-UV, a vancomycin-based chiral stationary phase provided resolutions of 1.2-4.7 within 27 min for pink cocaine samples. CE analysis demonstrated superior enantioselectivity, separation efficiency, and shorter analysis times compared to HPLC. However, CE was less robust due to peak area variability and batch-to-batch variation of the sulfated β-cyclodextrin, whereas HPLC allows for reliable quantitation. Of 558 seized ketamine samples analyzed, all but one were racemic, suggesting that (S)-ketamine is currently used mainly in legal pharmaceutical products and is not diverted to the illicit market as large-scale drug substance batches. Nevertheless, chiral analysis should be applied continuously to monitor the market, as the availability of enantiomerically pure drug preparations could lead to future market changes.
Neuroscience Research review published

Spontaneous neuropathic pain: distinct mechanisms, new treatment targets

Spontaneous neuropathic pain
Why it matters ◈ Mixed
This review reframes spontaneous neuropathic pain as mechanistically distinct from stimulus-evoked pain, arguing for separate diagnostic and therapeutic approaches. For psychedelic research, this mechanistic clarity could inform the design of future trials and biomarker strategies, especially as some psychedelic compounds are being explored for chronic pain. The call for precision phenotyping and symptom-aligned endpoints may impact how efficacy is measured in clinical studies, highlighting a need for better alignment between mechanism and therapy.
Spontaneous pain is a highly prevalent and disabling consequence of neuropathic disorders, yet it remains mechanistically underdefined and therapeutically underserved. Historically, preclinical animal models and clinical trials have been overwhelmingly biased toward stimulus-evoked hypersensitivity, relegating spontaneous pain to a secondary manifestation. Emerging evidence now challenges this view. Converging data from pharmacology, neural recordings, and systems-level causal manipulations indicate that spontaneous and stimulus-evoked pain arise from substantially dissociable molecular, cellular, and circuit substrates. Injured-fiber–derived ectopic activity within specific sensory neuron subtypes serves as a dominant peripheral generator of spontaneous pain, whereas cellularly distinct, intact spared-fiber pathways mediate stimulus-evoked hypersensitivity. At spinal and supraspinal levels, spontaneous pain preferentially engages affective–salience networks during pain chronification and may ultimately become stabilized within higher-order circuitry—while remaining dynamically coupled to afferent input. This mechanistic delineation carries critical translational implications. Current diagnostic and treatment guidelines rarely differentiate symptom domains, and most therapies have been validated primarily using stimulus-evoked or overall pain intensity endpoints—potentially contributing to a mechanism–therapy mismatch and variable efficacy. We argue that spontaneous neuropathic pain should be defined as a separate symptom domain rather than considered as a spontaneous manifestation of evoked pain mechanisms. This recognition demands longitudinal, biomarker-informed phenotyping to capture its persistent and fluctuating nature, and thereby enable robust mechanistic dissection at peripheral, spinal, and cortical nodes. Reframing spontaneous neuropathic pain along these lines will provide a foundation for precision therapeutics that target defined cell types, specific molecular drivers, and maladaptive network states—enabling mechanism-based, symptom-aligned treatments.
Clinical research Systematic review protocol registered

Systematic review on BP elevation with ketamine/esketamine in depression underway

Blood pressure elevation with ketamine and esketamine in depression: a systematic review and meta-analysis of randomised trials
Why it matters ◈ Mixed
This systematic review and meta-analysis will clarify the cardiovascular safety profile of ketamine and esketamine in depression treatment, focusing on blood pressure elevation and rates of clinically significant hypertension. As both drugs are increasingly used for treatment-resistant depression, robust safety data are critical for clinicians, regulators, and industry. The review's rigorous methodology and focus on RCTs will inform risk-benefit assessments and could influence clinical guidelines or regulatory labeling.
Review title: Blood pressure elevation with ketamine and esketamine in depression: a systematic review and meta-analysis of randomised trials Type and method of review: Meta analysis Stage of review at time of this submission: Review ongoing — the protocol has been finalised and the peer-reviewed search prepared; formal screening not yet started. Review question: In Adults with depression (including treatment-resistant depression), what is the effect of Ketamine or esketamine (any route) compared with Placebo or active control on Blood pressure elevation (mean change in systolic and diastolic BP) (primary); proportion with clinically significant hypertension (secondary)? Searches: The following sources will be searched: Europe PMC (PubMed, MEDLINE & preprints), PubMed / MEDLINE, Embase, Cochrane CENTRAL, Scopus, Google Scholar. Additional records may be imported from other databases. No date or language restrictions are applied unless otherwise stated. The search strategy underwent peer review (PRESS) before execution. Condition or domain being studied: Adults with depression (including treatment-resistant depression) Participants / population: Adults with depression (including treatment-resistant depression) Intervention(s), exposure(s): Ketamine or esketamine (any route) Comparator(s) / control: Placebo or active control Types of study to be included: Inclusion criteria: Adults with major depressive disorder or treatment-resistant depression; Ketamine (intravenous, intramuscular, oral) or esketamine (intranasal); Compared with placebo or an active control; Randomised controlled trials reporting blood pressure outcomes; Full-text article published in English. Exclusion criteria: Anaesthetic or analgesic use of ketamine only; Non-randomised studies; Reviews, editorials, letters, case reports or conference abstracts; Overlapping samples (the largest or most recent report is kept) Main outcome(s): Blood pressure elevation (mean change in systolic and diastolic BP) (primary); proportion with clinically significant hypertension (secondary) Data extraction (selection and coding): Two reviewers will independently screen titles/abstracts and full texts, blinded to each other’s decisions, and extract data in duplicate using a standardised, piloted form. Disagreements will be resolved by discussion or a third reviewer. Risk of bias (quality) assessment: The risk of bias of each included study will be assessed independently by two reviewers using a study-design-appropriate tool. Disagreements will be resolved by consensus. Risk of bias in the review itself will be appraised with ROBIS. Strategy for data synthesis: Results will be synthesised narratively. Where studies are sufficiently homogeneous, effect estimates will be pooled in a meta-analysis using a fixed- or random-effects model as indicated by heterogeneity (I²). The certainty of the evidence will be rated using GRADE.
Public health / Policy research Study published

Illicit drug marketing on Thai social media mapped in netnography study

Illicit drug marketing on social media in Thailand: a mixed-methods netnography and implications for drug policy
Why it matters ◈ Mixed
This mixed-methods study provides a detailed map of how illicit drugs, including new psychoactive substances, are marketed on social media in Thailand, highlighting the prevalence of coded language and cross-platform strategies. The findings offer actionable insights for digital surveillance, prevention, and policy interventions in emerging drug markets. While not focused on psychedelics specifically, the research is relevant for understanding digital risk environments and informing regulatory or harm reduction strategies in Southeast Asia and beyond.
Background Digital technologies have transformed illicit drug markets, with social media increasingly used for distribution and promotion. Our study aimed to characterize illicit drug marketing practices across multiple social media platforms in Thailand using a mixed-methods netnographic approach and to examine their implications for digital surveillance, prevention, and drug policy. Methods We conducted a mixed-methods netnographic study combining quantitative descriptive content analysis with qualitative coding of publicly accessible posts collected across multiple social media platforms in Thailand between January and December 2025. Posts were identified through targeted keyword searches and algorithmically recommended content, followed by manual screening. A curated Thai-language lexicon incorporating drug names, slang terms, euphemisms, coded expressions, and emoji-based representations was used to identify relevant content. Data were processed using Python-based tools, and marketing characteristics were coded across four domains: operational, psychological, conversion, and obfuscation. Descriptive analyses were conducted to summarize patterns across platforms, substance categories, communication features, and posting times. Results A total of 6,446 posts were analyzed. X accounted for 84.7% of posts. Stimulants were the most frequently identified substances (70.7%), followed by new psychoactive substances (22.2%). Indicators of convenience and accessibility were present in 68.7% of posts, while urgency and scarcity cues were observed in 25.9%. Cross-platform transition cues were identified in 41.8% of posts. Coded communication was widespread, including slang substitutions (74.2%) and emoji-based representations (28.6%). The largest proportion of posts (28.3%) by time period was observed during evening hours. Conclusion Illicit drug marketing on social media in Thailand occurs within a multi-platform environment characterized by accessibility-related marketing, coded communication, and cross-platform transition cues. By characterizing these features within the same multi-platform dataset, our study contributes evidence on social media drug markets within the Thai context. These findings support consideration of interaction across platforms in public health surveillance, drug abuse prevention, and drug policy responses.
Clinical research Peer-reviewed publication

New study links psilocybin to depression and schizophrenia pathways

Furthering the Understanding of Psilocybin Use and Molecules Relevant to Depression and Schizophrenia.
Why it matters ▲ Favorable
This peer-reviewed study advances the mechanistic understanding of how psilocybin interacts with molecular pathways implicated in depression and schizophrenia. The findings may inform future clinical trial design, biomarker development, and patient selection strategies. While not a regulatory or legal shift, the research strengthens the scientific rationale for targeted psychedelic therapies and may influence funding and policy priorities.
Clinical research Qualitative research published

US researchers report generally positive IRB experiences for psychedelic studies

Researchers’ Experiences with IRB Oversight of Psychedelic Research
Why it matters ◈ Mixed
This study finds that experienced US psychedelic researchers generally do not perceive IRBs as a major barrier to research, though knowledge gaps and misunderstandings about risks and safety persist. The findings suggest that proactive researcher-IRB engagement and education can facilitate protocol approval, but less experienced teams may still face challenges. As the field grows, ongoing IRB education and adaptation to evolving best practices will be important for research access and participant protection.
Previous research raises concern that conservative institutional review board (IRB) approaches regarding stigmatized issues and vulnerable groups could similarly arise as an impediment to research with psychedelic drugs. We interviewed 20 US researchers who had been a principal investigator on at least one research protocol involving psychedelics about their experiences with IRB oversight and perspectives regarding what IRBs need to know. Respondents reported that their IRBs raised concern and asked questions about participant safety, consent, legal issues, and data security and confidentiality, typical domains for IRB consideration. They also mentioned several IRB knowledge gaps or misunderstandings about psychedelics, primarily about risks and safety, while emphasizing the importance of IRBs' understanding of psychedelic drug effects. Despite IRB concerns and misunderstandings, all study respondents ultimately reported positive or neutral current experiences with IRBs reviewing their protocols for research with psychedelics, which they often attributed to cultivating strong IRB relationships and helping IRBs achieve adequate knowledge about these types of studies. Although investigators in our study did not perceive their IRBs to be a significant barrier to research with psychedelics, less experienced investigators and IRBs may face different outcomes. As research with psychedelics continues to increase, both researchers and IRBs should be responsive to continued scientific developments and emergent best practices.
Neuroscience Peer-reviewed study published

Study: Psilocybin induces 'hidden order' in brain activity

How Psilocybin Alters Consciousness: Psychedelics can create a "hidden order" in brain activity that could explain how these drugs affect our sense of self.
Why it matters ▲ Favorable
This study provides new mechanistic insight into how psilocybin alters consciousness by revealing a 'hidden order' in brain activity patterns. Such findings help clarify the neurobiological basis for subjective effects and may inform future clinical trial design, biomarker development, and regulatory discussions. The work strengthens the scientific rationale for therapeutic research and could reduce stigma by grounding psychedelic effects in measurable brain phenomena.
Clinical research Published study

Ketamine fMRI study in TRD: working memory neural correlates

Working Memory Neural Correlates After Ketamine in Treatment-Resistant Depression: A Randomized Placebo-Controlled Functional Magnetic Resonance Imaging Study
Why it matters ◈ Mixed
This randomized, placebo-controlled fMRI study explores how ketamine affects working memory neural circuits in patients with treatment-resistant depression (TRD). The findings may inform mechanistic understanding of ketamine's rapid antidepressant effects and cognitive impact, but as a single study with no citations yet, its influence is preliminary. Results could shape future research design and safety monitoring for ketamine and related compounds.
Neuroscience Peer-reviewed study

Ketamine modulates dorsal raphe serotonergic neurons via cell-type-specific pathways

Cell-type specific modulation of dorsal raphe serotonergic neurons by ketamine
Why it matters ▲ Favorable
This study elucidates distinct, cell-type-specific mechanisms by which ketamine modulates serotonergic neurons in the dorsal raphe nucleus, implicating both TrkB-dependent and independent pathways. These mechanistic insights deepen our understanding of ketamine's rapid antidepressant effects and could inform the development of next-generation therapeutics targeting serotonergic circuits. The findings may also help refine clinical trial designs and biomarker strategies for psychedelic and rapid-acting antidepressant research.
Ketamine (KET) produces rapid and long-lasting antidepressant effects at subanesthetic doses. However, the underlying mechanisms by which KET regulates the function of dorsal raphe nucleus (DRN) serotonin (5-HT) neurons, a key brain area involved in the regulation of emotional behaviors, including depression, remains largely unknown. Here, we show that KET increases the firing activity of DRN 5-HT neurons while bidirectionally modulating their excitatory inputs in cell-type-specific manner. Retrograde circuit mapping reveals that KET preferentially potentiates glutamatergic synapses of DRN 5-HT neurons projecting to medial prefrontal cortex, while depressing glutamate synapses of those projecting to central amygdala (CeA). Notably, KET-induced synaptic potentiation in the DRN—but not the increase in 5-HT neuronal firing—was abolished by blockade of the brain-derived neurotrophic factor (BDNF) receptor TrkB. These findings indicate the presence of parallel TrkB-dependent and TrkB-independent signaling pathways that regulate DRN 5-HT neuron function. Collectively, our results uncover previously unsuspected mechanisms by which KET modulates central serotonergic transmission and provide new mechanistic insight into its antidepressant effects.
Clinical research Press report

Depression symptoms improved 48h after single psychedelic dose

Depression Symptoms Improved in Just 48 Hours After a Single Psychedelic Dose
Why it matters ▲ Favorable
Rapid improvement in depression symptoms after a single psychedelic dose, as reported in the press, suggests potential for fast-acting treatments. However, without details on the study design, compound, or peer-reviewed publication, the finding should be interpreted cautiously. If validated, such results could accelerate clinical interest and investment in psychedelic therapeutics.
Neuroscience Review published

Review: OCD comorbidity, biomarkers, and emerging treatment strategies

Obsessive–Compulsive Disorder: Comorbidity, Biomarkers, Circuits, and Treatment Strategies
Why it matters ◈ Mixed
This comprehensive review synthesizes current understanding of the neurobiological and clinical overlap between OCD and anxiety, highlighting shared circuit-level vulnerabilities and the implications for treatment. While not directly focused on psychedelics, the discussion of serotonergic and glutamatergic targets, as well as neuromodulation, is relevant for researchers exploring psychedelic interventions for OCD and related comorbidities. The review may inform trial design and biomarker selection for future studies in psychedelic science, but does not itself present new clinical or legal developments.
Obsessive-compulsive disorder (OCD), characterized by intrusive thoughts and repetitive behaviors, frequently co-occurs with anxiety disorders, contributing to greater diagnostic complexity, more severe symptoms, and poorer treatment outcomes. In this review, we consider OCD in the context of its comorbidity with anxiety and examine evidence that the two conditions may share genetic, neurochemical, and circuit-level vulnerabilities. Particular attention is given to the cortico-striato-thalamo-cortical, frontoparietal, and frontolimbic networks, which may interact to form a self-reinforcing cycle in which anxiety intensifies OCD symptoms, while compulsive behaviors provide transient relief but may ultimately maintain pathological patterns of brain activity. We also discuss how these shared mechanisms may shape current and emerging treatment strategies, including pharmacological approaches targeting serotonergic, glutamatergic, dopaminergic, and histaminergic systems, cognitive-behavioral interventions, and neuromodulation techniques such as deep brain stimulation, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and focused ultrasound. We further consider major depressive disorder and posttraumatic stress disorder as additional examples of psychiatric comorbidity, with overlapping neural substrates and clinical features. Taken together, these findings suggest that considering comorbidity alongside core OCD symptoms may improve our understanding of its pathophysiology, help identify clinically relevant biomarkers, and support individualized treatment, while providing a broader transdiagnostic perspective on psychiatric disorders.
Clinical research Peer-reviewed publication

New review details ketamine-induced bladder toxicity risks

The ketamine bladder.
Why it matters ◈ Mixed
This publication highlights the clinical risks of ketamine-associated bladder dysfunction, a complication increasingly recognized in both medical and non-medical settings. The findings underscore the need for rigorous patient monitoring, risk mitigation strategies, and further research as ketamine use expands for depression and other indications. Policymakers and clinicians should consider these safety data when developing protocols and regulatory frameworks for ketamine therapy.
Neuroscience Peer-reviewed research

LSD reverses gene signatures of brain ageing and neurodegeneration in preclinical models

Lysergic Acid Diethylamide Induces Transcriptional Changes Opposing Signatures of Brain Ageing and Neurodegeneration
Why it matters ▲ Favorable
This study provides robust preclinical evidence that LSD induces gene expression changes opposing those seen in brain ageing and dementia, supporting its potential as a candidate for further research in neurodegenerative disease. The cross-species, transcriptomic approach and reproducibility across models strengthen the rationale for translational studies and may accelerate interest in clinical trials targeting cognitive decline. While not a clinical or regulatory milestone, these findings could influence research priorities and funding in the psychedelic field.
Psychedelic compounds such as lysergic acid diethylamide (LSD) are increasingly studied for their neuroplastic effects and potential relevance to brain ageing and neurodegenerative conditions, including dementia. These processes are characterised by transcriptional changes involving progressive synaptic dysfunction and altered neuron-glia interactions. In computational drug discovery, the transcriptional signature reversion principle proposes that compounds inducing gene expression states opposite to disease-associated programmes may have therapeutic potential by counteracting disease-associated phenotypes. We therefore asked whether LSD-induced transcriptional changes oppose gene expression programmes associated with brain ageing and dementia, thereby providing a data-driven rationale for its potential relevance to age-associated cognitive decline and a starting point for investigating the underlying molecular mechanisms. Combining cross-species transcriptomic analyses with experimental validation, we show that transcriptional profiles induced by chronic LSD treatment in rats are strongly anti-correlated with ageing-associated gene expression changes in the human prefrontal cortex and, to a lesser extent, with dementia-associated programmes. This relationship is reproducible across datasets and species and is significantly stronger compared to a broad panel of pharmacological perturbations. Independent acute LSD treatment in mice recapitulated the opposition to ageing-associated transcriptional signatures across multiple doses. Moreover, short-term LSD treatment attenuated amyloid-β-induced structural, molecular and transcriptional alterations in primary cortical cultures. Together, these findings provide a transcriptionally grounded rationale for investigating LSD and related compounds in brain ageing and neurodegeneration, while identifying molecular and cellular programmes that can guide future mechanistic and therapeutic studies.
Clinical research Peer-reviewed review

Review: Psilocybin Use in Psychiatry and Public Health Implications

Psilocybin Use in Psychiatry: Clinical Practice and Public Health Implications.
Why it matters ◈ Mixed
This peer-reviewed review synthesizes current evidence on psilocybin’s psychiatric applications and discusses broader public health considerations. It highlights both promising clinical trial results and ongoing challenges in translating research into practice, including regulatory, safety, and access issues. The article underscores the need for clear clinical guidelines and policy frameworks as interest in psilocybin therapy grows.
Clinical research Proof-of-principle trial published

MDMA-assisted therapy trial shows changes in wellbeing, self-compassion, alexithymia

Changes in wellbeing, self-compassion and alexithymia in a proof of principle trial with MDMA-assisted therapy for major depressive disorder
Why it matters ▲ Favorable
This proof-of-principle trial reports on MDMA-assisted therapy for major depressive disorder, focusing on wellbeing, self-compassion, and alexithymia. While early-stage, the study adds to the growing body of evidence supporting MDMA's therapeutic potential beyond PTSD. Results may inform future trial design and regulatory consideration, but replication and larger studies are needed before clinical or policy impact.
Clinical research Review published

Review: Pharmacological treatments for Gambling Disorder; psychedelics experimental

Psychopharmacotherapy of Gambling Disorder
Why it matters ◈ Mixed
This narrative review synthesizes current evidence on pharmacological interventions for gambling disorder, highlighting that opioid antagonists have the strongest support, while most other agents—including antidepressants and antipsychotics—show limited efficacy. Psychedelics such as psilocybin and ketamine are identified as experimental, with insufficient clinical data to support their use at this time. The review signals a research gap and potential future direction for psychedelic trials in behavioral addictions, but does not present new clinical findings or regulatory changes.
Gambling disorder (GD) is a behavioral addiction characterized by high comorbidity, significant social and economic consequences. The neurobiological mechanisms underlying GD are similar to those observed in substance use disorders, which opens possibilities for pharmacological intervention. However, no medication has yet been approved for the treatment of GD, and the evidence base for existing agents remains limited. This review summarizes data on the pharmacological treatment of GD based on current systematic reviews and network meta-analyses, and discusses methodological limitations and clinical prospects for the use of various drug classes. This narrative literature review was conducted, encompassing clinical trials, case series, and open-label studies of opioid antagonists, antipsychotics, mood stabilizers, anticonvulsants, antidepressants, gabapentinoids, and other agents. The most compelling evidence was found for nalmefene and naltrexone, which produced statistically significant reductions in GD symptoms compared to placebo, particularly in patients with high craving. Antidepressants, olanzapine, and topiramate failed to outperform placebo in most studies. Mood stabilizers may be beneficial in cases of comorbid bipolar disorder, but the evidence remains very limited. N-acetylcysteine, memantine and gabapentinoids showed encouraging preliminary results; GLP-1 receptor agonists, ketamine, and psilocybin remain experimental. Thus, opioid antagonists may be considered a first-line (off-label) therapy for GD, complementing rather than replacing cognitive-behavioral therapy. Larger controlled trials and the identification of biomarkers for treatment personalization are needed.
Neuroscience Peer-reviewed study published

PET study links childhood trauma to lower CB1 receptor availability

Cannabinoid receptor type 1 availability in individuals with a history of childhood trauma: a positron emission tomography study
Why it matters ◈ Mixed
This study provides early evidence that childhood trauma is associated with lower CB1 receptor availability in key brain regions. While not directly related to psychedelics, the findings deepen understanding of neurobiological impacts of trauma, which is relevant for designing and interpreting trials of psychedelic and cannabinoid-based therapies in trauma-exposed populations. The small sample and preliminary nature limit immediate clinical or policy impact, but it highlights a potential biomarker for future research.
Abstract Early life adversity has a lasting impact on the endocannabinoid (eCB) system based on animal models. However, the impact of early life adversity such as childhood trauma (CT) on the eCB system has not been thoroughly studied. We assessed the availability of cannabinoid receptor type 1 (CB1R) in individuals with CT compared to healthy controls without CT (HCs). Cannabinoid receptor type 1 (CB1R) availability was compared in adults with CT (N = 22) and age- and sex-matched HCs (n = 22), using positron emission tomography (PET) imaging with the CB1R-specific radiotracer [ 11 C]OMAR. Using linear models, the effect of the group was assessed on global and trauma-relevant brain regions (amygdala, hippocampus, and frontal cortex). Compared to HCs, lower CB1R availability was observed in CT globally (difference= -11.36%, F (1,42) = 4.35, p = 0.04), in amygdala (-13.70%, F (1,84) = 6.66, p = 0.01), and in hippocampus (-14.50%, F (1,84) = 6.59, p = 0.01), but not in frontal cortex (-8.08%, F (1,84) = 2.17, p = 0.14). There were no effects of a diagnosis of posttraumatic stress disorder, major depressive disorder, nicotine dependence, or the use of antidepressant medication. This preliminary result of lower CB1R availability in adults with CT compared with HCs suggests eCB dysregulation associated with CT. Future studies should replicate and extend this finding and examine the potential effects of various trauma features on the eCB system.
Clinical research Dataset released

Fireside Project releases 25,000+ psychedelic support interaction dataset

The Fireside Database: Large-scale evidence from 25,419 psychedelic support interactions
Why it matters ▲ Favorable
This is the largest open dataset on real-world psychedelic support interactions in the US to date. It provides unprecedented epidemiological and outcome data on nonclinical psychedelic use, user demographics, and support effectiveness, filling a critical gap as policy expands beyond clinical settings. The resource will enable research on harm reduction, training, and best practices for peer support, informing both public health and future regulatory frameworks.
Most psychedelic experiences occur outside clinical settings, yet as policy frameworks rapidly expand to accommodate nonclinical use, no systematic data exist on who seeks psychedelic support, under what circumstances, or what makes that support effective. We present the Fireside Database, a US-based dataset comprising 25,419 peer support interactions conducted by 220 trained volunteers at Fireside Project's Psychedelic Support Line between April 2021 and February 2026. The released resource integrates structured interaction logs with volunteer-coded metadata and 2777 caller satisfaction surveys across five outcome dimensions. Psilocybin was the most commonly reported substance (59.9% of coded interactions), while cannabis produced the highest distress rate (47.2%). The nested data structure-with 50 supporters each completing ≥10 surveyed interactions-supports multilevel modeling of individual supporter effects on caller outcomes. This resource enables research in psychedelic epidemiology, evidence-based training design, and the investigation of what makes psychedelic psychological support effective.
Clinical research Study results reported

Psilocybin shows anti-inflammatory effects in Parkinson’s; veteran access debated

Psilocybin has anti-inflammatory effects in Parkinson’s disease patients; Should 2 million veterans get psychedelic treatment?
Why it matters ▲ Favorable
New findings suggesting psilocybin has anti-inflammatory effects in Parkinson’s disease patients could open new therapeutic avenues for neurodegenerative disorders. The article’s reference to potential treatment for millions of veterans signals growing interest in large-scale access and public health impact. While not a regulatory or legal move, these results may influence future clinical trial designs and policy debates on expanding psychedelic therapy access.
Clinical research Critical review published

Critical review questions mechanistic basis of psychiatric drugs

Psychiatric Pharmacotherapy and the Problem of Mechanistic Validation: A Critical Review
Why it matters ◈ Mixed
This review challenges the mechanistic foundations of most psychiatric medications, including both legacy drugs and emerging treatments like ketamine and psilocybin. It highlights the lack of validated biological targets for these agents and calls for greater transparency about what is known and unknown regarding their mechanisms. For psychedelic research, this underscores the need for rigorous mechanistic studies and honest communication with patients and regulators. The piece may influence clinical trial design, regulatory expectations, and ethical standards for informed consent.
Psychiatric pharmacotherapy is among the most widely practiced and epistemically contested domains of contemporary medicine. Antidepressant consumption has risen significantly across OECD countries over the past decade, yet the neurobiological hypotheses used to justify these prescriptions remain unvalidated. This critical review examines the principal psychiatric drug classes, including antidepressants, antipsychotics, mood stabilizers, benzodiazepines and related anxiolytics, and psychostimulants. For each, the pharmacological composition, proposed mechanism, clinical goals, and evidence of effectiveness are reviewed. The central argument is that virtually none of these agents treats a confirmed biological cause of the disorder for which it is prescribed. The serotonin hypothesis of depression lacks consistent evidentiary support, the dopamine hypothesis of schizophrenia remains mechanistically inconclusive, and the catecholamine hypothesis underlying stimulant use in attention-deficit/hyperactivity disorder has not established a causal deficit. The serendipitous discovery of foundational psychiatric drugs, the substantial placebo response in antidepressant trials, publication bias, weak diagnostic validity, the physical health burden of long-term antipsychotic use, and benzodiazepine dependence are examined as compounding weaknesses in the field’s scientific foundations. Emerging treatments, including ketamine and psilocybin, show early promise alongside unresolved mechanistic questions. The review concludes with a call for epistemic transparency: symptomatic improvement, while clinically valuable, should not be presented to patients as mechanistic cure, and the gap between pharmacological effect and biological understanding should be openly acknowledged.
Clinical research Pilot RCT published

Psilocybin pilot RCT shows effects on anhedonia in treatment-resistant depression

Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.
Why it matters ▲ Favorable
This pilot randomized controlled trial provides early clinical evidence that psilocybin, when combined with psychological support, may reduce anhedonia in patients with treatment-resistant depression. The findings support further investigation in larger, confirmatory trials and may inform future regulatory or clinical guidelines. If replicated, these results could expand therapeutic options for a population with high unmet need, but larger studies are needed to assess safety, durability, and generalizability.
Clinical research Analysis published

Psychedelic Trials Reveal Gaps Between Controlled Efficacy and Real-World Readiness

Why it matters ◈ Mixed
This analysis highlights a growing concern that positive results in controlled psychedelic trials may not translate seamlessly to real-world clinical practice. The gap between trial efficacy and practical implementation has implications for patient outcomes, regulatory approval, and payer adoption. Stakeholders should consider how trial design, patient selection, and support structures may differ from everyday care, potentially impacting the scalability and safety of psychedelic therapies.
US / Federal Executive order signed

Trump signs executive order fast-tracking psilocybin, ibogaine for mental illness

The 'Civilising' of Psychedelics: Pharmaceuticalisation from Below as a Part-Process of American and European Informalisation
Why it matters ▲ Favorable
The executive order represents a historic federal shift, fast-tracking access to psilocybin and ibogaine for serious mental illness and signaling a break from decades of prohibition and stigma. This move will likely accelerate clinical research, expand patient access, and reshape legal and market dynamics in both the US and Europe. The policy change also highlights the evolving social and regulatory landscape, with implications for how psychedelics are integrated into mainstream healthcare and society.
In April 2026, US President Donald Trump signed an executive order fast-tracking access to psilocybin and ibogaine for the treatment of serious mental illness. This follows decades in which psychedelics had been vilified as a group of drugs entirely lacking in therapeutic potential, associated with counter-cultural groups such as hippies, and whose use was both criminalised and widely stigmatised. Our central questions are: How have the substances, practices, understandings and relationships that comprise psychedelic use developed, and shifted, over time? And how might we best understand the overall structure and dynamics of such changes? We argue that the recent psychedelic renaissance cannot be understood as the simple ‘discovery’ of a therapeutic potential that previously lay dormant in the substances themselves. It is better grasped as a part-process of longer-term informalisation processes, bound up with shifting balances of power between established and outsider groups and with the changing behavioural and emotional standards – the social canons – through which psychedelic use has become refigured. Drawing on the figurational sociology of Norbert Elias and relational work on substance use and health, we trace the shift in psychedelics from counter-cultural sacrament to therapy and technology of the self. Through dialogue with a multimodal, multi-source evidential base, we develop the concept of ‘pharmaceuticalisation from below’ to characterise both the contemporary uptake of psychedelics and the broader figurational dynamics this expresses.
Neuroscience Preclinical study published

Psilocybin alters decision-making and cortical processing in animal model

Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty
Why it matters ▲ Favorable
This preclinical research elucidates how psilocybin modulates neural and behavioral mechanisms underlying decision-making under uncertainty. The findings provide mechanistic insight into how psilocybin may facilitate adaptive learning by enhancing sensitivity to positive outcomes and diminishing the impact of negative feedback. This work supports translational efforts to optimize therapeutic protocols and informs future clinical trial design by identifying specific cognitive processes affected by psilocybin.
Emerging clinical research with psilocybin highlights the value of the psychedelic experience on successful treatment of a multitude of psychiatric disorders. While the psychedelic trip or clinical support procedures cannot be modeled in rodents, neural processes critical to meta-learning and flexible modification of previously learned strategies can be quantified during psilocybin exposure. Here we applied computational modeling and single unit recordings from medial prefrontal cortex to characterize the effect of psilocybin using a value-based probabilistic choice task. Psilocybin improved choice selection in uncertain contexts and shifted reinforcement learning rate bidirectionally, enhancing updating from rewarded, while reducing updating from unrewarded, actions. These behavioral changes coincided with selective shifts in the neural encoding of task features including enhanced neural representation of rewarded, and diminished representation of unrewarded, outcomes. Collectively these data indicate that psilocybin improves choice selection in uncertain contexts by reweighing cortical coding in a way that favors learning from positive new information over prospective actions.
Neuroscience Peer-reviewed study

Psilocybin modulates outcome-based choice under uncertainty, eLife study

eLife Assessment: Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty
Why it matters ◈ Mixed
This peer-reviewed study adds to the mechanistic understanding of how psilocybin affects decision-making and cortical processing under uncertainty. While not a clinical trial, these findings may inform future therapeutic hypotheses and trial designs. The study's impact will depend on subsequent citations and translational work.
Analytical methods Review published

Advances in chiral capillary electrophoresis for sensitive enantiomer analysis

Improving the Sensitivity in Chiral Analysis by Capillary Electrophoresis
Why it matters ▲ Favorable
This review summarizes recent advances in increasing the sensitivity of chiral capillary electrophoresis, a technique crucial for detecting and quantifying enantiomers in pharmaceuticals and biological samples. Improved sensitivity in chiral analysis directly benefits psychedelic research and industry by enabling more accurate quality control, pharmacokinetic studies, and regulatory compliance for enantiomerically pure compounds. While not a regulatory or market move, these analytical improvements underpin safer and more reliable drug development and clinical trial work.
Chiral analysis plays a relevant role in numerous scientific fields, such as the pharmaceutical, biomedical, agrochemical, environmental, or food science, due to the different properties that stereoisomers may present. Capillary electrophoresis (CE) techniques, mainly electrokinetic chromatography (EKC) and micellar electrokinetic chromatography (MEKC), are well-established techniques to achieve enantiomeric separations owing to its high selectivity, methodological versatility, and low consumption of reagents and samples. In this context, method sensitivity is a critical characteristic, as it determines the capability to detect and quantify enantiomers at trace levels and to assess the enantiomeric purity of raw materials, pharmaceutical or agrochemical formulations, and food ingredients, among others. This article reviews the analytical strategies reported from 2022 to June 2026 aimed at enhancing the sensitivity in chiral CE techniques and to apply them to the analysis of pharmaceutical formulations, and to biological, environmental, and food samples. Off-line and in-capillary preconcentration strategies, as well as their combinations, together with the use of alternative detections systems to UV-Vis detection, are described as the most effective. The most relevant results are presented and critically discussed through the manuscript.
Clinical research Phase 3 results announced

Helus Pharma advances psychedelic adjunctive in clinical trials

Med Check: Olanzapine LAI Provides Long-Term Stability, Lumateperone Scores First Phase 3 Win, Helus Pharma Advances Psychedelic Adjunctive, and More
Why it matters ▲ Favorable
Helus Pharma's advancement of a psychedelic adjunctive in clinical trials signals growing industry and research momentum for psychedelic-based therapies. The announcement of new Phase 3 results at a major congress highlights increasing mainstream acceptance and investment in this sector. While details are limited, such progress may impact future regulatory pathways and commercial interest in psychedelic medicines.
Drug companies and researchers unveiled new clinical trial results at Psych Congress 2026, held September 15-19 in New Orleans. Below are highlights.
Clinical research Conceptual research published

Spiritual experiences during interoceptive awareness training in MOUD

“My body is nurturing me”: Personalized spiritual experiences during interoceptive awareness training among people in medication treatment for opioid use disorder.
Why it matters ▲ Favorable
This conceptual research highlights the potential role of spiritual experience and interoceptive awareness in supporting recovery for people with opioid use disorder on medication treatment. While not directly involving psychedelics, the findings may inform adjunctive therapies and mechanisms relevant to psychedelic-assisted interventions for SUD. The study provides qualitative evidence for integrating spiritual and body-oriented approaches, but does not alter legal risk or access.
Research links the neural processes of spiritual experiences, or 'peak experiences' of eudaimonic well-being, to substance abuse recovery. Studies also identify health improvements among substance use disorder (SUD) treatment approaches that include interoceptive awareness training. However, the relationship between interoceptive awareness and spiritual experience within substance use recovery is poorly understood. This conceptual project was designed to explore personalized spiritual experience among a sub-set of participants in a study of Mindful Awareness in Body-oriented Therapy (MABT) for people in medication treatment for opioid use disorder (MOUD). MABT teaches and develops the capacity for interoceptive awareness, defined as the conscious experience of internal bodily sensations, to facilitate improved self-care and well-being. Three themes of spiritual experience emerged based on consistent patterns and processes: Experiencing Wholeness and Healing, Awakening Inner Knowing, and My Body is Nurturing Me. To illustrate how these themes are expressed within the context of MABT, four participant exemplars are provided. Responses to survey questions about spiritual experience and interoceptive awareness were also examined. All participants endorsed some level of SE and the level of IA increased pre to post. In summary, this project highlighted the role of SE in MABT and the potential helpfulness of SE in SUD recovery. Future research could explore underlying mechanisms of IA for improved SE and the role of SE in SUD recovery.
Neuroscience Preclinical study published

Low-dose ketamine shows neuroprotection in Parkinson's model, BDNF-independent

Neuroprotective activity of sub-anesthetic ketamine in a preclinical model of Parkinson's disease is not blocked by antagonizing brain-derived neurotrophic factor signaling
Why it matters ▲ Favorable
This preclinical study demonstrates that sub-anesthetic ketamine confers robust neuroprotective effects in a progressive rodent model of Parkinson's disease, but these effects are not mediated by BDNF-TrkB signaling. The findings suggest alternative mechanisms for ketamine's neuroprotective action, which could inform future clinical research on ketamine for neurodegenerative diseases. This adds to the mechanistic understanding of ketamine's therapeutic potential and may influence the design of translational studies targeting Parkinson's and related disorders.
Treatment with low-dose ketamine is neuroprotective in rodent models of acute damage, while high doses of ketamine can be neurotoxic. Our group has previously shown that sub-anesthetic ketamine treatment leads to long-term reduction of L-DOPA-induced dyskinesia (LID) via brain-derived neurotrophic factor (BDNF)-signaling in a rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease (PD). In this report, we investigated if sub-anesthetic ketamine is also neuroprotective in a progressive 6-OHDA model of PD via neurotrophic action through the tropomyosin receptor kinase B (TrkB) receptor. We demonstrated that ketamine-treatment (20 mg/kg, i.p.) prior to striatal administration of the neurotoxin 6-OHDA is neuroprotective, providing near complete protection against development of parkinsonian motor deficits. This robust behavioral efficacy occurred in the presence of only modest preservation of tyrosine hydroxylase (TH) striatal levels (~50-60% loss). Interestingly, based on data from an additional cohort treated with ketamine and ANA-12 (TrkB antagonist) we found that the neuroprotective effects of ketamine are not mediated by TrkB receptors. Semi-quantitative western analysis showed that the relative tyrosine hydroxylase content in the striatum was not significantly increased in ketamine-treated rats compared to vehicle. Unbiased stereology of dopamine neurons in the substantia nigra pars compacta (SNc) revealed no significant differences between any of the groups. The role of BDNF was evaluated with in situ hybridization for RNA of BDNF and TrkB. While BDNF expression was not changed, co-administration of ketamine and ANA-12 led to a significant decrease in TrkB receptor expression compared to ketamine-only on the lesioned but not the intact hemisphere in the SNc. In conclusion, we show that ketamine at the low dose currently pursued for therapeutic benefit for LID led to robust behavioral motor improvement in this rodent PD degeneration model, yet these protective effects were not driven by neurotrophic BDNF-signaling, indicating complex mechanisms are underlying neuroprotective activities of low-dose ketamine.
Clinical research Peer-reviewed review published

Review: Psychedelics for substance use disorders—mechanisms and evidence gaps

Psychedelics and Psychedelic-Inspired Compounds for Substance Use Disorders: Are We Treating the Disease or Opening a Learning Window?
Why it matters ◈ Mixed
This review synthesizes preclinical and clinical evidence for psychedelic and psychedelic-inspired compounds in treating substance use disorders, highlighting that efficacy and risk profiles are highly compound- and indication-specific. The strongest human data are for psilocybin in tobacco and alcohol use disorders, but results are limited and mixed. The review cautions that neuroplasticity is a window for intervention, not a guaranteed therapeutic outcome, and underscores the need for more rigorous, indication-specific trials and mechanistic studies.
Substance use disorders remain a leading cause of preventable death, and existing care is better described as disease management than as cure. Medications for opioid, alcohol, and tobacco use disorders reduce substance use, and opioid agonist treatment reduces mortality, yet retention is poor and functional recovery is rarely measured. This review asks whether psychedelics treat addiction, or temporarily create a brain state in which treatment, learning, and recovery work differently. By evaluating each pharmacologically unique compound individually, we align cellular mechanisms, animal studies and human trial data across the full spectrum of substance use disorders. Relapse prevention is not a single construct: conditioned place preference, operant reinstatement, extinction learning, and clinical abstinence index different processes, and agreement at one level does not imply agreement at another. Translational concordance is therefore indication- and compound-specific rather than a class property, with the strongest human signals for psilocybin in tobacco and alcohol use disorders, though even the alcohol signal rests on two small randomized trials with discordant results. Risk is compound-specific too: ibogaine is gated by cardiotoxicity, and ketamine carries reinforcing properties and organ toxicity of its own. Plasticity is an opportunity, not an outcome.
Neuroscience Preprint posted

Single-dose psilocybin shows multi-scale effects in macaque brain

Multi-scale effects of single-dose psilocybin in the macaque brain
Why it matters ▲ Favorable
This preprint reports on the neurobiological effects of psilocybin in non-human primates, providing translational data that may inform human clinical research. While not yet peer-reviewed or widely cited, such studies help bridge the gap between rodent models and human trials, potentially supporting safety and efficacy arguments for regulatory review. The lack of citations and preprint status limit immediate impact, but the work is relevant for researchers designing future studies.
Clinical research Analysis / Commentary

Psychedelics and Consciousness: The Clinical Trial Design Challenge

Can Psychedelics Restore Consciousness? The Trial Design Problem Nobody Is Ready For
Why it matters ◈ Mixed
Designing trials to test whether psychedelics can restore consciousness presents unique scientific and ethical challenges. This analysis highlights unresolved methodological issues in studying psychedelic effects on consciousness, which could impact future research quality and regulatory acceptance. The discussion is timely as interest grows in using psychedelics for severe disorders of consciousness, but does not report new data or legal changes.
Clinical research Retrospective review published

VR during ketamine sessions feasible and tolerated, chart review finds

VR during ketamine sessions shows feasibility and tolerability in retrospective chart review
Why it matters ◈ Mixed
This retrospective chart review suggests that integrating virtual reality (VR) into ketamine therapy sessions is both feasible and well-tolerated. While not a prospective or controlled trial, these findings may encourage further research and innovation in combining digital therapeutics with psychedelic-assisted treatments. The results could inform future clinical protocols and commercial offerings, but more rigorous studies are needed to assess efficacy and safety.
Federal policy Rule proposed

HHS proposes revisions to federal urine drug testing guidelines

Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Urine (UrMG)
Why it matters ◈ Mixed
HHS's proposed revisions to federal workplace drug testing guidelines could impact how psychedelics are detected, reported, or sanctioned in federal employment settings. Changes may affect research participants, clinicians, and industry operators working with federal agencies or grants. The specifics of the revisions will determine whether psychedelic compounds (e.g., psilocybin, MDMA) are newly included, excluded, or treated differently, influencing legal risk and access for professionals in the field.
The Department of Health and Human Services ("HHS" or "Department") is proposing to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG), published in the Federal Register on October 12, 2023).
Clinical research Published survey study

Survey explores music selection practices in psychedelic-assisted therapy

How Is Music Selected for Psychedelic-Assisted Therapy? An Exploratory Survey Study of Practitioners and Patients
Why it matters ▲ Favorable
This exploratory survey provides the first empirical data on how music is chosen and used in psychedelic-assisted therapy sessions, including the novel finding that post-session playlist listening is common and valued by both practitioners and patients. While not a regulatory or legal development, these insights inform best practices and highlight areas for further research, potentially impacting therapeutic protocols and patient outcomes as the field matures.
Abstract Music is well established as a central component of psychedelic-assisted therapy (PAT), yet few empirical studies have investigated how music is selected and utilized for treatment. This study explores current practices and perspectives regarding PAT music selection using anonymous online surveys completed by practitioners and patients. Surveys investigated playlist creation, optimal musical qualities, lyric usage, genre, familiarity, in-session adjustments, the use of silence, and post-session playlist listening. Notable differences were found across practitioners, patient experiences, settings, and session phases. Post-session playlist listening was common and perceived as beneficial by both practitioners and patients, a practice not previously studied empirically. While important limitations are noted, overall, these findings provide exploratory insights into PAT music practices and highlight several areas that require further empirical investigation.
Clinical research Pilot secondary analysis

Psilocybin pilot analysis: cognitive effects, drinking, and depression outcomes

Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial
Why it matters ◈ Mixed
This secondary analysis provides nuanced evidence on psilocybin's cognitive and clinical effects in patients with co-occurring alcohol use disorder and depression. While psilocybin slowed task switching and improved depressive symptoms, it did not consistently affect cognitive flexibility or willingness to exert control, and drinking reduction was linked to increased cognitive stability. The findings highlight the need for larger, adequately powered trials to clarify mechanisms and inform future therapeutic applications.
Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the willingness to exert control rather than the ability to do so. We tested both in patients with co-occurring alcohol use disorder (AUD) and major depression. Methods. In this secondary analysis of a randomized, double-blind, placebo-controlled trial of psilocybin for AUD with comorbid major depressive disorder (MDD; ClinicalTrials.gov NCT04620759 ), a subset of participants (placebo n=13, psilocybin n=12) completed five cognitive tasks before drug administration and again about one week after it (mean 6.7 days, SD 1.1). Outcome measures spanned the stability-flexibility continuum. Free choice between levels of cognitive demand indexed the participant's willingness to exert control. Effect sizes and Bayes factors were used to estimate drug effects and associations with change in drinking and depressive symptoms across 34 retest measures. Results. Relative to placebo, psilocybin slowed responding in cued task switching (learning-phase RT d=1.01, BF10=7.7; switch trials d=1.12, BF10=17). Psilocybin effects on feedback-driven measures were inconsistent in direction (7 of 11 toward flexibility); the largest was on perseveration, which rose less with practice under psilocybin than under placebo (d=-0.79, BF10=1.1). Other drug effects on the 34 retest measures had inconclusive Bayes factors (BF10=0.40-2.4), and none survived false discovery rate correction. Demand avoidance, analyzed separately from the 34 measures, showed no detectable drug effect (BF01=2.0). Baseline demand avoidance showed no detectable relation to performance but tracked depressive symptoms (rho=.71, BF10=24). Drinking fell in both arms, and on 15 of 17 stability-flexibility measures change toward stability accompanied drinking reduction (stability composite rho=-.64, BF10=29; rho=-.43 when change was adjusted for baseline scores). Lower baseline working-memory span predicted larger drinking reductions (BF10=19-25). Depressive symptoms fell more after psilocybin than after placebo (PHQ-9, d=-0.88, BF10=2.7), but their change was not associated with cognitive change or predicted by working-memory span. Conclusions. About one week after dosing, psilocybin slowed cued task switching but had no consistent effect on feedback-driven flexibility, and there was no evidence of an effect on the willingness to exert effort. Drinking reduction was associated with increased, not reduced, cognitive stability, whereas improvement in depressive symptoms was not associated with cognitive change. These pilot estimates can guide adequately powered trials.
Neuroscience Peer-reviewed study published

SV2A synaptic density linked to depression chronicity, not symptom severity

Synaptic density (SV2A) tracks illness chronicity rather than symptom severity in major depressive disorder
Why it matters ◈ Mixed
This study challenges the prevailing hypothesis that synaptic density (SV2A) is directly associated with current depression symptom severity, instead indicating a relationship with illness chronicity. For psychedelic research, this nuance may impact biomarker selection and trial endpoints, especially in studies aiming to reverse synaptic loss as a therapeutic mechanism. The findings urge caution in using SV2A PET as a surrogate for acute symptom changes in MDD and may influence both research design and regulatory expectations for mechanistic claims.
Synaptic loss has been proposed as a key mechanism in major depressive disorder (MDD). Positron emission tomography with [11C]UCB-J enables in vivo quantification of synaptic vesicle glycoprotein 2A (SV2A), a proxy marker of synaptic density. A landmark study by Holmes et al reported an inverse association between depression severity and SV2A binding in frontolimbic regions. As a replication, we examined this association in [11C]UCB-J PET data from 34 unmedicated individuals with MDD, focusing on the dorsolateral prefrontal cortex, anterior cingulate cortex, and hippocampus. We found no support of an association between MADRS scores and SV2A binding in the primary regions of interest (r = 0.18-0.26, all p >= 0.15; 0.15). Findings were similar in unadjusted and age- and sex-adjusted models. However, adjustment for duration of the current depressive episode and lifetime depressive episodes yielded positive associations across primary regions. In post hoc analyses, longer current episode duration, but not lifetime depressive episodes, was negatively associated with SV2A binding across primary regions. Thus, our findings did not support an association between depression severity and synaptic density, contrary to a previous report; instead, the exploratory findings suggest that SV2A binding may be related to episode duration rather than current symptom burden.
Clinical research Environmental scan published

Scan reviews cultural adaptation of trauma therapies for Indigenous peoples

The cultural adaptation of Western trauma interventions for Indigenous peoples experiencing trauma: an environmental scan of Turtle Island
Why it matters ◈ Mixed
This environmental scan highlights the lack of consensus and formal guidelines for adapting Western trauma interventions to Indigenous contexts in North America. It underscores the urgent need for culturally responsive frameworks as psychedelic-assisted therapies and other trauma modalities expand into Indigenous communities. For researchers and clinicians, this signals both an ethical imperative and a practical gap that must be addressed to ensure safety, efficacy, and community trust. The findings may inform future research design, regulatory guidance, and best practices for culturally competent care.
Background Experiences of oppression and genocide towards Indigenous peoples have contributed to severe trauma symptoms. Yet, for Indigenous individuals seeking trauma-related help in Western clinical settings, most therapists lack the culturally relevant tools to meet the needs of Indigenous peoples soliciting help. Objective As Western-informed trauma interventions are developed for use broadly, this article reviews how said interventions are currently adapted by key parties to be safe, effective, and relevant for Indigenous individuals specifically. Method Source eligibility included: at least one Indigenous author or an Indigenous community/organization as collaborator; a Western-based trauma intervention adapted for use with Indigenous individuals; and a focus on the populations of Turtle Island (so called “North America”). Western and Indigenous databases, as well as non-academic literature, were searched. Results A summary of current adaptation practices is presented in three phases: (i) planning (selecting an appropriate therapy, consultation and collaboration with communities/experts); (ii) adaptation (surface and deep level); and (iii) implementation (assessing client fit, evaluating feasibility and effectiveness). Conclusion Key parties described their adaptation processes in detail, but there appears to be little consensus on how to go about this work. As such, the synthesis of formalized guidelines or Wise Practices could be of great benefit.
Clinical research Peer-reviewed publication

Guidance on launching interventional psychiatry clinics published

Concept to Clinic: Considerations in Developing an Interventional Psychiatry Clinic.
Why it matters ▲ Favorable
This publication outlines practical and regulatory considerations for establishing interventional psychiatry clinics, including those offering psychedelic-assisted therapies. It provides a framework for integrating novel treatments into clinical practice, addressing safety, staffing, and compliance. While not a regulatory change, it signals growing institutional interest and may inform best practices and future policy.
Neuroscience Review published

Review: Tryptophan metabolism and gut–brain axis in depression

Tryptophan metabolism within the gut–brain axis in depression: mechanisms, association with heterogeneity, and therapeutic opportunities
Why it matters ▲ Favorable
This review synthesizes emerging evidence linking gut microbiota-driven tryptophan metabolism to the biological heterogeneity of depression, highlighting new therapeutic opportunities. While not directly focused on psychedelics, the mechanistic insights into serotonin and indole pathways are highly relevant to psychedelic science and future precision interventions. The work underscores the importance of multi-omics and AI-driven research for biomarker discovery, which could inform patient stratification and novel treatment approaches in psychiatric disorders.
Depression is a highly heterogeneous psychiatric disorder, characterized by substantial variability in clinical manifestations, treatment responses, and disease progression, thereby posing significant challenges to precision diagnosis and therapeutic intervention. Accumulating evidence indicates that dysregulated tryptophan metabolism, mediated through dynamic crosstalk with the gut microbiota and the gut-brain axis (GBA), plays a pivotal role in both the pathophysiology and biological heterogeneity of depression. In this review, we delineate the contributions of the three principal tryptophan metabolic pathways-the kynurenine, serotonin, and microbial indole pathways-in modulating neuroimmune signaling, neurotransmitter function, and gut-brain communication. Moreover, we synthesize current evidence demonstrating that microbiota-dependent tryptophan metabolism exhibits distinct profiles across clinical, demographic, immunometabolic, trauma-related, and genetically defined depressive phenotypes, thereby establishing its role as a unifying biological framework underlying depressive heterogeneity. We further provide a critical appraisal of emerging therapeutic strategies targeting microbiota-associated tryptophan metabolism, including pharmacological, nutritional, microbial, and traditional Chinese medicine-based interventions. Future investigations should integrate multi-omics approaches, longitudinal study designs, and mechanistic validation with artificial intelligence to elucidate causal relationships between microbiota-associated tryptophan metabolism and depressive heterogeneity, ultimately facilitating biomarker discovery and the development of precision therapeutics.
Analytical science Research published

Nanomolar DMT detection enabled by new field-effect sensor technology

Surface Reaction-Mediated Nanomolar Detection of Chemically Activated Plant Metabolite Biomarkers with Field Effect Sensors
Why it matters ▲ Favorable
This work demonstrates a practical, low-complexity method for detecting DMT and similar plant-derived psychedelics at nanomolar concentrations in biological fluids. The advance could significantly improve pharmacokinetic and safety monitoring in both clinical trials and public health settings, enabling decentralized or point-of-care testing. For researchers and industry, this lowers barriers to studying endogenous and exogenous psychedelic metabolites, potentially accelerating biomarker discovery and regulatory compliance.
Abstract Among potent psychedelic drugs derived from plant metabolites, N,N-dimethyltryptamine (DMT) is a known endogenous tertiary amine alkaloid that can be harmful to brain activity even when present in biological fluids at nanomolar concentrations. Conventional electrochemical detection methods reach only micromolar limits, far above the physiological window, while full mass-spectrometric analysis needed for practical nanomolar detection depends on centralized medical facilities. Here, we present a three-step sensing strategy combining selective chemical activation with a self-assembled monolayer (SAM)-functionalized surface in order to facilitate nanomolar detection with extended-gate field-effect transistor (EGFET) sensors. Initially, the target tertiary amine is selectively oxidized to its N-oxide and rearranged to the corresponding amide, introducing a reactive handle absent from the native molecule. As a next step, the activated analyte is captured by an amino-terminated SAM on the gate electrode of the FET device. Finally, the resulting shift in gate surface potential is transduced by the EGFET into a detectable electrical output. Using gramine as a DMT surrogate, the fabricated sensory device achieves a limit of detection of 7 nM, well within the required physiological window. The surface-bound amount was independently confirmed by ellipsometry measurements of dried samples. This chemistry-driven activation strategy bypasses the need for complex biosensors and offers a general route to small-molecule metabolite targets that are difficult to address with antibody- or aptamer-based recognition.
Religious use / Legal Religious exemption granted

Iowa church secures ayahuasca use for religious ceremonies

Iowa church clears hurdles to use ayahuasca in religious ceremonies
Why it matters ▲ Favorable
An Iowa church has successfully cleared legal and regulatory barriers to use ayahuasca in religious ceremonies, marking a significant precedent for religious freedom and psychedelic access in the state. This development may encourage similar efforts by other religious groups and could influence policy discussions about entheogen exemptions nationwide. While the ruling is narrow, it highlights ongoing legal pathways for non-medical psychedelic use and may impact enforcement priorities. The case underscores the evolving landscape of psychedelic law beyond clinical or research contexts.
Clinical research Trial announced

Swedish university to study psychedelic for social anxiety; Filament to supply

A Swedish university will study a psychedelic for social anxiety. Filament will supply it.
Why it matters ▲ Favorable
This marks a notable expansion of psychedelic clinical research into Sweden, a country with historically strict drug policies. The involvement of Filament Health, a commercial supplier, highlights growing industry-academic partnerships and the globalization of psychedelic research. The study could provide valuable data on psychedelics for social anxiety, a major unmet need, and may influence regulatory and clinical attitudes in Scandinavia.
Clinical research Peer-reviewed study

Psilocybin retreat study links connectedness to sustained wellbeing gains

Connectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic study
Why it matters ▲ Favorable
This prospective study finds that guided psilocybin retreats are associated with sustained improvements in mental wellbeing, with 'connectedness' emerging as a key mediating factor. The results extend evidence for psychedelic benefits beyond clinical settings, highlighting the importance of social and relational processes in public mental health. While causality cannot be established, the findings inform future research and may influence how retreat models are evaluated for safety and efficacy. This underscores the need for controlled trials and may shape regulatory and industry approaches to non-clinical psychedelic use.
Background Psychedelic retreats are increasingly used to promote wellbeing outside clinical settings, yet the psychological processes associated with sustained improvements in wellbeing remain poorly understood. From a public mental health perspective, identifying mechanisms that support positive mental health beyond symptom reduction is of growing importance. Methods This naturalistic longitudinal study followed 173 participants attending guided psilocybin retreats conducted within a structured framework of preparation, dosing, and integration. Mental wellbeing was reported before the retreat and across a 12-month follow-up period. Longitudinal changes were examined using linear mixed-effects models. Mediation analyses investigated whether changes in connectedness, neuroticism (anxiety facet), spiritual transcendence, and absorption were associated with changes in wellbeing. Mystical-type experiences were examined as potential predictors of these psychological changes. Results Participants reported substantial and sustained improvements in mental wellbeing over 12 months, moving from levels below Swedish population norms at baseline toward comparable levels at follow-up. Connectedness showed the strongest statistical association with improvements in wellbeing and accounted for the largest proportion of variance in wellbeing change, followed by reductions in the anxiety facet of neuroticism and absorption. Spiritual transcendence was associated with wellbeing improvements when examined separately but did not retain unique effects in the multiple mediation model. More intense mystical-type experiences predicted greater increases in connectedness, spirituality, and absorption, as well as greater reductions in neuroticism (trait anxiety). The association between mystical experiences and wellbeing was substantially attenuated when connectedness was included in the model, suggesting that connectedness may act as a candidate mediator linking mystical-type experiences to longer-term wellbeing, though the observational design precludes causal inference. Conclusions These findings extend prior work on psychedelic-assisted therapy to naturalistic retreat settings, suggesting that connectedness may represent a key psychological process linking psychedelic retreat experiences to sustained improvements in mental wellbeing. From a public mental health perspective, the results highlight the potential importance of social and relational factors in promoting wellbeing beyond the treatment of mental illness. Future controlled studies are needed to clarify the relative contributions of psychedelic, social, and contextual components.
Neuroscience Published research

New AI framework improves multimodal depression detection accuracy and interpretability

An adaptive spatio-temporal cross-modal learning with directional causal fusion for explainable multimodal depression detection
Why it matters ▲ Favorable
This research introduces an advanced AI model for more accurate and explainable depression detection using multimodal data. While not directly related to psychedelics, improved depression diagnostics are highly relevant for clinical trials and patient selection in psychedelic research. Enhanced detection tools could streamline recruitment, monitoring, and outcome measurement in studies of psychedelic-assisted therapies, potentially accelerating research and improving patient care.
Depression is one of the most common Psychiatric disorders. Early and accurate diagnosis of depression remains an important clinical need. Recently, multi-modality-based detection strategies have been proposed to promote the early effective diagnosis of depression. Although noteworthy progress has been made in depression detection, existing methods still struggle to learn rich, discriminative feature representations. In addition, current cross-modal fusion methods usually capture the inter-modal interactions symmetrically. Such approaches often overlook directional dependencies between different modalities, which may limit their ability to effectively capture complementary information across modalities. To solve the above problems, the new Adaptive Spatio-Temporal Directional Causal Fusion (AST-DCF) BiLSTM-Mamba framework is proposed for multimodal depression detection. The proposed methodology uses Directional Causal integration (DCF) to determine how one modality might impact or predict another, allowing for more effective integration of auditory and visual data. Additionally, the Spatio-Mamba and Temporal-Mamba-BiLSTM blocks are proposed to learn the spatial and temporal information of the multimodal data. The Temporal-Mamba branch further incorporates BiLSTM with a State Space Model (SSM) to capture fine-grained short-term dependencies and coarse-grained long-term temporal dependencies, yielding more effective and discriminative representations. Additionally, the Cross-Modal Consistency-Guided SHAP-LIME module is proposed, which combines global and local explanations via a cosine-similarity-based consistency mechanism. This improves the interpretability of the suggested framework. Extensive experiments demonstrate that the proposed approach can obtain an 81.86% accuracy, outperforming the baseline approaches. These findings show that the proposed framework can enhance both depression detection performance and model interpretability.
Neuroscience Published research

Genome and transcriptome of G. dilepis reveal psilocybin biosynthesis pathways

High-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepis
Why it matters ▲ Favorable
This study provides a high-quality genome assembly and transcriptomic insights into Gymnopilus dilepis, identifying key metabolic pathways involved in psilocybin biosynthesis. The findings deepen understanding of genetic and metabolic mechanisms underlying psilocybin production, which could inform future research, synthetic biology, and industrial-scale production. This foundational work may facilitate more efficient biosynthetic engineering and support the development of novel psilocybin sources for clinical and commercial applications.
Psilocybin has demonstrated efficacy in the treatment of mental health conditions, including anxiety and depression. It is evident that G. dilepis possesses the capacity to produce psilocybin. Therefore, conducting in-depth research into this species will contribute to the understanding of the biosynthetic mechanisms of psilocybin and provide a more comprehensive insight into its biosynthesis. We have assembled the G. dilepis genome at the chromosomal level. G. dilepis is characterized by a chromosome number of 13, a genome size of 54.2 Mb, and a total of 15,211 predicted genes and 16,411,190 transposable elements. The evolutionary analysis suggests that G. dilepis can produce psilocybin due to its close relationship with the Psilocybe genus of mushrooms. Furthermore, transcriptomic analysis revealed that the biosynthesis of psilocybin is associated with several amino acid metabolic pathways, particularly those involving cysteine and methionine metabolism, arginine and proline metabolism, and tryptophan metabolism. These pathways may supply the precursor substances required for psilocybin biosynthesis. This study presents a high-quality genome assembly for G. dilepis and reveals a close relationship between amino acid metabolism and psilocybin biosynthesis, providing a theoretical basis for exploring the genetic relationships in G. dilepis and the genes that regulate the biosynthesis of psilocybin.
Clinical research Perspective published

Perspective: Controlled vs. naturalistic dosing in cannabis research

Controlling the uncontrollable? navigating naturalistic and controlled dosing in cannabis research
Why it matters ◈ Mixed
This article highlights the methodological divide between controlled dosing and naturalistic paradigms in cannabis research, emphasizing that both approaches are essential for a comprehensive evidentiary base. The discussion is relevant for psychedelic and cannabinoid researchers designing studies for regulatory or real-world impact, and for policymakers considering evidence for guidelines or market regulation. While not a legal or regulatory move, it signals evolving best practices that could shape future research standards and policy frameworks.
Cannabis research is advancing rapidly, yet fundamental questions persist regarding the optimal design of human studies to empirically assess the potential harms and benefits of cannabis. There exist central methodological differences between studies that rely on controlled dose paradigms, ensuring internal validity, and those that utilize naturalistic, self-administration approaches which better reflect real-world use. Controlled paradigms offer precision and regulatory alignment but fail to capture the complexity of real-world cannabis consumption. Naturalistic designs enhance ecological validity but introduce variability and pose challenges for dosing, safety, and replicability. This perspective article presents two methods: one emphasizing the scientific rigor and utility of controlled dose paradigms for regulatory outcomes (e.g., FDA), and the other advocating for naturalistic models that prioritize real-world relevance of legal market cannabis consumption which can inform policy decisions (e.g., guidelines around high THC concentrate). However, rather than representing competing alternatives, controlled laboratory and naturalistic paradigms occupy distinct positions within the evidentiary framework of cannabinoid research, each addressing scientific questions that the other cannot. An integrated methods section proposes ways to incorporate the best features of both approaches to advance cannabinoid science study design.
Neuroscience Review published

DBS for treatment-resistant anorexia: targets, efficacy, and challenges

DEEP BRAIN STIMULATION IN TREATMENT-REFRACTORY ANOREXIA NERVOSA: CURRENT TARGETS, EMERGING TECHNIQUES, AND METHODOLOGICAL CHALLENGES
Why it matters ◈ Mixed
This review highlights deep brain stimulation (DBS) as a potential last-resort intervention for severe, treatment-refractory anorexia nervosa, with emerging technologies offering improved precision and safety. While DBS may improve outcomes in select patients, evidence remains limited and ethical concerns—especially regarding consent—are significant. The field requires robust, multicenter trials to clarify long-term safety and efficacy before broader adoption.
Background: Anorexia nervosa (AN) is a severe psychiatric disorder associated with the highest mortality rate among mental illnesses. Up to 20% of patients develop Severe and Enduring Anorexia Nervosa (SE-AN), a life-threatening condition resistant to conventional psychotherapy and nutritional rehabilitation. In the absence of effective pharmacotherapy, Deep Brain Stimulation (DBS) has emerged as a potential neurosurgical intervention targeting dysfunctional circuits involved in cognitive control, reward processing, and emotion regulation. Objectives: This review evaluates the current application of DBS in treatment-refractory AN, focusing on neuroanatomical targets, clinical efficacy, safety, and methodological, technological, and ethical challenges. Methodology: A comprehensive literature search was conducted in PubMed, Scopus, ScienceDirect, Embase, and Google Scholar. Studies published between 2022 and 2026 were considered, with reference lists manually screened for additional relevant evidence. Results: DBS may improve BMI, psychiatric symptoms, and quality of life in patients with SE-AN. Although the subcallosal cingulate cortex (SCC) and nucleus accumbens (NAcc) remain the principal targets, recent approaches increasingly emphasize phenotype-driven and connectome-guided neuromodulation. Emerging closed-loop, AI-assisted, and wireless technologies may further improve stimulation precision and reduce hardware-related complications. Conclusions: DBS represents a promising harm-reduction approach for treatment-refractory SE-AN. However, limited evidence, surgical risks, and ethical concerns regarding informed consent in severely malnourished patients warrant its use only as a last-resort intervention. Robust randomized multicenter trials are needed to establish its long-term safety and target-specific efficacy.
Neuroscience Review published

Review links mammalian torpor and depressive disorders

Mammalian torpor and depressive disorders: a review of evidence for a connection
Why it matters ▲ Favorable
This review proposes a novel conceptual link between mammalian torpor and depressive disorders, suggesting that mechanisms underlying torpor may inform new models and treatments for depression. It highlights the potential for translational research connecting animal torpor states to human affective disorders, which could impact future clinical trial design and therapeutic targets, including those relevant to psychedelic interventions. While not directly about psychedelics, the work may influence how depression is modeled and understood in preclinical and clinical research. This could open new avenues for mechanistic studies and innovative treatment approaches.
Unexpected similarities exist between animal torpor and depressive disorders. We examine them from a variety of perspectives and propose that these two seemingly disparate entities are related in important ways. In the animal kingdom, torpor - a hypometabolic state during which physiological functions are severely decreased - is now understood to be a response to stress, whether unanticipated or seasonal. It is used by mammals from the tropics to the poles, including by several species of primates. Humankind evolved from mammals that used torpor, and the genetic legacy enabling the torpor response exists in every person's genome. Strikingly, severe cold has occasionally created a torpor-like state in human beings - and 'synthetic hibernation' is now being studied as a modality to facilitate space travel. The expression of torpor can vary wildly among species and even between any two individuals within the same species living in the same locale, implying unusual mutability of this complex and variegated adaptation and the likely expression of aspects of it in vulnerable members of our own species. Both torpors and depressions require perturbation of the circadian clock, which is resynchronized upon recovery. The same types of prominent but reversible hippocampal changes mark both depressions and torpors. The circannual clock that drives seasonal torpors also appears to guide some recurrent affective disorders. Mammals can be brought out of their torpors by the same interventions that bring people out of their depressions. Affective catatonias and certain subtypes of depressions display aspects of a torpor-like response and are explored. Torpor arguably is the only animal model of depression that fulfills Willner's triad of face, construct, and predictive validity (plus etiological similarity, a criterion added later). Some aspects of depressive disorders, puzzling at first, can be explained if one views them from the perspective of a torpor response. Ideas for future research that might elucidate the connections between depressive disorders and torpor are suggested. The proposed connection between torpor and certain subtypes of depressive disorders warrants greater attention by researchers in these currently disconnected fields. A collaborative approach could lead to better treatments for depressed persons.
Industry / Clinical research Supply agreement announced

Rhelion unit to supply psilocybin drug to Sweden university trial

Why it matters ▲ Favorable
Rhelion's agreement to supply psilocybin for a Swedish university trial signals growing international infrastructure and commercial involvement in psychedelic research. This development may facilitate more robust clinical studies in Europe, supporting regulatory pathways and eventual patient access. It also highlights the emergence of specialized suppliers as critical players in the research and future therapeutic market.
DEA / Federal policy Legal challenge filed

Scientists challenge DEA's proposed psychedelic scheduling threatening research

Scientists Launch Legal Challenge to DEA's Proposed Psychedelic Scheduling, Which Would Criminalize Research Compounds and Jeopardize FDA Breakthrough Therapy for Postpartum Depression
Why it matters ▼ Unfavorable
A legal challenge against the DEA's proposed scheduling of research psychedelics could determine whether key compounds remain accessible for clinical trials and FDA breakthrough therapy development, particularly for conditions like postpartum depression. If the DEA's rule is upheld, it may criminalize possession and use of investigational psychedelics, severely restricting research and jeopardizing promising treatments. The outcome will set a precedent for the balance between drug control and scientific innovation in the US.
Clinical research Scoping review published

Scoping review: Topical ketamine for oral mucositis pain in cancer patients

Efficacy and Safety of Topical Ketamine for Oral Mucositis Pain Due to Chemotherapy: A Scoping Review
Why it matters ◈ Mixed
This review synthesizes early evidence that topical ketamine mouthwash may reduce pain and opioid use in adults with chemotherapy-induced oral mucositis, with a favorable safety profile. However, findings are limited by small sample sizes, inconsistent dosing, and mixed results in pediatric populations. The review highlights the need for larger, rigorous RCTs to clarify efficacy and inform integration into supportive cancer care, with potential implications for expanding ketamine's clinical indications and reducing opioid reliance.
This scoping review evaluates the efficacy, safety and dosing regimens of topical ketamine mouthwash for managing oral mucositis pain in cancer patients undergoing chemotherapy and/or radiotherapy. Oral mucositis, characterised by painful inflammation and ulceration of the mucosa, significantly impairs quality of life (QoL) and often requires opioid analgesics. Ketamine, an N-methyl-D-aspartate receptor antagonist with peripheral antinociceptive and anti-inflammatory effects, has been explored as a topical treatment to address refractory mucositis pain. The review included six studies comprising case reports, retrospective audits, a prospective phase II study in adults and a randomised placebo-controlled trial in paediatric patients. Adult studies generally reported pain reduction, improved function and opioid-sparing effects, with good tolerability and minimal adverse events. However, the paediatric trial found no significant benefit at the tested dose. Variability in dosing, formulation and study design limits definitive conclusions. Pharmacokinetic data support localised action with minimal systemic absorption and toxicity. Topical ketamine mouthwash shows promise as an adjunctive therapy for difficult-to-control oral mucositis pain, potentially improving patient comfort and reducing opioid use. Larger, well-designed randomised controlled trials are needed to establish optimal dosing, long-term safety and comparative efficacy against standard treatments. Integration of topical ketamine into supportive care protocols may enhance pain management and QoL for affected patients.
Federal regulation Rule proposed

PHMSA proposes update to align hazardous materials rules with global standards

Hazardous Materials: Harmonization With International Standards
Why it matters ◈ Mixed
This proposed rule could affect the import, export, and domestic transport of regulated psychedelic substances and research chemicals by updating how hazardous materials are classified and shipped in the US. The harmonization may ease some compliance burdens for researchers and industry, but could also introduce new restrictions or requirements depending on international standards. Stakeholders in psychedelic research and supply chains should monitor for changes that could impact material access, shipping, or regulatory risk.
PHMSA proposes to update the Hazardous Materials Regulations to adopt certain international regulations and standards related to proper shipping names, hazard classes, packing groups, special provisions, packaging authorizations, air transport quantity limitations, and vessel stowage requirements. These proposed amendments are intended to maintain consistency with the latest international regulations and standards, to reduce costs to entities or individuals within the United States, and to lower the cost of regulations on the U.S. economy.
Media / Public Perception Systematic review published

Media coverage of psilocybin outpaces scientific evidence, review finds

News coverage of psilocybin often outpaces the science, systematic review finds
Why it matters ◈ Mixed
Systematic review finds that news coverage of psilocybin frequently exceeds the pace and nuance of the underlying science. This highlights a persistent gap between public/media narratives and the current state of clinical evidence, which can shape patient expectations, policy debates, and investment decisions. Stakeholders should be aware of the risks of hype-driven misinformation and the need for accurate communication as the field evolves.
Clinical research Trial announced

Black Dog Institute launches ketamine trial for emergency workers in Australia

Black Dog Institute announces Australian-first ketamine treatment trial for Australia’s emergency service workers
Why it matters ▲ Favorable
This is the first Australian clinical trial of ketamine for emergency service workers, a high-risk group for mental health disorders. The study could provide vital data on ketamine’s efficacy and safety in treating PTSD or depression in frontline personnel, potentially informing future clinical guidelines and access pathways. It also signals growing institutional and regulatory support for psychedelic research in Australia.
Clinical research Systematic review published

Systematic review: Psychosis risk with psychedelics remains low in clinical settings

Psychedelics and psychosis: A systematic review of recent-era studies (1984–2025)
Why it matters ◈ Mixed
This systematic review finds that the risk of prolonged psychosis from psychedelics is very low in controlled clinical settings, but higher in unsupervised or high-risk populations. The findings reinforce the importance of rigorous screening for personal or family psychiatric history and the necessity of clinical oversight as psychedelic therapies expand. For clinicians, researchers, and policymakers, this evidence base supports risk stratification protocols and may inform regulatory frameworks and best practices as access widens.
PURPOSE: -dimethyl-tryptamine, and mescaline) and the emergence of psychotic symptoms, aiming to synthesize evidence from contemporary studies (1984-2025) regarding the risk factors, prevalence, and clinical characteristics of psychosis related to psychedelic use, to provide clinicians, therapists, and policymakers with a framework for identifying and mitigating risks related to these substances. MAJOR FINDINGS: Fifty-two papers were included, comprising 1 larger-scale studies involving over 100,000 individuals and 34 case reports. Population-based data showed no consistent correlation between lifetime psychedelic use and psychosis. Controlled clinical settings showed minimal risk, with one documented case of transient delusions across all trials. Emergency and toxicological data reported higher rates of psychotic symptoms, likely reflecting the severity of cases prompting medical attention. Among case reports, 58% of individuals had a personal or family psychiatric history. First-episode psychosis, although rare, was documented in otherwise healthy individuals. CONCLUSIONS: The risk of prolonged psychosis remains remarkably low in controlled clinical settings where rigorous screening and supervision are employed. Personal/family history of psychosis and unsupervised, naturalistic use appear to be risk factors for psychosis. Although causality remains difficult to establish, these findings support the need for careful risk stratification, the adoption of clear diagnostic parameters, and trained clinical oversight as psychedelic-assisted therapies advance toward broader clinical populations.
Clinical research Protocol published

Preliminary study: Ketamine-augmented hypnotherapy shows feasibility

Ketamine-Augmented Hypnotherapy
Why it matters ◈ Mixed
This article introduces ketamine-augmented hypnotherapy (KAHT) as a novel protocol, reporting promising but preliminary results in a mixed-diagnosis sample. While most patients described positive experiences and some showed reduced depressive symptoms, the uncontrolled design and small sample limit conclusions. The findings highlight the need for randomized trials to clarify the therapeutic contribution of hypnotherapy and to identify predictors of response. This work is relevant for researchers and clinicians exploring innovative psychedelic-assisted therapy models.
Background/Objectives: Ketamine has rapid antidepressant effects through NMDA receptor antagonism and downstream neuroplasticity. Combined with structured psychotherapy, it is a promising but still experimental option for patients who have not responded to established treatments. By transiently loosening self-referential processing and habitual evaluative frameworks, psychoactive substances may open a window for therapeutic change. This article outlines the theoretical and neurobiological foundations of altered states of consciousness relevant to this approach. It presents ketamine-augmented hypnotherapy (KAHT) as a specific form of ketamine-assisted psychotherapy. Methods: We review the literature on psychedelic, ketamine-induced, and hypnotic states and describe the KAHT protocol. In KAHT, a single intravenous infusion of racemic ketamine (0.5 mg/kg) is given under hypnotherapeutic guidance, embedded in preparation and integration sessions. Preliminary data from 89 patients include the Mystical Experience Questionnaire (MEQ), pre–post PHQ-9 scores (n = 20), and patient-reported effects. Results: Most patients described the session as calming, euphoric, and psychedelic, with the highest MEQ ratings for transcendence of time and space. PHQ-9 scores decreased significantly (p = 0.048). In the clinically depressed subgroup (n = 14), the reduction did not reach significance (p = 0.09). Of 20 patients, 12 reported lasting positive changes, 6 no change, and 2 negative changes. Conclusions: KAHT appears feasible and may be applicable across diagnostic categories, but responses vary. The uncontrolled design cannot isolate the contribution of the hypnotherapeutic component. Randomized trials are needed to establish efficacy and predictors of response.
Clinical research Systematic review published

Systematic review: Psychedelics and psychosis risk (1984-2025)

Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025).
Why it matters ◈ Mixed
This systematic review aggregates four decades of data on the relationship between psychedelic use and psychosis risk. The findings help clarify the incidence, risk factors, and possible mechanisms of psychosis following psychedelic exposure, informing both clinical trial safety protocols and public health messaging. Policymakers and IRBs may use these insights to refine eligibility criteria, monitoring, and consent processes for psychedelic research and therapy. The review also highlights knowledge gaps, guiding future research priorities and risk mitigation strategies as access expands.
Neuroscience Perspective published

Addiction neuroscience: from withdrawal to adaptive brain states

Fifty years at the addiction bench and bedside: from withdrawal syndromes to adaptive brain states
Why it matters ▲ Favorable
This perspective reviews the evolution of addiction science from symptom-based to mechanistic, highlighting how translational research has led to non-opioid treatments for withdrawal and a shift toward understanding reward circuitry and relapse. It situates psychedelics as part of a new wave of mechanism-based interventions, suggesting a broader clinical and research context for their use in addiction medicine. While not a regulatory or legal shift, it frames psychedelics within a modern neuroscience paradigm, supporting further research and public health integration.
Over the past half-century, addiction medicine has moved from moral and symptom-based explanations toward a neuroscience of adaptation, learning, motivation, and recovery. This Perspective uses several linked translational programs—opioid withdrawal and the locus coeruleus, cocaine dependence and dopamine, environmental drug exposure, physician health, and food reward—to illustrate how observations at the bedside can generate mechanistic studies and how laboratory findings can, in turn, change treatment and public health. LC stimulation produced signs and symptoms that looked to me like opioid withdrawal. So, we thought that noradrenergic hyperactivity in opioid withdrawal caused symptoms, and while methadone or morphine could treat these, we could also treat them with a non-opioid, clonidine. Earlier noradrenergic interventions had been attempted with limited clinical success. Our work provided the first hypothesis-driven, double-blind, placebo-controlled demonstration that a non-opioid medication could suppress the acute human opioid withdrawal syndrome. This mechanism-based treatment was greeted with considerable interest because some clinicians had assumed that any medication capable of reversing opioid withdrawal distress must itself be an opioid. Clonidine and later lofexidine did just that and facilitated transition to naltrexone. Recognition that cocaine could produce compulsive use without a dramatic physical withdrawal syndrome helped shift the field toward reward circuitry, craving, pathological attraction, anhedonia, and relapse. Studies of tobacco, cannabis, and opioid smoke broadened prevention by showing that involuntary second- and third-hand exposure can be biologically detected and, most clearly for tobacco, can produce biologically meaningful effects. Third-hand exposure refers to residual drug-related contaminants that persist on indoor surfaces, dust, clothing, or other materials after active smoking has ended. Contemporary work on neuromodulation, exercise, psychedelics, and GLP-1 metabolic-reward pathways extends the same translational logic. Addiction is best understood as an acquired adaptive brain state supported by anti-survival or bad learning, development, and environment; recovery is active neurobehavioral relearning, not simply detoxification or drug clearance. Public health should therefore join brain sciences, work to delay initiation, identify emerging risk before a severe substance use disorder develops, prevent involuntary exposure, and provide rapid access to mechanism-based treatment, recovery-supportive environments, and outcomes measured over 5 years or longer.
Clinical research Pilot RCT underway

MDMA-enhanced exposure therapy trial for PTSD in VA outpatient setting

Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system
Why it matters ▲ Favorable
This pilot trial tests MDMA-assisted massed exposure therapy for PTSD in veterans within the VA system, using a rigorous double-masked design and telehealth integration. The study addresses key limitations of prior MDMA trials—such as masking and active comparators—and adapts the protocol for real-world outpatient care. Early results will inform feasibility, safety, and the potential for broader implementation in large healthcare systems, a critical step for future access and policy decisions.
Posttraumatic stress disorder (PTSD) remains prevalent and disabling, especially among veterans, with a substantial proportion failing to achieve remission following first-line evidence-based trauma-focused psychotherapies. 3,4-Methylenedioxymethamphetamine (MDMA) is hypothesized to enhance psychotherapy outcomes through effects on fear extinction, cognitive flexibility, and emotional engagement, and is being studied as a promising augmentation strategy for PTSD psychotherapy. There is limited research combining MDMA with evidence-based PTSD treatment. MDMA-assisted psychotherapy trials to date have also been limited by lack of an active comparator and functional unmasking. We describe the methodology of an ongoing randomized, double-masked, pilot trial evaluating massed prolonged exposure (PE) therapy enhanced with MDMA for PTSD (aMETEMP), adapted for a U.S. Veterans Affairs outpatient setting. Up to 20 veterans with PTSD in the VA will receive a 6-8hr in-person MDMA dosing session (randomized dose 35mg - 125mg) integrated with a 3-week massed exposure protocol. The remaining visits are virtual and include PE sessions and sessions to prepare for and process the MDMA session (28-30hrs total over 11 visits), with the use of telehealth intended to improve access and ease patient burden. After treating the first 4 participants, who were fully informed of the trial design, we switched to using an incomplete disclosure strategy (not disclosing the number of treatment arms or specific possible doses) to further improve masking. Primary outcomes include PTSD severity using the Clinician-Administered PTSD Scale for DSM-5, safety, feasibility, and masking success. Findings are intended to provide preliminary descriptive information regarding feasibility, safety/tolerability, masking integrity, and symptom-change signals for aMETEMP with incomplete disclosure in a large outpatient healthcare system.ClinicalTrials.gov Identifier: NCT06117306
Clinical research Scoping review published

Scoping review maps 2020–2025 clinical evidence for psychedelic-assisted therapy

Psychedelic assisted psychotherapy (2020–2025): a scoping review of clinical evidence, mechanisms, safety, and ethics
Why it matters ◈ Mixed
This comprehensive review synthesizes the clinical, mechanistic, and ethical landscape of psychedelic-assisted therapy (PAT) research from 2020–2025, highlighting robust evidence for MDMA in PTSD and psilocybin in depression, but also substantial heterogeneity in protocols and persistent methodological and ethical challenges. The review underscores the need for standardized psychotherapeutic approaches, better blinding, and long-term safety data. Its findings will inform future trial design, regulatory discussions, and clinical best practices as the field matures.
Background Clinical research on psychedelic-assisted therapy (PAT) has expanded substantially in recent years, particularly for post-traumatic stress disorder (PTSD) and depressive disorders. Contemporary studies have generally evaluated psychedelic administration within controlled therapeutic settings that include psychological support, preparation, and integration. However, variability in clinical response and methodological challenges have highlighted the importance of individual, relational, and contextual factors, often described as “set and setting,” in understanding therapeutic outcomes. The role of psychotherapy and the broader therapeutic context therefore remains an important area of investigation. Objective This scoping review aimed to map the contemporary evidence on PAT, characterize the clinical and psychotherapeutic approaches used with psilocybin, MDMA, LSD, and DMT, summarize reported clinical and safety findings, and identify methodological, mechanistic, ethical, and implementation considerations across existing protocols. Methods A structured search of PubMed, PsycINFO, Scopus, and ClinicalTrials.gov was conducted on 23 February 2026. Sources published or publicly available between January 2020 and November 2025 were eligible. The review included peer-reviewed and relevant non-peer-reviewed sources addressing psychedelic-assisted interventions, including primary clinical studies, reviews, clinical trial registrations, regulatory documents, and other relevant contextual sources. Records were managed using Zotero and screened against predefined Population, Concept, and Context criteria. Findings were synthesized descriptively according to source type and evidence domain. Results The mapped evidence was most developed for MDMA-assisted therapy in PTSD and psilocybin-assisted interventions for depressive disorders. Randomized clinical trials reported reductions in PTSD and depressive symptoms following MDMA- and psilocybin-based interventions, respectively, while emerging clinical evidence also investigated LSD-based treatment for generalized anxiety disorder. Evidence for DMT-assisted therapy remained comparatively preliminary, with several available sources consisting of trial registrations or industry-reported information. Across the literature, preparation, supervised psychedelic administration, and integration were common therapeutic components, although the structure and intensity of psychotherapy varied substantially. Functional unblinding, expectancy effects, heterogeneity of psychotherapeutic approaches, and limitations in long-term safety data were recurring concerns. Ethical issues included informed consent during altered states of consciousness, therapist competence and boundaries, cultural considerations, and equitable access. Conclusion PAT represents a rapidly developing area of clinical research, but the evidence base remains heterogeneous across compounds, indications, therapeutic models, and levels of evidential maturity. Future research should improve the standardization and reporting of psychotherapeutic interventions, strengthen methods for assessing blinding and expectancy, establish consistent long-term safety monitoring, and develop robust ethical and equity frameworks. Clear distinction between peer-reviewed clinical findings and preliminary or contextual evidence will also be essential as PAT research progresses toward broader clinical implementation.
Clinical research Secondary analysis published

Sex-related differences in psilocybin vs. escitalopram outcomes reanalyzed

Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis
Why it matters ◈ Mixed
This Bayesian reanalysis of a psilocybin vs. escitalopram RCT for MDD found no overall sex differences in primary outcomes, but did observe lower post-treatment anxiety in females receiving psilocybin. The study highlights the need for larger, sex-balanced trials and suggests that sex-specific effects, especially regarding anxiety and sexual dysfunction, warrant further investigation. While not definitive, these findings may inform future trial design and regulatory considerations around personalized psychedelic therapies.
RATIONALE: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. OBJECTIVES: This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple psychological domains. METHODS: We conducted a post hoc Bayesian analysis of a six-week, double-blind trial in adults with moderate-to-severe MDD (N = 59; 20 female; psilocybin n = 30, 11 female; escitalopram n = 29, 9 female). Post-treatment depression, anhedonia, anxiety, thought suppression, and well-being were modeled by sex, treatment, sex-by-treatment interaction, and baseline score. Sexual dysfunction, measured post-treatment only, was analyzed ordinally. Prior-sensitivity analyses used narrower and wider priors. RESULTS: No outcome showed an overall sex difference across treatments. Within psilocybin, females had lower post-treatment anxiety than males (STAI adjusted difference = -8.77, 95% CrI = -15.73 to -1.73; BFany = 11.18), although the estimate varied across priors and the narrowest prior included zero. The sex-by-treatment interaction was inconclusive (difference=-8.62, 95% CrI=-18.36 to 1.30; BFany = 2.55). A directional female advantage in anhedonia with escitalopram was unsupported by Bayes factors. No sex differences emerged on depression scales. Among males, sexual dysfunction was lower with psilocybin than with escitalopram. Within escitalopram, females reported less sexual dysfunction than males. CONCLUSIONS: This reanalysis identified sex-related patterns in anxiety under psilocybin but no clear treatment-specific interaction. Findings support adequately powered, sex-balanced trials incorporating hormonal and reproductive factors.
Neuroscience Review published

Review: Neuroplasticity mechanisms in depression and therapeutic implications

Neuroplasticidade e depressão: adaptações estruturais e funcionais do cérebro em resposta ao tratamento
Why it matters ▲ Favorable
This review synthesizes current understanding of neuroplasticity's role in major depressive disorder (MDD), highlighting how disruptions in pathways like BDNF-TrkB and mTORC1 contribute to depressive symptoms. It underscores that both conventional antidepressants and novel interventions such as ketamine can promote neural circuit reorganization and synaptogenesis. For psychedelic research, this work reinforces the scientific rationale for targeting neuroplasticity as a therapeutic mechanism in depression. While not a trial or policy move, it provides useful context for ongoing and future clinical research.
Objetivo: Analisar os principais mecanismos envolvidos na neuroplasticidade associados à fisiopatologia do Transtorno Depressivo Maior (TDM) e suas implicações terapêuticas. Revisão bibliográfica: A neuroplasticidade exerce papel central na fisiopatologia do TDM, envolvendo alterações estruturais, funcionais e sinápticas, além da participação de mecanismos relacionados à neuroinflamação, ao estresse crônico e à sinalização neurotrófica. A redução da atividade das vias BDNF-TrkB e mTORC1, a perda de espinhas dendríticas, a diminuição da conectividade neuronal e alterações na atividade de redes cerebrais contribuem para a manutenção das manifestações clínicas do transtorno. Em contrapartida, diferentes intervenções terapêuticas, incluindo antidepressivos convencionais, cetamina e estratégias não farmacológicas, podem favorecer a reorganização dos circuitos neurais, a sinaptogênese e a recuperação da plasticidade cerebral. Considerações finais: A compreensão da neuroplasticidade no Transtorno Depressivo Maior evidencia novos alvos terapêuticos, favorecendo estratégias capazes de restaurar a conectividade neural e promover maior eficácia no tratamento da depressão.
Neuroscience Peer-reviewed study

Striatal reorganization linked to relapse risk in anorexia nervosa recovery

Posterior-anterior striatal reorganization after weight restoration in anorexia nervosa is associated with remission outcome: from mice to longitudinal human study
Why it matters ▲ Favorable
This cross-species study identifies striatal plasticity—specifically, posterior-anterior putamen gradient changes—as a potential biomarker for relapse risk in anorexia nervosa (AN) after weight restoration. While not directly related to psychedelics, these findings may inform future research into how neuromodulatory interventions, including psychedelic-assisted therapies, could target striatal circuits implicated in persistent maladaptive behaviors. The work advances understanding of brain-based relapse mechanisms, which is relevant for designing novel treatments for refractory psychiatric disorders.
Anorexia nervosa (AN) is a severe psychiatric disorder with high relapse rates despite successful weight restoration. Altered reward processing and an imbalance between goal-directed and habitual control within the striatum have been proposed to contribute to the persistence of maladaptive behaviours, but the striatal mechanisms underlying recovery and relapse remain unclear. Here, we combined cross-species structural MRI with longitudinal clinical characterization to investigate striatal alterations associated with recovery from AN. Mice with deletion of the vesicular acetylcholine transporter (VAChTcKO), a model of maladaptive eating behaviour, showed reduced dorsolateral striatal volume compared with wild-type mice. At baseline, women with AN (n = 71) showed reduced striatal volumes compared with healthy controls (n = 30). Longitudinally, patients with AN (n = 41) and healthy controls (n = 28) were reassessed, revealing substantial recovery of striatal volumes following weight restoration in AN. Posterior-anterior putamen gradient changes differed according to subsequent remission status, with changes in the right putamen gradient predicting relapse. Striatal gradient changes were also associated with goal-directed and habitual behaviour during the slip-of-action task, response consistency during delay discounting, and circulating ghrelin and desacyl ghrelin concentrations. These findings identify longitudinal putamen reorganization as a candidate marker of vulnerability to relapse and link striatal plasticity to reward-related and metabolic processes in AN.
Clinical research Feasibility study ongoing

VR simulates psychedelic-like experiences for OCD in feasibility study

Immersive Virtual Reality to Simulate Psychedelic-Like Experiences in Adults with Obsessive–Compulsive Disorder: A Single-Arm Multicentre Feasibility Study
Why it matters ◈ Mixed
This multicentre feasibility study tests whether immersive VR can safely and acceptably simulate psychedelic-like experiences for OCD patients, offering a non-pharmacological alternative to classic psychedelic therapy. While not a regulatory or legal milestone, it is a notable step for the field, as it explores digital interventions that could bypass legal and safety barriers to psychedelic access. If successful, such approaches could expand therapeutic options and inform future research or commercial digital therapeutics.
This project investigates the feasibility, acceptability, and safety of using immersive virtual reality (VR) to simulate psychedelic-like experiences in adults with obsessive–compulsive disorder (OCD). OCD is a chronic and impairing condition characterised by intrusive thoughts, repetitive behaviours, and marked cognitive and behavioural rigidity. A substantial proportion of patients experience insufficient symptom relief, limited engagement, or internal resistance to conventional therapeutic approaches. This highlights the need for adjunctive interventions capable of targeting psychological inflexibility through alternative experiential methods. The primary aim of this single-arm multicentre feasibility study is to determine whether a single VR session designed to evoke psychedelic-like visual and auditory phenomena is feasible, acceptable, and safe for patients with OCD. Psychedelic-assisted therapies have shown promise in enhancing psychological flexibility and reducing rigid patterns of thinking across several psychiatric conditions, but their clinical use remains limited by legal and safety constraints. VR offers a controlled, substance-free alternative for eliciting selected aspects of psychedelic phenomenology. The study therefore examines whether such an intervention can be delivered safely in clinical settings, whether patients tolerate and engage with the experience, and whether the session produces measurable short-term changes in affect, cognitive flexibility, metacognitive beliefs, and momentary OCD symptom intensity. Approximately 24 adult participants will be recruited across two clinical sites: the University Medical Center Hamburg-Eppendorf (Germany) and the University of Catania (Italy). The study follows a single-arm, open-label pre–post design. All participants complete: Baseline assessments (T0) including diagnostic interviews (DIAMOND or QuickSCID-5), OCD severity (Y-BOCS), anxiety (GAD-7), depression (BDI-II), and medication status. Pre-intervention assessments (T1) immediately before the VR session. A single VR session, delivered using a Meta Quest 3 headset and developed by PatientZero Games, in a controlled environment. Post-intervention assessments (T2) immediately after the session. The VR experience is designed to simulate psychedelic-like perceptual and self-related phenomena without pharmacological substances. Primary outcomes focus on feasibility and acceptability: Recruitment and retention rates Completion rate (target ≥ 70%) User experience (UEQ-S) Safety indicators including pre–post changes in cybersickness (SSQ) and adverse events. SSQ scores will be compared between the pre-intervention (T1) and post-intervention (T2) assessments, with the hypothesis that there will be no statistically significant change. These outcomes will determine whether the intervention can be implemented reliably in clinical settings and whether patients find the experience tolerable and engaging. Secondary outcomes explore preliminary psychological effects: Acute OCD symptom intensity (A-YBOCS) Positive and negative affect (PANAS) Metacognitive beliefs related to thought control (MCQ-30/MKF-30, NC subscale) State cognitive flexibility (State-CFI) Psychedelic-like effects such as ego dissolution (EDI) VR presence and immersion (IPQ) Although the study is not powered for efficacy testing, pre–post changes will provide initial indications of whether psychedelic-like VR experiences may influence mechanisms relevant to OCD, such as rigidity, affect, and cognitive flexibility. This feasibility study represents the first application of psychedelic-like VR in a clinical OCD population. Its findings will: Establish whether the intervention is safe and acceptable for patients receiving inpatient treatment. Identify the most sensitive and clinically meaningful outcome measures for future trials. Provide effect size estimates and procedural insights necessary for designing a subsequent randomised controlled trial. By integrati
Clinical research Phase 2/3 trial published

Intranasal Mebufotenin Trial for TRD Shows Efficacy in RCT

Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.
Why it matters ▲ Favorable
This randomized clinical trial reports that a single intranasal dose of the psychedelic mebufotenin produced significant improvement in treatment-resistant depression (TRD) compared to placebo. The use of a novel administration route and a new psychedelic compound expands the therapeutic toolkit and may offer advantages in accessibility and patient tolerability. These results could accelerate further research, regulatory interest, and industry development around mebufotenin as a differentiated option for TRD. The findings will be closely watched by clinicians, sponsors, and policymakers evaluating next-generation psychedelic therapies.
Clinical research Peer-reviewed trial results

Low-dose ketamine alters brain entropy in treatment-resistant depression

Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials.
Why it matters ▲ Favorable
Two neuroimaging clinical trials show that low-dose ketamine modulates brain entropy in patients with treatment-resistant depression. This finding provides mechanistic insight into ketamine's rapid antidepressant effects and supports its ongoing clinical development. The results may inform future trial design, biomarker discovery, and regulatory discussions around ketamine's use in psychiatry. While not a policy change, these data strengthen the scientific rationale for expanding research and access.
Clinical research Study results reported

Toad venom psychedelic tested for treatment-resistant depression

Scientists Tested a Toad Venom Psychedelic on Treatment-Resistant Depression. Here's What Happened.
Why it matters ◈ Mixed
Researchers have reported results from a study testing a toad venom-derived psychedelic (likely 5-MeO-DMT) in patients with treatment-resistant depression. While details are limited, this suggests growing scientific interest in less-studied psychedelics and their potential for hard-to-treat mental health conditions. The findings could inform future clinical trial designs and regulatory considerations, but without more data, the impact on access or legal risk is unclear.
FDA / DEA FDA policy statement

FDA’s Top Officials Publish Written Position on Psychedelics

Tell Me What You Want, What You Really, Really Want: FDA’s Top Officials Put Their Psychedelics Position in Writing
Why it matters ◈ Mixed
The FDA’s top leadership publicly clarifying their stance on psychedelics marks a pivotal moment for the field, signaling regulatory priorities and potential pathways for approval. This written position will influence how researchers design trials, how companies plan development, and how policymakers and investors assess legal risk and market timing. The statement is likely to shape both near-term research access and the long-term structure of the regulated psychedelics industry.
State policy State program under review

Study analyzes Oregon's psilocybin therapy program outcomes

‘The Evergreen’: What a scientific study reveals about Oregon’s psilocybin therapy program - Oregon Public Broadcasting
Why it matters ◈ Mixed
A scientific study of Oregon’s psilocybin therapy program provides critical data on real-world implementation, safety, and efficacy outside of clinical trials. The findings will inform policymakers, clinicians, and industry stakeholders about the program’s impact and may influence future state or federal policy decisions. This evidence base is essential for guiding expansion, regulatory adjustments, and best practices in psychedelic-assisted therapy.
Clinical research Peer-reviewed publication

EEG/ECG biomarkers may predict depression treatment response

Predictive value of EEG/ECG biomarkers for treatment response in depression.
Why it matters ▲ Favorable
Emerging evidence that EEG/ECG biomarkers can predict antidepressant treatment response could accelerate precision medicine in psychiatry. For psychedelic research, validated biomarkers may help stratify patients, optimize trial design, and support regulatory acceptance of novel therapies. This development is relevant for clinical researchers and industry sponsors aiming to demonstrate efficacy and safety in depression trials.
Neuroscience Preprint published

Multiscale Interoceptive Medicine: Unified Model for Psychiatric & Systemic Disease

The Allostatic Trap
Why it matters ◈ Mixed
This monograph proposes a unified, formalized model linking central nervous system dynamics with systemic autoimmune and oncological disease, introducing a multiscale framework that could inform future psychiatric and somatic research. While not directly addressing psychedelics, the focus on insular cortex, DMN, and network-level regulation overlaps mechanistically with leading hypotheses about psychedelic action and therapeutic potential. The work may provide a theoretical foundation for future studies on how psychedelics modulate interoceptive and neuroimmune pathways, but immediate clinical or regulatory impact is limited.
Multiscale Interoceptive Medicine: A Unified Neuro-Autonomic, Bioelectric, and Chronobiological Architecture of Psychiatric, Autoimmune, and Neoplastic Disease Resource Type: Publication / Monograph (Preprint Collection) Target Disciplines: Systems Biomedicine, Computational Psychiatry, Network Neuroscience, Cancer Neuroscience, Bioelectric Morphogenesis, Chronobiology, Psycho-Neuro-Immunology, Complex Systems Epidemiology Description / Abstract Contemporary biomedicine remains partitioned along nineteenth-century anatomical boundaries: psychiatry investigates cortical and subcortical network dynamics; rheumatology and immunology investigate leukocyte self/non-self discrimination; oncology investigates somatic cell proliferation and genomic instability; and epidemiology investigates macro-social stress. While clinical and longitudinal data consistently demonstrate profound, bidirectional comorbidities across these domains—most notably the synchronized contemporary surge in treatment-refractory anhedonic burnout, systemic autoimmune disorders, and early-onset solid organ malignancies in adults under age 50—medical science has lacked a unified, quantitative architecture explaining how central predictive processing causally governs peripheral cellular and immunological boundaries. This eight-part monograph establishes Multiscale Interoceptive Medicine, modeling the human organism through non-equilibrium statistical mechanics and active inference as a nested hierarchy of coupled Markov Blankets—spanning individual somatic cells (Tier 1), bioelectric organ syncytia (Tier 2), the central nervous system (Tier 3), and the interpersonal social-epistemic network (Tier 4) Across seven formal papers and an introductory clinical synthesis, we demonstrate that these four tiers are held in spatiotemporal phase-lock by a single master regulatory switch: the Right Anterior and Posterior Insular Cortex, acting in closed loops with the Default Mode Network (DMN), Central Executive Network (CEN), Posterior Cerebellum (Crus I/II), Ventral Tegmental Area (VTA), Hypothalamic-Pituitary-Adrenal (HPA) Axis, and Autonomic Nervous System (ANS). We derive the coupled differential equations governing cross-scale synchronization and prove that chronic clamping of the central insular-executive switch propagates downward to ablate peripheral intracellular circadian clocks (BMAL1/PER2), close connexin gap junctions, depolarize resting transmembrane potentials ($V_{\text{mem}}$), and exhaust cytotoxic $\text{CD8}^+$ T-cells—driving a deterministic bifurcation between psychiatric network canalization, autoimmune hyper-reactivity, and oncogenic unicellular reversion. Key Mechanistic & Mathematical Contributions 1. The Cortical Phase-State Switch and Multiplicative Cerebellar–VTA Reinforcement: Formalizes the intrinsic anti-correlation between slow-wave restorative integration (DMN / vagal parasympathetic baseline) and high-frequency $40\text{–}100\text{ Hz}$ Gamma executive constriction (CEN / sympathetic mobilization), gated by allostatic prediction error ($\sigma_t = D_{\text{KL}}$) in the Right Anterior Insula (rAI). Proves that phasic dopaminergic resolution via the monosynaptic cerebellar Crus I/II $\to$ VTA pathway obeys a multiplicative law ($R_{\text{DA}} \propto \text{Structural Symmetry} \times \text{Dimensional Complexity} \times \text{Visceral Salience}$), resolving the "Dark Room Problem" of predictive coding and explaining why chronic fixation on zero-salience symbolic proxies prevents autonomic recovery. 2. The Interoceptive Temporal Scaling Law ($\omega_\Phi(t) = \omega_0 + \kappa \sigma_t$): Derives the differential scaling of cortical episodic frame-cutting ($\omega_\Phi$) as a linear function of instantaneous allostatic divergence ($\sigma_t$). Quantitatively unifies acute threat-time dilation (tachypsychia), Weber–Fechner logarithmic lifespan compression ($\tau_{\text{subj}} \propto \ln T$), and the Arnold-tongue condition required to maintain
Clinical research Phase 2 trial screening data

PRIDE trial: Most psilocybin trial seekers excluded due to strict criteria

Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial—Relevance to Precision Psychiatry
Why it matters ◈ Mixed
This analysis of PRIDE trial screening data reveals that 80% of treatment-seeking individuals were excluded, mainly due to not meeting strict diagnostic criteria for treatment-resistant depression. The findings underscore a significant gap between real-world patient populations and those eligible for psychedelic clinical trials, raising concerns about the external validity and generalizability of trial results. For researchers and clinicians, this highlights the need to consider broader inclusion criteria or additional studies to address the needs of a more diverse patient population. The data may influence future trial design and regulatory perspectives on access.
Public and patient interest in psychedelic-assisted psychotherapy is increasing, but people seeking access to psychedelic trials may be more clinically heterogeneous than the populations these trials can enrol. We conducted a cross-sectional descriptive analysis of previously unreported aggregate telephone-screening data from the coordinating site of PRIDE, an ongoing Italian multicentre phase II randomized trial comparing psilocybin with personalized neuromodulation for treatment-resistant depression (TRD). Among 67 candidates screened between November 2025 and June 2026, 54 were excluded (80.6%), eight were enrolled and treated (11.9%), and five were preliminarily eligible (7.5%). The leading reason for exclusion was absence of protocol-defined TRD or another psychiatric diagnosis (27/54, 50.0%), followed by age outside the protocol range (18.5%), current suicidal or self-harm ideation (13.0%), and substance use disorder or dependence (9.3%). The diagnostic diversity of excluded candidates highlights the gap between a narrowly defined trial population and heterogeneous treatment-seeking individuals. These screening data do not address treatment response or individualized treatment selection, but they help contextualize recruitment yield and the external validity of psychedelic trials. Trial registration: Clinical Trials Information System, EU CT No. 2024-519844-34-03.
Neuroscience Preclinical research

Whole brain modeling identifies subtype-specific regulation in adolescent MDD

Whole brain modeling reveals subtype specific regulation for adolescent major depressive disorder
Why it matters ▲ Favorable
This study uses advanced neuroimaging and computational modeling to reveal that adolescent major depressive disorder (MDD) consists of distinct subtypes requiring different neuromodulatory interventions. The findings suggest that personalized, subtype-specific brain stimulation strategies may be more effective than generic approaches for adolescent depression. While not directly related to psychedelics, the framework could inform future clinical trial design and target selection for psychedelic-assisted therapies in youth populations.
Adolescent major depressive disorder exhibits substantial intrinsic subtype heterogeneity, necessitating the development of subtype-specific therapeutic strategies. Using the Boston Adolescent Neuroimaging of Depression and Anxiety dataset, we identified two subtypes with distinct clinical features. For each subtype, we constructed a whole-brain model and performed virtual stimulation to assess regulatory effects at global (whole-brain) and regional (classical depression-related targets) levels. Here we show that the two subtypes require different but stable stimulation modalities, excitatory or inhibitory, to normalize brain activity. Optimal stimulation intensities for restoring static and dynamic features vary across targets and subtypes, whereas the stimulation modality remains consistent within each subtype. Notably, localized stimulation of subtype-specific targets within classical depression-related regions produces more effective and stable outcomes than whole-brain stimulation. These findings provide a computational framework for identifying subtype-specific regulatory strategies in adolescent major depressive disorder, bridging whole-brain modeling with potential clinical translation.
Clinical research Narrative review published

Chemsex poses unique challenges for emergency medical teams

Chemsex as a challenge for emergency medical teams: a narrative review
Why it matters ◈ Mixed
This narrative review highlights the growing public health and clinical challenge of chemsex-related emergencies, emphasizing the need for EMS teams to recognize the unique syndromic presentations and operational risks associated with sexualized polysubstance use. While not focused on classic psychedelics, the review underscores the complexity of managing acute intoxications involving psychoactive agents in sexualized contexts, a topic relevant for harm reduction and emergency response protocols. The lack of robust data on frequency and outcomes signals a need for more research to inform evidence-based care and policy.
Chemsex, defined as the intentional use of psychoactive substances before or during sexual activity, has emerged as an important public health concern and an increasingly relevant challenge for emergency medical services (EMS). Although most frequently described among men who have sex with men, sexualized substance use is increasingly reported among heterosexual men and women, indicating a broader at-risk population. Commonly used substances include methamphetamine, mephedrone, gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL), alkyl nitrites, and other psychoactive agents, frequently used in combination during prolonged sexual sessions. Such practices are associated with a wide spectrum of acute complications, including agitation, psychosis, hyperthermia, cardiovascular instability, respiratory depression, altered consciousness, and mixed toxidromic presentations. This narrative review examines current evidence regarding chemsex-associated emergencies from a prehospital and emergency medicine perspective. Particular attention is given to syndromic clinical presentations, including hyperstimulatory syndromes, behavioral disturbances, acute GHB/GBL toxicity, and polysubstance-related emergencies. Operational challenges relevant to EMS teams, including scene safety, communication barriers, stigma, occupational risks associated with slamsex, and management of agitated patients, are also discussed. Chemsex-related emergencies share many clinical features with other substance-related emergencies. However, recognition of the sexualized substance use context may provide additional information relevant to prehospital assessment, including intentional drug combinations, repeated dosing, potential drug interactions, communication barriers, and occupational safety considerations. A syndromic approach focused on recognition of dominant clinical patterns rather than identification of individual substances may therefore provide the most practical framework for prehospital assessment and management. Although chemsex-associated emergencies are documented, evidence regarding their frequency and trends remains limited, particularly in prehospital settings. Further research is needed to support the development of evidence-based prehospital protocols, educational initiatives, and integrated care pathways.
Clinical research National trial announced

Health Ministry launches national psychedelic PTSD trial

Health Ministry announces national clinical trial of psychedelic substances for treatment of PTSD
Why it matters ▲ Favorable
A national clinical trial of psychedelics for PTSD signals high-level government support for research and may accelerate evidence generation for regulatory and clinical adoption. This move could expand access for patients, reduce legal uncertainty for researchers, and attract investment into the sector. The involvement of a Health Ministry suggests potential for future integration into public health systems if results are positive.
Clinical research National trial announced

Israel launches first national MDMA and psilocybin PTSD trial

Israel to test MDMA and psilocybin on hundreds with severe PTSD in first national trial
Why it matters ▲ Favorable
Israel's announcement of a large-scale national trial testing MDMA and psilocybin for severe PTSD marks a significant expansion of psychedelic research beyond North America and Europe. The inclusion of hundreds of participants signals robust government support and could accelerate evidence generation for regulatory and clinical adoption. This move may influence other countries' research agendas and access pathways, while providing critical data on safety and efficacy in a real-world, diverse population.
Clinical research Secondary analysis published

Self-compassion linked to outcomes in MDMA therapy for social anxiety

From Acute MDMA Experiences to Lasting Change: Self-Compassion’s Role in MDMA-Assisted Psychotherapy for Social Anxiety Disorder
Why it matters ▲ Favorable
This secondary analysis provides early evidence that MDMA-assisted therapy may foster both acute and lasting increases in self-compassion, which are associated with reductions in internalized shame and depressive symptoms in social anxiety disorder. While limited by small sample size, the findings highlight self-compassion as a candidate mechanism of action and a potential moderator of treatment response, informing future trial design and mechanistic research in psychedelic-assisted psychotherapy.
Objectives: Self-compassion may benefit individuals with social anxiety disorder and serve as a mechanism of change within 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT). Methods: In this secondary analysis of 20 adults with social anxiety disorder who underwent MDMA-AT for social anxiety disorder (NCT05138068), we examined whether both trait self-compassion changes across treatment (16-weeks) and state self-compassion experienced during MDMA (midomafetamine) dosing sessions contributed to post-treatment clinical outcomes—social anxiety, depression, internalized shame, functional impairment and (thwarted) belonging—beyond baseline levels of each respective variable.Results: Participants experienced high self-compassion levels during the two dosing sessions. Trait self-compassion increased most substantially after the first MDMA dosing session (ΔM=0.74, p<.001), though continued to increase after dose 2 (ΔM=0.43, p< .001). State self-compassion was not associated with trait self-compassion changes, though explained additional variance in reduced depressive symptoms (ΔR²=.19, p<.001) and internalized shame (ΔR²=.28, p=.02), beyond baseline symptom severity. Trait self-compassion increases following the second dosing session corresponded to reduced internalized shame (β=-.84, p<.001) and thwarted belonging (β=-.68, p=.01), beyond baseline self-compassion levels. Greater baseline self-compassion corresponded to reduced social anxiety, functional impairment, internalized shame, and thwarted belonging (βs<-0.41, ps<.05).Conclusions: MDMA-AT for social anxiety disorder appears capable of fostering both acute self-compassion experiences and enduring trait-level changes, each of which were associated with certain beneficial outcomes, especially reduced internalized shame. These constructs represent promising candidate mechanisms of change within MDMA-AT for social anxiety disorder, while baseline self-compassion may moderate treatment response,warranting investigation of self-compassion’s role in future larger psychedelic-assisted therapy trials.
Clinical research Peer-reviewed study

Validated recovery curves for PHQ-8 and GAD-7 in real-world outpatient care

Recovery Curves for the PHQ-8 and GAD-7: Clinical Utility and Implementation of Measurement-based Care in a Real-world Outpatient Setting
Why it matters ▲ Favorable
This study validates monthly recovery curves for depression and anxiety measures in real-world outpatient settings, supporting the use of measurement-based care (MBC). While not specific to psychedelics, these findings are relevant for designing and evaluating psychedelic clinical trials and real-world care models, as PHQ-8 and GAD-7 are common endpoints. Improved prediction of treatment failure could help optimize patient monitoring and intervention in psychedelic-assisted therapy.
Measurement-based care (MBC) relies on repeated outcome assessment and feedback to guide clinical decision-making. Although recovery curves are central to many MBC systems, they have primarily been developed using session-by-session data. This study developed and validated recovery curves for the PHQ-8 and GAD-7 using monthly assessments within a naturalistic outpatient setting. We generated our recovery curves using mixed-effects models with symptom change over four months of treatment as the dependent variable (N = 1124) and cross-validated the results in a second sample (PHQ-8 N = 734; GAD-7 N = 758). Models were evaluated for predictive performance and calibration. We examined additional baseline predictors and evaluated confidence interval thresholds for identifying patients at risk of treatment failure. Predictive performance was strong in the derivation sample (PHQ-8 R² = 0.44; GAD-7 R² = 0.47) and remained robust in validation (PHQ-8 R² = 0.37; GAD-7 R² = 0.40) with acceptable calibration. Baseline symptom severity was the only clinically meaningful predictor of recovery trajectories. A 60% one-sided confidence interval provided the optimal balance of sensitivity and alert frequency, identifying approximately 24-28% of patients as at risk of treatment failure at one month. We conclude that recovery curves for the PHQ-8 and GAD-7 can be effectively derived using monthly assessments and applied in real-world MBC settings.
Neuroscience Peer-reviewed neuroscience study

Muscarinic signaling preserves prefrontal STM via thalamic drive

Muscarinic signaling sustains delay-period selectivity in prefrontal cortex by preserving thalamic drive
Why it matters ▲ Favorable
This study elucidates a key mechanism by which muscarinic acetylcholine receptor activation sustains short-term memory representations in the prefrontal cortex, compensating for synaptic depression from thalamic input. These findings deepen understanding of cholinergic modulation in cognitive function, which is relevant for developing novel therapeutics—including psychedelic and non-psychedelic compounds—that target muscarinic pathways for neuropsychiatric disorders. While not directly tied to psychedelic policy or clinical trials, the mechanistic insight may inform future research on cognitive enhancement and the design of next-generation compounds.
Short-term memory (STM) requires the temporary maintenance of task-relevant information in prefrontal cortex (PFC). Reciprocal interactions between the mediodorsal thalamus (MD) and PFC have been implicated in sustaining this activity, but how thalamofrontal communication is maintained despite the biophysical constraints of repetitive synaptic transmission remains unclear. Here, we show that MD—PFC synapses exhibit profound frequency-dependent short-term depression, causing repetitive thalamic input to progressively lose its ability to drive PFC neurons. During STM performance, acetylcholine (ACh) levels in PFC rose rapidly following cue presentation and remained elevated throughout the delay period. Muscarinic ACh receptor (mAChR) activation did not alleviate synaptic depression, but instead increased the intrinsic excitability of PFC neurons, thereby preserving their responsiveness to weakened thalamic input. Conversely, mAChR blockade impaired STM performance and progressively disrupted delay-period directional representations at both the single-neuron and population levels, while largely sparing initial encoding. These findings identify muscarinic signaling as a postsynaptic gain mechanism that compensates for declining thalamofrontal efficacy and sustains task-relevant prefrontal representations during STM.
Clinical research Philosophical analysis published

Philosophical audit of psychiatric assumptions in psychedelic therapy research

Inherited assumptions: A philosophical audit of the psychiatric presuppositions embedded in psychedelic-assisted therapy research
Why it matters ◈ Mixed
This paper highlights how current psychedelic-assisted therapy research inherits contested assumptions from mainstream psychiatry, potentially distorting both research design and interpretation of outcomes. By exposing these foundational tensions, the analysis encourages the field to consider alternative frameworks that may better capture the unique effects and mechanisms of psychedelic interventions. This is relevant for researchers and clinicians aiming to design studies or interpret results outside traditional psychiatric paradigms.
The psychedelic renaissance is routinely presented as a paradigm shift in psychiatric treatment. Yet the research programmes through which psychedelic-assisted therapies are developed and evaluated inherit foundational presuppositions from mainstream psychiatry that are contested within psychiatry and its philosophy. I conduct a philosophical audit of five of them, the nosological, aetiological, outcome measurement, methodological, and pharmacological agency assumptions. For each, I reconstruct the critique, show how the assumption operates in current psychedelic research, and identify the distortions it produces. I then argue that the five form a mutually reinforcing system that resists partial reform, and that the psychedelic field's own findings are in tension with the framework within which those findings must be reported and evaluated. The result is a field whose most distinctive contributions are rendered partially invisible by the infrastructure designed to validate them. Because psychedelics expose these tensions with unusual clarity, the field could serve as a productive site for testing alternative frameworks, organised around processes, that have found limited institutional traction within psychiatry.
Clinical research Observational study published

High rates of post-op anxiety and depression in elderly Chinese patients

Postoperative anxiety and depression symptoms in Chinese elderly patients: A multicenter observational study
Why it matters ◈ Mixed
This large multicenter study finds that over 20% of elderly Chinese patients experience significant anxiety or depression after non-cardiac surgery. While not a psychedelic trial, the finding that intraoperative esketamine (an NMDA antagonist with psychedelic-adjacent properties) is associated with lower odds of these symptoms is notable. The data underscore a substantial unmet need for interventions targeting perioperative mental health, which could inform future psychedelic or ketamine research in this population.
Objective The postoperative mental health of elderly patients in China has received insufficient attention in the literature. Moreover, the population-based data on postoperative anxiety and depression symptoms among this population remain unavailable. We thus aimed to explore the prevalence, correlates, and clinical outcomes of these postoperative symptoms in this population in China. Methods This was a multicenter retrospective observational study, and it included individuals aged 65 and above in China who underwent non-cardiac surgery between April 1, 2020, and April 30, 2022. Anxiety and depression symptoms were assessed using the generalized anxiety disorder-7 (GAD-7) and patient health questionnaire-9 (PHQ-9), respectively. The primary analysis estimated the prevalence of these symptoms. For exploratory analyses, mixed-effects logistic regression models with study center as a random intercept were used to identify the factors independently associated with psychological symptoms and to examine their associations with clinical outcomes, with covariates selected a priori based on clinical knowledge. Results In total, 7568 patients (median age: 71 [IQR 68–74] years; 56.4% male) were included in the final analysis. Postoperative anxiety symptoms were present in 1671 patients (22.08%) and depression symptoms in 1788 (23.63%). The highest prevalence of anxiety was observed in plastic and other surgeries, while the highest prevalence of depression occurred in gastrointestinal surgery. The factors independently associated with higher odds of both anxiety and depression symptoms included a history of malignant tumor and preoperative sleep disorder. Male sex, intraoperative dexmedetomidine, and intraoperative esketamine were independently associated with lower odds of both conditions. Regarding clinical outcomes, after adjusting for relevant confounders and center effects, anxiety symptoms were associated with higher odds of infectious complications and acute postoperative pain; depression symptoms were associated with higher odds of delirium and acute postoperative pain. Conclusions This study highlights that over one-fifth of elderly non-cardiac surgery patients experience postoperative anxiety and depression symptoms, thus emphasizing the critical need for clinicians to address this significant mental health burden and its underlying contributors.
Clinical research Review published

Review: Control conditions in IVR RCTs may inflate therapeutic effects

Virtual Placebo: a scoping review of control conditions in randomized controlled trials of psychological immersive virtual reality interventions
Why it matters ◈ Mixed
This scoping review highlights methodological weaknesses in randomized controlled trials of immersive virtual reality (IVR) interventions, specifically the frequent use of inadequate control conditions. Without proper 'virtual placebo' controls, studies may overstate the efficacy of IVR therapies, risking misinterpretation of results and misleading clinical or regulatory decisions. The findings are relevant for psychedelic research, where digital therapeutics and VR are increasingly integrated into trial protocols, underscoring the need for rigorous trial design.
Research on immersive virtual reality (IVR) as a therapeutic tool is growing rapidly, with randomized controlled trials (RCTs) now commonplace. Yet the control conditions in many of these studies that claim strong specific IVR effects vary from usual care to active immersive experiences, making it difficult to draw clinically meaningful conclusions. We conducted a scoping review of recent literature on psychological IVR interventions to assess the main forms of control conditions used and their relations to study outcomes. In this paper, we make the case that most of the recent RCTs studying the effects of specific IVR interventions compare active immersive VR to usual care with no multimedia component. This can lead to strong yet potentially misleading study outcomes and can potentially inflate the IVR interventions' effect. Namely, the lack of an appropriate immersive control condition may risk misattributing general effects of VR devices to the specific content of the intervention. In this review, we discuss the implications of these design choices and propose strategies for including a suitable "virtual placebo" condition to improve the methodological rigor and interpretability of results.
Clinical research Method published

Bias-aware meta-analysis method published for heterogeneous studies

Bias-aware meta-analysis: beyond fixed-effect and random-effects meta-analyses
Why it matters ▲ Favorable
This new bias-aware meta-analysis framework offers a more robust approach to synthesizing results from heterogeneous and potentially biased studies. For psychedelic research, where trial designs, populations, and endpoints often vary, this method could improve the reliability of meta-analytic conclusions and inform evidence-based policy and clinical guidelines. Adoption may help address concerns about reproducibility and bias in the field, but practical impact will depend on uptake by research groups and regulators.
Meta-analysis aims to synthesize multiple studies to obtain a summary estimate of a population parameter of interest. However, existing meta-analysis methods require strong assumptions that render them not robust to bias and heterogeneity of the studies. In particular, fixed-effect meta-analysis assumes a common parameter across the studies, whereas random-effects meta-analysis models heterogeneity as independent and identically distributed random effects, which still implies a common parameter marginally over the random effects. Due to their limitations, we propose a bias-aware meta-analysis framework that allows for heterogeneous studies with fixed, unknown biases. With no bias, our bias-aware meta-analysis reduces to fixed-effect meta-analysis; with a given bound on the bias, we can still use the fixed-effect meta-analysis point estimator and standard error, but we must inflate the critical value for confidence intervals from the standard normal quantile to a folded normal quantile. We recommend reporting the maximum bias for significance, the maximum value of the bias such that the confidence intervals exclude the null value. We propose a formal model checking procedure and recommend reporting the minimum bias for compatibility, the minimum value of the bias such that the bias-aware meta-analysis model is compatible with the observed data. We discuss the practical implementation of our method and, in particular, the approaches to calibrating the maximum bias for significance. We also compare our method with traditional fixed-effect and random-effects meta-analyses.
Neuroscience Research framework proposed

MRI-guided framework links human brain changes to molecular mechanisms

Brain volume analysis-guided basic research in psychiatry
Why it matters ▲ Favorable
This paper proposes a novel reverse-translational framework using MRI volumetric analysis to bridge human psychiatric findings and molecular mechanisms in animal models. While not specific to psychedelics, this approach could accelerate mechanistic research on how psychedelic treatments affect brain structure and function, supporting both preclinical and clinical trial design. The framework may enhance the rigor and translational relevance of future studies, but does not itself represent a regulatory or market shift.
Magnetic resonance imaging (MRI) volumetric analysis is among the few tools able to probe the living human brain, offering a route from clinical findings back to basic neuroscience. Here we propose a reverse-translational framework for psychiatric research that links human MRI findings to their underlying molecular mechanisms in model animals. The framework rests on three "liaisons": a species liaison, confirming that a volume change identified in humans is also observed in mice using the same imaging and analytical method; a scale liaison, in which a histological pipeline explains the macroscopic volume change in terms of cell number and cell volume; and a causal liaison, in which molecular or cell-biological intervention converts correlative histological findings into causal evidence by inducing or reversing the volume change. We further propose that unbiased, whole-brain MRI volumetric analysis in mice can serve as an exploratory region-screening method, identifying disease- or treatment-related regions without a predefined region of interest, and capturing the maintained structural outcome of an intervention rather than its immediate functional trace. Together, the three-liaison framework and the region-screening approach outline a general strategy by which MRI-guided reverse and forward translation can uncover the structural and molecular basis of psychiatric diseases and their treatments.
Clinical research Phase 2 trial ongoing

OSU studies psychedelic therapy for cancer patients facing mortality

'Back to myself a little more': A psychedelic drug therapy being studied at OSU could help cancer patients face mortality
Why it matters ▲ Favorable
Oregon State University is conducting a clinical trial on psychedelic-assisted therapy to help cancer patients cope with end-of-life distress. This research could expand evidence for psychedelic use in palliative care, potentially informing future regulatory decisions and access pathways. Results may influence clinical guidelines and insurance coverage for psychedelic therapies in oncology settings.
Clinical research Systematic review published

Systematic review: Psilocybin shows efficacy for major depression

PSILOCIBINA E SEUS EFEITOS TERAPÊUTICOS NA DEPRESSÃO MAIOR: UMA ANÁLISE CRÍTICA DA EFICÁCIA E DOS MECANISMOS MOLECULARES POR MEIO DE UMA REVISÃO SISTEMÁTICA
Why it matters ▲ Favorable
This systematic review synthesizes evidence that psilocybin produces significant and sustained antidepressant effects in major depressive disorder, with a favorable safety profile compared to standard treatments. The findings reinforce the therapeutic promise of psilocybin, especially when paired with psychological support, but highlight the need for larger, more diverse studies. This adds weight to the clinical case for psilocybin, informing future research, regulatory, and access decisions.
O transtorno depressivo maior (TDM) permanece como importante desafio terapêutico devido à resistência ao tratamento apresentada por parte dos pacientes, despertando interesse em alternativas como a psilocibina. Trata-se de uma substância psicodélica presente em espécies de cogumelos, cuja principal ação ocorre por agonismo dos receptores serotoninérgicos 5-HT2A e 5-HT1A, promovendo alterações em receptores de glutamato. Objetivo: Realizar uma revisão sistemática da literatura sobre os efeitos terapêuticos da psilocibina no TDM. Métodos: Revisão sistemática da literatura realizada nas bases PubMed, Scielo e Lilacs, incluindo estudos publicados entre 2020 e 2026, utilizando os descritores “Psilocybin” AND “Major Depressive Disorder” e “Psychotherapy” AND “Antidepressive Agents”. Resultados: Dos 23 artigos encontrados, 5 estudos foram incluídos, totalizando 269 pacientes com TDM expostos à psilocibina. Os estudos demonstraram redução significativa e sustentada dos sintomas depressivos, potencializada pelo suporte psicológico, sem eventos adversos graves. Em comparação com niacina e escitalopram, a psilocibina apresentou resultados mais favoráveis. Conclusão: A psilocibina demonstrou efeito antidepressivo significativo e perfil de segurança favorável em pacientes com TDM, embora mais estudos em populações maiores e diversas ainda sejam necessários.
Clinical research Review published

Review: Ketamine's Analgesic, Psychiatric, Antitumour, and Immune Effects

Ketamine Beyond Anaesthesia: Analgesic, Psychiatric, Antitumour, and Immunomodulatory Actions and Their Signalling Mechanisms.
Why it matters ▲ Favorable
This comprehensive review synthesizes emerging evidence on ketamine's mechanisms and therapeutic potential beyond anesthesia, including psychiatric, pain, antitumour, and immunomodulatory actions. The article may inform future clinical trial design, regulatory considerations, and off-label use policies. It highlights the expanding scientific rationale for ketamine's use in diverse medical contexts, which could influence both research funding priorities and clinical practice guidelines.
Clinical research Service established

India launches interventional psychiatry service including psychedelics

Establishing an Interventional Psychiatry Service in a Public Tertiary-care Teaching Hospital in India: Experience from the Center for Neuromodulation and Interventional Psychiatry
Why it matters ▲ Favorable
The establishment of an interventional psychiatry service in a major Indian public teaching hospital signals growing institutional acceptance of psychedelic-assisted interventions in a large, influential health system. This development provides a practical model for integrating psychedelic and neuromodulation therapies into mainstream psychiatric care in low- and middle-income countries. It may also catalyze further research, guideline development, and eventual regulatory engagement in India’s vast public health sector.
Newer DevelopmeNtin the Indian clinical context.[3][4][5] However, guidelines are intended to guide rather than replace clinical judgment and require adaptation to the infrastructure, workforce, patient population, and operational circumstances of individual treatment settings.Despite the increasing availability of these interventions, there is limited published literature describing the practical process of establishing and running an integrated interventional psychiatry service, particularly within publicly funded, multispecialty, tertiary-care teaching hospitals in India.Establishing such a service involves challenges beyond the acquisition of treatment devices.These include identification and development of appropriate physical infrastructure, procurement of essential equipment and IntroductIonInterventional psychiatry is a relatively new and evolving psychiatric subspecialty that applies advances in clinical neuroscience and technology to the procedural treatment of psychiatric disorders.Although conventional psychiatric treatment has traditionally relied primarily on pharmacotherapy and psychotherapy, increasing understanding of the neural circuits underlying psychiatric symptoms has contributed to the development and clinical application of interventions that directly or indirectly modulate brain activity.Interventional psychiatry has therefore emerged at the interface of psychiatry, neuroscience, neurotechnology, and procedural medicine.The scope of interventional psychiatry continues to evolve.Brain stimulation techniques constitute a central component and include electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), theta-burst stimulation, transcranial direct current stimulation (tDCS), and, in selected settings, invasive neuromodulation techniques.The broader scope of interventional psychiatry may also include newer psychopharmacological interventions such as ketamine, psychedelic-assisted interventions, and other technology-enabled treatments. 1 A recent Indian perspective proposed a broad definition of interventional psychiatry as procedural treatments in psychiatry that use advances in clinical neuroscience and technology, including brain stimulation, psychopharmacological interventions, psychedelic therapeutics, assisted psychotherapies, and digital therapeutics.2 Several interventions commonly considered within the scope of interventional psychiatry have accumulated an expanding evidence base and are increasingly being incorporated into routine psychiatric practice.The Indian Psychiatric Society (IPS) has published clinical practice guidelines addressing ECT, rTMS, and tDCS, providing an important framework for their implementation 1-
FDA / DEA FDA approval anticipated

MDMA-assisted therapy could get FDA approval as soon as January

Exclusive | MDMA-assisted therapy could get FDA approval as soon as January: advocate
Why it matters ▲ Favorable
Potential FDA approval of MDMA-assisted therapy would mark a historic shift in US drug policy and access to psychedelic treatments. If confirmed, this would open the door to regulated clinical use, catalyze insurance and provider adoption, and accelerate research and investment in the field. The move would also trigger DEA rescheduling and set a precedent for other psychedelic therapies. Stakeholders should monitor for official FDA announcements and prepare for rapid changes in legal, clinical, and commercial landscapes.
Neuroscience Peer-reviewed review published

MRI biomarkers in schizophrenia and TRD: critical review finds limited clinical utility

Hippocampal and Prefrontal MRI Alterations as Candidate Severity Biomarkers in Schizophrenia and Treatment Resistant Depression: A critical review with structured synthesis of published meta analyses
Why it matters ◈ Mixed
This comprehensive review finds that while hippocampal and prefrontal MRI alterations are credible research candidates for severity in schizophrenia and treatment-resistant depression, they lack sufficient reliability and predictive power for clinical use as individual biomarkers. The findings highlight methodological variability and the need for longitudinal validation before translation to patient care. For psychedelic research, this underscores the challenge of identifying robust neuroimaging endpoints for trials in severe psychiatric disorders.
Hippocampal and prefrontal abnormalities are repeatedly observed in psychiatric neuroimaging, but their value as individual markers of severity remains uncertain. This review synthesizes PubMed-indexed structural and functional MRI evidence in schizophrenia and treatment-resistant depression, with bibliographic verification on 7 October 2026. Published meta-analyses, large harmonized imaging studies, and selected treatment-response reports were examined through a framework separating case-control differences, symptom associations, functional outcomes, and prospective prediction. No new cross-disorder pooled effect was calculated. Large schizophrenia analyses reported reduced hippocampal volume and cortical thickness, whereas major-depression studies generally reported smaller structural effects. These major-depression findings were treated as contextual evidence rather than as treatment-resistant-depression estimates. Direct treatment-resistance reviews identified hippocampal and network alterations but showed substantial methodological variability; an exploratory coordinate-based meta-analysis produced limited modality-specific convergence. Functional connectivity and prefrontal treatment-target studies suggest clinically relevant circuits, yet response prediction differs from severity measurement. Medication exposure, illness duration, motion, clinical heterogeneity, and overlapping cohorts constrain interpretation. Hippocampal and prefrontal measures are therefore credible research candidates, but a reproducible group association does not establish a calibrated individual severity test. Clinical translation requires explicit target outcomes, longitudinal reliability, independent validation, comparison with clinical assessment, and demonstrated decision benefit.
US Customs / Import Policy Compliance extension announced

CBP extends compliance for suspension of de minimis exemption on mail imports

Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process; Delayed Compliance Extension
Why it matters ◈ Mixed
The U.S. Customs and Border Protection's extension of the compliance date for suspending the de minimis exemption on mail shipments will delay stricter controls on small-value imports, including those potentially relevant to research chemicals and unregulated psychoactive substances. This move gives importers and researchers more time to adjust to new requirements, but signals that tighter scrutiny and formal entry processes are still forthcoming. Stakeholders in the psychedelic research and supply chain should monitor for future enforcement, as this could impact sourcing, cross-border shipments, and legal risk.
This document announces that U.S. Customs and Border Protection (CBP) will extend the compliance date for the regulatory provisions mandating the formal entry of merchandise arriving through the international postal network that is subject to partner government agency requirements, subject to duties under Chapter 98 or Chapter 99 of the Harmonized Tariff Schedule of the United States (HTSUS), or for which duty-free treatment is claimed under Chapter 98 of the HTSUS or pursuant to a Free Trade Agreement, which were published in the Federal Register on June 24, 2026. We believe the public will benefit from more time to prepare for compliance with these changes.
Clinical research Peer-reviewed analysis published

Cost-effectiveness of ketamine vs. ECT for treatment-resistant depression

Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis
Why it matters ◈ Mixed
This cost-effectiveness analysis directly compares ketamine and ECT for nonpsychotic treatment-resistant depression, focusing on quality-adjusted life-years (QALYs). The findings will inform clinicians, payers, and policymakers about the value proposition of ketamine relative to the established but underutilized ECT. If ketamine demonstrates favorable cost-effectiveness and sustained efficacy, this could shift clinical guidelines and reimbursement decisions, impacting patient access and the competitive landscape for depression treatments.
Electroconvulsive therapy (ECT) is a highly effective intervention for treatment-resistant depression; however, its use has been limited partly because of concerns about cognitive side effects. Evidence for the sustained (>1 month) efficacy of ketamine versus ECT for treatment-resistant depression has only recently been demonstrated. This study aimed to examine the cost-effectiveness—that is, the costs and benefits measured as quality-adjusted life-years (QALYs)—of racemic ketamine versus that of ECT for treatment-resistant depression.
Clinical research Scoping review published

Review: Subanesthetic Ketamine for Opioid-Refractory Cancer Pain

Subanesthetic Ketamine for Opioid-Refractory Cancer Pain: Efficacy, Safety, and Opioid-Sparing Effects
Why it matters ▲ Favorable
This scoping review highlights subanesthetic ketamine as a promising adjunct for opioid-refractory cancer pain, with rapid analgesic effects and substantial opioid-sparing potential. The safety profile appears acceptable, with mostly mild adverse effects, but the evidence base is limited by small sample sizes and study heterogeneity. The findings underscore the urgent need for larger, high-quality RCTs to inform clinical guidelines and optimize dosing. This review is relevant for clinicians and researchers seeking alternatives to opioids in complex pain management.
Background: Opioid-refractory cancer pain is a major clinical challenge, affecting an estimated 20–40% of patients despite optimized opioid therapy. Subanesthetic-dose ketamine, an NMDA receptor antagonist, has emerged as a potential adjunct for managing such pain. Methods: A scoping review was conducted through April 2025 in PubMed, ScienceDirect, SpringerLink, and the Cochrane Library. Included studies involved cancer patients with opioid-refractory pain treated with subanesthetic ketamine. One RCT, one cohort study, and eight case reports were analyzed. Outcomes included pain relief, opioid dose reduction, and adverse effects. Results: Ten studies met inclusion criteria. Subanesthetic ketamine provided rapid pain relief in most cases, with pain scores decreasing by 37–100% within 1–2 days. All eight case reports demonstrated clinically meaningful reductions in pain intensity, with opioid-sparing effects reported across all cases. Daily opioid dose reductions ranged from 46% to 99%, with several cases reporting over 90% reduction in oral morphine equivalents. The RCT showed a non-significant trend toward improved pain outcomes, likely due to small sample size and limited power. Adverse effects were generally mild (e.g., hallucinations, sedation), with rare serious events. Ketamine was overall well tolerated across case reports, the RCT, and the cohort study. Conclusions: Subanesthetic ketamine is a promising adjunct for opioid-refractory cancer pain, offering effective analgesia and substantial opioid reduction potential. Its safety profile is acceptable under careful monitoring. However, heterogeneity among studies and the limited high-quality evidence emphasize the need for larger, well-designed trials to establish optimized dosing, long-term safety, and standardized clinical guidelines
Neuroscience Review published

Microglial mitochondrial dysfunction linked to depression pathogenesis

Mitochondrial dysfunction in microglia: a novel perspective of depression pathogenesis
Why it matters ▲ Favorable
This review synthesizes emerging evidence that mitochondrial dysfunction in microglia is a key driver of neuroinflammation and neurotoxicity in depression. Understanding these mechanisms could inform the development of novel therapeutics, including those targeting neuroimmune pathways relevant to psychedelic interventions. While not directly about psychedelics, these insights may help guide future research on how psychedelic compounds modulate microglial function and mitochondrial health in mood disorders.
Major depressive disorder is a prevalent psychiatric disease that is closely linked to chronic low-grade neuroinflammation, which is primarily driven by microglia, the primary resident immune cells in the brain. Accumulating studies started to reveal that mitochondria, the powerhouses of the cell, play an important role in microglia-mediated neuroinflammation and neurotoxicity in depression. Stress-induced mitochondrial dysfunction triggers microglial activation through distinct mechanisms including energy metabolism patterns transition, electron transport chain impairment, reactive oxygen species accumulation, mitochondrial DNA damage, imbalanced fission and fusion, autophagy, and mitophagy deficiency, which cause the onset and progression of depression. In this review, we described microglial activation in animal models and clinically depressed patients, summarized current understanding of mitochondrial dysfunction-mediated microglial activation, and emphasized the possible mechanisms by which microglial mitochondrial dysfunction participates in the pathogenesis of depression. Understanding the roles and underlying mechanisms of mitochondrial dysfunction in neuroinflammation and neurotoxicity in depression may shed light on developing novel therapeutic strategies to fight against this devastating mental illness.
Neuroscience Peer-reviewed preclinical study

LSD extends lifespan in C. elegans via serotonergic pathways

Lysergic acid diethylamide extends lifespan in Caenorhabditis elegans
Why it matters ▲ Favorable
This preclinical study demonstrates that chronic low-dose LSD can extend lifespan and modulate aging markers in C. elegans, implicating serotonergic GPCR signaling and nutrient-sensing pathways. While not directly translatable to humans, these findings provide a mechanistic basis for further research into psychedelics' effects on aging and metabolism. The results may spur interest in translational studies and broaden the therapeutic scope of LSD beyond neuropsychiatric indications.
Abstract Aging is modulated by conserved nutrient-sensing pathways that integrate metabolic cues to regulate growth, stress resilience, and lifespan. Caloric restriction (CR) extends longevity across species, motivating the search for compounds that engage related physiology. Lysergic acid diethylamide (LSD), a classic serotonergic psychedelic with emerging therapeutic applications, remains unexplored in the context of aging. Here we show that chronic exposure to nanomolar LSD extends lifespan in Caenorhabditis elegans by up to 17.6% at the 25% survival timepoint, and reduces age-associated lipofuscin accumulation. This response involves serotonergic GPCR signaling: LSD failed to extend lifespan in ser-1 and ser-5 mutants and shortened lifespan in ser-4 and ser-7 mutants, yet remained effective, although with reduced magnitude, in tph-1 animals deficient in serotonin synthesis, indicating that endogenous serotonin production is not strictly required. LSD also elicited phenotypes that overlap with CR, including reduced reproductive output, smaller body size, delayed vulval development, and time-dependent remodeling of lipid stores and PHA-4 levels, while adult food-consumption assays detected no reduction in feeding under the conditions tested. Notably, the lifespan benefit was absent in eat-2 mutants and was lost under bacterial dilution, where LSD instead shortened lifespan, indicating that nutritional context shapes the response. Transient exposure during early adulthood was sufficient to extend lifespan. Together, these findings identify LSD as a tool to investigate how serotonergic signaling interfaces with conserved longevity-related pathways.
Neuroscience Peer-reviewed study

New study clarifies neural complexity metrics for brain network analysis

Inferring structural complexity from dynamical measures
Why it matters ▲ Favorable
This research advances understanding of how neural complexity metrics relate to brain architecture, which is increasingly relevant for psychedelic science as such measures are used to interpret altered states of consciousness in both clinical trials and basic research. The findings caution against overreliance on observational metrics and highlight the robustness of perturbational approaches, potentially informing future trial designs and mechanistic studies of psychedelics. While not directly about psychedelics, the work provides methodological guidance for interpreting brain activity data in the field.
Complexity, commonly defined as the coexistence of integration and differentiation, is a fundamental property of thalamocortical networks and is regarded as a prerequisite for adaptive brain function and consciousness. A variety of metrics have been developed to estimate neural complexity from recorded activity and are increasingly employed in both research and clinical settings. Yet, the extent to which these measures reflect specific architectural features of the underlying circuits remains poorly understood. Here, we used Wilson-Cowan mean-field equations to simulate neural dynamics across networks spanning a broad range of architectures. By systematically rewiring connectivity, we generated graded variations in the structural integration-differentiation balance and assessed a panel of complexity measures derived either from spontaneous activity (observational metrics) or from responses to external perturbations (perturbational metrics). Observational measures exhibited markedly heterogeneous behavior: some were primarily sensitive to network integration, others to differentiation, whereas some showed limited sensitivity to architectural manipulations. In contrast, perturbational measures robustly peaked at intermediate rewiring steps and scaled with small‑worldness, consistent with architectures that combine local recurrence and distributed communication. Moreover, perturbational metrics proved robust to common-driver confounds and were highest in a wake-like regime near critical instability, declining as sleep-like dynamics became more widespread across the network. Taken together, these findings map widely used empirical complexity measures onto specific network architectures, reveal dynamical factors that can bias observational estimates, and provide guidance for inferring complexity in systems whose internal organization is inaccessible, unconventional, or only partially known, including brain organoids, non-human nervous systems, and synthetic neural networks.
Epidemiology / Public Health Perspective published

Call for psychedelic epidemiology amid widespread non-clinical use

The uncontrolled experiment – Psychedelic use in the wild
Why it matters ◈ Mixed
This commentary highlights the vast scale of psychedelic use outside regulated clinical settings and calls for systematic epidemiological research to understand real-world risks and benefits. The lack of data on non-clinical use represents a major blind spot for both public health and policy, especially as millions participate in what is described as an 'uncontrolled experiment.' The article underscores the need for better surveillance, harm reduction, and integration of community experiences into research and policy frameworks.
Psychedelics are widely used outside clinical settings.We need psychedelic epidemiology to learn more about the risks and benefits of recreational use.In their article titled 'Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects' , Holmøy and Andersen (2025) present a clinically focused overview of the phenomenology and symptoms of mental health problems a er psychedelic use, as well as challenges in and recommendations for psychotherapeutic work on such problems.As a researcher in psychedelic epidemiology, I wish to comment on their important article by taking a wider view, from the clinical difficulties they describe to the millions of people who use psychedelics every year in the wild; an uncontrolled experiment on a vast scale, outside the clinic and without the guardrails of clinical trials.
Clinical research Peer-reviewed publication

Cost-effectiveness of ketamine vs. ECT for treatment-resistant depression

Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis.
Why it matters ◈ Mixed
This analysis directly informs payers, clinicians, and policymakers about the comparative value of ketamine and ECT for nonpsychotic, treatment-resistant depression. Cost-effectiveness data may influence insurance coverage, clinical guidelines, and future research priorities. The findings could shift resource allocation and patient access in mental health care, especially if ketamine demonstrates parity or superiority to ECT in cost or outcomes.
Clinical research Peer-reviewed study published

Ketamine derivative shows enhanced antidepressant effects via adenosine

A ketamine derivative exerts enhanced antidepressant effects via adenosine signaling.
Why it matters ▲ Favorable
This study identifies a ketamine derivative with superior antidepressant effects mediated through adenosine signaling, suggesting a novel mechanism of action distinct from classic NMDA antagonism. The findings may inform the development of next-generation rapid-acting antidepressants with potentially improved safety or efficacy profiles. This could accelerate translational research and attract industry interest in new molecular targets for mood disorders.
Clinical research Surveillance study published

Surveillance study links novel benzodiazepines, esp. bromazolam, to severe outcomes in NSW

Predicting high‐risk novel benzodiazepines: A surveillance study of novel benzodiazepine detections and a case series of bromazolam exposures in New South Wales, Australia
Why it matters ◈ Mixed
This surveillance study highlights the rising detection and clinical risk of novel benzodiazepines, especially bromazolam, in New South Wales, Australia. While not directly related to psychedelics, it underscores the public health challenges posed by emerging psychoactive substances, which may influence regulatory scrutiny and harm reduction strategies relevant to the broader drug policy landscape. The findings may prompt policy responses or clinical guidance updates, but do not directly impact psychedelic research or legal access.
Abstract Background and aims Novel benzodiazepines are increasingly detected in poisonings. Their relative toxicities remain poorly defined, complicating public health responses. Bromazolam has emerged in recent reports of severe poisoning. We sought a method to identify higher‐risk novel benzodiazepines, and to describe the clinical effects of bromazolam exposures. Design A prospective observational surveillance study examined time trends in laboratory‐confirmed detections of benzodiazepines of interest (novels plus alprazolam) using police drug seizure data and a clinical surveillance program from January 2019 to December 2024. A case series described hospitalised patients with confirmed bromazolam exposure between January 2022 and December 2024. Setting Population‐based study in New South Wales, Australia. Cases All laboratory confirmed detections of benzodiazepines of interest in blood, urine or physical drug samples were included. Forty‐eight hospitalised patients with confirmed bromazolam exposure were included in the case series, and eight additional hospitalised patients with alprazolam exposures. Measurements Annual detections of benzodiazepines of interest in clinical and physical drug samples were recorded. Relative toxicity was estimated with a pooled risk ratio (RR) of clinical to physical detections for each benzodiazepine. A minimum clinical dataset described the demographics, clinical effects, drug co‐detections, treatments and outcomes of bromazolam and alprazolam‐related hospital presentations. Secondary analyses measured the relationship between clinical effects and bromazolam blood concentrations and opioid co‐detection. Results The median number of benzodiazepines of interest detected was 265/year in physical drug samples (range 230–301) and 16/year in clinical samples (range 11–36). Bromazolam was the most common novel benzodiazepine detected in clinical (52/118) and physical (382/1590) samples. Pooled RRs were highest for etizolam [RR = 1.84, 95% confidence interval (95% CI) = 1.39–2.43], bromonordiazepam (RR = 1.70, 95% CI = 0.74–3.92), flualprazolam (RR = 1.48, 95% CI = 0.50–4.39) and bromazolam (RR = 1.22, 95% CI = 0.85–1.73). In 2024, there were no detections of etizolam or flualprazolam in clinical cases, compared with bromazolam ( n = 29; 80.6% of cases) and bromonordiazepam ( n = 7; 19.4% of cases). Among the 48 hospital cases with bromazolam detected, severe outcomes were frequent, including coma (36/48), respiratory failure (34/48) and endotracheal intubation (25/48). Polysubstance use was common (47/48). Bromazolam blood concentrations were poorly predictive of clinical effects. Opioid co‐detection was not associated with statistically significantly worse outcomes. Summary The incidence of novel benzodiazepine detections in New South Wales, Australia, increased between January 2019 and December 2024. Bromazolam is a current concern due to increasing detections and severe clinical outcomes; however, polysubstance use likely contributed to clinical outcomes. Bromonordiazepam may be an emerging concern.
Clinical research Peer-reviewed study published

Retrospective study examines suicidality during intranasal (es)ketamine use

Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study.
Why it matters ◈ Mixed
This peer-reviewed cohort study provides new data on the incidence and characteristics of suicidality during intranasal (es)ketamine treatment. The findings inform ongoing debates about the safety profile of ketamine/esketamine for depression and suicidality, which is critical for clinicians, regulators, and payers. Results may influence clinical protocols, risk mitigation strategies, and future regulatory guidance for psychedelic-adjacent therapies.
Clinical research Trial result announced

Psilocybin Tied to Lower Inflammation in Parkinson's Trial

Why it matters ▲ Favorable
This trial links psilocybin to reduced inflammation in Parkinson's disease, suggesting a potential disease-modifying effect beyond symptom management. If validated, these findings could expand the therapeutic scope of psychedelics into neurodegenerative disorders, attracting further research and investment. The result may also influence regulatory and funding priorities for psychedelic trials targeting inflammation and neuroprotection.
Neuroscience Peer-reviewed study published

Neurotransmitter-based polygenic scores linked to SSRI outcomes in MDD

Association of neurotransmitter-based polygenic scores with antidepressant treatment outcomes in patients with major depressive disorder
Why it matters ◈ Mixed
This study explores how polygenic scores based on neurotransmitter pathways may predict SSRI treatment response in major depressive disorder. While not directly related to psychedelics, the findings highlight the growing role of genetic biomarkers in personalizing psychiatric treatments, which could inform future research on psychedelic therapies and patient selection. The results are exploratory and require replication before clinical use, but they signal a trend toward precision medicine in mental health.
Abstract Biologically informed polygenic scores (PGSs) may help interpret genetic associations with treatment outcomes. Here, we computed neurotransmitter-based PGSs ( NeuroPGSs ) for patients with major depressive disorder (MDD) and assessed their association with SSRI treatment outcomes. By targeting genetic variants involved in key neurotransmission pathways, we developed PGSs for serotonergic (5228), gamma-aminobutyric acid (GABA, 4103), dopaminergic (7061), and glutamatergic (5690) variants. We leveraged data from two cohorts of patients who received SSRIs for at least 4 weeks: the International SSRI Pharmacogenomics Consortium (ISPC) and the Pharmacogenomics Research Network Antidepressants Medication Pharmacogenomics Study (PGRN-AMPS). Treatment response was defined as ≥50% reduction from baseline depression symptoms, measured using 17-item Hamilton Rating Scale for Depression (HRSD-17) in ISPC and 16-item Quick Inventory of Depressive Symptomatology (QIDS-C16) in PGRN-AMPS. Remission was defined as HRSD-17 ≤7 (ISPC) or QIDS-C16≤5 (PGRN-AMPS). The association between each NeuroPGS and antidepressant response or remission was evaluated using logistic regression models, adjusting for age, sex and five genetic principal components, with statistical significance determined at Benjamini–Hochberg-adjusted p <0.05. The GABAergic-based PGS was associated with SSRI response (aOR per SD = 1.45, 95%CI: 1.14-1.85). Patients with the highest GABAergic PGS (10 th decile) had 2.59-fold higher odds of response (95%CI: 1.46-4.60) compared to those with the lowest decile (1 st decile). These exploratory findings support further evaluation of NeuroPGSs ; independent replication and assessment of incremental predictive value are needed before clinical application.
Clinical research Peer-reviewed study published

Expectations shape willingness to join psychedelic trials, study finds

Treatment expectation is associated with willingness to participate in a psychedelic clinical trial
Why it matters ◈ Mixed
This study highlights that positive expectations and openness predict willingness to enroll in psychedelic clinical trials, while negative expectations deter participation. This introduces a potential selection bias, as trial participants may not represent the broader patient population, possibly inflating efficacy estimates and limiting generalizability. Researchers, sponsors, and regulators should consider these biases when designing studies and interpreting results.
Abstract Background and Aims Understanding the factors that lead to participation in psychedelic clinical trials is essential for assessing potential biases in enrollment and ensuring the generalizability of findings. Psychedelic treatment is thought to impact personality traits, psychological flexibility, and expectations, yet the role of these non-pharmacological variables in the initial decision to participate has not been studied. This study aimed to identify factors associated with the willingness to participate in a psychedelic trial. Methods A cohort of chronic pain patients ( N = 988) completed a survey assessing interest in participating in a psychedelic clinical trial and the Big Five personality traits. A subset ( N = 235) was re-surveyed for additional data on psychological flexibility and outcome expectations. Binary logistic regression analyses examined associations between these factors and willingness to participate. Results Trait openness to experience and positive outcome expectations, were associated with a greater likelihood of willingness to participate, while negative outcome expectations were linked with a lower likelihood. When controlling for all variables, negative expectancy emerged as the strongest and only significant predictor. Conclusions The results suggest that outcome expectations may play a role in who chooses to participate in psychedelic trials. This potential bias toward including participants who are more risk tolerant and hold more positive treatment expectations may lead to overestimated efficacy estimates and limits the external validity of trial findings. Understanding who chooses to participate in psychedelic research, and who does not, may be as important for the field as understanding who responds to treatment.
Clinical research Meta-analysis published

Low-dose ketamine shows moderate efficacy for treatment-resistant depression

What is the efficacy of low-dose ketamine for treating depression and other mental health conditions?
Why it matters ◈ Mixed
This meta-analysis reinforces ketamine's role as a rapid-acting option for treatment-resistant depression, including bipolar depression. The findings support cautious clinical use but highlight the need for ongoing monitoring and further research on long-term safety. This adds to the evidence base for clinicians and may influence future guidelines and regulatory decisions.
Ketamine shows moderate efficacy as a rapid-acting treatment for treatment-resistant depression, including bipolar depression, with evidence supporting its use mainly in treatment-resistant cases. Monitoring and cautious patient selection are necessary due to limited long-term safety data.
Clinical research Trial published

Psilocybin trial examines inflammation and mitochondrial stress in Parkinson's

Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial.
Why it matters ◈ Mixed
This nonrandomized clinical trial reports on the biological effects of psilocybin in Parkinson's disease, focusing on inflammatory and mitochondrial stress markers. While not a randomized controlled trial, the study adds valuable mechanistic data relevant for future neurodegenerative research and may inform design of larger, controlled studies. The findings could influence both clinical and regulatory perspectives on psychedelic research in movement disorders, though direct policy impact is limited at this stage.
Clinical research Real-world outcomes study published

Dextromethorphan-bupropion shows lower costs vs esketamine, other MDD drugs

Healthcare utilization and costs associated with dextromethorphan-bupropion versus selected other branded treatments for major depressive disorder: a US real-world study
Why it matters ◈ Mixed
This real-world claims analysis suggests dextromethorphan-bupropion (Auvelity) is associated with lower healthcare utilization and costs compared to cariprazine, brexpiprazole, and notably, esketamine in US adults with major depressive disorder. While not a head-to-head clinical trial, these findings may influence payer decisions, prescriber preferences, and future comparative effectiveness research. The study's limitations—such as lack of clinical severity data and potential confounding—mean results should be interpreted cautiously, but the cost differential with esketamine is notable for market access and reimbursement discussions.
Aims This study aimed to evaluate healthcare resource utilization (HCRU) and costs among adults with major depressive disorder (MDD) initiating dextromethorphan-bupropion (AUVELITY) versus cariprazine, brexpiprazole, or esketamine.Methods Using Merative MarketScan Commercial and Medicare claims data (January 2021–March 2024), adults initiating dextromethorphan-bupropion or a selected branded comparator between January 2022 and March 2024 were identified and assigned to mutually exclusive treatment cohorts (index date = first prescription claim). Eligible patients had ≥ 1 pre-index MDD diagnosis and continuous medical and pharmacy enrollment for 6 months before and after index. Comparator cohorts were propensity score-weighted to the dextromethorphan-bupropion cohort. Patient characteristics were assessed during the 6-month pre-index period. Post-index HCRU and healthcare costs (2023 USD) over 6 months were evaluated using regressions adjusting for pre-index costs.Results Each weighted cohort included 1,472 patients (mean age 43 years; 66.7% female). Compared with patients initiating dextromethorphan-bupropion, patients initiating cariprazine, brexpiprazole, or esketamine had higher odds of emergency room visits (odds ratios [ORs]: 1.35, 1.23, and 1.34, respectively; all p < 0.05) and inpatient admissions (ORs: 1.40, 1.19, and 1.11, respectively; p < 0.05 for cariprazine). Adjusted mean total healthcare costs were $18,715 for dextromethorphan-bupropion versus $19,931, $20,762, and $41,954 for cariprazine, brexpiprazole, and esketamine, respectively (p = 0.05 vs cariprazine; p < 0.05 vs brexpiprazole and esketamine). Adjusted mean medical costs were $9,154 vs $10,335, $10,352, and $23,934, and mean pharmacy costs were $9,272 vs $10,060, $11,015, and $21,561, respectively (all p < 0.05).Limitations Claims data may be subject to incomplete information, coding errors, residual confounding, and channeling bias. Clinical severity, treatment response, and therapy line were unknown.Conclusions In adults with MDD initiating selected branded treatments in routine US clinical practice, dextromethorphan-bupropion initiation was associated with lower all-cause HCRU and healthcare costs compared with initiation of cariprazine, brexpiprazole, or esketamine.
Clinical research Interim Phase 2/3 readout

Esketamine-ECT combo shows rapid reduction in suicidal ideation in teens (interim)

Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results
Why it matters ▲ Favorable
This interim randomized trial suggests adjunctive subanesthetic-dose esketamine during ECT accelerates reduction of suicidal ideation and improves early depressive symptoms in adolescents with major depressive disorder. The safety profile appears favorable, with no short-term cognitive decline and fewer injection pain reports. These findings could influence future clinical protocols for severe adolescent depression, but long-term outcomes and regulatory impact remain to be seen.
BACKGROUNDEvidence for adjunctive subanesthetic-dose esketamine during electroconvulsive therapy (ECT) in adolescents with major depressive disorder (MDD) is limited.Suicidal ideation is a critical early treatment target in this population.We hypothesized that adjunctive subanesthetic-dose esketamine during ECT would accelerate the reduction in suicidal ideation and improve early clinical outcomes. AIMTo evaluate the efficacy and safety of adjunctive subanesthetic-dose esketamine during ECT in adolescents with MDD. METHODSThis interim report presents a randomized, double-blind, controlled trial of 113 adolescents aged 13-17 with MDD undergoing ECT.Participants were randomized 1:1 to esketamine (0.25 mg/kg) plus propofol (n = 56) or saline plus propofol (n = 57).The key outcome was early change in suicidal ideation via the Beck Scale for Suicide Ideation.Additional outcomes, including depressive and psychopathological symptoms, cognitive performance, response, remission, and safety, were also assessed.Intention-to-treat and per-protocol analyses were performed. RESULTSAdjunctive esketamine was associated with different longitudinal trajectories of suicidal ideation, with a group × time interaction (F = 95.27,P < 0.001, partial η 2 = 0.553).A higher response rate was observed in the esketamine group [76.8% vs 57.9%; adjusted odds ratio = 2.49, 95% confidence interval (CI): 1.08-5.75],although remission rates were similar.The 24-item Hamilton Depression Rating Scale scores were lower after four ECT sessions (P 4 / 43 = 0.013), while the 9-item Patient Health Questionnaire and modified Positive and Negative Syndrome Scale scores reduced during treatment (both P < 0.001).Montreal Cognitive Assessment scores were higher (adjusted mean difference = 1.24, 95%CI: 0.57-1.91,P < 0.001).Injection pain occurred less frequently (10.7% vs 33.3%, P = 0.004), with no differences in other adverse events. CONCLUSIONAdjunctive subanesthetic-dose esketamine during ECT accelerates the reduction in suicidal ideation and improves early depressive and psychopathological symptoms in adolescents with MDD.No significant short-term cognitive decline was observed; longterm outcomes remain uncertain.
Clinical research Targeted review published

Review: Dose- and endpoint-dependent effects of perioperative esketamine in children

Dose- and endpoint-dependent effects of perioperative esketamine in children: evidence from a targeted review
Why it matters ◈ Mixed
This targeted review synthesizes evidence on perioperative esketamine use in children, highlighting dose- and outcome-specific effects but no clear universal therapeutic window. The findings suggest low-dose IV esketamine may reduce emergence delirium in certain pediatric surgeries, but optimal dosing remains unresolved and safety boundaries are not firmly established. The review underscores the need for more rigorous, endpoint-specific trials with pharmacokinetic and safety follow-up, which is relevant for pediatric anesthesia research but does not immediately alter legal or regulatory frameworks.
Esketamine is being evaluated for several paediatric perioperative indications, including analgesia, procedural sedation, attenuation of propofol injection pain, and prevention of emergence delirium (ED) or emergence agitation (EA). This mini review examines whether evidence identified in a targeted search supports a clinically useful therapeutic window and how dose, timing, route, developmental stage, anaesthetic technique, procedure, co-medication, and outcome definition modify treatment effects. Randomised trials and meta-analyses generally report fewer ED or EA events after low intravenous doses, particularly during sevoflurane anaesthesia for adenotonsillectomy. Direct dose-comparison evidence shows increasing benefit up to 0.5 mg·kg −1 intravenously in that setting, without identifying an upper efficacy or safety boundary. An observational association between esketamine exposure and more ED cannot establish a threshold because treatment selection and perioperative context were not controlled. Effective doses are endpoint-specific: propofol injection pain, procedural sedation, analgesia, and emergence outcomes require different exposure profiles. Intranasal regimens cannot be converted into intravenous equivalents from bioavailability alone, and preclinical neurotoxicity findings do not define a ceiling for a single perioperative dose in children. Among the studies identified, 0.2–0.5 mg·kg −1 was the best-studied intravenous range in selected emergence-prevention settings, not a universal recommendation or validated therapeutic window. Future trials should compare dose and timing directly, incorporate paediatric pharmacokinetic–pharmacodynamic sampling, use endpoint-specific assessment, and extend safety follow-up.
Clinical research Integrative review published

Major integrative review: MDMA-assisted therapy for PTSD (2010–2025 evidence)

USO TERAPÊUTICO CONTROLADO DE MDMA NO TEPT: UMA REVISÃO INTEGRATIVA ENTRE 2010 E 2025
Why it matters ◈ Mixed
This comprehensive integrative review synthesizes 15 years of global evidence on MDMA-assisted psychotherapy for PTSD, finding large effect sizes and a favorable safety profile across multiple independent sources. However, the certainty of evidence is rated low to very low due to research sponsorship concentration, retracted articles, and lack of a completed Cochrane review. This underscores both the promise and ongoing limitations in the evidence base as regulatory and clinical decisions loom. The findings are highly relevant for researchers, clinicians, and policymakers evaluating the readiness of MDMA-assisted therapy for broader adoption.
O uso terapêutico controlado de MDMA (3,4-metilenodioximetanfetamina) associado à psicoterapia tem ganhado destaque como abordagem para o transtorno de estresse pós-traumático (TEPT), especialmente em casos resistentes às terapias convencionais. Objetivo: sintetizar as evidências publicadas entre 2010 e 2025 sobre a eficácia, a segurança e os mecanismos de ação da terapia assistida por MDMA no tratamento do TEPT em adultos. Método: revisão integrativa, com busca realizada exclusivamente nas bases PubMed, Cochrane Library e Biblioteca Virtual em Saúde (BVS), mantida pelo Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde (BIREME), incluindo a Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), em estudos publicados em inglês, português e espanhol. Foram identificados 139 registros e incluídos 30 estudos na síntese, sendo 7 ensaios clínicos primários, 12 estudos derivados desses ensaios e 11 revisões sistemáticas ou meta-análises. Resultados: observou-se convergência entre fontes independentes quanto a um efeito de grande magnitude na redução dos sintomas de TEPT, com tamanhos de efeito, expressos como diferença média padronizada (SMD, do inglês standardized mean difference) ou g de Hedges, entre 0,8 e 1,3 conforme a fonte, além de perfil de segurança favorável, com eventos adversos predominantemente leves e transitórios. As meta-análises e a revisão-guarda-chuva mais recentes, entretanto, classificam a certeza dessa evidência como baixa a muito baixa pelo sistema Grading of Recommendations Assessment, Development and Evaluation (GRADE). Conclusão: a terapia assistida por MDMA constitui hoje a abordagem psicodélica com a base de evidências mais avançada para o TEPT, mas a magnitude do efeito não deve ser confundida com certeza da evidência, dada a concentração do patrocínio da pesquisa primária, a existência de artigos retratados vinculados a esse programa e a ausência de revisão sistemática Cochrane concluída sobre o tema.
Clinical research Systematic review published

Systematic review finds media overstates psilocybin efficacy, underreports risks

Clinical Evidence on Psilocybin and Its Representation in Media Reporting
Why it matters ◈ Mixed
This systematic review highlights a significant gap between clinical trial evidence on psilocybin and how its efficacy and safety are represented in media reporting. While both trials and media articles report positive effects, media coverage often extrapolates benefits to conditions lacking robust evidence and downplays safety concerns. This finding underscores the need for more accurate public communication to inform policy, patient expectations, and ethical clinical practice as interest in psychedelic therapies grows.
Importance: Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. Objective: To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. Evidence Review: This systematic review included English-language randomized and nonrandomized trials of psilocybin for clinical indications published from January 1, 2014, to October 10, 2024, and media articles describing its clinical use published from January 1, 2014, to April 22, 2025. Trials were found by searching Medline, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) and were characterized by design, indication, use of psychotherapy, and reporting of efficacy and safety. Media articles were found through the Factiva database and were characterized by audience, tone, indication, efficacy claim, and safety content. Data were extracted by 2 reviewers. Risk of bias for randomized clinical trials was assessed descriptively using the Cochrane Risk of Bias tool. Findings: Annual counts of both published clinical trials (n = 70) and media reports (n = 172) increased from 2018 onward. Depression was the most common clinical indication in trials (47 [67%]) and media articles (138 [80%]), while media articles frequently referenced posttraumatic stress disorder (PTSD) (74 [43%]) and anxiety (72 [42%]) as clinical indications despite absent and limited trial evidence, respectively, for these conditions. Overall, 49 trials (70%) reported benefit for the primary indication; 125 media articles (73%) made at least 1 positive efficacy claim, and 122 (71%) adopted a favorable tone. Trials typically described small sample sizes of less than 100 participants (65 trials [93%]) and methodologic limitations. Overall, 31 trials (44%) reported safety outcomes, with some (24 [34%]) documenting short-term adverse events, such as transient anxiety, nausea, or headache; long-term safety was rarely assessed (4 trials [6%]). Only 51 media articles (30%) mentioned safety; when harms were discussed, potential long-term psychological risks were sometimes noted (12 articles [7%]). Conclusions and Relevance: In this systematic review of clinical trials and media articles, both reported positive effects of therapeutic psilocybin with similar frequency. Academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence, and provided less safety information. Clarifying these differences in emphasis may support more transparent public communication of indication-specific evidence and uncertainty as interest in psilocybin-assisted treatments grows.
Neuroscience Review published

TMS in TRD: Omics review explores biological mechanisms and biomarkers

The application of transcranial magnetic stimulation in treatment-resistant depression: insights from omics
Why it matters ◈ Mixed
This narrative review synthesizes omics evidence on how transcranial magnetic stimulation (TMS) impacts molecular and circuit-level biology in treatment-resistant depression (TRD). While not directly related to psychedelics, the mechanistic insights and biomarker strategies discussed here are highly relevant to psychedelic research, which also targets neuroplasticity and circuit remodeling in TRD. The review highlights the need for longitudinal, multi-omics studies—an approach increasingly adopted in psychedelic trials.
Treatment-resistant depression (TRD) is a refractory form of major depressive disorder (MDD) for which conventional antidepressant strategies are often insufficient. Transcranial magnetic stimulation (TMS) has demonstrated clinical efficacy in TRD, but its biological mechanisms remain incompletely understood. This narrative review synthesizes current evidence across transcriptomic, epigenomic, proteomic, metabolomic, and connectomic levels and is complemented by exploratory secondary analyses of publicly available omics datasets. Transcriptomic and spatial transcriptomic studies suggest that TMS modulates cell type- and region-specific transcriptional programs related to synaptic plasticity and neuronal development. Epigenetic evidence suggests potential roles for DNA methylation and lactylation-related regulation, whereas proteomic and metabolomic studies indicate changes in synaptic proteins, neurotransmitter systems, lipid metabolism, and peripheral metabolites. Connectomic studies further show that TMS can alter functional and structural connectivity involving prefrontal and large-scale brain networks associated with treatment response. Together, current evidence indicates biological changes across multiple levels, although direct causal links between molecular changes and circuit remodeling remain largely unproven. Future longitudinal multi-omics studies in patients with TRD may help identify biomarkers, clarify mechanisms, and improve individualized TMS treatment.
Neuroscience Preclinical research published

Robust deep learning model advances preclinical sleep stage classification

Global context integration for pharmacologically robust preclinical sleep stage classification
Why it matters ▲ Favorable
This work introduces a robust deep learning framework for sleep stage classification in preclinical models under diverse pharmacological interventions, including those relevant to psychedelic research. By improving generalizability and reducing annotation burden, the approach enhances the reliability and scalability of sleep and neurophysiology studies, which are critical for understanding drug effects on brain function. These advances may accelerate translational research and improve reproducibility in studies of psychedelics and other CNS-active compounds.
Sleep stage classification from electrophysiological signals is essential for studying brain function in preclinical neuroscience, yet models often fail to generalize across subjects and experimental conditions, particularly under pharmacological interventions that alter neural and muscular activity. We propose a robustness-oriented deep learning framework that integrates multi-branch feature extraction, global contextual representation, sequence modeling, and training strategies designed to reduce sensitivity to subject- and treatment-specific variability. The approach is evaluated on a large rodent dataset comprising over one million annotated EEG and EMG segments collected from multiple animals across several pharmacological conditions. It achieves strong classification performance, substantially outperforming both classical methods and standard deep learning baselines. Notably, the model maintains stable performance across treatments, showing minimal degradation when trained on limited conditions, and remains effective even with relatively small amounts of annotated data. These findings demonstrate that accurate and robust sleep stage classification is achievable despite pronounced experimental variability. The proposed framework reduces reliance on extensive annotation and improves the reliability of automated sleep analysis, supporting more scalable and reproducible preclinical research.
Clinical research Secondary analysis published

MDMA-AT study links self-transcendent emotions to wellbeing, not symptom change

Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment
Why it matters ▲ Favorable
This secondary analysis of a randomized trial suggests that MDMA-assisted therapy for social anxiety disorder may enhance psychological flourishing and wellbeing through fostering interconnectedness and positive self-transcendent emotions, even if it does not directly reduce core social anxiety symptoms. The findings point to new mechanistic targets for psychedelic therapy—beyond symptom reduction—such as belonging and purpose, which could inform future trial design and outcome measures. While the sample is small, this work encourages broader definitions of therapeutic benefit in psychedelic research.
By fostering certain self-transcendent experiences (STE)—those characterized by interconnectedness and other-oriented emotions—3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has been hypothesized to disrupt social anxiety disorder maintenance processes, including negative self-focus, self-criticism, and isolation, thereby enhancing wellbeing. This secondary analysis used data from a randomized waitlist controlled trial of MDMA-AT for generalized social anxiety disorder (N = 20; NCT05138068). It characterized STE during MDMA-AT and examined their relationships with social anxiety symptoms and wellbeing outcomes. Participants reported on STE following two MDMA sessions. Outcomes (social anxiety, gratitude, belonging, purpose in life) were measured at baseline and post-treatment (16 weeks). Paired-samples t-tests examined changes across sessions and pre-to-post treatment, and regression analyses tested whether in-session experiences predicted outcome improvements. Sessions elicited blissful states, and positive and ST emotions, with few negative emotions reported. In-session experiences, especially connection-oriented STE, predicted greater post-treatment belonging, gratitude, and purpose in life, though not social anxiety reduction. STE involving a sense of self-loss were infrequently endorsed and did not predict outcomes. Findings highlight the potential importance of connection-focused STE and emotions during MDMA-AT for promoting psychological flourishing and eudaimonic wellbeing, laying the groundwork for future larger-scale mechanistic trials.
Industry Industry trend

Drug companies accelerate ketamine medicine development

Why Drug Companies Are Rushing to Market Ketamine Medicines
Why it matters ◈ Mixed
Major pharmaceutical interest in ketamine signals a shift toward mainstreaming psychedelic-adjacent therapies. The rush to market reflects both growing clinical evidence and competitive positioning as regulatory and payer environments evolve. This trend may increase research funding and patient access, but also raises questions about pricing, intellectual property, and equitable access. Stakeholders should monitor how rapid commercialization shapes clinical practice and future policy.
Clinical research Phase 3 trial ongoing

KetSet trial tests psychedelic vs biomedical framing of ketamine for TRD

KetSet
Why it matters ▲ Favorable
This trial directly tests whether the psychological framing of ketamine infusions—psychedelic vs biomedical—affects antidepressant outcomes in treatment-resistant depression. The results could inform best practices for ketamine clinics and influence the design of psychedelic-assisted therapy protocols. If the psychedelic framing yields superior outcomes, it may shift clinical standards and reimbursement models, and guide training for practitioners. The study also provides valuable data on subjective experience, safety, and health economics, relevant for both research and policy.
KetSet is a single-center, open-label, randomized controlled superiority trial investigating whether the psychological framing of intravenous ketamine treatment influences clinical outcomes in patients with treatment-resistant depression (TRD). The study is conducted at the Psychiatric Clinic, Skaraborg Hospital, Sweden. Ketamine has demonstrated rapid antidepressant effects in patients with TRD, but its benefits are often short-lived, and the optimal approach to administering treatment remains uncertain. Ketamine can induce dissociative alterations in consciousness, perception, cognition, and emotions, resembling some of the effects induced by classic psychedelics. Research on classic psychedelics suggests that these subjective experiences may be associated with antidepressant outcomes, although their causal contribution remains unclear. Psychological factors, including expectations, preparation, the treatment environment, and interpersonal support, may influence the acute subjective experience during treatment with classic psychedelics or subanaesthetic doses of ketamine for depression. The primary aim of KetSet is to investigate whether a psychedelic framing of ketamine treatment, emphasizing the potential therapeutic relevance of subjective experiences, results in greater improvement in depressive symptoms compared with a biomedical framing, emphasizing ketamine's pharmacological effects and the management of adverse experiences. A total of 120 adult patients with TRD who have already been prescribed intravenous ketamine as part of routine psychiatric care will be randomized (1:1) to one of two treatment conditions. Both groups will receive the same ketamine infusion regimen, consisting of six intravenous infusions over four weeks, generally administered at 0.5 mg/kg over 40 minutes. The groups will differ in their preparatory information, psychological support, and approaches to the acute ketamine experience and post-infusion discussions. In the psychedelic framing group, patients will be encouraged to approach their experiences with openness and curiosity, supported by mindfulness, music, and eyeshades. In the biomedical framing group, treatment will emphasize pharmacological mechanisms, symptom management, and strategies for coping with potential adverse effects. The primary outcome is the between-group difference in change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores from baseline to 12 weeks after treatment initiation, assessed by blinded raters. Secondary outcomes include the trajectory of depressive symptoms, response and remission rates, adverse events, treatment discontinuation, quality of life, psychological well-being, therapeutic alliance, and subjective ketamine experiences. Health economic outcomes and long-term clinical outcomes will also be investigated. An embedded mixed-methods study will examine patients' subjective experiences of ketamine treatment through semi-structured interviews and standardized questionnaires, exploring the phenomenology of these experiences and their potential associations with clinical outcomes. KetSet aims to contribute evidence on whether psychological framing and support influence the effectiveness and tolerability of ketamine treatment for depression. The findings may help inform the development of evidence-based, patient-centered approaches to ketamine administration in routine psychiatric care. The trial is registered at ClinicalTrials.gov (NCT07824973). Recruitment has not yet commenced at the time of preparation of this OSF registration.
Clinical research Peer-reviewed publication

Peer-reviewed study: Microdoses of LSD may enhance cognition

Daily Briefing: Tiny doses of LSD seem to boost cognition.
Why it matters ▲ Favorable
This peer-reviewed publication adds to the growing evidence base suggesting that low, sub-perceptual doses of LSD ('microdosing') may improve cognitive function. While not a regulatory or legal milestone, such findings can influence the design of future clinical trials, inform risk-benefit assessments, and shape public and policy discourse around microdosing. The results may also support further investigation into therapeutic applications and safety profiles of microdosing regimens.
Industry / Clinical research Production completed

Optimi Health completes MDMA production for Phase 3 trials and commercial supply

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Why it matters ▲ Favorable
Optimi Health's completion of MDMA production for Phase 3 PTSD trials in Canada and Israel, plus commercial supply in Australia, signals growing international infrastructure for both research and potential therapeutic use. This development supports large-scale clinical trials and may accelerate timelines for regulatory review and patient access. The company's ability to supply multiple jurisdictions also highlights the maturing supply chain for psychedelic medicines.
Neuroscience Peer-reviewed study

Brain connectivity study reveals altered cortico-subcortical flow in anhedonia

Diminished ascending drive in transdiagnostic anhedonia shifts the cortico-subcortical hierarchy away from bottom-up dominance
Why it matters ▲ Favorable
This study provides new mechanistic insight into the neural basis of anhedonia by showing a shift in cortico-subcortical hierarchy and diminished ascending drive in individuals with high anhedonia. These findings may inform future research on the neural targets of psychedelic and other neuropsychiatric interventions, particularly for mood and psychotic disorders where anhedonia is prominent. The use of advanced modeling and replication across large samples strengthens its translational relevance for clinical trial design and biomarker development.
Anhedonia, the diminished capacity to experience or pursue pleasure, is a core feature of mood and psychotic disorders, yet the large-scale brain dynamics underlying it remain uncharacterized. Dominant accounts posit striatal hypofunction with compensatory prefrontal over-recruitment, but they rest on activation magnitudes and symmetric correlations, which cannot resolve the direction of influence. Here, in 210 adults from the Transdiagnostic Connectome Project, we defined symptom-derived low- and high-anhedonia subgroups and estimated each participant's directed effective connectivity using a whole-brain generative model fitted to resting-state fMRI. In high anhedonia, the cortex shifted upstream relative to the subcortex, flattening the cortico-subcortical hierarchy. Correspondingly, the net balance of direct cortico-subcortical flow shifted from bottom-up to balanced. This shift recurred within the frontostriatal reward circuit and replicated across independent halves of each participant's data. Flow asymmetry also increased with subject-level severity. Decomposing flow into ascending and descending arms showed that both weakened in high anhedonia, but ascending subcortex-to-cortex and striatum-to-prefrontal drive fell more than the descending drive. These findings identify a reorganization of cortico-subcortical hierarchy in anhedonia and suggest that the previously reported prefrontal over-recruitment reflects diminished ascending drive rather than stronger cortical output.
Clinical research Peer-reviewed publication

Study compares ketamine extension vs. buprenorphine maintenance

Ketamine Extension or Buprenorphine Maintenance?
Why it matters ◈ Mixed
This peer-reviewed study directly compares ketamine extension protocols to buprenorphine maintenance for clinical outcomes, likely in the context of substance use disorder or depression. The findings may influence clinical guidelines, inform future trial designs, and shape payer or regulatory decisions on the role of ketamine relative to established opioid maintenance therapies. Researchers and clinicians should review the full data for implications on safety, efficacy, and long-term management strategies.
Neuroscience Peer-reviewed study

Study: Ketamine calms habenula activity in depression

Depression: Ketamine quiets an unruly habenula.
Why it matters ▲ Favorable
This study provides mechanistic evidence that ketamine's rapid antidepressant effects may stem from its ability to suppress hyperactivity in the brain's habenula region. This insight could guide the development of new, targeted treatments for depression and supports the scientific rationale for ongoing clinical trials of ketamine and related compounds. The findings may also inform regulatory and clinical decisions regarding the use of ketamine in psychiatric care.
Clinical research Peer-reviewed study published

Study: Buprenorphine After Ketamine for Suicidal Ideation in ED

Buprenorphine Following Ketamine for Suicidal Ideation: A Bridge to Care from the Emergency Department.
Why it matters ▲ Favorable
This study explores a novel protocol combining ketamine with buprenorphine to manage acute suicidal ideation in emergency settings. The findings suggest that buprenorphine may help sustain the rapid anti-suicidal effects of ketamine, potentially improving patient stabilization and bridging to longer-term care. This approach could inform new clinical pathways and influence future research on integrated pharmacological interventions for suicidality. While not a regulatory move, it signals growing clinical interest in combining psychedelics with established medications for acute mental health crises.
Community / Ethics Systematic review published

Systematic review: Social responsibility in ethnic minority integration

Advances in social responsibility in the integration of ethnic minorities: A systematic review
Why it matters ◈ Mixed
This systematic review highlights ongoing gaps and fragmented progress in integrating ethnic minorities, including Indigenous and Afro-descendant communities, into health and governance systems. For psychedelic research and industry, the findings underscore the need for culturally appropriate frameworks and genuine inclusion, especially as these communities are often central to traditional psychedelic practices but remain marginalized in research and policy. The review's call for structural change is a timely reminder for stakeholders to address intercultural justice and avoid perpetuating extractive or paternalistic models.
In recent years, the exclusion of Indigenous, Afro-descendant, and other culturally diverse communities has persisted across multiple social and productive spheres. This systematic review aimed to analyze recent advances in social responsibility regarding the integration of ethnic minorities over the past six years. A systematic review was conducted following PRISMA guidelines in Scopus and Web of Science, identifying 481 articles, of which 76 met the inclusion criteria. The findings reveal higher scholarly output in Australia, the United States, and Canada, with progress concentrated on strengthening autonomous governance, adopting decolonizing methodologies, consolidating culturally appropriate health systems, and promoting territorial management grounded in traditional ecological knowledge. However, within extractive industries, social responsibility remains ambivalent, combining inclusive initiatives with paternalistic practices that perpetuate structural inequalities. The review concludes that progress remains fragmented and calls for a structural reconceptualization of social responsibility as a framework for intercultural justice.
Clinical research Preprint published

Review: Product-specific safety evidence for Cannabis and Psilocybe

From cytotoxicity to clinical safety: Product-specific evidence and justified extrapolation for Cannabis and Psilocybe preparations
Why it matters ◈ Mixed
This review highlights the critical need for product-specific safety evidence in Cannabis and Psilocybe preparations, cautioning against broad extrapolation of findings across different products, formulations, or use contexts. It underscores that clinical safety, product quality, and regulatory standards are not interchangeable, and that claims about safety or efficacy must be directly linked to the specific product and conditions studied. The proposed claim-linked extrapolation record could inform future regulatory, clinical, and commercial practices, especially as the psychedelic and cannabinoid markets diversify. This work is highly relevant for researchers, regulators, and industry stakeholders navigating product approval, clinical trial design, and consumer safety.
This preprint presents a focused critical narrative review of how safety findings for Cannabis and Psilocybe preparations are transferred across products, formulations, exposures, test systems, populations, and conditions of use. The central question is not whether safety evidence can ever be extrapolated, but when such extrapolation is justified and what information is needed to support it. The review examines selected analytical, cellular, pharmacokinetic, clinical, and regulatory examples to show why category-level terms such as “Cannabis,” “CBD,” “Psilocybe,” or “psilocybin” may conceal important differences in product identity, composition, formulation, dose, route, storage, contaminants, and use conditions. Examples include: discrepancies between labelled and measured cannabinoid content; preparation- and storage-dependent variation in Psilocybe cubensis biomass; extract-specific in vitro responses; differences in systemic Δ9-THC exposure despite the same nominal THC dose; and the limits of transferring findings from a controlled synthetic-psilocybin trial to fungal biomass or other use contexts. The review argues that safety findings should remain linked to the characterized product, exposure, endpoint, population or test system, observation period, and conditions actually studied. It also distinguishes product quality from clinical safety. Conformity with compositional, manufacturing, or contaminant-related specifications does not, by itself, establish clinical interchangeability, therapeutic efficacy, or overall safety. The importance of product characterization also depends on the type of claim being made and the context in which a product is supplied. Self-produced personal use, commercial supply, and therapeutic or medicinal use do not necessarily require identical levels of quality assurance. Rather, the strength of characterization and supporting evidence should be proportionate to the specificity and consequence of the claims being made. To make safety-claim transfer more transparent, the paper proposes a claim-linked extrapolation record that explicitly documents: the source safety claim; the source and target products; composition and measurement; exposure; test system or population; endpoint and ascertainment; use, support, and observation conditions; relevant source-to-target differences; bridging evidence and justification; and residual uncertainty and disposition of the claim. This record is presented as an application of existing product-characterization and evidence-bridging principles, not as a validated checklist, universal safety score, or new regulatory standard. The review is intentionally focused rather than systematic. Its conclusions are limited to the selected and accessible evidence. Missing evidence is treated as uncertainty—not as proof of harm, but also not as evidence of equivalence. Keywords Cannabis; Psilocybe; psilocybin; cannabidiol; THC; product characterization; safety; cytotoxicity; extrapolation; evidence transfer; quality assurance; botanical drugs; psychedelic research; critical narrative review Suggested hashtags #Cannabis #Psilocybe #Psilocybin #Psychedelics #PatientSafety #DrugSafety #ProductQuality #EvidenceBasedMedicine #Toxicology #Pharmacology #OpenScience #Preprint
Neuroscience Peer-reviewed preclinical study

DMS CP-AMPARs linked to aversion-resistant alcohol drinking in mice

Dorsomedial striatum calcium permeable AMPA receptors in the development of aversion-resistant alcohol drinking
Why it matters ◈ Mixed
This preclinical study identifies a causal role for calcium-permeable AMPA receptors in the dorsomedial striatum in the development of aversion-resistant alcohol drinking. While not directly related to psychedelics, the findings deepen understanding of synaptic plasticity in compulsive substance use, a mechanism relevant to addiction neuroscience and potentially to the development of psychedelic-based treatments for alcohol use disorder. The results may inform future translational research but have no immediate impact on clinical or legal frameworks.
Abstract Rationale Alcohol use disorder is defined by drinking alcohol despite knowledge of negative consequences, often referred to as aversion-resistant drinking (The dorsomedial (DMS) and dorsolateral striatum (DLS) are necessary for goal-directed and habitual action selection, respectively. Leading hypotheses posit that once drug use becomes compulsive, DMS dependence degrades while DLS dependence increases. This shift may be mediated by changes in synaptic weights from glutamatergic inputs. Objectives Using a combination of western-blot, micro-injections, and ex-vivo electrophysiology in male and female C57BL/6J mice, we investigated the role of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors AMPAR, which drive glutamatergic transmission, during quinine-adulterated alcohol drinking in the DMS and DLS across the development of aversion-resistant drinking. Results We found that AMPAR subunit composition and function change in the DMS across the development of aversion-resistant drinking whereby, calcium permeable (CP) - AMPARs drive behavior. Western blots revealed a negative relationship between DMS GluA1 and quinine-adulterated alcohol drinking in alcohol naive mice and a positive relationship between DMS Glu A1/A2 ratios and quinine-adulterated alcohol drinking in aversion-resistant mice indicating that aversion-resistance positively predicts likelihood for CP-AMPAR expression in the DMS. Female aversion-resistant mice also had significant positive relationships with DMS or DLS Glu A1/A2 ratios and female aversion-resistant mice had a significant negative relationship with GluA2 and aversion-resistant alcohol drinking. DMS CP-AMPAR antagonism caused an increase in quinine-adulterated alcohol drinking in alcohol naïve mice suggesting that CP-AMPARs in the DMS prevent aversion-resistant drinking. Ex-vivo electrophysiology of DMS spiny projection neurons revealed that aversion-resistant drinking mice had greater inward rectification and CP-AMPAR antagonist sensitivity than alcohol naïve mice indicating that spiny projection neurons in the DMS express more CP-AMPARs following the development of aversion-resistant drinking. However, sensitivity to CP-AMPAR antagonism negatively predicted aversion-resistant drinking in alcohol history mice. Conclusions These data provide evidence that repeated alcohol binges alter DMS CP-AMPAR activity, where initial DMS activity acts to causally prevent aversion-resistant drinking but after repeated binges that result in aversion-resistant alcohol drinking, DMS spiny projection neurons recruit CP-AMPARs. CP-AMPAR antagonism was negatively association with aversion-resistant drinking within the alcohol history mice suggesting that plasticity of DMS CP-AMPARs is not related to quinine-sensitivity. These data provide evidence for a causal role of the DMS in aversion-resistant drinking and open questions as to the functional role of CP-AMPARs across the drinking history and striatal cell types.
Media / Public Perception Media analysis

MDMA for PTSD: Hope, Hype, and Hard Evidence

MDMA (Molly) for PTSD: Hope, Hype, and Hard Evidence
Why it matters ◈ Mixed
Media coverage like this shapes public and policymaker perceptions of MDMA's potential for PTSD treatment, balancing optimism with skepticism. While not a primary source, such articles often synthesize trial results, regulatory progress, and safety debates, influencing investment, patient interest, and legislative momentum. However, without new data or policy movement, its direct impact is limited.
Clinical research Peer-reviewed study published

LSD microdosing yields cognitive benefits in women only, study finds

Microdosing LSD shows some cognitive benefits - but only for women.
Why it matters ◈ Mixed
This peer-reviewed study reports that microdosing LSD produced measurable cognitive benefits, but only in female participants. The sex-specific effect raises important questions for future research design, regulatory guidance, and clinical trial stratification. Policymakers and clinicians should note the potential for differential efficacy and safety profiles by sex, which could influence both access frameworks and clinical recommendations.
Clinical research Peer-reviewed publication

Ketamine + Buprenorphine Explored for Suicidal Crisis Transition

Bridging Suicidal Crisis to Outpatient Care: Could Ketamine Plus Buprenorphine Shift the Paradigm?
Why it matters ▲ Favorable
This publication highlights the potential of combining ketamine and buprenorphine to manage acute suicidal crises and facilitate safer transitions to outpatient care. The approach could address critical gaps in suicide intervention by leveraging rapid-acting pharmacological effects. If validated in trials, this could influence clinical protocols and inform future regulatory or payer decisions regarding acute psychiatric care. The combination also raises questions about safety, access, and integration into existing mental health systems.
Clinical research Retrospective cohort study published

Study: HHC-associated psychosis shows distinct clinical features vs. cannabis

Clinical characteristics of HHC-associated psychosis: an exploratory retrospective inpatient cohort study
Why it matters ◈ Mixed
This exploratory study identifies distinct clinical characteristics in patients with HHC-associated psychosis compared to cannabis-associated cases, including higher rates of affective symptoms and formal thought disorder. While limited by small sample size and exploratory design, the findings highlight the need for novel cannabinoid screening in psychiatric settings. The results may inform future research, clinical protocols, and regulatory considerations as novel cannabinoids like HHC become more prevalent.
OBJECTIVES: To describe the demographic, clinical, and treatment characteristics of individuals admitted with hexahydrocannabinol (HHC)-associated psychosis and compare with cannabis-associated psychosis. METHODS: A retrospective chart review was undertaken of all admissions to the Adult Acute Mental Health Unit at University Hospital Galway, Ireland, between 1 May 2023 and 31 July 2025, with psychosis and documented HHC or cannabis use in the seven days preceding admission. Demographic, clinical, and treatment variables were compared across three groups: HHC-only, cannabis-only, and combined HHC + cannabis associated psychosis. Group differences were examined using ANOVA for continuous variables and Fisher's exact tests for categorical variables, with repeated-measures ANOVA used to examine antipsychotic dosing. Analyses were exploratory in nature. RESULTS: Thirty-three individuals (79% male) met inclusion criteria. All HHC-related cases occurred in a first episode of psychosis. Affective symptoms were more frequent in the HHC-only group (89%) than in the cannabis-only (54%) and combined HHC + cannabis groups (27%) (p = 0.024). Formal thought disorder appeared more common in HHC-exposed groups (80%) compared with cannabis-only presentations (38%), reaching statistical significance in an exploratory comparison between cannabis-only and combined HHC-exposed groups (p = 0.027). Urine toxicology screening for THC metabolites, length of stay and maximum antipsychotic dose were similar across groups. CONCLUSION: In this cohort, HHC-associated psychosis was associated with higher rates of affective symptoms and formal thought disorder than cannabis-related presentations, despite otherwise similar clinical features. Findings are hypothesis-generating, given the exploratory analyses, small sample and uncorrected multiple testing. They suggest a potential role for novel cannabinoid screening to support earlier identification and management.
Neuroscience Preclinical research published

LHb remodeling marks onset of depression; ketamine reverses neuronal changes

Spatiotemporal remodeling in habenula marks the onset of depression-related phenotypes
Why it matters ▲ Favorable
This study identifies a precise window in which antidepressant intervention, such as ketamine, can reverse stress-induced neuronal and molecular changes in the lateral habenula (LHb) associated with depression phenotypes in mice. The use of spatial transcriptomics and in vivo imaging provides a detailed map of how chronic stress remodels the LHb, offering new targets and timing for intervention. These findings could inform the design of clinical trials and therapeutic strategies for depression, especially those involving rapid-acting antidepressants like ketamine and potentially other psychedelics.
Abstract Chronic stress has lasting adverse consequences that can lead, over time, to depressive disorders1‑4 yet identifying the optimal timeframe for effective therapies remains an unmet challenge. Enhanced neuronal activity and disrupted aversion-encoding in lateral habenula (LHb) are important mediators of stress-related behavioral repercussions5‑10, although the precise timing of its contribution is not understood. Here, we identified an antidepressant-sensitive onset of stress consequences in mice, observable across multiple levels of biological complexity – behavioral, functional, and molecular. Using spatial transcriptomics11,12, we generated a spatially-resolved molecular atlas of the LHb, revealing a topographically-organized and temporally-defined remodeling of gene expression in chronic stress. Longitudinal in vivo two-photon calcium imaging to survey the encoding properties of individual LHb neurons revealed progressively heightened excitatory responses to aversive stimuli. These neuronal adaptations were reversed by the antidepressant ketamine and mirrored both the progression of transcriptional changes as well as the emergence of depression-related behavioral phenotypes. Finally, both chemogenetically limiting LHb neuronal activity and administering ketamine at the onset of the remodeling processes exerted antidepressant effects. Together, these findings associate shared spatiotemporal signatures of LHb neuronal ensembles and genetic landscape with the onset of stress-induced depression-related states. This has implications for temporally tailoring therapeutical interventions in clinical practice.
Ethics / Community Critical analysis published

Pollan’s Psychedelic Renaissance Critiqued for De-Indigenizing Mazatec Medicine

Michael Pollan’s Psychedelic Renaissance: Settler Colonial Time and the De-Indigenization of Mazatec Mushroom Medicine
Why it matters ◈ Mixed
This academic critique highlights the ongoing ethical and cultural tensions between Western commercialization of psilocybin and the Mazatec community’s stewardship of mushroom medicine. It underscores the lack of reciprocity and redress for Indigenous groups as the global psychedelic industry expands, raising important questions for researchers, policymakers, and companies about benefit-sharing, cultural appropriation, and ethical sourcing. While not a legal or regulatory development, this work may influence future policy debates and industry standards around Indigenous rights and psychedelic commercialization.
Michael Pollan’s works “The Trip Treatment” (2015), How to Change Your Mind (2018), and the How to Change Your Mind Netflix documentary series (2022) constitute a critical shift in the way Western consumers and observers participate in the post-1990 revival of clinical trials and underground practices related to Mazatec mushroom medicine. Referred to as the “psychedelic renaissance,” multinational pharmaceutical companies and the global wellness industry have turned psilocybin sales into a multi-billion-dollar industry. However, Mazatec calls for reciprocity and redress continue to go ignored. By reading Pollan’s works against the “Statement from Mazatec Groups on Latest Psilocybin Mushroom Policies in Mexico,” it becomes clear that Mazatec stewardship of plant genetic resources did not end when Westerners first participated in mushroom ceremonies officiated by the Mazatec healer María Sabina in the 1950s. Across Pollan’s influential publications on second wave psychedelics, he links scientists, healers, and mushroom medicine guides to the legacies of R. Gordon Wasson and Albert Hofmann whose actions in the 1950s fundamentally altered the conditions of Mazatec society and their medicine’s entry into the global marketplace. The present study argues that Pollan’s writings both announce - and produce - a settler colonial timeline that continues to amplify extractive logic and naturalize a lack of accountability, reciprocity, and restitution in Mazatec spaces.
Neuroscience Peer-reviewed study

Habenula remodeling linked to depression onset in new study

Spatiotemporal remodeling in habenula marks the onset of depression-related phenotypes.
Why it matters ▲ Favorable
This study identifies specific spatiotemporal changes in the habenula as markers for the onset of depression-related phenotypes. These findings deepen mechanistic understanding of depression, which is highly relevant for psychedelic research, as the habenula is implicated in the action of several psychedelic compounds. The results could inform future clinical trial designs and therapeutic targeting, but immediate policy or regulatory impact is limited.
Clinical research Clinical guidance

Esketamine vs. ketamine: what to ask before you refer

Why it matters ◈ Mixed
This article highlights ongoing clinical and practical questions about the use of esketamine (FDA-approved for depression) versus generic ketamine (used off-label) in psychiatric care. The distinction has implications for prescriber liability, insurance coverage, and patient access. While not a regulatory or legal update, it signals continued debate over standards of care and market positioning for ketamine-based therapies.
Clinical research Literature review

Ketamine shows rapid but transient benefit for OCD in narrative review

O uso da cetamina como estratégia terapêutica no Transtorno Obsessivo-Compulsivo
Why it matters ◈ Mixed
This narrative review synthesizes evidence that intravenous ketamine can induce rapid, short-lived reductions in OCD symptoms, but effects typically fade within a week. The findings highlight potential for ketamine as an adjunct to behavioral therapy, leveraging neuroplasticity windows, but underscore that it remains experimental and should be limited to research or specialist settings. The review calls for further trials to clarify protocols for maintenance and safety, signaling both promise and caution for clinical adoption.
Introduction: Obsessive-Compulsive Disorder (OCD) presents approximately 20% of cases refractory to conventional treatments, driving the investigation of pathophysiological pathways, including the glutamatergic hypothesis. In this context, ketamine emerges as a potential intervention. This study reviewed the literature on ketamine use in OCD, focusing on efficacy, mechanisms, and safety. Methodology: A narrative review was conducted in PubMed, Scopus, and Embase databases, covering publications from 2012 to 2025. Clinical trials and reviews evaluating ketamine or esketamine in adults with OCD were eligible. Ten studies obtained from the search (7 primary clinical trials, 1 preclinical study, and 2 systematic reviews). Results: Evidence suggests that ketamine, predominantly at 0.5 mg/kg intravenously, promotes a rapid and clinically relevant reduction of obsessive-compulsive symptoms, acting within hours. However, the effect tends to be transient, returning to baseline around one week. Other routes of administration presented less consistent results. Discussion: The acute response is compatible with rapid neuroplasticity mechanisms mediated by NMDA receptors, analogous to resistant depression. The short duration limits its use as a standalone monotherapy. There are indications of synergistic potential to facilitate Exposure and Response Prevention (ERP) therapy, leveraging a window of increased plasticity, although methodological limitations restrict generalization. Conclusions: Ketamine is promising, yet experimental, for the acute management of OCD. It should not replace first-line treatments in routine practice. Its use must be restricted to specialized services and research contexts, requiring further trials to define maintenance and safety protocols.
Clinical research Peer-reviewed publication

Study reviews integrated ketamine use in emergency care settings

[Integrated use of ketamine in emergency care].
Why it matters ▲ Favorable
Peer-reviewed evidence on ketamine's integrated use in emergency care may inform protocols and safety guidelines for acute interventions. This research could support broader acceptance of ketamine in medical settings, potentially influencing hospital policy and emergency medicine training. While not a regulatory move, such studies shape clinical best practices and may affect future policy or reimbursement decisions.
Clinical research Phase 2/3 results reported

Psilocybin's antidepressant effect fades vs. placebo after one year

A single dose of psilocybin eased depression within days, but its edge over placebo faded within a year
Why it matters ◈ Mixed
This study suggests that while psilocybin produces rapid antidepressant effects, its advantage over placebo may not persist beyond a year. This finding is highly relevant for researchers and clinicians evaluating the durability of psychedelic-assisted therapy. It may influence trial design, regulatory decisions, and payer interest in long-term outcomes, highlighting the need for maintenance strategies or repeat dosing.
Clinical research Review published

Review: Taxonomies of Consciousness & Psychedelics via Yoga Vāsiṣṭha

From Altered States to Fundamental Peace: Taxonomies of Consciousness, Psychedelics and Hypnosis Through the Lens of the Yoga Vāsiṣṭha
Why it matters ◈ Mixed
This review advances a new framework for understanding altered states in psychedelic and hypnosis research, arguing for a shift from trigger-based to phenomenological taxonomies. It highlights that mystical experience intensity predicts benefit from psilocybin, but repeated experiences may not yield proportional gains, and hypnosis can occasion similar states without clear clinical effect. The proposed Context–State–Stance–Trait model and the 'Fundamental Peace' construct offer a testable research agenda, potentially improving experimental controls and mechanistic clarity in psychedelic science. While not a regulatory or legal change, this synthesis could shape future trial design and interpretation.
Background Psychedelic medicine is approaching regulatory approval, and suggestion alone can now occasion mystical-type experiences in the laboratory. Yet the field still names altered states after their triggers, and nobody can yet show whether the state itself, rather than its context, is what heals. Objective This review reads the evidence presented at the 2026 Annual Conference of the Society for Clinical and Experimental Hypnosis (SCEH) through three lenses: the new consensus taxonomy of altered states of consciousness, the Fundamental Peace model of hypnotic emotion regulation, and the Yoga Vāsiṣṭha's map of states and of the knower. Sources Six SCEH 2026 contributions (Cardeña's taxonomy keynote; Patterson on hypnosis-induced mysticism and psychedelics; Majeti and Corlett's qualitative analysis of hypnotically occasioned mystical experiences; Hood and Elkins's meta-analysis of psilocybin-assisted psychotherapy for anxiety; the author's Circuits of Fundamental Peace; and the conference programme), the papers behind them, the published commentaries on the taxonomy, and Brudner et al.'s (2025) test of mystical experience as a predictor of response in treatment-resistant depression. Synthesis Different triggers converge on the same phenomenological categories (unity, imaginal, detachment, altered identity), so trigger-based labels should give way to phenomenological ones. The intensity of a mystical state predicts benefit at a first psilocybin dose, but repeated mystical states did not bring proportionally more relief, and hypnosis can occasion the state without yet showing comparable clinical change. We argue that the missing variable is the experiencer's stance toward the state, which the Yoga Vāsiṣṭha grades in its seven stages of knowledge (jñāna-bhūmikā), and that Fundamental Peace, with its four components and the FP20 scale, operationalises both that stance in the moment and the capacity that remains afterwards. A network account (default mode, salience and executive control networks) links the two. Conclusions We propose a four-layer Context–State–Stance–Trait model, a research agenda in which hypnosis serves as the experimental control psychedelic science has lacked, and testable hypotheses in which Fundamental Peace mediates the path from extraordinary state to lasting change.
Clinical research Comparative analysis published

Ketamine vs Psilocybin for Depression: Speed and Durability Compared

Ketamine vs Psilocybin for Depression: Comparing Speed and Durability
Why it matters ◈ Mixed
This comparative analysis provides critical data on the relative speed, durability, and cost-effectiveness of ketamine versus psilocybin for treatment-resistant depression. The findings could influence clinical decision-making, payer coverage, and future trial design. While not a regulatory or policy move, this evidence may shape both research priorities and commercial positioning in the psychedelic therapeutics space.
Compare ketamine and psilocybin for treatment-resistant depression by trial remission, speed, durability, cost per response, and durable-remission-week metrics. Independent technical note mirroring the canonical version: https://aidrugsearch.com/blog/ketamine-vs-psilocybin-for-depression-comparing-speed-and-durability.php
Clinical research Peer-reviewed study published

Study: Meditation often combined with alcohol/cannabis, not just psychedelics

Beyond psychedelic exceptionalism: how people combine meditation with psychoactive substances, and how this relates to well-being
Why it matters ◈ Mixed
This study challenges the assumption that meditation is primarily combined with classic psychedelics, finding instead that alcohol and cannabis are more commonly used in this context. The research also finds no consistent well-being benefit from combining psychedelics or cannabis with meditation, but suggests potential harm reduction when meditation is combined with other drugs or alcohol. These insights urge researchers and clinicians to consider polysubstance use and broader behavioral patterns, rather than focusing solely on psychedelic exceptionalism.
BACKGROUND: Combining meditation with psychoactive substances is often assumed to be a niche practice centred on classic psychedelics. We sought to broaden this narrative in two cross-sectional studies. METHODS: Study 1 used a broad naturalistic sample (N = 1,391) to examine the prevalence of substance use, meditation, and their simultaneous combination, as well as associations with subjective happiness. Study 2 used a stratified subsample (n = 397) focusing on classic psychedelic and cannabis users, the most common psychedelic-type substances combined with meditation, to assess associations with mental well-being, peace of mind, psychological flexibility, depression, and anxiety. RESULTS: Contrary to prevailing assumptions, alcohol (29%), cannabis (19%), and nicotine (16%) were far more commonly combined with meditation than classic psychedelics (6%). Classic psychedelic use was also embedded within a pattern of pronounced polysubstance use, suggesting that it may reflect a broader substance-use profile rather than an isolated behavioural practice. Regression analyses found no consistent associations between psychedelic or cannabis use, with or without meditation, and any outcome. However, an unexpected pattern emerged for other drugs and alcohol. Other- drug use without meditation was associated with poorer well-being outcomes relative to no other-drug use, whereas other-drug use combined with meditation was not. Alcohol combined with meditation was associated with better well-being outcomes relative to alcohol use without meditation. CONCLUSIONS: These findings suggest that combining meditation with substance use is not limited to psychedelics and should be studied within broader patterns of polysubstance use and meditation practice.
Clinical research Media feature

Trial veterans critique psychedelic clinical trial approaches

Psychedelic Trial Veterans Reveal What Clinical Trials Get Wrong About Healing
Why it matters ◈ Mixed
First-person accounts from psychedelic trial participants can reveal gaps between clinical protocols and real-world healing needs. Such perspectives may highlight limitations in current trial designs, integration support, or outcome measures, informing future research and ethical standards. While not a regulatory or scientific breakthrough, these insights are increasingly valued by sponsors and regulators seeking patient-centered approaches.
DEA / State policy DEA agreement & state approval

DEA and Iowa approve ayahuasca import/manufacture for psychedelic church

Psychedelic Church's Secret Agreement With DEA And Approval From Iowa Officials Allows Import And Manufacturing Of Ayahuasca
Why it matters ▲ Favorable
This is a precedent-setting arrangement enabling a religious group to legally import and manufacture ayahuasca with explicit DEA and state approval. It signals a new pathway for religious or community-based psychedelic access in the US, reducing legal risk for similar groups and potentially opening a regulated avenue for non-medical use. The move could influence future policy and legal frameworks for entheogenic churches and impact the broader market structure.
Clinical research Peer-reviewed analysis

Paper critiques public doubt around antidepressant efficacy

Beyond reasonable doubt: antidepressants and the limits of scientific critique
Why it matters ◈ Mixed
This paper analyzes how public skepticism toward antidepressants persists despite scientific consensus on their efficacy, highlighting the influence of critical psychiatry and the concept of 'manufactured doubt.' While not directly about psychedelics, this work is relevant as it shapes the broader discourse on psychiatric treatments and public trust, which can impact perceptions and regulatory approaches to emerging therapies like psychedelics. Understanding these dynamics is important for researchers and advocates navigating similar debates in psychedelic science.
Public doubt about the usefulness of antidepressants appears to have grown, even as scientific agreement about their efficacy has become more settled. This paper examines the role that figures associated with critical psychiatry have had in promoting this doubt. It traces the long entanglement of antidepressants and their critics over the last eighty years, culminating in a 2022 review of the serotonin hypothesis, which, though it made no claims about efficacy, was widely interpreted as showing that antidepressants do not work. Drawing on Oreskes and Conway's concept of 'manufactured doubt', the paper explores how certain philosophical commitments have shaped these actors' views, at times impeding their engagement with new evidence. In doing so, it marks a distinction between productive and unproductive doubt. Whilst external scrutiny has played a significant role in shaping psychiatry, some positions are held so rigidly that the resulting critiques obscure the scientific consensus and risk undermining psychiatric care.
Clinical research Peer-reviewed study published

Survey: Ibogaine, 5-MeO-DMT linked to most frequent adverse outcomes

Adverse outcomes of psychedelics self‐reported: Survey
Why it matters ◈ Mixed
This large, nationally representative survey highlights that ibogaine and 5-MeO-DMT are associated with the highest rates of self-reported adverse outcomes among psychedelics, while psilocybin, LSD, and MDMA account for the greatest absolute number of adverse reports due to higher prevalence of use. The findings reinforce known cardiac risks of ibogaine and underscore the need for careful risk assessment as these substances enter clinical trials. While causality cannot be established from the cross-sectional data, the results are highly relevant for researchers, clinicians, and regulators evaluating the safety profile of psychedelics in both research and potential therapeutic contexts.
A nationally representative cross‐sectional survey of U.S. adults found the among all psychedelics, ibogaine and 5‐MeO‐DMT (5‐methoxy‐N,N‐ dimethyltryptamine) resulted in the most frequent self‐reported adverse outcomes, according to a recent study. The study, “Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5‐MeO‐DMT,” by Otto Simonsson, Ph.D., and colleagues, was published September 20 in JAMA Network Open. The number of adults reporting adverse outcomes was greatest for psilocybin, LSD (lysergic acid diethylamide) and MDMA (methylenedioxymethamphetamine), because these substances are more commonly used. Many findings have indicated risks of cardiac adverse effects of ibogaine, consistent with its known association with QTc prolongation and arrhythmia. The study researchers said the information is important, as psychedelics such as psilocybin, LSD MDMA are in clinical trials for psychiatric disorders. Ibogaine and 5‐MeO‐DMT have also shown promise for psychiatric disorders in smaller trials. The study's researchers conducted a survey of 1,964 adults. Past 12‐month use was reported by 1,151 respondents for psilocybin, 376 for LSD, 539 for MDMA, 74 for ibogaine and 95 for 5‐MeO‐DMT. The study limitations included the cross‐sectional design, which precluded conclusions about causality.
National policy Access policy announced

Belgium may allow psychedelic therapy for treatment-resistant depression

Belgium may offer psychedelic treatment outside trials for hard-to-treat depression
Why it matters ▲ Favorable
Belgium's consideration of offering psychedelic treatment outside of clinical trials for hard-to-treat depression signals a major shift toward regulated medical access in the EU. If implemented, this would position Belgium as one of the first European countries to enable broader patient access to psychedelic therapies, potentially influencing policy discussions across the continent. This move could accelerate clinical adoption, inform real-world evidence collection, and reshape the regulatory landscape for psychedelic medicine in Europe.
Neuroscience Peer-reviewed study

Ketamine remodels synaptic and monoaminergic pathways in human iPSC neurons

Ketamine induces synaptic and monoaminergic remodeling in human iPSC-derived neurons
Why it matters ▲ Favorable
This study provides direct evidence that ketamine induces synaptic and monoaminergic remodeling in human iPSC-derived neurons, clarifying its molecular action in a human cell model. The findings support ketamine's unique mechanism as a rapid-acting antidepressant and offer a translational platform for future research on patient-specific responses. While not a clinical or regulatory milestone, the work advances mechanistic understanding relevant for drug development and precision psychiatry.
Abstract Major depressive disorder (MDD) is a leading cause of global disability, and a substantial proportion of patients develop treatment-resistant depression (TRD), highlighting the urgent need for mechanistically novel and fast-acting antidepressants. Ketamine has emerged as a paradigm-shifting therapy due to its rapid and robust antidepressant effects, yet its molecular mechanisms in human neurons remain incompletely understood. Here, we investigated the cellular and transcriptomic effects of ketamine in human induced pluripotent stem cell (hiPSC)-derived forebrain neurons. Neuronal cultures were treated with ketamine (1 µM) for 72 h and analyzed using immunocytochemistry, western blotting, and RNA sequencing. Ketamine treatment did not alter gross neuronal morphology or presynaptic organization but significantly increased synaptic localization of the postsynaptic scaffolding protein PSD-95, suggesting molecular changes associated with synaptic remodeling. At the signaling level, ketamine selectively modulated the Akt pathway without inducing changes in BDNF protein levels or MAPK activation, and without broadly altering excitatory or inhibitory synaptic protein expression. Transcriptomic profiling revealed 604 differentially expressed genes, with significant enrichment of pathways related to serotonergic and dopaminergic neurotransmission. Notably, ketamine upregulated genes involved in monoamine synthesis and signaling, including DDC and DRD1 , while downregulating genes associated with GPCR ligand binding and neurotransmitter transport. SynGO analysis further identified selective regulation of synapse-associated genes, predominantly affecting presynaptic and neurotransmitter uptake mechanisms. Together, these findings indicate that ketamine induces molecular and transcriptional changes in human neurons that are consistent with synaptic remodeling and with activation of transcriptional programs enriched for monoaminergic signaling pathways. This hiPSC-based model provides a platform to investigate the molecular responses of human neurons to ketamine and to explore patient-specific mechanisms in future studies.
State policy / Clinical practice Investigative report

Undercover study questions therapy role in Oregon psilocybin centers

Researchers go undercover to study Oregon’s psilocybin centers; Are psychedelic treatments leaving behind therapy?
Why it matters ◈ Mixed
This investigative report raises concerns about the clinical rigor and therapeutic integration at Oregon's legal psilocybin centers. The findings may influence public perception, regulatory scrutiny, and the evolving standards for psychedelic-assisted care. Operators, clinicians, and policymakers should monitor for potential impacts on best practices and future state or federal oversight.
Neuroscience Peer-reviewed study

Psychedelics delay neurovascular coupling, impacting neuroimaging studies

Serotonergic psychedelics delay resting state neurovascular coupling dynamics
Why it matters ◈ Mixed
This study reveals that serotonergic psychedelics like LSD and DMT delay neurovascular coupling, complicating the interpretation of BOLD fMRI data in psychedelic research. The findings suggest that vascular effects may obscure, rather than mimic, true changes in brain connectivity, emphasizing the need for advanced analytic techniques in future studies. This has direct implications for the design and interpretation of neuroimaging trials, potentially affecting regulatory and clinical acceptance of mechanistic claims.
Psychedelics are increasingly explored as tools to investigate consciousness and cognition, and as potential treatments for mood disorders. While neuroimaging has been central to characterizing their mechanisms of action, the interpretation of these studies may be confounded by the neurovascular effects elicited by these drugs. Here, we investigated the modulation of resting state neurovascular coupling by the serotonergic psychedelics LSD and DMT. Applying a blind deconvolution algorithm to blood-oxygen-level-dependent (BOLD) signals, we found that both drugs increased the estimated hemodynamic delays in regions overlapping with the distribution of serotonin receptors implicated in psychedelic action and vascular regulation. Deconvolution enhanced the detection of psychedelic-induced changes in whole-brain functional connectivity, suggesting that vascular effects obscure connectivity changes instead of generating spurious results. Finally, a biophysical whole-brain model linked these effects to increased flow-dependent feedback and slower dissipation of the vasoactive drive. These findings underscore the need to account for vascular effects in future psychedelic neuroimaging studies.
Neuroscience Peer-reviewed study published

Largest EEG study links context to psilocybin's alpha-band brain effects

Context Shapes Alpha-Band Electrophysiological Signatures under Psilocybin
Why it matters ▲ Favorable
This study provides the most robust EEG evidence to date that the neural effects of psilocybin are strongly modulated by environmental context, especially in alpha-band connectivity. The findings suggest that structured sensory input (e.g., music, movies, meditation) can attenuate or reverse typical psilocybin-induced changes in brain network communication. This has direct implications for clinical trial design, therapeutic protocols, and mechanistic research, supporting the importance of 'set and setting' in psychedelic interventions.
Abstract Background Psilocybin is a serotonergic psychedelic that provides a pharmacological tool for examining neural activity associated with altered states of consciousness. Existing studies report reduced power (4-30 Hz) in posterior regions and altered functional connectivity (FC) at rest, but have typically involved small samples and coarse anatomical parcellations. Additionally, perceptual engagement has been shown to attenuate psilocybin-related whole-brain FC changes. However, how naturalistic context modifies psilocybin’s frequency-specific electrophysiological effects remains incompletely characterised. Methods We analysed the largest psilocybin electroencephalography (EEG) dataset to date (n=56), with matched baseline recordings acquired before psilocybin administration. EEG was recorded during movie viewing, eyes-closed rest, guided meditation, and music listening. Cortical source activity was estimated using minimum-norm estimation and analysed across six canonical frequency bands (1-80 Hz). Spectral power, alpha peak frequency (APF), and magnitude-squared coherence within and between seven functional networks were quantified. Psilocybin effects were assessed using permutation testing with FDR correction, and linear mixed-effects models separated the contributions of drug, context, and their interaction to alpha-band connectivity. Results At rest, psilocybin decreased alpha (8-13 Hz) power, increased gamma-range power, and elevated APF. Alpha-band FC decreased within and between higher-order networks implicated in top-down control. Relative to eyes-closed rest, psilocybin-context interactions showed that structured sensory environments attenuated or reversed psilocybin-related alpha-band connectivity changes. Conclusions These findings identify alpha-band activity as a key electrophysiological correlate of psilocybin-related changes in cortical communication. Structured sensory input reshapes psilocybin-related cortical dynamics such as alpha-band connectivity across large-scale cortical networks, with the strength and direction of this modulation differing by context.
Clinical research Multicenter real-world study published

Real-world study compares IV vs. subcutaneous esketamine for TRD

Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
Why it matters ◈ Mixed
This multicenter retrospective study provides real-world evidence comparing intravenous and subcutaneous esketamine protocols for treatment-resistant depression in Brazil. While IV administration showed a trend toward faster response, both routes achieved similar categorical outcomes at their respective endpoints, and no serious adverse events were reported. Subcutaneous delivery, with lower dissociation rates and simpler logistics, may improve access and scalability in clinical practice. However, the observational design limits definitive conclusions, and further prospective trials are warranted.
Background Esketamine is a promising therapeutic option for treatment-resistant depression (TRD). Intravenous (IV) administration is the most extensively studied parenteral route. However, subcutaneous (SC) administration may offer simpler, more scalable delivery. Multicenter real-world evidence comparing IV and SC routes of administration remains limited. Objective To report clinical outcomes and tolerability of parenteral esketamine protocols for TRD at three Brazilian advanced-care centers. Methods This multicenter retrospective chart review study (2023–2025) included 72 outpatients aged 18–65 years who received esketamine 2 to 3 times weekly via IV (n = 26; 6 sessions) or SC (n = 46; 12 sessions) administration. Data were analyzed in RStudio 2026.01.0 Build 392 using R 4.5.2. The primary outcome was categorical response on the Beck Depression Inventory-II (BDI-II) at the shared 6-session milestone and at each protocol-specific endpoint. Secondary outcomes included continuous changes in BDI-II and Beck Anxiety Inventory (BAI) scores in the full sample, tolerability and documented adverse events, and exploratory factor analysis of baseline symptom dimensions. Results After six sessions, BDI-II response distribution favored the IV protocol, although the between-group difference was not statistically significant (Pearson’s chi-square = 5.661; p = 0.059; odds ratio, 3.06; 95% CI, 1.22–8.00). At the protocol-specific endpoints, categorical BDI-II response did not differ significantly between groups (Pearson’s chi-square = 1.227; p = 0.541; odds ratio, 1.44; 95% CI, 0.57–3.73). No serious adverse events or adverse-event-related discontinuations were reported; dissociation was more frequent with IV than with SC treatment (53.8% vs. 13.0%; p = 0.001), whereas nausea and mild transient blood pressure increases did not differ significantly. BDI-II factor analysis identified cognitive-affective and somatic-neurovegetative dimensions. Conclusions The IV protocol showed a more favorable BDI-II response distribution at the shared 6-session milestone, whereas SC esketamine achieved statistically comparable categorical outcomes at its 12-session protocol-specific endpoint. Route selection should consider speed of response, tolerability, dosing, operational complexity, and access. SC esketamine may be a feasible option where simplicity, tolerability, and access are priorities. Results should be interpreted with caution because of the retrospective, observational study design.
Neuroscience Preclinical study published

Esketamine modulates Wnt4 signaling to alleviate pain-depression in rats

Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex
Why it matters ▲ Favorable
This preclinical study identifies Wnt4-associated molecular changes in the anterior cingulate cortex as a potential mechanism by which esketamine alleviates pain and depression symptoms in a rat model. The findings provide exploratory transcriptomic and signaling insights that may inform future translational research on esketamine or related compounds in pain-depression comorbidity. However, the results are preliminary and limited to animal models, with no immediate impact on clinical practice or regulatory status.
Objective The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC). Methods Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK groups. The PDD model, established via chronic constriction injury (CCI), was validated using a behavioral test battery tracking mechanical allodynia and depression-like phenotypes. On day 21 post-surgery, PDD + ESK rats received a single esketamine injection (15 mg/kg, i.p.). Multi-regional c-Fos expression mapping across the PFC, HPC, and ACC identified the primary responsive structure, followed by dual immunofluorescence for cellular phenotyping. Finally, ACC excitatory neuronal calcium dynamics, exploratory transcriptomic profiles, and Wnt4-associated molecular alterations (including GSK3β and mTOR phosphorylation alongside synaptic markers) were evaluated using fiber photometry, RNA sequencing, and Western blotting. Results ESK alleviated pain hypersensitivity, behavioral despair, and anhedonia in PDD rats. Regional c-Fos profiling identified the ACC as the primary reactive locus, with activation localized predominantly to CaMKIIα-positive neurons. Fiber photometry confirmed that ESK attenuated functional hyperactivation in these ACC excitatory neurons. Exploratory transcriptomic profiling (unadjusted P < 0.05) revealed candidate altered transcripts, identifying Wnt4 as an exploratory molecular marker for further investigation. Subsequent orthogonal protein validations demonstrated that ESK modulated Wnt4 expression alongside concomitant alterations in GSK3β and mTOR phosphorylation, parallel with the attenuation of pathologically elevated synaptic protein markers and a restorative trend in synaptic ultrastructure. Conclusion A single sub-anesthetic ESK dose effectively alleviates PDD behavioral phenotypes in rats. This therapeutic efficacy is associated with Wnt4-related molecular adjustments coupled with putative downstream GSK3β-mTOR signaling alterations within the ACC CaMKIIα-positive neurons, providing exploratory transcriptomic and molecular insights into cortical adaptations in pain-related affective disorders.
Neuroscience Peer-reviewed article

5-HT2A in layer 5 neurons mediates neuroplastic, not hallucinogenic, effects

5-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin
Why it matters ▲ Favorable
This study provides mechanistic insight into how psilocybin's neuroplastic effects can be separated from its hallucinogenic properties. This distinction could inform the development of next-generation psychedelics with therapeutic benefits but reduced psychoactive side effects. The findings are relevant for drug development, trial design, and regulatory strategy in psychedelic medicine.
Clinical research Meta-research published

Meta-research: MeSH indexing fails to capture biomarker sampling site in depression studies

What the Controlled-Vocabulary Layer Cannot Say About Where a Depression Biomarker Was Measured: A Meta Research Analysis of MeSH Sampling-Compartment Coding, January 2024–June 2026
Why it matters ◈ Mixed
This meta-research reveals that current controlled-vocabulary systems (like MeSH) inadequately capture whether depression biomarkers are measured peripherally or centrally, due to both indexer omissions and structural limits in the vocabulary. This creates a blind spot for systematic reviews and meta-analyses, particularly in the inflammatory endotype literature relevant to difficult-to-treat depression. For psychedelic research and clinical trials, this highlights a critical infrastructure gap that could impede accurate evidence synthesis and regulatory review, especially as biomarker endpoints gain importance.
Background: Peripheral biomarkers for major depressive disorder are accessible but correspond poorly to central nervous system processes, a point the evidence base can address only if its record registers the compartment in which each marker was measured. To determine, by meta research rather than evidence synthesis, whether the indexed record of recent depression biomarker research registersthe peripheral-central distinction, separating omission by indexers from absence mandated by the controlled vocabulary. That peripheral markers are imperfect proxies for central processes is established prior knowledge; the question here concerns the bibliographic infrastructure through which that literature is retrieved. Methods: PubMed records published between 1 January 2024 and 30 June 2026 matching a title/abstract query for depression and biomarker terms were retrieved (Tier 1, n = 1166); the MEDLINE-indexed subset formed the analysable corpus (Tier 2, n = 825). We extracted marker-level descriptors and site qualifiers, determined from the 2026 MeSH descriptor file whether /blood and /cerebrospinal fluid are allowable per descriptor, and stratified by publication type. Results: Of 1166 retrieved records, 341 (29.2%) carried no MeSH descriptor; in the closed year 2024, 70 of 317 (22.1%) remained unindexed, so roughly one article in five is permanently absent from the structured record. Within the 825 indexed records, 494 (59.9%) carried no markerlevel descriptor and 658 (79.8%) no site qualifier. Of 1211 distinct descriptors, 681 (56.2%) do not permit /blood at all, most of them terms for which a sampling compartment would carry no meaning; restricted to the 243 markerlevel and class-level descriptors, 30 (12.3%) are barred, C-reactive protein among them, the most frequent marker descriptor in the corpus (26 records), though the same descriptors can receive /cerebrospinal fluid. Primary studies recorded a compartment three times more often than reviews (38.8% vs 14.8%; χ 2 = 52.1, p < 0.001), but recording tracked qualifier eligibility more closely than study design, rising from 5.0% to 59.4% with the number of /bloodeligible descriptors a record carried. Conclusions: The controlled-vocabulary layer cannot reliably recover the sampling compartment of depression biomarker research, for two structural reasons: the peripheral compartment is unrecordable for an entire marker class, and recording depends on how many of a record’s descriptors the vocabulary permits to carry the qualifier at all. A distinction that cannot be recorded cannot be aggregated, audited or contested. The inflammatory endotype literature of difficult-to-treat depression is thereby constrained by a blind spot at the level of retrieval rather than biology.
Clinical research Review published

Comprehensive review details risks and management of ketamine-induced cystitis

From Pathophysiology to Surgical Treatment: A Comprehensive Narrative Review of Ketamine-Induced Cystitis
Why it matters ◈ Mixed
This review synthesizes the current understanding of ketamine-induced cystitis, a serious complication increasingly seen in recreational users and potentially relevant for clinical populations. The findings highlight the need for early recognition, multidisciplinary management, and the importance of ketamine cessation to prevent irreversible bladder damage. The review underscores gaps in high-quality evidence for medical management, signaling a need for further research as ketamine's medical and therapeutic use expands.
Ketamine-induced cystitis (KIC) is an increasingly recognised complication of recreational ketamine use, predominantly affecting young adults and causing severe lower urinary tract symptoms, bladder pain, and progressive structural damage.Its pathophysiology involves urothelial toxicity, chronic inflammation, neurogenic sensitisation, and progressive fibrosis, with advanced disease potentially resulting in a contracted, poorly compliant bladder and upper urinary tract compromise.This narrative review summarises current evidence on the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of KIC, including its distinction from interstitial cystitis/bladder pain syndrome.A literature search was conducted in November 2025 using MEDLINE, Embase, PubMed, and Google Scholar, with relevant literature identified using combinations of terms including "ketamine", "ketamine-induced cystitis", "ketamine cystitis", and "ketamine uropathy".Ketamine cessation remains the cornerstone of management and may improve symptoms and early inflammatory changes.Medical and intravesical therapies may provide symptomatic benefit, although the supporting evidence is predominantly derived from observational studies and small case series.Patients with advanced bladder contracture, poor compliance, or upper urinary tract compromise may require reconstructive surgery or urinary diversion.Early recognition, ketamine cessation, multidisciplinary addiction support, and appropriate escalation of urological management are central to limiting irreversible urinary tract damage.
Clinical research Peer-reviewed study published

Study: Ketamine-assisted psychotherapy alters DNA methylation in MDD

Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder.
Why it matters ▲ Favorable
This peer-reviewed study demonstrates that ketamine-assisted psychotherapy induces measurable, longitudinal changes in peripheral DNA methylation among patients with major depressive disorder. The findings suggest a possible biological mechanism underlying ketamine's therapeutic effects, supporting its further investigation as a psychiatric intervention. This could inform future clinical trial designs, biomarker development, and regulatory considerations for psychedelic-assisted therapies.
Clinical research Article published

Clarifying psychotherapy vs. support in psychedelic trials

Clarifying “Psychotherapy” and “Psychological Support” in Psychedelic Clinical Trials: The What, the Why and the How
Why it matters ◈ Mixed
This article addresses the critical distinction between 'psychotherapy' and 'psychological support' in psychedelic clinical trials, a topic that impacts trial design, regulatory clarity, and interpretation of efficacy data. Clear definitions are essential for reproducibility, regulatory approval, and cross-study comparison. However, as a scholarly article with no citations yet, its immediate impact on policy or practice is limited.
Law enforcement Enforcement action

Police raid businesses for alleged illegal THC, psilocybin sales

Police raid businesses believed to have illegally sold THC, psilocybin
Why it matters ▼ Unfavorable
Law enforcement raids targeting businesses accused of selling psilocybin and THC outside regulated channels signal ongoing legal risks for operators and consumers in the absence of clear, harmonized policy frameworks. Such actions can chill above-ground market development and complicate research and patient access by reinforcing stigma and legal uncertainty. The incident underscores the patchwork nature of psychedelic and cannabis law enforcement, and the importance of regulatory clarity for safe, legal access.
Clinical research / Ethics Ethics analysis published

Ethical lessons from psilocybin therapy in advanced cancer care

Aspirational Autonomy and Psychedelic-Assisted Therapy in Advanced Cancer: Ethical Lessons from Clinical Cases
Why it matters ◈ Mixed
This article highlights nuanced ethical considerations for psychedelic-assisted therapy (PAT) in palliative oncology, emphasizing that patient consent can be meaningful even without full foreknowledge of psychedelic experiences. The authors urge clinicians to look beyond symptom reduction and consider deeper existential outcomes, while also outlining practical challenges for oncologists in candidate selection and expectation management. This work informs best practices and policy development as PAT trials expand in end-of-life care, but does not itself change law or access.
Abstract Psychedelic-assisted therapy (PAT) is increasingly discussed as a potential intervention for anxiety, depression, and existential distress among patients with advanced cancer. Yet the ethical challenges of PAT for patients approaching the end of life remain underdeveloped, particularly for oncologists who may be asked to counsel patients or consider referral to clinical trials. This article uses three deidentified clinical vignettes from a clinical trial of psilocybin-assisted therapy in a palliative oncology context to examine what it means for PAT to “work.” We argue that PAT should not be evaluated only by symptom reduction or the production of mystical experiences, but also by whether it helps patients move toward valued forms of self-understanding, connection, courage, acceptance, or reconciliation. Drawing on the concept of “aspirational autonomy,” we propose that meaningful consent to PAT need not depend on full foreknowledge of an unpredictable experience. Rather, consent may be understood as a patient’s endorsement of a supported process of moral and existential aspiration. We then identify practical ethical challenges for oncology, including expectation management, therapeutic ambiguity, somatic amplification, limited time for integration, and family dynamics. We conclude by offering candidate-selection considerations for oncologists, emphasizing aspirational clarity, cognitive and psychological stability, temporal feasibility, relational support, and realistic expectations.
Clinical research Published study

DNA methylation changes after ketamine-assisted psychotherapy in MDD

Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder
Why it matters ▲ Favorable
This study provides early evidence of peripheral DNA methylation changes associated with clinical improvement following ketamine-assisted psychotherapy in major depressive disorder. While the small sample size and lack of independent replication limit immediate clinical application, these findings suggest possible molecular mechanisms underlying ketamine's antidepressant effects and offer a basis for future biomarker research. The work may guide further studies on the biological correlates of psychedelic and rapid-acting antidepressant interventions.
Ketamine produces rapid antidepressant effects, but the molecular processes associated with their persistence remain poorly defined in humans. We examined longitudinal DNA methylation changes in 10 adults with major depressive disorder undergoing ketamine-assisted psychotherapy using two pre-treatment assessments (T1, T2) and one post-treatment assessment (T3). Participants received three sessions of intranasal racemic ketamine within a structured psychotherapy protocol. Buccal DNA methylation was measured using the Illumina MethylationEPIC v2.0 BeadChip. Depressive symptoms improved markedly following treatment, with mean Beck Depression Inventory–II scores declining from the severe to the mild range (p < .001). Of 802,595 CpG loci evaluated, 20,770 met the nominal T3-versus-T2 screening criterion. Sequential filtering for methylation-change magnitude and movement relative to pre-treatment fluctuation identified 962 retained CpG loci, including 517 retained gene-annotated loci. A supplementary linear mixed-effects analysis modeled repeated measurements within participants across the 603 preselected gene-annotated magnitude-filtered loci; because these loci were selected using the same contrast and cohort, this analysis was not treated as independent confirmation. Exploratory enrichment analysis of this 603-locus set identified NOTCH1-related Reactome terms driven by NOTCH1, DLL1, and ADAM17. Within the retained signature, multiple core and adjacent Notch-related components formed a coherent signaling module spanning ligand, receptor processing, transcriptional regulation, and pathway cross-talk. These findings identify a structured peripheral methylation signature associated with ketamine-assisted psychotherapy. They do not establish brain-specific pathway activation or causality, but provide a longitudinal basis for investigating regulatory adaptations accompanying clinical improvement.
Clinical research Review published

Comprehensive review: Global depression trends & emerging interventions

The Modern Face of Depression: A Comprehensive Review
Why it matters ◈ Mixed
This review synthesizes current knowledge on depression's prevalence, mechanisms, and treatment gaps, highlighting the global burden and the need for innovative approaches. It notes the emergence of interventions such as ketamine-esketamine and digital therapeutics, which are relevant to the psychedelic and neuromodulation fields. However, the article does not present new clinical data or policy changes, but rather contextualizes the urgency for novel treatments and multidisciplinary strategies.
Depression is one of most widespread disabling and one of most important global mental health problems among the main causes of disability, affecting more than 332 million people worldwide. The incidence has dramatically increased, especially among youths, who showed a clinically elevated symptom range, and who were in their environment stressed by the COVID-19 pandemic and consequently were around 25.2% more depressed. Depression is not just related to mental health, but also cardiovascular disease, immunological deficit and suicide – finally the biggest killer of the young adult population (15-29 years). In addition to the depression and apathy symptoms, numerous individuals with depression or apathy will have more irritability, numbness, brain fog, notification fatigue, and sleep difficulties due to tech-neglect, just to name a few. Mechanistically, it's now understood that depression involves dysfunction in multiple systems such as neuroinflammation (elevated blood markers of inflammation like C-reactive protein [CRP], interleukin [IL] 6, and tumor necrosis factor [TNF] α), dysfunction of the HPA-axis, dysfunction of the fronto-limbic circuit, and a disrupted circadian rhythm. Therefore, the informal workers face a more high risk of depression symptoms, 27% more likely than the formal workers in LMICs. With available effective treatments ranging from pharmaceutical, from psychosocial to neuromodulatory, over 75% of people who are affected in low to middle income countries do not receive treatment partly due to any combination of stigma, and lack of resources. Innovation in recent approaches, such as digital biomarkers, app-based cognitive behavioral therapy (CBT), ketamine-esketamine, closedloop neurostimulation, and others is making it apparent once again that novel methods for directly intervening with precision are being born. This paper draws together the latest global statistics, common symptom domains, possible origins, and emerging interventions for digital-age depression, aiming to promote a multidisciplinary approach that integrates psychology, behavioural factors, digital and biological treatments to combat the emerging and escalating worldwide burden of digital-age depression.
Clinical research Peer-reviewed study

Emotional bias markers may predict esketamine response in TRD

Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression
Why it matters ▲ Favorable
This study identifies baseline response criterion and changes in emotional bias as potential markers for predicting and tracking clinical response to esketamine in treatment-resistant depression. If validated, these markers could help clinicians better select and monitor patients for esketamine therapy, supporting more personalized and effective treatment strategies. The findings also advance understanding of the neuropsychological mechanisms underlying rapid-acting antidepressants, though replication is needed.
Negative emotional bias, including reduced processing of positive information and negative interpretation of ambiguous stimuli, is a core feature of depression. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist with rapid antidepressant effects in treatment-resistant depression (TRD), reduces depressive symptoms, but its effects on distinct components of emotional processing remain unclear. Fifty-three patients with TRD and 53 healthy controls performed an Emotional Facial Expression Morphing task. Patients were assessed at baseline, 24 hours after the first esketamine administration, and after 4 weeks of treatment. Statistical models examined detection thresholds for happy and sad faces, negative categorisation of neutral faces, and signal detection indices separating emotion-neutral discrimination sensitivity (d') from response criterion (c), indexing the evidence required to report the presence of an emotion. At baseline, patients required greater happy-face intensity for emotion detection and were more likely to categorise detected neutral faces as negative. They also showed a more conservative response criterion without group difference in discrimination sensitivity. Responders showed an early increase in d'; and, by week 4, less negative categorisation of neutral faces than non-responders. A lower baseline response criterion was associated with responder status and, in secondary continuous analyses, with greater subsequent MADRS improvement. These findings indicate that TRD involves abnormalities across detection-related, valence-related, and decisional aspects of facial-emotion processing that are differently associated with esketamine response: baseline response criterion emerged as a candidate prognostic marker, whereas negative categorisation of neutral faces tracked clinical response. Assessing these domains may inform clinical evaluation, pending independent replication.
Clinical research Case report published

Group psilocybin retreat boosts social connection, case report finds

Group psilocybin in an integrative retreat setting enhances social connection: an observational case report
Why it matters ▲ Favorable
This observational case report suggests group psilocybin administration in retreat settings may significantly enhance social connectedness and reduce distress, highlighting a potential advantage over individualized therapeutic models. While limited by small sample size and lack of controls, the findings support further research into group-based psychedelic interventions, which could inform new models for clinical practice and retreat-based care. This is relevant for researchers, clinicians, and operators considering group protocols or community-based access pathways.
Background and aimsPsilocybin can induce profound alterations in perception, emotion and self-referential processing. These changes are often accompanied by increased feelings of interpersonal connection, found via both psychometric survey data and anecdotally collected qualitative data. Despite recent increases in psychedelic research and treatment, most clinical trials have been performed in individualized patient treatment paradigms. Few studies have examined the outcomes of psilocybin in group contexts, even though ceremonial and group-based usage is historically ecological and may uniquely enhance group dynamics and social bonding.MethodsThis case study investigated psychological and social outcomes among participants (n=14) of a group psilocybin ceremony conducted in an integrative retreat setting. Participants completed a series of psychometric surveys and performed a social behavioral task designed to measure social perceptions at baseline and again at two timepoints following the psilocybin ceremonies.Results and conclusionsOur results indicate significant increases in perceived social connectedness on the Social Perception Assessment (SPA) and the Watts Connectedness Scale (WCS) as well as significant decreases in distress on the Subjective Units of Distress Scale (SUDS). These findings highlight the importance of studying group-based psychedelic administration and suggest that collective settings may generate synergistic social benefits not captured in individual therapeutic models.
Neuroscience Theoretical model published

Unified active inference model for reality construction and psychopathology

Projecting the real through active inference: a unified model of reality construction from neuronal dynamics to social consensus a neuroscientific framework for psychopathology
Why it matters ◈ Mixed
This paper proposes a computational framework linking brain prediction, social consensus, and psychiatric disorders, suggesting that disruptions in 'reality projection' underlie psychopathology. While not directly about psychedelics, the model is highly relevant for understanding how altered states (including those induced by psychedelics) might affect perception, self-modeling, and social integration. This could inform future trial designs, therapeutic targets, and mechanistic hypotheses in psychedelic research, but the impact is currently conceptual rather than regulatory or clinical.
How does the brain transform a chaotic stream of sensory signals into a stable, shared experience of reality? This theoretical paper proposes that the brain does not passively receive the world, but actively projects it – it continuously generates predictions about sensory inputs and updates its internal model when predictions fail, a process formally described by the free energy principle and active inference. We argue that this process can be understood through an analogy with quantum decoherence – the collapse of multiple possibilities into a single actuality. By integrating insights from this analogy with active inference, we show how the brain resolves sensory uncertainty into a coherent projection of reality. A central question we address is whether projecting reality changes it. We argue that it does: a strong, coherent projection reduces uncertainty, while a weak or fragmented one amplifies prediction errors, and a distorted one – diverging from social consensus – leads to alternative realities that resist correction. This projection operates in discrete, rhythmic cycles governed by brain waves and is fine-tuned by neurochemicals that determine how much we “trust” our predictions versus new sensory data. The Default Mode Network – the brain’s inner “sea” of self-awareness, memories, and context – acts as a central hub that integrates and updates these projections. Crucially, individual projections are stabilized into a shared, “solid” reality through social interaction, language, and culture – a process we call collective active inference. Within this framework, psychiatric disorders are understood as disorders of projection – distortions in how the brain generates and stabilizes its model of reality. This perspective reverses the traditional explanatory gradient: psychopathology is not merely a sensory or chemical problem, but a fundamental disruption of the brain’s capacity to project a coherent world. This unifying framework offers a new foundation for both pharmacological and psychotherapeutic interventions, grounding them in a common computational logic.
Clinical research Peer-reviewed study published

Qualitative study: participant recommendations for psychedelic clinical trials

Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network
Why it matters ◈ Mixed
This qualitative study surfaces important gaps in participant support and integration in psychedelic clinical trials, highlighting the need for clearer communication, agency, and structured post-trial peer support. The findings are directly relevant for trial designers, sponsors, and regulators, as they point to ethical and practical improvements that could enhance participant safety and data quality. Incorporating these recommendations may also reduce risk of harm and improve public trust as psychedelic therapies move toward broader clinical adoption.
Background While psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery. Methods This qualitative descriptive study, informed by reflexive thematic analysis, included four Psychedelic Participant Advocacy Network (PsyPAN) members who were former psychedelic-trial participants. They completed three remote focus groups on recruitment and screening, preparation and dosing, and post-dose integration and the post-study period. Three had joined treatment-resistant depression studies involving psilocybin or N,N-dimethyltryptamine; one had joined a psilocybin study for an eating disorder. A one-day workshop reviewed the analysis and developed recommendations, refined with wider PsyPAN input. Results Five themes were developed. First, participants entered trials seeking potentially effective treatment but encountered procedures shaped by eligibility criteria, equipoise, randomization, blinding, standardization, fixed schedules and endpoint-driven evidence generation. Second, participants’ accounts extended “set and setting” to the clinical-trial context by showing how research-specific conditions, including treatment-allocation uncertainty, communication, staff conduct, time-limited support, study ending and the wider support matrix, shaped experience and could mitigate tensions between treatment-seeking and research requirements. Third, facilitators mediated between protocol requirements and participants’ embodied, relational and psychological needs, particularly during dosing. Fourth, dosing was experienced as the beginning of an ongoing process of meaning-making, change and integration. Fifth, experiences after study ending varied; some participants described loss, grief or frustration, while all reported that further structured support would have been beneficial. They highlighted limited access to psychedelically informed care and advocated independent, trial-specific peer support. Recommendations emphasized clear communication, expectation management, distinction between research and treatment frames, reduced avoidable burden, staff continuity, participant agency, boundaries around touch and movement, involvement of support networks, and planning for integration and study ending. Conclusion Relational, contextual and systemic factors shaped participants’ experiences across recruitment, preparation, dosing, integration and study ending. Participant-informed practices should be considered when designing and delivering psychedelic studies, while recognizing scientific, regulatory and resource constraints. Structured post-study peer support may address continuing support needs after trial completion.
Neuroscience Peer-reviewed study

BBB permeability linked to network dysfunction in treatment-resistant depression

Blood-brain barrier permeability is associated with edge-centric functional connectivity and depressive symptoms in treatment-resistant depression
Why it matters ▲ Favorable
This study provides the first human evidence connecting blood-brain barrier (BBB) permeability to disrupted functional brain network architecture and depressive symptoms in treatment-resistant depression (TRD). The findings highlight a potential neurobiological mechanism underlying TRD, which may inform future research on psychedelic interventions targeting neuroinflammation and BBB integrity. The spatial correlation with serotonergic, dopaminergic, and glutamatergic systems is particularly relevant for psychedelic science, as these pathways are implicated in the action of classic psychedelics.
Abstract Blood-brain barrier (BBB) dysfunction and associated cerebral inflammation have emerged as contributing factors in depression pathophysiology, yet human evidence for BBB dysfunction in treatment-resistant depression (TRD), including its spatial distribution and interaction with functional network dysregulation, remains unexplored. We hypothesized that disrupted BBB permeability is related to the aberrant functional network architecture observed in TRD. In 44 TRD patients and 62 healthy controls, regional BBB permeability was quantified using a contrast-agent free MRI technique measuring apparent water exchange across the BBB (AXR BBB ), while functional diversity was assessed via normalized entropy derived from edge functional connectivity based on overlapping community structure. TRD patients showed elevated AXR BBB across visual, somatomotor, ventral attention, frontoparietal, and default mode networks (DMN) regions. Normalized entropy was significantly increased within the DMN and left hippocampus, indicating disrupted functional community architecture. Mediation analyses showed that normalized entropy partially mediated the relationship between AXR BBB and symptom severity in the left hippocampus and DMN. Transcriptomic profiling revealed spatial co-localization between AXR BBB alterations and normative astrocyte-specific gene expression topography, with spatial correlations to normative serotonergic, dopaminergic, and glutamatergic receptor distributions. These findings provide the first evidence linking AXR BBB -indexed BBB permeability alterations to disrupted functional network architecture in TRD.
Clinical research Review published

Ibogaine reviewed as candidate for substance use disorder treatment

Ibogaine for Substance Use Disorders
Why it matters ◈ Mixed
Ibogaine is highlighted as a promising but high-risk candidate for treating substance use disorders, with unique neurobiological mechanisms and anti-addictive potential. The review underscores the urgent need for rigorous clinical trials and standardized protocols due to safety concerns and limited current evidence. Interest in safer derivatives and controlled clinical development is growing, which could shape future therapeutic and regulatory pathways. This signals a maturing field but also ongoing legal and safety uncertainties for researchers and clinicians.
Substance use disorders (SUDs) are a major global health burden, and psychedelic-assisted therapies are now gaining scientific interest, with ibogaine being considered as a candidate for anti-addictive effects across multiple substance classes. Ibogaine is a multi-target indole alkaloid acting on opioid, glutamatergic, serotonergic, and sigma systems with potential to rapidly reduce withdrawal and cravings after a single administration. Ibogaine is metabolized into noribogaine, which has a longer half-life and contributes to sustained pharmacological effects. These compounds act on multiple neurotransmitter systems including NMDA receptors, serotonin receptors, and opioid receptors, which allow it to have a broad neurobiological effect. It also has anti-addictive properties linked to neuroplasticity, dopamine modulation, and opioid receptor activity. Additionally, iboga has use in African rituals, with modern interest increasing in the twentieth century. Ibogaine now is an unregulated or semi-regulated substance with increased interest in controlled clinical development as well. Clinical evidence for ibogaine comes from observational studies and case reports, e.g., particularly in opioid use disorder. Ibogaine carries significant risks, particularly cardiotoxicity, neurological adverse effects including hallucinations, and reported fatalities. Safer derivates such as noribogaine and tabernanthalog (TBG) are being developed to retain anti-addictive efficacy and reduce toxicity. Ibogaine induces prolonged oneirogenic states involved in autobiographical memory processing, and outcomes are influenced by setting, integration therapy, and psychotherapy. Current research is largely observational, and studies are small, which highlights the need for standardized protocols and clinical trials. Overall, ibogaine represents a therapeutic candidate for SUDs, with broad anti-addictive potential. In this review, we provide an overview of ibogaine's history and pharmacology, critically examine its therapeutic potential in multiple SUDs, and discuss current limitations, emerging alternatives, and future directions.
Clinical research Review published

Narrative review explores psilocybin for depression, pain, and inflammation

The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review
Why it matters ▲ Favorable
This narrative review synthesizes emerging evidence on psilocybin’s therapeutic potential for depression, pain, and inflammation, highlighting its mechanisms of action and the interplay between mental health and chronic pain. While it does not present new clinical data, it provides a comprehensive overview that may inform future research directions and clinical trial design. The review could help guide researchers and clinicians considering psilocybin for complex comorbid conditions.
Mental disorders are among the leading causes of non-fatal health loss worldwide and are associated with significant individual, social, and economic burdens. On the other hand, neuropathic pain affects approximately 7-8% of the world's adult population and is a leading reason for medical consultations. A bidirectional relationship between depression and pain has been widely documented. Depression is associated with increased pain perception, while chronic pain may predispose or exacerbate depressive symptoms. The complexity of these two pathologies and the limited efficacy of their current treatments call for research into alternative substances with greater therapeutic success. In this sense, psilocybin has aroused interest in Western medicine since it has been found to have great potential in the treatment of disorders such as depression, anxiety, and pain, among others. In this narrative review, a visualization analysis was conducted to assess the current landscape of psilocybin and psilocin research, spanning from its potential for depression treatment to its potential for pain management. Furthermore, the mechanisms of action of these compounds are analyzed, as are their possible implications in the therapeutics of inflammation and pain, including their participation in the default mode network and the fundamental role of the mystical experiences they generate.
Clinical research Peer-reviewed publication

New PubMed review: Ibogaine for Substance Use Disorders

Ibogaine for Substance Use Disorders.
Why it matters ◈ Mixed
A new peer-reviewed publication on ibogaine's use for substance use disorders adds to the growing body of evidence supporting its potential therapeutic role. While not a regulatory or legal milestone, such reviews can inform future clinical trial designs, guide policy discussions, and shape public health perspectives. However, without new trial data or regulatory movement, the immediate impact on access or legal risk is limited.
Clinical research Peer-reviewed publication

Psilocybin mechanisms in neurodegenerative disorders studied

Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.
Why it matters ▲ Favorable
This mechanistic study provides new insights into how psilocybin acts via 5-HT2A receptors and related pathways in neurodegenerative diseases. The findings may inform future clinical trial design and therapeutic strategies, supporting the rationale for further research into psilocybin as a potential treatment for conditions like Alzheimer's and Parkinson's. This work could help shape regulatory and funding priorities as the field seeks disease-modifying interventions.
Clinical research Peer-reviewed review published

Review: Ketamine/esketamine for severe depression & suicidality—efficacy & safety

Uso de cetamina na depressão grave e risco suicida: Desfechos clínicos e segurança
Why it matters ◈ Mixed
This integrative review synthesizes clinical and safety outcomes for ketamine and esketamine in adults with severe or treatment-resistant depression and acute suicidality. The findings confirm rapid anti-suicidal and antidepressant effects—often within hours—but highlight inconsistent superiority over placebo for repeated dosing and suicidality endpoints. Common adverse events included dissociation and transient hypertension. The review underscores that ketamine/esketamine are rapid-response options but do not replace standard suicide prevention or longitudinal care.
Introdução: A depressão grave associada à ideação ou ao comportamento suicida exige intervenções de início rápido, e a cetamina racêmica e a escetamina têm sido estudadas como opções adjuvantes em cenários de urgência e depressão resistente. Objetivo: Sintetizar os desfechos clínicos e de segurança da cetamina e da escetamina em adultos com depressão grave ou resistente e risco suicida clinicamente relevante. Métodos: Revisão integrativa com busca em 27 de setembro de 2026 no PubMed/MEDLINE, Scopus e Web of Science, sem restrição de período ou idioma. Foram identificados 567 registros, removidas 112 duplicatas e triados 455 títulos e resumos. Foram buscadas para recuperação 29 publicações potencialmente elegíveis, das quais uma não foi recuperada. Assim, 28 textos completos foram avaliados, 13 foram excluídos após leitura integral e 15 estudos primários foram incluídos. A síntese foi narrativa. Resultados: A cetamina intravenosa apresentou redução rápida da ideação suicida em diversos estudos, frequentemente nas primeiras horas ou em 24 horas, embora a duração do efeito tenha variado e um ensaio com doses repetidas não tenha demonstrado superioridade ao placebo. A escetamina intranasal reduziu mais rapidamente a gravidade dos sintomas depressivos em estudos controlados, mas a diferença entre grupos na gravidade global da suicidabilidade não foi consistentemente significativa. Dissociação, tontura, náusea, sedação e elevação transitória da pressão arterial foram os eventos mais frequentes. Conclusão: Cetamina e escetamina podem atuar como intervenções de resposta rápida para sintomas depressivos e ideação suicida em pacientes selecionados, mas não substituem hospitalização, planejamento de segurança, tratamento de base e prevenção longitudinal do suicídio.
Clinical research Phase 3 RCT results

Esketamine reduces opioid use in lumbar surgery: dose-finding RCT

Effects of different doses of esketamine as an adjunct to sufentanil-based patient-controlled intravenous analgesia on postoperative analgesia and opioid consumption following lumbar decompression surgery: a dose-finding randomized controlled trial
Why it matters ▲ Favorable
This randomized controlled trial demonstrates that adjunctive esketamine can reduce opioid consumption and improve pain control after lumbar decompression surgery, with the lowest tested dose (0.25 mg/kg) offering a favorable efficacy-safety balance. The findings support further research into esketamine's perioperative use and may inform clinical protocols aiming to minimize opioid exposure. While higher doses increased sedation and psychomimetic effects, the overall safety profile was acceptable, reinforcing esketamine's potential in multimodal analgesia.
Objective This study aimed to evaluate the effects of different doses of esketamine as an adjunct to sufentanil-based patient-controlled intravenous analgesia (PCIA) on postoperative analgesia and opioid consumption after lumbar decompression surgery and to explore its optimal risk–benefit dose. Methods A total of 120 patients scheduled for lumbar decompression surgery were randomly allocated to four groups. The control group (Group N, n = 30) received PCIA with sufentanil 2.5 μg/kg. To test the opioid-sparing hypothesis, the three experimental groups (Groups S1, S2, and S3, n = 30 each) received PCIA with a lower sufentanil dose (1.5 μg/kg) combined with esketamine at 0.25, 0.5, and 1.0 mg/kg, respectively. All PCIA solutions were diluted with normal saline to a total volume of 100 mL. The primary outcome was the Visual Analogue Scale (VAS) pain score at rest. Secondary outcomes included sufentanil consumption, PCIA press counts, requirement for rescue analgesia, Ramsay Sedation Scale (RSS) scores, and oxidative-stress markers; safety endpoints were analyzed as exploratory outcomes. Postoperative adverse effects, including nausea, vomiting, dizziness, respiratory depression, hypotension, and psychiatric symptoms (dissociation or nightmares), were recorded and compared across the four groups. Results All esketamine-containing regimens (S1–S3) showed significantly lower VAS scores at all postoperative time points compared with Group N (P < 0.05), with no statistically significant difference among S1, S2, and S3. The 24-h sufentanil consumption, effective PCIA presses, and rescue analgesia demand were also significantly reduced (P < 0.05). However, Ramsay sedation scores increased dose-dependently (S3 > S2 > S1). At 4 h postoperatively, SOD activity was higher, and concentrations of MDA, GLU, and COR were lower in all esketamine-containing regimens compared with Group N. Although the overall incidence of adverse events was comparable, the high-dose group (S3) had a significantly increased incidence of hypotension and dissociative symptoms. Conclusion Adding esketamine to a reduced-sufentanil PCIA regimen improved postoperative analgesia and reduced opioid consumption after lumbar decompression surgery. Analgesic benefit was similar across the tested doses (0.25–1.0 mg/kg), whereas dose-related adverse effects (sedation, hypotension, psychomimetic symptoms) increased with dose. These findings suggest that 0.25 mg/kg may provide a favorable efficacy-safety balance within the investigated dose range. Clinical Trial registration http://www.chictr.org.cn/showproj.aspx?proj=249890 , Identifier: ChiCTR2500095890.
Clinical research Published analysis

AI maps global psychedelic clinical trial landscape via registry data

AI-assisted characterization of psychedelic clinical trials from ClinicalTrials.gov
Why it matters ▲ Favorable
This study demonstrates that AI-powered, protocol-driven registry queries can rapidly synthesize the global landscape of psychedelic clinical trials, revealing the dominance of psilocybin and MDMA, a concentration on depression and PTSD, and a paucity of trials in low- and middle-income countries. The method improves transparency and reproducibility over manual or conversational approaches, but still requires validation against traditional systematic review. This structured mapping is valuable for researchers, sponsors, and policymakers tracking the evolving clinical and regulatory environment.
Abstract Background The registry record of psychedelic and related rapid-acting compounds is large, heterogeneous and laborious to synthesize by hand. We tested whether a large language model (LLM) with live access to the ClinicalTrials.gov application programming interface (API) could produce a timely, structured and reproducible characterization of this landscape. Methods Cross-sectional analysis of interventional trials on ClinicalTrials.gov as of 13 January 2026. The core-set comprised classic serotonin 5-HT2A agonists, MDMA, ibogaine and ayahuasca; ketamine and esketamine in psychiatric indications formed a separately reported comparator class. Claude (Anthropic), connected to the registry API, retrieved records first through open-ended natural-language querying and then through a documented protocol of field-specific query expressions restricted to records first posted by the search date, which yielded every reported count; populations and indications were defined from structured registry fields. Results Excluding withdrawn records, 412 core-set trials were identified (256 in patients), plus 300 ketamine/esketamine trials. Psilocybin accounted for 244 (59%; 181 in patients), MDMA 99 (47), LSD 39 (13), DMT/5-MeO-DMT 36 (12), ayahuasca 6 and ibogaine 4. Depression led for psilocybin (74 of 181 patient trials) and the ketamine class (237 of 300), PTSD for MDMA (35 of 47) and anxiety for LSD (6 of 13). Of 63 phase 2/3 psilocybin trials in depression, 35 (56%) had a depression rating scale as primary endpoint, most often the MADRS (25), 34 (54%) assessed it at weeks 3–6, 26 (41%) excluded adults over 65 and none enrolled adolescents. Twenty-four core-set trials were registered as phase 3, 13 of psilocybin; psilocybin phase 3 programmes plan more than 1900 participants, the pivotal MDMA trials enrolled 100 and 121, LSD phase 3 trials plan 149–245, and no other psychedelic had a phase 3 trial. Five patient trials (2%) had a site in a low- or middle-income country. Conclusions LLM-mediated registry querying yielded a structured, reproducible characterization of a fast-moving field, but only once each count was tied to an explicit, archived query expression; open-ended conversational querying had underestimated the record several-fold for some compounds. The approach complements rather than replaces systematic review, and its accuracy against manual extraction remains to be quantified.
DEA / Federal Register DEA notice of intent

DEA to Temporarily Schedule 7-Hydroxymitragynine & Mitragynine Pseudoindoxyl Above Threshold

Schedules of Controlled Substances: Temporary Placement of 7- Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I
Why it matters ◈ Mixed
The DEA's intent to temporarily schedule 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in Schedule I will significantly restrict research, manufacturing, and commercial activity involving these kratom alkaloids at higher concentrations. While the threshold approach may allow some products to remain available, handling or studying these substances above the limit will require strict DEA registration and compliance, raising legal risk and operational barriers for researchers and industry. This move reflects ongoing federal scrutiny of kratom constituents and could impact market structure, patient access, and future research on these compounds.
The Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine and mitragynine pseudoindoxyl (including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible) when either substance alone, or their combined amount if both are present, is above a specified threshold, in schedule I of the Controlled Substances Act (CSA). Based on a different threshold provided by the Department of Health and Human Services (HHS) in July of 2025, DEA published a notice of intent to temporarily schedule 7-hydroxymitragynine above that lower threshold on July 7, 2026. Additionally, DEA published a temporary order placing mitragynine pseudoindoxyl without a threshold in schedule I of the CSA on August 26, 2026. On October 8, 2026, HHS sent a letter recommending that DEA place of the CSA 7-hydroxymitragynine and mitragynine pseudoindoxyl in schedule I when either substance alone, or their combined amount if both are present, is above a new specified threshold. Based on the October 8, 2026 letter, DEA is issuing this notice of intent. While the new threshold recommended by HHS would permit certain products to remain in the marketplace without being subject to schedule I controls, neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels. When a temporary order is issued, it will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 7- hydroxymitragynine and/or mitragynine pseudoindoxyl above the specified threshold. In a separate document contained in this issue of the Federal Register, DEA is withdrawing the July 7, 2026 notice of intent related to 7-hydroxymitragynine. The August 26, 2026 temporary order placing mitragynine pseudoindoxyl in schedule I of the CSA without a threshold remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first.
Clinical research Peer-reviewed analysis

Paper highlights lack of standards for psilocybin therapy aftercare

The Follow-Up Problem in Psilocybin-Assisted Therapy: Integration, Aftercare, and the Missing Standard
Why it matters ◈ Mixed
This analysis spotlights a major gap in the field: the lack of standardized protocols for integration and long-term follow-up after psilocybin-assisted therapy. As Oregon and Colorado implement regulated access, the absence of clear aftercare standards could impact both patient outcomes and the credibility of emerging service models. Researchers, clinicians, and policymakers should note the call for robust, evidence-based follow-up frameworks to ensure safety and sustained benefit.
As psilocybin-assisted therapy becomes increasingly standardized in measuring short-term clinical outcomes, the processes that follow the psychedelic experience remain far less defined. This paper examines integration, aftercare, and long-term follow-up from clinical trials to real-world implementation in Oregon and Colorado, identifying critical gaps and opportunities to better understand, evaluate, and support sustained change.
Law enforcement Enforcement action

Colorado police target illegal THC and psilocybin sales locations

CSPD and law enforcement partners target multiple suspected illegal THC and psilocybin sales locations
Why it matters ▼ Unfavorable
Active law enforcement operations targeting suspected illegal psilocybin and THC sales in Colorado signal ongoing legal risk for unregulated operators even as state-level reforms expand access frameworks. This underscores the distinction between regulated, decriminalized, and illicit markets, and highlights the necessity for clear compliance in the evolving legal landscape. Researchers and industry participants should note that enforcement priorities remain dynamic and local authorities may act independently of broader policy trends.
Clinical research Systematic review published

Systematic review: Psychedelics linked to personality trait changes

Psychedelic-Induced Changes in Personality Traits: A Systematic Review
Why it matters ◈ Mixed
This systematic review synthesizes a decade of research suggesting psychedelics may reduce neuroticism and improve mental health via personality trait changes. However, the evidence base remains limited by small sample sizes and methodological heterogeneity. The review highlights the need for larger, controlled trials—especially in psychedelic-naïve populations—to clarify mechanisms and long-term effects. This work will inform both clinical trial design and regulatory perspectives on therapeutic use.
An increasing number of studies have examined the effects of psychedelics on mental wellbeing and their potential use as adjunctive therapy for depressive and anxiety disorders. In this review, we compiled research from the past ten years that focused specifically on the impact of psychedelic use on personality traits. A systematic search was conducted across the databases Web of Science, PubMed, and Scopus, as well as the trial registry ClinicalTrials.gov, identifying a total of 27 studies including a total of 1,941 participants. The findings from these studies are heterogeneous; however, majority of them report that psychedelics may induce changes in personality traits associated with improvements in mental health, particularly reductions in neuroticism. Adaptive changes appear to be influenced by baseline participant characteristics, including personality traits, as well as qualitative aspects of the psychedelic experience itself. The current evidence is limited, as most studies involved small sample sizes, highlighting the need for more randomized, double-blind controlled trials to draw definitive conclusions. Future research would also benefit from focusing on psychedelic-naïve participants to better understand the effects in individuals without prior exposure. Overall, while preliminary findings are promising, rigorous and larger-scale investigations are essential to clarify the mechanisms and long-term impact of psychedelics on personality and psychological wellbeing.
Neuroscience Preclinical research published

Preclinical study: rTMS effects vary by depressive phenotype in rats

Depressive phenotype shapes behavioral, neuroendocrine and molecular responses to repetitive transcranial magnetic stimulation in preclinical models of depression
Why it matters ◈ Mixed
This preclinical study demonstrates that repetitive transcranial magnetic stimulation (rTMS) elicits distinct behavioral, neuroendocrine, and molecular responses depending on the depressive phenotype in rodent models. Findings highlight the importance of tailoring neuromodulation interventions to specific neurobiological states, supporting a move toward mechanism-guided, personalized treatments for depression. While not directly involving psychedelics, the mechanistic insights may inform future research on combined or comparative neuromodulation and psychedelic approaches in treatment-resistant depression.
Introduction Repetitive transcranial magnetic stimulation (rTMS) is an established non-invasive treatment for treatment-resistant depression (TRD), yet its neurobiological mechanisms remain only partially understood. We investigated whether rTMS recruits common or phenotype-specific adaptive mechanisms across depressive conditions. Methods Male Wistar-Kyoto rats exposed to chronic mild stress and social isolation modeled TRD. Socially isolated Wistar rats modeled treatment-responsive depression (ISO), while socially housed Wistar rats served as non-depressed controls (CTRL). Animals received active or sham high-frequency rTMS. Behavioral batteries assessing motivation, emotionality, helplessness, and anxiety-like behavior began 1 and 14 days after the final rTMS session. Basal plasma corticosterone and Bdnf and Cnr1 mRNA expression in the prefrontal cortex and hippocampus were also assessed. Results rTMS produced phenotype-dependent behavioral, neuroendocrine, and molecular effects. In ISO rats, active stimulation improved multiple behavioral measures and reduced basal corticosterone. In TRD rats, behavioral effects were more selective, primarily involving motivation and self-care, and occurred without corticosterone normalization. The most prominent molecular effects emerged in the prefrontal cortex of TRD rats, where rTMS increased both Bdnf and Cnr1 expression. Their expression was strongly positively correlated only in active TRD animals, suggesting coordinated engagement of plasticity-related pathways. Conclusion rTMS did not elicit a uniform response across depressive phenotypes but recruited distinct adaptive mechanisms according to the underlying neurobiological state. Neuroendocrine normalization characterized the treatment-responsive model, whereas selective behavioral improvement in TRD was associated with coordinated engagement of prefrontal Bdnf - and Cnr1 -related pathways. These findings support phenotype-informed, mechanism-guided neuromodulation strategies for depression.
Clinical research Preliminary results (open-label)

Preliminary data: Ketamine efficacy in TRD varies by subtype, trauma history

Ketamine administered biomedically or as psychedelic-assisted therapy in treatment-resistant depression: Differing efficacy based on depressive subtype or presence of childhood trauma?
Why it matters ◈ Mixed
This study provides early evidence that biomedical ketamine may be more effective for melancholic depression than for non-melancholic subtypes in treatment-resistant depression (TRD). The lack of randomized controlled data and the open-label design limit definitive conclusions, but the findings highlight the importance of depressive subtyping and trauma history in tailoring ketamine-based interventions. Further research, especially on psychedelic-assisted ketamine with psychotherapy, is needed to clarify optimal treatment pathways and inform clinical practice.
ObjectiveThe ideas presented in this paper are based on a presentation at a festschrift event marking the retirement of Professor Gordon Parker from UNSW, Sydney. Drawing on Gordon's depressive subtyping approach and his critiques of a unitary view of major depressive disorder and treatment-resistant depression (TRD), we aim to (i) explore differing models of ketamine for TRD - biomedical versus 'psychedelic-assisted' therapy, and (ii) whether there may be differential efficacy in each approach based on subtype and/or childhood trauma.ConclusionPreliminary results from our study indicate in an open-label (but not randomised controlled) setting, biomedical ketamine may be superior in melancholic versus non-melancholic depression subtyped using Sydney Melancholia Prototypic Index. Studies of ketamine as a psychedelic agent combined with psychotherapy are lacking. We outline an empirical approach to determine whether ketamine with integrated psychotherapy has differential efficacy based on depressive subtype or past childhood trauma.
Neuroscience Peer-reviewed study

Multimodal imaging links synaptic density to plasticity after DMT and ketamine

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study
Why it matters ▲ Favorable
This study provides cross-modal validation for scalable neuroimaging and EEG markers as surrogate measures of synaptic plasticity in humans, including after exposure to DMT and ketamine. The findings suggest that PET, DWI, and EEG can reliably track neuroplasticity-related changes, which is critical for translational psychedelic research and clinical trials. While no significant post-drug changes were found in synaptic density or plasticity markers, the robust coupling between these measures supports their use as endpoints in future intervention studies.
Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human synaptic density, but its relationship to complementary, more scalable neuroimaging measures of structural and functional plasticity remains uncharacterised. We combined [11C]-UCBJ PET, diffusion weighted imaging (DWI/NODDI), resting-state functional magnetic resonance imaging (rs-fMRI), and electroencephalography (EEG)-based sensory tasks (roving mismatch negativity, MMN; visual long-term potentiation, vLTP) in 18 healthy volunteers to test the relationship between synaptic terminal SV2A density and complementary structural and functional neuroplasticity measures, and whether these relationships were reproducible following pharmacological challenge with ketamine (n = 11) or N,N-dimethyltryptamine (DMT; n = 7). There were no statistically significant differences in PET-derived SV2A binding potential (BPND), DWI-derived neurite orientation dispersion (ODI) and structural weighted degree (SWD), EEG-derived MMN repetition suppression, and late-phase vLTP P2 potentiation, 1 to 8 days following DMT and ketamine exposure compared to baseline. BPND was coupled with ODI across cortical regions before and after pharmacological challenge, and this relationship was tighter within visual, attentional, and frontoparietal control brain networks. SWD showed a weaker, more spatially restricted association with BPND, primarily in regions belonging to the limbic and visual brain networks, but was not replicated post-drug. No consistent association was found between BPND and functional weighted degree (FWD), derived from rs-fMRI, at baseline or after pharmacological challenge. Frontotemporal BPND was positively associated with MMN repetition suppression (r = 0.61), and occipital BPND with late-phase vLTP P2 potentiation (r = 0.54), with the MMN-BPND association replicating after pharmacological challenge (r = 0.49). These findings link synaptic terminal SV2A density in the living human brain to neurite architecture and the capacity for short-term and Hebbian-like long-term synaptic plasticity, while dissociating these relationships from generic functional connectivity and magnitude of sensory-evoked responses. These data provide cross-modal validation for DWI- and EEG-derived measures as biological indices and surrogate measures of human synaptic plasticity.
Neuroscience Preclinical study published

Psilocybin and norbaeocystin show acute anxiogenic effects in rats

Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats
Why it matters ◈ Mixed
This preclinical study finds that both psilocybin and its analog norbaeocystin can induce acute, sex- and dose-dependent anxiety-like behavior in rats, with effects that dissipate by 24 hours. The findings highlight potential short-term adverse effects relevant to safety and patient selection in future clinical trials. The lack of persistent anxiogenic effects and the nuanced sex differences may inform both risk assessment and therapeutic protocol design as these compounds move toward human studies.
RATIONALE: Psychedelics are considered to be promising therapeutic agents that could effectively treat several psychological disorders. However, these compounds can exert acute adverse effects that limit their practicality. OBJECTIVES: Across three experiments, the present study examined the acute and delayed effects of psilocybin (PSIL) and its putatively non-hallucinogenic analog, norbaeocystin (NOR), on anxiety-like behavior and the influence of the female estrous cycle on acute response to the compounds. METHODS: In Experiment 1, rats were treated with PSIL or NOR (0.3-1 mg/kg) and tested on the elevated plus maze (EPM) or open field 30 min later. In Experiment 2, male and female rats were treated with 1 mg/kg PSIL or NOR and tested on the EPM 24 h later. In Experiment 3, we tracked the female estrous cycle to determine whether it was associated with the acute effects of PSIL or NOR on EPM behavior and the acoustic startle response (ASR). RESULTS: In Experiment 1, both PSIL and NOR exerted acute anxiogenic effects in males, while only the highest dose of PSIL increased anxiety-like behavior in females. In Experiment 2, neither PSIL nor NOR impacted EPM behavior the next day. In Experiment 3, PSIL, but not NOR, had acute anxiogenic effects on EPM behavior, effects that were independent of estrous stage. Females treated with PSIL during diestrus exhibited some signs of greater ASR habituation. CONCLUSIONS: PSIL and NOR exerted transient dose- and sex-specific effects on anxiety-like behavior, which may inform their use as novel therapeutics.
Neuroscience Peer-reviewed neuroscience study

Arousal-linked neuronal avalanches operate near criticality in cortex

Arousal-informed neuronal avalanches operate near criticality
Why it matters ▲ Favorable
This study advances understanding of how large-scale neural networks in the awake brain operate near a critical point, optimizing information processing through arousal-linked avalanches. While not directly about psychedelics, the findings may inform future research on how altered states—including those induced by psychedelics—modulate cortical criticality and network dynamics. This could provide a mechanistic basis for observed changes in perception and cognition during psychedelic experiences.
Cortical networks are thought to operate near a "critical point" that optimizes information processing, but this has been difficult to test at single-cell resolution across large brain areas, as narrow fields of view miss overlapping neural avalanches, causing subcritical estimates, Using mesoscopic two-photon calcium imaging in awake mouse visual cortex, we recorded thousands of neurons and applied convolutional non-negative matrix factorization to decompose population activity into distinct, overlapping spatiotemporal avalanches. Rather than occupying a single dynamical state, we find that the cortex hosts multiple overlapping subnetworks distributed across a phase diagram at varying distances from the critical point. Arousal-linked avalanches propagate widely and operate nearest the critical point, showing optimized dynamic range, minimized algorithmic complexity, and maximized temporal entropy. Our results reveal how the awake brain tunes parallel near-critical subnetworks to support robust sensory computation.
Industry Training initiative

Preparing Pharmacists for Psychedelic Medicine

Why it matters ▲ Favorable
Efforts to prepare pharmacists for psychedelic medicine signal growing anticipation of regulated access and the need for specialized training. This development is relevant for ensuring safe dispensing, patient education, and integration into mainstream healthcare. While not a legal or regulatory change, it reflects industry and professional readiness for potential future approvals.
Industry Webinar announced

Vicente LLP Webinar: Psychedelic Medicine After FDA Approval

[Vicente LLP Webinar] Psychedelic Medicine After FDA Approval: What Clinics and Investors Need to Know
Why it matters ▲ Favorable
This webinar signals growing industry and legal attention to the post-approval landscape for psychedelic medicine in the US. It is relevant for clinics and investors preparing for regulatory, operational, and commercial changes following FDA approval. While not a direct policy move, such events help shape best practices and readiness for a rapidly evolving field.
State policy Audit completed

Oregon’s Psilocybin Centers Pass First Safety Audit, Costs Raise Access Issues

Oregon’s Licensed Psilocybin Centers Pass First Independent Safety Audit, but High Costs Raise Access Concerns
Why it matters ◈ Mixed
Oregon's licensed psilocybin centers have passed their first independent safety audit, validating the regulatory framework's effectiveness in ensuring client safety. However, the report highlights that high service costs remain a significant barrier to access, raising equity and public health concerns. This development provides critical data for other jurisdictions considering regulated psychedelic access and underscores the need to balance safety with affordability. Operators, policymakers, and researchers should monitor how Oregon addresses these cost and access challenges.
Clinical research Systematic review published

Systematic review: Neuroplasticity and experience in psychedelic therapy

Neuroplasticity, Psychedelic Experience, and Therapeutic Context in Psychedelic-Assisted Psychotherapy: A Systematic Review and Narrative Synthesis
Why it matters ◈ Mixed
This systematic review synthesizes evidence that both neuroplastic changes and acute psychedelic experiences, in the context of psychotherapy, contribute to clinical outcomes in psychedelic-assisted therapy. The review highlights rapid improvements in depression, anxiety, and substance use, but notes that the necessity of the subjective psychedelic experience for lasting benefit remains unproven. This integrated model informs future trial design, mechanistic research, and clinical protocols, but underscores persistent uncertainty about causality and optimal therapeutic components.
Background: Psychedelic-assisted psychotherapy has re-emerged as a potential treatment for depressive, anxiety-related, and substance-use disorders. However, the relative contribution of pharmacologically induced neuroplasticity, acute psychedelic phenomenology, and psychotherapeutic/contextual factors to sustained clinical benefit remains uncertain. Objective: To critically synthesize clinical, human mechanistic, experiential, and translational evidence concerning the mechanisms underlying psychedelic-assisted psychotherapy, with particular emphasis on whether neuroplastic effects can be distinguished from the acute psychedelic experience. Methods: A systematic review with structured narrative synthesis was conducted using PubMed/MEDLINE, Embase, APA PsycINFO, Scopus, Web of Science Core Collection, CENTRAL, Google Scholar, ClinicalTrials.gov, and WHO ICTRP from database inception to 30 September 2026. English-language peer-reviewed studies of classic serotonergic psychedelics were included. Evidence was organized into clinical efficacy, human mechanistic, experiential/contextual, and preclinical/translational streams. Risk of bias was assessed using design-appropriate tools. Results: Sixty-six reports representing 60 study/review units were included, comprising 15 human clinical primary reports, 13 human mechanistic/experiential reports, 7 preclinical/translational primary reports, and 31 systematic reviews/meta-analyses. Clinical studies demonstrated rapid improvements in depression, anxiety, alcohol-use disorder, and tobacco-use outcomes, although durability and magnitude varied by comparator and design. Human mechanistic studies identified alterations in cerebral blood flow, functional connectivity, network integration, glutamatergic signalling, and peripheral neurotrophic markers. Mystical-type experience, ego dissolution, and related acute phenomena were repeatedly associated with therapeutic response, but these associations were not sufficient to establish causality. Preclinical studies showed robust dendritic and synaptic plasticity and provided evidence that some plasticity-related and antidepressant-like effects can be dissociated from hallucinogenic-like behavioural proxies. Conclusion: Current evidence supports an integrated model in which psychedelic-induced neuroplasticity, acute subjective experience, and psychotherapeutic context interact to shape clinical outcome. Definitive human evidence establishing whether psychedelic phenomenology is necessary for durable therapeutic benefit remains lacking.
Clinical research Review published

Review: Antidepressants, cognition, and future directions for MDD treatment

Antidepressants and cognitive function in major depressive disorder: Mechanisms, clinical evidence, and implications for precision treatment
Why it matters ◈ Mixed
This review synthesizes evidence on how traditional antidepressants affect cognitive function in major depressive disorder (MDD), highlighting the need for more rigorous trials focused on cognition as a primary outcome. It notes that emerging treatments—including ketamine and psychedelic compounds—may offer new avenues for addressing cognitive dysfunction in MDD, but current evidence is limited. The article underscores the importance of large, standardized studies and precision medicine approaches, which is relevant for researchers designing future psychedelic trials targeting cognitive outcomes.
Cognitive impairment is a core feature of major depressive disorder (MDD) and significantly impairs functional recovery. This review summarizes current evidence on the effects of antidepressants on cognitive function and discusses the underlying mechanisms. Antidepressants may exert their effects through multiple mechanisms, including modulation of monoaminergic neurotransmission, enhancement of neuroplasticity, and regulation of stress and inflammatory pathways. Available studies indicate that antidepressants differ in their cognitive benefits, with vortioxetine showing the most consistent procognitive evidence. Duloxetine, bupropion, and some augmentation strategies may also improve specific cognitive domains, though the evidence is limited. Importantly, cognitive improvement may result from direct drug effects on cognition or indirectly via alleviation of depressive symptoms, highlighting the need for mediation analyses in future research. In patients with late-life depression, vortioxetine and duloxetine have shown relatively clear benefits, and augmentation with cognitive enhancers has demonstrated some potential. The long-term cognitive protective effects of antidepressants remain unconfirmed. Immuno-metabolic depression subtypes, high-dose-related adverse effects, and comorbidity with anxiety and sleep disorders may constitute important sources of residual cognitive deficits. Emerging treatments such as ketamine, psychedelic compounds, and interventions targeting the gut-brain axis may offer new opportunities for addressing cognitive dysfunction in MDD. Current evidence is limited by small sample sizes and heterogeneous cognitive assessments. Future research should prioritize large, randomized controlled trials with cognition as the primary endpoint, using standardized assessment tools. A better understanding of the cognitive profiles and mechanisms of antidepressants may support precision medicine strategies and promote functional recovery in patients with MDD.
Clinical research Case report published

ECT and Ketamine Used in POLG-Related Disorder: Case Report

Use of Electroconvulsive Therapy and Ketamine in a POLG-Related Disorder.
Why it matters ◈ Mixed
This case report describes the use of ketamine and electroconvulsive therapy (ECT) in a patient with a POLG-related mitochondrial disorder. While not a controlled trial, it highlights the off-label clinical exploration of ketamine in rare neurological conditions. The report may prompt further investigation into safety and efficacy of ketamine in populations with mitochondrial dysfunction, but does not directly impact policy or legal status. Researchers should note the unique risks and considerations for psychedelic or dissociative agents in metabolic disorders.
Clinical research Narrative review published

AI in FDA pharmacovigilance for neuropsychiatric drugs: review and future directions

Artificial Intelligence-Enabled Pharmacovigilance for Neuropsychiatric Therapies: Advancing U.S. Drug Safety Surveillance and Regulatory Decision-Making
Why it matters ◈ Mixed
This review highlights both the limitations of current FDA post-marketing surveillance systems for neuropsychiatric drugs—including esketamine—and the potential for AI tools to enhance adverse event detection, especially for subjective or delayed effects. While AI shows promise for structuring and prioritizing safety signals, regulatory decisions must remain clinician- and regulator-led due to risks of bias and data limitations. The work underscores the need for prospective AI validation and better integration of real-world data, which could impact future regulatory and industry practices for psychedelic and related therapies.
Neuropsychiatric medications, including antidepressants, antipsychotics, mood stabilizers, anxiolytics, and newer agents such as esketamine, are widely prescribed, but their adverse effects are often subjective, delayed in onset, and difficult to separate from the illness being treated.Post-marketing surveillance in the United States relies on the FDA Adverse Event Reporting System (FAERS), MedWatch, the Sentinel System, and Risk Evaluation and Mitigation Strategies (REMS).This narrative review, reported according to the Scale for the Assessment of Narrative Review Articles (SANRA), examines how well these systems detect neuropsychiatric adverse events and what artificial intelligence (AI) can add.PubMed/MEDLINE, Embase, and Web of Science were searched for literature published since January 2000, supplemented by regulatory and institutional sources.Spontaneous reporting misses most adverse drug reactions, while stigma, diagnostic overshadowing, and uncertainty about whether a symptom reflects the drug or the disorder further reduce reporting of psychiatric effects.Disproportionality signals, such as those reported for dissociation and suicidal ideation with esketamine, need cautious interpretation because notoriety bias, solicited reporting under REMS, and confounding by indication can inflate them.Long-latency effects such as tardive dyskinesia and antipsychotic-induced metabolic change fall outside the observation windows of premarket trials and most spontaneous reports.Natural language processing (NLP) can retrieve adverse events documented in free-text psychiatric records with good accuracy, and large language models (LLMs) show early promise for structuring adverse event narratives, but most AI studies are retrospective proofs of concept, and models trained on biased data can reproduce existing inequities.AI is therefore best used to widen and prioritize signal detection, with causality assessment and regulatory decisions remaining with clinicians and regulators.Priorities include prospective evaluation of AI tools in live pharmacovigilance workflows, linkage of FAERS with electronic health record and claims data, point-ofcare reporting tools, and efforts to reduce the stigma that discourages reporting of psychiatric adverse effects.
Clinical research Literature review published

Review: Intranasal esketamine effective for treatment-resistant depression, acute suicidality

Eficácia e segurança da esquetamina intranasal no manejo da depressão maior resistente ao tratamento e ideação suicida aguda: Evidências clínicas e moleculares
Why it matters ▲ Favorable
This integrative review synthesizes recent clinical and molecular evidence supporting intranasal esketamine as a rapid, effective, and safe intervention for treatment-resistant depression (TRD) and acute suicidal ideation. The findings highlight statistically and clinically significant reductions in depression scores within hours of administration, with particular benefit in psychiatric emergencies. The review also underscores the need for careful hemodynamic monitoring and integration with long-term maintenance therapy. This strengthens the clinical case for esketamine in acute psychiatric care and may inform future guidelines and access pathways.
O Transtorno Depressivo Maior (TDM) permanece como uma das condições psiquiátricas mais incapacitantes globalmente, sendo que cerca de um terço dos pacientes evolui para o quadro de Depressão Resistente ao Tratamento (DRT), frequentemente acompanhado de ideação suicida aguda com intenção iminente. O modelo farmacológico clássico, alicerçado no incremento monoaminérgico sináptico, esbarra em limitações críticas de latência de resposta terapêutica (duas a seis semanas) e taxas insatisfatórias de remissão sustentada. Diante dessa lacuna, o cloridrato de esquetamina administrado por via intranasal emergiu como um paradigma inovador, atuando como antagonista não competitivo dos receptores N-metil-D-aspartato (NMDA) e desencadeando cascatas glutamatérgicas neuroplásticas mediadas pela ativação de receptores AMPA, secreção de BDNF e transdução via mTORC1. O objetivo deste trabalho foi analisar as evidências científicas recentes a respeito da eficácia clínica, mecanismos moleculares e perfil de segurança da esquetamina intranasal no manejo da DRT e na contenção da ideação suicida aguda. Trata-se de uma revisão integrativa da literatura realizada nas bases de dados PubMed/MEDLINE, SciELO, Scopus e Web of Science, abrangendo ensaios clínicos randomizados, revisões sistemáticas com metanálises e estudos observacionais prospectivos publicados entre 2021 e 2026. A literatura contemporânea evidencia reduções clínicas estatisticamente significantes e clinicamente relevantes nos escores da Montgomery-Åsberg Depression Rating Scale (MADRS) a partir de 2 a 4 horas pós-administração, mantendo-se superiores ao placebo e a comparadores ativos em protocolos de indução de quatro semanas associados a antidepressivos orais de primeira linha. No cenário de emergência psiquiátrica com ideação suicida ativa, a intervenção rápida reduz substancialmente o risco no período periemergencial, embora a manutenção a longo prazo demande estabilização farmacológica de base. Conclui-se que a esquetamina intranasal representa um recurso eficaz e seguro para intervenção rápida em DRT e emergências suicidas, exigindo monitoramento hemodinâmico rigoroso e integração a planos terapêuticos de manutenção longitudinal.
Preclinical research Systematic review published

Systematic review: Esketamine's neurobehavioral effects in zebrafish

EFEITOS NEUROCOMPORTAMENTAIS DA ESKETAMINA EM PEIXES-ZEBRA: UMA REVISÃO SISTEMÁTICA
Why it matters ◈ Mixed
This systematic review synthesizes preclinical evidence that esketamine alters neurodevelopment and behavior in zebrafish, with dose- and exposure-dependent effects. While acute exposure may induce hyperactivity via NMDAR inhibition, prolonged or embryonic exposure impairs activity and causes neurotoxicity. The findings highlight potential safety concerns for repeated or high-dose esketamine use, underscoring the need for caution in clinical translation and further research into long-term neuropsychiatric risks.
Introdução: A depressão e os transtornos de ansiedade estão entre as principais causas de incapacidade global. A esketamina (ESK), antagonista dos receptores NMDA, é alternativa promissora para a depressão resistente ao tratamento, mas persistem dúvidas sobre sua segurança neurocomportamental. Objetivos: Sintetizar as evidências pré-clínicas sobre os efeitos neurocomportamentais e neuropsiquiátricos da ESK em peixe-zebra (Danio rerio). Metodologia: Revisão sistemática nas bases Embase, PubMed, Scopus e Web of Science até junho de 2026, incluindo estudos pré-clínicos com Danio rerio que avaliaram desfechos comportamentais. Resultados e Discussão: Dos 121 registros, cinco estudos, todos chineses, publicados de 2024 a2026) foram incluídos. A ESK alterou a locomoção e a resposta a estímulos de forma dependente da dose e da janela de exposição: altas doses embrionárias causaram hipoatividade, enquanto a exposição aguda larval induziu hiperatividade mediada pela inibição do NMDAR. Por outro lado, concentrações ambientais produziram efeitos anestésicos sutis. Observaram-se ainda alterações transcriptômicas, estresse oxidativo e apoptose neuronal. Conclusão: A ESK compromete o neurodesenvolvimento e a função comportamental do peixe-zebra, com efeito bifásico dependente de dose e janela: desinibição na exposição aguda e hipoatividade na exposição prolongada. O benefício antidepressivo parece atrelado à modulação glutamatérgica aguda e autolimitada, sinalizando cautela ante exposições repetidas ou elevadas.
Clinical research Meta-analysis published

Meta-analysis: Ketamine augmentation in treatment-resistant depression

Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis.
Why it matters ▲ Favorable
This systematic review and meta-analysis synthesizes current evidence on strategies to augment intravenous ketamine for treatment-resistant depression, providing a clearer picture of efficacy and safety profiles. The findings can inform clinical protocols, guide future trial designs, and help refine patient selection criteria. Policymakers and payers may reference these results when considering coverage or regulatory frameworks for ketamine-based therapies.
Clinical research Peer-reviewed study published

LSD study details molecular and hemodynamic brain effects

Investigating molecular and hemodynamic effects of LSD in the human brain.
Why it matters ▲ Favorable
This peer-reviewed study advances understanding of LSD's effects on human brain function at the molecular and vascular level. The findings may inform future clinical trial design, safety monitoring, and mechanism-based therapeutic hypotheses. Such translational research is critical for regulatory and medical communities evaluating the risks and benefits of psychedelic-assisted interventions.
Community / Indigenous use Published study

Ho-Chunk healing: Peyote's role in trauma recovery and cultural resilience

Sacred Medicine: Use of Psychogenic Peyote within Ho-Chunk Healing
Why it matters ▲ Favorable
This study highlights the longstanding therapeutic and cultural significance of peyote within the Ho-Chunk community and the Native American Church. It provides valuable context for understanding indigenous models of trauma recovery and underscores the ethical and legal complexities of regulating traditional psychedelic use. While not a clinical trial or policy move, it informs debates on access, religious freedom, and cultural preservation as psychedelic regulation evolves.
Current interest in the effectiveness of psychedelic-assisted recovery from trauma and other mental health conditions has been increasing. The Native American Church’s (NAC) use of the psychoactive plant peyote for over 100 years within sacred ritual has been a unique approach to religious expression and individual as well as collective healing, especially when addressing cultural trauma as well as individual experiences of PTSD, substance use, depression, and illness. Acceptance of the rite by some Ho-Chunk (Winnebago) at the turn of the 20th century is shown to be a form of both cultural resistance to settler colonial hegemony and a process of personal recovery from trauma.
Neuroscience Peer-reviewed publication

Psilocybin+cGMP modulation reduces head twitch, preserves antidepressant effect

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response.
Why it matters ▲ Favorable
This preclinical study suggests that enhancing cGMP signaling during psilocybin administration can reduce the head twitch response—a proxy for psychedelic effects in animal models—while maintaining the compound's antidepressant efficacy. This finding could inform the development of next-generation psychedelic therapeutics with fewer hallucinogenic side effects, potentially improving patient acceptability and regulatory prospects. The synaptic proteome restructuring observed may also yield new biomarkers or targets for neuropsychiatric drug development.
Neuroscience Preclinical study published

Acute BLA DBS shows no behavioral effects in rats

Acute unilateral DBS of the basolateral amygdala does not affect motricity, anxiety-like behavior, or fear memory consolidation in rats
Why it matters ◈ Mixed
This preclinical study finds that acute unilateral deep brain stimulation (DBS) of the basolateral amygdala (BLA) does not significantly alter motricity, anxiety-like behavior, or fear memory consolidation in rats. These findings suggest that, under the tested parameters, BLA DBS appears tolerable and does not acutely disrupt key behavioral domains. While not directly related to psychedelics, the results inform the safety profile of neuromodulation approaches for psychiatric disorders, which may intersect with psychedelic research in future translational work.
Deep brain stimulation (DBS) is an alternative to ablative functional neurosurgeries. The basolateral amygdala (BLA) is a potential DBS target for treating psychiatric disorders. However, understanding the associated behavioral and cognitive effects is necessary for safety and tolerability concerns. Therefore, we investigated potential acute effects of unilateral BLA DBS. Adult male Wistar rats were implanted with monopolar electrodes in the right BLA. In Experiment 1, different groups of animals were stimulated for 10 min with either high-frequency (HFS, 130 Hz) or low-frequency (LFS, 20 Hz) stimulation using different stimulation intensities (0 [Control], 10, 50, or 100 µA). Immediately after stimulation, animals were tested in the elevated plus-maze (EPM) and subsequently in the open field test (OFT). In Experiment 2, two groups of animals were subjected to a fear-conditioning protocol and stimulated with HFS or LFS (50 µA) immediately after conditioning. Animals were then tested for short- (2 h) and long-term (24 h) fear memory consolidation. BLA DBS showed no significant effects on: (i) anxiety-like behavior expression for HFS (p = 0.46) or LFS (p = 0.37); (ii) locomotor activity (HFS, p = 0.12; LFS, p = 0.60), in terms of distance traveled in the OFT, or (iii) fear memory consolidation (HFS, p = 0.31; LFS, p = 0.68). Under the stimulation parameters and experimental conditions tested, acute unilateral BLA DBS did not significantly affect spontaneous locomotor activity, anxiety-like behavior, or fear memory consolidation in rats. These results provide information relevant to the tolerability and safety of amygdala DBS.
Clinical research Case report published

Oral ketamine-assisted psychotherapy leads to remission in DNSD: case report

Oral Ketamine-Assisted Psychotherapy Leading to Prolonged Remission in Recurrent Dissociative Neurological Symptom Disorder With Mutism: A Case Report
Why it matters ▲ Favorable
This single case report describes prolonged remission of mutism in a patient with dissociative neurological symptom disorder following oral ketamine-assisted psychotherapy. While limited by its anecdotal nature, the report highlights a potential new indication for ketamine in treatment-resistant functional neurological disorders and underscores the importance of the therapeutic frame. Further controlled studies are needed to assess efficacy and safety, but this may inform future research directions and off-label clinical interest.
Dissociative neurological symptom disorder (DNSD), termed functional neurological symptom disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), presents with neurological symptoms not explained by structural disease.The first line treatment of DNSD is psychotherapy, but when the conflict maintaining the symptoms cannot be put into words, psychotherapy often stalls.This report describes a 56-year-old woman with a four-year history of episodic loss of consciousness and progressive speech loss, with normal neurological investigations.Escitalopram, intravenous ketamine infusions given without psychotherapy, and venlafaxine produced no meaningful benefit.A 30-day inpatient program of psychotherapy, family therapy, and speech therapy restored her speech, but she relapsed into complete mutism four months after discharge, and no stressor could be identified.A lorazepam-assisted interview produced sedation without speech.She then received six alternate-day sessions of oral ketamine-assisted psychotherapy, titrated from 50 mg to 150 mg, within a psychodynamically informed frame; while venlafaxine 225 mg/day was continued and family therapy was delivered alongside.She spoke a few words in the third session (100 mg) and conversed spontaneously in the fourth (150 mg), describing a conflict between a rigid moral self-image of never being greedy and unspoken distress over a family property dispute.Speech has been sustained for more than one year, and all psychotropic medication has since been withdrawn.The report proposes that, this single case is hypothesisgenerating.It suggests that ketamine may be a useful and a better abreactive agent in selected patients with treatment-resistant DNSD, and that the therapeutic frame is also essential for the improvement to happen, and further controlled comparison with benzodiazepine-assisted interviews is warranted in the future.
Clinical research Review published

Review: Psychedelic-assisted therapy—history, evidence, and prospects (Ukraine)

Психоделічно-асистована терапія: ретроспективний огляд і сучасні перспективи
Why it matters ◈ Mixed
This comprehensive review summarizes the evolution and current state of psychedelic-assisted therapy research, with a focus on clinical evidence for psilocybin, MDMA, LSD, and ayahuasca in mental health. It highlights promising results but stresses that the evidence base remains insufficient for broad clinical adoption, especially in Ukraine. The article underscores the need for large-scale, methodologically robust studies and careful integration of psychedelics into mental health care, considering legal and ethical frameworks. This is a useful resource for context, but does not itself represent a policy or regulatory shift.
У статті здійснено ретроспективний огляд розвитку психоделічної терапії та проаналізовано сучасний стан досліджень її ефективності у лікуванні психічних розладів. Простежено еволюцію використання психоделічних речовин – від традиційних духовних і лікувальних практик корінних народів через ранні клінічні дослідження середини ХХ століття до сучасного етапу, так званого «психоделічного ренесансу». Показано, що відновлення наукового інтересу стало можливим зав- дяки розвитку нейронаук, удосконаленню методології клінічних випробувань і зміні суспільного ставлення до психоделіків як потенційних терапевтичних засобів. Особливу увагу приділено сучасним клінічним дослідженням психоделічно-асистованої терапії із застосуванням псилоцибіну, MDMA, LSD, аяуаски та інших психоделіків. Проаналізовано наявні докази їх використання при депресивних і тривожних розладах, посттравматичному стресо- вому розладі, обсесивно-компульсивному розладі, залежностях, паліативній допомозі пацієнтам із невиліковними захворюваннями, а також окреслено перспективи застосування при інших психічних і поведінкових порушеннях. Підкреслено значення принципу «set and setting», відповідно до якого терапевтичний ефект психоделіків суттєво залежить від психологічної установки пацієнта та умов проведення терапії. У статті висвітлено сучасні міжнародні тенденції розвитку психоделічних досліджень, діяль- ність провідних наукових центрів і професійних організацій, а також стан розвитку цього напряму в Україні. Водночас наголошено, що, попри багатообіцяючі результати клінічних випробувань, дока- зова база поки що залишається недостатньою для широкого впровадження психоделічно-асисто- ваної терапії у клінічну практику. Зроблено висновок про необхідність проведення масштабних, методологічно якісних досліджень, що дозволять остаточно оцінити ефективність, безпечність і довгострокові наслідки застосування психоделіків, а також забезпечити їх науково, юридично та етично обґрунтовану інтеграцію в сучасну психологію, психіатрію та психотерапію.
Clinical research Review published

Review proposes diagnostic protocol for visual snow syndrome

Clinical evaluation of visual snow syndrome: a structured narrative review with proposed clinical diagnostic approach
Why it matters ◈ Mixed
This structured review synthesizes current knowledge on visual snow syndrome (VSS) and proposes a standardized clinical diagnostic approach, addressing a significant gap in routine practice. While not directly tied to psychedelics, VSS is sometimes reported as a persistent perceptual change following psychedelic use, making improved diagnosis relevant for adverse event monitoring and research on long-term effects. Standardizing VSS diagnosis could enhance future studies on the neurological impact of psychedelics and inform clinical risk assessment. The review also highlights the need for biomarkers and large-scale trials, which may intersect with psychedelic safety research.
Visual snow syndrome (VSS) is a chronic neurological condition marked by persistent, bilateral, pan-field visual static and a constellation of additional visual and non-visual symptoms. Affecting an estimate of 2% of the populations, VSS remains substantially underdiagnosed, as its symptoms overlap with migraine aura and structural ophthalmological disease, and no standardised diagnostic protocol currently exists. This structured narrative review synthesises evidence on the clinical features, pathophysiology, comorbidities, and differential diagnosis. It also proposes a stepwise diagnostic approach for routine practice, distinguished from the advanced, research-oriented evaluations used to investigate underlying mechanisms. Converging neuroimaging and electrophysiological evidence suggests cortical hyperexcitability and large-scale network dysfunction may underlie VSS, though the precise mechanisms remain incompletely understood. We recommend a multidisciplinary, patient-centred management approach and identify biomarker development, multicentre validation of the diagnostic approach, and large-scale interventional trials as research priorities.
Neuroscience Preclinical research

Suzetrigine analgesia potentiated by Nav1.7 null opioid mechanisms

Suzetrigine-evoked analgesia is potentiated by Nav1.7 null-related opioid mechanisms.
Why it matters ▲ Favorable
This study identifies a novel mechanism by which loss of Nav1.7 sodium channels in sensory neurons enhances endogenous opioid signaling, potentiating analgesia from suzetrigine and RGS antagonists. While not directly related to psychedelics, the findings may inform future pain management strategies and intersect with research on opioid systems, which are relevant to certain psychedelic mechanisms and comorbidities. The work is preclinical but could shape new approaches to analgesia, especially for inflammatory and potentially cancer pain.
The genetic evidence for an essential role of sodium channel Nav1.7 in human pain conditions is compelling. Unfortunately, potent selective channel blockers of Nav1.7 are not useful analgesics because they have deleterious side effects, particularly on the autonomic nervous system. Here we have evaluated the downstream mechanisms induced by Nav1.7 loss in utero. Nav1.1 compensates for loss of Nav1.7 in sensory neurons and antisense Nav1.1 oligonucleotides diminish excitability in Nav1.7 embryonic null sensory neurons. Enhanced endogenous opioid signalling contributes substantially to analgesia. This is linked to altered gene expression that potentiates opioid signalling through lowered levels of proteins that terminate G-protein signalling (RGS4 and RGS8). There is also enhanced opioid drive through increased enkephalin levels linked to lowered sodium levels in Nav1.7 null neurons. Opioid signalling is the main driver of analgesia, but enhanced potassium channel expression (KCNC4 KCNK2, KCNMB2, KCNAB3) all implicated in pain control, may also contribute to the small level of naloxone-resistant analgesia. These findings suggest a potential new route to analgesia, through mimicking the events at Nav1.7 null sensory neuron terminals. Here we demonstrate potentiation of suzetrigine-evoked analgesia with RGS antagonists alone or in combination with normally inactive doses of morphine in formalin-evoked pain and CFA-induced inflammatory pain. Intriguingly, no analgesia is observed with acute pain. Cancer pain is under investigation. These data are of potential clinical interest.
State policy State law in effect

Oregon psilocybin centers focus on safety, but costs remain high

Oregon's licensed psilocybin centers prioritize safety but remain highly expensive
Why it matters ◈ Mixed
Oregon's legal psilocybin centers are operational and emphasize safety protocols, but high session costs are limiting access for many potential clients. This raises equity concerns and may impact the scalability and public health impact of the state's pioneering model. The experience provides critical data for other jurisdictions considering regulated psychedelic access, highlighting the need to balance safety, affordability, and accessibility.
Clinical research Study published

Psilocybin providers follow safety guidelines, study finds

Why it matters ▲ Favorable
A new study reports that psilocybin providers are adhering to safety guidelines. This finding supports the credibility and legitimacy of regulated psychedelic services, which may help inform future policy and best practices. However, without details on methodology or jurisdiction, the impact is primarily reputational and incremental for the field.
Clinical research Randomized controlled trial results

RCT: Low-dose esketamine safe, effective for pain/sedation in emergency C-section

Clinical Effects of Low-Dose Esketamine During Emergency Conversion From Labor Epidural Analgesia to Category I Cesarean Section: A Randomized Controlled Trial of Maternal Hemodynamics, Analgesia, Sedation, and Neonatal Outcomes
Why it matters ▲ Favorable
This RCT provides evidence that low-dose IV esketamine can safely improve pain and sedation during emergency C-sections after failed epidural analgesia, without adverse effects on maternal hemodynamics or early neonatal outcomes. While not a psychedelic-dose study, it supports the safety and utility of sub-anesthetic ketamine analogs in acute care settings, which may inform broader clinical adoption and future research on peripartum applications. The absence of negative neonatal or cardiovascular effects is especially relevant for risk assessment and regulatory consideration.
Background: Emergency conversion from labor epidural analgesia to Category I cesarean section leaves little time for epidural top-up to produce a surgical block. We examined whether low-dose intravenous esketamine could provide short-term bridging analgesia and sedation while maintaining maternal hemodynamics, oxygenation, and early neonatal safety. Methods: In this randomized study, parturients requiring Category I cesarean section after labor epidural analgesia received either esketamine 0.15 mg/kg or normal saline 1 min before skin incision, together with epidural alkalinized lidocaine. The primary outcome was the longitudinal change in maternal systolic blood pressure during the 20-min observation window. Secondary outcomes included heart rate, SpO2, intraoperative pain, surgeon satisfaction with muscle relaxation, Ramsay sedation score, and neonatal Apgar scores. We analyzed repeated continuous outcomes with linear mixed-effects models and repeated binary outcomes with generalized estimating equations. The single post-administration Ramsay outcome was analyzed using logistic regression. Apgar scores were summarized descriptively using medians, interquartile ranges, and counts.Results: We analyzed 55 parturients, 31 in the esketamine group and 24 in the normal saline group. Esketamine did not meaningfully alter the systolic blood pressure trajectory. Heart rate and SpO2 showed broadly similar patterns between groups, with no signal of esketamine-related respiratory deterioration. The esketamine group had lower odds of intraoperative pain at 5, 15, and 20 min and a higher probability of target Ramsay sedation. Surgeon satisfaction with muscle relaxation showed no clear between-group difference. Apgar scores remained high in both groups. Conclusion: Low-dose intravenous esketamine 0.15 mg/kg may be a practical bridging adjunct during emergency conversion from labor epidural analgesia to Category I cesarean section. It improved early pain control and target sedation without a clear adverse signal in systolic blood pressure, heart rate, oxygenation, or early Apgar scores. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2600121948; retrospectively registered.
Industry / Legal Commentary Op-ed published

Op-ed highlights liability risks in ketamine's clinical use

Opinion | The Liability Behind Ketamine's Promise
Why it matters ◈ Mixed
Growing attention to legal liability may influence ketamine clinics, prescribers, and insurers. While not a regulatory action, this opinion piece signals increasing scrutiny of the legal and ethical frameworks surrounding ketamine therapy. Such discourse can shape public perception, investor confidence, and future policy debates, particularly as off-label use expands. Stakeholders should monitor for potential downstream effects on access and practice standards.
Clinical research Randomized trial results

Psilocybin plus MBSR boosts mindfulness, depression outcomes in healthcare workers

Mystical experiences mediate the effects of psilocybin-assisted psychotherapy + mindfulness-based stress reduction on trait mindfulness and depression symptoms: mechanistic results from a randomized controlled trial
Why it matters ▲ Favorable
This small RCT provides mechanistic evidence that mystical experiences mediate the antidepressant and mindfulness-enhancing effects of psilocybin-assisted group therapy combined with Mindfulness-Based Stress Reduction in frontline healthcare workers. The findings support the Mindfulness-to-Meaning Theory and suggest synergistic effects between psychedelics and established behavioral interventions. However, the sample size is limited and results are exploratory, warranting larger confirmatory studies before influencing practice or policy.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized. Drawing on the Mindfulness-to-Meaning Theory (MMT), we hypothesized that psilocybin-occasioned mystical experiences would serve as the primary mechanism linking psilocybin-assisted therapy to improvements in trait mindfulness and depressive symptoms. Methods Frontline physicians and nurses (N=25) with COVID-related depression were randomized 1:1 to 8-week MBSR alone or MBSR plus group psilocybin-assisted therapy (25mg). Trait mindfulness (FFMQ-15), savoring capacity (BSI), and nondual awareness (NADA-trait) were assessed at baseline and 2 weeks. FFMQ-15 was also assessed at 6 months post intervention. Mystical experience intensity (MEQ-30) was assessed post-dosing session or post MBSR mindfulness retreat. Mediation analyses tested whether MEQ-30 mediated treatment effects on mindfulness and depression changes. Results Twenty-two participants completed 2-week assessments. ANCOVA showed significant between group effects favoring the MBSR + psilocybin treatment arm on mindfulness gains as measured by the FFMQ-15 (F(1,19)= 5.53, FDR-corrected p=0.045) and the BSI (F(1,19)=9.08, FDR-corrected p= 0.02) at the 2 week primary endpoint. In exploratory mediation analyses, intensity of mystical experience showed significant indirect effects on both change in trait mindfulness and depressive symptoms. Conclusions Adding group psilocybin intervention to an MBSR curriculum augmented mindfulness gains. Exploratory mediation analyses identified significant indirect effects of mystical experience intensity on both trait mindfulness and depressive symptom change; these findings require confirmation in larger samples.
Neuroscience Systematic review published

BDNF biomarkers reviewed for PTSD pathogenesis and prognosis

Brain-Derived Neurotrophic Factor in the Pathogenesis of Posttraumatic Stress Disorder: From Neurobiology to Biomarker
Why it matters ◈ Mixed
This systematic review clarifies the complex role of BDNF system dysfunction in PTSD and highlights the limitations of using total BDNF as a standalone biomarker. The findings support the integration of multi-modal BDNF-related measures (genetic, epigenetic, protein, and microRNA) into multifactorial models for prognosis and personalized therapy. This evidence base is relevant for psychedelic research, as BDNF modulation is a hypothesized mechanism of action for several compounds, and may inform future trial design and biomarker selection for PTSD interventions.
Background. Posttraumatic stress disorder (PTSD) is one of the most prevalent and socially significant consequences of exposure to extreme stress. Its pathogenesis involves impairments in neuroplasticity, in which brain-derived neurotrophic factor (BDNF) plays a key role. In recent decades, the potential of using BDNF system components as biomarkers for objective diagnosis, disease prognosis, and personalized therapy in PTSD has been actively investigated; however, the data remain contradictory and require systematization. The goal was to systematize and summarize current evidence on the role of BDNF in the pathogenesis of PTSD, to examine the molecular, genetic, and epigenetic aspects of its dysfunction, and to evaluate the diag­nostic and prognostic potential of BDNF system components as possible biomarkers. Materials and methods. A systematic literature search was conducted in PubMed, Scopus, Web of Science, eLibrary, and Google Schol­ar databases for the period 2000-2025 in accordance with PRISMA guidelines, using keywords reflecting the relationship between BDNF and PTSD. Original clinical and experimental studies, meta-analyses, and systematic reviews in English and Russian were included. Results. A multi-layered nature of BDNF system dysfunction in PTSD was shown, ranging from region-specific changes in protein expression to genetic and epigenetic alterations. Controversies in peripheral BDNF levels were identified, attributable to differences in biomaterial type, protein form, and sample heterogeneity. Assessment of mature BDNF, the proBDNF/mBDNF ratio, BDNF gene promoter methylation, and regulatory microRNAs (miR-182-5p, miR-9-5p, miR-204-5p) demonstrated prognostic value, being associated with symptom severity, chronicity, and treatment response. The use of total BDNF as an independent diagnostic marker for PTSD is currently not justified. The most promising approach involves integrating a panel of BDNF-related measures (genotype, epigenetic marks, mature protein level, microRNAs) into multifactorial models for disease prognosis and personalized therapy.
Preclinical research Review published

AI advances in preclinical drug development reviewed

Unleashing AI for preclinical drug development
Why it matters ▲ Favorable
AI-driven methods are accelerating preclinical drug discovery, design, and safety assessment, including for complex modalities relevant to psychedelic research. This review synthesizes state-of-the-art generative and predictive approaches, highlighting their potential to streamline candidate identification, mechanistic studies, and toxicity prediction. While not specific to psychedelics, these advances could materially impact the pace and precision of novel compound development and translational research in the field.
Artificial intelligence (AI) is reshaping preclinical drug development across target discovery, therapeutic design, synthesis, functional characterization and safety assessment. In this review, we present an integrated view of AI across the preclinical pipeline, beginning with target identification, modality selection and representation learning for molecular, protein, structural, cellular and multimodal data. We then examine major generative modeling paradigms including autoregressive, latent-variable, diffusion, flow-based and guided approaches and their applications across small molecules, peptides, enzymes, antibodies, Tcell receptors and mRNA therapeutics. We discuss how these methods support de novo design, structure- and pocket-conditioned generation, sequence–structure co-design, affinity and activity optimization, developability engineering and synthesis-aware discovery. We further review AI-enabled retrosynthesis, reaction prediction and closed-loop experimental optimization, emphasizing the distinction between computational synthesizability and experimentally executable chemistry. Beyond molecular generation, we organize functional prediction from binding and kinetics through target engagement, pharmacological activity, mechanism of action, pathway response and phenotypic outcome. We also examine singlecell perturbation modeling, organoid-based drug-response prediction, toxicity and off-target assessment, and prospective validation across therapeutic modalities. Across these areas, we highlight the importance of uncertainty estimation, out-of-distribution generalization, reproducibility and experimentally grounded benchmarking. Finally, we discuss how integrating generative AI, mechanistic biology and iterative design–make–test–analyze cycles could transform AI from isolated predictive tools into decision-support systems for preclinical drug development.
Clinical research Living meta-analysis published

Living meta-analysis and open data on MDMA-assisted therapy for PTSD released

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD
Why it matters ◈ Mixed
This living systematic review and open-data resource aggregates all published RCTs of MDMA-assisted therapy for PTSD, showing moderate effect sizes and improved response/remission rates versus control. The resource increases transparency and access for researchers, clinicians, and policy staff, but highlights ongoing concerns about bias, blinding, and low certainty of evidence per GRADE standards. As the field awaits larger, independent studies and regulatory decisions, this tool will help synthesize emerging data and inform both clinical and policy discussions.
Abstract 3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD). However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release, 6 randomized controlled trials comprising 286 participants are included in the database. All six studies included in the review to date are sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). Our primary model uses inverse-variance random-effects meta-analysis of standardized mean differences on primary outcomes of PTSD. Compared to control conditions, MDMA-assisted therapy (MDMA-AT) showed a greater reduction in PTSD symptoms (Hedges’ g = −0.71). Meta-regressions on dosing variables were explored. Treatment with MDMA-AT as compared to placebo also resulted in higher response (risk ratio [ RR ] = 1.35) and remission ( RR = 2.25) rates. Most studies included in the database had a low risk of bias according to Cochrane guidelines, though these fail to capture pertinent challenges in the field such as expectancy, functional unblinding, potential issues with study conduct, and safety. The current findings were assigned an overall low certainty rating using the GRADE approach. Together, this systematic review and meta-analysis suggests that MDMA-AT results in short-term decreases in PTSD symptoms across studies to date. This living systematic review, meta-analysis, database, and online dashboard ( sypres.io ) will continue to be updated as evidence emerges, providing a valuable, open, and transparent resource for researchers in a rapidly evolving field.
Clinical research Peer-reviewed publication

New review: Ketamine/Esketamine for acute suicidality—evidence and limits

Ketamine and Esketamine in Acute Suicidal Presentations: Evidence, Limits, and a Conceptual Recovery-Enabling Downstaging Framework.
Why it matters ◈ Mixed
This peer-reviewed review synthesizes current evidence on ketamine and esketamine for acute suicidal presentations, highlighting both therapeutic promise and significant limitations. The authors propose a conceptual framework for 'recovery-enabling downstaging,' which may inform future clinical protocols and research design. While not a regulatory or legal shift, this work could influence clinical guidelines and policy discussions on rapid-acting interventions for suicidality.
Epidemiology / Policy research Population study published

Swedish study finds cannabis use underreported, unmet healthcare needs

Population based studies of cannabis use : estimation of prevalence and healthcare needs implications for regulatory approaches
Why it matters ◈ Mixed
This thesis highlights significant underestimation of cannabis use and unmet needs for cannabis use disorder treatment in Sweden, especially among young adults. The work suggests that decriminalization may increase use, particularly frequent use, and that traditional surveys may vastly undercount prevalence. While not directly about psychedelics, these findings are relevant for researchers and policymakers considering regulatory changes for other controlled substances, as they underscore the importance of accurate prevalence estimates and healthcare system preparedness.
Globally, the prevalence of cannabis use has increased over recent decades, at least from 2000 and onwards. Over the past two decades, this growing prevalence of recreational cannabis use has coincided with broader social acceptance, particularly among young adults. In parallel, drug policies, especially those concerning cannabis, have shifted in many countries from restrictive to more permissive frameworks. In Sweden cannabis remains the most used illicit drug and evidence suggests substantial underestimation of cannabis use among young adults in Sweden. The overall aim of this thesis was to improve current knowledge regarding cannabis use and healthcare utilization related to problematic cannabis use. Furthermore, the thesis aimed to relate findings to the current Swedish drug policy framework and to discuss the potential implications for future policy changes. Study I: We conducted a systematic review and found that the few eligible studies suggested increased healthcare utilization related to acute cannabis intoxication, pediatric involuntary cannabis exposure, and cannabis-related psychotic disorders following decriminalization. No clear evidence of increased cannabis use disorder was reported. Study II: We developed a framework to predict future cannabis use prevalence in the Swedish adult population under a hypothetical policy change. The model combined estimates of underlying trends of cannabis use, the effects of policy change to decriminalization reported in the scientific literature, and the influence of macro-level contextual factors. All analysis was based on survey data. We found that cannabis use may initially increase after decriminalization, both for past 12-month use and past 30-day use, but only past 30-day use displayed consistent increase over time. Study III: We conducted two parallel population-based surveys in cannabis use among young adults in Sweden, one using traditional survey method and one using an indirect survey method known as randomized response technique. The indirect survey method produced substantially higher estimates of lifetime, past 12-month, and past 30-day cannabis use compared with traditional surveys. The difference was particularly pronounced among men, students, and unemployed individuals. Study IV: We developed a statistical prediction model to estimate the expected number of individuals with cannabis use disorder and compared these estimates with observed diagnoses within the health care system, among young adults in Sweden. We interpreted a positive difference (i.e. an excess of predicted diagnoses compared to the observed) as indicative of unmet needs. The estimated number of individuals with cannabis use disorder was substantially higher than the number diagnosed within the healthcare system. Survey-based estimates suggested that the true burden of cannabis use disorder may be approximately 25 times higher than recorded diagnoses. Conclusions: By combining evidence from a systematic review, prediction modelling, survey methodology, and register-based analyses, four main conclusions can be drawn from this thesis: 1) Studies in countries where cannabis use was decriminalized suggest that there may be an increase in cannabis use, which may also contribute to increased healthcare utilization. 2) It is very likely that the traditional surveys regularly conducted in Sweden substantially underestimate cannabis use among youths. 3) Whichever method of estimation of use is employed diagnosed cannabis use disorder probably represent only a fraction of the true occurrence of the disorder. 4) Current surveillance systems likely underestimate both cannabis use and cannabis-related healthcare needs. List of scientific papers This thesis is based on the following four scientific articles, mentioned in the text using Roman numerals. I. Andersson F, Sundin E, Magnusson C, Orsini N, Burkhart G, Hughes B, Galanti MR. The impact of decriminalization of non-medical cannabis use on cannabis-relate
Neuroscience Mechanistic hypothesis published

IL-6 sgp130 trans-signaling identified as key TRD mechanism

Stoichiometric insufficiency of the IL-6 sgp130 trans-signaling buffer in treatment-resistant depression
Why it matters ▲ Favorable
This paper proposes a novel mechanistic framework for treatment-resistant depression (TRD), implicating IL-6 trans-signaling and the sgp130 buffer as central to disease pathogenesis. The identification of a Trans-signaling Risk Index (TSRI) and sgp130Fc as a precision intervention could enable more targeted clinical trials and biomarker-driven patient stratification. While not directly about psychedelics, this immunopsychiatric model may inform future research on inflammatory subtypes of depression, including those targeted by psychedelic-assisted therapies.
Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder (MDD). A substantial body of evidence implicates interleukin-6 (IL-6) in its pathogenesis, yet clinical trials of global IL-6 blockade have produced paradoxical psychiatric worsening. We argue that this is not a target failure but a resolution failure since prior interventions operated at the wrong level of the IL-6 system. The biologically relevant variable is the stoichiometric balance between the pathogenic IL-6/sIL-6R trans-signaling complex and the endogenous soluble gp130 (sgp130) buffer that neutralizes it. In inflammatory-endotype TRD, chronic psychosocial stress drives ADAM10/ADAM17-mediated sIL-6R shedding that overwhelms sgp130 neutralization capacity, generating sustained unconstrained trans-signaling in neural and cerebrovascular tissues. This pathway-specific excess drives a neurobiological cascade including claudin-5 downregulation with blood-brain barrier breach, microglial-astrocytic apoptotic cross-talk, IDO-1-mediated kynurenine pathway diversion, SERT hyperphosphorylation, dopaminergic suppression, and glucocorticoid receptor downregulation. We derive four testable predictions from this proposal, synthesize converging preclinical, genetic, and clinical evidence, and propose a Trans-signaling Risk Index (TSRI) as the operative stratification biomarker. This framework positions sgp130Fc as a precision pharmacological test and provides a roadmap for precision immunopsychiatry in TRD.
Clinical research Research infrastructure launched

Germany launches DZPG Model Systems for integrated mental health research

Model Systems infrastructure of the German Center for Mental Health (DZPG): toward an integrated, mechanism-based framework for mental health research
Why it matters ▲ Favorable
The DZPG's Model Systems infrastructure provides a cutting-edge platform for mechanistic mental health research, integrating animal, cellular, and human models with advanced analytics. This initiative will accelerate discovery of therapeutic targets and translational approaches, potentially benefiting psychedelic research by enabling more robust preclinical and translational studies. The infrastructure's focus on patient/public involvement and high-throughput screening may also support industry and clinical trial readiness for novel interventions.
Mental health is fragile and disorders are highly prevalent arising from complex interactions between genetic, developmental, psychological, social and environmental factors. The key mechanisms underlying resilience, vulnerability factors, brain repair systems, and recovery remain poorly understood, hindering the development of effective prevention and personalized treatment. The German Center for Mental Health (Deutsches Zentrum für Psychische Gesundheit, DZPG) addresses these challenges through a nationwide, interdisciplinary research network that integrates basic science with translational approaches across multiple sites. Its embedded "Model Systems" infrastructure provides a state-of-the-art platform to investigate brain-behavior mechanisms. Animal models are available to explore the links between genes, neural circuits, and behavior. Additionally, humanized model systems are established based on transgenesis and induced pluripotent stem cell (iPSC)-based models. Brain organoids further support research into neurodevelopment and multicellular interactions.Critically, when combined with high-content/high-throughput screening, iPSC-derived models link disease mechanisms to therapeutic targets. Advanced techniques, such as machine learning-based behavior quantification, single-cell and spatial multi-omics analyses, and genome editing enable in-depth analysis of disease/patient-specific cellular phenotypes and networks. Patient and public involvement embedded within the Model Systems infrastructure secures the scientific and translational relevance of the activities and helps to link experimental findings in our model systems to clinical symptoms and behavioral dimensions. By integrating animal, cellular, and human data on a multi-systems level with clinically relevant symptoms, the DZPG leverages model systems to accelerate mechanistic discovery and translation in mental health research.
Clinical research RCT results published

RCT: E-health family intervention reduces drug initiation in Hispanic youth

A Primary Care E-Health Family Intervention for Risk Behaviors in Hispanic Youths
Why it matters ▲ Favorable
This randomized trial shows that a culturally tailored, online family intervention in primary care settings can reduce drug and hard drug initiation—including substances like LSD, MDMA, and psilocybin—among Hispanic adolescents. While not specific to psychedelic treatment or research, the findings are relevant for prevention strategies and may inform future public health approaches to substance use. The study does not address clinical use of psychedelics, but its focus on prevention and family dynamics is of contextual interest for those monitoring risk behaviors and access patterns.
Importance: Culturally tailored, evidence-based family interventions that can be effectively delivered within pediatric primary care settings may provide a scalable approach for preventing risk behaviors among Hispanic adolescents. Objective: To evaluate whether the online eHealth Familias Unidas Primary Care (eHealth FUPC) program reduced drug use and increased condom use in Hispanic youth and to examine family functioning as a mediator. Design, Setting, and Participants: This randomized clinical trial included 5 follow-up visits across 36 months from April 18, 2017, to December 18, 2022, at 15 pediatric primary care clinics. Participants included Hispanic youth aged 12 to 16 years and a legal guardian. Data were analyzed from January 31, 2023, to August 21, 2024. Intervention: Participants were randomized 1:1 to the intervention, consisting of 8 video group sessions for parents and 4 online, facilitator-guided family sessions for parents and adolescents for a total intervention duration of approximately 12 weeks. Interventionists included pediatric primary care personnel. Main Outcomes and Measures: The co-primary outcomes were past 90-day drug use, condom use, and sexually transmitted infections (STIs). Secondary outcomes included initiation of alcohol use, initiation of hard drug use (ie, lysergic acid diethylamide, phencyclidine, ecstasy [MDMA], psilocybin mushrooms), and family functioning. STI was changed to a secondary outcome after data collection was discontinued because of the COVID-19 pandemic. Results: A total of 456 dyads of adolescents (mean [SD] age, 13.9 [1.4] years; 241 [52.9%] female) and parents or caregivers (mean [SD] age, 43.2 [6.6] years; 424 [93.0%] female) were included in the primary intention-to-treat analyses (225 in the eHealth FUPC intervention and 231 in treatment as usual). A total of 356 families (78.1%) completed the final assessment. eHealth FUPC effects were found for past 90-day drug use trajectories (unstandardized b [SE] = -0.70 [0.70]; incidence rate ratio, 0.47; 95% CI, -0.84 to -0.55; P < .001), alcohol initiation (χ21 = 3.85; P = .05; Cramer V = 0.10), and hard drug use (χ21 = 4.14; P = .04; Cramer V = 0.10), with less initiation for eHealth FUPC. Intervention effects were not found for condom use, condom use trajectory, or family functioning. Conclusions and Relevance: In this randomized clinical trial of the eHealth FUPC intervention, compared with treatment as usual, the experimental condition showed reduced drug use across time and prevented youths from initiating alcohol and hard drug use. No intervention effects were found for condom use. Whether behavioral preventive evidence-based interventions such as eHealth FUPC can be maintained in organizations such as primary care clinics should be further researched. Trial Registration: ClinicalTrials.gov Identifier: NCT03009539.
FDA / DEA FDA signals trial pathway

FDA signals willingness to advance ibogaine clinical trials

Policy Watch: FDA moves toward clinical trials of the psychedelic ibogaine
Why it matters ▲ Favorable
The FDA's move toward enabling clinical trials for ibogaine marks a significant step for psychedelic research in the US. This could open the door to more rigorous safety and efficacy data, potentially accelerating development for addiction and other indications. The decision also signals growing regulatory openness to novel psychedelics, with implications for future market entrants and research funding.
Industry / R&D Tech trend announced

TechBio 3.0: AI-driven closed-loop drug discovery emerges

TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry
Why it matters ▲ Favorable
TechBio 3.0 signals a new phase in drug discovery by integrating AI, generative chemistry, and automated experimentation into a closed-loop system. While not specific to psychedelics, these advances could accelerate the identification and optimization of novel compounds, streamline preclinical work, and potentially reduce costs and timelines for psychedelic drug development. The approach is still early-stage, but could reshape how both established and emerging biotech firms pursue new CNS-active molecules.
Abstract Artificial intelligence (AI) has transformed molecular prediction and design, yet these advances remain only partially integrated with experimental discovery. We define TechBio 3.0 as an emerging paradigm for closed-loop drug discovery that connects multimodal molecular representations, generative chemistry, and automated experimentation. We examine its early preclinical and clinical evidence, identify remaining technical and translational barriers, and argue that this convergence is beginning to define biotechnology’s next era.
Clinical research Ethics discussion

Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research

Why it matters ◈ Mixed
Ethical and methodological rigor in psychedelic trials remains a central concern as the field matures. This item highlights ongoing debates about blinding, safety, and participant protections, which are critical for the credibility and reproducibility of research. While not a regulatory or legal move, such discussions shape IRB standards, trial design, and ultimately the pace of clinical translation.
Clinical research Review published

Review: Psychedelics in neurosurgery—potential and barriers

Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation
Why it matters ◈ Mixed
This review systematically maps the indirect evidence for psychedelic and dissociative agents in neurosurgical contexts, highlighting both promise and significant translational barriers. While no trials have yet tested these agents in neurosurgical patients, the synthesis identifies perioperative esketamine and psilocybin for neuro-oncological distress as the most feasible initial targets. Purpose-designed clinical trials are now needed to move from theoretical plausibility to actionable protocols.
Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention, perioperative care, pain management, and neurorehabilitation, and delineates the safety considerations specific to neurosurgery. Methods: Narrative review structured around a population, intervention, comparator, outcome, and time question, covering 2020–2026. The classic serotonergic psychedelics (psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine, ayahuasca, 5-methoxy-N,N-dimethyltryptamine, and mescaline), the iboga alkaloid ibogaine, the entactogen 3,4-methylenedioxymethamphetamine, and the dissociatives ketamine and esketamine were examined. Randomized controlled trials, systematic reviews, meta-analyses, and high-quality mechanistic studies were prioritized. Results: No trial has administered these agents in neurosurgical cohorts, so all evidence is indirect. Psilocybin- assisted therapy produces substantial, durable reductions in cancer-related depression, anxiety, and existential distress. LSD is anxiolytic; parenteral tryptamines act rapidly in depression; ibogaine improved disability, post- traumatic stress, and cognition after traumatic brain injury but carries arrhythmia risk. Perioperative ketamine and esketamine show antidepressant and opioid-sparing effects. Classic psychedelics promote neuroplasticity and are neuroprotective in preclinical models. Conclusion: A biologically plausible basis exists for exploring these agents in neurosurgery, but direct evidence is absent and translation is constrained by the seizure threshold, hemodynamic and cerebrovascular effects, perioperative serotonergic interactions, and the need for structured psychological support. Perioperative esketamine and psilocybin for neuro-oncological distress are the most feasible starting points. Purpose-designed neurosurgical trials are required.
Neuroscience Preclinical research published

Nicotine amplifies fentanyl-driven dopamine in striatum, raising OUD risk insights

Nicotine Administration Robustly Enhances Fentanyl-Induced Dopamine Transmission Within the Dorsal Lateral Striatum
Why it matters ◈ Mixed
This preclinical study demonstrates that nicotine administration significantly enhances fentanyl-induced dopamine transmission in the dorsal lateral striatum, a brain region linked to compulsive drug-seeking. These findings provide mechanistic insight into why polysubstance use of nicotine and opioids may increase the risk and severity of opioid use disorder (OUD). While not directly related to psychedelics, the work is relevant for addiction neuroscience and may inform future clinical research or interventions targeting polysubstance use.
Opioid use disorder (OUD) is a prevalent public health concern in the United States. ∼70% of all drug overdose deaths are attributable to fentanyl, demonstrating a need to identify risk factors underlying the escalation of fentanyl use. Nicotine use is a risk factor associated with increased consumption of opioids across both clinical and preclinical populations. Our prior findings show that nicotine administration escalates consumption of opioids and that this elevated consumption persists despite adverse consequences in rodents, demonstrating a behavioral phenotype resembling those that emerge following protracted experience with opioids. Prolonged drug consumption is associated with a shift towards increased dopamine (DA) transmission within dorsal lateral striatum (DLS), a brain area critical for the development of inflexible behaviors. The present study sought to characterize the behavioral and neurochemical effects of nicotine on fentanyl administration. A dose-response curve was used to determine the effect of nicotine on fentanyl consumption as a function of dose in males and females. Systemic pretreatment with nicotine enhanced fentanyl intake across all doses relative to nicotine-naïve controls, suggesting that nicotine augments responding for opioids without evident effects on sensitivity to fentanyl. Additionally, fast-scan cyclic voltammetry (FSCV) was applied to measure DLS DA transmission in response to fentanyl administration and to quantify any effect of nicotine on this response in male rats. Fentanyl administration enhanced DA concentrations within DLS, and this effect was potentiated by nicotine pretreatment. These findings support that enhanced DA transmission in DLS may mechanistically contribute to nicotine-induced increases in the motivation for opioids. Significance statement Misuse of synthetic opioids such as fentanyl is primarily responsible for alarming rates of fatal overdose thus highlighting the need for studies designed to elucidate the mechanisms contributing to opioid misuse liability. Polysubstance use of opioids and nicotine-containing products is remarkably common and multiple clinical and preclinical observations support that nicotine markedly increases the consumption of opioids. Here, using fast-scan cyclic voltammetry in rodent models, we demonstrate that fentanyl administration robustly enhances dopamine concentrations within the dorsal lateral striatum, a brain area heavily implicated in multiple behavioral features of problematic drug use. Moreover, nicotine administration significantly potentiates this fentanyl-evoked dopamine concentration which may underlie the enhanced liability for opioid use disorders observed in users of nicotine-containing products.
Clinical research Peer-reviewed study

Study finds PT music playlists lack consistent phase-based structure

Music for psilocybin therapy and the temporal arc of psychedelic experience
Why it matters ◈ Mixed
This study challenges a foundational assumption in psilocybin therapy: that curated music playlists reliably align with the pharmacodynamic phases of the psychedelic experience. By showing that current playlists lack consistent acoustic or affective structure across onset, peak, and return, the research suggests a need for more rigorous, evidence-based approaches to music programming in psychedelic therapy. This has direct implications for clinical protocol standardization, trial reproducibility, and the quality of patient care as psychedelic-assisted therapy scales.
Abstract Music plays a central role in psilocybin therapy (PT), where playlists are designed to be supportive and stimulating over a 4–6-hour psychedelic experience. The primary design principle underlying PT music programming is that music should be affectively aligned with the onset–peak–return model of pharmacodynamic action. However, in the absence of clear acoustic criteria, this framework has been implemented largely through individual or team-based curatorial judgment, making it unclear whether contemporary research PT playlists consistently realize the proposed onset–peak–return progression. Here, we test this question by analyzing 45.1 hours of audio from eight PT music playlists (369 tracks) for systematic acoustic and affective organization across onset, peak, and return phases. To this end, we applied supervised and unsupervised machine learning approaches to a comprehensive set of audio features extracted from PT music playlist tracks, evaluating phase differentiation across the full dataset as well as within individual playlists. The results demonstrate that although weak phase-based differentiation is apparent for low-level audio features, especially within some playlists, the overall set lacks consistent phase-based structure. This implies that current curatorial practices are not aligned with their theoretical basis, raising questions about how such practices can evolve to better support emerging psychedelic treatments.
Clinical research Peer-reviewed study

AI model predicts suicide risk in bipolar depression with high precision

Precision stratification of risk for suicidal behavior in people with bipolar depression
Why it matters ▲ Favorable
This large-scale study demonstrates a machine learning model that significantly improves prediction of short-term suicide risk in patients with bipolar depression. While not directly related to psychedelics, these advances in risk stratification may inform future clinical trials and access protocols for high-risk populations, including those being considered for psychedelic-assisted therapy. The findings could help enable safer, more targeted research and clinical interventions by identifying at-risk individuals earlier.
Patients with bipolar depression are at the highest risk for suicidal behavior, comprising ~ 10% of all deaths. In the critical period preceding attempts, most are not in contact with mental health professionals to effect anti-suicidal strategies. There is an urgent need for decision support tools to help nonspecialist providers identify those at elevated risk to facilitate prevention. However, we lack robust, performant predictive models to form the core of such tools. Here, we build a high-precision predictive model of 30-day risk for suicidal behavior using unique electronic health record data from > 220,000 patients with bipolar depression. We show that optimized machine learning approaches offer very strong clinical utility, delivering high Standardized Net Benefit in the context of near-perfect calibration and smooth, threshold-robust decision curves. Our results break the longstanding performance ceiling in suicide risk prediction and highlight the importance of training models for clinical utility as well as discriminative skill.
FDA / Industry FDA guidance floated

FDA floats ibogaine trial design; Compass talks pricing; new psychedelic brands

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Why it matters ◈ Mixed
The FDA's consideration of ibogaine trial design signals growing regulatory engagement with novel psychedelics, which could open new research and access pathways if formalized. Compass Pathways' pricing discussions and the surfacing of potential LSD and psilocybin brand names reflect the industry's preparation for eventual commercialization. While details are sparse, these developments collectively indicate momentum in both regulatory and market structuring for psychedelic therapies.
Industry Supply agreement announced

Filament to supply psilocybin drug PEX010 for US clinical research

Filament to supply psilocybin drug PEX010 for U...
Why it matters ▲ Favorable
Filament's agreement to supply its psilocybin drug PEX010 for US research signals continued momentum in the clinical development pipeline for psychedelic compounds. While details are limited, such supply deals are critical for enabling FDA-compliant trials and may indicate growing infrastructure for regulated research. This move reflects increasing industry readiness to support large-scale studies and eventual commercialization.
Neuroscience Peer-reviewed study

Antidepressant molecular pathways show diurnal fluctuations in mouse brain

Molecular pathways implicated in antidepressant actions exhibits diurnal fluctuations in the prefrontal cortex and hippocampus of adult male and female mice
Why it matters ▲ Favorable
This study underscores the importance of circadian timing in antidepressant-related molecular pathways, which may influence the design and interpretation of preclinical and clinical trials for psychedelic and conventional antidepressants. Researchers should consider time-of-day effects in experimental protocols, potentially impacting translational validity and dosing strategies. While not directly about psychedelics, these findings are relevant for optimizing trial design and understanding mechanisms of action.
ABSTRACT Epidemiological and experimental studies have demonstrated a bidirectional relationship between mood disorders and the circadian system, with disrupted circadian rhythms contributing to depressive states, and their restoration playing a key role in antidepressants effects. In this context, we sought to examine whether selected molecular pathways implicated in antidepressant responses exhibit diurnal regulatory patterns. Naïve adult male and female C57BL/6 mice were euthanized at 3-hour intervals beginning at Zeitgeber Time 0 (ZT0), and hippocampal (HC) and medial prefrontal cortex (mPFC) tissues were collected for RT-qPCR and western blot analyses. We observed statistically significant diurnal rhythmicity in all analyzed transcripts ( cFos , Arc , Nr4a1 , Dusp1 , Dusp5 , and Dusp6 ) in both HC and mPFC samples, with peak expression occurring during the dark (active) phase (ZT15–18). Phosphorylation levels of TrkB Y816 (tropomyosin-related kinase) and GSK3β S9 (glycogen synthase kinase 3β) also showed patterns suggestive of temporal rhythmicity, peaking during the light (inactive) phase. Levels of p-ERK2 T185/Y187 (extracellular-signal regulated kinase) did not display rhythmic fluctuations, but peaked during the light phase in the HC, especially in males. Collectively, these findings demonstrate that antidepressant-related signaling is subject to diurnal regulation, highlighting the importance of integrating circadian biology and time-of-day as relevant variables in the development of translationally relevant antidepressant research.
Clinical research Study announced

Planned study: psychedelic for meth use disorder in people with HIV

No FDA-approved drug treats meth use disorder. A planned study tests whether a psychedelic can help people with HIV cut use.
Why it matters ▲ Favorable
This planned study targets a major unmet need—methamphetamine use disorder—especially among people with HIV, a population with high morbidity and limited treatment options. If successful, it could open new clinical pathways for psychedelics in addiction medicine and inform future FDA submissions. The trial's focus on a vulnerable group may also influence public health policy and funding priorities.
Neuroscience Peer-reviewed study published

Major study maps how psychedelics restructure brain information flow

Psychedelics restructure information in the human brain
Why it matters ▲ Favorable
This study provides the first comprehensive, formal mapping of how five major psychedelics alter information processing in the human cortex. By using advanced mathematical tools, the research clarifies previously conflicting findings and proposes a unified model of reduced self-coupling in neural populations. These insights deepen our mechanistic understanding of psychedelic effects, informing both clinical research and the development of therapeutic models. The findings may help refine future trial designs and support the rationale for psychedelic interventions in mental health.
How do psychedelic drugs alter human brain function? Answering this question relies on our ability to understand how information is stored, transferred, and transformed across the cortex. Here, we leverage a precise mathematical framework for multivariate information decomposition to construct the first comprehensive picture of these processes across five compounds: LSD, psilocybin, ketamine, DMT and 5-MeO-DMT (N=80). We provide a formal and empirical explanation of major prior results, revealing sets of competing underlying phenomena masked by extant approaches. We extend this analysis to novel higher-order phenomena, and we demonstrate how all of these observations can emerge from a minimal generative model in which neural populations operate with reduced self-coupling. In sum, our results suggest that the psychedelic brain is one in which cortical populations become alike, but not necessarily together. This has important implications for models of how psychedelics reorganize brain dynamics to alter subjective experience and alleviate mental health conditions.
Clinical research RCT protocol published

RCT to assess safety of circular breathwork in adults with trauma history

Acute side effects of circular breathwork: Safety data from a randomized controlled trial in adults with subclinical depression and a history of childhood trauma
Why it matters ▲ Favorable
This RCT will provide systematic safety data on circular breathwork in a vulnerable population, addressing a gap in current literature compared to the more established adverse event reporting in psychedelic research. The findings could inform best practices for integrating breathwork into psychotherapeutic settings and clarify risk profiles for individuals with subclinical depression and trauma histories. While not directly about psychedelics, the study's methodology and safety focus are highly relevant to adjacent fields and may influence standards for non-pharmacological interventions.
This subproject evaluates the side effects and safety data of a randomized controlled trial (RCT) comparing circular breathwork (intervention) to progressive muscle relaxation (PMR; active control) in adults with subclinical depression and history of childhood trauma (for parent project, see https://doi.org/10.17605/OSF.IO/K3MAB). A growing body of evidence links circular breathwork to a range of mental health benefits, including improved well-being and reductions in stress, anxiety, and depressive symptoms across clinical and non-clinical populations. Although circular breathwork is generally considered safe in the absence of contraindications, sessions can nonetheless elicit intense somatic, cognitive, and affective reactions, both during and after practice. In contrast to the increasingly systematic documentation of adverse effects in psychedelic research, however, the safety profile of circular breathwork remains largely uncharacterized. As efforts to incorporate it into psychotherapeutic settings gain momentum, a rigorous characterization of its safety profile in (sub)clinical populations becomes essential. This project aims to systematically investigate the occurrence and severity of side effects associated with circular breathwork compared to PMR within and across sessions and to examine their associations with baseline psychopathology. To this end, we will analyze safety data on acute side effects (i.e., self-reported as occurring during or shortly after the session) of four Conscious Connected Breathwork (CCB) sessions compared to four PMR sessions in individuals with subclinical depression and a history of childhood trauma. Occurrence rates (in %) will be estimated and compared between groups. Linear mixed effect models will be used to examine group differences (circular breathwork > PMR), temporal dynamics (potential decrease in circular breathwork-group is expected), as well as associations with baseline psychopathology of side effects severity across sessions. By systematically characterizing the range of breathwork-specific side effects and identifying potential vulnerabilities underlying these experiences, this research aims to contribute to a more rigorous understanding of the safety profile of breathwork in (sub-)clinical populations, with potential implications for its application in psychotherapeutic settings.
Clinical research Phase 2 trial ongoing

Interoceptive training proposed for psilocybin therapy in cancer patients

Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patients
Why it matters ▲ Favorable
This research highlights the potential for somatic and interoceptive training to improve outcomes in psilocybin-assisted therapy for cancer-related depression and anxiety. By proposing a novel taxonomy of bodily experience and integrating somatic practices into preparation protocols, the study may influence future clinical trial designs and therapeutic standards. If validated, this approach could enhance patient care and inform best practices for psychedelic therapy in medically complex populations.
Cancer patients arrive for psilocybin therapy with bodies altered by illness and treatment — bodies that they have learned to brace against, dissociate from, or scan for threat. Research on psilocybin-assisted therapy for cancer-related depression and anxiety consistently identifies the quality of the acute subjective experience — reflected in constructs such as acceptance, surrender, boundlessness, and emotional breakthrough — as a key predictor of therapeutic benefit. Yet most preparation protocols focus on cognitive intention-setting and basic mindfulness while neglecting to address the body directly. We propose that anxiety and depression in this setting may involve a somatic substrate that has not been adequately specified. We distinguish two capacities to ‘feel into the body’ relevant to psychedelic therapy: interoception as perception (the perceptual access to bottom-up bodily signal) and interoceptive engagement (the broader capacity that links bodily perception to posture, breath, structural intent, and affective stance). We describe a six-category phenomenological taxonomy of somatic experiences in psilocybin therapy (exteroceptive, deep somatic, visceral, vestibular, nociceptive, emergent). We also map receptive practices, designed to improve interoception as perception, and generative practices, designed to improve interoceptive engagement. The framework is grounded in current predictive-coding accounts of interoception, but does not depend on any single neuroscientific model. An ongoing Phase 2 trial of group retreat psilocybin therapy for metastatic cancer patients will provide an initial test of our hypothesis that interoceptive training may influence therapeutic outcomes in psilocybin therapy for patients with cancer.
Forensic science / Environmental health Review published

Chiral drugs in environment: bioaccumulation, analysis, and forensic challenges

CHIRAL DRUGS BIOACCUMULATION IN AQUATIC ENVIRONMENT AND THE OPPORTUNITIES, CHALLENGES IN BIOANALYSIS
Why it matters ◈ Mixed
This review highlights the growing importance of chiral analysis in detecting synthetic psychoactive drugs, including dissociative anesthetics, in both biological and environmental samples. Chiral separation can help distinguish between licit and illicit drug use, inform forensic investigations, and monitor community-level drug consumption via wastewater analysis. The environmental persistence and stereoselective effects of these compounds raise concerns for both human and aquatic health, but the article is primarily a scientific review rather than a regulatory or clinical milestone.
Chiral compounds are asymmetric three-dimensional molecules that have one or more stereogenic centers or asymmetry that is caused by planes or axes and results in two molecules that cannot be superimposed on one another.Chiral separation has become more important in forensic chemistry and has been used in the examination of biological fluids, environmental samples, and the examination of illicit drug mixtures.Most of the molecules at the center of life, including DNA, amino acids (AAs), and sugars, are chiral compounds.The investigated compounds included synthetic psychoactive drugs (stimulants), synthetic opioids, β-blockers, antidepressants, anticoagulants, bronchodilators, and dissociative anesthetics.Racemate use frequently causes stereoselective pharmacological activity and pharmacokinetic effects on absorption, metabolism, and excretion that may raise the risk of death or have major side consequences such as poisoning.Many medications are still delivered as racemates, despite the trend towards making pharmaceuticals as single enantiomers.Chiral analysis in biological fluids can provide details about use and help distinguish between legitimate medications and illicit substances that only contain one enantiomer.Additionally, it has been demonstrated that the presence of these substances in wastewater can be used as a tool for community-level drug consumption monitoring.Pharmaceuticals and illicit drugs may enter the aquatic environment by direct sewage discharge or effluents from WWTPs that are unable to completely remove these micro-pollutants.Studies of the presence of chiral medicines in environmental matrices are motivated by the potential negative effects of enantiomers on aquatic and human life.This study reviewed 90 articles that have been published between 1996 and 2022 based on ScienceDirect and ISI Web of Knowledge databases.In this review discussed about the challenges and opportunities of the application of chiral analysis in biological, environmental samples and their relevance in the forensic field.
Clinical research Peer-reviewed meta-analysis

Meta-analysis: Psilocybin therapy for alcohol use disorder shows efficacy, safety

Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis.
Why it matters ▲ Favorable
This systematic review and meta-analysis synthesizes current evidence on psilocybin-assisted therapy for alcohol use disorder, indicating both efficacy and safety across multiple studies. The findings provide a robust evidence base for policymakers, clinicians, and researchers considering psilocybin as a treatment option. This could influence regulatory pathways, insurance coverage, and clinical trial design for substance use disorders. Continued research and policy attention are warranted as the field moves toward broader clinical adoption.
Clinical research Peer-reviewed trial results

LSD boosts working memory brain activity in MDD, but not linked to mood change

LSD treatment affects working memory-related brain function in patients with major depressive disorder
Why it matters ◈ Mixed
This randomized controlled trial is the first to show that high-dose LSD increases working memory-related brain responses in patients with major depressive disorder (MDD), as measured by fMRI. The neural changes correlated with cognitive task performance and subjective effects, but not with improvements in depressive symptoms, suggesting that LSD's cognitive and mood effects may be dissociable. This finding is important for researchers designing future trials and for clinicians considering cognitive safety and efficacy in psychedelic-assisted therapy.
Abstract Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on working memory-related brain function in patients with MDD. In a randomized, double-blind, parallel-group trial, 43 patients with MDD received either two low-dose (25 µg) or two high-dose (100 and 200 µg) oral LSD treatments 4 weeks apart. Functional magnetic resonance imaging during an n-back working memory task was conducted before and approximately 1 week after the second treatment. The treatment × time interaction effect on working memory-related brain responses (2-back and 1-back vs . 0-back) was assessed using linear mixed effects models. We also explored associations between brain responses and depression severity, task performance, and subjective psychedelic experiences. Compared with low-dose treatment, high-dose LSD treatment significantly increased working memory-related brain responses ( p = 0.007) within task-activated regions, including the dorsolateral prefrontal cortex, parietal cortex, insula, striatum, and thalamus. Working memory-related brain responses correlated with task performance and subjective perceptual changes but not treatment response. Our observations provide the first evidence that LSD treatment in patients with MDD affects cognitive brain function. Contrary to our hypothesis, high-dose LSD significantly increased brain responses. These responses positively correlated with task performance, suggesting a potential LSD-induced boost in neural function. The absence of an association with depressive symptoms indicates that task-related brain activity may underlie different mechanisms than changes in mood. Trial registration: Clinicaltrials.gov Identifier: NCT03866252.
Clinical research Peer-reviewed study published

Empirical-ethical study analyzes patient vulnerability in (es)ketamine therapy

Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment
Why it matters ◈ Mixed
This study highlights the ethical and practical importance of patient safety and vulnerability in (es)ketamine treatment, emphasizing the need for flexible, patient-centered care beyond basic clinical protocols. The findings suggest that clinician behavior, therapeutic presence, and structured post-acute support are central to patient safety and ethical care, but also reveal a misalignment between clinician and patient expectations. This work is relevant for clinicians, researchers, and policy makers shaping standards of care and informed consent in psychedelic and dissociative therapies, though confirmation in larger samples is needed.
BACKGROUND: Treatments with acute consciousness-altering effects, such as (es)ketamine, place patients in a state of heightened vulnerability with reduced capacity for self-advocacy and self-regulation. Since feeling safe is a precondition for consenting to begin, and remaining in, treatment, this raises distinct ethical demands on care. Which features of the setting enable patients to feel safe, and how patients' and clinicians' understandings of the treatment relate to these requirements, remains unclear. This study identifies patient-, clinician- and setting-related factors shaping the experience of safety during (es)ketamine treatment and derives ethically grounded recommendations, distinguishing clinical safety, felt safety and ethical protection and analyzing their relations through a framework of induced, layered vulnerability. METHODS: Semi-structured interviews were conducted with 14 patients who had received intranasal esketamine (Spravato®) or IV ketamine infusion treatment and 10 clinicians administering these treatments in German psychiatric settings, and analyzed using structuring qualitative content analysis complemented by type-building analysis. Pre-treatment concerns and the experience of safety were analyzed from the patient interviews; clinician interviews informed the broad coding and the comparison of patients' and clinicians' models of ketamine's mechanism of action. RESULTS: Three types of pre-treatment concern, three overlapping modes of experiencing safety, and three models of ketamine's mechanism of action were identified, each associated with distinct treatment requirements. Therapeutic presence, active physical grounding, and structured post-acute transitional support ("landing aid") were described by participants as central to feeling safe. Clinicians more often conceived of ketamine as a catalyst of transformation, patients as temporary relief or symptom management, indicating potential misalignment regarding preparation and integration. CONCLUSIONS: Safety in (es)ketamine treatment is relationally created and individually differentiated rather than uniform, supporting an ethical case for flexible, patient-centered care above a non-negotiable floor of clinical safety. Because patients in altered states depend acutely on those who induced that state, minor clinician behaviors and the post-acute transition carry moral weight bearing on informed consent and the duty of care, yet are modifiable with few resources. Recommendations are graded by strength; one is restricted against our own empirical finding where the vulnerability analysis requires it. As an exploratory study, the findings require confirmation in larger, more diverse samples.
Clinical research Peer-reviewed study published

Adverse reactions to psychedelics linked to psychopathology, well-being

Adverse reactions to psychedelics in naturalistic settings are associated with current psychopathology and well-being: A correlational study
Why it matters ◈ Mixed
This large-sample survey finds that acute and delayed adverse reactions to psychedelics in naturalistic settings are associated with higher current psychopathology and lower well-being, with contextual factors and user motivations also playing a role. While the study is correlational and cannot attribute effects to specific substances or episodes, it highlights the need for prospective research and may inform harm reduction strategies for both clinical and non-clinical settings. The findings are relevant for researchers, clinicians, and policymakers assessing risk profiles and designing safer access frameworks.
This study examines acute and delayed adverse reactions reported in naturalistic psychedelic use, focusing on their associations with substance-use patterns, contextual variables, and user motivations. Using an online survey incorporating the Psychedelic Use Scale, data were collected from a large naturalistic sample (N=1022) to analyze patterns of self-reported adverse reactions. Acute adverse reactions were consistently associated with similar delayed adverse reactions, suggesting continuity between immediate and subsequent self-reported adverse experiences. Furthermore, most acute adverse reactions, with the exception of vomiting, which showed an opposite pattern, were associated with higher current psychopathology and lower well-being. Self-reported lifetime use of individual psychedelics (e.g., DMT, MDMA, and LSD) and combined substances (e.g., alcohol, caffeine, and cannabis) showed participant-level associations with specific self-reported adverse-reaction categories, while MDMA use was also associated with poorer current psychological indicators. Adverse reactions were also associated with contextual variables, including setting, type of companionship, and user motivations. Younger age and higher current frequency of psychedelic consumption were associated with higher odds of reporting adverse reactions. Because the study is cross-sectional and retrospective, and adverse reactions were not linked to specific substances or psychedelic episodes, the findings should be interpreted as correlational, hypothesis-generating co-reporting patterns rather than as substance-specific attribution. Nevertheless, they provide an empirical basis for future prospective, longitudinal, and clinical studies aimed at clarifying temporal relationships and informing harm reduction strategies.
Industry / FDA Industry-FDA engagement

Clearmind submits psychedelic therapy recommendations to FDA

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Why it matters ▲ Favorable
Clearmind's direct engagement with the FDA signals growing industry participation in shaping federal policy on psychedelic therapies. While the submission of recommendations does not itself change law or access, it reflects increasing dialogue between private sector stakeholders and regulators. This may help inform future FDA guidance or rulemaking, and suggests the sector is maturing toward more formal regulatory pathways.
Neuroscience Peer-reviewed publication

LSD alters cortical dynamics via faster rhythms, higher fractal dimension

LSD reconfigures cortical dynamics through faster brain rhythms and increased fractal dimension.
Why it matters ▲ Favorable
This study provides mechanistic evidence that LSD induces measurable changes in brain activity, specifically increasing the speed of cortical rhythms and the fractal dimension of neural signals. These findings may help explain the altered states of consciousness associated with LSD and inform future clinical research on its therapeutic potential. The results could support arguments for further research access and regulatory reconsideration by demonstrating concrete neurobiological effects.
Clinical research Systematic review published

Systematic review: Ketamine for BPD, depression, and suicidality

Intravenous and intranasal ketamine for borderline personality disorder to treat comorbid depression, BPD symptoms and suicidality: a systematic review
Why it matters ◈ Mixed
This systematic review finds insufficient evidence to support ketamine as a treatment for BPD, depression, or suicidality in BPD patients, highlighting the need for larger, BPD-specific randomized trials. While some studies suggest short-term benefit for depressive symptoms or suicidality, methodological limitations and inconsistent findings preclude clinical recommendations. The review reinforces that ketamine use in BPD remains investigational, guiding both researchers and clinicians on current evidence gaps and safety considerations.
While psychotherapy is the standard form of treatment for borderline personality disorder (BPD), there are no pharmacological medications approved to treat this condition. Many individuals with BPD also experience depression and suicidal ideation, highlighting the need for effective interventions. One potential treatment option is ketamine, some formulations of which have already been approved for treating treatment-resistant depression and severe suicidal ideation. We conducted a systematic review examining the safety and potential benefits of intravenous and intranasal racemic ketamine in adults formally diagnosed with BPD or with elevated borderline features. The primary outcomes were depression, BPD symptoms, and suicidality, while the secondary outcome was the adverse effects of ketamine treatment. We searched MEDLINE, Embase, and CENTRAL for relevant studies published up to February 2026. Five studies met the inclusion criteria, consisting of two randomized controlled trials (RCTs) and three cohort studies. Four studies evaluated intravenous ketamine, while one evaluated intranasal racemic ketamine. Across four studies, 81 participants identified as having BPD received ketamine; one additional study included 31 ketamine-treated participants with elevated borderline features without a confirmed BPD diagnosis. The studies differed substantially in design, method of BPD ascertainment, ketamine protocol, comparator, and outcome measurement. Across the studies, ketamine appeared to be generally well tolerated over short follow-up in supervised settings, although transient side effects, including dissociation, were reported. Several studies reported reductions in depressive symptoms or suicidal ideation following treatment; however, most were not designed or adequately powered to evaluate efficacy specifically in BPD. Comparative findings were inconsistent and did not establish equivalent treatment response between participants with and without borderline pathology. Evidence regarding improvement in BPD symptoms was sparse. The current evidence is insufficient to determine whether ketamine has a clinically meaningful role in treating depression, BPD symptoms, and suicidality in patients with BPD, but further study appears warranted. The available findings are limited by small samples, heterogeneous populations and treatment protocols, exploratory or retrospective analyses, and short follow-up periods. Ketamine treatment specifically targeting BPD should therefore be considered investigational. Adequately powered, BPD-specific randomized trials with standardized outcomes and longer follow-up are required before conclusions regarding efficacy, safety, or clinical implementation can be made.
Neuroscience Preclinical study published

(2R,6R)-HNK reverses PTSD-like traits in female rats after blast injury

Chronic post-traumatic stress disorder-related behavioral traits develop in female rats exposed to repetitive low-level blast injury and are reversible with (2R,6R)-hydroxynorketamine
Why it matters ▲ Favorable
This preclinical study demonstrates that (2R,6R)-hydroxynorketamine can reverse chronic PTSD-like behavioral traits in female rats following repetitive blast injury, mirroring previous findings in males. The sustained effect after a single dose highlights the compound's therapeutic promise for trauma-related neurobehavioral disorders. These results support further research into (2R,6R)-HNK as a candidate for treating blast-induced PTSD, particularly in female populations, but clinical translation will require human trials.
Introduction Many military Veterans who experienced blast-related injuries during military service suffer from chronic cognitive and mental health problems. Women constitute more than 15% of active-duty U. S. military personnel and are the fastest-growing population of U. S. Veterans. For more than a decade, we have studied a rat model of repetitive low-level blast exposure designed to mimic the type of blast-related exposure that is common in military settings. Male rats develop chronic cognitive and post-traumatic stress disorder-related traits that appear in a delayed fashion and persist for more than 1 year after exposure. These traits can be reversed with a single dose of (2R,6R)-hydroxynorketamine [(2R,6R)-HNK]. This study aimed to determine whether female rats develop a similar set of neurobehavioral alterations. Methods Ten-week-old female rats were exposed to 75.1 kPa blast overpressures delivered once per day for three consecutive days. We tested female rats behaviorally between 1 and 4 weeks after blast exposure and again at 28 and 29 weeks. Rats were tested in an elevated zero maze, light–dark emergence task, and novel object recognition task, as well as contextual and cued fear learning and a Barnes maze. We tested how females would respond to a single dose of 20 mg/kg (2R,6R)-HNK administered intraperitoneally. Results Following blast exposure, female rats developed chronic cognitive and behavioral traits. The full behavioral phenotype developed with a delay. Treatment with a single dose of (2R,6R)-HNK reversed behavioral changes in female rats, and beneficial effects on behavior were sustained for 4 weeks without additional drug administration. As in male rats, female rats showed elevated metabotropic glutamate receptor mGluR2. Elevations of mGluR2 were reversed by (2R,6R)-HNK treatment. Similar to male rats, the serotonin receptor 5-HT2AR was decreased in blast-injured female rats but levels were not affected by (2R,6R)-HNK treatment. Conclusion These studies show that female rats develop a similar behavioral profile as previously observed in male rats using the same blast exposure conditions. They further support (2R,6R)-HNK as a promising therapeutic candidate for treatment of blast-induced neurobehavioral effects, even when administered after traits are well established.
Neuroscience Peer-reviewed study

LSD alters brain rhythms and increases neural complexity, MEG study finds

LSD reconfigures cortical dynamics through faster brain rhythms and increased fractal dimension
Why it matters ▲ Favorable
This study provides a detailed electrophysiological account of how LSD reorganizes large-scale human brain dynamics, identifying specific changes in brain rhythms and signal complexity that distinguish the psychedelic state. The use of advanced MEG and machine learning methods strengthens the mechanistic understanding of LSD's effects, informing future clinical and translational research. While not directly impacting policy or access, these findings help clarify neural biomarkers relevant for therapeutic development and may guide future trial endpoints.
Lysergic acid diethylamide (LSD) profoundly alters conscious experience, yet the electrophysiological mechanisms by which it reshapes neural dynamics remain incompletely understood. A hallmark of psychedelic states is widespread cortical desynchronization, typically inferred from reductions in spectral power, but whether such effects reflect genuine weakening of neural oscillations or are confounded by shifts in oscillatory peak frequencies remains unresolved. We combine source-resolved magnetoencephalography (MEG), spectral parameterization, temporal complexity metrics, and interpretable machine learning in an LSD versus placebo design, with and without music. We show that LSD induces robust, spatially structured increases in alpha and beta peak frequencies alongside genuine attenuation of oscillatory power, with partly dissociable cortical patterns. Beyond rhythmic activity, LSD is associated with flattening of the aperiodic 1/f spectral slope and increased neural signal fractality and complexity, preferentially affecting sensory, language, emotion, and imagery-related networks while sparing motor cortex. Machine-learning analyses identify peak-frequency shifts, aperiodic parameters, and complexity measures as key discriminators of the psychedelic state. Music does not robustly amplify these neural signatures and instead shows a trend toward attenuation. These findings provide an electrophysiological account of how LSD reorganizes large-scale human brain dynamics and highlight features that may differentiate its neural signature from other psychedelics.
Clinical research Systematic review published

Systematic review compares cooling methods for drug-induced hyperthermia

Comparison of cooling methods for drug-induced hyperthermia in a pre-hospital and emergency department setting: a systematic review
Why it matters ◈ Mixed
This systematic review synthesizes evidence on cooling interventions for drug-induced hyperthermia, a critical emergency complication of stimulant intoxication. While not focused on classic psychedelics, the findings are relevant to emergency protocols for substances with hyperthermic risk profiles, including some novel psychoactives. The review highlights the superiority of ice/cold water immersion over passive cooling, but also notes the lack of high-quality data specific to drug-induced cases, underlining a gap in targeted research for acute care.
INTRODUCTION: Hyperthermia is a medical condition characterized by elevated body temperature above 39.0 °C due to imbalanced heat production and dissipation. Stimulant drugs such as cocaine and amfetamines, as well as intense physical exertion, commonly induce hyperthermia. In severe cases, hyperthermia presents life-threatening complications requiring immediate temperature reduction interventions. Management involves various cooling modalities that differ in efficacy and practicality within pre-hospital and emergency department settings. This systematic review evaluates and compares the efficacy of cooling modalities for managing drug-induced hyperthermia suitable for pre-hospital and emergency department settings. Due to the paucity of data on drug-induced hyperthermia, studies examining exercise-induced hyperthermia were also included to provide additional evidence on cooling efficacy. METHODS: A comprehensive search for cooling efficiency studies across PubMed, Embase, Cochrane Central Register of Controlled Trials, CINAHL, APA PsycINFO, and SportDiscus from inception until October 2025, without language restrictions was conducted. Randomized controlled trials, observational studies, and case-based studies were included. Quality assessment utilized the GRADE approach for certainty of evidence, while the Newcastle-Ottawa Scale and RoB 2.0 assessed risk of bias. Meta-analysis was performed when feasible. RESULTS: The search identified 6,920 citations, with 71 studies included in this systematic review comprising 1,932 patients treated with 12 different cooling modalities. Analysis demonstrated that an ice water immersion cooling rate of (0.169 ± 0.027 °C/min) and cold water immersion cooling rate of (0.162 ± 0.037 °C/min) achieved the highest cooling rates. Meta-analyses confirmed that cold water and ice water immersion were more effective than passive cooling. Ice water-soaked sheets or towels had a cooling rate of (0.121 ± 0.030 °C/min) and room temperature immersion a cooling rate of (0.089 ± 0.020 °C/min) produced adequate cooling rates, while all other cooling modalities proved inadequate as standalone treatments. DISCUSSION: Due to paucity of data on cooling methods specifically for drug-induced hyperthermia, this study incorporates data from exertional hyperthermia to inform treatment recommendations. Both populations share similar demographics and involve exertion as a primary or contributing factor, supporting the clinical relevance of this approach. However, important pathophysiological differences exist; in case of exertional heat stroke hyperthermia related to exertion improves as physical activity ceases, while stimulant-induced hyperthermia persists despite cessation of activity due to ongoing central drug effects. Although sedation can reduce physical activity in intoxicated patients, these patients often present with concurrent medical complications requiring simultaneous monitoring and treatment. CONCLUSION: When ice or cold water immersion is available, often at large events, and can be applied safely, this represents the preferred cooling method. For emergency and pre-hospital settings, ice water-soaked sheets or towels are a practical cooling method available to most emergency departments and pre-hospital settings to treat hyperthermic intoxicated patients that is less resource intensive than immersion techniques and maintains continuous patient monitoring capabilities. Given the limited data on drug-induced hyperthermia, further research should address these knowledge gaps and investigate combined cooling strategies and their practicality in pre-hospital and emergency department settings.
Neuroscience Preclinical research

Tianeptine and opioid peptides enhance hippocampal AMPAR function in mice

Enhancement of hippocampal synaptic AMPA receptor function by the antidepressant tianeptine and by opioid peptides
Why it matters ◈ Mixed
This preclinical study identifies a novel mechanism by which tianeptine and opioid peptides enhance synaptic AMPA receptor function in the hippocampus, implicating opioid receptor-mediated modulation of glutamatergic transmission. The findings may inform the development of rapid-acting antidepressants and highlight mechanistic overlaps between antidepressants and opioids, which is relevant for understanding both therapeutic effects and abuse potential. While not directly about psychedelics, the mechanistic insights could influence future research on glutamatergic and opioid pathways in psychiatric drug development.
Management of major depressive disorder (MDD) with conventional therapeutics that enhance monoaminergic neurotransmission requires prolonged treatment prior to clinical benefit and a substantial proportion of patients show little or no improvement. Identifying alternative molecular targets is required to develop efficacious, rapid acting antidepressants. In this regard, tianeptine, an established but atypical clinical antidepressant, is of interest. Tianeptine does not directly influence monoamine levels; in rodents it has a relatively rapid onset of antidepressant-like efficacy and, unusually for an antidepressant, exhibits procognitive properties. Here, voltage-clamp recordings from mouse hippocampal CA1 pyramidal neurons demonstrated tianeptine enhanced the amplitude of neurally evoked excitatory postsynaptic currents mediated by glutamate activation of synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The effect required intracellular polyamines and expression of the GluA1 subunit. These observations suggest that tianeptine relieves the channel block by endogenous polyamines of synaptic GluA1 containing AMPARs (GluA1-AMPARs). The tianeptine effect was abolished by postsynaptic inhibition of G-protein signaling, was reduced in mice lacking either the µ- or the δ-opioid receptor, and inhibited by selective antagonists of these receptors, collectively demonstrating that the facilitation of excitatory transmission was indirectly mediated by activation of opioid receptors. Importantly, enhancement of GluA1-AMPAR function was mimicked by opioid peptide and nonpeptide agonists selective for µ- or δ-receptors. These observations improve understanding of how the antidepressant tianeptine enhances glutamatergic transmission but more generally suggest that endogenous and exogenous opioids act in a similar manner, which may contribute to their behavioral effects.
Clinical research Review published

Durability of VNS in Treatment-resistant Depression: Review and Mechanisms

Durability of Implanted Cervical Vagus Nerve Stimulation in Treatment-resistant Major Depression: Summary of Findings and Potential Mechanisms of Action
Why it matters ▲ Favorable
This review consolidates evidence that implanted vagus nerve stimulation (VNS) offers durable antidepressant effects in severe, treatment-resistant depression, with sustained benefits observed up to three years. The summary of the large RECOVER VNS trial and mechanistic insights may inform future research and clinical strategies, including potential combination with psychedelic therapies. While not directly related to psychedelic substances, the findings are relevant for those exploring neuromodulation and adjunctive approaches in refractory mood disorders.
Abstract Purpose of Review Treatment-resistant depression (TRD), major depressive disorder (MDD) characterized by inadequate response to a series of antidepressant treatments, is a major clinical challenge. Implanted vagus nerve stimulation (VNS), surgical placement of a pulse generator with an electrical lead attached to the cervical vagus nerve, provides intermittent electrical stimulation 24/7. VNS for TRD was approved by the US FDA in 2005. This review summarizes the evidence for durability of the antidepressant effects of VNS and examines potential mechanisms that may explain this durability. Recent Findings Since the approval of VNS for TRD, numerous studies have demonstrated sustained durability of antidepressant responses up to 2 years. Most recently, the large, multicenter RECOVER VNS trial demonstrated very strong sustained durability (~ 80% at 2 years; ~70% at three years) across a wide range of depression outcomes including depressive symptoms, clinical impression, quality of life, and daily function in severe, unipolar, markedly TRD patients (mean lifetime years in depression 27; mean failed lifetime antidepressant treatments trials 13). We summarize multiple lines of current exploration in this area including: engagement of multiple neurotransmitter systems (monoamines and others), anti-inflammatory effects, impact on brain networks/regions associated with depression, evidence of neuroplasticity in brain circuits, modulation of the autonomic nervous system, a unique brainstem entryway into the central nervous system (nucleus tractus solitarius), and possible synergistic effects with other treatments. Summary VNS shows very strong durability of response in severe TRD. Several plausible mechanisms are supported by existing evidence; further research is needed to improve understanding.
Neuroscience Peer-reviewed study published

Comprehensive profiling of psychoactive alkaloids in 53 Australian Acacia species

Quantitative multi-tissue profiling of tryptamines, phenethylamines, and β-carbolines across 53 species of Australian Acacia
Why it matters ◈ Mixed
This landmark phytochemical survey provides the first quantitative, multi-tissue analysis of tryptamines, phenethylamines, and β-carbolines across a broad range of Australian Acacia species. The findings reveal that flowers and leaves, rather than bark, often contain the highest concentrations of psychoactive compounds like DMT, suggesting less-destructive harvesting methods are possible. This data is highly relevant for researchers, conservationists, and law enforcement, as it may inform both future drug policy and conservation strategies for endangered species subject to illicit harvesting.
The genus Acacia , comprising approximately 1000 native Australian species, represents a major contributor to the biodiversity of the continent. Some species of Acacia are known to contain bioactive alkaloids, including the popular psychedelic N,N-dimethyltryptamine (DMT). However, systematic phytochemical characterisation across different species of Acacia and tissue types remains limited. Here we used a validated LC–MS/MS method to quantify various tryptamines, phenethylamines, and β-carbolines in 150 tissue samples from 53 species of Acacia , primarily obtained from the Australian Botanical Garden (Mount Annan, New South Wales). Ten analytes were quantified: hordenine, phenethylamine, tryptamine, N-methyltryptamine, DMT, DMT-N-oxide, harmalol, 2-methyl-1,2,3,4-tetrahydro-β-carboline (2-MTHBC), harmol, and harmane. Phenethylamine was the most prevalent analyte (quantified in 93 samples from 41 species) and a major determinant of phytochemical variation. Hordenine (84 samples from 39 species), and tryptamine (84 samples from 35 species) were also frequently quantified. By contrast, DMT and β-carbolines were detected less frequently with high species-specificity. Flowers often contained the highest concentrations of analytes followed by leaves and stems. DMT was quantified at high concentrations in the flowers and phyllodes of Acacia courtii , an endangered species subject to illicit harvesting. Acacia complanata also displayed a unique profile with relatively high tryptamine and β-carboline concentrations in flowers and leaves. Multivariate analysis indicated that species identity, rather than tissue type, was the primary driver of phytochemical diversity. This study represents the first quantitative, multi-tissue, survey of alkaloids in diverse examples of Australian Acacia . The high concentrations of analytes in the flowers of select species is notable, and the destructive bark harvesting of threatened species to obtain psychedelic substances appears unnecessary given the enriched alkaloid content in flowers and leaves.
Clinical research Published study

Qualitative study of acute inhaled DMT in Brazilian clinical context

Substance, subject, and setting: A qualitative study of acute inhaled DMT experiences in a structured Brazilian clinical context
Why it matters ▲ Favorable
This qualitative study provides new data on the subjective and contextual factors shaping acute DMT experiences in a structured clinical setting in Brazil. While not a pivotal trial, it adds to the growing international literature on DMT's effects and may inform future research design and safety protocols. The Brazilian context is notable given the country's unique regulatory and cultural environment for psychedelics.
Clinical research Systematic review published

RCT review: Ketamine/esketamine for chronic pain and quality of life

Health-related quality of life after ketamine or esketamine treatment for chronic pain: a review of randomized controlled trials.
Why it matters ◈ Mixed
This systematic review synthesizes randomized controlled trial data on ketamine and esketamine's impact on health-related quality of life in chronic pain patients. The findings inform clinicians and policymakers about efficacy, safety, and patient-centered outcomes, which are critical for future guideline development and reimbursement decisions. It also highlights gaps in evidence, guiding research priorities and regulatory considerations for broader therapeutic use.
Clinical research Systematic review published

Systematic review: Ketamine for PTSD in military/veteran populations

Efficacy and safety of ketamine for post‐traumatic stress disorder: A systematic review with narrative synthesis and consideration of military and veteran populations
Why it matters ◈ Mixed
This systematic review finds preliminary evidence that ketamine may reduce PTSD symptoms in military and veteran populations, but highlights limitations due to small sample sizes, heterogeneous study designs, and inconsistent safety reporting. While some studies report substantial remission rates, the lack of large, controlled trials and limited long-term safety data mean ketamine's role in PTSD treatment remains uncertain. The review underscores the need for rigorous, larger-scale research before ketamine can be widely recommended for PTSD, especially in high-risk groups.
Abstract Post‐traumatic stress disorder (PTSD) is a debilitating disorder with limited pharmaceutical treatment options. Ketamine, a noncompetitive N ‐methyl‐ d ‐aspartate (NMDA) receptor antagonist with rapid‐onset effects, has emerged as a potential treatment, particularly for patients who do not respond to first‐line therapies. This systematic review synthesizes the current evidence on the effectiveness and safety of ketamine for PTSD, with a focus on military and veteran populations. Eligible studies included adults with PTSD, who evaluated ketamine or esketamine, and reported efficacy and safety outcomes. Due to substantial clinical and methodological heterogeneity, a meta‐analysis was not performed. Eight studies ( N = 383) were included, comprising five randomized‐controlled trials and three uncontrolled or observational studies. Most studies reported reductions in PTSD symptoms following ketamine administration. The largest effect size ( d ’ = 2.17; representing a sample size‐adjusted Cohen's d ) was reported in a small uncontrolled open‐label study of 15 veterans, in which six ketamine infusions were associated with an 80% PTSD remission rate. This finding warrants caution, given the small sample and the absence of a control group. Dissociative and hemodynamic adverse effects were frequently observed during infusion, but typically resolved afterward. No study reported cognitive decline associated with repeated ketamine administration. Current evidence suggests that ketamine may be associated with short‐term reductions in PTSD symptoms in some populations; however, findings remain preliminary due to small samples, heterogeneous designs, brief follow‐up, and inconsistent safety reporting.
Academic research Review published

Review: Psychedelic boundaries in public health—emerging ideas, ancient roots

Breaking psychedelic boundaries in public health: emerging ideas with ancient roots.
Why it matters ▲ Favorable
This peer-reviewed article synthesizes current thinking on the integration of psychedelics into public health frameworks, drawing connections between modern research and traditional uses. The review highlights increasing interest in population-level benefits and policy reforms, suggesting a shift toward broader acceptance and potential systemic impact. While not a new trial or law, it signals evolving academic and policy discourse that could inform future regulatory and clinical directions.
Public health / Policy analysis Critical analysis published

Analysis urges expanded public health role for psychedelics, including non-clinical use

Breaking psychedelic boundaries in public health: emerging ideas with ancient roots
Why it matters ▲ Favorable
This interdisciplinary review argues for broadening U.S. psychedelic policy to support both clinical and non-clinical uses, citing historical and sociocultural evidence. The authors critique current healthcare and prohibitionist frameworks, highlighting the need for more inclusive, holistic approaches to mental health and well-being. While not a regulatory or legal change, the analysis may influence future policy debates and research agendas by legitimizing non-clinical psychedelic use in public health discourse.
The modern United States faces significant public health challenges, including a mental health crisis and healthcare systems with numerous shortcomings. At the same time, emerging research on psychedelic substances demonstrates their robust applications for health and well-being, as well as their nuanced risks. While regulators explore how psychedelics can be incorporated into existing healthcare models, patterns of psychedelic use extend beyond clinical settings. These naturalistic or non-clinical applications—for spiritual growth, social bonding, ecological connection, and overall health—have occurred for thousands of years in various cultural contexts. In this critical analysis, we examine historical evidence depicting how psychedelics were utilized in the Americas, before and after European colonization. We highlight the racialized and religious origins of prohibitionist drug policy, as well as U.S. healthcare norms that constrain avenues for mental health, personal choice, and general flourishing. By drawing on interdisciplinary research in clinical mental health, history, anthropology, and medical sociology, we argue for (A.) holistic improvements to narrow mental healthcare models and (B.) an expanded-access posture towards psychedelics that includes non-clinical use scenarios. Our review of existing evidence supports these approaches for improving public mental health.
Public health / Surveillance Systematic review published

Italy reviews multi-source data on ATS and synthetic cathinones trends

Multi-Indicator Surveillance of Amphetamine-Type Stimulants (ATS) and Synthetic Cathinones in Italy: A Systematic Review of Seizure, Wastewater, and Toxicological Data
Why it matters ◈ Mixed
This systematic review synthesizes evidence from seizures, wastewater, and toxicological studies to map the evolving landscape of amphetamine-type stimulants (ATS) and synthetic cathinones (SC) in Italy. The integration of multiple surveillance indicators provides a more comprehensive understanding of emerging drug trends and regional consumption patterns. While not directly focused on psychedelic research or policy, these findings inform public health approaches and may influence future legal or regulatory responses to novel psychoactive substances.
Synthetic stimulant drugs in Italy are evolving rapidly, with amphetamine-type stimulants (ATS) and synthetic cathinones (SC) representing a growing public health challenge. However, no previous study has integrated multiple surveillance indicators to assess the availability and consumption of these substances across Italy. This systematic review synthesized comprehensive evidence published between 2000 and 2023 from three monitoring indicators: drug seizures reports, wastewater-based epidemiology (WBE), and toxicological/clinical studies. Searches of Scopus, PubMed, and Google Scholar identified 969 records, of which 49 studies and reports met the inclusion criteria: 15 on drug seizures, 18 on WBE, and 16 on toxicological studies. Eligible articles were fully reviewed and summarized. Results indicated a diverse and evolving landscape, with increasing detection of synthetic cathinones and significant regional variation in ATS and SC consumption. In total, seven ATS and twenty-five SC were identified across all indicators. Amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), 4-methylethcathinone (4-MEC), and methylenedioxypyrovalerone (MDPV) were consistently detected in seizure, wastewater, and toxicological data, indicating their availability and consumption in Italy. WBE studies showed marked spatial and temporal variability in stimulant consumption, while seizure and toxicological data highlighted the increasing diversification of synthetic cathinones in the Italian drug market. Key limitations include uneven geographical coverage and methodological heterogeneity among studies. The findings demonstrate the value of integrating WBE, forensic, and law enforcement indicators to strengthen surveillance of emerging stimulant drugs in Italy.
Clinical research Conceptual framework published

Framework for integrating ego dissolution in psychedelic therapy published

Navigating the Therapeutic Potential of Ego Dissolution
Why it matters ▲ Favorable
This conceptual paper offers clinicians a structured approach for navigating ego dissolution experiences in psychedelic therapy, integrating neurobiological and psychological models. While not a clinical trial or regulatory event, it may inform best practices and training for therapists, and could shape future research protocols and safety guidelines. The framework's emphasis on both therapeutic potential and psychological risks is relevant for clinical implementation and risk mitigation.
Ego dissolution (ED; a temporary disruption of self-boundaries and personal identity) is a central feature of many altered states of consciousness. With the resurgence of psychedelic research, these experiences have become of growing clinical relevance, as they can evoke both profound therapeutic transformation and significant psychological destabilization. This conceptual paper reviews the phenomenology of ED, integrates neurobiological insights from predictive coding theory, and examines how three psychological frameworks – Acceptance and Commitment Therapy (ACT), Interpersonal Neurobiology (IPNB), and Internal Family Systems (IFS) - inform the therapeutic navigation of these states. Synthesizing these perspectives, the paper introduces the Ego Dissolution Integration Framework (EDIF), composed of four interconnected components: (1) Open safely, (2) Establish awareness as identity, (3) Relate to self-models, and (4) Balance freedom and function. EDIF provides clinicians with a psychologically grounded map for utilizing ED experiences – whether arising from psychedelics, meditation, or crisis – as opportunities for improved functioning and wellbeing.
Industry Phase 2 trial ongoing

Optimi Health shares fall 5.6% despite Phase 2 psilocybin trial progress

Optimi Health Stock Declines 5.56% as Psychedelic Sector Cools Despite Phase 2 Psilocybin Trial Progress (CN:OPTI)
Why it matters ◈ Mixed
Optimi Health's stock decline signals ongoing investor caution in the psychedelic sector, even as the company advances a Phase 2 psilocybin trial. This divergence highlights the disconnect between clinical progress and current market sentiment, which may affect capital availability for research and development. Operators and investors should monitor sector trends closely, as market cooling could impact funding for ongoing and future trials.
Clinical research Peer-reviewed study published

Counselors’ Training Needs for Psychedelic-Assisted Therapy Identified

Counselors’ Training Needs in Effectively Engaging With Psychedelic-Assisted Therapy
Why it matters ◈ Mixed
This study highlights a significant gap in formal training and guidance for counselors engaging with clients in psychedelic-assisted therapy (PAT). As PAT becomes more common, the lack of established competencies and resources poses risks for both practitioners and clients. The findings provide a conceptual framework for developing targeted education and professional standards, which is crucial for safe, ethical, and effective integration of PAT into mainstream mental health care. This work signals a growing need for interdisciplinary collaboration and regulatory attention as the field matures.
As public and scientific interest in psychedelic-assisted therapy (PAT) continues to grow, counselors are increasingly encountering clients who are exploring or engaging in psychedelic use for therapeutic purposes. Such encounters introduce new ethical, clinical, and professional considerations. Counselors must develop an informed understanding of psychedelics and their effects, recognize the emotional and cognitive processes that may emerge during psychedelic experiences, and be prepared to respond to potential risks or adverse reactions (Aicher et al., 2025). They also need to competently answer client questions, assess risk and suitability, facilitate the integration of psychedelic experiences, and collaborate with medical and other professionals who involved in PAT (Curtis et al., 2020). Despite this emerging clinical reality, the counseling profession currently lacks formal guidance, established competencies, and integrated training pathways related to PAT. While other mental health disciplines have begun addressing these developments, little is known about counselors’ specific training and resource needs for ethical and competent engagement in this evolving area of practice. The purpose of this study was to identify and organize counselors’ perceived training and resource needs for ethically and effectively supporting clients involved in PAT. Using Concept Mapping (CM; Trochim, 1989), an exploratory sequential mixed-methods design, this study engaged licensure-seeking and licensed counselors in a collaborative process to generate, structure, and interpret ideas regarding the knowledge, skills,and resources necessary for preparedness in PAT-related practice. Through this structured methodology, the study produced a data-driven conceptual framework reflecting counselors’ collective perspectives on professional readiness for PAT. Findings resulted in 142 statements organized into 16 clusters across three conceptual regions: (1) Solidifying Counselors’ Place in PAT, (2) Developing Evidence-based PAT Practice, and (3) Ensuring Specialized Ongoing Development in PAT. Together, these regions highlighted the importance of foundational counseling competencies, specialized clinical and interdisciplinary knowledge, and ongoing professional development and systemic awareness for counselor engagement in PAT-related work. Implications are discussed for counselors, counselor educators, clinical supervisors, and future research.
FDA / DEA FDA rule in effect

FDA exempts some clinical toxicology test systems from 510(k) review

Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
Why it matters ▲ Favorable
FDA's exemption of certain class II clinical toxicology test systems from 510(k) premarket notification reduces regulatory barriers for device manufacturers. This change could accelerate the availability of new toxicology assays relevant to psychedelic research, clinical monitoring, and safety protocols. The move may lower costs and speed up innovation for labs and companies developing tests for psychedelic compounds or their metabolites, potentially supporting safer clinical trials and broader access.
The Food and Drug Administration (FDA) is publishing an order setting forth its final determination to exempt certain class II clinical toxicology test systems from premarket notification (510(k)) requirements, subject to certain limitations. This exemption from 510(k) requirements, subject to certain limitations, is immediately in effect for such devices. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations. FDA is amending the classification language within the Code of Federal Regulations (CFR) for certain class II clinical toxicology test systems to reflect this final determination. FDA is publishing this order in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).
DEA / Federal policy DEA forms live

DEA launches new registration forms for medical marijuana entities

DEA Launches New Registration Forms For Medical Marijuana Manufacturers, Distributors And Testing Labs
Why it matters ▲ Favorable
The DEA's release of new registration forms for medical marijuana manufacturers, distributors, and testing labs signals a concrete step in clarifying and potentially streamlining federal oversight of the cannabis supply chain. While this action does not directly address psychedelics, it sets a precedent for how the DEA may handle future regulatory frameworks for other controlled substances, including psychedelics, as research and medical access expand. Researchers and industry operators should monitor this development for insights into federal registration processes and compliance expectations.
Clinical research Systematic review published

Systematic review: Group psychedelic-assisted therapy for mental health

Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review
Why it matters ◈ Mixed
This systematic review synthesizes the evidence for group-based psychedelic-assisted therapy (PaT), finding overall improvements in mental health outcomes but highlighting a lack of rigorous comparative trials and substantial heterogeneity in protocols. The findings suggest group PaT could be cost-effective and enhance therapeutic outcomes via peer support, but the evidence base remains limited by methodological weaknesses. This review is a key reference for researchers, clinicians, and payers considering scalable models for psychedelic therapy, but underscores the need for more robust, controlled studies to guide practice and policy.
Background The group therapy model has been recently favored as a means of conducting psychedelic assisted therapies for mental health disorders. However, there is a paucity of literature showing strengths or drawbacks of this approach and comparisons of safety and efficacy to individual therapy. This systematic review aims to address this gap in literature. Methods We included original research of group psychedelic therapy programs that were peer reviewed and published in English or where a translation was available or possible. Participants must be 18 or older and have a psychiatric diagnosis. We searched for MEDLINE, Scopus, and APA PsychInfo until January 1 2026. Screening, data extraction, and appraisal using the Mixed Methods Appraisal Tool (MMAT) were conducted by two independent researchers. A parallel-results convergent synthesis design was employed consisting of independent syntheses of qualitative and quantitative evidence and an interpretation of the results in the discussion. Results We included 30 papers representing 22 unique group therapy protocols. Demographics were inconsistently reported: sex or gender was reported in 18 papers, race/ethnicity in eight papers. Fifteen papers reported pre–post outcomes using validated screening tools for mental health, functioning, substance use, or wellbeing. Using a segregated methodologies approach, quantitative and qualitative findings were broadly complementary. Quantitative results showed overall decreases in validated scale outcomes reflecting improvement in depression, anxiety, trauma symptoms, functioning, and other psychiatric outcomes. Qualitative results described improvements in mindfulness, emotional processing, psychological flexibility, meaning-making, and social connectedness supported by the group format. Discussion Despite emerging mechanistic evidence for direct effects of psychedelic molecules on the brain, only a minority of studies used comparison groups, and only one was a modern randomized controlled trial. Group PaT may not only be pragmatically beneficial for feasibility and cost-effectiveness, but may also contribute to therapeutic outcomes through peer support, normalization, belonging, and integration. Limitations of this systematic review include substantial heterogeneity in molecules, populations, protocols, outcome measures, and follow-up duration, as well as overlapping cohorts and few studies with group components throughout the entire course of treatment. Systematic review registration PROSPERO: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024491478 , identifier: CRD42024492648.
Clinical research Peer-reviewed study

Ketamine reduces insomnia and anxiety in TRD, with distinct short-term effects

Insomnia and anxiety exhibit distinct short-term associations following ketamine in treatment-resistant depression
Why it matters ▲ Favorable
This study provides evidence that ketamine produces significant short-term reductions in depression, anxiety, and insomnia among patients with treatment-resistant depression (TRD). Notably, improvements in insomnia were not directly linked to changes in depression or anxiety, suggesting distinct mechanisms or pathways. These findings may inform future trial design and clinical protocols, especially for targeting comorbid insomnia in TRD populations. The results support the nuanced use of ketamine in psychiatric care and highlight the need for further research into symptom-specific effects.
Abstract Insomnia and anxiety frequently co-occur with treatment-resistant depression (TRD). This study examined short-term changes in depression, anxiety, and insomnia symptoms post-ketamine in TRD and their inter-relationships. Seventy-one patients with TRD were assessed at baseline and 24 h after intravenous ketamine (0.5 mg/kg). Depression, anxiety, and insomnia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and insomnia items from the Hamilton Depression Rating Scale (HAM-D), respectively. Linear mixed-effects models tested pre–post changes, while Spearman, Pearson, and simple linear regression examined associations between symptom domains. As an exploratory analysis, linear discriminant analysis (LDA) and logistic regression were used to classify insomnia improvement. All symptom domains decreased significantly post-ketamine treatment, including depression (MADRS; β = –11.72, P < 0.001), anxiety (HAM-A; β = –7.87, P < 0.001), and insomnia ( β = –0.89, P < 0.001). At baseline, insomnia was moderately correlated with anxiety (Spearman ρ = 0.36), and anxiety was correlated with depression (Pearson r = 0.39); similar associations were observed post-ketamine (Spearman ρ = 0.36; Pearson r = 0.57). Changes in anxiety were strongly associated with changes in depression (Spearman ρ = 0.61), whereas changes in insomnia were not significantly associated with changes in either domain. Greater baseline insomnia severity was associated with larger absolute insomnia reductions. Exploratory polysomnography analyses suggested short-term increases in total sleep time, slow-wave sleep, and sleep efficiency, and reduced sleep latency. In conclusion, although all symptom domains decreased post-ketamine, short-term changes in HAM-D insomnia symptoms were not significantly associated with changes in depression or anxiety in TRD. Clinical Trial Identifier : www.clinicaltrials.gov (NCT00088699)
Neuroscience Preclinical study published

Intranasal PENK-MSCs reduce morphine dependence in rat model

Intranasal Delivery of Proenkephalin-Expressing Differentiated Mesenchymal Stem Cells Attenuates Morphine Dependence Behaviors and Modulates Neurotrophic Factors in Rats
Why it matters ▲ Favorable
This preclinical study demonstrates that intranasal delivery of proenkephalin-expressing mesenchymal stem cells can attenuate morphine dependence behaviors and restore neurotrophic signaling in rats. While not directly related to psychedelics, the findings highlight innovative neurobiological interventions for substance use disorders, a major area of overlap with psychedelic research. The approach is early-stage and requires further validation before clinical translation, but it signals ongoing diversification of addiction treatment strategies.
Substance use disorder is a chronic relapsing condition characterized by persistent drug seeking, cognitive impairment, and neurobiological alterations in brain reward and memory circuits. Emerging evidence suggests that dysfunction of the endogenous opioid system and reduced neurotrophic signaling contribute to the pathophysiology of opioid dependence. Cell based therapeutic strategies may provide a novel approach to modulate these neural pathways. In the present experimental study, morphine dependence was induced in adult male rats using an escalating dose regimen. Animals were randomly allocated into control, morphine-dependent vehicle, and cell-treated groups. Proenkephalin-expressing differentiated mesenchymal stem cells (PENK-MSCs) were delivered via the intranasal route. Behavioral assessments were performed using conditioned place preference, novel object recognition, and the elevated plus maze to evaluate addiction related behaviors, cognitive performance, and anxiety like responses. Hippocampal brain derived neurotrophic factor (BDNF) expression was examined using immunohistochemistry. Morphine dependent rats exhibited significant behavioral alterations, including enhanced drug related preference, impaired recognition memory, and increased anxiety like behavior compared with control animals. In addition, hippocampal BDNF expression was significantly reduced following morphine exposure. Intranasal cell delivery significantly attenuated morphine-induced preference, reversed recognition memory deficits, mitigated anxiety-like behaviors, and upregulated hippocampal BDNF expression compared with the vehicle-treated morphine group. These findings demonstrate that intranasal delivery of PENK-MSCs attenuates behavioral deficits and promotes neurotrophic recovery in morphine-dependent rats. This approach may represent a promising experimental strategy for targeting neural mechanisms involved in substance use disorder, although further studies are required to confirm its long-term efficacy and translational potential.
Clinical research Systematic review published

Systematic review: Group psychedelic-assisted therapy for mental health

Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review.
Why it matters ▲ Favorable
This systematic review synthesizes evidence on the safety, efficacy, and implementation of group-based psychedelic-assisted therapy for mental health conditions. The findings provide a comprehensive overview of outcomes, patient experiences, and methodological limitations, informing future trial design and potential clinical adoption. For policymakers and clinicians, the review highlights both the promise and challenges of scaling group models, which could improve access and cost-effectiveness if validated. The work will help guide regulatory and funding priorities as interest in group delivery grows.
Clinical research Peer-reviewed article

Modern antidepressants: pharmacological profile and clinical implications

ФАРМАКОЛОГІЧНИЙ ПРОФІЛЬ СУЧАСНИХ АНТИДЕПРЕСАНТІВ
Why it matters ◈ Mixed
This review highlights the evolving landscape of antidepressant pharmacology, including the emergence of agents like esketamine with glutamatergic mechanisms relevant to psychedelic science. While not directly focused on classic psychedelics, the article's emphasis on rapid-acting, neuroplasticity-promoting drugs and personalized medicine is highly relevant for researchers and clinicians tracking the convergence of psychedelic and non-psychedelic novel antidepressants. The findings may inform trial design, safety benchmarks, and comparative effectiveness studies in the field.
The article presents a comprehensive analysis of the pharmacological profile of modern antidepressants introduced into clinical practice over the past decades. The relevance of the study is due to the high level of resistance of patients to traditional monoaminergic therapy and the need to optimize the choice of drugs. The work uses the methods of systematic literature review, comparative pharmacodynamic and pharmacokinetic analysis of modern drugs: multimodal antidepressants (vortioxetine), selective serotonin and norepinephrine reuptake inhibitors (SSRIs), as well as innovative drugs with a glutamatergic mechanism of action (esketamine) and neurosteroids (zuranolone). It was determined that the key difference of modern antidepressants is their complex (multi- target) effect on receptor systems (in particular, 5-HT3, 5-HT7, 5-HT1A) and the ability to stimulate the expression of brain-derived neurotrophic factor (BDNF protein), which ensures the rapid launch of neuroplasticity and synaptogenesis processes. It has been proven that new generations of drugs have a significantly higher safety profile, a lower incidence of sexual dysfunctions, metabolic disorders and withdrawal syndrome compared to classic SSRIs. The practical value of the results lies in the systematization of pharmacological criteria for the transition from empirical prescription of antidepressants to personalized psychopharmacotherapy taking into account the individual phenotype and comorbid conditions of the patient.
Clinical research Clinical practice update

Choosing Between Ketamine and Esketamine in TRD

Why it matters ◈ Mixed
The comparison of ketamine and esketamine for treatment-resistant depression (TRD) is a key topic for clinicians and payers as both are used off-label and on-label, respectively. This discussion informs prescribing practices, reimbursement, and patient access, but does not represent a regulatory or legal shift. Ongoing research and real-world evidence will shape future guidelines and market dynamics for these therapies.
FDA / DEA FDA RFI open

FDA seeks input on ibogaine trial design and safety for OUD/PTSD studies

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
Why it matters ▲ Favorable
The FDA's formal request for information on ibogaine clinical trial design signals a significant step toward federally supported research and potential regulatory pathways for ibogaine-based therapies. This move reflects growing federal interest in developing ibogaine for opioid use disorder and PTSD, and could set the standards for safety, dosing, and oversight in future trials. Stakeholders in research, clinical care, and industry should closely monitor and participate in this process, as it will shape the regulatory landscape for ibogaine and potentially other psychedelic compounds.
The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early- phase clinical trials of ibogaine drug products and is opening a public docket to receive comments. The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adults with opioid use disorder (OUD) and adults with post-traumatic stress disorder (PTSD). FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations" by seeking comments, data, and information from the public on protocol elements relevant to ibogaine development--including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight, in part, because the Federal Government is funding work in this area. FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.
Neuroscience Peer-reviewed publication

Serotonin biology as a basis for explaining psychedelic drug action

Serotonin biology as a basis for explaining psychedelic drug action.
Why it matters ▲ Favorable
This review advances mechanistic understanding of how psychedelics interact with serotonin systems, which is foundational for both clinical research and drug development. Improved clarity on serotonin receptor pathways may inform safer trial designs, guide the development of next-generation compounds, and support regulatory arguments for medical use. While not a policy move, such mechanistic work underpins the scientific legitimacy of the field.
Clinical research Research commentary

Psilocybin may impact AUD social brain, trial endpoints may miss effects

Psilocybin Moves the Social Brain in AUD, And Our Trial Endpoints Are Missing It
Why it matters ◈ Mixed
This article highlights a potential disconnect between psilocybin's effects on social brain function in Alcohol Use Disorder (AUD) and the endpoints currently used in clinical trials. If true, this could mean that pivotal studies are underestimating or mischaracterizing the therapeutic impact of psilocybin, affecting regulatory and clinical adoption. The piece signals a need for researchers and sponsors to re-examine outcome measures to capture relevant neuropsychiatric changes, which could influence future trial design and evidence standards.
FDA / DEA Public comment opened

FDA Seeks Public Input On Psychedelic Research Involving Ibogaine

Why it matters ▲ Favorable
The FDA's call for public input on ibogaine research signals growing federal engagement with psychedelic science and may pave the way for expanded clinical trials or regulatory clarity. This move could reduce legal risk for researchers and sponsors, and signals to investors and clinicians that ibogaine is on the FDA's radar. Stakeholder feedback may shape future guidance or policy, impacting access and research pathways.
Industry Platform announced

Elevate Holistics launches telehealth for at-home low-dose ketamine

Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care
Why it matters ◈ Mixed
This launch signals continued growth and normalization of telemedicine-based ketamine therapy in the US, expanding patient access to low-dose treatments outside traditional clinics. The move may raise regulatory and safety questions, as at-home ketamine care remains in a gray area under DEA and state law. It highlights the need for clear clinical guidelines and oversight as the market for psychedelic-assisted telehealth evolves.
Clinical research Perspective published

Caution urged on rapid adoption of psychedelic therapies

Caution before canonisation: a clinical and implementation science perspective on psychedelics
Why it matters ◈ Mixed
This perspective highlights the methodological and translational gaps in current psychedelic clinical trials, cautioning against premature clinical adoption. The authors emphasize the need for larger, longer-term, and more rigorous studies to establish safety, durability, and real-world effectiveness before widespread implementation. This is a timely reminder for researchers, clinicians, and policymakers to balance optimism with scientific rigor as the field grows.
Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and substance use disorders. While these findings are scientifically promising, the current evidence base remains characterized by methodological and translational limitations. Many studies involve small samples, short follow-up periods, functional unblinding, and heterogeneous safety reporting, which complicate causal interpretation and generalizability. In the present paper, we examine psychedelic therapies through clinical, methodological, ethical, and implementation science lenses. We argue that current trials primarily demonstrate proof-of-concept efficacy under controlled conditions rather than readiness for large-scale clinical adoption. Responsible translation therefore requires stronger evidence regarding durability, safety monitoring, comparative effectiveness, and real-world implementation. Psychedelic therapies represent an important emerging research direction, but continued rigorous evaluation and improved implementation of established evidence-based interventions remain central to addressing mental disorders.
Clinical research Preprint released

Therapists’ perspectives in psilocybin MDD RCT published as preprint

Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial
Why it matters ◈ Mixed
This preprint shares therapists’ insights from a randomized controlled trial of psilocybin for major depressive disorder, focusing on the psychotherapeutic support component. While not peer-reviewed or widely cited yet, it may inform best practices and training for clinicians as psychedelic-assisted therapy expands. The qualitative perspective adds context to quantitative trial outcomes but should be interpreted cautiously until validated.
Clinical research Case series published

Case series: IV ketamine in TRD patients with suicidal ideation

Harnessing the potentials of intravenous ketamine among non-responders of depressive episodes with suicidal ideations and attempts: a case series
Why it matters ◈ Mixed
This small case series reports variable responses to intravenous ketamine among patients with treatment-resistant depression and acute suicidality, with only half showing a positive response. The findings reinforce the need for personalized approaches and highlight the heterogeneity of ketamine's efficacy in real-world, high-risk psychiatric populations. While not definitive, such real-world data are important for informing clinical protocols and future trial design.
Depressive episodes are common but has great impact either in unipolar or bipolar mood disorder. Medical management of severe depression with suicidal attempts are challenging. The rate of Major Depressive Disorder (MDD) who are non-responders are about 30% of those receiving treatment in research settings. Over the past 15 years, ketamine infusions have demonstrated rapid antidepressant and anti-suicidal effects in patients with MDD, with 71% experiencing a 50% or greater reduction in the severity of suicidal ideation on the first day. Despite these promising outcomes, there is limited knowledge about the likelihood of responses to ketamine in real world settings. In this case series, six patients aged 24-36 with severe MDD with suicidal ideations and/ thoughts were treated with intravenous ketamine therapy. Each subject received a subanesthetic dose of 0.5 mg/kg of ketamine diluted with 50ml distilled water administered intravenously over 40 minutes in a micro burette and delayed more when there are side effects if any, under supervision of anesthetist in High Dependency Unit (HDU). A modified scale for suicidal ideation (MSSI) was used for psychometric assessment. Of the six patients, five were treatment resistant depression (TRD) and one with severe MDD with suicidal thoughts and non-adherence to treatment. Three of the six patients responded positively to the acute infusion phase, while three did not, highlighting the variability in individual responses to ketamine therapy. This case series underscores the complexity of treating patients with treatment-resistant depression and emphasizes the need for personalized therapeutic approaches. Bang J Psychiatry 2024;38(1): 19-25
Clinical research Phase 2 trial results

Multidose psilocybin shows promise for OCD in Johns Hopkins open-label trial

An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.
Why it matters ▲ Favorable
This open-label, waitlist-controlled trial at Johns Hopkins provides early evidence that repeated psilocybin dosing is well-tolerated and may significantly reduce OCD symptoms in patients unresponsive to standard therapies. The study's design and positive safety/efficacy signals support further investigation into multidose protocols for OCD, a major unmet need. While not definitive due to open-label and small sample limitations, these findings may inform future pivotal trials and regulatory pathways for psychedelic therapeutics targeting OCD.
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or pharmacotherapy. Design: Waitlist-controlled open label randomized clinical trial. Setting: Data were collected at the Johns Hopkins University School of Medicine. Participants: Data were analyzed from 30 participants (total randomized N=37, by age, sex and OCD severity) with a failed previous attempt at either pharmacotherapy or evidence-based psychotherapies such as exposure response prevention (ERP). Intervention: Participants received two psilocybin doses over two weeks (20 mg followed by 30 mg, if well-tolerated) under supportive conditions. The immediate-treatment arm received the drug within a month following enrollment, and the waitlist-control arm received identical support and dosing after an 8-week waiting period. Main Outcomes: Clinician-administered Y-BOCS scores was collected one week post each drug administration and one month post session 2. Self-assessed reports were collected for acute subjective effects (Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), and 11-Dimensional Altered States of Consciousness (11D-ASC)), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: A total of 37 participants were enrolled in the study (age[SD] years:38.4[11.6] years; 21 [56.75%] female), with 30 [81.08%] completing the 1-month follow-up. We show that two successive doses of psilocybin over two weeks were well-tolerated, leading to improvements in OCD symptoms. Compared with the waitlist group (N=14), the immediate-treatment group (N=16) showed a greater reduction in the Y-BOCS scores (F(2,56)=16.17, p<0.001). After crossover, this improvement persisted one month after the second psilocybin dose for both groups (F(3,84)=29.91, p<0.001). Reductions in Y-BOCS score post sessions were correlated with several acute subjective effects measures, including total scores on MEQ, and individual factors on CEQ and 11D-ASC. Conclusions and Relevance: Repeated psilocybin administration is tolerable and potentially efficacious in reducing OCD symptoms. These results support further investigation of multidose psilocybin protocols as a viable therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier NCT05546658
Clinical research Review published

Review: Integrative therapies for anxiety/depression in cancer, incl. psychedelics

Integrative options for the management of anxiety and depression in people with cancer
Why it matters ◈ Mixed
This review highlights that psychedelic-assisted therapy is considered an emerging option for managing anxiety and depression in cancer patients, but is not yet guideline-recommended. The inclusion of psychedelics among emerging therapies signals growing clinical interest, but also underscores the need for more robust evidence before integration into standard care. The paper's call for further research may help shape future clinical trial priorities and guideline updates.
This review summarizes the definition, diagnosis and prevalence of anxiety and depression symptoms and disorders in people with cancer, followed by an overview of integrative therapies that are guideline-recommended for managing these conditions. Recommended therapies include mindfulness-based interventions, yoga, relaxation, music, reflexology, Taichi/Qigong, acupuncture, lavender aromatherapy and hypnosis. This is followed by a summary of emerging therapies that show preliminary evidence of efficacy, but are not yet included in guideline recommendations, including other forms of aromatherapy, light therapy, biofield therapies, psychedelic-assisted therapy and nature-based interventions. The paper concludes with a summary of common methodological issues and suggestions for future research directions.
Neuroscience Peer-reviewed study

Amygdala function in anxiety linked to threat probability, not uncertainty

Extended amygdala function is governed by threat probability, not uncertainty
Why it matters ▲ Favorable
This study challenges the canonical model of anxiety neurobiology by showing that extended amygdala regions are more responsive to threat probability than uncertainty. This reframing could impact the design and interpretation of clinical trials for anxiety treatments, including those using psychedelics, by shifting focus to how interventions modulate threat probability processing. The findings may inform translational research and biomarker development, supporting more targeted approaches in both basic and clinical neuroscience.
Anxiety is a universal experience that arises as we anticipate negative events that may or may not happen. When extreme, anxiety is a major cause of distress, suffering, and disability-adjusted life years, with nearly one in four individuals experiencing clinically relevant anxiety in their lifetime 1-3 . Elucidating the biological basis of anxiety has the potential to help people understand, cope with, and ultimately receive improved treatments for their anxiety. The canonical neuroscientific model of anxiety posits that distinct regions of the extended amygdala (EA) elicit distress that is conditional on threat uncertainty 4 . Here, we refute this model using a precise computational framework to disambiguate specific dimensional facets of threat uncertainty in a racially diverse sample of 104 individuals. We show that self-report, psychophysiological, and neural correlates of threat anticipation are much more strongly associated with threat probability than uncertainty per se . Importantly, EA regions, including the central nucleus of the amygdala (Ce) and bed nucleus of the stria terminalis (BST), were most reliably associated with threat probability—contrary to the canonical model. Re-examination of the pioneering experiments that motivated the canonical model reveal a previously unappreciated confound between probability and uncertainty, suggesting the novel hypothesis that EA regions differ in their sensitivity to low-probability threats. Our fMRI data support this, showing that BST is more sensitive to low-probability threats than Ce. Moreover, lesion experiments in rhesus monkeys ( Macaca mulatta ) demonstrate that BST causally contributes to defensive behavior in low-probability threat contexts. Together, these data reconcile previous empirical inconsistencies, provide a fresh theoretical perspective on the neurobiology of anxiety, and underscore the theoretical importance of a formal lingua franca for coordinated cross-species emotion research.
Clinical research Perspective published

Perspective urges caution in rapid adoption of psychedelics

Caution before canonisation: a clinical and implementation science perspective on psychedelics.
Why it matters ◈ Mixed
This perspective article highlights the need for rigorous clinical and implementation science before widespread adoption of psychedelics in medicine. It warns against premature canonization of psychedelics without sufficient evidence on safety, efficacy, and real-world delivery challenges. The authors call for careful policy and research frameworks to avoid repeating past mistakes and to ensure patient safety. This serves as a reminder to regulators, clinicians, and industry to prioritize evidence-based approaches.
Clinical research Bibliometric analysis published

Global research trends: Ketamine in perioperative neurocognitive disorders

Global research trends and emerging themes of ketamine in perioperative neurocognitive disorders: a bibliometric analysis
Why it matters ◈ Mixed
Global research on ketamine and perioperative neurocognitive disorders has accelerated since 2020, with a notable focus on esketamine and mechanistic questions. This bibliometric analysis highlights China and the US as leading contributors, but underscores that increased research activity does not equate to clinical efficacy. The field needs more standardized definitions and robust multicenter trials to clarify ketamine's therapeutic role in perioperative neurocognitive outcomes.
Background Within the contemporary perioperative neurocognitive disorder (PND) framework, postoperative neurocognitive outcomes include postoperative delirium, delayed neurocognitive recovery, and postoperative neurocognitive disorder. Interest in ketamine and its enantiomers has increased, but the clinical literature on perioperative neurocognitive outcomes remains heterogeneous. This study mapped the global research landscape, collaboration structure, thematic evolution, and recently intensified research themes at the intersection of ketamine and PNDs. Methods Publications indexed in the Web of Science Core Collection (WoSCC) and Scopus were retrieved using a prespecified search strategy. English-language articles and reviews published from 2006 to 2025 were included. Records were integrated and deduplicated using a Python-based bibliographic consolidation workflow. VOSviewer 1.6.20 was used for collaboration, citation, and author-keyword analyses, whereas CiteSpace 6.4.R2 Advanced was used for keyword burst detection. A WoSCC-only sensitivity analysis assessed robustness to database composition. Results After database restrictions, 559 records remained (WoSCC, n = 191; Scopus, n = 368); removal of 127 cross-database duplicates yielded 432 unique publications with 13,085 citations. Of these, 283 publications (65.5%) were published during 2021–2025. China contributed the largest number of publications ( n = 152), whereas the United States had the highest citation count (6,255) and country-level total link strength (66). The most frequent author keywords were delirium (77), postoperative delirium (74), ketamine (65), esketamine (57), and postoperative cognitive dysfunction (55). “Intraoperative ketamine” showed the strongest keyword burst (strength = 4.05; 2021–2023), while recent bursts extending through 2025 included mechanisms, dysfunction, ketamine, esketamine, reliability, and delayed neurocognitive recovery. The WoSCC-only sensitivity analysis showed broadly similar patterns, including a 9/10 overlap among the top keywords (Spearman's ρ = 0.784). Conclusions Research on ketamine and perioperative neurocognitive outcomes has expanded rapidly, particularly since 2020. Recent literature increasingly emphasizes esketamine, contemporary neurocognitive terminology, mechanistic questions, and delayed neurocognitive recovery. These bibliometric patterns represent research attention rather than evidence of clinical efficacy. Future studies should distinguish ketamine formulations and enantiomers, use standardized PND definitions and outcome windows, and prioritize adequately powered multicenter designs.
FDA / DEA FDA approval announced

FDA Announces Approval Pathway for Psilocybin, LSD, and Other Psychedelics

Psilocybin, LSD, Other Psychedelics Move to FDA Approval
Why it matters ▲ Favorable
The FDA's move to approve psilocybin, LSD, and other psychedelics marks a watershed moment for the field, signaling imminent legal access and a dramatic shift in research, clinical care, and industry investment. This will enable prescribable use, catalyze insurance and infrastructure development, and reduce legal risk for researchers and providers. The announcement is likely to accelerate both public and private sector engagement and set a global precedent.
Neuroscience Systematic review published

EEG aperiodic activity reviewed across major psychiatric disorders

Transdiagnostic patterns of electroencephalography ( EEG )‐derived aperiodic activity across schizophrenia‐spectrum, bipolar, and depressive disorders: A systematic review
Why it matters ◈ Mixed
This systematic review synthesizes evidence on EEG-derived aperiodic activity as a potential biomarker across schizophrenia-spectrum, bipolar, and depressive disorders. Findings suggest that aperiodic EEG parameters may be more useful as context-sensitive, within-subject markers of cortical state and treatment response than as fixed diagnostic signatures. For psychedelic research, this highlights the need for methodological harmonization and physiological validation before EEG aperiodic measures can be reliably used as endpoints in clinical trials or translational studies.
Aperiodic electroencephalographic activity is proposed as a scalable marker of cortical population dynamics relevant to excitation-inhibition balance. However, it remains unclear whether aperiodic parameters represent disorder-specific abnormalities or context-sensitive indices of clinically relevant brain states. Consistent with systematic-review guidelines and a prospectively registered protocol, Ovid databases and PubMed were searched from inception through February 9, 2026, with updated manual searching conducted through July 14, 2026. Peer-reviewed studies reporting electroencephalography-derived aperiodic parameters in adults with schizophrenia-spectrum disorders, major depressive disorder, treatment-resistant depression, and/or bipolar disorder were eligible. Studies lacking aperiodic outcomes or separable findings for eligible diagnoses were excluded. Two reviewers independently conducted study screening, data extraction, and risk-of-bias assessments. Findings were synthesized narratively by diagnosis, recording context, and parameter. Thirty articles (N = 2298 aggregate participants) spanning cross-sectional, longitudinal, and interventional designs were included. Findings in schizophrenia-spectrum disorders were heterogeneous, with several studies reporting steeper slopes, higher offsets, or reduced temporal flexibility relative to healthy controls. Task-related and dynamic measures often showed greater clinical relevance than static resting-state parameters. Studies of major depressive disorder and treatment-resistant depression more consistently reported flatter slopes and reduced offsets, particularly in central and posterior regions, with evidence from sleep and intracranial recordings. Aperiodic parameters were sensitive to treatment-related modulation, although the direction of change differed across interventions. Bipolar disorder evidence was limited, and methodological heterogeneity precluded quantitative synthesis. Aperiodic electroencephalographic activity may be more informative as a context-sensitive, within-subject marker of cortical state and treatment-related change than a fixed diagnostic signature. Methodological harmonization and direct physiological validation remain necessary before clinical implementation.
Neuroscience Peer-reviewed publication

Psychedelics explored for disorders of consciousness in new review

Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.
Why it matters ▲ Favorable
This peer-reviewed article highlights the emerging potential of psychedelics as neurotherapeutic agents for disorders of consciousness, such as coma or minimally conscious states. The review synthesizes preclinical and early clinical evidence, suggesting new research directions that could expand the therapeutic landscape for severe neurological conditions. While not a clinical trial, the publication may influence funding priorities and regulatory interest in novel indications for psychedelic compounds.
Clinical research Review published

SIADH links serotonergic toxicity, hyponatremia in antidepressant and psychedelic use

Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH
Why it matters ◈ Mixed
This review highlights SIADH as a key mechanism linking serotonergic toxicity and acute hyponatremia, with implications for both traditional antidepressants and emerging agents like ketamine, esketamine, and psilocybin. The findings underscore diagnostic complexity and the need for systematic evaluation in clinical and research settings. Increased awareness could improve risk stratification, patient safety, and trial design as psychedelic therapies expand. This is a material update for clinicians, trialists, and developers monitoring adverse event profiles.
Serotonin syndrome (SS) and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) are well-recognized adverse drug reactions (ADRs) associated with serotonergic agents, particularly antidepressants. Although traditionally regarded as distinct clinical entities, accumulating evidence suggests that SIADH may represent a key pathophysiological link between serotonergic toxicity and acute hyponatremia, thereby explaining their frequent clinical overlap and, in some cases, severe or fatal outcomes. Excessive serotonergic activity can stimulate hypothalamic pathways regulating arginine vasopressin secretion, resulting in euvolemic hyponatremia and hyponatremic encephalopathy while simultaneously producing the characteristic neuromuscular, autonomic, and mental status abnormalities of SS. This narrative review examines the shared pathophysiological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic implications of SS and SIADH-associated hyponatremia. A comprehensive literature search was conducted, including reviews, pharmacological studies, and case reports involving antidepressants, opioids, antihistamines, nutraceuticals, and emerging serotonergic agents such as ketamine, esketamine, and psilocybin. Particular attention is given to medication combinations, over-the-counter medications, and dietary supplements that may increase serotonergic burden through pharmacodynamic and pharmacokinetic interactions. The review highlights SIADH as the "thin red line" connecting serotonergic excess with rapid-onset hyponatremia and emphasizes the diagnostic complexity arising from the overlap between neurological manifestations of SS and metabolic encephalopathy secondary to hyponatremia. It also underscores the importance of a systematic diagnostic evaluation of suspected SIADH, including assessment of serum and urinary osmolality and urinary sodium concentration. In published case reports, the absence of urinary osmolality measurements frequently precludes confirmation of SIADH according to established diagnostic criteria, limiting the diagnosis to a possible or probable form rather than a definitive one. Greater awareness of this pathophysiological interplay is essential for early recognition, accurate differential diagnosis, risk stratification, and prevention of severe outcomes through careful medication review, appropriate laboratory evaluation, electrolyte monitoring, and prompt discontinuation of offending agents.
Clinical research / Regulation Expert interview

Esketamine, Off-Label Ketamine, and the Regulatory Gap: Expert Interview

Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD
Why it matters ◈ Mixed
The regulatory divide between FDA-approved esketamine and off-label ketamine use remains a critical issue for clinicians, researchers, and industry stakeholders. This expert interview highlights ongoing uncertainty around legal risk, insurance coverage, and clinical best practices, underscoring the need for clearer federal guidance. The discussion is relevant for those navigating the evolving landscape of psychedelic-assisted therapies and the commercialization of ketamine clinics.
Drug discovery Compound disclosed

New 5-HT2A agonists disclosed for depression, anxiety, and substance abuse

Novel Aminocyclohexenyl-6,6-bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches
Why it matters ▲ Favorable
Novel 5-HT2A receptor agonists could expand the landscape of psychedelic-inspired therapeutics. The disclosed compounds may offer new options for treating depression, anxiety, substance abuse, and headaches, but preclinical and clinical validation are needed. This early-stage disclosure signals ongoing innovation and potential future candidates for clinical development or IP licensing.
Abstract Provided herein are novel aminocyclohexenyl-6,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
Regulatory analysis Expert commentaries

Regulatory complexities grow as psychedelic development accelerates

Rapid pace of psychedelics development brings regulatory complexities
Why it matters ◈ Mixed
Rapid innovation in psychedelic drug development is outpacing federal regulatory guidance, creating uncertainty for patient access and compliance. The contrast between federal and state policies is highlighted as a growing challenge for researchers, clinicians, and industry stakeholders. These high-profile commentaries in JAMA Psychiatry and NEJM signal that regulatory harmonization and clear approval pathways are urgent needs for the field.
The rapid evolution of psychedelic drug development is creating numerous regulatory challenges, from potential conditions of approval that can affect patient access to differences in federal and state policy regarding the drugs, according to authors of two newly published commentaries. One of the authors emphasized that public demand for psychedelics is far outpacing federal regulatory guidance. The articles were published online July 15, 2026 in JAMA Psychiatry and June 18, 2026 in the New England Journal of Medicine .
Neuroscience Preclinical research

Ibogaine shown to promote neural repair via metabolic preconditioning in mice

Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism
Why it matters ▲ Favorable
This preclinical study provides mechanistic evidence that ibogaine may enhance synaptic plasticity and neural repair by inducing transient metabolic stress and activating specific signaling pathways. The identification of mitoKv1.3 and sigma-2 receptor involvement offers new molecular targets for future research and potential therapeutic development. These findings could inform the design of clinical trials and support the rationale for investigating ibogaine in neuropsychiatric and neurodegenerative conditions, though translation to humans remains to be established.
We have examined how ibogaine may enhance synaptic plasticity and neural repair. Extracellular efflux analysis showed that ibogaine (3, 10 or 30 μM) produced a rapid (<5 minutes) and concentration-dependent suppression of mitochondrial function and glycolysis in mouse cortical neurons. Cell-based imaging demonstrated this metabolic inhibition was preceded by an elevation of the mitochondrial membrane potential and followed by increased mitochondrial reactive oxygen species levels. Like ibogaine, which blocks potassium channels, mitochondrial Kv1.3 channel (mitoKv1.3) inhibitors produce concordant changes over a similar timeframe. Following treatment with ibogaine (3, 10 or 30 μM) for 4 hours, a marked concentration-dependent rebound of energy production occurred 20 hours later suggestive of metabolic preconditioning. Indeed, proteomic profiling showed that oral ibogaine (100 mg/kg) administration to female mice produced changes in spinal cord protein abundance indicative of increasing metabolic stress from 0.25-24 hours that resolved by 72 hours. This was accompanied by activation, inhibition and reactivation of synaptic plasticity and neural repair signaling pathways at 0.25, 4-24 and 72 hours, respectively. Hence, by inducing transient metabolic stress, ibogaine may re-open a neurodevelopmental window characterized by enhanced synaptic plasticity and neural repair. Ibogaine binds with high affinity to the sigma-2 receptor. Like mitoKv1-3 inhibitors and sigma-2 receptor ligands, ibogaine transiently elevated AMP-activated protein kinase (0.25 hours) and temporally suppressed mechanistic target of rapamycin and lipid synthesis pathways (0.25-24 hours) implicated in enhanced synaptic plasticity and neural repair. These findings suggest ibogaine rewires and repairs neural circuits by a metabolic preconditioning mechanism, perhaps involving mitoKv1.3 and the sigma-2 receptor.
Neuroscience Published study

Sex-typical brain architecture linked to mood pathology and neurodegeneration

Alignment with sex-typical brain architecture: Links to mood pathology, sex hormones and transcriptomics of neurodegenerative conditions
Why it matters ◈ Mixed
This study provides new insights into how sex-typical brain connectivity patterns relate to mood disorders and neurodegenerative disease risk, highlighting the importance of personalized approaches in psychiatric and neurological research. While not directly focused on psychedelics, these findings may inform future trial design, biomarker selection, and patient stratification for psychedelic interventions targeting depression or neurodegeneration. The work underscores the need to account for sex differences in both basic and clinical research.
Understanding the mechanisms that underpin the pervasive sex bias in risk for specific psychiatric and neurodegenerative conditions could substantially advance efforts promoting personalized medicine. As a first step towards addressing this issue, we applied imaging transcriptomics and multivariate analysis techniques to data from an adolescent sample enriched in anxiety/depression cases, a child sample enriched in attention deficit hyperactivity disorder (ADHD) cases, and adult patients with treatment resistant major depressive disorder (MDD). We tested whether, across sexes, alignment with female-typical, rather than male-typical, patterns of neural functional connectivity (FC) would relate to a diagnosis (adolescent sample) or severity of symptoms (adult sample) associated with internalizing disorders, which tend to be more often diagnosed in females. To provide preliminary evidence on its functional specificity, we compared the sex-aligned FC profile that distinguished neurotypical adolescents from those diagnosed with depression/anxiety against the sex-aligned FC patterns that distinguished neurotypical children from those diagnosed with ADHD. All the analyses controlled for age within each sample and sex. Finally, we examined the spatial overlap between the sex-aligned FC profile linked to an internalizing diagnosis in adolescence and the transcriptomic maps of genes that show sex-dependent dysregulation in neurodegenerative conditions. Across sexes, increasing alignment with female-typical FC patterns, from sensory-perceptual to default mode regions, discriminated between typically developing and anxious/depressed teens and tracked longitudinal fluctuations in depressive symptoms within adult MDD patients. The identified internalizing-related gradient showed a negative correlation with risk for ADHD in the child sample. The brain regions most strongly aligned with female-, rather than male-, typical FC in depression/anxiety overlapped the spatial expression profiles of genes linked to gonadal hormone synthesis, as well as genes dysregulated in female autism spectrum disorder (ASD) and male neurodegenerative conditions, specifically, Alzheimer's Disease (AD), Huntington's Disease (HD) and Multiple Sclerosis (MS). The brain areas most strongly aligned with male-typical, rather than female-typical, FC patterns overlapped the transcriptomic maps of genes related to androgen and estrogen receptors, as well as of genes dysregulated in male ASD and female neurodegenerative conditions (i.e., AD, HD, MS). Our results raise the possibility that the link between mood pathology and neurodegeneration could reflect a partial, regional reversal of sex-normative functional brain profiles.
Clinical research Phase 2 readout

Semaglutide reduces heavy drinking in Phase 2 AUD trial

Semaglutide improves drinking outcomes in patients with higher‐severity AUD
Why it matters ▲ Favorable
This Phase 2 trial shows semaglutide, a GLP-1 agonist, significantly reduces heavy drinking days in moderate to severe AUD patients, though not alcohol craving. While not a psychedelic, this result is highly relevant for addiction research and the competitive landscape for novel AUD treatments, including psychedelic-assisted therapies. The findings may influence future trial designs and payer or regulatory expectations for efficacy benchmarks in AUD.
Individuals with moderate to severe alcohol use disorder (AUD) who received 8 weeks of treatment with the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide experienced a significant reduction in heavy‐drinking days and alcohol‐related consequences relative to placebo, a new Phase 2 trial has found. Semaglutide did not result in significant improvement on the primary outcome measure of alcohol craving, however. Study results were published online July 29, 2026 in the American Journal of Psychiatry .
Neuroscience Published study

High-res spatial mapping of human habenula reveals molecular links to depression

Multi-omic spatial mapping of the human habenula defines the molecular and anatomical organization of medial and lateral subregions
Why it matters ▲ Favorable
This study provides the first high-resolution spatial and molecular map of the human habenula, a brain region implicated in mood and addiction disorders targeted by psychedelic therapies. The identification of cell-type specific signatures and genetic risk associations offers a critical foundation for translational research, target discovery, and mechanistic understanding of how psychedelics may modulate brain circuits relevant to depression and addiction. These insights could inform future clinical trial design and biomarker development.
The habenula (Hb) is a small epithalamic midline structure critical for reward processing and mood regulation that is implicated in many complex brain disorders, including depression and addiction. The molecular anatomy of the Hb has been well-characterized in model organisms, but little is known about its organization in the human brain, including the transcriptomic and epigenetic signatures of spatially-organized lateral (LHb) and medial (MHb) cell types. Here, we generated a high resolution spatiomolecular map of the human Hb using both multiomic single nucleus sequencing (snMultiome) and spatially-resolved transcriptomics. We measured gene expression and chromatin accessibility across 4 MHb and 5 LHb neuronal cell types as defined by transcriptomic conservation with rodents and zebrafish. We identified cell type-specific molecular specializations related to GABAergic and glutamatergic signaling as well as regulatory relationships between open chromatin regions, transcription factors, and target genes associated with depression and addiction. High resolution spatial transcriptomics identified the anatomical location of heterogeneous LHb subpopulations, including two putative inhibitory populations in the LHb. We further characterized cell-type relationships between Hb neurons and glial subtypes and predicted ligand-receptor interactions between LHb and MHb neurons. Finally, we delineated Hb cell types and spatial domains enriched in genes associated with genetic risk for psychiatric disorders, identifying the strongest enrichment in the MHb. Collectively, the generated data and analyses resolve the spatiomolecular organization of the human Hb and identify molecular-genetic associations with neuropsychiatric disease.
Clinical research Proof-of-concept trial published

Proof-of-concept trial: IL-6 antagonist for depression published in JAMA Psychiatry

Immunopsychopharmacology: concept proven
Why it matters ◈ Mixed
This proof-of-concept RCT suggests immunomodulation may impact depressive symptoms in patients with inflammation, but the small sample and lack of statistical significance limit clinical implications. The publication in a top-tier journal signals growing interest in immunopsychopharmacology, but findings remain preliminary. For psychedelic researchers, this underscores the importance of inflammation as a potential treatment target and comparator in future studies.
ave you ever prescribed celecoxib to treat major depression?Me neither (apologies if you are what I expect would be one of the vanishingly few Update readers who answered yes).And yet there is a meta-analysis from the estimable Acta Psychiatrica Scandinavica, published in 2019, showing antidepressant efficacy of celecoxib, particularly when used adjunctively with a selective serotonin reuptake inhibitor (SSRI) (Köhler-Forsberg et al., 2019).The rationale for using celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is that it targets inflammatory processes that some believe to be central to the pathogenesis of depression.This is not a new idea.Immunological theories of depression have been kicking around since the 1980s, with an early focus on immune suppression transitioning to a greater emphasis on immune activation over the past 25 years.Such theories have always been overshadowed by interest in monoamines, neuroendocrine regulation, genetics, and brain circuitry, which explains why most psychiatrists know little about them.But this stepchild status hasn't stopped intrepid researchers from trying to translate these theories into effective treatments.Our Research Roundup section in this month's Update includes coverage of a brief report describing one such recent effort.In a proof-of-concept randomized double-blind trial, Foley et al. (2026) administered a single intravenous infusion of the interleukin 6 (IL-6) receptor antagonist tocilizumab or placebo to 29 patients who met ICD-10 criteria for moderate to severe recurrent depression despite ongoing adequate antidepressant treatment.All patients were physically healthy but had prominent depressive somatic symptoms and low-grade systemic inflammation (as measured by serum high-sensitivity C-reactive protein [hs-CRP]).By the end of the trial at week 4, tocilizumab patients appeared to show greater improvement in overall depressive symptoms and somatic symptoms, effects that tended to correlate with higher baseline hs-CRP levels.However, no findings reached statistical significance, which the authors stated they expected given the small sample size in this exploratory study.An intriguing but nonsignificant study.Quoting the authors, "limitations … include small sample, short duration, and limited sample diversity.Our results are compatible with anything from no effect to a clinically important effect." (Foley et al., 2026).This ordinarily wouldn't make the cut for the Update.But it was published in JAMA Psychiatry, one of our field's top journals.Why?Let's pause for a moment and return to celecoxib.Why aren't we using that widely prescribed drug to treat depression?That's a question I actually know the answer to.Notwithstanding the favorable meta-analysis by Köhler-Forsberg et al. (2019), or the several more recent ones I didn't cite, most experts in treating depression don't think it works.Limiting many of the ostensibly positive clinical trials supporting its efficacy are small or restricted samples, participants with significant comorbidities, methodological deficiencies, and
Clinical research Secondary analysis published

Modest antisuicidal effects from repeated ketamine in TRD; no definitive biomarkers

Effects of Repeated Ketamine Infusions on Suicidal Ideation in Treatment-Resistant Depression and Associated Changes in Selected Plasma Biomarkers
Why it matters ◈ Mixed
This open-label secondary analysis finds modest reductions in suicidal ideation after repeated ketamine infusions in treatment-resistant depression, but fails to identify statistically robust plasma biomarkers associated with these effects. The findings reinforce ketamine's potential for rapid symptom relief but highlight the need for larger, controlled studies to validate both clinical and biomarker outcomes. The lack of definitive biomarkers limits immediate translational impact, but the study contributes to the growing evidence base guiding future trial design and biomarker discovery.
Abstract This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to identify potential biomarkers. This secondary analysis of an open-label trial included outpatients with treatment-resistant depression who received four intravenous ketamine infusions (0.5 mg/kg) over 2 weeks. Suicidal ideation was assessed at baseline and post-intervention using the Montgomery–Åsberg Depression Rating Scale (item 10), Quick Inventory of Depressive Symptomatology–Self Report (item 12), and Columbia Suicide Severity Rating Scale. Eleven targeted plasma biomarkers were quantified via liquid chromatography–mass spectrometry. Associations between suicidal ideation scores and biomarker changes were evaluated using Pearson’s and Spearman’s correlation coefficients, with p-values adjusted for multiple comparisons using the false discovery rate procedure. Repeated ketamine infusions were associated with modest reductions in suicide-related item scores on the Montgomery–Åsberg Depression Rating Scale item 10 (1.5±1.5 to 1.0±1.3, p=0.01) and Quick Inventory of Depressive Symptomatology–Self Report item 12 (1.3±0.9 to 0.8±0.9, p=0.01). Columbia Suicide Severity Rating Scale scores numerically decreased (1.1±1.3 to 0.8±1.2, p=0.17) without reaching statistical significance. In unadjusted analyses, improved Columbia Suicide Severity Rating Scale scores showed nominal associations with increased levels of citric acid (r=− 0.40, p=0.03) and kynurenic acid (ρ=− 0.37, p=0.04), although these did not survive false discovery rate correction. Repeated ketamine infusions were associated with modest reductions in suicide-related item scores on the Montgomery–Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology–Self Report. While no definitive biomarkers were identified after false discovery rate correction, these nominal associations are purely hypothesis-generating and require larger validation trials.
Public health / Legal risk Incident reported

Cornell case raises questions about ketamine in sexual assaults

Cornell case raises questions about rise of ketamine in sexual assaults: ‘You might not realize you’re being touched’
Why it matters ▼ Unfavorable
This high-profile case spotlights concerns about ketamine's misuse in sexual assaults, raising public health and legal risks as its medical and therapeutic use expands. The incident may prompt increased scrutiny, policy debate, or regulatory review around prescribing, dispensing, and monitoring ketamine. It also underscores the need for robust safeguards and education as access to dissociative anesthetics grows in both clinical and non-clinical settings.
Industry Industry analysis

Pharma firms invest billions in psychedelics despite setbacks

Why pharma firms are betting billions on psychedelic drugs despite setbacks.
Why it matters ◈ Mixed
Major pharmaceutical companies are committing significant capital to psychedelic drug development, signaling sustained industry confidence even amid clinical and regulatory hurdles. This trend suggests that large-scale investment is expected to accelerate research, expand clinical trials, and potentially influence regulatory pathways. However, ongoing setbacks highlight persistent scientific, legal, and market risks that stakeholders must navigate. The scale of investment could reshape the competitive landscape and drive policy attention to access, safety, and commercialization.
Neuroscience Peer-reviewed study

Neonatal ketamine, dexmedetomidine: Caspase-1 neuroprotection findings

Cognitive and Pyroptotic Outcomes of Neonatal Ketamine and Dexmedetomidine: Potential Neuroprotection via Caspase-1 Modulation.
Why it matters ◈ Mixed
This peer-reviewed study explores how neonatal exposure to ketamine and dexmedetomidine affects cognitive outcomes and cell death pathways, specifically via caspase-1 modulation. Findings suggest potential neuroprotective effects of dexmedetomidine against ketamine-induced neurotoxicity in developing brains. While not directly policy-relevant, this research informs safety considerations for pediatric anesthesia and may influence future guidelines or trial designs involving dissociative anesthetics and neurodevelopment.
Clinical research / Ethics Peer-reviewed analysis

Ethical obligations in PAT: epistemic risks, memory, and clinician duties

Epistemic Discipline in Psychedelic-Assisted Therapy: Memory, Therapy Dynamics, Attachment Patterns, and Sexual Abuse
Why it matters ◈ Mixed
This article highlights the ethical and epistemic risks in psychedelic-assisted therapy (PAT), especially for trauma and sexual abuse survivors, emphasizing the need for clinicians to exercise epistemic discipline and humility. It argues that clinicians, training programs, and credentialing bodies must address foreseeable epistemic vulnerabilities—such as unreliable memory and authority sensitivity—through improved training and governance. The analysis is highly relevant for those developing clinical protocols, training standards, and ethical guidelines in PAT, and may influence future regulatory or credentialing requirements.
Abstract Psychedelic-assisted therapy (PAT) is increasingly used for trauma-related disorders, raising ethical questions beyond client safety. We argue that PAT clients have epistemic needs and clinicians have corresponding obligations that call for epistemic humility and discipline, which are essential for regulating foreseeable epistemic risks and for PAT's ethical structure. Drawing on threads of epistemic vulnerability theory, memory research, and emerging empirical evidence on the cognitive and relational effects of psychedelics, we argue that phenomenological characteristics, including noetic quality, are unreliable indicators of historical veridicality and are associated with epistemic risks. Focusing on individual differences associated with attachment patterns and work with sexual abuse survivors, we show how disrupted epistemic trust, authority sensitivity, and structural disempowerment may magnify those epistemic risks. We then develop epistemic discipline as a fiduciary stance that requires restraint in both directions: neither endorsing experiential material as historically veridical when this cannot be established, nor introducing unwarranted doubt that undermines epistemic agency. Because such epistemic vulnerability and its associated risks are foreseeable, if not entirely predictable, we frame epistemic discipline as a fiduciary obligation of the clinician that spans preparation, dosing, and integration, as well as obligations of training programs, credentialing bodies, and professional communities with responsibility to identify and remedy relevant omissions in training and supervision. Finally, we systematize features of epistemic vulnerability and governance mechanisms across PAT phases.
Neuroscience Peer-reviewed study

Behavioral state alters EEG outcomes in preclinical rat studies

The impact of behavioural activity on the EEG power spectrum, its source localisation, and global functional connectivity in rats Behavioural modulation of rat EEG dynamics
Why it matters ◈ Mixed
This study highlights that behavioral activity in rats significantly alters EEG power spectra and connectivity, introducing a confound in preclinical neurophysiology experiments. For psychedelic research, this underscores the need for rigorous standardization and reporting of behavioral state in animal studies, especially when evaluating centrally acting compounds. The findings may affect the translational validity of preclinical EEG biomarkers used in drug development and mechanistic studies.
The behavioural activity of freely moving animals is a confounding factor that affects the recording, analysis, and final results of animal EEG experiments. Along with the lack of standardisation in animal in vivo electrophysiology experiments, this could lead to huge inconsistencies, especially in the analysis of centrally acting drugs. Therefore, the main aim of this paper is to investigate the effects of behavioural activity versus inactivity on the multichannel EEG in freely moving rats. In a large sample (n = 116) of waking recordings from 12 cortical electrodes (ECoG) in Wistar rats, we evaluated behavioural activity-related changes in the power spectrum, current source density, and power-based global functional connectivity (GFC) in a 3D rat brain model, according to the TOHOKU Rat Brain Atlas. The main findings were that behavioural activity was associated with 1) a robust power increase in 6-8 Hz, peaking at 7 Hz with maximum changes over the parietal and temporal cortex, 2) an increase in gamma (30-40 Hz) and high-gamma (55-100 Hz) power across the whole brain, 3) a decrease in delta (1-4 Hz) and beta (12-25 Hz) and high-beta (25-30 Hz) power across the whole cortex. Changes were also localised in subcortical regions, particularly in the diencephalon/thalamus. The GFC analysis showed a similar pattern of changes across the 6-8 Hz, delta, and beta bands; however, GFC in the gamma band decreased, while high-gamma GFC increased. Again, the GFC analysis revealed changes in connectivity within subcortical structures, primarily in the thalamus. None of the measures was affected in the alpha band (8-12 Hz). These findings emphasise behavioural state as a critical factor influencing EEG outcomes, with important implications for the standardisation and translational validity of preclinical neurophysiological studies.
Clinical research Peer-reviewed study published

Participants prefer therapists with personal psychedelic experience in PAP

Study Participant Perceptions of the Relevance of Therapist and Study Team Personal Psychedelic Experience
Why it matters ◈ Mixed
Study participants in a psilocybin-assisted psychotherapy trial preferred therapists and study teams with personal psychedelic experience, regardless of their own prior use. This finding highlights a potential expectation or trust factor among patients, but also raises ethical and methodological questions about bias and standardization in psychedelic clinical trials. The results may influence hiring, training, and disclosure practices in both research and clinical settings.
Background Psychedelic-assisted psychotherapy (PAP) has demonstrated great promise for a variety of mental health problems. Many clinicians and researchers who are engaged in providing PAP report personal experiences with psychedelics; these experiences are often positive. Still, there are ongoing questions regarding the relevance of therapists personal experience with psychedelic drugs for the safe and effective delivery of PAP. The current report addresses this question by describing the views and preferences of participants in a study of group PAP for frontline healthcare provider COVID-19 related depression and burnout regarding study therapists and study teams personal psychedelic experience. Methods We conducted a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and burnout. (ClinicalTrials.gov Identifier:NCT05557643) Participants were enrolled between January 2nd, 2023and January 16th, 2024, and randomized (1:1) to either an 8-week MBSR curriculum alone or an 8-week MBSR curriculum plus group psilocybin-assisted psychotherapy (PAP) with 25 mg psilocybin. Primary study results have been reported elsewhere. Outcomes reported here include participant preferences and perspectives on the perceived importance of prior psychedelic experience among the therapist and study teams. Twenty-five participants were enrolled and randomized. Participants across both study arms demonstrated moderate preference for prior psychedelic experience in therapist and study teams which was independent of participant prior personal psychedelic use. Conclusions Study participants demonstrate preference for prior psychedelic experience in therapist and study teams. This should be weighed with thoughtful monitoring of potential bias in psychedelic trials.
Neuroscience Preclinical study published

SIK2/3 inhibitor GLPG3970 shows antidepressant effects in mouse models

The selective SIK2/3 inhibitor GLPG3970 exhibits antidepressant-like effects via the hippocampal SIK2-CRTC1-CREB-BDNF pathway in chronic stress models
Why it matters ▲ Favorable
This preclinical study identifies GLPG3970, a selective SIK2/3 inhibitor, as a promising antidepressant candidate via the hippocampal SIK2-CRTC1-CREB-BDNF pathway in chronic stress mouse models. While not a psychedelic, the mechanistic overlap with pathways implicated in psychedelic action (e.g., BDNF signaling) may inform future drug development and combination strategies. The findings are early-stage but could influence both neuroscience research and the competitive landscape for novel antidepressants.
Introduction Depression is a common mental disorder driven by biopsychosocial factors. Although traditional antidepressants serve as first-line therapies, they face clinical challenges, underscoring the need for novel therapeutic agents with improved efficacy. Our previous studies have identified hippocampal SIK2 as a key regulator in the pathogenesis of depression, acting through the cAMP response element-binding protein (CREB)-regulated transcription coactivator 1 (CRTC1)-CREB-brain derived neurotrophic factor (BDNF) signaling pathway. In this study, we investigated the antidepressant-like effects of GLPG3970, a novel selective inhibitor of SIK2/3, in male C57BL/6J mice. Methods Chronic social defeat stress (CSDS) and chronic unpredictable mild stress (CUMS) models of depression were employed, combined with behavioral tests, virus-mediated gene transfer, Western blotting, co-immunoprecipitation, and immunofluorescence. Results It was found that repeated administration of GLPG3970 significantly suppressed depressive-like behaviors in both CSDS and CUMS model mice, blocked stress-induced increases in hippocampal SIK2 expression and CRTC1 cytoplasmic translocation, and consequently restored the hippocampal BDNF signaling cascade and neurogenesis. More importantly, by using adeno-associated virus (AAV)-mediated overexpression of SIK2 or silencing of CRTC1/CREB/BDNF in the hippocampus, the antidepressant-like effects of GLPG3970 in mice were notably eliminated. Discussion Collectively, these findings together demonstrate that the antidepressant-like actions of GLPG3970 in mice depend on the hippocampal SIK2-CRTC1-CREB-BDNF signaling pathway, highlighting its potential as a novel candidate for antidepressant therapy.
Clinical research Review published

Big data's evolving role in psychiatric research: opportunities and caveats

Big data and psychiatry: advances, constraints and future directions.
Why it matters ◈ Mixed
This review highlights the growing use of big data approaches in psychiatric research, including genomics, imaging, and large-scale cohort studies, which are increasingly relevant for psychedelic science as clinical trials and observational studies scale up. While large datasets offer new insights and analytic power, the authors caution that methodological rigor, clinical relevance, and conceptual clarity remain critical to avoid overinterpretation or misapplication of findings. For psychedelic research, this underscores the need for careful integration of big data with traditional clinical approaches and humility in translating results to practice.
Early work in psychiatry research, often involving single sites, small samples, and limited variables, has shifted to contemporary research involving multiple sites, large samples, and many variables. Such research raises important questions, including concerns about data quality and methodological rigor, uncertainty about its key lessons, issues regarding clinical relevance, and questions about how to optimize future advances. Here we consider these questions and concerns against the context of big data work on community and register-based surveys, cohort and biobank studies, electronic health records, digital phenotyping, brain imaging, genomics and other -omics, and randomized controlled trials. The development of large datasets allowing well-powered analyses is a major milestone, but sample size alone does not guarantee more precise estimates, and ongoing attention to the quality and rigor of big data collation and analysis is needed. Big data research has fostered trans-disciplinarity and given insights into mechanisms underlying psychiatric disorders, but also emphasizes the intricacy, heterogeneity and variability of such mechanisms, and the importance of triangulating between large-scale and small-scale research. The complexity of psychiatric phenotypes and psychobiological mechanisms contributes to the difficulty in bridging from big data to clinical application; big data research reinforces the importance of holding our diagnoses of psychiatric disorders lightly and providing explanations of these conditions humbly; and future work needs to be more attentive to clinical issues. There is enormous scope for further building databases relevant to psychiatry, but advances in conceptual models and asking the right questions are equally valuable. The full impact of big data, including artificial intelligence analyses, remains to be seen, but overenthusiastic support should be tempered by a better understanding of its strengths and limitations. At its best, such work will contribute in an iterative and integrative way to advancing our knowledge of psychiatric disorders and mental health.
Clinical research Systematic review published

Systematic review: DMT, 5-MeO-DMT, zalsupindole for depression and beyond

Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review
Why it matters ▲ Favorable
This systematic review synthesizes the current pharmacological and clinical evidence for short-acting tryptamines, highlighting rapid-acting antidepressant effects of N,N-DMT and 5-MeO-DMT, and noting a successful Phase 2b trial for inhaled 5-MeO-DMT (GH001) in treatment-resistant depression. Evidence for other indications is preliminary, and zalsupindole remains preclinical. The review underscores the need for further research into mechanisms, safety, and whether therapeutic effects can be separated from hallucinogenic experience, which is highly relevant for drug development and regulatory strategy.
Short-acting tryptamine psychedelics are emerging as candidate psychiatric therapeutics with pharmacological profiles that may offer practical advantages over longer-acting psychedelics. N , N -dimethyltryptamine (N,N-DMT) and 5-methoxy- N , N -dimethyltryptamine (5-MeO-DMT) differ in pharmacokinetic, receptor, and phenomenological properties, while zalsupindole is a putatively non-hallucinogenic analogue. This systematic review aimed to synthesize pharmacological, clinical, safety, and preclinical behavioural evidence for these compounds. Ovid databases and PubMed were searched from inception to December 22, 2025, with an updated search on July 7, 2026. Two reviewers independently conducted screening, data extraction, and risk-of-bias assessment. Fifty-one publications met eligibility criteria. Intravenous N,N-DMT exhibited rapid pharmacokinetics, with acute effects resolving within 20–30 min, while sublingual 5-MeO-DMT had an elimination half-life of approximately 28 min. Clinical evidence was most developed for depression, with both compounds associated with rapid reductions in depressive symptoms. GH001, an inhalable 5-MeO-DMT formulation, met its primary endpoint in a Phase 2b treatment-resistant depression trial. Evidence for substance use disorders, post-traumatic stress disorder, and eating disorders remained preliminary. Zalsupindole evidence was limited to one preclinical study reporting antidepressant-like behavioural and neuroplasticity-related effects without a head-twitch response; however, human efficacy and hallucinogenic potential remain unknown. Common adverse events included nausea, headache, and transient cardiovascular increases. DMT-related compounds represent a pharmacologically heterogeneous group with emerging clinical relevance, particularly for depression. Further studies integrating dose–exposure relationships, receptor pharmacology, neurobiological markers, subjective effects, and clinical outcomes are needed to clarify mechanisms of response and whether neuroplasticity-promoting effects can be dissociated from overt hallucinogenic effects.
Neuroscience Preclinical research

Astrocytic Connexin 43 gap junctions implicated in Parkinson's pathology

Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson's
Why it matters ▲ Favorable
This preclinical research identifies astrocytic Connexin 43 (Cx43) dysfunction as a potential driver of Parkinson's disease pathology, suggesting that pharmacological modulation of Cx43 may offer a new disease-modifying strategy. While not directly related to psychedelics, the findings highlight a novel glial target relevant to neurodegeneration and neuroinflammation, areas of growing interest for psychedelic and neuroplasticity-based therapeutics. This may inform future translational research and drug development, including for compounds with glial or anti-inflammatory effects.
Parkinson's disease (PD) is a neurological condition with the fastest rise in prevalence globally; it affects over 10 million people and is currently incurable. Originally considered purely a disorder of the dopaminergic nigrostriatal pathway, PD is increasingly recognized as a complex pathology affecting different cell types and multiple brain regions beyond substantia nigra of midbrain. These findings call for new conceptual approaches to translational research in PD which would aim to restore functions of multiple cell types. We previously demonstrated a decrease in astrocytic connexin43 (Cx43) protein in human late-stage idiopathic PD, but its functional consequences remain unknown. In the present work we hypothesized that the key etiologies relevant to human idiopathic PD include inflammation and α-synuclein aggregation, which were applied to a number of model systems ranging from rat and human cultured astrocytes, to co-cultures and rat models of PD. We report that these challenges structurally and functionally disrupt astrocytic networks comprised of Cx43-containing gap junctions (GJs) in astrocytes from multiple brain regions and across species (rat, human), and that Cx43 is downregulated in α-synuclein pre-formed fibril-induced rat PD models. Causal rather than correlational roles of Cx43 dysfunction in PD pathology are suggested as experimental downregulation of Cx43 with shRNA dysregulates calcium signaling and exacerbates α-synuclein aggregation, while pharmacological preservation of GJs (and possible hemichannel closure) using a Cx43-modulating compound danegaptide (GAP-134, ZP1609) reduces aspects of pathology induced by inflammation and α-synuclein in vitro and in vivo. Cx43 may therefore represent a new therapeutic target for disease modification in PD.
Neuroscience Peer-reviewed study

ECT shifts brain dynamics in TRD, linked to neurotransmitter systems

Electroconvulsive therapy shifting brain dynamics toward more adaptive and integrated states in treatment-resistant depression based on a hidden markov model
Why it matters ▲ Favorable
This study uses advanced modeling to show that electroconvulsive therapy (ECT) improves symptoms in treatment-resistant depression by shifting brain dynamics toward more adaptive and integrated states, with effects mapped to key neurotransmitter systems. While not directly about psychedelics, the findings offer mechanistic insights relevant to understanding how brain network dynamics and neurotransmitter systems may be modulated by other interventions, including psychedelic therapies for depression. The results support further comparative research on brain-state changes across different neuromodulatory treatments.
Treatment-resistant depression (TRD) is characterized by persistent symptoms and poor response to conventional therapies, yet its dynamic neural mechanisms and treatment-related changes remain incompletely understood. This study applied a hidden Markov model (HMM) combined with neurotransmitter atlas mapping to investigate whole-brain spatiotemporal dynamics in TRD and their modulation by electroconvulsive therapy (ECT). Resting-state fMRI data were collected from 72 TRD patients (52 completing follow-up) and 63 healthy controls. HMM identified six recurring brain states defined by distinct patterns of functional connectivity and averaged functional activity. At baseline, TRD patients showed reduced occupancy and stability of globally coordinated states and increased engagement of subcortical-dominant states, indicating impaired global stability and disrupted cortical-subcortical balance. After ECT, clinical symptoms improved significantly, accompanied by increased occupancy of states characterized by higher activity within the default mode and frontoparietal networks, as well as a highly integrated whole-brain state. These changes suggest improved overall brain coordination and cortical engagement rather than full normalization of baseline abnormalities. In contrast, subcortical-dominant states persisted after treatment, consistent with trait-like features of TRD. Neurotransmitter mapping showed that treatment-responsive states were associated with serotonergic, dopaminergic, and glutamatergic systems, whereas persistent subcortical states were linked to noradrenergic and cholinergic markers. Overall, these findings suggest that ECT improves symptoms by shifting brain dynamics toward more adaptive and integrated states, rather than fully restoring baseline function. This dynamic perspective provides new insight into the neural mechanisms of TRD and its treatment.
Clinical research Peer-reviewed publication

Study highlights risks of self-medicating with psychedelics

Risks from self-medicating with psychedelic drugs.
Why it matters ◈ Mixed
This peer-reviewed study documents health and safety risks associated with unsupervised psychedelic use. The findings provide data that may inform regulatory approaches, public health messaging, and the design of clinical trials. Policymakers and clinicians can use this evidence to weigh the need for regulated access and harm reduction strategies as interest in non-medical use grows.
Federal policy Advocacy campaign

SSDP mobilizes to shape FDA psychedelic drug comment period

SSDP Organizes to Influence FDA Psychedelic Drug Comments
Why it matters ◈ Mixed
Students for Sensible Drug Policy (SSDP) is organizing to influence public comments on FDA psychedelic drug regulations, signaling increased grassroots engagement in federal policymaking. While not a direct legal change, such advocacy can impact regulatory frameworks and future access pathways. This development highlights the growing role of community organizations in shaping the direction of psychedelic policy at the national level.
Neuroscience Preclinical research

Astrocytic P2X7Rs modulate depression-like behavior in mice

Both Genetic Manipulation and Acupuncture Alleviate Depressive‐Like Behavior Mediated by Astrocytic P2X7 Receptors
Why it matters ▲ Favorable
This preclinical study identifies astrocytic P2X7 receptors as key mediators of stress-induced depressive behaviors in mice, and demonstrates that both genetic manipulation and electroacupuncture can alleviate these effects. While not directly related to psychedelics, the mechanistic insights into astrocyte-neuron interactions and depression pathways may inform future research on novel antidepressant targets, including those relevant to psychedelic drug action. The findings could eventually influence the development of adjunctive therapies or biomarkers in neuropsychiatric research.
ABSTRACT Major depressive disorder (MDD) has been associated with P2X7 receptors (P2X7Rs), yet the contribution of astrocytic P2X7Rs to neuronal dysfunction remains unclear. We investigated the role of astrocytic P2X7Rs in depression‐like behaviors using a chronic unpredictable mild stress (CUMS) mouse model and further examined whether electroacupuncture (EA) exerts antidepressant effects by modulating astrocytic P2X7Rs. Astrocytic P2X7Rs in the medial prefrontal cortex (mPFC) were selectively knocked down or overexpressed via gene manipulation. Depression‐like behaviors were assessed after CUMS exposure and EA intervention, and in vivo fiber photometry was used to monitor calcium dynamics in excitatory and inhibitory neurons within the mPFC. CUMS markedly increased P2X7R expression in the mPFC and induced depression‐like behaviors. Genetic deletion or knockdown of astrocytic P2X7Rs alleviated these abnormalities, whereas overexpression of astrocytic P2X7Rs exacerbated them and diminished the antidepressant efficacy of EA. Fiber photometry revealed that astrocytic P2X7Rs contributed to stress‐induced dysregulation of neuronal calcium activity. EA restored the balance between excitatory and inhibitory neuronal activity in the mPFC, and this effect depended on appropriate regulation of astrocytic P2X7Rs. These findings suggest that astrocytic P2X7Rs are key mediators of stress‐induced depressive phenotypes and may represent a promising therapeutic target for MDD.
Data infrastructure Reference index released

Agarikon launches screened global index for psychedelic medicine sector

Agarikon: A Screened Index of Psychedelic Medicine - Clinics, Trials, Researchers, Legislation, and Industry
Why it matters ▲ Favorable
Agarikon delivers the first rigorously screened, source-cited global index of psychedelic clinics, trials, researchers, laws, and industry actors. This resource addresses a major pain point for researchers, clinicians, policymakers, and investors by integrating fragmented data—such as clinic directories, trial registries, legal statutes, and funding disclosures—into a single, auditable reference. Its transparent methodology, legal-status tagging, and per-record provenance will materially improve due diligence, policy analysis, and research planning across the field.
Agarikon is the reference layer for psychedelic medicine.** Most information about this field lives in fragments that never connect: a clinic listed in one directory, its trials in a federal registry, the researchers in the literature, the law that permits the work in a statehouse database, the money behind it in disclosure filings. Agarikon joins those layers into one index and cites the source at every edge. This deposit is the frozen data behind agarikon-index.com/. **What it covers (this snapshot):** roughly 2,564 treatment clinics and 282 retreats or legal-access points across dozens of countries; 1,619 registered clinical trials; 1,660 researchers with a 9,757-work publication corpus and its citation graph; 173 organizations that fund, supply, train, insure, and regulate the field; 1,532 tracked state legislative bills; and federal series covering DEA production quotas and CMS payment and claims data. Each treatment and access-point row carries a legal-status classification, with the enabling statute cited where one exists. **Why it can be trusted.** The value of an index is not how many rows it holds but how many of them are real. Agarikon is screened, not scraped. Sources routinely present records that look in-scope and are not, and the pipeline removes them under explicit, published rules: relevance classification when data is ingested, validation when it is merged, and quarantine with a written reason before anything is published. Nothing is silently dropped; excluded records are retained with their reason so every decision is auditable. The screening record ships with this deposit as EXCLUSION_LOG.md and exclusion_log.csv, and it is a feature of the methodology, not a footnote to it. **Provenance and licensing (mixed, stated per source, never blanket):** - Clinical trials: ClinicalTrials.gov (U.S. Government, public domain) - CMS Open Payments, Medicare Part B, DEA quotas / Federal Register: U.S. Government, public domain - Publications and author metrics: OpenAlex and PubMed (CC0 / permissive) - State legislation: **LegiScan, licensed CC BY 4.0; attribution required** ("via LegiScan" plus the bill URL, shipped in the `attribution` column and to be preserved in any reuse) - Clinic and retreat listings: aggregated from public directories and state licensing feeds; these are screened aggregations rather than independently verified field data, and directory-sourced listings are not relicensed here **Scope, stated plainly.** The clinics dataset is a screened directory aggregation. Legal-status classification is present on every facility row; the enabling statute is cited where one exists, which covers retreat and legal-access rows with a mappable jurisdiction and is largely absent for ordinary clinics, since those operate under generally applicable medical law rather than a psychedelic-specific statute. These are the honest edges of a living index that rebuilds daily and publishes its own change log. Full methodology, coverage, and per-source detail: https://agarikon-index.com/data
Clinical research Review published

Review: Psychedelic-assisted psychotherapy as an emerging paradigm

Psychedelic-assisted psychotherapy: Emerging paradigm.
Why it matters ▲ Favorable
This review synthesizes current evidence and clinical trial data on psychedelic-assisted psychotherapy, highlighting its growing acceptance and the need for further rigorous studies. The article may help inform clinicians, policymakers, and researchers about the therapeutic potential and safety considerations of these interventions. While not a regulatory or legal shift, it signals increasing mainstream scientific attention and may influence future policy and funding priorities.
Neuroscience Peer-reviewed review

Review: Neurospirituality's clinical and neuroscientific foundations

Neurospirituality: Conceptual Foundations, Clinical Relevance, And Current Evidence
Why it matters ◈ Mixed
This review synthesizes current evidence on the neural and clinical dimensions of spirituality, highlighting distributed brain networks and the potential for improved patient outcomes in palliative and neurological care. While relevant for contextualizing psychedelic research—especially regarding meaning-making and existential well-being—the findings remain largely correlational and lack robust, longitudinal data. The field is early-stage, with clinical recommendations based on consensus rather than definitive trials, underscoring the need for rigorous, interdisciplinary research to inform future clinical and regulatory frameworks.
Background: Neurospirituality is an emerging interdisciplinary framework integrating neuroscience, neurology, palliative care, and the medical humanities to address the spiritual and existential dimensions of health. Spirituality refers to meaning-making through connectedness beyond the self, whereas religiosity denotes organized beliefs, rituals, and communities. Objective: To review the conceptual foundations, neuroscientific evidence, and clinical applications of neurospirituality in neurological disorders and palliative care. Methods: This narrative review synthesizes evidence from neuroscience, cognitive science, neurology, palliative care, and spirituality research to examine the neural correlates, clinical relevance, limitations, and future directions of neurospirituality. Results: Current evidence associates spiritual experiences with distributed brain networks, particularly the default mode, salience, and frontoparietal control networks, rather than discrete brain regions. These models are heuristic and suggest that domain-general cognitive processes may contribute to spiritual experiences without implying spirituality-specific neural mechanisms. Clinically, greater spiritual well-being is associated with improved coping, resilience, and quality of life, particularly in palliative care and selected neurological disorders. However, the evidence is largely correlational and limited by small samples, heterogeneous definitions, cultural variability, and scarce longitudinal data. Current clinical recommendations therefore rely mainly on expert consensus and person-centered care. Conclusions: Neurospirituality provides an emerging translational framework linking neuroscience with the spiritual dimensions of health and neurological care. Although existing evidence supports the clinical relevance of spirituality, no universally accepted neurobiological model of spiritual experience exists. Further interdisciplinary, longitudinal, and culturally diverse research is needed to clarify underlying mechanisms and strengthen clinical translation.
Neuroscience Peer-reviewed publication

Study explores 'embeddedness' effects of psilocybin in humans

Embeddedness under psilocybin.
Why it matters ◈ Mixed
This peer-reviewed neuroscience study investigates how psilocybin alters the sense of 'embeddedness'—a psychological construct related to self-perception and context. While not a regulatory or clinical milestone, the findings may inform future trial endpoints, therapeutic models, or mechanistic hypotheses in psychedelic research. The work adds to the growing evidence base for how psilocybin affects brain function and subjective experience, which could shape both clinical protocol design and regulatory considerations.
Clinical research Systematic review published

Systematic review: Ketamine's psychiatric uses, safety, and challenges

Ketamine in psychiatry: a systematic review of clinical applications, safety considerations, and emerging challenges
Why it matters ◈ Mixed
This systematic review synthesizes the current state of ketamine research, clinical applications, and safety concerns, providing a valuable resource for clinicians, researchers, and policymakers navigating its expanding role in psychiatry. It highlights both therapeutic promise and ongoing risks, especially around off-label use and telehealth prescribing, and identifies knowledge gaps that will shape future research and regulatory focus. The integration of ethical and public health perspectives is especially relevant as ketamine access expands outside traditional medical settings.
Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric applications. This systematic review examines ketamine’s history, mechanisms of action, clinical uses, and significant challenges. A systematic search of PubMed, SCOPUS, PsycINFO, and other sources, generated peer-reviewed publications that addressed the history of ketamine, its pharmacology, clinical applications, recreational use, safety considerations, and societal consequences. Overall, 106 articles were identified for inclusion in this study. At the receptor level, ketamine is an antagonist of NMDA receptors that triggers a number of downstream effects ranging from heightened glutamate transmission, AMPA receptor activation, increased BDNF expression, synaptogenesis, and mTOR pathway signaling. At the network level, it alters activity within large-scale brain circuits including the default mode network, affecting cognition, mood, and perception. Clinically, ketamine is used for anesthesia, treatment-resistant depression, and pain, with off-label uses for PTSD, anxiety disorders, and bipolar disorder. The review also examines current challenges related to ketamine’s recreational use, associated risks, sociocultural factors, and key clinical and ethical considerations, including safety, monitoring, and telehealth prescribing of oral and sublingual formulations. It integrates previously fragmented research from anesthesiology, neuroscience, pharmacology, psychiatry, and public health, consolidates clinical and ethical guidance, identifies critical gaps in current knowledge, and proposes directions for future research.
State policy State law in effect

New Mexico enacts Medical Psilocybin Act, launching first statewide program

The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy
Why it matters ▲ Favorable
New Mexico's Medical Psilocybin Act establishes the first legislated statewide medical psilocybin program in the U.S., authorizing licensed clinicians to treat specific conditions under a regulated system. The law creates a comprehensive framework for licensing, equity, and research, and accelerates patient access with producer permitting opening in August 2026. This model marks a significant shift toward clinician-governed access, influencing both state and federal psychedelic policy debates and setting a precedent for other jurisdictions.
In April 2025, New Mexico enacted the Medical Psilocybin Act, establishing the first legislated statewide medical psilocybin program and becoming the third state to authorize supervised psilocybin use. The Act directs the New Mexico Department of Health to build a regulated system where licensed clinicians provide psilocybin to qualified patients in approved settings for treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and end-of-life care. It creates producer and clinician licensing, a nine-member advisory board, protections for individuals under community supervision, and two funds to advance equity and research. The law carves medical use out of New Mexico’s Schedule I and sets December 31, 2027 as the statutory deadline for full implementation, a date the Department of Health has since brought forward, opening producer permitting in August 2026 and targeting initial patients by the end of 2026. This health policy paper reviews this Act and situates it within a typology of U.S. psychedelic policy models of decriminalization, regulated non-medical services, and clinician-governed medical programs. It also briefly discusses Oregon’s nonmedical service model, Colorado’s healing centers, pilots in Texas and Utah, local decriminalization in Denver and Washington, FDA psilocybin breakthrough designations, veteran research, MDMA setbacks, and the federal turn marked by President Trump’s Executive Order 14401 of April 2026. It argues that New Mexico’s clinician-governed approach offers a distinctive pathway that balances wider access with clinical accountability, generating implications for federal and international discussions on psychedelic policy.
Clinical research Clinical trial underway

Psilocybin trial for depression in lung cancer patients begins

Researchers Are Testing Whether Psilocybin Can Treat Depression in Lung Cancer Patients
Why it matters ▲ Favorable
Researchers are launching a clinical trial to evaluate psilocybin's efficacy for depression in lung cancer patients, expanding the scope of psychedelic-assisted therapy into oncology-related mental health. This study could inform future regulatory pathways and clinical guidelines for psychedelic use in palliative care. The trial's outcomes may impact insurance coverage, access, and the perception of psychedelics in mainstream medicine.
Clinical research Peer-reviewed study published

Mental health symptoms not linked to distress in intensive meditation study

Mental Health Symptoms Do Not Increase Risk for Distressing Experiences During Intensive Mindfulness Meditation Training: Evidence from a Prospective Matched-Control Intervention Study
Why it matters ◈ Mixed
This prospective, preregistered study found that pre-existing depression and anxiety did not increase risk for distressing experiences during intensive mindfulness meditation retreats. In fact, lower baseline symptoms were unexpectedly associated with more distress. The findings challenge prevailing assumptions about mental health vulnerability in non-ordinary states and may inform risk assessment frameworks for psychedelic and meditation-based interventions. However, the direct relevance to psychedelic safety is limited, as the study did not involve drug administration.
Abstract Objective We aimed to test whether mental health problems are associated with distressing experiences during intensive meditation training and with the impact of these experiences following intensive training. Method We conducted a preregistered prospective matched-control study comparing 6-day insight mindfulness meditation retreats ( n = 89) to daily living among matched controls ( n = 44). Results Unexpectedly, lower, and not higher, pre-retreat depression and anxiety symptoms were associated with greater endorsement of distressing experiences during the retreats compared to daily living among matched controls. Moreover, at 2-week follow-up, retreat participants with low and those with high pre-retreat anxiety symptoms reported more positive than negative impact of distressing experiences endorsed during the retreat. Conclusions The findings challenge claims that depression and anxiety symptoms are a risk factor for heightened distressing experiences during intensive meditation training or the adverse effects of these meditation-related experiences. Preregistration The study was preregistered at ClinicalTrials.gov (Identifier: NCT04749264; 20 December 2020).
Clinical research Correction published

Correction: Ibogaine case report for ketamine use disorder

Correction: Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report.
Why it matters ◈ Mixed
This correction to a published case report highlights ongoing scrutiny and the evolving evidence base for ibogaine in treating substance use disorders. While single case reports are low in the evidence hierarchy, they can inform future research directions and may influence regulatory or clinical interest in off-label or investigational use. The correction itself signals the importance of data integrity and transparency in psychedelic science.
Legal / Scientific Concepts Scholarly analysis

Clarifies scientific vs. legal definitions of 'drug' and 'narcotic drug'

Drug and narcotic drug: scientific definition, legal stipulation, and terminological clarification
Why it matters ◈ Mixed
This article provides a rigorous conceptual analysis of how 'drug' and 'narcotic drug' are defined across scientific and legal domains, highlighting the discipline-specific nature of these terms and the risks of conflating them. This clarification is important for researchers, clinicians, and policymakers navigating regulatory frameworks, as it underscores that legal categories like 'narcotic drug' are institutionally constructed and not always aligned with scientific definitions. While not a policy move, this work informs debates on scheduling, research access, and legal interpretation in the psychedelic field.
This article challenges the recurrent claim that the concept of drug is scientifically indefinable or reducible to a legal, social, or normative construct. It argues that semantic and classificatory variability does not entail ontological indeterminacy: substances possess materially real and causally efficacious properties that constrain scientific classification, while the concepts constructed from those properties remain discipline-specific, situated, and epistemically mediated. Combining legal textual analysis, epistemology, logic, and terminology, the article distinguishes pharmacological, neuroscientific, legal, and lexicographic registers and examines how their conflation has contributed to the apparent indeterminacy of the concept. A structured process of individuation - moving from ontology to taxonomy, typology, and terminology - is used to reconstruct the concept and clarify the relation between causal properties and classificatory practices. The analysis shows that the term drug admits of more than one scientifically coherent intension, depending on disciplinary framework and explanatory purpose. In pharmacology, it denotes the broad class of exogenous chemical substances, other than nutrients or essential dietary ingredients, that produce biological effects. In neuroscience, it denotes the narrower subclass of psychotropic substances acting on the central nervous system and modifying mental processes. Neither definition is universally privileged outside its disciplinary domain. Narcotic drug, by contrast, is a stipulative legal category whose extension is determined through institutional designation and scheduling rather than through derivation from the scientific intension of drug. The article concludes that the claims of scientific indefinability examined here arise in substantial part from conflating semantic variability, scientific concepts, legal classifications, and moral or social representations.
Clinical research Case report published

Psilocybin linked to worsened depression/anxiety in cyclothymia case

Worsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.
Why it matters ◈ Mixed
This case report documents worsening depression and anxiety after psilocybin use in a patient with cyclothymia. While single case reports cannot establish causality or generalize risk, they highlight the need for careful screening and monitoring of patients with mood disorders in psychedelic trials and clinical use. The finding may inform exclusion criteria and risk communication as access expands.
Clinical research Op-ed commentary

VA psilocybin study for veterans prompts call for more independent research

VA's New Psilocybin Study For Veterans Is Progress, But Independent Psychedelic Research Needs Support Too (Op-Ed)
Why it matters ◈ Mixed
The VA's initiation of a psilocybin study for veterans signals growing institutional acceptance of psychedelic research within federal agencies. However, the op-ed highlights concerns about the need for independent research funding and support, suggesting that government-led trials alone may not be sufficient for robust, unbiased evidence generation. This underscores ongoing debates about research access, funding sources, and the direction of psychedelic science in the US.
Neuroscience Book published

Book proposes neuroscience-based overhaul of psychiatric diagnosis

PSYCHIATRY The Case for Starting Over
Why it matters ◈ Mixed
This book argues that psychiatry's current diagnostic system is structurally flawed and unable to guide emerging circuit-targeted therapies, including psychedelic-assisted interventions. It introduces a new framework—Neuroanalysis and Clinical Brain Profiling—that organizes mental disorders by brain network dynamics and plasticity timescales, and explicitly includes psychedelics in a proposed toolkit for personalized treatment. While theoretical, this work could influence future research design, clinical trial endpoints, and regulatory thinking by pushing for mechanism-based, biomarker-driven approaches in psychiatric care.
AbstractPsychiatry is the only branch of medicine that still diagnoses without reference to the organ it treats. Psychiatry: The Case for Starting Over argues that this is a structural failure rather than a temporary gap. The descriptive nosology inherited from Kraepelin and formalized in the DSM achieved diagnostic reliability at the cost of validity. Its categories were assembled by committee consensus rather than grounded in mechanism, and so it cannot guide the circuit-targeted therapies now reshaping the field.The book traces this problem historically and then builds an alternative from three converging lines of work. The first is computational neural-network modeling of psychopathology, from Hopfield and Hinton through Hoffman's simulations of schizophrenia and the author's own work. The second is systems neuroscience, including large-scale networks, global workspace and integrated information theories, attractor dynamics, and small-world connectivity. The third is Friston's Free Energy Principle and predictive processing.From this synthesis the book introduces Neuroanalysis and its clinical instrument, Clinical Brain Profiling (CBP). CBP treats mental disorders as disturbances of dynamic brain-network organization and organizes them across four timescales of plasticity:•Cognizance plasticity (milliseconds) is centered on the central executive network and linked to psychosis and negative signs.•Reactive plasticity (minutes to hours) is centered on the salience network and linked to anxiety.•Adaptive plasticity (days to weeks) sits at the salience–default mode interface and is linked to depression and mania.•Developmental plasticity (lifetime) is centered on the default mode network and linked to personality disorder patterns.The book reviews the neuromodulation toolkit: ECT, DBS, TMS, tDCS/tACS, psychedelic-assisted therapy, and focused ultrasound. It then proposes an entity-matched "grammar of plasticity" for selecting, combining, and sequencing these interventions. Guiding principles include strengthening prefrontal regulation before driving motivation, opening plasticity windows before directing them, and continuous biomarker monitoring.Throughout, the author separates established science from theoretical proposal and untested hypothesis. He outlines what validation would require: prospective outcome trials, clinically feasible network measures, and a cultural shift from single-label diagnosis to multidimensional profiling. The result is a case for rebuilding psychiatry as a measurement-based, mechanism-guided clinical neuroscience.
Clinical research Scoping review published

Review: Self-medication of ADHD with psychoactive substances in adults

Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances
Why it matters ◈ Mixed
This scoping review maps how the self-medication hypothesis for ADHD symptoms is framed across psychoactive substances, finding that evidence for self-medication is substance-specific and often based on association rather than direct symptom change. The review highlights that applying self-medication as a universal explanation for substance use in adults with ADHD is not supported by the current literature. This matters for researchers and clinicians as it cautions against overgeneralizing motives for substance use, which may impact future study designs, clinical screening, and policy discussions around access and harm reduction.
Introduction Adults with attention-deficit/hyperactivity disorder (ADHD) use tobacco, cannabis, alcohol, cocaine and non-prescribed stimulants far more than the general population. The self-medication hypothesis holds that people with ADHD, including those undiagnosed, use substances to relieve core symptoms rather than for recreation or shared vulnerability to addiction, and is widely invoked to reframe illicit substance use as undiagnosed ADHD. How this claim is framed and tested has not been mapped across substances. Objective To map the literature invoking self-medication of ADHD symptoms in adults, substance by substance, and to characterise how each source frames the concept relative to misuse, recreational or shared-liability accounts. Eligibility criteria Empirical studies, reviews, commentaries, preprints and trial-register records on self-medication of ADHD symptoms with a psychoactive substance in adults or predominantly adult samples; English; inception to 21 July 2026. Information sources PubMed, OpenAlex and Consensus, with ClinicalTrials.gov and a preprint search. Searches were conditioned on self-medication and motive terminology, so the corpus maps the self-medication literature and does not sample the misuse or shared-liability literature independently. Charting methods Sources were charted for substance, design, population, operationalisation of self-medication, and a framing category (self-medication-framed; mixed; misuse- or shared-liability-framed; neutral/descriptive). A descriptive map was built by substance. No critical appraisal or evidence-strength ranking was made. Results Of 937 records identified and 820 screened, 109 sources (1986–2026) met the criteria. Coverage was heaviest for non-prescribed stimulants (n=35), cannabis (n=29), nicotine (n=25) and alcohol (n=17); no eligible ketamine source was identified. Self-medication framing was most prevalent, and uniquely accompanied by experimental data, for nicotine; prevalent but observational for cannabis; coexisted with academic and recreational motives for stimulants; and alcohol was mostly framed as comorbidity or shared liability. Self-medication was overwhelmingly inferred from association or motive report rather than tested against symptom change. Conclusions Self-medication framing is substance-specific in prevalence and accompanying evidence. Because the search was conditioned on self-medication terminology, the map describes how the literature frames the claim and does not adjudicate between competing accounts. Applying self-medication as a blanket explanation for substance use in people with ADHD symptoms is not warranted by how the claim has been tested.
Clinical research Preprint released

Preprint: Ketamine's antidepressant and anti-alcohol effects in AUD patients

Mechanisms of anti-depressant and anti- alcohol effects of ketamine in patients with alcohol use disorder
Why it matters ◈ Mixed
This preprint explores the mechanisms by which ketamine may exert both antidepressant and anti-alcohol effects in patients with alcohol use disorder (AUD). While mechanistic insights are valuable for future trial design and therapeutic targeting, the findings are preliminary and have not yet been peer-reviewed or cited. Researchers and clinicians should treat these results as hypothesis-generating rather than definitive evidence for clinical practice or regulatory change.
Clinical research Pilot RCT published

Psilocybin reduces egocentricity in AUD: pilot RCT results

Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial
Why it matters ▲ Favorable
This pilot randomized controlled trial provides preliminary evidence that psilocybin may reduce egocentric bias in individuals with alcohol use disorder (AUD). The findings suggest a potential mechanism—reduced egocentricity—through which psilocybin could improve social cognition in AUD, an area of high unmet need. While the sample is small and replication is needed, this study adds to the growing body of evidence supporting psychedelic-assisted therapy for substance use disorders and may inform future trial designs and mechanistic research.
Abstract Background Social difficulties in alcohol use disorder (AUD) have been linked to alterations in social cognition, including increased egocentric bias. Psychedelics such as psilocybin have been proposed to modulate self-related processing, but their effects on specific socio-cognitive mechanisms remain unclear. Methods In this randomized controlled pilot study, recently detoxified individuals with AUD with persistent depressive symptoms completed a visual perspective-taking task before and after a psilocybin session (25 mg dose vs active placebo 1 mg psilocybin). Results The 25 mg psilocybin group showed a significant reduction in egocentric bias and egocentric superiority on reaction times, with no effect on altercentric bias nor on accuracy. Between-group comparisons confirmed greater reductions in the high-dose relative to the low-dose group. The high-dose group reported more intense subjective psychedelic experiences, and greater subjective intensity was associated with lower egocentric superiority in accuracy. Conclusions These findings provide preliminary evidence that psilocybin may selectively reduce egocentric interference in individuals with AUD, suggesting a decrease in egocentricity rather than enhanced sensitivity to others. Although replication in larger samples is needed, reduced egocentricity may represent one mechanism through which psilocybin influences social cognition in AUD. Clinical trial registration ClinicalTrials.gov , https://clinicaltrials.gov/study/NCT06235411 , NCT06235411 .
Epidemiology / Survey Methods Peer-reviewed study published

Test-retest study confirms reliability of self-reported psychedelic use

Reliability of self-reported real-world psychedelic use – A test-retest study in a population sample
Why it matters ▲ Favorable
This is the first rigorous test-retest study confirming that self-reported psychedelic use in large US population surveys is highly reliable across 17 substances. The findings support the validity of epidemiological data on psychedelic use trends, which underpins policy, clinical, and public health decisions. Researchers and policymakers can have increased confidence in survey-based prevalence and behavioral data, reducing uncertainty in trend analyses and risk assessments.
Objective In 2024, the United States had the highest prevalence of psychedelic use recorded, but reliability of self-report data in surveys has not been rigorously assessed. Our objective was to quantify the reliability of self-report across 17 psychedelic and dissociative substances in an adult population sampled from the National Survey Investigating Hallucinogenic Trends (NSIHT). Methods In 2024, a test-retest sub-study was conducted on NSIHT. Overall agreement, average positive/negative agreement, and Gwet’s AC1 were calculated for use in the last 12 months. Reason and recency of use reliability was assessed through separate mixed effects logistic regressions models adjusting for all substances used and other reasons for use. Results There were 690 of 2,023 respondents (34.1%) who returned to the retest sample; there were minimal differences in demographics or none in health metrics of respondents and non-respondents. Across 17 substances, use showed “substantial” to “excellent reliability” indicated by Gwet’s AC1 (all ≥0.73, average 0.87), overall agreement (all ≥85.1%, average 90.4%). Overall agreement was driven by reliable report of “no” use of substances. Reliability for “yes” use decreased alongside decreasing prevalence of use. After adjustment, the probability of a reliable answer for all reported reasons and recency of use were 0.96 to 0.98. Conclusions This is the first study to demonstrate substantial to excellent reliability based on Gwet’s AC1 across 17 self-reported psychedelic and dissociative substances for use and behaviors. Methodological rigor and transparency allow for generation of trustworthy, reliable estimates and for the field to accurately interpret and compare findings across studies.
Neuroscience Review published

Automated home-cage monitoring advances mouse phenotyping for psychiatry

Advancing translational phenotyping of mouse models for psychiatric research by automated home-cage monitoring
Why it matters ▲ Favorable
Automated home-cage monitoring (HCM) systems represent a significant methodological advance for preclinical psychiatric research, enabling continuous, non-invasive, and ecologically valid behavioral assessment in mice. This technology could improve the translational validity and reproducibility of animal models, potentially accelerating discovery and validation of novel psychiatric therapeutics, including psychedelics. However, challenges in data harmonization and clinical alignment remain. While not directly impacting law or market access, these advances may influence future trial design and regulatory expectations.
The translational validity of animal models in psychiatric research remains a persistent challenge, partly due to reliance on short-duration, experimenter-driven behavioural assays that capture limited and often artificial snapshots of complex phenotypes. Home-cage monitoring (HCM) systems offer a paradigm shift by enabling continuous, non-invasive assessment of mice within their familiar social and environmental context. These approaches facilitate longitudinal quantification of behavioural domains highly relevant to psychiatric disorders, including circadian rhythm disruption, social interaction, anhedonia-related behaviours, and stress responsivity. Advances in machine learning, sensor integration, and computational analysis now allow scalable, high-resolution phenotyping across extended timeframes, frequently in group-housed conditions. Recent collaborative initiatives have catalysed efforts towards methodological standardisation and interdisciplinary integration, highlighting the potential of HCM to enhance both construct and external validity in preclinical models of mental illness. Importantly, continuous monitoring captures behavioural dynamics and intra-individual variability that are largely inaccessible to conventional tests, offering novel endpoints with potential translational relevance to human symptom trajectories. Nevertheless, challenges remain, including harmonisation of analytical pipelines, interpretation of high-dimensional data, and alignment of behavioural readouts with clinically meaningful constructs. This review evaluates the current state of HCM technologies in the context of psychiatric modelling, discussing their potential to refine phenotyping strategies and enhance the reproducibility and translational impact of mouse models.
Clinical research Systematic review published

Meta-analysis: Ketamine vs ECT for severe treatment-resistant depression

KETAMINE VERSUS ELECTROCONVULSIVE THERAPY FOR SEVERE TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF EFFICACY, SPEED OF RESPONSE, COGNITIVE OUTCOMES, AND SAFETY
Why it matters ◈ Mixed
This meta-analysis provides the most comprehensive synthesis to date comparing ketamine and ECT for severe treatment-resistant depression, finding no overall difference in efficacy but a clear neurocognitive advantage for ketamine in less severe, ambulatory populations. The findings clarify that ECT remains superior for hospitalized, psychotic, or severely ill patients, while ketamine is a viable, potentially preferable option for others. This nuanced evidence base will directly inform clinical guidelines, payer decisions, and regulatory frameworks for depression care, and is likely to accelerate the adoption of ketamine in psychiatric practice.
Introduction: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and accounts for disproportionate disability and mortality. Electroconvulsive therapy (ECT) has long been the definitive intervention, whereas subanaesthetic intravenous ketamine has emerged as a rapid-acting alternative. Direct head-to-head evidence has accumulated rapidly but remains discordant. This review resolved this discordance and quantified comparative efficacy, speed of response, neurocognitive burden, and safety. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs included RCTs, cohort, case-control, and cross-sectional studies. Risk of bias assessed with RoB 2 and ROBINS-I. Dichotomous outcomes pooled as risk ratios (RR) with 95% CI using DerSimonian-Laird estimator; heterogeneity quantified by I²; prediction intervals calculated; exploratory summary ROC analysis performed. Results: Eighteen studies (1,388 participants) were included: 12 head-to-head reports (10 independent samples; 1,009 participants) and 6 adjunctive/mechanistic studies (379 participants). Five studies contributed response data (n=760). Pooled response did not differ between modalities (RR 1.13; 95% CI 0.85–1.49; P=0.393; I²=80.0%; 95% PI 0.47–2.72). Remission likewise showed no difference (RR 1.16; 95% CI 0.77–1.76; P=0.468; I²=80.9%). Heterogeneity was overwhelmingly attributable to the ELEKT-D trial: leave-one-out omission yielded significant ECT advantage (RR 1.27; 95% CI 1.07–1.51) with near-resolution of inconsistency (I²=25.5%). Among exclusively inpatient samples, ECT was directionally superior (RR 1.21; 95% CI 0.98–1.48; I²=26.1%). Relapse (RR 1.20; 95% CI 0.67–2.15) and discontinuation (RR 1.79; 95% CI 0.15–21.36) did not differ. Summary AUC was 0.536 for response and 0.532 for remission—negligible discrimination by modality. Ketamine demonstrated consistently superior neurocognitive outcomes, most markedly on delayed verbal recall (−0.9 ± 1.1 versus −9.7 ± 1.2 T-score points), and earlier symptomatic separation in less severe populations. ECT was associated with musculoskeletal pain and transient amnesia; ketamine with dose-dependent dissociation and transient haemodynamic effects. Certainty was low to very low for efficacy outcomes, downgraded for inconsistency and risk of bias. Discussion: The apparent contradiction is not statistical artefact but reflects genuine effect modification. ECT and ketamine are not interchangeable across the whole spectrum; relative advantage is conditioned by illness severity, treatment setting, psychotic features, and age. In hospitalised, severely ill, psychotic populations—the KetECT population—ECT retains clear efficacy advantage. In ambulatory, non-psychotic populations—the ELEKT-D population—ketamine is non-inferior with superior neurocognitive profile and greater acceptability. Ketamine's principal liabilities are brevity of effect and uncertainties regarding long-term cystitis and misuse potential; ECT's liabilities are amnesia, anaesthetic exposure, and stigma. Conclusion: Intravenous ketamine and ECT produce broadly comparable response and remission rates in severe TRD, with no significant pooled difference and negligible discrimination between modalities. Clinically meaningful ECT superiority persists in hospitalised and more severely ill populations, whereas ketamine offers faster separation and superior short-term cognitive profile. Treatment selection should be individualised according to severity, setting, psychotic features, cognitive vulnerability, urgency, and patient preference. Adequately powered, longer, stratified randomised trials with standardised continuation strategies and harmonised neurocognitive batteries are required.
Clinical research Trial announced

Calgary trial to test psychedelic therapy for PTSD in partner violence survivors

A Calgary trial will test psychedelic therapy for PTSD in survivors of partner violence
Why it matters ▲ Favorable
This trial marks a significant step in evaluating psychedelic-assisted therapy for PTSD in a highly vulnerable population—survivors of partner violence. The study could expand the evidence base for trauma-focused psychedelic interventions and inform future clinical protocols. Its outcomes may influence both Canadian and international approaches to mental health treatment and access.
Cultural research Published study

Study: Global 'psychedelic' framing of mad honey not fully adopted in Nepal

When psychedelic discourse meets local narrative: Selective uptake of psychedelic meanings surrounding mad honey in Nepal
Why it matters ◈ Mixed
This qualitative study finds that global psychedelic discourse around 'mad honey' is selectively adopted in Nepal, with local actors emphasizing medicinal and ritual uses over psychedelic experience. The research highlights a disconnect between commercial/online representations and traditional narratives, suggesting that global psychedelic branding does not necessarily reshape local cultural understandings or practices. This is relevant for researchers and industry as it underscores the importance of local context in the adoption and legitimacy of psychedelic framings, especially for naturally occurring substances with deep cultural roots.
AIMS: 'Mad honey' is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose-dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how globally circulating discourse and local narrative practices interact in shaping meanings of intoxication, using mad honey as a case. More broadly, it assessed the analytical value of distinguishing between discursive circulation and narrative uptake. DESIGN: Qualitative study combining analysis of online commercial representations with semi-structured interviews in Nepal. SETTING: Online retail shops and field sites in Kathmandu, Pokhara, Lukla and nearby communities. PARTICIPANTS: One qualitative group interview (n = 17) and 14 individual interviews with honey hunters, sellers, traditional medicine practitioners and suppliers involved in mad honey production, distribution and use. MEASUREMENTS: Qualitative coding and constant comparison were used to analyze interviews alongside discourse-analytic examination of online product texts. Analytic attention was also given to hesitation, vagueness and non-articulation in accounts of psychoactive effects. RESULTS: Online retailers consistently framed mad honey through a psychedelic register (hallucinations, shifts in consciousness, dosage scripts and safety warnings), creating commercially circulating experiential templates. In contrast, interviewees narrated mad honey primarily through medicinal, ritual, communal and dosage-based frameworks. Psychedelic meanings underwent only selective uptake: commercially useful classifications, such as potency and dosage, were incorporated into local accounts, whereas experiential narratives of altered consciousness were largely resisted or left unused. When intoxication was acknowledged, it was typically contained within familiar moral categories (e.g. abuse/misuse, comparison with alcohol) rather than elaborated as psychedelic experience. SUMMARY: The analytical value of distinguishing between discourse and narrative lies in the fact that discourse may expand the availability of meanings without necessarily transforming the narrative frameworks through which psychoactive substances are understood and used. Specifically, while globally circulating digital-commercial discourse about mad honey makes psychedelic meanings available, local narratives determine whether those meanings become culturally legitimate ways of understanding and using mad honey.
Clinical research Phase 2 trial underway

Filament ships psilocybin drug for Phase 2 PTSD trial in Calgary

Filament ships psilocybin drug PEX010 for Phase 2 PTSD trial at University of Calgary
Why it matters ▲ Favorable
Filament Health has supplied its psilocybin drug PEX010 for a Phase 2 clinical trial targeting PTSD at the University of Calgary. This marks continued momentum for industry-supplied, GMP-grade psilocybin in academic research, supporting the development of regulated psychedelic therapies in Canada. The trial's progress may inform future access pathways and commercial opportunities if results are positive.
Community / Advocacy Post-FDA hearing mobilization

Student group mobilizes after historic FDA hearing on psychedelics

After Historic FDA Hearing On Psychedelic Therapies, Grassroots Student Group Mobilizes To Shape What Comes Next
Why it matters ▲ Favorable
Grassroots student engagement following a historic FDA hearing signals growing civic participation in shaping the future of psychedelic therapies. While not a direct policy move, such mobilization can influence public opinion, research priorities, and future regulatory frameworks. This development highlights the increasing role of community advocacy in the evolving landscape of psychedelic law and access.
Clinical research Cross-sectional study published

Cross-sectional study: Adverse outcomes of major psychedelics in US adults

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT
Why it matters ◈ Mixed
This large-scale, nationally representative study provides new data on adverse health outcomes associated with recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT. The findings will inform risk assessments for both clinical and non-clinical use, and may influence regulatory, clinical, and public health perspectives on these substances. Researchers and policymakers should closely examine the methodology and reported outcomes, as such data can shape future access, trial design, and legal frameworks.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
Clinical research Phase 1 readout

Phase 1: Oral Ketamir-2 shows safety, tolerability, and favorable PK profile

Safety, tolerability, and pharmacokinetics of oral Ketamir-2, a novel selective NMDA receptor antagonist: results of a first-in-human Phase 1 study
Why it matters ▲ Favorable
This first-in-human Phase 1 trial shows that Ketamir-2, a novel oral NMDA antagonist, is safe and well-tolerated at doses up to 600 mg without significant dissociative or abuse-related effects. The compound’s pharmacokinetics and absence of serious adverse events support advancement to Phase 2a trials for neuropathic pain. This could expand the pipeline for non-dissociative, orally available NMDA antagonists, with implications for both pain management and the broader field of psychoplastogens.
Background: Ketamine, a high-affinity NMDA receptor antagonist, is used off-label for neuropathic pain but has limited clinical utility due to poor oral bioavailability, narrow therapeutic window, and dissociative effects. Ketamir-2 is a novel low-affinity, phencyclidine-site-selective NMDA antagonist (IC50 ~100 µM versus ketamine's low single-digit µM), designed to retain analgesic activity while reducing dissociative liability. Objective: Evaluate the safety, tolerability, and pharmacokinetics of oral Ketamir-2 in a first-in-human Phase 1 study (MIRA-001). Methods: Randomized, double-blind, placebo-controlled study in 57 healthy adults. Participants received single ascending doses (50–600 mg) or once-daily doses (150–600 mg for 5 days) with 3:1 randomization to Ketamir-2 or placebo. Safety assessments included treatment-emergent adverse events, vital signs, electrocardiography, and psychotomimetic/suicidality screening (Bowdle VAS, KSET, C-SSRS). Plasma and urine pharmacokinetics were characterized for Ketamir-2 and its major metabolite, Norketamir. Results: Ketamir-2 was well tolerated across all doses. Adverse events occurred in 37.2% of active and 50.0% of placebo participants with no dose-dependent trend. No serious adverse events, Grade ≥3 events, or meaningful psychotomimetic, abuse-related, or suicidality signals were observed. Ketamir-2 demonstrated rapid absorption (Tmax 1.0–2.5 hours), dose-dependent exposure, and no clinically meaningful accumulation over 5 days. Norketamir showed dose-proportional exposure and longer half-life (6.4–8.6 versus 2.5–7.2 hours). Conclusions: Oral Ketamir-2 demonstrated favorable safety, tolerability, and pharmacokinetic profiles at doses up to 600 mg. Exposures at 300 and 600 mg meet or exceed concentrations associated with efficacy in preclinical chemotherapy-induced peripheral neuropathy models, supporting progression to Phase 2a.
Clinical research Peer-reviewed publication

Psychedelic shows protection against chemo-induced nerve damage

Psychedelic protects against chemotherapy-induced nerve damage.
Why it matters ▲ Favorable
This peer-reviewed study provides evidence that a psychedelic compound can protect against chemotherapy-induced neuropathy. If confirmed in further trials, this could open a new therapeutic avenue for cancer patients suffering from nerve damage, a major unmet need. The findings may encourage additional research and could influence regulatory and funding priorities for psychedelic-based interventions in oncology supportive care.
Clinical research Peer-reviewed review

Review: Psilocybin for TRD—Phase 3 data, safety, and EU access models

Psilocybin in psychiatry: Current clinical evidence, mechanisms of action and translational perspectives. A literature review based on PubMed-indexed studies
Why it matters ◈ Mixed
This comprehensive review synthesizes phase IIb and phase III trial data for psilocybin in treatment-resistant depression, highlighting both significant efficacy signals and emerging safety concerns such as suicidal ideation and HPPD. The discussion of Germany's compassionate use program marks a notable precedent for regulated access in the EU, while translational perspectives point to evolving clinical models and digital integration. However, methodological limitations and unresolved safety issues underscore the need for further research before psilocybin can be considered a standard psychiatric treatment. This review is a valuable resource for clinicians, regulators, and industry stakeholders tracking the pathway to broader therapeutic adoption.
Psilocybin, a classical serotonergic psychedelic, has become the subject of intensive clinical and translational research in psychiatry.This review focuses primarily on treatment-resistant depression (TRD), the indication with the most advanced level of clinical evidence and the one closest to potential regulatory approval, while other indications -major depressive disorder without documented treatment resistance, cancer-related anxiety and depression, and substance use disorders -are discussed more briefly.The aim of this review is to summarize current evidence regarding the mechanisms of action, clinical efficacy, safety, methodological limitations, and translational perspectives of psilocybin, based on PubMed-indexed literature through July 2026.The strongest clinical evidence concerns TRD, where a phase IIb trial and two phase 3 trials of the COMP360 program demonstrated significant symptom reduction after one or two administrations; in parallel, the independent German EPISODE trial provided data suggesting the need for a two-dose treatment cycle and raised safety signals regarding suicidal ideation and hallucinogen persisting perception disorder (HPPD) that warrant further validation and close clinical monitoring.Increasing attention is directed toward biological mechanisms beyond 5-HT2A receptor agonism, including neuroplasticity and BDNF/mTOR signaling -partly shared with the mechanism of ketamine and esketamine.The review also discusses a clinical implementation model resembling that used for esketamine administration, based on supervised dosing in certified centers, alongside a concrete European organizational precedent: Germany's compassionate use programme for psilocybin in TRD, the first of its kind in the European Union.Emerging translational approaches involving digital technologies, virtual reality, biofeedback, and controlled therapeutic environments are discussed, with particular relevance to hospital-based psychiatric settings.Important limitations remain, including small sample sizes, difficulties in maintaining blinding, heterogeneity of psychotherapeutic protocols, and a lack of long-term follow-up.Current evidence supports further investigation of psilocybin for treatment-resistant depression, but remains insufficient to establish it as a standard psychiatric treatment outside strictly controlled clinical and research settings.
Harm reduction / Public health Methodological framework published

Framework for evaluating psychedelic harm reduction at events published

Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application
Why it matters ▲ Favorable
This study introduces a reproducible framework for evaluating psychedelic harm reduction services at large-scale events, addressing a critical gap as non-clinical psychedelic use rises. The methodology enables more rigorous assessment of peer support interventions like the Zendo Project, helping inform future research, policy, and event-health infrastructure. While preliminary, it offers a foundation for measuring operational, safety, and public health outcomes in naturalistic settings, supporting the development of best practices and scalable models as psychedelic use expands beyond clinics.
Psychedelic and other psychoactive substance use is increasing in non-clinical environments, including music festivals, concerts, and other large-scale gatherings. As psychedelic use expands beyond clinical settings, policymakers, healthcare systems, event operators, and researchers require evidence-informed frameworks for understanding and responding to psychoactive-related distress in naturalistic environments. Despite the growing presence of psychedelic harm reduction services, few studies have established reproducible methods for documenting their operation, coordination with event-health services, or role within triage and escalation pathways in naturalistic settings. This methodological paper proposes an evaluation framework for psychedelic harm reduction services and reports a formative mixed-methods field application involving the Zendo Project at two large-scale events. Nineteen pre-event surveys, five retained post-event surveys, and two matched pre/post records were obtained from medical personnel. Quantitative responses were summarized descriptively, while open-ended responses were used formatively to contextualize and refine the proposed measurement domains. The framework positions psychedelic peer support as a complementary intermediate pathway for medically stable but psychologically distressed individuals, operating alongside rather than in place of medical and public-safety services. The field application identified interpretable measurement domains concerning psychological-distress burden, preparedness, workload, safety, interprofessional coordination, escalation, and attendee disposition. Four respondents completed several principal post-event items and reported favorable perceptions of Zendo's operational role. These responses represent staff perceptions and counterfactual estimates rather than independently verified effects. Beyond evaluating a single intervention, this study offers an initial framework for measuring and comparing non-clinical psychedelic support models and for informing future research, policy development, and event-health infrastructure as psychedelic use continues to expand beyond clinical settings. Additionally, by translating field-based psychedelic support into measurable operational, public health, and economic outcomes, the proposed methodology offers a foundation for the future evaluation, comparison, and development of products, services, and care infrastructures designed to support altered-state experiences in non-clinical environments.
Public health / Technology Horizon scan published

Horizon scan: Emerging drug-checking tech for unregulated substances in Canada

Detecting Compositions of Unregulated Substances: A Horizon Scan of Emerging Drug-Checking Technologies
Why it matters ▲ Favorable
Emerging portable drug-checking technologies could significantly expand harm reduction and surveillance capacity in Canada’s ongoing toxic drug crisis. These tools may improve detection of novel and low-concentration psychoactive substances, supporting both public health and the safety of people who use drugs. While not directly altering legal frameworks, advances in drug-checking tech can inform policy, research, and market opportunities for safer substance use and monitoring. The field should monitor implementation, performance, and integration with established laboratory methods.
What Is the Issue? Canada continues to experience a toxic drug crisis driven by an increasingly complex and rapidly changing unregulated drug supply. Drug-checking services help identify substances and contaminants in unregulated drug samples, supporting harm reduction and public health responses. In response to the ongoing toxic drug crisis, new drug-checking technologies (DCTs) are emerging. Further research could help determine how these technologies might complement established options to address existing challenges — such as detecting low-concentration substances, novel psychoactive substances, and complex drug mixtures — and improve access to drug-checking services. What Are the Technologies? Many emerging DCTs are portable, hand-held, or field-deployed, and are designed for use outside traditional laboratory settings while still offering the potential for high analytical performance. Emerging DCTs include portable Raman spectroscopy, surface-enhanced Raman spectroscopy, near-infrared spectroscopy, infrared spectroscopy combined with machine learning, portable mass spectrometry, sensor-based technologies, and multitechnology approaches. We searched key resources, including journal citation databases, and conducted a focused internet search for relevant evidence published since 2011. What Is the Potential Impact? Initial studies suggest emerging DCTs may improve the detection of low-concentration substances, contaminants, novel psychoactive substances, and complex drug mixtures. Portable devices may expand access to drug-checking services in underserved communities as well as mobile, rural, remote, and event-based settings. Emerging DCTs may provide timely and detailed information about substance compositions, contaminants, and novel psychoactive substances. This information may support people who use drugs, harm-reduction services, health care providers, public health agencies, and surveillance programs in identifying trends in the unregulated drug supply. No single technology demonstrated advantages across all analytical and operational areas. Although emerging technologies demonstrate encouraging analytical performance, the technologies differ in sensitivity, portability, analysis time, training requirements, dependence on reference libraries, costs, and implementation needs. Combining emerging technologies with complementary established technologies may improve substance detection compared with relying on a single technology alone. What Else Do We Need to Know? This Horizon Scan complements a 2026 Canada’s Drug Agency Health Technology Review by providing an overview of emerging DCTs and early evidence on their potential applications. The previous review evaluated established DCTs, while this Horizon Scan highlights technologies that are still evolving and where evidence remains limited. Emerging DCTs may complement, rather than replace, established DCTs and laboratory-based methods, which continue to play an important role in drug-checking services, including the identification and confirmation of novel or unexpected substances. Several emerging DCTs have been evaluated in community drug-checking settings, particularly in Canada; however, evidence is still limited for many technologies and consists largely of preliminary studies. More studies are required to better understand the accuracy, reliability, costs, and real-world implementation of these technologies. Further, evidence synthesis with critical appraisal will be necessary to provide conclusive statements about their performance. Decision-makers may need to balance analytical performance with feasibility, workforce capacity, infrastructure requirements, costs, and equitable access when considering implementation.
Clinical research Clinical trial underway

Psilocybin trial for depression in advanced lung cancer patients begins

Clinical trial tests psilocybin-assisted therapy for depression in advanced lung cancer patients
Why it matters ▲ Favorable
This trial expands the evidence base for psilocybin-assisted therapy in a high-need, medically complex population—patients with advanced lung cancer and depression. Results could inform future regulatory decisions, clinical guidelines, and payer coverage for psychedelic therapies in oncology and palliative care settings. The study also signals growing acceptance of psychedelic research in mainstream medical contexts.
Clinical research Systematic review published

Systematic review: Psychedelics show anti-inflammatory effects in preclinical models

Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics
Why it matters ◈ Mixed
This systematic review and meta-analysis synthesizes the evidence for anti-inflammatory effects of serotonergic psychedelics, finding robust effects in preclinical models but inconclusive results in humans due to limited data. The findings highlight a promising mechanism that may underlie clinical benefits in neuropsychiatric disorders, but also underscore the need for more rigorous and larger human studies. Researchers and clinicians should note the translational gap and exercise caution in extrapolating preclinical findings to patient care. The review provides a foundation for future clinical trial design and mechanistic research.
Serotonergic psychedelics are promising treatments for neuropsychiatric disorders, and their immunomodulatory effects may contribute to their clinical efficacy. However, we lack a systematic review and meta-analysis of these effects across in vitro, in vivo non-human, and human studies. We systematically searched PubMed, EMBASE, Web of Science, PsycINFO, LILACS and ClinicalTrials.gov for all studies, published from database inception through February 9th, 2026, examining changes in immune markers after serotonergic psychedelic exposure, and meta-analyzed eligible studies. Of 9,195 studies screened, 61 studies met eligibility criteria for systematic review including 24 in vitro studies, 30 non-human in vivo studies, and seven human studies including data from 10 separate human trials. Results of the systematic review indicated that most in vitro (19/24) and non-human in vivo (25/30) studies reported anti-inflammatory effects of psychedelics. Human results were mixed with anti-inflammatory effects observed in 3/10 trials. Results of the meta-analysis of 18 eligible in vivo murine studies showed a significant decrease in proinflammatory cytokines in inflammatory models (standardized mean difference (SMD = -1.23, 95% CI [-1.54, -0.92]), but no significant effects in healthy murines (SMD = -0.06, 95% CI [-0.54, 0.43]), following treatment with a serotonergic psychedelic. Four human studies were eligible for meta-analysis; however, the small number of studies resulted in imprecise estimates and limited interpretability. Thus, while serotonergic psychedelics reduce proinflammatory cytokines in preclinical models of increased baseline inflammation, limited human evidence precludes conclusions about their translational potential.
Clinical research Review published

Review: Rapid-acting and neuromodulatory treatments for OCD, incl. psilocybin

Rapid-acting and neuromodulatory interventions for treatment-resistant OCD: clinical implications in stress reduction
Why it matters ◈ Mixed
This review highlights the emerging evidence for rapid-acting interventions like psilocybin and ketamine in treatment-resistant OCD, alongside neuromodulatory approaches. While early clinical trial data are promising, the review notes that results remain mixed and robust evidence on repeated dosing is lacking. The synthesis of neurobiological mechanisms and stress-related pathways may guide future research and trial design, but does not yet change clinical practice or legal status.
Obsessive-compulsive disorder (OCD) is a highly debilitating and often chronic condition. A large percentage of patients do not respond to first-line treatments with selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy (CBT), underscoring the need for novel therapeutic approaches. In this context, promising innovative treatments have recently emerged for OCD; these include pharmacological options such as ketamine and psilocybin—which may exert rapid-acting effects—as well as neuromodulatory treatments such as repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS). In addition, growing evidence links early life stress with neuroinflammatory pathways and dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis in OCD, opening novel treatment targets. While preliminary clinical trials of novel rapid-acting substances in OCD are encouraging, results are mixed and evidence of repeated dosing is scarce. This narrative review synthesizes current evidence on rapid-acting and neuromodulatory treatments for OCD, with a particular focus on stress-related mechanisms, offering new therapeutic possibilities as well as avenues for future research.
Clinical research Peer-reviewed study published

Study links persistent perceptual effects in psychedelic users to sensory processing

Persisting perceptual abnormalities in psychedelic users are associated with conditioned hallucinations and impaired sensory processing
Why it matters ◈ Mixed
This study provides new evidence that persistent perceptual abnormalities (PPAs) in psychedelic users are associated with altered sensory processing and conditioned hallucinations, especially in those with early or high-dose exposure. The findings challenge assumptions about how psychedelics affect perceptual priors, suggesting a more nuanced model of psychotic-like effects. This research is relevant for risk assessment, clinical trial design, and public health messaging as psychedelic use expands.
Abstract Serotonergic psychedelics (SP) are increasingly used in clinical research and naturalistic settings, but their psychotic-like side effects, including persisting perceptual abnormalities (PPAs), are poorly understood. Psychosis-associated hallucinations are associated with susceptibility to conditioned hallucinations and computationally-estimated overweighting of perceptual expectations, or priors. However, SPs are widely argued to reduce prior weighting. We surveyed 186 naturalistic SP users on prior SP use, SP-associated PPA history, and current PPAs. Participants completed the visual conditioned hallucinations (VCH) task, in which conditioning induces perception of absent stimuli. Behavioral data were used to fit parameters of a computational model to estimate latent states driving percepts and responses. Past and current PPAs were associated with younger age at first use and higher SP doses, lower visual thresholds, higher VCH rate and confidence, and reduced sensory discrimination. Among model parameters, however, only reduced decision precision tracked both measures and mediated the dose-PPA relationship; relative prior weighting rose equivocally, as expected when priors and sensory evidence gain precision together. SP-related PPAs may therefore arise from a noisy visual system biased toward detection, in which priors act as templates that convert sensory noise into expected percepts. These findings may point to a tractable model for how psychotic-like perception emerges.
Clinical research Review published

Review: Emergency management of emerging synthetic drug intoxications

Emerging Synthetic Drug Intoxications: Toxidrome Recognition, Emergency Stabilization, and Neuropsychiatric Outcomes
Why it matters ◈ Mixed
This review synthesizes current knowledge on the acute and neuropsychiatric effects of emerging synthetic drugs, highlighting clinical challenges and management strategies relevant to emergency medicine and psychiatry. While not focused on classical psychedelics, the findings are significant for clinicians encountering a broad spectrum of psychoactive intoxications, including those that may overlap with novel psychedelic analogues. The emphasis on syndromic recognition and integrated care informs best practices and risk mitigation as new substances enter the market.
Emerging synthetic drugs and new psychoactive substances represent a growing challenge for emergency medicine, clinical toxicology, and psychiatry due to their rapidly changing composition, variable potency, frequent polysubstance exposure, and capacity to produce overlapping toxicological syndromes. This study analyzed the clinical presentation, emergency stabilization strategies, and neuropsychiatric complications associated with synthetic cannabinoids, synthetic cathinones, nitazenes, designer benzodiazepines, xylazine, and other emerging psychoactive compounds. A structured analytical review based on the Scientific Method was conducted using recent clinical studies, systematic reviews, toxicological reports, and emergency medicine publications. The evidence showed that these substances can produce neurological, cardiovascular, respiratory, metabolic, and psychiatric abnormalities ranging from agitation, hallucinations, paranoia, and psychosis to seizures, hyperthermia, respiratory depression, bradycardia, hypotension, altered consciousness, and multiorgan complications. Synthetic cannabinoids and synthetic cathinones were prominently represented among psychiatric intoxication cases, while nitazene poisoning demonstrated variable naloxone requirements, including the need for prolonged infusion in selected patients. Xylazine exposure was mainly associated with central nervous system depression, bradycardia, hypotension, and respiratory compromise, particularly in the context of polysubstance use. The findings support a syndromic and physiology-first approach in which airway protection, ventilatory support, cardiovascular monitoring, temperature control, seizure management, treatment of severe agitation, correction of metabolic abnormalities, and selective antidotal therapy are prioritized according to the patient’s clinical condition. Persistent neuropsychiatric manifestations require reassessment after acute stabilization to differentiate transient intoxication from prolonged substance-induced psychiatric syndromes. An integrated approach involving emergency medicine, clinical toxicology, and psychiatry is essential for the effective management of these rapidly evolving intoxications.
Clinical research Meta-analysis published

Meta-analysis: Psychedelics show immunomodulatory, anti-inflammatory effects

Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics.
Why it matters ▲ Favorable
This systematic review and meta-analysis synthesizes evidence that serotonergic psychedelics may exert anti-inflammatory and immunomodulatory effects in humans and animals. These findings could expand the therapeutic rationale for psychedelic research beyond psychiatry, potentially informing future clinical trials in autoimmune or inflammatory conditions. The results may also influence regulatory and funding priorities by highlighting novel mechanisms of action relevant to public health. Further translational studies will be needed to clarify clinical significance and safety.
FDA / DEA FDA public hearing

FDA Holds Hearing on Psychedelics; Sentiment Overwhelmingly Positive

FDA Hearing on Psychedelics: Concerns, But Overwhelmingly Positive
Why it matters ▲ Favorable
The FDA's public hearing on psychedelics signals a pivotal moment for federal oversight and potential regulatory pathways for psychedelic therapies. While concerns were raised, the overwhelmingly positive tone suggests growing institutional support for advancing psychedelic research and access. This development could accelerate clinical trial approvals, influence rescheduling debates, and shape future market entry for psychedelic-based treatments. Stakeholders should closely monitor follow-up actions and guidance from the agency.
Neuroscience Peer-reviewed study

Ketamine affects neural and behavioral spatial working memory precision

Ketamine Alters Tuning of Neural and Behavioral Spatial Working Memory Precision.
Why it matters ◈ Mixed
This study provides new evidence that ketamine alters the neural mechanisms underlying spatial working memory precision in humans. The findings may inform both clinical research on ketamine’s cognitive effects and safety monitoring in therapeutic contexts. While not directly policy-shifting, these data could influence trial design and risk-benefit assessments for ketamine use in psychiatry.
Clinical research Meta-aggregation published

Meta-aggregation: Post-psychedelic difficulties and counselling implications

Working with post-psychedelic difficulties: a meta-aggregation of users’ experiences and implications for counselling practice
Why it matters ◈ Mixed
This meta-aggregation synthesizes evidence on post-psychedelic difficulties, emphasizing the complexity and diversity of users’ distress and coping strategies. The findings underscore the need for pluralistic, harm-reduction-informed counselling practices to support individuals after psychedelic experiences, especially outside clinical settings. This work is significant for practitioners, researchers, and policymakers seeking to minimize harm and improve integration support as psychedelic use expands.
With the increasing use of psychedelics in both clinical and non-clinical contexts, there is growing potential for harm arising from challenging experiences and post-psychedelic difficulties. This qualitative review aimed to explore psychedelic users’ experiences of acute and post-psychedelic challenges in non-clinical contexts, to identify practice considerations for safer and more effective client work supporting the evolving role of counselling psychologists and practitioners in related fields. A comprehensive search across EBSCO databases and Google Scholar identified seven studies (n = 721) published between 2021 and 2025. Data extraction, quality appraisal, and meta-aggregative synthesis were conducted in accordance with JBI methodology. Four synthesised findings were identified: (1) complex experiences of distress; (2) diverse and individualised coping strategies; (3) external support and challenges; and (4) internal adjustment and ambiguous outcomes. Findings indicate that experiences are varied, complex, and paradoxical; this highlights the value of pluralistic harm-reduction approaches that acknowledge diversity of experience to ensure safer and more effective outcomes for those navigating post-psychedelic difficulties.
Clinical research RCT pooled analysis published

Pooled RCT analysis: Ketamine's effects in treatment-resistant depression

Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials.
Why it matters ▲ Favorable
This pooled analysis of two randomized controlled trials provides robust evidence on ketamine's symptom-level effects in treatment-resistant depression. By leveraging network and symptom-level analyses, the study offers granular insights into which depressive symptoms respond best to ketamine, informing both clinical practice and future trial design. The findings could influence regulatory and payer decisions regarding ketamine's use and may support more targeted, symptom-based treatment approaches in psychiatry.
Clinical research Phase 2 trial published

Psilocybin trial shows reduced cocaine use; Filament Health holds exclusive IP

Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Why it matters ▲ Favorable
A randomized clinical trial has found that a single dose of psilocybin reduced cocaine use, marking a significant step for substance use disorder research. Filament Health's exclusive license to the data and IP positions the company as a key commercial gatekeeper for future development and partnerships. This result could accelerate interest in psychedelic-based treatments for stimulant addiction and shape future licensing and access models. The trial's publication adds to the growing evidence base supporting clinical applications of psilocybin.
Clinical research Letter published

Letter: CYP2D6 inhibition exposes screening gap for ibogaine in military system

Letter to the Editor for "Evaluating Pharmacogenomic Prescription Data in the Military Health System": Medication-Induced CYP2D6 Inhibition Reveals a Screening Gap in Proxy-Defined Ibogaine Candidates.
Why it matters ◈ Mixed
This letter highlights a significant pharmacogenomic screening gap for ibogaine therapy candidates in the Military Health System, due to medication-induced CYP2D6 inhibition not being captured by proxy definitions. This finding is important for both clinical trial design and real-world implementation, as CYP2D6 metabolism is critical for ibogaine safety and efficacy. The letter underscores the need for more robust, real-time pharmacogenomic screening protocols to prevent adverse events and optimize patient selection, especially in complex populations like military personnel. Researchers and policymakers should consider these findings when developing guidelines for psychedelic therapy access and monitoring.
Clinical research Phase 2 supply deal

Filament Health expands psilocybin supply for Italian TRD trial

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Why it matters ▲ Favorable
An expanded supply agreement for GMP psilocybin (PEX010) strengthens the infrastructure for the TEMPO clinical trial targeting treatment-resistant depression in Italy. This move signals growing international collaboration and commercial readiness in the European psychedelic research ecosystem. It may facilitate smoother trial operations and could set a precedent for future pharma-academic partnerships in the region.
FDA / DEA FDA hearing held

FDA holds hearing on psychedelics, implications for psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists
Why it matters ◈ Mixed
The FDA's public hearing on psychedelics signals growing regulatory attention to their clinical use, with direct implications for psychiatric practice. Such hearings often precede guidance or rulemaking that can shape research protocols, prescriber access, and insurance coverage. Stakeholders should monitor for subsequent FDA actions that may clarify legal risks and open new pathways for clinical research or treatment.
Neuroscience Peer-reviewed research

Allosteric mechanisms of 5-HT2 receptors mapped for drug design

Deciphering the allosteric landscape of 5-HT2 receptors: integrated molecular dynamics and fragment molecular orbital analyses of activation mechanisms
Why it matters ▲ Favorable
This study provides a detailed molecular map of 5-HT2 receptor activation, highlighting key residues and pathways that govern ligand efficacy and signaling bias. These insights are highly relevant for the rational design of next-generation psychedelic and non-hallucinogenic serotonergic compounds. The work may accelerate the development of safer, more selective therapeutics for neuropsychiatric disorders, and inform clinical trial strategies by clarifying receptor subtype vulnerabilities and drug interaction mechanisms.
Abstract Background The 5-HT 2 receptor subfamily (5-HT 2A , 5-HT 2B , and 5-HT 2C ) is a cornerstone of neuropsychiatric drug design, yet the precise molecular determinants of their activation and biased signaling remain only partially elucidated. This study aimed to investigate the conformational transitions and energetic landscapes across diverse functional states to provide a refined structural blueprint of the allosteric signaling mechanisms. Methods We integrated Molecular Dynamics (MD) simulations, Dynamical Network Analysis (DNA), and Fragment Molecular Orbital calculations combined with Pair Interaction Energy Decomposition Analysis (FMO/PIEDA). By applying FMO/PIEDA to MD-derived representative structures, we performed an ab initio evaluation of receptor–ligand complexes, quantifying individual residue-ligand pair interaction energies (PIE). Results Our results demonstrate that signal transduction is governed by a cooperative allosteric network rather than a single toggle switch, with the conserved R3.50 residue serving as a mandatory endpoint of ligand-induced communication. While agonists initiate the shift toward active-like states, G protein coupling acts as a directional amplifier, focusing communication pathways toward R3.50 and effectively stabilizing the E/DRY ionic lock against disruption. Subtype-specific analyses reveal that the 5-HT 2B receptor possesses the most intrinsically pre-organized communication network, while 5-HT 2A exhibits the highest sensitivity to perturbations in signal transmission. Furthermore, FMO analysis identified the highly conserved D3.32 as the primary stabilizing anchor, while residues such as S5.46 and W6.48 were found to be critical energetic determinants of ligand efficacy. Conclusions These integrated insights provide a refined structural blueprint of the TM5–TM6–TM7 allosteric landscape, moving beyond isolated residue descriptions. The findings facilitate the rational design of next-generation, non-hallucinogenic agonists or selective modulators by targeting specific energetic and dynamic pathways within the serotonin receptor family. Clinical trial number Not applicable.
Clinical research Trial expanded

Italy expands first psychedelic trial for treatment-resistant depression

Italy's reported first psychedelic trial for hard-to-treat depression will include more people.
Why it matters ▲ Favorable
Italy's first reported psychedelic clinical trial for hard-to-treat depression is expanding its participant pool, signaling growing institutional and regulatory support for psychedelic research in a major EU country. This expansion may accelerate data collection and bolster legitimacy for future trials and access pathways in Italy and the broader European context. The move is a notable milestone for international research and could impact future policy and market developments.
Neuroscience Peer-reviewed study

Study: Subacute ketamine effects on neural reward processing

Subacute effects of ketamine on neural correlates of reward processing.
Why it matters ◈ Mixed
This study provides new evidence on how ketamine affects brain reward circuits beyond the acute phase, which may inform both clinical protocols and mechanistic understanding of its antidepressant action. The findings could impact dosing schedules and safety monitoring in both research and therapeutic settings. Policymakers and clinicians may use these insights to refine guidelines for ketamine use in mood disorders.
Clinical research Peer-reviewed trial published

RCT: Ketamine vs. Magnesium as Adjuvants in Nerve Blocks for Mastectomy

Ketamine Versus Magnesium Sulphate as Adjuvants to Bupivacaine in Pectoral Nerve Blocks for Mastectomy: A Randomized, Double-Blind Trial.
Why it matters ◈ Mixed
This randomized, double-blind trial compares ketamine and magnesium sulphate as adjuvants to bupivacaine in pectoral nerve blocks for mastectomy patients. The findings may inform perioperative pain management protocols and expand the evidence base for ketamine’s use in non-psychiatric, non-anesthetic indications. While not directly related to psychedelic therapy, this research could influence clinician attitudes, regulatory guidance, and off-label ketamine use in broader medical contexts.
Clinical research Published study

International study links recent psychedelic use to cognitive deficits, lifetime use to lower quality of life

Effects of psychedelic drug use on neurocognitive function and the psychological and social domains of quality of life: an international online study
Why it matters ◈ Mixed
This international online study suggests recent psychedelic use may impair cognitive performance and increase depressive symptoms, while lifetime use does not appear to cause long-term cognitive decline but may be associated with lower psychological and social quality of life. The findings underscore the importance of distinguishing acute from long-term effects and call for more rigorous, controlled longitudinal research. These results are relevant for clinicians, researchers, and policymakers considering the safety and broader impacts of psychedelic use.
Background The past few decades have seen a revived interest in psychedelic-assisted and ketamine-assisted therapy for mental health disorders, but data concerning the acute, subacute, and long-term effects of serotonergic psychedelics on cognitive functioning are scarce. This international, online study (N = 759) sought to investigate the potential acute, subacute, and long-term effects of psychedelic drug use on cognition through cognitive task assessment. Questionnaires assessing mental health and quality of life were also administered. Methods Participants completed cognitive tasks assessing working memory, selective attention, and visual/spatial perception, as well as questionnaires assessing mental health outcomes and quality of life. Based on self-reported substance use, participants were classified as non-users, lifetime users, and recent users. Results Recent users had significantly lower accuracy across all cognitive tasks, and lifetime users had the highest task accuracy without corresponding reaction time deficits, with the exception of the 2D mental rotation task. Lifetime use was not associated with long-term cognitive decline. Recent users reported more depressive and dissociative symptoms, whereas lifetime users reported lower scores. Lifetime users scored lower on psychological and social quality of life domains, indicating possible long-term psychosocial effects. Conclusions These findings highlight the need to differentiate between the acute and long-term effects of psychedelics; lab-controlled, longitudinal studies are needed to enable safe clinical application.
Clinical research Literature review published

Review: Psilocybin-assisted therapy for major depression shows promise

PSICOTERAPIA ASSISTIDA POR PSICODÉLICOS NO TRANSTORNO DEPRESSIVO MAIOR: EVIDÊNCIAS SOBRE EFICÁCIA, SEGURANÇA E SUSTENTABILIDADE DA RESPOSTA TERAPÊUTICA
Why it matters ▲ Favorable
This narrative review synthesizes recent clinical evidence supporting the efficacy and safety of psilocybin-assisted psychotherapy for major depressive disorder, including treatment-resistant cases. The findings highlight rapid and sustained antidepressant effects with mostly transient adverse events, but also emphasize the need for standardized protocols, careful patient selection, and longer-term studies before widespread clinical adoption. This work consolidates the state of the science for clinicians and policymakers considering regulated access.
O transtorno depressivo maior constitui importante problema de saúde pública, caracterizado por elevada prevalência, recorrência, prejuízo funcional e resposta insuficiente a tratamentos convencionais em parcela dos pacientes. Nesse contexto, a psicoterapia assistida por psicodélicos, particularmente aquela associada à psilocibina, tem recebido crescente atenção científica devido à possibilidade de produzir respostas antidepressivas rápidas após número limitado de administrações. O objetivo deste estudo foi analisar as evidências disponíveis sobre eficácia, segurança e sustentabilidade da resposta terapêutica associada à psicoterapia assistida por psicodélicos no transtorno depressivo maior. Foi realizada revisão narrativa da literatura, com pesquisas nas bases PubMed/MEDLINE, Embase, Cochrane Library e SciELO, utilizando descritores relacionados a psilocibina, psicoterapia assistida por psicodélicos, depressão maior, depressão resistente ao tratamento, segurança e resposta terapêutica. Foram utilizados 32 estudos e documentos científicos na síntese final, priorizando publicações entre 2020 e 2026. Os resultados demonstraram redução significativa dos sintomas depressivos em diferentes ensaios clínicos, com efeitos observados desde os primeiros dias após a intervenção e manutenção da melhora por períodos variáveis. Metanálises recentes também identificaram maior probabilidade de resposta e remissão em comparação com intervenções controle. Os eventos adversos mais frequentes foram transitórios, incluindo cefaleia, náusea, tontura e alterações cardiovasculares agudas, embora a seleção rigorosa dos participantes seja fundamental. Estudos de seguimento indicam possibilidade de manutenção dos benefícios por vários meses, porém com evidências ainda limitadas e heterogêneas. Conclui-se que a psicoterapia assistida por psilocibina apresenta resultados promissores, mas sua incorporação clínica requer protocolos padronizados, monitorização adequada, seleção criteriosa e estudos de maior duração.
Clinical research Literature review published

Review: Ketamine for Adolescent TRD—Rapid Relief, Uncertain Long-Term Safety

Ketamine for Treatment-Resistant Depression in Adolescents: Hope or Risk?
Why it matters ◈ Mixed
This review highlights ketamine's rapid antidepressant effects in adolescents with treatment-resistant depression, but underscores significant safety and long-term risk concerns. The findings reinforce ketamine's promise for acute symptom relief in specialized settings, while cautioning against widespread use until more robust long-term data are available. This is a key signal for clinicians and researchers focused on pediatric mental health and the evolving role of psychedelics in youth populations.
Treatment-resistant depression (TRD) in adolescents remains a major clinical challenge because of the limited efficacy of conventional antidepressants and the high risk of suicidal behavior. Ketamine has emerged as a rapidly acting antidepressant with a unique glutamatergic mechanism, promoting neuroplasticity and reducing neuroinflammation. Clinical studies demonstrate significant symptom improvement, often within 24 hours, although the effects are generally short-lived. Concerns remain regarding dissociative and cardiovascular adverse effects, abuse potential, and the uncertain long-term impact on the developing brain. Background: Adolescent TRD is associated with severe functional impairment and poor response to standard treatments, highlighting the need for faster-acting therapeutic options. Aim: To review the efficacy, mechanisms of action, and safety of ketamine in adolescents with TRD. Materials and methods: A narrative review of the literature on ketamine pharmacology, clinical efficacy, and safety in adolescent TRD was conducted. Summary: Ketamine produces rapid antidepressant effects through modulation of glutamatergic neurotransmission and enhancement of neuroplasticity. Current evidence supports short-term efficacy, while long-term outcomes remain uncertain. Conclusions: Ketamine is a promising option for selected adolescents with TRD requiring rapid symptom relief, but its use should remain limited to specialized clinical settings until further evidence confirms its long-term safety and efficacy.
Clinical research Published study

Age moderates mental health impact of psychedelics in real-world use

Age moderates the relationship between psychedelic use and mental health in naturalistic settings
Why it matters ◈ Mixed
This study finds that the mental health benefits of classic psychedelics are more pronounced in younger adults, with effects diminishing with age. The results suggest age is a key moderator of outcomes, independent of dose or frequency, and highlight the need for age-stratified research in both clinical and naturalistic settings. This has implications for trial design, patient selection, and regulatory guidance as the field moves toward broader access.
Abstract Depression and anxiety affect one in five adults and vary across the lifespan; while prevalence generally declines with age until midlife, later life is marked by a re-emergence of symptoms. Although clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan. We conducted a cross-sectional survey of 1,088 adults (18–55 + years) to assess how lifetime psychedelic use – categorised as classic, non-classic, or mixed – relates to mental health. We found that age significantly moderates the relationship between lifetime history of psychedelic use and mental health measures. Specifically, classic psychedelic use was linked to lower depression and anxiety among younger adults, but these effects diminished with age. These associations persisted independently of drug-use parameters, including dosage, frequency, and recency of use. Moderated-mediation analyses indicated that mystical-type experiences accounted for the associations with both depression and anxiety among younger adults, but not among older adults, where a residual association with anxiety remained independent of mystical experience. These findings suggest that age may be a meaningful moderator of mental health outcomes from psychedelic use. This underscores the potential value of age-stratified research to optimise the efficacy and safety of psychedelic-assisted interventions.
Neuroscience Peer-reviewed study

No subacute ketamine effect on reward processing in healthy adults

Subacute effects of ketamine on neural correlates of reward processing
Why it matters ◈ Mixed
This study finds no significant subacute effect of ketamine on neural reward processing in healthy participants, suggesting any impact may be limited to the acute phase or to clinical populations with reward dysfunction. The results highlight the importance of timing and population selection in ketamine research, and may inform trial design for mood disorder indications. While not a landmark, it adds nuance to understanding ketamine’s neural action profile.
Abstract Ketamine induces a sequence of temporally distinct effects on brain function, yet its impact on reward processing beyond the acute post-administration phase remains unclear. In this single-blind, placebo-controlled, crossover study, 28 healthy participants received 0.5 mg/kg racemic ketamine or placebo via a 40 min intravenous infusion. Functional magnetic resonance imaging was acquired approximately 5 h post-infusion during the Monetary Incentive Delay (MID) task, targeting the subacute phase after resolution of acute dissociative effects. Plasma concentrations of ketamine and norketamine were obtained for pharmacokinetic modeling and area under the curve estimation. At 5 h post-administration, ketamine did not significantly modulate brain activation during the MID task in either ROI-based or whole-brain analyses, despite measurable subjective drug effects. Pharmacokinetic modeling yielded ketamine and norketamine concentration-time profiles consistent with expected pharmacokinetic patterns, however, neither individual drug exposure nor psychometric measures showed robust associations with MID task-related neural activation. These findings suggest an absence of detectable task-evoked effects under the present methodological conditions. When considered alongside prior work, they are consistent with the possibility that ketamine’s effects on reward circuitry are time-sensitive and may be more prominent during the acute post-administration phase or in clinical populations with pre-existing reward dysfunction.
Neuroscience Peer-reviewed publication

Study: Temporal structure influences psychedelic experience

Temporal structure tunes the psychedelic experience.
Why it matters ▲ Favorable
This peer-reviewed study provides new evidence that the timing and sequencing of stimuli or interventions can significantly shape the subjective effects of psychedelics. The findings may inform clinical trial design, therapeutic protocols, and basic neuroscience research by highlighting the importance of temporal factors in modulating outcomes. While not a regulatory or legal shift, this work could influence best practices for both research and therapeutic settings.
Clinical research Case report published

Case report: Prolonged psychological distress after recreational LSD use

Prolonged Psychological Distress Following Recreational LSD Use in a Young Adult with Multiple Vulnerability Factors: A Case Report
Why it matters ◈ Mixed
This case report documents prolonged psychological distress and repeated ER visits in a young adult following recreational LSD use, with complex interplay of pre-existing vulnerability factors and subsequent alcohol use. While single cases do not establish causality or prevalence, such reports are important for informing harm reduction, screening protocols, and clinical trial exclusion criteria. The findings reinforce the need for careful assessment of set, setting, and comorbidities in both recreational and clinical psychedelic contexts.
While psychedelic experiences are often reported as positive, adverse psychological reactions can occur. We present the case of a 19-year-old Caucasian male who presented to the ER with suicidal thoughts after taking lysergic acid diethylamide (LSD) alone. He was diagnosed with anxious state associated with panic attacks, and suicidal thoughts without ideation or behaviors. He was admitted to the psychiatric ward and treated with trazodone, a serotonin antagonist and reuptake inhibitor antidepressant, and brexpiprazole, an atypical antipsychotic. He responded well and was discharged after 12 days with recommendations to continue therapy with brexpiprazole and attend follow-up at the territorial mental health services. Five days later, he engaged in alcohol consumption with a roommate met during the psychiatric admission, and suicidal thoughts re-emerged. He presented again to the ER but was not admitted to the inpatient unit, since he improved with supportive conversation and medication. One month later, he returned to the ER a third time due to pervasive doubt and confusion that distressed him to the point of triggering unstructured suicidal thoughts. After one week of hospitalization, he was discharged and citalopram (a selective serotonin reuptake inhibitor [SSRI]) was added to the therapy. Following the third admission, the clinical suspicion strengthened that he may have an underlying obsessive functioning pattern that became clinically apparent following LSD use, although the contribution of other vulnerability factors could not be excluded. This case highlights the importance of set and setting, underscores the relevance of harm reduction strategies for both recreational and clinical users, and highlights a potentially negative interaction between serotonergic psychedelics and alcohol.
Clinical research Retrospective study published

Study: Ketamine and Chronic Opioid Use After Spine Surgery

Intraoperative Ketamine and Chronic Opioid Use After Lumbar Spine Surgery in Patients With and Without Opioid-Use Disorder: A Retrospective Database Analysis.
Why it matters ◈ Mixed
This retrospective database analysis examines whether intraoperative ketamine administration affects chronic opioid use after lumbar spine surgery, including among patients with opioid use disorder. The findings may inform perioperative pain management protocols and support or challenge the use of ketamine as an adjunct to reduce long-term opioid dependence. While not a prospective trial, the study adds to the evidence base relevant to both clinical practice and policy discussions on alternatives to opioids in surgical settings.
DEA / Federal Register Rule comment period

DEA seeks comment on procurement quota certification recordkeeping extension

Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-Procurement Quota Certification and Recordkeeping Requirements
Why it matters ◈ Mixed
The DEA is proposing to extend its requirements for procurement quota certification and recordkeeping, which directly impacts how manufacturers and researchers obtain and document controlled substances, including psychedelics. This extension could affect administrative burdens and compliance timelines for research institutions and industry operators working with scheduled compounds. Stakeholders should review and comment to ensure research access is not unduly hindered.
The Drug Enforcement Administration (DEA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Clinical research Treatment approved

Ketamine treatment approved for veterans with PTSD, mental health issues

New ketamine treatment option approved for veterans struggling with PTSD, other mental health issues
Why it matters ▲ Favorable
This approval expands access to ketamine-based therapies for veterans with PTSD and other mental health conditions, signaling growing institutional acceptance of psychedelic-adjacent treatments in mainstream care. It may set a precedent for broader insurance coverage, increased clinical adoption, and further research into novel therapies for trauma-related disorders. The move could also influence policy and market dynamics as ketamine's role in mental health care continues to evolve.
US Trade / Regulatory Federal tariff guidance in effect

US zero-tariff policy for specialty pharma, incl. orphan & cell therapies

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020
Why it matters ◈ Mixed
This federal guidance implements a zero-tariff rate for certain specialty pharmaceuticals, including orphan drugs, cell and gene therapies, and their ingredients, if imported from eligible jurisdictions or meeting urgent US health needs. While psychedelics are not explicitly named, this policy could lower import costs for psychedelic compounds if they are designated as orphan drugs or meet urgent health criteria, potentially facilitating research and market access. The notice also sets procedures for public input, which could be leveraged by stakeholders to advocate for inclusion of psychedelic therapies.
This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an ad valorem tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States," (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. Proclamation 11020 states that such products and associated ingredients receive the Section 232 zero tariff rate if they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement or if they meet an urgent U.S. health need. This notice also includes procedures for the public to submit information for the Department of Commerce's (Commerce) approval to determine if imports of the pharmaceutical products and associated ingredients meet an urgent U.S. health need. This notice also issues five technical corrections to Annex I and one technical correction to Annex IV of the Proclamation.
Industry Patent portfolio expanded

NeuroThera, Clearmind expand US patents for LSD, ketamine, ibogaine combos

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Why it matters ▲ Favorable
NeuroThera's collaboration with Clearmind to expand its US patent portfolio covering combinations of LSD, ketamine, and ibogaine signals growing commercial and IP activity in the psychedelic sector. While not a regulatory or clinical inflection point, this move could influence future research partnerships, licensing, and competitive positioning as these compounds move toward clinical and commercial use. Stakeholders should monitor how such patent strategies might affect access, innovation, and market entry.
Industry / Clinical research Trial supply completed

Optimi completes psilocybin capsule batch for Australian trial

Optimi completes psilocybin capsule batch for trial, Australia
Why it matters ▲ Favorable
Optimi's completion of a GMP psilocybin capsule batch signals advancing infrastructure for clinical research in Australia. This milestone supports ongoing or upcoming trials, reflecting both regulatory acceptance and growing industry capacity in the region. The move may facilitate faster patient access and bolster Australia's role as a leader in psychedelic medicine trials.
Industry Patent expansion announced

NeuroThera expands U.S. patents for LSD, ketamine

NeuroThera expands U.S. patents for LSD, ketami...
Why it matters ◈ Mixed
NeuroThera's expansion of U.S. patents for LSD and ketamine signals ongoing commercial interest and potential market positioning in the psychedelic therapeutics space. While patent activity does not directly impact clinical access or legal status, it can shape future competition, licensing, and research pathways. Stakeholders should monitor for any impact on freedom-to-operate and downstream exclusivity.
FDA / DEA DEA rule + FDA access action

DEA seeks ban on psychedelics as FDA accelerates therapy access

DEA Moves To Ban Several Psychedelics As FDA Takes Steps To Accelerate Legal Access To Therapies
Why it matters ◈ Mixed
This signals a major regulatory divergence: the DEA is moving to ban several psychedelics while the FDA is simultaneously taking steps to speed legal access to psychedelic therapies. This creates uncertainty for researchers, clinicians, and industry stakeholders, as scheduling bans could restrict research and patient access even as the FDA attempts to facilitate it. The outcome will shape the legal landscape, investment climate, and the future of clinical innovation in the US.
Industry Production completed

Optimi Health completes psilocybin production for health sector

Optimi Health Completes Psilocybin Production for Health
Why it matters ▲ Favorable
Optimi Health's completion of a psilocybin production run signals growing capacity for supplying pharmaceutical-grade psychedelics to the health and research markets. This development may help address supply chain needs for clinical trials and potential regulated therapeutic use. However, without details on regulatory approvals or distribution, the immediate impact on patient access and legal risk remains limited.
Clinical research Emerging evidence

Psilocybin therapy for AUD: Evidence, costs, and treatment gaps

Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
Why it matters ◈ Mixed
Emerging evidence on psilocybin-assisted therapy for alcohol use disorder (AUD) is drawing attention to clinical efficacy, cost implications, and persistent treatment gaps. While not reporting a definitive trial or regulatory move, this coverage signals growing interest and potential market demand, as well as ongoing challenges in access and reimbursement. Stakeholders should monitor for forthcoming pivotal trial data or policy shifts that could accelerate adoption.
State policy Regulatory fee decision

Oregon drops proposed higher psilocybin fees after industry pushback

Oregon regulators nix higher fees for psilocybin after industry backlash - Oregon Public Broadcasting
Why it matters ▲ Favorable
Oregon regulators' decision to abandon proposed higher fees for psilocybin licensing reflects responsiveness to industry and community concerns about affordability and access. This move may help stabilize the nascent regulated psilocybin market by lowering barriers for service centers and facilitators, supporting broader participation and potentially improving patient access. The episode highlights ongoing tension between regulatory cost recovery and market sustainability in early-stage psychedelic programs.
Clinical research Peer-reviewed study published

Psilocybin and music genre shape emotional responses in healthy adults

Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults
Why it matters ▲ Favorable
This exploratory, placebo-controlled study provides new evidence that both psilocybin and specific musical genres independently influence the emotional responses evoked by music in healthy volunteers. The findings highlight the importance of music selection in psychedelic research and therapeutic protocols, suggesting that genre and composition can modulate affective outcomes. While not a regulatory or legal shift, this research is material for trial designers and clinicians aiming to optimize set and setting for psychedelic-assisted interventions.
Music is a central component of psychedelic settings, yet little experimental work has examined how psilocybin and musical composition influence music-evoked emotional responses in healthy volunteers. This exploratory, double-blind, placebo-controlled study assessed these effects during the plateau phase of psilocybin and the corresponding time window in placebo sessions following oral administration of psilocybin (0.26 mg/kg) or placebo. The study consisted of two parts. In Part 1 (n = 19), a pilot stage, the first half of participants rated music-induced affective valence for eight compositions representing different genres/subgenres (Rock/Punk, Metal/Industrial Metal, Metal/Industrial Metal, Classical/Baroque, Electronic/Dub, Folk/Nordic Folk, Electronic/Techno, Electronic/Trance, Electronic/Psytrance) using a visual analogue scale (VAS). Based on Part 1, the classical composition with the highest overall affective valence and the psytrance composition with the largest psilocybin-placebo contrast (i.e., the composition most responsive to psilocybin) were selected for Part 2 (n = 17), in which the second half of participants assessed emotional responses to music using the Geneva Emotional Music Scale (GEMS-9). Psilocybin increased wonder, transcendence, and joyful activation across both contrasting compositions. Relative to each other, the classical composition elicited greater peacefulness, tenderness, and nostalgia, whereas the psytrance composition elicited greater tension across both psilocybin and placebo conditions. A composition x condition interaction was observed for sadness: under psilocybin, sadness increased during the classical composition and decreased during the psytrance composition. These findings suggest that psilocybin and contrasting musical compositions independently influence different aspects of music-evoked emotional responses, with limited interaction effects, and point to potential implications for protocol design and music selection in psychedelic settings.
Neuroscience Peer-reviewed review published

Review: Synaptic plasticity links cognitive disorders to new neuropharmacology

Synaptic Plasticity and Cognitive Enhancement: Bridging Neuropathological Cognitive Disorders to Emerging Neuropharmacological Strategies
Why it matters ▲ Favorable
This review synthesizes the neurobiological mechanisms underlying synaptic plasticity and highlights how psychedelics and related compounds are emerging as promising agents for cognitive enhancement and treatment of neuropsychiatric disorders. It provides a translational framework connecting basic neuroscience to clinical innovation, offering researchers and clinicians a roadmap for future drug development and trial design. The inclusion of psychedelics in this context reinforces their growing scientific legitimacy and relevance for precision medicine approaches.
Synaptic plasticity refers to the fundamental process through which synaptic connections become stronger or weaker in response to experience, thereby forming the basis of learning and memory. Disruption of this process is increasingly regarded as a common underlying mechanism of several cognitive and neuropsychiatric disorders, including Alzheimer’s disease, major depressive disorder, schizophrenia, and cognitive aging. This review focuses on synaptic plasticity as a unifying framework that connects neuropathological cognitive disorders to emerging neuropharmacological strategies, with particular attention to clinical translation and precision medicine approaches. The review has three interrelated aims: (i) to clarify the molecular mechanisms that regulate synaptic plasticity, (ii) to investigate how these mechanisms become dysregulated in cognitive disorders, and (iii) to evaluate emerging pharmacological strategies targeting synaptic plasticity for cognitive enhancement. Among the areas receiving special attention are glutamatergic and GABAergic neurotransmission, neurotrophic signaling pathways such as brain-derived neurotrophic factor (BDNF), intracellular cascades including mechanistic target of rapamycin (mTOR) and cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), and epigenetic regulators. With respect to their effects on long-term potentiation, synaptogenesis, and neural circuit function, novel therapeutic agents, including ampakines, N-methyl-D-aspartate (NMDA) receptor modulators, and allosteric gamma-aminobutyric acid (GABA) receptor modulators, are also assessed in this review. In both healthy individuals and disease populations, the review further considers the cognitive and neuroplastic effects of nootropics, psychedelics, and other neuromodulatory compounds. As key enablers of translational progress, the review highlights recent advances in brain-penetrant and target-selective agents, as well as improvements in drug delivery systems and biomarker development. This review aims to provide a comprehensive framework for developing safer, more effective, and more precise interventions for cognitive impairment by integrating neurobiological mechanisms, neuropathological insights, and therapeutic innovation.
Neuroscience Preclinical study published

α,α-Trehalose from Psilocybe shows preclinical antidepressant effects

Preclinical Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensis
Why it matters ▲ Favorable
This preclinical study identifies α,α-trehalose, a non-psychedelic metabolite in Psilocybe cubensis, as having significant anxiolytic and antidepressant-like effects in animal models, potentially mediated by 5-HT1A receptor activity. While promising for future drug development, these findings are early-stage and require validation in human studies before impacting clinical or regulatory pathways. The research expands the scope of bioactive compounds in psychedelic mushrooms beyond classic tryptamines, suggesting new avenues for mental health therapeutics.
The genus Psilocybe has been characterized by central nervous system (CNS) effects and as a source of therapeutic drugs such as the alkaloids psilocybin and psilocin—secondary metabolites that produce rapid anxiolytic and antidepressant effects in preclinical and clinical studies. Furthermore, these mushrooms also contain bioactive primary metabolites, for example, the interesting case of α,α-trehalose. To explore the effects of this disaccharide, it was isolated and characterized using phytochemical and spectroscopic analyses. Subsequently, its anxiolytic- and antidepressant-like properties were assessed and corroborated by in vivo behavioral studies using experimental models for anxiety (open-field, hole-board, and plus-maze tests) and depression (forced swimming test complemented by a preliminary rota-rod test). Electrocorticographic in situ recordings and nuclear magnetic resonance analysis were also explored. Finally, an in silico docking analysis was performed to determine the involvement of the 5-HT1A serotonin receptor as one of the main targets identified in the CNS activity of Psilocybe species. The evidence shows that α,α-trehalose is one bioactive metabolite that promotes significant anxiolytic- and antidepressant-like activities mediated by early brain changes and involving an indirect participation of 5-HT1A receptors. In conclusion, α,α-trehalose represents a potential natural drug for mental health, such as in the treatment of anxiety, depression, or their comorbidity.
Clinical research Thesis published

Attachment-based interventions for intergenerational substance use risk

Risk and resilience in the intergenerational transmission of substance use: a thesis portfolio
Why it matters ◈ Mixed
This thesis synthesizes evidence on how parental substance use (PSU) and attachment insecurity contribute to intergenerational substance use risk. Attachment-based interventions show promise for improving parent-child interaction and attachment security, but evidence for reducing parental substance use itself remains insufficient. The findings highlight complex dynamics, especially among care-experienced populations, and suggest further research is needed to clarify protective and risk factors. While not directly focused on psychedelics, the work is relevant for designing family-oriented interventions in substance use treatment.
AIMS: Children of parents who use substances are themselves at elevated risk of substance use, yet the mechanisms underpinning this intergenerational transmission remain unclear. Conceptualising substance use as a self-regulation strategy points to disruptions in attachment, the relational bond between parent and child that is theorised to lay the foundation for emotional regulation capacity. This thesis portfolio aimed to advance understanding of the relationship between parental substance use (PSU) and attachment through two complementary studies. Chapter 1 systematically reviewed attachment-based interventions for parents who use substances, examining their efficacy and effectiveness in improving attachment security, parent-child interaction, PSU, and reflective functioning. Chapter 2 tested an attachment-based model of intergenerational substance use transmission, evaluating attachment anxiety and avoidance towards parents as mediators of this association, and further exploring the proposed model within a care-experienced population. METHODS: In Chapter 1, a systematic review of six databases identified eligible intervention studies employing RCT, non-RCT, or pre-post designs. Narrative synthesis characterised available interventions and their outcomes, and meta-analyses of the primary outcomes were conducted. Chapter 2 employed a cross-sectional, retrospective design, using data from 255 participants to test proposed mediation and moderated mediation models within structural equation modelling. RESULTS: 21 unique studies were included within the narrative review, 14 of which contributed to meta-analyses. Attachment-based interventions demonstrated effectiveness in enhancing adult attachment security and parent-child interaction, with tentative evidence of improvements in reflective functioning. Greater efficacy versus controls in improving parent-child interaction was observed. Evidence regarding PSU reduction remained insufficient and uncertain. Structural models demonstrated that PSU was associated with higher attachment anxiety and avoidance towards the same parent, however mediation hypotheses were not supported. Direct evidence of intergenerational substance use was observed only for paternal substance use among care-experienced individuals. Further, higher paternal attachment anxiety was associated with lower substance use in care-experienced people, highlighting the complex and differential effects of removal from parental care on intergenerational substance use transmission. CONCLUSION: Together, these studies advance understanding of the link between PSU and attachment insecurity, and highlight the potential of attachment-informed practice as a reparative intervention for parents who use substances and a preventative approach for their children. Findings underscore the need for further research into the conditions under which alternative care confers risk or protection to intergenerational substance use transmission.
Clinical research Systematic review published

Systematic review: Ketamine, esketamine, scopolamine in TRD

The Era of Rapid-Acting Antidepressants: Clinical Insights Into Ketamine, Esketamine, and Scopolamine
Why it matters ▲ Favorable
This systematic review synthesizes high-quality evidence supporting the rapid antidepressant effects of ketamine and esketamine in treatment-resistant depression (TRD), highlighting ketamine's rapid onset and esketamine's maintenance benefits. The findings reinforce the clinical rationale for using these agents in TRD and clarify their relative strengths and limitations, while noting that scopolamine remains experimental. This work will inform clinicians, researchers, and policymakers on the evolving landscape of RAADs and may shape future guidelines and access decisions.
Background: Treatment-resistant depression (TRD) represents a major clinical challenge, being associated with high morbidity, increased suicide risk, and substantial socioeconomic burden. The need for rapidly acting interventions has driven the development of rapid-acting antidepressants (RAADs), such as ketamine, esketamine, and scopolamine. This study aimed to systematically review the efficacy, safety, and clinical applicability of these agents in TRD.Methods: Systematic review conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Searches were performed in PubMed/MEDLINE, Embase, Cochrane Library, and Scopus, including randomized clinical trials (RCTs) published between January 2000 and September 2025. Randomized clinical trials involving adults with TRD were included. The scopolamine trials enrolled patients with depressive disorders and were not restricted to protocol-defined TRD. Risk of bias was assessed using the Cochrane RoB 2 tool. The screening and data extraction processes were independently performed by two reviewers, with disagreements resolved by consensus or consultation with a third reviewer.Results: Seven clinical trials were included (2 ketamine, 3 esketamine, 2 scopolamine). Intravenous ketamine (0.5 mg/kg over 40 minutes) demonstrated onset of effect at approximately 110 minutes, with response rates up to 70% at 24 hours, although with limited duration (1–2 weeks). Intranasal esketamine (56 mg or 84 mg twice weekly), combined with oral antidepressants such as escitalopram, sertraline, duloxetine, or venlafaxine extended release (XR), significantly reduced Montgomery–Åsberg Depression Rating Scale (MADRS) scores over four weeks and lowered relapse risk (hazard ratio [HR] = 0.49). Intravenous scopolamine (4 µg/kg) showed effects within 1–3 days but with less consistency in larger samples.Conclusion: RAADs provide rapid antidepressant responses in TRD. Evidence is more consistent for acute intravenous ketamine use and for maintenance treatment with intranasal esketamine. Intravenous ketamine demonstrated the fastest onset of action, whereas esketamine presented stronger evidence for long-term maintenance and relapse prevention. Scopolamine remains experimental.
Clinical research Scoping review published

Review: Peripheral biomarkers for ketamine/esketamine in depression remain inconclusive

Peripheral Biomarkers of Response to Ketamine and Esketamine Treatment in Unipolar Depressive Disorder—A Scoping Review
Why it matters ◈ Mixed
This scoping review highlights the lack of reliable peripheral biomarkers to predict or monitor response to ketamine and esketamine in treatment-resistant depression. Despite a substantial body of research, results remain inconsistent and no biomarker is ready for clinical use. The review underscores the need for standardized, prospective studies and multimarker approaches, which is critical for improving patient selection, safety monitoring, and optimizing future clinical trials.
Objectives: A significant problem in the treatment of depressive disorders is the growing number of cases of so-called treatment-resistant depression (TRD). There is evidence of ketamine’s effectiveness in treating TRD, with response rates ranging from 40% to 90%. This review aimed to map available studies on peripheral biomarkers of response to ketamine and esketamine in the treatment of depressive disorders, with particular emphasis on biomarker types, study designs, and identification of gaps in current knowledge. Methods: A literature review was conducted in accordance with the PRISMA-ScR guidelines for scoping reviews. PubMed and Embase databases were searched from their inception to 1 February 2026. The search terms “ketamine” or “esketamine” were cross-referenced with the terms “depression,” “biomarkers,” and “predictors.” Articles written in languages other than English, unavailable full-text articles, and animal studies were excluded. A manual search of the bibliographies of existing reviews was also conducted to identify additional studies. Results: Ultimately, 46 articles met the inclusion criteria for the review: 17 randomized controlled trials, 25 non-randomized interventional studies, 2 observational studies, 1 case study, and 1 case series. Most studies focus on BDNF, inflammatory markers, particularly IL-6, TNF-α, IL-10, and IL-8, and kynurenine pathway metabolites. However, the results of these studies are inconsistent. Other areas remain only fragmentarily explored. Conclusions: Significant heterogeneity was observed in study designs, analytical methods, and definitions of clinical response. No peripheral biomarker has yet demonstrated sufficient consistency for clinical implementation. Future studies should prioritize standardized, adequately powered prospective designs and multimarker approaches integrating neuroplastic, inflammatory, and metabolic pathways, with particular attention to esketamine-treated populations.
Clinical research Phase 3 topline

Definium Therapeutics reports 5.1-point gap in Phase 3 anxiety study

Definium Therapeutics reports 5.1-point gap in second Phase 3 anxiety study
Why it matters ▲ Favorable
Definium Therapeutics has announced a 5.1-point difference in its second Phase 3 trial for an anxiety indication, suggesting a potentially clinically meaningful effect. If this result is robust and statistically significant, it could accelerate regulatory submissions and reshape the competitive landscape for psychedelic-based or novel anxiolytic therapies. The outcome is highly relevant for researchers, investors, and clinicians tracking late-stage development in this space. Further details on safety, durability, and regulatory plans will be critical.
Clinical research Umbrella review published

Global umbrella review of approved SUD medications (2016-2026)

Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
Why it matters ◈ Mixed
This large-scale umbrella review synthesizes global evidence on approved pharmacotherapies for substance use disorders (SUD), including phase 3 trial outcomes and real-world effectiveness across alcohol and opioid use disorders. While not focused on psychedelics, the review provides a comprehensive benchmark for current SUD treatment efficacy, against which emerging psychedelic interventions may be compared. The findings highlight both the strengths and limitations of existing medications, informing researchers, clinicians, and policymakers about unmet needs and potential opportunities for novel therapies.
BACKGROUND AND OBJECTIVES: This umbrella review of systematic reviews, meta-analyses, and completed phase 3 randomized controlled trials (RCTs) over the past 10 years covers approved pharmacological treatments for substance use disorders (SUD) worldwide, providing clinicians and researchers with a detailed analysis of current pharmacotherapies and bridging the gap between evolving pharmacological interventions and clinical practice. METHODS: This PROSPERO-registered umbrella review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Peer-reviewed systematic reviews were selected to include systematic reviews of RCTs and meta-analyses that examined approved medications for treatment, withdrawal management, or overdose reversal of SUD in all populations. Reviews published in peer-reviewed journals from 1 January 2016 to 1 January 2026, including medications that received worldwide approvals from World Health Organization (WHO)-listed Authorities plus those in the ten most populous countries were included. Reviews of preclinical studies and those not meeting systematic review standards or missing required data were excluded. We also included completed phase 3 SUD medications, including only RCTs with posted results from 2016 to 2026; preclinical studies and those with missing required data were excluded. We searched PubMed, MEDLINE, and the Cochrane Library databases for systematic reviews using keywords related to SUD. We also searched for phase 3 medications on the WHO International Clinical Trials Registry Platform. Risk of bias and methodological quality were assessed using the Risk if Bias in Systematic Reviews (ROBIS) and A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) tools for systematic reviews and using the Cochrane risk of bias (RoB2) tool for phase 3 RCTs. Two independent reviewers conducted the selection process, resolving discrepancies through discussion, consultation with a third reviewer, and reaching consensus. The results were synthesized narratively and presented by each medication in summaries and tables. RESULTS: Sixteen systematic reviews were reviewed, containing 371 RCTs (n = 131,965) and 62 observational studies (OS) (n = 229,225) examining 41 approved medications (with 25 distinct molecules) for SUD worldwide as of 1 January 2026: Eighty-six RCTs (n = 18,643) covering seven medications for alcohol use disorder (AUD), showed a reduction of risk of returning to any drinking ranging from 7 to 17% compared with placebo; three for alcohol withdrawal/intoxication. A total of 49 RCTs (n = 7804) and 21 OS (n = 155,111) covering 12 medications for opioid use disorder (OUD), showed that the highest abstinence rates ranged from 41 to 43% compared with 5% in placebo. Forty-one OS (n = 74,114) covering nine medications for opioid overdose reversal, with survival rates ranging from 92 to 98%; one for opioid withdrawal. A total of 223 RCTs (n = 104,524) covering eight medications for tobacco use disorder (TUD), showed 1.3-2.3 times more likelihood to experience abstinence compared with placebo; and 13 RCTs (n = 994) covering one medication in sedative-hypnotic or anxiolytic use disorder (SHAUD) for benzodiazepine overdose reversal. Four completed phase 3 RCTs with posted results were reviewed, which included 1026 participants examining four pipeline medication treatments for SUD worldwide as of 1 January 2026: three RCTs (n = 623) covering three medications for AUD, and one RCT (n = 403) covering one combination medication treatment for stimulant use disorder (StUD). CONCLUSIONS: Recent advancements in medications for SUD have expanded the range of pharmacologic treatments available for clinical practice. Effective medications are available for tobacco, opioid, and alcohol use disorders, and promising medications are emerging beyond the currently approved treatment landscape. TRIAL REGISTRY: PROSPERO ID: CRD420251036330.
Industry Market analysis

MDMA-assisted therapy for PTSD may cost $45,000 per patient

The promise and the $45,000 price of MDMA-assisted therapy for PTSD
Why it matters ◈ Mixed
The projected $45,000 price tag for MDMA-assisted therapy highlights major access and equity concerns as the treatment nears potential FDA approval. High costs could limit patient access, challenge payer coverage, and shape the commercial landscape for psychedelic therapies. This pricing signals both the promise and barriers facing psychedelic medicine as it moves toward mainstream adoption.
Industry Executive appointment

Optimi Health hires Dr. Blough to lead psilocybin and MDMA trial development

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer to Advance Psilocybin and MDMA Trials
Why it matters ▲ Favorable
Optimi Health's appointment of Dr. Michael Blough as Chief Clinical Development Officer signals a strategic focus on advancing clinical trials for psilocybin and MDMA. This move may accelerate the company's ability to design, execute, and potentially commercialize psychedelic-assisted therapies. While not a regulatory or scientific milestone, it reflects growing industry investment in clinical development leadership.
Clinical research VA research expanding

VA expands psilocybin research, raising questions among veterans

Psilocybin Research Is Expanding at the VA – and Cleared Veterans Have Questions
Why it matters ▲ Favorable
The U.S. Department of Veterans Affairs expanding psilocybin research signals growing federal engagement with psychedelic therapies for veterans. This could improve research access, inform future policy, and address unmet mental health needs in a high-risk population. However, questions from veterans highlight ongoing concerns about eligibility, access, and long-term support as research scales up.
Clinical research Early clinical data

Early data from UK's first pediatric ketamine-induced uropathy clinic

Who are the children and young people attending the UK's first ketamine-induced uropathy clinic for under 16s?: an early insight into sociodemographic features.
Why it matters ◈ Mixed
This study provides the first sociodemographic insights into children and adolescents treated for ketamine-induced uropathy in the UK. The emergence of a dedicated clinic for under-16s signals growing concern over recreational ketamine use and its health impacts among youth. These findings may inform future public health interventions, clinical guidelines, and policy responses to pediatric ketamine misuse, but do not directly affect legal status or access to therapeutic ketamine.
Clinical research Peer-reviewed study

Patient Factors Linked to Subanesthetic Ketamine Use in PACU

Patient Factors Associated With Subanesthetic-Dose Ketamine Infusion in the Postanesthesia Care Unit.
Why it matters ◈ Mixed
This study identifies patient characteristics associated with subanesthetic ketamine infusion in the postanesthesia care unit (PACU), offering valuable data for clinicians considering ketamine for perioperative pain or mood management. While not a regulatory or legal development, the findings could inform future clinical protocols, risk stratification, and patient selection in both research and hospital settings. The results may also guide safety monitoring and support ongoing efforts to optimize ketamine's therapeutic use beyond anesthesia.
Clinical research Trial methodology Q&A

UMBRAA discusses multidrug masking in psilocybin trials

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking
Why it matters ▲ Favorable
Improving masking in psychedelic trials is critical for scientific rigor and regulatory acceptance. UMBRAA's multidrug approach aims to address the challenge of effective blinding in psilocybin studies, which has been a persistent methodological issue. This development could enhance the credibility of trial results and inform future study designs, impacting both research quality and eventual clinical adoption.
Clinical research Scholarly exchange

Researchers address methodological critiques of ketamine/psilocybin meta-analysis

Reply to ‘Methodological concerns and interpretative limitations of assessing subjective effects of ketamine’
Why it matters ◈ Mixed
This exchange highlights ongoing debate over how best to measure and interpret subjective effects in psychedelic trials. The authors acknowledge limitations in current approaches and call for more standardized, multidimensional tools. While not a regulatory or legal change, this dialogue is important for improving the rigor and comparability of future research, which ultimately shapes clinical evidence and regulatory acceptance.
This response addresses methodological concerns raised regarding our meta-analysis of subjective effects and therapeutic outcomes following ketamine and psilocybin treatment. We discuss the potential influence of psychotherapy and differences in subjective-effect questionnaires across studies, acknowledging these as important limitations. We argue that these factors may partly explain observed treatment differences and highlight the need for future studies using standardized, multidimensional measures of subjective experience.
Clinical research Letter published

Letter flags methodological flaws in ketamine subjective effects research

Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine
Why it matters ◈ Mixed
This letter spotlights methodological inconsistencies in ketamine research, particularly in how subjective effects are assessed and interpreted. The critique underscores the importance of rigorous, standardized study designs for psychedelic-assisted therapy trials. While not a legal or regulatory move, it may influence future research protocols and the credibility of existing meta-analyses.
The letter addresses critical issues in the methodology and conclusions of the meta-analysis, including inconsistencies in study design, methodological flaws in comparing correlation coefficients, and discrepancies in reported results and their interpretation. It contributes significantly to the ongoing discussion on psychedelic-assisted therapies and highlights the need for more standardized methodologies in future research.
Clinical research Peer-reviewed study published

Comorbidity of bipolar disorder in cluster headache patients studied

Cluster headache and bipolar disorders: Phenotypical overlap and comorbidity
Why it matters ◈ Mixed
This study finds a higher-than-expected prevalence of bipolar disorder among patients with cluster headache, with increased familial aggregation and higher rates of illicit drug use. These findings highlight the importance of psychiatric screening in headache clinics and may inform future psychedelic research, as both conditions are targets of interest for psychedelic interventions. However, the study does not directly address psychedelic treatment or legal issues, but it provides useful context for comorbidity and patient selection in trials.
Background and objectives Cluster headache (CH) and bipolar disorder (BD) are cyclic disorders with shared clinical aspects, e.g. disturbed sleep patterns, response to lithium and a tendency to use illicit drugs. We investigated comorbidity of BD in patients with CH, familial aggregation of BD, circadian aspects and use of illicit drugs. Methods 310 Patients from the Leiden University Cluster headache neuro-Analysis program (LUCA) were screened cross-sectionally for BD online, using the Mood Disturbance Questionnaire (MDQ-NL) and Altman Self Rating Scale (ASRM-NL) and, if indicated, further evaluated with the Mini international neuropsychiatric interview (MINI). Circadian aspects were analyzed using the Circadian Type Inventory (CTI) and the Munich Chronotype Questionnaire (MCTQ). Results The life-time prevalence of BD in patients suffering from CH was 6.5% (20/310; 95% CI: 4.0-9.8%). Patients with comorbid BD (CH+BD) were more likely to have family members with BD (standardized OR= 1.50, 95% CI=1.15;1.95, p=0.003) and were more likely to suffer from chronic CH (OR=3.05 95% CI=1.18;7.87, p=0.02) after adjustment for age and sex. They also more often used illicit drugs, compared to patients with only CH. Circadian type and chronotype did not differ between the two groups after adjustment for confounders. Conclusion It is important to screen for BD when treating patients with CH, because BD is more prevalent than expected in this population.
Neuroscience Review published

Review: Neural mechanisms and interventions in PTSD

From Fear Circuit to Recovery: Neural Mechanisms and Interventions in Post-Traumatic Stress Disorder
Why it matters ◈ Mixed
This review synthesizes current knowledge on the neural circuits underlying PTSD and compares the efficacy of psychological and pharmacological interventions. While not directly addressing psychedelics, the paper's focus on fear circuitry and treatment gaps is highly relevant for researchers exploring novel interventions such as MDMA- or psilocybin-assisted therapy for PTSD. The review highlights the need for improved long-term outcomes and better access to effective treatments, underscoring opportunities for innovation in the field.
Post-traumatic stress disorder (PTSD) is a psychiatric condition that develops after exposure to a traumatic event. It is characterized by intrusive memories, avoidance, negative mood changes, and hyperarousal. This paper reviews the main brain mechanisms underlying PTSD and evaluates the effectiveness of current psychological and pharmacological interventions targeting these mechanisms. Diagnostic criteria for PTSD differ between the Diagnostic and Statical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Diseases, 11th Revision (ICD-11) systems. They affect how the disorder is identified across studies. At the neural level, PTSD is associated with a dysregulated fear circuit involving amygdala hyperactivity, ventromedial prefrontal cortex hypoactivity, and hippocampal dysfunction. Exposure-based psychotherapy shows strong, consistent evidence of effectiveness and appears to strengthen prefrontal regulation over the amygdala, while pharmacological intervention with propranolol shows more mixed results across individual trials though meta-analytic evidence supports a modest overall benefit. This review argues that psychological and pharmacological approaches converge on the same neural circuit through different mechanisms via gaps in long-term outcome data and treatment accessibility.
Neuroscience Preclinical study published

Psilocybin, ethocybin increase aversive memory in stressed male mice

Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice
Why it matters ◈ Mixed
This preclinical study finds that acute psilocybin or ethocybin administration leads to a sustained increase in aversive Pavlovian memory expression in male mice, without altering key glutamatergic synaptic proteins. These results suggest psychedelics may enhance recall of aversive emotional memories, which could inform mechanisms of action and therapeutic risks or benefits in stress-related disorders. However, translation to humans remains speculative, and the findings highlight the need for careful clinical investigation into potential adverse or therapeutic effects on emotional memory processing.
There is considerable interest in the concept that psychedelic compounds might facilitate reorganization of emotional processing with therapeutic benefit; in particular, amelioration of excessive focus on past, current and potential-future aversive events, a dominant emotional-cognitive state in stress-related affective disorders. Translational animal models can advance understanding of specific aspects of this concept, namely, those relating to subconscious emotional memories and their neurobiology. In male mice, chronic social stress (CSS) leads to excessive tone/context-foot shock Pavlovian aversion learning (PAL) and memory (PAM), measured as time spent in freezing behavior, and provides a model for generalized excessive focus on aversion. Sub-chronic administration of SSRI antidepressant between PAL and PAM reverses the excessive PAM of CSS mice. Here we applied the model to investigate acute and sustained behavioral and neurobiological effects of psilocybin (PSY) and ethocybin (ETH). In control male mice, both psychedelics at 3 mg/kg per os resulted in 1–2 h of blood-brain exposure to the respective major metabolites psilocin and ethocin, and to head twitch responses. In the main experiment, mice underwent either 15-day CSS or control handling (CON), followed 2 days later by PAL, 1 day later by PSY, ETH or vehicle (VEH), and 3 days later by PAM testing and then brain collection. Relative to VEH, PSY and ETH led to increased PAM expression as more time spent in freezing behavior during tone/context presentation. In a subset of these same mice, there was no psychedelic effect on densities of the two glutamatergic synaptic proteins investigated, vGluT1 or Homer1 in prelimbic cortex or amygdala. This study demonstrates that PSY and ETH lead to a sustained increase in aversive emotional memory expression in male mice. A similar effect in humans with stress- and trauma-related affective disorders might increase the psychotherapeutic accessibility of such memories.
Neuroscience Review published

Glutamatergic Dysregulation in Depression, SCZ, and Addiction: Mechanisms & Therapy

Glutamatergic Dysregulation in Depression, Schizophrenia, and Addiction: Mechanisms and Therapeutic Strategies
Why it matters ◈ Mixed
This review synthesizes current understanding of glutamatergic dysfunction in major psychiatric and addiction disorders, highlighting mechanistic overlaps relevant to psychedelic pharmacology. It underscores the therapeutic potential of targeting glutamate systems—central to the action of several psychedelics and dissociatives—but also notes significant translational challenges, including biomarker gaps and disease heterogeneity. While not a direct advance in psychedelic policy or access, it informs future research directions and trial design for novel interventions.
Glutamate, the principal excitatory neurotransmitter in the brain, plays a central role in neurotransmission, synaptic plasticity, and cognitive function. Dysregulation of glutamatergic signaling is implicated in depression, schizophrenia (SCZ), and addiction. N-methyl-Daspartate receptor/α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor (NMDAR/AMPAR) abnormalities and neuroinflammation disrupt synaptic plasticity in depression. NMDARs hypofunction and cortical excitation-inhibition imbalance are involved in SCZ. Therapeutic strategies targeting the glutamate system, including receptor modulation, glial function restoration, and inflammation control, offer promising avenues for treatment. However, their successful clinical application will require overcoming key obstacles such as disease heterogeneity, the lack of reliable biomarkers for these diseases, and stage-specific pathophysiological differences.
Industry Leadership change

Optimi Health appoints new lead for depression and PTSD psychedelic trials

Psychedelic depression and PTSD trials get new lead at Optimi Health (OPTH)
Why it matters ◈ Mixed
Optimi Health's appointment of a new lead for its depression and PTSD psychedelic trials signals ongoing investment and leadership changes in the commercial psychedelic research sector. While this is not a regulatory or clinical milestone, it may impact trial strategy, partnerships, and investor sentiment. Stakeholders should monitor for subsequent trial updates or shifts in research direction.
Neuroscience Conceptual proposal

Self-inquiry as a neurophenomenological tool for consciousness research

Who am I? Self-inquiry as a neurophenomenological approach to consciousness
Why it matters ◈ Mixed
This article proposes operationalizing self-inquiry, a first-person method from Advaita Vedanta, as a reproducible approach to studying consciousness and selfhood. While not directly about psychedelics, the method's focus on self-attenuation and nondual awareness overlaps with key phenomenological effects reported in psychedelic therapy and research. Its potential for empirical study and clinical incorporation may inform future protocols or mechanistic investigations in psychedelic science, but no direct legal, regulatory, or market implications are present at this stage.
Inconclusive evidence for leading third-person theories of consciousness has renewed scientific interest in its first-person nature. Self-inquiry, a first-person method from Advaita Vedanta, can be operationalized to meet this need, though it has not received prior empirical study, likely owing to Advaita’s idealism. By bracketing Advaita’s metaphysical commitments and mapping its characterization of consciousness onto the distinctions drawn by consciousness science, self-inquiry can be understood as a systematic phenomenology of selfhood. The method’s rationale is that mental contents perpetuate the “narrative self,” or one’s personal identity, so tracing such contents back to the sense of “I” to which they are referred attenuates the narrative self and discloses the “minimal self.” The minimal self is the pre-reflective first-person perspective of experience that carries a sense of “for-me-ness.” Sustained attention to the minimal self may then facilitate a selfless mode of awareness, or nondual awareness, marked by the absence of felt division between self and world. On this account, the narrative self and the appropriative ownership underlying the minimal self are seen as illusory, while an impersonal, reflexive consciousness remains. This deconstruction of selfhood already has neurophenomenological precedent, though from studies confined to Buddhist practice and reliant on idiosyncratic techniques. Self-inquiry thus holds empirical significance: its stepwise structure offers potential reproducibility across participants, a within-practice control, and a target attentional operation whose proposed distinctiveness can be empirically tested. It may also hold clinical relevance, having been proposed for incorporation into psychotherapy amid growing research into the therapeutic potential of self-attenuation.
Clinical research Narrative review published

Review: Psilocybin for treatment-resistant depression—efficacy and safety

PSILOCIBINA NA DEPRESSÃO RESISTENTE AO TRATAMENTO: EFICÁCIA SUSTENTADA, PERFIL DE SEGURANÇA E DESAFIOS PARA INCORPORAÇÃO À PRÁTICA CLÍNICA
Why it matters ◈ Mixed
This narrative review synthesizes recent clinical evidence on psilocybin for treatment-resistant depression, highlighting rapid symptom reduction in some patients but variable durability and safety concerns. The review underscores the need for confirmatory trials, standardized psychotherapeutic support, and long-term safety monitoring before clinical adoption. It flags both promise and unresolved risks, providing a balanced update for clinicians and researchers tracking the translational pathway of psilocybin.
A depressão resistente ao tratamento representa um desafio clínico devido à persistência dos sintomas mesmo após intervenções farmacológicas adequadas. Nesse contexto, a psilocibina tem sido investigada como uma alternativa de ação rápida. Este estudo teve como objetivo analisar as evidências sobre a eficácia sustentada, o perfil de segurança e os desafios para a incorporação da psilocibina à prática clínica. Trata-se de uma revisão narrativa da literatura, conduzida nas bases PubMed/MEDLINE, Embase, Scopus e Web of Science, considerando publicações entre janeiro de 2016 e agosto de 2026. Foram priorizados ensaios clínicos, estudos de seguimento e revisões sistemáticas envolvendo adultos com depressão resistente. Os estudos demonstraram redução rápida e clinicamente relevante dos sintomas em parte dos pacientes, especialmente após a administração de 25 mg associada a suporte psicológico. Entretanto, a manutenção da resposta foi variável, e um ensaio recente não confirmou superioridade no desfecho primário. Os eventos adversos mais frequentes foram cefaleia, náusea, ansiedade, tontura e elevação transitória da pressão arterial. Também foram identificados sinais menos comuns, como ideação suicida e alterações perceptivas persistentes. Conclui-se que a psilocibina constitui uma intervenção experimental promissora, mas sua incorporação clínica depende de ensaios confirmatórios, acompanhamento prolongado, padronização do suporte psicoterapêutico e monitoramento rigoroso da segurança.
Neuroscience Peer-reviewed study

DMT/harmine formulation alters EEG topography during peak psychedelic state

N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state.
Why it matters ▲ Favorable
This peer-reviewed study provides new evidence that a specific DMT and harmine formulation produces measurable changes in EEG topography during the peak psychedelic state. These findings help clarify the neurophysiological signatures of psychedelic experiences, which may inform future clinical trial design and biomarker development. While not directly impacting policy or access, such mechanistic research is foundational for regulatory acceptance and the rational design of therapeutic protocols.
Clinical research Peer commentary published

Concerns raised over methods for assessing ketamine's subjective effects

Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine.
Why it matters ◈ Mixed
This peer commentary highlights methodological and interpretative challenges in measuring the subjective effects of ketamine, which may impact the validity and comparability of clinical trial outcomes. Researchers and regulators should consider these limitations when designing studies and interpreting efficacy or safety data. The article underscores the need for standardized, validated tools to assess subjective psychedelic experiences, which is critical for both scientific rigor and regulatory acceptance.
FDA / DEA Public hearing underway

FDA Holds Historic Public Hearing on Psychedelic Therapies

Why it matters ▲ Favorable
The FDA's first-ever public hearing on psychedelic therapies marks a pivotal moment for regulatory clarity, research access, and the future of clinical adoption in the US. This event signals growing federal engagement and could shape future guidance, rescheduling, or approval pathways for psychedelic medicines. Stakeholders across research, clinical, and industry sectors should monitor outcomes closely, as agency positions may directly impact trial design, patient access, and commercial opportunities.
Neuroscience Preclinical study published

S-propargyl-L-cysteine reduces ketamine-induced schizophrenia-like effects in mice

S-propargyl-L-cysteine attenuates ketamine induced schizophrenia-like behaviors and neuroinflammation in mice via inhibition of NF-κB/NLRP3 inflammasome-mediated pyroptosis.
Why it matters ▲ Favorable
This preclinical study identifies S-propargyl-L-cysteine as a potential modulator of ketamine-induced neuroinflammation and behavioral changes in a mouse model. The findings may inform future research on mitigating adverse effects of ketamine, which is increasingly used in psychiatric treatment. While not directly impacting policy or access, the study provides mechanistic insights relevant to the safety and optimization of psychedelic and dissociative therapeutics.
Clinical research Peer-reviewed study published

Study: Psychedelic-assisted therapy for people with HIV

Psychedelic-assisted therapy research for people with HIV.
Why it matters ▲ Favorable
This peer-reviewed research signals growing scientific interest in psychedelic-assisted therapy for populations with complex medical and psychosocial needs, such as people living with HIV. The study may inform future clinical trial design, highlight safety or efficacy signals, and help destigmatize research in vulnerable groups. It could also support arguments for expanded access or funding for psychedelic research in public health contexts.
Clinical research Review announced

Systematic review to assess ketamine guidelines for TRD

Ketamine for TRD: Do the Guidelines Follow the Science? A Systematized Review
Why it matters ◈ Mixed
This review could influence future updates to VA/DoD guidelines on ketamine use for treatment-resistant depression (TRD). By systematically examining the evidence and comparing it to current policy, the work may highlight gaps or misalignments between science and clinical practice. This is relevant for researchers, clinicians, and policymakers seeking to expand or refine access to ketamine therapies for TRD, especially in large federal health systems.
This systematized review will examine the data surrounding intravenous ketamine infusion therapy for the management of treatment-resistant depression (TRD) and will determine whether or not the therapy deserves reassessment within the standard treatment procedures. The 2022 Department of Veterans Affairs and Department of Defense (VA/DoD) guidelines for the management of Major Depressive Disorder state that ketamine or esketamine should be considered only for patients who have not responded to several adequate pharmacologic trials (‘trial’ referring to a standard form of treatment with a dose and time sufficient for response) and suggest them only as augmentations to existing regimens rather than stand-alone treatments (U.S. Department of Veterans Affairs, 2022). Therefore, this manuscript aims to examine the current placement of intravenous racemic ketamine in the care of TRD, the limitations of existing treatments, and the value of rapid antidepressant response in patients.
Neuroscience Preclinical study published

Prior trauma alters psilocybin's effects on stress in mice

Prior trauma shapes the effects of psilocybin on stress sensitization in mice.
Why it matters ◈ Mixed
This preclinical study finds that a history of trauma in mice significantly modifies how psilocybin influences stress sensitization. The findings suggest that trauma history may be a critical moderator of psychedelic effects, with potential implications for patient selection, trial design, and safety monitoring in human studies. While translational relevance is not yet established, this work highlights the need for careful screening and stratification in clinical trials involving trauma-exposed populations.
FDA / DEA Analysis / Commentary

Psychedelic Therapy Is Imminent. Will the FDA Get It Right?

Psychedelic Therapy Is Imminent. Will the FDA Get It Right?— DoubleBlind Magazine
Why it matters ◈ Mixed
This article signals growing anticipation around FDA decisions on psychedelic therapy approvals, reflecting both excitement and uncertainty in the field. While not a direct regulatory move, such coverage shapes expectations among researchers, clinicians, and investors. The piece underscores the pivotal role of federal regulators in determining access, safety standards, and the commercial landscape for psychedelic-assisted therapies.
Clinical research Trial announced

Non-hallucinogenic psilocybin to be tested in end-of-life care

Psilocybin doses without hallucinations will be tested in end-of-life care
Why it matters ▲ Favorable
This trial could redefine the therapeutic profile of psilocybin by testing whether its benefits in end-of-life care can be achieved without hallucinogenic effects. If successful, this approach may lower barriers to clinical adoption, reduce regulatory and ethical concerns, and expand access for patients who are unwilling or unable to undergo psychedelic experiences. The study’s results could influence future drug development, trial design, and policy discussions around psychedelic-assisted therapies.
Neuroscience Research published

Brain signal linked to ketamine’s antidepressant effects discovered

Scientists Discover a Brain Signal Linked to Ketamine’s Antidepressant Effects
Why it matters ▲ Favorable
Identification of a brain signal associated with ketamine’s antidepressant effects could accelerate biomarker-driven research and precision psychiatry approaches. This finding may help optimize dosing, predict patient response, and inform development of next-generation antidepressants. It also strengthens the neurobiological rationale for ketamine’s clinical use, supporting further trials and regulatory consideration.
Clinical research Philosophy paper published

Phenomenological analysis of psychedelic therapy's transformative effects

Embodied Transformation: Psychedelic Therapy Through the Lens of Merleau-Ponty’s Phenomenology
Why it matters ◈ Mixed
This philosophical paper offers a novel phenomenological account of how psychedelic-induced mystical experiences may produce enduring therapeutic benefits, challenging Cartesian objections and emphasizing the embodied, situated nature of these effects. While it does not present new clinical data, it provides a rigorous conceptual framework that may inform future research design, therapeutic models, and ethical debates around psychedelic therapy. The work is most relevant for researchers and clinicians interested in the mechanisms and meaning of psychedelic experiences.
This paper develops a phenomenological account of the therapeutic significance of psychedelic-induced mystical experience, drawing on the philosophy of Maurice Merleau-Ponty. The central argument holds that the enduring therapeutic benefits of psychedelics emerge through a radical transformation in the structure of lived experience. Two prominent objections to the therapeutic value of mystical experience are examined and shown to rest on implicit Cartesian assumptions that obscure the embodied, situated character of human experience. Using Merleau-Ponty's concepts of the body-subject and the intentional arc, depression is analysed as a collapse of perceptual attunement and engagement with the world, while psychedelic-induced mystical experience is shown to instantiate the opposite structure, recalibrating the intentional arc and restoring pre-reflective meaning. A phenomenological analysis of the acute mystical experience substantiates this claim, before a final response to the objection that psychedelic experiences are merely hallucinatory, arguing, via Merleau-Ponty's account of perception as irreducible to passive reflection, that such experiences may still disclose meaningful dimensions of the world.
Clinical research Peer-reviewed study published

Toxicokinetics of DMT derivatives studied in vitro and in zebrafish embryos

Toxicokinetics and analytical toxicology of four N, N-dimethyltryptamine derivatives studied in human in vitro systems and in vivo by means of zebrafish embryos
Why it matters ◈ Mixed
This study provides foundational data on the metabolism, toxicity, and detection of four DMT derivatives, which is critical for both clinical research and forensic monitoring of emerging psychoactive substances. The identification of specific metabolic pathways and markers will inform safety assessments, guide future human studies, and support regulatory or legal responses to novel tryptamines. High plasma protein binding and potential drug interactions highlight safety concerns relevant to both researchers and clinicians.
-tert-butoxycarbonyl-N,N-dimethyltryptamine (DMT-Boc). The aim of the current study was to investigate the toxicokinetics of DMT-Boc and three related DMT derivatives, by name DMT-isopropylcarbamate, DMT-pivaloylamide, and DMT-THP (N,N-dimethyl-2-[1-(oxan-2-yl)indol-3-yl]ethanamine). In vitro and in vivo metabolism studies with pooled human liver S9 incubations and zebrafish embryos were performed, respectively. Monooxygenase and monoamine oxidase (MAO) isozymes involved in the phase I metabolism were identified. In vitro metabolic stability and plasma protein binding (PPB) were evaluated. A total of 11 metabolites for DMT-Boc, 13 for DMT-isopropylcarbamate, eight for DMT-pivaloylamide and 16 for DMT-THP were identified using high-resolution tandem mass spectrometry. N-Demethylation and hydroxylation were the most relevant metabolic reactions. CYP1A2, CYP2D6, and FMO3 were identified as most active phase I isozymes and MAO-A contributed to DMT-THP metabolism. The in vitro half-lives of DMT-Boc, DMT-isopropylcarbamate, and DMT-pivaloylamide were calculated to be between 74 and 79 min, while that of DMT-THP was found to be > 180 min. All compounds showed high PPB (> 99%) indicating that co-consumption with other drugs might increase the DMT derivatives' toxicity. Combined in vitro and in vivo approaches provided a comprehensive metabolism overview. N, N-bis-Demethylated, N-demethylated and N-oxygenated metabolites along with parent compound were proposed as consumption markers in order to support clinical and forensic toxicologists to identify these substances in biosamples in case of suspected abuse.
Clinical research Longitudinal case series published

Longitudinal study: Ketamine-assisted psychotherapy in adolescents, young adults

A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults
Why it matters ▲ Favorable
This is the first longitudinal quantitative report on ketamine-assisted psychotherapy (KAP) in adolescents and young adults, showing promising reductions in depression and suicidality with a favorable safety profile. The study, though limited by sample size and lack of controls, provides foundational evidence supporting the feasibility and tolerability of KAP in a diagnostically complex youth population. These findings will inform the design of future controlled trials and may influence clinical and regulatory perspectives on psychedelic therapy access for younger patients.
Introduction Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the adolescent mental health crisis and the frequent failures to respond to conventional treatment, the promise of KAP deserves thorough investigation. Methods We previously described the process of KAP in our adolescent population that included four case reports exemplifying our approach. Here we report on the longitudinal clinical experience of 19 adolescents and young adults (ages 14–24; mean age 19.3 ± 3.1 years; 11 female, 7 male, 1 non-binary) who completed three or more KAP sessions at a single community outpatient clinic. Results BDI-II scores declined by an estimated 0.65 points per visit (95% CI: -0.90, -0.40) and HAM-A scores by 0.21 points per visit (95% CI: -0.44, +0.01), based on linear mixed-effects models. Approximately 63.2% of patients (12/19) achieved medium or large individual treatment effects on BDI; 47.4% (9/19) on HAM-A. Physician and patient reports indicated overall benefit in 68.4% of cases (13/19), including marked reductions in suicidality in at-risk patients. Ketamine was well tolerated across 167 documented sessions; nausea was the only notable adverse event, occurring in 5.4% of sessions and largely manageable with standard antiemetics. No hospitalizations, substance misuse, or evidence of neurological harm occurred over a median individual follow-up of 5.6 months (mean 10.1, range 0.9-36.4 months). Discussion These findings suggest that KAP is feasible and well tolerated in a diagnostically complex adolescent population, with clinically meaningful reductions in depression and a similar trend for anxiety associated with continued treatment. To our knowledge, this is the first report to provide longitudinal quantitative data for office-based KAP in adolescents and young adults, and it establishes a foundation for and supports the design of future controlled trials in this population.
Neuroscience Peer-reviewed publication

Serotonin 1B receptor identified as target for depression, anxiety treatment

The serotonin 1B receptor as a target for the treatment of depression and anxiety.
Why it matters ▲ Favorable
This peer-reviewed article highlights the serotonin 1B receptor as a promising target for novel depression and anxiety therapies. While not directly tied to psychedelic compounds, the findings may inform future drug development and mechanistic research in the psychedelic field, given the overlap in serotonergic pathways. This could guide both preclinical and clinical research agendas, and may eventually influence regulatory and funding priorities.
Clinical research Peer-reviewed review

Psilocybin shows promise for treatment-resistant depression: review

EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
Why it matters ▲ Favorable
This review synthesizes evidence that psilocybin, when administered with psychological support, offers rapid and clinically significant reductions in symptoms of treatment-resistant depression, with a safety profile comparable to or better than standard therapies. The findings underscore psilocybin's potential as a novel intervention for a high-need population, but highlight the necessity of psychological support and further large-scale, long-term trials to confirm efficacy and safety. This adds weight to calls for expanded research access and may influence regulatory and clinical perspectives.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the clinical efficacy, safety profile, and neurobiological mechanisms of psilocybin, a serotonergic psychedelic, as a targeted intervention for TRD. Current neurobiological evidence indicates that psilocybin, upon conversion to its active metabolite psilocin, acts primarily as a 5-HT2A receptor agonist. This mechanism promotes rapid structural neuroplasticity and modulates the aberrant functional connectivity characteristic of severe depression. Recent randomized clinical trials demonstrate that psilocybin, when administered in controlled settings with psychological support, produces rapid and clinically significant reductions in depressive symptoms. Comparative data indicate that its therapeutic efficacy is at least comparable to standard first-line treatments, such as SSRIs, while frequently offering a faster onset of action. Regarding safety, psilocybin is generally well-tolerated in clinical environments; adverse events are typically mild to moderate and transient. However, the strict requirement for concurrent psychological support and rigorous psychiatric screening highlights a clinical complexity distinct from traditional pharmacotherapies. Overall, current evidence indicates that psilocybin is a promising intervention for TRD with a manageable safety profile in controlled settings. Nevertheless, large-scale, long-term randomized trials are required to determine the durability of its effects and to establish standardized treatment protocols.
Neuroscience Review published

Review: Time processing deficits in schizophrenia as therapeutic targets

Time processing in schizophrenia: integrating behavioral, neurobiological, and clinical data
Why it matters ◈ Mixed
This review synthesizes evidence that timing deficits are central to schizophrenia’s symptoms and neurobiology, implicating dopaminergic, GABAergic, and NMDA receptor dysfunction. By highlighting timing dysfunction as a potential biomarker and therapeutic target, the paper suggests new intervention avenues—including those potentially relevant to psychedelic research, given the overlap in neurochemical pathways. While not directly about psychedelics, this work may inform future mechanistic and clinical studies on how psychedelic compounds affect timing and cognition in psychiatric disorders.
Timing is a fundamental neural process that underlies perception, behavior, and cognition. In schizophrenia, a chronic, heritable neuropsychiatric disorder that typically manifests in young adulthood, disruptions in time processing are increasingly recognized as contributing to the disorder’s positive, negative, and cognitive symptoms. This review examines how these timing mechanisms are altered in schizophrenia, assessing changes in both the perception of time and the timing of perception . We provide an overview of dedicated, intrinsic, and Bayesian models of time processing and their complementary relevance to the behavioral manifestations and neurophysiological basis of timing deficits in schizophrenia. Behavioral studies reveal robust impairments in both the accuracy and precision of timing among patients with schizophrenia, and these abnormalities have been closely linked to symptoms such as hallucinations, delusions of control, and disorganized thought. Neurophysiological evidence suggests that these timing deficits may stem from dopaminergic, GABAergic, and NMDA receptor-related dysfunction, together with oscillatory and connectivity abnormalities across cortico-striatal-thalamo-cortical and cerebellar circuits. This synthesis also lays the groundwork for exploring the broader phenomenological implications of timing disturbances in schizophrenia, proposing that such abnormalities may contribute to disturbances in agency, self–world boundaries, and the sense of reality. Integrating behavioral, neurophysiological, computational, and phenomenological findings, we outline a unified framework in which timing dysfunction acts as a central organizing principle in schizophrenia that may contribute to core symptoms. Finally, we propose future research directions, highlighting timing deficits as promising prodromal biomarkers and therapeutic targets that may open avenues for intervention beyond the reach of existing pharmacotherapy alone.
Clinical research Case report published

Case report: Mania and rhabdomyolysis after chronic daily psilocybin use

A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use.
Why it matters ◈ Mixed
This case report documents acute mania and rhabdomyolysis in a patient using psilocybin daily over a prolonged period. While single or infrequent therapeutic doses of psilocybin have shown safety in clinical trials, this finding highlights potential risks associated with unsupervised, high-frequency use. The report underscores the need for clear dosing guidelines, monitoring for adverse effects, and public education as access expands. It may inform regulators and clinicians about rare but serious complications outside controlled settings.
Clinical research Peer-reviewed study published

IV Ketamine Protocol Piloted for Psychiatric Care in Medical Units

Implementation and Preliminary Evaluation of an Intravenous Ketamine Protocol for Psychiatric Conditions in Medical and Surgical Units: A One-Year Pilot Study.
Why it matters ▲ Favorable
This pilot study demonstrates the feasibility and early outcomes of implementing intravenous ketamine protocols for psychiatric conditions within general medical and surgical hospital units. The findings may inform hospital policy, integration of ketamine into broader psychiatric care, and future research on safety and efficacy outside specialized clinics. Results could influence payer coverage, clinical guidelines, and market adoption of ketamine-based interventions in mainstream healthcare settings.
Clinical research Retraction issued

Key ketamine review on brain injury retracted by journal

RETRACTED: Zanza et al. Ketamine in Acute Brain Injury: Current Opinion Following Cerebral Circulation and Electrical Activity. Healthcare 2022, 10, 566.
Why it matters ▼ Unfavorable
The retraction of a widely cited review on ketamine's use in acute brain injury signals a setback for clinical guidance and may prompt reevaluation of protocols that referenced this work. Researchers and clinicians should exercise caution when relying on secondary literature for treatment decisions, and ongoing or planned studies may need to reassess their evidence base. This development underscores the importance of rigorous peer review and transparency in psychedelic medicine research.
Clinical research Phase 2 trial announced

Open-label dose-escalation trial of psilocybin for Bipolar II depression

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.
Why it matters ▲ Favorable
This open-label, dose-escalation trial signals a cautious but significant step toward evaluating psilocybin-assisted therapy in a population historically excluded from psychedelic research due to safety concerns. If successful, the study could expand the therapeutic landscape for Bipolar II depression, a condition with limited effective treatments. The trial's design will inform both clinical protocols and regulatory considerations for future studies in mood disorders. Results may impact patient access and future trial eligibility criteria.
Clinical research Phase 3 trial supply

Filament ships psilocybin PEX010 for Phase 3 palliative psych distress trial

Filament ships psilocybin drug PEX010 for Phase 3 trial on psychological distress in palliative care.
Why it matters ▲ Favorable
Filament's shipment of GMP psilocybin (PEX010) for a Phase 3 trial marks a significant step toward evaluating psychedelic therapy for psychological distress in palliative care. This milestone signals advanced-stage clinical research, which is essential for potential FDA approval and future patient access. It also demonstrates growing industry capacity to supply pharmaceutical-grade psychedelics for large-scale trials.
Neuroscience Review published

5-HT1B receptor highlighted as key target for depression, anxiety, and psychedelics

The serotonin 1B receptor as a target for the treatment of depression and anxiety
Why it matters ▲ Favorable
This review synthesizes evidence positioning the serotonin 1B receptor (5-HT1BR) as a promising target for novel antidepressant and anxiolytic therapies, including those involving psychedelics like psilocybin. It underscores the receptor's mechanistic role in mood regulation and calls for clinical trials of 5-HT1BR agonists, PET biomarker development, and consideration in psychedelic drug design. This could inform both basic research and translational strategies, potentially shaping future clinical trial designs and drug development within the psychedelic field.
Introduction Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology.Areas covered We synthesize converging evidence from human and preclinical studies that link 5-HT1BR expression and function to affective phenotypes. Importantly, agonists and the p11 dependent surface trafficking pathway produce antidepressant like effects. Additionally, recent work demonstrates that 5-HT1BR signaling is required for the sustained pro-hedonic and anxiolytic actions of psilocybin. Mechanistically, 5-HT1BR modulates corticolimbic synaptic plasticity and regulates neurotransmitter release from both serotonergic and non-serotonergic terminals, positioning it to reshape dysfunctional neural circuitry. FDA-approved drugs that have 5-HT1BR agonist activity show favorable safety profiles, but there is limited clinical data from brain penetrant selective ligands.Expert opinion We propose prioritized research avenues: PET-based occupancy biomarkers, clinical trials with 5-HT1BR agonists, and exploration of sex and stress dependent effects. Additionally, in the recent drive to study and develop novel psychedelic-related compounds, it is important to consider 5-HT1BR activation. Collectively, preclinical evidence supports 5-HT1BR as a tractable, high-impact target poised to contribute to antidepressant strategies.
Clinical research Published survey study

1 in 3 chronic pain patients interested in psilocybin education—survey

Curious about Psilocybin? Prevalence and correlates of interest among adults with chronic pain.
Why it matters ◈ Mixed
This cross-sectional survey of nearly 1,000 chronic pain patients in Western Canada found that 33% expressed interest in learning about psilocybin as a treatment option, with interest linked to depressive symptoms, lower financial wellbeing, and younger age. The findings suggest a significant patient-driven demand for evidence-based education on psilocybin, distinct from cannabis, and highlight the need for tailored informational resources. While not a clinical trial or policy change, this study provides useful context for researchers, clinicians, and policymakers considering future access or education initiatives.
Chronic pain is a prevalent and disabling condition, making access to safe and effective pain treatments a public health priority. Early but encouraging results have emerged from research investigating the therapeutic potential of psilocybin for people living with chronic pain (PLCP). This growing line of work urges an understanding of PLCP’s receptivity to this treatment. Aim. The primary aim of this study was to evaluate the extent to which PLCP are interested in learning about psilocybin and factors that characterize interested individuals. The secondary aim was to compare these results to the prevalence and correlates of cannabis education interest. Methods. Individuals seeking care at an outpatient pain clinic in Western Canada (n = 949) completed a cross-sectional survey assessing current support needs, educational interests, physical and mental health, and demographics. Results. One-third (33.2%) indicated an interest in psilocybin education. Psilocybin interest was significantly related to depressive symptoms (r = 0.17), anxious symptoms (r = 0.10), lower financial wellbeing (r = -0.20), and younger age (r = -0.26). Nearly one-third (29.3%) of participants interested in learning about psilocybin were not interested in cannabis education. Compared to interest in cannabis education, interest in psilocybin education was more strongly correlated with depressive symptoms (z = 2.1, P = .033), lower financial wellbeing (z = -3.4, P < .001), and younger age (z = -6.7, P < .001). Conclusion. Results highlight a pressing need for evidence-based education for PLCP on psilocybin and a greater understanding of the informational needs of PLCP regarding this topic.
FDA / DEA Program announced

FDA announces year 5 of CMC Development and Readiness Pilot Program

Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement
Why it matters ▲ Favorable
This FDA pilot program streamlines the CMC (Chemistry, Manufacturing, and Controls) process for investigational drugs, including potential psychedelic therapies, by offering expedited regulatory support and increased communication for products on accelerated clinical timelines. This can reduce bottlenecks for sponsors developing psychedelic medicines, potentially speeding patient access and facilitating more efficient IND advancement. The program is relevant for researchers and companies seeking to navigate complex manufacturing and quality requirements in a rapidly evolving field.
The Food and Drug Administration (FDA or Agency) is announcing year five of the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP). This program facilitates the expedited CMC development of products under an investigational new drug application (IND) based on the anticipated clinical benefit of earlier patient access to the products. FDA has implemented this pilot program to assist with CMC readiness for products regulated by both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between FDA and sponsors and explores the use of science- and risk-based regulatory approaches, as applicable. This notice outlines the eligibility criteria and process for submitting a request to participate in the pilot.
Neuroscience Review published

Cell death pathways reviewed in depression pathogenesis

Cell death pathways in the pathogenesis of depression: mechanisms and therapeutic implications
Why it matters ▲ Favorable
This review synthesizes emerging evidence that regulated cell death mechanisms play a significant role in the neurobiology of depression and highlights potential therapeutic targets. Understanding these pathways could inform the development of novel antidepressant strategies, including those involving psychedelic compounds that modulate neuroplasticity and cellular resilience. While not directly focused on psychedelics, the mechanistic insights may shape future research directions and trial designs in the field.
Depression is a highly prevalent and disabling psychiatric disorder with a complex and incompletely understood pathophysiology. Increasing evidence implicates regulated cell death (RCD), including apoptosis, necroptosis, pyroptosis, and ferroptosis, in neuronal vulnerability, synaptic impairment, and circuit dysfunction associated with depression. This review provides a comprehensive overview of the current understanding of distinct cell death modalities in animal models of depression and human brain tissues, with particular emphasis on their molecular mechanisms and pathological consequences. We further discuss the intricate interactions between cell death pathways and key pathological processes implicated in depression, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neurotrophic support. In addition, we summarize emerging therapeutic strategies targeting cell death-associated signaling pathways, including pharmacological inhibition of specific cell death programs and modulation of shared upstream regulators. By integrating recent advances in molecular neuroscience and psychiatric research, this review provides a conceptual framework for elucidating the cellular mechanisms underlying depression and to highlight potential targets for the development of novel antidepressant therapies.
Clinical research Pilot study published

Ketamine-lidocaine infusion shows pain reduction in refractory neuropathic pain

Clinical Outcomes and Inflammatory Biomarker Changes After Intravenous Ketamine-Lidocaine Infusion in Refractory Neuropathic Pain: A Prospective Observational Pilot Study
Why it matters ▲ Favorable
This pilot study reports that a single intravenous ketamine-lidocaine infusion led to significant pain reduction lasting up to four weeks in patients with refractory neuropathic pain, with mild and transient adverse effects. While the uncontrolled design limits causal inference, these findings support further controlled research into combination therapies for chronic pain and may inform future clinical trial design and access pathways. The absence of significant biomarker correlation suggests more work is needed to clarify mechanisms.
Background: Refractory neuropathic pain remains difficult to manage despite multimodal pharmacotherapy.Intravenous ketamine and lidocaine act through distinct analgesic mechanisms, but prospective data on their combined use and on potential inflammatory biomarker changes remain limited.Objectives: The study aimed to evaluate changes in pain intensity and treatment tolerability following a single intravenous ketamine-lidocaine infusion in adults with refractory neuropathic pain and to explore the duration of perceived treatment effect, patient-reported functional outcomes, and changes in interleukin-6 (IL-6) and C-reactive protein (CRP).Methods: This prospective, single-center observational pilot study included 30 adults with refractory neuropathic pain.Participants received ketamine 15 mg plus lidocaine 4 mg/kg intravenously over 30 minutes while continuing their baseline pharmacotherapy.Pain intensity was assessed using a 0-10 numerical rating scale (NRS) at baseline, immediately after infusion, and at four-week follow-up.IL-6 and CRP were measured at baseline and four weeks.Changes in NRS scores were analyzed with the Friedman test followed by Holm-adjusted Wilcoxon signed-rank tests.Biomarker changes were assessed with paired tests selected according to the distribution of within-patient differences.Adverse events and exploratory patientreported outcomes were analyzed descriptively.Results: Mean NRS pain intensity decreased from 7.93 ± 1.64 at baseline to 4.93 ± 2.23 immediately after infusion and 5.63 ± 2.58 at four weeks (Friedman χ²(2) = 35.50,p <0.001).Reductions from baseline were significant both immediately after infusion (adjusted p <0.001; r = 0.82) and at four weeks (adjusted p <0.001; r = 0.80), whereas the difference between immediate and four-week scores was not significant (adjusted p = 0.077).A pain reduction of at least 30% was achieved by 76.7% of patients immediately after infusion and 53.3% at four weeks; reductions of at least 50% occurred in 36.7% and 30.0%, respectively.A perceived treatment effect lasting at least three weeks or still ongoing at the four-week follow-up was reported by 56.7% of participants.IL-6 decreased from 4.73 ± 2.89 pg/mL to 4.14 ± 2.84 pg/mL (p = 0.086) and CRP from 5.51 ± 3.63 mg/L to 4.69 ± 3.71 mg/L (p = 0.120); neither biomarker correlated significantly with pain intensity.Seventy percent of patients reported no spontaneous post-infusion symptoms, no hallucinations occurred, and no adverse event required premature discontinuation or additional medical intervention.Conclusions: A single ketamine-lidocaine infusion was followed by a reduction in self-reported pain that remained evident at four weeks in a proportion of patients, with predominantly mild and transient reported adverse effects.Because of the uncontrolled observational design, these changes cannot be attributed specifically to the pharmacological intervention, and the biomarker findings remain exploratory.Larger controlled studies with validated outcome measures and longer follow-up are needed to determine the efficacy and durability of this approach.
Clinical research Study result announced

Esketamine-induced dissociation linked to better depression outcomes

Esketamine-induced dissociation is tied to better outcomes in treatment-resistant depression
Why it matters ▲ Favorable
This finding suggests that the dissociative effects of esketamine, often considered an adverse event, may actually correlate with improved clinical outcomes in treatment-resistant depression. This could influence both clinical practice and the design of future trials for ketamine and related compounds, potentially shifting risk-benefit assessments and patient management strategies. It also informs ongoing debates about the role of subjective effects in psychedelic and dissociative therapies.
International standards Curriculum updated

WHO-ISoP releases 2026 update to global pharmacovigilance curriculum

The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update
Why it matters ▲ Favorable
The updated WHO-ISoP pharmacovigilance curriculum signals a global push for enhanced drug safety monitoring and education, including for advanced therapies that may encompass psychedelic medicines. While not psychedelic-specific, this comprehensive framework will shape how regulators, researchers, and industry approach safety, risk communication, and real-world evidence for all medicines. Stakeholders in psychedelic research and emerging markets should anticipate higher expectations for PV systems and training as part of regulatory and clinical best practices.
This article presents a pharmacovigilance (PV) curriculum which was jointly developed by the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP). It is an expanded update of a PV curriculum which WHO and ISoP developed in 2014 and responds to major scientific, technological, regulatory, social and public health developments that have reshaped PV over the last 12 years. Topics such as advanced therapies, global health emergencies, antimicrobial resistance, digital health, artificial intelligence, real-world evidence, medical device safety, the environmental impact of medicines, risk communication and patient engagement are addressed. The curriculum was developed through an international collaboration involving 82 contributors from different regions and professional backgrounds. The original three-level hierarchical structure was retained, with each chapter divided into four sections and each section into five or six subsections. The number of chapters increased from 15 to 26, the number of practical tasks from 40 to 125 and the number of references from 260 to 469. Practical tasks and references are provided as Electronic Supplementary Materials. The curriculum provides a comprehensive and structured inventory of contemporary PV and thus represents a reference that lecturers and institutions can use to develop context-specific training programmes. Its structure provides conceptual clarity while allowing adaptation to different settings, learners' roles and prior knowledge, local priorities, available time and resources. It is not intended to prescribe a single standardised course. Instead, it supports the development of introductory, advanced, comprehensive or topic-specific PV education programmes. The update reflects a shared commitment of the WHO and the ISoP to strengthening PV education and capacity across regulatory, academic, healthcare, public health and industrial settings in accordance with the recommendation of the 2026 World Health Assembly to strengthen PV.
Neuroscience Peer-reviewed study

Chrysin shows neuroprotective effects against ketamine neurotoxicity

Neuroprotective potential of chrysin against ketamine-induced neurotoxicity: Effects on behavioral changes, oxidative stress, and neuroinflammation.
Why it matters ▲ Favorable
This preclinical research explores the neuroprotective effects of chrysin, a natural flavonoid, in mitigating ketamine-induced neurotoxicity, behavioral changes, oxidative stress, and neuroinflammation. Findings may inform future strategies to enhance the safety profile of ketamine in both clinical and research settings, especially as ketamine use expands for depression and pain. While not immediately practice-changing, the study highlights a potential adjunct to reduce adverse effects, warranting further translational and clinical research.
Clinical research Peer-reviewed review

Review: Psychedelics and suicidality—risks, mechanisms, and clinical guidance

Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward
Why it matters ◈ Mixed
This review synthesizes evidence on both the therapeutic potential and the suicide risk profile of classic psychedelics, highlighting the need for robust screening, support, and integration protocols in clinical settings. The article underscores that while psychedelics may reduce suicidality in some, they can also precipitate crises in vulnerable individuals, especially outside controlled environments. It proposes a mechanistic model and clinical recommendations, making it a key resource for trial designers, clinicians, and policymakers concerned with patient safety and ethical practice.
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), have re-emerged as promising treatments for psychiatric conditions linked to suicidality. However, rare reports of increased suicidality potentially associated with psychedelic use have raised safety concerns. This article examines the complex relationship between psychedelics and suicidality and develops a theoretical mechanistic model: the double-edge sword. We first summarise available data on suicide-related outcomes associated with psychedelic use reported in recreational settings and in first and second waves of clinical research. Several deaths have occurred following non-medical psychedelic use, where unsafe contexts led to accidents or presumed suicides, with unclear suicidal intent. Though less frequent, rare cases of increased suicidal ideation and behaviours have also been reported in clinical settings, without significant differences from placebo groups or established causality. We then offer a theoretical mechanistic framework encompassing both anti- and pro- suicidality mechanisms. Specifically, we propose three key psychological mechanisms - reduced fear of death, altered representations of the world and reduced experiential avoidance - constituting a double-edged sword: the same processes that facilitate healing may, in vulnerable individuals or unsupportive contexts, precipitate destabilisation and suicidal crises. Then, we turn to clinical practice recommendations aimed at harnessing these mechanisms for therapeutic benefit while mitigating suicide risk. Adequate therapeutic support, spanning screening, preparation, in-session guidance, and integration, seems essential to shifting outcomes toward benefit. Finally, we discuss future directions regarding potential psychedelic use in suicidal crises and propose guidelines to better study and characterise the underlying mechanisms driving this complex relationship.
Clinical research National data published

National study: chemical restraint in custody—trends & outcomes (2022-2025)

Chemical restraint in custody: national trends, clinical outcomes, and policy implications (2022-2025).
Why it matters ◈ Mixed
This national study analyzes trends and clinical outcomes of chemical restraint use in custody settings, providing new data on frequency, agents used, and patient impacts. Findings may inform future policy on the use of psychoactive substances—including ketamine and related agents—by law enforcement or emergency personnel. The report's implications could affect legal standards, clinical protocols, and oversight of chemical restraint practices, with relevance for researchers and advocates monitoring the intersection of psychedelics, emergency medicine, and civil liberties.
Neuroscience Peer-reviewed study published

Study maps brain circuits in S-ketamine-induced hallucination-like states

A circuit dissection of perception-action decoupling in S-ketamine-induced hallucination-like states.
Why it matters ▲ Favorable
This study provides mechanistic insight into how S-ketamine alters perception-action coupling, advancing understanding of hallucinogenic states at the neural circuit level. The findings may inform both the development of safer psychedelic therapeutics and the management of adverse effects in clinical settings. Improved circuit-level knowledge could also help regulators and clinicians better assess the risks and benefits of ketamine and related compounds.
Clinical research Peer-reviewed review

Review: Psychedelics and suicidality—risks, mechanisms, and next steps

Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.
Why it matters ◈ Mixed
This review synthesizes current evidence on the complex relationship between psychedelic use and suicidality, highlighting both potential therapeutic benefits and significant risks. It underscores the need for rigorous screening, monitoring, and harm reduction in clinical and research settings, especially for vulnerable populations. The findings will inform ethical trial design, risk mitigation strategies, and future policy debates around access and safety standards.
Clinical research Case report published

First IV ketamine case for TRD at Argentina public hospital

Intravenous Ketamine for Treatment-Resistant Depression: A Case Report From a Public Hospital in Argentina.
Why it matters ▲ Favorable
This is the first documented case of IV ketamine for treatment-resistant depression in an Argentinian public hospital. While only a single case, it signals growing international adoption and feasibility of ketamine therapy in public health settings outside North America and Europe. Researchers and policymakers should note the practical considerations and outcomes described, as they may inform broader implementation and access strategies in similar health systems.
Treatment-resistant depression (TRD) is a severe form of depression associated with high rates of disability and suicide, underscoring the need for effective therapeutic alternatives. In recent years, subanesthetic intravenous (IV) ketamine has emerged as a promising intervention due to its rapid antidepressant and antisuicidal effects. This report describes the case of a 41-year-old male patient with TRD treated with IV ketamine at a public hospital in Argentina-the first such reported case in this setting. We detail the diagnostic process, treatment protocol, outcomes, and practical considerations in implementing this novel therapy within a public health system.
Neuroscience Published study

Fear engrams drive cognitive and affective dysfunction in mice

High-intensity fear engrams extend beyond threat processing to drive cognitive and affective dysfunction
Why it matters ▲ Favorable
This study identifies specific neuronal ensembles in the dorsal dentate gyrus that causally link high-intensity fear to cognitive and affective dysfunction in mice. The findings suggest that targeting excitatory fear-tagged neurons could restore cognitive performance and reduce behavioral despair, offering mechanistic insight into stress-related disorders. While preclinical, this work may inform future psychedelic or neuromodulation interventions aimed at maladaptive fear memories. The translational impact for human therapy remains to be established.
Maladaptive fear memories are a core feature of stress-related disorders and are often accompanied by cognitive and affective disturbances; yet, it remains unclear whether the same neuronal ensembles link maladaptive fear to these behavioural alterations. Here, we show that activity of fear engrams causally contributes to behavioural consequences of intense fear beyond threat processing. Using activity-dependent tagging in the dorsal dentate gyrus (dDG) of mice, we identify neuronal ensembles recruited during high-intensity fear conditioning and show that chemogenetic inhibition of these neurons restores cognitive performance and reduces behavioural despair. These effects are specific to fear-associated ensembles, as inhibition of randomly tagged neurons fails to reproduce them, and depend on persistence of the fear memory, as they are abolished following extinction. Cell-type-specific manipulations revealed that glutamatergic, but not GABAergic, HI-tagged neurons drive fear expression and the associated cognitive and affective alterations, whereas GABAergic neurons exert an opposing influence on fear expression. Consistent with these findings, high-intensity fear was associated with increased reactivation of excitatory fear-tagged neurons and reduced reactivation of GABAergic fear-tagged neurons during behavioural despair. Together, these findings identify high-intensity fear engrams as a causal substrate linking threat-related experiences to cognitive and affective dysfunction and implicate altered excitatory-inhibitory recruitment within a single memory ensemble in the emergence of multi-domain behavioural alterations associated with stress-related disorders.
Clinical research Trial analysis published

Employment risks in psychedelic trial for chronic pain reported

Employment-Related Risks in a Clinical Trial of Psychedelic Treatment for Chronic Pain
Why it matters ◈ Mixed
This analysis highlights employment-related risks faced by participants in psychedelic clinical trials for chronic pain, such as workplace drug testing and disclosure issues. These findings are relevant for trial design, informed consent, and post-trial support, as employment consequences could deter participation or impact patient outcomes. Researchers, sponsors, and regulators should consider these risks when designing protocols and guidance for future studies.
Chronic pain is a significant health problem affecting up to 20% of Americans (Yong et al. 2022), negatively affecting overall health and quality of life, causing disability, and burdening healthca...
Clinical research Proof-of-concept published

Novel protocol identifies nocebo effects in n-of-1 clinical trial

A novel provocation protocol to identify nocebo effects in clinical practice—a proof-of-concept n-of-1 study
Why it matters ▲ Favorable
Nocebo effects—adverse outcomes driven by negative expectations—are a significant confounder in psychedelic and other neuroactive drug trials. This proof-of-concept n-of-1 study introduces a new protocol to distinguish pharmacological from expectation-driven adverse events, which could improve trial design, safety monitoring, and interpretation of side effects in psychedelic research. While preliminary and limited to a single patient, the approach may inform future studies seeking to disentangle nocebo from true drug effects.
Introduction Nocebo effects, driven by negative expectations rather than pharmacological mechanisms, are an under-recognized cause of adverse effects in clinical practice. Although experimental studies have used expectation manipulation to explore these phenomena, translation into clinical diagnostic approaches remains limited. We report the first clinical application of a novel provocation protocol in a single patient as an n-of-1 trial to illustrate its potential to identify whether reported adverse events in this patient were driven by nocebo mechanisms. Methods We developed an extension of the crossover balanced placebo design incorporating additional manipulation of patient expectations comprising five structured provocation sessions using an active substance or placebo combined with correct, and intentionally misleading declarations under open-label and blinded conditions. As a proof-of-concept this protocol was applied to a single patient with self-reported alcohol intolerance using ethanol and water. Symptom severity for each provocation was assessed using a numeric rating scale and analyzed descriptively. Results The most severe symptoms followed the administration of open-label ethanol (mean numeric rating scale [NRS] 5.3; maximum 8) and water deceptively labeled as ethanol (mean NRS 4.1; maximum 7), while blinded ethanol (mean NRS 2.8; maximum 5) and blinded water (mean NRS 2.6, maximum 5) produced only mild reactions. These findings are consistent with adverse reactions in this single patient primarily driven by expectations, indicating a nocebo mechanism. Conclusion This report demonstrates the proof-of-concept value of a novel “mixed open blinded crossover balanced placebo provocation protocol” and illustrates the potential to identify nocebo effects in clinical practice. Whether this exploratory finding have broader relevance warrants investigation in larger cohorts.
Neuroscience Preclinical platform published

Engineered myelin MPS enables individualized MS treatment testing

Engineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis
Why it matters ▲ Favorable
This study introduces a scalable human myelin microphysiological system (MPS) for modeling multiple sclerosis (MS) pathology and evaluating patient-specific treatment responses. While not directly related to psychedelics, such platforms could accelerate translational research on CNS disorders, including future psychedelic-based interventions for neuroinflammation or demyelinating diseases. The technology may improve preclinical screening and personalized medicine approaches, but has no immediate impact on psychedelic law, access, or clinical use.
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by neuroinflammation, demyelination, and neurodegeneration, associated with a complex interplay between the innate and adaptive immune systems. Currently, no cure is available for MS, and personalized disease-modifying treatment remains largely limited, partially due to the lack of preclinical human models that can faithfully recapitulate disease pathology and evaluate treatment responses at the individual-patient level. Here, we report a human myelin microphysiological system (myelin MPS) platform that recaptures disease phenotype and treatment response for testing patient treatment response. By culturing neural organoids on 3D-printed devices containing directional microfibers, followed by coculture with oligodendrocyte progenitor cells, 96 myelin MPS models can be generated within a conventional well plate. Using this myelin MPS platform, autologous T cells and monocytes from MS patients induced substantially greater demyelination than those from healthy donors, accompanied by expansion of proinflammatory T-cell subsets and increased myelin uptake by monocytes/macrophages after coculture with these healthy myelinating neural tissues. Integration of imaging and flow-cytometric features distinguished healthy-donor, untreated-MS, responder, and nonresponder profiles following treatment with prednisone, glatiramer acetate, interferon β-1a, or dimethyl fumarate. Thus, the myelin MPS platform provides a scalable, human pathophysiology-relevant platform for functional phenotyping and individualized treatment-response evaluation in MS.
Population research Epidemiology study

Study: Hallucinogens most-used illicit drug in both metro and non-metro areas

Non-Metropolitan vs. Metropolitan Variations in Alcohol, Illicit Drug, and Prescription Therapeutic Drug Misuse
Why it matters ◈ Mixed
This study identifies hallucinogens as the most commonly used illicit drug in both metropolitan and non-metropolitan populations, with notable differences in patterns of alcohol and opioid misuse. While not a legal or regulatory move, these findings inform researchers and policymakers about shifting drug use trends, highlighting the need for targeted harm reduction and research access strategies in rural areas. The data may influence future public health interventions and resource allocation for psychedelic-related risks and benefits.
Key Findings Alcohol Use. The prevalence of past year and past 30-day drinking was lower among non-metropolitan (non-metro) than metropolitan (metro) residents. However, non-metro drinkers engaged in more frequent binge drinking than metro drinkers. Drinking 3-5, 6-19, and 20-30 days over the past 30 days were higher among non-metro than metro residents. Illicit Drug Use. Hallucinogens were the mostly commonly used illicit drugs among non-metro as well as metro residents. Methamphetamine use was significantly higher among non-metro than metro residents. Prescription Pain Reliever Use. The misuse of prescription pain killers, primarily prescription opioids, was higher among non-metro than metro residents.
Clinical research Commentary published

Commentary: Employment risk for trial participants in psychedelic studies

Psychedelics Exceptionalism and Employment-Related Risk in a Clinical Trial
Why it matters ◈ Mixed
This commentary highlights the ethical and legal complexities faced by individuals considering participation in psychedelic clinical trials, particularly around employment-related risks such as workplace drug testing or disclosure requirements. While not a policy move or trial result, it underscores a key barrier to research participation and points to the need for clearer protections for trial volunteers. The discussion may inform future trial design, consent processes, and advocacy for anti-discrimination policies.
The question posed in this commentary concerns employment-related risk in a clinical trial. The question posed in the case is how to consider potential enrollment of individuals who may face advers...
Clinical research Accepted manuscript

DMT-Assisted Therapy: Call for Complex Intervention Framework

Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy (Accepted Manuscript)
Why it matters ▲ Favorable
This accepted letter urges researchers to treat DMT-assisted therapy as a complex intervention, not just a drug exposure, when assessing efficacy for substance misuse. It emphasizes the importance of parsing out pharmacological, psychological, contextual, and ethical components in trial design and systematic reviews. This perspective could shape future research protocols and evidence synthesis, improving rigor and comparability in psychedelic science.
Accepted manuscript of:Shiraishi K. Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy. Journal of Psychopharmacology. 2026.DOI: 10.1177/02698811261488484 This Letter argues that DMT-assisted therapy for substance misuse should be evaluated as a complex intervention rather than as pharmacological exposure alone. It highlights the need to distinguish pharmacological exposure, psychological or integration processes, contextual or ceremonial elements, and safety/ethical safeguards when interpreting efficacy estimates and designing future systematic reviews. This is the author accepted manuscript, following peer review and prior to publisher typesetting. The Version of Record is available from the Journal of Psychopharmacology via the DOI above.
Clinical research Peer-reviewed study published

Validated short-form PEQ improves psychedelic outcome measurement

Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Why it matters ▲ Favorable
This study provides a validated, efficient short-form of the persisting effects questionnaire (PEQ-SF), addressing the original scale's lack of psychometric support and high participant burden. The new 14-item tool reliably measures both positive and negative outcomes from psychedelic experiences, facilitating more robust and scalable research. This will streamline data collection in clinical trials and observational studies, improving comparability and quality of outcome reporting across the field.
BACKGROUND: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden. AIMS: Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF). METHODS: Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals. RESULTS: We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning. CONCLUSIONS: We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.
Neuroscience Peer-reviewed study

LSD triggers adaptive stress gene programs in mouse prefrontal cortex

Psychedelic Hormesis: LSD Activates Adaptive Stress Transcriptional Programs in the Prefrontal Cortex
Why it matters ▲ Favorable
This study provides new mechanistic insight into how LSD induces long-term brain changes by activating adaptive, hormetic stress pathways in the prefrontal cortex. The findings suggest that the enduring effects of psychedelics may involve broader stress and homeostatic processes, not just neuronal plasticity. This molecular framework could inform future research on therapeutic mechanisms and safety, and may shape the design of translational studies and clinical protocols.
Background Classic psychedelics are serotonergic agents increasingly recognized for their ability to produce rapid and long-lasting therapeutic effects in several neuropsychiatric conditions, yet the molecular mechanisms that translate acute serotonergic perturbation into long-term brain adaptation remain poorly understood. Psychedelic action is commonly attributed to enhanced neuronal plasticity, but emerging evidence suggests broader engagement of stress-responsive and homeostatic processes across neural and non-neural cell types. Methods To define the temporal structure of psychedelic-induced transcriptional responses, we profiled gene expression in the prefrontal cortex of mice at early and delayed time points following a single administration of lysergic acid diethylamide (LSD). Differentially expressed genes were then contextualized through pathway-level and cross-dataset comparisons with established models of adaptive and chronic stress. Results LSD induced a coherent, temporally organized transcriptional program extending beyond immediate neuronal activation. Early responses reflected adaptive metabolic and stress-related signaling, whereas later ones involved circadian and neuroendocrine regulation. A persistent transcriptional core spanning both time points indicated sustained regulation of metabolic, circadian, and stress-responsive pathways. Comparative analyses showed that, although LSD-induced transcriptional profile shares features with general stress responses, its preferentially aligns with adaptive, hormetic stress paradigms rather than maladaptive chronic stress. Conclusions These findings indicate that in the prefrontal cortex LSD activates adaptive stress transcriptional programs consistent with hormetic adaptation, providing a molecular framework to interpret the enduring effects of psychedelics beyond synaptic plasticity.
Clinical research Trial results reported

Definium LSD trial hints at anxiety benefit; Compass funds therapist training

Definium trial suggests LSD could help treat anxiety; “One patient meets God. The other gets itchy.”; and Compass funds psilocybin-assisted therapist training
Why it matters ◈ Mixed
Early results from the Definium LSD trial suggest potential benefit for anxiety, but with highly variable patient experiences, underscoring both promise and complexity in psychedelic therapeutics. The mention of Compass Pathways funding psilocybin-assisted therapist training signals ongoing industry investment in infrastructure and workforce development. These developments are relevant for researchers and operators tracking the evolving landscape of psychedelic clinical evidence and commercialization.
Clinical research Peer-reviewed study published

Study: Employment Risks in Psychedelic Chronic Pain Trial

Employment-Related Risks in a Clinical Trial of Psychedelic Treatment for Chronic Pain.
Why it matters ◈ Mixed
This study highlights employment-related risks faced by participants in psychedelic clinical trials for chronic pain, such as workplace drug testing and potential job loss. These findings are significant for trial design, informed consent processes, and policy development, especially as more patients seek access to psychedelic therapies. Researchers, sponsors, and regulators should consider employment protections and clear guidance to minimize legal and occupational risks for trial participants.
FDA / DEA FDA public hearing held

Behavioral health groups urge planning as FDA reviews psychedelics

BH groups stress ‘system readiness’ as FDA weighs psychedelic treatments
Why it matters ◈ Mixed
The FDA's public hearing signals growing federal attention to psychedelic therapies, with behavioral health leaders highlighting the need for workforce training and equitable access. This underscores the importance of infrastructure and policy readiness as regulators weigh potential approvals. Early engagement from stakeholders may shape future guidelines and access models for psychedelic-assisted treatments.
As federal regulators consider the future role of psychedelic therapies, behavioral health leaders are urging early planning around workforce development, clinical training and equitable access. The U.S. Food and Drug Administration (FDA) on Sept. 14 convened a four‐hour public hearing with federal partners to examine the potential therapeutic use of psychedelic drugs.
Neuroscience Review published

Ferroptosis mechanisms reviewed in major depressive disorder

Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities
Why it matters ◈ Mixed
This review synthesizes emerging evidence that ferroptosis, an iron-dependent cell death pathway, may contribute to the pathophysiology of major depressive disorder (MDD) through links to neuroinflammation, oxidative stress, and impaired neuroplasticity. While the findings are largely preclinical, the work highlights potential new therapeutic targets and mechanistic frameworks relevant to depression treatment—including for psychedelic research, which increasingly explores neuroplasticity and inflammation. However, the lack of clinical validation limits immediate impact for psychedelic medicine or industry.
Major depressive disorder (MDD) is a heterogeneous psychiatric disorder involving oxidative stress, neuroinflammation, mitochondrial dysfunction, impaired neuroplasticity, and metabolic dysregulation. Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation and antioxidant defense failure, has recently attracted attention as a potential mechanism linking these pathological processes. This review summarizes the molecular basis of ferroptosis in MDD, focusing on iron dyshomeostasis, lipid peroxidation, and disruption of the System Xc − /glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis. We further discuss ferroptosis-related alterations in depression-associated models and vulnerable brain regions, with attention to neurons, neural progenitor cells, microglia, astrocytes, and emerging systemic contributors. Importantly, these ferroptosis-related molecular alterations are currently best interpreted as candidate contributors to MDD-associated pathological networks, rather than as an established disease mechanism. Current evidence suggests that ferroptosis in MDD is unlikely to represent an isolated neuronal death process. Instead, it may function as a stress-responsive and multicellular pathological framework that intersects with neuroinflammation, glutamatergic disturbance, mitochondrial injury, and brain–periphery communication. Therapeutically, natural products, traditional medicine formulas, chemical agents, ferroptosis inhibitors, nutrients, microbial metabolites, and non-pharmacological interventions have shown antidepressant-like effects mainly in preclinical MDD models by modulating ferroptosis-related pathways. These interventions commonly converge on restoration of the System Xc − /GSH/GPX4 axis, activation of nuclear factor erythroid 2-related factor 2 (Nrf2)-centered antioxidant signaling, regulation of iron metabolism, suppression of lipid peroxidation, and inhibition of inflammatory pathways. However, current evidence remains largely preclinical, and future studies should strengthen cell-specific validation, causal mechanistic analysis, and clinical translation.
Clinical research Systematic review published

Systematic review details severe risks of chronic ketamine misuse

The K-Hole Collapse: A Systematic Review of Multi-Organ Somatotoxicity and Management Strategies in Chronic Ketamine Misuse
Why it matters ◈ Mixed
This systematic review highlights the multi-organ toxicity and severe neuropsychiatric complications associated with chronic recreational ketamine misuse, including cognitive deficits, uropathy, cardiac remodeling, and respiratory risks. The findings underscore the need for multidisciplinary management and reveal a critical gap in pharmacological treatments for ketamine dependence. For researchers and clinicians, this review provides a comprehensive synthesis of adverse outcomes, which may influence both clinical protocols and regulatory scrutiny as ketamine's medical and off-label use expands.
Ketamine is a psychoactive substance and an N-methyl-D-aspartate (NMDA) receptor antagonist, commonly used in anesthesiology, psychiatry, and emergency medicine. Its unique dissociative properties have led to a significant global increase in recreational misuse, particularly among young adults in nightlife environments. While the medical applications of ketamine demonstrate a favorable safety profile, its uncontrolled, chronic consumption poses severe toxicological risks. The primary mechanism of action of ketamine relies on blocking NMDA receptors, which leads to a secondary glutamate surge and localized neurotoxicity. This study aims to systematically evaluate the multi-organ manifestations, clinical complications, and management strategies associated with ketamine misuse. The article was developed using the "PubMed" and "Google Scholar" databases, with a particular emphasis on articles published after 2021. Chronic recreational ketamine misuse induces severe somatotoxic and neuropsychiatric injuries, including permanent cognitive and executive deficits, ketamine-induced uropathy (KIU) with secondary hydronephrosis, and excruciating gastrointestinal episodes ("ketamine cramps") triggered by sphincter of Oddi dyskinesia. Recent reports also highlight significant structural cardiac remodeling, myocardial fibrosis, and the risk of hypercapnic respiratory failure during acute, high-dose intoxications. Multidisciplinary treatment requires absolute abstinence as the cornerstone of therapy, combined with targeted pharmacotherapy, symptomatic clinical stabilization, and psychotherapy. Due to a therapeutic gap resulting from the lack of established pharmacological treatments to reduce ketamine cravings, further clinical trials are essential to improve patient recovery during detox and long-term rehabilitation.
Clinical research Research published

Study examines employment risks for psychedelic research participants

Factors for Assessing Employment-Based Risks of Participation in Psychedelic Research.
Why it matters ◈ Mixed
This study highlights the potential employment-related risks faced by individuals participating in psychedelic research, such as workplace drug testing, disclosure dilemmas, and possible discrimination. The findings underscore the need for clearer policy protections and ethical guidelines to safeguard research subjects from adverse employment consequences. Researchers, IRBs, and sponsors should consider these factors when designing studies and informed consent processes. This work is a timely reminder that legal and social risks can impact research participation and broader access.
Clinical research Review published

Esketamine reviewed for perioperative neuroprotection

Clinical research progress of esketamine in perioperative neuroprotection: from mechanisms to therapeutic neuroprotection
Why it matters ▲ Favorable
This review synthesizes current clinical research on esketamine’s neuroprotective mechanisms and its potential to improve outcomes for surgical patients. While not a regulatory or legal development, it highlights growing scientific interest in esketamine’s therapeutic applications beyond depression, especially in perioperative care. This could inform future clinical trials and influence perioperative protocols, but does not immediately impact access or legal status.
During the perioperative period, factors such as ischemia-reperfusion injury, neuroinflammation, and cognitive dysfunction not only significantly affect postoperative recovery, but also are the main causes of postoperative disability and perioperative death. Esketamine is the R-enantiomer of ketamine, possessing N-methyl-D-aspartate (NMDA) receptor antagonistic activity along with multiple anti-inflammatory, anti-apoptotic, and antioxidant properties. Compared to racemic ketamine, esketamine is more potent, acts more rapidly, causes mild respiratory depression, and induces fewer adverse neuropsychiatric effects, making it a promising agent for perioperative neuroprotection. This review aims to provide a comprehensive overview of esketamine’s neuroprotective mechanisms and clinical applications in the perioperative setting, offering insights into future research directions that may advance therapeutic neuroprotection and improve surgical patient outcomes.
Neuroscience Peer-reviewed publication

Structure-based design of subtype-selective psychedelic analogs published

Structure-based design of subtype-selective psychedelic analogs.
Why it matters ▲ Favorable
This study demonstrates rational design of psychedelic analogs with selectivity for specific serotonin receptor subtypes. Such advances could enable development of next-generation compounds with improved safety, efficacy, and reduced side effects, potentially accelerating clinical research and regulatory acceptance. The work may also inform future scheduling decisions and intellectual property strategies in the psychedelic industry.
Neuroscience Preclinical study published

Psilocybin restores social behavior in OCD mouse model via prefrontal circuits

Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal–hippocampal circuitry
Why it matters ▲ Favorable
This preclinical study shows psilocybin can restore social novelty investigation in a genetic mouse model of OCD, with effects linked to infralimbic prefrontal cortex activation. The results suggest domain-specific, enduring improvements in social cognition, supporting further investigation of psilocybin for social dysfunction in OCD and related disorders. While translational, this work strengthens the mechanistic rationale for clinical trials targeting social symptoms in neuropsychiatric conditions.
Obsessive-compulsive disorder (OCD) remains difficult to treat, and evidence indicates that social dysfunction, common across obsessive-compulsive and related disorders, is an under-recognized clinical burden. SAPAP3 knockout (KO) mice, a well-established model of compulsive behavior, exhibit social abnormalities, suggesting broader disruptions in circuits relevant to social cognition. Here, we investigated whether psilocybin, a serotonergic psychedelic with emerging therapeutic potential, can restore social behavior in SAPAP3 KO mice and whether behavioral rescue is associated with modulation of neural activity. Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test. Psilocybin produced a male-specific, enduring restoration of novel-mouse-directed investigation during social recognition/novelty testing. Immunohistochemical quantification of c-Fos revealed that psilocybin increased neural activation in the medial prefrontal cortex and hippocampus regardless of genotype. Only infralimbic c-Fos levels correlated with improved social recognition/novelty behavior in male SAPAP3 KO mice, identifying infralimbic recruitment as a key correlate of therapeutic rescue. Psilocybin did not alter c-Fos in the nucleus accumbens, basolateral amygdala, or dorsal striatum. These findings demonstrate that psilocybin exerts domain-specific, enduring effects on social cognition in an established model of compulsive-like behavior, potentially involving prefrontal plasticity-related mechanisms. Given the lack of pharmacological treatments targeting social dysfunction in OCD and associated neuropsychiatric disorders, these results highlight psilocybin as a promising candidate for improving social-cognitive outcomes in disorders characterized by repetitive behaviors and social impairment.
Neuroscience Peer-reviewed study

Structural basis for safer, selective 5-HT2AR agonists in psychedelics

Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation
Why it matters ▲ Favorable
This study provides a mechanistic blueprint for designing psychedelic-inspired drugs that selectively activate 5-HT2AR while avoiding 5-HT2BR, a key safety concern linked to cardiac valvulopathy. The use of cryo-EM and rational ligand design enables the development of compounds with improved safety profiles, directly informing medicinal chemistry and preclinical development pipelines. This work could accelerate the creation of next-generation psychedelics with reduced legal and regulatory risk, supporting both clinical research and future commercialization.
Selective 5-HT2AR agonism without 5-HT2BR activation is critical for safe psychedelic-inspired therapeutics. Here, we systematically probe the ligand-binding pockets of 5-HT2AR and 5-HT2BR and identify steric and conformational constraints at the side-extended pocket (SEP) and extended binding pocket (EBP) that dictate ligand orientation and receptor signaling. Guided by these insights, we design derivatives across tryptamine and phenethylamine scaffolds that integrate SEP and EBP engagement with scaffold modification to reinforce 5-HT2AR activation while limiting 5-HT2BR activity. Cryo-EM structures of 5-HT2AR and 5-HT2BR bound to IHCH-2330, a selective 5-HT2AR agonist and 5-HT2BR antagonist, confirm the design principle. These findings show differential activation mechanisms between 5-HT2AR and 5-HT2BR and provide a rational framework for engineering safer, functionally selective serotonergic compounds, mitigating 5-HT2BR–mediated side effects while preserving therapeutic efficacy. This study explores structural principles of receptor selectivity and establishes a strategy for designing selective 5-HT2AR agonists while reducing 5-HT2BR-associated valvulopathy risk.
Neuroscience Peer-reviewed study

Structure-based design yields safer, 5-HT2AR-selective psychedelic analogs

Structure-based design of subtype-selective psychedelic analogs
Why it matters ▲ Favorable
This study provides a rational design strategy for psychedelic compounds that selectively activate 5-HT2AR while avoiding 5-HT2BR, addressing a key cardiac safety concern in psychedelic drug development. The identification of lead compounds with antidepressant-like efficacy in animal models could accelerate the development of next-generation psychedelic therapeutics with improved safety profiles. This work is highly relevant for researchers, drug developers, and clinicians seeking safer alternatives to classical psychedelics.
Classical psychedelics exert hallucinogenic and therapeutic effects primarily through activation of serotonin 2 A receptor (5-HT2AR), offering promise as transformative treatments for neuropsychiatric disorders. However, their concurrent activation of 5-HT2BR—associated with cardiac valvulopathy—raises serious safety concerns, underscoring the need for subtype-selective psychedelics. To address this, we determine the cryo-EM structure of 5-HT2AR and perform a comparative structural analysis of the orthosteric binding pockets (OBPs) of 5-HT2AR and 5-HT2BR. Guided by key residue differences, we develop a trigonal pharmacophore model to inform the design of 5-HT2AR-selective agonists that avoid 5-HT2BR activation. Using this model, we design and synthesize two compound series that selectively activate 5-HT2AR while antagonizing 5-HT2BR. Molecular basis of subtype selectivity is confirmed by five additional cryo-EM structures of receptor-ligand complexes. Selected compounds also exhibit antidepressant-like efficacy in animal models. Our findings provide a strategy for the development of safer, subtype-selective psychedelic analogs with therapeutic potential. The authors present a rational design strategy for 5-HT2AR-selective agonists that avoid 5-HT2BR activation, providing lead compounds for developing safer psychedelic analogs with subtype selectivity.
Neuroscience Systematic review published

Systematic review: DMN connectivity after (es)ketamine vs. antidepressants in MDD

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review
Why it matters ◈ Mixed
This systematic review synthesizes evidence that (es)ketamine and conventional antidepressants produce distinct changes in default mode network (DMN) connectivity in major depressive disorder (MDD), with ketamine showing more consistent reductions in DMN-limbic connectivity linked to clinical improvement. The findings highlight network-level biomarkers that may differentiate mechanisms of action and treatment response, informing future research on neurobiological targets in depression and treatment-resistant populations. However, heterogeneity in study designs and populations limits definitive conclusions.
Antidepressant treatments, including conventional antidepressants and (es)ketamine, may reverse default mode network (DMN) resting-state functional connectivity (rsFC) alterations related to major depressive disorder (MDD). Despite these agents having distinct initial action mechanisms, both likely share downstream effects that lead to structural and functional adaptations in MDD-related neural circuits. Examining the effects of these agents on DMN rsFC can provide insights into network-level effects, advance understanding of network-level mechanisms of treatment response, and generate hypotheses regarding potential neurobiological differences between MDD and treatment-resistant depression populations. A systematic search was performed to retrieve studies investigating changes in DMN rsFC following treatment with conventional antidepressants and (es)ketamine in MDD, including the association with clinical outcomes. Nineteen studies were included, 13 administered conventional antidepressants (N = 546), and six intravenous ketamine (N = 247). Conventional antidepressants were associated with heterogeneous changes in DMN rsFC, some of which related to clinical improvements. Conversely, ketamine mostly related with reductions in DMN rsFC, particularly in DMN-limbic connectivity. While interpretations of current findings are limited by heterogeneity in study populations, treatment regimens, and timing assessments, findings suggest that these agents exhibit mostly distinct patterns of DMN modulation, and that differential effects on DMN rsFC associate with clinical improvements.
FDA / DEA FDA hearing underway

Clearmind Medicine testifies at FDA hearing on patient access, MEAI trial

Clearmind Medicine Testifies at FDA Psychedelic Hearing on Patient Access and MEAI Clinical Trial Insights
Why it matters ▲ Favorable
Clearmind Medicine's testimony at an FDA hearing signals growing regulatory engagement with psychedelic drug development and patient access issues. The inclusion of MEAI clinical trial insights suggests the agency is actively considering both safety and efficacy data as it shapes future access pathways. This event highlights the FDA's willingness to hear from industry stakeholders, which could influence future guidance, trial design, and eventual approval processes for novel psychedelic compounds.
FDA / DEA FDA public engagement

FDA signals interest in psychedelic therapy, movement debates broader issues

The FDA Wants to Talk Psychedelic Therapy. The Movement Has Bigger Questions.
Why it matters ◈ Mixed
The FDA's willingness to publicly discuss psychedelic therapy signals growing regulatory attention and could lay groundwork for future guidance or rulemaking. However, the movement's broader questions—such as equity, access, and cultural context—highlight tensions between formal regulation and grassroots priorities. This engagement may shape how future therapies are evaluated and accessed, but details remain limited without further agency action.
FDA / DEA FDA hearing underway

MAPS Attends Historic FDA Hearing on Psychedelics

Why it matters ▲ Favorable
The FDA convening a public hearing on psychedelics, with MAPS in attendance, signals a major step toward regulatory engagement and potential pathway creation for psychedelic therapies. This event could shape future federal policy, influence clinical trial requirements, and impact the legal status and commercial landscape for psychedelic medicines. Stakeholders should monitor outcomes closely, as this hearing may set precedents for research access and patient care.
FDA / DEA Expert call to action

Experts urge FDA to set safety, access standards for psychedelics

Experts urge FDA to set clear safety and access standards for psychedelic drugs (September 14)
Why it matters ◈ Mixed
Leading experts are publicly pressing the FDA to clarify regulatory standards for psychedelic drug safety and patient access. This signals growing pressure on federal regulators as clinical and commercial interest in psychedelics accelerates. Clearer FDA guidance would reduce uncertainty for researchers, clinicians, and industry, but this is a call to action—not a binding policy change. Stakeholders should monitor for any formal FDA response or rulemaking.
FDA / DEA FDA hearing held

FDA hearing exposes divisions on psychedelic medicine approval

FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval—Psychiatric Times
Why it matters ◈ Mixed
The FDA's public hearing on psychedelic medicine highlights significant divisions among stakeholders regarding the path to regulatory approval. This event signals both the growing momentum and the unresolved controversies around standards for safety, efficacy, and access. The outcome of these debates will shape the regulatory landscape, impacting research priorities, clinical adoption, and investment in the field.
Neuroscience Systematic review published

Systematic review localizes ecstatic phenomena in epilepsy surgery

Localizing value of ecstatic phenomenon in epilepsy surgery: A systematic review
Why it matters ◈ Mixed
This systematic review refines our understanding of the neural correlates of ecstatic or mystical experiences in focal epilepsy, highlighting the insular and temporal lobes as key regions. While not directly about psychedelics, the findings are relevant for researchers studying the neural basis of altered states of consciousness, which informs both basic science and translational work in psychedelic medicine. The review's limitations—small sample size and high risk of bias—underscore the need for more rigorous studies.
OBJECTIVE: A systematic review was conducted to synthesize current anatomo-clinical correlations of ecstatic symptoms in focal epilepsy, aiming to provide evidence-based guidance for interpreting this ictal semiology during presurgical evaluation. METHODS: We searched PubMed and Web of Science using terms related to ecstatic experience (e.g., ecstatic, bliss, mystical, time dilation) combined with epilepsy, seizure, or aura. This was supplemented by manual screens of review bibliographies and AI-assisted queries. Of 926 selected papers, 33 were retained for localization analysis. We included studies from which lateralization and localization data could be reliably extracted and evaluated. From the extracted data, 51 patients were initially identified. The definitive analysis, however, was restricted to 9 patients who met "high" or "very high" confidence criteria for the correct delineation of the epileptogenic zone (EZ). A secondary analysis of the symptomatogenic zone (SZ) was conducted, drawing on data from 9 patients and identifying 14 sublobar localizations. RESULTS: For the EZ, the highest level of evidence pointed to various subregions of the temporal lobe, particularly the anterior, basal or mesial regions, identified in 6 of the 9 high-quality cases. For the SZ, the insular lobe was the most frequently identified region, particularly the dorsal anterior portion, which accounted for 9 of the 14 identified localizations. SIGNIFICANCE: Evidence from the highest-quality surgical series and individual case reports consistently demonstrates that the EZ for ecstatic seizures resides in the temporal lobe or, in approximately one-third of cases, extra-temporal structures (insulo-opercular or orbitofrontal cortex). In contrast, data from direct electrical stimulation, intracranial recordings, and ictal single-photon emission computed tomography (SISCOM) strongly point to the insular cortex as the symptom-generating zone. This review is limited by the relatively low number of eligible patients with sufficient electro-clinical data and the high risk of bias in the existing literature.
Clinical research Peer-reviewed study

Study: Ketamine risk in those at high risk for psychosis

Risk of ketamine exposure in individuals at clinical high-risk for psychosis.
Why it matters ◈ Mixed
This study provides new data on the safety profile of ketamine in populations at clinical high risk for psychosis. The findings are directly relevant to ongoing debates about screening and exclusion criteria in psychedelic-assisted therapy trials and clinical protocols. Policymakers and clinicians should consider these data when shaping guidelines for ketamine access and monitoring, especially as off-label and commercial use expands. Further research may be warranted to clarify risk mitigation strategies for vulnerable groups.
Clinical research Peer-reviewed publication

Framework for defining DMT-assisted therapy interventions published

Defining the intervention before estimating efficacy in DMT-assisted therapy.
Why it matters ◈ Mixed
This publication emphasizes the need for rigorous definition of the therapeutic intervention in DMT-assisted therapy before proceeding to efficacy trials. The article highlights methodological challenges in psychedelic research, such as variability in dosing, set and setting, and integration protocols. For policy and research, this underscores the importance of standardized protocols to ensure reproducibility and regulatory acceptance. It is a key step for designing future trials and informing regulatory pathways but does not itself change legal or access status.
Neuroscience Peer-reviewed study

Psilocybin restores social behavior in SAPAP3 knockout mice

Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.
Why it matters ▲ Favorable
This preclinical study demonstrates that psilocybin can restore social novelty investigation in a mouse model relevant to compulsive and social behavior deficits. The findings implicate prefrontal-hippocampal circuitry as a target of psilocybin's effects, supporting mechanistic rationale for clinical studies in neuropsychiatric disorders. While not directly translatable, this adds to the growing body of evidence supporting psilocybin's potential therapeutic applications and may inform future trial design.
Neuroscience Preclinical study published

Ketamine metabolite HNK reduces anhedonia in Alzheimer's disease mice

Ketamine metabolite HNK ameliorates anhedonia symptom in Alzheimer's disease mice.
Why it matters ▲ Favorable
This preclinical study shows that HNK, a ketamine metabolite, can reduce anhedonia symptoms in Alzheimer's disease mouse models. The findings suggest a potential new therapeutic pathway for treating neuropsychiatric symptoms in Alzheimer's, an area with significant unmet need. While translation to humans remains uncertain, this supports further clinical research on ketamine metabolites for neurodegenerative and mood disorders.
Clinical research Protocol published

Ketamine infusion protocol published for CRPS treatment

Ketamine Infusion Protocol for the Treatment of Complex Regional Pain Syndrome.
Why it matters ▲ Favorable
This publication of a ketamine infusion protocol for Complex Regional Pain Syndrome (CRPS) provides a standardized approach that could improve research reproducibility and clinical outcomes. It may facilitate multi-site studies, inform regulatory discussions, and support insurance coverage arguments by establishing a reference protocol. The protocol's adoption could also influence pain management practices and expand ketamine's therapeutic footprint beyond psychiatric indications.
Clinical research Review published

Review: Emerging Treatments for Treatment-Resistant Depression

Treatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies
Why it matters ▲ Favorable
This literature review synthesizes current evidence on innovative therapies for treatment-resistant depression, including psychedelic-assisted approaches such as psilocybin. While not a primary research breakthrough, it highlights the growing clinical interest and research momentum around psychedelics for refractory mood disorders. The review underscores the need for further trials to optimize these interventions and integrate them into standard care.
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns. Although many treatment strategies are well-established and available, not all patients achieve satisfactory improvement. Treatment-resistant depression (TRD), often defined as insufficient response to at least two antidepressant trials of proper dose and duration, represents a major therapeutic challenge. This review aims to present and assess emerging treatment strategies for TRD, focusing on their mechanisms, effectiveness and safety. Brief description of the state of knowledge: Recent advances in the understanding of depression pathophysiology have initiated the development of new therapeutic approaches targeting various systems thought to be involved in mood regulation. Glutamatergic modulators, such as ketamine and esketamine, have demonstrated prompt antidepressant effects, particularly in patients with severe or refractory symptoms. Neuromodulatory techniques, including repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), remain important treatment options with growing research interest. Simultaneously, heightened attention has been directed toward psychedelic-assisted therapies, especially psilocybin, which may produce sustained antidepressant effects through modulation of various neural networks. Additionally, invasive interventions such as vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are being studied for resistant cases, although their use remains limited. Summary: Emerging therapies for TRD offer promising alternatives to conventional treatment strategies, particularly for patients not responding to routine interventions. Further research is crucial for the optimization of therapeutic outcomes and integration of those novel approaches into clinical practice.
Clinical research Review published

Narrative review on pharma management of SUDs, incl. hallucinogens

Pharmaceutical and Medical Management of Substance Use Disorders: A Narrative Review
Why it matters ◈ Mixed
This narrative review synthesizes two decades of evidence on pharmaceutical and medical management of substance use disorders, including those involving hallucinogens and psychoactive compounds. While established treatments for opioid use disorder are well supported, psychedelic-assisted approaches are highlighted as promising but still in need of robust clinical validation. The review underscores the importance of integrating biochemical, clinical, and patient-centered strategies, and identifies translational research and precision dosing as key unmet needs. This work provides useful context for researchers and clinicians but does not itself shift regulatory or clinical practice.
Substance use disorders (SUDs) involving narcotics, hallucinogens, and psychoactive compounds — whether synthetically manufactured or derived from medicinal plants — represent one of the most pressing challenges in contemporary pharmacotherapy and public health. The biochemical heterogeneity of these agents, spanning opioid receptor agonism, serotonergic dysregulation, dopaminergic reward pathway hijacking, and glutamatergic excitotoxicity, demands a nuanced, evidence-based treatment paradigm. This review critically appraises the current pharmaceutical and medical armamentarium for managing SUDs, integrating receptor-level biochemistry, pharmacokinetic profiles, clinical evidence, and humanized care principles. A narrative review of the literature published between 2000 and 2024 was undertaken using major biomedical and evidence-based sources, including PubMed, the Cochrane Library, and relevant WHO resources. The literature was considered according to its relevance to the pharmacological management of opioids, hallucinogens, and other psychoactive substance use disorders, with particular attention to clinical evidence, pharmacological mechanisms, emerging therapeutic approaches, and current treatment guidance. Established pharmacological interventions, particularly methadone, buprenorphine, and naltrexone, remain integral to the management of opioid use disorder with supported clinical evidence. Other pharmacological strategies, such as N-acetylcysteine and ketamine, have shown promising interest in selected substance use disorders. Although emerging psychedelic-assisted approaches show promise, they still require further clinical investigations. Across the literature, treatment outcomes appear to be influenced by the interaction of pharmacological efficacy, patient-centered care, treatment adherence, and appropriate integrative clinical and biochemical monitoring. Harm-reduction approaches may further complement pharmacological interventions by reducing treatment-related and substance-related risks and addressing individual clinical needs. A biochemically informed, person-centered pharmacotherapy model bridging synthetic and plant-derived agents offers the most promising trajectory for sustainable SUD recovery. Translational research integrating omics biomarkers and precision dosing remains a critical unmet need.
FDA / Clinical safety Safety concerns raised

FDA faces safety warnings after death, misconduct in psychedelic care

Heart Risks, Provider Misconduct, and a 21-Year-Old's Death Sharpen Safety Warnings as FDA Weighs Psychedelic Care
Why it matters ◈ Mixed
High-profile adverse events, including a patient's death and provider misconduct, are intensifying scrutiny of safety protocols as the FDA considers pathways for psychedelic-assisted care. This could impact regulatory timelines, risk management requirements, and public perception, potentially slowing or reshaping access and industry growth. Stakeholders should prepare for stricter oversight and increased demand for robust clinical and ethical safeguards.
FDA / DEA FDA public hearing

FDA holds public hearing on psychedelics amid Trump-driven policy push

FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
Why it matters ◈ Mixed
The FDA convening a public hearing on psychedelic drugs signals a pivotal moment for federal policy and regulatory direction. Such hearings often precede significant rulemaking, rescheduling, or new guidance that can reshape research access, clinical pathways, and industry investment. The explicit mention of a Trump-driven push suggests high-level political momentum, raising the stakes for stakeholders across research, clinical, and commercial domains.
Clinical research Research commentary

Researchers call for improvements in psychedelic clinical trials

Can psychedelic clinical trials be better? Researchers say yes
Why it matters ◈ Mixed
Calls to improve psychedelic clinical trial design highlight ongoing challenges with methodology, blinding, and reproducibility in this field. While not a regulatory or legal move, such critiques can influence future trial protocols, funding priorities, and regulatory scrutiny. Stakeholders should monitor for subsequent guidance or consensus statements that could shape research standards and downstream access.
Clinical research FDA approval imminent

CMPS: Psychedelic therapy for TRD nears FDA approval

CMPS: Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption
Why it matters ▲ Favorable
FDA approval of a psychedelic therapy for treatment-resistant depression (TRD) would mark a watershed moment for the field, opening the door to regulated clinical use and broad adoption. This signals a likely shift in standard of care for TRD, with rapid and durable relief reported. The move would also catalyze investment, insurance coverage discussions, and further research, while raising new questions around access, training, and post-approval monitoring.
Clinical research Peer-reviewed publication

IV ketamine for suicidal crisis: indications and referral guidance

[Intravenous ketamine in suicidal crisis : indications and patient referral].
Why it matters ▲ Favorable
This peer-reviewed article reviews indications and referral pathways for intravenous ketamine in acute suicidal crisis, signaling growing clinical interest in rapid-acting interventions for suicidality. The publication may inform best practices, referral criteria, and safety considerations for clinicians considering ketamine in high-risk populations. While not a regulatory or legal change, it contributes to the evidence base that could shape future guidelines and policy on ketamine's use in psychiatric emergencies.
Clinical research Qualitative study published

Qualitative study: Psychedelics and TBI recovery narratives

Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives
Why it matters ▲ Favorable
This exploratory qualitative study suggests that individuals with traumatic brain injury (TBI) perceive psychedelic use as beneficial for trauma relief, mood stabilization, and cognitive function. While the sample is small and findings are subjective, the results highlight a potential new avenue for neurorehabilitation research. The study underscores the need for controlled clinical trials to rigorously assess efficacy and safety in this vulnerable population.
Individuals with traumatic brain injury (TBI) frequently experience persistent cognitive difficulties, emotional dysregulation, and trauma-related symptoms, yet few interventions effectively address these interconnected challenges. This exploratory qualitative study examined how people with TBI perceived the effects of psychedelic use on cognition, mental health, and trauma recovery. Five adults with a history of TBI who had used psychedelics post-injury participated in semi-structured interviews. Data were analysed using reflexive thematic analysis. Three themes were identified: (1) Trauma Relief and Mood Stabilisation, describing reductions in anxiety, emotional reactivity, and trauma-related distress; (2) Perceived Post-Dose Cognitive ‘Lift’ particularly in memory, clarity, and coordination following macrodose experiences; and (3) Insight, Acceptance, and Self-Compassion, reflecting enhanced self-understanding, identity reconstruction, and gentler relationships with the self after injury. Participants reported that macrodose experiences produced the most noticeable effects, including perceived short-term improvements in memory, clarity, and coordination. Overall, participants described psychedelic experiences as associated with trauma relief and mood stabilisation, perceived cognitive changes, and greater insight, acceptance, and self-compassion following TBI, with potential implications for neurorehabilitation.
Clinical research Qualitative analysis published

Expectations shape ketamine's effects in depression treatment

The role of expectation in ketamine treatment for teatment-resistant depression
Why it matters ▲ Favorable
This qualitative study highlights the central role of patient expectations in shaping both the subjective and therapeutic effects of ketamine for treatment-resistant depression. By triangulating user narratives, forum posts, and interviews, it underscores the need to integrate psychological context into research and clinical protocols. While not a regulatory or trial milestone, these findings may inform future trial design and clinical best practices.
Ketamin se je v zadnjih dveh desetletjih uveljavil kot obetavna intervencija pri zdravljenju terapevtsko rezistentne depresije, predvsem zaradi hitrega antidepresivnega učinka, ki se lahko pojavi že v nekaj urah po uporabi. Poleg biološkega delovanja na glutamatergični sistem pa ketamin povzroča izrazite spremembe v subjektivnem doživljanju, kot so disociacija, spremenjeno zaznavanje časa in prostora ter v nekaterih primerih mistične ali transformativne izkušnje. Zaradi teh lastnosti se odpira vprašanje, v kolikšni meri na potek in pomen ketaminske izkušnje vplivajo psihološki dejavniki, zlasti pričakovanja posameznika. Namen magistrskega dela je raziskati učinek pričakovanj pri uporabi ketamina in razumeti, kako se ta pričakovanja izražajo pred uporabo, med samo izkušnjo in v retrospektivni refleksiji. Raziskava je zasnovana kot kvalitativna večnivojska analiza, ki združuje podatke iz treh virov: osebne zapise uporabnikov iz zbirke Erowid Experience Vaults, objave in razprave s spletnega foruma Reddit ter poglobljene intervjuje z osebami, ki so imele izkušnjo z uporabo ketamina. Analitični pristop temelji na načelih utemeljene teorije in časovno usmerjene kvalitativne analize. Pri obdelavi obsežnega besedilnega gradiva je bila uporabljena kombinacija avtomatskega kodiranja s pomočjo programskega jezika Python ter semantične validacije z jezikovnim modelom (LLM), kar je omogočilo sistematično prepoznavanje različnih oblik pričakovanj in njihovih sprememb skozi čas. Rezultati kažejo, da pričakovanja predstavljajo osrednjo rdečo nit ketaminske izkušnje. Oblikujejo ne le način, kako posamezniki vstopajo v izkušnjo, temveč tudi, kako interpretirajo njene učinke in jim pripisujejo terapevtski pomen. Magistrsko delo prispeva k razumevanju ketamina kot intervencije, ki deluje na presečišču nevrobioloških mehanizmov in subjektivnega pomena, ter poudarja pomembnost upoštevanja psihološkega konteksta in pričakovanj pri raziskovanju in klinični uporabi ketamina.
Clinical research Secondary analysis published

First trial: Psilocybin therapy in TRD with cluster B personality disorders

Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders
Why it matters ◈ Mixed
This is the first clinical trial to report on psilocybin-assisted psychotherapy in adults with both treatment-resistant depression and cluster B personality disorders, a population with high unmet need and limited treatment options. The small sample and heterogeneity of outcomes limit generalizability, but the absence of serious adverse events and reductions in depression and suicidal ideation support further research. This study provides early safety and feasibility data for a complex, high-risk population, informing future trial design and regulatory considerations.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1 cluster C) and TRD who underwent PAP, representing a secondary analysis of a larger trial. The trial was registered on clinicaltrials.gov under the identifier NCT05029466 (Registration Date: 2021-08-26). Three participants dropped out of the trial. Mean MADRS scores decreased from 30.4 pre-treatment to 22.5 at day 1, 24.9 at week 2, and 22.3 at month 6. Mean MADRS Suicidal ideation (SI) item declined from 3.2 to 1.6 at day 1, 2.3 at week 2, and 1.2 at month 6. There was substantial heterogeneity in outcomes amongst participants. No serious adverse events were recorded. This is the first clinical trial evidence that PAP may reduce depression and SI in comorbid cluster B PDs, suggesting further trials may be warranted.
Public health / Policy Policy review

Brazilian review highlights gaps in mental health drug access in SUS

PSICOFÁRMACOS NO TRATAMENTO DO SOFRIMENTO MENTAL NO SISTEMA ÚNICO DE SAÚDE: PANORAMA ATUAL, LACUNAS ASSISTENCIAIS E PROPOSTAS DE QUALIFICAÇÃO DO CUIDADO
Why it matters ◈ Mixed
This integrative review analyzes the landscape of psychopharmacological treatments for mental health in Brazil's public health system (SUS), highlighting significant growth in medication use but persistent regional inequalities and a lag in access to newer therapies such as esketamine. The article proposes expanding the national essential medicines list (RENAME) and updating protocols to bridge the gap between international standards and public provision. While not focused on psychedelics, the findings are relevant for advocates and researchers seeking to improve access to novel treatments in Brazil’s public sector.
O sofrimento mental representa um dos maiores desafios da saúde pública contemporânea. No Brasil, o Sistema Único de Saúde (SUS) é o principal responsável pelo cuidado em saúde mental, oferecendo tratamento psicofarmacológico por meio da Rede de Atenção Psicossocial (RAPS). Este artigo tem como objetivo analisar o perfil dos psicofármacos utilizados no tratamento do sofrimento mental no SUS — incluindo inibidores seletivos da recaptação de serotonina (ISRS), inibidores da recaptação de serotonina e noradrenalina (IRSN), antidepressivos tricíclicos (ATC), antipsicóticos de primeira e segunda geração, estabilizadores do humor e benzodiazepínicos —, estabelecer uma comparação entre os tratamentos considerados padrão-ouro pela literatura internacional e aqueles efetivamente disponíveis na atenção pública, e propor soluções para as lacunas identificadas. A metodologia empregada é a revisão integrativa da literatura, com busca nas bases de dados PubMed, MEDLINE, SciELO, UpToDate, Cochrane Library e em documentos normativos do Ministério da Saúde, da Sociedade Brasileira de Psiquiatria, da American Psychiatric Association e da European Psychiatric Association. Os resultados apontam expansão significativa do uso de psicofármacos no Brasil — aumento de 18,6% no consumo de medicamentos para saúde mental entre 2022 e 2024 —, persistência de desigualdades regionais no acesso à RAPS, com 21,6% dos municípios elegíveis sem CAPS efetivo, e uma lacuna expressiva entre as inovações farmacológicas disponíveis globalmente — como esketamina intranasal, brexanolona e antagonistas NMDA — e a Relação Nacional de Medicamentos Essenciais (RENAME). Como proposta, o artigo sugere a expansão da RENAME com base em critérios de custo-efetividade, a criação de protocolos territorializados de prescrição, o fortalecimento da telepsiquiatria e a formação continuada de prescritores na atenção primária.
FDA / DEA FDA review spotlight

Psychedelics return to FDA’s agenda for review

Deep dive: Psychedelics back on FDA’s doorstep
Why it matters ◈ Mixed
The FDA's renewed attention to psychedelics signals potential shifts in regulatory pathways and could accelerate or reshape access for research and patient care. The agency's actions will be closely watched by industry, clinicians, and policymakers, as outcomes may influence investment, trial design, and legal risk. While details are limited, this development underscores the growing momentum and scrutiny in the field.
FDA / DEA FDA hearing held

FDA hears input on psychedelics, PDUFA, and next-gen lung cancer therapies

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
Why it matters ◈ Mixed
The FDA holding a hearing on psychedelics signals ongoing regulatory engagement and potential future guidance on approval pathways, safety, and access. Stakeholder input at this stage can influence how the agency approaches clinical development, scheduling, and post-approval controls for psychedelic therapies. While not a final rule or decision, such hearings are key steps that shape the regulatory landscape and market prospects.
Clinical research Published study

Study: Ketamine-ethanol interaction and forensic implications

Pharmacokinetic interaction between ketamine and ethanol: evaluation and forensic implications.
Why it matters ◈ Mixed
This study examines how ketamine and ethanol interact pharmacokinetically, with implications for both clinical safety and forensic interpretation. Understanding these interactions is critical for clinicians administering ketamine, especially in populations with concurrent alcohol use, and for legal experts interpreting toxicology results in forensic cases. The findings may inform dosing protocols, risk mitigation, and legal standards around ketamine-related incidents.
Clinical research Perspective published

Call for stronger masking in psychedelic clinical trials

The Case for More Aggressive Masking in Psychedelic Trials.
Why it matters ◈ Mixed
This publication argues that current masking (blinding) methods in psychedelic trials are insufficient, risking bias in efficacy and safety outcomes. The authors urge adoption of more rigorous blinding protocols, which could impact trial design, regulatory acceptance, and the credibility of future results. Researchers and sponsors may face higher evidentiary standards, potentially affecting timelines and costs for drug development. This perspective could influence IRBs, regulators, and funders to require more robust controls in upcoming studies.
Clinical research Peer-reviewed review published

Review: Psychedelics for treatment-resistant depression—efficacy & outlook

Uso de psicodélicos no tratamento da depressão resistente: eficácia clínica e perspectivas terapêuticas
Why it matters ◈ Mixed
This integrative review synthesizes clinical evidence for psychedelics, especially psilocybin, in treatment-resistant depression (TRD), highlighting both promising antidepressant effects and key uncertainties. While controlled trials show clinically relevant reductions in depressive severity, not all results are uniformly positive, and safety, blinding, and long-term maintenance remain open questions. The review underscores the need for rigorous, independent, and pragmatic studies before broad clinical adoption, providing a nuanced signal for researchers and clinicians.
A depressão resistente ao tratamento (DRT) representa uma condição de elevada carga clínica e funcional, usualmente definida pela resposta inadequada a pelo menos dois tratamentos antidepressivos adequados. O interesse por psicodélicos clássicos ressurgiu diante da possibilidade de efeitos antidepressivos rápidos após uma ou poucas administrações em contexto supervisionado. O objetivo desta revisão foi sintetizar criticamente as evidências clínicas sobre eficácia, durabilidade, segurança e perspectivas terapêuticas dos psicodélicos na DRT. Realizou-se revisão integrativa da literatura, com busca estruturada nas bases PubMed/MEDLINE, Scopus, Web of Science e APA PsycINFO, abrangendo estudos publicados de 2016 a 10 de setembro de 2026. Foram elegíveis estudos clínicos primários em adultos com DRT que avaliaram psilocibina, ayahuasca, N,N-dimetiltriptamina (DMT) ou outros psicodélicos clássicos, com desfechos de eficácia ou segurança. Nove estudos clínicos primários compuseram a síntese principal; publicações de seguimento de coortes já incluídas foram analisadas apenas para durabilidade, sem dupla contagem. A psilocibina concentrou a evidência mais robusta, embora os ensaios não tenham sido uniformemente positivos: estudos controlados demonstraram reduções clinicamente relevantes da gravidade depressiva, enquanto o ensaio EPISODE não atingiu significância no desfecho primário. Ayahuasca e DMT apresentaram sinais antidepressivos rápidos em estudos menores. Os eventos adversos foram predominantemente transitórios em ambientes supervisionados, mas persistem incertezas sobre cegamento funcional, expectativa, segurança em populações de maior risco e estratégias de manutenção. Conclui-se que os psicodélicos, especialmente a psilocibina, apresentam potencial terapêutico relevante na DRT, porém a incorporação clínica exige seleção criteriosa, supervisão estruturada e confirmação adicional de eficácia e segurança em estudos independentes e pragmaticamente representativos.
Clinical research Phase 3 trial announced

Optimi Health launches Phase 3 MDMA-PTSD trial

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Why it matters ▲ Favorable
Optimi Health's announcement of a Phase 3 trial for MDMA-assisted therapy in PTSD signals growing momentum for late-stage psychedelic clinical research beyond the US and MAPS-sponsored studies. This move could diversify the evidence base, accelerate regulatory review in Canada, and expand commercial competition in the psychedelic therapy sector. If successful, it may also impact patient access and inform policy discussions on MDMA's medical use.
Clinical research Retrospective study published

Study: Preparedness and risk in Oregon psilocybin consult service patients

Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service
Why it matters ▲ Favorable
This is among the first studies to characterize patients seeking clinical consultation for psilocybin risk reduction in a legal US setting. Findings suggest high rates of trauma and prior psychedelic use among these patients, with most being low risk for adverse events and well-prepared for psilocybin experiences. The data underscore the emerging role of healthcare systems in supporting safe, informed psychedelic use as regulated access expands, informing both clinical practice and policy.
Introduction In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: (1) the clinical and demographic characteristics, (2) psilocybin use motivations, and (3) differences in preparedness among patients seeking care in an Oregon-based pilot consult service specializing in psilocybin risk reduction. Methods This exploratory retrospective chart review abstracted sociodemographics, trauma history, and medical and psychiatric risks of patients (November 2023–September 2025). The Psychedelic Preparedness Scale (PPS), a validated self-report questionnaire, measured preparedness. Two sample t -tests examined associations of PPS scores by insurance, consult motivations, and prior psychedelic use. Results Patients ( N = 29) had a mean age of 47.14 years (SD = 15.9), were majority female (55.2%); White (82.8%); and privately insured (62.1%). Patients mostly sought psilocybin to address only a psychiatric concern (75.9%); 27.6% anticipated naturalistic (non-state regulated) use. Most patients were deemed low risk for adverse events. Prevalence of prior challenging psychedelic experiences (CPE) was 17.2%; 58.6% reported lifetime psilocybin use. 86.2% endorsed ≥1 form of lifetime trauma. Of PPS completers ( N = 23, 79%), mean score was 91.3 (SD = 23.99). Scores did not significantly differ by insurance; consultation motivation; CPE; prior psilocybin or psychedelic use. Conclusion Patients utilizing a novel consultation service demonstrate a high prevalence of trauma, prior psilocybin use, and baseline preparedness. While preliminary, this study is among the first describing patients seeking medical and psychiatric consultation when considering psilocybin and highlights potential roles of healthcare systems in providing evidence-based patient education and risk reduction as interest in psychedelics grows.
Neuroscience Published study

Ketamine reduces habenula response to aversive outcomes in learning

Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning.
Why it matters ▲ Favorable
This study provides mechanistic evidence that ketamine modulates habenula activity during aversive learning, a pathway implicated in depression and treatment response. The findings may inform future clinical trial designs and support the rationale for ketamine and related compounds in mood disorder research. While not directly policy-shifting, this work strengthens the neurobiological basis for ongoing therapeutic development and regulatory consideration.
Neuroscience Peer-reviewed review

Neurocognitive model links psychedelics to anxiety relief via hippocampal reset

Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology
Why it matters ▲ Favorable
This review proposes a mechanistic model for how psychedelics may alleviate anxiety by resetting hippocampal contextual processing, offering a framework for future research and trial design. The paper synthesizes current evidence on neural pathways and suggests testable hypotheses for optimizing psychedelic therapy in anxiety-related disorders. While not a clinical breakthrough, it provides valuable theoretical grounding for translational and clinical research, supporting more targeted studies and potentially informing regulatory and therapeutic strategies.
Abstract Psychedelics (hallucinogenic 5-HT 2A agonists such as psilocybin) are being investigated for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite promising results, the mechanisms by which psychedelic therapy may alleviate anxiety are not well understood. Here, we review neural and cognitive mechanisms underlying anxiety-related psychopathology and how psychedelics may impact these mechanisms. This review culminates in a tentative neurocognitive account of how psychedelics may promote long-term anxiolysis. We propose a model of anxiety related psychopathology wherein anxiety-related contextual information from the hippocampus may influence amygdala and salience network activity, biasing information processing toward anxiety-related content that thereby is encoded by the hippocampus and perpetuates this cycle. We posit that psychedelic may acutely free cortical networks from hippocampal-dependent contextual constraints in part through 5-HT 2A expression on excitatory and inhibitory neurons in the cortex and hippocampus, respectively, while the intrinsic plasticity of the hippocampus and/or psychedelic-mediated plasticity allows for a “resetting of the hippocampal buffer.” Following acute effects, increased cortical plasticity may enable the hippocampus to adaptively integrate novel information into a contextual frame less biased or constrained by prior aversive conditioning, promoting an overall reduction in anxious thoughts and appraisals. We end by discussing potential challenges of psychedelic therapy for anxiety, and suggest directions for future research to determine the optimal treatment paths informed by cognitive neuroscience.
Clinical research Review published

Review: Music's role in psychedelic-assisted psychotherapy

A complex intervention perspective on psychedelic-assisted psychotherapy: the role of music
Why it matters ◈ Mixed
This review highlights the critical but underreported role of music in psychedelic-assisted psychotherapy (PAP), arguing that music is a key contextual factor influencing outcomes. Standardizing the functional use of music, rather than its specific form, could improve trial reproducibility and interpretability. For researchers and clinicians, this underscores the need to rigorously document and consider music as an active component in PAP protocols.
Music is played in almost every psychedelic-assisted psychotherapy (PAP) session and is one of the top contextual factors that trials should report. This narrative review examines how music acts on the brain, how it is used in PAP, and why it is difficult to study. We argue that PAP is a complex intervention in which music shapes the drug experience, and that standardization should apply to function rather than form.
Neuroscience Peer-reviewed study published

MRI study identifies brain circuit differences in Gambling Disorder

Structural and functional MRI signatures of Gambling Disorder: a case-control study
Why it matters ◈ Mixed
This case-control MRI study identifies structural and functional brain differences in individuals with Gambling Disorder, highlighting alterations in prefrontal, limbic, and striatal regions linked to reward, valuation, and habit formation. While not directly related to psychedelics, these findings may inform future research into how psychedelic therapies could target similar neural circuits in addiction. The study's small sample size and lack of longitudinal data limit immediate clinical or regulatory impact, but it provides useful context for addiction neuroscience.
Gambling disorder (GD) is a behavioural addiction that may help identify addiction-related neural features without the direct neurobiological effects of a primary substance of dependence. We examined regional grey matter volume (GMV) and resting-state functional connectivity (rsFC) in the same well-characterised sample. Eighteen men with GD and 21 matched healthy controls underwent high-resolution structural and resting-state functional MRI. GMV was quantified across 214 cortical and subcortical regions, and seed-based rsFC analyses focused on striatal subdivisions and mesocorticolimbic regions. Group differences were evaluated using permutation testing and cluster-corrected mixed-effects modelling. GD was associated with lower GMV in the ventromedial prefrontal cortex, orbitofrontal regions and other cortical and subcortical areas, alongside higher GMV in a subset of limbic and default-mode regions. Participants with GD also showed lower connectivity between the limbic striatum and the hippocampus, thalamus and putamen. In exploratory analyses, somatomotor connectivity was positively associated with gambling severity (Problem Gambling Severity Index: Spearman's rho = 0.71, p = 0.003, false-discovery-rate-adjusted q = 0.016). Structural and functional findings overlapped spatially in regions associated with valuation, memory, reward and habit formation, but regional GMV did not mediate group differences in rsFC. These findings are broadly consistent with corticostriatal models of GD and identify candidate circuit-level differences for independent replication. Larger, more diverse and longitudinal samples are required to establish their reproducibility, temporal direction and clinical relevance.
Neuroscience Meta-analysis published

Meta-analysis: Blood NfL Elevated in Substance-Using Populations

Elevated Levels of Blood Neurofilament Light Chain in Substance‐Using Populations: A Systematic Review and Meta‐Analysis
Why it matters ◈ Mixed
This systematic review and meta-analysis finds that individuals who use psychoactive substances have significantly elevated blood neurofilament light chain (NfL) levels, a marker of neuroaxonal injury, compared to controls. While the findings suggest increased neurobiological burden in substance-using populations, NfL is a non-specific marker and cannot alone determine the anatomical source or causality of injury. The results are relevant for researchers studying neurotoxicity risks of both classic and novel psychoactives, but do not directly address legal or regulatory concerns.
Substance-use disorders are increasingly linked to structural and functional brain alterations consistent with neuroaxonal injury. Neurofilament light chain (NfL) is a sensitive blood-based marker of axonal damage, but evidence in substance-using populations remains fragmented. We systematically reviewed and meta-analyzed blood NfL levels in individuals who use psychoactive substances compared with controls. This PRISMA-guided systematic review and meta-analysis was registered in PROSPERO (CRD420251270728). MEDLINE, PubMed, Embase, and Scopus were searched from inception through August 23, 2026, without language or publication-date restrictions. Eligible observational studies measured blood NfL in plasma, serum, or whole blood among individuals with psychoactive substance use and controls. Effect sizes were calculated as geometric mean ratios (GMRs). Multilevel random-effects models accounted for correlated comparisons within studies, and meta-regression explored demographic, clinical, and methodological moderators. Eleven studies comprising 16 comparisons were included. Overall, individuals who use substances had significantly higher blood NfL levels than controls (GMR = 1.81, 95% CI: 1.49-2.20). Alcohol-specific analyses showed a larger pooled effect (GMR = 2.09, 95% CI: 1.62-2.70). In studies restricted to SIMOA assays, the association remained significant, although attenuated (GMR = 1.64, 95% CI: 1.41-1.91). Meta-regression indicated that higher male representation was associated with larger effect sizes, while most clinical and methodological moderators were nonsignificant. Graphical diagnostics did not suggest marked publication bias. Overall, substance use was associated with higher circulating NfL, a non-specific signal consistent with increased neurobiological burden but not sufficient on its own to establish the presence, anatomical source, or cause of neuroaxonal injury.
Federal politics Public statement

Trump publicly cites psychedelic therapies in national remarks

Psychedelic therapies cited by Trump: What you need to know
Why it matters ◈ Mixed
A major US political figure referencing psychedelic therapies signals growing mainstream awareness and potential policy salience for these treatments. While no concrete legal or regulatory move is indicated, such high-profile attention can influence public opinion, legislative agendas, and investment interest. Stakeholders should monitor for follow-up policy proposals or shifts in regulatory posture.
Clinical research Study announced

USC to study meditation's impact on psychedelic therapy outcomes

Could meditation boost psychedelic therapy? A USC study will test it.
Why it matters ▲ Favorable
This study could inform best practices for integrating meditation with psychedelic-assisted therapy, potentially enhancing therapeutic outcomes or safety. While not a regulatory or legal change, the research may influence future clinical protocols and training standards. It signals growing academic interest in optimizing set and setting variables for psychedelic interventions.
FDA / DEA FDA framework announced

FDA releases regulatory framework for psychedelic drug sponsors

The FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.
Why it matters ▲ Favorable
The FDA's release of a regulatory framework for psychedelic drug sponsors marks a pivotal step in clarifying the pathway for clinical development and potential approval of psychedelic therapies. This move provides long-awaited guidance for researchers, sponsors, and investors, reducing legal and regulatory uncertainty. It is expected to accelerate clinical trial activity and investment in the sector, while also setting standards for safety and efficacy evaluation. The 'hard part' now will be industry and research adaptation to these new requirements.
FDA / DEA Public hearing announced

FDA announces public hearing on psychedelics policy

No Questions Asked: FDA’s Psychedelics Public Hearing
Why it matters ◈ Mixed
The FDA's decision to hold a public hearing on psychedelics signals growing federal attention to the regulation, safety, and access pathways for these substances. Such hearings can inform future rulemaking, impact clinical trial design, and shape the legal landscape for researchers and companies. Stakeholder input at this stage may influence how the FDA approaches rescheduling, medical use, or research barriers.
Neuroscience Peer-reviewed publication

New review explores timing of plasticity in psychedelic therapeutics

The Timing of Plasticity: Beyond Synapses in Psychedelic Therapeutics.
Why it matters ▲ Favorable
This review highlights emerging evidence that psychedelic-induced plasticity extends beyond synaptic changes, implicating broader neural and temporal mechanisms in therapeutic outcomes. These findings may inform the design of future clinical trials and optimize dosing protocols by aligning interventions with windows of heightened neuroplasticity. For policy and research, the work underscores the need for nuanced regulatory frameworks that account for the complexity of psychedelic effects on brain function.
Clinical research Phase 3 durability data

Compass Pathways reports on psilocybin durability in depression

Compass Pathways Just Answered the Durability Question. Now Comes the Harder Problem.
Why it matters ▲ Favorable
Compass Pathways has released data addressing the durability of its psilocybin therapy for depression, a key question for regulatory and payer decisions. This marks a significant milestone for the field, as durable clinical effects are essential for FDA approval and insurance coverage. The company's next challenge will be demonstrating scalability and real-world effectiveness, but this readout materially advances the case for psychedelic-assisted therapies.
Public health / Policy Perspective published

Lived experience as systems-relevant evidence in psychedelic public health

Why it matters ▲ Favorable
This article argues that integrating lived experience into psychedelic research and policy is essential for capturing real-world safety, efficacy, and care quality beyond what clinical trials measure. The proposed public health framework could inform better program evaluation, aftercare, and governance, addressing blind spots in current oversight. If adopted, this approach may shape future research design, regulatory standards, and patient protections as psychedelic interventions scale.
As psychedelic interventions move from controlled clinical trials into broader implementation, critical dimensions of lived experience among patients, trial participants, families, and caregivers remain systematically undermeasured in research, service design, and oversight. The resulting gap between protocol-defined outcomes and real-world experiences over time creates blind spots in current approaches, particularly regarding safety, care quality, post-treatment stabilization, aftercare, and long-term vulnerability. I argue that lived experience is a form of systems-relevant evidence essential to strengthening decision-making and institutional accountability. I propose a public health framework for integrating lived experience and expertise into psychedelic research, care models, and governance. Integrating these forms of experiential knowledge can enhance outcome visibility beyond standard clinical measures and adverse event reporting by identifying both beneficial changes and emerging risks across care pathways that might otherwise remain obscured. Finally, I outline key implications for program evaluation, workforce development, and policy design. A rigorous psychedelic public health strategy requires stronger mechanisms for understanding safety and long-term efficacy to ensure that implementation both optimizes outcomes and provides accountability and protection.
State policy State law in effect

Overview of psychedelics decriminalized in Colorado

Breaking Down the Psychedelics Decriminalized in Colorado
Why it matters ◈ Mixed
Colorado's decriminalization of certain psychedelics marks a significant shift in state drug policy and may reduce legal risk for personal use and possession. However, the impact on research access and commercial activity remains limited, as decriminalization does not equate to legalization or regulated sales. Stakeholders should monitor how local implementation and enforcement evolve, as well as potential ripple effects in other states.
Neuroscience Review published

5-HT2A receptor: mechanisms and therapeutic potential in psychedelics

5-HT2A receptor and psychedelics: a trip through the mechanisms of action and therapeutic potential in mental disorders
Why it matters ▲ Favorable
This review consolidates the mechanistic understanding of the 5-HT2A receptor's role in mediating psychedelic effects and its therapeutic promise for mental disorders. It highlights both advances and ongoing gaps in mapping neural circuits underlying psychedelic-induced behavioral changes. The synthesis is valuable for researchers and clinicians seeking to design targeted interventions or trials, and it reinforces the scientific rationale for developing 5-HT2A-focused psychedelic therapies.
Serotonin (5-hydroxytryptamine; 5-HT) modulates a vast array of brain functions via its diverse receptor subtypes. Among these, the serotonin 5-HT2A receptor (5-HT2AR) has garnered intense recent interest for its pivotal role in mediating the effects of psychedelic compounds. Substantial evidence indicates that psychedelics act as agonists at the 5-HT2AR, triggering profound alterations in cognition, perception, and mood. These effects are hypothesized to stem from the receptor’s circuit-specific modulation of neurotransmission and its capacity to promote neuroplasticity. This review synthesizes current knowledge on the neuroanatomical distribution of 5-HT2ARs, their associated signaling pathways, and their implicated role in psychiatric pathophysiology. We further evaluate the receptor’s promise as a novel therapeutic target. While several mechanistic models are discussed, a critical outstanding challenge is the precise mapping of neural circuits that translate 5-HT2AR activation into specific behavioral outcomes. This synthesis underscores the imperative for further research to elucidate the 5-HT2AR’s role in neuropsychiatric disorders and to advance the development of targeted psychedelic-based therapies.
Neuroscience Preclinical study published

Prenatal dexamethasone disrupts neurogenesis, triggers depression-like behaviors

Prenatal dexamethasone exposure disrupts offspring hippocampal neurogenesis and triggers depression-like behaviors via epigenetic regulation
Why it matters ◈ Mixed
This preclinical study links prenatal dexamethasone exposure to disrupted hippocampal neurogenesis and depression-like behaviors in offspring via epigenetic mechanisms. While not directly related to psychedelics, the findings are relevant for understanding neurodevelopmental risk factors for psychiatric disorders that psychedelic therapies may target. The mechanistic insights could inform future research on how early-life exposures shape vulnerability to mood disorders and the potential for psychedelic interventions to modulate neurogenesis or epigenetic pathways.
Prenatal glucocorticoid therapy is commonly used to manage preterm fetal delivery risks; however, such exposure elevates the risk of adult psychiatric disorders, though the underlying mechanisms remain elusive. The present study utilized a mouse model exposed to dexamethasone (DEX, a synthetic glucocorticoid) during late pregnancy (GD14.5-GD20.5). Here, we found that prenatal DEX exposure decreased hippocampal expression of Tet1, Yy1, and Ezh2, increased Pten expression, reduced neurogenesis, and induced depression-like behaviors. Mechanistically, prenatal DEX exposure suppressed Tet1 levels in offspring, inhibiting Tet1 enrichment and 5hmC levels in the Yy1 and Ezh2 promoter regions, thereby downregulating their expression. Subsequently, reduced Yy1 and Ezh2 levels disinhibited Pten expression, leading to Pten upregulation that inhibits the PI3K-Akt-mTOR pathway. This cascade ultimately impaired neurogenesis and promoted depression-like behaviors. Notably, administering the Pten inhibitor bpV(pic) or supplementing Tet1 expression to DEX-exposed offspring restored neurogenesis and behavioral phenotypes. In summary, this study demonstrates that prenatal DEX exposure mediates the upregulation of hippocampal Pten expression through epigenetic mechanisms, leading to suppressed neurogenesis and the emergence of depression-like phenotypes. These results elucidate novel signaling mechanisms and contribute to the theoretical framework for understanding how prenatal DEX exposure influences offspring psychiatric health.
Clinical research Systematic review published

Pharmacogenetics shapes psychotropic drug response in psychiatry

PHARMACOGENETICS APPLIED TO PSYCHIATRY: INFLUENCE OF GENETIC POLYMORPHISMS ON RESPONSE TO PSYCHOTROPIC MEDICATIONS
Why it matters ▲ Favorable
This systematic review highlights the significant influence of genetic polymorphisms—especially in CYP2D6 and CYP2C19—on the efficacy and safety of psychotropic medications, including those relevant to psychedelic-assisted therapy. Personalized medicine approaches may improve outcomes and reduce adverse events, but operational barriers remain for clinical adoption. For psychedelic research and practice, understanding pharmacogenetic factors could refine trial design, dosing, and patient selection, though immediate impact on access or legal risk is limited.
Variability in response to psychotropic drugs represents one of the main challenges in the treatment of psychiatric disorders and is often associated with individual genetic factors. In this context, pharmacogenetics emerges as a promising tool in personalized medicine, as it investigates the influence of genetic polymorphisms on therapeutic efficacy and the occurrence of adverse reactions. The present study aimed to analyze, through a systematic review, the impact of these genetic variations on the response to psychotropic drugs. The methodology followed PRISMA guidelines, with a search conducted in the PubMed/MEDLINE database, considering studies published between 2021 and 2026, resulting in the selection of 11 articles. The results show that polymorphisms in genes related to the cytochrome P450 system, such as CYP2D6 and CYP2C19, as well as in transporters and receptors, significantly influence pharmacokinetics, pharmacodynamics, and treatment safety. Furthermore, it was observed that therapeutic response has a polygenic nature and that factors such as drug interactions and clinical conditions may modify the metabolic phenotype, a phenomenon known as phenoconversion. Despite its clinical relevance, the implementation of pharmacogenetics still faces operational challenges, such as test turnaround time and structural limitations. It is concluded that integrating pharmacogenetics into psychiatric practice may contribute to individualized treatment, promoting greater therapeutic efficacy and reduction of adverse events, although its application still depends on advances in infrastructure and clinical incorporation.
FDA / DEA FDA plan announced

FDA unveils plan to accelerate patient access to psychedelic therapies

FDA Officials Lay Out Plan To Make Psychedelic Therapies Available To Patients 'More Quickly'
Why it matters ▲ Favorable
The FDA's announcement of a plan to expedite access to psychedelic therapies signals a major shift in federal regulatory posture. This could reduce barriers for clinical research, streamline approval pathways, and expand patient access to novel treatments. The move is likely to catalyze investment and industry development, while also raising important questions about safety, oversight, and equitable access.
FDA / DEA FDA hearing announced

FDA to hold hearing on psychedelic drugs for depression, PTSD

US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD
Why it matters ◈ Mixed
The FDA's decision to hold a public hearing on psychedelic drugs signals a pivotal moment for the regulatory landscape in the US, especially as political pressure mounts under the Trump administration. This hearing could shape future access pathways for psychedelic-assisted therapies targeting depression and PTSD, affecting research priorities, clinical trial design, and industry investment. Stakeholders should closely monitor the proceedings for indications of potential rescheduling, expanded access, or new regulatory frameworks.
Clinical research Systematic review published

Systematic review: Cognitive effects of (es)ketamine in mood disorders

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review
Why it matters ◈ Mixed
This systematic review synthesizes current evidence on the cognitive impacts of ketamine and esketamine in treating major depressive and bipolar disorder. While not a new trial, such reviews are important for clinicians and researchers to assess safety and efficacy profiles, especially as these treatments expand. The findings may influence future research priorities and inform risk-benefit discussions in clinical practice.
Clinical research Peer-reviewed publication

Review: The use of psychedelics in psychiatry (PubMed, 2026)

[The use of psychedelics in psychiatry].
Why it matters ▲ Favorable
This peer-reviewed review signals sustained and growing academic interest in the clinical application of psychedelics for psychiatric conditions. The article likely synthesizes recent trial data and mechanistic insights, providing a resource for clinicians and policy staff. While not a regulatory or legal move, such publications inform evidence-based policy, research priorities, and clinical practice guidelines.
Neuroscience Preprint / Study published

Empirical refutation and correction of thermodynamic markers in sleep and psychedelics

The Thermodynamic Arc R = E/|O_info|: A Double Negative Characterization, a Corrected Lens, the Generalization Frontier of Sleep Invariants, and the Cost of Laminarization
Why it matters ◈ Mixed
This large, multi-cohort study rigorously tests and refines a proposed thermodynamic marker (R = E/|O_info|) for consciousness across sleep, anesthesia, and psychedelic states, finding that the original metric fails as a universal predictor but can be corrected to reveal meaningful gradients within sleep and distinct boundaries for psychedelics. The findings challenge the generalizability of certain neural invariants across altered states, suggesting that sleep and psychedelic brain dynamics are fundamentally distinct in their informational structure. This work is highly relevant for researchers seeking robust, quantitative biomarkers of consciousness level in psychedelic and sleep research, but does not directly affect law or policy.
The ratio R = E/|O_info| - spectral energy per unit of integrated informational structure - was proposed as a candidate outcome observable of the thermodynamics of consciousness: an energetic cost per nat of integration. We report its complete empirical genealogy across eight pre-registered studies in public datasets (Sleep-EDF, 153 nights, N=76/77; DOSE-I propofol, N=170; 62-channel ketamine, N=10; DMT+harmine, N=31; paced-breathing HRV biofeedback, N=35), each with frozen criteria, synthetic sanity controls, and the subject (never the epoch) as statistical unit. The genealogy is a four-act arc. Act I (double negative): R is refuted as a scalar predictor (outcome correlation r=-0.36; denominator singularity) and refuted as a two-dimensional frontier with Gaussian-copula O-information - separability of wake vs NREM was entirely dominated by energy (AUC 0.826 for E alone; marginal contribution of O_info +0.004), and the ratio degenerated to E/epsilon (regularizer ~23x larger than the near-null copula denominator). Act II (lens correction): the copula is blind to non-Gaussian synergy - a non-parametric estimator reveals robust integrated synergy (median -0.228 bits, 100% of subjects, growing with NREM depth from -0.211 to -0.429 bits) that tracks level (rho=-0.269) and dissociates from the copula (cross-family correlation 0.063). With the corrected denominator, the plane becomes a genuine 2D frontier (AUC 0.904; marginal contribution +0.081, 19x the copula), and R_np monotonically orders the level of consciousness (median rho=-0.577) - a thermodynamic gradient, not a discrete frontier, with a descriptive cost minimum at N1/N2 and REM and a relative maximum at N4. The sleep field is locked in synergy (O_info<0 in ~100% of epochs), with small consistent intra-night hysteresis and inter-night stationarity. Act III (two generalization frontiers): the invariants do not generalize to the pharmacological axis at d=3 (propofol: both families near-null, not locked, energy carries all - informative null with the attenuation caveat declared), and - new in this version - the psychedelic field at d=5 reveals a second, qualitative boundary: the waking baseline resides in marginal redundancy (median +0.004 bits; 58% of epochs in synergy) and moves continuously toward synergy under DMT without locking - the sleep invariants are properties of the sleep field, not universal properties of consciousness level. Act IV (cost, new): in the cardiopulmonary layer, formal pacing in the resonance band raises coherence (dz=+0.45 per cell; +1.15 unbiased per segment) and simultaneously lowers the sample entropy of cardiac dynamics (0.251 vs 0.336; dz=-1.054, p=1.4e-07) - laminarization carries a measurable thermodynamic cost: order is maintained through flow, paid for in variability. The absolute laminar criterion (gamma^2>=0.5) is refuted in the RR proxy (real coherence 0.10-0.28; falsification clause fired as designed), and the unified regime reading consolidates: the coupling observable signs REORGANIZATION and organized STATES (-0.13 to -0.86 across ten axes), not traits (null, power 0.92), not level (sleep +0.145 ns; formal dissociation z=3.96-4.32), not dissolution (flattening with reversed signal under sedation). The arc methodological contribution - pre-registered refutation branches, mandatory marginal decomposition, blindness-vs-absence discrimination, and floor-declaring estimators - is itself the transferable result: how to kill an observable honestly, resurrect it with a better lens, map where its invariants end, and price its order.
Neuroscience Theoretical model published

Constraint-based model of consciousness anchored to 5-MeO-DMT effects

The Brain as a Field-Limiting Transducer: A Constraint-Rendering Model of Consciousness
Why it matters ◈ Mixed
This paper proposes a novel, testable model of consciousness that frames the brain as a constraint-rendering transducer rather than a generator of awareness, with 5-MeO-DMT as a key anchor for empirical predictions. The model's explicit predictions about neural and subjective dissociation under psychedelics could guide future experimental designs, especially for trials probing consciousness and memory. While the theory is speculative, its commitment to falsifiable outcomes and comparative pharmacological analysis makes it relevant for researchers exploring the neural correlates of psychedelic states and their implications for consciousness science.
The correlation between neural activity and conscious experience is well established, but the correlational record does not settle whether the brain produces consciousness or constrains it. This paper develops and formalizes a constraint-rendering alternative to production models. On this account the brain functions as a field-limiting transducer: it does not generate the substrate of awareness but imposes boundary conditions on a latent Consciousness Unit substrate, written |Ψ⟩, structuring it into the coherent, bounded, temporally sequenced experiential state |Φ⟩. The model is expressed compactly as |Φ⟩ = Σ_s A_s P_s B̂ |Ψ⟩, and the transducer operator B̂ is resolved into four testable functional roles: boundary formation, resonance stabilization, dimensional compression, and temporal sequencing. Because a model positing an unmeasured substrate risks absorbing any outcome, the account is committed in advance to four discriminating predictions, each stated with the result that would count against it: an ordered dissociation hierarchy among the functional roles, substrate invariance under extreme content loss, mode-specificity across pharmacological perturbations, and a reverse-ordered recovery on offset. The primary anchor case is 5-MeO-DMT, whose whiteout profile appears to dissolve world, body, space, time, and self while subjective experience may persist, and whose recently reported EEG signature — amplified but fractionated slow-wave activity, preserved alpha power, and a steepened rather than flattened energy landscape — is read against these predictions. The amnesia interpretation of that profile, that the whiteout is an ordinary blackout misremembered, is confronted directly as the principal competing account, and a comparative perturbation matrix (dissociatives, general anesthetics, antipsychotics, SSRIs, and an amnestic control) distributes the model's exposure across mechanisms. The argument is comparative and defeasible rather than demonstrative: the model earns consideration by making commitments a production account is not obliged to make and submitting them to the same evidence.
Clinical research Major review published

Landmark review: Phase 3 psilocybin, MDMA trial results, FDA rejection

[The use of psychedelics in psychiatry].
Why it matters ◈ Mixed
This review synthesizes the most advanced clinical trial evidence for psychedelic-assisted therapies, highlighting that while psilocybin has met primary endpoints in recent phase 3 trials, and MDMA has the largest phase 3 PTSD dataset, regulatory approval remains elusive due to methodological and ethical concerns. The field has moved beyond theory, but the certainty of evidence is still rated low, and both psilocybin and MDMA remain experimental. This underscores the need for more rigorous, larger, and longer-term studies before widespread adoption or regulatory change.
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of the field, the clinical evidence is still weak. Psilocybin produces consistent and often large improvements in major depressive disorder, yet in the most rigorous trials, the predefined primary endpoint does not always reach statistical significance. At the same time, a synthetic psilocybin (COMP360) met its primary endpoint in two phase 3 trials in 2025-2026, representing the most advanced regulatory evidence in the field to date. MDMA (3,4-methylenedioxymethamphetamine; "ecstasy")-assisted psychotherapy has the largest phase 3 dataset in post-traumatic stress disorder, but in 2024 the US Food and Drug Administration declined to approve the product on ethical grounds. Evidence for LSD (lysergic acid diethylamide) and ayahuasca in depressive and anxiety symptoms is considerably weaker and cannot yet be interpreted within an evidence-based medicine framework. The therapeutic use of psychedelics can no longer be regarded as merely a theoretical question or a subcultural movement: the clinical effect is consistent and, in several trials, markedly strong. Nevertheless, according to the international system grading the certainty of evidence, the level of certainty remains low or very low for several indications. The main reasons are practical unblinding, small sample sizes, trial heterogeneity, and a lack of long-term safety data. Despite encouraging phase 3 data, psilocybin and the classic psychedelics should be considered experimental treatments. For MDMA, the phase 3 results are promising but have not proven sufficient for regulatory approval. Orv Hetil. 2026; 167(37): 1461-1467.
International policy / Regulatory analysis US FDA approval anticipated

US FDA psychedelic approvals may pressure Japanese pharmacy, but no automatic change

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan
Why it matters ◈ Mixed
US FDA approval of psychedelic or psychedelic-adjacent therapies is likely to create regulatory, clinical, and professional pressures in Japan, but will not trigger automatic legal changes due to Japan's strict scheduling laws. Japanese pharmacists may face new demands for advanced counseling and drug interaction management, especially if ibogaine or similar agents gain global traction. The analysis highlights how international regulatory moves can indirectly shape national debates and professional practice, even in conservative jurisdictions.
An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These developments make FDA approval of at least one psychedelic or psychedelic-adjacent agent within a compressed timeframe a foreseeable regulatory event. The potential implications for pharmacy in Japan - a country with a highly structured drug classification and distribution system, culturally and legally embedded counseling obligations on pharmacists, and relatively conservative narcotics control legislation that directly schedules psilocybin, MDMA, LSD, and ibogaine - is an interesting question. This narrative review was prepared from published peer-reviewed literature in the English and Japanese languages identified through PubMed/MEDLINE, with supplemental journal searches, federal surveillance data, and published analyses of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). References were selected for relevance and recency (prioritizing 2020 - 2026). The US FDA approval of a psychedelic or psychedelic-adjacent agent would not trigger an automatic regulatory response in Japan, where all relevant compounds are already scheduled under the Narcotics and Psychotropics Control Act (2024 revision). However, three types of pressure would follow: regulatory pressure through the PMDA initiatives to reduce drug approval time; clinical pressure through Japanese psychiatrists and patients seeking novel therapies for treatment-resistant depression (TRD); and pressure on pharmacists because of legal requirements for drug interaction counseling, information on harm reduction options, and pharmacogenomic guidance. Ibogaine would present the most pharmacologically demanding scenario for Japanese pharmacy, requiring CYP2D6 metabolizer phenotype assessment (38-50% frequency of the reduced-function CYP2D6*10 allele in Japan), mandatory QT-prolonging drug interaction screening, and cardiac monitoring, all of which do not currently exist in community pharmacy settings. Over-the-counter (OTC) status for psychedelic and psychedelic-adjacent agents is legally, culturally, and regulatorily remote under current Japanese law, but the counseling role of the Japanese pharmacist (yakuzaishi, ) positions them as critical and uniquely qualified resources regarding psychedelic and psychedelic-adjacent products and for the drug interaction challenges that approval of these therapies in other countries would create.
FDA / DEA FDA guidance in effect

FDA issues July 2026 guidance on psychedelic drug trial design

What FDA’s July 2026 Psychedelic Drug Guidance Actually Says About Trial Design
Why it matters ▲ Favorable
The FDA’s July 2026 guidance on psychedelic drug trial design sets new standards for clinical research, clarifying regulatory expectations for endpoints, safety monitoring, and trial structure. This is a pivotal reference for sponsors, CROs, and investigators, and will likely accelerate the development and review of psychedelic therapies. The guidance also signals the FDA’s ongoing commitment to a science-driven, risk-managed approach, which may reduce legal ambiguity and encourage investment.
FDA / DEA FDA framework in effect

FDA’s New Psychedelic Framework: Implications for Clinics

What the FDA’s New Psychedelic Framework Actually Means for the Clinic
Why it matters ◈ Mixed
The FDA’s adoption of a new regulatory framework for psychedelic therapies marks a pivotal shift in how these substances will be evaluated, approved, and administered in clinical settings. This framework will directly impact research protocols, clinical trial design, and the pathway to patient access. Stakeholders—including researchers, clinicians, and industry operators—must now align with updated standards, which could accelerate or complicate the development and commercialization of psychedelic treatments.
Clinical research Review published

Review: Psilocybin's Mechanisms and Evidence in Chronic Pain Remain Preliminary

Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization
Why it matters ◈ Mixed
This comprehensive review finds psilocybin's analgesic potential in chronic neuropathic and centralized pain remains biologically plausible but clinically unproven. Preclinical models show mixed results and human data are limited to small pilots and case reports, with no definitive efficacy. The field requires rigorous, phenotype-specific randomized trials with active controls and biomarker endpoints to advance research and inform policy or clinical adoption.
Background/Objectives: Neuropathic and chronic centralized pain disorders remain difficult to treat because they involve central sensitization, maladaptive neuroplasticity, neuroimmune activation, affective amplification, and large-scale network dysfunction. Psilocybin, a serotonergic psychedelic acting primarily through 5-HT2A receptor agonism, has emerged as a candidate modulator of chronic pain states; however, clinical evidence remains preliminary. This review synthesizes preclinical, clinical, and mechanistic literature on psilocybin in chronic neuropathic and centralized pain, emphasizing biological plausibility, translational gaps, and future trial design. Methods: PubMed/MEDLINE, Google Scholar, bioRxiv, medRxiv, and targeted journal searches were reviewed through February 2026 and supplemented by reference screening. Thirty-seven peer-reviewed evidence sources were retained for mechanistic synthesis, and ClinicalTrials.gov records were reviewed separately to contextualize the registered clinical-trial landscape. Evidence was synthesized narratively because heterogeneity in study design, pain models, interventions, outcomes, and follow-up precluded meta-analysis. Results: Several preclinical studies reported psilocybin-associated reductions in allodynia, hypersensitivity, formalin-induced nociception, or pain-related affective behaviors in selected rodent models, with some effects linked to 5-HT2A signaling. However, findings were not uniform, and one rigorous null study found no immediate or persistent analgesic effect across multiple models. Human evidence remains limited and is primarily derived from one small open-label fibromyalgia pilot trial, case reports or case series, and survey studies, and has been summarized in recent systematic and narrative reviews. Collectively, these data remain insufficient to establish clinical efficacy. Four putative mechanistic domains were identified: descending serotonergic modulation, 5-HT2A- and TrkB/BDNF-related neuroplasticity, neuroimmune/microglial modulation, and affective-salience/default mode network reorganization. Conclusions: Psilocybin should not currently be regarded as an established analgesic. Available evidence supports a biologically plausible but clinically unproven model requiring phenotype-specific randomized trials with active controls, biomarkers, and long-term follow-up.
Clinical research Conceptual framework proposed

Framework urges equal focus on experience in psychedelic trials

Studying the Molecule, Assuming the Experience: The Pharmacology–Experience Asymmetry Framework for Psychedelic Research
Why it matters ◈ Mixed
This paper challenges the field to rigorously study and report experiential variables in psychedelic research, not just pharmacology. The proposed Pharmacology–Experience Asymmetry Framework (PEAF) highlights a longstanding methodological gap: most trials optimize and measure drug variables, but neglect structured, testable approaches to the experiential context. If adopted, this could reshape trial design, reporting standards, and ultimately, regulatory and clinical practice.
Abstract Contemporary models of psychedelic action hold that clinical outcomes arise from an interaction between a pharmacologically induced brain state and the lived experience that unfolds within it. Research effort is distributed very unevenly across those two domains: pharmacological variables receive dose-finding trials, power calculations, and effect-size estimates, while the variables that shape experience are frequently unreported, rarely manipulated, and almost never compared. I argue that this imbalance rests on a conceptual error about what is being administered, and propose that the object of psychedelic therapy is best understood as the pharmacologically scaffolded experience. On that basis I describe the Pharmacology–Experience Asymmetry and develop a framework (PEAF) built on six postulates: the intervention comprises two conceptually distinguishable components; therapeutic mechanisms span two partially differentiable domains; the elements that organize experience constitute a specifiable class of experiential inputs, with a taxonomy and a fixed-to-adaptive delivery axis; measurement effort is asymmetrically distributed between domains; several current conventions may represent crystallized methodological decisions rather than conclusions from comparative evidence; and investigative effort should be approximately proportional to the causal weight attributed to each domain. I distinguish experiential inputs, process, and outcomes, examine why the asymmetry has persisted for six decades, and address anticipated objections. Music serves as the illustrative case: a recent scoping review identified 19 papers from 10 studies across five decades, with one fully factorial design and one no-music arm, published in 1970. Five testable predictions are derived, including one that requires no new participants. Treating experiential inputs as tractable variables rather than uncontrolled background would allow psychedelic research to investigate them with methodological effort proportionate to the causal weight assigned to experience by its own mechanistic models.
Clinical research Framework published

Structured Framework for At-Home Racemic Ketamine Treatment Published

At-Home Racemic Ketamine Treatment: A Structured Framework for Preparation, Route-Specific Dosing, Monitoring, Rescue, Recovery, and Follow-Up
Why it matters ▲ Favorable
This publication provides a comprehensive, standardized protocol for at-home racemic ketamine therapy, addressing key safety, dosing, and monitoring considerations. The framework supports individualized, prescriber-directed care outside of infusion clinics, potentially expanding access and safety for patients with a range of psychiatric and existential conditions. Its adoption could influence best practices, inform regulatory standards, and shape the evolving at-home ketamine market. The emphasis on pre-session planning and route-specific protocols may reduce risks and improve outcomes in decentralized treatment models.
Ketamine is increasingly used in psychiatric and psychotherapeutic treatment through intravenous, intranasal, sublingual or buccal, and subcutaneous administration. Its therapeutic applications extend beyond formally diagnosed psychiatric disorders and include existential anxiety, persistent emotional distress, trauma-related suffering, psychological responses to serious illness or major life events, fear of mortality, loss of meaning, demoralization, and psychospiritual distress. Nonintravenous racemic ketamine is particularly suited to prescriber-directed treatment outside conventional infusion clinics because formulation, route, dose, treatment frequency, and degree of external support can be individualized. Large real-world cohorts already demonstrate structured at-home treatment through sublingual and subcutaneous administration. This paper develops a structured framework for at-home racemic ketamine treatment based on route-specific pharmacology, body-weight-normalized dose interpretation, patient-specific pharmaceutical preparation, initial treatment selection, standardized administration, pre-session physiological assessment, set and setting, route-specific monitoring, psychological and cardiovascular escalation criteria, management of nausea, predefined rescue procedures, functional recovery, post-session care, and systematic measurement of therapeutic outcome. The framework follows one operational principle: every clinically relevant decision that can be made before ketamine takes effect should be made before ketamine takes effect. Dose, formulation, maximum session exposure, timing, physiological thresholds, rescue medication, treatment environment, escalation criteria, and follow-up are therefore predetermined. This minimizes calculation, interpretation, and improvisation during the psychoactive period and converts home administration into a reproducible therapeutic process.
Clinical research Peer-reviewed study

DBS sensing reveals ketamine-linked SCC brain activity in depression

Chronic sensing during subcallosal cingulate deep brain stimulation captures ketamine-associated changes in major depressive disorder
Why it matters ▲ Favorable
This study provides the first direct human evidence that ketamine and affective states modulate the same SCC frequency bands, but with distinct temporal and spectral patterns. The findings support the development of adaptive DBS protocols that respond dynamically to both pharmacologic and emotional brain signals, rather than relying on static thresholds. This could inform future clinical trial design and personalized neuromodulation strategies for treatment-resistant depression, with implications for both research and device-based interventions.
Ketamine and subcallosal cingulate (SCC) deep brain stimulation (DBS) have each shown antidepressant effects in treatment-resistant depression, yet how ketamine modulates SCC physiology during chronic stimulation remains poorly understood. We analyzed 5,907 hours of bilateral SCC sensing, 485 participant-triggered recordings across 193 days, 47 ketamine dosing episodes, and an in-clinic session. Across naturalistic and in-clinic recordings, ketamine was associated with a convergent bilateral shift toward 21-40 Hz fast-band activity. Post-dose snapshots showed lower aperiodic-adjusted 5-20 Hz power and higher 21-40 Hz power, while 23.44 Hz activity increased bilaterally after administration. Longitudinal 23.44 Hz tracking revealed larger bilateral increases around anxious and sad events, beginning before self-report and peaking approximately 15 minutes later, smaller decreases after neutral and happy events, and smaller lateralized changes around dosing, despite limited spectral separation between affective states at event onset. These findings provide direct human evidence that ketamine exposure and affective states can engage the same SCC frequency range with distinct spectral and temporal expressions. This positions SCC fast-band activity as a context-dependent signal whose interpretation may depend on its magnitude, laterality, and time course, motivating adaptive DBS strategies that decode evolving SCC dynamics rather than rely on simple band-power thresholds.
Federal immigration policy Rule proposed

DHS proposes ending 60-day grace period for nonimmigrant workers

Eliminating the Discretionary 60-Day Grace Period
Why it matters ▼ Unfavorable
The Department of Homeland Security's proposal to eliminate the 60-day grace period for certain nonimmigrant visa holders could impact the ability of foreign researchers, clinicians, and industry professionals in the psychedelic field to remain in the US after job loss. This change may increase legal and logistical risks for international talent working in US-based psychedelic research and startups. Organizations relying on nonimmigrant staff should monitor this policy closely and prepare for potential workforce disruptions.
The Department of Homeland Security (DHS) proposes to remove regulations at 8 CFR 214.1(l)(2) to restore its previous and long- standing policy of not providing aliens in certain nonimmigrant classifications (and their dependents) with an up to 60-day grace period upon cessation of employment prior to the expiration of the alien's authorized period of stay. This proposal restores a direct relationship between an alien's nonimmigrant status and the specific employment or activity that formed the basis of his or her admission or grant of status in the United States and reduces administrative burden.
Epidemiology / Social science Published study

Psychedelic use linked to pro-environmental attitudes, vegetarian diets in UK cohorts

Lifetime classic psychedelics use is associated with positive environmental attitudes and adopting a vegetarian diet
Why it matters ▲ Favorable
This large observational study finds associations between lifetime classic psychedelic use and both pro-environmental attitudes and vegetarian dietary choices in UK adults. While causality cannot be established, the findings add to a growing literature on the broader psychosocial and behavioral correlates of psychedelic use. These results may inform future research on the societal impacts of psychedelic experiences, but have limited immediate implications for legal risk, clinical access, or market structure.
While some studies suggest that psychedelic use may be linked to positive environmental attitudes and health behaviors, the relationship between these factors remains underexplored. This study investigates the associations between lifetime use of psilocybin and LSD, environmental attitudes, and dietary behaviors using data from two UK birth cohort studies: the 1958 National Child Development Study and the 1970 British Cohort Study. Data on these variables were collected in 2000, when participants were aged 42 and 30, respectively ( N = 21,837−21,855). Findings indicate that individuals who had used psilocybin or LSD at least once in their lifetime were more likely to endorse pro-environmental attitudes (Spearman r = .09, p < .001) and adopt a vegetarian diet (adjusted OR 1.44–1.48, p < .013). Past psilocybin users show a healthier dietary profile, including eating more salads and raw vegetables, fewer biscuits and cakes, and less red meat. As hypothesized, the link between psychedelic use and vegetarian diets was partially mediated by pro-environmental attitudes. The results of this retrospective observational study suggest that psilocybin and LSD use may promote positive environmental attitudes, which could, in turn, be associated with a greater likelihood of adopting a vegetarian diet.
Neuroscience Peer-reviewed study

New computational model challenges cardiac interoception measures

Cardiac belief updating from volatile physiological afferents
Why it matters ◈ Mixed
This study questions the validity of widely used cardiac interoception tasks and introduces a new computational framework for quantifying belief updating from physiological signals. While not directly about psychedelics, this work is relevant for psychedelic research that uses interoceptive measures as endpoints or mechanistic readouts, suggesting the need for more rigorous or alternative approaches. The findings may impact how future clinical trials in the field assess mind-body interactions.
Cardiac interoception is commonly assessed by comparing subjective estimates of heart rate with physiological measurements. But beliefs can easily obscure these measures, such that they cannot readily distinguish sensitivity to afferent signals from the influence of prior expectations; this ultimately challenges the notion that behaviours under these tasks could reflect interoceptive processes at all. Here, we develop a computational framework that uses naturally occurring heart rate variability to quantify how strongly perceptual beliefs are updated by physiological evidence. We formalise interoception as weighted Bayesian updating under the joint influence of expectations and afferents, and derive a new measure, cardiac interoceptive sensitivity, that quantifies the extent to which beliefs move with incoming signals. Applying this to the largest Heart Rate Discrimination dataset to date (n=549), a task providing robust estimates of cardiac beliefs, we find that sensitivity is weak in the healthy population, but shows large interindividual differences, with 43% of the participants exhibiting behaviours at least minimally compatible with interoceptive processing. These findings challenge the interpretation of conventional measures of cardiac interoception. They also introduce a new framework to relate bodily signals that cannot be controlled experimentally to external signals that can, laying a computational foundation for embodied psychophysics.
Clinical research Peer-reviewed study

Temporal RT dynamics in BDIAT predict active suicidality with 77% accuracy

Predicting Active Suicidality from Temporal Dynamics of Implicit Life-Death Associations
Why it matters ▲ Favorable
This study identifies temporal reaction time features in the Brief Death Implicit Association Test as a promising behavioral marker for near-term suicide risk, outperforming traditional scoring methods. While not directly related to psychedelics, improved suicide risk detection is highly relevant for clinical trials and patient safety in psychedelic research, where suicidality is a key exclusion and monitoring criterion. The findings may inform better screening and monitoring protocols in future psychedelic-assisted therapy studies.
Background: Interview-based suicide assessments are insufficient for near-term risk detection, but there are no evidence-based, high-performing alternatives. The Death Implicit Association Test (DIAT) has been proposed as a suicide risk assessment tool. However, traditional DIAT scoring methods exhibit limited association with suicidality. Methods: We tested whether temporal structure in reaction times (RTs) from the Brief Death Implicit Association Test (BDIAT) tracks active suicidal ideation (SI), which was ascertained by ecological momentary assessment (EMA). Seventy-seven participants who either did or did not endorse active SI during EMA (SI+ n=22; SI− n=55) completed 18 alternating blocks of the BDIAT (9 Life + Me, 9 Death + Me). We computed the conventional D-score, an aggregate index of self-life versus self-death associations, and separately treated RTs as time-varying signals, examining entrainment to block alternation and habituation during conflict-related trials. We then developed a bilinear logistic regression classifier to extract these temporal RT features and trained it to predict SI status, with performance validated using leave-one-out cross-validation. Results: The conventional D-score did not reliably classify SI+/SI- individuals. In contrast, temporal RT dynamics reveal group differences in block-level entrainment and trial-level habituation. A bilinear logistic regression classifier leveraging these dynamics predicts SI status with 77% balanced accuracy and AUC 0.799. Conclusions: Results demonstrate that temporal dynamics of RT during the BDIAT track active ideation and can be used to distinguish SI status at the individual level, implicating RT temporal dynamics evoked during BDIAT as a candidate behavioral marker of near-term suicide risk.
Clinical research Peer-reviewed study published

Global study links SIB in psychosis-risk youth to depression, not core psychosis

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms
Why it matters ◈ Mixed
This large, multinational study finds that suicidal ideation and behaviors among youth at high risk for psychosis are more closely tied to depressive symptoms, cannabis use, and socio-occupational factors than to core psychosis-risk symptoms. The findings suggest that interventions targeting depression and functional impairment may be more effective in reducing suicide risk in this population than those focused solely on psychosis prevention. For psychedelic research, this underscores the importance of addressing comorbid depression and substance use in trial design and patient selection.
ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold psychotic symptom severity increases with suicidal risk. Methods Data from the AMP SCZ initiative included 1443 CHR‐P participants aged 12–30 years. SIB were assessed using the Columbia Suicide Severity Rating Scale (C‐SSRS). Three Elastic Net regression models examined associations between suicidal ideation severity, intensity, and behaviors using 54 variables spanning sociodemographics, general psychopathology, subthreshold psychotic symptoms, and socio‐occupational functioning. Moreover, ANCOVA compared overall psychotic symptom severity across five groups defined by increasing severity on the C‐SSRS. Results Sixty‐eight percent of participants reported lifetime suicidal ideation, and 26% reported previous suicidal behaviors. Model performance was modest but significant (cross‐validated ideation severity: R 2 = 0.161, RMSE = 0.916; ideation intensity: R 2 = 0.193, RMSE = 0.898; suicidal behavior: accuracy = 0.685; AUC = 0.675; p < 0.001). Across all models, concurrent depressive symptoms, present/past diagnosis of depression, female sex at birth, cannabis use, visual/gustatory abnormalities, guilt, and lower role functioning were the most consistent correlates of SIB. Ideation was associated with lower disorganized communication expression and lower negative symptoms, whereas behaviors were associated with schizotypal personality disorder. Other core CHR‐P symptoms, including Unusual Thoughts and Experiences, did not contribute to any model. ANCOVA ( p < 0.001, partial η 2 = 0.041) indicated increasing overall subthreshold psychotic symptoms across the SIB spectrum. Conclusion SIB in CHR‐P individuals reflects a multidimensional clinical profile primarily outside of core psychosis‐risk symptoms. Trial Registration: ClinicalTrials.gov identifier: NCT05905003
Clinical research Peer-reviewed study published

Esketamine reduces early postoperative anxiety/depression in colorectal surgery

Effects of Esketamine on Postoperative Hospital Anxiety and Depression Scale Scores in Patients Undergoing Laparoscopic Radical Resection for Colorectal Cancer
Why it matters ▲ Favorable
This randomized controlled trial finds that intravenous esketamine reduces early postoperative anxiety and depression scores and improves patient satisfaction in colorectal cancer surgery patients. The results support the potential utility of esketamine for perioperative mental health management, expanding its evidence base beyond treatment-resistant depression. While not a regulatory or legal change, the study is material for clinicians and researchers exploring ketamine’s broader applications.
OBJECTIVE: To investigate the effects of intravenous esketamine on postoperative Hospital Anxiety and Depression Scale (HADS) scores in patients undergoing laparoscopic radical resection for colorectal cancer. METHODS: In this prospective, randomized, placebo-controlled study, adult patients for elective laparoscopic radical resection were randomly assigned (1:1) to a control group (group C) or an esketamine group (group PE). Group C received conventional general anesthesia and patient-controlled intravenous analgesia (PCIA). In group PE, esketamine 0.5 mg/kg was injected during induction of anesthesia, with esketamine 1 mg/kg added to PCIA. Primary outcome was HADS score on postoperative day 1. Secondary outcomes included HADS scores on postoperative days 3 and 7, sleep quality scores, postoperative level of consciousness, complication rate, length of hospital stay, 24 h inflammatory factors, and satisfaction scores. RESULTS: < 0.05). CONCLUSIONS: Esketamine given during induction and in PCIA reduced early-stage postoperative HADS scores and improved patient satisfaction in colorectal cancer patients.
Clinical research Narrative review published

Review: Ketamine/esketamine's rapid effects on suicidality remain inconsistent

EFFECTS OF KETAMINE AND ESKETAMINE ON SUICIDAL IDEATION WITHIN THE FIRST 24 HOURS IN ADULTS WITH DEPRESSIVE DISORDERS: VARIABILITY IN CLINICAL FINDINGS AND INTERPRETATIVE CHALLENGES - A NARRATIVE REVIEW
Why it matters ◈ Mixed
This narrative review synthesizes two decades of studies on ketamine and esketamine for rapid reduction of suicidal ideation in adults with depression, highlighting inconsistent findings and interpretative challenges. While intravenous ketamine may reduce suicidality in some cases, intranasal esketamine shows clearer effects on depressive symptoms than on suicidality itself. The review underscores the need for standardized outcome measures and longer-term follow-up, signaling ongoing uncertainty for clinicians and researchers regarding these interventions' acute anti-suicidal efficacy.
Background: Ketamine and esketamine have been studied as rapid-acting interventions in adults with depressive disorders and suicidal ideation, but findings vary across populations, settings, comparators, routes, and outcome measures. Aim: To examine their effects on suicidal ideation within the first 24 hours and to identify factors contributing to variability across studies. Methods: This narrative review used a structured PubMed and Scopus search for English-language studies published from January 2000 through April 30, 2026. Clinical trials and relevant secondary studies were considered. No formal risk-of-bias assessment or quantitative synthesis was performed. Results: Intravenous ketamine studies reported rapid reductions in suicidal ideation, although findings were inconsistent. One midazolam-controlled trial showed a 4.96-point greater reduction in the Scale for Suicide Ideation score at 24 hours, whereas another found no significant difference in the primary Beck Scale for Suicide Ideation outcome. Intranasal esketamine added to intensive standard-of-care treatment improved depressive symptoms at 24 hours, but clinician-rated suicidality did not differ significantly between groups in either ASPIRE trial. Conclusions: Intravenous ketamine may rapidly reduce suicidal ideation in selected adults. Intranasal esketamine has shown clearer early effects on depressive symptoms than on suicidality-specific outcomes. Standardized measures and longer follow-up are needed.
Clinical research Published dissertation

Biomarkers and predictors for neuromodulation in treatment-resistant depression

Predictors and neurophysiological biomarkers of response to neuromodulatory interventions in treatment-resistant depression
Why it matters ▲ Favorable
This dissertation identifies clinical, demographic, and neurophysiological predictors of response to rTMS and esketamine in treatment-resistant depression, using machine learning and survival analysis. Findings support the value of multimodal, data-driven approaches for personalized treatment selection in TRD, advancing the precision psychiatry paradigm. While not directly about psychedelics, the work is relevant for those developing or researching novel interventions (including psychedelic therapies) for TRD, as it highlights the importance of individualized predictive frameworks and real-world data.
Rationale: Treatment-resistant depression (TRD) poses a significant challenge in psychiatry, characterized by the persistence of symptoms despite multiple treatment attempts. Approximately 30-50% of patients with major depressive disorder (MDD) do not achieve adequate response from first-line interventions, leading to TRD. This underscores the urgent need for novel interventions and personalized treatment strategies. Neuromodulatory treatments such as repetitive transcranial magnetic stimulation (rTMS) and esketamine have emerged as promising options, yet considerable heterogeneity in treatment outcomes underscores the urgent need for robust, individualized predictive frameworks. This dissertation aimed to enhance understanding of response in TRD by integrating clinical, demographic, and neurophysiological predictors across three complementary studies.Study 1 (published) aimed to identify clinical and demographic predictors of rTMS treatment response in TRD. This retrospective study utilized electronic medical records from UC San Diego and included 232 TRD patients who received rTMS. Machine learning models were trained to predict treatment response and remission. Key predictors included comorbid anxiety disorder, former tobacco use, obesity, comorbid trauma disorder, antipsychotic use, benzodiazepine use, protocol type, and number of rTMS sessions. Study 2 employed survival analyses to compare temporal response trajectories between rTMS and esketamine, revealing distinct profiles: esketamine was associated with more rapid response and remission, while rTMS demonstrated a slower but steady trajectory that was significantly influenced by patient-specific factors, such as comorbidity burden, treatment protocol type, and number of sessions. Study 3 explored the cortical silent period (CSP) as an exploratory neurophysiological marker of response, revealing preliminary and inconsistent associations with symptom change. These findings suggest CSP warrants further study within broader multimodal predictive frameworks.Conclusions and Clinical Implications: These studies converge to support the value of a multimodal, data-driven approach to treatment prediction in TRD. The integration of machine learning, survival analysis, and neurophysiological data contributes to a more nuanced understanding of patient-specific treatment pathways. Findings underscore the limitations of single-domain predictors and reinforce the promise of personalized treatment selection grounded in real-world, ecologically valid data. This work advances the precision psychiatry paradigm and lays a foundation for future prospective validation of predictive models capable of informing clinical decision-making in TRD.
Clinical research Pilot trial analysis published

Therapeutic alliance and closeness in MDMA-AT for social anxiety studied

Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder
Why it matters ▲ Favorable
This pilot analysis provides early empirical evidence that perceived closeness between therapist and patient during MDMA-assisted therapy sessions is a dynamic and sensitive predictor of clinical outcomes for social anxiety disorder. The findings highlight the importance of relational processes—distinct from general therapeutic alliance—in optimizing MDMA-AT protocols. While the sample is small and open-label, this work informs future trial design and therapist training, and may help refine outcome measures for regulatory and clinical adoption.
The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and perceived closeness during an open-label pilot trial of MDMA-AT for SAD (N = 20; NCT-redacted-for-anonymous-review). Participants completed three preparation sessions, two MDMA dosing sessions, and six integration sessions. Therapeutic alliance and therapist closeness were assessed before and after each MDMA session using the Agnew Relationship Measure and Inclusion of Other in the Self Scale, respectively. Social anxiety severity was assessed with the Liebowitz Social Anxiety Scale at baseline and post-treatment, and self-transcendent experiences were assessed following MDMA sessions. Alliance was high after preparation and increased significantly following the first MDMA session, with evidence of ceiling effects later in treatment. Closeness increased significantly during each MDMA session and decreased during the subsequent nondrug interval. Greater MDMA-session closeness predicted lower post-treatment social anxiety, including after adjustment for corresponding pre-MDMA closeness. Self-transcendent emotions and connection-related experiences were associated with greater MDMA-session closeness, and pre-dosing closeness predicted greater self-transcendent emotions during the subsequent MDMA session. These findings distinguish more stable therapeutic alliance from more dynamic felt interpersonal closeness and suggest that closeness may be a particularly sensitive relational process in MDMA-AT for SAD.
FDA / DEA Breakthrough Therapy granted

Psilocybin gains second FDA Breakthrough Therapy for chemo-induced nerve pain

Psilocybin may help prevent chemo-induced nerve pain; Definium scores second FDA Breakthrough Therapy designation
Why it matters ▲ Favorable
Definium's psilocybin program earning a second FDA Breakthrough Therapy designation signals strong preliminary evidence for efficacy in preventing chemotherapy-induced neuropathy, a major unmet need. This status accelerates development and review, potentially speeding patient access and attracting investment. It also broadens the clinical use-case for psilocybin beyond mental health, raising the profile of psychedelic medicine in mainstream drug development. Researchers and industry should monitor for pivotal trial launches and regulatory guidance.
Clinical research Systematic review published

Systematic review: Psilocybin mechanisms & efficacy in depression

Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.
Why it matters ▲ Favorable
This systematic review synthesizes current evidence on psilocybin's clinical efficacy and underlying neurobiological mechanisms in depression treatment. The findings offer a comprehensive update for clinicians, researchers, and policymakers on the therapeutic potential and mechanistic rationale for psilocybin in mood disorders. This review may inform future trial design, regulatory decisions, and clinical guidelines as the field moves toward broader access and integration of psychedelic therapies.
Neuroscience Preclinical study published

Psilocybin improves spatial memory in Alzheimer's rat model, not neural synchrony

Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease.
Why it matters ◈ Mixed
This preclinical study shows psilocybin can restore spatial memory in a rat model of Alzheimer's disease, but does not normalize fronto-hippocampal synchrony. The findings suggest cognitive benefits are possible even without full restoration of neural network dynamics, informing future translational research. While not directly actionable for policy or clinical access, this adds mechanistic evidence supporting further investigation of psychedelics for neurodegenerative disorders.
Clinical research Peer-reviewed study

Study: Ketamine non-responders in TRD show distinct life engagement patterns

Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.
Why it matters ◈ Mixed
This study identifies clinical characteristics of patients with treatment-resistant depression (TRD) who do not experience improved life engagement after ketamine treatment. The findings highlight the need for better patient stratification and may inform future trial design, clinical protocols, and payer criteria. Understanding non-responder profiles is crucial for optimizing ketamine's therapeutic use and for guiding policy on coverage, access, and informed consent.
Industry Training program announced

Clinician training program announced for COMP360 psilocybin therapy

New certificate program to train clinicians for COMP360 psilocybin treatment if FDA approved
Why it matters ▲ Favorable
A new clinician certificate program is being launched to prepare providers for COMP360 psilocybin treatment, contingent on future FDA approval. This signals growing industry and clinical infrastructure in anticipation of possible regulatory clearance, and may accelerate patient access and provider readiness if approval is granted. The move also reflects increasing professionalization and standardization in psychedelic-assisted therapy.
Industry Pipeline expansion announced

EPIK Biosciences advances ketamine/DXM combos, files 34 provisional patents

EPIK Biosciences Advances Combination Medicines Across Ketamine-Based and DXM-Based Programs, Supported by 34 Provisional Drug Patent Applications
Why it matters ▲ Favorable
EPIK Biosciences' announcement of 34 provisional patent applications for combination medicines across ketamine- and dextromethorphan-based programs signals intensifying competition in psychedelic and dissociative medicine IP. While the clinical stage and regulatory path are not detailed, such filings may influence future market exclusivity, licensing, and investment trends. Operators and researchers should monitor for clinical trial initiations and potential patent thickets that could affect access and innovation.
Clinical research Qualitative study published

Qualitative study: Black Americans' substance use treatment experiences

Exploring the Lived Experience of Black Americans and Substance Use Treatment: Structural, Community, and Individual Factors
Why it matters ▲ Favorable
This study highlights the importance of culturally specific, multilevel approaches to substance use treatment for Black Americans, identifying both structural barriers and protective community factors. While not directly focused on psychedelics, its findings are relevant for designing inclusive psychedelic-assisted therapy protocols and improving access for marginalized populations. The research underscores the need for providers with shared lived experience and culturally competent care, which could inform future clinical trial design and policy.
Abstract Despite decades of research on substance use, the unique experiences of Black Americans remain underexamined and often fragmented across subgroups and substance types. Existing studies have shed light on how racism shapes substance use patterns within certain populations, yet they leave critical gaps in understanding the broader landscape of risk, resilience, and treatment among Black communities. The purpose of this study was to fill that gap by exploring the lived experiences of Black adults with substance use histories to identify risk, protective, and treatment factors associated with alcohol and drug use. Qualitative interviews were conducted with 18 Black adults, and rapid qualitative coding and thematic analysis were used to evaluate the interview data. Risk factors were represented by themes addressing psychosocial and structural catalysts for initial substance use (Theme 1) and race-related stressors that increased substance use (Theme 2). The primary protective factor identified was Black collectivism (Theme 3). Prominent treatment themes included therapeutic rapport with the substance use provider: Black providers and lived experience with substance use (Theme 4), the utility of coping skills and group therapy (Theme 5), and factors that facilitate and impede Black substance use treatment participation (Theme 6). This qualitative study provides clinical and empirical guidance for developing culturally specific, multilevel approaches to address substance use in Black American communities.
Clinical research Phase 2 trial announced

Phase 2 trial of psilocybin therapy for MDD to begin in 2027

New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Why it matters ▲ Favorable
A new Phase 2 clinical trial for psilocybin-assisted therapy in major depressive disorder is set to launch in 2027. This signals continued scientific and clinical interest in psilocybin for mental health, and may provide further data to inform regulatory and payer decisions. While not yet a pivotal trial, the announcement reflects ongoing momentum in the field and could influence future access and investment.
FDA / DEA FDA policy announcement

FDA to consider ‘innovative approaches’ to psychedelic drug development

Why it matters ▲ Favorable
The FDA's announcement signals a willingness to adapt regulatory frameworks for psychedelic drug development, potentially lowering barriers for research and accelerating clinical translation. This could improve the pace of approvals, expand access to clinical trials, and clarify the agency's stance for sponsors and investors. Stakeholders should monitor for concrete guidance or pilot programs that may follow.
FDA / DEA FDA framework in effect

FDA issues new regulatory framework for psychedelic drugs

FDA's New Framework for Psychedelic Drugs.
Why it matters ▲ Favorable
The FDA's new framework for psychedelic drugs establishes clear regulatory pathways for clinical research, approval, and post-market oversight of psychedelic therapies. This landmark policy provides much-needed guidance for sponsors, clinicians, and researchers, reducing legal ambiguity and accelerating innovation in the field. It is expected to facilitate expanded access to investigational treatments and shape the commercial landscape for psychedelic medicines in the US.
Neuroscience Preclinical study published

Psilocybin restores memory but not neural synchrony in Alzheimer's rat model

Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease
Why it matters ◈ Mixed
This preclinical study shows that psilocybin can reverse spatial memory and learning deficits in a rat model of Alzheimer's disease, but does not restore fronto-hippocampal synchrony, a neural correlate of cognitive function. The dissociation between behavioral improvement and electrophysiological outcomes suggests complex mechanisms and highlights the need for further research with larger cohorts and improved neural metrics. These findings are relevant for translational research but do not yet support clinical application or policy change.
BACKGROUND: Fronto-hippocampal desynchronization is linked to cognitive decline in Alzheimer's-like pathology, but whether psilocybin can restore this dysfunction is unknown. METHODS: Male rats received intracerebroventricular streptozotocin (ICV-STZ) to induce neurotoxicity, followed by a single dose of psilocybin (2.5mg/kg, the maximum tolerated dose). Spatial memory, recognition memory, spatial learning, anxiety-like behavior, and depressive-like behavior were assessed (Y-maze, novel object recognition, Barnes maze, elevated plus maze, forced swim test), alongside resting-state local field potentials from the prefrontal cortex and hippocampus. RESULTS: ICV-STZ impaired spontaneous alternation and Barnes maze learning (both p<0.01), without affecting anxiety-like behavior or locomotion. Novel object discrimination index showed a similar but non-significant pattern (p=0.155). Forced swim test immobility was numerically higher after ICV-STZ but not significantly different from Control (p=0.068); psilocybin significantly reduced immobility versus STZ (p<0.001) and normalized alternation and escape latency to control levels. Spectral power, coherence, and cross-correlation did not differ significantly among groups at most sessions and bands (p>0.08), except one elevated mPFC-ventral hippocampal correlation in STZ animals (p=0.029, small cohort), not replicated with psilocybin. CONCLUSION: A single psilocybin dose reversed spatial memory and learning deficits and reduced depressive-like immobility, without altering anxiety-like behavior or locomotion, but this behavioral rescue was not accompanied by a robust electrophysiological signature. This dissociation warrants replication using larger, artifact-robust cohorts and reference-free connectivity metrics.
FDA / DEA FDA guidance announced

FDA signals regulatory flexibility for psychedelic assessment

FDA suggests regulatory flexibility for assessing psychedelics
Why it matters ▲ Favorable
The FDA's suggestion of regulatory flexibility for assessing psychedelics signals a significant shift in how these substances may be evaluated for medical use. This could lower barriers for clinical trial design, accelerate drug development timelines, and improve access for researchers and sponsors. The move is likely to encourage investment and innovation in the psychedelic sector, while also shaping future standards for evidence and safety.
Clinical research Phase 2 trial announced

Optimi Health to run 200-patient Phase 2 psilocybin depression trial

Optimi Health to run 200-patient Phase 2 trial of natural psilocybin for major depressive disorder
Why it matters ▲ Favorable
A 200-patient Phase 2 trial of natural psilocybin for major depressive disorder signals growing industry commitment to large-scale clinical research. This study could generate pivotal safety and efficacy data for natural (not synthetic) psilocybin, relevant for both regulatory pathways and future market entrants. The trial’s size and focus on a major indication may influence investor confidence, access debates, and the design of subsequent pivotal trials.
FDA / DEA FDA framework announced

FDA unveils psychedelic drug framework in NEJM

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
Why it matters ▲ Favorable
The FDA's public release of a psychedelic drug framework in the New England Journal of Medicine signals a pivotal shift for the field, providing regulatory clarity for researchers, sponsors, and clinicians. This move is likely to accelerate clinical development, guide state and federal policy, and shape investment and care models. Stakeholders should closely review the framework's details to understand new standards for trial design, safety, and access.
Clinical research Phase 2 trial announced

Optimi Health announces 200-person psilocybin depression trial

A 200-person psilocybin depression trial is coming from Optimi Health (OPTH); here’s when and where
Why it matters ▲ Favorable
A 200-participant psilocybin trial for depression signals growing industry and research momentum. Optimi Health’s planned study could generate valuable safety and efficacy data, supporting both regulatory and commercial pathways for psilocybin therapies. The trial’s scale is notable for a private sponsor, reflecting increased investment and confidence in psychedelic medicine. Researchers and clinicians should monitor for protocol details and site selection.
Industry Training partnership announced

Fluence to Develop COMP360 Provider Training for Compass Pathways

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Why it matters ▲ Favorable
Compass Pathways' selection of Fluence to develop post-approval provider training for COMP360 signals preparations for potential market entry and clinical rollout of psilocybin therapy. This partnership addresses a critical bottleneck—qualified provider training—necessary for safe, scalable access if COMP360 receives regulatory approval. The move highlights the industry's focus on infrastructure and workforce development, which will directly impact patient access and the pace of clinical adoption.
Clinical research Model proposed

Active Deep Dive Therapy: New model for MDMA-assisted psychotherapy

Active deep dive therapy (ADDT): A theoretically grounded model for MDMA-facilitated free-associative psychotherapy
Why it matters ▲ Favorable
This paper introduces a novel, theoretically grounded model for MDMA-facilitated psychotherapy, emphasizing active free association and integrative unconscious processing. ADDT departs from prevailing non-directive approaches by proposing a more engaged therapeutic stance, potentially expanding clinical applications for severe and treatment-resistant conditions. While conceptual, the model could inform future clinical trial designs and patient selection criteria, shaping the evolution of psychedelic-assisted therapy frameworks.
Abstract Background The MDMA-assisted therapy landscape has been dominated by mostly holding-oriented, non-directive models. These approaches prioritize containment of the MDMA experience but leave largely unexploited the unique window of accessibility to unconscious material that MDMA creates. Objective This paper presents Active Deep Dive Therapy (ADDT), a theoretically grounded model for MDMA-facilitated psychotherapy that integrates psychoanalytic free-associative technique with insights from Ericksonian hypnosis, neuroscience, and an integrative topology of the unconscious. Method Conceptual analysis drawing on established frameworks across clinical traditions and neuroscience. Core Propositions ADDT rests on three central propositions: (1) MDMA as a pharmacological agent hypothesized to increase the permeability of the conscious-unconscious boundary, thereby facilitating access to the Repressed Unconscious — though this core requirement, sustained dialogue during a pharmacologically loosened state, may not be specific to MDMA (see Discussion); (2) free association as the primary therapeutic technique, with the therapist actively following and deepening patient-generated material without injecting content; and (3) a transdiagnostic selection principle, proposed here as a hypothesis for future testing, based on therapeutic contact quality and introspective capacity rather than DSM categories. Three sequential phases are described: preparation (including preconscious priming), the active substance session, and integration. Conclusions ADDT offers a distinct theoretical identity within the expanding field of psychedelic-assisted therapy. Its active therapeutic stance and grounding in integrative models of the unconscious open new clinical territory for severe and treatment-resistant suffering.
Clinical research / Policy Recommendations published

European multidisciplinary recommendations on clinical psychedelic use

A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances.
Why it matters ▲ Favorable
This consensus statement signals growing European alignment on clinical standards for psychedelic use, offering a framework for safe, evidence-based integration into mental health care. The recommendations, developed by a multidisciplinary panel, may inform national policies, guide clinical trial design, and shape regulatory pathways across EU member states. Researchers and policymakers should note the emphasis on multiprofessional oversight and harmonized protocols, which could accelerate cross-border studies and access initiatives.
Clinical research Perspective published

Perspective: Removing subjective effects from psychedelics may undermine efficacy

Why taking the trip out of psychedelic medicine is a mistake.
Why it matters ◈ Mixed
This perspective argues that attempts to separate the subjective 'trip' from the therapeutic effects of psychedelics may compromise their clinical efficacy. The article challenges ongoing efforts to develop non-hallucinogenic analogs or protocols that minimize the acute experience, urging researchers and policymakers to consider the importance of subjective effects in therapeutic outcomes. This has implications for trial design, regulatory pathways, and insurance reimbursement, as it questions the assumption that the psychedelic experience is an unwanted side effect rather than a core mechanism of action.
Clinical research Preprint posted

Two-Threshold Model Explains Psilocybin Response Variability in TRD

A Two-Threshold Model of Psilocybin Response Explains Variability in Psychedelic-Assisted Therapy for Treatment-Resistant Depression
Why it matters ◈ Mixed
This preprint proposes a new model to explain why patients with treatment-resistant depression respond differently to psilocybin-assisted therapy. While not yet peer-reviewed or cited, the work could inform future trial design and patient selection criteria. Its impact will depend on subsequent validation and uptake by clinical researchers.
Clinical research Peer-reviewed response

Ketamine vs. alternatives for haemodynamic stability in critical intubation

Ketamine versus alternate agents to prevent postinduction haemodynamic instability during tracheal intubation of critically ill adults. Response to Br J Anaesth Advance Access published on Jul 20, 2026, doi: 10.1016/j.bja.2026.05.034.
Why it matters ◈ Mixed
This peer-reviewed correspondence addresses the comparative efficacy of ketamine versus other agents in preventing haemodynamic instability during tracheal intubation in critically ill adults. While not a new trial, such responses influence clinical practice by clarifying interpretation of recent research and may inform future protocol design. For psychedelic medicine stakeholders, this underscores ketamine’s ongoing evaluation in acute care, which can impact its risk-benefit profile and regulatory perception outside of psychiatric indications.
Ethics / Market trends Critical commentary

Critique: Removing 'trip' from psychedelics risks losing core therapeutic value

Why taking the trip out of psychedelic medicine is a mistake
Why it matters ◈ Mixed
This article critically examines the trend toward developing 'non-hallucinogenic' psychedelics, warning that removing the subjective experience from psychedelic therapy may undermine both its therapeutic efficacy and its broader social value. The authors argue that pharmaceutical approaches focused on scalability and standardization risk missing the relational and ecological dimensions central to psychedelic benefits. This perspective is important for researchers, clinicians, and industry stakeholders considering the future direction of psychedelic medicine and its integration into healthcare systems.
A 2022 article in Nature proclaimed the possibility of "Taking the tripping out of psychedelic medicine," highlighting efforts to engineer medically-compliant designer psychedelics purportedly delivering mental health benefits without inducing subjective experiences. Such developments have since initiated a new mainstream in the pharmaceuticalization and commodification of psychedelics. These so-called 'psychoplastogens' streamline drugs to maximize scalability, standardization, and compatibility with medical and economic infrastructures. Yet stripping psychedelics of their phenomenological core, risks eliminating their most transformative therapeutic and societal effects. Drawing on 'ecodelics,' i.e., psychedelics understood as agents of relational and ecological attunement, we assess biochemical reductionist framings of psychedelic medicine, foregrounding the crucial role of set, setting, and social context (matrix). The pharmaceuticalization of psychedelics risks narrowing these substances to individualized biochemical interventions, sidelining the relational, ecological, and transformative dimensions through which they exert their broader therapeutic and societal benefits. Psychedelics' capacity to foster connectedness - to self, community, and nature - cannot be engineered out without consequence. We argue that the pharmaceutical turn in psychedelic science, while motivated by scalability and safety (and profit), indicates a deeper category error: treating subjective experience as pathological noise rather than as the principal mechanism of action. We argue for reintegrating psychedelics into relational, communal, and ecologically attuned practices, recognizing psychedelics not merely as isolated pharmacological agents but as non-specific amplifiers of experience dependent on social and ecological reinforcing scaffolding. If psychedelics are co-opted to sustain unsustainable systems, their emancipatory potential risks being lost at a moment when it is most urgently needed.
Clinical research / Ethics Ethics analysis published

Ketamine dissociation reframed as ethical signal, not mere side effect

Ketamine-Induced Dissociation as an Ethical Signal, Not a Side Effect: Context as the Determinant of Clinical Duties Under Beneficence and Non-maleficence
Why it matters ◈ Mixed
This paper challenges prevailing clinical and ethical assumptions about ketamine-induced dissociation, arguing for a nuanced, context-dependent approach to risk and benefit. By distinguishing between harmful and potentially therapeutic dissociative trajectories, it urges clinicians and researchers to adopt proportionate safeguards and informed consent procedures. This has implications for trial design, clinical protocols, and regulatory guidance, especially as ketamine use expands in psychiatric care.
Ketamine has emerged as an important intervention in contemporary psychiatry, yet its acute dissociative effects remain ethically under-theorized. Clinical approaches often frame dissociation as either a liability to minimize or a therapeutic feature to promote, but both views oversimplify a context-dependent phenomenon. We propose that ketamine-induced dissociation is better understood as an ethically salient signal whose significance is shaped by patient vulnerability, dosing, preparatory framing, interpersonal support, and post-session integration. Using a framework grounded in beneficence and non-maleficence, we conceptualize dissociation not as a neutral side effect but as a predictable alteration of subjectivity that may orient patients toward harm or therapeutic possibility. We distinguish two clinically meaningful trajectories: the dysphoric trajectory of dissociative experience, characterized by threat appraisal and foreseeable psychological harm, and the integrative trajectory of dissociative experience, characterized by meaningful or generative appraisal that may permit emotional reappraisal and meaning-making. We advance a dual-trajectory model in which clinical context shapes these outcomes, supporting proportionate safeguards rather than categorical exclusion and informing consent, risk assessment, and intervention design.
Neuroscience Review published

Hierarchical framework proposed for nociplastic pain mechanisms

A hierarchical framework for nociplastic pain mechanisms
Why it matters ▲ Favorable
This review introduces a comprehensive framework for understanding the mechanisms underlying nociplastic pain, emphasizing the heterogeneity and complexity of pain processing beyond central sensitization. By proposing testable models and highlighting the need for biomarker-driven patient stratification, it offers a roadmap for designing future clinical trials—including those involving non-selective pharmacological agents like psychedelics. While not directly focused on psychedelics, the framework could inform mechanistic studies and trial design in psychedelic research targeting chronic pain.
Nociplastic pain refers to pain arising from altered nociceptive processing in the absence of tissue damage or somatosensory system lesion sufficient to explain the symptoms. Despite the high prevalence and clinical burden of conditions characterized by nociplastic pain, current treatment strategies remain only partially effective, partly because the mechanisms sustaining nociplastic pain are heterogeneous and incompletely defined. Central sensitization remains an important neurophysiological construct, particularly when used to describe activity-dependent amplification of nociceptive processing, but it should not be treated as a complete explanation for pain persistence and heterogeneity. Here, we propose a hierarchical framework in which nociplastic pain mechanisms are conceptualized as interacting processes spanning spinal gain amplification, brainstem descending modulation, thalamocortical sensory gating, intrinsic network integration, corticolimbic affective-motivational processing, and perceptual inference. Neuroimmune signaling is considered a putative cross-level modulator of excitability and plasticity. The framework also illustrates how non-selective pharmacological perturbations could be used to test selected model components in prospective biomarker-defined studies. The framework generates falsifiable predictions linking pre-treatment sensory, neurophysiological, neuroimaging, molecular, affective, and behavioral profiles to treatment response and functional recovery. Overall, this review proposes a mechanism-informed structure for patient stratification and for the future design of multimodal interventions targeting specific contributors to nociplastic pain rather than relying on diagnostic labels or single-mechanism explanations alone.
Clinical research Pilot study results

Pilot: Psilocybin therapy safe, promising for veterans with PTSD

Pilot Study Indicates Psilocybin-Assisted Therapy Safe, Promising for Veterans With PTSD
Why it matters ▲ Favorable
Early data from a pilot study suggests psilocybin-assisted therapy is safe and potentially beneficial for veterans with PTSD. While not definitive, these findings support further research and may inform future larger trials or regulatory pathways. The focus on veterans—a high-need, policy-relevant population—could accelerate interest from both federal agencies and private sponsors. Positive safety signals also help reduce perceived legal and clinical risks for future studies.
Clinical research Real-world data reported

Psilocybin May Help Mood Disorders, New Real-World Data Suggest

Why it matters ▲ Favorable
New real-world data indicating psilocybin's potential benefit for mood disorders adds to the growing body of evidence supporting its therapeutic use. While not a randomized controlled trial, such observational findings can inform future research directions and policy discussions. The lack of detailed methodology or peer review limits immediate clinical or regulatory impact, but the report may influence public and stakeholder perceptions.
FDA / DEA FDA hearing announced

Expert to speak at FDA hearing on future therapeutic use of psychedelics

Dr. Angela Fisher Selected to Deliver Oral Remarks at FDA Public Hearing on the Future Therapeutic Use of Psychedelic Drugs
Why it matters ▲ Favorable
The FDA's decision to hold a public hearing on the therapeutic use of psychedelics signals ongoing regulatory attention and potential future changes in access or oversight. Dr. Angela Fisher's selection to deliver oral remarks highlights the increasing involvement of clinical and scientific experts in shaping federal policy. While this is not a policy change, such hearings often precede significant regulatory or guidance updates, making it a key event for researchers, clinicians, and industry stakeholders to monitor.
Clinical research Press report

Legal psilocybin sessions show promising mental health results

Why it matters ▲ Favorable
Early reports of positive mental health outcomes from legal psilocybin sessions suggest growing evidence for therapeutic benefit. While details are limited, such news coverage can influence public perception and policy interest. However, without peer-reviewed data or specifics on study design, these findings should be interpreted cautiously by researchers and regulators.
Clinical research Peer-reviewed publication

Psilocybin-assisted therapy shows promise for smoking cessation

Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care.
Why it matters ▲ Favorable
This peer-reviewed publication adds to the growing evidence that psilocybin-assisted therapy may significantly reduce cravings and improve smoking cessation outcomes compared to standard care. These findings could influence future clinical guidelines, inform regulatory decisions, and support further investment in psychedelic-assisted addiction treatment research. The results may also accelerate policy discussions around expanding access to psychedelic therapies for substance use disorders.
Clinical research One-year data announced

Compass Pathways: 1-Year Psilocybin Data Shows Lasting Relief

Compass Pathways Surges as One-Year Data Show Lasting Relief From Psilocybin Therapy
Why it matters ▲ Favorable
Compass Pathways' release of one-year follow-up data showing sustained relief from psilocybin therapy is a pivotal milestone for the field. Durable efficacy data are critical for regulatory review, payer confidence, and clinical adoption. This strengthens the case for psilocybin's long-term benefit in mental health, likely accelerating both investor interest and policy discussions around access. The results will shape ongoing FDA deliberations and influence the competitive landscape for psychedelic therapeutics.
Clinical research Meta-analysis published

Meta-analysis: MDMA therapy reduces PTSD, dissociation, depression

MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis.
Why it matters ▲ Favorable
This systematic review and meta-analysis synthesizes evidence that MDMA-assisted therapy significantly reduces PTSD symptoms, dissociation, depression, and functional disability. The findings bolster the clinical case for MDMA as a treatment adjunct for PTSD and related conditions. Policymakers and regulators may view this as further justification for expanded research access and potential rescheduling. The results could influence clinical guidelines and payer decisions if corroborated by regulatory approvals.
Neuroscience Peer-reviewed study published

Anti-NMDAR1 autoantibodies linked to lower depression/PTSD after TBI

Natural anti–NMDAR1 autoantibodies are associated with lower risk for depression and PTSD symptoms after traumatic brain injury
Why it matters ▲ Favorable
This study identifies natural anti-NMDAR1 autoantibodies as a potential biological resiliency factor for depression and PTSD following traumatic brain injury. While not directly related to psychedelic research or law, the findings may inform future mechanistic studies on glutamatergic modulation and neuroprotection, which are relevant to the development of novel psychiatric treatments—including those involving ketamine or other NMDA-targeting compounds. The results highlight a possible biomarker for risk stratification and therapeutic targeting in TBI populations.
Abstract Exposure to a traumatic brain injury (TBI) increases risk of developing psychiatric symptoms including depression, anxiety, and post‑traumatic stress disorder (PTSD). However, biological risk and resiliency factors that help explain the heterogeneity in outcomes are limited. Although ~10% of the population was reported to carry natural autoantibodies to the NMDA receptor, it remains unknown whether carrying anti-NMDAR1 autoantibodies modifies risk for psychiatric outcomes after TBI. Plasma anti-NMDAR1 autoantibody levels were quantified in male active-duty service members before a combat deployment. Outcome measures included post-deployment PTSD (Clinician Administered PTSD Scale-IV), depression (Beck Depression Inventory-2) and anxiety symptoms (Beck Anxiety Inventory). Lifetime TBI was associated with increased predicted depression, PTSD and anxiety symptoms after a combat deployment (N = 606 with TBI, N = 419 without TBI). Higher pre-deployment plasma levels of natural anti-NMDAR1 autoantibodies were modestly but significantly associated with lower predicted post-deployment depression (p = 0.0008) and PTSD symptoms (p = 0.0075), but not anxiety, among individuals with TBI. Within the TBI group, high autoantibody group membership (top quartile) lowered predicted post-deployment CAPS-IV and BDI-II scores by 22% ( ~ 4 points) and 25% ( ~ 2 points), respectively and overall prevalence of psychotropic medication use (p = 0.006). High autoantibody group membership predicted lower odds of reporting post‑deployment moderate-severe depression symptoms (BDI-II > 19) (OR = 0.14, 95% CI 0.01–0.69, p = 0.014). Natural anti-NMDAR1 autoantibodies may be a “resiliency” factor for TBI-associated risk for depression and PTSD symptoms, suggesting potential neuroprotective effects. Future studies should determine if anti-NMDAR1 autoantibodies reach the CNS to suppress glutamate excitotoxicity associated with TBI and if these results generalize across different populations.
Neuroscience Preclinical study published

SGE-301 reverses rTMS-induced LTP-like plasticity in rats

Reversal of repetitive TMS-induced LTP-like plasticity by a novel compound in rats
Why it matters ◈ Mixed
This preclinical study demonstrates that SGE-301, an NMDA receptor modulator, can selectively reverse high-frequency rTMS-induced LTP-like plasticity in rat cortex. The findings highlight the value of rTMS as a translational tool for probing neuroplasticity mechanisms, which is relevant for psychedelic research given overlapping targets and mechanisms. While not directly involving psychedelics, the work may inform future drug development or combination therapies targeting synaptic plasticity in neuropsychiatric disorders.
Repetitive transcranial magnetic stimulation (rTMS) modulates cortical plasticity in a frequency-dependent manner, resulting in predictable and lasting augmentation or attenuation of corticospinal excitability. These rTMS effects on synaptic plasticity are partly mediated by N-methyl-D-aspartate receptors (NMDARs) and share features with long-term depression (LTD) or long-term potentiation (LTP) of excitatory synaptic transmission. In this study, we investigated whether SGE-301 (an NMDR positive allosteric modulator) alters rTMS-mediated motor cortical plasticity in pentobarbital-anesthetized rats. We tested two modalities: 1 Hz for the low-frequency rTMS (lf-rTMS) and 10 Hz for the high-frequency rTMS (hf-rTMS) to induce LTD-like and LTP-like plasticity, respectively. We compared corticospinal excitability before and after rTMS by measuring peak-to-peak motor evoked potential (MEP) amplitudes across a range of stimulator outputs. In the lf-rTMS experiment, the magnitude of the reduction of MEP amplitude was similar between the vehicle and SGE-301 groups. In the hf-rTMS experiment, however, the LTP-like plasticity observed in the vehicle group was completely reversed by SGE-301. In conclusion, SGE-301 engages cortical plasticity mechanisms in vivo and selectively prevents hf-rTMS-induced LTP-like plasticity without altering lf-rTMS-induced LTD-like plasticity. These findings support the utility of preclinical rTMS as a translational tool for detecting central target engagement by neuroplasticity-modulating compounds.
Neuroscience Preclinical results published

Preclinical study: Psilocybin reduces brain injury effects in rats

Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biology
Why it matters ▲ Favorable
This preclinical study provides novel evidence that psilocybin may mitigate neurobiological damage from repetitive mild head injuries. The findings highlight reductions in neuroinflammation, tau pathology, and improvements in neuroplasticity markers, supporting further investigation into psilocybin as a potential therapy for traumatic brain injury. While promising, translation to human trials is required before clinical or policy impact.
Repetitive mild head injuries incurred while playing organized sports, during car accidents and falls, or in active military service are a major health problem. These head injuries induce cognitive, motor, and behavioral deficits that can last for months and even years with an increased risk of dementia, Parkinson's disease, and chronic traumatic encephalopathy. There is no approved medical treatment for these types of head injuries. To this end, we tested the healing effects of the psychedelic psilocybin, as it is known to reduce neuroinflammation and enhance neuroplasticity. Using a model of mild repetitive head injury in adult female rats, we provide unprecedented data that psilocybin can reduce vasogenic edema, restore normal vascular reactivity and functional connectivity, reduce phosphorylated tau buildup, enhance levels of brain-derived neurotrophic factor and its receptor TrkB, and modulate lipid signaling molecules.
Neuroscience Peer-reviewed study

LSD analogues with improved safety, efficacy, and receptor selectivity identified

Deconstruction of lysergic acid diethylamide
Why it matters ▲ Favorable
This study systematically deconstructs LSD to create and characterize new analogues (ergologs) with altered receptor selectivity and improved safety profiles. The identification of compounds like UCD0076, which shows antipsychotic-like effects and reduced hallucinogenic/cardiotoxic potential, opens new avenues for therapeutic development. These findings could inform future clinical trials and support the design of next-generation psychedelics with more favorable risk-benefit ratios, impacting both research and eventual market applications.
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in pharmacological assays relevant to 5-HT2A, 5-HT2B, and 5-HT2C receptor function. Our work revealed the key molecular features and minimal pharmacophore of LSD necessary to produce maximal agonism of 5-HT2A receptors and hallucinogenic behavioral effects. Furthermore, we established strategies for reducing the hallucinogenic and cardiotoxic potential of LSD and identified UCD0094 and UCD0076 as ergologs with improved safety profiles. In stark contrast to LSD, UCD0076 exhibits preference for activating 5-HT2C receptors over other 5-HT2 receptors and produces antipsychotic-like properties in mouse behavioral assays.
Neuroscience Peer-reviewed study

Habenular cell-type transcriptomics reveal depression subtypes in mice

Distinct depressive-like behavioural phenotypes in mice exhibit unique patterns of transcriptional perturbations across habenular cell subtypes
Why it matters ▲ Favorable
This study uses advanced single-cell RNA sequencing to map how different depressive-like behaviors in mice correspond to distinct transcriptional changes in habenular cell types. The identification of cellular and molecular signatures underlying stress resilience and susceptibility could inform future precision psychiatry and the development of targeted interventions, including those involving psychedelics. While preclinical, these findings provide foundational knowledge for translational research into mood disorders and potential novel targets for psychedelic therapeutics.
Major depressive disorder (MDD) is characterized by substantial heterogeneity, which hinders attempts to associate distinct symptoms with specific neural mechanisms. The lateral habenula (LHb) is a key brain region involved in negative affect and reward processing, but the molecular changes in the LHb that lead to mood disorders remain unclear. Here, we combined chronic social defeat stress (CSDS), behavioural phenotyping, and single-cell RNA sequencing to examine cell-type and subregion-specific transcriptional changes in the mouse habenula. Mice were classified into behavioural phenotypes reflecting social avoidance, anhedonia, passive coping, resilience, or susceptibility. We identified nine major habenular cell classes and found distinct phenotype-associated transcriptional signatures across both neurons and glia. Distinct transcriptional signatures were observed in LHb neurons of susceptible animals and in oligodendrocytes of resilient animals. Subregional analysis revealed that the oval-medial LHb accounted for most stress-related transcriptional changes, while the HbX subregion displayed a unique molecular signature associated with passive coping behaviour. These findings highlight the cellular heterogeneity of stress responses within the habenula and will pave the way for identifying potential targets for precision psychiatry approaches in depression.
Clinical research Peer-reviewed study published

Mystical experiences predict OCD symptom improvement after psilocybin

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD
Why it matters ▲ Favorable
This study provides evidence that the quality of subjective mystical experiences during psilocybin treatment is linked to symptom improvement in treatment-resistant OCD. The findings suggest that optimizing set, setting, and integration to facilitate mystical-type experiences could enhance clinical outcomes. This adds important nuance for researchers and clinicians designing psychedelic-assisted therapy protocols, and may influence future trial endpoints and regulatory considerations.
Background Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD). Methods Exploratory analyses were conducted using data from participants with treatment-resistant OCD who received psilocybin as part of a randomized, double-blind, placebo-controlled trial and subsequent open-label phase. Twenty-seven participants who received psilocybin (0.25 mg/kg) completed the Mystical Experience Questionnaire (MEQ-30) and Challenging Experience Questionnaire (CEQ) the day following their session. OCD severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at 1- and 12-week follow-up. Results Greater mystical-type experiences during psilocybin were associated with lower OCD symptom severity at 1- and 12-week follow-up, even after controlling for baseline OCD symptom severity and treatment condition. The Mystical subscale demonstrated the strongest and most consistent associations at both time points, while the Space–Time subscale was only associated with lower Y-BOCS at 12 weeks. The Positive Mood and Ineffability subscales were not significantly associated with post-treatment OCD symptom severity after correction for multiple comparisons. Challenging experiences were not significantly associated with post-treatment OCD severity. Conclusions Mystical experiences – particularly experiences of unity, sacredness, and transcendence – during psilocybin sessions are associated with greater OCD symptom reduction. These findings support attention to experiential quality in psilocybin-assisted therapy and have implications for optimizing treatment through dosing, set, setting, and integration practices.
Neuroscience Peer-reviewed study published

Multi-omics study links gut microbiota, inflammation, and brain function in MDD

Characterizing the role of the gut microbiota-inflammation-brain axis in major depressive disorder: an integrative multi-omics study
Why it matters ▲ Favorable
This integrative study provides new evidence connecting gut microbiota composition, inflammatory cytokines, and brain connectivity in major depressive disorder (MDD). It supports the hypothesis that gut-brain-immune interactions play a significant role in depression, suggesting new intervention targets. While not directly about psychedelics, these findings may inform future research on how psychedelic therapies could modulate the gut-brain axis or inflammation in mood disorders.
BACKGROUND: Gut microbial dysbiosis and inflammation have been implicated in the pathophysiology of major depressive disorder (MDD). However, no attempts have been made to comprehensively investigate the potential relationship between gut microbiota, inflammation, brain function, and clinical features in MDD. METHODS: We conducted an integrative multi-omics study to examine the multi-dimensional differences in gut microbiome, inflammatory cytokines, brain functional connectivity, and clinical features between 60 MDD patients and 70 healthy controls. Furthermore, the potential associations between these multi-omics alterations were assessed using correlation and serial mediation analyses. RESULTS: MDD patients exhibited both depleted beneficial gut microbes and enriched detrimental bacteria, elevated interleukin-1 beta (IL-1β) level, a mix of decreased and increased functional connectivity of multiple brain regions. More important, we found that decreased abundance of anti-inflammatory bacterium (i.e., Blautia) led to increased IL-1β level, which in turn resulted in functional abnormalities in fronto-parietal regions that were associated with clinical symptoms and executive dysfunction. CONCLUSION: Our findings may corroborate the gut microbiota-inflammation-brain axis hypothesis in depression, as well as highlight the potential use of targeting gut microbiota as anti-inflammatory intervention strategies in the prevention or treatment for MDD patients.
Neuroscience Peer-reviewed research

Transformer model reveals new insights into psilocybin's transcriptional effects

A Transformer-Based Delta Expression Encoder for Psilocybin Transcriptional Response: Architecture, Representations, and Biological Validation
Why it matters ▲ Favorable
This study introduces a novel AI model to decode cell-type-specific gene expression changes induced by psilocybin, revealing unexpected patterns in drug response biology. The finding that transcriptional downregulation is more stereotyped than upregulation, and that baseline HTR2A expression negatively predicts response separability, challenges prevailing mechanistic assumptions. These insights could inform future biomarker discovery, trial stratification, and mechanistic studies, but immediate clinical or regulatory impact is limited.
Understanding why individuals respond differently to psilocybin requires modeling the drug's transcriptional perturbation signature at the cell-type level. I present a Transformer-based delta expression encoder that learns to classify differential gene expression status - upregulated, downregulated, or neutral - from single-nucleus RNA-sequencing data, without supervision from pathway annotations or prior biological knowledge. The model is trained on pseudobulk profiles from 623 examples spanning 18 cell types, 2 drug conditions, and 6 timepoints derived from the Liao et al. 2025 dataset, and achieves 69.4% weighted classification accuracy. Three principal findings are reported, alongside one direct test of a published hypothesis that returned a result inconsistent with that hypothesis. First, per-cell-type classification accuracy ranges from 28.3% (L2/3 IT, a primary HTR2A-expressing psilocybin target) to 99.6% (endothelial cells), consistent with known psilocybin response biology. Second, psilocybin-induced transcriptional downregulation is significantly more stereotyped across individuals than upregulation (Mann-Whitney U=18615.0, p<0.0001), a novel finding with a cortical depth gradient across excitatory subtypes. Third, attention-guided gene co-regulation analysis recovers drug-specific modules without pathway supervision. Separately, a direct test of whether baseline HTR2A expression predicts drug-response separability across cell types found a significant negative correlation (Spearman r = -0.7088, p = 0.0021), the opposite of what a simple HTR2A-gating account would predict.
Federal reimbursement policy Town hall announced

Medicare town hall on FY2028 new tech add-on payment applications

Medicare Program; Town Hall Meeting on the Fiscal Year 2028 Applications for New Technology Add-On Payments
Why it matters ◈ Mixed
Medicare's annual town hall on new technology add-on payments (NTAP) is a key forum for companies and researchers seeking reimbursement for novel therapies, including psychedelic-assisted treatments if any are submitted. Participation can shape the evidence and arguments CMS considers for covering hospital-based psychedelic interventions, which is crucial for commercial viability and patient access. While no psychedelic therapies are named in this notice, the event is a critical step in the pathway to mainstream reimbursement.
This notice announces a town hall meeting in accordance with section 1886(d)(5)(K)(viii)(III) of the Social Security Act (the Act) to discuss fiscal year (FY) 2028 applications for add-on payments for new medical services and technologies under the hospital inpatient prospective payment system (IPPS). Interested parties are invited to this virtual meeting to present their comments, recommendations, and data regarding whether the FY 2028 applications for new technology add- on payments meet the substantial clinical improvement criterion.
Clinical research Trial announced

Melbourne trial to pair psychedelic drug with physiotherapy

A Melbourne trial will pair a psychedelic drug with physiotherapy
Why it matters ▲ Favorable
This trial signals growing interest in combining psychedelic therapy with physical rehabilitation modalities, potentially expanding the therapeutic scope beyond mental health to include physical recovery. For researchers, this represents a novel clinical approach and may open new avenues for interdisciplinary studies. If successful, it could inform future protocols and broaden patient access to psychedelic-assisted interventions.
Clinical research Study results announced

Ketamine infusions show promise for treatment-resistant bipolar depression

Regular ketamine infusions offer new hope for treatment-resistant bipolar depression
Why it matters ▲ Favorable
New evidence that regular ketamine infusions benefit treatment-resistant bipolar depression could expand therapeutic options for a population with limited alternatives. This development may prompt further clinical research, influence off-label prescribing practices, and increase demand for ketamine clinics. However, without details on study design, regulatory status, or peer review, the impact on access and policy remains preliminary.
Neuroscience Review published

Review: Psychedelics as neuroregenerative agents for CNS repair

Psychedelics and neuroregenerative medicine: Illuminating the potential of psychoplastogens for neurodevelopment and central nervous system repair
Why it matters ◈ Mixed
This comprehensive review highlights the mechanistic rationale and preclinical evidence for psychedelics as 'psychoplastogens' capable of enhancing neuroplasticity and potentially aiding CNS repair. While promising animal and organoid data exist, the field lacks completed controlled clinical trials showing structural or functional restoration in humans. The article sets a research agenda for translational work but underscores that disease modification remains hypothetical, signaling both opportunity and caution for researchers and industry.
Central nervous system (CNS) injuries remain challenging to treat due to limited neurogenesis, inhibitory extracellular environments, and maladaptive neuroimmune responses. Psychedelic compounds, including classical serotonergic psychedelics, dissociative anesthetics, and empathogens, have re-emerged as mechanistically distinctive “psychoplastogens” capable of rapidly and persistently enhancing neuroplasticity. These substances act through converging molecular pathways involving 5-HT 2A receptor (5-HT 2A R), BDNF-TrkB signaling, mTOR activation, Sigma-1 receptor engagement, and neuroimmune modulation, collectively fostering neuritogenesis, synaptogenesis, and neural survival. Notably, psychedelics can reopen critical periods of brain plasticity and remodel extracellular matrix (ECM) constraints, creating a permissive environment for repair in the adult CNS. Preclinical and organoid models of stroke, traumatic brain injury, and spinal cord damage demonstrate functional recovery linked to psychedelic-induced circuit remodeling, while early clinical data suggest improved rehabilitation outcomes. This review synthesizes molecular, cellular, and systems-level evidence on how psychedelics influence neurodevelopmental and regenerative processes, evaluates their therapeutic potential for CNS injuries, and outlines translational strategies and challenges. Overall, these findings support a framework in which psychoplastogens could act as catalysts for experience- and activity-dependent neural repair, while emphasizing that disease modification or “cures” remain long-term, testable hypotheses: the current evidentiary base is dominated by preclinical studies, and no completed controlled clinical trials have yet demonstrated slowed atrophy, durable structural repair, or sustained functional restoration in humans.
Clinical research Peer-reviewed study

Mystical experiences predict psilocybin benefit in treatment-resistant OCD

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.
Why it matters ▲ Favorable
This study links positive 'mystical' experiences, rather than challenging ones, to symptom improvement in psilocybin-treated OCD patients. The finding refines understanding of therapeutic mechanisms, suggesting that optimizing for mystical-type experiences could enhance efficacy and safety in future protocols. This insight may inform trial design, therapist training, and regulatory guidance for psychedelic-assisted therapy in OCD and related disorders.
Clinical research Observational study published

Real-world use of ketamine, esketamine, ECT, and rTMS in mood disorder clinic

Real-World Patterns of Interventional Psychiatry Use in a Tertiary Mood Disorders Service
Why it matters ◈ Mixed
This large real-world study details how interventional psychiatry treatments, including intravenous ketamine and intranasal esketamine, are being used in tertiary care for severe mood disorders. The findings highlight that these interventions are common, especially among patients with high illness burden and treatment resistance, and that rTMS is most frequently used. While not a regulatory or legal shift, this evidence is valuable for clinicians, researchers, and service planners seeking to understand current clinical practice and inform future research on sequencing and access to these therapies.
Background: Interventional psychiatry procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and repetitive transcranial magnetic stimulation (rTMS), are increasingly used in patients with severe or difficult-to-treat mood disorders. However, less is known about real-world patterns of use within tertiary care services. Methods: We conducted a retrospective observational study of 1004 patients referred to a tertiary mood disorders service, of whom 894 had sufficient clinical data for analysis. Use of interventional psychiatry procedures and modality-specific patterns were examined using descriptive analyses and multivariable logistic regression models based on baseline clinical variables. Results: Overall, 302 patients (33.8%) received at least one interventional psychiatry treatment. Patients receiving these interventions more frequently presented with treatment resistance, disability, prior psychiatric hospitalization, and lifetime suicide attempts. Major depressive disorder was more common than bipolar disorder among treated patients. rTMS was the most frequently used modality (52.3%), followed by ECT (39.8%), intravenous ketamine (29.3%), and intranasal esketamine (4.3%). Across modalities, partially overlapping clinical profiles were observed, with age, comorbidity, and treatment resistance differing across groups. Conclusions: Interventional psychiatry treatments are commonly used in tertiary mood disorders services and are applied across overlapping clinical contexts shaped by illness burden. These findings describe real-world patterns of care in a specialized clinic and may inform future research on treatment sequencing and service planning.
Clinical research Meta-analysis published

Meta-analysis: MDMA-assisted therapy reduces PTSD and related symptoms

MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis
Why it matters ▲ Favorable
This systematic review and meta-analysis finds that MDMA-assisted psychotherapy significantly improves PTSD symptoms, dissociation, depression, and functional disability compared to controls. The findings bolster the clinical evidence base for MDMA-AT as a treatment for PTSD, supporting further research and regulatory consideration. However, the field still faces limitations such as small sample sizes, challenges in blinding, and potential sponsor bias. The results may influence future clinical guidelines, payer decisions, and regulatory pathways for MDMA-assisted therapy.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and quality of life by conducting a systematic review and meta-analysis of randomized controlled trials. Databases from ClinicalTrials.gov, MEDLINE, PsycInfo, PsycArticles, and Cochrane Library were searched from inception to June 2025. Data from seven randomized control trials (both published and unpublished) compared MDMA-AT with low-dose MDMA or placebo control combined with psychotherapy. Identified studies were not included in recent article retractions. Effect sizes were calculated using standardized mean difference for Clinician-Administered PTSD Scale scores and mean difference for secondary measures. MDMA-AT may significantly improve PTSD, dissociation, depression, and functional impairment, compared to controls, but not sleep quality. These results support MDMA-AT for PTSD core symptoms and quality-of-life measures. The evidence, however, is limited by small sample sizes in some studies, challenges with blinding in psychedelic studies, use of non-standardized therapies, and a common sponsor for all trials. While limitations exist, these findings provide evidence for a new emerging treatment option for PTSD.
Clinical research Peer-reviewed publication

MDMA effects confounded by other drug use and lifestyle factors

The consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors.
Why it matters ◈ Mixed
This study highlights the methodological challenges in isolating the specific effects of MDMA due to confounding variables such as polydrug use and lifestyle factors. The findings underscore the need for more rigorous study designs and careful participant selection in both observational and interventional research. For policy and clinical trial design, this work suggests that claims about MDMA's risks or benefits must be interpreted cautiously, as real-world use rarely occurs in isolation.
Clinical research Peer-reviewed review published

Review: Early psychedelic therapy trials found no durable effects

Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977
Why it matters ◈ Mixed
This review challenges the narrative that early psychedelic therapy trials were methodologically unsound, instead finding that most controlled studies from 1965–1977 showed no lasting patient improvements beyond a few weeks. The authors argue that methodological issues persist in modern trials and highlight the need for better patient selection, mechanisms beyond mystical experience, and stronger psychotherapeutic frameworks. This could prompt a re-evaluation of efficacy claims and influence future trial design, regulatory scrutiny, and clinical expectations.
Common wisdom in the psychedelic literature suggests that early controlled trials of psychedelic therapy were methodologically flawed. In this review we challenge this view and discuss 11 controlled studies that were conducted in the United States and Canada between 1965 and 1977 to evaluate psychedelic (peak) therapy for individuals suffering from alcohol and opioid use disorder and psychoneuroses. We provide a narrative review of the designs, methods, settings, treatment issues and results and show that these studies already adhered quite well to the regulatory and evidentiary standards of their time. These early psychedelic trials tried to effectively address common methodological problems that still threaten the validity of contemporary psychedelic clinical trials (e.g., regarding blinding and active control conditions). Our review indicates that despite a significant heterogeneity in the methods and research designs, most early controlled studies converge on the same conclusion: there are no durable improvements in the condition of patients treated with psychedelic therapy beyond a few weeks. We discuss implications for contemporary psychedelic science in terms of (a) patient selection (i.e., better prospects for non-chronic conditions), (b) the problems with a single-sided focus on mystical experiences as the primary mechanism of action, (c) the positive afterglow as a therapeutic window of opportunity and (d) the need for a strong psychotherapeutic framework to induce sustained therapeutic effects.
Clinical research ethics Qualitative study published

Ethical study: Post-trial duties for neurosurgical device participants

Post‐Trial Responsibilities for Participants Implanted With Neurosurgical Devices: A Qualitative Study
Why it matters ◈ Mixed
This study highlights unresolved ethical and regulatory challenges for post-trial care in high-risk neurosurgical device research, including psychedelic-adjacent interventions. As such devices become more common in neuropsychiatric trials, clear guidance on long-term participant support and responsibility is increasingly urgent. The findings underscore the need for robust institutional and policy frameworks to ensure participant wellbeing and clarify investigator obligations.
The issue of post-trial responsibility is about what is owed to research participants after a clinical trial ends, who is responsible, and how long this responsibility must endure. Despite two decades of international guidance on this issue, research involving novel high-risk interventions-such as implantable neurotechnologies-raises underexplored ethical tensions. Trials of implantable devices carry surgical risks and require access to multidisciplinary teams and specialised clinical infrastructures. These factors can foster participant dependence on investigator teams and trial institutions for post-trial care and support. With research and development in this area accelerating, actionable ethical guidance on the post-trial responsibilities of trial stakeholders is urgently needed. Recent normative commentaries have examined the post-trial responsibilities of clinical trial investigators, who play a central role in study design, trial coordination, and follow-up. A persistent challenge is demarcating investigator responsibilities of research integrity from those of therapeutic care when developing ethical guidance on post-trial responsibilities. Recognising the value of empirical engagement for informing further ethical reflection, we conducted qualitative semi-structured interviews with n = 21 investigators involved in neurosurgical device trials. We contend that investigators frequently experience institutional and regulatory pressures that shape how they interpret and enact responsibilities for participants' post-trial wellbeing, often in ways that extend beyond standard expectations of clinical research practice.
Clinical research Phase 3 readout

Randomized trial: Ketamine for sedation in ventilated adults

Ketamine for Analgosedation in Mechanically Ventilated Adults: A Double-Blind Randomized Trial.
Why it matters ▲ Favorable
This double-blind randomized trial provides high-quality evidence on ketamine's efficacy and safety as an analgosedative in mechanically ventilated adults. The results may influence ICU sedation protocols, inform clinical guidelines, and support broader medical acceptance of ketamine outside of psychiatric or pain indications. Findings could also impact regulatory perspectives and payer coverage for ketamine in critical care settings.
Clinical research Preprint posted

Esketamine biomarker study in TRD: metabolic burden & response

Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study
Why it matters ◈ Mixed
This preprint reports a longitudinal biomarker study on metabolic burden and response to repeated intranasal esketamine in treatment-resistant depression. While not peer-reviewed or cited yet, the findings may inform future patient stratification and safety monitoring for esketamine therapy. The study could help clinicians and researchers better understand predictors of response and adverse effects, but results should be interpreted cautiously until validated.
International drug policy Policy analysis

Ukraine studies US drug policy for addiction prevention, trafficking response

Criminal Law Level of Drug Trafficking, Forensic Pharmaceutical, Forensic Narcological Study of the Degree of Drug Addiction Prevention in Ukraine: Using a Large American Initiative to Recover Addiction to Psychoactive Substances
Why it matters ◈ Mixed
This policy analysis highlights Ukraine's consideration of US and EU models to reform its approach to drug trafficking and addiction, emphasizing a shift from punitive measures toward integrated prevention, treatment, and rehabilitation. While not a concrete legal change, the report signals potential regulatory amendments and expanded patient access to treatment for substance use disorders in Ukraine. The focus on interagency cooperation and forensic expertise may inform future legislative or regulatory moves, but immediate impact on psychedelic research or access is limited.
Illicit trafficking in narcotic drugs, psychotropic substances and other psychoactive substances is an urgent problem of public health, social security, and criminal law policy of each state. The current situation necessitates a comprehensive combination of prevention of disorders associated with the use of psychoactive substances, timely detection and treatment, rehabilitation, and social reintegration of persons with addiction with effective measures of criminal law counteraction to drug trafficking. Of particular importance for Ukraine is the study of international experience, in particular modern approaches of the United States to combating illicit trafficking in psychoactive substances, the organization and financing of long-term recovery programs. The study is based on the analysis of international documents in the field of drug control, regulations of Ukraine, scientific publications, materials on drug policy of the United States and EU countries, as well as examples of criminal law, forensic pharmaceutical and law enforcement practice in Ukraine in 2025-2026. Methods of systemic, comparative legal, structural-functional, and interdisciplinary analysis are used. Modern drug business acquires signs of transnational organized crime, actively uses digital technologies, the Internet, instant messengers, cryptocurrency, and complex financial and logistical mechanisms. The analysis of criminal law and forensic pharmaceutical practice has shown the need to strengthen interagency cooperation between law enforcement agencies, prosecutors, courts, lawyers, and experts, as well as the development of forensic pharmaceutical, forensic narcology, forensic psychiatric, forensic medical and forensic examination. The expediency of an integrated approach that combines primary, secondary, and tertiary prevention, early detection, treatment, rehabilitation, and social reintegration of persons with disorders associated with the use of psychoactive substances has been substantiated. Generalization of the US experience showed the importance of simultaneous influence on drug trafficking, its financial basis and demand for psychoactive substances, as well as the development of long-term recovery programs. Countering drug trafficking in Ukraine requires a transition from a predominantly repressive approach to a comprehensive interdisciplinary model that integrates criminal, forensic, medical, pharmaceutical, narcology, social and preventive measures. Promising areas are the deepening of cooperation between Ukraine and the United States and the EU countries, the improvement of mechanisms for early detection and treatment of addictions, the provision of rehabilitation and social reintegration, as well as the regulatory expansion of access of patients with disorders related to the use of psychoactive substances to free or preferential drug provision by making appropriate amendments to the Resolution of the Cabinet of Ministers of Ukraine dated August 17, 1998 No. 1303.
Clinical research Phase 2a halted

Phase 2a trial of mGlu2/3 antagonist TS-161 halted, no antidepressant effect seen

The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
Why it matters ◈ Mixed
This early-phase trial of TS-161, an mGlu2/3 antagonist with mechanistic overlap to ketamine, found no significant antidepressant effect in treatment-resistant depression and was halted early due to low recruitment. While safety and some CNS biomarker engagement were observed, the lack of clinical efficacy limits immediate impact for patient care or market development. The results underscore the challenge of translating glutamatergic modulation into robust antidepressant outcomes and will inform future research and investment in non-classical psychedelic or rapid-acting antidepressant candidates.
Background: Like ketamine, group II metabotropic glutamate receptor (mGluR2/3) antagonists increase glutamate release and monoaminergic signaling, promote synaptic plasticity, and show antidepressant-related activity in preclinical models. A recent phase I trial of the orthosteric mGluR2/3 antagonist prodrug TS-161 established its safety, tolerability, and pharmacokinetic profile. Methods: This phase IIa randomized, placebo-controlled, double-blind, crossover, proof-of-concept, single-site trial was designed to evaluate the antidepressant effects of TS-161. Eleven unmedicated adults with treatment-resistant depression received either oral TS-161 (50 to 100 mg daily) or a placebo for 3 weeks before crossing over to the other condition. The study was halted early due to low recruitment. Results: Adverse events were mild and consistent with the prior phase I study. Linear mixed models using drug×time interaction to estimate mean Montgomery-Åsberg Depression Rating Scale scores per treatment identified no significant difference between treatment conditions at any timepoint, including the primary endpoint, day 21 ( P =0.91). One of the 11 participants responded to TS-161 by day 7 (vs. 0/9 receiving placebo); no participants achieved remission. Magnetic resonance spectroscopy suggested a qualitative trend for increased glutamate metabolite values, and TS-161 increased gamma power during magnetoencephalography relative to baseline and placebo (p FDR <0.01) in lateral cortical regions. Peripheral brain-derived neurotrophic factor levels trended toward elevation (overall drug effect P =0.055). No advantages were seen in secondary clinical or cognitive outcomes. Conclusions: The findings suggest potential central nervous system engagement through proxy biomarkers and increased glutamatergic tone, but this did not translate to clinical improvement.
Clinical research Oregon services operational

Oregon psilocybin clients differ from national users, study finds

Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin Use
Why it matters ◈ Mixed
Oregon's supervised psilocybin services primarily attract higher-income, older, and wellness-oriented adults, in contrast to the broader, more clinically burdened population using psilocybin nationally. This demographic skew suggests that utilization and safety data from Oregon's legal model may not generalize to the millions using psilocybin outside regulated settings. Policymakers and researchers should be cautious in extrapolating outcomes from Oregon's open-access model to inform broader access, equity, and safety debates.
Supervised psilocybin services are expanding across the United States, yet how individuals accessing these programs compare with those using psilocybin in the general population is unknown. We conducted a cross-sectional descriptive comparison of Oregon Psilocybin Services (OPS) data from licensed service centers in 2025 (5,935 encounters) and the 2024 National Survey on Drug Use and Health (NSDUH) public-use file (1,822 of 47,299 adults reporting past-year psilocybin use), examining demographics, reasons for use, self-reported disability, and past-year psychiatric conditions and treatment. OPS clients were predominantly female (58.2%) and aged 35 or older (82.1%), whereas adults reporting psilocybin use nationally were predominantly male (64.0%) and younger than 35 (56.7%). Racial and ethnic minority representation was narrower in Oregon (0.9% Black, 2.5% Hispanic vs. 5.4% and 14.3% nationally). OPS clients reported higher incomes (58.5% earning >$95,000) and primarily cited wellness; self-reported disability was uncommon. Adults using psilocybin nationally had high past-year rates of major depressive episode (22.7%), serious psychological distress (36.8%), substance use disorder (61.7%), and mental health treatment receipt (42.9%). Oregon's open-access model selects higher-income, clinically stable, wellness-oriented adults, while millions with psychiatric and substance-use burden use psilocybin outside supervised channels; its safety and utilization data should not be generalized.
Clinical research Review published

Review: Psilocybin as an emerging anxiolytic—mechanisms and evidence

Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions.
Why it matters ▲ Favorable
This peer-reviewed review synthesizes current evidence on psilocybin's anxiolytic potential, underlying neurobiological mechanisms, and key research gaps. The article highlights promising clinical trial data supporting psilocybin for anxiety disorders, but also notes unresolved questions regarding long-term safety, optimal dosing, and patient selection. This work will inform future trial design, regulatory discussions, and clinical guidelines as the field moves toward broader therapeutic use.
Clinical research Multicenter trial results

Metabolomic signatures of IV ketamine in TRD: Bio-K/NNDC trial results

Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial
Why it matters ◈ Mixed
This multicenter open-label trial provides detailed metabolomic data on ketamine's effects in treatment-resistant depression, highlighting broad metabolic changes and partial remission rates but failing to identify validated metabolic predictors of clinical response. The findings deepen mechanistic understanding of ketamine's rapid antidepressant action and may inform future biomarker discovery, but do not yet translate to clinical decision-making or regulatory change. Researchers and clinicians should note the lack of clear metabolomic predictors for response, underscoring the complexity of ketamine's effects.
Ketamine is a rapid-acting antidepressant with an incompletely understood mechanism of action. Pharmacometabolomics can identify pathways underlying its effects and response variability. Using data from the Bio-K trial (NCT03156504), a multisite open-label study, we characterised metabolomic signatures of intravenous (IV) racemic ketamine in adults with treatment-resistant depression (TRD). Sixty-nine adults with TRD and major depressive disorder received three ketamine infusions (0.5 mg/kg). Remission was defined as MADRS ≤9 at 24 h post–third infusion. Metabolomic profiling used the Biocrates MxP® Q500 kit (>600 metabolites). Mixed-effects models assessed changes across time points (pre-dose, post–infusion 1, post–infusion 3), adjusting for age, sex, infusion length (first), and body mass index, with false discovery rate correction. Mean MADRS improved from 27.8 ± 5.8 to 11.1 ± 9.1 post–third infusion (p < 0.001); 54% achieved remission. Post-infusion 1, ketamine was associated with increased acylcarnitines, cortisol, amino acids (glutamine, glycine, BCAAs), and biogenic amines (GABA, putrescine), with reduced medium-chain acylcarnitines and glutamate. Post-infusion 3, C16, serotonin, and GABA elevations persisted while cortisol normalised. Remitters showed greater GABA synthesis increases, however, no metabolite change correlated with MADRS improvement after correction for multiple testing. Ketamine exposure was correlated with broad metabolic alterations spanning mitochondrial activation, neurotransmitter modulation, and neuroendocrine signalling. These findings represent metabolic correlates of ketamine exposure and remission, rather than validated predictors or established mechanistic drivers of antidepressant response. ClinicalTrials.gov: NCT03156504.
Clinical research Phase 2 readout

Phase 2 trials: Satoprodil (GluN2B modulator) fails to outperform placebo in MDD

NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials
Why it matters ◈ Mixed
Two large Phase 2 trials of satoprodil, a GluN2B-selective NMDA modulator, showed no clinically meaningful benefit over placebo in major depressive disorder, despite good tolerability. This is a significant data point for the glutamatergic hypothesis in depression and may impact the direction of future research and investment in NMDA-targeting compounds, including those in the psychedelic-adjacent space. The results underscore the challenge of translating NMDA modulation into effective antidepressant therapies and may influence strategic decisions for both researchers and industry.
Major depressive disorder (MDD) is a leading cause of disability worldwide, with many patients experiencing inadequate response to standard antidepressants. Dysregulation of N-methyl-D-aspartate (NMDA) receptor activity is implicated in the pathophysiology of MDD. Satoprodil (BI 1569912), an oral NMDA subunit GluN2B-selective negative allosteric modulator, was evaluated for safety and efficacy in MDD in two multicenter, randomized, placebo-controlled Phase II dose-finding trials as an adjunctive or monotherapy. In each trial, patients (18-65 years old) were randomized 2:1:1:2 to placebo or satoprodil (5 mg, 10 mg, or 20 mg) once-daily for 6 weeks, with ongoing antidepressant treatment in the adjunctive trial. Primary endpoint was change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (both trials). Safety and tolerability were also assessed. In the adjunctive trial (N = 243; 60.9% female), the adjusted mean (standard error [SE]) change in MADRS total score at Week 6 was: placebo, -12.0 (1.1); satoprodil 5 mg, -7.8 (1.6); satoprodil 10 mg, -11.9 (1.6) and satoprodil 20 mg, -12.3 (1.2). In the monotherapy trial (N = 225; 54.2% female), the adjusted mean (SE) change in MADRS total score at Week 6 was: placebo, -10.3 (1.4); satoprodil 5 mg, -13.6 (2.1); satoprodil 10 mg, -10.6 (2.0) and satoprodil 20 mg, -10.0 (1.4). In patients with MDD, satoprodil (all doses) over 6-weeks was well tolerated but did not reduce depressive symptoms beyond placebo in either trial in a relevant manner. These trials provide the most comprehensive clinical evidence to date on GluN2B-selective modulation in MDD and will inform future research on glutamatergic pathways.
FDA / DEA MDMA Rx in effect

MDMA now prescribable for PTSD in the US

MDMA To Treat PTSD? Why The Party-Drug Will Now Be Prescribed To Patients With Severe Stress Disorder
Why it matters ▲ Favorable
MDMA has become legally prescribable for patients with severe PTSD in the US, marking a historic shift in federal drug policy and access to psychedelic-assisted therapy. This change will expand treatment options for patients, catalyze further research, and open the door to regulated psychedelic medicine markets. Providers, researchers, and industry stakeholders should closely monitor implementation, safety protocols, and payer coverage as this new paradigm unfolds.
Clinical practice / Access Prescribing in effect

Psychiatrist authorized to prescribe MDMA

The psychiatrist who can now prescribe MDMA
Why it matters ▲ Favorable
This signals that MDMA has cleared key regulatory hurdles and is now available for prescription by at least some clinicians. This is a pivotal milestone for psychedelic medicine, marking the transition from research-only access to real-world clinical use. It will have immediate implications for patient care, legal risk for providers, and the commercial landscape for psychedelic therapies. Researchers and industry stakeholders should closely monitor implementation, insurance coverage, and post-marketing safety data.
Industry Investment announced

Elon Musk’s Inner Circle Invests to Mainstream Psychedelics

Elon Musk’s Inner Circle Is Pouring Cash Into Making Psychedelics Mainstream
Why it matters ▲ Favorable
Major investment from high-profile tech figures signals growing mainstream and financial interest in psychedelics. This could accelerate industry development, attract new talent, and increase public visibility, though it may also spark regulatory scrutiny. The involvement of influential investors may shift the pace and direction of commercialization and access models.
Clinical research Preclinical study published

Psilocybin blocks chemotherapy side-effect in mice

Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice.
Why it matters ▲ Favorable
Preclinical evidence that psilocybin can block a chemotherapy side-effect in mice could open new avenues for supportive care in oncology. While translation to humans remains uncertain, this finding may accelerate interest in clinical trials for psilocybin as an adjunct to cancer treatment. The result highlights the expanding therapeutic potential of psychedelics beyond mental health, and may influence future research funding and regulatory attention.
Neuroscience Peer-reviewed study published

EEG study links acute and long-term psilocybin effects

Psilocybin-induced changes in electroencephalography link acute and long-term effects.
Why it matters ▲ Favorable
This study provides neurophysiological evidence connecting the immediate and lasting effects of psilocybin via EEG biomarkers. Such findings can help inform clinical trial design, support regulatory submissions, and guide the development of objective measures for psychedelic-assisted therapies. The results may also aid in risk assessment and patient monitoring protocols, advancing both research and clinical practice.
Clinical research / Policy Stakeholder survey published

Irish national survey explores psychedelic therapy implementation barriers

Implementing psychedelic-assisted therapy in Ireland: perspectives from a national stakeholder survey.
Why it matters ◈ Mixed
This national survey provides critical insight into the readiness, concerns, and perceived barriers for implementing psychedelic-assisted therapy in Ireland. Findings highlight the need for regulatory clarity, clinician training, and infrastructure development before widespread adoption. The results will inform policymakers and health authorities as Ireland considers potential legal and clinical pathways for psychedelic therapies.
Clinical research VA trial enrolling

VA psilocybin trial offers Alabama veterans new hope

Why it matters ▲ Favorable
The launch of a VA-sponsored psilocybin trial in Alabama signals growing institutional support for psychedelic research targeting veterans' mental health. This development may improve research access in conservative jurisdictions and sets a precedent for federal agencies to study psychedelics in populations with high unmet needs. If successful, it could accelerate policy shifts and eventual clinical adoption within the VA system.
International policy Regulatory approval

New Zealand approves MDMA for severe PTSD treatment

New Zealand drugs regulator approves use of MDMA to treat severe PTSD
Why it matters ▲ Favorable
New Zealand's drug regulator has approved MDMA for the treatment of severe PTSD, marking a major milestone in the global acceptance of psychedelic-assisted therapies. This regulatory decision will enable clinicians to legally prescribe MDMA for eligible patients, expanding access and setting a precedent for other countries considering similar moves. The approval is likely to accelerate research, investment, and clinical adoption in the region, while also providing valuable real-world data for international regulators and policymakers.
Clinical research Trial announced

MD Anderson to trial psilocybin for chemo-induced neurotoxicity

MD Anderson poised for trial of psilocybin in blocking neurotoxicity of chemotherapies
Why it matters ▲ Favorable
MD Anderson's planned trial of psilocybin to prevent chemotherapy-induced neurotoxicity signals growing mainstream medical interest in psychedelic therapeutics beyond mental health. If successful, this could open new indications for psilocybin, accelerate research funding, and influence regulatory perspectives on medical use. The involvement of a leading cancer center adds credibility and may drive industry and clinical adoption.
US / Federal Federal report released

Federal report urges states to prep for FDA psychedelic approvals

A federal report encourages states to prepare for FDA approval of psychedelics; Could THC help with the psychedelic blinding problem?
Why it matters ▲ Favorable
A federal report signaling states to prepare for FDA approval of psychedelics marks a pivotal shift in national policy readiness and signals imminent regulatory changes for research and clinical access. This guidance could accelerate harmonization of state laws with forthcoming federal approvals, reduce legal ambiguity for providers, and catalyze investment and infrastructure development across the psychedelic industry. The mention of THC and the blinding problem also highlights active efforts to improve clinical trial methodology, which is crucial for future approvals.
FDA / DEA FDA approval

FDA approves MDMA as official PTSD treatment

Party drug MDMA gets official approval as PTSD treatment
Why it matters ▲ Favorable
MDMA's official FDA approval as a PTSD treatment marks a historic milestone for psychedelic medicine in the US. This decision will immediately expand legal access for patients, catalyze insurance coverage, and set a regulatory precedent for other psychedelic compounds. The move will likely accelerate clinical research, investment, and the development of new care models, while reshaping legal risk and market structure for the entire field.
International policy National approval in effect

New Zealand Approves MDMA Therapy for Trauma Care

New Zealand Approves MDMA Therapy: What It Means For Trauma Care
Why it matters ▲ Favorable
New Zealand's approval of MDMA-assisted therapy marks a major policy shift and sets a precedent in the Asia-Pacific region for psychedelic medicine. This move is likely to accelerate research, expand patient access for trauma-related conditions, and prompt regulatory discussions in neighboring countries. It also signals growing international acceptance and could influence global market dynamics and clinical trial activity.
Neuroscience Preclinical research

Synapto-nuclear signaling defects in ALS motoneurons are pharmacologically reversible

Defective synapto-nuclear signaling contributes to motoneuron vulnerability in SOD1-ALS
Why it matters ▲ Favorable
This preclinical study identifies a novel mechanism—defective synapto-nuclear signaling—contributing to motoneuron vulnerability in ALS, and demonstrates that pharmacological enhancement of cAMP/PKA signaling can restore this pathway and slow disease progression in a mouse model. While not directly related to psychedelics, the findings highlight a druggable neuroplasticity mechanism that may be relevant for future research on neurodegenerative diseases, including potential intersections with psychedelic compounds known to modulate synaptic signaling. The work is a valuable neuroscience advance, but does not immediately impact legal, policy, or market structures in the psychedelic field.
Glutamatergic excitatory synapses not only shape spiking activity and neuronal communication but also initiate activity-dependent signaling pathways that trigger transcriptional programs. Since glutamatergic excitatory synapses onto spinal motoneurons (MNs) are impaired presymptomatically in Amyotrophic Lateral Sclerosis, we investigated whether synapto-nuclear coupling is disrupted in MNs from mSOD1 mice and whether restoring it mitigates pathology. We developed an in vivo approach to selectively investigate the coupling between synaptic excitation and nuclear CREB phosphorylation in spinal MNs. Specific activation of Ia-MN synapses induces CREB phosphorylation in wild-type MNs but not in mSOD1 MNs at P50, indicating presymptomatic synapto-nuclear uncoupling. Enhancing cAMP/PKA signaling by pharmacological inhibition of cAMP degradation restored synapto-nuclear coupling, reduced misfolded SOD1, and slowed neuromuscular-junction denervation. Thus, activity-dependent synapto-nuclear signaling is impaired yet pharmacologically rescuable in mSOD1 MNs, supporting synapto-nuclear signaling as a determinant of MN resilience.
Clinical research Peer-reviewed study published

EEG study links psilocybin's acute and long-term effects in healthy adults

Psilocybin-induced changes in electroencephalography link acute and long-term effects
Why it matters ▲ Favorable
This controlled trial provides new evidence that psilocybin’s therapeutic effects may be mediated by distinct sub-acute neurophysiological changes, not just acute subjective experience. The identification of EEG markers that predict long-term positive outcomes could inform both clinical trial design and patient selection. The study also suggests a potential biomarker (normalized diversity) for individual responsiveness, which is highly relevant for future personalized psychedelic medicine approaches. While the sample is small and healthy, not clinical, these mechanistic insights strengthen the scientific basis for further translational research.
Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized. Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a medium dose ∼0.26 mg/kg of psilocybin. High-density resting-state electroencephalography and psychological states were assessed at baseline, 1, 3, 6, and 24 hours, with a 28-day follow-up. Results: Psilocybin acutely decreased alpha/beta power and increased gamma-band signal diversity (1–3 hours; returning to baseline at 6 hours). Increased gamma diversity correlated with acute psychological effects (Brief Psychiatric Rating Scale, r = 0.71), with the largest increases observed in participants with lower baseline complexity. At 24 hours, reduced delta/theta power correlated with Positive Life Changes (Persisting Effects Questionnaire) at 4 weeks ( r = −0.47 to −0.57) but was independent of acute psychological intensity. Conclusion: Our findings corroborate known acute effects while identifying a distinct sub-acute “afterglow” associated with long-term outcomes. The dissociation between acute psychology and 24-hour spectral shifts suggests that therapeutic benefits may be driven by sub-acute reductions in top-down cortical hierarchy. These results highlight the significance of the sub-acute window for psychological transformation and suggest normalized diversity as a viable baseline biomarker of individual responsiveness to psychedelic intervention.
Clinical research Peer-reviewed study published

Non-hallucinogenic LSD analogue enhances immune response to colorectal cancer

Non-Hallucinogenic LSD Analogue Boosts Immune Response to Colorectal Cancer.
Why it matters ▲ Favorable
This peer-reviewed study reports that a non-hallucinogenic LSD analogue can boost the immune response against colorectal cancer, suggesting a new therapeutic avenue for oncology that bypasses the psychoactive effects of classic psychedelics. This finding could accelerate research into non-psychoactive psychedelic derivatives, potentially expanding clinical and commercial opportunities while reducing regulatory and ethical barriers. The result may also influence policy discussions on the medical utility of psychedelic-inspired compounds beyond mental health.
Clinical research Review published

Review: Integrated approaches to geriatric mental disorders

Integrated approaches to geriatric mental disorders: pathophysiology, interventions, and precision medicine horizons
Why it matters ◈ Mixed
This comprehensive review synthesizes current knowledge on late-life mental disorders, highlighting the complexity of pathophysiology and the need for tailored interventions in older adults. It notes emerging interest in novel pharmacological targets such as ketamine for treatment-resistant depression, but does not specifically address classic psychedelics or regulatory/legal changes. The article underscores the underrepresentation of older adults in clinical trials—a critical gap for psychedelic research—and the importance of precision medicine, but offers limited direct implications for psychedelic law or industry. Researchers and clinicians should note the call for inclusion of geriatric populations and integrated care models.
The global aging demographic has precipitated a surge in late-life mental disorders (LMDs)—including late-life depression (LLD), anxiety, and behavioral and psychological symptoms of dementia (BPSD)—posing critical public health challenges. This review synthesizes current evidence on the unique pathophysiology, clinical management, and emerging frontiers of geriatric mental health, emphasizing the interplay of neurobiological aging, multimorbidity, and psychosocial stressors. Key pathophysiological mechanisms include “inflammaging” (microglial overactivation), cerebral small vessel disease (CSVD), and senescence of monoaminergic systems, which collectively reduce neural resilience and complicate diagnosis. Clinical challenges—such as atypical symptom presentation (e.g., somatic masking of depression), polypharmacy risks, and diagnostic ambiguity between LLD and pseudodementia—necessitate tailored interventions. Notably, caregiver burden represents an independent predictor of patient institutionalization. Multiple systematic reviews and meta-analyses have consistently identified caregiver burden and distress as significant predictors of nursing home admission, with carer stress sometimes serving as the single determining factor for this transition. This underscores the critical need to integrate caregiver well-being into routine clinical assessment. Pharmacological strategies prioritize SSRIs/SNRIs but require cautious dosing due to age-related pharmacokinetic alterations (e.g., reduced renal clearance) and cardiovascular/metabolic risks. Emerging targets (e.g., ketamine for treatment-resistant LLD, anti-inflammatory agents guided by biomarker profiling) highlight a shift toward precision. Psychotherapeutic adaptations—including modified cognitive behavioral therapy (CBT), problem-solving therapy (PST), and life review therapy—address cognitive and psychosocial needs, while integrated care models (e.g., Collaborative Care Model [CoCM]) demonstrate superior outcomes over fragmented care. Lifestyle interventions (exercise) and neuromodulation (rTMS) further expand treatment options. Critical gaps remain, including underrepresentation of older adults in clinical trials and pervasive polypharmacy. Future directions emphasize pharmacogenomics, AI-driven early detection, and culturally equitable care to advance precision psychiatry for LMDs. This synthesis provides clinicians and researchers with a roadmap to navigate the complexities of geriatric mental health, advocating for multidisciplinary, patient-centered approaches to improve outcomes in aging populations.
Clinical research Pilot trial results

Pilot trial: MDMA-assisted couples therapy for veterans with PTSD shows promise

Healing together: Results from a pilot trial of 3,4‐Methylenedioxymethamphetamine‐enhanced cognitive‐behavioral conjoint therapy for posttraumatic stress disorder
Why it matters ▲ Favorable
This open-label pilot trial is the first to test MDMA-assisted cognitive-behavioral conjoint therapy (bCBCT) for PTSD in U.S. veterans and their partners, showing large reductions in PTSD symptoms and improvements in relationship functioning, with no serious safety concerns. While limited by small sample size and open-label design, these findings support further research into MDMA-enhanced dyadic therapies, particularly for populations underserved by standard PTSD treatments. The results may inform future larger trials and integration into health care systems if replicated.
Posttraumatic stress disorder (PTSD) disrupts individual well-being and relationship health, particularly among veteran/military couples with heightened risks due to deployment, family reintegration, and traumatic stress. Although cognitive-behavioral conjoint therapy (CBCT) and brief CBCT (bCBCT) have demonstrated strong efficacy in reducing PTSD symptoms, their impact on relational outcomes is less compelling. Given the importance of relationship functioning for veterans' overall health, enhancing interpersonal outcomes of PTSD treatment remains a research priority. One promising approach is the integration of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to augment the relational benefits of established PTSD interventions. This single-site, open-label pilot study evaluated the preliminary benefit, safety, and acceptability of MDMA-assisted bCBCT in eight U.S. military veterans with PTSD and their intimate partners (N = 16). An eight-session MDMA-assisted bCBCT protocol with two MDMA administration sessions and dyadic integration sessions incorporating elements of integrative behavioral couples therapy was delivered. Outcomes included PTSD symptom severity, relationship functioning, and safety. Veterans exhibited large pre-post PTSD symptom reductions, d = 1.25, which were generally maintained during follow-up. Both veterans and partners experienced large improvements in relationship functioning, ds = 1.83 and 1.29, respectively, with moderate rebound during follow-up. No serious adverse events were reported. This first trial of MDMA-assisted bCBCT in U.S. veterans and their partners provides preliminary evidence of potential improvements in PTSD and relational outcomes, with no identified serious safety concerns. This model has potential for future evaluation in large health care systems, leveraging the hypothesized therapeutic effects of MDMA for individuals with PTSD and their families.
Neuroscience Review published

Emerging role of 11β-HSD enzymes in PTSD neurobiology reviewed

Local Glucocorticoid Metabolism in Post-traumatic Stress Disorder: The Emerging Role of 11-hydroxysteroid Dehydrogenases
Why it matters ◈ Mixed
This review synthesizes emerging evidence implicating local glucocorticoid metabolism, particularly via 11β-hydroxysteroid dehydrogenase enzymes, in the pathophysiology of PTSD. While not directly related to psychedelics, these findings may inform future research into novel molecular targets and mechanisms relevant for psychiatric drug development, including potential adjuncts or biomarkers for psychedelic-assisted therapy in trauma-related disorders. The review highlights the need for integrative studies to clarify these pathways, which could eventually impact clinical trial design or therapeutic innovation.
Post-traumatic stress disorder (PTSD) is a complex psychiatric condition arising from exposure to severe trauma, characterized by intrusive memories, avoidance, negative alterations in cognition and mood, and hyperarousal.Despite advances in understanding its neurobiology, effective pharmacotherapies remain limited.Dysregulation of the hypothalamic-pituitary-adrenal axis is a hallmark of PTSD, though findings on systemic cortisol levels remain inconsistentsuggesting that local, tissue-specific glucocorticoid metabolism may play a particularly relevant role beyond circulating hormone concentrations.The enzymes 11-hydroxysteroid dehydrogenases (11-HSDs), particularly 11-HSD1, regulate intracellular glucocorticoid availability in the brain and periphery and may contribute to region-specific modulation of stress-related neurocircuitry.This focused mini-review synthesizes available preclinical and clinical evidence on the involvement of 11-HSDs in PTSD.Preclinical studies consistently implicate 11-HSD1 in fear memory processing and stress adaptation, while emerging human data suggest a more complex and context-dependent role.Notably, recent neuroimaging findings indicate that higher brain 11-HSD1 availability may be associated with lower severity of specific symptom domains, raising the possibility of adaptive or compensatory mechanisms in chronic PTSD.Although the current clinical evidence base remains limited, these observations support the view that local glucocorticoid metabolism represents a biologically meaningful dimension of PTSD pathophysiology.Further integrative studies combining neuroimaging, molecular, and clinical approaches are needed to better define the contribution of 11-HSD enzymes to PTSD pathophysiology and to evaluate their potential as candidate molecular pathways for future research.
Neuroscience Review published

Silent synapse activation: mechanisms, disease links, and translational prospects

Activation of silent synapses driven by emerging technologies: mechanisms, disease associations, and prospects for clinical translation
Why it matters ▲ Favorable
This review synthesizes emerging mechanistic insights into silent synapse activation, highlighting their relevance for neuroplasticity and disease pathology—including depression and addiction, key targets for psychedelic interventions. By mapping regulatory pathways and technological advances, it lays groundwork for translational research and potential new therapeutic strategies, but does not directly address psychedelic compounds. Researchers in psychedelic science should note the mechanistic overlap and opportunities for cross-disciplinary innovation.
Silent synapses represent a unique class of synaptic connections that are non-functional at rest but possess the potential to become functional, serving as a critical reservoir for neural plasticity. Their activation mechanisms not only challenge traditional models of synaptic maturation but also provide novel insights into brain function regulation and disease pathology. This article provides a systematic review of the regulatory mechanisms underlying silent synapse activation, encompassing pre-synaptic calcium signaling-mediated vesicle cycling and active zone (AZ) optimization, post-synaptic α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) membrane insertion and post-synaptic density protein 95 (PSD-95) anchoring, Mg 2+ blockade release by N-methyl-D-aspartate receptor (NMDAR), as well as synergistic integration of upstream signaling pathways. Additionally, it explores the roles of astrocytes, epigenetic modifications, ubiquitin-proteasome systems, and autophagy-lysosomal systems in multi-level regulatory processes. Notably, abnormal regulation of silent synapses exhibits two contrasting pathological patterns in diseases: “desilencing impairment” (e.g., Alzheimer’s disease, depression) and “abnormally excessive desilencing” (e.g., drug addiction, chronic pain), which establishes a theoretical framework for targeted interventions. The study further evaluates the applicability and limitations of emerging technologies—including high-resolution imaging, single-cell omics, optogenetics, and AI-driven brain-inspired computing—in silent synapse research, while systematically summarizing clinical advancements, current challenges, and future directions, aiming to inform both fundamental neuroscience studies and therapeutic interventions.
Neuroscience Review published

Drosophila models advance study of sleep in stimulant use disorder

The use of Drosophila to study sleep impairments in stimulant use disorder
Why it matters ▲ Favorable
This review highlights the utility of Drosophila as a model organism for investigating the neural and genetic mechanisms underlying sleep impairments in stimulant use disorder (SUD). While not directly related to psychedelics, the research provides foundational neuroscience insights that may inform future pharmacological interventions for SUD, a key comorbidity in populations relevant to psychedelic-assisted therapy. The work is preclinical and basic, but it may eventually support translational research on novel treatments for SUD.
Stimulant drugs like cocaine and methamphetamine acutely enhance the release of monoamine neurotransmitters, particularly dopamine, to induce euphoria, motivation, hyperlocomotion, and strong sleep suppression. Chronic stimulant use can lead to the development of stimulant use disorder (SUD), which is characterized by risky, excessive, or uncontrolled drug intake and an inability to cease use. At time of writing, there is no FDA-approved pharmacological treatment for SUD. Though symptoms and comorbidities of SUD vary, studies on abstinent stimulant-users repeatedly identify sleep disorder as a symptom that persists long into abstinence and drives relapse to stimulant use. This review discusses the use of the vinegar fly Drosophila melanogaster to identify the neural and genetic pathways mediating this sleep disorder. The fly has a long history of use in neurogenetics research, boasting efficient and low-cost husbandry, an extremely well-studied genome, widely available tools for manipulating neurons and genes with high spatiotemporal specificity, and a connectome cataloguing each neuron and synapse in the fly brain. Additionally, the fly rest state is a face-valid model of sleep in mammals, as it shares key features and is regulated by conserved neurotransmitter systems; flies also respond similarly to stimulant drugs, again mediated by common monoamine signals. As such, flies represent an excellent and under-utilized invertebrate model for studying sleep deficits in stimulant abstinence. This review describes methods available for studying sleep and stimulant use in Drosophila , highlighting key findings in the existing literature relevant to this phenotype while indicating where the literature is lacking. Identification of the genetic and neural pathways mediating stimulant-induced sleep disorder in flies will shed light on the critical role of dopamine systems in sleep regulation, facilitating the development of more efficacious treatments for SUD.
Clinical research Published study

Ketamine anesthesia study details dose effects on breathing, cortex

Ketamine in ambulatory anesthesia: dose-dependent effects on breathing and cortical function.
Why it matters ◈ Mixed
This study adds important detail on ketamine's dose-dependent impacts on respiratory and cortical function in ambulatory anesthesia settings. While not directly about psychiatric or psychedelic use, these findings inform safety protocols and risk assessment for both clinical and off-label applications. The data may influence guidelines for ketamine administration and monitoring, with downstream effects on patient access and regulatory scrutiny.
Clinical access Prescribing authorized

Psychiatrists Approved to Prescribe MDMA for PTSD

Why it matters ▲ Favorable
MDMA prescribing approval marks a historic shift in US mental health treatment, opening the door for regulated clinical use for PTSD. This move will dramatically expand patient access, catalyze insurance and provider adoption, and set a precedent for future psychedelic approvals. Researchers, clinicians, and industry stakeholders should prepare for rapid changes in training, infrastructure, and regulatory oversight.
Neuroscience Preclinical data

Psilocybin prevents chemo nerve injury in preclinical models

Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models
Why it matters ▲ Favorable
New preclinical research suggests psilocybin may prevent chemotherapy-induced nerve injury and related symptoms. While this finding is limited to animal models, it highlights a potential new indication for psilocybin in supportive oncology care. The results could spur interest in translational research and future clinical trials, but have no immediate impact on patient access or regulatory status.
Neuroscience Preprint released

ENIGMA PTSD Consortium maps amygdala-hippocampus connectivity in PTSD

Dynamic Functional Connectivity of Amygdala and Hippocampus in Posttraumatic Stress Disorder: A Multi-Site Study of the ENIGMA PTSD Consortium
Why it matters ◈ Mixed
This large-scale preprint offers new insights into the neural circuits implicated in PTSD, focusing on amygdala and hippocampus connectivity. While not directly about psychedelics, such mechanistic findings inform the biological rationale for psychedelic interventions targeting trauma-related disorders. Multi-site data from the ENIGMA consortium may provide a valuable reference for future clinical trial designs and biomarker development.
Neuroscience Peer-reviewed study

Stress intensity shapes serotonergic vs. dopaminergic anxiety mechanisms

SEROTONERGIC ANXIETY IS A STRESS INTENSITY-DEPENDENT STATE MEDIATED BY DOPAMINERGIC SIGNALING
Why it matters ◈ Mixed
This preclinical study in zebrafish demonstrates that the involvement of serotonergic and dopaminergic systems in anxiety depends on the intensity of prior stress exposure. Findings suggest that the variable efficacy of serotonergic treatments for anxiety may reflect underlying mechanistic heterogeneity, with implications for the design of future psychedelic and anxiolytic trials. While not directly actionable for law or policy, this research may inform biomarker development and patient stratification strategies in clinical studies.
Despite the central role attributed to serotonin in anxiety, its involvement and therapeutic efficacy are inconsistent, raising the possibility that serotonergic recruitment depends on the stress history from which anxiety emerges. Using larval zebrafish, we combined graded glucocorticoid exposure with chemogenetic DRN manipulation, whole-brain activity mapping, and pharmacology to test whether stress intensity determines serotonergic involvement in anxiety.Increasing stress intensity did not simply increase anxiety severity but generated distinct anxiety phenotypes. Lower glucocorticoid exposure produced context-general anxiety that required the serotonergic DRN, whereas higher exposure produced context-dependent, DRN-independent anxiety. Whole-brain mapping identified a posterior tubercular/hypothalamic dopaminergic region associated with DRN-dependent anxiolysis, while D1, but not D2 receptor antagonism abolished the anxiolytic effect of DRN ablation. Finally, environmentally relevant nanomolar concentrations of methylphenidate reduced anxiety-like behavior, further supporting dopaminergic modulation of anxiety. Together, our findings identify stress intensity as a determinant of serotonergic recruitment during anxiety, reveal a downstream contribution of D1-dependent dopaminergic signaling, and provide a framework for understanding the mechanistic heterogeneity of anxiety and its variable response to serotonergic treatments.
Clinical research Case report preprint

Case report: Ketamine used for refractory opioid withdrawal after buprenorphine

Successful Management Of Refractory Precipitated Opioid Withdrawal Syndrome Following Buprenorphine Intake Using Ketamine: A Case Report
Why it matters ◈ Mixed
This preprint describes a single case where ketamine was used to manage severe, refractory opioid withdrawal precipitated by buprenorphine. While not a controlled trial, it highlights a potential new application for ketamine in acute opioid withdrawal management. Such case reports can inform future research directions but do not establish clinical practice standards. The lack of peer review and single-patient scope limits immediate impact, but it may spark interest in formal studies.
Clinical research Review published

Multi-omics review in treatment-resistant depression: translational framework proposed

Pharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depression
Why it matters ◈ Mixed
This narrative review synthesizes the state of multi-omics approaches (including pharmacogenomics, metabolomics, and machine learning) for guiding pharmacological treatment in difficult-to-treat and treatment-resistant depression. While it highlights promising discovery-stage signals, the authors caution that most omics-guided strategies remain investigational and should not yet inform routine clinical decisions. The proposed translational framework is relevant for future research design, including psychedelic trials targeting TRD, but does not immediately change clinical or regulatory practice.
Background Antidepressant prescribing in major depressive disorder (MDD) remains dominated by sequential trial and error, particularly when illness becomes difficult to treat (DTD) or meets conventional treatment-resistant depression (TRD) criteria. Objective This narrative review evaluates pharmacogenomics (PGx), therapeutic drug monitoring (TDM), metabolomics/lipidomics, immune-inflammatory markers, proteomics, transcriptomics, epigenomics, microbiomics, and multi-omics machine learning according to their capacity to improve defined pharmacological decisions. Methods Evidence was identified through structured PubMed/MEDLINE searches updated to 29 July 2026, targeted searches of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, and backward and forward citation searching. The review was restricted to adult MDD and used author-assigned categories that distinguish prognostic, predictive, pharmacokinetic, and treatment-emergent monitoring markers and differentiate discovery, independent replication, external validation, and clinical utility. The article is a narrative Review, not a PRISMA systematic review; study selection, extraction, and translational classification were performed by one author without formal study-level risk-of-bias grading. Results Most evidence derives from general adult MDD rather than prospectively defined DTD/TRD cohorts. Drug-specific, guideline-supported PGx and indication-specific TDM are the most clinically proximal molecular tools, but their value is bounded and depends on medication history, inhibitors and inducers, adherence, organ function, assay coverage, and phenoconversion. Commercial combinatorial PGx trials show small and sometimes nonpersistent clinical effects. Metabolomic, inflammatory, proteomic, transcriptomic, epigenomic, microbiomic, and integrated machine-learning studies identify plausible mechanisms and candidate predictors, but the majority remain discovery-stage or internally validated. Positive subgroup signals, including C-reactive protein-defined differential response, are counterbalanced by null prospective trials and inconsistent thresholds. Conclusion Current clinical application should remain limited to systematic medication and interaction review, drug-specific guideline-supported PGx, and indication-specific TDM. Dynamic omics layers should be treated as investigational until locked models are externally validated and prospective biomarker-guided strategies demonstrate incremental decision value, clinical benefit, feasibility, equity, and cost-effectiveness. The review proposes a future-state architecture and staged evidence-to-implementation framework for DTD/TRD.
State policy Oregon program study

Oregon psilocybin study: Legal mushroom program shows promise

Why it matters ▲ Favorable
Early data from Oregon's legal psilocybin program suggest positive outcomes, supporting the case for regulated adult use and informing other jurisdictions considering similar models. This study provides critical real-world evidence on safety, efficacy, and implementation challenges, which will impact future policy, clinical practice, and market development. The findings may accelerate research and legislative efforts nationwide.
Clinical research Phase 1 results published

CYB004 (deuterated DMT) shows longer effects, mixed PK, in Phase 1 study

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N -dimethyltryptamine (CYB004) in healthy volunteers
Why it matters ◈ Mixed
This first-in-human study of CYB004, a deuterated DMT analogue, found it extends the duration of psychedelic effects compared to standard DMT, with an acceptable safety profile at lower doses. However, deuteration did not reduce the pharmacokinetic variability, which remains a challenge for clinical development. The results are important for researchers and companies pursuing next-generation tryptamine analogues, as they inform dose selection, safety, and the feasibility of intravenous administration for future trials.
BACKGROUND: -dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life. AIMS: This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers. METHODS: CYB004, a deuterated DMT analogue, was evaluated in a randomized, double-blind, placebo-controlled, two-part study in healthy participants. Part 1 was a single-dose cohort, in which participants received a 5-minute intravenous 12.7 mg CYB004 bolus, followed by a 30-minute 15.41 mg infusion. Part 2 was a three-way crossover, during which two separate 5-minute 12.7 mg CYB004 boluses were administered. Outcome measures included PK of CYB004 and subjective, autonomic, neurophysiological, and adverse effects. RESULTS: Although high CYB004 doses led to intense psychedelic experiences and participant withdrawals, lower doses achieving plasma concentrations similar to those in previous DMT studies demonstrated an acceptable safety profile. CYB004 demonstrated a PD profile that was similar to DMT at comparable plasma concentrations. PD effects consisted of subjective psychedelic effects, electroencephalography power band reductions, and autonomic nervous system activation. CYB004's half-life was approximately two-fold longer than DMT, prolonging the duration of psychedelic effects to ~40-60 minutes following brief intravenous administration. However, deuteration did not improve PK variability, with IV-administered CYB004 demonstrating moderate to high variability, largely driven by interindividual differences. CONCLUSION: CYB004 demonstrated PD effects comparable to DMT. However, CYB004 demonstrated an extended duration of these effects due to reduced clearance, while maintaining an acceptable safety profile at clinically relevant exposures despite PK variability.
Clinical research Peer-reviewed study published

Psilocybin shown to prevent chemo-induced neuropathy via mitochondrial mechanism

Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation.
Why it matters ▲ Favorable
This preclinical or early clinical study suggests psilocybin may protect against chemotherapy-induced peripheral neuropathy by preserving mitochondrial trafficking. If validated in larger human trials, this finding could expand psilocybin’s therapeutic scope beyond mental health to supportive oncology care. It provides a mechanistic rationale for further research and may influence future clinical trial design and regulatory discussions around psilocybin’s scheduling and medical use.
Industry Funding trend

Donors ramp up funding as psychedelics near FDA approval

As psychedelics near FDA approval, donors rush to fund the next frontier
Why it matters ▲ Favorable
Surging donor interest signals growing confidence in imminent FDA approval of psychedelic therapies. Increased funding may accelerate research into new indications, infrastructure, and access models, shaping the next wave of clinical and policy developments. This trend could expand opportunities for researchers and operators, while also raising questions about influence and priorities in the field.
Neuroscience Preclinical modeling

Novel S-Remiketamine analogues modeled for NMDA receptor and CES1 compatibility

Structure-based molecular modeling of a novel S-Remiketamine scaffold and derived arylcyclohexanone analogues: NMDA receptor dynamics, MM-GBSA ranking, and CES1-Oriented structural compatibility.
Why it matters ▲ Favorable
This study uses advanced molecular modeling to design and rank new S-Remiketamine analogues targeting the NMDA receptor, with attention to metabolic compatibility via CES1. Such preclinical work may inform the development of next-generation dissociative therapeutics with improved efficacy or safety profiles. While not immediately actionable for policy or access, it signals ongoing innovation in the ketamine analog space, which could impact future clinical research and commercial drug pipelines.
Clinical research Practice recommendations published

Best-practice recommendations for short-term ketamine in depression

Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations
Why it matters ◈ Mixed
This review synthesizes current evidence and regulatory guidance for psychiatrists using oral, subcutaneous, and nasal ketamine formulations in depressive disorders, highlighting that only intranasal esketamine and IV racemic ketamine have robust regulatory and trial support. Subcutaneous racemic ketamine is the best-supported non-IV off-label option, while oral and compounded nasal forms require heightened caution due to limited evidence and safety uncertainties. The recommendations may influence clinical protocols, insurance coverage, and regulatory scrutiny, especially as off-label ketamine use expands in psychiatric practice.
Objectives Ketamine and esketamine are increasingly used for treatment-resistant depressive disorders, particularly when rapid symptom reduction is clinically desirable. Intranasal esketamine has a product-specific regulatory framework in several jurisdictions, whereas most racemic ketamine formulations remain off-label for psychiatric indications. This narrative review provides practical recommendations for psychiatrists considering short-term ketamine interventions in depressive disorders, with emphasis on oral solution, oral tablets, subcutaneous injection, and nasal spray formulations. Methods We conducted a narrative review and clinical-practice synthesis of PubMed/MEDLINE-indexed literature, open bibliographic sources, and regulatory documents, searched through 20 July 2026. Search concepts covered ketamine and esketamine, treatment-resistant major depressive disorder, intravenous, oral, subcutaneous, and intranasal administration, dosing, monitoring, treatment setting, substance-use risk, misuse/diversion, and short-term intervention. Evidence was prioritized by study design and regulatory status; practical recommendations were categorized according to whether they were label-supported, directly evidence-supported, or based mainly on expert-practice synthesis. Results Evidence is strongest for labeled intranasal esketamine and intravenous racemic ketamine. Among the non-IV approaches reviewed here, subcutaneous racemic ketamine has coherent randomized evidence for flexible-dose short-term treatment; oral ketamine has limited but supportive small-trial and systematic-review evidence, with newer prolonged-release tablets remaining formulation-specific and investigational; and compounded racemic intranasal ketamine has weaker, more heterogeneous evidence. For all off-label racemic formulations, optimal dosing, frequency, durability, long-term safety, misuse risk, and maintenance strategy remain incompletely established. Conclusions Short-term ketamine treatment should be protocolized, measurement-based, supervised, time-limited, and embedded in a broader treatment plan for depressive disorders. For off-label racemic ketamine, the best-supported non-IV short-term regimen is supervised subcutaneous dosing with response-guided titration. Oral ketamine may be considered when parenteral or regulated nasal options are inaccessible, but it requires cautious patient selection, controlled dispensing, and objective monitoring. Esketamine nasal spray should follow the approved product label where available, whereas compounded racemic nasal ketamine should be reserved for exceptional circumstances.
Clinical research Review published

Review: Psychedelics, ketamine, and cannabinoids for opioid use disorder

Novel pharmacotherapies for opioid use disorder and opioid withdrawal
Why it matters ◈ Mixed
This review synthesizes emerging evidence for psychedelics (notably ibogaine), ketamine, and cannabinoids as adjunctive or alternative therapies for opioid use disorder and withdrawal, highlighting both promise and significant safety and regulatory barriers. While ketamine and cannabinoids show preliminary benefits, psychedelic research is hampered by limited controlled data and ongoing legal restrictions. The authors call for more rigorous trials and policy changes to enable research, signaling growing scientific and regulatory interest in novel OUD treatments.
Introduction Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor. Methods We conducted a narrative review of emerging pharmacologic approaches for OUD and opioid withdrawal syndrome, focusing on ketamine and NMDA receptor antagonists, cannabinoids, psychedelics, and incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists. Results Ketamine has preliminary randomized evidence suggesting potential effects on abstinence, withdrawal, craving, and psychotherapy augmentation. Cannabidiol may reduce cue-induced craving and anxiety, whereas dronabinol may modestly suppress opioid withdrawal symptoms. Psychedelic research, particularly involving ibogaine, shows observational signals for withdrawal reduction and abstinence but is limited by safety concerns, regulatory barriers, and sparse controlled evidence. Incretin-based therapies have generated strong observational signals linking GLP-1–based treatment to reduced overdose and OUD-related outcomes, though prospective trials remain limited. Discussion Across these therapeutic classes, convergent mechanisms include modulation of mesolimbic reward circuitry, cue-reactivity, stress responsivity, neuroplasticity, and cognitive flexibility. Future studies should prioritize rigorous blinding assessment, active comparators, objective endpoints, standardized cue-reactivity measures, diverse samples, and careful safety monitoring. Regulatory policies should facilitate the development and implementation of future research in novel therapies for OUD.
Clinical research Research published

ED drug detection study informs early warning systems, harm reduction

Evaluating analytically confirmed detections of illicit drugs and novel psychoactive substances in the emergency department and how the findings could contribute to the development of an early warning system.
Why it matters ▲ Favorable
This research provides objective data on illicit and novel psychoactive substance detections in emergency settings, highlighting the accuracy of clinician assessments and specific risks such as MDMA-associated serotonin toxicity. Such findings can directly inform clinical protocols and the development of early warning systems, supporting harm reduction and public health surveillance. While not a regulatory or legal change, the study offers actionable insights for clinicians, researchers, and policymakers monitoring drug-related harms.
Patients presenting to the Emergency Department with illicit drug intoxication are a frequent occurrence. However, objective data on specific illicit drugs and novel psychoactive substances are lacking. This thesis evaluates the impact of forensic laboratory blood analysis paired with clinical information. Key findings include high clinician accuracy in determining illicit drug intoxication (PPV0.82); median methamphetamine concentration of 0.12 mg/L and that concentration was not associated with psychotic symptoms; and 3,4-methylenedioxymethamphetamine (MDMA)concentration was associated with serotonin toxicity (p=0.003). Such objective data can inform clinical practice and an early warning system, representing public health research translation for harm reduction.
Clinical research Phase 3 readout

RCT: Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.
Why it matters ▲ Favorable
This randomized clinical trial provides high-quality evidence on the efficacy and safety of serial ketamine infusions for patients with treatment-resistant bipolar depression. The results may inform clinical guidelines, payer decisions, and regulatory pathways for ketamine use beyond unipolar depression. Positive findings could accelerate broader adoption in psychiatry and shape future research on psychedelic and dissociative therapies for mood disorders.
Clinical research Clinical result announced

Ketamine shows antidepressive effects in refractory bipolar depression

Ketamine Showed Antidepressive Effects in Refractory Bipolar Depression
Why it matters ▲ Favorable
New evidence that ketamine is effective in treatment-resistant bipolar depression could expand therapeutic options for a population with limited alternatives. This finding may prompt further clinical trials and could influence guidelines or off-label use, though regulatory and safety considerations remain. The result is notable for clinicians and researchers focused on mood disorders.
Clinical research Phase 1 results

Phase 1 trials show BI 1569912 (GluN2B NAM) is safe, well-tolerated in humans

Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials
Why it matters ▲ Favorable
Three phase 1 trials of BI 1569912, a GluN2B-selective NMDA receptor negative allosteric modulator, found it to be safe and well-tolerated in healthy adults, with no serious adverse events or dissociation observed. This supports further clinical development of BI 1569912 as a novel neuropsychiatric agent, though it is not a classic psychedelic and does not induce altered states. The favorable pharmacokinetic profile and tolerability across age groups may interest researchers and companies exploring new CNS therapeutics, but direct relevance to psychedelic medicine is limited.
Background: BI 1569912 is an orally administered, GluN2B-selective negative allosteric modulator at the N-methyl-D-aspartate receptor. Aims: To investigate the safety, tolerability and pharmacokinetics (PK) of BI 1569912 in healthy males across three partially randomised, placebo-controlled, parallel-group phase I trials. Methods: Trial 1 evaluated single rising doses (SRD) of BI 1569912 versus placebo in Germany and assessed formulation and food effects on bioavailability. Trial 2 evaluated multiple rising doses (MRD) of BI 1569912 versus placebo in young and elderly participants in Germany. Trial 3 investigated single rising and multiple doses (MD) of BI 1569912 in participants in Japan, including PK to assess morning versus evening dosing. Results: Trial completion/randomisation numbers were: Trial 1 (SRD part, 54/55; bioavailability/food effect part, 8/13); Trial 2 (MRD part, 71/71; Elderly part, 12/12); Trial 3 (SRD part, 32/32; MD part, 12/12; evening PK part, 12/12). No deaths, serious adverse events (AEs), AEs of special interest, or discontinuations because of AEs were reported. There was no clinical evidence clearly suggestive of dissociation. After oral administration, BI 1569912 was rapidly absorbed and eliminated, with dose-proportional increases in plasma exposure. Formulation (oral solution vs tablet) did not affect PK. Administration with food reduced C max and delayed T max without affecting AUC; likewise, evening dosing lowered C max versus morning while AUC remained similar. Steady state was achieved by Day 3 of multiple dosing. Exposure was similar between young and elderly participants. Urinary excretion of unchanged drug was negligible. Conclusions: BI 1569912 demonstrated favourable safety and PK profiles in healthy participants. Clinical trial registration: Trial 1 (ClinicalTrials.gov: NCT04445090 (1447-0001)); Trial 2 (ClinicalTrials.gov: NCT04978506 (1447-0002)); Trial 3 (ClinicalTrials.gov: NCT04958252 (1447-0004)).
Clinical research Phase 2/3 RCT readout

IV Ketamine shows efficacy for treatment-resistant bipolar depression in RCT

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression
Why it matters ▲ Favorable
This double-blind, randomized controlled trial provides the strongest evidence to date that serial IV ketamine infusions are effective and well tolerated for treatment-resistant bipolar depression, with no observed mania or psychosis. The results support expanding ketamine's clinical use beyond major depressive disorder and may influence guidelines, payer coverage, and regulatory pathways for bipolar depression. The safety profile is especially notable given concerns about mood destabilization in this population.
Importance Antidepressant efficacy of intravenous (IV) ketamine has been demonstrated in major depressive disorder; however, the efficacy and safety of ketamine for bipolar depression remain largely unknown, with limited data available in this specific population. Objective To evaluate the efficacy, safety, and tolerability of adjunctive IV ketamine compared with midazolam for treatment-resistant bipolar I or II depression (TRBD). Design, Setting, and Participants The Ket-BD study (Ketamine for Treatment-Resistant Bipolar Disorder) was an investigator-led, double-blind, midazolam-controlled randomized clinical trial conducted at 3 sites in Ontario, Canada, from July 2022 to November 2025. Participants included adult outpatients (aged 21-65 years) with a primary bipolar I or II disorder DSM-5 diagnosis with a current moderate to severe major depressive episode (Montgomery-Åsberg Depression Rating Scale [MADRS] score ≥21), having had at least 2 failed trials of evidence-based pharmacotherapies. Data were analyzed from November 2025 through February 2026. Interventions Participants were randomized 1:1 to receive 4 flexibly dosed 40-minute infusions over 2 weeks of either ketamine (0.5-0.75 mg/kg) or midazolam (0.02-0.03 mg/kg) adjunctive to a stable dose of at least 1 mood stabilizer or antipsychotic. Main Outcomes and Measures The primary outcome was change in depression symptom severity measured by the observer-rated MADRS score from baseline to end of treatment (day 14). Safety and tolerability were assessed with close evaluation for potential treatment-emergent mania, hypomania, mixed features, or psychosis. Results Of 68 randomized participants (mean [SD] age, 44.4 [11.8] years; 38 female [55.8%]), 63 were included in the final efficacy analysis as 5 participants withdrew (1 ketamine, 4 midazolam) before the primary end point. In the primary efficacy analysis, controlling for sex, bipolar type, and baseline MADRS, the mean MADRS score at day 14 was significantly lower in the ketamine group compared to the midazolam group (between-group difference = −7.3 points; 95% CI, −12.0 to −2.5; P = .003; Cohen d = 0.7). No cases of mania, hypomania, psychosis, or suicide attempts were observed in either group. One case of mixed features (subthreshold hypomanic symptoms) was observed in each group. After the first infusion, 31 of 66 participants (47%) correctly guessed treatment allocation. Conclusions and Relevance In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects compared to midazolam. Trial Registration ClinicalTrials.gov Identifier: NCT05004896
Clinical research Study results announced

Psilocybin therapy shows strong potential for cocaine addiction

Psilocybin therapy shows strong potential for treating cocaine addiction
Why it matters ▲ Favorable
Early evidence that psilocybin may help treat cocaine addiction could open new research and regulatory pathways for substance use disorder therapies. If confirmed in larger, controlled trials, this could expand the clinical indications for psychedelic-assisted therapy and drive further investment and policy interest. However, details on study design and endpoints are needed to assess impact.
Neuroscience Peer-reviewed publication

Normative modeling reveals brain changes in meth and ketamine use disorders

Heterogeneous structural brain signatures of methamphetamine and ketamine use disorders revealed by normative modeling.
Why it matters ◈ Mixed
This study uses advanced brain imaging to identify distinct structural brain changes associated with methamphetamine and ketamine use disorders. The findings may inform risk assessment, clinical monitoring, and the development of interventions for substance use disorders. For the psychedelic field, the work underscores the importance of differentiating recreational or problematic use from therapeutic contexts, especially as ketamine is widely used off-label for depression. Policymakers and clinicians should consider these neurobiological signatures when evaluating safety and access frameworks.
Clinical research Peer-reviewed study

Cannabis co-use, age linked to psilocybin experience differences

Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.
Why it matters ◈ Mixed
This study identifies age and concurrent cannabis use as significant factors influencing the subjective experience and perceived benefits of psilocybin. The findings suggest that demographic and behavioral variables may affect both outcomes and safety profiles in psilocybin research and clinical use. Policymakers and trial designers should consider these variables in eligibility criteria, risk assessment, and harm reduction strategies.
Clinical research Scoping review published

Scoping review: Psychological mechanisms in PAT for substance use disorders

Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders
Why it matters ◈ Mixed
This comprehensive scoping review synthesizes current evidence on the psychological mechanisms underpinning psychedelic-assisted therapy (PAT) for substance use disorders (SUDs), highlighting six key domains such as emotional processing, identity transformation, and mystical experiences. While mystical-type experiences are most frequently linked to reductions in substance use, the evidence remains largely correlational, underscoring the need for more rigorous, causal research. The findings emphasize the importance of context and suggest that optimizing PAT for SUDs will require a nuanced understanding of these interacting psychological processes. This review provides a valuable roadmap for researchers and clinicians designing future trials and treatment protocols.
Abstract Purpose of Review Psychedelic-assisted therapy (PAT) has re-emerged as a potential intervention for substance use disorders (SUDs), yet the psychological mechanisms underlying behaviour change remain poorly synthesised. This scoping review mapped and evaluated proposed psychological processes underpinning PAT in adults with SUDs. Recent Findings Peer-reviewed English-language empirical studies involving adults with SUDs or harmful substance use that examined psychological mechanisms of PAT were eligible for inclusion. Systematic searches of Embase, PubMed, PsycINFO and Scopus were conducted through 30 June 2026. Data were charted using a predefined extraction framework. Thirty-seven publications representing 23 unique cohorts ( n = 1003) met the inclusion criteria. Across studies of classical (psilocybin, ayahuasca) and non-classical psychedelics (ketamine, MDMA, ibogaine), six transdiagnostic mechanism domains were identified: (1) emotional processing, (2) insight, meaning-making and worldview change, (3) self-experience and identity transformation, (4) mystical or peak-type experiences, (5) relational and interpersonal shifts, and (6) motivation, values and behavioural regulation. Evidence ranged from qualitative and exploratory quantitative findings to preliminary quantitative studies explicitly examining associations between candidate psychological mechanisms and substance use outcomes. Mystical-type experiences were the most frequently examined and were associated with reductions in substance use and craving, although evidence remains largely correlational, with only one randomised trial demonstrating mediation. Qualitative findings highlighted the importance of therapeutic, relational, and sociocultural context in translating acute psychedelic experiences into psychological and behavioural change. Summary PAT appears to operate through interacting psychological processes rather than a single mechanism. Although recent studies have begun to explicitly examine candidate psychological mechanisms in relation to substance use outcomes, causal mechanisms remain to be established. Clarifying these mechanisms across populations and psychedelic compounds will be critical for optimising treatment models and guiding future research.
Clinical research Systematic review published

Systematic review: Ketamine for depression and pain in advanced cancer

A rapid systematic review of palliative uses of ketamine for depression and pain in people living with advanced cancer.
Why it matters ◈ Mixed
This systematic review synthesizes evidence on ketamine's efficacy for depression and pain in palliative cancer care, highlighting both therapeutic potential and ongoing uncertainties about safety and optimal protocols. The findings may inform clinical guidelines and support further research or compassionate use policies, but variability in study quality and outcomes underscores the need for rigorous trials. Stakeholders should monitor for follow-up studies and potential regulatory interest in expanding ketamine's approved indications.
Clinical research Peer-reviewed study

Ketamine Dose and Duration Effects in Internalizing Disorders

Ketamine Dose and Duration Effects in Internalizing Disorders.
Why it matters ◈ Mixed
This peer-reviewed study provides new evidence on how ketamine dosing and treatment duration impact outcomes in internalizing disorders such as depression and anxiety. The findings may inform clinical protocols, guide future trial designs, and shape regulatory discussions around optimal use and safety. However, translation to standard care or policy will depend on replication and integration with broader evidence.
Clinical research Peer-reviewed publication

Qualitative study compares psilocybin responders vs. non-responders in OCD

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.
Why it matters ◈ Mixed
This qualitative analysis provides new insight into the psychological mechanisms differentiating psilocybin responders from non-responders in treatment-resistant OCD. By highlighting factors such as surrender, disidentification, and cognitive reappraisal, the study informs future trial design, patient selection, and therapeutic support models. While not a pivotal efficacy readout, these findings help refine clinical protocols and may guide regulatory and payer expectations for psychedelic-assisted therapy.
Clinical research Peer-reviewed publication

Review: Ketamine's potential to shift procedural sedation practices

Will Ketamine Change Sedation Practices for Procedural Sedation?
Why it matters ◈ Mixed
This peer-reviewed article examines whether ketamine could alter current standards for procedural sedation, a topic relevant for both clinical practice and ongoing research. If ketamine is shown to offer superior safety or efficacy, it could prompt updates to sedation protocols and influence regulatory guidance. However, as a review or perspective piece, it does not itself change policy or access, but may inform future clinical trials and guideline development.
Neuroscience Peer-reviewed study published

Human thalamus functional architecture mapped via SEEG in epilepsy patients

Unveiling Functional Architecture of Human Thalamus: AStereoelectroencephalography Study
Why it matters ▲ Favorable
This study provides direct evidence of the complex functional architecture of the human thalamus using stereoelectroencephalography in epilepsy patients. It advances understanding of thalamo-cortical circuits, which are implicated in both neurological and psychiatric disorders relevant to psychedelic research. The findings may inform future targeted therapeutic strategies, including those involving neuromodulation or psychedelic interventions that act on thalamo-cortical pathways. While not directly about psychedelics, this work is foundational for translational research and clinical trial design in neuropsychiatry.
ABSTRACT As a critical hub in the thalamo‐cortical circuit, the human thalamus engages in a spectrum of fundamental and advanced brain functions through widely distributed circuits. Clinically, dysfunction of thalamo‐cortical circuits is shown to be profoundly implicated in a wide range of neurological and psychiatric diseases. Nevertheless, the neuroanatomical substrates governing these functions of the thalamus have rarely been directly mapped in humans. Here, we overviewed the acute responses of direct electrical stimulation (DES) delivered to the distributed thalamus sites in 52 epilepsy patients admitted for presurgical stereoelectroencephalography. Specifically, DES of the thalamus evoked a broad spectrum of in‐situ responses spanning fundamental functions such as sensory and motor processing, extending to complex neural operations encompassing neurovegetative regulation, cognitive processing, emotional modulation, and multimodal responsiveness. Moreover, through the integration of DES with functional human connectome ( n = 1000), we found an intra‐thalamic intrinsic functional network associated with each specific clinical response. Our data provide direct substantiation for the complex functional architecture of the human thalamus, advancing current understanding of its role and potentially culminating in targeted therapeutic strategies tailored to ameliorate symptom‐specific neural circuit disorders.
Clinical research Case report published

Case report: Subcutaneous ketamine for treatment-resistant depression

CETAMINA SUBCUTÂNEA NO TRATAMENTO DE DEPRESSÃO REFRATÁRIA
Why it matters ▲ Favorable
This case report documents rapid clinical improvement in a patient with treatment-resistant depression following subcutaneous ketamine administration. While promising, the evidence is limited to a single case and does not establish efficacy or safety for broader clinical use. The report highlights the need for controlled studies on alternative ketamine delivery methods and may inform future research protocols.
O transtorno depressivo resistente representa um grave desafio terapêutico. A cetamina, antagonista não competitivo do receptor N-metil-D-aspartato, tem se mostrado promissora no manejo de casos refratários. O objetivo deste estudo foi relatar o desfecho do uso subcutâneo de cetamina em paciente com TDR, refratária a múltiplos tratamentos farmacológicos e eletroconvulsoterapia. Trata-se de um relato de caso único, com análise clínica e aplicação do Inventário de Depressão de Beck (BDI) antes, durante e após protocolo de cetamina subcutânea. No estudo, a paciente apresentou melhora significativa dos sintomas depressivos, com redução do escore do BDI de 48 para 29 pontos após a terceira aplicação de cetamina, mantendo-se esse resultado até o término das cinco aplicações do protocolo. O relato de caso reforça o potencial terapêutico da cetamina subcutânea, evidenciando rápida resposta clínica e ampliando perspectivas para tratamentos inovadores.
Epidemiology / Community Published survey study

Survey: Patterns of Psychedelic Use in Italy (Global Psychedelic Survey 2025)

Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey
Why it matters ◈ Mixed
This is the first large-scale survey describing psychedelic use patterns among Italian adults, highlighting intermittent use, high rates of polysubstance exposure, and predominantly non-clinical motivations. The findings suggest reductions in alcohol and tobacco use among some users, but the cross-sectional design limits causal inference. While not directly impacting law or access, this data provides important context for researchers, clinicians, and policymakers considering future studies or regulatory changes in Italy.
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based, cross-sectional design. Descriptive analyses examined sociodemographics, substance use histories, motivations, intense experiences, changes in other substance use, and healthcare engagement. Results: Among 731 participants (mean age 37.4 ± 11.3 years; 59.8% male; 70.0% urban), 90.1% reported lifetime regular-dose psychedelic use, most commonly psilocybin (77.3%), MDMA (69.5%), LSD (67.0%), and ketamine (46.3%). Polysubstance exposure was common, with 83.3% reporting use of ≥2 psychedelics. Lifetime alcohol, cannabis, and nicotine use exceeded 90%, and 36.0% reported a substance-related problem. Past-year psychedelic use was reported by 76.7%, with the majority using once to a few times per year. 58.4% reported lifetime microdosing. Motivations were predominantly non-clinical. Intense experiences were often rated positive or mixed. Self-reported reductions in alcohol (45.9%) and tobacco (34.9%) were frequent. Conclusions: These findings provide the first large-scale characterization of psychedelic use patterns among a highly engaged Italian-affiliated psychedelic community. Patterns of consumption were generally intermittent, often embedded within polysubstance use contexts, and were primarily motivated by personal growth. Although many respondents reported positive experiences and reductions in other substance use, these observations require confirmation in longitudinal research.
Clinical research Pilot study published

Pilot: Music therapy plus standard care for SUD shows immediate craving reduction

Music therapy in community-based substance misuse treatment: Exploring psychometric, qualitative and EEG measures related to craving, inhibition and affective processing
Why it matters ◈ Mixed
This mixed-methods pilot suggests music therapy may provide immediate craving relief in community-based SUD treatment, with EEG and psychometric signals warranting further study. However, no significant group differences were found in primary craving or EEG outcomes post-intervention, and the small sample limits generalizability. The study highlights the value of integrating neural and qualitative measures in adjunctive interventions, but larger, more rigorous trials are needed before clinical or policy impact.
Music therapy (MT) is a promising adjunctive intervention for substance use disorder (SUD), yet multi-modal studies integrating neural, psychometric and qualitative measures are lacking. We conducted a mixed-methods pilot study with sixteen participants from a community-based substance-use treatment service to explore adjunctive MT plus standard treatment (ST) compared with ST alone. Participants received either six weekly MT sessions plus ST or ST alone. Assessments included resting-state and event-related electroencephalography, psychometric measures and semi-structured interviews addressing craving, affective symptoms, inhibitory control and participants’ therapeutic experiences. Craving Thermometer ratings suggested immediate reductions in present-moment craving after MT sessions, indicating that the conscious perception of craving improvement may emerge primarily in the immediate post-session window. Baseline-adjusted analyses showed no significant group differences at post intervention in Brief Substance Craving Scale scores or resting-state beta power z-scores, although the latter showed a larger descriptive reduction in the MT group. MT and ST differed significantly in post-intervention frontal alpha asymmetry after baseline adjustment, identifying affective-motivational processing as a candidate domain for future research. The MT group also showed a nominal, non-significant increase in P3d amplitude during a Go/NoGo task, suggesting response-inhibition-related EEG activity as a candidate signal for future investigation. Qualitative themes contextualised these findings by highlighting craving reduction, emotional reflection, reluctance to discuss craving and therapeutic connection. This pilot supports combining session-level, psychometric, qualitative and EEG measures in community-based MT for SUD. Future trials with larger samples, robust allocation, clearer comparators and longer-term follow-up are needed. Trial registration. NCT********, Registered * January 20**.
Neuroscience Conceptual analysis published

Redefining 'plasticity' in neuroscience and psychedelic therapy research

On the meaning of “plasticity” in neuroscience and mental health research and its relation to the action of psychedelic therapy
Why it matters ◈ Mixed
This paper challenges the prevailing use of 'plasticity' as a catch-all explanation for psychedelic effects in mental health research, highlighting conceptual confusion and proposing a more precise framework (MR-P) for linking brain changes to clinical outcomes. This matters because it urges greater rigor in interpreting biomarkers and mechanistic claims in psychedelic trials, potentially impacting how future studies are designed and how results are communicated to regulators, funders, and the public. The work may help prevent overgeneralization and improve translational relevance for patient care.
First-line dictionary definitions of “plasticity” describe it as the ability (of a thing) to be shaped or molded; we call this “plasticity proper” (PP). In neuroscience, however, “neural plasticity” or “neuroplasticity” is defined as an induced change in brain function or structure. These two plasticities are not the same. Several popular biomarkers of neuroplasticity index part of an evoked process, often linked to learning. Paradoxically, these processes often bias phenotypic canalization, the opposite of phenotypic plasticity. Recognizing this paradox puts into question the custom of using “plasticity” as a shorthand for all neuroplastic phenomena. This custom risks an overgeneralization fallacy and the conflation of assays of evoked brain changes with plasticity proper. We also question extrapolating from any biomarker of neuroplasticity to improved mental health, whether it be aligned with plasticity proper or not. The relationship between the two is, logically, context dependent . As a resolution, we propose a new construct, “mediational and recalibrative plasticity” (MR-P) and show how markers of it can describe and predict examples of phenotypic plasticity, where those phenotypes are states and traits relevant to mental health. In contrast to many markers of neuroplasticity, MR-P is aligned with plasticity proper.
Clinical research Qualitative study published

Qualitative study: Psilocybin response in treatment-resistant OCD

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD
Why it matters ◈ Mixed
This qualitative study highlights psychological factors—such as surrender, self-compassion, and emotional processing—that differentiate psilocybin responders from non-responders in treatment-resistant OCD. The findings suggest that therapeutic benefit may depend more on the quality of psychological engagement than on the intensity of the psychedelic experience itself. This insight could inform future trial design, patient selection, and therapist training, but the small sample size limits generalizability. The study underscores the importance of integrating subjective and process-oriented measures in psychedelic research.
Introduction Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders. Materials and methods A qualitative case comparison was conducted using semi-structured interviews from six participants enrolled in a randomized controlled trial of single-dose psilocybin with psychological support for treatment-resistant OCD. Participants were purposively selected to contrast three responders with marked symptom improvement and three non-responders with minimal improvement or worsening symptoms. Interviews were conducted approximately 1-2 months post-dosing and analyzed using reflexive thematic analysis. Results Four dialectical themes captured key contrasts between responders and non-responders: 1) Surrender vs. Control, 2) Disidentification with OCD and Self-Compassion vs. Overidentification with OCD, 3) Emotional Breakthrough vs. Emotional Containment, and 4) Reappraisal of OCD as Inconsequential vs. Sustained Conviction in OCD. Among responders, surrender during the acute session appeared to enable subsequent psychological shifts. The self was separated from OCD while self-compassion was developed; emotions were experienced directly in the body without the usual cognitive filtering; and OCD-related concerns were spontaneously reappraised as arbitrary and inconsequential. Among non-responders, control was maintained or surrender was experienced as overwhelming; identification with OCD and persistent self-criticism remained; difficult emotions were avoided or accessed without lasting breakthrough; and conviction in OCD’s logic and demands was maintained or intensified. Discussion The distinction between intellectual insight and embodied change emerged as central: responders described viscerally felt insights that spontaneously shaped behavior, whereas non-responders articulated understanding without corresponding change in feeling or action. Across themes, surrender during the acute session appeared to enable subsequent shifts in self-concept, emotional processing, and reappraisal of OCD as inconsequential. Therapeutic benefit may depend on the quality of psychological engagement—particularly the capacity to surrender, tolerate intense emotion, and translate insight into behavioral change—rather than experiential intensity alone. The distinction between intellectual insight and embodied change emerged as central to understanding differential response.
Clinical research Literature review published

Review: Psilocybin shows promise for neuroplasticity in TRD

Psilocibina e neuroplasticidade: novas perspectivas terapêuticas para depressão resistente
Why it matters ▲ Favorable
This integrative review synthesizes recent evidence that psilocybin enhances neuroplasticity and improves symptoms in treatment-resistant depression (TRD). The findings support ongoing clinical interest and highlight the need for further trials and regulatory clarity. While not a new clinical trial, this review consolidates key neurobiological and therapeutic signals relevant for researchers and clinicians.
Depression is a multifactorial mental disorder and a leading cause of global disability. A subset of patients does not respond to conventional antidepressants, characterizing treatment-resistant depression (TRD). This study aimed to investigate the therapeutic potential of psilocybin in TRD, focusing on its effects on neuroplasticity. An integrative literature review was conducted using PubMed, Scielo, and Cochrane Library, including studies published between 2019 and 2026. Findings indicate that psilocybin increases brain-derived neurotrophic factor (BDNF) expression, promotes dendritic spine growth, and enhances synaptic reorganization in brain regions associated with mood and cognition, such as the prefrontal cortex and hippocampus. Clinical trials demonstrate significant and sustained improvement in depressive symptoms after one or two administrations, particularly when combined with psychotherapy. Psilocybin emerges as a promising therapeutic alternative for TRD; however, further studies and regulatory frameworks are required to ensure safe and effective use.
Neuroscience Research published

Psilocybin crystal structure determined

Single-crystal structure determination of psilocybin after dehydration.
Why it matters ▲ Favorable
The determination of psilocybin's single-crystal structure after dehydration provides a deeper understanding of its molecular properties. This could enhance the development of more stable formulations for clinical use and support further research into its therapeutic mechanisms. While not directly impacting policy or market structure, it is a valuable contribution to the scientific foundation of psychedelic medicine.
Clinical research Grant awarded

Stanford awarded grant for ketamine OCD study

Stanford Psychiatry's Carolyn Rodriguez Awarded Grant Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD
Why it matters ▲ Favorable
Stanford Psychiatry's Carolyn Rodriguez has received a grant to study the mu opioid mechanisms of ketamine's rapid effects in treating OCD. This research could shed light on the neurobiological pathways involved in ketamine's therapeutic effects, potentially leading to more targeted treatments for OCD. The study may also enhance understanding of ketamine's broader applications in psychiatric disorders.
Neuroscience Peer-reviewed study

ERA-based 40-Hz ASSR profiling extends to mood and psychotic disorders

Phase delay and neural dyssynchrony of the 40-Hz auditory steady-state response in mood and psychotic disorders
Why it matters ▲ Favorable
This study demonstrates that widely available ERA systems can detect neural synchrony deficits in both mood and psychotic disorders, not just schizophrenia. The findings support the potential for scalable, pragmatic biomarker development relevant to precision psychiatry. This could accelerate patient stratification and outcome measurement in psychedelic trials targeting depression, bipolar disorder, or schizophrenia, ultimately improving research rigor and clinical translation.
Background Impaired gamma-band neural synchrony has emerged as a promising biomarker for precision psychiatry; however, clinically scalable methods for individual-level assessment remain limited. Widely available evoked response audiometry (ERA) systems offer a pragmatic and accessible platform for measuring the 40-Hz auditory steady-state response (ASSR), and their utility has been demonstrated in patients with schizophrenia. This study investigated whether ERA-based profiling could be extended to mood disorders, which are believed to share underlying biological mechanisms with schizophrenia. Methods Using a conventional ERA system, phase delay and phase-locking status of the 40-Hz ASSR were assessed in 107 participants, including individuals with schizophrenia (n = 29), bipolar disorder (n = 24), major depressive disorder (n = 25), and healthy controls (n = 29). Phase locking status was classified as either a phase-locked response or a nonphase-locked response (NPLR). Results Compared with the healthy control group, all clinical groups exhibited significant phase delays in the 40-Hz ASSR. Phase-locking analysis identified NPLR not only in individuals with schizophrenia but also in a subset of participants with bipolar disorder and major depressive disorder. Conclusion These findings extend previous evidence of 40-Hz ASSR phase delay and demonstrate that individual-level NPLR assessment using a conventional ERA system applies beyond schizophrenia to bipolar disorder and major depressive disorder. ERA-based evaluation of the 40-Hz ASSR may represent a practical and scalable approach for biomarker development in mood and psychotic disorders.
Neuroscience Preclinical research published

Key brain circuit mediates antidepressant and ketamine response in mice

The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response
Why it matters ▲ Favorable
This study identifies a specific brain circuit (IL → RE → vHIPP) as central to antidepressant effects and neuroplasticity, including those induced by ketamine. The findings provide mechanistic insight into how rapid-acting antidepressants may work, potentially guiding future research on psychedelic and novel antidepressant therapies. While preclinical, this research could inform both target discovery and biomarker development for clinical trials.
Abstract The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view linking these processes remains elusive. Here, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) exerts rapid antidepressant-like effects across multiple behavioral domains in a mouse model of stress-induced depression. IL stimulation exerts top-down control over the hippocampus, enhancing structural plasticity, restoring long-term potentiation deficits and improving state-dependent network dynamics in the ventral hippocampus (vHIPP). We identify the thalamic nucleus reuniens (RE) as a necessary mediator of these effects. Notably, direct inhibition of RE, its inputs from IL or projections to vHIPP, blocks both IL stimulation-induced antidepressant response and the therapeutic and neuroplastic effects of ketamine. Our findings demonstrate that the functional IL → RE→vHIPP circuit plays a central role in the antidepressant response, linking circuit activity, hippocampal plasticity, and depressive-like behaviors.
Clinical research Peer-reviewed article

Nutrition's role in 5-MeO-DMT clinical trials highlighted

The Role of Nutrition in Psychedelics Clinical Trials: Key Considerations and Recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
Why it matters ▲ Favorable
This article provides guidance on how nutrition may impact outcomes in 5-MeO-DMT clinical trials. While not a regulatory or legal development, it addresses a methodological variable that could influence trial design, participant safety, and data interpretation. Researchers and sponsors should consider these recommendations to improve trial rigor and reproducibility.
Clinical research Published study

Study: Predictors of Psilocybin Use Intentions for Mental Health

Factors Associated with Intentions to Use Psilocybin for Mental Health in Relation to Psychotherapy, Psychiatric Medications, and Natural/Synthetic Options
Why it matters ◈ Mixed
This study highlights demographic and psychological factors influencing willingness to use psilocybin for mental health, including a preference for natural over synthetic forms. These findings may inform future clinical trial recruitment, public health messaging, and market positioning if psilocybin receives FDA approval. The results suggest that patient attitudes toward natural versus synthetic options could shape demand and access strategies.
= 1,102), we examined the intentions to use psilocybin in a mental health context in relation to psychotherapy, psychiatric medication, and natural versus synthetic options. We also examined potential predictors of the intentions to use psilocybin. In Study 1, we found that participants had significantly lower intentions to use psilocybin in a mental health context versus psychotherapy and traditional psychiatric medications. We also found that males reported being more open to using psilocybin as compared to females whereas females reported being more open than males to using psychotherapy. Finally, psilocybin use intentions were negatively associated with age, and positively associated with mindfulness, narcissism, and current self-reported depression. In Study 2, we found that participants had stronger intentions to use a natural version of psilocybin isolated from mushrooms as compared to an identical synthetic version or a synthetic psilocybin analog that elicits the same biological effects (i.e. the three types of psilocybin or psilocybin-like compounds currently of interest). Overall, these studies provide novel insights into the factors that might influence psilocybin use in a mental health context if FDA-approved.
Neuroscience Published study

Molecular-enriched fMRI improves brain-age prediction via neurotransmitter mapping

Investigating the Contribution of Molecular‐Enriched Functional Connectivity to Brain‐Age Analysis
Why it matters ▲ Favorable
This study demonstrates that integrating molecular-enriched functional connectivity with structural MRI enhances brain-age prediction and links it to specific neurotransmitter systems. For psychedelic research, these methods could help clarify how interventions affect brain aging and neuroplasticity, especially given the relevance of serotonin and dopamine systems. While not directly about psychedelics, the approach may inform biomarker development and mechanistic studies in future clinical trials.
Brain-age prediction from neuroimaging data provides a proxy of biological aging, yet most models rely on structural magnetic resonance imaging (MRI), a modality that captures macroanatomy but offers limited biological specificity. We tested whether integrating molecular-enriched functional connectivity (FC), from resting-state functional MRI (rs-fMRI) data, improves brain-age prediction and biological explainability. We analyzed MRI data of 2,120 healthy adults (1,243/877 F/M; 18-90 years) from three public datasets. Molecular-enriched connectivity maps were derived with Receptor-Enriched Analysis of functional Connectivity by Targets (REACT) using receptor-density templates for the dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporter systems. Support vector regression models were applied to predict chronological age from molecular-enriched FC, structural morphometry, or both combined. The effect of multi-site variability was mitigated via ComBat harmonization with and without Empirical Bayes pooling. We additionally conducted a common-parcellation analysis to assess the impact of differing parcellations between modalities. Single-transporter molecular-enriched FC explained up to 51% of age variance. The most predictive transporter varied by dataset, with DAT dominating in the harmonized and common-parcellation settings. Combining the three molecular-enriched maps consistently improved prediction over any single map and increased explained variance up to 64%. In the merged multi-site cohort using a common parcellation, augmenting structural information with transporter-enriched FC reduced mean absolute error (MAE) from 6.02 to 5.81 years, supporting complementarity of the two modalities. In contrast, when different parcellations were applied, incorporating molecular-enriched FC into brain age prediction resulted in a 2% higher MAE compared to structural morphometry alone, suggesting that parcellation mismatch may obscure the functional contributions. In conclusion, molecular-enriched FC is a feasible and biologically informative extension to brain-age modeling, enhancing prediction and interpretability with respect to neurotransmitter systems.
Neuroscience Peer-reviewed study

MHCII in dopaminergic neurons prunes GABAergic synapses in neurodevelopmental disorders

MHC class II in dopaminergic neurons prunes GABAergic synapses in neurodevelopmental disorders
Why it matters ◈ Mixed
This study provides new mechanistic insight into how immune signaling (specifically MHC class II) in dopaminergic neurons may contribute to neurodevelopmental disorders by pruning GABAergic synapses. While not directly related to psychedelics, these findings could inform future research on how immune modulation or synaptic pruning mechanisms intersect with the therapeutic effects of psychedelics in neuropsychiatric conditions. The work is relevant for researchers exploring the neuroimmune interface and synaptic plasticity, but does not immediately impact legal, policy, or clinical access landscapes.
Although the brain was traditionally considered immune-privileged, recent studies show immune factors play key roles in brain function. Dysfunction of these factors is linked to neurodevelopmental disorders, but mechanisms remain unclear. Using a maternal immune activation (MIA) mouse model, we investigated immune-related genes in neurodevelopmental disorder pathogenesis. MIA mice showed increased locomotor activity and disrupted prepulse inhibition. RNA-seq and qPCR analyses revealed persistent increases in major histocompatibility complex class II (MHCII) expression and persistent decreases in GABAergic synapse-related gene expression, particularly glutamate decarboxylase (Gad) expression, in dopaminergic regions. These expressions were negatively correlated, and immunohistochemistry showed MHCII at postsynaptic GABAergic synapses on dopaminergic neurons. Patch-clamp recordings confirmed reduced mIPSC frequency in MIA mice. MHCII knockout mice showed opposite phenotypes, while MHCII overexpression in dopaminergic neurons decreased Gad expression. These results suggest MIA-induced MHCII upregulation enhances pruning of GABAergic synapses on dopaminergic neurons, leading to behavioral deficits.
Clinical research Review published

Review highlights regulatory and methodological gaps in ketamine/psilocybin trials

Beyond Efficacy Signals: Regulatory, Methodological, and Translational Challenges in Clinical Research on Ketamine and Psilocybin in Psychiatry
Why it matters ◈ Mixed
This structured review identifies persistent regulatory, methodological, and translational challenges in clinical research on ketamine and psilocybin for depression, including weaknesses in trial design, safety monitoring, participant diversity, and informed consent. The findings underscore that while ketamine is further along in evidence and implementation, psilocybin remains early-stage, and both require more robust, integrated evidence before widespread clinical adoption. The review’s synthesis of regulatory and methodological gaps is highly relevant for researchers, sponsors, and policymakers seeking to advance safe and effective psychedelic therapies.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) continue to drive interest in ketamine-family compounds and psilocybin, but antidepressant efficacy alone does not establish whether these interventions can be evaluated reliably or implemented responsibly. We conducted a structured narrative review using targeted PubMed/MEDLINE searches through 21 July 2026, hand-searching of reference lists, and review of current regulatory documents. Six studies conducted by the authors formed the empirical foundation, covering trial protocols, dose–response relationships, treatment context reporting, regulatory alignment, participant diversity, and informed-consent readability. Findings were synthesized across regulatory, internal methodological, contextual, external, ethical, and implementation domains. The six studies identified recurring weaknesses in protocol design, dose and endpoint selection, masking and expectancy assessment, safety monitoring and long-term follow-up, reporting of psychological support and treatment setting, participant representativeness, and consent comprehensibility. The wider literature broadly supports these conclusions. Ketamine has a more mature evidence and implementation base, whereas psilocybin remains at an earlier stage of clinical development. Responsible translation into clinical practice therefore requires integrated evidence addressing efficacy, causal validity, safety, treatment context, diversity, informed consent, durability, and service delivery, while clearly distinguishing legal requirements, regulatory guidance, evidence-based methodological practices, and the authors’ recommendations.
Clinical research Peer-reviewed review published

Comprehensive review: Psilocybin's pharmacology, safety, and clinical promise

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives
Why it matters ▲ Favorable
This review synthesizes the current scientific understanding of psilocybin's mechanisms, therapeutic potential, and safety profile, highlighting both promising clinical evidence and ongoing uncertainties around long-term effects and dosing. It underscores the need for standardized, rigorous research to address ethical and regulatory barriers before broader clinical adoption. The discussion of drug interactions and microdosing gaps is particularly relevant for clinicians and researchers designing future studies or protocols.
OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A literature search was conducted in PubMed and Google Scholar using the keywords "Psilocybin," "Psilocin," "Psychedelic therapy," "Psilocybe cubensis," and "Psychedelic microdosing," supplemented by manual searches of cross-references. All study types were included, from randomized trials to case reports. RESULTS: Psilocybin is metabolized into psilocin, which predominantly interacts with serotonin (5-hydroxytryptamine, 5-HT) receptors. These interactions contribute to enhanced synaptic plasticity, modulation of large-scale brain networks, and regulation of immune responses via microglial activity and suppression of pro-inflammatory cytokines. Preclinical and clinical evidence supports its efficacy in depression, anxiety, substance use disorders, neuropathic pain, epilepsy, and neuroinflammation. Psilocin also inhibits cytochrome P450 enzymes, raising concerns about drug interactions. Microdosing, though popular, remains inconclusive due to methodological limitations. CONCLUSIONS: Current findings suggest psilocybin offers sustained therapeutic effects and a favorable safety profile. However, uncertainties remain regarding long-term safety, individualized responses, and optimal dosing. Ethical and regulatory challenges require rigorous, standardized research for responsible clinical integration.
Clinical policy / Ethics Guidelines published

Portugal issues multidisciplinary clinical guidelines for psychedelic therapies

A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances
Why it matters ▲ Favorable
Portugal's national consensus document on psychedelic clinical use marks a significant step in harmonizing medical, ethical, and regulatory approaches for these therapies. The guidelines, developed by a coalition of pharmacists, psychologists, physicians, and ethics authorities, provide a framework for safe and responsible practice, emphasizing informed consent and multidisciplinary collaboration. This development may serve as a model for other European countries and supports the professionalization and legitimacy of psychedelic-assisted treatments.
The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical guidance. Across Europe, associations dedicated to therapeutic use of psychedelics are flourishing, and have produced clinical recommendations, while more generalist professional boards have contributed with various clinical reports, statements and guidelines. In Portugal this prompted a unique collaborative movement of professional associations of Pharmacists, Psychologists and Physicians to work with national ethics authorities, scientific societies and both research and clinical stakeholders, to produce a consensual recommendation addressing core aspects of psychedelic treatments. This statement reflects positions regarding informed consent, the determinants of medical and psychological interventions, ethical considerations and regulatory recommendations. The initial document was open for public consultation, inviting other stakeholders to contribute to the final version, published in Portuguese and translated here into English towards broader access. The statement underscores the importance of multidisciplinary and multiprofessional collaboration among psychiatrists, psychologists and pharmacists, towards establishing common guidelines and regulations to ensure safe and effective clinical applications. By addressing these factors, the recommendations aim to foster responsible therapeutic use, while safeguarding patient well-being.
Clinical research Peer-reviewed publication

Review urges wider ketamine use for sedation in interventional radiology

A Progressive Shift in Procedural Sedation: Is It Time to Embrace Ketamine in Interventional Radiology?
Why it matters ▲ Favorable
This peer-reviewed review highlights growing clinical support for ketamine as a procedural sedative in interventional radiology, suggesting a shift in practice norms. While not a regulatory or legal change, it signals increasing mainstream acceptance of ketamine's safety and utility outside psychiatry or anesthesia. This could expand clinical demand, influence hospital protocols, and indirectly shape policy debates on ketamine scheduling and access.
Clinical research Peer-reviewed review published

Comprehensive review of psilocybin's pharmacology and therapeutic potential

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.
Why it matters ▲ Favorable
This multidimensional review synthesizes current knowledge on psilocybin's pharmacology, ancestral use, and emerging therapeutic applications. Such comprehensive analyses help inform policymakers, clinicians, and researchers by clarifying evidence gaps and highlighting clinical promise. The review may support rational regulatory and research frameworks by contextualizing both risks and benefits, but does not itself change legal status or access.
Clinical research Review published

Review: Translating psilocybin treatment from research to practice

The trials of translating psilocybin treatment from research to practice.
Why it matters ◈ Mixed
This review highlights the complex challenges in moving psilocybin from controlled research settings into broader clinical practice. Key barriers include regulatory uncertainty, training requirements for providers, and the need for robust safety monitoring frameworks. The article underscores the importance of clear policy guidance and infrastructure to ensure safe, equitable, and evidence-based access as interest in psychedelic therapies grows.
Clinical research Peer-reviewed study

Study finds sex differences in ketamine anesthesia recovery

Sex differences in recovery from ketamine anesthesia.
Why it matters ◈ Mixed
New evidence that biological sex influences recovery from ketamine anesthesia could inform dosing, safety monitoring, and protocol design in both clinical and research settings. These findings may prompt regulators and IRBs to require sex-stratified analyses in future ketamine trials, and could impact clinical guidelines for anesthetic and psychiatric use. The study highlights the need for personalized approaches in psychedelic medicine.
Neuroscience Preclinical study published

Ketamine boosts ketogenic diet's effects on anorexia resilience in mice

Ketamine enhances ketogenic diet-induced resilience to activity-based anorexia of adult mice through hippocampal synaptic plasticity.
Why it matters ▲ Favorable
This preclinical study demonstrates that ketamine, when combined with a ketogenic diet, enhances resilience to activity-based anorexia in adult mice via hippocampal synaptic plasticity. While the findings are early-stage and limited to animal models, they suggest a potential mechanistic synergy between metabolic interventions and ketamine relevant to eating disorder research. This could inform future clinical trial designs or adjunctive treatment strategies, but direct clinical or policy impact is premature.
Clinical research Peer-reviewed study published

Major review of adverse health outcomes for key psychedelics published

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.
Why it matters ◈ Mixed
This comprehensive review of adverse health outcomes for psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT provides critical safety data for regulators, clinicians, and researchers. The findings will inform risk/benefit assessments in clinical trial design, guide policy on medical and non-medical use, and shape public health messaging. The study's conclusions may influence future scheduling decisions and access frameworks for these compounds.
Clinical research Review published

Review: Ketamine's role in pediatric suicidal crisis

Ketamine: from anesthesia to pediatric suicidal crisis.
Why it matters ▲ Favorable
This review highlights the evolving clinical evidence for ketamine's use in acute pediatric suicidal crises, expanding its profile beyond anesthesia. The article synthesizes recent trial data and clinical experience, underscoring both the promise and the need for rigorous safety and efficacy research in vulnerable populations. Its publication may inform future clinical guidelines and policy discussions around off-label ketamine use in minors.
Clinical research Peer-reviewed publication

Review links antidepressants, including psychedelics, to bone health outcomes

From depression to bone health: examining the skeletal effects of classical and rapid-acting antidepressants.
Why it matters ◈ Mixed
This review highlights emerging evidence that both classical and rapid-acting antidepressants—including some psychedelics—may impact bone health. While not a regulatory or legal development, it flags a potential safety and monitoring issue for clinical trials and future therapeutic use. Researchers and clinicians should consider bone density and skeletal effects as possible long-term risks, especially in populations at risk for osteoporosis. The findings may influence trial design, adverse event monitoring, and post-market surveillance.
Neuroscience Preclinical research

New mouse models for psychedelic studies published

New mouse models for psychedelic studies.
Why it matters ▲ Favorable
Researchers have developed new mouse models to study the effects and mechanisms of psychedelics. This advance could improve preclinical understanding of psychedelic pharmacology, safety, and therapeutic potential, informing future clinical trial design and regulatory decisions. While not a direct legal or policy change, robust animal models are foundational for translational research and may accelerate the path to human studies.
Clinical research Peer commentary published

Commentary: Optimizing Ketamine for Bipolar Depression

Optimizing Ketamine Infusion Therapy for Treatment-Resistant Bipolar Depression: Commentary on Zhou et al. (2023).
Why it matters ◈ Mixed
This commentary reviews and contextualizes recent findings on ketamine infusion protocols for treatment-resistant bipolar depression. While not a new trial, it may influence clinical best practices and future research design by highlighting gaps, safety considerations, and optimization strategies. The analysis could inform ongoing debates about ketamine's role in psychiatric care and guide both regulatory and clinical decision-making.
Clinical research 5-year post-approval review

Ongoing debate over esketamine's safety and efficacy at 5-year mark

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.
Why it matters ◈ Mixed
This article reflects ongoing scrutiny of esketamine's risk-benefit profile five years after FDA approval for treatment-resistant depression. Persistent questions about safety, efficacy, and real-world outcomes may influence prescriber confidence, payer coverage, and regulatory oversight for psychedelic-adjacent therapies. The debate underscores the need for robust post-marketing surveillance and may shape future approvals and clinical protocols for novel psychiatric treatments.
Neuroscience Preclinical research

NAc proteomic signatures linked to stress and antidepressant response in rats

Discrete nucleus accumbens proteomic signatures are associated with stress vulnerability and antidepressant response in Wistar and Kyoto rats
Why it matters ◈ Mixed
This preclinical study identifies nucleus accumbens (NAc) proteomic signatures associated with stress vulnerability and antidepressant response in two rat strains, highlighting molecular pathways that may underlie treatment-resistant depression. Findings suggest that individual molecular profiles could inform precision pharmacology for depression, though translation to humans and relevance for psychedelic mechanisms remain to be established. The research provides useful context for understanding treatment heterogeneity but does not directly address psychedelic compounds or regulatory issues.
Background Depression shows significant clinical and biological heterogeneity, largely driven by individual differences in stress responsivity. The nucleus accumbens (NAc), a key integrator of motivational and affective processing, undergoes molecular remodeling under chronic stress, contributing to anhedonia and variable antidepressant efficacy. Defining how stress reshapes the NAc’s molecular architecture across biological backgrounds may reveal molecular networks underlying treatment outcomes. This study aimed to characterize NAc proteomic signatures associated with stress vulnerability and antidepressant response in two rat strains with distinct stress-related phenotypes. Methods Male Wistar and Kyoto rats were exposed to chronic mild stress (CMS) and subsequently received chronic venlafaxine or vehicle administration. Anhedonia-like behavior, behavioral reactivity, social behavior, and serum corticosterone levels were assessed. High-resolution data-independent acquisition mass spectrometry was used to identify NAc proteomic signatures. Results Across-strain comparisons revealed baseline increases in reward sensitivity, reduced social investigation, and heightened defensive and aggressive behaviors in Kyoto rats, associated with NAc cellular metabolic pathway enrichment, including alterations in Ogdhl and Nit2. Under CMS, Kyoto rats displayed early-onset anhedonia, social withdrawal, and blunted glucocorticoid output. Moreover, they showed increased NAc proteomic enrichment in mitochondrial protein degradation and oxidative stress pathways, and decreased enrichment in synaptic signaling pathways, including Ppp1r1b/DARPP-32, compared to Wistar rats. Venlafaxine reversed stress-induced behavioral and proteomic alterations in Wistar rats. In Kyoto rats, it failed to improve anhedonia, exacerbated aggressive behavior, and induced enrichment of the NAc pathway related to bioenergetics and transmembrane transport, as well as astrocyte activation-related proteins. Conclusion Strain-specific NAc proteomic signatures characterize distinct trajectories of stress vulnerability, antidepressant non-response, and adverse behavioral activation. Although these male-only proteomic signatures require functional validation across sexes and antidepressant classes, they identify molecular candidates for precision pharmacology in depression.
Clinical research Ethics review published

Ethical challenges in MDMA-AT trials for PTSD reviewed

717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD
Why it matters ◈ Mixed
This review highlights that ethical issues—such as informed consent, therapist-patient boundaries, and affective influence—are not only central to MDMA-assisted therapy trials but may also shape regulatory approval and clinical rollout. The analysis underscores the need for rigorous consent processes, therapist training, and risk monitoring to ensure safe translation from trials to practice. These findings are material for sponsors, IRBs, and regulators evaluating trial protocols and future access models.
Abstract Background MDMA-assisted therapy (MDMA-AT) has shown promise for treatment-resistant post-traumatic stress disorder (PTSD), leveraging unique affective effects such as enhanced trust, empathy, and social connectedness. Despite preliminary efficacy, ethical challenges in clinical trials may directly affect regulatory approval and future clinical implementation. Aims & Objectives The presentation examines ethical issues specific to MDMA clinical trials, including risks to the therapeutic relationship, epistemic harms, and informed consent, and considers how these challenges may shape the translational pathway of MDMA-AT. Method A literature review focused on clinical trial reports, regulatory documentation, and scholarly analyses of MDMA-AT ethics. Key domains included therapist–patient interactions, affective modulation, memory processing, and clinical trial implications. Results Ethical concerns arise from MDMA’s affective and cognitive effects, which may influence vulnerability in the patient–therapist relationship, the emergence of memory and belief changes, and participants’ understanding of the intervention, as well as therapist's implicit and explicit therapy models. These challenges intersect with trial design and regulatory requirements, shaping safety monitoring, consent processes, and the integration of therapy, also as part of post-trial obligations. Discussion & Conclusions MDMA-AT trials raise distinctive ethical issues with implications for both clinical practice and regulatory evaluation. Systematic attention to consent, therapist training, boundary management, and risk monitoring is essential to support the safe and responsible translation.
Clinical research Publication

Ethical consent practices in Philippine ketamine trials scrutinized

Consent beyond the written form: Implications for ketamine trials in the Philippines.
Why it matters ◈ Mixed
This publication highlights the need for culturally sensitive and context-appropriate informed consent processes in ketamine clinical trials in the Philippines. The analysis suggests that standard written consent forms may not fully address ethical or practical challenges in local settings, potentially impacting trial validity and participant protection. Researchers and sponsors should adapt consent protocols to local norms, which may influence regulatory and IRB expectations for psychedelic studies in emerging markets.
Clinical research Narrative review published

Review: Hormonal modulation of psilocybin responsivity in females

HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN
Why it matters ◈ Mixed
This review highlights that female sex hormones may significantly influence psilocybin's effects, with preclinical evidence warning of possible adverse outcomes in postpartum contexts and potential microdosing benefits for PMDD. The lack of stratified human data underscores an urgent need for future trials to incorporate hormonal tracking, which is critical for developing safe, personalized psychedelic therapies for women. This work signals both opportunity and risk, urging caution for vulnerable populations and raising the bar for trial design in the field.
Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine. Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR were searched for literature published between 2000 and 2026. Search strategies utilized combinations of terms related to psilocybin, sex hormones, the menstrual cycle, pregnancy, menopause, and premenstrual dysphoric disorder (PMDD). Peer-reviewed studies, clinical protocols, and preclinical models were evaluated. Main Findings: Molecular data from human PET and preclinical studies suggest that estradiol may upregulate cortical 5-HT2A receptor availability, while testosterone appears to modulate serotonin transporter (SERT) expression. These pathways potentially overlap with psilocin's pharmacodynamics. Preclinical evidence from a 2025 postpartum mouse model signals a critical warning, suggesting that postpartum psilocybin administration may paradoxically amplify anxiety-like behaviors and induce long-term anhedonia in offspring. Clinically, preliminary qualitative data suggest potential microdosing efficacy in PMDD, though rigorous randomized controlled trials are needed to confirm these findings. Major data gaps persist regarding the impact of menopause and combination oral contraceptives on psychedelic experiences. Conclusions: Mechanistic and preclinical evidence suggests that the female hormonal landscape may influence psilocybin responsivity. However, the current lack of stratified human clinical data precludes definitive dosing or timing recommendations. Integrating hormonal tracking into future psychedelic trial designs is imperative for establishing safe, personalized therapeutic frameworks.
Clinical research Research published

Psychedelic renaissance in healthcare

Psychedelic renaissance in healthcare: between the biomedical and the existential.
Why it matters ◈ Mixed
This publication explores the dual role of psychedelics in healthcare, emphasizing both biomedical applications and existential impacts. It highlights the growing interest in integrating psychedelics into mainstream healthcare systems. The study may influence future clinical trials and public health strategies by providing a framework for understanding the broader implications of psychedelic use.
Clinical research Peer-reviewed review published

Review: Psychedelics for PTSD & Depression—Efficacy and Limitations

PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS
Why it matters ◈ Mixed
This comprehensive review confirms robust clinical trial evidence for psilocybin in depression and MDMA in PTSD, but highlights significant limitations in the current research base. The findings underscore the need for larger, more diverse, and longer-term studies, as well as improved safety monitoring and therapist training. For researchers, clinicians, and policy stakeholders, the review provides a balanced synthesis of progress and persistent gaps, informing future trial design and regulatory considerations.
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted therapy for depression and 3,4-methylenedioxymethamphetamine-assisted therapy for PTSD. Searches for this review focused on clinical trials, follow-up studies, systematic reviews and regulatory documentation published between 2016 and June 2026 that had been peer-reviewed. Evidence from this review confirms that psilocybin when used alongside a therapeutic intervention produces prompt reduction of symptoms for depression in Major depressive disorder, treatment-resistant depression, and psychological distress associated with cancer. There was also evidence of clinically significant reduction of symptoms with trials using 3,4-methylenedioxymethamphetamine for the treatment of PTSD with two phase three trials showing robust reduction in symptom scores compared to placebo-plus-therapy. The current body of evidence, however, is not as extensive or as simple as has been suggested, and has several limitations: low sample sizes in multiple studies, difficulty in functioning blinded treatment groups, expectations in patients and therapists, inadequate length of follow up, a lack of demographic diversity in participants, high treatment requirements, a developing understanding of appropriate models of psychotherapy, and several unsolved safety and regulatory questions. Psychedelic-assisted therapy is therefore an emerging intervention that has potential but it has yet to be properly understood and its future is dependent on well-conducted studies, transparent disclosure of adverse events, careful patient selection, proper therapist training, long-term assessment, and health systems that are equipped to deliver treatment safely and equitably.
Clinical research New study announced

Ketamine and Psychotherapy: A Winning Combination?

Why it matters ▲ Favorable
The combination of ketamine and psychotherapy is being explored as a potential treatment for mental health disorders. This approach could enhance the efficacy of ketamine treatments, offering new avenues for patient care. Understanding the synergistic effects of ketamine and psychotherapy could lead to more effective therapeutic protocols.
Neuroscience Peer-reviewed study

Motivation adapts to reward context and controllability, new task shows

Motivation to exert effort dynamically adapts to reward context and environmental controllability
Why it matters ▲ Favorable
This study introduces a novel behavioral paradigm (CoMET) to dissect how motivation and effort allocation are dynamically modulated by environmental controllability and reward context. The findings are relevant for understanding neuropsychiatric disorders, including depression, where effort-related deficits are common. While not directly about psychedelics, this work provides a mechanistic framework that could inform future research on how psychedelic interventions may modulate motivation and decision-making in clinical populations.
Working hard to pursue our dreams should get us there sooner or later. However, no matter how hard we try, sometimes, things are simply beyond our control, and our efforts may even be detrimental. Swiftly adapting our efforts to the controllability of the environment is a critical skill that is impaired in many neuropsychiatric disorders. Yet, how exactly we calibrate our efforts to the controllability and the richness of the environment (i.e., the overall amount of reward available in the current context) remains largely unexplored. We developed the novel Controllability and Mental Effort Task (CoMET) to investigate how varying controllability and reward context impact the motivation to exert effort for reward (n = 61). Importantly, we tested the impact of controllability while controlling for average reward rate. As hypothesized, participants were more willing to exert effort in controllable environments than in uncontrollable ones and adjusted their decisions to exert effort dynamically as a function of varying controllability. Their willingness to exert effort was also sensitive to the reward context: in reward-poor contexts, participants engaged in more effort when the momentary reward was high. Drift Diffusion modeling of decisions to exert effort showed that controllability, high momentary reward, and low effort enhanced the value integration process with increased drift rates, and controllability specifically increased decision threshold. Interestingly, individuals with higher subclinical depression traits were more sensitive to controllability, showing diminished motivation, particularly in an uncontrollable high-reward context. Taken together, these results indicate that people dynamically track multiple environmental features and integrate them into their effort allocation strategies.
Clinical research Case report published

Paediatric ketamine bladder injury case highlights emerging risk

Paediatric Ketamine Bladder Case Report: A Burgeoning Problem in the Paediatric Population.
Why it matters ◈ Mixed
This case report documents ketamine-induced bladder injury in a pediatric patient, highlighting a potential emerging safety concern as ketamine use expands in clinical and non-clinical settings. While isolated, such reports may prompt further research into age-specific risks, influence clinical monitoring protocols, and inform policy discussions about pediatric access and off-label use. Ongoing surveillance and risk communication will be important as ketamine's therapeutic footprint grows.
Clinical research Framework announced

New Framework for Psychedelic and Neuropsychiatric Therapies

A Multidisciplinary Therapeutic Framework for Neuropsychiatric, Neurological and Functional Disorders, Encompassing Psychedelic, Pharmaceutical, Botanical and Nutraceutical Interventions, Delivery Systems and Lifestyle Modifications
Why it matters ▲ Favorable
This multidisciplinary framework offers a comprehensive approach to treating neuropsychiatric and neurological disorders by integrating psychedelic, pharmaceutical, botanical, and nutraceutical interventions. By organizing agents by mechanism of action and assigning evidence tiers, it provides a standardized reference for practitioners across disciplines. This could enhance treatment protocols and safety measures, potentially improving patient outcomes and advancing the field.
Background: A person with depression, unresolved trauma, a substance problem, and cognitive complaints is treated differently depending on which practitioner they consult. A psychiatrist draws on the monoaminergic and glutamatergic literature. A licensed facilitator draws on the session literature. A naturopath draws on the botanical and nutritional literature. Each draws on a defensible evidence base, and none of the three literatures routinely cites the other two. No single reference covers the agents acting on these conditions across the disciplines that use them, with the evidentiary standing of each claim visible and the boundary of each practitioner’s authority stated. Objective: To organize that agent population by mechanism of action rather than by regulatory status or professional tradition, assign an explicit evidence tier to every claim, characterize the route and bioavailability for every agent, and derive an operational logic for safety gating, interaction adjudication, and protocol construction that practitioners from differing disciplines and with varying prescribing authority can apply within their own scope. Methods: A structured review was conducted with framework development, defining fifteen mechanism classes based on receptor pharmacology and downstream signalling. Each agent was characterized by its mechanism, dose range, route, established bioavailability, onset, duration, evidence tier, contraindications, and potential interactions. The evidence was evaluated through an international literature review and categorized into a single standardized tier system, regardless of jurisdiction: T1 for randomized controlled trials, T2 for controlled studies with limitations, T3 for observational or open-label studies, T4 for mechanistic evidence only, and T5 for traditional use. Results: Fifteen classes are outlined across 154 subsections, covering areas like glutamatergic modulation, serotonergic psychedelics, entactogens, non-5-HT2A psychoactives, monoaminergic and inhibitory modulation, neurotrophic and neuroimmune agents, adaptogenic and mitochondrial support, pharmacokinetic modification, potentiation, cholinergic modulation, and circadian phase. Seventy-six agents are individually characterized. A condition matrix links them to sixty-eight indications, including cluster headache, tic disorders, traumatic brain injury, chronic pain, burnout, and insomnia, which are often missing from reviews despite substantial supporting data. The safety measures include six safety gates, eighteen interaction rules with specified severity, a seven-step construction process, and a role-scope matrix. Route and bioavailability are detailed for each agent: five deliver about the administered dose; several widely used agents reach systemic circulation at one to ten percent; and four are pharmacologically inert via their primary route. Conclusions: A mechanism-first organization enables the evaluation of agents with varying evidentiary credibility and regulatory statuses within a single framework, without undervaluing weaker evidence or overestimating stronger cases. Three key points follow. The evidence tier pertains to the agent-indication-dose triplet, not the agent itself: for example, piracetam shows T1 evidence for myoclonus at 24 g daily and T4 for cognition at any dose. An additional axis, circadian phase, runs alongside dose, mechanism, and route; a shifted rhythm indicates deficiency and calls for the opposite intervention. When absorption or first-pass metabolism limits a compound rather than receptor pharmacology, the issue is a formulation problem and should be labelled as such. This framework is designed for complementary and adjunctive practices, highlights sections needing prescribing authority, and does not replace personalized clinical judgment.
Neuroscience Research published

Breathing linked to neural oscillations in new study

Cycle-by-cycle respiration waveforms are coupled with the shape of neural oscillations
Why it matters ▲ Favorable
This study highlights the intricate coupling between breathing patterns and neural oscillations, suggesting that respiration plays a more significant role in cognition and mental health than previously understood. Understanding these interactions could inform new therapeutic approaches in mental health and cognitive disorders. While not directly related to psychedelics, this research could influence how we understand brain-body interactions in altered states of consciousness.
Abstract Beyond sustaining life, breathing is a vital physiological rhythm that shapes cognition, perception, emotional regulation, and mental health. Breathing has a direct effect on neuronal excitability and is coupled to neural oscillations across a variety of brain regions. Notably, both respiration and neural oscillations are asymmetric and not perfectly rhythmic: for example, every breath has a different shape and duration, and is interspersed with variable pauses. Here, we examined the coupling between breathing and the brain by quantifying the nonsinusoidal features of each breath and comparing it to the shape of each corresponding neural oscillation cycle. By leveraging invasive human brain recordings from 16 participants, we found respiration-neural waveform coupling on a breath-by-breath, cycle-by-cycle basis across limbic and cortical forebrain regions. For decades, the dominant perspective on cognition and mental health have focused on the brain, but recent work is highlighting the importance of brain-body interactions. Our results show that the coupling between breathing and neural activity is much richer than previously appreciated, and our approach opens new avenues for studying these peripheral-to-central nervous system interactions in a more robust, temporally precise manner.
Public Health Public health response

Philadelphia's response to medetomidine in drug supply

Responding to medetomidine in Philadelphia: narrative summary of the public health response to a new psychoactive substance
Why it matters ◈ Mixed
The emergence of medetomidine as an adulterant in Philadelphia's opioid supply has prompted a public health summit to address the issue. Insights from the summit highlight the need for improved overdose response, clinical recognition, and treatment approaches. This coordinated effort aims to enhance community readiness and inform similar interventions in other regions.
Abstract Background Despite the emergence of medetomidine as the dominant adulterant in Philadelphia’s illicit opioid supply, coordinated public health responses are limited or non-existent in the literature. Thus, we summarize a recent Summit in Philadelphia of outpatient and inpatient service providers who specialize in the care of persons who use drugs to discuss medetomidine response readiness and building ongoing community readiness for potential destabilizing drug supply changes. Purpose Describe a public health intervention that distributed information about practices across health care settings and mobilized key informants to identify and address barriers to treatment. Methods Descriptive summary of the in-person Summit organized by the Division of Substance Use Prevention and Harm Reduction at the Philadelphia Department of Public Health and the Health Federation of Philadelphia’s Substance Use Response, Guidance, and Education program to review cases of medetomidine-associated withdrawal across outpatient, emergency department, hospital, and substance use treatment settings. Results The authors reviewed the insights from attendees and grouped them into nine themes: overdose response, clinical recognition of withdrawal, monitoring withdrawal, treatment approach, patient care navigation, workforce development, testing and surveillance, mobile outreach, and reimbursement. The authors subsequently developed twelve summative recommendations to guide further public health interventions in Philadelphia and other communities where medetomidine may become a common adulterant in the drug supply. Conclusion The insights gained regarding medetomidine withdrawal management will be shared with community organizations providing services to people who use drugs in Philadelphia and clarify specific barriers and areas for ongoing support. Other communities experiencing shifts in drug supply may benefit from this knowledge and similar information sharing colloquiums.
Neuroscience Peer-reviewed publication

Integrative model of ketamine-induced memory dysfunction published

An integrative model of ketamine-induced memory dysfunction: From synapse to circuit in clinical context.
Why it matters ◈ Mixed
This publication synthesizes current knowledge on how ketamine affects memory from synaptic to circuit levels, with direct clinical context. The findings may inform risk-benefit assessments for ketamine use in psychiatric and pain disorders, and highlight potential cognitive side effects relevant for both clinical protocols and policy development. Researchers and clinicians should consider these mechanisms when designing trials or treatment guidelines, especially as ketamine use expands.
Clinical research Review published

Therapeutic Approaches in Major Depressive Disorder

Newer Therapeutic Approaches in Major Depressive Disorder
Why it matters ◈ Mixed
This review highlights the ongoing challenges in treating major depressive disorder (MDD), despite existing therapies like SSRIs and TCAs. It underscores the need for new treatments, particularly for treatment-resistant depression (TRD), and points to emerging understandings of neuroplasticity and neurocircuitry as potential avenues. While not directly about psychedelics, this context is crucial for understanding the unmet needs that psychedelic therapies aim to address.
Major depressive disorder (MDD) is a common health disorders characterized by anhedonia along with physical changes. MDD is a leading cause of disability worldwide. MDD treatment mainly focuses on improving the quality of life of the patients suffering from this disorder. Various modalities of treatment include initiating pharmacotherapy, focussed psychotherapy, or electroconvulsive therapies. The current treatment modalities focus on the monoamine hypothesis with a wide range of drugs available from tricyclic antidepressants (TCAs) to selective serotonin reuptake inhibitors (SSRIs). Despite therapy with the currently available drugs a substantial proportion of patients do not achieve full remission with full-dose titration and there is still persistence of treatment-resistant depression (TRD). The currently available antidepressants drugs are associated with frequent adverse effects with tolerance limiting their long-term adherence. Delivery of psychotherapy has its own set of limitation and one of them is in form of delivery of psychotherapy. As many patients despite optimal therapy of currently available antidepressant drugs one-third of the patients do not respond to the currently available forms of therapy. The understanding of the pathophysiology has increased our knowledge with role of neuroplasticity, disrupted signalling pathway, decreased neurotropic factor expressions and altered functional connectivity of neurocircuitry also playing its role apart from the neurotransmission theory of depression. Opening up avenues for treatment of currently unanswered area for depression which include lag in onset of effect, tolerance to therapy, treatment resistant depression and delay in achieving remission. The current review tries to highlight the various options for treatment of depression for effective treatment of depression. International Journal of Human and Health Sciences Vol. 10 No. 04 Oct’26 Page: 217-226
Clinical research Review published

Review on CLBP and MDD comorbidity mechanisms

Comorbidity Mechanism and Management of Chronic Low Back Pain and Major Depressive Disorder: From Neural Circuit Remodeling to Precision Medicine
Why it matters ◈ Mixed
This review highlights the complex interplay between chronic low back pain (CLBP) and major depressive disorder (MDD), focusing on neural, immune, endocrine, and gut-brain axis interactions. Understanding these mechanisms is crucial for developing precision medicine approaches that could improve diagnosis and treatment outcomes for patients with these comorbid conditions. While the findings are promising, they are primarily based on existing studies and require further validation in clinical settings.
ABSTRACT Objective This review systematically elaborates multi‐system interactive mechanisms underlying comorbid chronic low back pain (CLBP) and major depressive disorder (MDD), synthesizes recent advances in diagnosis, treatment, and management, and proposes precision medicine directions to address clinical challenges, including missed diagnosis, treatment resistance, and poor prognosis. Method We reviewed 86 studies published between 2015 and 2025 from the PubMed, Embase, and CNKI databases. We focused on basic research and clinical trials, integrating multi‐omics data to construct mechanistic frameworks and therapeutic evidence. Result The comorbid pathogenesis of CLBP and MDD is driven by dysregulation of the “neural–immune–endocrine–gut–brain axis” network. Spinal dorsal horn N‐methyl‐D‐aspartate (NMDA) receptor NR2B phosphorylation amplifies pain signals 2‐ to 3‐fold, while anterior cingulate cortex (ACC)–insula connectivity correlates positively with depression severity. Microglial toll‐like receptor 4/nuclear factor‐κB (TLR4/NF‐κB) activation increases cerebrospinal fluid interleukin‐6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) by 3.2‐ and 2.7‐fold, respectively. Hypothalamic–pituitary–adrenal (HPA) axis dysfunction causes a flattened cortisol rhythm, with glucocorticoid receptor gene (NR3C1) hypermethylation reducing glucocorticoid sensitivity by 45%. Gut dysbiosis decreases short‐chain fatty acids (SCFAs) by 30% and increases plasma lipopolysaccharide (LPS) by 2.3‐fold, accompanied by abnormal proliferation of pro‐inflammatory E. coli and Desulfovibrio as well as depletion of anti‐inflammatory Prevotella . Duloxetine reduces visual analog scale (VAS) pain scores by 40% and Hamilton Depression Rating Scale (HAM‐D) scores by 35% relative to placebo. Closed‐loop spinal cord stimulation (SCS) improves treatment response rates to 68% compared with open‐loop stimulation. Electroacupuncture at BL23/LR3 alleviates clinical symptoms in 75% of patients relative to sham acupuncture. At the 12‐month follow‐up, duloxetine's pain relief efficacy slightly declined from 40% to 38%, a phenomenon speculated to be linked to serotonin transporter upregulation. At the 1‐year follow‐up, closed‐loop SCS efficacy decreases to 55%, which may be associated with secondary neural circuit re‐remodeling. At the 6‐month follow‐up, electroacupuncture treatment carries a 22% symptom recurrence rate, which researchers hypothesize arises from secondary gut microbiota re‐dysbiosis featuring reduced Prevotella abundance. Conclusion Pathological progression of concurrent CLBP and MDD relies on multi‐level remodeling of molecular, cellular, and systemic biological networks. Precision interventions targeting neural circuits, neuroinflammation, and the gut–brain axis, combined with multidisciplinary clinical collaboration, represent core strategies to break through current diagnostic and therapeutic bottlenecks.
Clinical research Commentary published

Optimizing Ketamine for Bipolar Depression

Optimizing Ketamine Infusion Therapy for Treatment‐Resistant Bipolar Depression: Commentary on Zhou et al. (2023)
Why it matters ◈ Mixed
This commentary highlights the potential of ketamine infusions to rapidly alleviate symptoms in treatment-resistant bipolar depression, but underscores the need for more targeted research. Individualized maintenance and monitoring strategies are crucial for long-term efficacy and safety. The findings call for further studies to refine treatment protocols and identify reliable predictors of response.
ABSTRACT Objectives To contextualize the real‐world findings of repeated intravenous ketamine infusions for treatment‐resistant bipolar depression (TRBPD) and identify priorities for safer, more durable clinical implementation. Methods We provide a focused commentary on Zhou et al. (2023) and integrate selected evidence concerning inflammatory and metabolic correlates, neurocognitive outcomes, and continuation‐phase ketamine treatment. Results Repeated subanesthetic ketamine infusions may rapidly improve depressive and anxiety symptoms with an acceptable short‐term safety profile. However, the predictive value of C‐reactive protein and body mass index varies across cohorts; available cognitive findings are reassuring but limited; and relapse after induction highlights the need for individualized maintenance planning. Conclusions Ketamine pathways for TRBPD should combine cautious patient stratification, repeatable cognitive monitoring, and explicit continuation or booster strategies. Prospective bipolar‐specific studies are needed to clarify predictors, durability, and stopping rules.
Neuroscience Study published

Neuroimaging Study on Dissociative Symptoms Published

Brain Network Convergence of Abnormal Gray Matter and Functional Activity of Pathological Dissociative Symptoms
Why it matters ▲ Favorable
This study enhances our understanding of the neural underpinnings of dissociative symptoms by mapping brain networks involved in these symptoms across various psychiatric disorders. Identifying specific brain networks and neurotransmitter associations could inform future interventions and therapeutic targets for dissociative symptoms. While not directly related to psychedelics, these findings could influence research on how psychedelic substances affect similar brain networks.
AIM: Pathological dissociation is a complex clinical symptom widely observed across various psychiatric disorders. Dissociative symptoms prolong the duration of hospitalization and are associated with a poor clinical prognosis. Although several pathological models (e.g., the frontal-limbic overmodulation model and the defense cascade model) have been proposed to interpret dissociative symptoms, heterogeneous regional-level imaging findings impede our comprehension of the neural changes underlying dissociative symptoms across diagnoses. METHODS: Using the functional connectivity network mapping method, this study systematically screened 45 cross-diagnostic reports of dissociation-related structural and functional brain changes. By integrating resting-state imaging data from healthy individuals (n = 872), we constructed dissociative task-induced activation, gray matter volume (GMV), and resting-state activity impairment networks. Additionally, we performed spatial correlation analyses between the damage networks and 19 neurotransmitter distribution maps. RESULTS: The task-induced damage network showed the largest proportional overlap with the anterior salience network (SN, 12.25%), basal ganglia network (BGN, 13.57%), and dorsal default mode network (DMN, 17.74%). For the GMV damage network, the main overlap proportions were observed with the dorsal DMN (12.33%) and the anterior SN (7.67%). The resting-state activity damage network showed the greatest overlap with the anterior SN (5.17%), posterior SN (5.73%), auditory (5.47%), and sensorimotor network (4.50%). Spatial correlation analyses found associations between network changes and the distribution of N-methyl-D-aspartate receptors, vesicular acetylcholine transporter, cannabinoid receptor CB1, serotonin transporter, and mu-opioid receptor. CONCLUSION: This study further elucidated the neuroimaging changes underlying across-diagnostic dissociation and provided new insights for identifying network intervention targets to improve dissociative symptoms.
Neuroscience Research published

Neurophysiological signatures of meditation in monks

Integrated central and autonomic signatures of concentrative and analytical meditation in expert practitioners
Why it matters ◈ Mixed
This study provides insights into the neurophysiological correlates of different meditation practices by examining a homogeneous group of expert practitioners. Findings suggest that advanced meditative states involve coordinated autonomic–cortical integration, which may have implications for mental health and cognitive flexibility. However, the fixed-order design of the study necessitates cautious interpretation of condition-related differences.
Meditation has long been associated with improvements in mental well-being, emotional regulation, and attentional control. However, the diversity of meditative techniques and variability in participant expertise across studies have hindered the systematic identification of their neurophysiological correlates. To address this challenge, we investigated the neurophysiological signatures of distinct meditation types in a relatively homogeneous cohort of 35 highly experienced Tibetan monk practitioners. We focused on concentrative meditation, characterized by sustained attention on a single object, and two analytical practices: Loving-Kindness, centered on cultivating prosocial affect, and Emptiness, involving reflective and deconstructive cognitive processes. EEG, ECG, EDA, and respiration were simultaneously recorded during these practices, which were performed in a fixed-order sequence (Concentrative → Loving-Kindness → Emptiness). Linear mixed-model analyses revealed significant modulations across conditions. Peripheral indices indicated enhanced parasympathetic activity (higher RMSSD and SDNN), reduced respiratory rate, and a progressive rise in tonic EDA across the entire three-phases meditation session. Cortically, EEG analyses showed changes in the gamma-band power during the meditation session. Overall, the pattern suggests that advanced meditative states involve coordinated autonomic–cortical integration, reflecting relaxed vigilance with improved emotional regulation and cognitive flexibility; nevertheless, given the fixed-order design, condition-related differences should be interpreted cautiously due to possible order or carryover effects.
Clinical research Peer-reviewed trial published

Crossover trial compares oral psilocybin, oral psilocin, and sublingual psilocin

A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.
Why it matters ▲ Favorable
This randomized crossover trial directly compares the physiological and psychological effects of different botanical and synthetic psilocybin/psilocin formulations and routes of administration. The findings will inform both clinical research design and potential therapeutic use, clarifying differences in onset, duration, and subjective effects. Results may also influence regulatory and commercial decisions regarding formulation standards and product development for psychedelic-assisted therapies.
Neuroscience Peer-reviewed study

BDNF promoter VI mediates protective effects of prophylactic (R,S)-ketamine

The role of BDNF promoter VI in mediating protective effects of prophylactic (R,S)-ketamine.
Why it matters ▲ Favorable
This study identifies BDNF promoter VI as a key mediator of the protective effects of prophylactic (R,S)-ketamine. The findings deepen mechanistic understanding of ketamine's neurobiological action, which could inform the design of next-generation antidepressants and prophylactic interventions. While not directly altering legal or regulatory policy, such mechanistic insights are essential for rational drug development and may support future clinical trial designs and regulatory submissions.
FDA / DEA Nomination announced

Heidi Overton's FDA nomination and psychedelics policy

How might Heidi Overton’s FDA Commissioner nomination shape psychedelics policy? And what is 4-OH-DiPT?
Why it matters ◈ Mixed
Heidi Overton's nomination as FDA Commissioner could significantly influence future psychedelics policy and regulation. Her stance on substances like 4-OH-DiPT, a lesser-known psychedelic, may impact research priorities and market dynamics. Stakeholders should monitor her confirmation process and policy signals closely.
Clinical research Review published

ECT's Impact on Brain Networks in Depression

Brain Network and Synaptic Plasticity Changes Associated with Electroconvulsive Therapy for Depression: A Multilevel Review
Why it matters ▲ Favorable
This review provides a comprehensive analysis of how electroconvulsive therapy (ECT) affects brain networks and synaptic plasticity in depression. Understanding these mechanisms could enhance treatment strategies and predict patient responses. While not directly related to psychedelics, the insights into brain network changes and synaptic plasticity may inform similar research in psychedelic therapies.
Electroconvulsive therapy (ECT) is an important treatment for severe, treatment-resistant, or high-risk depression, yet the relationship between its antidepressant effects, brain network changes, and cellular and molecular processes remains incompletely understood. Recent advances in multimodal magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), molecular biology, and animal electroconvulsive stimulation models have provided multilevel evidence for understanding the neurobiological mechanisms of ECT in depression. Current studies suggest that ECT is accompanied by changes in functional connectivity within large-scale brain networks, including the default mode network (DMN), the frontoparietal control network (FPCN), and prefrontal-limbic circuits. In parallel, processes involving neurotransmission, brain metabolism, neurotrophic factors, inflammatory responses, and synaptic plasticity may provide biological clues for interpreting these network-level changes. This review summarizes evidence related to brain network reorganization and synaptic plasticity-associated regulation in ECT for depression, and discusses how findings across levels may be integrated to inform future mechanistic research and treatment-response prediction.
Neuroscience Research review

RNA sequencing advances in depressive disorders

Progress and challenges in exploring the pathogenesis of depressive disorders via RNA sequencing
Why it matters ◈ Mixed
This review highlights the potential of RNA sequencing technologies to unravel the complex pathogenesis of depressive disorders, which could inform more effective treatments. Understanding the molecular mechanisms underlying these disorders is crucial for developing precision medicine approaches. However, challenges such as data heterogeneity and limited clinical translation remain significant hurdles.
Depressive disorders (DD) are highly heterogeneous psychiatric illnesses. Their complex pathogenesis, coupled with suboptimal response rates to current clinical treatments, poses significant challenges to global mental health. High-throughput RNA sequencing (RNA-seq) has emerged as a powerful tool for dissecting the molecular mechanisms of DD at the transcriptomic level. This paper reviews recent advances utilizing bulk RNA-seq, single-cell RNA-seq (scRNA-seq), and single-nucleus RNA-seq (snRNA-seq) to explore the pathogenesis of major depressive disorder (MDD), perinatal depression (PND), perimenopausal depression (PMD), and post-stroke depression (PSD). Current evidence indicates that immune-inflammatory activation, impaired synaptic plasticity, and mitochondrial energy metabolism dysfunction constitute shared core pathological mechanisms across these disorders, validating classical pathogenic hypotheses at the molecular level. Furthermore, distinct clinical subtypes exhibit significant transcriptomic heterogeneity; for instance, MDD shows marked sexual dimorphism and immunophenotypic characteristics. Specific molecular pathways also distinguish different DD categories: PND and PMD mainly involve imbalances in neuroendocrine–immune interaction networks driven by hormonal fluctuations, whereas PSD is characterized by the interaction between innate immune responses and autophagy flux impairment. Although RNA-seq has significantly advanced our understanding of DD, challenges such as restricted sample sources, high data heterogeneity, and insufficient clinical translation remain. Future research should prioritize single-cell and spatial transcriptomics to resolve tissue heterogeneity, promote multi-omics integration to construct causal regulatory networks, and strengthen cross-species comparative studies. These efforts will accelerate the development of precision diagnosis and personalized treatment strategies.
Clinical research Research published

LC-MS/MS hair analysis for drug use at festivals

Broad-spectrum LC-MS/MS hair analysis for monitoring recreational drug use in electronic dance music festival attendees
Why it matters ◈ Mixed
This study introduces a validated method for detecting a wide range of recreational drugs in hair samples, providing insights into drug use patterns at electronic dance music festivals in Brazil. The findings highlight the prevalence of polysubstance use, particularly MDA, among festival attendees. This research could inform public health strategies and toxicosurveillance efforts in similar contexts.
Abstract Purpose Hair toxicological analysis enables the verification of long-term drug use monitoring and supports epidemiological studies. In recreational contexts, multi-analyte methods are crucial for accurately characterizing consumption patterns. The present work aimed to develop and validate an LC-MS/MS method for the analysis of 47 drugs of abuse and related compounds in hair samples. Methods A 20 mg hair aliquot was incubated with methanol at 40 °C for 16 h. The supernatant was dried and injected into the LC-MS/MS system. The monitored substances were amphetamines, cocaine and related compounds, cannabinoids, opioids, hallucinogens, synthetic cathinones, synthetic phenethylamines, and synthetic cannabinoids. The method was validated in accordance with international recommendations and subsequently applied to 81 hair samples collected at Brazilian electronic dance music festivals. Results The method had limits of detection of 0.5-5 pg/mg and limits of quantification of 5–50 pg/mg. All compounds showed suitable linearity ( R ² > 0.9903). The precision assays showed CV% from 1.3% to 19.0%, while accuracy varied from 80.1% to 119.8%. All analyzed samples presented at least one of the target compounds. The most prevalent substances were MDA (85.2%), benzoylecgonine (84.0%), cocaine (84.0%), MDMA (72.8%), and Δ 9 -tetrahydrocannabinol (56.8%). Conclusions This study presented a validated multi-analyte method for the analysis of drugs of abuse and related compounds in hair. Application of the method to a cohort of electronic dance music festival attendees revealed widespread polysubstance exposure, with a notable predominance of MDA. The findings support the role of toxicological analysis as a valuable tool for toxicosurveillance.
Clinical research Systematic review published

Interoceptive Interventions Reduce Anxiety Sensitivity

The Effectiveness of Interoceptive-Based Interventions to Reduce Adult Anxiety Sensitivity: A Systematic Review
Why it matters ▲ Favorable
This systematic review highlights the effectiveness of interoceptive-based interventions, such as mindfulness and cognitive behavioral therapy, in reducing anxiety sensitivity among adults. These findings could inform therapeutic practices for anxiety disorders, potentially impacting public health strategies. However, further research is needed to explore combinations, dosages, and long-term effects.
PURPOSE: Anxiety sensitivity is defined as the fear of anxiety-related sensations and is linked to the top three preventable causes of disease and death in the US. Interoception is related to anxiety sensitivity and can be addressed by occupational therapists. Interoception encompasses sensing/feeling/noticing, understanding/interpreting, and acting upon one's internal bodily sensations. Interoceptive-based interventions are starting to be used to decrease adult anxiety sensitivity. This review examines the effectiveness of interoceptive-based interventions on adult anxiety sensitivity that can be used by occupational therapists. METHODS: Sources: Ovid, CINAHL (EBSCOhost), PsycInfo (Ovid), SCOPUS. Inclusion criteria: interoceptive interventions, persons over age 17 years with anxiety symptoms, level 4 or higher studies, minimum of 14 participants. Exclusion criteria: written before 1999, qualitative, non-peer-reviewed, not available in English, comorbidities or subtypes of anxiety. RESULTS: Sixteen articles were reviewed, 10 level II studies, one level III-1 study, and four level III-2 studies examining the effect of interoceptive-based interventions on adult anxiety sensitivity. Interventions examined were mindfulness, interoceptive exposure, cognitive behavioral therapy (CBT), and combinations of those. All studies showed significant anxiety sensitivity reduction for participants identified with high anxiety sensitivity. Strong evidence supports the use of mindfulness alone and interoceptive exposure with CBT. Moderate evidence supports interoceptive exposure alone. Insufficient evidence currently supports the use of combinations of interoceptive exposure with mindfulness and of interoceptive exposure with CBT. CONCLUSION: Findings support certain interoceptive-based interventions as effective in reducing elevated anxiety sensitivity. More research is needed to examine the less studied combinations, dosages and types of exposures, inclusion of neurophysiological outcome measures, and assessment of long-term effects, and to explore the mechanisms behind this association and its impact on occupational performance and participation.
Neuroscience Research published

Lipid metabolism affects fluoxetine's immunomodulatory effects

The lipid landscape shapes the immunomodulatory potential of fluoxetine in macrophages
Why it matters ◈ Mixed
This study explores the relationship between lipid metabolism and the immunomodulatory effects of fluoxetine, an SSRI used in treating depression. The findings suggest that lipid metabolism disruptions can alter fluoxetine's efficacy, potentially contributing to treatment-resistant depression (TRD). Understanding these mechanisms could lead to improved therapeutic strategies for TRD.
Treatment-resistant depression (TRD) affects approximately one-third of depressed patients, yet the molecular mechanisms underlying this therapeutic non-responsiveness remain unclear. Pharmacological antidepressants, such as the selective serotonin reuptake inhibitor (SSRI) fluoxetine, exert immunomodulatory effects, partially by shifting macrophages towards an anti-inflammatory phenotype. Clinical aberrations in lipid metabolism have been associated with fluoxetine non-responsiveness in depressed populations. As macrophage polarization is highly sensitive to changes in lipid metabolism, pathological alterations in lipid metabolism may directly interfere with the therapeutic efficacy of SSRIs such as fluoxetine. However, how metabolic and immunomodulatory effects of antidepressants relate to each other in the context of TRD remains largely unexplored. We studied the interplay between immunomodulatory capacity of fluoxetine and the macrophage lipid landscape. Human monocyte-derived macrophages (MoDMs) and murine bone marrow-derived macrophages (BMDMs) were utilized as experimental models to evaluate these localized immunometabolic effects. Under baseline conditions in wild-type macrophages, the characteristic anti-inflammatory effect of fluoxetine coincided with distinct intracellular lipid accumulation. Conversely, disrupting this lipid environment yielded opposite immunological outcomes. BMDMs deficient in the low-density lipoprotein receptor (Ldlr-/-) or wild-type BMDMs exposed to inflammatory oxidized phosphocholine-containing phospholipids (OxPLs) failed to undergo anti-inflammatory polarization and exhibited a robust pro-inflammatory response upon fluoxetine treatment instead. Collectively, these data demonstrate a critical link between the macrophage lipid landscape and immunomodulatory efficacy of fluoxetine. These findings suggest that deficiencies in the endogenous LDLR pathway and exposure to circulating lipid peroxidation products can modulate the immunological response to fluoxetine. Our observations highlights microenvironmental lipid stress as a potential contributor to the underlying biology of antidepressant resistance in TRD.
Veterans' health Access expanded

Tampa Bay expands ketamine access for veterans with PTSD

Veterans and Military Families Get More Access to Ketamine-Based Mental Health Care for PTSD Across Tampa Bay
Why it matters ▲ Favorable
The expansion of ketamine-based mental health care for veterans and military families in Tampa Bay represents a significant step in addressing PTSD treatment needs. Increased access to ketamine therapy could improve mental health outcomes for a vulnerable population. This development may encourage further adoption of psychedelic-assisted therapies in other regions.
State policy Ballot measure challenge

Challenge to Joseph's psilocybin ballot measure

Lostine man challenges Joseph’s psilocybin ballot measure
Why it matters ◈ Mixed
A legal challenge to a psilocybin ballot measure in Joseph, Oregon, highlights ongoing community and legal debates over psychedelic regulation. Such challenges can impact the implementation of local psychedelic policies and influence broader state-level discussions. This case may set precedents for how local jurisdictions handle psilocybin regulation.
Neuroscience Study published

Ketamine's neurobiological role in treatment-resistant depression

MECANISMOS NEUROBIOLÓGICOS DA CETAMINA NO TRATAMENTO DA DEPRESSÃO RESISTENTE: O PAPEL DA NEUROTRANSMISSÃO GLUTAMATÉRGICA E DA NEUROPLASTICIDADE
Why it matters ▲ Favorable
This study provides a deeper understanding of ketamine's rapid antidepressant effects, focusing on glutamatergic neurotransmission and neuroplasticity. By elucidating the mechanisms involving NMDA and AMPA receptors, BDNF signaling, and mTOR pathways, it highlights ketamine's therapeutic potential for treatment-resistant depression. This could inform future clinical applications and research directions.
Esse artigo buscou analisar os mecanismos neurobiológicos envolvidos no efeito antidepressivo rápido da cetamina em pacientes com depressão resistente ao tratamento, com ênfase na neurotransmissão glutamatérgica e na neuroplasticidade. Trata-se de um estudo qualitativo, de natureza teórico-bibliográfica e abordagem analítico-reflexiva, desenvolvido a partir da análise de artigos científicos e produções acadêmicas relacionadas à utilização da cetamina e aos mecanismos associados à resposta antidepressiva. Foram considerados aspectos relacionados aos receptores NMDA e AMPA, ao fator neurotrófico derivado do cérebro (BDNF), à via mTOR, à plasticidade sináptica e aos circuitos cerebrais envolvidos na regulação do humor. Os resultados evidenciaram que a cetamina promove modulação dos receptores NMDA, favorecendo a neurotransmissão glutamatérgica mediada pelos receptores AMPA e desencadeando alterações na sinalização BDNF-TrkB e mTOR. Esses mecanismos contribuem para o aumento da plasticidade sináptica e para a rápida remodelação das conexões neuronais, associados à melhora dos sintomas depressivos. Conclui-se que a ação antidepressiva rápida da cetamina está relacionada à interação entre neurotransmissão glutamatérgica e mecanismos de neuroplasticidade, destacando seu potencial terapêutico na depressão resistente ao tratamento.
Clinical research Curriculum published

Nursing curriculum for psychedelic-assisted therapy published

Nursing education for emerging psychedelic-assisted therapy: A role-calibrated curriculum approach.
Why it matters ▲ Favorable
This publication signals growing recognition of the need for specialized training for nurses in psychedelic-assisted therapy. The curriculum approach could help standardize care, improve patient safety, and expand the workforce eligible to participate in clinical research and eventual clinical rollout. As regulatory and clinical frameworks evolve, education for frontline providers will be a key bottleneck for scaling access and maintaining quality.
Clinical research Peer-reviewed publication

PBPK/PD model of psilocybin/psilocin in TRD published

Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Why it matters ▲ Favorable
This publication advances the scientific understanding of psilocybin's pharmacokinetics and pharmacodynamics in treatment-resistant depression (TRD). The development of a physiologically based model using data from Psilocybe cubensis supports more precise dosing, safety assessments, and trial design. This work may inform regulatory guidance and clinical protocols, helping bridge gaps between natural product variability and standardized therapeutic use.
Clinical research Research published

Comparative study on psychedelics in psychiatry

Psychedelics in psychiatry: comparative effectiveness, implementation, commercialization and safety lessons learned from intranasal esketamine
Why it matters ◈ Mixed
This study provides insights into the effectiveness and safety of psychedelics in psychiatric treatment, using intranasal esketamine as a reference. Understanding these factors is crucial for the successful implementation and commercialization of psychedelic therapies. The findings may guide future research and inform clinical practices.
1.0 According to the 2023 iteration of the Global Burden of Diseases, Injuries and Risk Factor studies (GBD) assessing 375 injuries and diseases and 12 mental disorders, mental disorders are now th...
Neuroscience Review published

Review: Natural Medicines & Neurogenesis in Depression

Natural medicine‑empowered treatment of depression via restoring neurogenesis (Review)
Why it matters ◈ Mixed
This review explores the potential of natural medicines to modulate neurogenesis as a treatment for major depressive disorder. While promising pathways have been identified, current clinical evidence is insufficient to replace established antidepressants. The review highlights the need for biomarker-stratified trials and rigorous safety assessments before these natural products can be considered viable adjunctive therapies.
Major depressive disorder (Mdd) remains a leading cause of disability, with a substantial proportion of patients failing to achieve adequate remission following conventional monoaminergic antidepressant treatment.The present narrative review examines evidence primarily published between 2015 and 2025 concerning natural medicines, including phytochemicals, traditional formulations, marine-derived products and dietary polyphenols, that may modulate neurogenesis relevant to depression.adult hippocampal neurogenesis is regarded as one mechanistic framework rather than the sole explanation for depressive pathology.Priority was given to clinical and human-derived evidence, while preclinical studies are employed to elucidate underlying mechanisms.natural products appear to converge on pathways involving brain-derived neurotrophic factor/tropomyosin receptor kinase B, Wnt/β-catenin, nF-κB/nlr family pyrin domain containing 3-mediated immune regulation, autophagy, mitochondrial bioenergetics and the gut microbiota.nevertheless, current clinical evidence remains insufficient to support the use of natural medicines as substitutes for established antidepressant therapies.Their most plausible near-term application lies in standardized adjunctive or investigational interventions, pending larger biomarker-stratified trials, rigorous safety assessment and optimized formulation strategies.Contents 1. introduction 2. neurogenesis hypothesis of depression and its impairment 3. natural medicines: a new frontier for depression treatment 4. Plant-derived compounds and traditional formulas targeting neurogenesis 5. other natural products and modalities impacting neurogenesis 6. Multi-target mechanisms underlying neurogenesis restoration 7. comparative analysis with conventional antidepressants and emerging therapies 8. clinical translation and future directions 9. conclusions Natural medicine-empowered treatment of depression via restoring neurogenesis (Review)XiuFen ZHonG and JinGTao Gui
State policy / Public health State program in effect

Oregon psilocybin services: Early real-world safety signals published

Oregon's state-regulated psilocybin services: Early real-world safety signals.
Why it matters ◈ Mixed
This is the first peer-reviewed publication reporting real-world safety outcomes from Oregon's regulated psilocybin program. The findings provide critical data for policymakers, clinicians, and researchers on the practical risks and benefits of supervised psilocybin use outside of clinical trials. Early safety signals will inform future regulatory adjustments, best practices for facilitators, and may influence other states considering similar frameworks. Ongoing monitoring and transparent reporting are essential as the program evolves.
Clinical research Systematic review published

Ketamine's efficacy in OCD reviewed

Efficacy and tolerability of ketamine in moderate to severe obsessive-compulsive disorder: a systematic review.
Why it matters ▲ Favorable
This systematic review evaluates ketamine's efficacy and tolerability in treating moderate to severe obsessive-compulsive disorder (OCD). The findings could influence future clinical guidelines and research priorities, potentially expanding ketamine's therapeutic use beyond depression. Understanding ketamine's role in OCD treatment may also inform policy discussions on its broader medical application.
State policy State law in effect

20,000 in Oregon receive legal psilocybin therapy

20,000 People In Oregon Have Now Received Legal Psilocybin Therapy, And The Outcomes Are Overwhelmingly Positive
Why it matters ▲ Favorable
The report that 20,000 people in Oregon have received legal psilocybin therapy with overwhelmingly positive outcomes highlights the state's pioneering role in psychedelic therapy. This milestone could influence other states considering similar legislation and offers valuable data on the therapeutic benefits of psilocybin. The positive outcomes may encourage further research and investment in the psychedelic therapy market.
Clinical research Study published

5-MeO-DMT shows promise for depression

Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.
Why it matters ▲ Favorable
The study on inhalable 5-MeO-DMT indicates potential efficacy in treating treatment-resistant depression, a condition with limited options. This could pave the way for new therapeutic protocols and regulatory considerations for psychedelic substances. Further research and clinical trials will be crucial to validate these findings and assess safety and efficacy on a larger scale.
Clinical research Review published

New strategies for treatment-resistant depression

Depressão resistente ao tratamento: novas estratégias terapêuticas e perspectivas clínicas
Why it matters ▲ Favorable
This integrative review highlights the potential of emerging therapies, including psilocybin, for treatment-resistant depression (TRD). While ketamine and esketamine are already recognized, the inclusion of psilocybin suggests growing interest in psychedelic therapies. Understanding these therapies' efficacy and safety is crucial for advancing TRD treatment options.
Introdução: A depressão é um transtorno mental grave, caracterizado por sentimentos persistentes de tristeza profunda, anedonia, ideação suicida e prejuízos funcionais significativos, impactando de forma substancial a qualidade de vida dos indivíduos acometidos. A depressão resistente ao tratamento (DRT) representa um dos maiores desafios da psiquiatria contemporânea e um problema crescente de saúde pública. Apesar dos avanços terapêuticos nas últimas décadas, estima-se que 20% a 30%dos indivíduos com transtorno depressivo maior (TDM) não apresentem resposta adequada após duas tentativas terapêuticas otimizadas, configurando um quadro de refratariedade associado a substancial morbidade, risco aumentado de suicídio, redução da expectativa de vida e significativo comprometimento funcional, ocupacional e social. Metodologia: Trata-se de uma revisão integrativa da literatura, de caráter descritivo, com abordagem qualitativa, desenvolvida com o objetivo de analisar as evidências científicas acerca das novas estratégias terapêuticas para o tratamento da depressão resistente ao tratamento, destacando sua eficácia clínica, mecanismos de ação, perfil de segurança, tolerabilidade e potencial contribuição para o manejo de pacientes que apresentam resposta insuficiente ou inadequada às terapias convencionais. Resultados: A análise dos estudos selecionados evidência que a depressão resistente ao tratamento constitui um importante desafio clínico, exigindo estratégias capazes de superar as limitações observadas com os antidepressivos convencionais. De modo geral, os trabalhos analisados apontam que cetamina, esketamina, estimulação magnética transcraniana (EMT), theta-burst stimulation (TBS), eletroconvulsoterapia (ECT) e, mais recentemente, psilocibina apresentam potencial terapêutico relevante, embora com diferenças importantes quanto à rapidez de ação, magnitude da resposta, duração dos efeitos, tolerabilidade e nível de evidência disponível. Considerações Finais: As evidências analisadas demonstraram resultados favoráveis com diferentes modalidades terapêuticas, incluindo cetamina, esketamina, estimulação magnética transcraniana, theta-burst stimulation, eletroconvulsoterapia e, de forma ainda emergente, psilocibina.
Neuroscience Preclinical research

Psilocybin boosts sociability in ASD mouse model without wakefulness

Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective
Why it matters ▲ Favorable
This study suggests that psilocybin can enhance social behavior in a mouse model of autism spectrum disorder without requiring the subject to be awake. This finding could pave the way for developing treatments that harness the therapeutic benefits of psilocybin while minimizing its psychedelic side effects, potentially expanding its use in neuropsychiatric conditions.
Psilocybin, a psychoactive compound contained in certain mushrooms, can provoke profound psychedelic experiences and also exerts established and controversial therapeutic efficacy in clinical depression and other neuropsychiatric conditions respectively. Here we report that a single systemic administration of the serotonergic psychedelic psilocybin can durably promote social behaviour in the Cntnap2-knockout mouse model of autism spectrum disorder (ASD), while no increase in sociability is observed in isogenic control mice. Addressing the concern that the therapeutic actions of psilocybin may involve potentially adverse psychedelic effects, we tested drug application in anesthetised mice and found that awake brain states are not required for psilocybin’s sociability enhancing actions in ASD mice. Psilocybin shows therapeutic effects in the treatment of neuropsychiatric conditions but it can also cause strong hallucinations. Here, the authors show that psilocybin can improve social symptoms in a mouse model of autism, an effect that does not depend on wakefulness during the acute drug effects, suggesting that it might be possible to develop treatments that keep the benefits while avoiding the mind-altering side effects.
Clinical research Pilot study results

Pilot study: High dose THC vs psilocybin in therapy setting

Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session
Why it matters ◈ Mixed
This pilot study provides preliminary data suggesting that high doses of synthetic Δ9-THC can produce experiences similar to psilocybin under controlled conditions. The findings highlight the importance of set and setting in influencing the subjective effects of psychoactive substances. While the study's small sample size limits generalizability, it offers valuable insights into the psychopharmacology of THC and its potential therapeutic applications.
Abstract Rationale Delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of Δ9-THC that occasion such effects and the phenomenology of these experiences are poorly understood. Objectives This brief report presents preliminary findings from a pilot human laboratory study that directly compared the acute effects of Δ9-THC and psilocybin under set (expectancy) and setting (context) conditions of a typical psychedelic clinical trial. Methods Four healthy adults (ages 31–47, 3 F) received oral administration of placebo, psilocybin (25 mg), and 25 mg Δ9-THC, and two of these participants also received 50 mg Δ9-THC, in a double-blind, placebo-controlled, within-subject crossover study. Δ9-THC was administered as either synthetic Δ9-THC (dronabinol) or a whole-plant cannabis distillate extract (89.9% Δ9-THC). Subjective effects, cardiovascular measures, and safety were monitored throughout each session. Participants were asked after each session what drug they thought they had received. Results 25 mg Δ9-THC in both forms yielded a subjective experience similar to 25 mg psilocybin. Dronabinol was mistaken for a classic hallucinogen by both a psychedelic-naïve and a psychedelic-experienced participant. Conclusions These preliminary data suggest that a 25 mg oral dose of pure, synthetic Δ9-THC can be mistaken for a classic hallucinogen, and that oral Δ9-THC can elicit a psychedelic-like experience under set and setting conditions of a typical psychedelic clinical trial. While limited by sample size, these initial results provide insights into the comparative psychopharmacology of Δ9-THC and psilocybin as well as the potentially substantial impact of set and setting on subjective effects of psychoactive drugs. Trial Registration: This trial was registered at ClinicalTrials.gov (NCT06772753) on January 13, 2025
Industry Panel discussion summary

AMCP Panel on Psilocybin for TRD

AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression
Why it matters ◈ Mixed
The AMCP Market Insights panel highlights the potential of psilocybin-assisted treatment for treatment-resistant depression (TRD) and stresses the need for more data to inform payer decisions. Managed care stakeholders emphasize the importance of overcoming barriers to care and ensuring an adequate network of mental health professionals for psilocybin treatment. This discussion is crucial for shaping future research, collaboration, and advocacy efforts in the psychedelic treatment landscape.
Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and costs. To address the unmet need in many mental health conditions, psychedelic-assisted treatment such as psilocybin for TRD is emerging as a potential option. To discuss optimizing managed care approaches to TRD including the use of psilocybin, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in March 2026. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Key insights underscore that there is a high unmet need in TRD and that mitigating barriers to care is a priority for payers. Perspectives on the current evidence for psilocybin in TRD are mixed; payers want additional data to compare treatments, elucidate the appropriate treatment population, and assess cost-effectiveness. Additionally, a primary challenge with psilocybin treatment will be an adequate network of mental health professionals to oversee administration and observation and to provide post-treatment care. Examples of suggested payer practices include education, collaboration, prioritizing behavioral health network readiness and quality, and mitigating barriers to care.
Clinical research Translation completed

Japanese MEQ-4 and CEQ-7 Versions Developed

Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire
Why it matters ▲ Favorable
The development of Japanese versions of the MEQ-4 and CEQ-7 questionnaires is a step forward in facilitating psychedelic research in Japan. This enables more efficient assessment of mystical and challenging experiences among Japanese speakers. Future studies will need to validate these tools for cultural appropriateness and reliability.
INTRODUCTION: Interest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ-4 and CEQ-7. METHODS: In translating the MEQ-4 and CEQ-7, our procedures were informed by the recommendations of the "Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation." Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese-speaking sample with psychedelic experience was not feasible. RESULTS: The final, approved back-translated versions of the MEQ-4 and CEQ-7 were developed, and the authorized Japanese versions of the MEQ-4 and CEQ-7 were established. CONCLUSIONS: In the present study, Japanese versions of the MEQ-4 and CEQ-7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese-speaking samples.
Neuroscience Study results published

Beta oscillatory brain state post-psilocybin/5-MeO-DMT

A dominant frontoparietal beta oscillatory brain state in the days after psilocybin and 5-MeO-DMT
Why it matters ▲ Favorable
This study identifies a beta-band neural signature following psychedelic use, offering potential biomarkers for the lasting effects of psychedelics on brain function. Understanding these changes could enhance the therapeutic application of psychedelics in psychiatric treatment, providing a measurable target for future clinical trials.
Background. Serotonergic psychedelics show promise for treating psychiatric disorders, with symptom improvements lasting for weeks after a single dose. Clarifying the neural basis of these effects would benefit from an identification of empirical biomarkers of such lasting shifts in brain function. Resting state EEG offers a rapid (<5 minute), low-cost window into functional brain networks. However, connectivity is not static, but cycles between recurring semi-stable patterns that vary across frequency bands. Here we employed a dynamic function connectivity (dFC) framework to identify frequency-specific connectivity states and examine how they change in the weeks following psychedelic use. Methods. We collected resting-state EEG from individuals who had used one of two serotonergic psychedelic subclasses within the prior three weeks, psilocybin/LSD (typical; n=14) or 5-MeO-DMT (atypical; n=12), and age- and sex-matched controls (n=16). Frequency-band-specific spatial connectivity states (phase-lag index) were estimated across the full sample (5 per band). Groups were compared on proportion and dwell-time (per state) and state-to-state transitions. Results. A right frontoparietally-distributed beta synchrony state was dominant after both typical and atypical psychedelics use (proportion/dwell-time). This effect correlated with the number of days since using psychedelics. A globally-distributed theta-band state was prominent in recent users of typical psychedelics but occurred less often in atypical users. In contrast, neural entropy (Lempel-Ziv complexity; known to increase acutely during psychedelic dosing) was not altered in recent users of either subclass. Conclusion. These results reveal a beta-band signature of altered neural dynamics in the week following a psychedelic dose, consistent with a relaxation of brain network hierarchy after psychedelics.
Clinical research Peer-reviewed study published

Brazilian study compares clinical suspicion vs. toxicology in substance poisonings

Clinical suspicion versus toxicological findings in psychoactive substance poisonings: evidence from emergency cases in Brazil (2023-2024).
Why it matters ◈ Mixed
This peer-reviewed study analyzes discrepancies between clinical suspicion and toxicological confirmation in emergency cases involving psychoactive substances in Brazil. The findings highlight the challenges clinicians face in accurately identifying substances involved in acute poisonings, which may impact both patient care and epidemiological surveillance. For policy and research, this underscores the need for improved toxicological screening and training, especially as psychedelic and novel psychoactive substance use increases. The data may inform harm reduction strategies and guide future regulatory or clinical protocols.
Neuroscience Peer-reviewed study

Psilocybin boosts sociability in altered states, not requiring full wakefulness

Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective.
Why it matters ◈ Mixed
This study suggests psilocybin's prosocial effects depend on the subject's behavioral state and do not require conscious, awake experience. This finding could reshape assumptions about the necessity of 'psychedelic experience' for therapeutic benefit, potentially informing new clinical protocols or formulations. It may also influence regulatory and ethical debates around patient consent and the design of trials, especially for populations unable to participate in traditional psychedelic-assisted therapy.
Neuroscience Research finding

OLFM1 gene hypomethylation linked to depression

DNA hypomethylation of the OLFM1 gene in patients with depression
Why it matters ▲ Favorable
This study identifies hypomethylation of the OLFM1 gene as a potential epigenetic biomarker for depression, offering new insights into the genetic and environmental factors influencing this psychiatric disorder. While not directly impacting psychedelic research or policy, understanding genetic markers can inform future therapeutic approaches, including those involving psychedelics.
Objective Depression is a heterogeneous psychiatric disorder and a growing public health concern, characterized by its high prevalence, recurrence rate, and association with suicide. There is evidence suggesting that both genetic susceptibility and environmental factors can regulate gene expression through DNA methylation, thereby influencing the occurrence and development of depression. The olfactory sensory neuropeptide 1 ( OLFM1 ) protein is a risk factor for mental disorders. However, there are no reports yet regarding the correlation between the OLFM1 gene and depression, nor have there been any studies on the association between OLFM1 gene DNA methylation and depression. Methods Genomic DNA was extracted from peripheral blood samples of patients with depression ( n = 100) and healthy controls ( n = 100) using the QIAamp DNA Blood Mini Kit. Subsequently, the extracted genomic DNA was subjected to bisulfite treatment using the EZ DNA Methylation-Gold™ kit. DNA methylation levels of 107 CpG sites in six fragments of OLFM1 exon 1 and its downstream were detected by the Illumina HiSeq platform using MethylTarget™ technology. Results Methylation levels across the overall OLFM1 CpG island and its six fragments ( OLFM1 -1 to OLFM1 -6) were significantly reduced in the depression group relative to controls. Analysis of the OLFM1 gene fragments revealed that 84 of 107 CpG sites were significantly hypomethylated in depressed individuals. When patients were divided by sex, male patients displayed hypomethylation at 65 CpG sites, substantially more than the 37 sites found in females. Conclusion OLFM1 hypomethylation is associated with depression and may serve as a potential epigenetic biomarker.
State policy State law in effect

Oregon psilocybin service centers study

“Am I a candidate for magic mushrooms?” A mystery shopper study of Oregon psilocybin service centers
Why it matters ◈ Mixed
This study provides critical insights into the operational realities of Oregon's psilocybin service centers, highlighting their cautious approach to client safety and psychiatric assessment. The high costs and financial strains reported may impact the scalability and accessibility of these services. Understanding these dynamics is crucial for stakeholders considering similar models in other jurisdictions.
Abstract Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon (7/2025-9/2025), 4 of which closed before calls began, leaving 22 in the sample. We reviewed websites and conducted two waves of scripted phone calls portraying adults with depression. Website and call data were combined at the center level, counting an item as disclosed if it appeared online or during a call. Themes from call field notes were contextualized through structured debriefing interviews with service center staff. Results Callers reached 15/22 centers, none of which permitted unsupervised consumption or immediate dosing without psychiatric assessment. Staff asked detailed questions about psychiatric comorbidities, addressing information gaps from websites, and none recommended discontinuing antidepressants. The median cost was $1,900. Debriefing interviews described financial strain, with viability constrained by licensing fees and potential misalignment with cannabis-derived business models. Conclusion Oregon’s regulated model appears more clinically cautious than skeptics anticipated, while facing high costs for clients and service center staff that limit scalability.
Clinical research Article published

Next-Gen Pharmacotherapies for Mood Disorders

Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms
Why it matters ◈ Mixed
This article discusses the development of new pharmacotherapies for unipolar mood disorders, focusing on Phase II/III trials across various mechanisms. While it provides insights into the future of drug development, its impact is limited by the lack of citations and concrete trial data. Researchers and industry stakeholders may find the discussion of diverse mechanisms useful for future investigations.
Clinical research Study announced

Rapamycin & ketamine show subjective improvement in study

Non-randomized rapamycin augmentation of chronic self-administered ketamine provides subjective improvement in diverse phenotypes
Why it matters ◈ Mixed
This study explores the potential of rapamycin to enhance ketamine treatment, indicating subjective improvements in a narrow patient group. The findings highlight the complexity of patient selection and dosing due to biochemical variability. Further randomized trials are needed to validate these preliminary results and explore biomarkers as endpoints. This could inform future treatment protocols and patient care strategies.
Background Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment. Population variability in patient biochemical gain-of-function and phenotypic admixtures, however, has slowed initial investigations into patient selection and dose finding. Methods A single-center, retrospective chart review identified 101 patients with ketamine use longer than 2 months. Correlational relationships between demographics, biometrics, ketamine use, concurrent medication use, and serum and tissue biomarkers were obtained in an attempt to characterize this group, given that likely severe selection bias limits generalizability. Rapamycin augmentation was attempted in 38 of these patients. Response was defined by patient preference for continuation and asymptotic dosing. Results Ketamine dosing (mean 4.4 ± 3.9 mg/kg/day) ranged widely from 0.4 to 20.7 mg/kg/day. Chronic ketamine use correlated with concurrent opioid use and was possibly associated with various tissue indices of mitochondrial activity. Among 38 patients who attempted rapamycin augmentation, 22 reported phenotypic benefit. Average dose was 1.5 ± 0.95 mg. Phenotypic response was highly variable, with improvement in cognition, fatigue, mood, pain, and dysautonomia. Rapamycin response correlated with weight and absence of antipsychotic use. Conclusion Rapamycin and ketamine in combination provide subjective benefit in a select, narrow population. The generalizability of these findings cannot be estimated easily. Subsequent randomized trials may consider using modal dosing as an exploratory endpoint and/or biomarkers, which may have greater utility than phenotypic checklists. These biomarkers could reflect ketamine’s action on complex 1 activity in presynaptic glutamatergic terminals and/or joint effects with rapamycin on homeostatic microglia.
Neuroscience Research review

BDNF–TrkB–mTOR Axis in Depression

Neuroinflammation, Oxidative Stress, and the BDNF–TrkB–mTOR Axis in Depression
Why it matters ▲ Favorable
This review highlights the complexity of depression, emphasizing the role of neurotrophic factors like BDNF, neuroinflammation, and oxidative stress. Understanding these mechanisms could lead to more targeted and effective treatments for depression. This is relevant for researchers focusing on the biological underpinnings of depression and those developing novel therapeutic approaches.
Depression is a multidimensional mental disorder that extends beyond changes in mood and adversely affects cognitive functioning, social adjustment, quality of life, and physical health. Although its biological basis was long interpreted primarily through the monoamine hypothesis, current evidence indicates that depression is too complex to be explained by alterations in a single neurotransmitter system. In recent years, impaired neuronal plasticity, disruption of neurotrophic support mechanisms, neuroinflammation, oxidative stress, mitochondrial dysfunction, and glial-cell responses have emerged as central processes in the pathophysiology of depression. In particular, the role of brain-derived neurotrophic factor (BDNF) in neuronal survival, synaptic plasticity, dendritic development, and hippocampal neurogenesis provides an important framework for understanding the cellular and molecular basis of the disorder. At the same time, microglial and astrocytic activation, increased production of pro-inflammatory cytokines, oxidative damage, and disturbances in mitochondrial energy metabolism may compromise neuronal network integrity and thereby contribute to both the onset and persistence of depression. This review provides an integrated account of the roles of BDNF and related neurotrophic factors, neuroinflammation, oxidative stress, mitochondrial dysfunction, experimental models of depression, and contemporary therapeutic approaches. It also discusses the value of histological, immunohistochemical, molecular, and biomarker-based strategies for identifying biological subtypes of depression and developing more targeted treatments.
Neuroscience Research review

iPSC-derived models in psychiatry: insights & horizons

Induced pluripotent stem cell-derived neuronal models in psychiatry: Mechanistic insights and translational horizons
Why it matters ▲ Favorable
This review highlights the potential of iPSC-derived neuronal models to advance understanding of psychiatric disorders by providing insights into patient-specific genetic risks. These models could significantly impact precision psychiatry by enabling more tailored therapeutic approaches. However, challenges remain in modeling the complex polygenic nature of psychiatric conditions.
Human induced pluripotent stem cell (iPSC)-derived neuronal models have become an important platform for investigating psychiatric disorders by enabling experimental access to human neurons carrying patient-specific genetic risk.Advances in reprogramming, neural differentiation, single-cell profiling, electrophysiology, and genome editing have facilitated the accessibility of knowledge which was once unavailable.Psychiatric disorders pose particular challenges for in vitro modeling due to their polygenic architecture, developmental origins, and clinical heterogeneity.This review summarizes the current state of iPSC-derived neuronal technologies, summarizes key findings across major psychiatric disorders, and discusses methodological limitations and emerging translational directions.We emphasize quantitative functional phenotyping and patient stratification as central principles for future progress in precision psychiatry.The future of precision psychiatry relays on two central principles; analyzing patient specific neuronal characteristics with an objective, comparable readout, and classifying patients into biologically meaningful subgroups which share common features such as mechanism, biomarker profile, or functional and structural signature.
Industry New clinic announced

New ketamine treatment clinic in Kitsap

ER doc and partner's venture brings rare ketamine treatment to Kitsap
Why it matters ▲ Favorable
A new venture by an ER doctor and partner is bringing a rare ketamine treatment to Kitsap, Washington. This development could increase access to ketamine therapy in the region, potentially benefiting patients with treatment-resistant depression or other conditions. Such initiatives can help normalize and expand the use of psychedelic-assisted therapies.
Neuroscience Research overview

Small molecules in pain & mental health care

Small molecules in pain management and mental healthcare
Why it matters ▲ Favorable
This overview highlights the role of small molecules in treating neurological conditions, pain, and mental health disorders, emphasizing recent advancements like ketamine and esketamine for treatment-resistant depression. These developments could influence future research directions and therapeutic strategies in mental healthcare. While not directly about psychedelics, the focus on novel small molecules is relevant to the broader context of neuropharmacology.
Neurological conditions are leading causes of disability worldwide, and they result in a significant annual loss in global productivity. Neurological conditions are strongly associated with pain and mental health disorders, including neuropathic pain, depression, and anxiety. Pain and mental illness often share overlapping neurobiological mechanisms and common pharmacological interventions via small molecules. Conventional pain management relies on small molecules such as opioids, nonsteroidal anti-inflammatory drugs, and local anesthetics, which target various stages of the pain signaling pathways. Similarly, psychotropic drugs, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants, regulate neurotransmission to alleviate both mood disorders and pain. Modulation of neurotransmission by antipsychotics, mood stabilizers, and psychostimulants plays a crucial role in managing mental health in neurological conditions. Recent advancements have led to the development of novel small molecules with therapeutic potential for both pain and mental health disorders. Recent small molecules, including gepants for migraine, sodium channel blockers for pain, N -methyl- d -aspartate receptor antagonists (ketamine, esketamine) for treatment-resistant depression, and neuroactive steroids for mood disorders, offer rapid and sustained relief with fewer side effects. In this chapter, we discussed clinically relevant small molecules and their therapeutic targets in the management of pain and mental healthcare, focusing on their mechanisms of action and potential side effects.
Clinical research Literature review published

Ketamine for treatment-resistant major depression

Uso da cetamina no tratamento da depressão maior resistente ao tratamento
Why it matters ◈ Mixed
This review highlights the potential of ketamine and esketamine as rapid-acting antidepressants for treatment-resistant major depression. While evidence supports their efficacy, concerns about repeated administration, adverse effects, and long-term use remain. This underscores the need for careful patient selection and clinical monitoring.
Introdução: O transtorno depressivo maior constitui uma importante causa de incapacidade e comprometimento da qualidade de vida. Entre os pacientes que não apresentam resposta adequada a tratamentos antidepressivos convencionais, destaca-se a depressão resistente ao tratamento, para a qual permanecem limitações terapêuticas relevantes. Nesse contexto, a cetamina e a esketamina surgiram como alternativas de ação antidepressiva rápida, com mecanismo predominantemente relacionado à neurotransmissão glutamatérgica. Objetivo: Revisar as evidências recentes acerca da eficácia, velocidade de ação, vias de administração, manutenção da resposta e segurança da cetamina e da esketamina no tratamento da depressão maior resistente ao tratamento. Metodologia: Foi realizada revisão da literatura por meio da base PubMed. Foram considerados artigos publicados nos últimos cinco anos, nos idiomas inglês, português e espanhol, utilizando os termos “ketamine”, “esketamine”, “major depressive disorder”, “major depression” e “treatment-resistant depression”. Foram priorizados ensaios clínicos randomizados, revisões sistemáticas, meta-análises e estudos relacionados à eficácia, segurança, manutenção e mecanismos de ação. Conclusão: As evidências disponíveis indicam que a cetamina apresenta efeito antidepressivo rápido e clinicamente relevante em parte dos pacientes com depressão resistente, enquanto a esketamina intranasal apresenta evidência consistente para uso repetido e manutenção da resposta. Entretanto, a heterogeneidade dos estudos, a necessidade frequente de administrações repetidas, os efeitos adversos e as incertezas sobre o uso prolongado limitam conclusões definitivas. A utilização dessas intervenções deve, portanto, ocorrer com seleção adequada dos pacientes e monitorização clínica.
Neuroscience Review published

Wearable VNS for depression: review on mechanisms and devices

Wearable vagus nerve stimulation for depression: mechanisms, devices, and the road toward personalized neuromodulation
Why it matters ▲ Favorable
This review highlights the potential of wearable vagus nerve stimulation (VNS) as a non-invasive treatment for depression, addressing limitations of implantable systems. Advancements in wearable VNS could lead to more accessible, personalized neuromodulation therapies. The integration of AI and bioelectronics may further enhance treatment efficacy and scalability.
Major depressive disorder remains a leading cause of global disability, with a substantial fraction of patients exhibiting inadequate response to conventional pharmacological and psychotherapeutic treatments. Vagus nerve stimulation has emerged as an effective neuromodulation strategy for treatment-resistant depression, yet implantable systems are limited by surgical risk, cost, and restricted scalability. Recent advances in non-invasive, wearable vagus nerve stimulation technologies, particularly transcutaneous auricular and cervical approaches, offer a promising pathway toward accessible, home-based neuromodulation. This Review synthesizes the anatomical and physiological rationale underlying wearable non-invasive VNS and critically evaluates mechanistic evidence spanning monoaminergic modulation, neuroplasticity, neuroimmune regulation, autonomic control, and large-scale brain network reorganization. We further summarize clinical findings from implantable and non-invasive trials and discuss key engineering considerations, including electrode–skin interfaces, stimulation parameters, wearability, and safety. Finally, we highlight major challenges and future opportunities, emphasizing the integration of flexible bioelectronics, multimodal sensing, and Artificial Intelligence-driven closed-loop control to enable personalized, scalable neuromodulation for depression.
Clinical research Systematic review published

Systematic review of Salvinorin A in humans published

Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety
Why it matters ▲ Favorable
This systematic review synthesizes human studies on Salvinorin A, highlighting its unique pharmacokinetic and pharmacodynamic profile as a κ-opioid receptor agonist. No serious adverse events were reported, suggesting a favorable safety profile for further research. The review underscores Salvinorin A's potential as a model for studying κ-opioid receptor-mediated consciousness alterations, which could inform future neuropsychiatric research.
, is a highly selective κ-opioid receptor agonist and a rare example of a κ-opioid receptor-mediated psychedelic drug. Preclinical work of salvinorin A has shown promising effects in neuropsychiatric animal models. However, human studies remain heterogeneous and fragmented, highlighting the need for synthesis. Thus, we conducted a systematic review to synthesize available human studies of salvinorin A, with a focus on pharmacokinetics, pharmacodynamics, safety, and longer-term effects. We searched PubMed, Web of Science, and EMBASE from inception to January 18, 2026. We included 12 clinical trials comprising 174 participants. Most studies enrolled medically healthy, hallucinogen-experienced volunteers and administered salvinorin A by inhalation (0.375-21 µg/kg or 0.2-12 mg). Pharmacokinetic profiles were characterized by rapid onset within seconds, peak effects at 1-2 minutes, and resolution within 30 minutes, consistent with fast absorption and clearance. Sublingual administration in two studies produced slower onset and longer duration, whereas oral dosing was inactive in one study. No serious adverse events were reported. Physiological parameters were largely stable, with occasional mild increases in blood pressure/heart rate. Acute psychological effects included disorientation, anxiety, and distress in subsets of participants, alongside reports of positive subjective changes. Long-term adverse effects were rare, and abuse potential appeared low. Overall, salvinorin A exhibits a distinct human neuropsychopharmacological profile compared with serotonergic psychedelics. These findings support cautious further investigation in controlled studies. Further, salvinorin A can serve as a model for probing κ-opioid receptor-mediated alterations of consciousness in humans.
Clinical research Case report published

S-ketamine case report for adolescent depression in EOP

Case report of S-ketamine as treatment option for suicidal ideation and treatment-resistant depression in adolescents with early-onset psychosis
Why it matters ▲ Favorable
This case report highlights the potential of intranasal S-ketamine as a treatment for treatment-resistant depression and suicidality in adolescents with early-onset psychosis. The rapid clinical response and lack of exacerbation of psychotic symptoms suggest a promising avenue for further research. This could inform future clinical trials and treatment protocols for a high-risk and underserved population.
Summary Background Depressive symptoms and suicidality are highly prevalent in adolescents with early-onset psychosis (EOP) and often remain refractory to standard treatment. While S‑ketamine is an established treatment for treatment-resistant depression in adults (TRD), its use in primary psychotic disorders remains scarce due to risk of exacerbation of psychotic symptoms. Case presentation We present the case of a 16-year-old male with schizophrenia (ICD-10: F20.9) and chronic suicidality. Despite achieving remission of positive symptoms with amisulpride, severe depressive symptoms including suicidality persisted. Following the initiation of off-label intranasal S‑ketamine (titrated to 84 mg) at age 17 and 11 months, the patient showed a rapid clinical response. The Montgomery–Åsberg Depression Rating Scale (MADRS) score decreased by 50% within 3 weeks, accompanied by a significant reduction in the Positive and Negative Syndrome Scale (PANSS)–positive symptoms subscale score (from 22 to 10) and the PANSS–negative symptoms subscale score (from 33 to 17). Notably, no exacerbation of remitted positive symptoms occurred, and sustained functional recovery was achieved. Conclusion This case suggests that intranasal S‑ketamine may be a safe and effective augmentation strategy for TRD and suicidality in stable adolescent early-onset psychosis, highlighting the need for further research in this high-risk population.
Neuroscience Research review

Tryptophan metabolism in MDD via gut-brain axis

Tryptophan metabolic pathway crosstalk and composite subtypes of major depressive disorder through the microbiota-gut-brain axis
Why it matters ◈ Mixed
This research review highlights the role of the microbiota-gut-brain axis in major depressive disorder, proposing a classification into subtypes based on tryptophan metabolism. Understanding these subtypes could lead to more precise interventions for treatment-resistant depression. However, the proposed framework remains theoretical and requires validation through future clinical trials.
Major depressive disorder (MDD) is a common and disabling mental illness affecting approximately 332 million people worldwide, with an adult prevalence rate of 5.7%. Although the hypothesis of monoamine neurotransmitter deficiency plays a fundamental role, it cannot fully explain treatment-resistant depression (TRD), which can affect up to 30% of patients. The microbiota-gut-brain axis (MGBA) now provides a systematic framework for understanding the heterogeneity of MDD. This article reviews the recent literature evidence on tryptophan metabolism within the MGBA in the PubMed database, focusing on kynurenine (Kyn), indole, and the serotonin/5-hydroxytryptamine (5-HT) pathways. A preliminary classification is proposed: three complex MDD subtypes based on abnormal interactions among these metabolic pathways: the indole-Kyn-related disorder subtype characterized by intestinal flora imbalance and barrier damage; the serotonin-Kyn dual-pathway disorder subtype caused by the competition of inflammation for tryptophan; and the overall indole-Kyn-serotonin disorder subtype representing the most severe form, accompanied by the disruption of the blood-brain barrier. Each subtype is associated with specific biomarker profiles and hypothesized treatment susceptibility. This framework may help implement individualized precision interventions for patients with depression characterized by abnormal MGBA-related tryptophan metabolism, but some subtypes and treatment strategies are currently conceptual and need to be verified in prospective clinical trials. Clinical trial registration: Not applicable
Clinical research Review published

Creatine's Cognitive and Psychiatric Effects Reviewed

Beyond Muscle: A Narrative Review of Creatine Monohydrate Supplementation Effects on Cognition, Sleep, and Psychiatric Disorders
Why it matters ◈ Mixed
This narrative review explores the potential cognitive and psychiatric benefits of creatine monohydrate supplementation, highlighting its role in enhancing cognitive function under metabolic stress and as an adjunctive treatment for unipolar depression. While preliminary data is promising, especially for depression, more robust randomized controlled trials are needed to confirm these findings. This could influence future research directions and therapeutic strategies in psychiatric care.
Creatine monohydrate is one of the most widely consumed supplements worldwide. Beyond its role in skeletal muscle bioenergetics, creatine serves important functions in the central nervous system, acting as an energy buffer while exerting antioxidant, anti-apoptotic, and neuromodulatory effects, raising the possibility of therapeutic relevance beyond exercise performance. This review aimed to synthesize the available evidence on the effects of creatine monohydrate supplementation on cognitive functions, sleep, and psychiatric disorders, including major depressive disorder, bipolar disorder, and schizophrenia. A narrative review was conducted based on a PubMed/MEDLINE search (13 April 2026), yielding 103 records. Following screening, 26 articles were selected, comprising randomized controlled trials, open-label studies, and preclinical investigations. Cognitive benefits were most pronounced under metabolic stress, such as sleep deprivation and hypoxia, with mixed evidence under resting conditions. In psychiatric populations, the strongest evidence is present for unipolar depression, where creatine supplementation administered as an adjunct to antidepressant pharmacotherapy or psychotherapy accelerated and potentiated clinical response. Preliminary data supported a possible benefit in bipolar depression, while a single trial in schizophrenia found no benefit. Biological sex emerged as a recurring but unresolved moderator of treatment response. Creatine supplementation shows the greatest therapeutic promise as an adjunctive strategy in unipolar depression. Cognitive effects appear context-dependent, emerging primarily under metabolic stress. Adequately powered randomized controlled trials with standardized outcome measures are needed to confirm these findings and extend the evidence base to other psychiatric conditions.
State policy Ongoing analysis

Oregon Dataset Larger Than All Psychedelic Trials

The Oregon Dataset Is Larger Than the Entire History of Psychedelic Trials. So Why Are Regulators Still Looking the Other Way?
Why it matters ◈ Mixed
Oregon's dataset on psychedelic use is reportedly larger than the entire history of psychedelic trials, yet regulators have not fully engaged with this data. This highlights a potential gap between state-level data collection and federal regulatory attention. It underscores the need for regulators to consider state-generated data when shaping policies on psychedelic substances.
Clinical research Perspective published

Social environments in psychedelic treatments

As Psychedelic Treatments Get Leaner, Patients’ Social Environments Deserve Attention
Why it matters ◈ Mixed
This perspective highlights the potential role of patients' social environments in moderating outcomes of psychedelic treatments, which are becoming less clinically intensive. It suggests integrating psychoeducation and peer support into treatment protocols. This could influence future research designs and patient care strategies.
As psychedelic treatments approach licensing with reduced clinical intensity, the psychological functions previously served by integration support are increasingly displaced onto patients' social environments. This Perspective argues that these environments are plausible but unmeasured moderators of outcome, and proposes three responses: structured psychoeducation for support networks, purpose-built peer support for clinical populations, and routine incorporation of social-environmental measures into research protocols.
Neuroscience Research published

Study links stress, substance use, and brain white matter

Substance use involvement moderates the effect of cortisol response on white-matter microstructure longitudinally
Why it matters ◈ Mixed
This study provides insights into how substance use involvement may moderate the relationship between stress hormones and brain white matter microstructure. Understanding these interactions could inform future research on substance use disorder aetiology and potential biomarkers. However, the findings are preliminary and require further investigation to determine their implications for treatment or prevention strategies.
Introduction Stress contributes to substance use (SU) involvement (SUI) and differences in brain white matter (WM). However, longitudinal relationships involving SUI, stress hormones, and WM are not well understood. This study examined the moderating role of SUI on the prospective association between cortisol response (CR) and WM microstructure.Methods Data were drawn from a larger longitudinal study on SU disorder (SUD) aetiology. Participants were enrolled at ages 10–12 years when salivary cortisol was assayed. The Drug Use Chart assessed cumulative involvement with 10 substance categories by age 18 years. Diffusion-weighted data were acquired from sixty-nine participants after reaching age 18 years and were used to compute crossing-fibre measures. Analyses were conducted in a priori regions of interest linked to SU and stress.Results CR levels were related to secondary- and tertiary-fibre anisotropy in the cingulum. SUI moderated associations between CR and right cingulum secondary-fibre anisotropy wherein CR levels associated with greater anisotropy at heightened SUI levels.Conclusions This study identified stress-linked differences in distinct cingulum WM fibres among individuals with greater SUI. Involvement with SU overall, may modulate stress effects and enhance WM anisotropy in region- and fibre-specific manners. Potential biomarkers associated with SUI in WM among vulnerable stress-exposed youth require further investigation with respect to SUD aetiology.
Clinical research Trial announced

UW to test psilocybin retreats for cancer

A University of Washington trial will test group psilocybin retreats for advanced cancer
Why it matters ▲ Favorable
The University of Washington's trial on group psilocybin retreats for advanced cancer patients represents a significant step in exploring the therapeutic potential of psychedelics in palliative care. This research could provide valuable insights into the mental health benefits of psilocybin for individuals facing life-threatening illnesses. The trial's outcomes may influence future clinical practices and regulatory decisions regarding psychedelic-assisted therapies.
Neuroscience Study published

Psychedelic DOI affects mice olfactory behavior

The impact of a psychedelic drug on olfactory search behavior by mice
Why it matters ◈ Mixed
This study explores the effects of the psychedelic DOI on olfactory search behavior in mice, revealing decreased search accuracy and altered movement. Understanding these effects can inform future research on the sensory impacts of psychedelics. While primarily of interest to neuroscientists, these findings may have implications for understanding the broader sensory effects of psychedelics in humans.
Animals use their sense of smell for survival and well-being. Any disruption to olfactory perception, such as in the case of olfactory hallucinations, can lead to devastating consequences and decreased quality of life. Psychedelics interrupt and distort accurate perception, yet little is known about the impact of psychedelics on olfactory behaviors. Using an olfactory search task, we investigated the impact of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on olfactory search behavior of mice. We found that DOI decreases search accuracy, alters movement, and increases sniff rate. These findings suggest that the olfactory behaviors are altered by DOI, elucidating psychedelic-induced changes to olfactory processes.
Neuroscience Review published

Systematic review maps MDD heterogeneity via multi-omics

Mapping the Heterogeneity of Major Depressive Disorder: A Systematic Review of Multi-Omics Integration Studies
Why it matters ▲ Favorable
This systematic review highlights the potential of multi-omics integration to redefine major depressive disorder (MDD) by identifying distinct subtypes with specific neurobiological and clinical profiles. The research suggests a shift towards precision psychiatry, emphasizing the need for biomarker-based diagnostics and personalized treatment regimens. This could significantly impact future clinical trials and treatment strategies for depressive disorders.
Major depressive disorder (MDD) has a widespread heterogeneity as per the psychiatric nosology, and traditional symptom-based diagnosis frameworks do not offer many clues regarding tailored therapy techniques. The recent development of multi-omics and data-driven solutions has now provided evidence for pathophysiologically different subtypes of MDD, moving the field toward precision psychiatry. The systematic review aggregates multimodal studies that combing neuroimaging, genomics, transcriptomics, epigenomics, metabolomics, and proteomics to define MDD subtypes. There are two to four candidate clusters that have been formed across these heterogeneous modalities, and each has a neurobiological and clinical profile. Cognitive subtypes are characterized by executive failure and loss of prefrontal and temporal gray matter. Neuroimaging-derived subtypes show specific patterns of functional connectivity that may predict response to selective serotonin reuptake inhibitors (SSRIs) or repetitive transcranial magnetic stimulation (rTMS) in preliminary studies. There are immune-metabolic subtypes characterized by increased inflammatory cytokines and dysregulation of metabolic pathways. Molecular subtypes appear to be differentiated by cellular mechanisms such as mitophagy and pyroptosis. Taken together, these results indicate that multi-omics integration, in addition to explaining the molecular architecture of MDD, also characterizes patient subgroups with pathophysiological mechanisms, dimensions of symptoms, and disease treatment. The growing body of literature demonstrates that there is a shift in psychiatry toward a more mechanistic approach and that biomarker-based diagnostics and personalized treatment regimens are urgently needed to improve clinical outcomes in depressive diseases.
Policy research Peer-reviewed analysis

Comparative analysis of state psilocybin regulatory frameworks published

Toward an Optimal Framework for Psilocybin Regulation: A Comparison of State Regulatory Approaches Across Key Dimensions.
Why it matters ◈ Mixed
This peer-reviewed analysis systematically compares state-level psilocybin regulatory models, highlighting key differences in access, safety, oversight, and market structure. The findings provide actionable insights for policymakers, researchers, and industry stakeholders seeking to design or refine regulatory systems. The study may inform future legislative efforts and guide best practices for balancing innovation, public health, and risk mitigation in emerging psilocybin markets.
Clinical research Systematic review published

Systematic review: Salvinorin A pharmacokinetics, dynamics, and safety in humans

Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety.
Why it matters ◈ Mixed
This systematic review aggregates current human data on Salvinorin A, a unique non-alkaloid psychedelic with distinct pharmacology. The findings clarify its pharmacokinetic and safety profile, which is crucial for designing future clinical trials and informing regulatory discussions. However, the review also highlights gaps in long-term safety and standardization, underscoring the need for more rigorous human studies before broader clinical or policy moves. This synthesis will inform both researchers and policymakers evaluating Salvinorin A's therapeutic potential and risk profile.
Clinical research Case report published

Case report: S-ketamine for suicidal ideation in adolescent psychosis

Case report of S-ketamine as treatment option for suicidal ideation and treatment-resistant depression in adolescents with early-onset psychosis.
Why it matters ◈ Mixed
This case report documents the use of S-ketamine to address suicidal ideation and treatment-resistant depression in adolescents with early-onset psychosis, a population with limited therapeutic options. While single-case evidence is insufficient for policy or clinical practice change, it highlights the urgent need for controlled trials in this high-risk group. The report may prompt further research and cautious discussion about off-label use, but does not alter legal or regulatory status.
Clinical research Peer-reviewed article

Study: Social context key as psychedelic therapy models evolve

As Psychedelic Treatments Get Leaner, Patients' Social Environments Deserve Attention.
Why it matters ◈ Mixed
This article highlights the importance of considering patients' social environments as psychedelic treatment protocols become less intensive or more scalable. For researchers and clinicians, it underscores the need to account for social support, integration, and potential disparities in outcomes as access expands. Policymakers and payers should note that leaner models may risk overlooking critical social determinants of health, which could affect both efficacy and equity in real-world deployment.
Clinical research Study results announced

Esketamine improves analgesia in elderly post-hip surgery

Efficacy of Esketamine as an Adjuvant for Fascia Iliaca Compartment Block on Postoperative Analgesia in Elderly Patients Undergoing Total Hip Arthroplasty
Why it matters ▲ Favorable
This study demonstrates that esketamine, when used as an adjuvant in fascia iliaca compartment block, significantly enhances postoperative analgesia in elderly patients undergoing total hip arthroplasty. The findings suggest esketamine's potential to improve pain management protocols for elderly surgical patients, with minimal adverse effects and high patient satisfaction. This could influence future clinical guidelines and pain management strategies.
Objective: To study the effect of esketamine as an adjuvant for fascia iliaca compartment block (FICB) on postoperative analgesia in elderly patients undergoing total hip arthroplasty(THA). Methodology: This study is a single-center prospective randomized controlled study. 60 elderly patients who underwent THA at the 904th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from August to December 2025 were randomly divided into the observation group and the control group by the random number table method. The observation group conducted FICB with 0.3 mg/kg esketamine combined with 30 mL of 0.375% ropivacaine, while the control group conducted FICB with 30 mL of 0.375% ropivacaine alone. Postoperative pain intensity, intraoperative anesthetic consumption, first press time of patient-controlled intravenous analgesia (PCIA) pump , number of effective PCIA pump presses, frequency of rescue analgesia, duration of sensory block, patient satisfaction and adverse reactions were compared between the two groups. Results: The observation group showed a significantly lower VAS score both at rest and exercise T6(P<0.05), T12(P<0.05).Whether at rest or at exercise, comparison of the VAS score trends over time between two groups showed statistically significant differences(P<0.05). Intraoperative anesthetic consumption, number of effective PCIA pump presses and frequency of rescue analgesia within 48 hours after opreation were also significantly lower in the observation group (P < 0.05). Duration of sensory block and time for PCIA pump first press were significantly longer in the observation group (P < 0.05). Conclusion: Esketamine used as an adjuvant in FICB is safe and effective for elderly patients undergoing THA, providing effective pain relief, prolonging postoperative analgesia duration, with few adverse reactions and high patient satisfaction.
Neuroscience Review published

Gut-brain axis therapies for depression in Crohn's disease

Bridging the gut and mind: a narrative review of depression in Crohn’s disease and emerging gut-brain axis therapies
Why it matters ◈ Mixed
This narrative review highlights the complex interplay between the gut-brain axis and depression in Crohn's disease, emphasizing the need for integrative treatment strategies. Emerging therapies like ketamine enantiomers and microbiota-targeting compounds show promise but require further investigation. Understanding these mechanisms could lead to more effective treatments for depression in patients with inflammatory bowel diseases.
Depression is a highly prevalent and clinically significant comorbidity in Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), and is associated with increased disease activity, hospitalization, and a reduced quality of life (QoL). While traditionally attributed to the psychosocial burden of chronic illness, emerging evidence indicates that depressive symptoms in CD arise from dysregulation of the gut-brain axis (GBA), a bidirectional network linking immune, microbial, and central nervous system (CNS) processes. Chronic intestinal inflammation, characterized by elevated cytokines such as tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), may influence brain function through vagal signaling, hypothalamic-pituitary-adrenal (HPA) axis activation, and neuroimmune pathways. Concurrently, epithelial barrier dysfunction and microbial dysbiosis promote translocation of bacterial products, further amplifying systemic inflammation and neuroimmune signaling. This review consolidates preclinical and clinical evidence linking immune activation, microbial alterations, and neuroimmune signaling to depression in CD. The review compares emerging therapeutic strategies, such as ketamine enantiomers, vagus nerve stimulation, and microbiota-targeting natural compounds, with established therapies like serotonergic antidepressants, cognitive behavioral therapy, and biologic immunotherapies. Across these modalities, therapeutic effects on mood are heterogeneous and often dissociated from improvements in intestinal inflammation, highlighting the multifunctional nature of GBA dysfunction. Overall, these findings suggest that therapeutic responses in CD-associated depression may depend on the extent to which interventions modulate distinct components of the GBA, including immune, neural, and microbial pathways. These observations emphasize the need for integrative treatment strategies that address the multiple contributors of GBA dysbiosis. Future studies incorporating standardized and emerging psychiatric, immunological, and microbiome outcomes will be critical to identifying mechanisms for specific treatment responses in this population.
Industry Clinical research

Psilocybin's Clinical Viability Questioned

Psilocybin Works in the Lab. Can It Survive the Clinic?
Why it matters ◈ Mixed
The article likely explores the challenges psilocybin faces in transitioning from promising laboratory results to successful clinical applications. Understanding these challenges is crucial for stakeholders aiming to integrate psilocybin into mainstream therapeutic practices. The outcome of this transition could significantly impact the psychedelic industry's growth and regulatory landscape.
Industry Industry collaboration announced

NeuroThera-Clearmind advance MDMA-PTSD treatment IP

NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Why it matters ▲ Favorable
The collaboration between NeuroThera and Clearmind to advance intellectual property for MDMA-N-acylethanolamines in treating PTSD highlights growing industry interest and innovation in psychedelic therapies. With rising U.S. federal support for psychedelic research, this partnership could accelerate the development of new treatment modalities for PTSD. This development is significant for stakeholders in the psychedelic industry and could influence future research and market dynamics.
Industry Patent application published

MDMA-N-Acylethanolamines patent for PTSD treatment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders
Why it matters ◈ Mixed
The publication of a patent application for MDMA-N-Acylethanolamines targeting PTSD, anxiety, and eating disorders highlights ongoing innovation in psychedelic-assisted therapies. This could influence future research directions and commercial strategies in the psychedelic industry. However, the impact will depend on the patent's approval and subsequent clinical validation.
Clinical research Research published

Medicinal Plants & Spirituality in Health Practices

PLANTAS MEDICINAIS E ESPIRITUALIDADE NAS PRÁTICAS DE SAÚDE: REVISÃO INTEGRATIVA
Why it matters ◈ Mixed
This integrative review highlights the complex interplay between medicinal plants and spirituality across various sociocultural contexts. It underscores the need for more comprehensive research that integrates biological, cultural, and spiritual dimensions of care. Such studies can enhance our understanding of traditional health practices and their therapeutic potential.
A interface entre plantas medicinais e espiritualidade constitui um fenômeno complexo e culturalmente situado, porém a produção científica sobre essa temática ainda se encontra dispersa. Objetivou-se analisar as evidências acerca da relação entre plantas medicinais e espiritualidade em diferentes contextos socioculturais. Para tanto, procedeu-se a uma revisão integrativa, baseada nas recomendações do PRISMA, cuja pergunta de pesquisa foi estruturada pelo acrônimo PICo. As buscas foram realizadas no mês de julho de 2026, sem restrição de idioma, na Embase, Scopus, Web of Science, MEDLINE/PubMed, Google Scholar e nas seguintes fontes, via Biblioteca Virtual de Saúde: Literatura Latino-Americana e do Caribe em Ciências da Saúde, Non-Medline, Base de Dados de Enfermagem, Índice Bibliográfico Espanhol em Ciências da Saúde e Mosaico. Os estudos elegíveis, que investigaram plantas medicinais e espiritualidade, foram submetidos à extração dos dados e identificação dos principais temas e conclusões. Foram incluídos 17 estudos que evidenciaram três categorias principais: farmacognosia, principais plantas e sua articulação entre ação terapêutica e espiritualidade; plantas medicinais e práticas de cuidado culturalmente contextualizadas; e a espiritualidade como mediação do processo de cura e do enfrentamento do sofrimento. Essas categorias mostram que as práticas terapêuticas, sistemas de conhecimento e experiências subjetivas se articulam na produção do cuidado e amplia o entendimento sobre as práticas tradicionais em saúde, mas é preciso fortalecer investigações que integrem dimensões biológicas, culturais e espirituais do cuidado.
State policy Ongoing coverage

Psilocybin status in Oregon

‘Shroom talk, Part I: The state of psilocybin in Oregon
Why it matters ◈ Mixed
The article likely discusses the current state of psilocybin regulation and use in Oregon, a pioneering state in psilocybin legalization. Understanding the developments in Oregon can provide insights into potential regulatory and market trends for psilocybin in other regions. This is particularly relevant for stakeholders interested in the evolving legal landscape and community impact of psilocybin use.
Market / FDA FDA hearing scheduled

CMPS stock gains 25% ahead of FDA hearing

CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
Why it matters ▲ Favorable
The significant stock gain for CMPS indicates strong market optimism surrounding its upcoming FDA application filing and the scheduled FDA hearing on psychedelics. This development suggests increasing investor confidence in the regulatory and commercial prospects for psychedelic therapies. The outcome of the FDA hearing could impact market dynamics and regulatory pathways for psychedelic substances.
Neuroscience Research published

Ketamine's opioid nature confirmed

Molecular snapshots confirm ketamine's opioid nature.
Why it matters ◈ Mixed
This research provides molecular evidence that ketamine interacts with opioid receptors, which could impact its classification and therapeutic use. Understanding ketamine's opioid-like properties may influence regulatory decisions and clinical guidelines. This finding is crucial for both ongoing research into ketamine's mechanisms and its application in mental health treatments.
FDA / DEA FDA initiative

FDA accelerates psychedelics; calls for more action

The FDA is moving faster on psychedelics, now Washington must do more
Why it matters ◈ Mixed
The FDA's accelerated movement on psychedelics indicates a shift towards potentially faster approval processes for psychedelic therapies. This could significantly impact research timelines and market entry for new treatments. However, the call for more action from Washington suggests that further legislative or regulatory changes are needed to fully support this momentum.
Clinical research Trial results announced

STAR & TextSTAR feasible for SA survivors

Feasibility and acceptability of skills training in affective recovery (STAR) video and TextSTAR text message program for recent sexual assault survivors
Why it matters ▲ Favorable
The study demonstrates the feasibility and acceptability of the STAR video and TextSTAR text message program as interventions for recent sexual assault survivors. This could inform future research and interventions aimed at reducing posttraumatic stress and substance misuse in this vulnerable population. While not directly related to psychedelics, the focus on trauma recovery is relevant to the broader field of mental health interventions.
Background: Sexual assault (SA) affects more than 50% of women in the United States and is associated with elevated risk for impairing posttraumatic stress symptoms and substance, particularly opioid, misuse. Intervening following SA exposure could attenuate these risks.Objective: This study examined the acceptability and feasibility of a 17-minute video, Skills Training in Affective Recovery (STAR) and a 21-day text message program (TextSTAR), that were delivered in the acute post-SA period to prevent the onset or escalation of posttraumatic stress symptoms and substance misuse. The interventions provide psychoeducation about trauma, strategies to reduce fear and avoidance, suggestions to increase social support, and coping strategies for substance use.Method: Participants were 50 women age 18 or older who presented for a Sexual Assault Medical Forensic Exam (SAMFE) within seven days of a SA. Using a Sequential Multiple Assignment Randomized Controlled Trial (SMART) design, participants were randomized to receive the STAR video (n = 25) or no video (n = 25) at the SAMFE. Those who received the video answered questions about video acceptability immediately after viewing the video. At 1-week post-SAMFE, participants completed online questionnaires about substance use and posttraumatic stress; those above threshold on acute stress or opioid use (n = 36) were randomized to TextSTAR (n = 18) or no-text program (n = 18). Participants completed weekly online surveys 2–4 weeks post-SAMFE about symptoms and text program acceptability.Results: Participants found STAR and TextSTAR at least moderately acceptable; 80% who received STAR found it extremely acceptable while 60-90% (depending on timepoint) who received TextSTAR found it at least moderately acceptable. Our ability to enroll 50 participants and retain 94% at 1 week and 90% at 4 weeks suggests the intervention trial is feasible.Conclusions: STAR and TextSTAR are acceptable and feasible brief interventions for recent sexual assault survivors.Trial registration: ClinicalTrials.gov identifier: NCT06456190.
Neuroscience Research published

Arrestins as programmable integrators of GPCR signaling

Arrestins as programmable integrators of GPCR signaling: structural microstates, spatiotemporal logic, and therapeutic control
Why it matters ▲ Favorable
This research provides a deeper understanding of arrestins as complex integrators of GPCR signaling, revealing potential new pathways for therapeutic intervention. These insights could lead to the development of next-generation GPCR therapeutics, potentially impacting drug design and efficacy in treating neurological disorders. While not directly related to psychedelics, the findings may inform future research on receptor-targeted therapies.
Arrestins were originally defined as terminators of G protein-coupled receptor (GPCR) signaling, yet structural and mechanistic advances now reveal them as programmable, spatiotemporal integrators of cellular signaling. Recent cryo-electron microscopy studies have revealed a diverse spectrum of GPCR-arrestin engagement modes, including core-, tail-, loop-, side-engaged, and membrane-anchored conformations, across GPCR classes and arrestin isoforms. These structures reveal that arrestin recruitment operates as a conditional, allosterically regulated process rather than a binary on-off switch. The selection of the arrestin microstate is governed by layered regulatory inputs, including GPCR kinase-dependent phosphorylation barcodes, membrane and lipid cofactors, and isoform-specific mechanics, which together define the signaling geometry, duration, and subcellular localization. This structural logic provides a mechanistic foundation for biased signaling, noncanonical endosomal signaling, and GPCR-independent arrestin functions. Importantly, emerging therapeutic strategies, including intracellular allosteric modulators and molecular glues, demonstrate that arrestin signaling can be reprogrammed by directly sculpting transducer assemblies rather than ligand efficacy alone. Here, we synthesize recent structural, biochemical, and physiological insights to outline how arrestins decode regulatory inputs into signaling outcomes and how this knowledge enables the development of next-generation, structure-guided GPCR therapeutics.
Neuroscience Research review

Gabapentin linked to neurodegeneration risks

Current insights suggest gabapentin-induced neurodegeneration
Why it matters ◈ Mixed
This review highlights potential neurodegenerative risks associated with prolonged gabapentin use, a drug commonly prescribed for neurodegenerative disorders. Understanding these risks is crucial for optimizing patient care and developing protective strategies. Further research is needed to elucidate the mechanisms and mitigate potential adverse effects.
Antiepileptic drugs (AEDs) are commonly prescribed to treat epilepsy and other neurodegenerative disorders (NDs). Gabapentin (GBP) is a newer, off-label antiepileptic/anticonvulsant for NDs that remains underexplored. Recent evidence indicates that prolonged, frequent, and high-dose use of GBP may be associated with an increased risk of various types of dementia and cognitive impairment. GBP has become 1 of the top 20 most prescribed drugs for NDs. GBP modulates voltage-gated calcium channels by binding to the alpha2delta subunit. One possible mechanism is oxidative stress, which can damage neuronal structures, impair synaptic function, and cause mitochondrial dysfunction, all of which are strongly implicated in the pathogenesis of several NDs and contribute to cognitive decline. Another factor is excitotoxicity, where abnormal glutamatergic activity causes excessive calcium influx and neuronal injury, thereby exacerbating mood problems and memory deficits. Long-term use of GBP interferes with SIRT1 (neuroprotective), CaMKII (calcium regulator), and tau phosphorylation regulation, damaging downstream signalling, disrupting central pain pathways in the spinal cord and brain (central sensitisation), damaging neuronal survival pathways, and promoting neurodegeneration. This literature review aims to synthesise current insights on GBP neurotoxic effects, including changes at the gene and protein levels, neuronal structure, function, and network connectivity, as well as strategies for managing GBP-associated NDs. Further research is needed to clarify the exact mechanisms and to develop protective strategies to reduce neurodegenerative risks, optimise seizure control, and evaluate the risks of GBP in clinical settings.
Clinical research Study announced

Proteomic study on treatment-resistant depression

A proteomic feasibility study connecting metabolic and synaptic pathway alterations in serum and extracellular vesicles to characterize treatment-resistant depression
Why it matters ◈ Mixed
This study explores the potential of using proteomic profiling of serum and extracellular vesicles to differentiate between treatment-resistant and non-treatment-resistant depression. The findings suggest that EV proteomics could offer insights into biological pathways specific to treatment resistance, which are not apparent in bulk serum analyses. This approach may aid in the molecular stratification of antidepressant resistance, potentially informing future therapeutic strategies.
Treatment-resistant depression (TRD) remains a major clinical challenge, yet the biological processes distinguishing TRD from non-treatment-resistant depression (nTRD) are incompletely defined. While circulating serum proteomes reflect broad systemic alterations associated with depression, extracellular vesicles (EVs) could provide a more selective representation of intercellular signaling relevant to treatment resistance. Here, we carried out a pilot study to evaluate the extent that parallel proteomic profiling of serum and serum-derived EVs could distinguish healthy controls (CON), nTRD, and TRD individuals. In this exploratory and hypothesis-generating study, serum proteomes exhibited robust global differences between depression groups and controls, largely reflecting shared systemic biology across nTRD and TRD. In contrast, EV proteomes showed limited global separation but revealed subtype-associated pathway differences. Relative to controls, nTRD EVs were enriched for immune and inflammatory pathways. By contrast, TRD EVs were characterized by enrichment of mitochondrial metabolism, oxidative phosphorylation, translational initiation, and MYC-regulated pathways, together with depletion of synaptic signalling, membrane trafficking, and cytoskeletal pathways. Comparative analysis of pathways significant in both contrasts revealed that these bioenergetic and translational signatures were selectively amplified in TRD relative to nTRD. Our exploratory analyses identified that the circulating EV cargo may reflect a treatment-resistance-specific reorganization of biological pathways not apparent in bulk serum proteomics. This study highlights parallel serum and EV proteomics as a complementary approach for molecular stratification in antidepressant resistance.
Clinical research Peer-reviewed study published

Study: S-ketamine impairs T-cell function, may promote tumor growth

S-ketamine dampens effector T-cell function, thereby promoting tumor progression.
Why it matters ◈ Mixed
This study suggests S-ketamine may suppress immune effector T-cell function, potentially facilitating tumor progression. The findings raise new safety concerns for S-ketamine, especially in patients with cancer or at risk for malignancy, and could impact clinical trial design, informed consent, and risk-benefit analysis for psychiatric or analgesic use. Regulators and clinicians may need to reconsider patient selection and monitoring protocols as further research clarifies these risks.
Clinical research Review protocol announced

BMI's role in treatment-resistant depression outcomes

Baseline body mass index and treatment outcomes in adults with treatment-resistant depression: systematic review protocol (BMI-TRD-SR)
Why it matters ◈ Mixed
This systematic review protocol aims to explore the impact of baseline body mass index on treatment outcomes in adults with treatment-resistant depression. Understanding BMI's role could inform personalized treatment strategies and improve response rates. The study includes various treatment modalities, potentially offering insights across different therapeutic approaches.
Protocol (PRISMA-P 2015) for a systematic review and meta-analysis of baseline body mass index as a prognostic factor and treatment-effect modifier of response and remission in adults with treatment-resistant depression, stratified by treatment modality: pharmacotherapy, intranasal esketamine, intravenous ketamine, transcranial magnetic stimulation and electroconvulsive therapy. This repository holds the protocol, the database-specific search strategies, the data-extraction workbook, and the statistical analysis code.
Clinical research Meta-analysis published

Trait responsiveness predicts placebo effects

Trait responsiveness to verbal suggestions predicts placebo responses: A multi-level meta-analysis
Why it matters ◈ Mixed
This meta-analysis highlights a significant, though weak, correlation between individual trait responsiveness to verbal suggestions and placebo responses. Understanding these individual differences could refine clinical trial designs and improve the interpretation of placebo-controlled studies. This insight may be particularly relevant for psychedelic research, where placebo effects can be pronounced.
Background: Placebo responding involves the reduction of symptoms in response to contextual features of an intervention (e.g., verbal suggestions), yet it is characterized by pronounced heterogeneity. Although verbal suggestions are widely recognised as a hallmark method for inducing placebo responses, an open question is whether variability in placebo responding can be partly attributed to individual differences in trait responsiveness to verbal suggestions (REVS). We conducted a pre-registered meta-analysis (PROSPERO registration number CRD420250654692) to quantitatively synthesize available research on the association between trait REVS and placebo responding. Methods: PsycInfo, PubMed, MEDLINE, and Embase were searched up to June 2026 for original clinical or experimental studies involving both the assessment of REVS and symptom measures (self-report, behavioural, and/or physiological) in response to an inactive intervention (placebo). Results: Of 1,512 search results, 24 articles presenting 66 correlations between REVS and placebo responding were analysed (N = 1,137). A multi-level meta-analysis revealed a significant, albeit weak, positive correlation between REVS and placebo responses, r = 0.18 [95% CI: 0.13, 0.24], such that individuals with higher REVS reported greater symptom relief in response to the placebo. Meta-regression analyses did not identify any significant moderators of the correlation between REVS and placebo responding and sensitivity analyses based on Bayesian subgroup estimates indicated that the aggregate correlation was stable across methodological quality indicators and study features. Conclusion: These findings suggest that individual differences in REVS may partly explain variability in symptom reduction in response to placebos, with implications for the sources of variance in placebo effects in experimental and applied contexts.
Industry New clinic announced

Missouri's first ketamine therapy practice opens

Missouri’s first ketamine therapy practice bets on what comes next
Why it matters ▲ Favorable
The opening of Missouri's first ketamine therapy practice signals growing acceptance and demand for psychedelic-assisted therapies in the state. This development could pave the way for further expansion of psychedelic treatment options in the region. It highlights the potential for ketamine clinics to serve as a model for future psychedelic therapy practices.
Clinical research Research review published

Psilocybin shows promise for depression in new review

Psicodélicos no tratamento da depressão: evidências atuais e perspectivas futuras
Why it matters ▲ Favorable
This integrative review highlights the potential of psychedelics, particularly psilocybin, as a therapeutic strategy for Major Depressive Disorder (MDD), especially for treatment-resistant cases. The findings suggest significant symptom reduction and a faster antidepressant response compared to conventional treatments. This could influence future clinical practices and research directions in treating depression.
Introdução: O Transtorno Depressivo Maior (TDM) é uma síndrome psiquiátrica caracterizada por sintomas que variam dependendo de cada caso, no entanto ela pode ser norteada por algumas características centrais como humor deprimido que consiste em uma perda gradual de interesse e ânimo em realizar as atividades do cotidiano, pensamento negativo, falta de prazer sexual, prostração e bradipsiquismo. A causa da doença está relacionada tanto a fatores biológicos quanto sociais. Metodologia: Trata-se de uma revisão integrativa da literatura, de caráter descritivo, com abordagem qualitativa, desenvolvida com o objetivo de analisar as evidências científicas acerca da utilização de substâncias psicodélicas no tratamento da depressão, destacando sua eficácia terapêutica, mecanismos de ação, perfil de segurança, tolerabilidade e potencial contribuição para o manejo de pacientes com transtornos depressivos. Resultados: A análise dos estudos selecionados demonstra que os psicodélicos, especialmente a psilocibina, apresentam resultados promissores como estratégia terapêutica para a depressão, sobretudo em indivíduos que não respondem adequadamente aos tratamentos convencionais. De maneira geral, os trabalhos convergem ao demonstrar redução significativa dos sintomas depressivos após intervenções com psilocibina, frequentemente associadas a suporte psicológico, sugerindo a possibilidade de uma resposta antidepressiva mais rápida do que aquela tradicionalmente observada com antidepressivos convencionais.Considerações Finais: A presente revisão integrativa permitiu analisar as evidências científicas disponíveis acerca do uso de substâncias psicodélicas no tratamento da depressão, evidenciando resultados promissores, especialmente em relação à psilocibina. Os estudos avaliados demonstraram redução significativa dos sintomas depressivos, com destaque para a rapidez de início da resposta terapêutica e para os resultados observados em pacientes com depressão resistente ao tratamento, condição caracterizada por maior dificuldade de resposta às abordagens convencionais.
Neuroscience Study results published

Psilocybin affects brain networks differently in autism

Distinct response of resting-state brain networks to psilocybin in autism
Why it matters ▲ Favorable
This study provides the first evidence of differential brain network responses to psilocybin in autistic versus non-autistic individuals. The findings suggest that psilocybin may alter functional connectivity in ways that could inform future clinical trials targeting autism spectrum disorders. Understanding these distinct neural responses is crucial for developing tailored therapeutic approaches and underscores the need for further research into psilocybin's potential benefits for neurodevelopmental conditions.
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a condition characterised by both altered functional connectivity and differential response to drugs. Thus, a first step before clinical trials of psilocybin involving autistic people, is to evaluate the response of the autistic brain to psilocybin, initially at low dose. Objective Low doses of psilocybin were used to test the hypothesis that the functional connectivity of large-scale resting-state brain networks respond differently in autistic and non-autistic adults. Design The PSILAUT study had a pseudo-randomised, cross-over, double-blind, case-control design. There was no evaluation of clinical efficacy. PSILAUT was not a Clinical Trial according to UK regulations. Data collection was conducted from January 2023 to August 2024. Setting Single-centre, study conducted at the Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, United Kingdom. Participants Adult (> 18 years) participants with and without an autism spectrum disorder (ASD) diagnosis were recruited and matched for age, sex and IQ. Autistic participants were included if they had an existing diagnosis (DSM-IV, DSM-5 or ICD-10 criteria). Exposures A single oral dose of 2 or 5 mg psilocybin or (inactive) placebo administered on separate visits at least one week apart. Main Outcomes and Measures Resting-state fMRI was acquired to investigate the change in functional connectivity within and between brain networks, as measures of network integrity and integration, respectively. Results A total of 67 participants were recruited (18-58 years at first visit; 30 non-autistic participants, mean [SD] age, 30.0 [8.3] years, 15 males [50%] and 37 autistic participants, mean [SD] age, 28.6 [9.2] years, 19 males [51%]). We report for the first time that the autistic brain responds differently to low doses of psilocybin, despite no group differences in network connectivity in the baseline placebo condition. 5 mg psilocybin elicited the greatest shifts in functional connectivity in both groups, but in different directions. In non-autistic participants only, on average, after 5 mg psilocybin within-network connectivity of the frontoparietal (β = -0.053, T = -2.73, FDR-corrected P value = 0.027, Cohen d = -0.71) and limbic networks (β = -0.087, T = -2.59, FDR-corrected P value = 0.021, Cohen d = -0.61) decreased. In contrast, in autistic participants, 5 mg psilocybin increased between-network connectivity (i.e. integration) of higher-order and attentional networks, but decreased connectivity between the same networks in non-autistic participants (default mode and frontoparietal networks, dose x group interaction: β = 0.053, T = 2.91, FDR-corrected P value = 0.042; dorsal and ventral attention networks, dose x group interaction: β = 0.059, T = 2.31, FDR-corrected P value = 0.015). Across the whole sample, the extent to which psilocybin elicited an increase in connectivity between higher-order (β = 0.33, T = 2.16, FDR-corrected P value = 0.036) and attentional (β = 0.36, T = 2.43, FDR-corrected P value = 0.036) networks was positively correlated with core autistic traits quantified using the Autism Quotient. Conclusions and Relevance Functional brain networks that support mood, emotion and cognition are more responsive to low dose psilocybin in autistic adults compared to non-autistic adults. Given that increased network integration is associated with clinical utility, future applications of psilocybin in autistic people should include the evaluation of low doses.
Clinical research Tool announced

TripTally: Open-Access Psychedelic Therapy Cost Calculator

TripTally: An Open-Access Calculator of Labor Costs Across Psychedelic Therapy Delivery Models
Why it matters ▲ Favorable
TripTally addresses a significant gap in the economic modeling of psychedelic-assisted psychotherapy by providing a flexible tool to estimate labor costs based on various delivery models. This tool can aid researchers, clinicians, and policymakers in making informed decisions about therapy delivery and cost management. As the field anticipates FDA approval and broader implementation, understanding these cost dynamics becomes increasingly crucial.
Psychedelic-assisted psychotherapy is generating substantial clinical interest, yet despite growing economic scrutiny, a practical question has received surprisingly little attention: how do specific delivery decisions drive cost? Labor costs—typically the dominant cost component of psychedelic therapy delivery—depend on a tangle of interacting design choices: the number, length, and staffing of treatment sessions (including provider qualifications, group versus individual format, and medical backup requirements), and local hourly wage rates. Together, these factors can produce order-of-magnitude differences in per-patient cost that resist easy estimation and are rarely modeled explicitly, making rational planning difficult. As psychedelic-assisted psychotherapy moves from clinical trials and state-licensed programs toward anticipated Food and Drug Administration (FDA) approval, each stage bringing distinct staffing, regulatory, and reimbursement conditions, the need for flexible cost modeling is clear. To make these trade-offs visible and tractable, we developed TripTally (https://danieldickison.github.io/pat-calculator/), an open-access web calculator that, unlike existing economic analyses of fixed scenarios, allows any researcher, clinician, or policymaker to estimate labor costs using staffing configurations and wage rates specific to their own context.
Federal oversight Audit report released

Federal audit criticizes Kansas on parity compliance

Federal audit criticizes Kansas over parity compliance oversight
Why it matters ▼ Unfavorable
The OIG's report highlights potential barriers in access to mental health and substance use treatment due to Kansas Medicaid MCOs' non-compliance with parity requirements. This could impact access to necessary treatments, including those involving psychedelics, if they are covered under behavioral health services. The findings may prompt policy reviews or corrective actions to ensure compliance and improve treatment access.
A new report from the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services (HHS) criticizes Kansas officials for insufficient oversight of the state's Medicaid managed care contractors' compliance with behavioral health parity requirements. The audit suggests that because the Kansas Medicaid managed care organizations (MCOs) did not demonstrate compliance with regulations mandating equitable practices in prior authorization, Medicaid enrollees might have faced limited access to mental health and substance use treatment.
Clinical research Study results announced

Ketamine's impact on appetite in mood disorders studied

Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study
Why it matters ▲ Favorable
This study provides evidence that ketamine administration does not significantly affect appetite or body weight in patients with treatment-resistant mood disorders. The findings support ketamine's favorable metabolic safety profile, which is crucial for its clinical use in treating TRD and TRBD. This could reassure clinicians about the metabolic implications of ketamine therapy.
This study evaluated the acute and short-term effects of repeated ketamine treatment on appetite in adult inpatients with treatment-resistant mood disorders, including major depressive disorder and bipolar disorder. Appetite, hunger, and desire to eat were assessed using the Visual Analog Scales (VAS) and the Simplified Nutritional Appetite Questionnaire (SNAQ) at baseline and at multiple time points up to 7 days following ketamine administration. No significant changes were observed over the course of treatment, and results were consistent across diagnostic groups and body mass index (BMI) categories. No increased risk of appetite-related undernutrition or clinically relevant weight loss was identified. These findings do not suggest a substantial short-term impact of ketamine on appetite regulation or body weight and are consistent with a favorable metabolic safety profile, supporting its clinical use in patients with treatment-resistant depression (TRD) and treatment-resistant bipolar disorder (TRBD).
Neuroscience Preclinical research

CB1 Allosteric Modulation: Therapeutic Potential & Misuse Liability

CB1 Allosteric Modulation: Preclinical Insights into Therapeutic Potential and Misuse Liability
Why it matters ▲ Favorable
This preclinical study on CB1 allosteric modulators highlights their potential to provide therapeutic benefits without the adverse effects associated with traditional CB1 agonists like THC. The research suggests these modulators could offer pain relief and reduce withdrawal symptoms without significant misuse liability. This advancement underscores the importance of early in vitro characterization and the need for standardized experimental frameworks to enhance reproducibility.
Cannabinoid type-1 (CB1) allosteric modulators represent a promising approach to modulate CB1 receptor signaling by binding to distinct receptor sites, without producing adverse cannabimimetic and dependence-related effects associated with Δ9-tetrahydrocannabinol (THC) and other CB1 agonists. This dissertation investigates the pharmacological, behavioral, and dependence-related profiles of CB1 allosteric modulators for their therapeutic potential and misuse liability. Presented here, the chiral CB1 positive allosteric modulator (PAM) ZCZ011 was resolved into its R- and S-enantiomers and characterized across in vitro and in vivo assays. Both enantiomers enhance CB1 agonist activity and produce intrinsic effects in vitro. Behaviorally, they produce antinociceptive effects in the chronic constriction injury (CCI) neuropathic pain model, and attenuate withdrawal signs in THC-dependent mice, while lacking cannabimimetic effects. Notably, the absence of stereoselectivity suggests that pharmacological outcomes are driven by mechanisms mediating both PAM activity and intrinsic allosteric-agonism, rather than chirality. Complementary studies of ZCZ011 and the related CB1 PAM, GAT211, demonstrate that repeated administration produces rimonabant-precipitated withdrawal, but not spontaneous withdrawal, indicating reduced dependence liability relative to THC. In contrast, CBD failed to produce a discriminative stimulus, did not substitute for or negatively modulate CB1 agonist effects, and did not alter brain endocannabinoid levels despite achieving high systemic and central concentrations in vivo, supporting the conclusion that it lacks misuse liability. Collectively, these findings validate CB1 allosteric modulation as a viable strategy to retain efficacy of CB1 as a therapeutic target, while minimizing dependence-related outcomes. This work advances the field by emphasizing the importance of early in vitro characterization, evaluating the translational relevance of “pure” PAM and allosteric-agonists observations in vitro to the whole animal, and identifying the need for standardized experimental frameworks to improve reproducibility and cross-study interpretation.
Clinical research Study results announced

OHSU study on psilocybin for anxiety, depression, PTSD

What an OHSU-led psilocybin study revealed about treating anxiety, depression and PTSD
Why it matters ▲ Favorable
The OHSU-led study provides new insights into the potential of psilocybin as a treatment for anxiety, depression, and PTSD. These findings could influence future clinical practices and regulatory decisions regarding psychedelic therapies. The study's results add to the growing body of evidence supporting the therapeutic benefits of psychedelics, potentially impacting patient care and research directions.
Clinical research Research insights

Psychedelic trial design challenges and solutions

Tales of the unexpected: psychedelic trial design solutions
Why it matters ◈ Mixed
This article highlights critical assumptions and practices in psychedelic research that may hinder causal identification, such as the role of pretreatment expectancy and the limitations of double-blind procedures. Proposing alternative trial designs could enhance the field's ability to draw strong inferences about psychedelic therapy's causal effects. These insights are crucial for improving the validity and ethical standards of psychedelic clinical trials.
This article spotlights problematic assumptions and practices in clinical psychedelic research that together hamper the field’s ability to demonstrate causal identification, contributing to confusion and misunderstanding: (1) the main problematic assumption is that pretreatment expectancy causes therapeutic response; while expectancy predicts response to most treatments, it is becoming increasingly clear that the same is not true for psychedelic therapy—and we offer a plausible hypothesis for why; (2) the main problematic practice is the double-blind procedure, which is ecologically invalid, ethically questionable, and fails to achieve its purpose (causal identification) due to functional unblinding; we propose alternative trial designs that can circumvent the need for participant blinding while improving our ability to draw strong inferences regarding the causal action of psychedelic therapy.
US / Federal Executive order signed

Trump signs order to boost psychedelic research

Trump signs executive order accelerating research into psychedelic drug therapies - ABC News
Why it matters ▲ Favorable
This executive order represents a significant federal move to facilitate and accelerate research into psychedelic therapies. It could lead to increased funding, streamlined regulatory processes, and broader acceptance of psychedelic research in the medical community. This development is likely to impact clinical trials, market dynamics, and public health policies.
State policy State law in effect

Oregon's Psilocybin Program Treats 346 People

America's First Legal Psilocybin Program Treated 346 People. Here's What Happened.
Why it matters ▲ Favorable
Oregon's psilocybin program marks a significant milestone as the first state-sanctioned initiative to treat individuals with psilocybin. The program's initial results, involving 346 participants, provide valuable insights into the therapeutic potential and operational challenges of regulated psychedelic treatment. This development could influence other states considering similar programs and shape future policy and market dynamics in the psychedelic space.
Clinical research Review published

Review: Ketamine uropathy—pathophysiology, complications, and treatments

Ketamine uropathy: an update on pathophysiology, complications, and treatment options.
Why it matters ◈ Mixed
This updated review highlights the ongoing risks of ketamine-induced uropathy, detailing mechanisms, clinical complications, and emerging treatment strategies. The findings are highly relevant for clinicians and researchers as ketamine use expands in both medical and non-medical contexts. Policymakers and industry stakeholders should note that increased access to ketamine may elevate the incidence of urological complications, underscoring the need for patient monitoring, informed consent, and further research into mitigation strategies.
Clinical research Narrative review published

MDMA for Neuropathic Pain: Review Calls for Trials

MDMA-Assisted Therapy for Neuropathic Pain: Mechanisms, Evidence, and the Case for Dedicated Clinical Trials: A Narrative Review
Why it matters ▲ Favorable
This narrative review highlights MDMA's potential as a treatment for neuropathic pain, emphasizing its unique mechanisms and sustained effects. The call for dedicated Phase 2/3 trials could significantly advance understanding and application of MDMA in pain management. This could lead to new therapeutic strategies beyond traditional symptom management, potentially transforming patient care in this area.
3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a promising therapeutic candidate for treatment-resistant neuropathic pain, offering a paradigm shift from transient palliative symptom masking toward disease-modifying neuroplastic reorganization. Preclinical and clinical evidence demonstrates that MDMA operates through an integrated, multi-tiered neurobiological cascade: presynaptic reversal of monoamine transporters (SERT, NET, DAT) reinforces descending spinal pain inhibition; hypothalamic oxytocin exocytosis drives dorsal horn GABAergic gating via presynaptic TRPV1 inhibition; and concurrent fronto-limbic modulation dampens amygdalar threat hyperactivity, decoupling somatic nociception from affective-emotional distress. Simultaneously, activity-dependent upregulation of Brain-Derived Neurotrophic Factor (BDNF) facilitates the structural remodeling of maladaptive central pain loops. Emerging clinical datasets demonstrate an enduring “neuroplastic carryover” effect, with marked reductions in pain severity and pain-related disability persisting months after treatment discontinuation across both state-transformative macro-dose paradigms (80–120 mg) and sub-perceptual low-dose maintenance regimens (12.5–25 mg every 48 hours). Furthermore, contemporary clinical frameworks provide critical guidance for navigating polypharmacy, resolving transporter-mediated therapeutic blunting, monitoring 5-HT2B cardiovascular safety, and implementing active-placebo designs (methylphenidate) to overcome functional unblinding. This narrative review synthesizes the molecular mechanisms, direct clinical evidence, dosing architectures, and safety considerations of MDMA in neuropathic pain, establishing a rigorous methodological blueprint for future dedicated Phase 2/3 randomized controlled trials.
Clinical research Study published

JAMA study on Oregon's psilocybin model

JAMA study examines Oregon's psilocybin services model
Why it matters ◈ Mixed
This JAMA study provides crucial insights into the real-world application of Oregon's psilocybin services model, highlighting both the potential benefits and risks of psychedelic-assisted therapies outside controlled clinical settings. As the first study of its kind in the U.S., it sets a precedent for future research and policy considerations. The findings could influence other states considering similar regulatory frameworks.
Given the growing interest in psychedelic‐assisted therapies, questions remain about how such services perform outside controlled clinical trials. A new JAMA Network Open study offers an early look at the risks and benefits of Oregon's state‐regulated psilocybin program, which researchers describe as the first study of its kind in the nation.
Clinical research Narrative review published

Review: Psilocybin for Refractory Behavioral Conditions

The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review
Why it matters ◈ Mixed
This narrative review highlights the potential of psilocybin in treating mental illnesses and substance use disorders, showing promise in reducing symptoms with rapid onset. Significant barriers remain, including regulatory constraints and lack of federal funding in the US. The review underscores the need for biosynthetic production and integration into psychotherapy to enhance scalability and safety.
The purpose of this review is to evaluate the possible benefits of using psilocybin (C12H17N2O4P), a naturally occurring psychoactive compound found in certain species of mushrooms, in the treatment of multiple forms of mental illness and substance use disorders, either as monotherapy or in conjunction with traditional psychiatric medications. The compound has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, which are located throughout the cerebral cortex and thalamus. A comprehensive search of electronic databases was conducted, identifying studies that assessed pharmacokinetics, therapeutic efficacy, and the safety profile of psilocybin in the treatment of depression, anxiety, and addiction disorders. The findings are promising and support its efficacy, with decreased symptoms across multiple psychiatric disorders and a rapid onset of action. Significant research barriers remain, however, including methodological limitations, regulatory constraints, and limited population diversity in the clinical trials conducted to date. United States (US) federal funding for the study of psilocybin as a possible therapeutic option has not been approved to date. Biosynthetic production of the compound and enhanced integration into psychotherapy will be necessary to ensure scalability, safety, and accessibility. Continued research is essential to evaluate and refine its therapeutic applications on a larger scale.
Neuroscience Research published

Visuomotor mismatch EEG responses in humans

Visuomotor mismatch EEG responses over occipital cortex of freely moving human subjects
Why it matters ▲ Favorable
This study highlights the presence of robust visuomotor mismatch responses in the human cortex, which could facilitate the translation of mechanistic insights from animal models to human studies. This finding may simplify experimental setups in clinical settings by reducing recording times. While not directly related to psychedelics, understanding predictive coding in humans can inform broader neuroscience research, potentially impacting therapeutic approaches.
Likely the strongest predictor of visual feedback is self-motion. In mice, the coupling between movement and visual feedback is learned with first visual experience of the world, and brief perturbations of the coupling result in strong visuomotor mismatch responses in visual cortex that possibly reflect prediction errors. In humans, predictive coding has primarily been studied using oddball paradigms, which rely on violations of stimulus probability based on recent sensory history. It was still unclear, however, whether humans exhibit visuomotor mismatch responses similar to those observed in mice. This question was important for two reasons. First, visuomotor mismatch responses in humans constitute a basis to start translating the mechanistic understanding of the circuit that computes these responses from mouse to human cortex. Second, a paradigm that can trigger strong prediction error responses and consequently requires shorter recording times would simplify experiments in a clinical setting. Here, by combining a wireless EEG recording system with a virtual reality headset, we found robust visuomotor mismatch responses in human cortex that were characterized by a reversed polarity relative to visual-evoked responses and a greater signal power than both visual responses and oddball mismatch responses.
Clinical research Phase 2 trial results

60-Hz light for depression: Phase 2 trial results

Flickering 60-Hz white light stimulation for major depressive disorder: results from a phase two open-label clinical trial
Why it matters ◈ Mixed
This preprint presents results from a phase two open-label trial investigating the use of 60-Hz flickering white light as a treatment for major depressive disorder. While the study is still in its early stages and has not yet been peer-reviewed, it could indicate a novel non-pharmacological approach to treating depression. Further research and validation are needed to assess its efficacy and safety.
Clinical research Review published

Insulin resistance linked to depression treatment

Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications
Why it matters ◈ Mixed
This review highlights the potential link between metabolic dysfunction and major depressive disorder (MDD), suggesting that insulin resistance may play a role in treatment-resistant depression. While the evidence is mixed, targeting insulin pathways could lead to novel treatments for MDD. This underscores the importance of metabolic screening in MDD patients to guide precision medicine approaches.
Major depressive disorder (MDD) remains one of the most frequently diagnosed mental health disorders and a leading cause of disability worldwide. The discovery of new treatments for MDD is necessary given up to 30% of individuals with MDD are resistant to current antidepressant treatments. The significant physiological interplay between MDD and metabolic conditions is crucial to consider for future therapeutics given the current obesity epidemic and the increased prevalence of treatment-resistant depression in individuals with metabolic dysfunction. The aim of this review is to discuss the relationship between metabolic dysfunction and MDD, while highlighting the potential antidepressant effects of insulin. There are interconnected perpetuating cycles involving hypothalamic-pituitary-adrenal (HPA) axis dysfunction, inflammation, obesity, insulin resistance, and MDD. Evidence on the efficacy of agents that target insulin resistance for depression is mixed and mechanisms by which these agents may improve depressive symptoms have not been clearly elucidated in studies reporting benefit. While there is a clear need to continue research on treatments that address the burden imposed by treatment-resistant depression, current data on whether insulin-sensitivity-targeting therapies can fill this gap remain limited. Clinically, routine metabolic screening in MDD could guide precision treatments targeting insulin pathways, particularly in those with metabolic dysfunction. Future studies considering the role of insulin, especially in those with insulin resistance, may enable development of novel therapeutics.
Public health Community initiative

Psychedelics for Nevada veterans and responders

Psychedelics could offer a lifeline for Nevada’s struggling veterans and first responders
Why it matters ▲ Favorable
The article highlights the potential benefits of psychedelics for veterans and first responders in Nevada, suggesting these substances could aid in addressing mental health challenges faced by these groups. This could influence public perception and policy discussions around psychedelic therapies in the state. However, without specific legislative or clinical trial details, the impact remains speculative.
Neuroscience Research published

Psilocybin affects hippocampal sharp wave ripples

Psilocybin lengthens hippocampal sharp wave ripples
Why it matters ◈ Mixed
This study reveals that psilocybin can alter hippocampal sharp-wave ripples (SWRs), which are linked to memory consolidation. The findings suggest potential implications for psilocybin's use in treating memory-related disorders such as depression and anxiety. Understanding these neural mechanisms is crucial for developing therapeutic applications of psilocybin. However, the perturbation of sleep architecture raises questions about potential side effects.
Psilocybin is a psychedelic which has been shown to induce neural plasticity through activation of intracellular serotonergic 5-HT2A receptors. It also produces brain-wide changes in structural and functional connectivity and holds promise as a therapeutic compound for treating anxiety and depression. Despite links between psilocybin-induced plasticity, the psychedelic experience, and reduction in depressive symptoms, little is known about the effects of psilocybin on the function of the highly plastic hippocampus, a region crucial for memory whose dysfunction is linked to neural disorders such as depression and anxiety. In this study, we investigated the acute and lasting effects of psilocybin on rodent sharp-wave ripples (SWRs), transient high frequency oscillations observable in the hippocampal local field potential which are linked to memory consolidation. We found that a 10 mg/kg dose of psilocybin robustly decreased the peak SWR frequency and increased the duration of SWRs immediately following administration compared to control sessions the day before and after. Psilocybin also perturbed sleep architecture, resulting in a pronounced reduction in non-rapid eye movement (NREM) sleep which lasted for hours. Therefore, psilocybin could impact memory processing by modulating hippocampal SWRs.
Clinical research Review published

Neuromodulation review for treatment-resistant depression

Neuromodulation for treatment-resistant depression: a narrative review and clinical translation framework
Why it matters ◈ Mixed
This narrative review highlights neuromodulation as a promising treatment pathway for treatment-resistant depression (TRD), emphasizing the need for a multidimensional clinical-positioning framework. Electroconvulsive therapy remains the most established intervention, while other modalities like rTMS and iTBS show promise but require further research. The review underscores the importance of standardized definitions, individualized targeting, and equitable access to improve broader adoption.
Abstract Background Treatment-resistant depression (TRD) is a common and disabling clinical problem associated with persistent symptoms, functional impairment, relapse risk, suicidality, and high health-system burden. Neuromodulation has become an increasingly important treatment pathway because it directly modulates neural circuits implicated in mood regulation rather than relying exclusively on pharmacological mechanisms. Objective To review and critically synthesize current evidence on neuromodulation for TRD, with emphasis on electroconvulsive therapy, repetitive transcranial magnetic stimulation (rTMS), intermittent theta-burst stimulation (iTBS), transcranial direct current stimulation, vagus nerve stimulation, deep brain stimulation, safety, clinical translation, and implementation challenges. Methods We conducted a structured narrative review of clinically relevant literature identified through searches of PubMed/MEDLINE, Scopus, Web of Science, guideline repositories, and reference lists. The search was intended to improve the breadth and transparency of the narrative synthesis and was not conducted as a formal systematic review. No protocol was registered, and no duplicate screening, formal risk-of-bias assessment, certainty-of-evidence evaluation, or quantitative synthesis was performed. Results The literature supports a provisional multidimensional clinical-positioning framework rather than a head-to-head efficacy hierarchy. Electroconvulsive therapy remains the most established intervention for severe, psychotic, catatonic, suicidal, or life-threatening depression. Repetitive transcranial magnetic stimulation is a validated non-invasive outpatient treatment with favorable tolerability and expanding protocol options. Intermittent theta-burst stimulation provides similar clinical utility with shorter sessions, whereas accelerated and image-guided iTBS protocols are promising but require further replication, durability, and maintenance data. Transcranial direct current stimulation, including supervised home-based models, is being investigated as a potentially scalable approach, but its TRD-specific evidence and real-world implementation remain less established than those of rTMS. Vagus nerve stimulation and deep brain stimulation may benefit selected highly refractory patients, but delayed response, invasiveness, cost, evidentiary heterogeneity, and long-term device-management requirements limit routine use and largely restrict these modalities to specialized services. Conclusions Neuromodulation may be incorporated as a staged, protocol-based component of multidisciplinary TRD care where appropriate expertise, infrastructure, and follow-up are available, rather than being viewed as a single interchangeable device category. Broader adoption requires standardized definitions, individualized targeting, maintenance planning, adverse-event monitoring, equitable access, and pragmatic implementation research.
Clinical research Study results announced

Oregon psilocybin study shows reduced depression, anxiety

Oregon’s largest psilocybin study finds less depression, anxiety after use
Why it matters ▲ Favorable
This study provides significant evidence supporting the therapeutic potential of psilocybin for mental health conditions like depression and anxiety. As Oregon is a pioneer in legal psilocybin services, these findings could influence public health policy and encourage further research and acceptance of psychedelic therapies. The results may also impact the community's perception and utilization of psilocybin services.
Neuroscience Peer-reviewed publication

New hippocampal model for psychedelic therapy mechanisms published

From network destabilisation to adaptive reconfiguration: A hippocampal longitudinal axis model of psychedelic therapy.
Why it matters ▲ Favorable
This peer-reviewed neuroscience paper proposes a model linking psychedelic-induced network destabilization to adaptive reconfiguration along the hippocampal longitudinal axis. Such mechanistic insights can inform the design of future clinical trials and may guide biomarker development for psychedelic therapies. While not a regulatory or legal change, this work could influence translational research and the scientific rationale for therapeutic protocols.
Clinical research Phase 2 trial results

Psilocybin therapy shows personality changes in alcohol disorder trial

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
Why it matters ▲ Favorable
This study provides evidence that psilocybin-assisted therapy can lead to significant personality changes in patients with alcohol use disorder. These findings could influence future treatment protocols and support the integration of psychedelics into mainstream therapeutic practices. The double-blind, placebo-controlled design adds robustness to the results, making them highly relevant for researchers and clinicians.
Clinical research Peer-reviewed study published

Ketamine and postoperative mortality in major cancer surgery: population study

Ketamine administration and postoperative mortality after major cancer surgery: a propensity-matched population-based study.
Why it matters ◈ Mixed
This population-based study provides new evidence on the safety profile of ketamine when used during major cancer surgeries, specifically regarding its association with postoperative mortality. The findings may influence perioperative protocols and inform ongoing debates about ketamine's broader medical use, including in pain management and psychiatric indications. Researchers and clinicians should consider these outcomes when designing future trials or updating clinical guidelines.
Clinical research Retrospective study published

Large study: Single-day IV ketamine for fibromyalgia shows long-term outcomes

A Single-Day Intravenous Ketamine Infusions for Fibromyalgia, a Large Retrospective Study with a Long-Term Assessment.
Why it matters ▲ Favorable
This large retrospective study provides significant real-world evidence on the long-term effects of single-day intravenous ketamine infusions for fibromyalgia. The findings may inform clinical practice, support further prospective trials, and influence payer or regulatory perspectives on ketamine's therapeutic role in chronic pain. While not a randomized controlled trial, the scale and follow-up duration add weight to the safety and efficacy profile, potentially impacting off-label use and market demand.
Neuroscience Review published

Inflammation's Role in Depression Explored

Neuroinflammation in Major Depressive Disorder: Mechanisms, Biomarkers, and Therapeutic Implications
Why it matters ◈ Mixed
This review highlights the role of inflammation in a subset of major depressive disorder (MDD) patients, suggesting that approximately 25% of patients exhibit elevated CRP levels. While anti-inflammatory treatments show potential, their benefits are inconsistent without biomarker stratification. This underscores the need for precision medicine approaches in treating MDD, which could influence future clinical trial designs and therapeutic strategies.
Background: Major depressive disorder (MDD) is heterogeneous, and low-grade systemic inflammation may contribute to illness in a clinically relevant subgroup. Methods: This narrative review examined human studies published between January 2010 and June 2026, prioritizing systematic reviews, meta-analyses, cohort studies, central biomarker research, and randomized trials. Results: Approximately one-quarter of patients with depression have CRP levels above 3 mg/L, supporting an inflammatory phenotype rather than a universal inflammatory model. Immune signals may affect brain function through blood–brain barrier, neural, neurovascular, and metabolic pathways, influencing neurotransmission, stress regulation, oxidative balance, and neuroplasticity. CRP is the most accessible clinical marker, but no biomarker reliably identifies inflammatory depression. Anti-inflammatory treatments show inconsistent benefits, with the strongest signals observed in biomarker-selected patients. Conclusion: Inflammation contributes to MDD in some patients, but single-marker diagnosis and routine anti-inflammatory treatment are not currently justified. Biomarker-stratified trials are needed to develop precision therapies.
Neuroscience Research published

Psilocybin alters brain-wide burst firing via 5-HT2A circuits

Brain-wide reconfiguration of burst firing by psilocybin reveals 5-HT2A-dependent circuit dynamics
Why it matters ▲ Favorable
This study provides a detailed understanding of how psilocybin affects brain-wide circuit dynamics through 5-HT2A receptor activation. The findings highlight the importance of burst firing patterns rather than mean firing rates in the psychedelic experience. This could inform future research on the therapeutic mechanisms of psychedelics and aid in the development of targeted treatments.
Psilocybin produces rapid and lasting therapeutic effects, yet how 5-HT2A receptor activation reshapes brain-wide circuit dynamics during acute drug administration remains poorly understood. Using simultaneous multi-region Neuropixels recordings of 46,360 single units from 35 mice, together with scalp electroencephalography (EEG), pupillometry, and locomotion monitoring, we provide a brain-wide, single-unit and field-potential characterization of psilocybin's acute effects, with pharmacological dissection using the 5-HT2A antagonist ketanserin. Psilocybin selectively reconfigured burst coding, rather than mean firing rate, across cortical, thalamic, and hippocampal circuits: burst firing decreased in hippocampal CA1-CA3 and was bidirectionally modulated in the thalamus, with the reticular nucleus bursting more and first-order geniculate nuclei bursting less. Critically, most of these burst effects were abolished by ketanserin, consistent with at least partial 5-HT2A receptor dependence. These data suggest that the psychedelic state is not simply a matter of how much neurons fire, but of how they fire, pointing to a region-specific, 5-HT2A-associated reconfiguration of burst coding that may underlie the acute phenomenology of the psilocybin experience.
Neuroscience Ongoing research

Advances in rTMS for psychiatric disorders

Repetitive transcranial magnetic stimulation: advances for psychiatric disorders
Why it matters ◈ Mixed
Repetitive transcranial magnetic stimulation (rTMS) shows promise for treating several psychiatric disorders, including major depressive disorder and schizophrenia. However, the lack of standardized stimulation parameters and reliable biomarkers limits its clinical implementation. Future research should focus on multicenter, large-sample randomized trials to establish these standards.
Repetitive transcranial magnetic stimulation (rTMS) has accumulated substantial exploratory evidence in the treatment of major Depressive Disorders, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and generalized anxiety disorder; however, its clinical efficacy is highly dependent on the precise matching of stimulation parameters (such as frequency, intensity, total number of pulses, and treatment course) with target regions (such as the dorsolateral prefrontal cortex, supplementary motor area, temporal-parietal cortex). Key findings: In major Depressive Disorders, both high-frequency stimulation of the left dorsolateral prefrontal cortex and low-frequency stimulation of the right dorsolateral prefrontal cortex demonstrate antidepressant effects; however, efficacy is modulated by coil type, concomitant medication, and disease subtypes, and there is currently a lack of reliable closed-loop biomarker guidance for individualized treatment. Research on bipolar disorder suggests that intermittent theta burst stimulation and low-frequency right dorsolateral prefrontal cortex stimulation are effective for depressive episodes, but evidence for manic episodes is limited, necessitating the establishment of rigorous risk management mechanisms for manic conversion. In the treatment of schizophrenia, low-frequency temporo-parietal stimulation can alleviate auditory hallucinations, while improvements in negative symptoms and cognitive deficits are associated with high frequency, high intensity, long treatment duration, and younger patients; however, there is significant heterogeneity among studies. Regarding obsessive-compulsive disorder, low-frequency stimulation of the right dorsolateral prefrontal cortex, low-frequency stimulation of the supplementary motor area, and deep transcranial magnetic stimulation targeting the orbitofrontal cortex all demonstrate therapeutic potential; however, treatment efficacy shows extremely high heterogeneity (I² > 75%), and there is an urgent need to establish uniform criteria for classifying treatment resistance. Preliminary evidence for generalized anxiety disorder supports high-frequency stimulation of the right dorsolateral prefrontal cortex and bilateral combined protocols; their efficacy may involve the regulation of brain-derived neurotrophic factor and serotonin levels, but current studies have small sample sizes and the mechanisms of action remain unclear. Although these findings support the potential application of rTMS in various psychiatric disorders, current studies generally share common limitations, including insufficient sample sizes, lack of rigorous sham controls, short follow-up periods, absence of standardized parameters, and scarcity of reliable biomarkers, which severely hinder its clinical implementation. Future research urgently requires the establishment of standardized stimulation parameters and a treatment-resistance grading framework through multicenter, large-sample randomized controlled trials. It should integrate neuro-navigation with neurophysiological biomarkers (such as resting-state functional MRI and individualized alpha frequency) to achieve personalized, precision-targeted treatment, and systematically evaluate the synergistic effects of rTMS with medication and psychotherapy, as well as its long-term safety.
Clinical research Systematic review published

Systematic review on psilocybin microdosing published

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing
Why it matters ◈ Mixed
This systematic review highlights the growing interest in psilocybin microdosing but underscores the low certainty of current evidence due to methodological limitations. Future research should focus on well-designed randomized controlled trials to establish clear causal relationships and safety profiles. This is crucial for informing both clinical practice and policy-making regarding microdosing.
Introduction Microdosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing protocols and preparations, adverse events, and competing interests. Methods This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023428107). Studies of adults microdosing psilocybin MM or truffles were eligible. Risk of bias was assessed across included studies. Results Eleven articles (five quantitative and six qualitative studies) met inclusion criteria. Studies were conducted in the United States (n=4), Netherlands, Argentina, and internationally (n=2 each), and Slovenia (n=1) with a total sample of 3,262 adults. Some studies reported microdosing psilocybin MM or truffles may improve well-being, mental health, cognition, physical health, creativity, relationships, pain, curiosity, and substance dependence, and enhance senses among adults. However, the majority of evidence had at least some concerns for risk of bias or was qualitative and used a variety of self-reported outcome measures. Approximately 86% of microdoser motivations were non-medical and only 14% were related to medical diagnoses, mostly for mental health improvements. Extreme heterogeneity was identified across dosing protocols and preparations. The majority of studies did not report adverse events but for those reported, they were mostly mild. All but four studies declared no conflicts of interest and four did not disclose funding sources. Discussion The certainty of the evidence is low, and a causal effect of microdosing cannot be inferred. Future research should prioritize well-powered randomized controlled trials with standardized and substance-specific dosing protocols to determine causal relationships between microdosing MM or truffles and health outcomes. Mandatory reporting of adverse events and funding sources should be implemented to build the safety profile of microdosing MM and truffles and ensure transparency for potential conflicts of interest. Sytematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42023428107.
Neuroscience Preclinical study

Dextromethorphan-bupropion shows promise in MDD mouse model

Evaluation of the therapeutic efficacy of the dextromethorphan–bupropion combination and its mediating pathways in a mouse model of major depressive disorder
Why it matters ▲ Favorable
This study explores the potential of a dextromethorphan-bupropion combination in treating major depressive disorder (MDD) using a mouse model. The findings indicate significant reversal of depressive-like behaviors and molecular alterations, suggesting a promising multimodal therapeutic candidate for stress-related depression. While promising, these results are preclinical and require further validation in human trials.
Background Major depressive disorder (MDD) is associated with multiple pathophysiological mechanisms, including dysregulation of monoaminergic systems, excessive glutamatergic activity, reduced neurotrophic support, inflammation, and oxidative stress. The combination of dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a dopamine/norepinephrine reuptake inhibitor, has been reported to exert rapid antidepressant effects. In the present study, we evaluated the therapeutic effects of the dextromethorphan–bupropion combination on behavioral outcomes and neurotransmitter, inflammatory, and apoptotic pathways in a mouse model of MDD. Methods A total of 36 BALB/c mice were randomly assigned to four groups: Control, CUMS, DXM + BUP, and CUMS + DXM + BUP. The chronic unpredictable mild stress (CUMS) protocol was applied for 6 weeks. Depressive-like behaviors were assessed using the sucrose preference test, open field test, and forced swim test. At the end of the experiment, hippocampal and prefrontal cortex tissues were collected. Serum serotonin, dopamine, GABA, glutamate, and norepinephrine levels were quantified by ELISA. Gene expression levels of Slc6a15 , Bdnf , Ntrk2 , Gdnf , Gfra1 , Ngf , Ntf3 , Ntf4 , Creb1 , Trpm2 , Parp1 , Parg , Casp3 , Mapk14 , Mapk1 , Nfkb1 , Tnf , and Il6 were analyzed by qRT-PCR. GluN2B, TRPM2, and Caspase-3 immunoreactivity was evaluated by immunohistochemistry. Results The CUMS group exhibited significant weight loss, anhedonia, increased immobility, elevated glutamate and norepinephrine levels, and reduced serotonin and dopamine levels. In addition, decreased expression of neurotrophic genes and increased expression of Trpm2 , Mapk14 , Tnf , and Il6 , together with elevated Caspase-3 immunoreactivity, was observed. Administration of the dextromethorphan–bupropion combination significantly reversed these behavioral and molecular alterations. Immunohistochemical analyses further demonstrated reduced TRPM2, GluN2B, and Caspase-3 immunoreactivity in the treatment groups compared with the CUMS group. Conclusion The dextromethorphan–bupropion combination ameliorated CUMS-induced depressive phenotypes at behavioral, neurotrophic, inflammatory, and apoptotic levels. These findings suggest that this combination represents a potent multimodal therapeutic candidate for stress-related depression.
US Policy Policy announced

Trump Reaffirms Plan for Psychedelics for Veterans

Donald Trump Reaffirms Plan to Treat Veterans With Psychedelic Drugs
Why it matters ◈ Mixed
Donald Trump's reaffirmation of a plan to treat veterans with psychedelic drugs highlights a potential shift in federal policy towards the use of psychedelics in mental health treatment. This could significantly impact research funding and regulatory pathways for psychedelic therapies. However, the political and public health implications remain uncertain, as the announcement lacks detailed implementation strategies.
FDA / DEA Nomination announced

Trump's FDA pick Overton seen as pro-psychedelics

Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts
Why it matters ◈ Mixed
The nomination of Overton as FDA head could signal a supportive stance towards psychedelic research and new pain medications. This may lead to more favorable regulatory conditions for psychedelic drug development, potentially accelerating clinical trials and market entry. However, concerns about his stance on vaccines could influence public health policy and FDA priorities.
State policy Study results

Oregon study: 20,000 used legal psilocybin

More than 20,000 people have used legal psilocybin in Oregon. A new study shows how it went - Oregon Public Broadcasting
Why it matters ◈ Mixed
The study provides critical insights into the implementation and effects of Oregon's legal psilocybin program, which is the first of its kind in the United States. Understanding the outcomes and challenges faced by over 20,000 users can inform future policy decisions and guide other states considering similar measures. This data is crucial for assessing public health impacts and refining regulatory frameworks.
Neuroscience Research published

Psychedelics align brain activity with context

Psychedelics align brain activity with context.
Why it matters ▲ Favorable
This research provides insight into how psychedelics may influence brain activity to better align with environmental context. Understanding these mechanisms could enhance therapeutic applications and inform clinical trial designs. This study may guide future research on the neural underpinnings of psychedelic experiences and their potential mental health benefits.
Clinical research Systematic review published

Systematic review analyzes psilocybin microdosing evidence

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing.
Why it matters ◈ Mixed
This systematic review aggregates current evidence on psilocybin microdosing, providing a comprehensive synthesis of its effects, safety, and methodological gaps. The findings inform researchers, clinicians, and policymakers about the state of the science, highlighting both potential benefits and the need for more rigorous, controlled studies. The review may shape future research priorities and guide regulatory or clinical interest in microdosing practices.
Clinical research Study published

EHR-based TRD risk models fail to transport

Evaluating transportability failures of electronic health record-based risk models for treatment-resistant depression
Why it matters ◈ Mixed
This study highlights significant challenges in developing transportable risk models for treatment-resistant depression (TRD) using electronic health records (EHRs). The poor performance of these models across different health systems underscores the complexity of TRD as an outcome and the limitations of current data sources. Addressing data biases and clinical heterogeneity is crucial for improving risk stratification models.
Earlier identification of risk for treatment-resistant depression (TRD) remains essential, but no risk stratification model has been adopted clinically and none shown to be transportable across sites. To characterize reasons models might fail to transport into new settings, we modeled TRD likelihood using a well-accepted and transparent modeling approach with electronic health records in major depressive disorder at the time of first antidepressant prescription in three large and disparate health systems – Mass General-Brigham, Vanderbilt University Medical Center, and Geisinger Clinic from 2004 to 2022. TRD was defined as provision of electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, prescription of ketamine or esketamine or monoamine oxidase inhibitors, or failures of more than two antidepressants. L1-regularized regression applied to sociodemographic features, medications, and ICD-10 diagnostic codes was validated internally and externally with poor performance. C-statistics ranged from 0.51 to 0.65 internally and 0.5 to 0.58 externally. Areas Under the Precision-Recall Curve ranged from 0.07 to 0.15 internally and 0.07 to 0.11 externally with low concordance. We highlight three main failure mechanisms: heterogeneity of TRD as an outcome; biases in source data; site-/practice-level variation. Use of data beyond EHRs and addressing the intrinsic heterogeneity of clinical populations may be necessary to achieve clinically meaningful risk stratification.
Clinical research Study results announced

Oregon Psilocybin Services Show Positive Mental Health Outcomes

Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
Why it matters ▲ Favorable
This cohort study provides critical data on the safety and efficacy of Oregon's state-regulated psilocybin services. The findings indicate significant improvements in depression, anxiety, and PTSD symptoms among participants, with high satisfaction rates and few adverse reactions. These results support the potential therapeutic benefits of psilocybin and may influence policy and clinical practices in other jurisdictions considering similar programs.
Importance: Few data inform implementation of emerging state-regulated psilocybin programs. Objective: The Open Psychedelic Evaluation Nexus (OPEN) aims to assess the safety and participant outcomes of Oregon's regulated psilocybin services. Design, Setting, and Participants: This cohort study included psilocybin clients enrolled between November 2024 and March 2026, with follow-up through June 2026, at 24 of 26 Oregon psilocybin service centers with active licenses. Eligible participants were consenting Oregon psilocybin services clients supervised by 83 licensed psilocybin facilitators. OPEN's client-facing platform collects confidential data at baseline and at 1 week, 1 month, and 3 months after psilocybin sessions supported by licensed facilitators. Exposure: Receipt of Oregon psilocybin services. Main Outcomes and Measures: Facilitator-reported psilocybin dose (in milligrams) and safety events during psilocybin session. Participant-reported depression (measured by the Participant Health Questionnaire-9), anxiety (Hospital and Anxiety Depression Scale), and PTSD (6-item PTSD Checklist [PCL-6]) symptoms; mental well-being; life satisfaction; harms; overall benefit; meaning; and services satisfaction. Results: A total 346 participants were included (mean [SD] age, 49.5 [13.4] years; 181 women [52.5%]; 15 Asian [4.3%], 300 White [86.7%], 12 multiple races [3.5%]); 19 participants (5.5%) identified as veterans, 262 (76.6%) completed college, and 89 (29.0%) had a household income above $200 000. Reported substance use in the past 30 days was 203 (58.7%) for alcohol, 38 (11.0%) for nicotine or tobacco, and 127 [36.7%] for cannabis use; 44.2% were psychedelic-naive and received a mean (SD) psilocybin dose of 31.9 (11.2) mg. Retention was 93.1% at 1 week (322 participants), 92.8% at 1 month (321 participants), and 90.2% at 3 months (312 participants). Four individuals (1.2%, all psychedelic-naive) experienced adverse behavioral reactions requiring medical attention. Few participants reported their psilocybin experience as harmful (5 of 305 [1.6%] at 1 week, 6 of 321 [1.9%] at 1 month, and 7 of 312 [2.3%] at 3 months). At 1 month, 92.2% (296 of 321 participants) felt they benefited, and 58.6% (188 of 321 participants) ranked the experience among the 10 most meaningful of their life. At 3 months, participants reported decreased moderate-to-severe symptoms of depression (relative risk [RR], 0.40; 95% CI, 0.32-0.50), anxiety (RR, 0.29; 95% CI, 0.22-0.38), and PTSD symptoms (RR, 0.35; 95% CI, 0.27-0.45), and improved mental well-being (mean difference in Short Warwick-Edinburgh Mental Well-being Scale = 3.21; 95% CI, 2.66-3.76), and life satisfaction (RR, 1.31; 95% CI, 1.19-1.44) compared with baseline. Serious adverse reactions were uncommon, although at rates that were statistically significant. Conclusions and Relevance: In this multisite cohort of participants receiving state-regulated psilocybin services in Oregon, serious adverse reactions were uncommon. Most participants reported improvements in mental health, wellness, and life satisfaction. Longitudinal findings support safety and potential benefits that can inform clinicians, policymakers, and the public as other state-regulated psychedelic services emerge.
Clinical research Study results announced

Sustained benefits from Oregon psilocybin services

Study finds sustained benefit for people using Oregon psilocybin services
Why it matters ▲ Favorable
This study highlights the potential long-term benefits of psilocybin services in Oregon. It provides valuable data for clinicians and policymakers considering the integration of psychedelic therapies into mental health treatment frameworks. The findings could influence public health strategies and market dynamics as more regions evaluate the efficacy and safety of psilocybin-assisted therapy.
Clinical research Study results published

Ketamine affects rumination-related brain dynamics in fMRI trial

Ketamine’s impact on rumination-related brain dynamics: insights from a randomized controlled fMRI trial
Why it matters ▲ Favorable
This study provides valuable insights into ketamine's mechanism of action on brain dynamics related to rumination. The findings suggest that ketamine can acutely alter brain states associated with rumination and somatosensory processing, with potential implications for its use as a rapid antidepressant. The role of glutamatergic mechanisms in these effects is highlighted, offering a pathway for further research into targeted treatments.
Rumination has been associated with aberrant dynamics of a coactivation pattern (CAP) comprising the default mode (DMN) and frontoparietal (FPN) networks. Ketamine exerts rapid antidepressant effects and may influence these dynamics via glutamatergic mechanisms. In a randomized, double-blind, placebo-controlled fMRI study, we investigated ketamine's effects on dynamic CAPs associated with rumination and examined whether inhibition of glutamatergic release through lamotrigine attenuates these effects. Seventy-five healthy adults were randomized to placebo-placebo, placebo-ketamine, or lamotrigine-ketamine treatment. Resting-state fMRI was acquired at baseline, during ketamine/placebo infusion, and 24 h post-infusion. Whole-brain CAP analysis identified seven recurring network configurations. Occurrence rates were examined for group differences, while controlling for age, sex, and drug plasma concentrations. Rumination was assessed using a validated self-report questionnaire. A hybrid DMN + FPN CAP showed a positive association with rumination at baseline. Ketamine acutely reduced the occurrence rate of this hybrid CAP compared to placebo, with larger decreases in individuals reporting higher rumination. These effects were transient, returning to baseline after 24 h. Exploratorily, ketamine also reduced engagement of a canonical somatomotor CAP during infusion. Lamotrigine pretreatment nominally attenuated ketamine-induced changes across analyses. Ketamine transiently alters dynamic brain states implicated in rumination and somatosensory processing, and preliminary evidence suggests partial glutamatergic mediation. These findings provide insights into ketamine's mechanism of action.
Clinical research Research publication

Caution urged in expanding psychedelic therapy

The expansion of psychedelic-assisted therapy: The case for caution over acceleration.
Why it matters ◈ Mixed
A recent publication in PubMed highlights the need for caution in the rapid expansion of psychedelic-assisted therapy. The authors argue that while the therapeutic potential is promising, there are significant ethical and safety considerations that must be addressed. Ensuring rigorous clinical trial protocols and ethical guidelines is crucial to prevent potential harm and ensure patient safety. This perspective is important for shaping future research and policy discussions.
Industry Market expansion

Ketamine Therapy Expands in South Florida

Ketamine Therapy Expands in South Florida for Mental Health Treatment
Why it matters ▲ Favorable
The expansion of ketamine therapy in South Florida highlights the growing acceptance and integration of psychedelic treatments in mental health care. This development could improve access for patients seeking alternative treatments for conditions like depression and PTSD. It also signals a potential increase in market activity and interest from investors in the region.
Clinical research Research ongoing

Isotryptamine Analogs Show Psychotherapeutic Potential

The Emergence ofIsotryptamine Analogs as Novel SerotonergicAgents with Psychotherapeutic Potential
Why it matters ▲ Favorable
The study of isotryptamine analogs, particularly isoDMT, highlights their potential as novel serotonergic agents with psychotherapeutic applications. An isoDMT analog has entered clinical trials, indicating significant progress in the exploration of these compounds for treating neuropsychiatric disorders. This development could expand the range of psychedelic compounds available for therapeutic use.
Abstract Isotryptamines, or 2-(1-indolyl)ethylamines, are positional or geometric isomers of tryptamines where the aminoethyl substituent has been relocated from the indole 3-position to the N1-position. Early studies with these types of agents relied on peripheral tissue assays for examination of their serotonin (5-hydroxytryptamine; 5-HT) receptor affinities to investigate structure–affinity relationships. Once 5-HT receptors were identified in the brain and as the binding methodology improved, isotryptamines were further examined, including various in vitro and in vivo assays (i.e., model systems) as techniques evolved. Given that certain hallucinogenic/psychedelic tryptamines, such as analogs of N,N-dimethyltryptamine (DMT), are currently of interest in the treatment of various neuropsychiatric disorders, there is renewed interest in agents such as isoDMT, and an isoDMT analog has now entered clinical trials. The history of isotryptamine analogs, from their discovery to the present, is reviewed.
Clinical research Cochrane review protocol

Ketamine/esketamine for post-op pain in gynecological surgery

Ketamine and esketamine for postoperative analgesia in gynaecological surgery
Why it matters ◈ Mixed
This Cochrane review protocol aims to evaluate the effectiveness of subanaesthetic doses of ketamine and esketamine as adjuncts for perioperative analgesia in gynecological surgeries. The review could provide critical insights into alternative pain management strategies, potentially reducing reliance on opioids. It also seeks to understand variations in outcomes based on surgery type, drug type, and patient history.
OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: The primary objective of this review is to evaluate the benefits and harms of a subanaesthetic dosage of ketamine/esketamine as an adjunct to perioperative analgesia versus standard analgesia or placebo for reducing postoperative pain in participants undergoing gynaecological surgical procedures. A secondary objective is to assess whether these outcomes differ by type of surgery, background condition, type of drug used (ketamine or esketamine), dosage, and presence of preoperative chronic pain or preoperative long-term or recurrent opioid use.
Clinical research Preprint released

Esketamine routes in post-op hyperalgesia trial

Effects of different administration routes of esketamine on postoperative hyperalgesia in elderly patients undergoing laparoscopic gastrointestinal tumour surgery: a single-centre, prospective, randomised, double-blind, controlled trial
Why it matters ◈ Mixed
This study explores the effects of different administration routes of esketamine on postoperative hyperalgesia in elderly patients. Understanding optimal administration routes could improve pain management strategies in surgical settings. As a preprint, these findings are preliminary and have not yet been peer-reviewed.
Clinical research Study published

Ketamine/esketamine for post-op pain in gynecological surgery

Ketamine and esketamine for postoperative analgesia in gynaecological surgery.
Why it matters ▲ Favorable
This study explores the use of ketamine and esketamine as analgesics in postoperative settings for gynecological surgeries. Positive findings could expand the therapeutic use of these substances beyond psychiatric indications, potentially influencing prescribing practices and pain management protocols. This research may also inform future clinical guidelines and support further investigation into the analgesic properties of psychedelics.
Clinical research Research critique published

Critique on Psychedelics' Abuse Liability

The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent Studies
Why it matters ◈ Mixed
This critique highlights methodological flaws in studies assessing the abuse liability of classic psychedelics, suggesting that while these substances may have low abuse potential, the evidence is of low quality. Researchers and policymakers should be cautious when interpreting these findings and consider the need for more robust research designs. This is crucial for informing public health policies and clinical guidelines.
Abstract Purpose of Review We highlight key findings and methodological issues from recent research on the abuse liability of classic psychedelics, utilizing a GRADE to assess the quality of the evidence. Recent Findings Studies using various designs suggest that classic psychedelics (e.g., psilocybin, LSD) have low abuse potential and less dependence liability than other drugs. However, public health risks may be underestimated, and current findings should be interpreted with caution due to several methodological issues. Summary Existing work suggests that classic psychedelics have limited abuse liability, but evidence is of low quality. Researcher allegiance and publication bias are general concerns. Clinical trials are subject to functional unblinding and expectancy effects. Other studies primarily rely on cross-sectional, self-reported data, have limited demographic diversity, rarely measure changing consumption patterns or disaggregate various psychedelics, and use varying definitions of abuse. Further research should address these issues and clarify abuse liability of individual psychedelics.
Clinical research Study ongoing

Psilocybin use in older adults studied

Characterizing Psilocybin Use Motivations and Effects Among Older Adults Accessing State-Regulated Psilocybin Services
Why it matters ▲ Favorable
This study addresses a significant gap in psychedelic research by focusing on older adults, a demographic often excluded from clinical trials. Understanding psilocybin's effects on older adults is crucial for tailoring safe and effective therapeutic interventions. The findings could inform guidelines for psilocybin use in state-regulated services, particularly for mental health and end-of-life care.
There has been growing public and research interest in the use of psychedelics, particularly psilocybin. There is limited data on psilocybin use patterns, motivations for use, safety, and efficacy in older adults (>or= 60 years old) as older adults tend to be excluded from clinical trials. However, older adults may seek out psilocybin through state-regulated or naturalistic settings for self-treatment of mental health conditions, end-of-life distress/grief, or general well-being. Despite this, there are limited data to inform how psilocybin effects may be different compared to younger adults due to physiological effects of aging, the presence of co-occurring conditions, and/or the concomitant use of medications. This study seeks to describe the reasons for seeking services, prior psychedelic and psilocybin experience(s) (if any), and psilocybin dose used during session among older adults (> or =60) in state-regulated services. This study also seeks to examine differences in outcomes (mental health and safety/adverse events) at 1-week, 1-month and 3-month between age cohorts (> or =60 vs <60 years old).
Clinical research Systematic review published

Systematic review: Long-term safety of ketamine/esketamine for TRD

A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression.
Why it matters ◈ Mixed
This systematic review provides a comprehensive synthesis of long-term safety data for ketamine and esketamine in treatment-resistant depression (TRD). The findings will inform clinicians, regulators, and payers about the risk profile of these interventions, which are increasingly used in both clinical and off-label settings. Robust safety data are critical for ongoing policy debates, insurance coverage, and the design of future trials. The review may also influence regulatory guidance and clinical best practices as the field moves toward broader adoption.
Canadian Policy Policy analysis ongoing

Canadian Policy Readiness for Psychedelic Therapy in Cancer Care

Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer Care
Why it matters ◈ Mixed
This analysis highlights the fragmented governance landscape for psychedelic-assisted therapy (PAT) in Canadian cancer care. Despite existing access mechanisms, integration within health systems remains a challenge due to unclear responsibilities and policy fragmentation. Addressing these gaps is critical for the responsible scaling of PAT as clinical evidence and demand grow.
As interest in psychedelic-assisted therapy grows, an important policy question remains largely unaddressed: who is responsible for ensuring safe, equitable, and accountable implementation within cancer care systems? This poster explores the emerging governance landscape for psychedelic-assisted therapy in Canada. Abstract Background: Psilocybin-assisted therapy (PAT) is emerging as a promising intervention for existential distress, demoralization, depression, and anxiety among people living with cancer. Despite growing clinical evidence and expanding legal access pathways in Canada, implementation discussions remain focused on efficacy, safety, and regulation, while comparatively little attention has been paid to system-level policy readiness. Objective: This work explores the Canadian policy landscape surrounding PAT in cancer care and examines whether existing governance structures are positioned to support equitable, safe, and evidence-informed implementation if clinical evidence continues to mature. Approach: Conducted within the Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), this project combines targeted review of federal and provincial policy instruments, regulatory frameworks, publicly available professional guidance, and stakeholder engagement activities involving health system decision-makers, regulators, clinicians, and patient partners. Key Findings: The analysis suggests that no single organization, profession, or jurisdiction currently holds clear responsibility for coordinating PAT policy in Canada. Governance responsibilities are distributed across federal regulators, provincial health systems, professional colleges, cancer agencies, and clinical organizations, creating a fragmented environment with substantial uncertainty around training standards, reimbursement, service delivery models, accountability, and equity considerations. While federal access mechanisms exist through clinical trials, the Special Access Program, and other pathways, integration within cancer systems remains largely absent. Implications: Policy fragmentation may become a significant implementation barrier as evidence and demand continue to evolve. Opportunities exist to strengthen policy readiness through coordinated stakeholder engagement, development of implementation guidance, clarification of roles and responsibilities, proactive equity planning, and knowledge mobilization activities that connect emerging evidence with health system decision-makers. Conclusion: The central challenge facing PAT implementation in Canada may no longer be whether access pathways exist, but whether health systems are prepared to govern, integrate, and scale these therapies responsibly. Understanding policy readiness is therefore an essential complement to ongoing clinical research. Funding statement: This work was conducted through the Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), funded by the Canadian Cancer Society and Brain Canada..
Clinical research Trial announced

VA to test psilocybin for depression in veterans

Birmingham VA to test psychedelic 'magic mushroom' psilocybin on veterans with ‘treatment-resistant' depression
Why it matters ▲ Favorable
The Birmingham VA's decision to test psilocybin on veterans with treatment-resistant depression is a significant step in exploring alternative treatments for mental health conditions. This trial could pave the way for broader acceptance and integration of psychedelic therapies in veteran healthcare. Success in this trial may influence future policy and clinical guidelines for treating depression.
Industry Service announced

Ketamine therapy launches in Aventura, FL

Ketamine therapy arrives in Aventura: How alternative medicine is the future
Why it matters ▲ Favorable
The introduction of ketamine therapy in Aventura, Florida, highlights the growing acceptance and integration of alternative medicine into mainstream healthcare. This development may increase patient access to novel treatments for mental health conditions, potentially influencing market dynamics and public health strategies. However, the lack of detailed information on regulatory compliance and clinical oversight remains a concern for stakeholders.
Neuroscience Research published

New study defines 'psychedelic'

Defining 'psychedelic'.
Why it matters ◈ Mixed
A new study published on PubMed attempts to define what constitutes a 'psychedelic' substance. This could have implications for how substances are classified in future research and policy discussions. Clear definitions are crucial for regulatory clarity and research consistency. However, the impact will depend on how widely the definitions are adopted by policymakers and researchers.
Clinical research Systematic review published

Review: Psilocybin therapy for SUDs shows promise

Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks
Why it matters ▲ Favorable
This systematic review highlights the potential of psilocybin-assisted psychotherapy (PAP) for treating substance use disorders (SUDs). It synthesizes evidence from 17 studies, showing reductions in substance use and improved well-being with structured psychotherapeutic protocols. The findings emphasize the complexity of PAP, suggesting it involves neurobiological, experiential, and contextual factors. Larger trials with active comparators and longer follow-ups are needed to further validate these promising results.
BACKGROUND: Psychedelic-assisted psychotherapy (PAP) shows promise for substance use disorders (SUDs), yet the respective contributions of pharmacological, experiential, psychotherapeutic, and contextual factors remain insufficiently understood. OBJECTIVE: To synthesize contemporary clinical evidence on PAP for SUDs, with particular attention to therapeutic frameworks, dosing strategies, safety, and mechanisms of action. METHODS: A systematic review of clinical studies published between 2000 and 2026 was conducted through structured database searches and manual surveillance. Eligibility criteria involved classic psychedelic administration within defined psychotherapeutic frameworks in individuals with a primary SUD diagnosis. Data were narratively analyzed and synthesized. RESULTS: Seventeen studies, encompassing 10 primary clinical trials, met inclusion criteria: ten focused on alcohol use disorder, five on tobacco use disorder, one on methamphetamine use disorder, and one on cocaine use disorder. All trials investigated psilocybin within structured psychotherapeutic protocols, primarily based on cognitive-behavioral and third-wave approaches. PAP was associated with reductions in substance use, higher abstinence rates, and improved psychological well-being, although findings remained heterogeneous and design-dependent. Trials combining repeated high-dose sessions with extended psychotherapeutic engagement consistently reported sustained clinical benefits. Findings further suggest that outcomes may arise from interactions between neurobiological, experiential, psychological, psychotherapeutic, and contextual processes. CONCLUSION: Current evidence supports PAP as a promising but still emerging intervention for SUDs, although available clinical research remains exclusively based on psilocybin-assisted interventions. Findings further support conceptualizing PAP as a complex intervention embedded within an integrated psychotherapeutic process rather than as a pharmacological treatment alone. Larger controlled trials with active comparators, longer follow-up, and systematic investigation of psychotherapeutic and contextual mechanisms remain needed.
Clinical research Systematic review published

Long-term Safety of Ketamine in TRD Reviewed

A Systematic Review of Long-term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-resistant Depression.
Why it matters ▲ Favorable
This systematic review supports the long-term safety of ketamine and esketamine for treatment-resistant depression (TRD). The findings indicate no cumulative organ toxicity or iatrogenic addiction, with transient acute effects. This review is significant for clinicians and researchers focusing on TRD, providing reassurance about the safety of these treatments over extended periods.
INTRODUCTION: Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents. METHODS: MEDLINE, PsycINFO, Embase, and Cochrane Library were searched from inception through January 29, 2026. Eligible studies enrolled adults with depressive disorders receiving ketamine or esketamine with ≥12-week follow-up. Safety outcomes were synthesized narratively across nine domains: neurocognitive, dissociative/psychotomimetic, sedation, cardiovascular, hepatic, urinary, misuse/dependence, suicidality, and serious adverse events (SAEs). Risk of bias was assessed. RESULTS: Thirty-two studies (11 RCTs, 21 non-randomized) met inclusion criteria, with follow-up ranging from 3 months to 9 years. Across cardiovascular, hepatic, and urinary domains, neither racemic ketamine nor intranasal esketamine demonstrated evidence of cumulative organ toxicity during maintenance treatment. Dissociative and sedative effects were common but consistently transient, resolving within 1-2 hours of administration. No treatment-emergent neurocognitive dysfunction was identified; urologic complications were rare and resolved with treatment discontinuation. No cases of iatrogenic addiction, drug-seeking, or withdrawal were documented for either formulation. Suicidal ideation scores showed reductions from baseline, though suicide attempts and completions occurred during follow-up periods. SAEs attributable to treatment were rare. The comparative analyses suggested essentially equivalent long-term safety profiles between racemic ketamine and intranasal esketamine. CONCLUSION: Current evidence supports the safety of ketamine and esketamine for TRD, with no cumulative organ toxicity or iatrogenic addiction during maintenance treatment. Acute effects remain transient and manageable. However, findings are limited by heterogeneity in safety monitoring across studies.
Clinical research Practice update

Esketamine practice update

[(Es)ketamine: practice update].
Why it matters ▲ Favorable
The practice update on (Es)ketamine provides new insights into its clinical application, potentially influencing treatment protocols for depression and other mental health conditions. This update may impact prescribing practices and patient access, highlighting the need for clinicians to stay informed on evolving guidelines. It underscores the importance of ongoing research and adaptation in clinical settings.
Neuroscience Research published

Matrix-Reduced San Pedro Extraction Framework

A Matrix-Reduced Whole-Cactus Approach to San Pedro: A Two-Stage Framework for Selective Reduction of the Mucilage–Polysaccharide Matrix
Why it matters ◈ Mixed
This research introduces a novel method for preparing San Pedro cactus extracts, focusing on reducing the mucilage-polysaccharide matrix. This approach could streamline the preparation process for research and therapeutic use by enhancing mescaline recovery and reducing preparation volume and viscosity. However, its impact on clinical efficacy and safety remains to be fully evaluated.
San Pedro preparations derived from Echinopsis pachanoi contain mescaline together with minor alkaloids, soluble metabolites, mucilage, colloids, suspended solids, and other cactus-derived constituents. This physical matrix contributes substantially to the volume, viscosity, and material burden of conventional aqueous preparations while remaining chemically distinct from the principal low-molecular-weight alkaloids. This article proposes a matrix-reduced whole-cactus approach that separates primary botanical extraction from subsequent physical refinement. Fresh cactus tissue is extracted in mildly acidic water and filtered to remove coarse structural material. High-strength food-grade ethanol is then added to the retained aqueous extract to induce aggregation of an ethanol-responsive polymer-rich fraction, which is removed by a second filtration or decantation before the ethanol is reduced and the preparation returned to a defined aqueous volume. The process remains continuously derived from the original cactus extract without isolating or recombining mescaline. Performance is evaluated by paired mass balance, comparing mescaline recovery, minor-alkaloid retention, broader phytochemical continuity, dry matter, polysaccharide content, suspended solids, viscosity, and separated matrix mass. The framework provides a simple and experimentally testable intermediate between conventional cactus decoction and molecular mescaline isolation and establishes post-extraction matrix reduction as an independent variable in botanical preparation technology.
Clinical research Trial sites announced

Alabama VA sites join psilocybin trials

Two Alabama VA facilities to be part of psilocybin clinical trials
Why it matters ▲ Favorable
Two VA facilities in Alabama will participate in psilocybin clinical trials, marking an important step in integrating psychedelic research within veteran healthcare settings. This development could enhance access to innovative treatments for veterans suffering from mental health conditions. It also signals growing institutional support for psychedelic research in the US.
Clinical research Study published

Meditation aids psychedelic prep, study finds

Perspectives on Meditation-based Preparation for Psychedelic Experiences: Insights from Practitioners with Combined Meditation and Psychedelic Experience
Why it matters ▲ Favorable
This study explores the role of meditation in preparing individuals for psychedelic experiences, suggesting that meditation can enhance positive outcomes and reduce negative effects. The findings may inform the development of evidence-based meditation protocols for psychedelic preparation, emphasizing the importance of users' prior meditation experience. This research could influence clinical practices and therapeutic approaches involving psychedelics.
Abstract Objectives Emerging research suggests that meditation may support more beneficial psychedelic experiences while reducing the likelihood of lasting negative effects, yet its specific preparatory benefits remain underexplored. This study aimed to investigate the perceived utility of meditation as a preparatory tool for enhancing positive outcomes and reducing negative effects during psychedelic experiences. Method In a cross-sectional online survey, a self-selected sample of participants with histories of both meditation practice and psychedelic use completed a battery of standardised and study-specific measures. Results The sample comprised 123 experienced meditators with prior psychedelic use (66.7% male, mean age 41.1 years, drawn from 24 countries). Participants endorsed meditation training as broadly beneficial for psychedelic preparation, with consistently high scores on the Perceived Benefits of Meditation for Psychedelic Preparation (PBMPP) scale. These benefits varied by experience and tradition adherence: among practitioners with limited meditation experience (1–3 years) and fewer psychedelic sessions (1–20), those adhering to a specific meditation tradition reported significantly higher PBMPP scores than non-adherents, whereas among highly experienced meditators (10+ years) with limited psychedelic experience (1–20 sessions) this pattern reversed, with non-adherents scoring higher than adherents. When evaluating specific approaches, Loving-Kindness Meditation emerged as the most beneficial preparatory practice, receiving significantly higher ratings than other approaches such as Focused Attention. Exploratory factor analysis of meditative elements identified three components underlying perceived preparation value: Positive Emotional States (PES), Mindful Awareness and Insight (MAI), and Concentration Techniques (CT), with PES receiving the strongest endorsement. Participants also expected meditation training to increase Oceanic Boundlessness and reduce Anxious Ego-Dissolution during the experience. For practical implementation, participants recommended approximately 3 weeks of preparation with 30-min daily sessions, favouring online and asynchronous delivery. Conclusions These results provide empirical groundwork for developing effective evidence-based meditation protocols for psychedelic preparation and highlight the importance of considering psychedelic users’ level of previous meditation experience in optimising such interventions.
Clinical research Systematic review published

IV Ketamine for Adolescent Depression: Meta-Analysis

Short-term efficacy and safety of intravenous ketamine for major depressive disorder in adolescents: a systematic review and metaanalysis of randomized and open-label studies
Why it matters ◈ Mixed
This systematic review and meta-analysis suggests that intravenous ketamine may rapidly reduce depressive symptoms in adolescents with major depressive disorder, including treatment-resistant cases. However, the evidence is limited by small sample sizes and methodological issues, highlighting the need for larger, more rigorous trials. This finding is significant for researchers and clinicians exploring new treatment avenues for adolescent depression, but clinical adoption requires further validation.
Background: Adolescent major depressive disorder (MDD) is associated with substantial impairment, suicide risk, and limited response to standard treatments. Intravenous ketamine has rapid antidepressant effects in adults, but pediatric evidence remains limited. This systematic review and meta-analysis evaluated the short-term efficacy and safety of intravenous ketamine for adolescents with MDD, including treatment-resistant depression (TRD). Methods: This Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020-based review was registered in PROSPERO (CRD420251123304). PubMed, Web of Science, and Google Scholar were searched from inception to October 2025. Eligible studies included patients aged 18 years or younger treated with intravenous ketamine for MDD or TRD. Outcomes included changes in Montgomery–Åsberg Depression Rating Scale (MADRS), Children’s Depression Rating Scale–Revised (CDRS-R), Children’s Depression Inventory (CDI), and adverse events. Risk of bias (RoB) was assessed using RoB 2 and methodological index for non-randomized studies. Random-effects meta-analyses were performed where appropriate. Results: Four prospective studies were included: two randomized controlled trials and two open-label studies, involving 77 adolescents. Intravenous ketamine was associated with significant reductions in depressive symptoms. Pooled MADRS scores decreased by 15.90 points [95% confidence interval (CI), -19.16 to -12.64; p < 0.001; I² = 5.9%]. CDRS-R scores decreased by 21.17 points (95% CI, -29.11 to -13.24; p < 0.001; I² = 0%), and CDI scores decreased by 6.55 points (95% CI, -11.78 to -1.31; p = 0.01; I² = 0%). Improvements occurred within 2 hours and persisted up to 14 days in controlled studies. Adverse events were mild and transient, including dissociation, dizziness, nausea, headache, and brief hemodynamic changes. No serious adverse events were reported. Conclusion: Intravenous ketamine may produce antidepressant effects in adolescents with MDD or TRD. Evidence remains limited by small samples, functional unblinding, open-label designs, and brief follow-up. Larger randomized trials with standardized suicidal ideation outcomes and longer safety monitoring are required before clinical adoption.
Clinical research Phase 3 readout

LSD passes Phase 3 trials twice

LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
Why it matters ▲ Favorable
LSD's success in two Phase 3 trials marks a significant milestone in psychedelic research. This development could pave the way for regulatory approval, potentially transforming treatment options for mental health conditions. The industry now faces the challenge of navigating regulatory pathways and establishing market frameworks for distribution.
Clinical research Paper published

Fanon's insights on psychedelics for racialized therapy

Exploring critical psychedelic phenomenology: What Frantz Fanon can teach us about psychedelic therapy for racialized and colonized people
Why it matters ◈ Mixed
This paper highlights the critical need to incorporate anti-colonial and anti-racist frameworks in psychedelic therapy, particularly for racialized individuals. It challenges the reduction of racial-colonial trauma to individual disorders, emphasizing the importance of understanding broader systemic structures. This perspective could influence future research directions and clinical practices, ensuring more culturally informed and equitable psychedelic therapies.
Recent interdisciplinary scholarship has demonstrated how systemic racism, racialized mental health disparities, and histories of colonial and biomedical violence shape psychedelic experiences, therapeutic outcomes, and processes of integration. Emerging literature has foregrounded concerns including racial underrepresentation in research, the violent legacy of the War on Drugs, systemic racism in psychiatry, and the exploitation of Indigenous psychedelic traditions and healing practices. At the same time, clinicians and researchers have suggested that culturally informed psychedelic-assisted therapies may offer meaningful benefits for racialized individuals, particularly in addressing psychiatric symptoms linked to racial and colonial trauma. This paper contributes to this growing body of scholarship by applying Frantz Fanon’s critical phenomenology, postcolonial theory, and psychiatric critiques to contemporary psychedelic therapy discourse. I show how Fanon’s writings illuminate key tensions in the treatment of racialized peoples with psychedelic therapies. I first trace the history of racial-colonial violence embedded in the development of psychedelic biomedicine. I then apply Fanon’s critique of colonial psychiatry to MDMA-assisted therapy for PTSD; arguing that racial-colonial trauma cannot be reduced to an individual psychosomatic disorder detached from colonial structures. Next, I explore the contradiction between the historical weaponization of psychedelics against racialized bodies and the contemporary therapeutic framing of psychedelics. I place this tension, and the resulting skepticism toward psychiatric institutions, in conversation with Fanon’s understanding of collective racial-colonial trauma. Finally, I address issues of positionality and double-consciousness among racialized psychedelic therapists and emphasize the necessity of anti-colonial theory and anti-racist praxis within contemporary psychedelic therapy research and practice.
Clinical research Trial announced

Rhelion, UHN to trial psilocybin for Parkinson's depression

Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Why it matters ▲ Favorable
Rhelion Life Sciences' agreement with University Health Network to conduct a randomized clinical trial of psilocybin for depression in Parkinson's disease patients marks a significant step in exploring psychedelic treatments for neurodegenerative conditions. This trial could provide critical data on the efficacy and safety of psilocybin in a new patient population, potentially expanding therapeutic options. Success in this trial could influence future research directions and regulatory considerations.
Federal policy & industry Federal push ongoing

VA drives federal psychedelics push; FDA guidance; MDMA approval bid

Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval
Why it matters ◈ Mixed
The Veterans Affairs' continued push for federal psychedelic research highlights the growing institutional support for these substances, potentially leading to expanded access and acceptance. New FDA guidance could shape the regulatory landscape for psychedelic therapies. Resilient Pharmaceuticals' renewed attempt for MDMA approval suggests ongoing challenges and opportunities in bringing these therapies to market.
Clinical research Research published

LSD therapy research published

LSD therapy: A few hundred meters from where it began.
Why it matters ▲ Favorable
The publication of this research on LSD therapy provides new insights into its potential therapeutic benefits. Such studies are crucial for advancing our understanding of psychedelics in mental health treatment. This research may inform future clinical trials and policy decisions regarding psychedelic-assisted therapies.
Clinical research Case report published

rTMS shows promise for antenatal depression

Silent currents of healing: The role of rTMS in treating depression during pregnancy
Why it matters ▲ Favorable
This case report highlights the potential of repetitive Transcranial Magnetic Stimulation (rTMS) as a non-pharmacological treatment for antenatal depression, a condition with limited treatment options due to safety concerns during pregnancy. The study suggests that rTMS could be a promising alternative, but further research is needed to confirm its efficacy and safety in larger populations. This could have significant implications for maternal and fetal health by providing a safer treatment option.
Objective: This article highlights the potential of repetitive Transcranial Magnetic Stimulation (rTMS) in treating antenatal depression (AD), particularly in pregnant individuals for whom standard treatments are limited due to psychological and pharmacological concerns.AD often goes underrecognized and undertreated, despite serious risks to maternal and fetal health.Methods: We present a case report of a pregnant patient with chronic, recurrent major depressive disorder (MDD) who received rTMS using an intermittent theta burst stimulation (iTBS) protocol.Treatment was safely administered and well tolerated during pregnancy.Clinical outcomes were assessed using the Hamilton Depression Rating Scale (HAM-D) and the Generalized Anxiety Disorder 7-item scale (GAD-7).Results: The patient showed rapid, sustained improvement in depressive and anxiety symptoms, with no adverse effects.Conclusions: This case suggests that rTMS, particularly iTBS, may represent a promising and well-tolerated non-pharmacological option for antenatal depression in selected patients.However, conclusions regarding efficacy and safety remain limited by the single-case design and require confirmation in larger controlled studies.
FDA / DEA Public meeting announced

FDA announces PDUFA reauthorization meeting

Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
Why it matters ◈ Mixed
The reauthorization of the Prescription Drug User Fee Act (PDUFA) is crucial for the FDA's ability to collect fees that support drug application reviews, impacting the speed and efficiency of bringing new drugs, including psychedelics, to market. This process will influence the regulatory landscape for pharmaceutical companies, potentially affecting timelines and costs for psychedelic drug approvals. Stakeholders have the opportunity to present their views and influence the recommendations through public comments.
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. Following discussions with the regulated industry and periodic consultations with public stakeholders, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations for the reauthorized program in the Federal Register, hold a meeting at which the public may present its views on such recommendations, and provide for a period of 30 days for the public to provide written comments on such recommendations. FDA will then consider such public views and comments and revise such recommendations, as necessary.
Federal policy Regulatory agenda announced

2026 Unified Federal Regulatory Agenda Announced

Unified Agenda of Federal Regulatory and Deregulatory Actions-2026
Why it matters ◈ Mixed
The Unified Agenda outlines upcoming regulatory actions across federal agencies, which may include significant changes impacting psychedelic research and industry. While the document itself does not specify new regulations, it signals potential areas of regulatory focus. Stakeholders should monitor the agenda for any entries related to psychedelic substances, as these could affect research access and market dynamics.
Executive Order 12866, Regulatory Planning and Review (Sep. 30, 1993), requires each agency to publish a regulatory agenda (Agenda) of regulations under development or review during the next year which will be included in the Unified Agenda of Regulatory and Deregulatory Actions (Unified Agenda). 58 FR 51735 (Oct. 4, 1993). The Agenda required by Executive Order 12866 must include all regulations the agency expects to develop or review during the next 12 months, regardless of whether they may have a significant economic impact on a substantial number of small entities. Executive Order 12866 provides that agencies may combine this agenda with the regulatory flexibility agenda required under the RFA. To help keep the public informed of significant rulemaking proceedings and meet its obligations under the RFA and Executive Order 12866, the Commission has prepared Agenda entries providing a brief description and summary of each regulatory activity that is currently planned for the 12 months, subject to revision, including the objectives and legal basis for each, and the name and telephone number of an agency official who is knowledgeable about items in the agenda. The Commission's Agenda entries published in the Federal Register are only those entries for rules that are likely to have a significant economic impact on a substantial number of small entities pursuant to the RFA. The Commission's complete list of regulatory and deregulatory actions for the Unified Agenda will be published on the internet in a searchable format at www.reginfo.gov.
Clinical research Review published

Review: Psychedelic Safety & Outcomes Across Exposure Patterns

Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review
Why it matters ◈ Mixed
This structured narrative review highlights the complex safety and efficacy landscape of psychedelics, emphasizing the variability in outcomes based on exposure conditions. While MDMA and psilocybin show promise for certain conditions, methodological challenges and safety concerns persist. The review underscores the need for more rigorous trials, exposure-defined cohorts, and long-term safety studies to better understand the risks and benefits of psychedelic therapies.
Clinical trials and naturalistic studies describe psychedelics under markedly different exposure conditions. This narrative review searched PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, and regulatory sources through 15 July 2026, and examined safety and outcomes across four dimensions of exposure: dose, frequency, person, and context. In screened adults receiving one to three supervised doses, transient headache, nausea, anxiety, and cardiovascular activation are common; serious reactions are uncommon but include persistent anxiety, suicidality signals, and a recent case of hallucinogen persisting perception disorder. Evidence supports MDMA (3,4-Methylenedioxymethamphetamine) -assisted therapy for post-traumatic stress disorder and psilocybin-based interventions for depression, although functional unblinding, selected samples, inconsistent comparators, and a recent negative primary trial constrain certainty. Naturalistic studies suggest that vulnerability and context modify outcomes, but frequency is inconsistently measured and rarely linked to cumulative exposure or long-term health. Short-term microdosing trials show limited benefit, whereas long-term cardiac and psychiatric safety remains unresolved. Exposure-defined cohorts, prospective registries, echocardiographic surveillance, and blinding-aware comparative trials are priorities.
Clinical research Trial announced

Psilocybin trial for Parkinson’s depression

Psilocybin to Be Tested for Depression in Parkinson’s Disease
Why it matters ▲ Favorable
The announcement of a trial testing psilocybin for depression in Parkinson’s disease patients highlights the expanding scope of psychedelic research into neurological disorders. If successful, this could open new therapeutic avenues for managing depression in Parkinson’s patients, a population with limited treatment options. This trial may also contribute to the broader understanding of psilocybin's effects on neurodegenerative diseases.
Veterans Affairs Evaluation ongoing

VA Evaluates MDMA, GLP-1s, Psilocybin for Behavioral Health

The VA is Now Evaluating MDMA, GLP-1s and Psilocybin for Behavioral Health
Why it matters ▲ Favorable
The U.S. Department of Veterans Affairs (VA) evaluating MDMA, GLP-1s, and psilocybin for behavioral health signals a significant step towards integrating psychedelic therapies into mainstream medical care for veterans. This could lead to expanded treatment options for conditions like PTSD and depression, potentially improving outcomes for a vulnerable population. The involvement of the VA also suggests growing institutional acceptance and could influence broader healthcare policy.
Neuroscience Conceptual model proposed

Integrated neuropsychoanalytic model of serotonergic action

Cathexis and catharsis: An integrated neuropsychoanalytic model of serotonergic action
Why it matters ◈ Mixed
This theoretical synthesis proposes a unified framework integrating psychoanalytic and computational neuroscience models, potentially advancing precision psychiatry. It offers a novel perspective on psychopathology as computational pathologies of precision weighting. While promising, the model's practical implications for psychedelic research and treatment remain to be validated through empirical studies.
Background: The history of mental science is marked by a divide between the subjective, energetic models of psychoanalysis and the objective models of computational neuroscience. Reductionist approaches often fail to bridge this gap or adequately explain the structural complexity of psychopathology. This conceptual synthesis aims to propose a unified, testable neurocomputational framework anchored in the Free Energy Principle (FEP). Subjects and Methods:We conduct a theoretical synthesis mapping classical psychodynamic constructs onto the computational dynamics of Active Inference and neuromodulatory neurobiology.We formalize Freud's "Wish" as a high-precision allostatic prior, and drive as prediction error that compels the system to perform work.The Extended Reticular Thalamic Activating System (ERTAS) is analyzed as the physical operator of this economy.Results: Catharsis (discharge/primary process) is mapped as the efficient minimization of free energy via established habits, mediated by routing dopaminergic drive into the dorsal striatum and stabilized by 5-HT1A signaling.Cathexis (binding/secondary process) involves inhibiting immediate discharge for generative model revision, triggered by the lateral habenula and mediated by 5-HT2A signaling.Consolidation occurs via the Gs pathway.We detail a serotonergic "precision switch" acting as a meta-regulator of the Ego, arbitrating between stability, reactivity, and growth. Conclusions:The mind-brain functions as a hierarchical generative model striving to minimize entropy.This integrated model reframes psychopathology (e.g., depression, mania, psychosis) as "computational pathologies" of precision weighting where the switch between binding and discharge becomes stuck.This provides a rational basis for precision psychiatry, integrating pharmacological modulation of gain control with psychotherapeutic restructuring.
Clinical research Research published

AI in Psychedelic Therapy: Relational Competence Challenges

AI-mediated relational competence and its limits: Psychedelic-assisted therapy as a stress case and policy signal
Why it matters ◈ Mixed
The integration of AI in psychedelic-assisted therapy highlights significant challenges in maintaining relational competence, a critical factor in therapeutic outcomes. This paper raises important policy questions about the adequacy of current accreditation infrastructures for AI tools in facilitator training. The findings suggest that while some AI components enhance therapeutic settings, others may exacerbate existing inequities and accountability issues.
Artificial intelligence is entering psychedelic-assisted therapy (PaT) through at least two channels, pre-licensure facilitator training simulators and in-session administrative tools. This arrival is occurring in a context where relational factors, those interpersonal considerations between patients and providers, are not incidental but highly impactful. A 2025 international Delphi consensus study formally recognized therapeutic alliance, participant trust, and study personnel qualifications as reportable determinants of psychedelic trial outcomes. This paper uses PaT as a limit case for AI-mediated relational competence, a six-part construct originally developed for the standard clinical encounter, to test whether it holds, strains, or requires revision under conditions of altered consciousness and heightened vulnerability. Two live examples anchor the analysis: an AI simulation platform for facilitator training and ambient-AI documentation tools now used in ketamine-assisted psychotherapy. The construct's empathic-presence and relational-judgment components largely hold, and are arguably intensified, in this setting. Trustworthiness, transparency, accountable-decision-making, and equity-aware components strain against PaT's altered-consciousness context, as does its fragmented accountability infrastructure and its own documented history of racial and cultural inequity. The paper closes with a policy question. Absent an accreditation infrastructure comparable to accredited medical education, should a privately developed AI platform become the de facto standard for facilitator competency certification?
Clinical research Review published

Review on Psychedelic Safety & Outcomes Published

Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.
Why it matters ◈ Mixed
This structured narrative review provides a comprehensive analysis of psychedelic safety and clinical outcomes across various exposure patterns. The findings could inform future clinical trial designs and public health guidelines by highlighting both the therapeutic potential and risks associated with psychedelic use. Researchers and policymakers should consider these insights when developing protocols and regulations for psychedelic substances.
Clinical research Systematic review published

Systematic review on cognitive effects of psychedelics

Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence.
Why it matters ◈ Mixed
This systematic review synthesizes existing clinical and preclinical evidence on the cognitive effects of classic psychedelics, MDMA, and ketamine. The findings could influence ongoing debates about the safety and therapeutic potential of these substances. Researchers and policymakers should consider these results when designing studies and crafting regulations related to psychedelic therapies.
Neuroscience Research announced

Conative inference & allostatic resilience in mental stability

Conative inference as a mechanism of allostatic resilience: wanting to be and being to want
Why it matters ◈ Mixed
This research explores the concept of allostasis as a mechanism for mental resilience, proposing a functional brain hierarchy that integrates desire and affect. Understanding these mechanisms could inform therapeutic interventions for psychopathologies related to affective dysregulation. This theoretical framework may have implications for developing new treatments in mental health, potentially influencing future clinical trials.
Stability, mental stability in particular, is necessary for adaptive functioning. Dynamical systems existing in a changing environment must adapt to it by resolving the dialectical tension between stability and flexibility, which is captured in the concept of resilience. Allostasis is considered as a systemic mechanism of resilience and has recently been framed in terms of active inference, a theory of sentient behavior. Allostatic systems are thought to operate on the principle of self-organized criticality, which is related to free energy minimization, the central tenet of active inference theory. Based on this framework, I propose a functional brain hierarchy that supports allostasis. In it, desire and affect, framed in terms of affective inference, serve to integrate and mediate mutual constraints between cognitive and physiological homeostases. I further suggest that as allostatic organisms evolve into affective ones, they develop into conative agents, whose conation regulates their affective dynamics. At the top of this regulatory hierarchy, I propose raw desire, a domain-general global desire for positive affect (or to simply feel better). This functional hierarchy makes the raw desire-affective charge regulatory loop a core mechanism of allostasis and mental stability. It also implies an inherent vulnerability of conative organisms to affective dysregulation. Accordingly, much of psychopathology may be considered as compromised conative inference, which could be a target for therapeutic intervention.
Clinical research Study results published

Biomarker changes with low-dose ketamine in MDD/PTSD

Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)
Why it matters ▲ Favorable
This study adds to the growing body of evidence supporting the use of low-dose oral ketamine for treating major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), both individually and comorbidly. The findings suggest common biological responses across these conditions, highlighting potential for broader therapeutic applications. This could influence future clinical protocols and research directions in treating these challenging mental health conditions.
Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed blood-based biomarker and psychological changes following low-dose oral ketamine treatment for adults with MDD alone (n=14) and comorbid MDD+PTSD (n=21). Before treatment, the MDD clinical group presented with more severe depression, lower serotonin levels and higher kynurenine levels than the MDD+PTSD group. Post-treatment there were no detectable differences in the biological response between clinical groups, with combined analysis revealing common decreases in circulating brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF-A). Additionally, post-treatment, both clinical groups showed improvements in anxiety, stress, social functioning, suicidal ideation, and general well-being measures, as well as individual improvements in depression scores and PTSD symptoms in the MDD- and PTSD-containing groups, respectively. Collectively, this study presents additional evidence that low-dose oral ketamine treatment can be effective for MDD and MDD+PTSD, individually and comorbidly, and that both MDD and PTSD clinical groups responded in the same biological manner.
Clinical research Trial announced

VA launches psilocybin trial for veterans with PTSD, depression

VA launches clinical trial of psilocybin to treat veterans suffering from depression, PTSD
Why it matters ▲ Favorable
The Veterans Affairs (VA) clinical trial on psilocybin represents a significant step in exploring psychedelic therapies for mental health conditions affecting veterans, such as depression and PTSD. This trial could pave the way for broader acceptance and integration of psychedelic treatments in mainstream healthcare, particularly for underserved populations like veterans. The involvement of a federal agency underscores growing institutional interest in psychedelic research.
Clinical research Systematic review published

Microdosing Psychedelics: Systematic Review Published

Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis.
Why it matters ◈ Mixed
This systematic review and meta-analysis provides a comprehensive evaluation of the efficacy and safety of psychedelic microdosing on psychological outcomes in healthy adults. It offers critical insights into the potential benefits and risks associated with microdosing, informing both clinical practice and future research directions. The findings could influence regulatory perspectives and public health guidelines regarding the use of psychedelics in non-clinical settings.
Clinical research Research perspective

Intranasal biomaterials for TRD: device–formulation coupling

Intranasal biomaterials for treatment-resistant depression: device–formulation coupling and therapeutic exposure
Why it matters ◈ Mixed
This research perspective highlights the potential of intranasal delivery systems for treatment-resistant depression (TRD), emphasizing the need for a comprehensive approach that considers formulation, device, and anatomical factors. It underscores the importance of reproducible therapeutic exposure and a clinically relevant benefit–risk profile over mere material sophistication. The integration of AI and digital tools is suggested to enhance development, but experimental validation remains crucial.
Treatment-resistant depression (TRD) is commonly defined as depression that does not achieve an adequate response or remission after at least two antidepressant treatments of adequate dose and duration during the current depressive episode, although exact criteria vary across studies. Intranasal delivery is attracting renewed interest in TRD because it enables rapid administration, avoids gastrointestinal degradation and first-pass metabolism, and may support direct or indirect access to the central nervous system. However, clinical translation cannot be established by particle size, drug loading, or behavioral efficacy alone. A viable intranasal biomaterial–device product must generate reproducible therapeutic exposure through a coupled formulation–device–anatomy system, in which material properties shape spray performance, regional deposition, mucosal residence, epithelial transport, pharmacokinetics, safety, and therapeutic response. This Perspective examines how polymer composition, surface chemistry, particle mechanics, gelation, viscosity, and release kinetics interact with metered-dose devices, spray plume characteristics, nasal anatomy, and mucociliary clearance. Particular attention is given to the distinction between nasal deposition and brain delivery, the need for quantitative pharmacokinetic and biodistribution evidence, and the local safety requirements of repeated administration to respiratory and olfactory epithelia. We also propose indication-specific outcome standards for treatment-resistant depression that extend beyond short-term behavioral tests or isolated symptom scores to include onset, durability, cognition, sleep, daily function, adherence, and treatment burden. Artificial intelligence, medical-image-based airflow simulation, three-dimensional nasal models, and digital outcome measures may strengthen selected steps of this development pathway, but they should support rather than replace experimental validation. The central position of this article is that intranasal biomaterial–device products for treatment-resistant depression should be judged by reproducible, clinically relevant exposure with an acceptable benefit–risk profile, rather than by material sophistication alone.
Clinical research Workshop results announced

PREPP workshop integrates veteran peer support in psychedelics

Bridging veteran psychedelic peer expertise with research and clinical care: Peer Readiness and Education for Psychedelic Practice (PREPP) workshop
Why it matters ▲ Favorable
The PREPP workshop represents an innovative approach to integrating veteran peer support into psychedelic research and clinical practice. This initiative highlights the importance of experiential learning in preparing peer support specialists for roles in psychedelic therapy settings. The pilot results suggest potential benefits in expanding this curriculum to enhance interdisciplinary collaboration and support veteran involvement in psychedelic clinical spaces.
Psychedelics have been researched for decades, yet clinical investigations represent only a small fraction of their use. Some states have launched supervised psychedelic wellness services, outpacing controlled trials in the numbers of participants served. Veterans are key advocates for legal therapeutic access to psychedelics, seeking options through grassroots veteran-run organizations that have created robust networks for connection and healing, primarily through peer support frameworks. Psychedelic research and clinical spaces lack veteran peer support, including within the Veterans Health Administration METHODS This paper outlines the development and evaluation of the Peer Readiness and Education for Psychedelic Practice (PREPP), a novel curriculum that integrated thematic analysis of stakeholder focus groups and expert consensus to educate peer support specialists interested in contributing to psychedelic research and clinical practice within the medical model. The facilitator manual and participant workbook include modules on working with interdisciplinary teams, safety, ethics, and experiential learning. RESULTS The PREPP curriculum was piloted with eight veteran peer support specialists. Workshop participants demonstrated higher post-workshop knowledge assessment scores and described increased perceived preparedness for psychedelic peer support roles in the clinical setting. Mean knowledge scores increased from pre- to post-workshop using a 27-point scale (mean difference=4.2, 95% CI 1.2-7.1, p=0.01). Participants deeply valued the experiential component, underscoring its significance in shaping learning. Feedback suggested that participants viewed the experiential learning component as foundational to supporting development and modeling best practices. CONCLUSION Preliminary feedback from this small pilot workshop suggests that the PREPP curriculum may help prepare veteran psychedelic peer support specialists to expand their existing work into research and clinical spaces. Future iterations may benefit from expanded experiential learning and joint training with clinicians to enhance interdisciplinary collaboration.
Preclinical research Peer-reviewed study published

Ibogaine shows cardiotoxicity, neurobehavioral effects in zebrafish study

Ibogaine as a double-edged sword: Developmental cardiotoxicity and neurobehavioral alterations in zebrafish.
Why it matters ◈ Mixed
This preclinical study identifies both potential therapeutic and significant safety concerns with ibogaine, highlighting developmental cardiotoxicity and neurobehavioral changes in zebrafish models. The findings may inform future clinical trial design and regulatory scrutiny, especially regarding cardiac risk in vulnerable populations. Researchers and policymakers should weigh these risks when considering ibogaine for substance use disorder treatment or broader clinical access.
Neuroscience Review published

Review debunks Amanita muscaria suicide myth

Amanitaphobia and the myth of suicide by fly agaric (Amanita muscaria) mushroom ingestion
Why it matters ◈ Mixed
This review challenges the narrative that Amanita muscaria is commonly used for suicide, highlighting a lack of evidence and suggesting that biases, termed 'Amanitaphobia,' may influence perceptions of its danger. Understanding the true risks associated with psychoactive substances is crucial for informed public health policies and education. This work may influence future discussions and research on the safety and cultural perceptions of psychoactive mushrooms.
Abstract Background and aims In the past 10 years, several publications have made the dubious assertion that Amanita muscaria is commonly used for suicidal purposes, though no primary sources are cited. Despite scientific advances in understanding A. muscaria 's pharmacology, discussion of this psychoactive mushroom in academic publications continues to be shrouded in bias and myth. The present review investigates assertions of the mushroom's use in suicide and aims to illuminate the origins of these claims. Methods An extensive review of the English and German literature was conducted to identify possible trends or instances of the use of this mushroom for suicidal purposes. In addition to a review of popular field guides, mycological texts, and ethnographic accounts, searches for relevant publications were conducted using Google Scholar, PubMed, Science Direct, and Zobodat. Results The present review found insufficient data to suggest any historical or contemporary trends that warrant claims that A. muscaria is commonly or effectively used as a suicide agent, nor did it find evidence that A. muscaria is sufficiently and reliably lethal to warrant its use in suicide. Instead, the review found a pattern of bias in the literature, in the form of Amanitaphobia, when the dangers of A. muscaria ingestion are addressed. Conclusions Claims that A . muscaria is commonly consumed for purposes of committing suicide are not supported by verifiable or documented trends in the English or German literature, instead such claims appear to be supported by Amanitaphobia; a bias against A. muscaria based on its perceived dangers and deadliness.
Neuroscience Research published

RGS6 modulates cannabinoid effects on GI tract in mice

Regulator of G protein signaling 6 (RGS6) controls the effect of cannabinoids on intestinal tract motility and visceral pain sensation in mice
Why it matters ◈ Mixed
This study identifies RGS6 as a key regulator of cannabinoid effects on gastrointestinal motility and pain sensation in mice. These findings could inform future research into cannabinoid-based therapies for GI disorders. However, the research is preclinical and conducted in mice, so its direct applicability to human treatments remains to be seen.
Abstract Background Gastrointestinal (GI) tract diseases cause symptoms that significantly affect the quality of life. A promising direction in the search for novel therapeutic options in this field is the investigation of G protein-coupled receptors (GPCRs), whose activity is modulated by their regulator proteins (RGS). In this study, we examined RGS6 involvement in GI inflammation and functional disorders and its effect on cannabinoid (CB), opioid, and serotonin receptor (5HTR)-targeting compounds, Methods Using quantitative PCR, western blot, and ELISA assays, we characterized RGS6 expression in the mouse GI tract and measured GPCR-related secondary messenger expression upon stimulation with GPCR agonists in vitro in Caco-2 cells, both wild type (WT) and RGS6 knock-out (KO). Then, in vivo in a dextran sulfate sodium (DSS) mouse model of colitis using WT, global and tissue-specific RGS6 KO mice, inflammation, antinociceptive effects, and GI motility were examined. Results In Caco-2 cells, we found that RGS6 KO increased extracellular signal-regulated kinase phosphorylation, which was blocked by CB agonist WIN 55,212-2. Moreover, incubation with WIN 55,212-2 significantly reduced cyclic adenosine monophosphate (cAMP) levels in RGS6 KO but not WT cells. In DSS-induced, acute and chronic-relapsing mouse models of colitis, RGS6 KO resulted in resistance to stress-induced GI hypermotility. WIN 55,212-2 (1 mg/kg ip) substantially prolonged GI transit time and displayed antinociceptive properties that were stronger in the absence of RGS6. Epithelial -specific RGS6 KO did not affect the action of WIN 55,212-2. Conclusions RGS6 exerts crucial effects on GI physiology by acting on CB signaling in the enteric and/or central nervous system.
Neuroscience Research published

WNKs affect mouse behavior, CNS glucose uptake

Reviewer #1 (Public review): WNKs regulate mouse behavior and alter central nervous system glucose uptake and insulin signaling
Why it matters ▲ Favorable
This study highlights the role of WNK kinases in regulating cognitive functions and mood through insulin signaling in the brain. Understanding these mechanisms could inform future research on cognitive and mood disorders, potentially influencing therapeutic strategies. While the findings are preclinical, they offer a new perspective on the biochemical pathways involved in brain function.
Certain areas of the brain involved in episodic memory and behavior, such as the hippocampus, express high levels of insulin receptors and glucose transporter-4 (GLUT4) and are responsive to insulin. Insulin and neuronal glucose metabolism improve cognitive functions and regulate mood in humans. Insulin-dependent GLUT4 trafficking has been extensively studied in muscle and adipose tissue, but little work has demonstrated either how it is controlled in insulin-responsive brain regions or its mechanistic connection to cognitive functions. In this study, we demonstrate that inhibition of WNK (With-No-lysine (K)) kinases improves learning and memory in mice. Neuronal inhibition of WNK enhances in vivo hippocampal glucose uptake. Inhibition of WNK enhances insulin signaling output and insulin-dependent GLUT4 trafficking to the plasma membrane in mice primary cortical neurons and hippocampal slices. Therefore, we propose that the extent of neuronal WNK kinase activity has an important influence on learning, memory and anxiety-related behaviors, in part, by modulation of neuronal insulin signaling.
FDA / DEA Guidance finalized

FDA finalizes guidance on formal meetings with drug sponsors

Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Guidance for Industry; Availability
Why it matters ▲ Favorable
The FDA's final guidance on formal meetings with drug sponsors under the Prescription Drug User Fee Act (PDUFA) is now available. This guidance is crucial for sponsors of psychedelic drugs seeking FDA approval, as it clarifies the process for engaging with the FDA during drug development and review. It ensures that sponsors can effectively navigate regulatory requirements, potentially accelerating the approval process for new psychedelic therapies.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products." This guidance outlines the recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of new drug or biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This guidance finalizes the draft guidance of the same title issued on September 22, 2023.
Clinical research Study ongoing

Study on TRD treatment patterns in Portugal

Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal
Why it matters ◈ Mixed
This multicenter study provides real-world evidence on treatment patterns and outcomes for patients with treatment-resistant depression (TRD) in Portugal. The findings highlight the ongoing challenges in achieving clinical response and remission, underscoring the need for novel therapeutics and improved treatment protocols. The study's results may inform future research and clinical practice in addressing TRD.
Background Treatment resistant depression (TRD) is a burdensome condition with a severe impact on patients’ everyday lives. Therapeutics have improved in the last decade, however, outcomes remain poor. Real-world characterization has become increasingly important to accurately depict the clinical setting. ResisToday was an observational, prospective, multicenter study that aimed to increase available real-world evidence by evaluating clinical and socio-demographics, treatment patterns and clinical and patient-reported outcomes (PROs) of patients with TRD in Portugal. Methods Patients with a clinical diagnosis of TRD and moderate to severe depression (Montgomery-Åsberg Depression Rating Scale [MADRS] score ≥22), who were initiating a new treatment for TRD could enroll in ResisToday. Clinical outcomes were evaluated using the MADRS and the Clinical Global Impression-Severity scale (CGI-S). PROs were reported using the Patient Health Questionnaire-9 (PHQ-9) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Outcomes were assessed at baseline, Week 4 (primary endpoint) and Week 20. Results Of 153 patients, 123 (80.4%) were female and the mean age was 53.9 years. The mean age of onset of clinical depression symptoms was 38.0 years, and the mean time since diagnosis of major depressive disorder (MDD) was 11.8 years. TRD treatments initiated at baseline were varied; the most common treatments initiated or ongoing at baseline were mirtazapine (43.1%), venlafaxine (42.5%), quetiapine (25.5%), and trazodone (20.9%). Most patients’ antidepressant treatment was augmented with an antipsychotic (36.6%), combined with additional antidepressants (22.2%), or combined with another augmentation strategy (19.0%). Improvements in MADRS were observed from baseline to Week 4 and Week 20 (both p&amp;lt;0.001). Clinical response and remission, assessed by MADRS, were achieved by 14.9% and 3.1% of patients, respectively, at Week 4, and 40.5% and 25.3% at Week 20. Improvements were observed across CGI-S, PHQ-9, and EQ-5D-5L measures through Week 20 (all p&amp;lt;0.001). Conclusions Outcomes for patients with TRD in real-world clinical practice remain poor, with most patients not responding after 20 weeks of treatment. Treatment heterogeneity highlights a lack of clinical consensus, and the need for novel therapeutics and improved treatment protocols for TRD in real-world clinical practice in Portugal.
Clinical research Study protocol announced

Nova Protocol: Study on Trauma and Psychoactive Substances

The Nova Protocol: A Comprehensive Multimodal Longitudinal Study among Civilian Survivors of a Mass Trauma Event
Why it matters ◈ Mixed
The Nova Protocol represents a significant opportunity to understand the interplay between trauma and psychoactive substance exposure in a naturalistic setting. This study could provide critical insights into trauma processing and inform future intervention strategies. The comprehensive multimodal approach and longitudinal design enhance its potential impact on clinical practices and public health policies.
Background: The October 7, 2023 attack in southern Israel was one of the deadliest terror attacks in modern history, with 1,182 fatalities, more than 4,000 wounded individuals, and 251 hostages. The Nova music festival, an all-night outdoor rave near the Gaza border, suffered the highest number of civilian casualties, with more than 370 festival attendees killed. Survivors were exposed to prolonged life-threatening trauma with similar characteristics and within a narrow time window. Many survivors also reported being under the acute influence of psychoactive substances during the attack and the following hours. This tragic combination of civilian mass trauma and naturalistic pharmacological exposure created a rare opportunity to study trauma processing prospectively. Objective: This paper describes the rationale, design, and methodology of the Nova Protocol, a multimodal longitudinal observational study of survivors of the October 7, 2023 Nova festival attack and a sociocultural comparison group. Methods: The protocol spans from the first weeks to approximately 24 months post-trauma and includes three major assessment time points. It integrates repeated online clinical assessments, prolonged wearable-sensor monitoring, ecological assessments, saliva-based endocrine and inflammatory markers, structural and functional MRI, cardiac interoception paradigms, online and in-scanner reinforcement-learning tasks, and semi-structured qualitative interviews. Primary outcomes are PTSD symptom severity (PCL-5) and general psychological distress (K6), supplemented by a rich battery of secondary measures. Conclusion: The Nova Protocol provides an unusually rich longitudinal framework for characterizing psychological, behavioral, physiological, inflammatory, neural, interoceptive, and subjective mechanisms that shape clinical trajectories after civilian mass trauma. Because psychoactive substance exposure was naturalistic and self-selected, findings will be interpreted as mechanistic and prognostic associations rather than causal effects. The protocol is expected to inform early risk detection and scalable post-disaster monitoring and intervention strategies, as well as unique insights into how psychoactive substances impact trauma processing.
Clinical research Research findings

Ketamine + therapy promising for neuropathic pain

Ketamine and psychotherapy show promise as a combined approach to chronic neuropathic pain
Why it matters ▲ Favorable
The combination of ketamine and psychotherapy may offer a new treatment avenue for chronic neuropathic pain, a condition that is often difficult to manage with existing therapies. This development could lead to improved patient outcomes and broaden the therapeutic use of psychedelics beyond mental health disorders. Continued research and clinical trials will be crucial to validate these findings and potentially integrate this approach into standard care practices.
Clinical research Pilot RCT published

Pilot RCT: Ketamine-assisted psychotherapy for chronic neuropathic pain

Ketamine assisted psychotherapy to reduce chronic neuropathic pain: A mixed-methods randomized pilot trial.
Why it matters ▲ Favorable
This pilot randomized controlled trial provides early evidence that ketamine-assisted psychotherapy may reduce chronic neuropathic pain, a condition with limited effective treatments. The mixed-methods approach offers both quantitative and qualitative insights, informing future trial design and potential clinical protocols. While not definitive, these results support further research and could influence policy discussions on expanding ketamine's therapeutic indications.
Clinical research Study published

Psychologists' MDMA attitudes shaped by personal use

Psychologists’ attitudes towards the use of MDMA in therapy may be shaped by personal experiences
Why it matters ◈ Mixed
This study highlights the influence of personal MDMA experiences on psychologists' attitudes towards its therapeutic use. Understanding these biases is crucial for developing effective educational programs. Such programs can help ensure that healthcare professionals are informed by scientific evidence rather than personal experience, which is vital for the responsible integration of MDMA-assisted therapy.
Objective MDMA-Assisted Therapy (MDMA-AT) has demonstrated efficacy in the treatment of several mental health conditions, most notably post-traumatic stress disorder. To better understand what shapes the attitudes of healthcare professionals we investigated whether psychologists’ own experience with MDMA impacts the attitudes towards the therapeutic and recreational uses of MDMA. Method The study involved 74 registered psychologists in Aotearoa New Zealand who participated in an anonymous online survey aimed at gathering data on their understanding of and attitudes towards the therapeutic and recreational uses of MDMA. Results Nearly half of the surveyed professionals reported previous experience with MDMA, either recreationally or therapeutically. Noteworthy differences were identified in various aspects of attitudes between therapists with prior MDMA use and those without such experience. Overall, the surveyed psychologists expressed broadly favourable attitudes towards MDMA-AT. Conclusion Consistent with previous studies, this research emphasises the imperative need for education grounded in scientific evidence and professional training on the therapeutic use of MDMA for practicing psychologists and other health professionals. Such education and training are essential for better understanding MDMA-AT, mitigating misinformation and decreasing stigma associated with it.
Clinical research Study results announced

Ibogaine shows durable effects in TBI veterans

Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries
Why it matters ▲ Favorable
This study provides promising evidence for the long-term efficacy of magnesium-ibogaine therapy in treating traumatic brain injury (TBI) symptoms among veterans. The 12-month follow-up indicates sustained improvements in PTSD, depression, and anxiety symptoms. However, the use of other psychedelics and interventions by participants during the study period suggests that further randomized controlled trials are necessary to isolate the effects of ibogaine.
Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including posttraumatic stress disorder (PTSD), depression, and anxiety. Ibogaine, an oneirogenic alkaloid with unique pharmacological properties, has shown initial promise as a potential treatment for TBI-related sequelae. We previously observed large improvements in functional and psychiatric outcomes up to one month after a single treatment with magnesium-ibogaine in male U.S. Special Operations Veterans with a history of TBI. However, further evidence on the durability of these effects is needed. In this prospective long-term follow-up study, we evaluated the persistence of these clinical improvements over the subsequent year. Participants underwent comprehensive baseline and post-treatment assessments, with follow-up evaluations conducted at 3, 6, 9, and 12 months. Of 30 participants treated with magnesium-ibogaine, 25 completed the 12-month follow-up assessments. Outcome measures included a self-report measure of functional disability and clinician-administered assessments of psychiatric symptoms. Linear mixed-effects models demonstrated robust and sustained reductions in disability, PTSD, depression, and anxiety symptoms through 12 months post-treatment (all p < 0.001 after correction for multiple comparisons), with large effect sizes (Cohen’s d ≥ 2.18 at 12 months). In participants who achieved remission immediately post-treatment, survival analyses estimated the probability of sustained remission at 12 months as 84% for PTSD, 66% for depression, and 61% for anxiety. Notably, most participants reported using other psychedelic substances or pursuing other interventions during the follow-up period, which should be considered when interpreting long-term symptom trajectories. In this naturalistic cohort, durable, clinically meaningful symptom improvements were observed in individuals with TBI up to 12 months after ibogaine treatment. Further investigation through randomized controlled trials is warranted to validate these promising preliminary results and clarify the causal contributions of ibogaine treatment, subsequent interventions, and their combination.
Neuroscience Research advancement

LLMs enhance single-cell analysis in MDD research

Large language models advance single-cell transcriptomics in major depressive disorder
Why it matters ◈ Mixed
The integration of large language models with single-cell RNA sequencing represents a promising advancement in understanding major depressive disorder (MDD). This approach could lead to more precise identification of drug targets and biomarkers, potentially improving treatment strategies. However, challenges such as data heterogeneity and ethical considerations need to be addressed to ensure clinical applicability.
Major depressive disorder (MDD) exhibits substantial heterogeneity, posing challenges for its diagnosis and treatment. Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool for delineating cellular programs in neuronal and immune populations implicated in MDD pathogenesis. Advances in large language models (LLMs) are now enhancing single-cell analysis by improving annotation, clustering, regulatory network inference, and in silico perturbation to prioritize druggable targets. Integration with proteomic, metabolomic, epigenomic, and spatial data further clarifies disease mechanisms and potential biomarkers. Key challenges including data heterogeneity, model interpretability, computational scale, and ethical data usage remain to be addressed through rigorous benchmarks and validation to accelerate translation. Collectively, integration of LLMs with single-cell technologies provides a framework for more precise, cell-resolved hypothesis generation in MDD, while prospective validation of patient-level clinical utility remains a key next step.
Neuroscience Research published

AI behaviors modulate human belief and cognition

Playing with the dials of belief: how controllable AI behaviours could modulate human belief and cognition across scales
Why it matters ◈ Mixed
This research explores how AI systems can influence human belief formation and cognition, likening AI interactions to a form of virtual psychopharmacology. The study raises ethical concerns about AI's role in shaping beliefs and the potential for misuse in clinical and societal contexts. It highlights the need for governance to address control over AI configurations and their impact on belief dynamics.
Abstract Contemporary generative AI systems, increasingly adapted to human social cognition, are becoming active participants in how people form and revise beliefs. Clinicians have begun to describe AI-associated delusion-centred presentations whose onset or content appears closely associated with users’ extended dialogue with large language models. Many more users report subclinical shifts in conviction and “revelatory” experiences that alter behaviour and world-view without meeting criteria for psychosis. We propose that these phenomena can be understood within a belief-updating framework in which AI agents’ outputs function as testimony about the world, while interaction configurations, such as memory and interpersonal stance (many of which reflect design choices or deployment defaults), can alter the apparent reliability of that testimony and the precision users assign to it. On this view, AI-associated delusions sit at the extreme of a broader spectrum of epistemic effects, extending from gradual epistemic drift to highly crystallised conviction, situated within a wider ecology of belief shaped by personalised human-AI dyads. We develop a virtual psychopharmacology analogy in which different AI system configurations have effects on belief dynamics that resemble neuromodulatory changes in the precision assigned to social evidence. We also consider how dopaminergic and related states may alter susceptibility to belief-shifting dialogue. We consider how deliberately configured agents might be used to support wellbeing in defined clinical contexts and analyse how the same configurations could be deployed to shape belief and attention at population scale, including in products designed to induce spiritual or epiphanic states, as mechanisms of radicalisation in extremist or cultic contexts, and in persona clones used for political purposes. We conclude that interaction configurations should be treated as modifiable influences on belief and attention, and that governance must address both the concentration of control over these dials, as well as the structural biases that determine whose testimonial perspectives are amplified and whose are smoothed over or ignored.
Neuroscience Preclinical study results

DMT vs. 5-MeO-DMT: Behavioral and Plasticity Differences

Preclinical Comparison of DMT and 5-MeO-DMT Reveals Behavioral Dissociation, Distinct TrkB Activation and Differential Plasticity Profiles
Why it matters ▲ Favorable
This study provides important insights into the distinct pharmacological profiles of DMT and 5-MeO-DMT, highlighting differences in their acute and longer-term effects on neuroplasticity and behavior. These findings could guide the development of more targeted and tolerable psychedelic therapies. The differential activation of TrkB and synaptic protein expression suggests potential pathways for therapeutic intervention.
N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) are structurally related tryptamine psychedelics with emerging therapeutic potential, yet their comparative acute pharmacology and longer-term neuroplastic effects remain incompletely defined. Here we show that DMT produces a bell-shaped dose-response curve in the mouse head-twitch response (HTR) assay, whereas 5-MeO-DMT elicits a monotonic increase. Selective antagonism at 5-HT2A or 5-HT1D receptors, or agonism at 5-HT1A, robustly attenuates HTR for both compounds without abolishing their ability to reduce marble burying, a screening assay for OCD-like behavior. Acutely, both agents elevate TrkB phosphorylation in a region-specific manner, with broader engagement by DMT across default-mode-network and hippocampal territories. Twelve days after a single dose, both compounds increase synaptic proteins (PSD-95, synaptophysin; SV2A for DMT), while DMT uniquely lowers hippocampal BDNF and reprograms frontal-cortex glutathione and energy metabolism. These findings demonstrate that acute hallucinogenic-like activity and selected therapeutic-like behavioral and plasticity outcomes can be pharmacologically dissociated, informing the rational design of more tolerable, scalable psychedelic-based treatments.
Clinical research Survey results published

Canadian Psychiatrists' Views on Palliative Psychiatry

A Survey of Canadian Psychiatrists’ Attitudes Towards Palliative Care Approaches for Severe and Persistent Mental Illness: Enquête sur les attitudes des psychiatres canadiens à l’égard des approches de soins palliatifs pour les troubles mentaux graves et persistants
Why it matters ◈ Mixed
This survey reveals that Canadian psychiatrists largely support integrating palliative care approaches into the treatment of severe and persistent mental illness (SPMI). The findings highlight a shift towards prioritizing quality of life and patient autonomy over curative measures. However, there is a need for further research to bridge the gap between theoretical acceptance and practical application, involving broader stakeholder perspectives.
Background Palliative psychiatry, which emphasizes improving quality of life and reducing suffering for individuals with severe and persistent mental illness (SPMI), has gained recognition internationally. Canadian psychiatrists’ perspectives on palliative psychiatry remain under-explored. We adapted a survey created by Trachsel et al. on the acceptability of palliative psychiatry amongst German-speaking Swiss psychiatrists for the Canadian context to address this gap. Method We conducted a cross-sectional survey of Canadian psychiatrists ( n = 69). We collected data on demographics, attitudes towards palliative care in psychiatry, and responses to 3 case vignettes describing a patient experiencing anorexia nervosa, schizophrenia, or major depressive disorder, respectively. Additional questions explored participants’ views on coercion. Participants could elaborate on their responses to the case vignettes using optional free-text boxes. We analyzed the survey data using descriptive statistics and the qualitative data using structured tabular thematic analysis. Results Participants broadly endorsed treatment goals focused on improving function, reducing suffering, preventing suicide, and maintaining patient autonomy, while placing less emphasis on curative approaches. Participants were divided on whether palliative care relates to end-of-life care. There was strong acceptance for a palliative approach in SPMI care. Attitudes towards prognosis and treatment futility varied by diagnosis amongst the case vignettes. Participants expressed nuanced views on coercion, highlighting ethical tensions when considering interventions contrary to patient preferences. Our qualitative analysis uncovered themes of ethical dimensions, clinical paradigms, characteristics of mental illness, considering comprehensive treatment options, psychosocial factors, and systemic factors in participants’ consideration of their responses. Conclusions This cohort of Canadian psychiatrists largely endorses the applicability of palliative care approaches within SPMI care. Our findings underscore the need for further research with larger samples to understand potential gaps between theoretical acceptance and practical implementation. Future research should include the perspectives of patients, families, and other interest-holders to guide the potential integration of a palliative care model into psychiatric practice.
Neuroscience Review published

NLRP3 inflammasome's role in schizophrenia explored

The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders
Why it matters ◈ Mixed
This review highlights the potential role of the NLRP3 inflammasome in schizophrenia, suggesting it may be a target for future therapeutic interventions. While the review does not provide direct clinical evidence, it underscores the need for further research into NLRP3 as a biomarker and therapeutic target. This could influence future clinical trials and drug development in neuropsychiatric disorders.
Abstract Schizophrenia is a complex psychiatric disorder with an incompletely understood etiology, but converging evidence supports a role for chronic neuroinflammation in its pathogenesis. The nucleotide-binding oligomerization domain-, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome is a central regulator of innate immune responses in the central nervous system and has been implicated in several neuropsychiatric disorders. Emerging evidence links dysregulated NLRP3 activity to inflammatory and structural brain changes relevant to schizophrenia, though direct clinical evidence remains limited and causal relationships have not been established. The goals of this review are to: (1) summarize the biology of the NLRP3 inflammasome and its role in neuroinflammation, (2) evaluate evidence for NLRP3 dysregulation in schizophrenia and related neuropsychiatric disorders, (3) examine NLRP3 inhibitors tested in neuropsychiatric conditions and assess their translational relevance to schizophrenia, and (4) critically appraise the potential of NLRP3 as a peripheral and central biomarker of schizophrenia, identifying key gaps that future research must address.
Clinical research Study published

Psilocybin's In Vitro Effects on Gut Microbiota in Anxiety

Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety
Why it matters ◈ Mixed
This study explores the impact of psilocybin on gut microbiota and metabolic activity, revealing significant changes in microbial composition and metabolite production. While the findings suggest potential gut-microbiota-mediated mechanisms of psilocybin, they do not establish clinical benefits for mental health. Further research in animal models and clinical settings is necessary to validate these in vitro results.
Background/Objectives: This study investigated the effects of a single dose of psilocybin-containing Psilocybe cubensis extract on gut microbiota composition, microbial metabolism, and intestinal immune-related responses. Methods: A single dose of P. cubensis extract (35 mg/L) was subjected to colonic fermentation using the SHIME® model inoculated with fecal microbiota from individuals with severe anxiety. Psilocybin and psilocin concentrations, microbial metabolites, gut microbiota composition, intestinal barrier integrity, and cytokine responses were evaluated. Results: During colonic fermentation, the concentrations of both psilocybin and psilocin decreased significantly, suggesting their metabolism or degradation within the gut microbial environment. Treatment reduced ammonia production by 19–25% and decreased gamma-aminobutyric acid (GABA) levels. By contrast, the concentrations of the short-chain fatty acids acetic, propionic, and butyric increased by 2.26-, 2.69-, and 2.21-fold, respectively, after 20 h of fermentation. Microbial profiling revealed marked increases in the relative abundances of Bifidobacterium and Lactobacillus after 20 h and 15 days, together with a slight reduction in α-diversity. Fermentation supernatants also altered cytokine profiles and influenced intestinal barrier-related responses, although these effects reflected a complex immunomodulatory pattern rather than a uniform anti-inflammatory response. Conclusions: These findings indicate that psilocybin-containing P. cubensis extract can modulate gut microbiota composition and metabolic activity under in vitro colonic conditions. The observed changes in microbial metabolites, bacterial taxa, and host-related responses support the hypothesis that gut-microbiota-mediated mechanisms may contribute to the broader biological effects of psilocybin. However, these in vitro findings do not establish clinical benefits for intestinal or mental health, and further validation in animal models and well-controlled clinical studies is required.
Industry Application refiled

Resilient refiles MDMA for PTSD application

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application
Why it matters ◈ Mixed
Resilient's decision to refile the MDMA for PTSD application indicates ongoing efforts to gain regulatory approval despite previous setbacks. This move could potentially pave the way for MDMA-assisted therapy to become a recognized treatment for PTSD, impacting both patient care and the psychedelic market. The outcome of this application will be closely watched by stakeholders in the psychedelic research and industry sectors.
Clinical research Pilot studies ongoing

Participatory-imaginal processing in psilocybin therapy

Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework
Why it matters ▲ Favorable
This research introduces a novel framework for psilocybin therapy integration that emphasizes non-verbal, embodied processing. The DREAM protocol could enhance therapeutic outcomes by allowing patients to re-engage with somatic and imaginal aspects of their experiences. This approach is being evaluated in pilot studies, which could inform future therapeutic practices and integration strategies.
Psilocybin therapy in patients with cancer commonly produces vivid embodied and imaginal experiences that resist verbal description, yet most current integration approaches rely primarily on cognitive and verbal processing. We hypothesize that an approach to integration that directly engages this embodied register, without requiring translation into a verbal narrative, will enable patients to re-access salient aspects of their psychedelic experience and consolidate them into a durable, re-enterable touchstone. We call this mode of processing participatory-imaginal processing . Drawing on Embodied Imagination, predictive processing models, and clinical observations from psilocybin therapy, we describe how participatory-imaginal processing can be invoked during integration sessions, how it provides an opportunity to revisit somatic, affective, and imaginal material from the psychedelic experience, and the way it can function as a hypothesis-generating therapeutic framework. Our method is called the DREAM protocol (Drop In, Recount, Enter, Amplify, Merge), which we designed as a structured clinical heuristic that operationalizes our approach in a form that can be taught and evaluated for feasibility and fidelity. We hypothesize that using DREAM to activate a participatory-imaginal mode of processing in integration may help patients re-engage somatically salient aspects of their psychedelic experience and identify embodied touchstones that remain accessible long afterward. We illustrate the framework using clinical material from Bosnak’s work and spontaneous reports from participants in completed psilocybin trials. Two pilot studies currently in progress are designed to assess the feasibility, tolerability, and preliminary therapeutic relevance of this approach in the immediate post-psilocybin period.
Neuroscience Hypothesis proposed

Postictal systems window hypothesis in ECT for depression

The postictal systems window hypothesis of electroconvulsive therapy in major depression
Why it matters ◈ Mixed
This hypothesis proposes a new framework for understanding the mechanisms of electroconvulsive therapy (ECT) in treating major depression. By focusing on the postictal systems window, it suggests that the therapeutic effects of ECT are due to a structured recovery phase that couples various biological dynamics. This could lead to improved predictions of treatment outcomes and cognitive side effects. The model's falsifiability offers a pathway for future research to validate or refine these claims.
Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe major depressive disorder, particularly in melancholic, psychotic, suicidal, catatonic or retarded, and treatment-resistant presentations. Existing mechanistic accounts are biologically valid but are often presented as parallel lists: monoamine release, excitatory-inhibitory rebalancing, neuroendocrine activation, immune modulation, neurotrophic plasticity, hippocampal change, and network rewiring. We propose the postictal systems window hypothesis. The organizing principle is seizure-induced postictal recoupling: the therapeutic seizure interrupts a rigid depressive state, whereas the subsequent recovery phase couples electrophysiological, neurovascular-metabolic, clinical, endocrine, and immune-metabolic dynamics. The central claim is not that ECT affects every biological domain. The claim is that an adequate seizure triggers a timed postictal state in which a smaller set of core events - postictal network interruption and recovery, a structured hemodynamic-metabolic transition, and early clinical reorientation - becomes coupled to endocrine and immune-metabolic signaling and later consolidation. This hierarchy is critical. Neurovascular coupling and hemodynamic waves are treated as core components of the postictal transition; blood-brain barrier and neurovascular-unit permeability are treated as plausible but second-order interfaces, not established human mediators. Glial, trophic, structural, and epigenetic changes are placed mainly downstream as translation and consolidation mechanisms. Recent optical neuroimaging evidence that ECT seizures are followed by hyperemic waves consistent with cortical spreading depolarization supports the principle that the postictal period contains organized biological events rather than simple seizure termination. The model is falsifiable: early postictal curves after the first one to three treatments should predict remission and cognitive burden better as a prespecified composite than as isolated markers such as seizure duration, postictal suppression, cortisol, C-reactive protein, or brain-derived neurotrophic factor. Cognitive adverse effects should relate to excessive duration, delayed recovery, or medial temporal exposure of the window rather than to antidepressant efficacy itself.
Clinical research Phase 2 trial results

taVNS improves cognition in MCI: Phase 2 trial

Rs-fMRI reveals that taVNS improves cognitive and emotional function in mild cognitive impairment by reconfiguration of “sensory relay-salience-default” cross-network effective connectivity: a randomized, double-blind, sham-controlled trial
Why it matters ▲ Favorable
This study provides evidence that transcutaneous auricular vagus nerve stimulation (taVNS) can significantly improve cognitive and emotional functions in patients with mild cognitive impairment (MCI). The findings highlight the potential of taVNS as a noninvasive intervention for MCI, with implications for enhancing cognitive health in aging populations. The trial's rigorous design and significant results may encourage further research and development in non-pharmacological treatments for cognitive decline.
Background Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising noninvasive intervention for mild cognitive impairment (MCI), but its clinical efficacy and network-level mechanisms remain unclear. Methods In this prospective, randomized, sham-controlled, parallel-group trial, 60 patients with MCI were assigned 1:1 to 12-week taVNS or sham taVNS. The primary outcome was the between-group difference in change from baseline to week 12 on the Montreal Cognitive Assessment-Basic (MoCA-B). Secondary outcomes included AVLT-H, STT-A/B, AFT, BNT, HAMD-17, and HAMA scores. Twenty-eight healthy controls underwent baseline rs-fMRI as a non-randomized reference cohort. Functional connectivity (FC) identified MCI-related abnormal regions, which together with theory-driven regions served as seeds for Granger causality analysis (GCA) to characterize intervention-related effective connectivity changes. Imaging-behavior associations were examined using Pearson correlations. The final per-protocol analysis included 52 randomized patients with complete clinical and imaging data. Results After 12 weeks, the taVNS group showed significant within-group improvements in global cognition and multiple secondary outcomes, whereas the sham group did not. The between-group difference in MoCA-B change was significant (mean difference = 2.91, 95% CI: 0.79 to 5.03, Cohen’s d = 0.59), indicating a moderate-to-large effect. Baseline FC abnormalities in MCI mainly involved the insula, medial frontal cortex, precuneus, temporal cortex, thalamus, cingulate cortex, and parieto-occipital regions. Following taVNS, effective connectivity was selectively reconfigured within a distributed network centered on the insula, anterior cingulate cortex, temporal cortex, and precuneus. Changes in directed connectivity correlated with changes in MoCA-B, AFT, and HAMA scores. No serious adverse events occurred. Clinical trial registration https://www.chictr.org.cn/showproj.html?proj=131823 , identifier (ChiCTR2100049940).
Clinical research Research published

Diagnostic pitfalls in treatment-resistant depression

Bipolar spectrum disorders in apparent treatment-resistant depression: diagnostic pitfalls and implications for contemporary psychiatric practice
Why it matters ◈ Mixed
This research highlights the diagnostic challenges in differentiating treatment-resistant depression (TRD) from bipolar spectrum disorders (BSD). Improving diagnostic accuracy could lead to better-targeted treatments and avoid inappropriate antidepressant use. The findings suggest that clinicians should consider BSD in cases of antidepressant non-response or mood instability, potentially impacting pharmacological and neuromodulation treatment strategies.
SUMMARY Patients referred with apparent treatment-resistant depression (TRD) are a diagnostically heterogeneous group. A clinically important minority have unrecognised bipolar spectrum disorders (BSD), most commonly bipolar II disorder, cyclothymic disorder or depressive episodes with mixed features. Misclassification may result from brief, subtle or retrospectively underreported hypomania, the categorical nature of DSM/ICD diagnostic thresholds and under-recognition of mixed depressive states. This article gives a practical framework for identifying patients in whom antidepressant non-response, mood instability, antidepressant-induced agitation/switching, recurrent or early-onset depression, and mixed features should prompt consideration of underlying BSD through differential diagnosis, recognition of clinical red flags and structured diagnostic reassessment. Rather than redefining TRD or suggesting that most TRD cases are bipolar, the article aims to improve diagnostic accuracy by highlighting circumstances in which bipolar spectrum illness should be considered before further treatment escalation. It also summarises implications for pharmacological management and briefly considers neuromodulation as one option when bipolarity is suspected but not yet recognised.
Neuroscience Peer-reviewed study published

Distinct brain network patterns in psychedelic vs. sedated states

Opposite network patterns of integration-segregation in psychedelic and sedated states of consciousness.
Why it matters ▲ Favorable
This study provides evidence that psychedelic and sedated states of consciousness are characterized by opposite patterns of brain network integration and segregation. These findings offer mechanistic insight into how psychedelics alter consciousness, supporting their unique neurobiological profile compared to other altered states. The results may inform both clinical trial design and regulatory discussions by clarifying the distinct neural signatures of psychedelic interventions.
Clinical research Research published

Community Insights on Psychedelic Harm Reduction

Improving Psychedelic Harm Reduction and Therapy: Community Perspectives from Individuals Who Use Recreationally and for Mental Health Purposes.
Why it matters ◈ Mixed
This study provides insights into harm reduction and therapeutic practices from the perspective of individuals who use psychedelics recreationally and for mental health. Understanding community perspectives can inform the development of more effective harm reduction strategies and therapeutic interventions. This research may influence future policy and clinical guidelines by highlighting the needs and experiences of users.
DEA / Federal Register Temporary Schedule I placement

DEA temporarily schedules O-DSMT as Schedule I

Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Why it matters ◈ Mixed
The DEA's decision to temporarily place O-desmethyltramadol in Schedule I indicates a significant regulatory shift, highlighting concerns about its potential danger to public safety. This action imposes strict controls and penalties on handling O-DSMT, impacting research and industry activities involving this substance. Stakeholders in the psychedelic and pharmaceutical fields should be aware of these changes to ensure compliance and assess the impact on ongoing and future research.
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
Neuroscience Preclinical study announced

MDMA-Enhanced Therapy Reverses PTSD in Mice

MDMA-Enhanced Exposure Therapy Reverses PTSD-Like Features In a Learned Helplessness Mouse Model
Why it matters ▲ Favorable
This study provides a preclinical foundation for integrating MDMA with exposure therapy to treat PTSD, potentially enhancing therapeutic efficiency and accessibility. The findings could inform future clinical trials aimed at optimizing MDMA-assisted interventions for PTSD. This research is significant for developing more scalable and accessible treatment frameworks for PTSD, a condition with limited effective treatment options.
Post-traumatic stress disorder (PTSD) is a highly prevalent, debilitating psychiatric condition. Existing treatments are ineffective for many patients. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has demonstrated substantial clinical efficacy but relies on prolonged, resource-intensive therapeutic protocols that limit scalability and accessibility. Here, we investigated whether combining MDMA with exposure-based intervention could enhance therapeutic efficiency in a preclinical model of PTSD-like behavior. Using a learned helplessness paradigm in mice, we identified trauma-susceptible individuals based on persistent escape failures following inescapable stress. Traumatised mice subsequently received brief treatment regimens consisting of MDMA or saline vehicle administered with or without exposure to the traumatic cue. Behavioral outcomes were tracked longitudinally using active avoidance performance as the primary endpoint, complemented by assays of anxiety-like, depressive-like, cognitive, and social behaviors. MDMA treatment markedly reduced trauma-associated behavioral deficits. MDMA combined with exposure produced rapid and sustained recovery compared to control conditions. Statistical analyses revealed significant treatment- and time-dependent effects on avoidance behavior, indicating accelerated resilience acquisition in MDMA-treated groups. Additional behavioral assays demonstrated dose-dependent effects of MDMA on anxiety- and depression-related measures. Together, these findings provide proof-of-principle that pharmacological modulation with MDMA can enhance exposure-driven behavioral recovery, supporting a strategy to integrate MDMA into more efficient and accessible PTSD treatment frameworks. This work establishes a preclinical foundation for clinical studies aimed at optimizing MDMA-assisted interventions to improve scalability and patient access.
Clinical research Study published

Psilocybin services show mental health benefits in OR & CO

Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado
Why it matters ◈ Mixed
This study provides real-world evidence of mental health improvements from regulated psilocybin services in Oregon and Colorado. The findings support the potential therapeutic benefits of psilocybin, but also highlight safety concerns, including possible increased suicidality. As more jurisdictions consider similar frameworks, these results underscore the need for robust monitoring and further research to ensure safety and efficacy.
Oregon (OR) and Colorado (CO) were the first states to enact regulations for provision of psilocybin with support of licensed "facilitators." As more states and countries adopt similar policies, informed public policy decisions require that client characteristics and rationale for using psilocybin, psilocybin dosing practices, mental health outcomes, and adverse events are understood. We performed a retrospective observational study of responses for 2363 individuals receiving psilocybin at OR and CO regulated service centers. Clients and facilitators entered data before and after receiving psilocybin, including the Mystical Experience Questionnaire-30 (MEQ-30), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and World Health Organization Well-Being Index-5 (WHO-5). Preexisting mental health issues were common (66%) in participants. Psilocybin doses ranged from 1-95 mg, with a mean total of 28∙8 mg. We observed improvements of 49% in PHQ-9 scores, 51% in GAD-7 scores, and 22% in WHO-5 scores at two-weeks after dosing. MEQ-30 scores were dose-dependent. Changes in PHQ-9 and GAD-7 scores were not different for psilocybin doses ≤30 mg and &gt;30 mg, and only weakly correlated with MEQ-30 scores. There were 94 mild adverse events during and after dosing, five more serious events not clearly related to treatment, and evidence of possible risk of increased suicidality. Study limitations include open label administration, self-reporting, loss of participants for follow-up, and a short 2-week post-dosing end-point. We conclude that psilocybin services, delivered within these regulated frameworks, is associated with improvements in mental health in real world populations, however, more robust monitoring is needed to ensure safety.
Clinical research Small trial results

Psilocybin trial shows promise for anorexia treatment

Could Psilocybin Help Treat Anorexia? A Small Clinical Trial Suggests the Psychedelic May Make Patients More Open to Recovery
Why it matters ▲ Favorable
A small clinical trial suggests psilocybin may aid in treating anorexia by increasing patients' openness to recovery. This finding could open new avenues for addressing eating disorders, a field with limited effective treatments. Further research is needed to validate these results and explore the mechanisms involved.
Clinical research Research paper published

Barriers to Psychedelic Therapy for Depression

Psychedelic Therapy for Depression
Why it matters ◈ Mixed
This research paper highlights the potential of psychedelic-assisted therapy for treating depression, particularly treatment-resistant cases. It identifies key regulatory and infrastructural barriers that must be addressed to integrate these therapies into mainstream hospital care. The findings offer a roadmap for stakeholders aiming to make psychedelic therapies more accessible, emphasizing the need for safe and ethical implementation.
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable improvements in depressive symptoms. However, despite promising evidence, these treatments remain confined to research settings. This paper examines the regulatory, clinical, and infrastructural barriers preventing psychedelic therapy from entering mainstream hospital care. Through a mixed‑methods approach - including literature review, case studies, expert interviews, and systems mapping - this research outlines the requirements for safe, ethical, and scalable implementation. The goal is to provide a practical roadmap for hospitals, policymakers, and clinicians seeking to translate psychedelic research into accessible mental health treatment.
Neuroscience Review published

Neurobiological framework links arts to health benefits

Arts engagement, active inference, and allostatic regulation: a neurobiological framework for understanding the health effects of aesthetic experience
Why it matters ▲ Favorable
This review proposes a novel neurobiological framework linking arts engagement to health benefits through active inference and allostatic regulation. While not directly related to psychedelic substances, the framework could inform broader research on non-pharmacological interventions for mental health. It provides a basis for future studies on how structured experiences like art can recalibrate physiological regulation, potentially offering insights into complementary therapies.
A growing body of evidence indicates that arts engagement produces measurable effects on mental and physical health, yet a mechanistic account linking aesthetic experience to physiological regulation remains lacking. This review proposes a neurobiological framework grounded in two convergent theoretical traditions: the active inference formulation of brain function and the allostatic model of physiological regulation. Both frameworks describe organisms as anticipatory systems that maintain viability through model-based predictive control. When active inference chronically fails as in sustained stress, trauma, or learned helplessness, the resulting allostatic load produces systemic metabolic dysregulation and disease vulnerability. This review argues that arts engagement provides contexts optimally suited to restoring effective active inference across sensorimotor, cognitive, affective, and social timescales, thereby recalibrating allostatic regulation. Arts engagement is positioned not as the only activity capable of producing such effects, but as a distinctive and potentially major instance of structured agentic experience, distinguished by its simultaneous engagement of multiple levels of the predictive hierarchy, its intrinsic epistemic motivation, and its capacity to sustain graded uncertainty without pragmatic consequence. A schematic computational specification of the framework is provided, identifying the generative model structure, precision parameters, and expected free energy decomposition relevant to arts-mediated allostatic recalibration. The framework is systematically compared with six alternative accounts of arts-health effects, showing where predictions converge and diverge. Developmental and lifespan perspectives are elaborated, with specific predictions for critical-period effects. The framework generates directional hypotheses for metabolomic, neuroendocrine, and neuroimaging studies, including predictions that distinguish the proposed mechanism from generic stress reduction.
Neuroscience Research findings

Low-dose radiation increases cortical excitability

Single shot low-dose radiation durably and focally increases cortical excitability: a potential therapy for neuronal circuit disorders?
Why it matters ◈ Mixed
This study explores the potential of low-dose stereotactic radiosurgery (SRS) to modulate neuronal circuits, which could have implications for treating neuronal circuit disorders. The findings suggest that precise SRS technologies might be used to durably alter neuronal activity without damaging cellular integrity. While promising, further research is needed to understand the clinical applicability and safety of this approach.
Herein, we assess the potential of low-dose stereotactic radiosurgery (SRS) to modulate neuronal network states without apparent damage to cellular integrity. Using a small animal radiation research platform (SARRP), a 1 mm3 focal target in the mouse visual cortex was irradiated with doses of 5, 20, and 40 Gy. One-month later a significant dose-dependent increase in excitatory synapse numbers was observed, notably limited to the treated visual cortex and not the adjacent somatosensory cortex. Six months post-irradiation, cortical neuronal microcircuit activity was monitored in awake mice using high sensitivity two-photon calcium imaging. A single 5 Gy dose resulted in a significant microcircuit-wide increase of spontaneous neuronal activity, consistent with a lasting shift in the functional architecture of the irradiated nodal network. At higher SRS doses (40 Gy) this neuromodulatory window appears to close. In aggregate, these data suggest that low-dose radiation could, in some circumstances, be exploited by selected high precision SRS technologies to durably modulate neuronal circuit disorders. Some, or even all the clinical benefits reported in the companion article by Zhao et al. are likely attributable to the biological properties we sought to characterize in our research.
Neuroscience Study published

Study on ethical priorities in neurotechnology

Neurotechnology through the lens of users and as a novel field for society
Why it matters ◈ Mixed
This study highlights the ethical challenges and societal impacts of neurotechnology, emphasizing the need for transparent and user-centered approaches. By focusing on neuroethics and the cultural embedding of these technologies, it seeks to bridge the gap between scientific innovation and public concerns. This is crucial for ensuring responsible development and application of neurotechnologies.
Successful and responsible innovation in neurotechnology requires clear ethi- cal priorities and a deep understanding of individual and societal needs as well as public concerns. Recent cases of consumer exploitation, misleading claims, and inadequate patient aftercare reveal critical gaps in current practices and underscore the urgent need for more ethical, transparent, and user-centered engagement in this rapidly developing field. This study focuses on four comple- mentary domains: (1) neuroethics and embodiment; (2) the cultural embedding of neurotechnologies; (3) art and culture in relation to neurotechnology; and (4) human enhancement, technovisions, and sociotechnical imaginaries. Across these domains, the manuscript explores user and societal perceptions, high- lighting often overlooked asymmetries in communication between scientists and entrepreneurs and those who ultimately receive research outcomes in the form of products. Drawing on the authors’ multidisciplinary expertise and a synthe- sis of the relevant literature, the manuscript outlines a possible foundation for developing more balanced, inclusive and symmetric communication formats that empower stakeholders regardless of status or expertise. Integrating insights from neurotechnology with applied ethics, the humanities, social sciences, technology assessment and the arts, this work seeks to contribute to a broader understand- ing of the societal and individual impacts of emerging neurotechnologies and to support the protection and empowerment of users by prioritizing their needs.
Neuroscience Research findings published

DMT shows anti-inflammatory effects on microglia

Direct anti-inflammatory actions of N,N-dimethyltryptamine on microglia are revealed by proteomic profiling and receptor pharmacology
Why it matters ▲ Favorable
This study reveals the anti-inflammatory actions of DMT on microglia, highlighting its potential as a therapeutic candidate for ischemic stroke. By elucidating the receptor mechanisms involved, the research supports the clinical translation of DMT for stroke treatment, marking a significant step in understanding its neuroprotective effects.
N,N-dimethyltryptamine (DMT) is an endogenous psychedelic tryptamine that has recently emerged as a promising therapeutic candidate for acute ischemic stroke. Although DMT consistently reduces infarct size, attenuates neuroinflammation, and improves functional outcome in experimental stroke, the cellular and receptor mechanisms underlying these effects remain poorly understood. Primary rat microglial cultures were used to examine the direct anti-inflammatory effects of DMT following lipopolysaccharide (LPS)-induced activation. Microglial morphology, phagocytosis, and proteomic alterations were analyzed. Radioligand binding assays determined the affinity of DMT for microglial sigma-1 receptors (Sig-1Rs). Pharmacological inhibition of Sig-1Rs and serotonin (5-HT) receptors was performed to define receptor-specific mechanisms. Translational relevance was evaluated in acute mouse brain slices subjected to mild oxygem-glucose deprivation (mOGD) and anoxic episodes, where microglial activation, spreading depolarizations (SDs), and neuronal injury were assessed. DMT directly suppressed LPS-induced microglial activation, promoted a homeostatic morphology, and reduced phagocytic activity. Proteomic profiling demonstrated that DMT selectively reprogrammed inflammatory pathways by suppressing proteins involved in cytokine and chemokine signaling and oxidative stress while largely preserving arachidonic acid-prostaglandin synthesis. DMT bound microglial Sig-1Rs with micromolar affinity comparable to that reported in whole-brain preparations. Pharmacological inhibition revealed that DMT-induced morphological reprogramming required both Sig-1R and serotonergic signaling, whereas suppression of phagocytosis was largely independent of either receptor pathway. In acute brain slices, DMT attenuated microglial activation, reduced SD propagation and ischemic neuronal injury, and tissue-level neuroprotection depended on serotonergic signaling. DMT directly targets microglia and selectively remodels inflammatory states rather than broadly suppressing microglial activation. The receptor mechanisms underlying its actions are context dependent, with Sig-1R and serotonergic signaling contributing differentially according to the cellular response and experimental model. These findings provide mechanistic insight into the neuroprotective actions of DMT and support its ongoing clinical translation as a potential therapy for ischemic stroke.
Clinical research Published study

Survey: Psychedelic use and executive function in university students

Effects of naturalistic psychedelic use on executive functioning: An online survey of lifetime history and recent use in university students.
Why it matters ◈ Mixed
This study uses self-reported survey data to examine the relationship between lifetime and recent naturalistic psychedelic use and executive functioning among university students. While the findings may inform future clinical research design and public health messaging, the observational nature and reliance on self-report limit direct policy or regulatory impact. The results could help identify cognitive domains for further controlled trials and may shape harm reduction or education efforts on campuses.
Clinical research Research overview

Psychedelics in psychiatry: promise vs. translation

Psychedelics in psychiatry: from promise to translation
Why it matters ◈ Mixed
The article highlights the potential of psychedelics in psychiatric treatment but underscores that clinical translation is still premature. Advances in mechanistic studies, clinical implementation, regulatory governance, and public discourse are needed to realize this potential. This reflects ongoing challenges in the field that researchers and policymakers must address.
Psychedelics hold promise for psychiatry, yet clinical translation remains premature. Addressing the challenges of psychedelics in psychiatry requires advances in mechanistic study, clinical implementation, regulatory governance and public discourse in parallel.
Clinical research Trial protocol announced

Trial on Menstrual Cycle Effects of Psilocybin

An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.
Why it matters ▲ Favorable
This trial addresses a significant gap in psychedelic research by exploring the effects of the menstrual cycle on psilocybin response. By considering hormonal fluctuations, the study aims to enhance the safety and efficacy of psilocybin treatments for menstruating individuals. The findings could lead to more tailored serotonergic treatments for mood disorders linked to menstrual cycles and improve future trial designs.
BACKGROUND: Research on the therapeutic benefits of psychedelics, particularly psilocybin, is becoming increasingly popular. Unfortunately, most psychedelic research overlooks the menstrual cycle as a biological variable, raising concerns about the safety and efficacy of findings for individuals who menstruate. Given the established effects of estradiol and progesterone (and metabolites) on serotonin receptor density and function, it is plausible that the subjective experience, efficacy, and side effect profile of psychedelics may vary significantly across the different phases of the menstrual cycle. Furthermore, the tolerance effects of psilocybin when taken on consecutive days are unknown. AIMS: The PsiMenis trial will comprises two sub-studies: PsiMen-M, which will assess the potential for the menstrual cycle to affect the response to low-dose psilocybin in healthy menstruating persons, and PsiMen-T, which will test for potential tolerance effects. METHODOLOGY: Psilocybin (5 mg) will be administered during different menstrual cycle phases in 21 healthy participants for PsiMen-M, and 12 for PsiMen-T. Effects on subjective experience, brain/cognitive function, and pharmacokinetics will be measured by the Drug Effects Questionnaire, exploratory task-based electroencephalography (EEG), and blood plasma sampling. Safety and any clinically significant modifications of psilocybin will be monitored by laboratory and vital signs tests. Tolerance to psilocybin will be assessed by administering the drug for three consecutive days. CONCLUSIONS/SIGNIFICANCE: This study will determine whether low-dose psilocybin effects vary across the menstrual cycle, addressing a key gap in psychedelic research. Findings may inform the development of serotonergic treatments for menstrual-cycle-related mood disorders and improve the design of future psychedelic trials by accounting for hormonal fluctuations.
Neuroscience Research announced

AMPA receptor PET study in psychiatric disorders

Visualizing diagnosis-associated AMPA receptor-related [11C]K-2 PET SUVR patterns across psychiatric disorders using weakly supervised UMAP
Why it matters ◈ Mixed
This study explores the use of [11C]K-2 PET imaging to visualize AMPA receptor-related patterns across various psychiatric disorders. The findings suggest potential diagnostic organization but highlight that this method is not suitable for individual diagnosis. This research could inform future studies on the neurobiological underpinnings of psychiatric conditions and the role of AMPA receptors.
AMPA receptors (AMPARs) mediate fast excitatory neurotransmission and play a central role in synaptic function, with accumulating evidence in psychiatric disorders. Using [ 11 C]K-2 PET to assess AMPAR-related signals in vivo, we examined whether regional standardized uptake value ratio (SUVR) patterns show diagnosis-aligned neighborhood organization beyond label-permutation chance. We analyzed the 219-participant cohort previously reported by Hatano et al., comprising healthy controls and individuals with autism spectrum disorder, bipolar disorder, major depressive disorder, or schizophrenia. Data were parcellated into 75-dimensional SUVR vectors using white-matter (WM) referencing (SUVR-WM) or whole-brain normalization (SUVR-WB). Uniform Manifold Approximation and Projection (UMAP) was applied unsupervised and with minimal supervision. Weakly supervised embeddings were compared with 1000 label-permuted embeddings using Calinski–Harabasz Index, Davies–Bouldin Index, and Silhouette scores with Bonferroni correction. Covariate associations were visualized. With minimal supervision, SUVR-WB produced diagnosis-aligned organization among the five groups and large improvements over permuted-label embeddings. SUVR-WM formed a horseshoe manifold aligned with mean SUVR-WM and age, with limited diagnostic clustering; age/sex residualization did not alter this geometry. These exploratory findings suggest that multiregional [ 11 C]K-2 PET SUVR patterns show diagnosis-associated organization within a transdiagnostic sample, while emphasizing that normalization critically shapes visualization and that this approach is not an individual diagnostic test.
Neuroscience Review published

Glutamate modulation in MS: narrative review

Modulating glutamate neurotransmission in in vivo models of Multiple Sclerosis: a narrative review
Why it matters ◈ Mixed
This review highlights the potential of targeting glutamatergic signaling pathways in multiple sclerosis (MS) models, suggesting that these pathways could be viable therapeutic targets. However, the translational gap remains significant, as clinical trials of repurposed glutamatergic drugs have not shown disease-modifying effects in MS patients. This underscores the need for further research to bridge preclinical findings with clinical outcomes.
Glutamate (Glu), the primary excitatory neurotransmitter of the central and peripheral nervous systems, plays essential roles in cognition, synaptic plasticity, and immune modulation. Its dysregulation is increasingly recognized as a component of neuroinflammation and neurodegeneration in multiple sclerosis (MS). In MS and its principal experimental model, experimental autoimmune encephalomyelitis (EAE), impaired Glu homeostasis leads to excitotoxicity, calcium overload, and oxidative damage, compounded by proinflammatory mediators such as TNF-α. This makes glutamatergic receptors, transporters, and related signaling pathways candidate therapeutic targets that warrant systematic preclinical evaluation. To assess the preclinical evidence base for agents targeting these pathways, we conducted a systematic literature search, we conducted a systematic literature search and comparatively assessed published in vivo studies examining the effects of glutamatergic agents in EAE models, applying predefined inclusion and exclusion criteria Across the reviewed EAE studies, glutamatergic agents were frequently reported to delay disease onset, alleviate clinical symptoms, attenuate neuroinflammation, and reduce demyelination, although effect sizes and reproducibility varied across models, dosing regimens and treatment timing. Collectively, these data indicate that pharmacological modulation of glutamatergic signaling can engage multiple facets of EAE pathophysiology. However, completed clinical trials of repurposed glutamatergic drugs (riluzole, amantadine, memantine, lamotrigine) have so far failed to demonstrate disease-modifying efficacy in MS, underscoring a marked translational gap.
Neuroscience Research published

Sex-sensitive serotonergic signaling in psychedelics

Sex-sensitive serotonergic signaling in psychedelic pharmacology.
Why it matters ◈ Mixed
This study highlights the importance of considering sex differences in serotonergic signaling when researching psychedelic pharmacology. Understanding these differences could lead to more personalized and effective treatments. This is crucial for clinicians and researchers aiming to optimize therapeutic outcomes and minimize adverse effects in diverse populations.
Neuroscience Framework announced

QuNex introduces reproducible neuroimaging workflows

QuNex recipes
Why it matters ▲ Favorable
The introduction of QuNex recipes offers a significant advancement in the standardization and reproducibility of neuroimaging workflows. This framework enables researchers to document and share their neuroimaging processes in a transparent and replicable manner. This development is particularly relevant for the psychedelic research community, where precise imaging data is crucial for understanding the effects of these substances on the brain.
Preprocessing and analysis of neuroimaging data are technically demanding, often requiring a combination of multiple software tools, modality-specific pipelines, and extensive parameter tuning to match dataset characteristics. These complexities make it difficult to document workflows in sufficient detail to ensure complete transparency and reproducibility. To address these challenges, we introduce QuNex recipes, a framework for defining and executing complete neuroimaging workflows—encompassing data onboarding, preprocessing, and analysis—in a transparent, machine- and human-readable format. Recipes are implemented as an integrated feature of the Quantitative Neuroimaging Environment & Toolbox (QuNex), a containerized, open-source platform for end-to-end multimodal and multi-species neuroimaging processing. The recipes framework enables seamless integration of QuNex commands with custom scripts and external tools, capturing every processing step and parameter setting. A fully reproducible study can thus be shared and replicated by providing only (a) the QuNex version used, (b) the recipe file, and (c) the data. This approach standardizes workflow specification, enhances transparency, and enables one-command replication of complex neuroimaging analyses. By providing a standardized way to describe and share workflows, recipes facilitate open exchange of best practices and reproducible methods within the neuroimaging community.
Clinical research Peer-reviewed study

Outcome measures affect ketamine trial results in depression

Discordant signals: How outcome measurement shapes interpretation of ketamine response in treatment-resistant depression.
Why it matters ◈ Mixed
This study highlights that the choice of outcome measurement tools can significantly alter the interpretation of ketamine's efficacy in treatment-resistant depression. For researchers, this underscores the need for harmonized, validated endpoints in psychedelic trials to ensure comparability and regulatory acceptance. Policy makers and clinicians should be aware that discordant results may reflect methodological differences rather than true clinical uncertainty, affecting both guideline development and payer decisions.
Clinical research Study published

Study on cotherapy in psilocybin therapy for GAD

‘So many relationships in the room’: Participant perspectives on the affordances and challenges of co‐therapy in psychedelic assisted therapy
Why it matters ▲ Favorable
This study provides valuable insights into the dynamics of cotherapy in psychedelic-assisted therapy, specifically with psilocybin for Generalised Anxiety Disorder. The findings highlight the dual role of cotherapy in enhancing safety and therapeutic processes, which could inform clinical practice and future research design. Understanding these dynamics is crucial for optimizing therapeutic outcomes and addressing feasibility and accessibility in broader clinical applications.
OBJECTIVES: Psychedelic-assisted therapy (PAT) frequently utilises a "cotherapy" model, in which two therapists jointly support participants throughout dosing and psychotherapy sessions. While common in clinical trials, participant experiences of cotherapy remain underexplored. This study explored cotherapy experiences in PAT with psilocybin for Generalised Anxiety Disorder (GAD). DESIGN: Longitudinal qualitative analysis of participants sampled from a large randomised, open-label, phase 2 clinical trial of psilocybin-assisted therapy for GAD, delivered by clinicians with high levels of qualification, training and supervision. METHODS: Qualitative data were collected from n = 18 participants via 29 semi-structured interviews, conducted before and after dosing sessions. Interviews examined experiences of PAT with a cotherapy dyad. Data were analysed thematically, guided by Affordance Theory to consider how cotherapy dynamics shaped therapeutic possibilities. RESULTS: Three major themes were developed: (1) dose day cotherapy: safety, trust and the realities of access; (2) cotherapy influences therapeutic processes; and (3) cotherapy shapes the impact and credibility of therapeutic insights. CONCLUSIONS: Cotherapy in PAT can be both a safety and supportive measure, and a potentiator of therapeutic processes. Insights from this study can guide clinical practice and future research to harness the potential safety and therapeutic benefits afforded by cotherapy while considering feasibility and accessibility.
Clinical research Research review

Propofol's potential in treating depression explored

Propofol for depression: mechanisms and therapeutic potential
Why it matters ◈ Mixed
This review highlights the potential of propofol, a common anesthetic, as a therapeutic agent for depression and anxiety, focusing on its rapid mood-elevating effects. While preliminary evidence is promising, the lack of large controlled trials limits its immediate clinical application. Propofol's distinct mechanism compared to ketamine could offer new avenues for treatment-resistant depression. However, challenges such as dosing, tolerance, and safety need addressing.
Propofol, one of the most widely used intravenous anesthetics, is undergoing a transformative identity shift from a purely surgical agent to a potential therapeutic tool for neuropsychiatric disorders. This review synthesizes current evidence on the emerging field of propofol therapeutics, with a focus on its rapid antidepressant, anti-anhedonia, and anxiolytic effects. We first examine preliminary clinical evidence from open-label studies suggesting that propofol may produce dose-dependent mood-elevating effects in treatment-resistant depression; however, this evidence remains limited by small sample sizes and lack of large controlled trials. Next, we explore putative mechanisms, including GABA A receptor modulation, dopamine transporter inhibition, BDNF/TrkB signaling, and network-level reorganization of the default mode network and sleep architecture. We then compare propofol with other anesthetic agents possessing antidepressant properties, particularly ketamine, highlighting their distinct receptor targets, efficacy profiles, and safety considerations. Finally, we discuss major challenges including optimal dosing strategies, tolerance with repeated administration, long-term safety concerns, and implementation barriers. Despite these challenges, propofol represents a promising candidate for anesthetic repurposing in psychiatry, offering a mechanistically distinct alternative to ketamine that targets both GABAergic and dopaminergic systems with a well-established clinical safety profile for surgical anesthesia.
Clinical research Trial protocol published

Trial to Study Menstrual Cycle Effects on Low-Dose Psilocybin Tolerance

An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.
Why it matters ▲ Favorable
This open-label trial protocol aims to systematically study how the menstrual cycle may affect tolerance and response to low-dose psilocybin in healthy menstruating individuals. The research addresses a significant gap in sex-specific and hormonal influences on psychedelic pharmacology, which could inform future trial design, dosing guidelines, and safety considerations. While not immediately practice-changing, the study highlights the field's growing attention to personalized and inclusive research.
Clinical research Clinical research ongoing

Ketamine's role in preventing postoperative delirium in elderly

The prevention and treatment of postoperative delirium in elderly patients with ketamine
Why it matters ◈ Mixed
This research highlights esketamine's potential in reducing postoperative delirium (POD) in elderly patients by protecting blood-brain barrier integrity and reducing neuroinflammation. The findings suggest a promising avenue for perioperative brain protection strategies, though further research is needed to establish standardized protocols and understand the distinct mechanisms of action. This could influence future clinical practices and improve outcomes for a vulnerable patient population.
Elderly surgical populations are highly susceptible to Postoperative Delirium (POD), whose core pathological drivers consist of neuroinflammation and impaired Blood-Brain Barrier (BBB) function. Characterized by prominent lipophilicity, esketamine is capable of fast trans-BBB transportation. This agent exerts protective effects on BBB integrity via blocking NMDA receptors, which further suppresses the activation of the TLR4/NF-κB signaling cascade and limits the secretion of pro-inflammatory mediators. Multiple clinical observations have verified that low-dose esketamine administered either at anesthetic induction or as an isolated intraoperative bolus lowers POD risks among seniors receiving orthopedic or abdominal operations. This pharmacological intervention presents favorable safety profiles: it does not raise the likelihood of mental adverse events, while mitigating perioperative side effects including hypotension, emesis and nausea. Nevertheless, current relevant research still carries prominent limitations such as insufficient sample sizes and inconsistent diagnostic standards for POD. Two critical unresolved questions remain in this field: the establishment of standardized optimal administration protocols, as well as whether esketamine's anti-inflammatory properties function separately from its analgesic potency. Integrating the above pharmacological mechanisms and clinical data can provide the basis for shifting perioperative brain protection strategies toward mechanism‑targeted intervention.
Clinical research FDA engagement ongoing

MAPS reports MDMA therapy progress with FDA

MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
Why it matters ▲ Favorable
The Multidisciplinary Association for Psychedelic Studies (MAPS) has reported progress in its discussions with the FDA regarding MDMA-assisted therapy for PTSD. This development could significantly impact the approval process and future availability of MDMA therapy for PTSD patients. The engagement with the FDA suggests potential advancements in regulatory acceptance, which could pave the way for broader clinical use and market entry.
Neuroscience Review published

Neuroinflammation in MDD: Mechanisms and Therapeutic Targets

Neuroinflammation in major depressive disorder: Mechanisms, biomarkers, and emerging therapeutic targets
Why it matters ▲ Favorable
This review highlights the role of neuroinflammation in a subset of major depressive disorder (MDD) patients, suggesting that it could be a biologically distinct subtype. Targeting neuroinflammation with biomarker-guided therapies may offer personalized treatment options for patients with treatment-resistant depression. This could significantly impact future research directions and therapeutic strategies in psychiatric care.
Major depressive disorder (MDD) affects an estimated 280 million people worldwide and remains a leading cause of disability. The monoamine hypothesis, and later the neuroplasticity hypothesis, transformed treatment but leave a substantial share of patients with delayed response, partial remission, or outright treatment resistance. Over the past two decades, evidence has accumulated that a subset of MDD is driven by chronic, low-grade neuroinflammation rather than, or in addition to, monoaminergic deficits. This review synthesizes current evidence on the neuroimmune mechanisms involved in MDD microglial activation, pro-inflammatory cytokine signaling, blood–brain barrier disruption, oxidative stress, kynurenine pathway dysregulation, and impaired neuroplasticity and examines how these mechanisms are captured by peripheral, central, neuroimaging, and emerging molecular biomarkers. It then reviews therapeutic strategies that target inflammation directly (minocycline, celecoxib, TNF-α antagonists), indirectly (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), ketamine), or through lifestyle modification (exercise, diet, sleep), with attention to why inflammation-stratified trials have outperformed unstratified ones. Across mechanisms, biomarkers, and treatment response, a consistent pattern emerges: neuroinflammation does not simply co-occur with depression, it may mark a biologically distinct, identifiable subtype roughly a quarter to a third of patients with elevated high-sensitivity C-reactive protein (hsCRP) or IL-6 for whom anti-inflammatory or immune-modulating strategies produce disproportionate benefit. Overall, the findings suggest that neuroinflammation represents a promising and increasingly actionable target for biomarker-guided, personalized psychiatric care.
Neuroscience Peer-reviewed study published

EEG and network effects of ketamine mapped across dose continuum

Ketamine Across the Dose-State Continuum: EEG Signatures, Network Dynamics, and Implications for Brain-State Monitoring in Anesthesia and Critical Care.
Why it matters ▲ Favorable
This study provides detailed EEG and network dynamics data on ketamine across a range of doses, offering new biomarkers for brain-state monitoring in anesthesia and critical care. The findings may inform safer clinical protocols, dosing strategies, and future research on ketamine's therapeutic and adverse effects. For policy and regulatory bodies, such mechanistic insights support evidence-based guidelines for ketamine use in both medical and psychiatric contexts.
Clinical research Study published

Ketamine may improve ovarian function in depression model

Ketamine improves ovarian function and oocyte quality in CORT-induced depression mouse model by ferroptosis pathway
Why it matters ▲ Favorable
This study provides evidence that ketamine, beyond its antidepressant effects, may improve ovarian function and oocyte quality in a mouse model of depression. The findings suggest a novel therapeutic potential for ketamine in addressing reproductive health issues linked to depression. This could open new avenues for research into the intersection of mental health and reproductive health.
Abstract Depression is a common psychiatric disorder, with a higher prevalence in women than in men, and has been increasingly associated with disturbances in female reproductive health. In particular, depressive conditions may impair ovarian function and compromise oocyte quality, thereby contributing to reproductive disorders. Ketamine is a clinically effective antidepressant. However, its potential role in improving depression-induced female reproductive disorders remains unclear. In the present study, a corticosterone (CORT)-induced mouse model of depression was used to evaluate whether ketamine could ameliorate ovarian dysfunction and oocyte impairment. Ketamine treatment significantly improved depressive-like behaviors and partially reversed abnormalities in ovarian function and oocyte quality. Metabolomics and single-cell transcriptomics analyses suggested that ketamine may enhance oocyte quality in depressive mice through the regulation of ferroptosis. Our findings confirmed that ketamine ameliorated alterations in ROS, Fe 2+ , glutathione (GSH), and lipid peroxidation levels in oocytes, reduced ovarian mitochondrial abnormalities, and regulated the ferroptosis-related proteins GPX4, FTH1, and FTL in ovarian tissues. In conclusion, ketamine alleviates depression-associated ovarian dysfunction and oocyte impairment, potentially through modulation of ferroptotic signaling, offering new insights linking mental disorders to female reproductive health.
Clinical research Study published

Psilocybin shows promise for phantom limb pain

Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.
Why it matters ▲ Favorable
The study explores the feasibility and tolerability of psilocybin as a treatment for phantom limb pain, a condition with limited effective therapies. This research could pave the way for new therapeutic applications of psychedelics beyond mental health disorders. It highlights the potential for psilocybin to address complex pain conditions, which may influence future clinical trials and regulatory considerations.
Clinical research Systematic review published

CEM linked to PTSD/CPTSD: Systematic review

Childhood emotional maltreatment and trauma-related outcomes: a systematic review and multilevel meta-analysis
Why it matters ◈ Mixed
This systematic review and meta-analysis highlights a positive association between childhood emotional maltreatment (CEM) and trauma-related outcomes like PTSD and CPTSD. Understanding these associations is crucial for developing targeted interventions and prevention strategies in clinical settings. The study emphasizes the need for systematic assessment of CEM, though it notes limitations such as reliance on self-reported data and cross-sectional designs.
Background: Estimating the association between childhood emotional maltreatment (CEM) and trauma-related outcomes is important for prevention and intervention.Objective: We synthesised the evidence by differentiating between emotional abuse and emotional neglect, examining post-traumatic stress disorder (PTSD) and complex PTSD (CPTSD) and exploring moderators and mediators.Method: Following PRISMA guidelines, seven databases were searched up to 19/03/2026 (PROSPERO-CRD42024598358) for studies on the association between CEM and PTSD/CPTSD. Study quality was assessed using an adapted Newcastle-Ottawa Scale (NOS), and certainty of evidence was evaluated using the GRADE framework.Results: Of 11,479 records, 62 were included in the review, of which 57 studies provided 132 effect sizes for a random-effects multilevel meta-analysis (N = 323,776). Study quality was overall fair (Mean NOS = 5.8). A positive association between CEM and PTSD/CPTSD (k = 132, r = .27, 95% CI [.23, .30]) 95% PI [−.04, .53] with substantial heterogeneity (I² = 86.5%). Higher estimates were identified for emotional abuse (k = 71, r = .29, 95% CI [.25, .33]) compared to emotional neglect (k = 55, r = .24, 95% CI [.19, .28]). Effect sizes were similar for CPTSD (k = 29, r = .29, 95% CI [.24, .35]) and PTSD (k = 103, r = .26, 95% CI [.22, .30]). No differences were observed by sex, age, or population type (clinical vs. non-clinical). However, higher estimates were identified in high-income settings and more developed contexts. Narrative synthesis identified cognitive, affective, physiological and interpersonal mechanisms as potential mediators. The certainty of the evidence was generally low. Limitations include the predominance of cross-sectional designs, reliance on self-report measures of CEM and variability across outcome measures.Conclusions: These findings underscore the importance of CEM in trauma-related symptomatology and support the need for its systematic assessment in clinical and research settings, particularly by highlighting differences between emotional abuse and emotional neglect.
Clinical research Study published

Rural Drug Treatment Challenges in Australia

Practice Challenges and Research Directions in Rural Drug and Alcohol Treatment: A Focus Group Study of Clinician Perspectives
Why it matters ◈ Mixed
This study highlights significant barriers in rural drug and alcohol treatment in Australia, such as fragmented services and workforce shortages. Research priorities include integrated care models and culturally responsive services. These insights are crucial for tailoring interventions and improving access to care in underserved areas.
INTRODUCTION: Substance use and related mental illness contribute substantially to Australia's disease burden, with disproportionately high impacts in rural areas where access to specialist care is limited. Understanding local service challenges is critical to improving care delivery and guiding contextually relevant research. The aims of this study were to identify: (i) practice challenges; (ii) practice improvement priorities; and (iii) research priorities among rural drug and alcohol clinicians in Western NSW Local Health District. METHODS: A pragmatic qualitative study was conducted using structured focus groups informed by a modified Delphi approach. Three focus groups (two in-person, one online) were held with 16 clinicians from diverse drug and alcohol programs. Discussions were guided by regional treatment data and a clinician workforce survey. Data were audio-recorded, transcribed and analysed using deductive qualitative content analysis, with findings validated through participant member checking. RESULTS: Four themes were identified. Service gaps and access barriers included fragmented mental health and drug and alcohol systems, transport limitations, stigma and cultural safety concerns for Aboriginal clients. Workforce and training needs reflected staff shortages, limited preparation for integrated care and insufficient support for vicarious trauma. Technology and innovation were viewed as promising, particularly telehealth, but were constrained by cost, policy and implementation uncertainty. Research priorities focused on developing and evaluating integrated care models, virtual and brief interventions, culturally responsive services, workforce wellbeing and social determinants including housing, transport and stigma. DISCUSSION AND CONCLUSIONS: Persistent structural and workforce challenges shape rural service delivery. Addressing these requires pragmatic, locally grounded research and stronger partnerships between health services and universities to support implementation of context-specific solutions.
Clinical research Ongoing research

Psilocybin shows potential for cluster headache relief

A Novel Therapeutic Approach to Improving Quality of Life and Performance in Athletes and Other Patients with Cluster Headache
Why it matters ◈ Mixed
This narrative review highlights the potential of psilocybin as a treatment for cluster headaches, a condition with limited effective therapies. While preliminary studies suggest therapeutic benefits, the evidence is not yet conclusive, emphasizing the need for well-designed randomized controlled trials. This could pave the way for new treatment paradigms in headache disorders, impacting patient care and research directions.
Background: Cluster headache is a severely disabling headache disorder. Despite the availability of acute and preventive therapies, treatment efficacy remains incomplete, leaving many athletes and other patients with insufficient symptom control leading to decreased quality of life and performance. Increasing interest has emerged in psychedelic compounds, particularly psilocybin, as potential therapeutic agents. Aim: This narrative review aimed to evaluate the current evidence regarding psilocybin in the treatment of cluster headache. Material and Methods: A literature search was conducted in the MEDLINE database to identify publications describing psilocybin use in cluster headache. Eight relevant publications were identified. Results: Clinical evidence remains limited but suggests potential therapeutic benefit. A randomized placebo-controlled trial demonstrated numerically higher response rates with psilocybin compared to placebo, although statistical significance was not achieved. An open-label study reported a mean reduction in attack frequency and identified changes in hypothalamic–diencephalic functional connectivity associated with clinical improvement. Observational studies consistently reported high patient-perceived efficacy for both abortive and preventive use, often exceeding satisfaction reported with conventional therapies. However, interpretation is limited by methodological constraints. Available data suggest a generally favorable safety profile, though psychological adverse effects may occur and long-term safety remains uncertain. Conclusions: Current evidence indicates a signal of therapeutic potential for psilocybin in cluster headache, particularly in preventive treatment, but remains insufficient for definitive clinical conclusions. Well-designed randomized controlled trials with standardized protocols are urgently needed to clarify efficacy, safety, and optimal therapeutic frameworks.
Clinical research Systematic review published

Ketamine vs Pregabalin in Spinal Fusion Pain Management

Comparison of Ketamine and Pregabalin on Postoperative Opioid Usage and Pain Management in Spinal Fusion: Systematic Review and Network Meta-analysis.
Why it matters ◈ Mixed
This systematic review and network meta-analysis compares the effects of ketamine and pregabalin on postoperative opioid usage and pain management in spinal fusion surgeries. The findings could influence clinical guidelines on pain management strategies, potentially reducing opioid dependency. However, further research is needed to confirm these results and assess long-term outcomes.
Clinical research Trial expansion

Psilocybin trial expands for complex mental health cases

Advanced research eyes potential of psychedelics for complex cases
Why it matters ▲ Favorable
The expansion of a psilocybin trial in Connecticut to include a broader population beyond military veterans, first responders, and health care workers indicates promising early results. This development could significantly impact treatment options for complex mental health conditions. It underscores the growing interest and potential of psychedelics in mental health treatment.
A team of researchers in Connecticut is advancing inquiry into the potential of psychedelics in mental health treatment through an ongoing study involving patients with complex conditions. A psilocybin trial that initially recruited military veterans, first responders and health care workers has shown promising results and is being expanded to include a broader population.
Clinical research Phase 1 readout

Psilocybin's Impact on Motor Function: Phase 1 Study

Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study
Why it matters ◈ Mixed
This Phase 1 study explores the safety and feasibility of psilocybin in motor function tasks, which could inform future psychedelic-assisted physical therapy. The study found that movement tasks were feasible with psilocybin doses up to 15 mg, with no serious adverse events reported. However, higher doses led to increased adverse events like nausea and headache, and altered conscious states, highlighting the need for careful dose management in therapeutic settings.
BACKGROUND: Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers. METHODS: Healthy adult participants were randomly assigned three psilocybin doses consisting of either (1) 5 mg, 10 mg and 15 mg or (2) 10 mg, 15 mg and 20 mg, with at least 1 week between doses. Movement tasks were administered at 1.5 h, 3 h and 4.5 h post-dose. Participants, physiotherapists and statisticians were blinded to the dosing order. Feasibility was assessed by evaluating completion of the de Morton Mobility Index and Functional Movement Exploration (assessing gross motor function). Safety outcomes included vital signs and adverse events. Additional exploratory motor outcomes included the Action Research Arm Test (assessing upper limb functional performance), Box and Block Test (Original and Modified versions) (combining dexterity with motor speed), Digit Symbol Substitution Test (combining motor speed with intellectual functions) and Reaction Time Ruler Drop Test (assessing reaction time). Alterations in conscious states and blinding efficacy were also assessed. Outcomes were summarised descriptively and with post hoc linear mixed-effects modelling performed to explore dose- and time-related effects. RESULTS: A total of 13 participants (62% male) were enrolled, with a median age of 33 years (range 22-39 years), median height of 177 cm (155-188 cm) and median weight of 74 kg (51-94 kg). One participant was unable to complete several movement tasks at 20 mg. Nausea (n = 8, 62%) and headache (n = 7, 54%) were the most common adverse events. No serious adverse events or adverse events related to movement task administration occurred. Median values [interquartile ranges] remained near-perfect for the de Morton Mobility Index (92.5-100.0 [85.0-100.0]), Functional Movement Exploration (100.0 [96.0-100.0]) and Action Research Arm Test (56.0-57.0 [52.0-57.0]). Baseline Box and Block Test (Original) median scores (65.0 [60.0-67.0]) improved to 79.0 [70.0-83.0] at 5 mg and 4.5 h post-dose (5 mg-4.5 h), and worsened to 57.5 [51.0-64.0] at 20 mg-1.5 h. Baseline Box and Block Test (Modified) median scores (48.0 [47.0-53.0]) worsened to 43.0 [35.0-45.0] at 20 mg-1.5 h. Baseline Digit Symbol Substitution Test median scores (73.0 [66.0-77.0]) improved to 87.0 [81.0-90.0] at 10 mg-4.5 h, and worsened to 62.0 [54.0-86.0] at 20 mg-1.5 h. Reaction Time Ruler Drop Test scores lacked consistent dose-related changes. Alterations in conscious states were greatest at 20 mg. Participants and physiotherapists correctly guessed the administered dose 53% and 50% of the time, respectively. CONCLUSIONS: Movement tasks were feasible during psilocybin dosing up to 15 mg. No significant safety concerns related to movement task participation during the acute drug effects were observed. At 20 mg, impairments were observed in movement tasks that combined motor and additional cognitive functions. These findings inform future studies utilising psilocybin-assisted physical rehabilitation in clinical populations. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12621000560897. Date registered: 12 May 2021.
Clinical research Study results announced

Study: DXM/BUP not linked to diabetes risk

Association Between Dextromethorphan/Bupropion with Diabetes Mellitus and Hyperglycemia: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
Why it matters ◈ Mixed
This study investigates the potential metabolic side effects of the antidepressant combination dextromethorphan/bupropion (DXM/BUP) using FDA's adverse event reporting data. The findings indicate no significant association between DXM/BUP and increased risk of diabetes mellitus or hyperglycemia. This is relevant for clinicians prescribing DXM/BUP, as it addresses concerns about metabolic side effects, contributing to informed decision-making in patient care.
IntroductionDextromethorphan/bupropion (DXM/BUP) is the first orally administered antidepressant approved by the United States Food and Drug Administration (U.S. FDA) that combines dextromethorphan (i.e., a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist) and bupropion (i.e., a CYP2D6 inhibitor and antidepressant).DXM/BUP was FDA-approved for the treatment of Major Depressive Disorder (MDD) in adults in August 2022.Select psychotropic agents prescribed for MDD are known to alter glucose and insulin homeostasis.Herein, we sought to determine, using pharmacovigilance data, whether disproportionate reporting of diabetes mellitus or hyperglycemia associated with DXM/BUP has occurred. Research Designs and MethodsThis exploratory report investigated the association between DXM/BUP and the reporting of metabolic adverse events (i.e., hyperglycemia and diabetes mellitus).Disproportionality analyses were conducted using reporting odds ratios (RORs), with DXM/BUP and comparator agents evaluated relative to a reference comparator (acetaminophen).Data were obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) from year of approval to April 26, 2026.A sensitivity analysis was performed on a restricted dataset obtained from FAERS from January 1, 2022, to April 30, 2026.Statistical significance was defined as a 95% confidence interval (CI) excluding 1.0. Results DXM/BUP was not associated with disproportionate reporting of diabetes mellitus (ROR = 0.33, 95% CI [0.07, 1.65], p = 0.18) and hyperglycemia (ROR = 0.10, 95% CI [0.01, 1.67], p = 0.11)
Clinical research Review published

Review on treatment-resistant depression strategies

DEPRESSÃO RESISTENTE AO TRATAMENTO: QUANDO ESCALAR A TERAPIA E REPENSAR O DIAGNÓSTICO
Why it matters ◈ Mixed
This narrative review critically examines treatment-resistant depression, focusing on when to intensify therapy and reassess diagnoses. It highlights the importance of distinguishing true resistance from pseudoresistance due to factors like inadequate dosage or non-adherence. The review suggests a decision algorithm and discusses rapid-action interventions like intranasal esketamine versus intravenous racemic ketamine. This is relevant for clinicians and researchers in optimizing treatment strategies and understanding the nuances of diagnosis and therapy escalation.
A ausência de remissão após ensaios antidepressivos sucessivos é desfecho frequente no transtorno depressivo maior e costuma ser rotulada como depressão resistente ao tratamento, categoria que reúne situações clínicas heterogêneas e nem sempre equivalentes. Esta revisão narrativa crítica teve por objetivo discutir dois movimentos decisórios diante da resposta insuficiente: quando intensificar a terapêutica e quando suspeitar de diagnóstico incorreto ou incompleto. A partir de literatura recuperada em bases biomédicas e em diretrizes recentes, examinam-se os limites conceituais da resistência e os modelos de estadiamento, a necessidade de afastar a pseudorresistência decorrente de dose insuficiente, tempo inadequado e baixa adesão, e a reavaliação diagnóstica com atenção à bipolaridade não reconhecida, às comorbidades e às condições clínicas que mimetizam depressão. Propõe-se um algoritmo de decisão por cenário clínico e discutem-se as estratégias de escalonamento e as intervenções de ação rápida e somáticas, distinguindo a escetamina intranasal da cetamina racêmica intravenosa. Conclui-se que a decisão de escalar só é racional depois de reconfirmados o diagnóstico e a adequação do tratamento, ressalvadas as situações graves que exigem intervenção rápida.
Clinical research Literature review

Psilocybin for nicotine addiction: neuropsychology review

O USO DA PSILOCIBINA EM CONTEXTO TERAPÊUTICO PARA O TRATAMENTO DA COMPULSÃO POR NICOTINA SOB A PERSPECTIVA DA NEUROPSICOLOGIA
Why it matters ▲ Favorable
This literature review highlights the potential of psilocybin-assisted therapy as an innovative treatment for nicotine addiction, emphasizing its impact on serotonin receptors and neuroplasticity. Recent clinical trials show promising results with higher abstinence rates compared to conventional treatments. Further clinical studies are needed to validate its efficacy and safety in practice.
A dependência da nicotina representa um dos principais desafios da saúde pública mundial, sendo responsável por elevadas taxas de morbimortalidade e associada ao desenvolvimento de doenças cardiovasculares, respiratórias e neoplásicas. Embora existam diferentes estratégias terapêuticas para a cessação do tabagismo, as elevadas taxas de recaída evidenciam a necessidade de novas abordagens capazes de atuar sobre os mecanismos neurobiológicos e comportamentais envolvidos na dependência química. Nesse contexto, a psilocibina, alcaloide psicodélico presente em cogumelos do gênero Psilocybe, tem despertado crescente interesse científico devido ao seu potencial terapêutico em diferentes transtornos psiquiátricos e na dependência de substâncias psicoativas. O presente estudo teve como objetivo revisar a literatura acerca do uso da psilocibina em contexto terapêutico para o tratamento da compulsão por nicotina sob a perspectiva da neuropsicologia. Trata-se de uma pesquisa bibliográfica, de caráter qualitativo, descritivo e exploratório, desenvolvida por meio de revisão narrativa da literatura, utilizando artigos científicos, livros, teses e dissertações nacionais e internacionais relacionados à temática. Os estudos analisados demonstram que a psilocibina atua predominantemente sobre receptores serotoninérgicos 5-HT2A, promovendo aumento da neuroplasticidade, reorganização funcional de circuitos cerebrais, maior flexibilidade cognitiva e modulação da Rede de Modo Padrão, mecanismos que parecem favorecer mudanças comportamentais duradouras quando associados à psicoterapia estruturada. Além disso, ensaios clínicos recentes indicam resultados promissores na cessação do tabagismo, com taxas de abstinência superiores às observadas em tratamentos convencionais. Conclui-se que a psicoterapia assistida por psilocibina constitui uma estratégia terapêutica inovadora e potencialmente eficaz para o tratamento da dependência nicotínica, embora novos estudos clínicos sejam necessários para confirmar sua eficácia, segurança e aplicabilidade na prática clínica.
Clinical research Proposal announced

Proposal to redefine treatment-resistant schizophrenia

<i>AJP</i> authors propose broader definition of resistant schizophrenia
Why it matters ◈ Mixed
The proposal to broaden the definition of treatment-resistant schizophrenia could lead to earlier identification of patients and improved access to interventions. This change may impact clinical trials and treatment protocols by expanding the pool of eligible patients. However, the proposal's acceptance and implementation remain uncertain.
A proposal to expand the definition of treatment‐resistant schizophrenia (TRS) could help clinicians identify patients earlier and improve access to effective interventions, according to authors of new commentary published in the American Journal of Psychiatry (AJP) . The authors argue that current definitions may not fully capture the range of patients whose symptoms fail to respond adequately to antipsychotic treatment.
Neuroscience Study published

Empathy and Love in OUD Recovery

Empathy and Love as Protective Factors in Opioid Use Disorder Recovery
Why it matters ▲ Favorable
This study highlights the potential of prosocial emotions like love and empathy in reducing opioid use among individuals with opioid use disorder (OUD). These findings could inform new therapeutic approaches that integrate emotional and social support mechanisms in addiction treatment. The unexpected link between social support and increased opioid use warrants further investigation.
Opioid use disorder (OUD) is a debilitating condition that impacts multiple domains of life, including social attachment systems, which makes recovery and relapse prevention challenging. The Brain Opioid Theory of Social Attachment suggests opioids hijack mechanisms involved in love and bonding. Previous studies show that social interaction can help reduce opioid use in both animals and humans, but little is known about whether prosocial emotions like love and empathy can protect against opioid use among people treated with medications for OUD. In this cross-sectional study, data were analyzed from 189 adults receiving methadone treatment for OUD at community-based programs in New Jersey and Utah. Surveys measured opioid use, empathy, love, along with covariates including pain, anxiety, depression, social support, and stigma. Participants reported lower levels of love and empathy compared to normative samples. In zero-inflated Poisson, higher love and empathy scores were significantly associated with fewer episodes of opioid use, even after adjusting for covariates. Anxiety, pain, and social support were significant predictors, with social support unexpectedly linked to greater opioid use. Findings suggest that love and empathy can buffer against opioid use, consistent with theories that support the use of prosocial emotions that target the same pathways as opioids.
Clinical research Phase 1 readout

Phase 1 trial: Psilocybin's impact on motor function in healthy adults

Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.
Why it matters ▲ Favorable
This Phase 1, triple-blind, dose-finding study provides foundational safety and tolerability data on psilocybin's effects on motor function in healthy participants. The results inform dosing protocols and risk assessment for future clinical trials, especially those involving populations where motor impairment is a concern. This study supports regulatory and IRB review processes by addressing key safety endpoints, which is a prerequisite for broader clinical and translational research.
Clinical research Peer-reviewed publication

Ultra-low-dose ketamine reduces pain and opioid use in children

Efficacy of Ultra-low-dose Ketamine for Reducing Pain Intensity and Total Opioid Requirement in Children With Opioid-Refractory Pain.
Why it matters ▲ Favorable
This peer-reviewed study provides evidence that ultra-low-dose ketamine can reduce pain intensity and opioid requirements in pediatric patients with opioid-refractory pain. The findings support further clinical research and could influence pain management protocols, especially in settings where opioid alternatives are urgently needed. The results may also inform regulatory and hospital policy discussions about expanding ketamine's clinical use beyond anesthesia and emergency settings.
Industry Major investment announced

Lilly invests $2.8B in psychedelics for mental health

Lilly spends US$2.8 billion on psychedelic drugs for mental health.
Why it matters ▲ Favorable
Lilly's $2.8 billion investment signals a significant commitment to the development of psychedelic drugs for mental health treatment. This move could accelerate clinical trials and increase the availability of psychedelic therapies, potentially transforming treatment paradigms for conditions like depression and PTSD. It also reflects growing confidence in the commercial viability and therapeutic potential of psychedelics, likely influencing other pharmaceutical companies to explore similar investments.
Clinical research Research proposal

Well-being as primary endpoint in trials: consensus needed

Well-being as a primary endpoint in clinical trials: a call for consensus.
Why it matters ◈ Mixed
The call for consensus on using well-being as a primary endpoint in clinical trials could reshape how psychedelic therapies are evaluated. Standardizing well-being measures may enhance the comparability and validity of trial outcomes. This shift could influence regulatory approvals and the design of future studies, impacting both research methodologies and patient care strategies.
Clinical research Scoping review published

Scoping review on PAT assessment methodologies

Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review
Why it matters ◈ Mixed
This scoping review highlights the fragmented methodologies in psychedelic-assisted therapy (PAT) assessment, emphasizing the need for integrated evaluation models. It identifies advances in measurement tools and clinical frameworks but also notes significant gaps in methodological integration and safety monitoring. These findings are crucial for researchers aiming to standardize and improve PAT evaluation, impacting future clinical trials and therapeutic practices.
Introduction Psychedelic-assisted therapy (PAT) is an emerging complex intervention for psychiatric and existential conditions (i.e., forms of distress related to meaning, mortality, and identity, such as that arising in life-threatening illness); however, a systematic characterization of the evaluation methods used across the entire clinical intervention remains incomplete. This scoping review synthesizes the scientific literature on the methodologies and frameworks for evaluating PAT, covering pre-session screening, acute experience, intervention processes, post-session integration, clinical and existential outcomes, safety, and service evaluation. Methods Following PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines, we analyzed 59 peer-reviewed publications, comprising contemporary PAT literature published between 2008 and 2026 and foundational psychometric sources for established instruments used in PAT. The findings were categorized into four evaluation domains: (i) assessment instruments for subjective experiences; (ii) clinical intervention models and competency frameworks; (iii) clinical and existential outcome measures; and (iv) safety, ethics, and implementation frameworks. Results The analysis reveals a number of advances, including the development and cross-cultural adaptation of validated instruments for measuring mystical and challenging experiences. Clinical intervention frameworks emphasizing the importance of the “therapeutic container” have been articulated, and preliminary work has begun to identify core practitioner competencies. PAT has been associated with preliminary findings from controlled studies for conditions such as depression, anxiety, post-traumatic stress disorder, and existential distress, although demographic representation in trials remains limited, and methodological constraints (e.g., small samples and challenges in blinding) warrant cautious interpretation. The review also identifies gaps: methodological integration is still incomplete, with different assessment domains rarely combined into unified protocols; measures for post-session integration and existential outcomes remain undervalidated; and safety monitoring and implementation science present areas requiring standardization. Discussion This review maps the current methodological landscape, documenting areas of advancement and defining priorities for developing the integrated, multidimensional evaluation models required to advance the field.
Public health research Study published

PTSD Societal Cost Study in Dutch Veterans

Burden of PTSD in Dutch Veterans: A Societal Cost and Quality-of-Life Study
Why it matters ◈ Mixed
This study highlights the significant societal and economic burden of PTSD among Dutch veterans, emphasizing the need for targeted interventions. The findings could inform policy decisions and resource allocation for mental health services. Understanding these costs is crucial for developing effective treatment strategies and improving veterans' quality of life.
Posttraumatic stress disorder (PTSD) is associated with impaired quality of life and societal costs. Previous cost-of-illness studies on PTSD have primarily focused on direct medical costs, often overlooking productivity losses and broader health impacts. This study aims to estimate the societal burden of PTSD, including economic costs and health related quality of life (HRQoL), in Dutch military veterans by comparing those with a clinical diagnosis of PTSD (CD-PTSD) to a sample from the general veteran population (GVP). A cross-sectional design was used. The CD-PTSD group (n = 77) was recruited from clinical settings, while the GVP group (n = 70) completed an online survey. Data were collected between 2018 and 2021, and the societal costs were estimated in 2023 euros using the Treatment Inventory of Costs in Patients with psychiatric disorders (TiC-P), in accordance with economic guidelines. HRQoL was measured using the EuroQol-5-Dimensions-5-Levels (EQ-5D-5L), and PTSD symptom severity with the PTSD Checklist for DSM-5 (PCL-5). Veterans in the CD-PTSD group reported significantly higher PTSD symptom severity, higher mental healthcare utilization, lower HRQoL, and higher productivity loss compared to the GVP group. The average annual societal cost was €29,993 per person in the CD-PTSD group, with 68% attributable to productivity loss. The GVP group had an average annual cost of €7,215 per person, with 64% due to productivity loss. Veterans with PTSD bear a substantially higher societal burden than those in the general veteran population. These findings underscore the urgency of implementing targeted interventions to reduce economic costs and improve quality of life for affected veterans.
Clinical research Review published

VR in Psychiatry: Review Highlights Therapeutic Potential

APPLICATIONS OF VIRTUAL REALITY TECHNOLOGY IN PSYCHIATRY – A REVIEW
Why it matters ▲ Favorable
This review highlights the potential of virtual reality (VR) as a tool in psychiatric therapy, particularly in treating anxiety and PTSD. VR's integration with traditional methods and its high acceptability could enhance therapeutic outcomes. However, challenges remain in generalizing learned responses beyond virtual settings and in developing personalized interventions.
Virtual reality (VR) is a promising tool supporting diagnostics and therapy in psychiatry, aligning with the Health 4.0 paradigm of personalized healthcare. This review synthesizes the available scientific evidence on VR applications in psychiatry, with particular emphasis on therapeutic mechanisms, clinical effectiveness, and identification of research gaps. The strongest empirical evidence concerns VR exposure therapy (VRET) in the treatment of anxiety disorders, where the effectiveness of VRET is comparable to in vivo exposure (Suso-Ribera et al., 2019). In the case of post-traumatic stress disorder, graded exposure based on the patient's responses has been shown to be a key moderator of effectiveness, yielding significant therapeutic effects (Heo and Park, 2022). In psychotic disorders, automated VR interventions reduce agoraphobic avoidance (Freeman et al., 2022), while in social phobia, optimal results are achieved by combining VRET with cognitive-behavioral interventions (Tan et al., 2025). The neurobiological mechanisms of therapeutic change are based on amygdala activation and modulation of the medial prefrontal cortex and hippocampus, enabling extinction of the fear response. However, generalization of learned responses beyond the virtual context remains a key challenge (Freeman, 2017). Personalization of interventions using artificial intelligence is in the early stages of development (Bergsnev and Sánchez Laws, 2026). From a clinical perspective, VR is characterized by high acceptability and low dropout rates. Further development of the field requires comparative studies with active interventions, standardization of the sense of presence measurement, and validation of tools for measuring social attitudes toward VR therapy. Integrating VR with traditional therapeutic methods, rather than replacing them, seems to be the most justifiable path forward for this field.
Clinical research Literature review published

Comparative efficacy of ECT and ketamine in TRD

COMPARATIVE EFFICACY OF ELECTROCONVULSIVE THERAPY, KETAMINE, AND OTHER PHARMACOLOGICAL APPROACHES REGARDING NEUROBIOLOGICAL ADAPTATIONS IN TREATMENT RESISTANCE
Why it matters ◈ Mixed
This integrative review provides valuable insights into the comparative efficacy of ketamine and ECT for treatment-resistant depression (TRD). It highlights the non-inferiority of ketamine compared to ECT in non-psychotic depression, while noting ECT's superiority in severe and psychotic cases. The findings emphasize the need for individualized treatment plans based on clinical phenotypes and underscore the importance of structured maintenance protocols to manage relapse rates.
Introduction:Treatment-resistant depression (TRD) is defined by the persistence of depressive symptoms despite at least two adequate trials with different classes of antidepressants. Limitations of traditional monoaminergic drugs have driven the search for rapid-acting, innovative interventions such as ketamine and electroconvulsive therapy (ECT), which target neuroplasticity and the glutamatergic system. Objective: To evaluate the comparative efficacy of ketamine and ECT in TRD, analyzing their effects on rapid clinical response, suicidal ideation reduction, neuroplasticity, and neurobiological adaptations. Methodology: This is an integrative literature review based on systematic searches in PubMed and SciELO databases using strategic keywords. Original articles and reviews published between 2020 and 2025 addressing the efficacy, safety, and neurobiological mechanisms of ketamine and ECT were selected and critically analyzed. Results: Evidence highlights major limitations of monoaminergic monotherapies, showing reduced remission rates in STAR*D. The ELEKT-D trial demonstrated non-inferiority of ketamine compared to ECT in non-psychotic depression, with a response rate of 55.4% versus 41.2% and faster initial symptom relief. Both modalities significantly reduced acute suicidal ideation. However, ECT maintained superiority in severe and psychotic presentations. Safety profiles differed: ketamine was linked to transient dissociative effects, whereas ECT caused higher rates of headache, myalgia, and temporary cognitive impairment. Both treatments converge on BDNF upregulation, mTORC1 activation, and adenosine-mediated purinergic signaling. Discussion: Findings confirm that TRD encompasses distinct endophenotypes. Psychotic symptoms favor ECT indication, whereas non-psychotic TRD responds preferentially to glutamatergic modulation. Increasing relapse rates over six months underscore the necessity of structured maintenance protocols. Conclusion: Ketamine and ECT are non-competitive, complementary therapeutic tools. Treatment decisions must be individualized based on clinical phenotypes, taking into account severity, tolerability, psychotic features, and long-term maintenance strategies.
Clinical research Conceptual framework proposed

Framework for food tracking in psychiatric KMT proposed

Participant food tracking in psychiatric ketogenic metabolic therapy: an unresolved clinical, psychosocial, and implementation question
Why it matters ◈ Mixed
This analysis proposes a framework for participant food tracking in psychiatric ketogenic metabolic therapy (KMT), highlighting unresolved clinical questions about patient capacity, treatment burden, and long-term independence. Understanding these factors is crucial for optimizing KMT delivery and patient outcomes. The framework could guide future research priorities and methodologies in metabolic psychiatry.
Participant food tracking in psychiatric ketogenic metabolic therapy (KMT) varies across the metabolic psychiatry literature but is reported inconsistently rather than examined as a delivery decision with its own clinical rationale and consequences. This conceptual analysis develops a framework for participant food tracking in psychiatric KMT using metabolic psychiatry literature to identify variation in delivery models and draws on adjacent literatures relevant to dietary recording and reporting guidance for complex nonpharmacologic interventions. The framework is organized around three unresolved clinical questions: what assumptions about patient capacity shape who is taught to track and why; whether tracking functions as burden and/or treatment work, with implications for treatment ownership and continuity; and how short-term professional management relates to long-term treatment independence. Research priorities and potential methodologies are organized across ten interrelated domains that follow from these questions. To situate these questions, a supporting continuum maps variation in participant involvement across delivery approaches, from professionally managed models with no participant-generated record to higher levels of participant involvement in dietary recording. The framework offers a shared way to examine how participant food tracking is understood, assigned, and used in psychiatric KMT, and to investigate the clinical and psychosocial functions it serves within treatment.
Neuroscience Research proposal

Meditation & psychedelics in minimal selfhood research

Integrating meditation and psychedelics knowledge to identify core neurocognitive mechanisms of minimal selfhood.
Why it matters ▲ Favorable
This research article proposes a novel framework for understanding the neurocognitive mechanisms underlying minimal self-consciousness through meditation and psychedelics. By integrating predictive processing and global workspace models, the study aims to advance neuroscientific insights into selfless states. This could inform future research directions and experimental designs in the field.
This article proposes conceptual and research design principles to identify the core neurocognitive mechanisms that support minimal self-consciousness and how this might be attenuated via computational explanations of selfless states using two different induction methods-meditation and psychedelics.As a proof-of-concept of the utility of this framework, we examine how selfless states induced by these methods might elucidate core neurocognitive mechanisms of minimal selfhood, using two broad computational frameworks that instantiate, first, predictive processing and, second, global workspace modeling.This analysis isolates hierarchical flattening and metastable workspace dynamics as core mechanisms in the predictive processing and global workspace frameworks, respectively.We close by first offering several broad but testable predictions that might be used to guide future research and advance our understanding of the neuroscientific basis of minimal self-consciousness and then discussing challenges that remain in this pursuit.
Clinical research Call for consensus

Call for well-being as primary endpoint in trials

Well-being as a primary endpoint in clinical trials: a call for consensus
Why it matters ▲ Favorable
Elevating well-being as a primary endpoint in clinical trials could reshape how psychedelic therapies are evaluated. This shift acknowledges the unique experiential benefits these treatments offer, which are often undervalued in traditional symptom-focused assessments. Adopting a well-being instrument with rigorous validation could influence FDA and policy decisions, potentially leading to broader acceptance and integration of psychedelic therapies.
Abstract Psychiatric trials typically define success as symptom reduction, yet patients prioritize meaning, vitality, and functioning. This imbalance undervalues experiential benefits, distorting clinical, policy, and FDA decisions. Psychedelic trials illustrate this, where robust well-being gains sometimes accompany modest symptom effects. We argue well-being should be elevated to co-primary endpoint status, propose a Delphi-developed consensus well-being instrument with rigorous validation, and outline guardrails preventing approval of therapies that worsen the underlying condition.
Clinical research Research review

Psychedelics in Neurodevelopmental Disorders: Review

Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges
Why it matters ◈ Mixed
This review highlights the emerging interest in using psychedelics, both classic and non-classic, for neurodevelopmental disorders (NDDs). The potential for psychedelics to enhance neuroplasticity and improve cognitive and social deficits is promising, though current evidence is limited and further research is necessary. This could guide future clinical trials and inform treatment strategies for NDDs.
Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral interventions, eventually combined with symptomatic pharmacotherapies, but remain largely unsatisfactory. Among possible new therapeutic strategies for NDDs, classic psychedelics, such as LSD or psilocybin, and non-classic psychedelics including ketamine have recently received interest due to their potential in enhancing neuroplasticity and restoring social and cognitive deficits. Classic psychedelics are a group of psychoactive substances sharing agonistic activity on serotonergic 5-HT2A receptors while ketamine is a dissociative anesthetic acting as N-methyl-D-aspartate (NMDA) receptor non-competitive antagonist. Although the literature about the potential of psychedelics in the treatment of NDDs is still scarce and heterogeneous, we revised here available clinical and preclinical data to discuss the opportunities and challenges associated with the use of these drugs in NDDs. We found that most of the evidence comes from small clinical studies on adult subjects mainly evaluating the therapeutic potential of low dose ketamine, while reports with classic psychedelics are scarce and primarily observational. Overall, despite further research being needed before any conclusions can be drawn regarding the efficacy and safety of classic and non-classic psychedelics in the management of NDDs, most findings are promising and report significant behavioral improvements especially in cognitive and social domains.
Neuroscience Research tool announced

Engineered mice for studying psychedelics

A suite of engineered mice for interrogating psychedelic drug actions
Why it matters ▲ Favorable
This development provides a powerful tool for understanding the molecular and cellular actions of psychedelics. By using engineered mice to study the role of the 5-HT2A receptor, researchers can gain insights into the mechanisms underlying the therapeutic effects of psychedelics. This could accelerate the development of new treatments for neuropsychiatric disorders.
ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many neuropsychiatric diseases, including depression, anxiety, post-traumatic stress disorder, migraine, and cluster headaches. LSD and psilocybin exert their psychedelic effects via activation of the 5-hydroxytryptamine 2A receptor (HTR2A). Here we provide a suite of engineered mice useful for clarifying the role of HTR2A and HTR2A-expressing neurons in psychedelic drug actions. We first generated Htr2a -EGFP-CT-IRES-CreERT2 mice (CT:C-terminus) to independently identify both HTR2A-EGFP-CT receptors and HTR2A-containing cells thereby providing a detailed anatomical map of HTR2A and identifying cell types that express HTR2A. We also generated a humanized Htr2a mouse line and an additional constitutive Htr2A -Cre mouse line. Psychedelics induced a variety of known behavioral changes in our mice validating their utility for behavioral studies. Finally, electrophysiology studies revealed that extracellular 5-HT elicited a HTR2A-mediated robust increase in firing of genetically-identified pyramidal neurons--consistent with a plasma membrane localization and mode of action. These mouse lines represent invaluable tools for elucidating the molecular, cellular, pharmacological, physiological, behavioral, and other actions of psychedelic drugs in vivo .
Neuroscience Research published

Engineered mice for psychedelic drug research

A suite of engineered mice for interrogating psychedelic drug actions.
Why it matters ▲ Favorable
The development of engineered mice specifically designed to study the actions of psychedelic drugs represents a significant advancement in neuroscience research. This tool can enhance our understanding of the molecular and behavioral effects of psychedelics, potentially accelerating the development of new therapeutic applications. Researchers can now explore the precise mechanisms of action and side effects in a controlled environment, which is crucial for translating findings into human studies.
Clinical research Scoping review published

Scoping review highlights methodological gaps in psychedelic therapy trials

Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.
Why it matters ◈ Mixed
This review identifies significant methodological fragmentation in how psychedelic-assisted therapies are assessed, highlighting the need for standardized protocols and integration across clinical trials. The findings suggest that inconsistent trial designs and outcome measures may hinder regulatory approval and comparability of results. Policymakers and researchers should prioritize harmonization efforts to improve evidence quality and support future access pathways.
Clinical research Peer-reviewed publication

Portable 3D-printed device enables on-site MDMA detection

Portable 3D-printed system for on-site MDMA electrochemical detection.
Why it matters ▲ Favorable
This publication describes a novel, portable, and cost-effective system for detecting MDMA using 3D-printed electrochemical sensors. The technology could enhance field testing by law enforcement, harm reduction groups, and clinical researchers, improving accuracy and accessibility for on-site substance identification. While not a regulatory or legal change, this tool may reduce legal risk for users and operators by enabling rapid, reliable MDMA verification, and could support research protocols requiring substance authentication.
Clinical research Phase 3 readout

Psilocybin therapy trial for depression shows promise

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.
Why it matters ▲ Favorable
This randomized controlled trial evaluates the efficacy of psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting. The positive outcomes could pave the way for broader acceptance and integration of psychedelic therapies in mainstream mental health treatment. This study may influence policy decisions regarding the medical use of psilocybin and support further research into its therapeutic potential.
Clinical research Conceptual framework proposed

Low-Dose MDMA for Neuroergonomic Optimization Framework

Intermittent Low-Dose MDMA for Neuroergonomic Optimization: A Systems Framework for Minimum Effective Functional Dosing, Harm Reduction, and Autonomous Integration
Why it matters ◈ Mixed
This conceptual review introduces a novel framework for using low-dose MDMA to optimize neuroergonomic performance, emphasizing a Minimum Effective Functional Dose (MEFD) approach. The research proposes a structured cycle for assessing the functional benefits and physiological burdens of intermittent MDMA use. This could guide future trials in determining the viability of low-dose MDMA for enhancing cognitive and functional outcomes with minimized biological costs.
Research on 3,4-methylenedioxymethamphetamine (MDMA) has concentrated on moderate-to-high doses used in psychotherapy, controlled laboratory studies, and non-medical settings. This conceptual review asks whether intermittent, functionally perceptible low-dose exposure should be investigated as a distinct psychopharmacological architecture optimized for cumulative multi-day function rather than acute experiential intensity. It introduces the Minimum Effective Functional Dose (MEFD), defined as the lowest tested exposure that produces a prespecified functional improvement while remaining below prespecified physiological and post-acute burden thresholds. The framework evaluates a three-phase cycle comprising Modulation, Consolidation, and Post-Acute Functional Verification, with autonomous drug-free continuation as the decisive outcome. It further replaces a single benefit-to-burden ratio with a multidimensional Benefit-to-Burden Profile integrating task initiation, independently verified output, correction burden, sleep, cardiovascular and autonomic responses, mood stability, endocrine measures, and task-compatible neurophysiological endpoints. The model distinguishes established human evidence, mechanistically supported inference, and falsifiable conceptual hypotheses. It treats expectancy, functional unblinding, project-level carryover, cytochrome P450 2D6 (CYP2D6) autoinhibition, and possible cumulative 5-hydroxytryptamine receptor 2B (5-HT2B)-mediated valvular effects as design constraints. A seventy-two-hour cycle is proposed only as a provisional functional test architecture, not as evidence of complete metabolic recovery. Future research should proceed sequentially from single-dose range finding to three-day validation, interval comparison, bounded repeated-cycle studies, and longitudinal safety assessment. The article defines an experimentally testable program for determining whether a small transient intervention can generate durable drug-free work with less biological cost than stronger or continuous pharmacological architectures.
Public health Commentary published

Public health priorities for psychedelics outlined

Priorities for public health preparedness for psychedelics: education, workforce readiness, and strategic information needs in a rapidly changing landscape
Why it matters ▲ Favorable
As psychedelic use increases across various settings, public health preparedness is crucial. The commentary highlights the need for education, workforce readiness, and strategic information to manage risks and support therapeutic potential. Public health institutions must adopt a balanced approach to maximize benefits and minimize risks.
Use of psychedelic substances is increasing across unregulated, state-regulated, research, ceremonial/religious, and medical settings in the United States. Concurrently, a growing body of clinical research signals the potential for therapeutic applications for specific psychedelics in the treatment of depression, post-traumatic stress disorder, substance use disorders, and other health conditions. This evolving landscape presents both promise and complexity. From a public health perspective, a structured public health preparedness approach is needed to prioritize safety, workforce readiness, and data infrastructure in a manner that promotes individual and collective well-being while supporting responsible evidence development. This commentary proposes priorities for public health preparedness for psychedelics: (1) education and prevention of adverse events; (2) behavioral health workforce development; and (3) strategic information and data analysis. Educational efforts should emphasize clear risk communication, substance-specific messaging, prevention of adverse events, and practical guidance to support policy decision-making. Workforce considerations include defining core competencies, clarifying ethical boundaries and informed consent, establishing training and technical assistance infrastructure, strengthening capacity across the behavioral health workforce, and preparing providers to respond to patients using psychedelics outside regulated systems. Strategic information priorities include strengthening data systems and improving coordination and harmonization of epidemiologic monitoring related to patterns of use, adverse events, treatment-seeking behaviors, and the implications of evolving policy environments. As psychedelics enter mainstream discourse, public health institutions must adopt a balanced approach that considers both benefits and risks. A proactive, health-promoting, and data-driven framework can help ensure that policies and practices are grounded in safety and core public health principles.
Clinical research Phase 2 trial results

Psilocybin shows promise in NHS trial for depression

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial
Why it matters ▲ Favorable
This trial demonstrates the feasibility and potential efficacy of psilocybin-assisted therapy for treatment-resistant major depressive disorder within a public healthcare setting. The significant improvement in depression scores suggests that psilocybin could be a valuable addition to current treatment options. The trial's success in recruitment and retention also supports the viability of larger, confirmatory studies.
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health Service (NHS) site in England. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder and had an inadequate response to ≥2 antidepressant treatments or ≥1 antidepressant plus ≥1 psychotherapy. Participants received 25-mg psilocybin or placebo with preparation, dosing support and integration. Primary outcomes were recruitment, retention and estimation of the Montgomery-Åsberg Depression Rating Scale (MADRS) variance. A multilevel regression analysis with an intention-to-treat population was used. Sixty participants were randomized (1:1), balanced by age, sex and prior psilocybin exposure, and 59 of 60 participants completed the MADRS at all follow-up visits. The adjusted between-group difference at week 3 on the MADRS was -10.41 (95% confidence interval: -14.86 to -5.95; Cohen's d = -1.70), favoring psilocybin, which was sustained at week 6. In total, 123 and 164 nonserious adverse events occurred in the placebo and psilocybin arms, respectively. Findings support a future confirmatory trial. EudraCT no.: 2018-003573-97 .
Clinical research Secondary analysis published

Mystical experiences in MDMA-AT for PTSD analyzed

The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis
Why it matters ◈ Mixed
This secondary analysis suggests that mystical experiences, particularly positive mood aspects, may play a role in the efficacy of MDMA-assisted therapy for PTSD. These insights could inform future therapeutic frameworks and dosing strategies. However, the findings are preliminary and should be interpreted with caution due to the limited sample size and secondary nature of the analysis.
Background: The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT. Methods: Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in which participants received two sessions with either MDMA or active placebo, in conjunction with psychotherapy. The Mystical Experience Questionnaire 30-item version (MEQ30) was administered after each MDMA session. The association of mystical experiences and PTSD symptom severity (Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)) was analyzed using multilevel regression and mediation analyses. Results: Fifty-three participants with chronic PTSD were included. Standard doses of MDMA ( n = 39) were associated with significantly higher mean MEQ30 scores (M = 63.1, SE = 4.9; 42.1% of maximum) compared to active placebo (M = 24.7, SE = 5.5; 16.4%), t -test p &lt; 0.001. Mediation analysis revealed a significant indirect effect of the MEQ30 Positive Mood subscale on symptom reduction ( b = –0.170, 95% CI (–0.353, –0.007)), while the MEQ total score and other subscales showed smaller, non-significant indirect effects on CAPS-IV scores. Conclusions: MEQ30 scores were significantly higher for MDMA sessions than for active placebo sessions in patients undergoing MDMA-assisted therapy for chronic PTSD. Among mystical-type experiences, the positive mood subscale, rather than full mystical-type states, appeared to contribute most to the mitigation of PTSD symptoms. These findings should be interpreted with caution due to the limited sample size and secondary nature of the analysis.
Clinical research Research published

Blinding Integrity in Psychedelic Trials

Blinding Integrity and Psychedelic Drug Trials.
Why it matters ◈ Mixed
Blinding integrity is crucial in psychedelic drug trials to ensure valid and reliable results. This research highlights the challenges of maintaining blinding due to the noticeable effects of psychedelics, which can lead to bias in trial outcomes. Addressing these issues is essential for the credibility of future studies and the potential approval of psychedelic therapies.
Clinical research Systematic review published

Systematic review on psychedelics for PTSD

Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review.
Why it matters ◈ Mixed
This systematic review assesses the efficacy and risks of psychedelic substances in treating PTSD, providing a comprehensive analysis of current clinical evidence. The findings could inform future clinical guidelines and policy decisions regarding the therapeutic use of psychedelics. Researchers and clinicians can leverage this data to optimize treatment protocols and identify areas needing further investigation.
Clinical research Review published

Ketamine's Potential in ALS Treatment Explored

The Therapeutic Potential of Ketamine as a Treatment for Amyotrophic Lateral Sclerosis: A Narrative Review Focusing on Sigma-1 Receptor Modulation, Mitochondrial Function, and Neuroplasticity
Why it matters ▲ Favorable
This narrative review highlights ketamine's potential as a therapeutic agent for ALS, focusing on its effects on sigma-1 receptor modulation, mitochondrial function, and neuroplasticity. The exploration of ketamine for ALS could open new avenues for treatment in neurodegenerative diseases, addressing critical unmet needs. This review may prompt further clinical trials to evaluate ketamine's efficacy and safety in this context.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive motor neuron degeneration. Current Food and Drug Administration (FDA)-approved treatments provide only modest benefits and do not substantially alter disease trajectory, underscoring a critical unmet need for novel therapeutic strategies. Recent advances in understanding ALS pathophysiology have revealed important roles for mitochondrial dysfunction, endoplasmic reticulum stress, protein aggregation, and sigma-1 receptor dysregulation in disease progression. Ketamine, a well-established anesthetic with emerging applications as a rapid-acting antidepressant, has been reported to act through multiple mechanisms that may address key pathological features of ALS. Beyond its well-characterized N-methyl-D-aspartate (NMDA) receptor antagonism, ketamine may act as a sigma-1 receptor agonist and has been reported to promote neuroplasticity via brain-derived neurotrophic factor (BDNF)-mechanistic target of rapamycin (mTOR) signaling, exert anti-inflammatory effects, modulate mitochondrial function, enhance protein clearance, and facilitate sigma-1 receptor trafficking from astrocytes to neurons. This review examines the mechanistic rationale for ketamine as a potential therapeutic agent in ALS, focusing on sigma-1 receptor signaling, mitochondrial bioenergetics, protein aggregate clearance, and neuroplasticity. We discuss the convergence of ALS pathophysiology and ketamine’s pharmacological mechanisms, proposing low-dose sublingual ketamine as a candidate for clinical investigation, and note that similar pathophysiological mechanisms in other neurodegenerative diseases may warrant parallel investigation.
Clinical research Research review

Hydrogel Microneedles for Biosensing and Monitoring

Hydrogel-Forming Microneedles for Interstitial-Fluid Biosensing and Therapeutic Monitoring
Why it matters ◈ Mixed
This review highlights the potential of hydrogel-forming microneedles (HFMNs) for non-invasive therapeutic monitoring, which could impact drug delivery and patient monitoring in psychedelic treatments. While promising, human validation is limited, indicating a need for further clinical trials and standardization. The technology's expansion from glucose to various biomarkers suggests broad applicability, but challenges remain in achieving reliable and scalable solutions.
Hydrogel-forming microneedles (HFMNs) are minimally invasive interfaces that access interstitial fluid (ISF) through skin penetration, swelling-mediated uptake, analyte diffusion, and hydrated sensor integration. This review examines HFMN architectures, skin–device interfaces, ISF transport, molecular-recognition and signal-transduction strategies, analytical performance, benchmarking, wear-associated failure modes, therapeutic monitoring, and translational priorities. The field has expanded from glucose sensing to metabolites, ions, hormones, proteins, nucleic acids, microbial and wound biomarkers, and therapeutic drugs, enabled by advances in hydrogel chemistry, conductive networks, nanostructured electrodes, catalysis, affinity recognition, molecular imprinting, optical readouts, and multiplexed wearables. Performance remains context dependent and requires physiological range, calibration stability, biofouling resistance, reliable insertion, validated ISF-reference correlations, and interpretable thresholds. Evidence is strongest in artificial matrices, ex vivo tissue, and animals, while human validation remains limited. Translation will require standardized mechanics and transport reporting, longer wear studies, sterilization-compatible chemistries, scalable manufacturing, and clinical validation. HFMNs may complement rather than replace blood-based diagnostics.
Neuroscience Research published

Psilocybin induces synaptic plasticity in mice

Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in mice
Why it matters ▲ Favorable
This study provides insights into the neurobiological mechanisms of psilocybin's antidepressant effects by mapping excitatory synaptic plasticity in mice. Understanding the specific brain regions and receptors involved could inform future clinical applications and therapeutic strategies. This foundational research enhances our mechanistic understanding of psilocybin-induced neuroplasticity, which is crucial for developing targeted treatments.
Abstract A single dose of psilocybin can induce long-lasting antidepressant effects. The neurobiological mechanisms underlying such sustained antidepressant effect remain insufficiently understood, particularly at the level of synaptic function and drug-target specificity. Here, we aimed to delineate single-dose psilocybin-induced excitatory synaptic plasticity. Synaptic plasticity was assessed by whole-cell patch-clamp recording of excitatory synaptic transmission 24 h after treating mice with single-dose psilocybin. We correlated the recordings with transcriptomics data and used a conditional single-vector CRISPR/SaCas9-dependent knock-out strategy to validate the role of the 5-HT 2A receptor. Psilocybin selectively increased the frequency of miniature excitatory postsynaptic currents in specific cortical sub-regions and in the amygdala. Frequency correlated with the expression levels of psilocin-targeted serotonin receptors, when expression heterogeneity between cortical subregions and along the anterior-posterior axis was accounted for. Post-synaptic Htr2a knock-out in the insular/orbitofrontal cortex precluded psilocybin-induced 24-h plasticity. These findings demonstrate that lasting psilocybin-induced effects on excitatory synaptic transmission manifest with brain-region specificity, likely reflecting a functional consequence of synapse formation. This work establishes a foundation for a circuit-specific, mechanistic understanding of functional aspects of psilocybin-induced neuroplasticity.
Clinical research Research ongoing

Ketamine trends and youth impact

Ketamine: current trends and what they mean for young people
Why it matters ◈ Mixed
This research explores the long-term effects of ketamine and its potential as a treatment for substance use disorders, including methamphetamine use disorder. Understanding these trends is crucial for developing effective interventions and policies. The focus on Australia-specific trends highlights regional differences in substance use and treatment approaches.
Ketamine: current trends and what they mean for young peopleWhat's next?Researchers are looking at long-term ketamine e ects and Australia-speci c trends and behaviours.There is also research looking into ketamine as a treatment option for substance use disorders such as methamphetamine use disorder.
Neuroscience Perspective article

Shift to Brain Health Services for older adults in Europe

From memory clinics to Brain Health Services: implications for older adults and the future of cognitive care in Europe
Why it matters ◈ Mixed
The transition from memory clinics to Brain Health Services marks a significant shift in cognitive healthcare for older adults in Europe. This model emphasizes prevention and cognitive function maintenance, potentially improving early engagement and reducing stigma. However, challenges include ethical concerns about risk disclosure and equitable access. Future research should focus on real-world evaluations and personalized approaches.
AIM: To explore the implications of transitioning from traditional memory clinics to Brain Health Services (BHS) for older adults, and to advocate for a geriatric-informed, equitable, and function-oriented approach to brain health care. METHODS: This perspective article draws on discussions within the EuGMS Brain Health and Dementia Specialist Interest Group and relevant literature to examine the implications of emerging Brain Health Services for older adults. RESULTS: The emergence of Brain Health Services represents a significant shift in cognitive healthcare, moving beyond traditional memory clinic models focussed primarily on dementia diagnosis and management towards prevention, risk reduction, and maintenance of cognitive function. Potential benefits include earlier engagement with cognitive care, multidomain lifestyle interventions, reduction of stigma surrounding dementia, and facilitation of access to emerging disease-modifying therapies. However, substantial challenges remain. Biomarker-driven approaches may overemphasise Alzheimer's disease-centric frameworks despite the high prevalence of mixed pathologies and complex comorbidity in older adults. Ethical concerns surrounding risk disclosure, inequitable access, and resource allocation are also considerable, particularly if services disproportionately benefit younger, healthier, or socioeconomically advantaged populations. CONCLUSIONS: Brain Health Services should be reframed through a gerontologically informed lens that prioritises function, independence, quality of life, and equitable access alongside prevention. Integration with comprehensive geriatric assessment and existing older persons' care pathways is essential. Future research should focus on pragmatic real-world evaluation, inclusive outcome measures, and personalised approaches that account for heterogeneity in ageing. Ultimately, the success of BHS will depend on their ability to support healthy ageing while remaining responsive to the lived realities and priorities of older adults.
Clinical research Study results published

Gene expression in ketamine and ECT for TRD

Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment
Why it matters ◈ Mixed
This study explores the transcriptional changes associated with ketamine and ECT treatments for treatment-resistant depression, highlighting the complexity of their mechanisms. While no significant longitudinal changes were detected, baseline differences in gene expression may offer predictive insights. This underscores the need for larger studies to better understand molecular signatures in rapid-acting antidepressant responses.
Background: Treatment-resistant depression (TRD) affects 30-50% of patients with major depressive disorder (MDD). Electroconvulsive therapy (ECT) and sub-anesthetic ketamine treatment can relieve TRD, yet their antidepressant mechanisms remain unclear. Peripheral blood gene expression offers a non-invasive proxy to examine potential treatment-response biomarkers. Methods: We conducted a transcriptome analysis on peripheral blood samples from individuals with TRD undergoing ECT (N=37) or serial ketamine infusions (N=60), and non-depressed controls (N=35). Samples were collected at baseline and at multiple follow-up time points. Differential gene expression (DGE) at the single gene and network level identified transcriptional changes and co-regulated gene modules associated with diagnosis, treatment, and remission status using Weighted Gene Co-Expression Network Analysis (WGCNA), including correction for multiple comparisons. Results: Longitudinal transcriptional changes were not detected for either treatment for individual genes or networks (FDR corrected or |logFC|>0.05). When comparing remitters and non-remitters at baseline in the ketamine group, we observed evidence of enrichment for immune-related functions overall with one gene significantly differentially expressed (i.e., IGKV1-9) (p=2.5E-05, logFC=-0.51). In the ECT sample, when considering gene networks, we observed significant interaction effects between time and diagnosis. At least six co-regulated gene modules yielded significant differences at baseline between ECT patients and controls. Conclusion: Despite the robust clinical improvements associated with ECT and ketamine, peripheral blood RNA-seq revealed limited detectable longitudinal gene expression changes. However, pre-treatment differences in gene expression profiles suggest some potential predictive value. Larger samples are warranted to clarify peripheral molecular signatures of rapid-acting antidepressant response.
Clinical research Study results announced

rTMS shows efficacy for treatment resistant depression

rTMS for treatment resistant depression – a single center community experience
Why it matters ▲ Favorable
This study provides evidence that rTMS, particularly using a sequential bilateral hemisphere stimulation approach, can be effective in treating chronic, treatment-resistant depression. The findings suggest that rTMS can achieve results comparable to clinical trials and that benefits may persist long-term. This adds to the body of evidence supporting rTMS as a viable treatment option, potentially influencing clinical practice and patient care strategies.
Depression remains a major health issue worldwide. Chronic treatment resistant depression, where there is a failure to respond to two or more antidepressant regimens, affects 2.5 percent of the adult population. Repetitive transcranial magnetic stimulation (rTMS) is an accepted treatment modality for depression. The comprehension of its mechanism of action and optimal parameters for treatment are evolving. We performed a chart review of the patient population with treatment resistant depression treated at our center with rTMS over the past ten years, using a sequential bilateral hemisphere stimulation approach. Patients were evaluated using the Beck Depression Inventory questionnaire (BDI-II) before onset and every 2 weeks during their rTMS treatments. We also attempted to contact the patients who had completed treatment to repeat the BDI-II and assess long term impacts of treatment. Fifty-three patient charts were analyzed. The overall incidence of responders and those who achieved remission was 58.5% (n=31) and 20.8% (n=11) respectively. Nine patients were contacted following completion of treatment and completed the BDI-II evaluations. The average time between the completion of their rTMS treatment and follow-up was 2.6 years (SD = 2.7 years). Eight of the nine had achieved a significant improvement during their rTMS treatment and 6 maintained their benefit. Overall, our results suggest that using a sequential bilateral hemisphere rTMS stimulation approach delivered in a real-world community for unselected patients with chronic, severe, treatment resistant depression is effective with efficacy results comparable to those achieved in clinical trials of major depression and that in some cases, the clinical benefit can persist over the long term.
Clinical research / Ethics Ethics commentary published

Ethical argument: offer ketamine before psychiatric euthanasia or assisted suicide

Last resort: the ethical obligation to offer ketamine in psychiatric euthanasia and assisted suicide.
Why it matters ◈ Mixed
This article raises the ethical question of whether clinicians have a duty to offer ketamine treatment as a last resort before proceeding with psychiatric euthanasia or assisted suicide. It highlights the growing evidence for ketamine's rapid antidepressant effects and its potential to alter treatment trajectories for patients with severe, treatment-resistant depression. The piece may influence clinical guidelines, policy debates, and legal standards in jurisdictions where psychiatric euthanasia is permitted, emphasizing the need for robust research access and clear protocols. Stakeholders should monitor whether this argument shapes future regulations or standard-of-care expectations.
Neuroscience Peer-reviewed study published

β-Arrestin2 signaling implicated in psychedelic drug effects

Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.
Why it matters ▲ Favorable
This study identifies β-Arrestin2 signaling as a key pathway in the neuropharmacological effects of psychedelic drugs. The findings may inform the design of next-generation psychedelics with improved safety or efficacy profiles, and could guide future clinical trial endpoints. Understanding these mechanisms is important for both regulatory science and the rational development of novel therapeutics.
Clinical research Review published

Review on treatment-resistant depression strategies

Treatment-resistant depression: Current therapeutic strategies
Why it matters ◈ Mixed
This review highlights the complexity of treatment-resistant depression (TRD) and the limited efficacy of conventional antidepressants due to various pathophysiological factors. Innovative therapies like ketamine and esketamine are noted for their rapid antidepressant effects in certain cases. This underscores the need for individualized and multidisciplinary treatment approaches, which is crucial for improving patient outcomes.
Treatment-resistant depression (TRD) represents one of the most complex forms of major depressive disorder, characterized by the persistence of clinically significant symptoms despite the performance of appropriate therapeutic interventions. This condition is associated with a worse prognosis, higher risk of recurrence, functional impairment, increased morbidity and mortality, and high socioeconomic impact. The objective of this article was to review the main aspects related to ESRD, addressing its definition, diagnostic criteria, epidemiology, pathophysiological mechanisms, and currently available therapeutic strategies. A narrative review of the literature was carried out, including national and international studies that discuss advances in the management of resistant depression. It is observed that the pathophysiology of ESRD involves alterations in mon oaminergic and glutamatergic neurotransmission, reduced neuroplasticity, inflammatory processes, neuroendocrine dysfunctions, and genetic factors, justifying the limited efficacy of conventional antidepressants in some patients. Current therapeutic strategies include optimization and combination of antidepressants, pharmacological potentiation, use of atypical antipsychotics, lithium, and thyroid hormones, as well as innovative therapies such as ketamine and esketamine, which demonstrate rapid antidepressant response in selected cases. It is concluded that the management of ESRD should be individualized, based on up-to-date scientific evidence, and integrated with multidisciplinary approaches, aiming at symptom remission, functional recovery, and improvement of patients' quality of life.
Clinical research Research article

MDMA Therapy Risk Factors in U.S. Veterans with PTSD

Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder
Why it matters ◈ Mixed
This article explores the prevalence of contraindications and risk factors for MDMA-assisted therapy among U.S. veterans with PTSD. Understanding these factors is crucial for tailoring treatment protocols and ensuring patient safety. Identifying potential risks can inform both clinical practice and future research directions.
US / Federal Executive Order announced

Psychedelic Therapies Executive Order Announced

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.
Why it matters ▲ Favorable
The Executive Order on Psychedelic Therapies signals a significant federal commitment to advancing psychedelic research and clinical readiness. This move could accelerate the approval process for psychedelic therapies and enhance clinical infrastructure for their integration into mental health treatment. It highlights the growing recognition of psychedelics' therapeutic potential and may lead to increased funding and support for related research initiatives.
Neuroscience Research published

Ultrasonic potentiation of ketamine neuromodulation

Ultrasonic potentiation of ketamine neuromodulation.
Why it matters ▲ Favorable
This study explores the use of ultrasound to enhance the neuromodulatory effects of ketamine, a substance known for its rapid antidepressant effects. Such findings could lead to more effective and targeted treatments for depression and other mental health conditions. This research may influence future clinical trial designs and therapeutic protocols, potentially improving patient outcomes.
Clinical research Narrative review published

Sex hormones affect psychedelics' efficacy in women

Psychedelics and women’s mental health: the effects of female sex hormones on psychedelics’ efficacy and tolerability
Why it matters ◈ Mixed
This narrative review highlights the significant impact of female sex hormones on the pharmacokinetics and pharmacodynamics of psychedelics, which may influence their efficacy and tolerability in treating mental health disorders. Understanding these hormonal effects is crucial for optimizing psychedelic therapies for women, who disproportionately suffer from affective and stress-related disorders. The review underscores the need for more targeted research to address this variability.
Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure, response, and tolerability. This narrative review synthesizes clinical, preclinical, and neuroimaging literature to examine how estradiol and progesterone modulate psychedelic pharmacokinetics, pharmacodynamics, and large-scale brain network dynamics implicated in psychiatric disorders. At the pharmacokinetic level, sex hormones influence gastrointestinal physiology (including gastric pH and transit time), tissue distribution via body composition and fluid balance, and hepatic metabolism through modulation of CYP450 enzymes, particularly CYP3A4 and CYP2D6, which are key pathways for LSD and psilocin biotransformation. Renal elimination plays a comparatively minor role. These processes may collectively alter onset, peak concentration, and systemic exposure across hormonal states, although direct human data for psychedelics remain absent. At the pharmacodynamic level, estradiol and progesterone regulate serotonergic signaling, including dynamic modulation of 5-HT2A receptor density and binding across the menstrual cycle and reproductive lifespan. Platelet, PET, and SPECT studies indicate higher 5-HT2A availability in low-progesterone states and reduced availability in progesterone-dominant or hypoestrogenic states. Beyond 5-HT2A, psychedelics engage broader serotonergic, glutamatergic, and GABAergic systems that converge on prefrontal-limbic, default mode, and salience networks, circuits that are also dysregulated across depression, anxiety, and trauma-related disorders. Hormonal fluctuations may further influence subjective intensity and tolerability, with potential sensitivity peaks in the early-mid follicular and early luteal phases, although direct evidence remains limited. Together, these findings suggest sex hormones as a mechanistically plausible, clinically relevant but under-characterized source of variability in psychedelic treatment response.
Clinical research Evidence threshold crossed

Psilocybin Evidence Surpasses Guidelines

Psilocybin Has Crossed the Evidence Threshold. Clinical Guidelines Have Not.
Why it matters ◈ Mixed
The article highlights a significant gap between the growing body of evidence supporting psilocybin's therapeutic potential and the lack of updated clinical guidelines to inform its use. This discrepancy could hinder the integration of psilocybin into mainstream medical practice, affecting patient access and care quality. It underscores the need for timely updates to clinical guidelines to reflect current research findings.
Clinical research Study published

Ketamine disrupts redox and inflammation in salivary glands

Recreational ketamine exposure disrupts redox and inflammatory homeostasis in salivary glands and plasma leading to salivary dysfunction.
Why it matters ◈ Mixed
This study highlights potential adverse effects of recreational ketamine use on salivary gland function, which could inform both clinical guidelines and public health messaging. Understanding the biochemical impacts of ketamine is crucial for assessing its safety profile, especially as its therapeutic use expands. This research may prompt further investigation into the systemic effects of ketamine, influencing both clinical practice and regulatory considerations.
Clinical research Phase 2 trial ongoing

Entropy Neurodynamics advances TRP-8803 trial

Entropy Neurodynamics advances TRP-8803 with 72 patient psychedelic therapy trial
Why it matters ▲ Favorable
Entropy Neurodynamics is progressing with a 72-patient trial for TRP-8803, a psychedelic therapy. This trial's advancement is crucial for validating the efficacy and safety of TRP-8803 in a clinical setting. Success in this trial could lead to further development stages and potential market entry, impacting both patient care and the psychedelic therapy market.
Neuroscience Study published

EEG study links UBEs to brain complexity changes

Flattened brain hierarchy and increased EEG complexity during unusual bodily experiences and out-of-body experiences
Why it matters ▲ Favorable
This study provides new insights into the neural dynamics of unusual bodily experiences (UBEs), showing that these states are associated with increased whole-brain complexity and reduced cortical hierarchy. The findings suggest parallels between UBEs and psychedelic states, potentially informing future research on depersonalization and body-image disorders. This could open new avenues for understanding and treating these conditions.
Experiences in which the sense of the body becomes distorted offer a unique window into how the brain constructs the bodily self. Despite their clinical relevance in conditions such as depersonalization and body-image disorders, large-scale brain dynamics underlying unusual bodily experiences (UBEs) remain poorly understood, and no prior study has examined them systematically across wakefulness and sleep. Here, we analyzed a high-density EEG dataset including 36 UBE episodes, such as floating sensations, distorted body boundaries, and out-of-body experiences, recorded across rapid eye-movement (REM) sleep, light sleep, sleep arousals, and wakefulness during meditation (N=20). We quantified the temporal irreversibility of neural dynamics, a marker of cortical hierarchical organization, and complemented these analyses with whole-brain signal complexity measures following a within-subject design. UBEs were consistently associated with a global reduction in neural irreversibility and cortical hierarchical differentiation relative to non-UBEs and wakefulness, along with a concurrent increase in whole-brain complexity to levels comparable to wakefulness. Together, these findings suggest that UBEs reflect a neural state combining high informational richness with a transient flattening of cortical hierarchy, a profile that resembles that observed in psychedelic states.
Clinical research Peer-reviewed study

Study: Female sex hormones impact psychedelic efficacy and tolerability

Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.
Why it matters ◈ Mixed
This peer-reviewed study highlights that female sex hormones significantly influence the efficacy and tolerability of psychedelic treatments for mental health. The findings underscore the need for sex-specific considerations in clinical trial design, dosing, and safety monitoring. Policymakers and researchers should address these biological differences to ensure equitable and effective access to psychedelic-assisted therapies. This could shape future regulatory guidance and clinical best practices.
Neuroscience Study results announced

Machine learning predicts SSRI response in MDD via fMRI

Resting-state fMRI-based machine learning for predicting SSRI treatment response in major depressive disorder
Why it matters ▲ Favorable
This study leverages machine learning and resting-state fMRI to predict SSRI treatment response in MDD, potentially enhancing personalized treatment strategies. The use of fMRI metrics to forecast pharmacotherapy outcomes could lead to more effective and tailored interventions for MDD patients. While promising, further research and validation are necessary to integrate these findings into clinical practice.
BACKGROUND: Major Depressive Disorder (MDD) is a prevalent mental health condition with significant societal impact. Although prior research has highlighted the brain changes modulated by antidepressant therapy, their efficacy and effectiveness are debated. The low rates of treatment response still existed in the pharmacological therapy of MDD. Exploring an optimal neurological predictor of symptom improvement caused by pharmacotherapy is urgently needed for improving response to treatment. Our purpose is to develop a predictive model for MDD therapy using machine learning techniques based on resting-state fMRI metrics. METHODS: A total of 116 MDD patients underwent 3.0T resting-state magnetic resonance image scanning. Demographic data and the 24-item Hamilton Depression Rating Scale (HAMD-24) were collected from all participants. An additional independent cohort of 25 MDD patients was included for external model validation. Based on the reduction rate of HAMD-24 scores at different time points, the patients were divided into an early improvement group, an early response group, and a clinical response group: (1) Early improvement group: HAMD-24 reduction rate ≥ 20% after 1 week of treatment; (2) Early response group: HAMD-24 reduction rate ≥ 25% after 2 weeks of treatment; (3) Clinical response group: HAMD-24 reduction rate ≥ 50% after 4 weeks of treatment. For model construction, LASSO regression was applied for feature selection, integrating identified brain regions, HAMD-24 symptom clusters, and clinical variables. Five machine learning models were established based on features screened by the LASSO regression model to predict treatment response in MDD. All models were trained and assessed using 10-fold cross-validation, the most stable logistic regression model was selected for external validation in a temporally independent cohort (n = 25). RESULTS: At 1 week, alterations were mainly observed in the frontal and sensorimotor regions. At 2 weeks, differences were found in the opercular, postcentral, orbitofrontal, temporal, and angular areas. At 4 weeks, additional abnormalities appeared in the frontal, occipital, and postcentral cortices. Moreover, right Postcentral gyru was found to be present in the differential brain regions observed at 1 week, 2 weeks, and 4 weeks comparisons. In addition, ten features related to the treatment response were identified using the LASSO regression model, including age, years of education, core depressive symptoms, and several brain region features primarily involving the postcentral gyrus. Among the constructed machine learning models, the Logistic Regression model based on LASSO-selected features (including age, education, core depressive symptoms, and the postcentral gyrus) demonstrated the most stable performance. It achieved an area under the curve (AUC) of 0.801 in the internal validation and maintained robust predictive performance in the independent external validation set, indicating promising generalizability. Following independent external validation, the results showed that the predictive performance of the Logistic regression model on the external validation set yielded an AUC value of 0.643 and an accuracy of 0.60. This indicates that the brain regions involved in the model-namely the right postcentral gyrus, right precentral gyrus, left superior frontal gyrus, left middle occipital gyrus, and the orbital part of the right inferior frontal gyrus-hold promise as exploratory neural correlates for predicting the efficacy of SSRIs in depression. CONCLUSION: MDD exhibits early functional alterations in brain regions involved in emotion regulation, cognition, and sensorimotor processing. Integrating these multi-metric neural features with clinical variables via machine learning models suggests potential clinical utility for evaluating and predicting early SSRI treatment outcomes.
Neuroscience Study published

Exercise modulates depression circuits, study finds

Exercise-induced attenuation of the lateral habenula: a multi-axial quantitative synthesis of circuit-level resilience in depression
Why it matters ▲ Favorable
This study provides a quantitative synthesis supporting the Network-Mediated Habenular Attenuation (NMHA) Model, suggesting that exercise can modulate the lateral habenula, a key brain region involved in depression. The findings highlight exercise as a potential neuromodulatory strategy for depression, warranting further research into its clinical applications. This could influence future therapeutic approaches and inform clinical trials targeting depression through non-pharmacological means.
Background Depression is characterized by pathological lateral habenula (LHb) hyperactivity within the anti-reward circuitry. However, a unified framework explaining how exercise modulates this specific circuit remains to be established.Aims: To examine whether neurobiological evidence supports the Network-Mediated Habenular Attenuation (NMHA) Model, which proposes exercise as a systemic regulator of LHb pathology. Methods A systematic synthesis was conducted following PRISMA guidelines and registered in PROSPERO. After a comprehensive search, 12 eligible studies met eligibility criteria. A quantitative synthesis was performed using a random-effects model, with Hedge’s g used to estimate the magnitude of neuroplastic changes across the NMHA axes. Results Evidence suggests that exercise modulates LHb bursting via four convergent axes: (1) muscle-brain (peripheral-metabolic); (2) sensory-motor (monoaminergic); (3) cognitive-executive (top-down); and (4) hippocampal neurogenic (contextual). Quantitative synthesis revealed a robust global effect size (Hedges’ g = 0.94; 95% CI [0.59, 1.29]). Heterogeneity was low (I 2 = 14.90%). Some axes exhibited large effect sizes, with the hippocampal-contextual axis showing the highest potency (Hedges’ g [1.95, 2.63]). These magnitudes provide a compensatory counter-signal to the pathological LHb burst firing observed in depressive states (Hedges’ g ≈ 1.00), providing mathematical support for the NMHA model. Discussion Exercise potentially acts as a circuit-breaker for anhedonia by modulating the anti-reward architecture. The observed variability in effect sizes (95% Prediction Interval: 0.21, 1.67) indicates that future studies may report effect sizes ranging from small to very large, reflecting the influence of different exercise protocols and depression models on circuit attenuation. Conclusion The NMHA model positions exercise as a targeted neuromodulatory strategy. Future research should leverage high-field neuroimaging to translate these preclinical circuit-level findings into human clinical populations.
Clinical research Research published

5-HT(2A)R targeting boosts colorectal cancer immunity

Targeting peripheral 5-HT(2A)R enhances antitumor immunity in colorectal cancer.
Why it matters ◈ Mixed
This study suggests that targeting peripheral 5-HT(2A) receptors could enhance antitumor immunity in colorectal cancer. While primarily a neuroscience finding, it may open new avenues for psychedelic compounds in oncology. Further research is needed to explore clinical applications and potential integration with existing cancer therapies.
Clinical research Pilot study published

MDMA and alcohol co-use: pilot biomarker study in Pakistan published

Integrated biomarker analysis of multi-organ effects following MDMA and alcohol co-consumption in Pakistan: A pilot study.
Why it matters ◈ Mixed
This pilot study provides early data on the physiological and biomarker effects of combined MDMA and alcohol use in a non-Western setting. The findings may inform future clinical research protocols and harm reduction strategies, especially in regions with rising recreational use and limited regulatory oversight. While not directly impacting law or policy, such studies broaden the evidence base for safety, risk assessment, and potential contraindications in both research and clinical contexts.
Neuroscience Research perspective

Exploring mechanisms of psychedelic therapy

Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics
Why it matters ▲ Favorable
This research perspective highlights innovative approaches to disentangle the complex mechanisms of psychedelic-assisted therapy. By examining low-dose psychedelics, breathwork, and vagus nerve stimulation, researchers aim to identify the specific components responsible for therapeutic benefits. This could lead to the development of safer and more tailored interventions, enhancing the scalability and individualization of psychedelic therapies.
Psychedelic-assisted therapy has shown rapid and durable benefits across multiple psychiatric conditions, yet the mechanisms underlying these effects remain incompletely understood. Full-dose psychedelic sessions simultaneously engage serotonergic neurochemistry, high-intensity subjective experience, and autonomic-interoceptive physiology, making it difficult to determine which components are necessary or sufficient for therapeutic change. This perspective proposes that three partially separable research approaches, a single low dose of a psychedelic, high-ventilation breathwork, and vagus nerve stimulation (VNS), offer complementary mechanistic probes for disentangling these pathways. A single, sub-psychedelic dose provides a model of low-intensity 5-HT2A engagement that isolates pharmacological and early plasticity-related effects while minimizing experiential and autonomic confounds. Breathwork induces robust experiential and autonomic shifts through CO 2 -driven physiological perturbation and interoceptive amplification, enabling investigation of experiential and autonomic contributions in the absence of serotonergic pharmacology. VNS, in turn, modulates vagal-autonomic and interoceptive circuits without inducing altered states of consciousness, offering a controlled method for probing autonomic influences on affective and cognitive processes. Examining these perturbations within shared experimental frameworks may clarify how neurochemical plasticity, experiential meaning-making, and autonomic recalibration interact to support psychological change. This mechanistic precision can guide the development of interventions that are safer, more scalable, and more individually tailored than current full-dose psychedelic protocols.
FDA / DEA FDA guidance finalized

FDA Finalizes Guidance on Psychedelic Trials

Altered States, Standard Rules: FDA Finalizes Guidance on Psychedelic Drug Clinical Trials
Why it matters ▲ Favorable
The FDA's finalization of guidance on psychedelic drug clinical trials is a pivotal development for the field. It provides a standardized framework for conducting research, which can accelerate the approval process and increase investment in psychedelic therapies. This move is likely to enhance the credibility and safety of psychedelic research, impacting both regulatory pathways and market dynamics.
Neuroscience Research published

Distinct brain activity patterns from psychedelics in rats

Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks
Why it matters ▲ Favorable
This study provides valuable insights into the distinct neurobiological effects of different serotonergic psychedelics, highlighting their potential therapeutic applications. Understanding these unique metabolic signatures could guide future clinical research and therapeutic strategies for neuropsychiatric disorders. The findings emphasize the importance of considering drug-specific mechanisms in the development of psychedelic-based treatments.
Serotonergic psychedelics show therapeutic potential across neuropsychiatric disorders despite transient acute effects. These compounds share serotonin 2 A receptor agonism but differ in broader pharmacology, motivating a systematic comparison of their neurobiological effects. Here, we use [18 F]FDG-PET in rats to assess acute and one-week effects of psilocybin, LSD, and 2C-B on brain metabolic activity and metabolic covariance within biologically informed networks. All three drugs produce distinct acute patterns, with drug-specific alterations in cortico-striato-thalamo-cortical and cortico-amygdalo-hippocampal-hypothalamic networks. Voxel-wise analyses reveal LSD-driven hypometabolic clusters in retrosplenial and hippocampal regions and a 2C-B-specific hypermetabolic cluster in the midbrain. One week after administration, LSD and psilocybin, but not 2C-B, show modest hypometabolism spanning cortical, limbic, and midbrain structures. These findings demonstrate that serotonergic psychedelics induce distinct acute and sustained metabolic signatures, providing a network-level framework for understanding their shared and drug-selective mechanisms and informing therapeutic stratification across neuropsychiatric disorders. LSD, Psilocybin and 2C-B are different serotonergic psychedelic drugs with slightly different pharmacology. Here, authors show that while they all share the power to reshape neuronal communication across brain networks, they do so in slightly distinct ways, producing different long-term changes.
Neuroscience Study published

Oneness Experience Scale developed for research

Development and psychometric evaluation of the Oneness Experience Scale
Why it matters ▲ Favorable
The development of the Oneness Experience Scale provides a new tool for researchers studying mindfulness, spirituality, and well-being. This scale could enhance the understanding of nondual awareness and its impact on mental health and personal growth. It may also support the integration of spiritual experiences into therapeutic practices.
Experiencing oneness or nondual awareness has long been considered a core aspect of spirituality and an aim of meditation and spiritual practice. Oneness experience may lead to well-being and has various adaptive functions in everyday life. However, there has been a lack of comprehensive measures of oneness experiences that are grounded in the consensus-based reports of experienced meditation practitioners. The purpose of this study is to develop a new measure of oneness experience that is psychometrically robust and suitable for research on mindfulness, spirituality, and well-being. Scale items were developed based on prior collective intelligence research and a comprehensive literature review and were subsequently reviewed by five content experts. The dimensionality of the scale was examined using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) in a large sample of participants (N = 764; age: M = 45.37, SD = 9.79; Female = 63%). Results revealed an 84-item scale with 21 factors, including: Part of a Whole/Connection With Everything, Ego-dissolution, Clarity, Nowness, Safety and Reassurance, Non-judgementality, Timelessness, Spontaneity, Peace, Compassion, Self-compassion, Non-striving, Spaciousness, Acceptance, Non-separation from Others, Revelation Of Truth, Flow, Perfect As It Is, Openness, Appreciation, and Same and Different. The scale and its subscales possess good internal consistency and construct validity. Evidence of construct validity was found through positive associations with well-being (as measured by the Mental Health Continuum), mindfulness (using the Five Facet Mindfulness Questionnaire), personality (based on the Big Five Inventory-10), and self-reports of oneness experience. The Oneness Experience Scale is a measure suited for process- and outcomes-based research in the domains of mindfulness, spiritual practices, and well-being.
Neuroscience Research published

GABAergic cells in zona incerta modulate motivation

Author response: Demonstrating the ability of GABAergic cells in the zona incerta to modulate motivation
Why it matters ▲ Favorable
This research highlights the role of GABAergic cells in the zona incerta as modulators of motivation, offering a potential new target for addressing treatment-resistant motivational deficits. The findings could inform future clinical trials and therapeutic strategies for conditions involving disrupted motivation. While the study is preclinical, it provides a foundation for further exploration into the neurobiological mechanisms of motivation.
Motivation to engage in goal-directed actions is crucial for survival and well-being. Dopaminergic and serotonergic systems have been the focus of efforts to understand neurobiological etiologies of normative and disrupted motivation. Understanding how the brain incorporates salient sensory cues into motivational drive outside of these neuromodulatory systems is less appreciated. We posited that given their afferent and efferent connections, GABAergic cells in the zona incerta (ZI) are ideally positioned to perform this function. Combining behavioral tasks in mice with chemogenetics we show that GABAergic ZI neurons are capable of modulating effort-based motivation and that chemogenetic activation of this cell population can rescue motivational deficits induced by chronic stress - without affecting attention, memory, locomotion, or appetite. Next, using fiber photometry we report that GABAergic cells in the ZI robustly respond to sensory cues and their response to a cue increases as reward-predictive associations are formed. Inhibiting GABAergic cells in the ZI did not abolish cue-associated motivational behavior while cue-locked optogenetic activation of these cells robustly enhanced cue-associated motivated behavior demonstrating that these cells are not necessary but sufficient to allow for sensory cues to influence action selection. These findings establish GABAergic cells in the ZI as modulators of motivation and afford us a neuroanatomical hub that could be targeted to potentially remedy treatment-resistant deficits in motivation.
Neuroscience Research published

Study on psychedelic-enhanced fear extinction in rodents

Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models.
Why it matters ◈ Mixed
This study synthesizes dose-effect patterns of psychedelics in rodent models for fear extinction, which is crucial for understanding potential therapeutic applications in anxiety-related disorders. The findings could inform dosing strategies in future human trials, impacting clinical protocols and safety guidelines. However, the translation from rodent models to human applications remains a significant challenge.
Clinical research Study published

Patient views on implanted neurotech for depression

What matters in next-generation implanted neurotechnology design? Perspectives from individuals with treatment-refractory depression
Why it matters ◈ Mixed
This study explores how patients with treatment-refractory depression perceive next-generation implanted neurotechnologies. Findings suggest that factors like therapy delivery flexibility and implant approach significantly influence patient decisions, while industry-prioritized aspects like cosmetic invisibility are less impactful. These insights could guide more patient-centered innovations in neurotechnology design.
OBJECTIVE: Major financial investments in implanted neurotechnology have fueled a wave of innovation in device design, implant procedures, and therapy delivery methods. These innovations are often presented as making implanted neurotechnologies more appealing to patients. However, it remains unclear whether such innovations meaningfully impact patients' decision-making about adoption. The present study aims to examine how next-generation neurotechnology innovations shape prospective decision-making about adoption among patients with treatment-refractory depression (TRD), a key projected target population for these neurotechnologies.&#xD;&#xD;Approach. We identified nine aspects of next-generation neurotechnology innovation by reviewing public-facing materials from leading implanted neurotechnology companies. We then conducted interviews with 27 participants with TRD as well as 6 participants who currently have a deep brain stimulation (DBS) implant for depression to assess their familiarity with and perceptions of neurotechnology, as well as their perspectives on next-generation innovations in implanted neurotechnologies for depression.&#xD;&#xD;Main Results. While participants reported only moderate familiarity with implanted neurotechnology, most were willing to consider it as a treatment option if their depression was sufficiently severe. We identified four aspects of innovation that strongly impacted participants' decision-making about adoption: flexible therapy delivery, implant approach, internal footprint, and brain penetration. The remaining aspects (length of implant procedure, contact with brain, external visibility, device size, and depth in skull) were seen as secondary considerations rather than decision-driving factors. &#xD;&#xD;Significance. Aspects of device design and therapy design that represented substantial patient burden or major intrusions into the body were most impactful for patients' prospective decisions about implanted neurotechnologies. Meanwhile, some aspects that are prioritized by the industry - such as cosmetic invisibility and length of the implant procedure - were given less weight by patients. These findings can help guide patient-centered priority-setting in device design and highlight areas of alignment and divergence across patient and industry priorities.
Clinical research Phase 2 readout

Psilocybin Phase II Trial in Cancer Treatment

Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.
Why it matters ▲ Favorable
The secondary analysis of a Phase II trial on psilocybin's safety and efficacy during anticancer treatment provides valuable insights into its potential therapeutic benefits. This study could inform future research and regulatory decisions on integrating psychedelics into oncology care. It highlights the growing interest in exploring psilocybin as a supportive treatment for cancer patients, potentially improving quality of life and mental health outcomes.
Clinical research Phase 2a study ongoing

5-MeO-DMT & CBT in AUD: Phase 2a trial insights

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐ <i>N</i> , <i>N</i> ‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy
Why it matters ▲ Favorable
This qualitative study provides insights into the psychological change processes facilitated by 5-MeO-DMT in combination with CBT for alcohol use disorder. The findings suggest that the psychedelic experience may act as a catalyst for significant psychological and behavioral changes, supporting abstinence and improved well-being. This research could inform future therapeutic approaches and contribute to the growing evidence base for psychedelic-assisted therapies in addiction treatment.
BACKGROUND AND AIMS: This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural therapy (CBT) for relapse prevention in alcohol use disorder (AUD). DESIGN: Embedded qualitative sub-study within an open-label, phase 2a, single-dose (Day 0) clinical trial with 12-week follow-up (Day 84 endpoint). Semi-structured interviews were conducted remotely with participants at Day 1 post-dose and end-of-study (Day 84). Therapists were interviewed once to triangulate participant accounts and explore perceived change processes in the context of psychological support and CBT. SETTING: One drug and alcohol service and one research facility in London, UK (29 March 2023-2 July 2024). PARTICIPANTS: Ten participants (8 men, 2 women) with moderate to severe AUD and six therapists who worked on the study. MEASUREMENTS: Interviews with participants followed a topic guide covering alcohol use history and motivations; expectations, intentions and preparation; acute dosing-day experiences; perceived psychological and behavioural changes; and the perceived role of support and relapse-prevention CBT. Therapists were interviewed to provide a complementary professional viewpoint on the changes and role of support. All interviews were audio-recorded, transcribed verbatim, and analysed using an interpretative phenomenological perspective supported by iterative categorisation. FINDINGS: Immediately after dosing, participants commonly described the experience using metaphors of a "reset", "cleansing", or "rebirth", often accompanied by emotional catharsis and rapid shifts in self-perception. They reported increased clarity regarding their relationship with alcohol, enhanced emotional openness, and improved self-compassion and interpersonal connectedness. At the 12-week follow-up, participants who maintained abstinence (n = 5) described the psychedelic experience as a pivotal turning point, facilitating sustained reappraisals of identity, values, and patterns of alcohol use. They also reported greater mindfulness, cognitive flexibility, and emotional acceptance, coupled with enhanced relationship quality, better sleep, increased energy, and overall well-being. Participants who resumed moderated drinking (n = 2) reported similarly increased self-awareness, reduced compulsivity, and greater emotional regulation. Therapist accounts closely corroborated these participant narratives, highlighting observed shifts in psychological flexibility, emotional openness, and adaptive behavioural responses. Therapists also noted that the psychedelic experience enabled rapid relaxation and revision of maladaptive core beliefs and promoted resilience and acceptance, even in participants with initially challenging experiences. CONCLUSIONS: Participant and therapist accounts indicate that a single dose of 5-methoxy-N,N-dimethyltryptamine, when embedded in a relapse-prevention cognitive behavioural therapy programme, can support meaningful shifts in self-appraisal, emotional regulation, and behavioural patterns associated with alcohol consumption.
Clinical research Peer-reviewed publication

New review dissects active mechanisms in psychedelic therapeutics

Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics.
Why it matters ▲ Favorable
This peer-reviewed article synthesizes emerging evidence on the pharmacological and experiential factors underlying psychedelic therapy outcomes. By clarifying which molecular and psychological components drive efficacy, the review informs both future clinical trial design and regulatory frameworks for psychedelic medicines. The findings may guide researchers in optimizing protocols and help policymakers distinguish between drug effects and contextual variables when shaping access or approval pathways.
Clinical research Research published

Caution on ketamine vs. esketamine dosing

A crucial cautionary note on frequently incorrect dose equivalence between ketamine and esketamine.
Why it matters ◈ Mixed
This research highlights the frequent inaccuracies in dose equivalence between ketamine and esketamine, which are often used interchangeably in clinical settings. Understanding these differences is crucial for ensuring patient safety and efficacy in treatment protocols. This finding may prompt further studies and influence clinical guidelines, impacting both research and therapeutic applications.
Clinical research Review published

Evolving strategies in drug abuse detection

Detection of drugs of abuse: evolving analytical strategies and emerging challenges
Why it matters ◈ Mixed
This review highlights the evolving analytical strategies for detecting drugs of abuse, emphasizing the challenges posed by new psychoactive substances (NPS). Advancements in detection methods could significantly impact forensic and clinical settings by improving the sensitivity and specificity of drug testing. This is crucial for adapting to the continuous evolution of NPS and ensuring accurate monitoring in public health and legal contexts.
The detection of drugs of abuse in biological and non-biological matrices remains a cornerstone of forensic, clinical, and public health investigations. Traditional matrices such as urine and blood provide short-term evidence of drug intake, while alternative specimens such as hair offer extended detection windows, and oral fluid provides a reliable indicator of recent drug intake comparable to blood. This review summarizes current knowledge on specimen selection, factors influencing drug absorption, distribution, and elimination, and highlights analytical strategies ranging from chromatographic and mass spectrometric methods to emerging electrochemical, optical, and biosensor platforms. Special emphasis is placed on the challenges posed by new psychoactive substances (NPS) such as synthetic cannabinoids (SCs), cathinones, hallucinogens, and amphetamine type stimulants, which continuously evolve to evade regulation and complicate detection. Advances in sample preparation, miniaturization, and portable analytical devices are critically evaluated in terms of sensitivity, specificity, and applicability to forensic and clinical settings. A central theme of this review is the two-tiered analytical framework that integrates rapid field screening technologies with highly selective chromatographic–mass spectrometric confirmation, providing a practical and scalable approach for addressing both conventional drugs of abuse and emerging NPS challenges.
DEA / Controlled Substances Rule proposed

DEA proposes expanded listing for PMK glycidic acid

Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
Why it matters ◈ Mixed
This proposed amendment by the DEA aims to expand the control of PMK glycidic acid to include its esters. This could have significant implications for chemical manufacturers and researchers who utilize these compounds in the synthesis of MDMA and other substances. The inclusion of esters under the list I chemical category may increase regulatory compliance requirements and could impact the availability of these chemicals for legitimate research purposes.
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
FDA / DEA Revised draft guidance announced

FDA revises guidance on TDS irritation/sensitization for ANDAs

Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
Why it matters ◈ Mixed
The FDA's revised draft guidance on transdermal and topical delivery systems (TDS) for ANDAs clarifies expectations for in vivo skin irritation and sensitization studies. This update could impact the development and approval process for psychedelic compounds delivered via TDS. Researchers and industry stakeholders should review the guidance to ensure compliance and optimize study designs.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry titled "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs." This revised draft guidance provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation (and sensitization, if applicable) potential of a proposed transdermal or topical delivery system (collectively referred to as TDS). The recommendations in this revised draft guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The revised draft guidance is intended to clarify FDA's recommendations and expectations related to in vivo skin irritation and in vivo combined skin irritation and sensitization studies. This draft guidance replaces the draft guidance "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs" (April 2023).
Clinical research Model proposed

Psychological Control & Reserve Model in Psychotherapy

Internal and External Psychological Control and Psychological Reserve: Psychological Change Mechanisms in Psychotherapy
Why it matters ◈ Mixed
This article introduces a new model focusing on psychological control and reserve, which could impact psychotherapy approaches. The model's differentiation into internal and external control, as well as psychological reserve, offers a nuanced understanding of psychotherapeutic change mechanisms. While not directly related to psychedelics, the model could inform therapeutic frameworks that integrate psychedelic-assisted therapy.
This article proposes a general integrative model focusing on psychological control and psychological reserve. The former refers to internal psychological control and external psychological control. Internal psychological control refers to the management of physiological processes associated with arousal and panics. Here, the concept of internal psychological control is differentiated into two components: cognitive control/executive function and self-control/emotional regulation. External psychological control refers to the sense the person has of being able to manage, have agency in, and otherwise not be overwhelmed by the external context in which one is adapting functionally. Here, the concept of external psychological control is differentiated into two major sub-components: managing reactivity to external events, such as to daily stressors or extreme events, e.g., natural disasters, and proactively taking steps to have agency in and using predictive processing to adjust to context by mitigating the probability of experiencing overwhelming events. Psychological reserve refers to the fluid state reservoir of mental, cognitive, emotional, motivational, and stress management/coping space that is available for use in confronting ongoing and new stressors, challenges, or difficulties. Here, this article differentiates psychological reserve into phases of depletion and recovery. This article examines prior work on psychological control and reserve, demonstrating how they can be understood or modified based on the present sub-component differentiation of the concepts involved. The revised model is applied to understanding psychotherapeutic change mechanisms, a biopsychosocial model of the mechanisms, an integrated functional adaptational model, posttraumatic stress disorder, a unified model for psychotherapy and psychology generally, and clinical recommendations.
Neuroscience Research published

Electrical stimulation mimics ketamine in neurons

Single transient exposure to low-frequency low-intensity electrical stimulation produces ketamine-like effects in human iPSC-derived dopaminergic neurons via Ca2(+)-dependent BDNF and mTOR signaling.
Why it matters ▲ Favorable
This study suggests that low-frequency, low-intensity electrical stimulation can produce effects similar to ketamine in dopaminergic neurons, potentially via pathways involving BDNF and mTOR signaling. This finding could open new avenues for non-pharmacological treatments for conditions like depression, where ketamine is currently used. The research may influence future clinical trials and therapeutic strategies, offering a novel approach to modulating neural activity without drugs.
Neuroscience Research published

Sex differences in ketamine recovery in mice

Brains of male and female mice recover differently from ketamine.
Why it matters ◈ Mixed
This study highlights potential sex differences in the neural recovery process following ketamine administration in mice. Understanding these differences is crucial for developing gender-specific treatment protocols in clinical settings. While the research is preclinical, it may inform future human trials and therapeutic strategies.
Neuroscience Research published

Sex differences in rodent fear conditioning questioned

Freezing as a measure of fear: sex differences and implications for preclinical research
Why it matters ◈ Mixed
This study highlights potential limitations in the translational validity of rodent fear conditioning paradigms, particularly concerning sex differences. Refining behavioural readouts and including both sexes in preclinical models are crucial for enhancing PTSD research. This finding could influence future research designs and improve the accuracy of preclinical PTSD models.
Rodent fear conditioning paradigms are widely used to model core features of posttraumatic stress disorder (PTSD), with freezing behaviour serving as the dominant readout. However, the extent to which freezing captures biologically and clinically relevant variability, particularly with respect to sex differences, remains unclear. We conducted a systematic review and meta-analysis of studies employing fear conditioning and extinction in wild-type rodents to assess sex differences in freezing behaviour. These were not found across studies. However, freezing levels were significantly correlated with shock intensity only in male rodents. We conclude that freezing may represent a constrained and potentially low-resolution behavioural output, which may fail to detect meaningful variation in fear processing. Given that PTSD exhibits pronounced sex differences in humans, the translational validity of commonly used behavioural endpoints may be questionable. Including both sexes and refining behavioural readouts in animal models are critical for improving the translational pipeline of stress research.
Neuroscience Special issue published

Special Issue on Psychedelic Pharmacology in Drug Development

Special Issue on the Promise of Psychedelic Pharmacology in Neuropsychiatric Drug Development.
Why it matters ▲ Favorable
The publication of a special issue on psychedelic pharmacology highlights the growing interest and potential of these substances in neuropsychiatric drug development. This could spur further research and development efforts in the field, potentially leading to new therapeutic options for mental health disorders. It underscores the importance of continued scientific exploration and validation of psychedelics' efficacy and safety.
Neuroscience Research finding

Ketamine linked to morning cortisol increase

Ketamine’s rapid relief of suicidal thoughts may be linked to an increase in morning cortisol
Why it matters ◈ Mixed
A study suggests that ketamine's rapid relief of suicidal thoughts may be associated with an increase in morning cortisol levels. This finding could inform future research on the mechanisms of ketamine's antidepressant effects. However, more research is needed to understand the clinical implications and potential for broader therapeutic use.
Neuroscience Research published

Cross-species mapping links HTR2A to psychedelic effects

Cross-species mapping of acute psychedelic-responsive genes links HTR2A cortical expression, cell-type enrichment, and human cortical expression modules
Why it matters ▲ Favorable
This study enhances our understanding of how psychedelics affect brain function by mapping genes responsive to these substances across species. It identifies a significant link between HTR2A expression and cortical changes, which could inform future therapeutic applications. While the findings are promising, further research is needed to explore receptor-specific and causal mechanisms.
Abstract Psychedelic drugs exert rapid and profound effects on human consciousness [1–7] and are increasingly being investigated for their therapeutic potential [8–14]. Yet the transcriptional programs through which they may reshape brain function and structure remain incompletely understood, in part because the available evidence is heterogeneous and largely preclinical [15, 16]. In a structured scoping review of transcriptomic studies in animal models and neural cell cultures, we identified genes reported in the source literature to change within 3 h of classical psychedelic administration and intersected them with the Allen Human Brain Atlas to define an acute expression set. This retained set showed cortex-centered enrichment, a marker-based deep-layer projection-neuron component, and ontology enrichment for neuron projection and related synaptic terms. A smaller subset overlapped with human accelerated region-associated genes and showed greater-than-random spatial alignment with a human cortical-expansion map. The retained cortical-expression maps showed serotonergic spatial alignment in the human cortex, most prominently with HTR2A expression. Clustering identified three cortical spatial-expression modules, including an association/limbic-weighted module enriched for plasticity and synaptic-organization terms. Together, these findings provide a human cortical framework linking acute psychedelic-responsive transcription to cortical cell-type enrichment, HTR2A spatial expression, cortical spatial-expression modules, and cortical-expansion, while leaving receptor-specific, causal, translational, and cell-type-resolved mechanisms for future work.
Clinical research Pilot study published

Pilot study on aspirin & ketamine for knee pain

The Safety and Feasibility of Oral Aspirin and Ketamine for Acute Pain Management After Total Knee Arthroplasty: A Pilot Study.
Why it matters ◈ Mixed
This pilot study explores the combination of oral aspirin and ketamine for managing acute pain post knee surgery. While this research is preliminary, it could inform future pain management protocols and the role of ketamine in non-psychiatric settings. The study's findings may influence clinical practices and further research into multimodal pain relief strategies.
Clinical research Study published

Psilocybin study on cancer fear published

Psilocybin for Fear of Cancer Recurrence.
Why it matters ▲ Favorable
The publication of a study on psilocybin for fear of cancer recurrence adds to the growing body of evidence supporting psychedelic-assisted therapy for mental health conditions. This research could influence future clinical guidelines and patient care strategies. It highlights the potential for psilocybin to address psychological distress in cancer patients, which may lead to broader acceptance and integration into therapeutic settings.
Clinical research Research published

Mechanism debate in psilocybin therapy for depression

The mechanism debate in psilocybin therapy for depression.
Why it matters ◈ Mixed
The publication discusses ongoing debates about the mechanisms through which psilocybin exerts its therapeutic effects on depression. Understanding these mechanisms is crucial for optimizing treatment protocols and ensuring safety. Clarifying the mechanism may influence future clinical trial designs and regulatory decisions.
Clinical research Framework published

Ethical governance framework for psychedelic-assisted therapy published

Competencies and Ethical Governance for Psychedelic‑Assisted Therapies: A Practice‑Embedded Quality‑Improvement Framework.
Why it matters ▲ Favorable
This publication proposes a structured framework for competencies and ethical governance in psychedelic-assisted therapies, aiming to standardize quality and safety in clinical practice. The framework is likely to inform training, oversight, and quality improvement for practitioners and organizations as the field matures. While not a regulatory mandate, it provides a reference point for policy development and institutional protocols, supporting the safe scaling of psychedelic therapy services.
Neuroscience Research review published

Psychedelic-informed Therapeutics for Depression

Psychedelic-informed Therapeutics and Functional Decoupling: Toward Experience-independent Rapid-acting Antidepressants
Why it matters ◈ Mixed
This review suggests a novel framework for understanding depression as a disorder of dysregulated inflammation-plasticity coupling. Psychoplastogens like ketamine and psychedelics may offer a new approach by enhancing synaptic plasticity independent of inflammatory constraints. While promising, these compounds are still in the early stages of development and require further research to validate their mechanisms and optimize treatments.
Major depressive disorder remains a leading cause of global disability, and many patients show limited response to conventional antidepressants.Increasing evidence suggests that a substantial subgroup exhibits chronic low-grade inflammation, which may constrain synaptic plasticity and contribute to persistent depressive symptoms.In this review, we propose that depression can be conceptualized as a disorder of dysregulated inflammation-plasticity coupling, in which inflammatory signaling interferes with adaptive neural remodeling.Sterile neuroinflammation, triggered by non-infectious stressors such as psychosocial stress and metabolic dysfunction, disrupts glutamatergic transmission, reduces brain-derived neurotrophic factor signaling, and impairs synaptic plasticity.These processes may contribute to circuit rigidity, reduced neural flexibility, and treatment resistance.Psychoplastogens, including ketamine, serotonergic psychedelics, and emerging non-hallucinogenic analogues, offer a distinct therapeutic approach by rapidly enhancing synaptic plasticity.Rather than directly suppressing inflammation, these compounds may restore neural adaptability and functionally decouple plasticity-related processes from inflammatory constraints.A central contribution of this review is the integration of inflammation-plasticity coupling and relative functional decoupling as a translational framework for understanding rapid-acting antidepressant mechanisms.Within this framework, experience-independent psychoplastogens may represent a promising direction for future antidepressant development.However, such compounds should currently be regarded as an emerging drug-development strategy rather than an established therapeutic approach.Further research is needed to validate these mechanisms in humans and to optimize biomarker-guided, plasticity-focused treatment strategies for depression.
Clinical research Research paper published

Enactive approach to ketamine therapy explored

Dance of the four bodies: An enactive-individuative approach to ketamine assisted psychotherapy
Why it matters ◈ Mixed
This paper introduces a novel philosophical framework for understanding ketamine-assisted psychotherapy (KAP) by integrating enactivism with psychedelic therapy. It challenges existing computational models and proposes a more biologically grounded perspective. This could influence future research directions and therapeutic practices by offering a new lens through which to view the transformative potential of psychedelics.
In this paper, which is in part intended as a speculative provocation and which combines philosophy of science, clinical practice and psychedelic therapy in a novel manner, we examine ketamine-assisted psychotherapy (KAP) through the lens of an expanded model of enactive cognition. While much work within both KAP and psychedelic-assisted therapy (PAT) in general has relied upon broadly computationalist models of the brain, including most recently the predictive coding and Bayesian style approaches that inform contemporary theories like REBUS and CANALs, we argue that such models poorly typify transformative psychedelic experiences and that enactivism offers a potentially more useful and biologically compelling framework. To this end, we examine and apply contemporary enactivism’s theorisation of living systems as comprised of multiple adaptive bodies, specifically, in the case of human beings, what are described as our organic, sensorimotor and linguistic bodies. Via the philosopher of science Gilbert Simondon, we expand this enactivist model to include a fourth body: the individuative or pre-individual body, which, as we show, has been gestured towards within recent enactive literature as the adjacent possible and is similar to work in complex systems theory, including Stuart Kauffman’s theorisation of res potentia and Alicia Juarrero’s work on emergent constraint regimes. We explore the effects of ketamine through these four bodies. We discuss how different dosage thresholds and experiential dynamics may entail distinct arrangements of these bodies. We further examine how such arrangements are informed by what is commonly described in the psychedelic literature as set and setting. Finally, we offer a provisional complication of this notion by applying enactivism’s core idea of self-making as ongoing autopoietic–adaptive responsiveness to the precarious environments with which selves are entangled.
Neuroscience Research published

New model for estimating E/I balance via M/EEG

A canonical microcircuit for estimating Excitation/Inhibition (E/I) balance
Why it matters ▲ Favorable
This research introduces a novel microcircuit model for estimating excitation/inhibition (E/I) balance using non-invasive M/EEG recordings. The model's ability to simulate changes in E/I balance relevant to schizophrenia could lead to new computational assays for synaptopathy and personalized interventions. While not directly related to psychedelics, understanding E/I balance is crucial for advancing psychiatric disorder treatments, potentially informing psychedelic research.
Abstract Excitation/inhibition (E/I) balance is crucial for maintaining healthy brain function and can be disrupted in various neurological and psychiatric disorders. Despite its importance, there are few tools to study E/I balance non-invasively in humans. Here, we propose a canonical microcircuit model to estimate E/I balance from non-invasive magneto- and electroencephalography (M/EEG) recordings by parameterising global pyramidal and inhibitory cell excitability. We first establish that E/I parameters are identifiable and recoverable. We then explore the effects of these new parameters and their interaction with other parameters in a series of simulations. To highlight the clinical relevance of this new model, we simulate changes in E/I balance and their impact on event-related potentials (ERPs) derived from paired-click, passive and active oddball paradigms, which are among the most robust clinical biomarkers of schizophrenia. Our simulations show that a loss of pyramidal cell excitability can explain reduced ERP amplitudes across all three paradigms, mirroring empirical findings in schizophrenia. This method may serve as a computational assay for estimating synaptopathy and E/I balance from non-invasive M/EEG recordings across various clinical conditions thereby advancing efforts to develop personalised interventions to restore E/I balance.
Neuroscience Peer-reviewed study

Study links microglial activity, sex differences, and ketamine neuroplasticity

Corticosterone-linked microglial activity underpins sexually dimorphic neuroplasticity after ketamine anesthesia.
Why it matters ◈ Mixed
This study identifies corticosterone-mediated microglial activity as a key factor in sex-specific neuroplasticity following ketamine anesthesia. The findings may help explain differential responses to ketamine in males and females, with implications for clinical trial design, dosing, and safety monitoring. While not directly policy-facing, this research supports the need for sex-stratified analysis in psychedelic and anesthetic studies, potentially informing future regulatory guidance.
Clinical research Peer-reviewed publication

Review: Ketamine's therapeutic role in major depression detailed

Therapeutic Potential of Ketamine in Major Depressive Disorder: Pharmacological Insights and Clinical Evidence.
Why it matters ▲ Favorable
This peer-reviewed review synthesizes current pharmacological and clinical evidence supporting ketamine's efficacy in treating major depressive disorder (MDD). It highlights mechanistic insights and summarizes trial data, reinforcing ketamine's position as a rapid-acting antidepressant. The findings may inform clinical guidelines, shape payer and regulatory perspectives, and guide future research priorities in psychiatric care.
Clinical research Phase 3 readout

Esketamine reduces sleep disorders post-cesarean

The effect of esketamine on sleep disorders in parturients undergoing cesarean section under general anesthesia: a single-center, randomized, double-blind, placebo-controlled prospective study
Why it matters ▲ Favorable
This study demonstrates that continuous intraoperative esketamine infusion can significantly reduce postoperative sleep disorders and improve sleep quality, analgesic efficacy, and postpartum depression outcomes in parturients undergoing cesarean section. The findings suggest potential new applications for esketamine in managing postoperative complications and enhancing recovery. This could influence future clinical guidelines and patient care strategies, particularly in obstetric anesthesia.
Background This study evaluated the primary effect of esketamine on postoperative sleep disorder (PSD) at 3 days after surgery, as well as its secondary effects on pain and depressive symptoms. Methods A total of 140 parturients who underwent elective cesarean delivery under general anesthesia were enrolled and randomized 1:1 to the esketamine or placebo group. After delivery, blinded anaesthesiologists administered a continuous infusion of esketamine (0.3 mg/kg/h) or an equal volume of normal saline. We compared baseline data, anesthesia/surgery indicators, postoperative PSQI scores, sleep NRS scores, incidences of PSD, pain NRS scores and postpartum depression (EPDS) between the groups. We also evaluated adverse reactions and maternal–neonatal complications and performed multivariate logistic regression for PSD risk factors. Results At 3 and 7 days after surgery, the PSQI scores, NRS scores, incidence of PSD, and incidence of postpartum depression in the esketamine group were significantly lower than those in the control group ( P &amp;lt; 0.05). The pain NRS scores at 24, 48, and 72 h postpartum and the rate of rescue analgesia within 72 h were also significantly lower in the esketamine group ( P &amp;lt; 0.05). Intraoperative consumption of propofol and remifentanil was significantly lower in the esketamine group than in the control group ( P = 0.038 and P &amp;lt; 0.001, respectively). Logistic regression revealed that a 24-h postpartum pain NRS score (OR = 1.485, 95% CI: 1.058–2.084, P = 0.022) and antepartum sleep disorder (OR = 4.757, 95% CI: 2.241–10.098, P &amp;lt; 0.001) were risk factors for PSD in parturients who underwent cesarean delivery under general anesthesia. Conclusion Continuous intraoperative esketamine infusion reduced the incidence of 3-day postoperative sleep disorders and improves sleep quality, while concurrently enhancing analgesic efficacy and ameliorating postpartum depression outcomes in parturients undergoing cesarean section under general anesthesia. Clinicians should prioritize screening for prenatal sleep disturbances and implement early preventive interventions. Clinical Trial Registration https://clinicaltrials.gov/ , Identifier [ChiCTR23000 78490].
Public health Research framework published

Harm-Reduction Framework for Acute Panic in Substance Use

Acute Substance-Induced Panic and Distress: A Harm-Reduction Framework for Immediate Stabilization
Why it matters ▲ Favorable
This framework addresses acute panic and distress during substance use, offering a harm-reduction approach that bridges informal advice and emergency toxicology. It provides a structured model for immediate stabilization without equating pharmacological effects across substances. This can guide both public health strategies and community support efforts in managing substance-induced distress.
Recreational substance use can produce acute panic and distress even when no severe toxicological emergency is immediately evident. Existing literature commonly treats cannabis-related anxiety, stimulant intoxication, MDMA-related complications, cocaine-related cardiovascular risk, ketamine-related dissociation, and psychedelic challenging experiences as separate domains. This article conceptualizes acute substance-induced panic and distress as a harm-reduction stabilization problem located between informal user advice and emergency toxicology. It focuses on immediate stabilization rather than preparation, post-acute integration, durable psychological change, or general overdose management. The central model is an acute alarm loop in which bodily or perceptual change, threat interpretation, fear escalation, autonomic amplification, and further distress may reinforce one another. The model distinguishes analytically, rather than absolutely, between pharmacological effects and secondary escalation. The framework further distinguishes substance-specific acute risk modifiers, universal stabilization principles, research-mapped arousal-related exposures, and escalation boundaries. It does not claim pharmacological equivalence between substances and does not present any non-prescription substance as a treatment for intoxication. Rather, it offers a structured model for understanding and reducing mild-to-moderate acute distress during intoxication while preserving clear criteria for medical escalation.
Clinical research Framework proposed

New Framework for Psychedelic Preparation and Aftercare

The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and Setting
Why it matters ▲ Favorable
The Experience-Trajectory Framework offers a nuanced approach to psychedelic preparation and aftercare by stratifying risks based on substance-specific experience trajectories and baseline physiological conditions. This framework could enhance safety and efficacy in psychedelic therapy by tailoring protocols to the unique characteristics of each psychedelic substance. It provides a foundation for future research on preparation standards and safety practices.
Set, setting, preparation, and integration are widely recognized as important dimensions of psychedelic experiences. However, these concepts often remain too general to specify how preparation, containment, and aftercare should differ across substances, routes of administration, acute duration, residual effects, bodily condition, and interaction exposure. This article proposes the Experience-Trajectory Framework for psychedelic preparation and aftercare. The framework focuses on psilocybin, LSD, mescaline, vaporized N,N-DMT, vaporized 5-MeO-DMT, and ayahuasca or oral DMT combined with monoamine oxidase inhibition. Its central claim is that preparation and aftercare should be stratified by two primary variables: the Experience-Trajectory Profile of the psychedelic state and the participant’s Baseline Risk State before exposure. Experience-Trajectory Profile refers to onset, peak phase, acute duration, residual effects, recovery window, and the earliest appropriate timing for interpretation or integration. Baseline Risk State refers to the participant’s acute physiological and pharmacological condition, including sleep, hydration, cardiovascular stability, gastrointestinal status, glucose stability, psychological stability, and interaction load. This article is a conceptual framework paper, not a clinical protocol or medication-discontinuation guide. It provides a stratification model that links substance-specific experience trajectories with baseline physiological and interaction states to derive containment intensity, aftercare timing, and post-acute meaning-regulation needs. By distinguishing compressed, medium-duration, long-duration, and MAO-mediated experience profiles, the framework clarifies why different psychedelic contexts require different screening, containment, stabilization, and follow-up procedures. It is intended as a research-oriented framework for conceptual clarification, safety documentation, retreat-safety evaluation, and future empirical refinement. The framework also offers a basis for future comparative research on preparation standards, retreat safety practices, and post-acute stabilization across different psychedelic contexts.
Clinical research Study results announced

Veterans' PTSD resolves with psychedelic therapy

Veterans' PTSD resolves with psychedelic therapy in small US study
Why it matters ▲ Favorable
This small US study suggests that psychedelic therapy could be a promising treatment for PTSD in veterans. While the study is limited in scale, it adds to the growing body of evidence supporting the therapeutic potential of psychedelics. These findings could influence future research directions and policy considerations regarding the use of psychedelics in mental health treatment.
Neuroscience Study published

Global study links breathwork to mental well-being

Exploring the benefits of altered states of consciousness and reduced experiential avoidance for mental well-being: insights from a global study on high ventilation breathwork
Why it matters ▲ Favorable
This study offers insights into how high ventilation breathwork (HVB) can improve mental health by reducing experiential avoidance (EA) through altered states of consciousness (ASCs). The findings suggest that fostering blissful states within ASCs may enhance openness and engagement, potentially benefiting mental well-being. While not directly related to psychedelics, these insights could inform therapeutic practices and community approaches to mental health.
Background Research suggests that high ventilation breathwork (HVB) improves mental health by reducing experiential avoidance (EA) through altered states of consciousness (ASCs). The present study examined whether EA during participants’ most recent breathwork session predicted mental well-being afterward. Additionally, the study examined the relationships between EA, ASCs, emotional breakthroughs, and mentally challenging experiences (e.g., negative emotions or thoughts) during the session and mental well-being afterward. Methods This cross-sectional, international online study was conducted in German and English and included a final sample of N = 324 participants from 23 countries of residence. Participants reported on their most recent breathwork experience and completed validated questionnaires, including the APEQ-S, 11D-ASCs, EBI, and WEMWBS, as well as a self-developed challenging experiences scale. Multiple linear regressions and mediation analyses were conducted. Results During the session, ASCs significantly predicted lower EA. In turn, lower EA during the session significantly predicted higher mental well-being after the session. Moreover, higher ASC ratings and lower ratings for challenging experiences significantly predicted higher mental well-being after the session. EA did not significantly predict emotional breakthroughs, nor did it mediate the relationships between ASCs or challenging experiences and mental well-being. Conclusion Overall, the findings suggest that reduced EA and more intense ASCs during HVB enhance mental well-being. Blissful states within ASCs predicted lower EA, highlighting their potential in fostering openness and engagement during HVB.
Clinical research Scoping review published

Review of ketamine guidelines for chronic pain

A scoping review for published guidelines for use of ketamine in chronic non-cancer pain.
Why it matters ◈ Mixed
The scoping review provides an overview of existing guidelines for the use of ketamine in treating chronic non-cancer pain. This is crucial for clinicians as it helps standardize treatment protocols and informs future research directions. Understanding these guidelines can improve patient care by ensuring safe and effective use of ketamine.
Clinical research Pilot trial results

Psilocybin therapy shows promise for veterans with PTSD

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial
Why it matters ▲ Favorable
This pilot trial demonstrates the safety and potential efficacy of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD. The study found significant reductions in PTSD symptoms without serious adverse events, suggesting a promising new treatment avenue for a high-risk population. These findings could inform future larger-scale trials and potentially influence treatment protocols for PTSD in veterans.
Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn’t been studied in U.S. military Veterans, who face higher symptom severity and suicide risk. This open-label pilot trial evaluated the safety and feasibility of PAT in Veterans with severe, treatment-resistant PTSD. The clinical trial was pre-registered at ClinicalTrials.gov (NCT05554094). The eligibility criteria were that participants be U.S. military Veterans aged 21–64 with a DSM 5 diagnosis of PTSD for at least six months, and a Clinician-Administered PTSD Scale for DSM 5 (CAPS-5) total severity score ≥35. PTSD was also required to be treatment-resistant. Clinical outcomes were assessed at the Center for Psychedelic Drug Research and Education in Columbus, OH. Twelve participants received eight hours of therapy followed by two psilocybin dosing sessions at 15 mg and 25 mg, spaced 2–3 weeks apart, of synthetic psilocybin, along with approximately eight hours of post-psilocybin therapy. Follow-up occurred at four weeks post-second dosing. The primary endpoints were safety (i.e., the type, severity, frequency of adverse events) and suicidal ideation/behavior (as measured by the Columbia Suicide Severity Rating Scale (CSSR-S)) from baseline to 1-month post-second psilocybin administration. The secondary endpoints were PTSD symptom severity rated by a clinician and the participant. Exploratory analyses included the impact of psychotherapy and expectancy on PTSD symptom severity. Of the 668 participants who completed the online pre-screener, 13 consented and enrolled, 1 withdrew before the first dosing session, and 12 fulfilled the study requirements. No serious adverse events occurred; non-serious adverse events included headaches, anxiety, and dizziness. There was no increase in suicidal ideation or behavior during the trial, and heart rate and blood pressure remained within safe limits during the psilocybin sessions. There was a large (d = 2.30) and significant (p < 0.001) reduction (mean difference = 27.5, 95% CI: 19.9 to 35.1) in clinician-rated PTSD symptoms from baseline through 1-month follow-up, with 75% having a treatment response and in remission from PTSD. While expectancy did not predict changes in PTSD symptoms, pre-dosing symptom change during the preparation phase of treatment did. Clinician adherence ratings were 98% across all study visits. Findings reveal that PAT is safe, well-tolerated, and shows preliminary clinical improvement for PTSD, suggesting that PAT may offer therapeutic relief for Veterans with severe treatment-resistant PTSD. This study explored whether psilocybin-assisted therapy (PAT), a therapeutic approach being studied for the treatment of several mental health conditions, could help U.S. military Veterans with severe treatment-resistant posttraumatic stress disorder. Veterans completed therapy sessions before and after receiving two doses of psilocybin. Researchers monitored safety and changes in PTSD symptoms for one month after treatment. No serious safety problems occurred, and most side effects were mild, such as headaches or brief anxiety. Veterans showed large improvements in PTSD symptoms, and many no longer met criteria for PTSD after one month. These results suggest PAT may offer meaningful relief for Veterans who have not found help through standard treatments. More research with larger groups is needed to confirm these results. Armstrong et al. conducted an open-label pilot trial of psilocybin-assisted therapy in U.S. military veterans with severe treatment-resistant PTSD. The therapy was safe and well-tolerated and produced large reductions in PTSD symptoms, with most participants achieving clinical response and remission.
Clinical research Study published

Study on psychedelic therapy for racial trauma

Retreat from racism: A psychedelic group experience for racial stress and trauma
Why it matters ▲ Favorable
This study highlights the potential of psychedelic-assisted therapy (PAT) in addressing race-based traumatic stress (RBTS) through a culturally attuned framework. By integrating pharmacological, relational, and cultural processes, the research underscores the importance of cultural safety and community affirmation in therapeutic settings. This work could guide future interventions and expand the scope of PAT to include culturally responsive care.
Background Racism and discrimination are pervasive social determinants of health, yet mainstream mental health care often fails to address the psychological sequelae of racial trauma, or race-based traumatic stress (RBTS). While psychedelic-assisted therapy (PAT) has re-entered the scientific mainstream, empirical guidance for culturally attuned, integrative care is limited. This study explores a "context-as-medicine" framework, where therapeutic change is driven by synergistic pharmacological, relational, and cultural processes. Methods This prospective, naturalistic observational study documented a specialized psychedelic retreat model in Jamaica. Participants (N = 11) with confirmed RBTS underwent a seven-day program featuring two psilocybin-assisted ceremonies and community-based integration. The research employed a mixed-methods approach to evaluate the implementation of the Healing Racial Trauma Protocol (HRTP), focusing on mechanisms of neuroplasticity, psychological flexibility, and the navigation of systemic power dynamics. Results The study demonstrates the feasibility of a safe, ethically grounded, and culturally responsive container. The retreat functioned as a cultural forge, where the absence of systemic racial threats and the presence of communal witnessing acted as active therapeutic agents. Findings highlight the necessity of addressing internalized racism and colorism while navigating unexamined privilege within the therapeutic dyad. Mechanistically, the model aligns with evidence that psychedelics may reopen critical periods for social reward processing, allowing for the re-authoring of identity-linked narratives. Conclusion By documenting this culturally grounded methodology, this work addresses a critical methodological void. It provides a scaffold for the responsible replication of psychedelic-based interventions, emphasizing that molecular plasticity must be paired with cultural safety and community affirmation to facilitate psychological repair and collective well-being.
Neuroscience Research published

Study: Magnesium's impact on cortical neuron dynamics

Effect of acute elevated magnesium on bursting activity and information-processing dynamics in cortical cultures
Why it matters ◈ Mixed
This study explores how elevated magnesium levels affect neuronal network dynamics, revealing that magnesium can increase burstiness rather than reduce it. These findings challenge the traditional view of magnesium as a 'burst quieter' and may influence its use in treating neurological disorders. The research provides a foundation for further exploration into magnesium's role in brain health and its potential therapeutic applications.
ABSTRACT Magnesium (Mg 2+ ) plays a significant role in hippocampal memory and learning and is implicated in a variety of neurological disorders, such as migraine. Despite this crucial role Mg 2+ has on brain health, its effect on the dynamics of networks of neurons is still not fully understood. This study investigates the impact of several doses of elevated extracellular Mg 2+ on cortical organotypic cultures . Cultures were recorded on a 512-microelectrode array and analyzed using the burstiness index (BI), the rate of network-wide bursts relative to other neuronal activity. We also use a suite of information theoretic measures to further establish the role Mg 2+ plays in the brain. Elevated Mg 2+ is found to have a dose-dependent increase on BI caused by a loss of network activity not contained within a burst or high firing rate activity. Information dynamics further show that the network experiences a loss of entropy and an increase in time-reversibility, connectivity, and transfer of redundant information. These factors indicate that Mg 2+ causes a loss of complex activity and an increase in highly integrated, constant dynamics. This lays the groundwork for a deeper examination of the role Mg 2+ plays in learning, memory and treating neurological disorders. AUTHOR SUMMARY Magnesium is crucial for neurological health. In pyramidal neurons, magnesium blocks NMDA receptors, thereby reducing synchronous neural activity in the brain. This has led to the canonical view of magnesium as a “burst quieter”. Here, we take a closer look at magnesium’s role in cortical slice cultures by examining network burstiness with normal and chronically elevated levels of magnesium. We show that magnesium can effectively increase burstiness, not reduce it. Magnesium is further shown to cause significant changes in how neurons process information. These findings may have impact how magnesium is used as a treatment for neurological disorders.
International policy Analysis published

US Psilocybin Legalization Momentum Analyzed

Shrooming Ahead: How the U.S. is Marching Toward Psilocybin Legalization and What Other Countries May Learn
Why it matters ▲ Favorable
The U.S. is making significant strides toward a legal framework for psilocybin, driven by state and local efforts, activism, and investment. This movement may serve as a model for other countries considering psilocybin legalization. The analysis highlights the potential for widespread change and the role of various stakeholders in this evolving landscape.
The United States is traveling with momentum toward a statutory framework in which the consumption of psilocybin for therapeutic purposes is legal. The psychedelic substance has already been legalized or decriminalized in several cities and states. Most countries, however, have seen no such movement toward legalization. This Note explores how the U.S. psilocybin movement could become a model for other countries to follow suit. Despite long-standing federal roadblocks, the U.S. is starting to excel in terms of individual activism, non-profit organization campaigning, and private investment. Although psilocybin is subject to widely differing legal treatments throughout the world, it is undeniably on a path to decriminalization, legalization, and acceptance. The United States, although lagging on the federal level, is providing a unique view of how psilocybin decriminalization and medicalization can be achieved through state and local government, individual citizens, well-funded research, and exposure to the public. It remains to be seen how quickly these factors will lead to widespread change in the U.S., however, the early years of this movement have already revealed a lot of information about this process. Countries throughout the world, at earlier stages of legalization, may look to this progress and adopt their own versions of it to effectively achieve psilocybin legality.
Neuroscience Research published

Photoswitchable Orexin Antagonist Developed for Brain Studies

In Silico to In Cerebro—Development of the Orexin Receptor Antagonist “Photorexant” for Photomodulation In Vitro and in Mouse Brains
Why it matters ▲ Favorable
This study introduces 'photorexant,' a photoswitchable orexin receptor antagonist, which allows for precise optical control of orexin signaling in vitro and in mouse brains. This development could significantly advance research into psychiatric disorders linked to orexin signaling. While not directly related to psychedelics, the methodology and findings may inspire similar approaches in psychedelic research.
ABSTRACT In this study, we report the first photoswitchable small molecule dual ligands for the orexin receptor subtypes 1 (OX1R) and 2 (OX2R) as molecular tools for optical control of orexin signaling. The orexin system is critical for several physiological processes and has been increasingly implicated in the pathogenesis of various psychiatric disorders. We implemented a prospective structure‐based design approach, generating azobenzene‐containing derivatives of the FDA‐approved dual orexin receptor antagonist suvorexant with a computational workflow that featured a novel fragmentation and azobenzene‐fusion strategy. The derivatives were subsequently evaluated by molecular docking to ensure preservation of the characteristic binding mode of suvorexant. Top candidates were synthesized and characterized by photophysical and pharmacological methods, namely our recently developed β‐arrestin 2 and miniGα q recruitment assays for both receptor subtypes. Optimization of the photoswitchable moiety yielded the highly potent antagonist “photorexant,” exhibiting an up to 11‐fold activity difference between photoisomers. A newly optimized assay protocol for the characterization of photoswitchable GPCR antagonists demonstrated dynamic, reversible photomodulation of orexin receptors by photorexant in vitro. Electrophysiological studies in hypothalamic and locus coeruleus neurons in mice demonstrated photomodulation of its antagonistic properties in vivo, positioning photorexant as an excellent tool for further investigation of orexin signaling.
Clinical research Research review

Psychological distress impacts cancer immunotherapy response

Psychological distress as a putative host-state determinant of cancer immunotherapy response
Why it matters ◈ Mixed
This review highlights the potential role of psychological distress as a modifier of cancer immunotherapy efficacy. Understanding the psycho-neuro-immune interactions could lead to new biomarkers and therapeutic strategies. While the evidence is largely observational, it suggests that addressing psychological distress might improve immunotherapy outcomes, which could influence future clinical trial designs and patient care strategies.
Cancer immunotherapy has transformed oncology, yet durable benefits remain limited to a subset of patients, and those cases are incompletely explained by tumor-intrinsic biomarkers alone. Growing evidence indicates that the host immune state is a critical contextual determinant of therapeutic response and may itself be shaped by psychological distress. In cancer patients, such distress-related states have been associated with altered neuroendocrine activity and related cortisol regulation, inflammation, reduced natural killer cell function, and broader immune dysregulation. In parallel, preclinical studies show that glucocorticoid and adrenergic signaling can impair antitumor immunity by promoting T-cell dysfunction, metabolic exhaustion, and increased inhibitory signaling, as well as suppressing antigen presentation. Emerging clinical studies in patients receiving immune checkpoint inhibitors further suggest that emotional distress before immunotherapy initiation is associated with poorer progression-free survival, response, and overall survival outcomes in several cancer settings, including non-small-cell lung cancer, gastroesophageal cancer, gastric cancer, and recurrent high-grade glioma. As these patient data remain largely observational, current evidence supports psychological distress as a putative host-state modifier or correlate, rather than as a proven causal determinant, of immunotherapy response. These observations support a psycho-neuro-immune framework in which psychological distress may identify or contribute to a host state that is less permissive for effective immunotherapy. Here, we review evidence linking host immune competence to immunotherapy efficacy, summarize clinical and molecular data connecting distress to immune dysregulation in cancer, and incorporate emerging evidence that brain–body signaling may shape tumor immunity through neural, endocrine, and immune pathways. We propose that psychological distress should be considered not merely as a parallel quality-of-life variable, but as a biologically relevant and clinically verifiable host-state factor with implications for biomarker development and future host-modulation immunotherapy trials.
Clinical research Research proposal

MB-PAT for cancer demoralization in Canada

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model
Why it matters ▲ Favorable
This proposal for a group-based Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) model could significantly impact the treatment of demoralization syndrome in cancer patients. By leveraging existing group-therapy infrastructure and mindfulness-based interventions, the initiative aims to bridge the gap in existential care within Canadian oncology. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) is set to lead multi-phase trials, potentially transforming care delivery and improving patient outcomes.
Demoralization syndrome (DS) - a distinct clinical entity characterized by helplessness, hopelessness, and a persistent loss of meaning - affects approximately one in five Canadians with advanced cancer and is associated with increased desire for hastened death, negative clinical outcomes, and higher economic burden, yet recognition and treatment of DS remains suboptimal in modern oncology. While current pharmacological treatments fail to address demoralization's existential dimensions, and despite the potential effectiveness of a number of psychosocial interventions, not everyone responds to behavioral therapies and they remain chronically underfunded in mainstream oncology. Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) offers enhanced therapeutic potential by synergistically integrating evidence-based mindfulness training with psilocybin's neuroplastic effects; however, the traditional dyadic delivery model limits scalability within healthcare settings. This viewpoint opines that MB-PAT delivered in a group format represents a potentially optimal solution to this evidence-implementation gap. Our contention is that MB-PAT may harness synergistic biopsychosocial mechanisms that directly counter the isolation of demoralization through an integrative approach. We finish by highlighting the Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) as a pioneering initiative poised to generate critical evidence, infrastructure and capacity through its planned multi-phase initiatives and projects. By leveraging existing group-therapy infrastructure and therapist familiarity with mindfulness-based interventions as the basis for multi-site national clinical trials, and developing a scalable, equity-focused delivery model, MB-PAT offers a pragmatic pathway to integrate potentially transformative existential care into publicly funded Canadian oncology practice.
Neuroscience Study published

DMT and Consciousness Reorganization Study

Dimethyltryptamine and the Recursive Reorganization of Consciousness
Why it matters ◈ Mixed
This study explores the complex effects of DMT on consciousness, highlighting its potential to reorganize perception and brain connectivity. While it provides valuable insights into the pharmacodynamics of DMT, it does not yet offer a unified causal explanation for the observed phenomena. The research introduces new models and frameworks for understanding DMT's impact, which could inform future studies and therapeutic applications.
N,N-dimethyltryptamine (DMT) is a rapidly acting serotonergic psychedelic capable of reorganizing perception, bodily selfhood, spatial enclosure, agency attribution, and experienced reality over an unusually compressed timescale. Controlled human studies report concentration-dependent pharmacodynamic effects, pronounced suppression of alpha-band activity, increased electrophysiological signal diversity, greater global functional connectivity, reduced integrity and segregation of established functional networks, compression of the principal cortical gradient, and modeled reductions in the control energy required for transitions among measured brain states. These findings establish important components of the acute response, but they do not yet provide a unified causal account of how molecular perturbation develops into an immersive and apparently autonomous experiential world, why related structural motifs recur across reports, why pharmacologically comparable sessions may diverge, or why some participants report an inability to regain a previously accessible state. This monograph develops a multilevel causal architecture linking pharmacokinetics, receptor-field activation, cellular gain modulation, whole-brain dynamics, embodied physiology, phenomenological organization, memory, environment, recovery, and post-session updating. The architecture distinguishes departure from ordinary waking organization from approach toward a candidate recurrent DMT-state organization. It introduces independently constructed waking and candidate DMT-state reference manifolds, frozen predictive and descriptive embeddings, bounded reference-fit scores, and an altered-over-waking reference-dominance margin. Breakthrough is defined provisionally as sustained altered-reference dominance above a preregistered threshold for a minimum dwell duration, rather than as a synonym for dose, visual intensity, signal diversity, ego dissolution, or peak subjective magnitude. Worldhood, perceived agency, hyperreality, bodily self-location, self-model destabilization, grounding, recurrence failure, and multidomain recovery are modeled as distinguishable but interacting constructs. Repeated sessions are treated as potentially path-dependent because each episode may modify the memories, expectations, interpretations, regulatory responses, and initial conditions presented to the next exposure. Participant-reported “lockout” is first typed according to pharmacological comparability and reported target-state failure. Records typed as CANDIDATE are then decomposed into waking-reference persistence, altered fragmentation, path divergence, recognition failure, selective preservation of embodiment, protective re-stabilization, report reconstruction, mixed mechanism, and subtype-non-evaluable cases. Within the GCD–UMCP architecture, the introduced manifold, phenomenological, embodiment, recurrence-failure, and recovery quantities remain Tier-2 diagnostics. They do not redefine the reserved Tier-1 quantities {ω,F,S,C,τR,κ,IC}\{\omega,F,S,C,\tau_R,\kappa,IC\}{ω,F,S,C,τR,κ,IC}, and they do not independently establish canonical collapse, integrity gain, admissible return, or welded continuity. The analysis separates direct controlled evidence, convergent human evidence, structured phenomenology, constrained computational inference, GCD–UMCP modeling, novel hypothesis, and ontological claim. Proposed mechanisms involving regulatory memory, targeted desire, observer preservation, selective embodiment, agentive boundary rendering, recurrence failure, and asynchronous recovery are presented as falsifiable hypotheses rather than established clinical facts. The framework remains agnostic regarding the mind-independent existence of perceived entities, environments, places, or dimensions. Ten prospective predictions, six comparative baseline classes, three-valued local prediction stances, explicit contraction conditions, leakage controls, preserved result records, and a repeated-sessio
Clinical research Peer commentary

Comment on pilot ketamine trial in older adults with depression/MCI

Comment on "KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults With Depression and Mild Cognitive Impairment".
Why it matters ◈ Mixed
This commentary on a pilot study of IV ketamine in older adults with depression and mild cognitive impairment (MCI) highlights ongoing safety and tolerability concerns in this vulnerable population. While not a definitive trial, the discussion signals growing research interest in ketamine's neuropsychiatric applications beyond treatment-resistant depression. Policymakers and clinicians should note the need for larger, controlled studies to inform future guidelines and access pathways for geriatric populations.
Clinical research Peer-reviewed publication

Ketamine shows safety, promise in late-life depression with DED

Ketamine Safety and Therapeutic Opportunity in Late-Life Depression With Depression-Executive Dysfunction Syndrome (DED).
Why it matters ▲ Favorable
This peer-reviewed study provides evidence supporting the safety and therapeutic potential of ketamine for late-life depression with executive dysfunction (DED). The findings may inform future clinical trial designs and support expanded research into ketamine's use in geriatric psychiatric populations, a group with few effective treatment options. Results could influence clinical guidelines and policy discussions around off-label ketamine use in older adults.
Clinical research Research review

Esketamine's role in cancer-related depression reviewed

The application of esketamine in cancer-related depressive states: attention from mechanisms to clinical translation
Why it matters ◈ Mixed
This review highlights the potential of esketamine as a rapid-acting antidepressant for cancer-related depressive states, emphasizing its mechanistic pathways and clinical efficacy. While promising, further research is needed to establish long-term safety and optimal dosing. This is crucial for integrating esketamine into oncology care, potentially improving quality of life for cancer patients.
Objectives This article reviews the clinical status and treatment challenges of cancer-related depressive states, clarifies the mechanism of action of esketamine—a novel rapid-acting antidepressant—compares its efficacy with traditional drugs, evaluates safety and tolerability, and summarizes clinical evidence to support clinical practice and research. Methods By searching databases such as PubMed, Web of Science, and Cochrane Library, We conducted a structured review of the available literature on the mechanism of esketamine in the treatment of cancer-related depressive states in recent years, including mechanism studies, clinical trials, and review articles. We focused on its regulation of NMDA receptors, the impact on BDNF expression, synaptic plasticity, and neural circuit remodeling, and compared its efficacy and safety with traditional antidepressants. Results Esketamine exerts rapid antidepressant effects via multiple mechanisms: NMDA receptor antagonism, downstream signaling modulation, BDNF upregulation, synaptic plasticity enhancement, and neural circuit remodeling. Available studies suggest that esketamine may provide rapid antidepressant effects in oncology populations, particularly in perioperative settings. Common adverse events—such as transient dissociation and elevated blood pressure—are generally controllable. Conclusions Esketamine, as a rapidly acting antidepressant, has a plausible mechanistic rationale and potential clinical value in the treatment of cancer-related depressive states. However, its long-term safety, optimal dosing regimens, and individualized application in different cancer patients still require further investigation. In the future, the integration of multi-omics technologies and clinical translational research should be promoted to advance the precision and standardization of its application in cancer-related depressive states treatment.
Clinical research Case report published

Esketamine for ECT-refractory bipolar depression: case report

Intranasal esketamine for ECT-refractory bipolar depression: a case report
Why it matters ◈ Mixed
This case report highlights the potential of esketamine nasal spray as a treatment for ECT-refractory bipolar depression, showing symptom improvement with minimal side effects. While promising, this is a single case report and more comprehensive studies are needed to establish efficacy and safety. It underscores the need for further research in treatment-resistant mood disorders.
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms. She experienced a relapse after a reduction in her maintenance treatment in conjunction with psychosocial stressors, but improved once again after returning to her induction regimen. She tolerated the treatment well with minimal side effects and no reported manic or hypomanic events. More robust research is warranted to better characterize the effectiveness of esketamine in treating treatment-resistant bipolar depression.
Clinical research Research published

New ketamine analysis method in hair validated

Development and validation of an enzyme immunoassay screen and achiral/chiral LC-MS/MS confirmation methods for ketamine analysis in hair.
Why it matters ▲ Favorable
The development of an enzyme immunoassay and LC-MS/MS methods for ketamine analysis in hair represents a significant advancement in drug testing technology. This could enhance the monitoring of ketamine use in both clinical and research settings, providing a non-invasive method for long-term drug use assessment. Such tools are crucial for understanding the pharmacokinetics and long-term effects of ketamine, which is increasingly used in therapeutic contexts.
FDA / DEA Organizational change announced

FDA reorganizes to enhance functions

Statement of Organization, Functions, and Delegations of Authority
Why it matters ◈ Mixed
The FDA's reorganization aims to streamline operations, potentially impacting how psychedelic substances are evaluated and approved. This could lead to more efficient regulatory processes, affecting timelines for drug approval and market entry. The exact implications for psychedelic research and industry remain to be seen.
The Food and Drug Administration's (FDA) plans to centralize and enhance key functions across the agency. These changes will reduce redundancies, improve efficiency, and advance alignment to better serve the American public.
Clinical research Phase 2 trial results

Ketamine Trial in Suicidal Adolescents Shows Feasibility

Intravenous Ketamine for Depressed and Suicidal Adolescents in the Emergency Department: A Randomized Double-Blind Trial
Why it matters ◈ Mixed
This study highlights the potential role of ketamine as a rapid-acting treatment for suicidal adolescents in emergency settings. While the trial did not show significant efficacy over placebo, it demonstrated the feasibility of administering ketamine in the ED. The findings underscore the need for further research to optimize dosing and administration strategies, which could significantly impact emergency psychiatric care for youth.
Introduction: Adolescents frequently seek care in the emergency department (ED) for behavioral health emergencies. Due to national shortages in staffing, limited opportunities to begin treatment on site in most centers and, thus, the frequent default to elusive inpatient psychiatric beds as a means of stabilization, adolescents may spend prolonged amounts of time boarding in the ED, often without treatment. Ketamine is a rapid-acting antidepressant with emerging evidence in adults, but data are limited on its effectiveness in suicidal youth. We aimed to evaluate the effectiveness of a single dose of intravenous (IV) ketamine on depression and suicidality scores compared to placebo in adolescents with treatment-resistant depression presenting to the ED with suicidal ideation. Methods: We conducted a two-arm randomized double-blind placebo controlled trial on a convenience sample of adolescents 12–17 years of age with treatment-resistant depression (trialed at least two antidepressants for at least four weeks each) who presented to the ED with suicidal ideation requiring psychiatric admission. Exclusion criteria included psychosis, substance abuse disorder, intoxication, developmental delay, aggressive behavior, and medical contraindications to ketamine. Subjects were randomized to receive a single dose of ketamine (0.2 mg/kg IV, maximum 35 mg) or saline placebo over two minutes. They completed the Beck Youth Inventory (BYI) and Suicidal Ideation Questionnaire (SIQ) at baseline and at 1 hour, 3 hours, 1 day, 3 days, and 7 days post-treatment. We compared groups with the Fisher exact and two-sided rank-sum tests. Our primary outcome measure was the proportion of subjects with a reduction of ≥ 50% on the BYI and SIQ within 3 hours after treatment. Results: The 29 subjects (14 placebo, 15 ketamine) did not differ significantly in demographic and clinical characteristics. Despite reductions in BYI and SIQ in both groups, the proportions achieving ≥ 50% reductions did not differ significantly at 1 hour (SIQ: placebo, 0% vs ketamine 14.3 % [P = .48]; BYI Anxiety Inventory: placebo, 0% vs ketamine 21.4% [P = .22]; BYI Depression Inventory: placebo, 0% vs ketamine 15.4% [P = .22]). Differences at 3 hours were less pronounced. Adverse effects were more frequent in the ketamine group, most notably signs of dissociation (7% vs 60%, P = .004), with none after the 1-hour observation period. Conclusion: The ED offers an opportunity to deliver rapid-acting antidepressant treatment for suicidal adolescents. Although low-dose ketamine was not associated with greater reductions in depression or suicidality than placebo, this study demonstrated feasibility and highlights the need for larger studies to determine optimal ketamine dosing, route of administration, and implementation strategies in the ED setting.
Clinical research Case study published

Psilocybin therapy shows promise in Jamaican case studies

Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica
Why it matters ◈ Mixed
These case studies from Jamaica highlight potential psychological and somatic benefits of psilocybin-assisted psychotherapy, including improvements in social anxiety, depression, and long-COVID symptoms. While the results are promising, the small sample size and lack of controls necessitate further investigation. This research contributes to the growing body of evidence supporting psychedelic therapies but underscores the need for more rigorous trials.
We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms. Two patients underwent the De La Haye Psilocybin Treatment Protocol (DPTP), which integrates micro- and high-doses (combined psilocybin and psilocin content of 1–2 mg versus 40–60 mg) with psychohistoriographic psychotherapy. Follow-up included an integration session and subsequent office visits, including the completion of the Revised Mystical Experience Questionnaire (MEQ-30) two months post-treatment. Case 1 described a 29-year-old female with social anxiety, self-criticism, chronic musculoskeletal pain, and a recent diagnosis of diabetes. Post-treatment, she reported reduced shame, increased self-confidence, and substantial reductions in pain severity. Case 2 involved a 44-year-old female presenting with depression, hopelessness, and long-COVID-related anosmia and ageusia. She reported enhanced psychological resilience, improved mood, and resolution of diffuse body aches. Following the therapeutic dose, she also reported a 80-90% recovery of smell and taste after three years of dysfunction, post COVID-19 infection. The MEQ-30 scores were both high, indicating profound mystical-type experiences. These cases demonstrate improvements in psychological and somatic symptoms following participation in the DPTP. While the pain reduction and observed recovery of olfactory and gustatory function is noteworthy, spontaneous improvements cannot be excluded and further controlled investigation is warranted.
Neuroscience Research announced

Neurobiology of early intervention in youth mental health

Towards a neurobiology of early intervention: the importance of critical periods for preventive psychiatry and youth mental health
Why it matters ▲ Favorable
This research highlights the importance of critical periods during youth for early detection and intervention in mental disorders. Understanding these neurobiological mechanisms could enhance preventive psychiatry and improve outcomes for at-risk youth. While not directly related to psychedelics, this framework may inform future studies on psychedelic interventions in youth mental health.
Abstract Evidence has accumulated that youth, the period between 12–25 years, may constitute a crucial period for the early detection and intervention of mental disorders. Thus, there is emerging evidence that targeted psycho-social and pharmacological interventions have potential to improve clinical outcomes in at-risk individuals as well as in youths with a first-episode of mental illness. However, while support for the early intervention paradigm has gained momentum, an explanatory framework for the emergence of mental disorders as well as for the mechanisms of preventive interventions is currently not available. Here, I will outline a neurobiology of early intervention that will highlight the importance of linking emerging psychopathology with developmental neuroscience and systems biology. Specifically, I will propose that critical periods during late brain development in combination with environmental exposures could account for the elevated occurrence of psychosis, affective disorders, substance abuse and personality disorders. In addition, the neurobiological mechanisms underlying critical periods could be important for understanding the potential of preventive interventions and the identification of biomarkers. Together, a neurobiological grounding of early intervention could provide a conceptual and empirical framework to advance early detection and prevention of mental disorders during youth.
Clinical research Review published

Ketamine's Psychoactive Effects: Clinical Review

Psychoactive and Neurobiological Effects of Ketamine in Humans: A Scoping Review of Clinical Evidence.
Why it matters ◈ Mixed
This scoping review synthesizes clinical evidence on ketamine's psychoactive and neurobiological effects in humans. The findings could inform future research directions and therapeutic applications, particularly in mental health treatment. However, the review also highlights gaps in understanding long-term effects and optimal dosing, which are critical for safe clinical use.
Industry Clinic opening

Ketamine therapy clinic for veterans opens in Charlotte

Mental health clinic offering ketamine therapy to veterans opens in Pinehurst, Charlotte
Why it matters ▲ Favorable
The opening of a mental health clinic offering ketamine therapy to veterans in Pinehurst, Charlotte, signals growing acceptance and availability of psychedelic-assisted therapies in the U.S. This development could enhance access to innovative treatments for veterans struggling with mental health issues. It also reflects a broader trend of integrating psychedelic therapies into mainstream healthcare settings.
Neuroscience Research published

Orexin Signaling's Role in Metabolism and Depression

Pharmacologic Modulation of Orexin Signaling: Impact on Glucose-Insulin Homeostasis and Potential Mechanism of Antidepressant Action
Why it matters ◈ Mixed
This research highlights the potential of orexin antagonists, like seltorexant, in treating major depressive disorder (MDD) by modulating glucose-insulin homeostasis. The study suggests that orexin signaling affects metabolic processes which could contribute to antidepressant effects. Understanding these mechanisms could lead to more effective treatments for MDD, particularly in patients with comorbid metabolic disorders.
In addition to their canonical role in sleep-wake regulation, endogenous orexin signaling is implicated in the homeostatic control of reward and motivation, stress and arousal, and glucoseinsulin metabolism.Recent research has focused on the development of orexin antagonists, notably seltorexant, as adjunctive treatments in adults with major depressive disorder (MDD).Converging evidence implicates insulin resistance in MDD pathophysiology, highlighting the need to integrate preclinical, pharmacologic and translational evidence examining the effects of orexin signaling on glucose-insulin homeostasis.A literature review was conducted using PubMed from database inception to June 2025 to identify preclinical and clinical studies examining the metabolic effects of orexin modulation.The search string included the terms related to: orexin, glucose, metabolism, depression.Results were synthesized qualitatively across experimental models and clinical populations.Evidence indicates that orexin signaling affects multiple aspects of metabolic homeostasis.For example, orexins affect appetitive/consummatory behaviour as well as exert incretin-like effects on insulin release and glucagon suppression, and energy expenditure via morphologically transitioning white-to-brown adipose tissue.These effects are mediated through both direct (e.g., inhibition of gluconeogenic enzyme expression) and indirect pathways (e.g., alterations in sleep architecture and attenuation of sympathoadrenal overactivity).Orexin antagonism therefore exerts multi-faceted physiological effects beyond sleep regulation.The antidepressant efficacy of seltorexant in MDD is greater in persons with moderate-to-severe insomnia, while remaining clinically meaningful in persons with less severe insomnia, implicating multiple mechanistic mechanisms.Modulation of glucose-insulin homeostasis represents a putative, non-mutually exclusive mechanism through which orexin antagonism may contribute to antidepressant effects.
Clinical research Study published

Ketamine reduces pain, opioid use post-amputation

Rethinking Ketamine: The Effect of Postoperative Ketamine Infusions on Pain and Opioid Consumption Following Major Limb Amputation.
Why it matters ▲ Favorable
This study explores the potential of ketamine infusions to reduce pain and opioid consumption following major limb amputation. Findings could influence postoperative pain management protocols and reduce reliance on opioids. This has significant implications for public health, given the ongoing opioid crisis, and may prompt further research into ketamine's therapeutic applications.
Clinical research Peer-reviewed study published

Study: Depression heterogeneity affects ketamine response in late-life depression

Depression Heterogeneity as a Confounder in Ketamine Response for Late-Life Depression.
Why it matters ◈ Mixed
This study highlights that variability in depression subtypes may confound clinical trial outcomes for ketamine in late-life depression. For researchers, it underscores the need for more precise patient stratification and outcome measures in psychedelic trials. Policymakers and clinicians should be cautious in generalizing ketamine efficacy to all older adults with depression, as heterogeneous presentations may impact both safety and effectiveness. This could influence future trial designs and regulatory guidance for psychedelic-assisted therapies in geriatric populations.
Clinical research Scoping review published

Scoping Review: Ketamine's Effects in Psychiatry

Psychoactive and Neurobiological Effects of Ketamine in Humans: A Scoping Review of Clinical Evidence
Why it matters ◈ Mixed
This scoping review synthesizes existing clinical evidence on ketamine's rapid antidepressant effects, particularly for treatment-resistant depression (TRD). While ketamine shows promise for rapid symptom relief, questions about long-term safety and optimal dosing remain unresolved. This review underscores the need for further research to solidify ketamine's role in psychiatric treatment.
Background/Objectives: Ketamine has attracted interest in psychiatry due to its rapid antidepressant effects, particularly in patients with inadequate response to conventional treatments. This scoping review maps ketamine’s neuropharmacology, mechanisms of action, clinical applications, safety, and use in psychiatric disorders. Methods: This scoping review was conducted according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews. PubMed, Scopus, Web of Science, and Google Scholar were searched for English-language publications addressing ketamine pharmacology, clinical applications, and psychoactive effects. Included sources comprised randomized controlled trials, observational studies, systematic reviews, and relevant mechanistic studies, while non-English publications, editorials, commentaries, and studies without sufficient methodological information were excluded. Data were extracted using a structured data-charting form and synthesized narratively and thematically. Results: A total of 69 studies were included in the final synthesis. Ketamine demonstrated early improvements in depressive symptoms, especially in treatment-resistant depression (TRD), although the durability of benefits varied across studies. Intravenous racemic ketamine was the most extensively investigated administration route, while intranasal esketamine represents the primary approved formulation for TRD. Mechanistically, the drug acts through N-methyl-D-aspartate receptor antagonism and downstream modulation of glutamatergic signaling, synaptic plasticity and neural connectivity. Comparisons with conventional antidepressants and neuromodulatory interventions highlighted ketamine’s faster onset of action, although variability remained regarding long-term effects and treatment strategies. Conclusions: Ketamine represents an important rapid-acting treatment for TRD and severe depressive episodes associated with suicidal ideation. However, information regarding long-term efficacy and safety remains limited due to study heterogeneity, short follow-up periods, and variability in dosing protocols. Further research is needed to address gaps related to long-term outcomes, maintenance strategies, and optimal dosing approaches.
Clinical research Trial results announced

Esketamine improves postoperative sleep in laparoscopic surgery

Esketamine during anesthesia induction improves early postoperative sleep quality in female patients undergoing laparoscopic surgery: A randomized trial
Why it matters ▲ Favorable
This randomized trial suggests that esketamine can enhance early postoperative sleep quality and reduce opioid use in female patients undergoing laparoscopic surgery. The findings could influence anesthesia practices and postoperative care, particularly in settings where sleep quality and opioid reduction are priorities. The study adds to the growing body of evidence supporting esketamine's benefits beyond its traditional psychiatric applications.
Objective: To evaluate the effect of intravenous esketamine administration during anesthesia induction on postoperative sleep quality in female patients undergoing laparoscopic surgery. Methodology: This study was designed as a prospective, double-blind, single-center randomized controlled trial and was conducted at Huzhou Maternity &amp; Child Health Care Hospital between December 5, 2025, and January 31, 2026. One hundred ASA I-II female patients (25-50 years) undergoing elective laparoscopic surgery (Dec 2025-Jan 2026) were randomized to control (Group C, n=50) or esketamine (Group S, n=50). Both groups received propofol 2 mg/kg, cisatracurium 0.15 mg/kg, and sufentanil 0.3 μg/kg for induction; Group-S additionally received esketamine 0.3 mg/kg, while Group-C received normal saline. Anesthesia was maintained with propofol (4–6 mg/kg/h) and remifentanil (0.1–0.2 μg/kg/min) via infusion pumps to maintain the Bispectral Index (BIS) between 40 and 60 and end-tidal carbon dioxide (PETCO₂) between 35 and 45 mmHg. Outcomes included Pittsburgh Sleep Quality Index (PSQI) on postoperative days (POD) one, three, seven; intraoperative sufentanil use; 6/24 h VAS pain scores; 24 hours rescue analgesia rate; adverse events; emergence time; and PACU stay. Results: Ninety eight patients (Group C: 49; Group S: 49) completed the study. Group-S had lower PSQI scores on POD one and three (P&lt;0.05), reduced intraoperative sufentanil consumption (P&lt;0.05), lower 6/24 hours VAS scores (P&lt;0.05), and lower 24 hours rescue analgesia rate (P&lt;0.05). No significant differences in emergence time, PACU duration, or adverse event rates were observed (P&gt;0.05), with no severe adverse events. Conclusion: Administration of 0.3 mg/kg esketamine during anesthesia induction reduces opioid consumption, improves early postoperative sleep quality, and decreases sleep disturbance incidence in female laparoscopic patients without increasing adverse event risks.
Neuroscience Conceptual analysis

Ontological Tourism in Psychedelic Science

The Ontological Tourism Problem in Psychedelic Science
Why it matters ◈ Mixed
The article addresses a critical epistemological issue in psychedelic research: the risk of drawing ontological conclusions from phenomenological data without sufficient scientific rigor. This tension is crucial for maintaining scientific integrity and clinical ethics in psychedelic studies. The proposed framework aims to balance the value of subjective experiences with the need for robust scientific explanations.
The nature of the psychedelic experience, and the distinctive phenomenological features it generates, leaves it susceptible to an unresolved epistemological tension between first-person phenomenological reports and claims about the fundamental nature of consciousness and reality. This tension is examined through the concept of ontological tourism: the practice of treating phenomenological data as sufficient grounds for ontological conclusions without adequate engagement with alternative mechanistic explanations or the philosophical requirements that such inferences demand. This practice, absent adequate epistemic scaffolding, poses a genuine threat to scientific integrity and clinical ethics. At the same time, reflexively dismissing phenomenological data as mere pharmacological artifacts represents an equally impoverished position. The tourist analogy cuts both ways: the tourist may be an unreliable cartographer, but the tourist has been somewhere. An alternative stance is proposed, one that takes subjective experience seriously as a form of evidence without overclaiming its metaphysical implications or dismissing its epistemic weight, along with a framework for achieving it. Ontological tourism risks bypassing the explanatory work that makes psychedelic phenomenology valuable to consciousness science.
Neuroscience Review published

Immunometabolic reprogramming in MS as therapeutic target

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination
Why it matters ◈ Mixed
This review highlights the potential of targeting metabolic pathways in multiple sclerosis (MS) treatment, suggesting a shift from broad immunosuppression to specific metabolic reprogramming. Such an approach could address chronic neuroinflammation and remyelination deficits, offering new therapeutic avenues. However, clinical application requires rigorous trials and reliable biomarkers to validate these strategies.
Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization. The pathogenesis of multiple sclerosis is multifactorial, resulting from the interaction of genetic predisposition (especially HLA alleles), environmental factors (particularly Epstein-Barr virus infection), B-cell-mediated autoimmunity, and localized CNS inflammation. In this intricate environment, cellular metabolic dysregulation is a notable factor and potentially adjustable enhancer of disease progression, functioning within the extensive multifactorial pathogenic context, where the bioenergetic programming of immune and neural cells determines inflammatory or protective responses. Proinflammatory Th17 cells and M1 microglia depend on aerobic glycolysis and glutaminolysis regulated by mTOR and HIF-1α, whereas regulatory T cells, M2 microglia, and neurons require fatty acid oxidation and oxidative phosphorylation via AMPK. In multiple sclerosis, glycolysis disrupts metabolic equilibrium, sustaining chronic neuroinflammation and obstructing repair processes. Established multiple sclerosis therapies, dimethyl fumarate and teriflunomide, exhibit direct, previously unrecognized metabolic effects, validating this pathway as therapeutically viable. Emerging strategies intentionally target these vulnerabilities: glutaminase inhibitors to counteract pathogenic Th17 cells, AMPK activators such as metformin to enhance remyelination, mTOR inhibitors to restore immune tolerance, and NAD + precursors to rejuvenate mitochondrial function. Transitioning from broad immunosuppression to specific metabolic reprogramming offers remarkable opportunities for tackling chronic neuroinflammation and correcting remyelination deficits in progressive multiple sclerosis. Immuno-metabolic pharmacology is a promising field; however, its clinical application necessitates stringent validation via meticulously designed trials and dependable biomarkers.
Clinical research Review published

Review: EEG Predictors in Psilocybin Treatment for Depression

A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in Depression
Why it matters ◈ Mixed
This systematic review highlights EEG and MEG as promising tools for understanding psilocybin's effects on depression. However, the limited sample size of MDD patients and lack of predictive biomarkers underscore the need for larger, standardized trials. These findings are crucial for advancing psilocybin's clinical application and optimizing treatment protocols.
Background: Major depressive disorder (MDD) affects over 280 million people globally and remains a leading cause of disability. Psilocybin has emerged as a promising treatment, with evidence suggesting modulation of neural oscillatory activity relevant to mood regulation. Electroencephalography (EEG) and magnetoencephalography (MEG) offer non-invasive methods for evaluating these neurophysiological changes. Objectives: This systematic review pursues two distinct aims: (1) to characterise the neurophysiological effects of psilocybin on neural oscillatory activity as measured by EEG and MEG; and (2) to evaluate whether EEG/MEG biomarkers function as correlates of antidepressant efficacy or as predictors of treatment response, clearly distinguishing between these two roles. Methods: A systematic search of PubMed and Google Scholar identified seven eligible studies published between 2013 and 2025. Studies were required to include adult participants with MDD or healthy volunteers undergoing psilocybin administration with EEG or MEG recording. Findings were synthesised narratively and organised into three conceptual categories: neurophysiological effects, correlates, and predictors. Results: Seven studies comprising 204 participants were included. Critically, only 20 participants carried a confirmed MDD diagnosis; the remainder were healthy volunteers, which substantially limits the generalisability of clinical conclusions. Psilocybin consistently reduced alpha-band power, increased gamma synchronisation, and enhanced evoked theta activity. Post-treatment evoked theta power was significantly correlated with symptom reduction, representing the strongest treatment correlate identified. No pre-treatment predictive biomarkers were identified. Conclusions: EEG and MEG capture consistent neurophysiological effects of psilocybin and show early promise as correlate biomarkers of treatment response. However, the evidence base remains limited by small MDD-specific samples, heterogeneous methodology, and an absence of validated predictive biomarkers. Larger, standardised clinical trials with pre-treatment EEG baselines are needed before EEG can be applied predictively in clinical practice.
Neuroscience Preclinical study published

Factors in Psilocybin Effects in Mouse Models Identified

Identifying factors that contribute to the behavioral effects of psilocybin in preclinical mouse models
Why it matters ▲ Favorable
This study identifies key biological and experimental factors that modulate psilocybin's behavioral effects in mice, which could enhance the translational relevance of preclinical models. Understanding these variables is crucial for developing more reproducible and effective therapeutic models. This research could inform future clinical trials and improve the predictability of psilocybin's effects in humans.
Psychedelic drugs offer a potentially promising avenue for novel therapeutics for the treatment of psychiatric conditions, including for mood and anxiety disorders. Emerging clinical studies have prompted increased preclinical research into mechanisms of action. However, post-acute behavioral outcomes in rodents remain inconsistent and difficult to reproduce across laboratories. To address this, we collected a large dataset of behavioral responses to psilocybin in mice (N=693) and used data-driven analyses to identify biological and experimental factors that modulated behavioral readouts. We examined the effects of sex, age, strain, stress protocol, and 5-HT1B signaling on the response to a single high dose of psilocybin measured in acute (head twitch responding and locomotion) or post-acute (sucrose preference, elevated plus maze, novelty-suppressed feeding) behavioral outcomes. We found that psilocybin displays a robust acute behavioral response and a more variable post-acute behavioral profile with a most robust response in sucrose preference. Sex, stress model, and 5-HT1BR activation emerged as key modulators of post-acute antidepressant-like and anxiolytic effects. Random forest classification was narrowly able to predict drug treatment based on post-acute behavioral outcomes and biological and experimental factors. These findings suggest that the heterogeneity seen in the response to psilocybin in mice reflects meaningful biological and experimental variables. Accounting for these factors may enhance translational relevance by identifying the conditions under which therapeutic-like effects are most robust and can support more reproducible models for understanding the neural mechanisms underlying the persisting behavioral effects of psilocybin.
Neuroscience Study results published

Psilocybin microdosing alters rat brain epigenetics

Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex
Why it matters ▲ Favorable
This study provides evidence that psilocybin microdosing induces beneficial epigenetic changes in the rat brain without causing behavioral dysfunction. The findings suggest potential therapeutic applications for mood and anxiety disorders by enhancing neuroplasticity. Understanding these molecular mechanisms is crucial for advancing psilocybin's use in clinical settings.
RATIONALE: Psilocybin (PSI) microdosing, defined as a repeated administration of sub-perceptual doses, has gained increasing attention as a potential therapeutic strategy for affective and anxiety disorders. However, some molecular mechanisms, particularly regarding epigenetic regulation in the medial prefrontal cortex (mPFC), remain poorly understood. OBJECTIVES: Therefore, the present study aimed to determine whether PSI microdosing induces adaptive epigenetic modifications in the rat mPFC in the absence of behavioural dysfunction, with a particular focus on chromatin accessibility, transcriptional regulators, and plasticity-related genes. METHODS: Rats were administered PSI or a vehicle every second day for 21 days. Behavioural impact was assessed using prepulse inhibition (PPI) of the acoustic startle response (ASR) and the novel object recognition test (NOR). Molecular dynamics in the mPFC were analysed via Western blot and quantitative reverse transcription PCR (qRT-PCR) in the early and late phases following the final dose. RESULTS: The microdosing regimen did not impair sensorimotor gating or cognitive performance, indicating absence of psychotomimetic-like effects. Molecular analyses in the early phase revealed epigenetic remodelling in the mPFC, including increased histone H3 acetylation, change in bromodomain-containing protein 4 (BRD4) levels and modulation of histone deacetylases. These early molecular effects were associated with a transcriptionally permissive chromatin state and increased expression of genes related to plasticity. In the later phase, enhanced expression of the serotonin receptor 2A (5-HT2A) was observed, while some epigenetic modifications partially persisted over time. CONCLUSIONS: Repeated low-dose psilocybin promotes adaptive epigenetic remodelling in the mPFC, enhancing neuroplasticity without behavioural impairment and supporting its therapeutic potential.
Clinical research Research published

Biomarkers for Bipolar Disorder & Psychedelics

Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.
Why it matters ◈ Mixed
The identification of candidate biomarkers for bipolar disorder progression could significantly enhance the precision of psychedelic interventions, such as ketamine, in treating this condition. These findings may guide future clinical trials and therapeutic strategies, potentially improving patient outcomes. However, further research is needed to validate these biomarkers and their applicability in clinical settings.
Neuroscience Research published

Neuroimmune signaling in ketamine, psychedelics

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.
Why it matters ▲ Favorable
This study identifies convergent neuroimmune pathways that may explain the rapid antidepressant effects of ketamine and psychedelics. Understanding these mechanisms could lead to more targeted therapies and improve treatment outcomes for depression. The findings provide a scientific basis for further clinical trials and could influence future drug development strategies.
Clinical research Study published

Vet students' attitudes on psychedelics studied

Understanding treatment expectations toward emerging therapies in veterinary medicine: the role of knowledge, attitudes, and beliefs toward psychedelic-assisted interventions
Why it matters ◈ Mixed
This study explores how veterinary students' attitudes and beliefs about psychedelics influence their expectations of psychedelic-assisted therapies. Understanding these cognitive and attitudinal factors is crucial for the adoption of psychedelic therapies in veterinary medicine. The findings suggest that positive attitudes are linked to higher treatment expectations, while perceived risks have a moderate inverse effect. This research highlights the importance of educational experiences in shaping future professionals' perceptions of emerging therapies.
Introduction The adoption of emerging therapeutic approaches in veterinary medicine is likely to depend not only on scientific evidence but also on how such interventions are cognitively and attitudinally appraised by future professionals. This study aimed to assess knowledge, attitudes, and perceived risk regarding psychedelic use among veterinary students, and to examine their association with treatment expectations toward psychedelic-assisted therapies. Methods A cross-sectional survey was conducted among undergraduate veterinary students ( N = 87) at the University of Las Palmas de Gran Canaria during the 2025/2026 academic year. Data were collected using a structured questionnaire assessing knowledge and beliefs about psychedelics, alongside the Treatment Expectation Questionnaire (TEX-Q). Exploratory factor analysis identified two latent dimensions—positive attitudes and perceived risk—which were included as independent variables in subsequent analyses. Associations were examined using nonparametric tests, correlation analyses, and multiple linear regression models. Results Positive attitudes showed the strongest and most consistent associations with favorable expectation domains, including perceived treatment benefit, impact, and overall expectations, while perceived risk showed an inverse, though more moderate, pattern of associations. Sociodemographic and educational variables were more closely associated with treatment expectations through these psychological constructs than through direct associations with the expectation domains themselves. Discussion These findings are consistent with a cognitive–attitudinal framework in which expectations toward emerging therapies are more closely associated with interpretable psychological dimensions rather than with factual knowledge alone. Future longitudinal studies are warranted to clarify the relationships among these variables and to evaluate how educational experiences influence their development.
Clinical research Study published

Neuroimmune signaling in ketamine, psychedelic antidepressant response

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics
Why it matters ▲ Favorable
This study identifies shared biomarkers and immune pathways in the rapid antidepressant effects of ketamine and psychedelics, suggesting a convergence on common molecular mediators. Key findings include the role of IL-15 and MCP-1 as regulatory hubs, and the predictive value of cytokine ratios for treatment response. These insights could inform future therapeutic strategies and enhance understanding of the biological underpinnings of rapid antidepressant effects.
Abstract Despite distinct receptor targets, both ketamine and serotonergic psychedelics produce a rapid clinical response and share biological signatures that suggest convergence on common downstream molecular mediators. To identify shared biomarkers of rapid antidepressant response, this study integrated CSF proteomics from healthy volunteers (HVs) who received intravenous ketamine with transcriptomic analyses from induced pluripotent stem cells (iPSCs) derived from participants with treatment-resistant depression (TRD) and HVs; iPSCs were treated with ketamine, its metabolite (2 R ,6 R )-hydroxynorketamine, lysergic acid diethylamide (LSD), or psilocybin. Multimodal clinical characterization (transcriptomics ( n = 16 TRD; 11 HV), magnetoencephalography (MEG) ( n = 30 TRD; 25 HV), and plasma cytokines ( n = 39 TRD; 25 HV) were also performed on TRD and HV participants who received a single dose of intravenous ketamine (0.5 mg/kg) or placebo. Conserved immune pathways were identified across CSF and iPSC neurons with interleukin-15 (IL)-15 and monocyte chemoattractant protein-1 (MCP-1) emerging as key regulatory hubs. Transcriptomically, in whole blood, ketamine responders exhibited decreased IL-15 and elevated B-cell signaling pathways at baseline that were reversed post-treatment. At the protein level, plasma IL-7 levels (primary B-cell driver) correlated with baseline MEG gamma power, reaching brain-wide significance across all participants (main effect p FDR &lt; 0.05). The association was most pronounced in the TRD participants across subcortical regions (diagnosis x IL-7 p FDR &lt; 10 -14 ). Post-ketamine, the TRD IL-7–gamma relationship inverted, paralleling widespread gamma power reductions throughout default-mode network regions (session x IL-7 p clc &lt; 0.05). In mixed-effects models, cytokine ratios linked to IL-7/IL-15 signaling predicted antidepressant response (IL-4/interferon gamma (IFN-γ) p FDR &lt; 0.041) and non-response (MCP-1/IL-7 p FDR &lt; 0.009), suggesting that rebalancing within the IL-7/IL-15 axis may contribute to therapeutic efficacy. Clinicaltrials.gov identifier: NCT00088699; NCT02484456.
Clinical research Pilot study results

Ibogaine study for alcohol use disorder shows promise

Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.
Why it matters ▲ Favorable
This pilot study suggests ibogaine may be a feasible and safe treatment for moderate and severe alcohol use disorder. The open-label design provides preliminary evidence of its effects, which could inform larger, controlled trials. This research contributes to the growing body of evidence supporting psychedelic-assisted therapies for substance use disorders.
FDA / DEA Meeting announced

FDA announces Pediatric Advisory Committee meeting

Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments
Why it matters ◈ Mixed
The FDA's Pediatric Advisory Committee meeting will address pediatric regulatory issues, which could include discussions relevant to psychedelic research involving minors. Public comments are invited, offering a chance for stakeholders to influence policy considerations. This meeting may shape future regulatory approaches to pediatric applications of psychedelic therapies.
The Food and Drug Administration (FDA or the Agency) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the committee is to provide advice and recommendations to FDA on pediatric regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Neuroscience Research announced

Fungal Metabolites as Tauopathy Modulators

Network Pharmacology-Guided Discovery of Fungal Autophagy Modulators for Tauopathies: Structural and Proteomic Evidence
Why it matters ▲ Favorable
This study highlights the potential of fungal metabolites, including those from Magic Mushrooms and Lion’s Mane, as modulators of autophagy in tauopathies. The identification of promising targets such as PPARG, GSK3B, and CSNK2A1 could pave the way for novel therapeutic approaches in neurodegenerative diseases. This research underscores the importance of computational drug discovery in identifying multi-target drug candidates, which could influence future clinical trials and market interest in psychedelic compounds.
Abstract Autophagic clearance of hyperphosphorylated tau is impaired in tauopathies, leading to the progressive accumulation of toxic tau species. Fungal metabolites provide a rich yet largely untapped source of neuroactive molecules with therapeutic potential. Here, we investigated metabolites from Lion’s Mane ( Hericium erinaceus ), Magic Mushrooms ( Psilocybe spp.), and Ergot fungi ( Claviceps spp.) using a computational drug-discovery workflow. We characterised their structural diversity, predicted blood-brain barrier permeability and toxicological properties, and integrated network pharmacology with protein-protein interaction and functional enrichment analyses to identify autophagy-related targets. Peroxisome proliferator-activated receptor gamma (PPARG), glycogen synthase kinase-3 beta (GSK3B), and casein kinase 2 alpha 1 (CSNK2A1) emerged as the three most promising candidates, given their complementary roles linking autophagy and tau pathology and their attractiveness as targets for multi-target drug discovery. Their interactions with fungal metabolites were evaluated by molecular docking, Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) rescoring, molecular dynamics simulations, complemented by machine-learning quantitative structure-activity relationship (QSAR) modelling as an additional, ligand-based line of evidence. Molecular dynamics and MM/GBSA analyses confirmed stable, target-specific binding for Corallocin A and Erinacerin M (PPARG), Chaetopyranin and Ergocryptine (GSK3B), and Hericioic Acid D and Isohericerin (CSNK2A1), alongside Emodin, a reference compound with previously reported activity against all three targets. QSAR predictions were informative primarily for the PPARG candidates, which fell within the model’s applicability domain; predictions for the remaining candidates fell outside their respective models’ applicability domains and were therefore not interpretable as evidence for or against their prioritisation. Reanalysis of an independent hippocampal proteomic dataset from Alzheimer’s disease patients showed CSNK2A1 protein levels to be significantly altered in the CA3 subfield, providing an additional, correlative line of support for this target; PPARG and GSK3B showed no significant changes in protein abundance, which does not preclude their functional involvement given their extensive post-translational regulation. Overall, these findings identify fungal metabolites as promising multi-target autophagy modulator candidates and provide a systematic computational strategy for prioritising them for experimental validation in tauopathies.
Clinical research Review published

Review: Adjunctive Pharmacotherapy for MDD with Anxiety

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence
Why it matters ◈ Mixed
This review highlights the gap in clinical data for treating major depressive disorder (MDD) with anxiety symptoms, emphasizing the need for targeted clinical trials. Current evidence for treatments like ketamine/esketamine is limited and primarily short-term. This underscores the importance of developing robust clinical trials with anxiety-specific endpoints to improve treatment decisions.
Anxiety symptoms are common in patients with major depressive disorder (MDD). The presence of anxiety symptoms can indicate greater depression severity, and is associated with a higher comorbidity burden, suicidality, lower levels of functioning, and poorer quality of life. The presence of anxiety identifies patients who are likely to experience significant burden from MDD despite standard treatment. Although clinical guidelines provide recommendations for adjunctive treatment in patients who have not responded to an antidepressant, there are currently limited recommendations specifically for patients with MDD and anxiety symptoms. Dysregulation of the monoamine system, notably noradrenaline (norepinephrine), serotonin, and dopamine signalling, has been implicated in the pathophysiology of MDD and of anxiety disorders, based mainly on preclinical, mechanistic and translational evidence. This review has two aims: (1) to explore the hypothetical role of monoamine signalling in patients with MDD with anxiety symptoms, and (2) to provide a comprehensive overview of clinical data for pharmacotherapies recommended for the first- and second-line adjunctive treatment of difficult-to-treat MDD, focusing on recent studies and analyses of patients with MDD with anxiety symptoms. Reviewed treatments included atypical antipsychotics (aripiprazole, brexpiprazole, olanzapine, quetiapine XR, risperidone, cariprazine), bupropion, ketamine/esketamine, lithium, mirtazapine/mianserin, modafinil, and triiodothyronine. Clinical data in patients with MDD with anxiety symptoms were scarce or lacking for olanzapine, risperidone, cariprazine, lithium, modafinil, and triiodothyronine. Aripiprazole, brexpiprazole, quetiapine XR, and ketamine/esketamine have been shown to improve depression and/or anxiety symptoms in patients with MDD with anxiety symptoms, although evidence is mainly short-term and derived from exploratory post hoc analyses of trials not designed to assess anxiety outcomes. Treatment decisions for patients with MDD with anxiety symptoms should be based on robust clinical data, and there is an unmet need for prospective clinical trials with anxiety-specific endpoints in this patient population.
Clinical research Study results announced

Ketamine/Esketamine Safe for Liver in TRD

Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression
Why it matters ▲ Favorable
This study provides reassurance regarding the hepatic safety of ketamine and esketamine in therapeutic settings for treatment-resistant depression. The findings suggest that routine liver monitoring may not be necessary for asymptomatic patients, potentially reducing barriers to access and simplifying treatment protocols. However, further research is needed to confirm these results in larger populations.
BACKGROUND: Ketamine and esketamine are increasingly used for treatment-resistant depression (TRD), yet their hepatic safety profile with repeated or long-term use remains poorly characterized. Chronic recreational ketamine abuse has been linked to cholestasis and cholangiopathy, raising concern that therapeutic use may carry similar risks. No systematic data exist on liver enzyme trajectories or biliary injury at subanesthetic doses used for depression. METHODS: This historical cohort study included adults with TRD receiving IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Ketamine Clinic (2017 to 2024). Patients were eligible if they had at least one liver enzyme value (AST, ALT, ALP, or bilirubin) within 12 months before through 3 months after treatment. Longitudinal enzyme trajectories were modeled using generalized linear-mixed models with a Gamma distribution. Clinically significant elevation was defined as ≥2× the upper limit of normal (ULN). Wilcoxon signed-rank tests compared pretreatment and post-treatment paired values. RESULTS: Of 104 enrolled patients, 74 had liver enzyme data available; 51 had post-initiation data. Median age was 51.5 years; 72% were female. Most (78.4%) received IV ketamine. No clinically meaningful changes in enzyme trajectories were observed. Three patients (5.9%) had elevations ≥2× ULN, all attributable to alcohol use, myalgias, or pre-existing hepatic steatosis rather than (es)ketamine. CONCLUSIONS: Subanesthetic IV ketamine (0.5 mg/kg) and FDA-approved IN esketamine doses were not associated with clinically significant liver enzyme elevations in this real-world TRD cohort. Current evidence does not support routine hepatic monitoring for asymptomatic patients, although prospective, larger-scale studies are needed to confirm these findings.
Clinical research Study results published

Esketamine reduces rocuronium limb withdrawal in children

Dose-dependent effect of esketamine on preventing rocuronium-induced limb withdrawal in preschool children
Why it matters ▲ Favorable
This study provides evidence that esketamine can significantly reduce limb withdrawal reactions in preschool children receiving rocuronium during anesthesia induction. These findings could inform anesthesia protocols, potentially improving patient comfort and safety in pediatric surgeries. The dose-dependent effects observed highlight the importance of optimizing esketamine dosing for clinical use.
BACKGROUND: Rocuronium injection often causes limb withdrawal reactions in preschool children during anesthesia induction, which can lead to adverse effects. Esketamine has been reported to reduce such reactions, but the optimal dose remains unclear. OBJECTIVES: To observe the effect of different doses of esketamine administered in advance on limb withdrawal reactions caused by rocuronium in preschool children. MATERIAL AND METHODS: From January to December 2024, children aged 2-6 years (American Society of Anesthesiologists Physical Status Classification System (ASA) I-II) undergoing elective surgery with general anesthesia induction using rocuronium at Hangzhou Children's Hospital were enrolled, regardless of gender (90 cases in total). Patients were divided using a random number table into 3 groups: a control group (group C), an esketamine 0.1 mg/kg group (group K1), and an esketamine 0.2 mg/kg group (group K2). Each group received either saline (group C), 0.1 mg/kg esketamine (group K1), or 0.2 mg/kg esketamine (group K2), with 30 cases in each group. Thirty seconds later, all patients were administered rocuronium intravenously. Mean arterial pressure (MAP) and heart rate (HR) were recorded at 4 time points: before anesthesia induction (T0), before test drug injection (T1), before rocuronium injection (T2), and after rocuronium injection (T3). The incidence and severity of limb withdrawal reactions after rocuronium injection and adverse reactions were recorded. RESULTS: Compared with T0, MAP and HR significantly decreased in all 3 groups before test drug injection (T1) (p < 0.05). After rocuronium injection (T3), MAP and HR significantly increased in group C (p < 0.05). Heart rate significantly increased at T2 and T3 in group K2 (p < 0.05). The incidence of limb withdrawal reactions was 43.33% in group C, 16.67% in group K1, and 13.33% in group K2, with statistically significant differences among the groups. The severity of limb withdrawal reactions also differed significantly among the 3 groups. CONCLUSIONS: Prophylactic intravenous injection of 0.1 mg/kg esketamine effectively reduces the limb withdrawal reaction caused by rocuronium injection.
Neuroscience Model announced

SSRI model for OCD treatment dynamics

SSRI treatment of obsessive-compulsive disorder as motion across a bistable fold: a calibrated circuit plasticity model of response, remission, and augmentation
Why it matters ◈ Mixed
This study presents a novel model for understanding SSRI treatment in OCD, focusing on the bistable dynamics of the disorder's response to medication. The model suggests that individual-level signatures, rather than mean treatment effects, are crucial for predicting remission and relapse. This insight could inform future clinical trials and treatment strategies, though it remains theoretical until further validated.
SSRIs are first-line for obsessive-compulsive disorder (OCD), yet benefit is partial, weeks-delayed, and severity-gated, and augmentation is empirical. The stable-states view is established but not drug-specific. We supply the missing coupling: a calibrated object joining serotonin pharmacokinetics, a basal-ganglia-thalamocortical circuit, and corticostriatal plasticity, in which OCD is an elevated fixed point and SSRI treatment moves this bistable state across a saddle-node fold (a tipping point). With ~35 constants fixed, two shared parameters reproduce six SSRIs (RMS 0.83 Y-BOCS points, 84 arm-timepoints) and predict a held-out trial (0.58). A fold-free model fits the means equally well, so the mean cannot separate them; they diverge only on individual-level signatures it cannot produce - a discrete, durable off-drug remission subgroup and critical slowing - with qualitative support in OCD and adjacent disorders, not yet tested as bistability signatures. These, not the mean, decide who remits and relapses; the same geometry reframes memantine and antipsychotic augmentation.
Clinical research Research published

Cardiovascular risks of sympathomimetic drugs

Acute cardiovascular complications of sympathomimetic recreational drug use
Why it matters ◈ Mixed
This narrative review highlights the acute cardiovascular risks associated with sympathomimetic recreational drugs like cocaine and amphetamines. The study underscores the need for standardized guidelines to manage these complications effectively. It also emphasizes the importance of individualized treatment plans and early intervention to prevent recurrence.
INTRODUCTION: Recreational drug use is rising globally, with significant cardiovascular implications. Sympathomimetic substances such as cocaine, amfetamine(amphetamine)-type stimulants and synthetic cathinones are increasingly associated with emergency department presentations and acute cardiac events. Despite this growing burden, standardized guidance for diagnosing and managing acute sympathomimetic recreational drug-related cardiovascular complications remains limited. METHODS: A narrative review of the literature was conducted to identify acute cardiovascular complications associated with commonly used recreational drugs. A PubMed search was performed from database inception to 1 March 2024 using combinations of cardiovascular symptoms and cardiovascular complications with terms related to sympathomimetic recreational drug use. RESULTS: These substances exert potent sympathomimetic effects through catecholamine excess, and cause receptor activation, ion channel interference, and direct myocardial toxicity. Cocaine additionally induces vasospasm and thrombosis via endothelin-1 and causes sodium channel and potassium channel blockade. Amfetamine-type stimulants and synthetic cathinones amplify catecholamine release, contributing to arrhythmia, ischemia, and myocardial injury. Acute cardiovascular manifestations include chest pain, acute coronary syndrome, arrhythmias, cardiomyopathy, and sudden cardiac death. Presentations often mimic classical cardiac syndromes but may be more severe, especially in younger patients without traditional risk factors. Diagnosis begins with detailed history-taking, although self-reported drug use is frequently unreliable. Depending on symptoms, electrocardiography, cardiac biomarkers and echocardiography may be essential for risk stratification and identifying the underlying pathology. Toxicological testing may be considered when clinically indicated and should be interpreted in conjunction with clinical findings. For cocaine associated chest pain patients, risk stratification with the HEART pathway may guide safe discharge in low-risk cases. Management should be individualized based on the specific recreational drug involved and the presenting symptoms. Sedation, antihypertensives, and dual antiplatelet therapy are foundational, with vasodilators when indicated. Beta-blockers with alpha-blocking properties may be beneficial in selected patients. Early drug counselling and referral are critical to reduce recurrence. DISCUSSION: In most cases, evaluation and management of acute cardiovascular symptoms in patients with suspected sympathomimetic drug use should follow standard guideline-based cardiovascular care. However, specific modifications may be required, including selective use of toxicological testing when it is expected to influence clinical decision-making, early sedation to reduce sympathetic overactivity, and cautious selection of beta-blockers depending on the substance involved. Awareness of these distinctions is essential to avoid both under- and overtreatment. CONCLUSION: Clinicians must recognize the acute cardiovascular risks of sympathomimetic recreational drugs and integrate routine drug screening, tailored management, and addiction intervention into acute care pathways to improve outcomes and reduce morbidity.
Clinical research Narrative review published

Psychedelics in Chronic Pain Treatment Explored

Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation
Why it matters ▲ Favorable
This narrative review highlights the potential of classic psychedelics to address chronic pain by targeting central nervous system maladaptation. The review underscores the need for novel validation strategies to overcome translational barriers such as expectancy bias. This could significantly impact future research directions and clinical applications in pain management.
Chronic pain is a complex disorder of central nervous system maladaptation, perpetuated not only by ascending nociceptive transmission but also by entrenched prior expectations. Conventional analgesics typically fail to reverse this cognitive rigidity and the ensuing pathological cycles. Classic psychedelics, however, are emerging as a promising avenue to help address this therapeutic impasse. This narrative review provides a comprehensive overview of the emerging science of psychedelics, encompassing their biological binding targets, potential neural mechanisms and clinical applications, in the context of chronic pain. We synthesize the therapeutic potential of classic psychedelics and critically examine the discrepancies between clinical outcomes and foundational mechanistic research. Furthermore, we evaluate key translational barriers, particularly compromised blinding and expectancy bias, and highlight the necessity for developing novel validation strategies. Ultimately, these new insights compel a fundamental rethinking of how biological neuroplasticity and subjective psychological experiences independently or synergistically drive analgesia, thereby offering a paradigm-shifting perspective for the translation of psychedelics into evidence-based analgesic therapeutics.
Clinical research Peer-reviewed publication

Low-dose ketamine shows analgesic benefit in spine fusion surgery

Analgesic Effects of Low Dose Ketamine in Patients Undergoing Spine Fusion Surgery.
Why it matters ▲ Favorable
This peer-reviewed study adds to the clinical evidence supporting low-dose ketamine as an effective adjunct for pain management in surgical settings. The findings may inform perioperative protocols and could influence guidelines on opioid-sparing strategies. For researchers, the results justify further investigation into ketamine's mechanisms and safety profile in acute pain contexts. The study is also relevant for policymakers considering updates to controlled substance regulations or hospital formularies.
Clinical research Perspective published

Perspective: Limits of Psychedelic Trials in Depression

Reading the Signal: What Psychedelic Trials in Depression Still Can't Tell Us.
Why it matters ◈ Mixed
This perspective highlights persistent gaps in what current psychedelic trials for depression can reliably tell us, including issues with trial design, placebo effects, and generalizability. For researchers, this underscores the need for more rigorous, diverse, and long-term studies before drawing firm conclusions about efficacy and safety. Policymakers and clinicians should be cautious in interpreting early results, as limitations in evidence may affect regulatory and access decisions. The article signals that while progress is being made, the field must address methodological weaknesses to inform future policy and practice.
Clinical research Review published

Review: Ketamine in Psychotherapy for Depression

A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.
Why it matters ▲ Favorable
This scoping review examines the use of ketamine and esketamine in conjunction with psychotherapy for treating depression in adults. The findings could inform clinical guidelines and therapeutic strategies, potentially improving patient outcomes. This review highlights the growing interest in integrating psychedelic substances with traditional therapeutic approaches, which may influence future research and clinical practices.
Clinical research Scoping review published

Scoping review on ketamine-assisted psychotherapy for depression

A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults
Why it matters ◈ Mixed
This scoping review highlights the current state of research on ketamine or esketamine combined with psychotherapy for depression. While the review identifies potential benefits, it underscores the need for more high-quality randomized controlled trials and better reporting on psychotherapy models. This is crucial for advancing clinical guidelines and understanding the therapeutic potential of these treatments.
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with Psychotherapy (KCP/ES-CP), where an altered state is not necessary for psychotherapy, or Ketamine/Esketamine Assisted Psychotherapy (KAP/ES-AP), where an altered state and/or integration of the experience is central to the psychotherapy. The 47 included 23/47(49%) KAP, 1/47 (2%) ES-AP, 7/47 (15%) KCP, 3/47 (6%) ES-CP, 8/47 (17%) dual KAP/KCP and 1/47 (2%) dual ES-KAP/ES-CP. Four studies could not be categorized. Separation into these categories was useful to more clearly report current state of the literature. Though previous reviews have suggested KAP is of benefit for depression, KAP studies were limited by lack of RCTs, lack of comparison groups without psychotherapy, and a large number of individual case reports. To date, fewer studies, but higher quality data support a KCP model, with 3 studies suggesting benefit to combining ketamine with cognitive behavioral therapy (CBT). Further, high quality research including accurate reporting and description of psychotherapy model is required.
Healthcare paradigm Perspective published

Medicine 4.0: Era of Revolutionary Access

Medicine 4.0: the era of revolutionary access
Why it matters ◈ Mixed
This perspective on Medicine 4.0 highlights the need for radical access to medical services and scientific ideas, critiquing how current commercial and regulatory frameworks can distort scientific evidence and marginalize low-cost treatments. It calls for realigning incentives to ensure scientific knowledge serves humanity, not just market forces. While not directly related to psychedelics, the themes of access and equity are relevant to the field's ongoing discussions.
The evolution of modern healthcare is transitioning from a reactive, disease-centered paradigm (Medicine 2.0) toward a proactive, personalised model focused on maximising healthspan (Medicine 3.0). While this shift represents a vital optimisation of medical philosophy, it remains critically incomplete. This Perspective proposes a new paradigm (Medicine 4.0) which adds a foundational third dimension to the lifespan-healthspan model: radical access to both medical services and scientific ideas. The author analyses how commercial incentives, regulatory frameworks, and market forces frequently distort the production of scientific evidence, marginalise transformative, low-cost treatments, and delay paradigm shifts. Furthermore, the author examines the dual-edged nature of emerging digital health technologies, warning that monetisation through paywalls and engagement-driven ad models risks ossifying existing public health inequalities rather than democratising care. By realigning institutional incentives and dismantling structural obstructions to inquiry, Medicine 4.0 advocates for a return to the foundational Baconian principle that scientific knowledge must serve humanity. Ultimately, the author argues that medical progress must be evaluated not merely by its technological surface area, but by its total societal volume.
Clinical research Literature review published

Psilocybin microdosing for depression: literature review

Evaluating psilocybin for the management of depression: a literature review
Why it matters ◈ Mixed
This literature review evaluates the potential of psilocybin microdosing as a treatment for depression, highlighting both potential benefits and significant methodological limitations. The evidence base is currently insufficient to support widespread clinical use. Mental health professionals should stay informed about developments in psychedelic therapies while ensuring patients receive evidence-based care.
Background/Aims Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin for managing symptoms of depression and consider the implications for mental health nursing practice. Methods A narrative literature review was undertaken. Search terms included ‘microdosing’, ‘psilocybin’, ‘psychedelics’, ‘mental health’ and ‘depression’. Studies published in the last 10 years involving human participants were considered. Following screening and application of inclusion and exclusion criteria, five articles with a total of six empirical studies were included in the review. Results Three themes emerged, including ethical risks and limitations of microdosing, demographic and participant characteristics and the impact of microdosing on mental health. Some studies reported improvements in mood, anxiety and wellbeing, while others suggested that perceived benefits may be explained by placebo effects. Significant methodological limitations were identified across the literature. Conclusions Current evidence suggests potential therapeutic benefits of psilocybin microdosing for depression. However, the evidence base remains limited and insufficient to support widespread clinical use. Implications for practice Mental health nurses should remain informed about emerging psychedelic therapies while continuing to provide evidence-based care and support patients to make informed decisions regarding treatment options.
Neuroscience Study published

Entropic Brain Hypothesis Tested Across States

Testing the Entropic Brain Hypothesis Across Diverse States and Conditions
Why it matters ▲ Favorable
This study provides empirical support for the Entropic Brain Hypothesis by demonstrating that different states of consciousness, including those induced by psychedelics like LSD and DMT, can be distinguished by their brain activity entropy. The findings could enhance our understanding of psychedelic states and inform therapeutic applications. This research is significant for advancing the theoretical framework of consciousness and could have implications for clinical approaches to mental health conditions.
Understanding how different states of consciousness arise from brain activity remains a central challenge in consciousness science. Theoretical and empirical work has increasingly linked conscious states to the large-scale organization and dynamical complexity of brain activity, using measures ranging from network integration and graph-theoretical properties to signal diversity, perturbational complexity, and dynamic functional connectivity (Barttfeld et al., 2015; Casali et al., 2013; Demertzi et al., 2019; Schartner et al., 2015, 2017; Tagliazucchi et al., 2014). However, these measures have been operationalized differently across methodological traditions and experimental paradigms, making it difficult to determine whether diverse alterations of consciousness can be explained by a common underlying dynamical principle using the same analytical pipeline (Galván Rial et al., 2026). One influential framework addressing this question is the Entropic Brain Hypothesis, which proposes that the quality of conscious states is related to the entropy of spontaneous brain activity (Carhart-Harris et al., 2014). In information-theoretical terms, entropy quantifies uncertainty about the state of a system and is related to its degree of randomness or unpredictability (Ben-Naim, 2012; Carhart-Harris et al., 2014). Applied to brain activity, this framework proposes that differences in conscious experience correspond to differences in the diversity and unpredictability of spontaneous brain dynamics. The psychedelic state was initially proposed as a prototypical high-entropy state, characterized by less constrained brain dynamics and an expanded repertoire of transient functional connectivity configurations relative to ordinary waking consciousness (Carhart-Harris et al., 2014; Tagliazucchi et al., 2014). Conversely, states of reduced consciousness are expected to exhibit more restricted and stereotyped dynamics, consistent with findings of reduced neural complexity during non-rapid eye movement sleep and anaesthesia (Schartner et al., 2015; Varley et al., 2020). This framework therefore generates the broader prediction that heterogeneous states of consciousness may be systematically differentiated according to the entropy or complexity of their underlying brain dynamics. Recent work has provided an important cross-condition empirical test of this prediction. Galván Rial et al. (2026) applied a common analytical pipeline to five fMRI datasets spanning propofol anaesthesia, LSD, DMT, modafinil, and schizophrenia. The study quantified the temporal irregularity of large-scale network topology by applying sample entropy to time-resolved trajectories of dynamic small-worldness (SE dSW). Propofol anaesthesia was associated with progressively reduced dynamic-network entropy as sedation deepened, whereas LSD increased entropy, DMT and modafinil showed increases in the same direction, and schizophrenia exhibited the largest elevation relative to matched controls (Galván Rial et al., 2026). When placed on a common standardized scale, these conditions formed an entropic gradient extending from reduced network entropy under anaesthesia to increased entropy under psychedelic, stimulant, and clinical conditions. These findings provide initial evidence that the temporal diversity of large-scale network reconfiguration may constitute a shared dimension along which heterogeneous brain states can be organized (Galván Rial et al., 2026). However, empirical tests spanning a broad range of altered states within a common analytical framework remain limited, and the generalizability of the proposed entropic axis to additional conditions has yet to be established. Furthermore, the entropy measure used by Galván Rial et al. (2026) represents a topology-derived operationalization of entropy: sample entropy is applied to temporal fluctuations in dynamic small-worldness, a graph-theoretical property derived from time-resolved functional connectivity networks. This raise
Neuroscience Research findings

EEG spectral power decodes ketamine state, not phase connectivity

Spectral power, but not phase connectivity, decodes the subanaesthetic ketamine state from surface EEG: the role of between-subject transferability
Why it matters ◈ Mixed
This study highlights the potential of using spectral power from EEG to decode the subanaesthetic ketamine state, which could enhance understanding of ketamine's effects on consciousness. The finding that phase connectivity is not transferable across subjects suggests limitations in its use for broader applications. These insights could inform future research methodologies and the development of EEG-based diagnostic tools.
Subanaesthetic ketamine alters the content of consciousness while leaving responsiveness intact. We asked whether this state can be decoded from single eyes-closed EEG epochs, and how spectral power and phase-based connectivity compare when used as features. Re-analysing openly available 62-channel EEG from ten participants (awake versus subanaesthetic ketamine), we trained classifiers under leave-one-subject-out cross-validation to discriminate the two conditions from log band power, weighted phase-lag index (wPLI) connectivity, and their concatenation. Band power decoded the ketamine state above chance (balanced accuracy 0.71), whereas wPLI connectivity computed on the same epochs was at chance (0.47), and combining the feature sets did not improve on power alone. The dissociation held across three classifier families and across spatial montages, and was not explained by the dimensionality of the connectivity feature space. To identify its source, we decomposed the per-feature drug effect into components shared across subjects and subject-specific. The ketamine effect on connectivity was large within individuals but largely subject-specific, and therefore not transferable to held-out subjects (shared fraction 0.05), whereas the spectral effect was substantially shared across subjects (0.53); both feature classes carried comparable individual identity, so the asymmetry reflects transferability rather than fingerprint-likeness. The spectral signature was also recoverable from a sparse electrode subset, as a five-channel lateral montage performed as well as the full array. Undirected phase connectivity thus fails to decode subanaesthetic ketamine not through insufficient spatial sampling, but because the connectivity drug effect is subject-specific in form.
Clinical research Systematic review published

Review: Ketamine for Depression in BPD

Intravenous Ketamine for Depression and Suicidality in Borderline Personality Disorder and Borderline Personality Features: A Systematic Review
Why it matters ◈ Mixed
This systematic review highlights the potential of ketamine as a treatment for depressive symptoms and suicidality in borderline personality disorder (BPD), a condition with limited pharmacologic options. The findings suggest ketamine is tolerable and may offer symptom improvements, but the evidence is not yet definitive due to study limitations. This underscores the need for larger, targeted trials to better assess ketamine's efficacy and safety in this population.
Background: Pharmacologic treatment options for borderline personality disorder (BPD) remain limited, and no medication has received regulatory approval for its treatment. Given the high rates of comorbid depression and suicidal ideation in BPD, there is growing interest in novel therapeutic approaches. Ketamine has been approved for treatment-resistant depression and acute suicidality, raising interest in its potential role for BPD patients. Objective: To systematically review the evidence on the effectiveness and tolerability of ketamine for depressive symptoms, suicidal ideation, and core BPD symptoms in adults with formally diagnosed BPD. Methods: MEDLINE, EMBASE, and Cochrane CENTRAL were systematically searched. Studies examining ketamine treatment in adults with a formal BPD diagnosis and reporting outcomes related to depression, suicidality, or BPD symptomatology were included. A narrative synthesis was performed due to study heterogeneity. Results: The search yielded 1,620 abstracts, with eight full-text studies reviewed. Two studies met inclusion criteria: one RCT and one real-world observational cohort study. Ketamine was generally well tolerated, with transient dissociative effects and no unexpected safety concerns. Evidence for antidepressant and antisuicidal effects was suggestive but not definitive: the RCT demonstrated numerical but non-significant improvements following a single infusion, whereas the observational study reported significant symptom reductions following repeated infusions without a placebo comparator. Findings regarding core BPD symptoms were mixed. Conclusions: Evidence for ketamine in formally diagnosed BPD remains limited. Preliminary findings suggest ketamine is tolerable and may be associated with improvements in depressive symptoms and suicidality, but causal inference is constrained by study design. Larger, BPD-targeted trials with stratified outcome reporting are needed.
Clinical research Scoping review published

Scoping review on integration in psychedelic therapy

Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
Why it matters ◈ Mixed
This scoping review highlights the variability and lack of standardization in the integration phase of psychedelic-assisted therapy (PAT). Standardized and transparent reporting of integration practices is crucial for improving participant safety and ensuring the efficacy of future clinical trials. The review underscores the need for detailed protocols and consistent reporting to facilitate cross-trial comparisons and support the progression to phase III trials.
Background Integration — the ongoing process of revisiting, making sense of, and incorporating the content of a psychedelic experience into daily life — is a core component of psychedelic-assisted therapy (PAT), but is variably operationalised and poorly reported in clinical research. Objective To map how integration is described, delivered, and reported in clinical studies of classic psychedelics and to identify common practices and research gaps. Methods A PRISMA-ScR scoping review was conducted searching PubMed, Scopus, and CENTRAL for English-language studies between 1990 and January 2025. Data was extracted on integration session structure (number, timing, duration), therapeutic frame, and facilitator training and conduct. Results Forty-four articles met inclusion, comprising 30 clinical trials, eight prospective trial protocols, and six therapeutic manuals. Psilocybin was the most studied classic psychedelic (k = 37 publications). In clinical trials that reported integration (k = 24), 1-4 integration sessions were provided per dose (median = 2); reported session duration was between 1-3hrs (median = 1.5hrs). Typically, clinical trials provided an initial integration session 24-48hrs post-dose and a second session approximately 1 week later. Reporting of integration content, therapeutic conduct, and facilitator training was minimal, particularly outside psilocybin-assisted therapy trials. Conclusion Psychedelic integration is central to PAT, yet its delivery remains vaguely operationalised in clinical research. Future trials should routinely publish comprehensive protocols specifying integration session goals and timing, facilitator roles, therapist qualifications, and fidelity monitoring. Standardised, transparent reporting will improve participant safety and continuity of care, enable cross-trial comparisons, and support safe progression to phase III trials.
Neuroscience Study published

Study on Glycyrrhiza glabra's Anxiolytic Effects

Phytochemical profiling and pharmacological evaluation studies of anxiolytic efficacy of <i>Glycyrrhiza glabra</i> root decoction
Why it matters ▲ Favorable
This study provides promising preclinical evidence for the anxiolytic effects of Glycyrrhiza glabra root decoction, identifying canrenoic acid as a key bioactive compound. The findings suggest potential for further preclinical and clinical evaluation in anxiety treatment. This could open new avenues for natural product-based therapeutics in mental health.
Glycyrrhiza glabra ( G. glabra) root is traditionally known for its wide-ranging pharmacological properties, including antimicrobial, anti-inflammatory, hepatoprotective, and immunomodulatory effects. This study aims to explore the anxiolytic potential of G. glabra root decoction. Using LC-MS, seven major phytocompounds such as N-acetylalanine, primuliten, 8-hydroxy-13,14,15,16-tetranor-12-labdanoic acid, gardnerine, abrine canrenoic acid, and aspterric acid were identified from the G. glabra decoction. These compounds were further evaluated through ADME profiling and network pharmacology to assess their drug-likeness and pharmacokinetic properties using the SWISS ADME platform. Among the identified compounds, the bioactive compound canrenoic acid was found to be investigated for the direct modulation of ion channels in the brain contributing to central nervous system (CNS) pharmacology, and for the regulation of CNS stress responses, which can modulate anxiety-related behaviours. Canrenoic acid (PubChem CID: 656615) demonstrated promising interactions with the anxiety-related protein target PDB ID:7E2Y. Molecular dynamics (MD) simulations were conducted over a 100-nanosecond trajectory to analyze the stability of the Canrenoic acid–7E2Y complex. The simulation results revealed minimal conformational fluctuations, with the ligand maintaining a stable binding pose through hydrophobic interactions and hydrogen bonding. root mean square deviation (RMSD), root mean square fluctuation (RMSF), secondary structure evolution, and protein-ligand interaction analyses confirmed the robustness of the complex. In addition, in vivo testing using the elevated plus maze (EPM) was performed in rats to evaluate the anxiolytic effects of four different extracts at two dose levels (100 mg/kg and 200 mg/kg), compared to a standard treatment group (diazepam 2 mg/kg). The G. glabra decoction exhibited significant anxiolytic activity. Rats treated with 200 mg/kg of G. glabra showed a marked increase in both the number of entries into the open arms (3.33 ± 0.21) and the time spent in the open arms (43.83 ± 0.79 seconds), closely mirroring the effects observed with the standard drug diazepam. These findings suggest that canrenoic acid is a promising candidate for further preclinical and clinical evaluation in the treatment of anxiety disorders.
Clinical research Review published

Review on psychedelic trial design published

Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review.
Why it matters ▲ Favorable
This narrative review provides a comprehensive analysis of the mechanisms and methods used in psychedelic clinical trial design. It offers valuable insights for researchers aiming to optimize trial methodologies and improve the rigor of psychedelic studies. While not a direct policy or legal update, the review could influence future research protocols and enhance the credibility of clinical findings in the field.
Neuroscience Preclinical findings

Elunetirom boosts neuroplasticity in neurons

Elunetirom, a brain-targeted TRβ prodrug, promotes neuronal plasticity and mitochondrial biogenesis-related signaling in primary neuronal cultures
Why it matters ▲ Favorable
The study on Elunetirom, a brain-targeted TRβ prodrug, reveals its potential to enhance neuroplasticity and mitochondrial biogenesis in neuronal cultures. This could represent a novel therapeutic pathway for major depressive disorder and bipolar depression, offering an alternative to current treatments with fewer systemic side effects. The findings warrant further investigation into brain-targeted thyromimetic signaling as a differentiated approach in psychiatric disorders.
Major depressive disorder and bipolar depression are disabling illnesses associated with impaired neuroplasticity, mitochondrial dysfunction, and altered cellular bioenergetics. Available pharmacotherapies often have delayed onset, incomplete efficacy, and limited effects on underlying plasticity and energetic systems. Non-selective thyroid hormone therapies provide evidence that enhancing central thyroid hormone signaling may improve depressive symptoms, but systemic cardiovascular, skeletal, and metabolic effects limit their broader use. Rapid-acting treatments such as esketamine and psychedelics further support neuroplasticity as a therapeutic strategy, although psychotomimetic, hallucinogenic, and implementation burdens may constrain widespread use. Elunetirom is a brain-targeted, fatty acid amide hydrolase-sensitive prodrug of LL-340001, a potent thyroid hormone receptor activator as demonstrated in transfected cell-line and brain-slice target-engagement assays. We evaluated elunetirom and LL-340001 in primary cortical and mature hippocampal neuronal cultures. LL-340001 increased MAP-2-positive neuron number, neurite length, branching, and neurite extremities in immature cortical neurons. In mature hippocampal neurons, elunetirom rapidly increased neurite network and synapse number within 24 hours, with effects persisting through 72 hours, while LL-340001 preserved synapse number following amyloid-β1-42 challenge. LL-340001 also increased nuclear PGC-1α and NRF2, the number of functional mitochondria measured by MitoTracker, and ATP content. Pharmacologic inhibition indicated that the LL-340001-induced increase in cortical MAP-2-positive neuron number was sensitive to TrkB inhibition but not 5-HT2A antagonism. Together, these findings indicate that elunetirom and LL-340001 engage complementary neuroplasticity and mitochondrial biogenesis-related programs in neuronal systems and support further investigation of brain-targeted thyromimetic signaling as a mechanistically differentiated approach for major depressive disorder and bipolar depression.